Heparin	O
plus	O
dipyridamole	O
in	O
childhood	Age
hemolytic-uremic	O
syndrome	O
:	O
a	O
prospective	O
,	O
randomized	O
study	O
.	O

From	O
1976	O
to	O
1985	O
,	O
a	O
total	O
of	O
58	SampleSize
infants	Age
and	Age
children	Age
with	O
the	O
hemolytic-uremic	Condition
syndrome	Condition
were	O
randomly	O
assigned	O
to	O
treatment	O
either	O
with	O
heparin	O
and	O
dipyridamole	O
or	O
with	O
supportive	O
management	O
only	O
.	O

In	O
the	O
treatment	O
group	O
,	O
two	O
patients	O
died	O
in	O
the	O
early	O
weeks	O
of	O
the	O
disease	O
.	O

Analysis	O
of	O
clinical	O
and	O
laboratory	O
data	O
showed	O
no	O
significant	O
difference	O
between	O
either	O
group	O
of	O
patients	O
as	O
to	O
the	O
evolution	O
of	O
their	O
illness	O
except	O
for	O
a	O
significantly	O
higher	O
incidence	O
of	O
anuria	O
and	O
a	O
significantly	O
faster	O
recovery	O
from	O
hypertension	O
in	O
the	O
treated	O
group	O
.	O

Renal	O
biopsy	O
studies	O
showed	O
no	O
differences	O
between	O
the	O
two	O
groups	O
in	O
terms	O
of	O
incidence	O
and	O
severity	O
of	O
the	O
histologic	O
lesions	O
.	O

The	O
long-term	O
data	O
on	O
blood	O
pressure	O
and	O
creatinine	O
clearance	O
values	O
in	O
the	O
survivors	O
were	O
similar	O
in	O
both	O
groups	O
.	O

This	O
study	O
indicates	O
that	O
treatment	O
with	O
heparin	O
and	O
dipyridamole	O
has	O
no	O
benefit	O
over	O
symptomatic	O
therapy	O
alone	O
in	O
the	O
typical	O
form	O
of	O
childhood	Condition
hemolytic-uremic	Condition
syndrome	Condition
.	O

Comparison	O
of	O
enoxaparin	O
and	O
standard	O
heparin	O
in	O
gynaecologic	O
oncologic	O
surgery	O
:	O
a	O
randomised	O
prospective	O
double-blind	O
clinical	O
study	O
.	O

OBJECTIVE	O
This	O
study	O
aimed	O
to	O
compare	O
the	O
haemorrhagic	O
complications	O
and	O
efficacy	O
of	O
enoxaparin	O
,	O
a	O
low	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
,	O
and	O
conventional	O
standard	O
heparin	O
(	O
SH	O
)	O
in	O
gynaecological	O
oncologic	O
surgery	O
.	O

MATERIALS	O
METHODS	O
A	O
double	O
blind	O
,	O
randomised	O
trial	O
was	O
performed	O
on	O
102	O
consecutive	O
women	O
undergoing	O
gynaecologic	O
cancer	O
surgery	O
with	O
pelvic	O
and	O
paraaortic	O
lymphadenectomy	O
.	O

The	O
women	O
were	O
separated	O
into	O
those	O
who	O
were	O
given	O
2,500	O
IU	O
enoxaparin	O
once	O
daily	O
and	O
SH	O
in	O
a	O
dose	O
of	O
5,000	O
IU	O
three	O
times	O
daily	O
.	O

The	O
groups	O
were	O
analysed	O
for	O
intraoperative	O
blood	O
loss	O
,	O
drainage	O
,	O
transfusion	O
requirements	O
,	O
perioperative	O
haemoglobin	O
decrease	O
,	O
wound	O
haematoma	O
,	O
and	O
clinical	O
deep	O
venous	O
thrombosis	O
.	O

RESULTS	O
The	O
two	O
groups	O
were	O
well	O
matched	O
for	O
age	O
,	O
weight	O
,	O
and	O
other	O
factors	O
,	O
which	O
could	O
predispose	O
to	O
the	O
development	O
of	O
deep	O
venous	O
thrombosis	O
(	O
DVT	O
)	O
and	O
haemorrhage	O
.	O

No	O
patient	O
developed	O
clinical	O
significant	O
DVT	O
,	O
wound	O
haematoma	O
or	O
intra-abdominal	O
bleeding	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
bleeding	O
complications	O
between	O
the	O
two	O
regimens	O
.	O

The	O
antiFXa	O
level	O
in	O
the	O
plasma	O
was	O
correlated	O
strongly	O
with	O
patient	O
weight	O
.	O

CONCLUSIONS	O
A	O
dose	O
of	O
2,500	O
IU	O
enoxaparin/day	O
does	O
not	O
cause	O
more	O
bleeding	O
complications	O
than	O
SH	O
5,000	O
IU	O
three	O
times	O
daily	O
when	O
used	O
to	O
prevent	O
thrombosis	O
.	O

However	O
,	O
the	O
dose	O
of	O
enoxaparin	O
must	O
be	O
adjusted	O
to	O
the	O
patient	O
's	O
weight	O
.	O

Evaluation	O
of	O
asthma	O
knowledge	O
and	O
quality	O
of	O
life	O
in	O
Hungarian	O
asthmatics	Condition
.	O

BACKGROUND	O
The	O
objective	O
was	O
to	O
develop	O
an	O
educational	O
instrument	O
,	O
to	O
assess	O
its	O
impact	O
as	O
an	O
intervention	O
instrument	O
and	O
to	O
examine	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
.	O

METHODS	O
119	SampleSize
asthmatics	O
were	O
randomized	O
(	O
64	O
in	O
the	O
intervention	O
and	O
55	O
in	O
the	O
reference	O
group	O
)	O
.	O

The	O
education	O
instrument	O
was	O
developed	O
based	O
on	O
the	O
EuroPharm-Forum	O
Guidelines	O
and	O
its	O
impact	O
assessed	O
by	O
a	O
self-developed	O
questionnaire	O
.	O

Patients	O
'	O
QoL	O
,	O
asthma	O
knowledge	O
was	O
assessed	O
twice	O
,	O
once	O
before	O
and	O
after	O
the	O
education	O
seminar	O
,	O
education	O
was	O
only	O
provided	O
for	O
the	O
intervention	O
group	O
.	O

QoL	O
was	O
measured	O
with	O
the	O
St	O
George	O
's	O
Respiratory	O
Questionnaire	O
(	O
SGRQ	O
)	O
and	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
.	O

RESULTS	O
We	O
found	O
significant	O
differences	O
in	O
answers	O
to	O
the	O
asthma	O
questions	O
,	O
by	O
40	O
%	O
improvement	O
,	O
but	O
no	O
changes	O
in	O
the	O
control	O
group	O
.	O

In	O
inhaler-use	O
technique	O
,	O
we	O
could	O
not	O
find	O
significant	O
changes	O
neither	O
in	O
the	O
intervention	O
nor	O
in	O
the	O
control	O
group	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
results	O
of	O
the	O
two	O
visits	O
neither	O
with	O
the	O
VAS	O
nor	O
with	O
the	O
SGRQ	O
on	O
the	O
QoL	O
data	O
.	O

CONCLUSION	O
The	O
results	O
indicate	O
that	O
asthmatics	O
experience	O
lower	O
QoL	O
.	O

As	O
the	O
subjects	O
were	O
regularly	O
controlled	O
asthmatics	O
they	O
had	O
better	O
general	O
knowledge	O
and	O
inhaler-use	O
technique	O
was	O
expected	O
.	O

The	O
results	O
suggest	O
that	O
it	O
is	O
necessary	O
to	O
regularly	O
refresh	O
asthma	O
knowledge	O
,	O
to	O
assess	O
patients	O
'	O
self-management	O
plans	O
to	O
achieve	O
long-term	O
effectiveness	O
of	O
asthma	O
management	O
.	O

Anti-IgG	O
antibodies	O
during	O
immunotherapy	O
with	O
purified	O
grass	O
pollen	O
extracts	O
.	O

In	O
a	O
double	O
blind	O
study	O
40	O
patients	O
were	O
allocated	O
specific	O
immunotherapy	O
(	O
hyposensitization	O
)	O
with	O
partially	O
purified	O
timothy	O
extract	O
or	O
two	O
timothy	O
major	O
allergens	O
19	O
,	O
25	O
.	O

All	O
patients	O
had	O
typical	O
grass	O
pollen	O
hay	O
fever	O
,	O
in	O
27	O
%	O
associated	O
with	O
grass	O
pollen	O
asthma	O
and	O
in	O
13	O
%	O
with	O
birch	O
pollen	O
allergy	O
.	O

Serum	O
IgG	O
anti-IgG	O
antibodies	O
were	O
determined	O
after	O
dithiothreitol	O
treatment	O
.	O

Before	O
hyposensitization	O
,	O
IgG	O
anti-IgG	O
titres	O
greater	O
than	O
or	O
equal	O
to	O
9	O
were	O
demonstrated	O
in	O
45	O
%	O
of	O
the	O
patients	O
.	O

During	O
hyposensitization	O
IgG	O
anti-IgG	O
titres	O
showed	O
a	O
slight	O
initial	O
increase	O
followed	O
by	O
a	O
decrease	O
below	O
pretreatment	O
level	O
.	O

Neither	O
increase	O
nor	O
decrease	O
was	O
statistically	O
significant	O
.	O

Reactions	O
to	O
rabbit	O
IgG	O
F	O
(	O
ab	O
'	O
)	O
2	O
fractions	O
were	O
only	O
obtained	O
during	O
hyposensitization	O
.	O

The	O
occurrence	O
of	O
anti-IgG	O
antibodies	O
did	O
no	O
correlate	O
with	O
symptoms	O
,	O
side	O
effects	O
,	O
or	O
the	O
level	O
of	O
allergen-specific	O
IgG	O
.	O

In	O
a	O
previous	O
study	O
it	O
was	O
demonstrated	O
that	O
patients	O
with	O
multiallergy	O
hyposensitized	O
with	O
combined	O
allergen	O
extracts	O
showed	O
a	O
statistically	O
significant	O
increase	O
in	O
IgG	O
anti-IgG	O
titres	O
during	O
treatment	O
.	O

The	O
increase	O
failed	O
to	O
appear	O
in	O
the	O
present	O
patients	O
allergic	O
only	O
to	O
pollen	O
and	O
treated	O
with	O
purified	O
allergen	O
extracts	O
.	O

It	O
is	O
therefore	O
suggested	O
that	O
a	O
multiallergic	O
condition	O
and	O
the	O
combination	O
and/or	O
purification	O
of	O
allergen	O
extracts	O
administered	O
during	O
hyposensitization	O
may	O
influence	O
the	O
production	O
of	O
IgG	O
anti-	O
IgG	O
antibodies	O
.	O

14	O
day	O
endoscopy	O
study	O
comparing	O
risedronate	O
and	O
alendronate	O
in	O
postmenopausal	Condition
women	Sex
stratified	O
by	O
Helicobacter	Condition
pylori	Condition
status	O
.	O

OBJECTIVE	O
Bisphosphonates	O
are	O
effective	O
treatment	O
for	O
osteoporosis	O
but	O
have	O
been	O
associated	O
with	O
gastrointestinal	O
(	O
GI	O
)	O
mucosal	O
injury	O
.	O

This	O
study	O
compared	O
the	O
incidence	O
of	O
gastric	O
ulcers	O
after	O
treatment	O
with	O
risedronate	O
,	O
a	O
pyridinyl	O
bisphosphonate	O
,	O
or	O
alendronate	O
,	O
a	O
primary	O
amino	O
bisphosphonate	O
,	O
in	O
healthy	Condition
postmenopausal	Condition
women	Sex
stratified	O
by	O
Helicobacter	Condition
pylori	Condition
status	O
.	O

METHODS	O
Subjects	O
were	O
randomized	O
to	O
receive	O
risedronate	O
5	O
mg	O
(	O
n	O
=	O
318	O
)	O
or	O
alendronate	O
10	O
mg	O
(	O
n	O
=	O
317	O
)	O
daily	O
for	O
14	O
days	O
.	O

Endoscopy	O
and	O
evaluator-blind	O
assessments	O
of	O
the	O
esophageal	O
,	O
gastric	O
,	O
and	O
duodenal	O
mucosa	O
were	O
performed	O
at	O
baseline	O
and	O
on	O
Days	O
8	O
and	O
15	O
.	O

RESULTS	O
Overall	O
,	O
gastric	O
ulcers	O
>	O
or	O
=	O
3	O
mm	O
were	O
observed	O
in	O
18	O
(	O
6.0	O
%	O
)	O
of	O
300	O
evaluable	O
subjects	O
in	O
the	O
risedronate	O
group	O
and	O
36	O
(	O
12.1	O
%	O
)	O
of	O
297	O
in	O
the	O
alendronate	O
group	O
during	O
treatment	O
(	O
p	O
=	O
0.013	O
)	O
.	O

On	O
Day	O
8	O
,	O
the	O
incidences	O
of	O
gastric	O
ulcers	O
in	O
the	O
risedronate	O
and	O
alendronate	O
groups	O
were	O
3.6	O
%	O
and	O
6.6	O
%	O
,	O
respectively	O
(	O
p	O
=	O
0.133	O
)	O
,	O
and	O
on	O
Day	O
15	O
,	O
they	O
were	O
3.3	O
%	O
and	O
8.7	O
%	O
(	O
p	O
=	O
0.008	O
)	O
.	O

The	O
incidence	O
of	O
gastric	O
ulcers	O
was	O
not	O
affected	O
by	O
H.	O
pylori	O
status	O
.	O

Mean	O
gastric	O
endoscopy	O
scores	O
at	O
Days	O
8	O
and	O
15	O
were	O
significantly	O
lower	O
in	O
the	O
risedronate	O
group	O
than	O
in	O
the	O
alendronate	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Mean	O
esophageal	O
and	O
duodenal	O
endoscopy	O
scores	O
were	O
similar	O
in	O
the	O
2	O
groups	O
at	O
Days	O
8	O
and	O
15	O
.	O

When	O
the	O
treatment	O
groups	O
were	O
combined	O
,	O
gastric	O
endoscopy	O
scores	O
were	O
significantly	O
higher	O
among	O
H.	O
pylori	O
negative	O
than	O
H.	O
pylori	O
positive	O
subjects	O
at	O
Days	O
8	O
and	O
15	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Upper	O
GI	O
adverse	O
events	O
were	O
reported	O
by	O
18	O
(	O
5.7	O
%	O
)	O
subjects	O
in	O
the	O
risedronate	O
group	O
(	O
19	O
events	O
)	O
and	O
28	O
(	O
8.8	O
%	O
)	O
subjects	O
in	O
the	O
alendronate	O
group	O
(	O
32	O
events	O
)	O
.	O

Symptoms	O
did	O
not	O
predict	O
the	O
presence	O
of	O
mucosal	O
damage	O
.	O

CONCLUSION	O
Risedronate	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
incidence	O
of	O
gastric	O
ulcers	O
than	O
alendronate	O
.	O

H.	O
pylori	O
infection	O
did	O
not	O
increase	O
the	O
incidence	O
of	O
bisphosphonate	O
related	O
gastric	O
ulcers	O
.	O

The	O
findings	O
from	O
this	O
14	O
day	O
study	O
in	O
healthy	O
volunteers	O
support	O
the	O
hypothesis	O
that	O
bisphosphonates	O
may	O
differ	O
from	O
one	O
another	O
in	O
their	O
potential	O
to	O
produce	O
upper	O
GI	O
mucosal	O
damage	O
.	O

Scales	O
for	O
the	O
assessment	O
of	O
neuroleptic	O
response	O
in	O
schizophrenic	Condition
children	Age
:	O
specific	O
measures	O
derived	O
from	O
the	O
CPRS	O
.	O

This	O
article	O
reports	O
the	O
psychometric	O
properties	O
of	O
two	O
scales	O
for	O
rating	O
positive	O
and	O
negative	O
schizophrenic	O
signs	O
and	O
symptoms	O
.	O

These	O
Positive	O
and	O
Negative	O
Syndrome	O
Scales	O
consist	O
of	O
items	O
selected	O
from	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
(	O
CPRS	O
)	O
,	O
which	O
contains	O
items	O
covering	O
a	O
wide	O
range	O
of	O
childhood	O
psychopathology	O
.	O

CPRS	O
rating	O
data	O
were	O
analyzed	O
for	O
19	SampleSize
schizophrenic	Condition
children	Age
,	O
16	SampleSize
males	Sex
and	O
3	SampleSize
females	Sex
,	O
mean	Age
age	Age
8.9	Age
years	Age
(	O
range	O
5.5-11.7	Age
)	O
,	O
evaluated	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
of	O
haloperidol	O
.	O

We	O
describe	O
the	O
item	O
composition	O
and	O
coherence	O
of	O
each	O
scale	O
,	O
the	O
interrater	O
reliabilities	O
of	O
clinicians	O
using	O
the	O
scales	O
,	O
and	O
the	O
sensitivity	O
of	O
the	O
scales	O
for	O
resolving	O
treatment	O
response	O
.	O

Schizophrenic	Condition
children	Age
showed	O
both	O
positive	O
and	O
negative	O
signs	O
and	O
symptoms	O
,	O
and	O
both	O
improved	O
with	O
neuroleptic	O
treatment	O
.	O

Prophylactic	O
cranial	O
irradiation	O
for	O
patients	O
with	O
small-cell	Condition
lung	Condition
cancer	Condition
in	Condition
complete	Condition
remission	Condition
.	Condition

BACKGROUND	O
Prophylactic	O
cranial	O
irradiation	O
in	O
patients	Condition
with	Condition
small-cell	Condition
lung	Condition
cancer	Condition
decreases	O
the	O
overall	O
rate	O
of	O
brain	O
metastases	O
without	O
an	O
effect	O
on	O
overall	O
survival	O
.	O

It	O
has	O
been	O
suggested	O
that	O
this	O
treatment	O
may	O
increase	O
neuropsychological	O
syndromes	O
and	O
brain	O
abnormalities	O
indicated	O
by	O
computed	O
tomography	O
scans	O
.	O

However	O
,	O
other	O
retrospective	O
data	O
suggested	O
a	O
beneficial	O
effect	O
on	O
overall	O
survival	O
for	O
patients	Condition
in	Condition
complete	Condition
remission	Condition
.	O

PURPOSE	O
Our	O
purpose	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
prophylactic	O
cranial	O
irradiation	O
on	O
brain	O
metastasis	O
,	O
overall	O
survival	O
,	O
and	O
late-occurring	O
toxic	O
effects	O
in	O
patients	Condition
with	Condition
small-cell	Condition
lung	Condition
cancer	Condition
in	Condition
complete	Condition
remission	Condition
.	O

METHODS	O
We	O
conducted	O
a	O
prospective	O
study	O
of	O
300	SampleSize
patients	Condition
who	Condition
had	Condition
small-cell	Condition
lung	Condition
cancer	Condition
that	Condition
was	Condition
in	Condition
complete	Condition
remission	Condition
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
prophylactic	O
cranial	O
irradiation	O
delivering	O
24	O
Gy	O
in	O
eight	O
fractions	O
during	O
12	O
days	O
(	O
treatment	O
group	O
)	O
or	O
no	O
prophylactic	O
cranial	O
irradiation	O
(	O
control	O
group	O
)	O
.	O

A	O
neuropsychological	O
examination	O
and	O
a	O
computed	O
tomography	O
scan	O
of	O
the	O
brain	O
were	O
performed	O
at	O
the	O
time	O
of	O
random	O
assignment	O
and	O
repeatedly	O
assessed	O
at	O
6	O
,	O
18	O
,	O
30	O
,	O
and	O
48	O
months	O
.	O

Patterns	O
of	O
failure	O
were	O
analyzed	O
according	O
to	O
total	O
event	O
rates	O
and	O
also	O
according	O
to	O
an	O
isolated	O
first	O
site	O
of	O
relapse	O
,	O
using	O
a	O
competing-risk	O
approach	O
.	O

RESULTS	O
Two	SampleSize
hundred	SampleSize
ninety-four	SampleSize
patients	SampleSize
who	O
did	O
not	O
have	O
brain	O
metastases	O
at	O
the	O
time	O
of	O
random	O
assignment	O
were	O
analyzed	O
.	O

The	O
2-year	O
cumulative	O
rate	O
of	O
brain	O
metastasis	O
as	O
an	O
isolated	O
first	O
site	O
of	O
relapse	O
was	O
45	O
%	O
in	O
the	O
control	O
group	O
and	O
19	O
%	O
in	O
the	O
treatment	O
group	O
(	O
P	O
<	O
10	O
(	O
-6	O
)	O
)	O
.	O

The	O
total	O
2-year	O
rate	O
of	O
brain	O
metastasis	O
was	O
67	O
%	O
and	O
40	O
%	O
,	O
respectively	O
(	O
relative	O
risk	O
=	O
0.35	O
;	O
P	O
<	O
10	O
(	O
-13	O
)	O
)	O
.	O

The	O
2-year	O
overall	O
survival	O
rate	O
was	O
21.5	O
%	O
in	O
the	O
control	O
group	O
and	O
29	O
%	O
in	O
the	O
treatment	O
group	O
(	O
relative	O
risk	O
=	O
0.83	O
;	O
P	O
=	O
.14	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
terms	O
of	O
neuropsychological	O
function	O
or	O
abnormalities	O
indicated	O
by	O
computed	O
tomography	O
brain	O
scans	O
.	O

CONCLUSIONS	O
Prophylactic	O
cranial	O
irradiation	O
given	O
to	O
patients	Condition
with	Condition
small-cell	Condition
lung	Condition
cancer	Condition
in	Condition
complete	Condition
remission	Condition
decreases	O
the	O
risk	O
of	O
brain	O
metastasis	O
threefold	O
without	O
a	O
significant	O
increase	O
in	O
complications	O
.	O

A	O
possible	O
beneficial	O
effect	O
on	O
overall	O
survival	O
should	O
be	O
tested	O
with	O
a	O
higher	O
statistical	O
power	O
.	O

IMPLICATIONS	O
The	O
results	O
of	O
the	O
trial	O
favor	O
,	O
at	O
present	O
,	O
the	O
indication	O
of	O
prophylactic	O
cranial	O
irradiation	O
for	O
patients	Condition
who	Condition
are	Condition
in	Condition
complete	Condition
remission	Condition
.	O

A	O
longer	O
follow-up	O
and	O
confirmatory	O
trials	O
are	O
needed	O
to	O
fully	O
assess	O
late-occurring	O
toxic	O
effects	O
.	O

The	O
possible	O
effect	O
on	O
overall	O
survival	O
needs	O
to	O
be	O
evaluated	O
with	O
a	O
larger	O
number	O
of	O
patients	Condition
in	Condition
complete	Condition
remission	Condition
,	O
and	O
a	O
meta-analysis	O
of	O
similar	O
trials	O
is	O
recommended	O
.	O

A	O
trial	O
with	O
3'-azido-2',3'-dideoxythymidine	O
and	O
human	O
interferon-?	O
in	O
cats	O
naturally	O
infected	O
with	O
feline	O
leukaemia	O
virus	O
.	O

Feline	O
leukaemia	O
virus	O
(	O
FeLV	O
)	O
infection	O
is	O
still	O
one	O
of	O
the	O
leading	O
causes	O
of	O
infection-related	O
deaths	O
in	O
domestic	O
cats	O
.	O

Treatment	O
with	O
various	O
drugs	O
has	O
been	O
attempted	O
,	O
but	O
none	O
has	O
resulted	O
in	O
cure	O
or	O
complete	O
virus	O
elimination	O
.	O

Human	O
interferon-?2a	O
(	O
huIFN-?2a	O
)	O
and	O
3'-azido-2',3'-dideoxythymidine	O
(	O
AZT	O
)	O
have	O
been	O
proven	O
to	O
decrease	O
antigenaemia	O
in	O
cats	O
infected	O
experimentally	O
with	O
FeLV	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
huIFN-?2a	O
,	O
AZT	O
and	O
a	O
combination	O
of	O
both	O
drugs	O
in	O
cats	O
infected	O
naturally	O
with	O
FeLV	O
in	O
a	O
placebo-controlled	O
double-blinded	O
trial	O
.	O

Fourty-four	O
FeLV-infected	O
cats	O
in	O
which	O
free	O
FeLV	O
p27	O
antigen	O
was	O
detected	O
in	O
serum	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
were	O
included	O
in	O
the	O
study	O
.	O

Cats	O
were	O
assigned	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
that	O
received	O
either	O
high	O
dose	O
huIFN-?2a	O
(	O
10	O
(	O
5	O
)	O
IU/kg	O
q24h	O
;	O
12	O
cats	O
)	O
,	O
AZT	O
(	O
5	O
mg/kg	O
q12h	O
;	O
10	O
cats	O
,	O
both	O
of	O
these	O
treatments	O
(	O
12	O
cats	O
)	O
or	O
placebo	O
(	O
10	O
cats	O
)	O
.	O

All	O
cats	O
were	O
treated	O
for	O
6	O
weeks	O
.	O

Clinical	O
variables	O
,	O
including	O
stomatitis	O
,	O
and	O
laboratory	O
parameters	O
,	O
such	O
as	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
counts	O
and	O
serum	O
FeLV	O
p	O
27	O
antigen	O
concentration	O
,	O
were	O
recorded	O
throughout	O
the	O
treatment	O
period	O
.	O

No	O
significant	O
difference	O
among	O
the	O
groups	O
was	O
observed	O
during	O
the	O
treatment	O
period	O
for	O
any	O
of	O
the	O
parameters	O
.	O

Aside	O
from	O
anaemia	O
in	O
one	O
cat	O
treated	O
with	O
AZT	O
,	O
no	O
adverse	O
effects	O
were	O
observed	O
.	O

It	O
was	O
not	O
possible	O
to	O
demonstrate	O
efficacy	O
of	O
huIFN-?2a	O
or	O
AZT	O
alone	O
or	O
together	O
in	O
cats	O
infected	O
naturally	O
with	O
FeLV	O
when	O
given	O
according	O
to	O
this	O
regimen	O
for	O
6	O
weeks	O
;	O
however	O
,	O
no	O
notable	O
side	O
effects	O
were	O
detected	O
.	O

Use	O
of	O
EORTC	O
target	O
definition	O
guidelines	O
for	O
dose-intensified	O
salvage	O
radiation	O
therapy	O
for	O
recurrent	O
prostate	O
cancer	O
:	O
results	O
of	O
the	O
quality	O
assurance	O
program	O
of	O
the	O
randomized	O
trial	O
SAKK	O
09/10	O
.	O

PURPOSE	O
Different	O
international	O
target	O
volume	O
delineation	O
guidelines	O
exist	O
and	O
different	O
treatment	O
techniques	O
are	O
available	O
for	O
salvage	O
radiation	O
therapy	O
(	O
RT	O
)	O
for	O
recurrent	O
prostate	O
cancer	O
,	O
but	O
less	O
is	O
known	O
regarding	O
their	O
respective	O
applicability	O
in	O
clinical	O
practice	O
.	O

METHODS	O
AND	O
MATERIALS	O
A	O
randomized	O
phase	O
III	O
trial	O
testing	O
64	O
Gy	O
vs	O
70	O
Gy	O
salvage	O
RT	O
was	O
accompanied	O
by	O
an	O
intense	O
quality	O
assurance	O
program	O
including	O
a	O
site-specific	O
and	O
study-specific	O
questionnaire	O
and	O
a	O
dummy	O
run	O
(	O
DR	O
)	O
.	O

Target	O
volume	O
delineation	O
was	O
performed	O
according	O
to	O
the	O
European	O
Organisation	O
for	O
the	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
guidelines	O
,	O
and	O
a	O
DR-based	O
treatment	O
plan	O
was	O
established	O
for	O
70	O
Gy	O
.	O

Major	O
and	O
minor	O
protocol	O
deviations	O
were	O
noted	O
,	O
interobserver	O
agreement	O
of	O
delineated	O
target	O
contours	O
was	O
assessed	O
,	O
and	O
dose-volume	O
histogram	O
(	O
DVH	O
)	O
parameters	O
of	O
different	O
treatment	O
techniques	O
were	O
compared	O
.	O

RESULTS	O
Thirty	SampleSize
European	O
centers	O
participated	O
,	O
43	O
%	O
of	O
which	O
were	O
using	O
3-dimensional	O
conformal	O
RT	O
(	O
3D-CRT	O
)	O
,	O
with	O
the	O
remaining	O
centers	O
using	O
intensity	O
modulated	O
RT	O
(	O
IMRT	O
)	O
or	O
volumetric	O
modulated	O
arc	O
technique	O
(	O
VMAT	O
)	O
.	O

The	O
first	O
submitted	O
version	O
of	O
the	O
DR	O
contained	O
major	O
deviations	O
in	O
21	O
of	O
30	O
(	O
70	O
%	O
)	O
centers	O
,	O
mostly	O
caused	O
by	O
inappropriately	O
defined	O
or	O
lack	O
of	O
prostate	O
bed	O
(	O
PB	O
)	O
.	O

All	O
but	O
5	O
centers	O
completed	O
the	O
DR	O
successfully	O
with	O
their	O
second	O
submitted	O
version	O
.	O

The	O
interobserver	O
agreement	O
of	O
the	O
PB	O
was	O
moderate	O
and	O
was	O
improved	O
by	O
the	O
DR	O
review	O
,	O
as	O
indicated	O
by	O
an	O
increased	O
?	O
value	O
(	O
0.59	O
vs	O
0.55	O
)	O
,	O
mean	O
sensitivity	O
(	O
0.64	O
vs	O
0.58	O
)	O
,	O
volume	O
of	O
total	O
agreement	O
(	O
3.9	O
vs	O
3.3	O
cm	O
(	O
3	O
)	O
)	O
,	O
and	O
decrease	O
in	O
the	O
union	O
volume	O
(	O
79.3	O
vs	O
84.2	O
cm	O
(	O
3	O
)	O
)	O
.	O

Rectal	O
and	O
bladder	O
wall	O
DVH	O
parameters	O
of	O
IMRT	O
and	O
VMAT	O
vs	O
3D-CRT	O
plans	O
were	O
not	O
significantly	O
different	O
.	O

CONCLUSIONS	O
The	O
interobserver	O
agreement	O
of	O
PB	O
delineation	O
was	O
moderate	O
but	O
was	O
improved	O
by	O
the	O
DR.	O
Major	O
deviations	O
could	O
be	O
identified	O
for	O
the	O
majority	O
of	O
centers	O
.	O

The	O
DR	O
has	O
improved	O
the	O
acquaintance	O
of	O
the	O
participating	O
centers	O
with	O
the	O
trial	O
protocol	O
.	O

Randomised	O
placebo-controlled	O
trial	O
of	O
rhesus-human	O
reassortant	O
rotavirus	O
vaccine	O
for	O
prevention	O
of	O
severe	O
rotavirus	O
gastroenteritis	O
.	O

BACKGROUND	O
Rotavirus	O
is	O
the	O
most	O
common	O
cause	O
of	O
acute	O
childhood	O
gastroenteritis	O
.	O

Vaccination	O
with	O
live	O
oral	O
heterologous	O
rotavirus	O
vaccines	O
may	O
prevent	O
rotavirus	O
gastroenteritis	O
.	O

We	O
assessed	O
the	O
efficacy	O
of	O
rhesus-human	O
reassortant	O
rotavirus	O
tetravalent	O
vaccine	O
(	O
RRV-TV	O
)	O
against	O
severe	O
rotavirus	O
gastroenteritis	O
in	O
Finnish	O
children	O
in	O
a	O
randomised	O
placebo-controlled	O
double-blind	O
trial	O
.	O

METHODS	O
Placebo	O
or	O
RRV-TV	O
(	O
titre	O
4x10	O
(	O
5	O
)	O
plaque-forming	O
units	O
)	O
was	O
given	O
to	O
infants	O
at	O
ages	O
2	O
,	O
3	O
,	O
and	O
5	O
months	O
.	O

The	O
children	O
were	O
followed	O
up	O
for	O
one	O
or	O
two	O
rotavirus	O
epidemic	O
seasons	O
.	O

The	O
main	O
outcome	O
measure	O
was	O
protection	O
against	O
severe	O
rotavirus	O
gastroenteritis	O
(	O
score	O
>	O
or	O
=11	O
on	O
a	O
20-point	O
severity	O
scale	O
)	O
.	O

2398	SampleSize
children	O
were	O
enrolled	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
RRV-TV	O
(	O
n=1191	O
)	O
or	O
placebo	O
(	O
n=1207	O
)	O
.	O

The	O
primary	O
efficacy	O
analysis	O
was	O
based	O
on	O
children	O
who	O
received	O
three	O
doses	O
of	O
RRV-TV	O
(	O
n=1128	O
)	O
or	O
placebo	O
(	O
n=1145	O
)	O
.	O

FINDINGS	O
256	O
episodes	O
of	O
rotavirus	O
gastroenteritis	O
occurred	O
at	O
any	O
time	O
during	O
the	O
study	O
;	O
65	O
were	O
among	O
1191	O
RRV-TV	O
recipients	O
,	O
and	O
191	O
among	O
1207	O
placebo	O
recipients	O
(	O
vaccine	O
efficacy	O
66	O
%	O
[	O
95	O
%	O
CI	O
55-74	O
]	O
;	O
intention-to-treat	O
analysis	O
)	O
.	O

226	O
episodes	O
were	O
included	O
in	O
the	O
primary	O
efficacy	O
analysis	O
of	O
fully	O
vaccinated	O
children	O
(	O
54	O
among	O
1128	O
RRV-TV	O
recipients	O
,	O
172	O
among	O
1145	O
placebo	O
recipients	O
;	O
vaccine	O
efficacy	O
68	O
%	O
[	O
57-76	O
]	O
)	O
.	O

100	O
episodes	O
were	O
severe	O
,	O
eight	O
in	O
RRV-TV	O
recipients	O
and	O
92	O
in	O
placebo	O
recipients	O
(	O
vaccine	O
efficacy	O
91	O
%	O
[	O
82-96	O
]	O
)	O
.	O

INTERPRETATION	O
RRV-TV	O
vaccine	O
was	O
highly	O
effective	O
against	O
severe	O
rotavirus	O
gastroenteritis	O
in	O
young	O
children	O
.	O

Incorporation	O
of	O
this	O
vaccine	O
into	O
routine	O
immunisation	O
schedules	O
of	O
infants	O
could	O
reduce	O
severe	O
rotavirus	O
gastroenteritis	O
by	O
90	O
%	O
and	O
severe	O
gastroenteritis	O
of	O
all	O
causes	O
in	O
young	O
children	O
by	O
60	O
%	O
.	O

Video	O
rating	O
analysis	O
of	O
effect	O
of	O
maprotiline	O
in	O
patients	O
with	O
dementia	O
and	O
depression	O
.	O

In	O
patients	O
with	O
dementia	O
and	O
mild	O
depression	O
(	O
DSM-III-R	O
290.21	O
)	O
,	O
the	O
effect	O
of	O
low	O
doses	O
of	O
the	O
antidepressant	O
maprotiline	O
(	O
up	O
to	O
75	O
mg/d	O
)	O
was	O
examined	O
.	O

The	O
main	O
parameter	O
was	O
a	O
video	O
rating	O
of	O
global	O
impression	O
.	O

The	O
Mini-Mental	O
State	O
Examination	O
(	O
MMS	O
)	O
and	O
the	O
Geriatric	O
Depression	O
Scale	O
(	O
GDS	O
)	O
were	O
applied	O
to	O
evaluate	O
the	O
effect	O
of	O
maprotiline	O
on	O
cognitive	O
and	O
depressive	O
symptoms	O
.	O

The	O
double-blind	O
,	O
placebo-controlled	O
trial	O
was	O
of	O
eight	O
weeks	O
'	O
duration	O
and	O
included	O
127	O
patients	O
,	O
randomized	O
in	O
two	O
groups	O
.	O

The	O
antidepressant	O
effect	O
of	O
maprotiline	O
was	O
reflected	O
in	O
the	O
GDS	O
.	O

There	O
was	O
,	O
however	O
,	O
no	O
indication	O
of	O
an	O
effect	O
of	O
maprotiline	O
on	O
cognitive	O
performance	O
.	O

The	O
global	O
impression	O
,	O
evaluated	O
by	O
video	O
rating	O
,	O
gave	O
no	O
indication	O
as	O
to	O
a	O
beneficial	O
effect	O
of	O
the	O
treatment	O
.	O

-	O
The	O
video	O
analysis	O
showed	O
a	O
significant	O
interrater	O
reliability	O
.	O

The	O
discrepancy	O
between	O
the	O
results	O
of	O
the	O
video	O
rating	O
and	O
the	O
GDS	O
is	O
discussed	O
.	O

-	O
The	O
results	O
confirm	O
similar	O
findings	O
of	O
other	O
authors	O
;	O
i.e.	O
,	O
that	O
a	O
sedating	O
antidepressant	O
with	O
some	O
anticholinergic	O
effects	O
can	O
not	O
be	O
expected	O
to	O
improve	O
cognitive	O
functions	O
despite	O
its	O
antidepressant	O
effect	O
.	O

The	O
main	O
interest	O
of	O
this	O
study	O
,	O
however	O
,	O
lies	O
in	O
its	O
methodology	O
(	O
video	O
analysis	O
)	O
.	O

A	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound-guided	O
laser	O
photocoagulation	O
for	O
treatment	O
of	O
benign	Condition
thyroid	Condition
nodules	Condition
.	O

This	O
randomized	O
controlled	O
study	O
was	O
designed	O
to	O
test	O
the	O
efficacy	O
and	O
safety	O
of	O
percutaneous	O
ultrasound	O
(	O
US	O
)	O
-guided	O
laser	O
photocoagulation	O
(	O
PLP	O
)	O
for	O
treatment	O
of	O
subjects	O
with	O
compressive	O
symptoms	O
due	O
to	O
benign	Condition
thyroid	Condition
nodules	Condition
and/or	O
at	O
high	O
surgical	O
risk	O
.	O

Twenty	SampleSize
six	SampleSize
subjects	O
were	O
randomized	O
to	O
the	O
intervention	O
(	O
no	O
.	O

13	O
,	O
age	O
68+/-3	Age
yr	Age
,	O
mean+/-SEM	O
)	O
or	O
observation	O
(	O
no	O
.	O

13	O
,	O
age	O
71+/-2	Age
yr	Age
)	O
groups	O
.	O

In	O
the	O
control	O
group	O
,	O
the	O
volume	O
of	O
nodules	O
did	O
not	O
significantly	O
change	O
over	O
the	O
30	O
week	O
period	O
of	O
observation	O
.	O

In	O
the	O
intervention	O
group	O
,	O
median	O
nodule	O
volume	O
at	O
baseline	O
was	O
8.2	O
ml	O
(	O
range	O
2.8-26.9	O
)	O
and	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O

Nodules	O
decreased	O
significantly	O
(	O
p	O
<	O
0.0001	O
)	O
by	O
22	O
%	O
after	O
2	O
weeks	O
(	O
6.5	O
ml	O
;	O
range	O
2.4-16.7	O
)	O
and	O
by	O
44	O
%	O
after	O
30	O
weeks	O
(	O
4.6	O
ml	O
;	O
range	O
0.69-14.2	O
)	O
.	O

Energy	O
given	O
was	O
correlated	O
(	O
p	O
<	O
0.05	O
)	O
with	O
the	O
reduction	O
of	O
thyroid	O
nodule	O
volume	O
.	O

All	O
patients	O
tolerated	O
the	O
treatment	O
well	O
and	O
reported	O
relief	O
from	O
compressive	O
and	O
cosmetic	O
complaints	O
(	O
p	O
<	O
0.05	O
)	O
.	O

At	O
the	O
time	O
of	O
enrolment	O
7/13	O
(	O
54	O
%	O
)	O
and	O
6/13	O
(	O
46	O
%	O
)	O
of	O
patients	O
in	O
the	O
intervention	O
and	O
control	O
groups	O
,	O
respectively	O
,	O
had	O
sub	O
clinical	O
hyperthyroidism	O
.	O

PLP	O
normalized	O
thyroid	O
function	O
at	O
6	O
and	O
30	O
weeks	O
after	O
treatment	O
.	O

In	O
conclusion	O
,	O
PLP	O
is	O
a	O
promising	O
safe	O
and	O
effective	O
procedure	O
for	O
treatment	O
of	O
benign	Condition
thyroid	Condition
nodules	Condition
in	O
patients	O
at	O
high	O
surgical	O
risk	O
.	O

Predictors	O
of	O
response	O
to	O
ziprasidone	O
:	O
results	O
from	O
a	O
6-week	O
randomized	O
double-blind	O
,	O
placebo-controlled	O
trial	O
for	O
acute	Condition
depressive	Condition
mixed	Condition
state	Condition
.	O

INTRODUCTION	O
The	O
present	O
study	O
is	O
aimed	O
at	O
investigating	O
possible	O
predictors	O
of	O
response	O
to	O
ziprasidone	O
in	O
a	O
sample	O
of	O
patients	O
with	O
mixed	Condition
depressive	Condition
state	Condition
.	O

METHODS	O
72	SampleSize
patients	O
were	O
randomized	O
to	O
either	O
ziprasidone	O
or	O
placebo	O
and	O
treated	O
prospectively	O
for	O
6	O
weeks	O
.	O

The	O
clinical	O
response	O
and	O
remission	O
were	O
defined	O
with	O
various	O
clinical	O
variables	O
including	O
Montgomery	O
Asberg	O
Depression	O
Rating	O
Scale	O
.	O

Further	O
outcome	O
measures	O
included	O
predictors	O
of	O
remission	O
and	O
other	O
clinical	O
variables	O
over	O
time	O
.	O

RESULTS	O
None	O
of	O
the	O
variables	O
under	O
investigation	O
were	O
significantly	O
associated	O
with	O
response	O
or	O
remission	O
at	O
6	O
weeks	O
(	O
all	O
p-values	O
>	O
0.003	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
Further	O
investigations	O
are	O
warranted	O
due	O
to	O
clear	O
limitations	O
,	O
mostly	O
small	O
sample	O
size	O
and	O
use	O
of	O
concomitant	O
medications	O
.	O

Central	O
neuronal	O
mechanisms	O
of	O
gastric	O
electrical	O
stimulation	O
in	O
diabetic	O
gastroparesis	Condition
.	O

OBJECTIVE	O
The	O
mechanisms	O
underlying	O
symptom	O
improvement	O
in	O
gastric	O
electrical	O
stimulation	O
(	O
GES	O
)	O
are	O
not	O
fully	O
understood	O
.	O

Modulation	O
of	O
the	O
central	O
nervous	O
system	O
excitability	O
may	O
be	O
involved	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
central	O
effects	O
of	O
GES	O
,	O
including	O
the	O
possible	O
modulation	O
of	O
the	O
visceral	O
sensory	O
nervous	O
system	O
.	O

MATERIAL	O
AND	O
METHODS	O
A	O
gastric	O
electrical	O
stimulator	O
was	O
implanted	O
in	O
seven	SampleSize
diabetic	Condition
patients	O
with	O
medically	Condition
refractory	Condition
gastroparesis	Condition
.	O

A	O
double-blinded	O
protocol	O
was	O
used	O
to	O
investigate	O
the	O
patients	O
at	O
baseline	O
and	O
one	O
month	O
after	O
recovery	O
with	O
the	O
stimulator	O
turned	O
on	O
and	O
off	O
(	O
1-month	O
periods	O
)	O
.	O

The	O
following	O
assessments	O
were	O
carried	O
out	O
:	O
mechanical	O
,	O
thermal	O
and	O
electrical	O
stimulations	O
with	O
sensory	O
recordings	O
in	O
the	O
esophagus	O
and	O
duodenum	O
,	O
and	O
standardized	O
,	O
self-administered	O
,	O
daily	O
symptom	O
questionnaires	O
.	O

RESULTS	O
No	O
difference	O
was	O
found	O
between	O
baseline	O
and	O
the	O
on-	O
and	O
off	O
periods	O
in	O
overall	O
gut	O
pain	O
thresholds	O
across	O
all	O
stimulus	O
modalities	O
in	O
the	O
esophagus	O
(	O
p=0.63	O
)	O
,	O
duodenum	O
(	O
p=0.19	O
)	O
or	O
esophagus	O
and	O
duodenum	O
combined	O
(	O
p=0.76	O
)	O
.	O

No	O
difference	O
in	O
the	O
sensory	O
response	O
to	O
mechanical	O
stimulation	O
was	O
found	O
in	O
the	O
esophagus	O
before	O
(	O
all	O
p	O
>	O
0.31	O
)	O
and	O
after	O
(	O
all	O
p	O
>	O
0.43	O
)	O
smooth	O
muscle	O
relaxation	O
with	O
butylscopolamine	O
.	O

Similar	O
findings	O
were	O
observed	O
in	O
the	O
duodenum	O
.	O

No	O
differences	O
were	O
found	O
in	O
thermal	O
sensitivity	O
(	O
esophagus	O
(	O
p=0.67	O
)	O
and	O
duodenum	O
(	O
p=0.17	O
)	O
)	O
,	O
sensory	O
response	O
to	O
electrical	O
stimulation	O
(	O
esophagus	O
(	O
p=0.57	O
)	O
and	O
duodenum	O
(	O
p=0.52	O
)	O
)	O
or	O
induced	O
somatic	O
referred	O
pain	O
areas	O
(	O
esophagus	O
(	O
p=0.75	O
)	O
and	O
duodenum	O
(	O
p=0.51	O
)	O
)	O
.	O

No	O
difference	O
was	O
seen	O
in	O
the	O
induced	O
somatic	O
referred	O
pain	O
areas	O
or	O
self-reported	O
symptoms	O
.	O

CONCLUSIONS	O
No	O
evidence	O
was	O
found	O
for	O
GES-induced	O
modulation	O
of	O
the	O
visceral	O
sensory	O
system	O
and	O
central	O
excitability	O
.	O

However	O
,	O
GES	O
has	O
been	O
proven	O
to	O
modulate	O
the	O
central	O
nervous	O
system	O
in	O
animal	O
studies	O
,	O
necessitating	O
further	O
human	O
experiments	O
in	O
order	O
unambiguously	O
to	O
establish	O
the	O
possible	O
central	O
effects	O
of	O
GES	O
.	O

Milk	O
production	O
of	O
dairy	O
cows	O
fed	O
wet	O
corn	O
gluten	O
feed	O
during	O
the	O
dry	O
period	O
and	O
lactation	O
.	O

An	O
experiment	O
was	O
conducted	O
with	O
36	SampleSize
primiparous	O
and	O
40	SampleSize
multiparous	O
Holstein	O
cows	O
to	O
examine	O
the	O
effects	O
of	O
feeding	O
wet	O
corn	O
gluten	O
feed	O
(	O
WCGF	O
)	O
on	O
305-d	O
milk	O
production	O
,	O
dry	O
matter	O
(	O
DM	O
)	O
intake	O
,	O
body	O
condition	O
score	O
(	O
BCS	O
)	O
,	O
and	O
health	O
.	O

The	O
experimental	O
treatments	O
included	O
:	O
1	O
)	O
control	O
--	O
WCGF	O
not	O
fed	O
(	O
n	O
=	O
27	O
)	O
;	O
2	O
)	O
WCGF-L-cows	O
received	O
diets	O
containing	O
WCGF	O
(	O
38	O
%	O
DM	O
basis	O
)	O
during	O
lactation	O
(	O
n	O
=	O
23	O
)	O
;	O
and	O
3	O
)	O
WCGF-DL	O
--	O
cows	O
received	O
diets	O
containing	O
WCGF	O
(	O
38	O
%	O
DM	O
basis	O
)	O
during	O
the	O
dry	O
period	O
and	O
lactation	O
(	O
n	O
=	O
26	O
)	O
.	O

During	O
the	O
dry	O
period	O
,	O
cows	O
consuming	O
WCGF	O
were	O
observed	O
to	O
have	O
a	O
significant	O
gain	O
in	O
BCS	O
(	O
0.07	O
+/-	O
0.06	O
)	O
compared	O
with	O
a	O
loss	O
in	O
BCS	O
in	O
cows	O
fed	O
the	O
control	O
diet	O
(	O
control	O
=	O
-0.11	O
+/-	O
0.06	O
and	O
WCGF-L	O
=	O
-0.04	O
+/-	O
0.06	O
)	O
.	O

During	O
lactation	O
,	O
there	O
were	O
no	O
differences	O
by	O
treatment	O
on	O
BCS	O
.	O

Cows	O
consuming	O
WCGF	O
during	O
lactation	O
consumed	O
more	O
feed	O
compared	O
with	O
the	O
control	O
:	O
25.4	O
,	O
23.8	O
,	O
and	O
21.2	O
+/-	O
0.76	O
kg/d	O
for	O
WCGF-L	O
,	O
WCGF-DL	O
,	O
and	O
the	O
control	O
,	O
respectively	O
.	O

Milk	O
production	O
was	O
higher	O
for	O
cows	O
consuming	O
WCGF	O
:	O
35.0	O
,	O
34.7	O
,	O
and	O
31.1	O
+/-	O
2.1	O
kg/d	O
for	O
WCGF-L	O
,	O
WCGF-DL	O
,	O
and	O
the	O
control	O
,	O
respectively	O
.	O

No	O
differences	O
were	O
found	O
in	O
either	O
DM	O
intake	O
or	O
actual	O
milk	O
yield	O
between	O
the	O
WCGF-L	O
and	O
WCGF-DL	O
treatments	O
,	O
indicating	O
that	O
prepartum	O
diets	O
did	O
not	O
influence	O
lactational	O
performance	O
.	O

The	O
WCGF	O
diets	O
resulted	O
in	O
significant	O
reductions	O
in	O
the	O
concentration	O
of	O
milk	O
fat	O
(	O
3.94	O
,	O
3.74	O
,	O
and	O
4.15	O
+/-	O
0.08	O
%	O
for	O
WCGF-L	O
,	O
WCGF-DL	O
,	O
and	O
the	O
control	O
,	O
respectively	O
)	O
,	O
but	O
because	O
total	O
milk	O
yield	O
was	O
increased	O
,	O
there	O
were	O
no	O
differences	O
in	O
total	O
milk	O
fat	O
yield	O
.	O

In	O
addition	O
,	O
3.5	O
%	O
of	O
fat-corrected	O
milk	O
tended	O
to	O
be	O
affected	O
by	O
diet	O
:	O
38.9	O
,	O
36.3	O
,	O
and	O
34.7	O
+/-	O
1.93	O
kg/d	O
for	O
WCGF-L	O
,	O
WCGF-DL	O
,	O
and	O
the	O
control	O
,	O
respectively	O
.	O

The	O
increasing	O
effect	O
of	O
DM	O
intake	O
and	O
milk	O
yield	O
in	O
cows	O
consuming	O
WCGF	O
resulted	O
in	O
a	O
similar	O
efficiency	O
of	O
3.5	O
%	O
fat-corrected	O
milk	O
production	O
for	O
all	O
treatments	O
,	O
averaging	O
1.5	O
+/-	O
0.09	O
.	O

Total	O
protein	O
yields	O
were	O
significantly	O
higher	O
for	O
cows	O
consuming	O
WCGF	O
diets	O
during	O
lactation	O
:	O
1.15	O
,	O
1.10	O
,	O
1.00	O
+/-	O
0.06	O
kg/d	O
for	O
WCGF-L	O
,	O
WCGF-DL	O
,	O
and	O
the	O
control	O
,	O
respectively	O
.	O

These	O
results	O
indicate	O
that	O
diets	O
may	O
be	O
formulated	O
to	O
contain	O
as	O
much	O
as	O
37.5	O
%	O
WCGF	O
(	O
DM	O
basis	O
)	O
.	O

Benefit	O
of	O
FSH	O
priming	O
of	O
women	Sex
with	O
PCOS	Condition
to	O
the	O
in	O
vitro	O
maturation	O
procedure	O
and	O
the	O
outcome	O
:	O
a	O
randomized	O
prospective	O
study	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
rates	O
of	O
in	O
vitro	O
oocyte	O
maturation	O
,	O
fertilization	O
and	O
cleavage	O
,	O
as	O
well	O
as	O
implantation	O
rate	O
and	O
pregnancy	O
rate	O
,	O
could	O
be	O
improved	O
by	O
low-dose	O
priming	O
with	O
FSH	O
in	O
vivo	O
before	O
retrieval	O
of	O
immature	O
oocytes	O
in	O
patients	O
with	O
polycystic	Condition
ovary	Condition
syndrome	Condition
(	Condition
PCOS	Condition
)	Condition
.	Condition

From	O
March	O
1998	O
to	O
June	O
2000	O
,	O
a	O
total	O
of	O
28	SampleSize
women	Sex
underwent	O
36	O
completed	O
treatment	O
cycles	O
,	O
randomized	O
sequentially	O
in	O
one	O
of	O
two	O
groups	O
.	O

Women	O
in	O
group	O
1	O
(	O
n	O
=	O
12	O
cycles	O
)	O
received	O
no	O
stimulation	O
and	O
women	O
in	O
group	O
2	O
(	O
n	O
=	O
24	O
cycles	O
)	O
received	O
150	O
iu	O
recombinant	O
FSH	O
day	O
(	O
-1	O
)	O
for	O
3	O
days	O
,	O
initiated	O
on	O
day	O
3	O
after	O
menstruation	O
.	O

Aspiration	O
was	O
performed	O
transvaginally	O
between	O
day	O
9	O
and	O
day	O
17	O
in	O
the	O
unstimulated	O
group	O
and	O
on	O
day	O
8	O
or	O
day	O
9	O
in	O
the	O
FSH-primed	O
group	O
after	O
FSH	O
deprivation	O
for	O
2	O
or	O
3	O
days	O
.	O

All	O
cumulus-enclosed	O
oocytes	O
of	O
healthy	O
appearance	O
were	O
matured	O
in	O
culture	O
medium	O
(	O
TCM-199	O
)	O
in	O
vitro	O
for	O
28-36	O
h	O
before	O
intracytoplasmic	O
sperm	O
injection	O
(	O
ICSI	O
)	O
.	O

After	O
oocyte	O
retrieval	O
the	O
women	O
were	O
given	O
oestradiol	O
(	O
6	O
mg	O
day	O
(	O
-1	O
)	O
)	O
and	O
progesterone	O
administration	O
(	O
300	O
mg	O
day	O
(	O
-1	O
)	O
)	O
was	O
initiated	O
2	O
days	O
later	O
.	O

Suitable	O
embryos	O
(	O
maximum	O
two	O
embryos	O
)	O
were	O
transferred	O
on	O
day	O
3	O
after	O
ICSI	O
.	O

The	O
percentage	O
of	O
oocytes	O
reaching	O
metaphase	O
II	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
FSH-primed	O
group	O
(	O
59	O
%	O
,	O
92/156	O
)	O
compared	O
with	O
the	O
non-primed	O
group	O
(	O
44	O
%	O
,	O
36/81	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
rates	O
of	O
oocyte	O
fertilization	O
and	O
cleavage	O
between	O
these	O
groups	O
.	O

No	O
pregnancies	O
were	O
obtained	O
in	O
group	O
1	O
(	O
0	O
%	O
,	O
0/12	O
)	O
,	O
whereas	O
seven	O
clinical	O
pregnancies	O
were	O
obtained	O
in	O
group	O
2	O
(	O
29	O
%	O
,	O
7/24	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
group	O
2	O
,	O
37	O
embryo	O
transfers	O
resulted	O
in	O
eight	O
implantations	O
(	O
21.6	O
%	O
)	O
.	O

Three	O
healthy	O
singleton	O
children	O
have	O
been	O
born	O
at	O
term	O
;	O
the	O
remaining	O
pregnancies	O
ended	O
with	O
spontaneous	O
abortions	O
in	O
the	O
first	O
trimester	O
.	O

These	O
results	O
indicate	O
that	O
priming	O
with	O
recombinant	O
FSH	O
before	O
harvesting	O
of	O
immature	O
oocytes	O
from	O
patients	O
with	O
PCOS	Condition
may	O
improve	O
the	O
maturational	O
potential	O
of	O
the	O
oocytes	O
and	O
the	O
implantation	O
rate	O
of	O
the	O
cleaved	O
embryos	O
.	O

[	O
Management	O
of	O
the	O
perineal	O
wounds	O
after	O
abdominoperineal	O
resection	O
:	O
simple	O
drainage	O
only	O
or	O
with	O
continuous	O
irrigation	O
?	O
]	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
effects	O
of	O
presacral	O
irrigation	O
and	O
simple	O
drainage	O
on	O
the	O
perineal	O
wound	O
healing	O
in	O
patients	O
after	O
abdominoperineal	Condition
resection	Condition
(	Condition
APR	Condition
)	Condition
.	O

METHODS	O
From	O
October	O
2004	O
to	O
August	O
2009	O
,	O
patients	O
with	O
rectal	Condition
cancer	Condition
,	O
ulcerative	Condition
colitis	Condition
or	O
rectal	Condition
gastrointestinal	Condition
stromal	Condition
tumor	Condition
,	O
who	O
underwent	O
APR	O
or	O
proctocolectomy	O
,	O
were	O
randomized	O
into	O
two	O
arms	O
:	O
simple	O
drainage	O
group	O
(	O
n	O
=	O
37	O
)	O
and	O
continuous	O
irrigation	O
(	O
n	O
=	O
37	O
)	O
.	O

Patients	O
randomized	O
to	O
arm	O
B	O
received	O
simple	O
drainage	O
only	O
to	O
presacral	O
space	O
;	O
while	O
those	O
patients	O
in	O
arm	O
A	O
received	O
continuous	O
irrigation	O
in	O
addition	O
to	O
simple	O
drainage	O
.	O

Perineal	O
wound	O
healing	O
was	O
taken	O
as	O
endpoint	O
of	O
this	O
study	O
.	O

Major	O
complication	O
was	O
defined	O
as	O
wound	O
dehiscence	O
or	O
wound	O
infection	O
that	O
the	O
perineal	O
wound	O
should	O
be	O
reopened	O
for	O
drainage	O
.	O

Minor	O
complication	O
was	O
defined	O
as	O
delayed	O
healing	O
wound	O
with	O
seroma	O
or	O
hematoma	O
.	O

RESULTS	O
A	O
total	O
of	O
74	SampleSize
patients	O
were	O
enrolled	O
in	O
present	O
study	O
,	O
with	O
37	O
patients	O
in	O
each	O
arm	O
,	O
and	O
there	O
were	O
12	O
cases	O
and	O
10	O
cases	O
who	O
received	O
preoperative	O
radiation	O
therapy	O
,	O
respectively	O
.	O

In	O
the	O
arm	O
A	O
,	O
2	O
patients	O
developed	O
major	O
complications	O
,	O
3	O
patients	O
incurred	O
with	O
minor	O
complications	O
and	O
32	O
patients	O
got	O
primary	O
healing	O
of	O
the	O
perineal	O
wounds	O
.	O

In	O
arm	O
B	O
,	O
8	O
patients	O
suffered	O
major	O
complications	O
,	O
3	O
patients	O
incurred	O
with	O
minor	O
complications	O
and	O
26	O
patients	O
got	O
primary	O
healing	O
of	O
the	O
perineal	O
wounds	O
.	O

The	O
incidence	O
of	O
major	O
complication	O
was	O
significantly	O
lower	O
in	O
arm	O
A	O
(	O
5.4	O
%	O
vs.21.6	O
%	O
,	O
P	O
=	O
0.042	O
)	O
.	O

Patients	O
received	O
preoperative	O
radiation	O
therapy	O
had	O
significantly	O
higher	O
rate	O
of	O
minor	O
complications	O
than	O
patients	O
underwent	O
surgery	O
only	O
(	O
18.2	O
%	O
vs.	O
3.9	O
%	O
,	O
P	O
=	O
0.039	O
)	O
.	O

CONCLUSIONS	O
Simple	O
drainage	O
with	O
continuous	O
irrigation	O
of	O
the	O
presacral	O
space	O
,	O
in	O
patients	O
with	O
abdominoperineal	O
resection	O
or	O
proctocolectomy	O
,	O
could	O
significantly	O
lower	O
the	O
incidence	O
of	O
major	O
complication	O
and	O
improve	O
wound	O
healing	O
for	O
perineal	O
wound	O
when	O
compared	O
with	O
simple	O
drainage	O
only	O
.	O

Preoperative	O
radiation	O
therapy	O
tends	O
to	O
increase	O
the	O
incidence	O
of	O
minor	O
complications	O
.	O

Caregiver-mediated	O
intervention	O
for	O
low-resourced	O
preschoolers	Age
with	O
autism	Condition
:	O
an	O
RCT	O
.	O

OBJECTIVES	O
To	O
compare	O
2	O
short-term	O
,	O
community	O
caregiver	O
training	O
interventions	O
for	O
preschool-aged	Age
children	Age
with	O
Autism	Condition
Spectrum	Condition
Disorder	Condition
who	O
had	O
low	O
resources	O
.	O

Low	O
resource	O
was	O
defined	O
by	O
the	O
US	O
Department	O
of	O
Housing	O
and	O
Urban	O
Development	O
low-income	O
index	O
or	O
1	O
indicator	O
,	O
(	O
e.g.	O
,	O
Medicaid	O
eligibility	O
)	O
.	O

Child	O
outcomes	O
focused	O
on	O
joint	O
engagement	O
,	O
joint	O
attention	O
,	O
and	O
play	O
.	O

METHODS	O
Participants	O
included	O
112	SampleSize
families	O
of	O
a	O
child	Age
who	O
had	O
Autism	Condition
Spectrum	Condition
Disorder	Condition
who	O
met	O
criteria	O
for	O
being	O
low-resourced	O
and	O
who	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
2	O
3-month	O
interventions	O
,	O
group	O
caregiver	O
education	O
or	O
individualized	O
caregiver-mediated	O
intervention	O
(	O
CMM	O
)	O
.	O

Children	O
were	O
assessed	O
for	O
social	O
communication	O
skills	O
pre-	O
and	O
post-treatment	O
,	O
and	O
followed	O
up	O
at	O
3	O
months	O
.	O

RESULTS	O
All	O
children	O
improved	O
in	O
joint	O
engagement	O
and	O
initiating	O
joint	O
attention	O
,	O
with	O
significantly	O
greater	O
improvement	O
by	O
the	O
CMM	O
group	O
.	O

Outcomes	O
on	O
play	O
skills	O
were	O
mixed	O
,	O
with	O
improvement	O
of	O
symbolic	O
play	O
for	O
the	O
CMM	O
group	O
and	O
no	O
change	O
in	O
functional	O
play	O
skills	O
.	O

Joint	O
engagement	O
maintained	O
over	O
time	O
for	O
the	O
CMM	O
group	O
,	O
and	O
initiating	O
joint	O
attention	O
maintained	O
for	O
both	O
groups	O
over	O
time	O
.	O

CONCLUSIONS	O
This	O
study	O
is	O
among	O
the	O
first	O
randomized	O
trials	O
comparing	O
2	O
active	O
interventions	O
with	O
a	O
large	O
sample	O
of	O
low-resourced	O
families	O
.	O

Results	O
suggest	O
improvements	O
in	O
core	O
autism	O
deficits	O
of	O
joint	O
engagement	O
,	O
joint	O
attention	O
,	O
and	O
symbolic	O
play	O
with	O
relatively	O
brief	O
,	O
caregiver-mediated	O
interventions	O
,	O
but	O
additional	O
support	O
is	O
necessary	O
to	O
maintain	O
and	O
generalize	O
these	O
gains	O
over	O
time	O
.	O

EEG	O
mapping	O
and	O
psychopharmacological	O
studies	O
with	O
denbufylline	O
in	O
SDAT	Condition
and	O
MID	Condition
.	O

Computed	O
tomography	O
(	O
CT	O
)	O
,	O
electroencephalograms	O
(	O
EEG	O
)	O
,	O
clinical	O
and	O
psychometric	O
data	O
were	O
obtained	O
in	O
96	SampleSize
mildly	O
to	O
moderately	O
demented	O
patients	O
(	O
72	SampleSize
women	Sex
,	O
24	SampleSize
men	Sex
)	O
,	O
aged	O
61-96	Age
years	Age
(	O
mean	O
82	Age
)	O
,	O
diagnosed	O
according	O
to	O
DSM-III	O
criteria	O
.	O

Patients	O
were	O
off	O
drugs	O
for	O
at	O
least	O
2	O
weeks	O
and	O
subdiagnosed	O
according	O
to	O
the	O
modified	O
Marshall-Hachinski	O
ischemic	O
score	O
and	O
CT	O
in	O
45	SampleSize
senile	Condition
dementia	Condition
of	O
the	O
Alzheimer	Condition
type	Condition
(	Condition
SDAT	Condition
)	Condition
and	O
51	SampleSize
multiinfarct	Condition
dementia	Condition
(	Condition
MID	Condition
)	Condition
patients	O
.	O

Evaluations	O
were	O
carried	O
out	O
before	O
and	O
12	O
weeks	O
after	O
treatment	O
with	O
either	O
100	O
mg	O
denbufylline	O
BID	O
or	O
placebo	O
and	O
included	O
EEG	O
mapping	O
,	O
the	O
Sandoz	O
Clinical	O
Assessment	O
Geriatric	O
(	O
SCAG	O
)	O
score/factors	O
,	O
the	O
Clinical	O
Global	O
Impression	O
(	O
CGI	O
)	O
,	O
the	O
Digit	O
Symbol	O
Substitution	O
Test	O
(	O
DSST	O
)	O
,	O
the	O
Trail-Making	O
Test	O
(	O
TMT	O
)	O
and	O
the	O
Digit	O
Span	O
Test	O
(	O
DS	O
)	O
.	O

Descriptive	O
data	O
analysis	O
including	O
confirmatory	O
statements	O
found	O
delta/theta	O
activity	O
enhanced	O
,	O
alpha	O
and	O
beta	O
activity	O
reduced	O
,	O
total	O
power	O
augmented	O
,	O
and	O
the	O
centroid	O
slowed	O
down	O
over	O
various	O
brain	O
regions	O
in	O
patients	O
as	O
compared	O
with	O
controls	O
.	O

The	O
two	O
subtypes	O
of	O
dementia	O
could	O
be	O
differentiated	O
in	O
some	O
conventional	O
EEG	O
variables	O
but	O
mostly	O
by	O
means	O
of	O
power	O
asymmetry	O
indices	O
.	O

Denbufylline	O
induced	O
a	O
statistically	O
significant	O
and	O
clinically	O
relevant	O
improvement	O
in	O
both	O
SDAT	O
and	O
MID	O
patients	O
,	O
whereas	O
after	O
placebo	O
this	O
was	O
not	O
the	O
case	O
in	O
CGI	O
,	O
the	O
TMT	O
,	O
and	O
the	O
DS	O
,	O
with	O
interdrug	O
differences	O
being	O
significant	O
in	O
all	O
primary	O
target	O
variables	O
such	O
as	O
the	O
CGI	O
,	O
MMS	O
,	O
SCAG	O
,	O
and	O
DSST	O
.	O

Thus	O
,	O
both	O
the	O
degenerative	O
and	O
vascular	O
type	O
of	O
dementia	O
exhibited	O
a	O
therapeutic	O
benefit	O
that	O
could	O
be	O
objectified	O
at	O
the	O
neurophysiological	O
level	O
by	O
EEG	O
mapping	O
in	O
an	O
improvement	O
of	O
vigilance	O
.	O

Effects	O
of	O
propranolol	O
on	O
bone	O
metabolism	O
in	O
the	O
rat	O
.	O

Propranolol	O
,	O
a	O
nonspecific	O
beta-blocker	O
has	O
many	O
physiologic	O
effects	O
.	O

Its	O
effects	O
on	O
bone	O
in	O
vivo	O
are	O
unknown	O
,	O
although	O
beta	O
receptor	O
sites	O
have	O
been	O
found	O
on	O
osteoblasts	O
.	O

In	O
this	O
study	O
,	O
the	O
hypothesis	O
tested	O
was	O
that	O
low	O
doses	O
of	O
propranolol	O
could	O
alter	O
bone	O
properties	O
and	O
enhance	O
orthotopic	O
endochondral	O
bone	O
formation	O
.	O

In	O
a	O
group	O
of	O
nonsurgical	O
rats	O
,	O
propranolol	O
treatment	O
increased	O
femoral	O
torsional	O
strength	O
on	O
biomechanical	O
testing	O
.	O

In	O
the	O
rat	O
surgical	O
model	O
used	O
,	O
right	O
femora	O
were	O
fixed	O
to	O
a	O
polyethylene	O
plate	O
and	O
then	O
defects	O
were	O
created	O
mid-diaphysis	O
and	O
subsequently	O
filled	O
with	O
demineralized	O
bone	O
matrix	O
.	O

These	O
rats	O
(	O
defect	O
rats	O
)	O
were	O
randomly	O
divided	O
into	O
groups	O
that	O
were	O
given	O
propranolol	O
or	O
a	O
saline	O
carrier	O
for	O
19	O
consecutive	O
days	O
.	O

In	O
the	O
defect	O
rats	O
,	O
increased	O
trabecular	O
femoral	O
metaphyseal	O
mineral	O
apposition	O
rates	O
were	O
observed	O
in	O
propranolol-treated	O
groups	O
.	O

Densitometry	O
and	O
roentgenographic	O
scoring	O
of	O
callus	O
formation	O
after	O
12	O
weeks	O
in	O
propranolol-treated	O
rats	O
revealed	O
increased	O
callus	O
and	O
bone	O
union	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
propranolol	O
treatment	O
can	O
significantly	O
affect	O
bone	O
properties	O
.	O

Serum	O
C-peptide	O
after	O
6	O
months	O
on	O
glibenclamide	O
remains	O
higher	O
than	O
during	O
insulin	O
treatment	O
.	O

Serum	O
C-peptide	O
was	O
measured	O
fasting	O
and	O
6	O
minutes	O
after	O
glucagon	O
(	O
1	O
mg	O
given	O
intravenously	O
)	O
in	O
49	SampleSize
patients	O
with	O
non-insulin-dependent	Condition
diabetes	Condition
mellitus	Condition
,	O
after	O
4	O
and	O
6	O
months	O
of	O
successive	O
periods	O
of	O
treatment	O
with	O
insulin	O
and	O
oral	O
hypoglycaemics	O
(	O
glibenclamide	O
and	O
metformin	O
)	O
,	O
given	O
in	O
random	O
order	O
.	O

Glycaemic	O
control	O
was	O
not	O
significantly	O
different	O
on	O
the	O
two	O
treatments	O
,	O
but	O
C-peptide	O
was	O
much	O
higher	O
while	O
the	O
patients	O
were	O
on	O
glibenclamide	O
.	O

We	O
conclude	O
that	O
glibenclamide	O
stimulates	O
pancreatic	O
insulin	O
production	O
even	O
after	O
6	O
months	O
treatment	O
.	O

Chemoradiation	O
comparing	O
cisplatin	O
versus	O
carboplatin	O
in	O
locally	O
advanced	Condition
nasopharyngeal	Condition
cancer	Condition
:	O
randomised	O
,	O
non-inferiority	O
,	O
open	O
trial	O
.	O

PURPOSE	O
This	O
single	O
centre	O
,	O
open	O
labelled	O
,	O
randomised	O
non-inferiority	O
trial	O
compared	O
concurrent	O
chemoradiotherapy	O
with	O
carboplatin	O
versus	O
standard	O
concurrent	O
chemoradiotherapy	O
with	O
cisplatin	O
in	O
patients	O
with	O
locoregionally	Condition
advanced	Condition
nasopharyngeal	Condition
cancer	Condition
(	O
NPC	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
From	O
August	O
1999	O
to	O
December	O
2004	O
,	O
206	SampleSize
patients	O
with	O
locally	O
advanced	O
NPC	O
were	O
randomised	O
with	O
101	SampleSize
to	O
cisplatin	O
arm	O
and	O
105	SampleSize
to	O
carboplatin	O
arm	O
.	O

Planned	O
radiotherapy	O
was	O
the	O
same	O
in	O
both	O
groups	O
.	O

All	O
the	O
patients	O
were	O
evaluated	O
for	O
toxicity	O
and	O
survival	O
according	O
to	O
the	O
as-treated	O
principle	O
.	O

RESULTS	O
With	O
a	O
median	O
follow-up	O
of	O
26.3	O
months	O
(	O
range	O
3-74.6	O
months	O
)	O
,	O
59	O
%	O
of	O
patients	O
in	O
the	O
cisplatin	O
arm	O
completed	O
the	O
planned	O
concurrent	O
chemoradiation	O
treatment	O
,	O
compared	O
to	O
73	O
%	O
in	O
the	O
carboplatin	O
arm	O
.	O

Forty-two	O
percent	O
of	O
cisplatin	O
patients	O
completed	O
the	O
3	O
cycles	O
of	O
adjuvant	O
therapy	O
compared	O
to	O
70	O
%	O
in	O
the	O
carboplatin	O
group	O
.	O

There	O
were	O
more	O
renal	O
toxicity	O
,	O
leucopenia	O
,	O
and	O
anaemia	O
in	O
the	O
cisplatin	O
group	O
,	O
and	O
more	O
thrombocytopenia	O
in	O
the	O
carboplatin	O
arm	O
.	O

The	O
3	O
year	O
disease	O
free	O
survival	O
rates	O
were	O
63.4	O
%	O
for	O
the	O
cisplatin	O
group	O
and	O
60.9	O
%	O
for	O
the	O
carboplatin	O
group	O
(	O
p=0.9613	O
)	O
(	O
HR	O
0.70	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.50-0.98	O
)	O
.	O

The	O
3	O
year	O
overall	O
survival	O
rates	O
were	O
77.7	O
%	O
and	O
79.2	O
%	O
for	O
cisplatin	O
and	O
carboplatin	O
groups	O
,	O
respectively	O
(	O
p=0.9884	O
)	O
(	O
HR	O
0.83	O
,	O
95	O
%	O
CI	O
:	O
0.63-1.010	O
)	O
.	O

CONCLUSION	O
We	O
concluded	O
that	O
the	O
tolerability	O
of	O
carboplatin	O
based	O
regimen	O
is	O
better	O
than	O
that	O
of	O
the	O
cisplatin	O
regimen	O
.	O

Moreover	O
,	O
the	O
treatment	O
efficacy	O
of	O
carboplatin	O
arm	O
is	O
not	O
different	O
from	O
the	O
standard	O
regimen	O
in	O
the	O
treatment	O
of	O
locoregional	Condition
advanced	Condition
stage	Condition
NPC	Condition
.	O

Comparison	O
of	O
mastectomy	O
with	O
tamoxifen	O
for	O
treating	O
elderly	Age
patients	O
with	O
operable	O
breast	Condition
cancer	Condition
.	O

STUDY	O
OBJECTIVE	O
Comparison	O
of	O
tamoxifen	O
and	O
mastectomy	O
in	O
treatment	O
of	O
breast	Condition
cancer	Condition
in	O
elderly	Age
patients	O
.	O

DESIGN	O
Randomised	O
trial	O
of	O
treatment	O
of	O
operable	O
breast	O
cancer	O
by	O
wedge	O
mastectomy	O
or	O
tamoxifen	O
,	O
with	O
median	O
follow	O
up	O
24	O
and	O
25	O
months	O
respectively	O
(	O
range	O
1-63	O
)	O
.	O

SETTING	O
University	O
hospital	O
;	O
most	O
patients	O
from	O
primary	O
catchment	O
area	O
.	O

PATIENTS	O
135	SampleSize
consecutive	O
patients	O
with	O
breast	Condition
cancer	Condition
aged	O
over	O
70	Age
with	O
operable	O
tumours	Condition
(	O
less	O
than	O
5	O
cm	O
maximum	O
diameter	O
)	O
;	O
68	O
were	O
allocated	O
to	O
tamoxifen	O
group	O
and	O
67	O
to	O
mastectomy	O
group	O
.	O

Histological	O
diagnosis	O
by	O
biopsy	O
.	O

Two	O
incorrect	O
randomisations	O
in	O
each	O
group	O
.	O

Patient	O
characteristics	O
similar	O
in	O
the	O
two	O
groups	O
and	O
all	O
under	O
care	O
of	O
one	O
surgical	O
team	O
.	O

INTERVENTIONS	O
Mastectomy	O
group	O
received	O
wedge	O
mastectomy	O
plus	O
excision	O
of	O
symptomatic	O
axillary	O
lymph	O
nodes	O
.	O

Tamoxifen	O
group	O
received	O
continuous	O
treatment	O
with	O
tamoxifen	O
20	O
mg	O
twice	O
daily	O
.	O

Patients	O
in	O
tamoxifen	O
group	O
received	O
wedge	O
mastectomy	O
if	O
there	O
was	O
sign	O
of	O
local	O
progression	O
.	O

Those	O
in	O
mastectomy	O
group	O
received	O
further	O
excision	O
or	O
radiotherapy	O
for	O
locoregional	O
recurrence	O
and	O
when	O
local	O
treatments	O
had	O
been	O
exhausted	O
or	O
metastatic	O
disease	O
diagnosed	O
they	O
received	O
tamoxifen	O
.	O

END	O
POINT	O
Treatment	O
efficacy	O
was	O
assessed	O
by	O
local	O
control	O
of	O
disease	O
and	O
by	O
survival	O
.	O

MAIN	O
RESULTS	O
Mortality	O
from	O
metastatic	O
cancer	O
in	O
tamoxifen	O
group	O
was	O
7	O
(	O
10.6	O
%	O
)	O
and	O
in	O
mastectomy	O
group	O
10	O
(	O
15.3	O
%	O
)	O
(	O
NS	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
survival	O
between	O
the	O
two	O
groups	O
.	O

In	O
mastectomy	O
group	O
70	O
%	O
remained	O
alive	O
and	O
free	O
of	O
local	O
recurrence	O
at	O
24	O
months	O
;	O
in	O
tamoxifen	O
group	O
only	O
47	O
%	O
remained	O
alive	O
and	O
free	O
of	O
local	O
progression	O
.	O

In	O
mastectomy	O
group	O
locoregional	O
recurrence	O
occurred	O
in	O
16	O
patients	O
and	O
metastatic	O
disease	O
in	O
13	O
;	O
in	O
tamoxifen	O
group	O
locoregional	O
progression	O
occurred	O
in	O
29	O
patients	O
and	O
metastatic	O
disease	O
in	O
seven	O
.	O

CONCLUSIONS	O
As	O
a	O
high	O
proportion	O
of	O
patients	O
treated	O
with	O
tamoxifen	O
eventually	O
required	O
surgery	O
treatment	O
of	O
elderly	Age
patients	O
with	O
breast	Condition
cancer	Condition
should	O
include	O
mastectomy	O
.	O

Optimum	O
treatment	O
may	O
include	O
both	O
mastectomy	O
and	O
tamoxifen	O
.	O

Evaluation	O
of	O
mood	O
profiles	O
during	O
malaria	Condition
chemoprophylaxis	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
four-arm	O
study	O
.	O

BACKGROUND	O
To	O
objectively	O
compare	O
the	O
mood	O
profiles	O
of	O
users	O
of	O
malaria	Condition
chemoprophylaxis	O
regimens	O
(	O
atovaquone-proguanil	O
,	O
chloroquine-proguanil	O
,	O
doxycycline	O
,	O
or	O
mefloquine	O
)	O
in	O
a	O
group	O
of	O
nonimmune	O
tourists	O
to	O
sub-Saharan	O
Africa	O
.	O

METHODS	O
In	O
a	O
randomized	O
,	O
double-blind	O
,	O
four-arm	O
study	O
with	O
placebo	O
run-in	O
phase	O
conducted	O
at	O
travel	O
clinics	O
in	O
Switzerland	O
,	O
Germany	O
,	O
and	O
Israel	O
,	O
we	O
compared	O
moods	O
and	O
feelings	O
in	O
chemoprophylaxis	O
users	O
(	O
n=	O
547	SampleSize
)	O
by	O
administering	O
the	O
standardized	O
Profile	O
of	O
Mood	O
States	O
(	O
POMS	O
)	O
questionnaire	O
.	O

This	O
is	O
designed	O
to	O
provide	O
data	O
on	O
six	O
categories	O
of	O
feelings	O
:	O
tension	O
,	O
depression	O
,	O
anger	O
,	O
vigor	O
,	O
fatigue	O
,	O
and	O
confusion	O
.	O

The	O
questionnaire	O
was	O
administered	O
at	O
four	O
time	O
points	O
:	O
recruitment	O
(	O
T1	O
)	O
,	O
13	O
to	O
11	O
days	O
before	O
departure	O
(	O
T2	O
)	O
,	O
6	O
to	O
4	O
days	O
before	O
departure	O
(	O
T3	O
)	O
,	O
and	O
7	O
to	O
14	O
days	O
after	O
return	O
from	O
Africa	O
(	O
T4	O
)	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
with	O
respect	O
to	O
overall	O
mood	O
impact	O
between	O
the	O
medication	O
arms	O
.	O

All	O
scores	O
were	O
in	O
the	O
normal	O
range	O
,	O
and	O
no	O
means	O
were	O
more	O
than	O
1	O
SD	O
from	O
the	O
norm	O
.	O

The	O
POMS	O
data	O
were	O
reanalyzed	O
with	O
respect	O
to	O
sex	O
,	O
age	O
,	O
medication	O
group	O
,	O
and	O
control	O
time	O
points	O
(	O
T1-T4	O
)	O
.	O

There	O
were	O
significant	O
interaction	O
effects	O
between	O
sex	O
and	O
medication	O
group	O
--	O
women	O
in	O
the	O
mefloquine	O
group	O
showed	O
more	O
fatigue	O
(	O
p=	O
.011	O
)	O
and	O
confusion	O
(	O
p=	O
.011	O
)	O
than	O
men	O
.	O

Significant	O
effects	O
of	O
age	O
group	O
(	O
below	O
median	O
age	O
34	Age
y	O
vs	O
median	O
age	O
and	O
above	O
)	O
were	O
noted	O
on	O
the	O
tension	O
and	O
fatigue	O
scales	O
in	O
that	O
less	O
tension	O
(	O
p=	O
.045	O
)	O
and	O
less	O
fatigue	O
(	O
p=	O
.000	O
)	O
were	O
noted	O
in	O
those	O
aged	O
34	Age
years	O
and	O
older	O
.	O

Younger	Age
participants	O
,	O
aged	O
<	O
34	Age
years	O
,	O
reported	O
more	O
confusion	O
(	O
p=	O
.013	O
)	O
at	O
T2	O
than	O
at	O
T1	O
and	O
T4	O
.	O

CONCLUSIONS	O
Although	O
the	O
overall	O
mood	O
profiles	O
were	O
similar	O
for	O
the	O
users	O
of	O
any	O
of	O
the	O
standard	O
malaria	Condition
chemoprophylaxis	O
regimens	O
,	O
we	O
found	O
that	O
women	O
using	O
mefloquine	O
showed	O
more	O
fatigue	O
and	O
confusion	O
than	O
men	O
and	O
that	O
younger	Age
persons	O
aged	O
less	O
than	O
34	Age
years	O
,	O
regardless	O
of	O
chemoprophylaxis	O
used	O
,	O
reported	O
more	O
tension	O
and	O
fatigue	O
than	O
their	O
older	Age
counterparts	O
.	O

Zinc	O
and	O
copper	O
balances	O
in	O
preterm	Condition
infants	Age
.	O

Preterm	Condition
infants	Age
are	O
at	O
risk	O
for	O
copper	O
and	O
zinc	O
depletion	O
if	O
sufficient	O
quantities	O
of	O
these	O
nutrients	O
are	O
not	O
provided	O
in	O
a	O
bioavailable	O
form	O
in	O
postnatal	O
life	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
a	O
whey-predominant	O
,	O
50	O
%	O
medium	O
chain	O
triglyceride	O
formula	O
with	O
relatively	O
high	O
concentrations	O
of	O
zinc	O
and	O
copper	O
would	O
promote	O
the	O
achievement	O
of	O
the	O
in	O
utero	O
accretion	O
rate	O
for	O
zinc	O
and	O
copper	O
in	O
the	O
preterm	Condition
infant	Age
.	O

Two	O
groups	O
of	O
five	SampleSize
preterm	Condition
infants	Age
were	O
fed	O
a	O
diet	O
containing	O
12.5	O
mg/L	O
of	O
zinc	O
and	O
either	O
0.9	O
mg/L	O
or	O
2.1	O
mg/L	O
of	O
copper	O
.	O

Seventy-two-hour	O
metabolic	O
balance	O
studies	O
were	O
performed	O
at	O
an	O
average	O
postconceptual	O
age	O
of	O
34	O
weeks	O
and	O
an	O
average	O
weight	O
of	O
1,549	O
g.	O
All	O
infants	O
were	O
in	O
positive	O
zinc	O
balance	O
and	O
nine	O
of	O
ten	O
achieved	O
the	O
in	O
utero	O
accretion	O
rate	O
for	O
zinc	O
for	O
a	O
34-week	O
gestation	O
fetus	O
(	O
greater	O
than	O
or	O
equal	O
to	O
0.432	O
mg/d	O
)	O
.	O

Three	O
infants	O
receiving	O
the	O
high	O
copper	O
formula	O
and	O
two	O
receiving	O
the	O
lower	O
copper	O
formula	O
were	O
in	O
positive	O
copper	O
balance	O
.	O

Two	O
infants	O
from	O
each	O
group	O
achieved	O
the	O
in	O
utero	O
accretion	O
rate	O
for	O
copper	O
for	O
a	O
34-week	O
gestation	O
fetus	O
(	O
0.088	O
mg/d	O
)	O
.	O

A	O
formula	O
that	O
provides	O
12.5	O
mg/L	O
of	O
zinc	O
permits	O
positive	O
zinc	O
balance	O
and	O
zinc	O
retention	O
similar	O
to	O
in	O
utero	O
rates	O
.	O

A	O
formula	O
that	O
provides	O
as	O
much	O
as	O
2.1	O
mg/L	O
of	O
copper	O
,	O
however	O
,	O
may	O
not	O
always	O
permit	O
positive	O
copper	O
balance	O
.	O

Bupropion	O
SR	O
and	O
counseling	O
for	O
smoking	Condition
cessation	Condition
in	O
actual	O
practice	O
:	O
predictors	O
of	O
outcome	O
.	O

To	O
date	O
,	O
only	O
one	O
study	O
has	O
been	O
published	O
on	O
individual	O
characteristics	O
associated	O
with	O
outcome	O
following	O
standard	O
treatment	O
with	O
bupropion	O
SR	O
for	O
smoking	O
cessation	O
.	O

To	O
investigate	O
treatment	O
outcome	O
beyond	O
the	O
6-week	O
end-of-treatment	O
point	O
,	O
the	O
present	O
study	O
examined	O
characteristics	O
associated	O
with	O
more	O
clinically	O
relevant	O
smoking	O
endpoints	O
following	O
treatment	O
with	O
bupropion	O
SR	O
in	O
a	O
large	O
health	O
care	O
system	O
.	O

A	O
total	O
of	O
1,524	SampleSize
smokers	O
(	O
649	SampleSize
men	Sex
and	O
875	SampleSize
women	Sex
)	O
of	O
average	Age
age	Age
45.1	Age
years	Age
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
combinations	O
of	O
bupropion	O
SR	O
(	O
150	O
or	O
300	O
mg	O
)	O
and	O
behavioral	O
counseling	O
(	O
tailored	O
mailings	O
or	O
proactive	O
telephone	O
counseling	O
)	O
and	O
assessed	O
for	O
point-prevalent	O
smoking	O
status	O
at	O
3	O
and	O
12	O
months	O
.	O

Multiple	O
logistic	O
regression	O
analyses	O
of	O
potential	O
risk	O
factors	O
for	O
12-month	O
point-prevalent	O
smoking	O
and	O
for	O
persistent	O
smoking	O
(	O
point-prevalent	O
smoking	O
at	O
both	O
follow-ups	O
)	O
following	O
treatment	O
were	O
conducted	O
for	O
men	O
and	O
women	O
combined	O
and	O
separately	O
.	O

Risk	O
factors	O
for	O
smoking	O
at	O
both	O
endpoints	O
in	O
the	O
combined	O
sample	O
included	O
treatment	O
with	O
tailored	O
mailings	O
,	O
female	O
gender	O
,	O
younger	O
age	O
,	O
higher	O
levels	O
of	O
tobacco	O
dependence	O
,	O
shorter	O
previous	O
quit	O
attempts	O
,	O
previous	O
use	O
of	O
nicotine	O
replacement	O
therapy	O
,	O
and	O
report	O
of	O
current	O
depressive	O
symptoms	O
or	O
lifetime	O
depression	O
.	O

Risk	O
factors	O
for	O
smoking	O
following	O
treatment	O
identified	O
in	O
women	O
only	O
included	O
treatment	O
with	O
the	O
lower	O
dose	O
of	O
bupropion	O
SR	O
,	O
younger	O
age	O
,	O
and	O
higher	O
perceived	O
stress	O
,	O
whereas	O
those	O
that	O
were	O
unique	O
to	O
men	O
included	O
the	O
presence	O
of	O
lifetime	O
depression	O
.	O

The	O
results	O
are	O
discussed	O
in	O
terms	O
of	O
their	O
implications	O
for	O
the	O
need	O
for	O
more	O
effective	O
treatments	O
in	O
general	O
,	O
and	O
the	O
role	O
of	O
individual	O
differences	O
in	O
the	O
likelihood	O
of	O
returning	O
to	O
smoking	O
following	O
treatment	O
for	O
quitting	O
.	O

Prevention	O
of	O
venous	O
thromboembolism	O
after	O
knee	Condition
arthroplasty	Condition
.	O

A	O
randomized	O
,	O
double-blind	O
trial	O
comparing	O
enoxaparin	O
with	O
warfarin	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
effectiveness	O
and	O
safety	O
of	O
fixed-dose	O
enoxaparin	O
and	O
adjusted	O
dose	O
warfarin	O
in	O
preventing	O
venous	O
thromboembolism	O
after	Condition
knee	Condition
arthroplasty	Condition
.	O

DESIGN	O
A	O
randomized	O
,	O
double-blind	O
controlled	O
trial	O
.	O

SETTING	O
8	O
university	O
hospitals	O
.	O

PATIENTS	O
670	SampleSize
consecutive	O
patients	O
who	O
had	O
knee	Condition
arthroplasty	Condition
.	O

INTERVENTION	O
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
enoxaparin	O
(	O
30	O
mg	O
subcutaneously	O
every	O
12	O
hours	O
)	O
or	O
adjusted-dose	O
warfarin	O
(	O
international	O
normalized	O
ratio	O
,	O
2.0	O
to	O
3.0	O
)	O
.	O

Both	O
regimens	O
were	O
started	O
after	O
surgery	O
.	O

MEASUREMENTS	O
The	O
primary	O
end	O
point	O
was	O
the	O
incidence	O
of	O
deep	O
venous	O
thrombosis	O
in	O
patients	O
with	O
adequate	Condition
bilateral	Condition
venograms	Condition
;	O
the	O
secondary	O
end	O
point	O
was	O
hemorrhage	O
.	O

RESULTS	O
Among	O
the	O
417	SampleSize
patients	O
with	O
adequate	Condition
venograms	Condition
,	O
109	O
of	O
211	O
warfarin	O
recipients	O
(	O
51.7	O
%	O
)	O
had	O
deep	O
venous	O
thrombosis	O
compared	O
with	O
76	O
of	O
206	O
enoxaparin	O
recipients	O
(	O
36.9	O
%	O
)	O
(	O
P	O
=	O
0.003	O
)	O
.	O

The	O
absolute	O
risk	O
difference	O
was	O
14.8	O
%	O
in	O
favor	O
of	O
enoxaparin	O
(	O
95	O
%	O
Cl	O
,	O
5.3	O
%	O
to	O
24.1	O
%	O
)	O
Twenty-two	O
warfarin	O
recipients	O
(	O
10.4	O
%	O
)	O
and	O
24	O
enoxaparin	O
recipients	O
(	O
11.7	O
%	O
)	O
had	O
proximal	O
venous	O
thrombosis	O
(	O
P	O
>	O
0.2	O
)	O
.	O

The	O
absolute	O
risk	O
difference	O
was	O
1.2	O
%	O
in	O
favor	O
of	O
warfarin	O
(	O
Cl	O
,	O
-7.2	O
%	O
to	O
4.8	O
%	O
)	O
.	O

The	O
incidence	O
of	O
major	O
bleeding	O
was	O
1.8	O
%	O
(	O
6	O
of	O
334	O
patients	O
)	O
in	O
the	O
warfarin	O
group	O
and	O
2.1	O
%	O
(	O
7	O
of	O
336	O
patients	O
)	O
in	O
the	O
enoxaparin	O
group	O
(	O
P	O
>	O
0.2	O
)	O
.	O

The	O
absolute	O
risk	O
difference	O
was	O
0.3	O
%	O
in	O
favor	O
of	O
warfarin	O
(	O
Cl	O
,	O
-2.4	O
%	O
to	O
1.8	O
%	O
)	O
.	O

CONCLUSIONS	O
A	O
postoperative	O
,	O
fixed-dose	O
enoxaparin	O
regimen	O
is	O
more	O
effective	O
than	O
adjusted-dose	O
warfarin	O
in	O
preventing	O
deep	O
venous	O
thrombosis	O
after	Condition
knee	Condition
arthroplasty	Condition
.	O

No	O
differences	O
were	O
seen	O
in	O
the	O
incidence	O
of	O
proximal	O
venous	O
thrombosis	O
or	O
clinically	O
overt	O
hemorrhage	O
.	O

Phase	O
III	O
comparative	O
study	O
of	O
high-dose	O
cisplatin	O
versus	O
a	O
combination	O
of	O
paclitaxel	O
and	O
cisplatin	O
in	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
.	O

PURPOSE	O
New	O
effective	O
chemotherapy	O
is	O
needed	O
to	O
improve	O
the	O
outcome	O
of	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Paclitaxel	O
administered	O
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
cisplatin	O
has	O
been	O
shown	O
to	O
be	O
a	O
potentially	O
new	O
useful	O
agent	O
for	O
the	O
treatment	O
of	O
NSCLC	O
.	O

PATIENTS	O
AND	O
METHODS	O
Between	O
January	O
1995	O
and	O
April	O
1996	O
,	O
414	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	O
were	O
randomized	O
to	O
received	O
either	O
a	O
control	O
arm	O
of	O
high-dose	O
cisplatin	O
(	O
100	O
mg/m	O
(	O
2	O
)	O
)	O
or	O
a	O
combination	O
of	O
paclitaxel	O
(	O
175	O
mg/m	O
(	O
2	O
)	O
,	O
3-hour	O
infusion	O
)	O
and	O
cisplatin	O
(	O
80	O
mg/m	O
(	O
2	O
)	O
)	O
every	O
21	O
days	O
.	O

RESULTS	O
Compared	O
with	O
the	O
cisplatin-only	O
arm	O
,	O
there	O
was	O
a	O
9	O
%	O
improvement	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
%	O
to	O
19	O
%	O
)	O
in	O
overall	O
response	O
rate	O
for	O
the	O
paclitaxel/cisplatin	O
arm	O
(	O
17	O
%	O
v	O
26	O
%	O
,	O
respectively	O
;	O
P=.028	O
)	O
.	O

Median	O
time	O
to	O
progression	O
was	O
2.7	O
and	O
4.1	O
months	O
in	O
the	O
control	O
and	O
paclitaxel/cisplatin	O
arm	O
,	O
respectively	O
(	O
P=.026	O
)	O
.	O

The	O
study	O
,	O
however	O
,	O
failed	O
to	O
show	O
a	O
significant	O
improvement	O
in	O
median	O
survival	O
for	O
the	O
paclitaxel/cisplatin	O
arm	O
(	O
8.6	O
months	O
in	O
the	O
control	O
arm	O
v	O
8.1	O
months	O
in	O
the	O
paclitaxel/cisplatin	O
arm	O
,	O
P=.862	O
)	O
.	O

There	O
was	O
more	O
hematotoxicity	O
,	O
peripheral	O
neuropathy	O
,	O
and	O
arthralgia/myalgia	O
on	O
the	O
paclitaxel/cisplatin	O
arm	O
,	O
whereas	O
the	O
high-dose	O
cisplatin	O
arm	O
produced	O
more	O
ototoxicity	O
,	O
nausea	O
,	O
vomiting	O
,	O
and	O
nephrotoxicity	O
.	O

Quality	O
of	O
life	O
(	O
QOL	O
)	O
was	O
similar	O
overall	O
between	O
the	O
two	O
arms	O
.	O

CONCLUSION	O
This	O
large	O
randomized	O
phase	O
III	O
trial	O
failed	O
to	O
show	O
a	O
significant	O
improvement	O
in	O
survival	O
for	O
the	O
paclitaxel/cisplatin	O
combination	O
compared	O
with	O
high-dose	O
cisplatin	O
in	O
patients	O
with	O
advanced	O
NSCLC	O
.	O

However	O
,	O
the	O
paclitaxel/cisplatin	O
combination	O
did	O
produce	O
a	O
better	O
clinical	O
response	O
,	O
resulting	O
in	O
an	O
increased	O
time	O
to	O
progression	O
while	O
providing	O
a	O
similar	O
QOL	O
.	O

Methylphenidate	O
and/or	O
a	O
nursing	O
telephone	O
intervention	O
for	O
fatigue	O
in	O
patients	Condition
with	Condition
advanced	Condition
cancer	Condition
:	Condition
a	O
randomized	O
,	O
placebo-controlled	O
,	O
phase	O
II	O
trial	O
.	O

PURPOSE	O
Cancer-related-fatigue	O
(	O
CRF	O
)	O
is	O
common	O
in	O
advanced	O
cancer	O
.	O

The	O
primary	O
objective	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
methylphenidate	O
(	O
MP	O
)	O
with	O
those	O
of	O
placebo	O
(	O
PL	O
)	O
on	O
CRF	O
as	O
measured	O
using	O
the	O
Functional	O
Assessment	O
of	O
Chronic	O
Illness	O
Therapy-Fatigue	O
(	O
FACIT-F	O
)	O
fatigue	O
subscale	O
.	O

The	O
effect	O
of	O
a	O
combined	O
intervention	O
including	O
MP	O
plus	O
a	O
nursing	O
telephone	O
intervention	O
(	O
NTI	O
)	O
was	O
also	O
assessed	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
advanced	O
cancer	O
with	O
a	O
fatigue	O
score	O
of	O
?	O
4	O
out	O
of	O
10	O
on	O
the	O
Edmonton	O
Symptom	O
Assessment	O
Scale	O
(	O
ESAS	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
four	O
groups	O
:	O
MP+NTI	O
,	O
PL+NTI	O
,	O
MP	O
+	O
control	O
telephone	O
intervention	O
(	O
CTI	O
)	O
,	O
and	O
PL+CTI	O
.	O

Methylphenidate	O
dose	O
was	O
5	O
mg	O
every	O
2	O
hours	O
as	O
needed	O
up	O
to	O
20	O
mg	O
per	O
day	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
median	O
difference	O
in	O
FACIT-F	O
fatigue	O
at	O
day	O
15	O
.	O

Secondary	O
outcomes	O
included	O
anxiety	O
,	O
depression	O
,	O
and	O
sleep	O
.	O

RESULTS	O
One	O
hundred	O
forty-one	O
patients	O
were	O
evaluable	O
.	O

Median	O
FACIT-F	O
fatigue	O
scores	O
improved	O
from	O
baseline	O
to	O
day	O
15	O
in	O
all	O
groups	O
:	O
MP+NTI	O
(	O
median	O
score	O
,	O
4.5	O
;	O
P	O
=	O
.005	O
)	O
,	O
PL+NTI	O
(	O
median	O
score	O
,	O
8.0	O
;	O
P	O
<	O
.001	O
)	O
,	O
MP+CTI	O
(	O
median	O
score	O
,	O
7.0	O
;	O
P	O
=	O
.004	O
)	O
,	O
and	O
PL+CTI	O
(	O
median	O
score	O
,	O
5.0	O
;	O
P	O
=	O
.03	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
median	O
improvement	O
in	O
FACIT-F	O
fatigue	O
between	O
the	O
MP	O
and	O
PL	O
groups	O
(	O
5.5	O
v	O
6.0	O
,	O
respectively	O
;	O
P	O
=	O
.69	O
)	O
and	O
among	O
all	O
four	O
groups	O
(	O
P	O
=	O
.16	O
)	O
.	O

Fatigue	O
(	O
P	O
<	O
.001	O
)	O
,	O
nausea	O
(	O
P	O
=	O
.01	O
)	O
,	O
depression	O
(	O
P	O
=	O
.02	O
)	O
,	O
anxiety	O
(	O
P	O
=	O
.01	O
)	O
,	O
drowsiness	O
(	O
P	O
<	O
.001	O
)	O
,	O
appetite	O
(	O
P	O
=	O
.009	O
)	O
,	O
sleep	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
feeling	O
of	O
well-being	O
(	O
P	O
<	O
.001	O
)	O
,	O
as	O
measured	O
by	O
the	O
ESAS	O
,	O
significantly	O
improved	O
in	O
patients	O
who	O
received	O
NTI	O
.	O

Grade	O
?	O
3	O
adverse	O
events	O
did	O
not	O
differ	O
between	O
MP	O
and	O
PL	O
(	O
40	O
of	O
93	O
patients	O
v	O
29	O
of	O
97	O
patients	O
,	O
respectively	O
;	O
P	O
=	O
.06	O
)	O
.	O

CONCLUSION	O
MP	O
and	O
NTI	O
alone	O
or	O
combined	O
were	O
not	O
superior	O
to	O
placebo	O
in	O
improving	O
CRF	O
.	O

Estradiol	O
and	O
the	O
addition	O
of	O
progesterone	O
increase	O
the	O
sensitivity	O
to	O
a	O
neurosteroid	O
in	O
postmenopausal	Condition
women	Sex
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
pharmacodynamic	O
response	O
to	O
a	O
neuroactive	O
steroid	O
,	O
pregnanolone	O
,	O
before	O
and	O
during	O
different	O
hormonal	O
settings	O
of	O
postmenopausal	O
hormone	O
replacement	O
therapy	O
(	O
HRT	O
)	O
,	O
using	O
natural	O
progesterone	O
.	O

A	O
second	O
aim	O
was	O
to	O
investigate	O
whether	O
the	O
response	O
to	O
pregnanolone	O
was	O
associated	O
with	O
cyclicity	O
in	O
negative	O
mood	O
symptoms	O
during	O
treatment	O
.	O

Twenty	SampleSize
six	SampleSize
postmenopausal	Condition
women	Sex
with	O
climacteric	Condition
symptoms	Condition
were	O
administered	O
HRT	O
in	O
a	O
randomized	O
,	O
double	O
blinded	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
.	O

The	O
women	O
received	O
2	O
mg	O
oral	O
estradiol	O
(	O
E	O
(	O
2	O
)	O
)	O
continuously	O
during	O
two	O
28-day	O
cycles	O
and	O
800	O
mg	O
of	O
vaginal	O
progesterone	O
or	O
placebo	O
sequentially	O
for	O
the	O
last	O
14	O
days	O
of	O
each	O
treatment	O
cycle	O
.	O

Pharmacodynamic	O
response	O
to	O
pregnanolone	O
was	O
assessed	O
before	O
treatment	O
,	O
and	O
during	O
the	O
last	O
week	O
of	O
each	O
treatment	O
cycle	O
,	O
by	O
comparing	O
the	O
effects	O
of	O
intravenous	O
pregnanolone	O
(	O
3alpha-hydroxy-5beta-pregnan-20-one	O
)	O
on	O
saccadic	O
eye	O
velocity	O
(	O
SEV	O
)	O
,	O
saccade	O
acceleration	O
,	O
saccade	O
latency	O
and	O
self-rated	O
sedation	O
.	O

Throughout	O
the	O
study	O
daily	O
symptom	O
rating	O
scales	O
were	O
kept	O
.	O

According	O
to	O
the	O
daily	O
symptom	O
rating	O
scales	O
,	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
;	O
one	O
group	O
who	O
displayed	O
a	O
significant	O
variance	O
in	O
negative	O
mood	O
symptoms	O
during	O
HRT	O
(	O
cyclicity	O
)	O
and	O
one	O
group	O
with	O
no	O
cyclical	O
changes	O
in	O
negative	O
mood	O
symptoms	O
during	O
treatment	O
.	O

During	O
treatment	O
with	O
either	O
E	O
(	O
2	O
)	O
alone	O
or	O
E	O
(	O
2	O
)	O
+progesterone	O
the	O
response	O
in	O
saccadic	O
eye	O
movement	O
parameters	O
and	O
in	O
self-rated	O
sedation	O
to	O
pregnanolone	O
was	O
enhanced	O
compared	O
to	O
pretreatment	O
values	O
.	O

The	O
SEV	O
,	O
saccade	O
acceleration	O
and	O
sedation	O
responses	O
to	O
pregnanolone	O
was	O
also	O
increased	O
in	O
women	O
expressing	O
cyclicity	O
in	O
negative	O
mood	O
symptoms	O
compared	O
to	O
women	O
with	O
no	O
cyclical	O
changes	O
in	O
negative	O
mood	O
during	O
HRT	O
.	O

In	O
conclusion	O
,	O
during	O
treatment	O
with	O
either	O
E	O
(	O
2	O
)	O
alone	O
,	O
or	O
E	O
(	O
2	O
)	O
+progesterone	O
,	O
pregnanolone	O
sensitivity	O
was	O
increased	O
.	O

Women	O
expressing	O
cyclicity	O
in	O
negative	O
mood	O
symptoms	O
were	O
more	O
sensitive	O
to	O
pregnanolone	O
than	O
women	O
without	O
symptom	O
cyclicity	O
during	O
HRT	O
.	O

Concurrent	O
administration	O
of	O
donepezil	O
HCl	O
and	O
digoxin	O
:	O
assessment	O
of	O
pharmacokinetic	O
changes	O
.	O

AIM	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
pharmacokinetics	O
of	O
donepezil	O
HCl	O
and	O
digoxin	O
separately	O
,	O
and	O
in	O
combination	O
,	O
following	O
administration	O
of	O
single	O
oral	O
doses	O
.	O

Changes	O
in	O
cardiac	O
conduction	O
parameters	O
following	O
drug	O
administration	O
were	O
also	O
assessed	O
.	O

METHODS	O
This	O
was	O
an	O
open-label	O
,	O
randomized	O
,	O
three-period	O
crossover	O
study	O
in	O
healthy	O
male	Sex
volunteers	O
(	O
n=12	O
)	O
.	O

During	O
each	O
treatment	O
period	O
,	O
subjects	O
received	O
a	O
single	O
dose	O
of	O
either	O
donepezil	O
HCl	O
(	O
5	O
mg	O
)	O
,	O
digoxin	O
(	O
0.25	O
mg	O
)	O
,	O
or	O
a	O
combination	O
of	O
both	O
drugs	O
.	O

Each	O
treatment	O
period	O
was	O
followed	O
by	O
a	O
2-week	O
,	O
drug-free	O
washout	O
period	O
.	O

RESULTS	O
All	O
12	SampleSize
volunteers	O
completed	O
the	O
study	O
without	O
incident	O
.	O

No	O
statistically	O
significant	O
differences	O
in	O
donepezil	O
pharmacokinetics	O
(	O
Cmax	O
,	O
tmax	O
,	O
AUC	O
(	O
0-120	O
)	O
,	O
AUC	O
(	O
0-infinity	O
)	O
or	O
t1/2	O
)	O
were	O
observed	O
when	O
donepezil	O
administered	O
alone	O
was	O
compared	O
with	O
donepezil	O
administered	O
in	O
combination	O
with	O
digoxin	O
.	O

Similarly	O
,	O
no	O
statistically	O
significant	O
differences	O
in	O
digoxin	O
pharmacokinetics	O
were	O
observed	O
when	O
digoxin	O
was	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
donepezil	O
.	O

No	O
clinically	O
relevant	O
changes	O
in	O
cardiac	O
conduction	O
(	O
lead	O
II	O
ECG	O
)	O
were	O
observed	O
in	O
any	O
subject	O
during	O
any	O
treatment	O
period	O
.	O

CONCLUSIONS	O
Co-administration	O
of	O
single	O
doses	O
of	O
donepezil	O
HCl	O
(	O
5	O
mg	O
)	O
and	O
digoxin	O
(	O
0.25	O
mg	O
)	O
produced	O
no	O
changes	O
in	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	O
.	O

In	O
addition	O
,	O
co-administration	O
produced	O
no	O
changes	O
in	O
cardiac	O
conduction	O
parameters	O
during	O
the	O
24	O
h	O
of	O
telemetry	O
monitoring	O
following	O
drug	O
administration	O
.	O

Inhibition	O
of	O
epidural	O
morphine-induced	O
pruritus	O
by	O
intravenous	O
droperidol	O
.	O

The	O
effect	O
of	O
increasing	O
the	O
doses	O
of	O
morphine	O
and	O
of	O
droperidol	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Because	O
the	O
mechanism	O
of	O
inhibition	O
of	O
epidural	O
morphine-induced	O
pruritus	O
by	O
droperidol	O
is	O
not	O
clear	O
,	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effects	O
of	O
larger	O
doses	O
of	O
droperidol	O
or	O
morphine	O
,	O
or	O
both	O
.	O

METHODS	O
A	O
double-blind	O
study	O
was	O
performed	O
in	O
210	SampleSize
ASA	O
I	O
or	O
II	O
patients	O
undergoing	O
cesarean	O
delivery	O
,	O
who	O
were	O
randomly	O
assigned	O
to	O
six	O
groups	O
.	O

All	O
patients	O
received	O
epidural	O
anesthesia	O
with	O
0.5	O
%	O
bupivacaine	O
containing	O
1:200,000	O
epinephrine	O
,	O
to	O
which	O
2	O
mg	O
(	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
or	O
4	O
mg	O
(	O
groups	O
4	O
,	O
5	O
,	O
and	O
6	O
)	O
morphine	O
sulfate	O
was	O
added	O
.	O

Just	O
after	O
delivery	O
,	O
2.5	O
mg	O
droperidol	O
was	O
given	O
intravenously	O
to	O
groups	O
2	O
and	O
5	O
,	O
and	O
5	O
mg	O
was	O
given	O
to	O
groups	O
3	O
and	O
6	O
.	O

During	O
the	O
postoperative	O
period	O
,	O
the	O
patients	O
were	O
assessed	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
pruritus	O
(	O
classified	O
as	O
absent	O
,	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
)	O
or	O
other	O
untoward	O
symptoms	O
.	O

The	O
groups	O
were	O
compared	O
for	O
the	O
incidence	O
of	O
pruritus	O
by	O
the	O
Mann-Whitney	O
nonparametric	O
test	O
.	O

RESULTS	O
The	O
incidence	O
of	O
pruritus	O
was	O
significantly	O
reduced	O
only	O
when	O
the	O
control	O
group	O
.	O

(	O
no	O
droperidol	O
)	O
was	O
compared	O
with	O
the	O
group	O
that	O
received	O
2.5	O
mg	O
droperidol	O
,	O
both	O
when	O
2	O
mg	O
and	O
when	O
4	O
mg	O
morphine	O
was	O
used	O
.	O

A	O
5-mg	O
dose	O
of	O
droperidol	O
had	O
no	O
inhibitory	O
effect	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
incidence	O
of	O
pruritus	O
between	O
use	O
of	O
2	O
mg	O
and	O
4	O
mg	O
morphine	O
.	O

Other	O
untoward	O
effects	O
of	O
morphine	O
either	O
could	O
not	O
be	O
observed	O
or	O
occurred	O
with	O
an	O
incidence	O
unaffected	O
by	O
either	O
dose	O
of	O
droperidol	O
.	O

CONCLUSION	O
Pruritus	O
caused	O
by	O
epidural	O
use	O
of	O
2	O
or	O
4	O
mg	O
of	O
morphine	O
is	O
inhibited	O
by	O
the	O
intravenous	O
use	O
of	O
2.5	O
mg	O
droperidol	O
but	O
not	O
by	O
a	O
larger	O
dose	O
.	O

Is	O
periprostatic	O
local	O
anesthesia	O
for	O
transrectal	Condition
ultrasound	Condition
guided	Condition
prostate	Condition
biopsy	Condition
associated	O
with	O
increased	O
infectious	O
or	O
hemorrhagic	O
complications	O
?	O
A	O
prospective	O
randomized	O
trial	O
.	O

PURPOSE	O
Periprostatic	O
local	O
anesthesia	O
for	O
prostate	O
biopsy	O
requires	O
2	O
or	O
more	O
extra	O
needle	O
punctures	O
and	O
injection	O
of	O
the	O
local	O
anesthetic	O
through	O
the	O
highly	O
colonized	O
rectum	O
.	O

To	O
our	O
knowledge	O
we	O
report	O
the	O
first	O
prospective	O
randomized	O
trial	O
to	O
assess	O
the	O
infectious	O
or	O
hemorrhagic	O
complications	O
associated	O
with	O
this	O
method	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
of	O
100	SampleSize
consecutive	O
patients	O
with	O
sterile	Condition
urine	Condition
cultures	Condition
underwent	O
transrectal	Condition
ultrasound	Condition
guided	Condition
prostate	Condition
biopsy	Condition
.	O

They	O
were	O
randomized	O
to	O
receive	O
a	O
periprostatic	O
nerve	O
block	O
or	O
no	O
anesthesia	O
.	O

Patients	O
were	O
evaluated	O
for	O
the	O
amount	O
of	O
rectal	O
and	O
urethral	O
bleeding	O
,	O
and	O
symptoms	O
and	O
signs	O
of	O
infection	O
after	O
biopsy	O
.	O

RESULTS	O
The	O
amount	O
of	O
urethral	O
bleeding	O
was	O
slight	O
and	O
similar	O
in	O
the	O
2	O
groups	O
.	O

Rectal	O
bleeding	O
was	O
significantly	O
less	O
in	O
the	O
patients	O
who	O
received	O
anesthesia	O
.	O

High	O
fever	O
(	O
greater	O
than	O
37.8C	O
)	O
was	O
more	O
frequent	O
in	O
the	O
nerve	O
block	O
group	O
and	O
2	O
patients	O
in	O
this	O
group	O
required	O
rehospitalization	O
.	O

Bacteriuria	O
in	O
post-biopsy	O
urine	O
cultures	O
was	O
significantly	O
more	O
common	O
in	O
the	O
anesthesia	O
group	O
.	O

CONCLUSIONS	O
Our	O
results	O
suggest	O
that	O
periprostatic	O
local	O
anesthesia	O
for	O
prostate	O
biopsy	O
does	O
not	O
increase	O
the	O
risk	O
of	O
urethral	O
bleeding	O
.	O

It	O
is	O
associated	O
with	O
a	O
decreased	O
incidence	O
of	O
rectal	O
bleeding	O
,	O
presumably	O
due	O
to	O
decreased	O
patient	O
discomfort	O
.	O

The	O
incidence	O
of	O
bacteriuria	O
was	O
significantly	O
higher	O
in	O
the	O
anesthesia	O
group	O
.	O

High	O
fever	O
and	O
hospitalization	O
due	O
to	O
infectious	O
complications	O
were	O
also	O
more	O
common	O
in	O
the	O
local	O
anesthesia	O
group	O
,	O
although	O
not	O
statistically	O
significant	O
.	O

Prospective	O
randomized	O
trials	O
seem	O
warranted	O
to	O
determine	O
the	O
optimum	O
antibiotic	O
prophylaxis	O
regimen	O
in	O
patients	O
undergoing	O
biopsy	O
with	O
a	O
periprostatic	O
nerve	O
block	O
.	O

Treatment	O
of	O
gastrointestinal	Condition
cancer	Condition
:	Condition
the	O
Southeastern	O
Cancer	O
Study	O
Group	O
experience	O
,	O
1979	O
to	O
1983	O
.	O

The	O
treatment	O
of	O
gastrointestinal	O
cancer	O
was	O
studied	O
in	O
20	O
phase	O
I	O
,	O
II	O
,	O
and	O
III	O
clinical	O
trials	O
from	O
1979	O
to	O
1983	O
at	O
30	O
member	O
institutions	O
of	O
the	O
Southeastern	O
Cancer	O
Study	O
Group	O
(	O
SECSG	O
)	O
.	O

These	O
studies	O
used	O
both	O
new	O
and	O
commercially	O
available	O
drugs	O
,	O
as	O
well	O
as	O
surgery	O
and/or	O
radiation	O
therapy	O
in	O
1,087	O
patients	O
.	O

No	O
significant	O
benefit	O
was	O
seen	O
from	O
18	O
agents	O
,	O
and	O
one	O
agent	O
is	O
still	O
under	O
evaluation	O
.	O

Unfortunately	O
,	O
no	O
recommendations	O
can	O
be	O
drawn	O
from	O
these	O
studies	O
that	O
would	O
alter	O
presently	O
accepted	O
methods	O
of	O
management	O
.	O

Adenocarcinoma	O
of	O
the	O
gastrointestinal	O
tract	O
remains	O
a	O
major	O
challenge	O
to	O
tumor	O
biologists	O
and	O
clinical	O
oncologists	O
because	O
it	O
is	O
generally	O
resistant	O
to	O
chemotherapy	O
and	O
radiation	O
therapy	O
,	O
yet	O
common	O
enough	O
to	O
represent	O
a	O
vital	O
public	O
health	O
concern	O
in	O
America	O
.	O

Effect	O
of	O
exercise	O
,	O
training	O
,	O
and	O
glycogen	O
availability	O
on	O
IL-6	O
receptor	O
expression	O
in	O
human	O
skeletal	O
muscle	O
.	O

The	O
cytokine	O
interleukin-6	O
(	O
IL-6	O
)	O
exerts	O
it	O
actions	O
via	O
the	O
IL-6	O
receptor	O
(	O
IL-6R	O
)	O
in	O
conjunction	O
with	O
the	O
ubiquitously	O
expressed	O
gp130	O
receptor	O
.	O

IL-6	O
is	O
tightly	O
regulated	O
in	O
response	O
to	O
exercise	O
,	O
being	O
affected	O
by	O
factors	O
such	O
as	O
exercise	O
intensity	O
and	O
duration	O
,	O
as	O
well	O
as	O
energy	O
availability	O
.	O

Although	O
the	O
IL-6	O
response	O
to	O
exercise	O
has	O
been	O
extensively	O
studied	O
,	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
the	O
IL-6R	O
response	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
exercise	O
,	O
training	O
,	O
and	O
glycogen	O
availability	O
,	O
factors	O
known	O
to	O
affect	O
IL-6	O
,	O
on	O
the	O
regulation	O
of	O
gene	O
expression	O
of	O
the	O
IL-6R	O
in	O
human	O
skeletal	O
muscle	O
.	O

Human	O
subjects	O
performed	O
either	O
10	O
wk	O
of	O
training	O
with	O
an	O
acute	O
exercise	O
bout	O
before	O
and	O
after	O
the	O
training	O
period	O
,	O
or	O
a	O
low-glycogen	O
vs.	O
normal-glycogen	O
acute	O
exercise	O
trial	O
.	O

The	O
IL-6R	O
mRNA	O
response	O
was	O
evaluated	O
in	O
both	O
trials	O
.	O

In	O
response	O
to	O
acute	O
exercise	O
,	O
an	O
increase	O
in	O
IL-6R	O
mRNA	O
levels	O
was	O
observed	O
.	O

Neither	O
training	O
nor	O
intramuscular	O
glycogen	O
levels	O
had	O
an	O
effect	O
on	O
the	O
IL-6R	O
mRNA	O
response	O
to	O
exercise	O
.	O

However	O
,	O
after	O
10	O
wk	O
of	O
training	O
,	O
the	O
skeletal	O
muscle	O
expressed	O
a	O
higher	O
mRNA	O
level	O
of	O
IL-6R	O
compared	O
with	O
before	O
training	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
the	O
IL-6R	O
gene	O
expression	O
levels	O
in	O
skeletal	O
muscle	O
are	O
increased	O
in	O
response	O
to	O
acute	O
exercise	O
,	O
a	O
response	O
that	O
is	O
very	O
well	O
conserved	O
,	O
being	O
affected	O
by	O
neither	O
training	O
status	O
nor	O
intramuscular	O
glycogen	O
levels	O
,	O
as	O
opposed	O
to	O
IL-6	O
.	O

However	O
,	O
after	O
the	O
training	O
period	O
,	O
IL-6R	O
mRNA	O
production	O
was	O
increased	O
in	O
skeletal	O
muscle	O
,	O
suggesting	O
a	O
sensitization	O
of	O
skeletal	O
muscle	O
to	O
IL-6	O
at	O
rest	O
.	O

5-Fluorouracil	O
,	O
adriamycin	O
,	O
cyclophosphamide	O
(	O
FAC	O
)	O
vs.	O
5-fluorouracil	O
,	O
epirubicin	O
,	O
cyclophosphamide	O
(	O
FEC	O
)	O
in	O
metastatic	O
breast	O
cancer	O
.	O

94	O
evaluable	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
were	O
randomly	O
assigned	O
to	O
5-fluorouracil	O
,	O
adriamycin	O
,	O
and	O
cyclophosphamide	O
(	O
FAC	O
)	O
or	O
5-fluorouracil	O
,	O
epirubicin	O
,	O
and	O
cyclophosphamide	O
(	O
FEC	O
)	O
,	O
with	O
cycles	O
repeated	O
every	O
3	O
weeks	O
.	O

The	O
objective	O
response	O
rate	O
to	O
FAC	O
was	O
46	O
%	O
versus	O
44	O
%	O
to	O
FEC	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
median	O
duration	O
of	O
response	O
and	O
median	O
survival	O
for	O
the	O
two	O
regimens	O
.	O

Toxicity	O
was	O
more	O
frequent	O
and	O
more	O
pronounced	O
in	O
patients	O
receiving	O
FAC	O
.	O

Results	O
indicate	O
therapeutic	O
equivalence	O
of	O
the	O
two	O
regimens	O
and	O
reduced	O
toxicity	O
of	O
the	O
epirubicin	O
arm	O
.	O

Effects	O
of	O
topical	O
boswellic	O
acid	O
on	O
photo	O
and	O
age-damaged	O
skin	O
:	O
clinical	O
,	O
biophysical	O
,	O
and	O
echographic	O
evaluations	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
split-face	O
study	O
.	O

Boswellic	O
acids	O
(	O
BAs	O
)	O
are	O
pentacyclic	O
triterpenes	O
with	O
strong	O
anti-inflammatory	O
activity	O
;	O
their	O
most	O
important	O
source	O
is	O
the	O
extract	O
of	O
the	O
gum	O
resin	O
of	O
Boswellia	O
serrata	O
,	O
a	O
tropical	O
tree	O
that	O
grows	O
in	O
India	O
and	O
Africa	O
.	O

In	O
the	O
present	O
randomized	O
,	O
double-blind	O
,	O
split-face	O
,	O
comparative	O
study	O
we	O
have	O
assessed	O
efficacy	O
,	O
tolerability	O
,	O
and	O
safety	O
of	O
a	O
base	O
cream	O
containing	O
0.5	O
%	O
BAs	O
as	O
compared	O
to	O
the	O
same	O
cream	O
without	O
these	O
active	O
ingredients	O
in	O
the	O
treatment	O
of	O
clinical	O
manifestations	O
of	O
photoaging	O
of	O
facial	O
skin	O
.	O

Fifteen	O
female	O
volunteers	O
were	O
enrolled	O
;	O
they	O
applied	O
creams	O
once	O
daily	O
for	O
30	O
days	O
.	O

At	O
baseline	O
,	O
at	O
the	O
end	O
of	O
the	O
treatment	O
,	O
and	O
after	O
a	O
2-month	O
follow-up	O
,	O
clinical	O
findings	O
were	O
assessed	O
according	O
to	O
the	O
Dover	O
classification	O
scale	O
for	O
photoaging	O
and	O
by	O
biophysical	O
and	O
ecographic	O
measurements	O
.	O

We	O
registered	O
a	O
significant	O
improvement	O
of	O
tactile	O
roughness	O
and	O
fine	O
lines	O
in	O
the	O
half	O
side	O
of	O
the	O
face	O
treated	O
with	O
BAs	O
;	O
noninvasive	O
instrumental	O
diagnostic	O
investigations	O
showed	O
an	O
improvement	O
of	O
elasticity	O
,	O
a	O
decrease	O
of	O
sebum	O
excretion	O
,	O
and	O
a	O
change	O
of	O
echographic	O
parameters	O
suggesting	O
a	O
reshaping	O
of	O
dermal	O
tissue	O
.	O

The	O
treatment	O
was	O
always	O
well	O
tolerated	O
without	O
adverse	O
effects	O
.	O

The	O
present	O
findings	O
seem	O
to	O
indicate	O
that	O
the	O
topical	O
application	O
of	O
BAs	O
may	O
represent	O
a	O
suitable	O
treatment	O
option	O
for	O
selected	O
features	O
of	O
skin	O
photoaging	O
.	O

Randomised	O
clinical	O
trial	O
:	O
efficacy	O
of	O
a	O
new	O
synbiotic	O
formulation	O
containing	O
Lactobacillus	O
paracasei	O
B21060	O
plus	O
arabinogalactan	O
and	O
xilooligosaccharides	O
in	O
children	O
with	O
acute	Condition
diarrhoea	Condition
.	O

BACKGROUND	O
Acute	O
diarrhoea	O
is	O
a	O
frequent	O
problem	O
in	O
children	O
with	O
heavy	O
economic	O
burden	O
for	O
families	O
and	O
society	O
.	O

AIM	O
To	O
test	O
the	O
efficacy	O
of	O
a	O
new	O
synbiotic	O
formulation	O
containing	O
Lactobacillus	O
paracasei	O
B21060	O
,	O
arabinogalactan	O
and	O
xilooligosaccharides	O
in	O
children	O
with	O
acute	Condition
diarrhoea	Condition
.	O

METHODS	O
Double-blind	O
,	O
randomised	O
,	O
placebo-controlled	O
trial	O
,	O
including	O
children	O
(	O
age	Age
3-36	Age
m	Age
)	O
with	O
acute	O
diarrhoea	O
who	O
were	O
allocated	O
to	O
placebo	O
or	O
synbiotic	O
group	O
.	O

Major	O
outcome	O
was	O
resolution	O
rate	O
of	O
diarrhoea	O
at	O
72	O
h.	O
Total	O
duration	O
of	O
diarrhoea	O
,	O
daily	O
stool	O
outputs	O
,	O
stool	O
consistency	O
,	O
working	O
days	O
lost	O
by	O
parents	O
,	O
adjunctive	O
medications	O
,	O
and	O
hospitalisation	O
were	O
also	O
assessed	O
.	O

RESULTS	O
We	O
enrolled	O
55	SampleSize
children	O
in	O
placebo	O
group	O
and	O
52	SampleSize
in	O
synbiotic	O
group	O
.	O

The	O
two	O
groups	O
were	O
similar	O
for	O
demographic	O
and	O
clinical	O
characteristics	O
.	O

Resolution	O
rate	O
of	O
diarrhoea	O
at	O
72	O
h	O
was	O
significantly	O
higher	O
in	O
synbiotic	O
group	O
(	O
67	O
%	O
)	O
compared	O
to	O
placebo	O
group	O
(	O
40	O
%	O
,	O
P	O
=	O
0.005	O
)	O
.	O

Children	O
in	O
synbiotic	O
group	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
duration	O
of	O
diarrhoea	O
(	O
90.5	O
h	O
,	O
78.1-102.9	O
vs.	O
109.8	O
h	O
,	O
96.0-123.5	O
,	O
P	O
=	O
0.040	O
)	O
,	O
daily	O
stool	O
outputs	O
(	O
3.3	O
,	O
2.8-3.8	O
vs.	O
2.4	O
,	O
1.9-2.8	O
,	O
P	O
=	O
0.005	O
)	O
and	O
stool	O
consistency	O
(	O
1.3	O
,	O
0.9-1.6	O
vs.	O
0.6	O
,	O
0.4-0.9	O
,	O
P	O
=	O
0.002	O
)	O
compared	O
to	O
placebo	O
group	O
(	O
data	O
expressed	O
as	O
mean	O
,	O
95	O
%	O
CI	O
)	O
.	O

Rate	O
of	O
parents	O
that	O
missed	O
at	O
least	O
one	O
working	O
day	O
(	O
41.8	O
%	O
vs.	O
15.4	O
%	O
,	O
P	O
=	O
0.003	O
)	O
,	O
rate	O
of	O
children	O
that	O
needed	O
adjunctive	O
medications	O
(	O
25.5	O
%	O
vs.	O
5.8	O
%	O
,	O
P	O
=	O
0.005	O
)	O
or	O
hospitalisation	O
(	O
10.9	O
%	O
vs.	O
0	O
%	O
,	O
P	O
=	O
0.014	O
)	O
after	O
the	O
first	O
72	O
h	O
of	O
treatment	O
,	O
were	O
reduced	O
in	O
synbiotic	O
group	O
.	O

CONCLUSION	O
The	O
synbiotic	O
formulation	O
studied	O
is	O
effective	O
in	O
children	O
with	O
acute	O
diarrhoea	O
.	O

Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
(	O
ACTRN12611000641998	O
)	O
.	O

Randomized	O
evaluation	O
of	O
octreotide	O
vs	O
prochlorperazine	O
for	O
ED	O
treatment	O
of	O
migraine	O
headache	O
.	O

UNLABELLED	O
Patients	O
with	O
headaches	O
account	O
for	O
approximately	O
2	O
%	O
of	O
all	O
ED	O
visits	O
,	O
with	O
migraines	O
being	O
the	O
most	O
common	O
defined	O
primary	O
headache	O
syndrome	O
.	O

Our	O
goals	O
were	O
to	O
evaluate	O
the	O
efficacy	O
of	O
intravenous	O
octreotide	O
(	O
OC	O
)	O
for	O
the	O
treatment	O
of	O
migraines	O
,	O
when	O
compared	O
to	O
standard	O
therapy	O
with	O
prochlorperazine	O
.	O

METHODS	O
The	O
study	O
was	O
conducted	O
as	O
a	O
double-blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O

Each	O
subject	O
received	O
either	O
100	O
microg	O
of	O
octreotide	O
or	O
10	O
mg	O
of	O
prochlorperazine	O
intravenously	O
for	O
a	O
2-minute	O
period	O
.	O

RESULTS	O
Comparison	O
of	O
the	O
change	O
in	O
median	O
visual	O
analog	O
scale	O
scores	O
for	O
60	O
minutes	O
demonstrated	O
that	O
octreotide	O
was	O
less	O
effective	O
at	O
reducing	O
pain	O
(	O
P	O
=	O
.03	O
)	O
and	O
producing	O
clinical	O
success	O
(	O
P	O
<	O
.01	O
)	O
.	O

Restlessness	O
consistent	O
with	O
akathisia	O
was	O
noted	O
by	O
35	O
%	O
of	O
the	O
PC	O
group	O
and	O
8	O
%	O
of	O
the	O
OC	O
group	O
(	O
P	O
<	O
.01	O
)	O
.	O

At	O
60	O
minutes	O
,	O
rescue	O
medication	O
was	O
required	O
by	O
48	O
%	O
of	O
the	O
patients	O
in	O
the	O
OC	O
group	O
,	O
whereas	O
10	O
%	O
of	O
the	O
PC	O
group	O
required	O
such	O
therapy	O
(	O
P	O
<	O
.01	O
)	O
.	O

All	O
44	O
patients	O
were	O
contacted	O
for	O
follow-up	O
at	O
48	O
to	O
72	O
hours	O
after	O
enrollment	O
.	O

At	O
that	O
time	O
,	O
10	O
%	O
of	O
the	O
prochlorperazine	O
and	O
25	O
%	O
of	O
the	O
octreotide	O
patients	O
had	O
experienced	O
some	O
headache	O
recurrence	O
(	O
P	O
=	O
.1	O
)	O
.	O

CONCLUSION	O
Prochlorperazine	O
was	O
statistically	O
superior	O
to	O
octreotide	O
in	O
clinical	O
success	O
rate	O
and	O
decrease	O
in	O
pain	O
in	O
migraine	O
patients	O
but	O
caused	O
more	O
restlessness	O
and	O
sedation	O
.	O

Development	O
of	O
the	O
WAIS-III	O
general	O
ability	O
index	O
estimate	O
(	O
GAI-E	O
)	O
.	O

The	O
WAIS-III	O
General	O
Ability	O
Index	O
(	O
GAI	O
;	O
Tulsky	O
,	O
Saklofske	O
,	O
Wilkins	O
,	O
&	O
Weiss	O
,	O
2001	O
)	O
is	O
a	O
recently	O
developed	O
,	O
6-subtest	O
measure	O
of	O
global	O
intellectual	O
functioning	O
.	O

However	O
,	O
clinical	O
use	O
of	O
the	O
GAI	O
is	O
currently	O
limited	O
by	O
the	O
absence	O
of	O
a	O
method	O
to	O
estimate	O
premorbid	O
functioning	O
as	O
measured	O
by	O
this	O
index	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
regression	O
equations	O
to	O
estimate	O
GAI	O
scores	O
from	O
demographic	O
variables	O
and	O
WAIS-III	O
subtest	O
performance	O
.	O

Participants	O
consisted	O
of	O
those	O
subjects	O
in	O
the	O
WAIS-III	O
standardization	O
sample	O
that	O
has	O
complete	O
demographic	O
data	O
(	O
N=2,401	O
)	O
and	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

The	O
first	O
group	O
(	O
n=1,200	O
)	O
was	O
used	O
to	O
develop	O
the	O
formulas	O
(	O
i.e.	O
,	O
Development	O
group	O
)	O
and	O
the	O
second	O
(	O
n=1,201	O
)	O
group	O
was	O
used	O
to	O
validate	O
the	O
prediction	O
algorithms	O
(	O
i.e.	O
,	O
Validation	O
group	O
)	O
.	O

Demographic	O
variables	O
included	O
age	O
,	O
education	O
,	O
ethnicity	O
,	O
gender	O
and	O
region	O
of	O
country	O
.	O

Subtest	O
variables	O
included	O
vocabulary	O
,	O
information	O
,	O
picture	O
completion	O
,	O
and	O
matrix	O
reasoning	O
raw	O
scores	O
.	O

Ten	O
regression	O
algorithms	O
were	O
generated	O
designed	O
to	O
estimate	O
GAI	O
.	O

The	O
GAI-Estimate	O
(	O
GAI-E	O
)	O
algorithms	O
accounted	O
for	O
58	O
%	O
to	O
82	O
%	O
of	O
the	O
variance	O
.	O

The	O
standard	O
error	O
of	O
estimate	O
ranged	O
from	O
6.44	O
to	O
9.57	O
.	O

The	O
correlations	O
between	O
actual	O
and	O
estimated	O
GAI	O
ranged	O
from	O
r=.76	O
to	O
r=.90	O
.	O

These	O
algorithms	O
provided	O
accurate	O
estimates	O
of	O
GAI	O
in	O
the	O
WAIS-III	O
standardization	O
sample	O
.	O

Implications	O
for	O
estimating	O
GAI	O
in	O
patients	O
with	O
known	O
or	O
suspected	O
neurological	O
dysfunction	O
is	O
discussed	O
and	O
future	O
research	O
is	O
proposed	O
.	O

Treatment	O
of	O
Wilms	Condition
'	Condition
tumor	Condition
.	Condition

Results	O
of	O
the	O
Third	O
National	O
Wilms	Condition
'	Condition
Tumor	Condition
Study	O
.	O

The	O
Third	O
National	O
Wilms	O
'	O
Tumor	O
Study	O
sought	O
to	O
reduce	O
treatment	O
for	O
low-risk	O
patients	O
and	O
find	O
better	O
chemotherapy	O
for	O
those	O
at	O
high	O
risk	O
for	O
relapse	O
.	O

Eligible	O
patients	O
(	O
1439	SampleSize
)	O
were	O
randomized	O
according	O
to	O
stage	O
(	O
I-IV	O
)	O
and	O
histology	O
(	O
favorable	O
[	O
FH	O
]	O
or	O
unfavorable	O
[	O
UH	O
]	O
)	O
,	O
and	O
contributed	O
data	O
to	O
survival	O
and	O
relapse-free	O
survival	O
(	O
RFS	O
)	O
analyses	O
.	O

Four-year	O
(	O
postnephrectomy	O
)	O
survival	O
percentages	O
and	O
randomized	O
treatment	O
regimens	O
for	O
low-risk	O
patients	O
were	O
96.5	O
%	O
for	O
607	O
Stage	O
I/FH	O
patients	O
who	O
received	O
dactinomycin	O
(	O
Actinomycin	O
D	O
[	O
AMD	O
]	O
,	O
Merck	O
Sharp	O
&	O
Dohme	O
,	O
West	O
Point	O
,	O
PA	O
)	O
and	O
vincristine	O
(	O
VCR	O
)	O
for	O
10	O
weeks	O
versus	O
6	O
months	O
;	O
92.2	O
%	O
for	O
278	O
Stage	O
II/FH	O
patients	O
;	O
and	O
86.9	O
%	O
for	O
275	O
Stage	O
III/FH	O
patients	O
who	O
received	O
AMD	O
+	O
VCR	O
+/-	O
Adriamycin	O
(	O
ADR	O
,	O
Adria	O
Laboratories	O
,	O
Columbus	O
,	O
OH	O
)	O
for	O
15	O
months	O
.	O

Stage	O
II/FH	O
patients	O
also	O
had	O
either	O
zero	O
or	O
2000	O
cGy	O
irradiation	O
(	O
RT	O
)	O
postoperatively	O
and	O
Stage	O
III/FH	O
patients	O
either	O
1000	O
or	O
2000	O
cGy	O
.	O

Four-year	O
survival	O
was	O
73.0	O
%	O
for	O
279	O
high-risk	O
patients	O
(	O
any	O
Stage	O
IV	O
,	O
all	O
UH	O
)	O
who	O
received	O
postoperative	O
radiation	O
therapy	O
(	O
RT	O
)	O
and	O
AMD	O
+	O
VCR	O
+	O
ADR	O
+/-	O
cyclophosphamide	O
(	O
CPM	O
)	O
.	O

Statistical	O
analysis	O
of	O
survival	O
and	O
RFS	O
experience	O
shows	O
that	O
the	O
less	O
intensive	O
therapy	O
does	O
not	O
worsen	O
results	O
for	O
low-risk	O
patients	O
and	O
CPM	O
does	O
not	O
benefit	O
those	O
at	O
high	O
risk	O
.	O

Low-intensity	O
exercise	O
and	O
reduction	O
of	O
the	O
risk	O
for	O
falls	O
among	O
at-risk	O
elders	O
.	O

BACKGROUND	O
Among	O
elderly	O
persons	O
,	O
falls	O
account	O
for	O
87	O
%	O
of	O
all	O
fractures	O
and	O
are	O
contributing	O
factors	O
in	O
many	O
nursing	O
home	O
admissions	O
.	O

This	O
study	O
evaluated	O
the	O
effect	O
of	O
an	O
easily	O
implemented	O
,	O
low-intensity	O
exercise	O
program	O
on	O
the	O
incidence	O
of	O
falls	O
and	O
the	O
time	O
to	O
first	O
fall	O
among	O
a	O
clinically	O
defined	O
population	O
of	O
elderly	O
men	O
and	O
women	O
.	O

METHODS	O
This	O
community-based	O
,	O
randomized	O
trial	O
compared	O
the	O
exercise	O
intervention	O
with	O
a	O
no-intervention	O
control	O
.	O

The	O
participants	O
were	O
294	O
men	O
and	O
women	O
,	O
aged	O
60	O
years	O
or	O
older	O
,	O
who	O
had	O
either	O
a	O
hospital	O
admission	O
or	O
bed	O
rest	O
for	O
2	O
days	O
or	O
more	O
within	O
the	O
previous	O
month	O
.	O

Exercise	O
participants	O
were	O
scheduled	O
to	O
attend	O
exercise	O
sessions	O
lasting	O
45	O
minutes	O
,	O
including	O
warm-up	O
and	O
cool-down	O
,	O
3	O
times	O
a	O
week	O
for	O
8	O
weeks	O
(	O
24	O
sessions	O
)	O
.	O

Assessments	O
included	O
gait	O
and	O
balance	O
measures	O
,	O
self-reported	O
physical	O
function	O
,	O
the	O
number	O
of	O
medications	O
being	O
taking	O
at	O
baseline	O
,	O
participant	O
age	O
,	O
sex	O
,	O
and	O
history	O
of	O
falling	O
.	O

Falls	O
were	O
tracked	O
for	O
1	O
year	O
after	O
each	O
participant	O
's	O
baseline	O
assessment	O
.	O

RESULTS	O
29	O
%	O
of	O
the	O
study	O
participants	O
reported	O
a	O
fall	O
during	O
the	O
study	O
period	O
.	O

The	O
effect	O
of	O
exercise	O
in	O
preventing	O
falls	O
varied	O
significantly	O
by	O
baseline	O
physical	O
function	O
level	O
(	O
p	O
<	O
or	O
=.002	O
)	O
.	O

The	O
risk	O
for	O
falls	O
decreased	O
for	O
exercise	O
participants	O
with	O
low	O
baseline	O
physical	O
functioning	O
(	O
hazard	O
ratio	O
,	O
.51	O
)	O
but	O
increased	O
for	O
exercise	O
participants	O
with	O
high	O
baseline	O
physical	O
functioning	O
(	O
hazard	O
ratio	O
,	O
3.51	O
)	O
.	O

CONCLUSIONS	O
This	O
easily	O
implemented	O
,	O
low-intensity	O
exercise	O
program	O
appears	O
to	O
reduce	O
the	O
risk	O
for	O
falls	O
among	O
elderly	O
men	O
and	O
women	O
recovering	O
from	O
recent	O
hospitalizations	O
,	O
bed	O
rest	O
,	O
or	O
both	O
who	O
have	O
low	O
levels	O
of	O
physical	O
functioning	O
.	O

The	O
influence	O
of	O
pre-	O
and	O
intraoperative	O
positioning	O
of	O
the	O
condyle	O
in	O
the	O
centre	O
of	O
the	O
articular	O
fossa	O
on	O
the	O
position	O
of	O
the	O
disc	O
in	O
orthognathic	Condition
surgery	O
.	O

A	O
magnetic	O
resonance	O
study	O
.	O

OBJECTIVE	O
We	O
investigated	O
the	O
changes	O
in	O
the	O
temporomandibular	Condition
joint	Condition
(	Condition
TMJ	Condition
)	Condition
after	O
bilateral	Condition
sagittal	Condition
split	Condition
osteotomy	Condition
of	O
the	O
mandible	O
for	O
orthognathic	Condition
surgery	O
and	O
the	O
influence	O
of	O
positioning	O
of	O
the	O
condylar	O
process	O
in	O
the	O
centre	O
of	O
the	O
articular	O
fossa	O
before	O
and	O
during	O
the	O
operation	O
for	O
preventing	O
changes	O
in	O
the	O
TMJ	O
postoperatively	O
.	O

STUDY	O
DESIGN	O
A	O
total	O
of	O
28	SampleSize
patients	O
with	O
mandibular	Condition
retrognathism	Condition
had	O
bilateral	Condition
sagittal	Condition
split	Condition
osteotomies	Condition
for	O
mandibular	O
advancement	O
.	O

In	O
one	O
group	O
of	O
14	SampleSize
patients	O
(	O
28	SampleSize
TMJ	Condition
)	O
,	O
the	O
condyles	O
were	O
placed	O
in	O
the	O
centre	O
of	O
the	O
articular	O
fossa	O
before	O
and	O
during	O
the	O
operation	O
,	O
and	O
in	O
the	O
other	O
group	O
they	O
were	O
not	O
.	O

Differences	O
on	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
calculated	O
and	O
the	O
results	O
were	O
evaluated	O
.	O

RESULTS	O
The	O
main	O
differences	O
were	O
found	O
at	O
maximal	O
mouth	O
opening	O
.	O

15/28	SampleSize
TMJs	Condition
(	O
54	O
%	O
)	O
that	O
had	O
not	O
been	O
positioned	O
changed	O
the	O
position	O
of	O
the	O
disc	O
from	O
physiological	O
to	O
anterior	O
disc	O
derangement	O
with	O
and	O
without	O
reduction	O
postoperatively	O
.	O

In	O
the	O
28	SampleSize
that	O
had	O
been	O
positioned	O
,	O
changes	O
were	O
found	O
in	O
only	O
3	SampleSize
TMJs	Condition
(	O
11	O
%	O
)	O
postoperatively	O
.	O

CONCLUSIONS	O
Fixing	O
the	O
condylar	O
process	O
in	O
the	O
centre	O
of	O
the	O
articular	O
fossa	O
intraoperatively	O
before	O
bilateral	O
sagittal	O
split	O
osteotomy	O
is	O
a	O
factor	O
in	O
preventing	O
postoperative	O
structural	O
changes	O
in	O
the	O
temporomandibular	O
joint	O
.	O

Absence	O
of	O
cervical	O
radiation	O
myelitis	O
after	O
hyperfractionated	O
radiation	O
therapy	O
with	O
and	O
without	O
concurrent	O
chemotherapy	O
for	O
locally	Condition
advanced	Condition
,	Condition
unresectable	Condition
,	Condition
nonmetastatic	Condition
squamous	Condition
cell	Condition
carcinoma	Condition
of	Condition
the	Condition
head	Condition
and	Condition
neck	Condition
.	Condition

PURPOSE	O
To	O
evaluate	O
the	O
risk	O
of	O
developing	O
radiation	O
myelitis	O
after	O
a	O
cervical	O
spinal	O
cord	O
dose	O
of	O
50.6	O
Gy	O
given	O
via	O
1.1	O
Gy	O
b.i.d	O
.	O

fractionation	O
during	O
a	O
prospective	O
,	O
randomised	O
trial	O
of	O
hyperfractionated	O
radiation	O
therapy	O
(	O
HFX	O
RT	O
)	O
to	O
a	O
total	O
dose	O
of	O
77	O
Gy	O
given	O
in	O
70	O
fractions	O
of	O
1.1	O
Gy	O
b.i.d.	O
,	O
with	O
and	O
without	O
concurrent	O
low-dose	O
,	O
daily	O
cisplatin	O
(	O
CDDP	O
)	O
for	O
head	Condition
and	Condition
neck	Condition
cancer	Condition
.	O

METHODS	O
Of	O
130	SampleSize
patients	O
with	O
locally	O
advanced	O
,	O
unresectable	O
,	O
nonmetastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
(	O
SCC	O
H	O
&	O
N	O
)	O
who	O
entered	O
a	O
prospective	O
,	O
randomised	O
trial	O
,	O
101	O
patients	O
received	O
50.6	O
Gy	O
to	O
a	O
portion	O
of	O
their	O
spinal	O
cord	O
and	O
survived	O
>	O
1	O
year	O
following	O
the	O
beginning	O
of	O
therapy	O
.	O

Forty-five	O
patients	O
were	O
treated	O
with	O
HFX	O
RT	O
alone	O
and	O
fifty-six	O
patients	O
also	O
received	O
CDDP	O
.	O

RESULTS	O
None	O
of	O
these	O
101	O
patients	O
developed	O
cervical	O
radiation	O
myelitis	O
.	O

Therefore	O
,	O
it	O
was	O
not	O
possible	O
to	O
investigate	O
the	O
influence	O
of	O
potentially	O
contributing	O
factors	O
on	O
the	O
occurrence	O
of	O
radiation	O
myelitis	O
,	O
such	O
as	O
interfraction	O
interval	O
,	O
cord	O
length	O
,	O
and	O
administration	O
of	O
concurrent	O
CDDP	O
.	O

CONCLUSIONS	O
Given	O
the	O
increasing	O
number	O
of	O
studies	O
with	O
both	O
altered	O
fractionated	O
regimens	O
and	O
concurrent	O
radio-chemotherapy	O
in	O
SCC	O
H	O
&	O
N	O
,	O
new	O
studies	O
with	O
more	O
patients	O
are	O
needed	O
to	O
gain	O
better	O
insight	O
into	O
the	O
risks	O
of	O
developing	O
cervical	O
radiation	O
myelitis	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
as	O
adjunct	O
therapy	O
in	O
relapsed	O
Hodgkin	O
disease	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
clinical	O
and	O
economic	O
effects	O
of	O
granulocyte	O
macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
as	O
adjunct	O
therapy	O
in	O
relapsed	O
or	O
refractory	O
Hodgkin	O
disease	O
.	O

DESIGN	O
A	O
randomized	O
,	O
double-blind	O
,	O
phase	O
III	O
clinical	O
trial	O
.	O

SETTING	O
A	O
tertiary	O
referral	O
center	O
.	O

PATIENTS	O
Twenty-four	O
patients	O
(	O
twelve	O
of	O
whom	O
were	O
controls	O
)	O
treated	O
with	O
high-dose	O
chemotherapy	O
and	O
autologous	O
bone	O
marrow	O
transplantation	O
.	O

MAIN	O
RESULTS	O
The	O
12	O
patients	O
treated	O
with	O
GM-CSF	O
,	O
when	O
compared	O
with	O
placebo	O
recipients	O
,	O
had	O
shorter	O
periods	O
of	O
neutropenia	O
(	O
median	O
duration	O
of	O
an	O
absolute	O
neutrophil	O
count	O
of	O
less	O
than	O
1000	O
cells/mm3	O
,	O
16	O
days	O
compared	O
with	O
27	O
days	O
;	O
P	O
=	O
0.02	O
)	O
,	O
shorter	O
periods	O
of	O
platelet-transfusion	O
dependency	O
(	O
median	O
duration	O
,	O
13.5	O
days	O
compared	O
with	O
21	O
days	O
;	O
P	O
=	O
0.03	O
)	O
,	O
and	O
shorter	O
hospitalizations	O
(	O
median	O
hospital	O
stay	O
,	O
32	O
days	O
compared	O
with	O
40.5	O
days	O
;	O
P	O
=	O
0.004	O
)	O
.	O

Other	O
clinical	O
outcomes	O
,	O
such	O
as	O
frequency	O
and	O
severity	O
of	O
toxicities	O
,	O
development	O
of	O
pneumonia	O
or	O
infection	O
,	O
in-hospital	O
death	O
,	O
and	O
response	O
rate	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Actuarial	O
long-term	O
disease-free	O
survival	O
was	O
64	O
%	O
for	O
patients	O
treated	O
with	O
GM-CSF	O
and	O
58	O
%	O
for	O
patients	O
who	O
received	O
placebo	O
after	O
32	O
months	O
of	O
follow-up	O
(	O
P	O
=	O
0.15	O
)	O
.	O

The	O
group	O
treated	O
with	O
GM-CSF	O
had	O
lower	O
total	O
charges	O
after	O
infusion	O
of	O
autologous	O
marrow	O
than	O
the	O
placebo	O
group	O
(	O
median	O
in-hospital	O
charges	O
,	O
$	O
39,800	O
compared	O
with	O
$	O
62,500	O
;	O
P	O
=	O
0.005	O
)	O
because	O
of	O
lower	O
post-infusion	O
charges	O
for	O
room	O
and	O
board	O
,	O
antibiotic	O
therapy	O
,	O
transfusions	O
,	O
laboratory	O
tests	O
,	O
and	O
physical	O
therapy	O
visits	O
.	O

CONCLUSIONS	O
Administration	O
of	O
GM-CSF	O
was	O
associated	O
with	O
acceleration	O
of	O
myeloid	O
and	O
platelet	O
recovery	O
and	O
was	O
cost	O
effective	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
relapsed	O
Hodgkin	O
disease	O
who	O
received	O
intensive	O
chemotherapy	O
.	O

Acute	O
intervention	O
studies	O
in	O
patients	Condition
with	Condition
myocardial	Condition
infarction	Condition
using	O
atenolol	O
,	O
propranolol	O
,	O
oxprenolol	O
and	O
disopyramide	O
phosphate	O
.	O

The	O
value	O
of	O
beta-blockade	O
and	O
of	O
disopyramide	O
phosphate	O
in	O
the	O
immediate	O
treatment	O
of	O
patients	O
with	O
suspected	O
acute	O
myocardial	O
infarction	O
was	O
assessed	O
in	O
two	O
placebo	O
controlled	O
trials	O
.	O

In	O
the	O
first	O
study	O
388	O
patients	O
with	O
suspected	O
acute	O
myocardial	O
infarction	O
were	O
randomly	O
allocated	O
to	O
treatment	O
with	O
propranolol	O
,	O
atenolol	O
,	O
or	O
placebo	O
,	O
and	O
when	O
analysed	O
on	O
an	O
initial	O
intention	O
to	O
treat	O
basis	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
three	O
groups	O
in	O
respect	O
of	O
the	O
mortality	O
at	O
one	O
year	O
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
evidence	O
to	O
suggest	O
that	O
either	O
atenolol	O
,	O
or	O
propranolol	O
reduced	O
the	O
incidence	O
of	O
'serious	O
'	O
ventricular	O
arrhythmias	O
in	O
the	O
coronary	O
care	O
unit	O
.	O

In	O
the	O
second	O
study	O
473	O
patients	O
with	O
suspected	O
acute	O
myocardial	O
infarction	O
were	O
randomly	O
allocated	O
to	O
treatment	O
with	O
oxprenolol	O
,	O
disopyramide	O
phosphate	O
,	O
or	O
placebo	O
.	O

Again	O
no	O
significant	O
differences	O
were	O
seen	O
with	O
respect	O
to	O
the	O
mortality	O
at	O
six	O
weeks	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significantly	O
increased	O
incidence	O
of	O
heart	O
failure	O
in	O
the	O
group	O
which	O
received	O
disopyramide	O
phosphate	O
.	O

Patients	Condition
who	O
received	O
this	O
drug	O
also	O
showed	O
a	O
reduced	O
number	O
of	O
dysrhythmic	O
episodes	O
on	O
24-hour	O
ECG	O
recordings	O
,	O
but	O
this	O
trend	O
did	O
not	O
achieve	O
statistical	O
significance	O
.	O

These	O
results	O
suggest	O
that	O
none	O
of	O
the	O
three	O
beta-blockers	O
tested	O
nor	O
disopyramide	O
phosphate	O
is	O
likely	O
to	O
reduce	O
the	O
mortality	O
from	O
acute	O
myocardial	O
infarction	O
when	O
given	O
prophylactically	O
,	O
although	O
disopyramide	O
phosphate	O
does	O
reduce	O
the	O
incidence	O
of	O
'serious	O
'	O
ventriicular	O
arrhythmias	O
.	O

A	O
randomized	O
comparison	O
of	O
tamoxifen	O
with	O
surgical	O
oophorectomy	O
in	O
premenopausal	Condition
patients	O
with	O
advanced	Condition
breast	Condition
cancer	Condition
.	O

We	O
randomized	O
122	SampleSize
premenopausal	Condition
women	Sex
to	O
receive	O
tamoxifen	O
or	O
to	O
undergo	O
a	O
surgical	O
oophorectomy	O
.	O

Of	O
54	SampleSize
evaluable	O
women	Sex
treated	O
with	O
tamoxifen	O
,	O
24	O
%	O
had	O
an	O
objective	O
response	O
,	O
as	O
compared	O
with	O
21	O
%	O
of	O
53	SampleSize
women	Sex
having	O
an	O
oophorectomy	O
.	O

The	O
median	O
duration	O
of	O
response	O
for	O
tamoxifen	O
(	O
20	O
months	O
)	O
was	O
longer	O
than	O
that	O
for	O
surgical	O
oophorectomy	O
(	O
7	O
months	O
)	O
,	O
but	O
this	O
did	O
not	O
achieve	O
statistical	O
significance	O
(	O
P	O
=	O
.056	O
)	O
.	O

Overall	O
median	O
survival	O
was	O
15	O
months	O
for	O
58	SampleSize
patients	O
receiving	O
tamoxifen	O
and	O
25	O
months	O
for	O
53	O
patients	O
undergoing	O
oophorectomy	O
(	O
P	O
=	O
.18	O
)	O
.	O

Toxicity	O
was	O
greater	O
in	O
those	O
undergoing	O
oophorectomy	O
,	O
though	O
both	O
treatments	O
were	O
well	O
tolerated	O
.	O

In	O
those	O
premenopausal	Condition
women	Sex
for	O
whom	O
hormonal	O
therapy	O
is	O
indicated	O
,	O
tamoxifen	O
is	O
a	O
suitable	O
alternative	O
to	O
surgical	O
oophorectomy	O
.	O

Gradual	O
withdrawal	O
of	O
diazepam	O
after	O
long-term	O
therapy	O
.	O

41	SampleSize
outpatients	O
who	O
were	O
long-term	O
consumers	O
of	O
diazepam	O
in	O
therapeutic	O
dosage	O
were	O
gradually	O
withdrawn	O
from	O
the	O
drug	Condition
over	O
3	O
months	O
by	O
stepwise	O
reduction	O
.	O

In	O
a	O
double-blind	O
procedure	O
half	O
the	O
patients	O
began	O
withdrawal	O
immediately	O
and	O
half	O
after	O
8	O
weeks	O
.	O

Of	O
36	SampleSize
patients	O
who	O
completed	O
treatment	O
,	O
16	O
(	O
44.4	O
%	O
)	O
experienced	O
true	O
withdrawal	O
phenomena	O
on	O
reducing	O
their	O
drugs	O
,	O
but	O
8	O
other	O
patients	O
had	O
pseudo-withdrawal	O
reactions	O
at	O
a	O
time	O
when	O
their	O
drug	O
treatment	O
was	O
unchanged	O
.	O

The	O
pseudo-withdrawal	O
reactions	O
consisted	O
of	O
an	O
increase	O
in	O
anxiety	O
symptoms	O
only	O
,	O
whereas	O
true	O
withdrawal	O
symptoms	O
also	O
included	O
perceptual	O
changes	O
and	O
psychotic	O
symptoms	O
.	O

Examination	O
of	O
pharmacological	O
and	O
clinical	O
predictors	O
of	O
withdrawal	O
phenomena	O
and	O
later	O
relapse	O
showed	O
that	O
personality	O
factors	O
were	O
the	O
most	O
important	O
,	O
patients	O
with	O
passive-dependent	O
traits	O
having	O
a	O
significantly	O
greater	O
prevalence	O
of	O
withdrawal	O
reactions	O
.	O

Safety	O
and	O
tolerability	O
of	O
cold-adapted	O
influenza	O
vaccine	O
,	O
trivalent	O
,	O
in	O
infants	Age
younger	Age
than	Age
6	Age
months	Age
of	Age
age	Age
.	O

OBJECTIVE	O
Young	Age
children	Age
are	O
at	O
high	O
risk	O
for	O
influenza-related	O
complications	O
.	O

Vaccination	O
of	O
close	O
household	O
contacts	O
is	O
recommended	O
to	O
provide	O
indirect	O
protection	O
to	O
children	Age
<	Age
6	Age
months	Age
of	Age
age	Age
.	O

Studies	O
have	O
shown	O
that	O
live	O
,	O
cold-adapted	O
influenza	O
vaccine	O
,	O
trivalent	O
,	O
is	O
efficacious	O
in	O
children	O
.	O

To	O
assess	O
the	O
risks	O
associated	O
with	O
inadvertent	O
exposure	O
of	O
infants	O
to	O
vaccine	O
viruses	O
from	O
vaccinated	O
contacts	O
,	O
this	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
cold-adapted	O
influenza	O
vaccine	O
,	O
trivalent	O
,	O
administered	O
intranasally	O
to	O
healthy	Condition
children	Age
6	Age
to	Age
<	Age
24	Age
weeks	Age
of	Age
age	Age
.	O

METHODS	O
Healthy	Condition
infants	Age
aged	Age
6	Age
to	Age
<	Age
16	Age
weeks	Age
and	Age
16	Age
to	Age
<	Age
24	Age
weeks	Age
,	O
respectively	O
,	O
were	O
randomly	O
assigned	O
to	O
receive	O
2	O
doses	O
of	O
influenza	O
vaccine	O
,	O
or	O
placebo	O
intranasally	O
35	O
+/-	O
7	O
days	O
apart	O
.	O

Reactogenicity	O
events	O
were	O
monitored	O
for	O
11	O
days	O
after	O
each	O
dose	O
.	O

Other	O
adverse	O
events	O
were	O
monitored	O
through	O
28	O
to	O
35	O
days	O
after	O
dose	O
2	O
.	O

RESULTS	O
Of	O
the	O
infants	O
aged	O
6	Age
to	Age
<	Age
16	Age
weeks	Age
,	O
31	O
received	O
influenza	O
vaccine	O
and	O
28	O
received	O
placebo	O
,	O
and	O
of	O
those	O
aged	O
16	Age
to	Age
<	Age
24	Age
weeks	Age
,	O
30	O
received	O
influenza	O
vaccine	O
and	O
31	O
received	O
placebo	O
.	O

In	O
the	O
6-	O
to	O
<	O
16-week	O
cohort	O
,	O
more	O
influenza	O
vaccine	O
,	O
recipients	O
experienced	O
irritability	O
(	O
66.7	O
%	O
vs	O
35.7	O
%	O
)	O
and	O
runny	O
nose	O
or	O
nasal	O
congestion	O
(	O
63.3	O
%	O
vs	O
33.3	O
%	O
)	O
after	O
dose	O
1	O
but	O
not	O
dose	O
2	O
.	O

There	O
were	O
no	O
significant	O
increases	O
in	O
any	O
other	O
reactogenicity	O
events	O
or	O
adverse	O
events	O
in	O
the	O
vaccine	O
recipients	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

CONCLUSIONS	O
Although	O
there	O
was	O
an	O
increase	O
in	O
mild	O
reactogenicity	O
events	O
in	O
children	O
6	Age
to	Age
<	Age
16	Age
weeks	Age
of	O
age	O
,	O
cold-adapted	O
influenza	O
vaccine	O
,	O
trivalent	O
,	O
was	O
generally	O
well	O
tolerated	O
in	O
infants	O
6	Age
to	Age
<	Age
24	Age
weeks	Age
of	O
age	O
.	O

These	O
findings	O
support	O
further	O
evaluation	O
of	O
cold-adapted	O
influenza	O
vaccine	O
,	O
trivalent	O
,	O
in	O
infants	O
<	O
6	Age
months	Age
of	O
age	O
.	O

Mending	O
the	O
rhythm	O
does	O
not	O
improve	O
prognosis	O
in	O
patients	O
with	O
persistent	Condition
atrial	Condition
fibrillation	Condition
:	O
a	O
subanalysis	O
of	O
the	O
RACE	O
study	O
.	O

AIMS	O
To	O
compare	O
outcome	O
of	O
AF	Condition
patients	O
with	O
effective	O
rhythm	O
control	O
with	O
patients	O
treated	O
with	O
rate	O
control	O
.	O

METHODS	O
AND	O
RESULTS	O
Out	O
of	O
the	O
266	SampleSize
AF	O
patients	O
randomized	O
to	O
rhythm	O
control	O
in	O
the	O
RACE	O
study	O
,	O
49	SampleSize
patients	O
turned	O
to	O
long-term	O
sinus	O
rhythm	O
and	O
were	O
continuously	O
treated	O
with	O
oral	O
anticoagulation	O
.	O

The	O
incidence	O
of	O
the	O
primary	O
endpoint	O
in	O
these	O
patients	O
was	O
compared	O
to	O
that	O
in	O
178	O
patients	O
out	O
of	O
the	O
initial	O
256	SampleSize
rate-control	O
patients	O
of	O
RACE	O
who	O
were	O
in	O
AF	O
and	O
using	O
oral	O
anticoagulation	O
continuously	O
.	O

Baseline	O
characteristics	O
of	O
both	O
groups	O
were	O
not	O
different	O
.	O

After	O
a	O
mean	O
follow-up	O
of	O
2.3+/-0.6	O
years	O
,	O
the	O
primary	O
endpoint	O
(	O
a	O
composite	O
of	O
cardiovascular	O
mortality	O
,	O
heart	O
failure	O
,	O
thrombo-embolic	O
complications	O
(	O
TECs	O
)	O
,	O
bleeding	O
,	O
serious	O
adverse	O
effects	O
of	O
antiarrhythmic	O
drugs	O
and	O
pacemaker	O
implants	O
)	O
was	O
22.4	O
%	O
in	O
the	O
rhythm-control	O
group	O
vs.	O
15.2	O
%	O
in	O
the	O
rate-control	O
group	O
.	O

Multivariable	O
regression	O
analysis	O
indicated	O
coronary	O
artery	O
disease	O
,	O
heart	O
failure	O
,	O
and	O
digitalis	O
as	O
independent	O
risk	O
indicators	O
of	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O

Chronic	O
sinus	O
rhythm	O
did	O
not	O
matter	O
.	O

CONCLUSION	O
Among	O
patients	O
who	O
remained	O
on	O
warfarin	O
,	O
those	O
who	O
mostly	O
were	O
maintained	O
in	O
sinus	O
rhythm	O
under	O
a	O
rhythm-control	O
strategy	O
did	O
not	O
have	O
a	O
superior	O
prognosis	O
compared	O
to	O
those	O
who	O
remained	O
in	O
AF	O
under	O
a	O
rate-control	O
strategy	O
.	O

The	O
effect	O
of	O
patient	O
position	O
on	O
the	O
reproducibility	O
of	O
cardiac	O
output	O
measurements	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
effect	O
of	O
patient	O
position	O
on	O
the	O
reproducibility	O
of	O
cardiac	O
output	O
measurements	O
.	O

DESIGN	O
Prospective	O
,	O
two-group	O
quasi-experimental	O
design	O
.	O

Convenience	O
sample	O
.	O

SETTING	O
The	O
study	O
involved	O
two	O
intensive	O
care	O
units	O
in	O
two	O
adult	O
acute	O
care	O
hospitals	O
.	O

PATIENTS	O
Thirty	SampleSize
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
who	O
had	O
a	O
thermodilution	O
pulmonary	O
artery	O
catheter	O
in	O
place	O
.	O

Ages	O
ranged	O
from	O
39	Age
to	Age
80	Age
years	O
(	O
mean	O
of	O
66.4	O
+/-	O
11.3	O
years	O
)	O
.	O

OUTCOME	O
MEASURES	O
Thermodilution	O
cardiac	O
output	O
measurements	O
.	O

INTERVENTION	O
The	O
subjects	O
were	O
placed	O
in	O
one	O
of	O
two	O
groups	O
,	O
initially	O
by	O
flipping	O
a	O
coin	O
then	O
into	O
alternate	O
groups	O
.	O

Group	O
A	O
subjects	O
were	O
placed	O
supine	O
,	O
and	O
after	O
5	O
minutes	O
had	O
cardiac	O
output	O
measurements	O
performed	O
.	O

They	O
were	O
then	O
placed	O
in	O
the	O
45-degree	O
upright	O
position	O
,	O
and	O
after	O
an	O
additional	O
5	O
minutes	O
had	O
cardiac	O
output	O
measurements	O
performed	O
.	O

Group	O
B	O
subjects	O
were	O
first	O
placed	O
in	O
the	O
45-degree	O
upright	O
position	O
,	O
and	O
after	O
5	O
minutes	O
had	O
cardiac	O
output	O
measurements	O
performed	O
.	O

They	O
were	O
then	O
placed	O
in	O
the	O
supine	O
flat	O
position	O
,	O
and	O
after	O
an	O
additional	O
5	O
minutes	O
had	O
cardiac	O
output	O
measurements	O
performed	O
.	O

RESULTS	O
Seventy	O
percent	O
(	O
n	O
=	O
30	O
)	O
of	O
the	O
sample	O
population	O
displayed	O
a	O
lower	O
cardiac	O
output	O
in	O
the	O
45-degree	O
upright	O
position	O
than	O
that	O
obtained	O
in	O
the	O
supine	O
position	O
,	O
with	O
the	O
decrease	O
ranging	O
from	O
1	O
%	O
to	O
32	O
%	O
(	O
mean	O
decrease	O
11	O
%	O
)	O
.	O

Forty	O
percent	O
(	O
n	O
=	O
30	O
)	O
of	O
cardiac	O
output	O
measurements	O
obtained	O
in	O
the	O
45-degree	O
upright	O
were	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
less	O
than	O
those	O
obtained	O
in	O
the	O
supine	O
flat	O
position	O
.	O

The	O
differences	O
in	O
cardiac	O
output	O
were	O
analyzed	O
with	O
the	O
paired	O
t	O
test	O
.	O

which	O
produced	O
a	O
95	O
%	O
confidence	O
interval	O
from	O
-0.539	O
to	O
-0.083	O
.	O

The	O
two-group	O
Wilcoxon	O
test	O
was	O
used	O
to	O
analyze	O
the	O
mean	O
cardiac	O
output	O
with	O
the	O
patient	O
in	O
the	O
supine	O
,	O
flat	O
position	O
and	O
in	O
the	O
45-degree	O
upright	O
position	O
.	O

The	O
mean	O
cardiac	O
output	O
at	O
0	O
degrees	O
was	O
found	O
to	O
be	O
statistically	O
significant	O
higher	O
(	O
p	O
=	O
0.0083	O
)	O
than	O
the	O
mean	O
cardiac	O
output	O
at	O
45	O
degrees	O
.	O

The	O
effect	O
of	O
coexisting	O
variables	O
was	O
analyzed	O
with	O
the	O
Kruskal-Wallis	O
.	O

The	O
use	O
of	O
vasoconstrictors	O
was	O
the	O
only	O
variable	O
that	O
had	O
a	O
statistically	O
significant	O
change	O
in	O
cardiac	O
output	O
associated	O
with	O
a	O
change	O
in	O
position	O
.	O

CONCLUSIONS	O
These	O
results	O
indicate	O
that	O
cardiac	O
output	O
measurements	O
are	O
affected	O
by	O
alterations	O
in	O
patient	O
position	O
.	O

To	O
ensure	O
accurate	O
comparisons	O
between	O
consecutive	O
cardiac	O
output	O
measurements	O
,	O
the	O
researchers	O
recommend	O
that	O
the	O
position	O
in	O
which	O
the	O
cardiac	O
output	O
measurements	O
are	O
performed	O
be	O
documented	O
and	O
the	O
cardiac	O
output	O
measurements	O
be	O
conducted	O
in	O
a	O
uniform	O
position	O
.	O

Vilazodone	O
lacks	O
proarrhythmogenic	O
potential	O
in	O
healthy	O
participants	O
:	O
a	O
thorough	O
ECG	O
study	O
.	O

OBJECTIVE	O
Vilazodone	O
is	O
a	O
potent	O
serotonin	O
reuptake	O
inhibitor	O
and	O
5-HT1A	O
receptor	O
partial	O
agonist	O
approved	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adults	O
.	O

The	O
effect	O
of	O
clinical	O
and	O
supratherapeutic	O
doses	O
of	O
vilazodone	O
on	O
cardiac	O
repolarization	O
was	O
determined	O
in	O
healthy	O
volunteers	O
.	O

METHODS	O
In	O
this	O
Phase	O
1	O
,	O
randomized	O
,	O
doubleblind	O
,	O
placebo-	O
and	O
active-controlled	O
,	O
3-arm	O
,	O
parallel	O
,	O
single-center	O
study	O
,	O
healthy	O
subjects	O
received	O
placebo	O
;	O
moxifloxacin	O
400	O
mg	O
;	O
or	O
vilazodone	O
(	O
sequentially	O
escalated	O
every	O
3	O
days	O
)	O
10	O
,	O
20	O
,	O
40	O
,	O
60	O
,	O
and	O
80	O
mg/day	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
time-matched	O
change	O
from	O
baseline	O
in	O
the	O
QT	O
interval	O
corrected	O
for	O
heart	O
rate	O
(	O
QTc	O
)	O
using	O
an	O
individual	O
correction	O
method	O
(	O
QTcI	O
)	O
.	O

RESULTS	O
Placebo-corrected	O
time-matched	O
analysis	O
of	O
the	O
QTcI	O
duration	O
for	O
the	O
vilazodone	O
treatment	O
effect	O
indicated	O
that	O
no	O
vilazodone	O
dose	O
had	O
an	O
upper	O
bound	O
that	O
approached	O
or	O
exceeded	O
10	O
ms	O
,	O
demonstrating	O
no	O
signal	O
for	O
a	O
significant	O
vilazodone	O
effect	O
on	O
cardiac	O
repolarization	O
.	O

Vilazodone	O
had	O
no	O
significant	O
effect	O
on	O
heart	O
rate	O
,	O
PR	O
,	O
or	O
QRS	O
interval	O
duration	O
.	O

The	O
pharmacokinetic/pharmacodynamic	O
model	O
showed	O
that	O
the	O
QTcI	O
slope	O
for	O
vilazodone	O
was	O
not	O
different	O
from	O
0.0	O
and	O
that	O
the	O
predicted	O
increase	O
from	O
baseline	O
in	O
the	O
QTc	O
at	O
Cmax	O
for	O
the	O
highest	O
therapeutic	O
dose	O
(	O
156	O
ng/ml	O
after	O
40	O
mg/day	O
)	O
was	O
<	O
1	O
ms	O
.	O

The	O
incidence	O
of	O
adverse	O
events	O
(	O
AEs	O
)	O
was	O
higher	O
in	O
the	O
vilazodone	O
group	O
(	O
57.6	O
%	O
)	O
than	O
in	O
the	O
moxifloxacin	O
(	O
37.0	O
%	O
)	O
and	O
placebo	O
(	O
35.6	O
%	O
)	O
groups	O
,	O
though	O
AEs	O
were	O
generally	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resulted	O
in	O
few	O
discontinuations	O
.	O

CONCLUSIONS	O
Vilazodone	O
had	O
no	O
significant	O
effect	O
on	O
cardiac	O
repolarization	O
,	O
heart	O
rate	O
,	O
PR	O
or	O
QRS	O
interval	O
duration	O
,	O
or	O
ECG	O
morphology	O
in	O
healthy	O
adult	O
participants	O
.	O

The	O
relationship	O
between	O
the	O
response	O
of	O
Plasmodium	O
falciparum	O
malaria	O
to	O
mefloquine	O
in	O
African	O
children	O
and	O
its	O
sensitivity	O
in	O
vitro	O
.	O

The	O
clinical	O
efficacy	O
of	O
two	O
doses	O
of	O
mefloquine	O
(	O
15	O
and	O
25	O
mg/kg	O
body	O
weight	O
)	O
was	O
evaluated	O
in	O
85	SampleSize
children	Age
suffering	O
from	O
acute	Condition
symptomatic	Condition
falciparum	Condition
malaria	Condition
.	Condition

The	O
cure	O
rate	O
on	O
day	O
28	O
was	O
100	O
%	O
in	O
both	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0.05	O
)	O
in	O
the	O
mean	O
parasite	O
and	O
fever	O
clearance	O
times	O
in	O
both	O
groups	O
(	O
48.5	O
+/-	O
14.6	O
and	O
32.0	O
+/-	O
12.7	O
h	O
respectively	O
for	O
the	O
25	O
mg/kg	O
group	O
and	O
49.0	O
+/-	O
15.1	O
and	O
30.0	O
+/-	O
13.3	O
h	O
respectively	O
for	O
the	O
15	O
mg/kg	O
group	O
)	O
.	O

There	O
was	O
also	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0.05	O
)	O
in	O
these	O
values	O
between	O
children	O
with	O
hyperparasitaemia	Condition
(	O
53.6	O
+/-	O
11.1	O
and	O
36.0	O
+/-	O
17.0	O
h	O
respectively	O
)	O
and	O
those	O
without	O
hyperparasitaemia	O
(	O
49.1	O
+/-	O
13.6	O
and	O
31.8	O
+/-	O
14.6	O
h	O
respectively	O
)	O
.	O

Recurrence	O
of	O
parasitaemia	O
was	O
observed	O
after	O
day	O
30	O
in	O
2	O
patients	O
in	O
the	O
15	O
mg/kg	O
group	O
and	O
in	O
1	O
patient	O
in	O
the	O
25	O
mg/kg	O
group	O
.	O

In	O
vitro	O
,	O
3	O
of	O
21	O
isolates	O
showed	O
reduced	O
susceptibility	O
to	O
mefloquine	O
,	O
with	O
minimum	O
inhibitory	O
concentrations	O
(	O
MIC	O
)	O
>	O
67	O
nM/litre	O
.	O

The	O
MIC	O
and	O
50	O
%	O
,	O
90	O
%	O
and	O
99	O
%	O
inhibitory	O
concentrations	O
were	O
200.8	O
,	O
6.27	O
,	O
31.7	O
and	O
119.6	O
nM/litre	O
respectively	O
.	O

Four	O
of	O
22	O
isolates	O
were	O
resistant	O
to	O
chloroquine	O
(	O
MIC	O
>	O
108	O
nM/litre	O
)	O
.	O

Isolates	O
that	O
showed	O
low	O
sensitivity	O
to	O
mefloquine	O
in	O
vitro	O
were	O
sensitive	O
to	O
chloroquine	O
in	O
vitro	O
,	O
and	O
the	O
4	O
that	O
were	O
resistant	O
to	O
chloroquine	O
were	O
sensitive	O
to	O
mefloquine	O
.	O

Irrespective	O
of	O
MIC	O
and	O
dose	O
of	O
mefloquine	O
,	O
parasitaemia	O
cleared	O
in	O
all	O
subjects	O
in	O
96	O
h	O
or	O
less	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
double-blind	O
,	O
randomized	O
,	O
controlled	O
,	O
multicenter	O
study	O
to	O
assess	O
the	O
safety	O
and	O
cardiovascular	O
effects	O
of	O
skeletal	O
myoblast	O
implantation	O
by	O
catheter	O
delivery	O
in	O
patients	O
with	O
chronic	Condition
heart	Condition
failure	Condition
after	O
myocardial	Condition
infarction	Condition
.	O

BACKGROUND	O
We	O
sought	O
to	O
determine	O
the	O
safety	O
and	O
preliminary	O
efficacy	O
of	O
transcatheter	O
intramyocardial	O
administration	O
of	O
myoblasts	O
in	O
patients	O
with	O
heart	Condition
failure	Condition
(	Condition
HF	Condition
)	Condition
.	O

METHODS	O
MARVEL	O
is	O
a	O
randomized	O
placebo-controlled	O
trial	O
of	O
image-guided	O
,	O
catheter-based	O
intramyocardial	O
injection	O
of	O
placebo	O
or	O
myoblasts	O
(	O
400	O
or	O
800	O
million	O
)	O
in	O
patients	O
with	O
class	Condition
II	Condition
to	Condition
IV	Condition
HF	Condition
and	O
ejection	O
fraction	O
<	O
35	O
%	O
.	O

Primary	O
end	O
points	O
were	O
frequency	O
of	O
serious	O
adverse	O
events	O
(	O
safety	O
)	O
and	O
changes	O
in	O
6-minute	O
walk	O
test	O
and	O
Minnesota	O
Living	O
With	O
HF	O
score	O
(	O
efficacy	O
)	O
.	O

Of	O
330	SampleSize
patients	O
intended	O
for	O
enrollment	O
,	O
23	SampleSize
were	O
randomized	O
(	O
MARVEL-1	O
)	O
before	O
stopping	O
the	O
study	O
for	O
financial	O
reasons	O
.	O

RESULTS	O
At	O
6	O
months	O
,	O
similar	O
numbers	O
of	O
events	O
occurred	O
in	O
each	O
group	O
:	O
8	O
(	O
placebo	O
)	O
,	O
7	O
(	O
low	O
dose	O
)	O
,	O
and	O
8	O
(	O
high	O
dose	O
)	O
,	O
without	O
deaths	O
.	O

Ventricular	O
tachycardia	O
responsive	O
to	O
amiodarone	O
was	O
more	O
frequent	O
in	O
myoblast-treated	O
patients	O
:	O
1	O
(	O
placebo	O
)	O
,	O
3	O
(	O
low	O
dose	O
)	O
,	O
and	O
4	O
(	O
high	O
dose	O
)	O
.	O

A	O
trend	O
toward	O
improvement	O
in	O
functional	O
capacity	O
was	O
noted	O
in	O
myoblast-treated	O
groups	O
(	O
?6-minute	O
walk	O
test	O
of	O
-3.6	O
vs	O
+95.6	O
vs	O
+85.5	O
m	O
[	O
placebo	O
vs	O
low	O
dose	O
vs	O
high	O
dose	O
;	O
P	O
=	O
.50	O
]	O
)	O
without	O
significant	O
changes	O
in	O
Minnesota	O
Living	O
With	O
HF	O
scores	O
.	O

CONCLUSIONS	O
In	O
HF	O
patients	O
with	O
chronic	O
postinfarction	O
cardiomyopathy	O
,	O
transcatheter	O
administration	O
of	O
myoblasts	O
in	O
doses	O
of	O
400	O
to	O
800	O
million	O
cells	O
is	O
feasible	O
and	O
may	O
lead	O
to	O
important	O
clinical	O
benefits	O
.	O

Ventricular	O
tachycardia	O
may	O
be	O
provoked	O
by	O
myoblast	O
injection	O
but	O
appears	O
to	O
be	O
a	O
transient	O
and	O
treatable	O
problem	O
.	O

A	O
large-scale	O
outcome	O
trial	O
of	O
myoblast	O
administration	O
in	O
HF	O
patients	O
with	O
postinfarction	O
cardiomyopathy	O
is	O
feasible	O
and	O
warranted	O
.	O

The	O
anesthetic	O
and	O
recovery	O
profile	O
of	O
two	O
doses	O
(	O
60	O
and	O
80	O
mg	O
)	O
of	O
plain	O
mepivacaine	O
for	O
ambulatory	O
spinal	Condition
anesthesia	Condition
.	O

UNLABELLED	O
Reports	O
of	O
transient	O
neurological	O
symptoms	O
with	O
the	O
use	O
of	O
subarachnoid	O
lidocaine	O
has	O
generated	O
interest	O
in	O
alternate	O
local	O
anesthetics	O
of	O
intermediate	O
duration	O
,	O
such	O
as	O
mepivacaine	O
.	O

This	O
prospective	O
randomized	O
,	O
double-blinded	O
,	O
dose-response	O
study	O
examined	O
the	O
anesthetic	O
and	O
recovery	O
profiles	O
of	O
60-	O
and	O
80-mg	O
doses	O
of	O
preservative-free	O
plain	O
mepivacaine	O
for	O
ambulatory	O
spinal	O
anesthesia	O
.	O

Sixty	O
patients	O
undergoing	O
ambulatory	O
anterior	O
cruciate	O
ligament	O
repair	O
of	O
the	O
knee	O
under	O
spinal	Condition
anesthesia	Condition
were	O
randomized	O
into	O
two	O
groups	O
;	O
Group	O
1	O
(	O
29	O
patients	O
)	O
received	O
4	O
mL	O
of	O
1.5	O
%	O
(	O
60-mg	O
dose	O
)	O
and	O
Group	O
2	O
(	O
31	O
patients	O
)	O
received	O
4	O
mL	O
of	O
2	O
%	O
(	O
80-mg	O
dose	O
)	O
of	O
plain	O
mepivacaine	O
.	O

All	O
patients	O
received	O
a	O
combined	O
spinal-epidural	O
anesthetic	O
technique	O
.	O

The	O
epidural	O
catheter	O
was	O
used	O
only	O
in	O
the	O
event	O
the	O
surgery	O
outlasted	O
the	O
duration	O
of	O
surgical	O
anesthesia	O
with	O
subarachnoid	O
mepivacaine	O
.	O

Epidural	O
supplementation	O
was	O
administered	O
in	O
three	O
patients	O
(	O
12	O
%	O
)	O
in	O
Group	O
1	O
and	O
one	O
patient	O
(	O
3	O
%	O
)	O
in	O
Group	O
2	O
when	O
the	O
sensory	O
block	O
regressed	O
to	O
L-1	O
with	O
surgery	O
expected	O
to	O
last	O
longer	O
than	O
15	O
min	O
.	O

The	O
cephalad	O
dermatome	O
level	O
of	O
the	O
block	O
and	O
degree	O
of	O
motor	O
block	O
was	O
comparable	O
in	O
the	O
two	O
groups	O
.	O

Times	O
to	O
two-segment	O
and	O
T-10	O
regression	O
were	O
comparable	O
in	O
the	O
two	O
groups	O
(	O
112	O
+/-	O
26	O
min	O
in	O
Group	O
1	O
versus	O
122	O
+/-	O
28	O
min	O
in	O
Group	O
2	O
)	O
.	O

Time	O
to	O
L-1	O
regression	O
was	O
significantly	O
longer	O
in	O
Group	O
2	O
(	O
146	O
+/-	O
28	O
min	O
in	O
Group	O
1	O
versus	O
159	O
+/-	O
19	O
min	O
in	O
Group	O
2	O
)	O
.	O

All	O
of	O
the	O
ambulatory	O
milestones	O
were	O
significantly	O
faster	O
in	O
Group	O
1	O
.	O

Side	O
effects	O
,	O
such	O
as	O
hypotension	O
and	O
emesis	O
were	O
negligible	O
,	O
severe	O
bradycardia	O
and	O
urinary	O
retention	O
did	O
not	O
occur	O
,	O
and	O
none	O
of	O
the	O
patients	O
in	O
the	O
two	O
groups	O
reported	O
transient	O
neurological	O
symptoms	O
over	O
24	O
h.	O
In	O
conclusion	O
,	O
plain	O
mepivacaine	O
in	O
a	O
60-	O
or	O
80-mg	O
dose	O
is	O
a	O
suitable	O
local	O
anesthetic	O
choice	O
for	O
ambulatory	O
spinal	O
anesthesia	O
with	O
respect	O
to	O
anesthetic	O
,	O
as	O
well	O
as	O
recovery	O
profiles	O
.	O

IMPLICATIONS	O
We	O
evaluated	O
the	O
anesthetic	O
and	O
recovery	O
profiles	O
of	O
60-	O
and	O
80-mg	O
doses	O
of	O
plain	O
mepivacaine	O
for	O
ambulatory	O
spinal	O
anesthesia	O
.	O

Both	O
doses	O
produced	O
comparable	O
sensory	O
and	O
motor	O
block	O
.	O

Sensory	O
and	O
motor	O
regression	O
and	O
ambulatory	O
milestones	O
were	O
20-30	O
min	O
longer	O
with	O
the	O
80-mg	O
dose	O
.	O

Side	O
effects	O
were	O
negligible	O
and	O
transient	O
neurological	O
symptoms	O
were	O
not	O
reported	O
during	O
a	O
24-h	O
follow-up	O
.	O

Prevention	O
of	O
type	O
2	O
(	O
non-insulin-dependent	O
)	O
diabetes	O
mellitus	O
by	O
diet	O
and	O
physical	O
exercise	O
.	O

The	O
6-year	O
Malm?	O
feasibility	O
study	O
.	O

From	O
a	O
previously	O
reported	O
5-year	O
screening	O
programme	O
of	O
6,956	O
47-49-year-old	O
Malm?	O
males	O
,	O
a	O
series	O
of	O
41	O
subjects	O
with	O
early-stage	O
Type	O
2	O
(	O
non-insulin-dependent	O
)	O
diabetes	O
mellitus	O
and	O
181	O
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
were	O
selected	O
for	O
prospective	O
study	O
and	O
to	O
test	O
the	O
feasibility	O
aspect	O
of	O
long-term	O
intervention	O
with	O
an	O
emphasis	O
on	O
life-style	O
changes	O
.	O

A	O
5-year	O
protocol	O
,	O
including	O
an	O
initial	O
6-months	O
(	O
randomised	O
)	O
pilot	O
study	O
,	O
consisting	O
of	O
dietary	O
treatment	O
and/or	O
increase	O
of	O
physical	O
activity	O
or	O
training	O
with	O
annual	O
check-ups	O
,	O
was	O
completed	O
by	O
90	O
%	O
of	O
subjects	O
.	O

Body	O
weight	O
was	O
reduced	O
by	O
2.3-3.7	O
%	O
among	O
participants	O
,	O
whereas	O
values	O
increased	O
by	O
0.5-1.7	O
%	O
in	O
non-intervened	O
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
and	O
in	O
normal	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
;	O
maximal	O
oxygen	O
uptake	O
(	O
ml.min-1.kg-1	O
)	O
was	O
increased	O
by	O
10-14	O
%	O
vs	O
decreased	O
by	O
5-9	O
%	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

Glucose	O
tolerance	O
was	O
normalized	O
in	O
greater	O
than	O
50	O
%	O
of	O
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
,	O
the	O
accumulated	O
incidence	O
of	O
diabetes	O
was	O
10.6	O
%	O
,	O
and	O
more	O
than	O
50	O
%	O
of	O
the	O
diabetic	O
patients	O
were	O
in	O
remission	O
after	O
a	O
mean	O
follow-up	O
of	O
6	O
years	O
.	O

Blood	O
pressure	O
,	O
lipids	O
,	O
and	O
hyperinsulinaemia	O
were	O
reduced	O
and	O
early	O
insulin	O
responsiveness	O
to	O
glucose	O
loading	O
preserved	O
.	O

Improvement	O
in	O
glucose	O
tolerance	O
was	O
correlated	O
to	O
weight	O
reduction	O
(	O
r	O
=	O
0.19	O
,	O
p	O
less	O
than	O
0.02	O
)	O
and	O
increased	O
fitness	O
(	O
r	O
=	O
0.22	O
,	O
p	O
less	O
than	O
0.02	O
)	O
.	O

Treatment	O
was	O
safe	O
,	O
and	O
mortality	O
was	O
low	O
(	O
in	O
fact	O
33	O
%	O
lower	O
than	O
in	O
the	O
remainder	O
of	O
the	O
cohort	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Response	O
to	O
tubular	O
airway	O
resistance	O
in	O
normal	Condition
subjects	O
and	O
postoperative	O
patients	O
.	O

Critically	Condition
ill	Condition
patients	O
must	O
often	O
breathe	O
spontaneously	O
through	O
an	O
endotracheal	O
tube	O
that	O
acts	O
as	O
a	O
fixed	O
inspiratory	O
and	O
expiratory	O
tubular	O
airway	O
resistor	O
.	O

Although	O
this	O
practice	O
is	O
common	O
,	O
its	O
effect	O
on	O
the	O
pattern	O
of	O
breathing	O
is	O
not	O
known	O
.	O

The	O
mean	O
breathing	O
patterns	O
of	O
seven	SampleSize
normal	Condition
,	Condition
healthy	Condition
male	Sex
subjects	O
and	O
eight	SampleSize
male	Sex
patients	O
who	O
had	O
undergone	O
upper	O
abdominal	O
surgery	O
2-4	O
days	O
previously	O
were	O
studied	O
breathing	O
through	O
a	O
mouthpiece	O
fitted	O
in	O
random	O
order	O
with	O
a	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
or	O
15	O
mm	O
diameter	O
(	O
17	O
mm	O
long	O
)	O
resistor	O
.	O

These	O
diameters	O
were	O
selected	O
because	O
they	O
simulate	O
the	O
pressure-flow	O
relationships	O
of	O
adult	O
endotracheal	O
tubes	O
.	O

With	O
the	O
15	O
mm	O
aperture	O
,	O
the	O
patients	O
had	O
a	O
greater	O
breathing	O
frequency	O
(	O
f	O
)	O
than	O
did	O
the	O
normal	O
subjects	O
(	O
21	O
+/-	O
5	O
[	O
SD	O
]	O
vs.	O
14	O
+/-	O
4	O
breaths/min	O
,	O
P	O
less	O
than	O
0.01	O
)	O
as	O
well	O
as	O
a	O
smaller	O
mean	O
tidal	O
volume	O
(	O
VT	O
)	O
.	O

In	O
both	O
groups	O
,	O
minute	O
ventilation	O
(	O
VE	O
)	O
and	O
f	O
progressively	O
decreased	O
as	O
resistance	O
was	O
increased	O
by	O
decreasing	O
the	O
aperture	O
size	O
from	O
15	O
to	O
16	O
mm	O
.	O

In	O
the	O
normal	O
subjects	O
but	O
not	O
the	O
patients	O
,	O
VT	O
also	O
progressively	O
decreased	O
.	O

When	O
the	O
diameter	O
was	O
decreased	O
from	O
6	O
mm	O
to	O
5	O
mm	O
,	O
there	O
were	O
increases	O
in	O
VT	O
and	O
decreases	O
in	O
f	O
that	O
were	O
more	O
marked	O
in	O
the	O
normal	O
subjects	O
.	O

In	O
both	O
groups	O
,	O
the	O
changes	O
in	O
VE	O
were	O
accompanied	O
by	O
decreases	O
in	O
mean	O
and	O
peak	O
inspiratory	O
and	O
expiratory	O
flow	O
rates	O
.	O

Throughout	O
the	O
study	O
,	O
oxygen	O
consumption	O
(	O
VO2	O
)	O
and	O
carbon	O
dioxide	O
production	O
(	O
VCO2	O
)	O
did	O
not	O
change	O
.	O

This	O
,	O
coupled	O
with	O
the	O
decreases	O
in	O
VE	O
resulted	O
in	O
decreases	O
in	O
the	O
ventilatory	O
equivalents	O
to	O
CO2	O
and	O
O2	O
(	O
VE/VCO2	O
,	O
VE/VO2	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Citalopram	O
for	O
post-stroke	O
pathological	O
crying	O
.	O

Post-stroke	O
pathological	O
crying	O
is	O
a	O
distressing	O
condition	O
in	O
which	O
episodes	O
occur	O
in	O
response	O
to	O
minor	O
stimuli	O
without	O
associated	O
mood	O
changes	O
.	O

There	O
is	O
preliminary	O
evidence	O
of	O
disturbed	O
serotoninergic	O
neurotransmission	O
in	O
such	O
cases	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
citalopram	O
on	O
uncontrolled	O
crying	O
in	O
stroke	Condition
patients	O
in	O
a	O
double-blind	O
placebo-controlled	O
crossover	O
study	O
.	O

16	SampleSize
consecutive	O
patients	O
(	O
median	O
age	O
58.5	O
years	O
,	O
range	O
40-83	O
)	O
entered	O
the	O
9-week	O
study	O
a	O
median	O
of	O
168	O
days	O
(	O
range	O
6-913	O
)	O
post	O
stroke	O
and	O
were	O
treated	O
with	O
citalopram	O
10-20	O
mg	O
daily	O
for	O
3	O
weeks	O
.	O

Crying	Condition
history	Condition
was	O
determined	O
from	O
semistructured	O
interviews	O
and	O
from	O
diaries	O
kept	O
by	O
the	O
patients	O
.	O

Psychiatric	O
assessment	O
was	O
made	O
with	O
the	O
Hamilton	O
depression	O
scale	O
(	O
HDS	O
)	O
,	O
and	O
unwanted	O
effects	O
were	O
measured	O
with	O
the	O
UKU	O
side-effect	O
scale	O
.	O

In	O
13	SampleSize
patients	O
in	O
whom	O
frequency	O
of	O
crying	Condition
could	O
be	O
assessed	O
,	O
the	O
number	O
of	O
daily	O
crying	O
episodes	O
decreased	O
by	O
at	O
least	O
50	O
%	O
in	O
all	O
cases	O
during	O
citalopram	O
treatment	O
vs	O
2	O
patients	O
during	O
placebo	O
treatment	O
(	O
p	O
<	O
0.005	O
,	O
McNemar	O
's	O
test	O
)	O
,	O
the	O
effect	O
being	O
rapid	O
(	O
1-3	O
days	O
)	O
and	O
pronounced	O
in	O
11	O
(	O
73	O
%	O
)	O
.	O

There	O
was	O
a	O
concomitant	O
significant	O
decrease	O
in	O
depression	O
rating	O
from	O
HDS	O
8.9	O
to	O
5.3	O
(	O
p	O
<	O
0.005	O
,	O
Wilcoxon	O
's	O
test	O
)	O
.	O

Citalopram	O
was	O
well	O
tolerated	O
,	O
the	O
few	O
side-effects	O
being	O
mild	O
and	O
transient	O
.	O

We	O
conclude	O
that	O
serotoninergic	O
neurotransmission	O
plays	O
an	O
important	O
part	O
in	O
post-stroke	O
pathological	O
crying	O
and	O
that	O
citalopram	O
is	O
an	O
effective	O
and	O
well-tolerated	O
treatment	O
.	O

[	O
Effects	O
of	O
small	O
needle-knife	O
comprehensive	O
therapy	O
on	O
pain	O
and	O
lumbar	O
flexion	O
range	O
in	O
the	O
chronic	Condition
nonspecific	Condition
low	Condition
back	Condition
pain	Condition
patient	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
therapeutic	O
effect	O
of	O
small	O
needle-knife	O
comprehensive	O
therapy	O
on	O
pain	O
and	O
lumbar	O
flexion	O
range	O
in	O
the	O
chronic	Condition
nonspecific	Condition
low	Condition
back	Condition
pain	Condition
patient	O
.	O

METHODS	O
Three	SampleSize
hundred	SampleSize
and	SampleSize
five	SampleSize
cases	O
were	O
randomly	O
divided	O
into	O
a	O
needle-knife	O
group	O
of	O
153	O
cases	O
and	O
a	O
physiotherapy	O
group	O
of	O
152	O
cases	O
.	O

The	O
needle-knife	O
group	O
were	O
treated	O
with	O
small	O
needle-knife	O
releasing	O
therapy	O
,	O
blocking	O
and	O
functional	O
training	O
.	O

The	O
physiotherapy	O
group	O
were	O
treated	O
with	O
ultra-short	O
wave	O
,	O
modulated	O
medium	O
frequency	O
current	O
,	O
massage	O
and	O
functional	O
training	O
.	O

Pain	O
was	O
assessed	O
by	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
the	O
lumbar	O
flexion	O
range	O
was	O
determined	O
before	O
and	O
after	O
treatment	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
pain	O
and	O
the	O
lumbar	O
flexion	O
range	O
were	O
significantly	O
improved	O
in	O
the	O
two	O
groups	O
;	O
and	O
after	O
treatment	O
,	O
the	O
VAS	O
score	O
and	O
the	O
lumbar	O
flexion	O
range	O
were	O
(	O
1.60	O
+/-	O
0.38	O
)	O
points	O
and	O
(	O
65.76	O
+/-	O
15.11	O
)	O
cm	O
in	O
the	O
needle-knife	O
group	O
and	O
(	O
4.59	O
+/-	O
1.09	O
)	O
points	O
and	O
(	O
53.74	O
+/-	O
15.13	O
)	O
cm	O
in	O
the	O
physiotherapy	O
group	O
,	O
respectively	O
,	O
the	O
needle-knife	O
group	O
being	O
significantly	O
better	O
than	O
the	O
physiotherapy	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Follow-up	O
survey	O
of	O
6-36	O
months	O
showed	O
that	O
the	O
VAS	O
score	O
and	O
the	O
lumbar	O
flexion	O
range	O
in	O
the	O
needle-knife	O
group	O
were	O
superior	O
to	O
those	O
in	O
the	O
physiotherapy	O
group	O
.	O

CONCLUSION	O
Small	O
needle-knife	O
comprehensive	O
therapy	O
can	O
significantly	O
improve	O
pain	O
and	O
lumbar	O
flexion	O
range	O
in	O
the	O
chronic	Condition
nonspecific	Condition
low	Condition
back	Condition
pain	Condition
patient	O
,	O
with	O
a	O
stable	O
long-term	O
therapeutic	O
effect	O
.	O

The	O
effect	O
of	O
fasting	O
on	O
total	O
serum	O
bilirubin	O
concentrations	O
.	O

Thirty-seven	O
healthy	O
volunteers	O
,	O
19	O
of	O
whom	O
had	O
consistently	O
elevated	O
total	O
serum	O
bilirubin	O
(	O
TSB	O
)	O
concentrations	O
,	O
took	O
part	O
in	O
an	O
open	O
,	O
randomised	O
cross-over	O
study	O
to	O
determine	O
the	O
effect	O
of	O
fasting	O
on	O
TSB	O
concentrations	O
.	O

The	O
study	O
comprised	O
of	O
two	O
treatments	O
.	O

During	O
one	O
treatment	O
period	O
volunteers	O
ate	O
a	O
standard	O
supper	O
but	O
fasted	O
for	O
24	O
h	O
thereafter	O
.	O

During	O
the	O
other	O
treatment	O
period	O
volunteers	O
ate	O
a	O
standard	O
supper	O
,	O
snacks	O
,	O
breakfast	O
and	O
lunch	O
.	O

TSB	O
concentrations	O
were	O
measured	O
at	O
regular	O
intervals	O
.	O

In	O
both	O
the	O
normal	O
and	O
high	O
bilirubin	O
groups	O
,	O
minimum	O
TSB	O
values	O
were	O
recorded	O
4	O
h	O
after	O
the	O
supper	O
.	O

A	O
24	O
h	O
fast	O
more	O
than	O
doubled	O
TSB	O
concentration	O
from	O
baseline	O
values	O
in	O
both	O
the	O
normal	O
and	O
high	O
bilirubin	O
groups	O
.	O

A	O
clinically	O
relevant	O
rise	O
in	O
TSB	O
took	O
place	O
after	O
12	O
h	O
into	O
the	O
fasting	O
period	O
(	O
TSB	O
of	O
17.3	O
mumol	O
l-1	O
in	O
the	O
fasted	O
group	O
vs	O
14.0	O
mumol	O
l-1	O
in	O
the	O
non-fasted	O
group	O
)	O
.	O

When	O
designing	O
a	O
clinical	O
trial	O
,	O
selecting	O
volunteers	O
,	O
or	O
judging	O
the	O
tolerance	O
of	O
a	O
new	O
drug	O
,	O
the	O
rise	O
in	O
TSB	O
caused	O
by	O
fasting	O
must	O
therefore	O
be	O
taken	O
into	O
account	O
,	O
particularly	O
in	O
trials	O
where	O
volunteers	O
or	O
patients	O
fast	O
before	O
entering	O
the	O
study	O
.	O

Efficacy	O
and	O
safety	O
of	O
selamectin	O
against	O
fleas	O
and	O
heartworms	O
in	O
dogs	O
and	O
cats	O
presented	O
as	O
veterinary	O
patients	O
in	O
North	O
America	O
.	O

A	O
series	O
of	O
randomized	O
,	O
controlled	O
,	O
masked	O
field	O
studies	O
was	O
conducted	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
selamectin	O
in	O
the	O
treatment	O
of	O
flea	O
infestations	O
on	O
dogs	O
and	O
cats	O
,	O
and	O
in	O
the	O
prevention	O
of	O
heartworm	O
infection	O
in	O
dogs	O
.	O

In	O
addition	O
,	O
observations	O
were	O
made	O
on	O
the	O
beneficial	O
effect	O
of	O
selamectin	O
treatment	O
on	O
dogs	Condition
and	Condition
cats	Condition
showing	Condition
signs	Condition
of	Condition
flea	Condition
allergy	Condition
dermatitis	Condition
(	Condition
FAD	Condition
)	Condition
.	Condition

In	O
all	O
studies	O
selamectin	O
was	O
applied	O
topically	O
,	O
once	O
per	O
month	O
,	O
in	O
unit	O
doses	O
providing	O
a	O
minimum	O
dosage	O
of	O
6mgkg	O
(	O
-1	O
)	O
.	O

Dogs	O
and	O
cats	O
with	O
naturally	O
occurring	O
flea	Condition
infestations	Condition
,	O
some	O
of	O
which	O
also	O
had	O
signs	O
associated	O
with	O
FAD	O
,	O
were	O
assigned	O
randomly	O
to	O
receive	O
three	O
months	O
of	O
topical	O
treatment	O
with	O
selamectin	O
(	O
220	O
dogs	O
,	O
189	O
cats	O
)	O
or	O
a	O
positive-control	O
product	O
(	O
dogs	O
:	O
fenthion	O
,	O
n=81	O
;	O
cats	O
:	O
pyrethrins	O
,	O
n=66	O
)	O
.	O

Selamectin	O
was	O
administered	O
on	O
days	O
0	O
,	O
30	O
,	O
and	O
60	O
.	O

Day	O
0	O
was	O
defined	O
as	O
the	O
day	O
that	O
the	O
animal	O
first	O
received	O
treatment	O
.	O

Flea	O
burdens	O
were	O
assessed	O
by	O
flea	O
comb	O
counts	O
and	O
clinical	O
evaluations	O
of	O
FAD	O
were	O
performed	O
before	O
treatment	O
,	O
and	O
on	O
days	O
14	O
,	O
30	O
,	O
60	O
,	O
and	O
90	O
.	O

On	O
days	O
30	O
,	O
60	O
,	O
and	O
90	O
,	O
mean	O
flea	O
counts	O
in	O
selamectin-treated	O
dogs	O
were	O
reduced	O
by	O
92.1	O
,	O
99.0	O
,	O
and	O
99.8	O
%	O
,	O
and	O
mean	O
flea	O
counts	O
in	O
fenthion-treated	O
dogs	O
were	O
reduced	O
by	O
81.5	O
,	O
86.8	O
,	O
and	O
86.1	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
day	O
0	O
counts	O
.	O

Also	O
,	O
on	O
days	O
30	O
,	O
60	O
,	O
and	O
90	O
,	O
mean	O
flea	O
counts	O
in	O
selamectin-treated	O
cats	O
were	O
reduced	O
by	O
92.5	O
,	O
98.3	O
,	O
and	O
99.3	O
%	O
,	O
and	O
mean	O
flea	O
counts	O
in	O
pyrethrin-treated	O
cats	O
were	O
reduced	O
by	O
66.4	O
,	O
73.9	O
,	O
and	O
81.3	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
day	O
0	O
counts	O
.	O

Selamectin	O
also	O
was	O
beneficial	O
in	O
alleviating	O
signs	O
in	O
dogs	O
and	O
cats	O
diagnosed	O
clinically	O
with	O
FAD	O
.	O

A	O
total	O
of	O
397	O
dogs	O
free	O
of	O
adult	O
heartworm	O
infection	O
from	O
four	O
heartworm-endemic	O
areas	O
of	O
the	O
USA	O
were	O
allocated	O
randomly	O
to	O
six	O
months	O
of	O
treatment	O
with	O
selamectin	O
(	O
n=298	O
)	O
or	O
ivermectin	O
(	O
n=99	O
)	O
.	O

Selamectin	O
achieved	O
a	O
heartworm	O
prevention	O
rate	O
of	O
100	O
%	O
,	O
with	O
all	O
dogs	O
testing	O
negative	O
for	O
microfilariae	O
and	O
adult	O
heartworm	O
antigen	O
on	O
days	O
180	O
and	O
300	O
.	O

Selamectin	O
was	O
administered	O
to	O
a	O
total	O
of	O
673	O
dogs	O
and	O
347	O
cats	O
having	O
an	O
age	O
range	O
of	O
6	O
weeks	O
to	O
19	O
years	O
(	O
3954	O
doses	O
)	O
.	O

The	O
animals	O
included	O
19	O
purebred	O
or	O
crossbred	O
Collies	O
(	O
Bearded	O
,	O
Border	O
,	O
and	O
unspecified	O
)	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
events	O
.	O

Results	O
of	O
these	O
studies	O
indicated	O
that	O
selamectin	O
was	O
highly	O
effective	O
in	O
the	O
control	O
of	O
flea	O
infestations	O
in	O
dogs	O
and	O
cats	O
without	O
the	O
need	O
for	O
simultaneous	O
treatment	O
of	O
the	O
environment	O
or	O
of	O
in-contact	O
animals	O
and	O
also	O
was	O
beneficial	O
in	O
alleviating	O
signs	O
associated	O
with	O
FAD	O
.	O

Selamectin	O
also	O
was	O
100	O
%	O
effective	O
in	O
preventing	O
the	O
development	O
of	O
canine	O
heartworms	O
and	O
was	O
safe	O
for	O
topical	O
use	O
in	O
dogs	O
and	O
cats	O
.	O

Does	O
single	O
use	O
of	O
an	O
autologous	O
transfusion	O
system	O
in	O
TKA	Condition
reduce	O
the	O
need	O
for	O
allogenic	O
blood	O
?	O
:	O
a	O
prospective	O
randomized	O
trial	O
.	O

BACKGROUND	O
Mechanical	O
autotransfusion	O
systems	O
for	O
washed	O
shed	O
blood	O
(	O
WSB	O
)	O
were	O
introduced	O
to	O
reduce	O
the	O
need	O
for	O
postoperative	O
allogenic	O
blood	O
transfusions	O
(	O
ABTs	O
)	O
.	O

Although	O
some	O
authors	O
have	O
postulated	O
decreased	O
requirements	O
for	O
ABT	O
by	O
using	O
autologous	O
retransfusion	O
devices	O
,	O
other	O
trials	O
,	O
mostly	O
evaluating	O
retransfusion	O
devices	O
for	O
unwashed	O
shed	O
blood	O
(	O
USB	O
)	O
,	O
verified	O
a	O
small	O
or	O
no	O
benefit	O
in	O
reducing	O
the	O
need	O
for	O
postoperative	O
ABT	O
.	O

Because	O
of	O
these	O
contradictory	O
findings	O
it	O
is	O
still	O
unclear	O
whether	O
autologous	O
retransfusion	O
systems	O
for	O
WSB	O
can	O
reduce	O
transfusion	O
requirements	O
.	O

QUESTIONS/PURPOSES	O
We	O
therefore	O
asked	O
whether	O
one	O
such	O
autologous	O
transfusion	O
system	O
for	O
WSB	O
can	O
reduce	O
the	O
requirements	O
for	O
postoperative	O
ABT	O
.	O

METHODS	O
In	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
,	O
we	O
enrolled	O
151	SampleSize
patients	O
undergoing	O
TKA	Condition
.	O

In	O
Group	O
A	O
(	O
n=76	SampleSize
patients	O
)	O
,	O
the	O
autotransfusion	O
system	O
was	O
used	O
for	O
a	O
total	O
of	O
6	O
hours	O
(	O
intraoperatively	O
and	O
postoperatively	O
)	O
and	O
the	O
WSB	O
was	O
retransfused	O
after	O
processing	O
.	O

In	O
Control	O
Group	O
B	O
(	O
n=75	SampleSize
patients	O
)	O
,	O
a	O
regular	O
drain	O
without	O
suction	O
was	O
used	O
.	O

We	O
used	O
signs	O
of	O
anemia	O
and/or	O
a	O
hemoglobin	O
value	O
less	O
than	O
8	O
g/dL	O
as	O
indications	O
for	O
transfusion	O
.	O

If	O
necessary	O
,	O
we	O
administered	O
one	O
or	O
two	O
units	O
of	O
allogenic	O
blood	O
.	O

RESULTS	O
Twenty-three	O
patients	O
(	O
33	O
%	O
)	O
in	O
Group	O
A	O
,	O
who	O
received	O
an	O
average	O
of	O
283	O
mL	O
(	O
range	O
,	O
160-406	O
mL	O
)	O
of	O
salvaged	O
blood	O
,	O
needed	O
a	O
mean	O
of	O
2.1	O
units	O
of	O
allogenic	O
blood	O
,	O
compared	O
with	O
23	O
patients	O
(	O
33	O
%	O
)	O
in	O
Control	O
Group	O
B	O
who	O
needed	O
a	O
mean	O
of	O
2.1	O
units	O
of	O
allogenic	O
blood	O
.	O

CONCLUSIONS	O
We	O
found	O
the	O
use	O
of	O
an	O
autotransfusion	O
system	O
did	O
not	O
reduce	O
the	O
rate	O
of	O
postoperative	O
ABTs	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
Level	O
II	O
,	O
therapeutic	O
study	O
.	O

See	O
the	O
Guidelines	O
for	O
Authors	O
for	O
a	O
complete	O
description	O
of	O
levels	O
of	O
evidence	O
.	O

Interactive	O
effects	O
of	O
indomethacin	O
,	O
angiotensin	O
II	O
and	O
frusemide	O
on	O
renal	O
haemodynamics	O
and	O
natriuresis	O
in	O
man	O
.	O

The	O
responses	O
of	O
renal	O
haemodynamic	O
and	O
natriuretic	O
indices	O
to	O
the	O
oral	O
prostaglandin	O
synthetase	O
inhibitor	O
indomethacin	O
(	O
200	O
mg	O
)	O
,	O
to	O
infused	O
angiotensin	O
II	O
(	O
1	O
ng	O
min-1	O
kg-1	O
)	O
and	O
to	O
the	O
combination	O
of	O
the	O
two	O
were	O
studies	O
in	O
placebo-controlled	O
fashion	O
in	O
eight	Condition
normal	O
male	Condition
subjects	O
both	O
prior	O
to	O
and	O
following	O
administration	O
of	O
intravenous	O
frusemide	O
(	O
20	O
mg	O
)	O
.	O

As	O
compared	O
with	O
placebo	O
,	O
angiotensin	O
II	O
infusion	O
alone	O
caused	O
significant	O
reductions	O
in	O
absolute	O
rate	O
of	O
sodium	O
excretion	O
,	O
fractional	O
sodium	O
excretion	O
,	O
urine	O
flow	O
rate	O
and	O
effective	O
renal	O
plasma	O
flow	O
(	O
all	O
P	O
<	O
0.001	O
vs	O
placebo	O
)	O
but	O
had	O
no	O
effect	O
on	O
glomerular	O
filtration	O
rate	O
.	O

The	O
only	O
change	O
observed	O
in	O
these	O
parameters	O
with	O
indomethacin	O
alone	O
was	O
a	O
small	O
but	O
significant	O
reduction	O
in	O
urine	O
flow	O
rate	O
(	O
P	O
<	O
0.005	O
vs	O
placebo	O
)	O
.	O

As	O
compared	O
with	O
the	O
effects	O
of	O
angiotensin	O
II	O
alone	O
,	O
indomethacin	O
pre-treatment	O
followed	O
by	O
angiotensin	O
II	O
infusion	O
led	O
to	O
much	O
greater	O
falls	O
in	O
absolute	O
rate	O
of	O
sodium	O
excretion	O
,	O
fractional	O
sodium	O
excretion	O
,	O
urine	O
flow	O
rate	O
and	O
effective	O
renal	O
plasma	O
flow	O
(	O
all	O
P	O
<	O
0.0001	O
vs	O
placebo	O
)	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
P	O
<	O
0.0001	O
)	O
not	O
observed	O
with	O
angiotensin	O
II	O
alone	O
.	O

Frusemide	O
administration	O
at	O
the	O
midpoint	O
of	O
each	O
study	O
limb	O
resulted	O
in	O
each	O
case	O
in	O
a	O
prompt	O
15	O
to	O
20	O
fold	O
increase	O
in	O
natriuresis	O
.	O

The	O
renal	O
haemodynamic	O
and	O
natriuretic	O
effects	O
of	O
angiotensin	O
II	O
,	O
indomethacin	O
and	O
their	O
combination	O
were	O
not	O
qualitatively	O
different	O
from	O
those	O
observed	O
in	O
the	O
pre-frusemide	O
phase	O
.	O

Our	O
findings	O
provide	O
a	O
clear	O
demonstration	O
in	O
man	O
of	O
the	O
important	O
homeostatic	O
role	O
of	O
renal	O
prostaglandins	O
in	O
preserving	O
renal	O
function	O
,	O
particularly	O
glomerular	O
filtration	O
,	O
under	O
conditions	O
of	O
elevated	O
circulating	O
angiotensin	O
II	O
.	O

Zolmitriptan	O
(	O
311C90	O
)	O
does	O
not	O
interact	O
with	O
fluoxetine	O
in	O
healthy	Condition
volunteers	Condition
.	Condition

Zolmitriptan	O
(	O
Zomig	O
,	O
formerly	O
311C90	O
)	O
is	O
a	O
selective	O
5-hydroxytryptamine	O
(	O
5-HT	O
)	O
1B/1D-receptor	O
agonist	O
with	O
central	O
and	O
peripheral	O
activity	O
for	O
the	O
acute	O
treatment	O
of	O
migraine	O
.	O

This	O
randomized	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
investigated	O
the	O
effects	O
of	O
fluoxetine	O
administration	O
on	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
zolmitriptan	O
.	O

Twenty	SampleSize
volunteers	O
were	O
given	O
single	O
doses	O
of	O
fluoxetine	O
20	O
mg	O
or	O
an	O
identical	O
placebo	O
daily	O
for	O
28	O
days	O
prior	O
to	O
receiving	O
a	O
single	O
10	O
mg	O
oral	O
dose	O
of	O
zolmitriptan	O
.	O

Sixteen	SampleSize
volunteers	O
completed	O
the	O
two	O
treatment	O
phases	O
.	O

The	O
pharmacokinetic	O
parameters	O
of	O
zolmitriptan	O
and	O
its	O
metabolites	O
were	O
not	O
significantly	O
affected	O
by	O
fluoxetine	O
pretreatment	O
.	O

The	O
pharmacodynamic	O
effects	O
of	O
zolmitriptan	O
were	O
also	O
unaffected	O
by	O
fluoxetine	O
pretreatment	O
.	O

There	O
were	O
small	O
,	O
clinically	O
insignificant	O
increases	O
in	O
blood	O
pressure	O
following	O
zolmitriptan	O
which	O
were	O
unaltered	O
by	O
fluoxetine	O
.	O

Zolmitriptan	O
was	O
well	O
tolerated	O
when	O
given	O
alone	O
or	O
concomitantly	O
with	O
fluoxetine	O
.	O

These	O
results	O
indicate	O
that	O
there	O
is	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
zolmitriptan	O
in	O
patients	O
treated	O
concurrently	O
with	O
selective	O
serotonin	Condition
reuptake	Condition
inhibitors	Condition
and	O
that	O
no	O
adjustment	O
of	O
the	O
zolmitriptan	O
dose	O
is	O
required	O
in	O
these	O
circumstances	O
.	O

Independent	O
prognostic	O
information	O
provided	O
by	O
sphygmomanometrically	O
determined	O
pulse	O
pressure	O
and	O
mean	O
arterial	O
pressure	O
in	O
patients	O
with	O
left	Condition
ventricular	Condition
dysfunction	Condition
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
of	O
baseline	O
pulse	O
pressure	O
and	O
mean	O
arterial	O
pressure	O
to	O
mortality	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
.	O

BACKGROUND	O
Increased	O
conduit	O
vessel	O
stiffness	O
increases	O
pulse	O
pressure	O
and	O
pulsatile	O
load	O
,	O
potentially	O
contributing	O
to	O
adverse	O
outcomes	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
.	O

METHODS	O
Pulse	O
and	O
mean	O
arterial	O
pressure	O
were	O
analyzed	O
for	O
their	O
effect	O
on	O
mortality	O
,	O
adjusting	O
for	O
other	O
modifiers	O
of	O
risk	O
,	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
analysis	O
of	O
data	O
collected	O
from	O
6,781	SampleSize
patients	O
randomized	O
into	O
the	O
Studies	O
of	O
Left	O
Ventricular	O
Dysfunction	O
trials	O
.	O

RESULTS	O
Pulse	O
and	O
mean	O
arterial	O
pressure	O
were	O
related	O
positively	O
to	O
each	O
other	O
,	O
age	O
,	O
ejection	O
fraction	O
and	O
prevalence	O
of	O
diabetes	O
and	O
hypertension	O
and	O
inversely	O
to	O
prior	O
myocardial	O
infarction	O
and	O
beta-adrenergic	O
blocking	O
agent	O
use	O
.	O

Higher	O
pulse	O
pressure	O
was	O
associated	O
with	O
increased	O
prevalence	O
of	O
female	O
gender	O
,	O
greater	O
calcium	O
channel	O
blocking	O
agent	O
,	O
digoxin	O
and	O
diuretic	O
use	O
,	O
lower	O
heart	O
rate	O
and	O
a	O
higher	O
rate	O
of	O
reported	O
smoking	O
history	O
.	O

Higher	O
mean	O
arterial	O
pressure	O
was	O
associated	O
with	O
higher	O
heart	O
rate	O
,	O
lower	O
calcium	O
channel	O
blocker	O
and	O
digoxin	O
use	O
and	O
lower	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
.	O

Over	O
a	O
61-month	O
follow-up	O
1,582	O
deaths	O
(	O
1,397	O
cardiovascular	O
)	O
occurred	O
.	O

In	O
a	O
multivariate	O
analysis	O
adjusting	O
for	O
the	O
above	O
covariates	O
and	O
treatment	O
assignment	O
,	O
higher	O
pulse	O
pressure	O
remained	O
an	O
independent	O
predictor	O
of	O
total	O
and	O
cardiovascular	O
mortality	O
(	O
total	O
mortality	O
relative	O
risk	O
,	O
1.05	O
per	O
10	O
mm	O
Hg	O
increment	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.01	O
to	O
1.10	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Mean	O
arterial	O
pressure	O
was	O
inversely	O
related	O
to	O
total	O
and	O
cardiovascular	O
mortality	O
(	O
total	O
mortality	O
relative	O
risk	O
,	O
0.89	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.85	O
to	O
0.94	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

CONCLUSIONS	O
One	O
noninvasive	O
blood	O
pressure	O
measurement	O
provides	O
two	O
independent	O
prognostic	O
factors	O
for	O
survival	O
.	O

Increased	O
conduit	O
vessel	O
stiffness	O
,	O
as	O
assessed	O
by	O
pulse	O
pressure	O
,	O
may	O
contribute	O
to	O
increased	O
mortality	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
,	O
independent	O
of	O
mean	O
arterial	O
pressure	O
.	O

Training	O
referential	O
communicative	O
skills	O
to	O
individuals	O
with	O
autism	O
spectrum	O
disorder	O
:	O
a	O
pilot	O
study	O
.	O

The	O
present	O
study	O
reports	O
the	O
effects	O
of	O
referential	O
communication	O
training	O
in	O
individuals	O
formally	O
diagnosed	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O

Participants	O
were	O
20	O
children	O
with	O
ASD	O
(	O
M	O
age	O
=	O
14.3	O
yr.	O
,	O
SD	O
=	O
4.2	O
;	O
6	O
girls	O
,	O
14	O
boys	O
)	O
in	O
the	O
role	O
of	O
speakers	O
and	O
20	O
control	O
children	O
,	O
who	O
acted	O
as	O
listeners	O
.	O

They	O
were	O
all	O
enrolled	O
in	O
mainstream	O
compulsory	O
education	O
.	O

Inclusion/exclusion	O
criteria	O
were	O
defined	O
according	O
to	O
the	O
clinical	O
diagnosis	O
of	O
ASD	O
,	O
the	O
presence	O
or	O
absence	O
of	O
additional	O
or	O
associated	O
disability	O
,	O
previous	O
training	O
in	O
referential	O
communication	O
,	O
and	O
any	O
drug	O
treatment	O
.	O

Speakers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
(	O
trained	O
vs	O
untrained	O
)	O
.	O

Linguistic	O
age	O
,	O
cognitive	O
level	O
and	O
autistic	O
symptoms	O
were	O
analyzed	O
,	O
respectively	O
,	O
with	O
the	O
Peabody	O
Picture	O
Vocabulary	O
Test	O
(	O
PPVT	O
)	O
,	O
the	O
Wechsler	O
Intelligence	O
Scale	O
(	O
WISC-R	O
or	O
WAIS-III	O
)	O
,	O
and	O
the	O
Autistic	O
Behavior	O
Checklist	O
(	O
ABC	O
)	O
.	O

Communicative	O
abilities	O
were	O
analyzed	O
through	O
two	O
indexes	O
related	O
to	O
message	O
complexity	O
and	O
self-regulation	O
.	O

The	O
trained	O
group	O
was	O
trained	O
in	O
referential	O
communication	O
tasks	O
(	O
task	O
analysis	O
,	O
role	O
taking	O
,	O
and	O
task	O
evaluation	O
)	O
,	O
while	O
the	O
untrained	O
group	O
took	O
part	O
in	O
a	O
communicative	O
game	O
but	O
without	O
any	O
specific	O
communicative	O
training	O
.	O

The	O
results	O
showed	O
that	O
the	O
complexity	O
of	O
emitted	O
messages	O
had	O
improved	O
statistically	O
significantly	O
in	O
the	O
trained	O
group	O
as	O
an	O
effect	O
of	O
training	O
.	O

Ecological	O
referential	O
communication	O
is	O
shown	O
to	O
be	O
an	O
appropriate	O
paradigm	O
for	O
studying	O
the	O
communicative	O
process	O
and	O
its	O
products	O
and	O
could	O
be	O
used	O
to	O
develop	O
and	O
implement	O
a	O
training	O
program	O
focused	O
on	O
those	O
skills	O
in	O
which	O
individuals	O
with	O
ASD	O
are	O
most	O
deficient	O
.	O

Are	O
oral	O
cathartics	O
of	O
value	O
in	O
optimizing	O
the	O
gallium	O
scan	O
?	O
Concise	O
communication	O
.	O

The	O
normal	O
intestinal	O
secretion	O
of	O
9-15	O
%	O
of	O
an	O
administered	O
dose	O
of	O
gallium-67	O
may	O
prevent	O
early	O
detection	O
of	O
intra-abdominal	O
disease	O
.	O

We	O
randomized	Condition
50	SampleSize
patients	O
to	O
receive	O
either	O
no	O
bowel	O
preparation	O
or	O
30	O
cc	O
of	O
milk	O
of	O
magnesia	O
plus	O
5	O
cc	O
of	O
cascara	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
groups	O
in	O
frequency	O
with	O
which	O
gallium	O
interfered	O
with	O
readings	O
or	O
time	O
to	O
complete	O
the	O
study	O
.	O

ROMEO	O
:	O
rethink	O
organization	O
to	O
improve	O
education	O
and	O
outcomes	O
.	O

AIMS	O
Scarcity	O
of	O
resources	O
,	O
expertise	O
and	O
evidence-based	O
models	O
have	O
so	O
far	O
limited	O
delivery	O
of	O
patient-centred	O
diabetes	O
education	O
.	O

We	O
have	O
developed	O
and	O
validated	O
a	O
group	O
care	O
approach	O
that	O
is	O
applicable	O
to	O
everyday	O
clinical	O
practice	O
and	O
cost-effective	O
in	O
improving	O
metabolic	O
control	O
,	O
knowledge	O
of	O
diabetes	O
,	O
health	O
behaviours	O
,	O
and	O
quality	O
of	O
life	O
in	O
Type	O
2	O
diabetes	O
.	O

A	O
clinical	O
trial	O
(	O
ROMEO	O
)	O
was	O
planned	O
to	O
evaluate	O
applicability	O
and	O
reproducibility	O
of	O
group	O
care	O
in	O
other	O
outpatients	O
facilities	O
and	O
assess	O
its	O
impact	O
on	O
a	O
larger	O
patient	O
population	O
.	O

METHODS	O
Multicentre	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
of	O
group	O
vs.	O
individual	O
care	O
in	O
the	O
routine	O
management	O
of	O
Type	O
2	O
diabetes	O
.	O

Nine	O
hundred	O
patient	O
aged	O
<	O
80	O
,	O
with	O
diabetes	O
of	O
>	O
or	O
=1	O
year	O
known	O
duration	O
,	O
treated	O
by	O
either	O
diet	O
alone	O
or	O
diet	O
and	O
oral	O
agents	O
,	O
will	O
be	O
recruited	O
in	O
15	O
centres	O
and	O
followed	O
for	O
4	O
years	O
.	O

Training	O
of	O
physicians	O
,	O
nurses	O
and	O
dietitians	O
included	O
preparation	O
of	O
operating	O
manual	O
and	O
videos	O
,	O
interactive	O
sessions	O
,	O
and	O
evaluation	O
of	O
local	O
facilities	O
and	O
resources	O
.	O

RESULTS	O
PRIMARY	O
MEASUREMENTS	O
3-monthly	O
HbA1c	O
,	O
fasting	O
blood	O
glucose	O
,	O
body	O
weight	O
,	O
waist-hip	O
ratio	O
,	O
yearly	O
blood	O
lipids	O
,	O
and	O
bi-yearly	O
assessment	O
of	O
knowledge	O
of	O
diabetes	O
,	O
health	O
behaviours	O
and	O
quality	O
of	O
life	O
.	O

SECONDARY	O
OUTCOMES	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
,	O
evaluation	O
of	O
ECG	O
for	O
ischaemia	O
and	O
QT	O
interval	O
,	O
hypoglycaemic	O
and	O
anti-hypertensive	O
medication	O
and	O
cardiovascular	O
events	O
.	O

Analysis	O
will	O
be	O
by	O
intention-to-treat	O
.	O

DISCUSSION	O
If	O
ROMEO	O
confirms	O
that	O
group	O
care	O
can	O
be	O
successfully	O
implemented	O
in	O
different	O
clinics	O
,	O
a	O
novel	O
clinico-pedagogic	O
tool	O
will	O
have	O
been	O
acquired	O
to	O
support	O
patient-centred	O
education	O
,	O
improve	O
lifestyle	O
and	O
outcomes	O
,	O
support	O
team	O
work	O
,	O
enhance	O
providers	O
'	O
attitudes	O
and	O
competencies	O
and	O
ameliorate	O
diabetes	O
care	O
organization	O
.	O

Intramuscular	O
depot	O
medroxyprogesterone	O
versus	O
oral	O
megestrol	O
for	O
the	O
control	O
of	O
postmenopausal	O
hot	O
flashes	O
in	O
breast	O
cancer	O
patients	O
:	O
a	O
randomized	O
study	O
.	O

BACKGROUND	O
Hot	O
flashes	O
are	O
frequent	O
in	O
postmenopausal	O
breast	O
cancer	O
patients	O
,	O
especially	O
when	O
treated	O
with	O
tamoxifen	O
.	O

Estrogen	O
replacement	O
therapy	O
is	O
the	O
most	O
effective	O
treatment	O
for	O
hot	O
flashes	O
,	O
but	O
its	O
use	O
is	O
controversial	O
in	O
breast	O
cancer	O
survivors	O
.	O

Progestins	O
may	O
offer	O
a	O
good	O
alternative	O
for	O
the	O
control	O
of	O
hot	O
flashes	O
in	O
this	O
setting	O
;	O
in	O
particular	O
,	O
oral	O
megestrol	O
acetate	O
has	O
been	O
proven	O
effective	O
in	O
a	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O

With	O
the	O
aim	O
of	O
further	O
improving	O
these	O
results	O
,	O
we	O
have	O
designed	O
a	O
randomized	O
study	O
comparing	O
oral	O
megestrol	O
acetate	O
with	O
depot	O
intramuscular	O
(	O
i.m	O
.	O

)	O
medroxyprogesterone	O
acetate	O
(	O
MPA	O
)	O
for	O
the	O
control	O
of	O
hot	O
flashes	O
in	O
postmenopausal	O
patients	O
with	O
a	O
history	O
of	O
breast	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
Seventy-one	O
postmenopausal	O
patients	O
were	O
randomized	O
to	O
receive	O
an	O
i.m	O
.	O

injection	O
of	O
depot	O
MPA	O
500	O
mg	O
on	O
days	O
1	O
,	O
14	O
and	O
28	O
,	O
or	O
oral	O
megestrol	O
acetate	O
40	O
mg	O
daily	O
for	O
6	O
weeks	O
.	O

Patients	O
recorded	O
daily	O
the	O
number	O
and	O
severity	O
of	O
their	O
hot	O
flashes	O
;	O
response	O
was	O
defined	O
as	O
a	O
>	O
or	O
=50	O
%	O
decrease	O
in	O
the	O
number	O
and	O
severity	O
of	O
hot	O
flashes	O
.	O

RESULTS	O
At	O
week	O
6	O
,	O
hot	O
flashes	O
were	O
reduced	O
by	O
86	O
%	O
on	O
average	O
in	O
the	O
whole	O
group	O
of	O
patients	O
,	O
without	O
significant	O
differences	O
between	O
the	O
two	O
progestins	O
.	O

Response	O
was	O
obtained	O
by	O
75	O
and	O
67	O
%	O
of	O
patients	O
receiving	O
MPA	O
or	O
megestrol	O
,	O
respectively	O
(	O
P	O
=	O
0.5	O
)	O
.	O

Responders	O
were	O
followed	O
to	O
assess	O
maintenance	O
of	O
response	O
(	O
without	O
further	O
treatment	O
)	O
,	O
which	O
was	O
significantly	O
better	O
with	O
i.m	O
.	O

MPA	O
:	O
in	O
this	O
group	O
,	O
89	O
%	O
of	O
responders	O
still	O
showed	O
a	O
benefit	O
at	O
week	O
24	O
,	O
compared	O
with	O
45	O
%	O
in	O
the	O
megestrol	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O

CONCLUSIONS	O
Our	O
study	O
shows	O
that	O
a	O
short	O
cycle	O
of	O
i.m	O
.	O

depot	O
MPA	O
injections	O
provides	O
significant	O
and	O
long-lasting	O
relief	O
from	O
postmenopausal	O
hot	O
flashes	O
in	O
patients	O
with	O
a	O
history	O
of	O
breast	O
cancer	O
,	O
offering	O
an	O
alternative	O
to	O
estrogen	O
replacement	O
therapy	O
or	O
prolonged	O
administration	O
of	O
oral	O
megestrol	O
.	O

[	O
Neoton	O
and	O
thrombolytic	O
therapy	O
of	O
myocardial	Condition
infarction	Condition
]	O
.	O

AIM	O
To	O
evaluate	O
neoton	O
therapy	O
effects	O
in	O
acute	Condition
myocardial	Condition
infarction	Condition
(	Condition
MI	Condition
)	Condition
on	O
systolic	O
function	O
of	O
the	O
left	O
ventricle	O
,	O
arrhythmia	Condition
and	O
clinical	O
symptoms	O
in	O
patients	O
on	O
thrombolytic	O
therapy	O
(	O
TLT	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
106	SampleSize
males	Sex
with	O
Q-MI	Condition
entered	O
the	O
study	O
.	O

47	O
received	O
treatment	O
without	O
TLT	O
and	O
neoton	O
,	O
30	O
patients	O
received	O
TLT	O
with	O
streptokinase	O
preparations	O
,	O
29	O
patients	O
were	O
given	O
streptokinase	O
preparations	O
and	O
neoton	O
.	O

Left	O
ventricular	O
systolic	O
function	O
was	O
measured	O
by	O
echocardiography	O
on	O
day	O
1	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
21	O
and	O
28	O
;	O
arrhythmia	O
was	O
analysed	O
at	O
Holter	O
monitoring	O
in	O
day	O
1	O
and	O
2	O
of	O
MI	O
.	O

RESULTS	O
TLT	O
failed	O
to	O
arrest	O
progression	O
of	O
left	O
ventricular	O
dilation	O
by	O
the	O
end	O
of	O
the	O
hospital	O
stay	O
.	O

Patients	O
given	O
neoton	O
in	O
acute	O
period	O
of	O
MI	O
had	O
no	O
increase	O
in	O
the	O
end	O
systolic	O
and	O
diastolic	O
volumes	O
of	O
the	O
left	O
ventricle	O
in	O
the	O
course	O
of	O
the	O
first	O
months	O
after	O
MI	O
onset	O
.	O

Antiarrhythmic	O
action	O
of	O
neoton	O
manifested	O
on	O
MI	O
day	O
2	O
.	O

CONCLUSION	O
Neoton	O
given	O
to	O
MI	O
patients	O
receiving	O
TLT	O
prevents	O
progression	O
of	O
left	O
ventricular	O
systolic	O
dysfunction	O
and	O
establishment	O
of	O
predictors	O
of	O
unfavourable	O
outcome	O
.	O

Ketorolac	O
versus	O
fentanyl	O
for	O
gynaecological	Condition
day-case	Condition
surgery	Condition
.	O

The	O
effectiveness	O
of	O
fentanyl	O
and	O
ketorolac	O
in	O
providing	O
analgesia	O
for	O
day-case	Condition
gynaecological	Condition
procedures	Condition
was	O
evaluated	O
in	O
55	SampleSize
healthy	Condition
volunteers	Condition
in	O
a	O
single	O
blinded	O
fashion	O
.	O

Fentanyl	O
(	O
1	O
mcg/kg	O
iv	O
)	O
and	O
ketorolac	O
(	O
30	O
mg	O
im	O
)	O
were	O
administered	O
immediately	O
following	O
induction	O
of	O
anaesthesia	O
.	O

Anaesthesia	O
was	O
standardized	O
with	O
propofol	O
,	O
nitrous	O
oxide	O
and	O
enflurane	O
.	O

Outcome	O
variables	O
assessed	O
were	O
pain	O
,	O
additional	O
analgesic	O
requirements	O
,	O
and	O
incidence	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
.	O

All	O
variables	O
were	O
recorded	O
at	O
15	O
minutes	O
,	O
2	O
hours	O
and	O
24	O
hours	O
postoperatively	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
with	O
respect	O
to	O
any	O
of	O
the	O
measured	O
variables	O
.	O

Both	O
drugs	O
were	O
ineffective	O
as	O
sole	O
analgesic	O
agents	O
in	O
half	O
of	O
their	O
respective	O
groups	O
.	O

It	O
may	O
be	O
that	O
a	O
combination	O
of	O
these	O
drugs	O
,	O
providing	O
a	O
multireceptor	O
approach	O
to	O
analgesia	O
,	O
will	O
prove	O
to	O
be	O
more	O
effective	O
.	O

Heat-exercise	O
performance	O
of	O
pyridostigmine-treated	O
subjects	O
wearing	O
chemical	O
protective	O
clothing	O
.	O

Pyridostigmine	O
bromide	O
is	O
currently	O
the	O
pretreatment	O
of	O
choice	O
for	O
operation	O
in	O
a	O
chemical	O
warfare	O
(	O
CW	O
)	O
environment	O
.	O

Under	O
CW	O
conditions	O
,	O
subjects	O
are	O
exposed	O
to	O
thermal	Condition
stress	Condition
caused	O
by	O
CW	O
protective	O
clothing	O
.	O

This	O
investigation	O
was	O
conducted	O
to	O
determine	O
if	O
pyridostigmine	O
affects	O
various	O
physiological	O
and	O
biophysical	O
parameters	O
of	O
human	O
temperature	O
regulation	O
in	O
subjects	O
wearing	O
CW	O
protective	O
clothing	O
.	O

Pyridostigmine	O
was	O
administered	O
orally	O
in	O
a	O
randomized	O
double-blind	O
cross-over	O
study	O
in	O
four	O
doses	O
of	O
30	O
mg	O
every	O
8	O
h.	O
An	O
average	O
of	O
33	O
%	O
whole	O
blood	O
cholinesterase	O
inhibition	O
was	O
induced	O
in	O
the	O
pyridostigmine	O
treated	O
group	O
4	O
h	O
after	O
ingestion	O
of	O
last	O
tablet	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
170	O
min	O
exercise-heat	O
stress	O
(	O
Tdb	O
=	O
33	O
degrees	O
C	O
;	O
rh	O
=	O
60	O
%	O
)	O
consisting	O
of	O
60	O
min	O
in	O
a	O
sitting	O
position	O
and	O
two	O
50-min	O
walks	O
(	O
1.39	O
m.s-1	O
,	O
5	O
%	O
grade	O
)	O
separated	O
by	O
10	O
min	O
of	O
rest	O
.	O

Non-evaporative	O
heat	O
exchange	O
was	O
significantly	O
higher	O
,	O
-14.0	O
and	O
-10.6	O
W.m-2	O
(	O
p	O
less	O
than	O
0.03	O
)	O
,	O
for	O
the	O
pyridostigmine-treated	O
subjects	O
.	O

No	O
additional	O
differences	O
were	O
found	O
between	O
treatments	O
in	O
the	O
physiological	O
responses	O
and	O
heat	O
balance	O
parameters	O
at	O
the	O
end	O
of	O
exposure	O
:	O
heart	O
rate	O
(	O
HR	O
)	O
was	O
(	O
mean	O
+/-	O
S.D	O
.	O

)	O
154	O
+/-	O
16	O
and	O
151	O
+/-	O
24	O
bpm	O
,	O
rectal	O
temperature	O
(	O
Tre	O
)	O
was	O
39.0	O
+/-	O
0.4	O
and	O
38.9	O
+/-	O
0.2	O
degrees	O
C	O
,	O
heat	O
storage	O
over	O
the	O
2	O
h	O
of	O
exercise	O
was	O
62	O
+/-	O
15	O
and	O
70	O
+/-	O
15	O
W.m-2	O
,	O
and	O
sweat	O
rate	O
was	O
832	O
+/-	O
185	O
and	O
748	O
+/-	O
52	O
g.h-1	O
,	O
in	O
the	O
pyridostigmine	O
and	O
placebo	O
treatments	O
,	O
respectively	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
randomized	O
trial	O
of	O
radiation	O
therapy	O
compared	O
to	O
split	O
course	O
radiation	O
therapy	O
combined	O
with	O
mitomycin	O
C	O
and	O
5	O
fluorouracil	O
as	O
initial	O
treatment	O
for	O
advanced	O
laryngeal	O
and	O
hypopharyngeal	O
squamous	O
carcinoma	O
.	O

Two	O
hundred	O
and	O
twelve	O
patients	O
with	O
previously	Condition
untreated	Condition
advanced	Condition
squamous	Condition
carcinoma	Condition
of	Condition
the	Condition
larynx	Condition
or	Condition
hypopharynx	Condition
were	O
randomized	O
to	O
receive	O
initial	O
treatment	O
with	O
radiotherapy	O
,	O
50	O
Gy	O
in	O
20	O
fractions	O
in	O
28	O
days	O
or	O
split	O
course	O
radiotherapy	O
and	O
concurrent	O
chemotherapy	O
,	O
25	O
Gy	O
in	O
10	O
fractions	O
in	O
14	O
days	O
followed	O
by	O
a	O
4	O
week	O
rest	O
and	O
a	O
further	O
25	O
Gy	O
in	O
10	O
fractions	O
in	O
14	O
days	O
starting	O
on	O
day	O
43	O
;	O
Mitomycin	O
C	O
was	O
given	O
on	O
day	O
1	O
and	O
day	O
43	O
and	O
5FU	O
continuous	O
infusions	O
on	O
days	O
1	O
--	O
4	O
and	O
days	O
43	O
--	O
46	O
.	O

Surgery	O
was	O
reserved	O
for	O
persistent	O
or	O
recurrent	O
disease	O
.	O

Two	O
hundred	O
and	O
nine	O
of	O
the	O
212	O
patients	O
randomized	O
were	O
included	O
in	O
the	O
analyses	O
.	O

Outcome	O
analyses	O
were	O
performed	O
at	O
a	O
median	O
follow-up	O
interval	O
of	O
4.4	O
years	O
.	O

No	O
patients	O
were	O
lost	O
to	O
follow-up	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
arms	O
for	O
the	O
end	O
points	O
of	O
local	O
relapse-free	O
rate	O
(	O
p	O
=	O
0.91	O
)	O
,	O
regional	O
relapse-free	O
rate	O
(	O
p	O
=	O
0.17	O
,	O
adjusted	O
)	O
or	O
overall	O
survival	O
(	O
p	O
=	O
0.86	O
)	O
.	O

Eight-eight	O
patients	O
had	O
attempted	O
surgical	O
resection	O
following	O
radiotherapy	O
failure	O
.	O

The	O
contribution	O
of	O
salvage	O
surgery	O
to	O
overall	O
survival	O
was	O
similar	O
for	O
both	O
arms	O
of	O
the	O
study	O
as	O
was	O
the	O
surgical	O
complication	O
rate	O
.	O

Serious	O
late	O
radiation	O
toxicity	O
was	O
minimal	O
(	O
3	O
%	O
in	O
the	O
RT	O
group	O
,	O
0	O
%	O
in	O
the	O
radiation	O
therapy	O
plus	O
chemotherapy	O
group	O
)	O
.	O

The	O
result	O
of	O
the	O
trial	O
shows	O
no	O
advantage	O
in	O
terms	O
of	O
local	O
control	O
or	O
survival	O
for	O
the	O
experimental	O
treatment	O
arm	O
of	O
split	O
course	O
radiotherapy	O
and	O
concurrent	O
chemotherapy	O
with	O
Mitomycin	O
C	O
and	O
5	O
Fluorouracil	O
compared	O
to	O
radiotherapy	O
alone	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
treatment	O
before	O
doxorubicin	O
and	O
cyclophosphamide	O
chemotherapy	O
priming	O
in	O
women	O
with	O
early-stage	O
breast	O
cancer	O
.	O

PURPOSE	O
To	O
determine	O
if	O
inhibition	O
of	O
stem-cell	O
activity	O
induced	O
by	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
[	O
GM-CSF	O
]	O
;	O
Sargramostim	O
;	O
Immunex	O
Corporation	O
,	O
Seattle	O
,	O
WA	O
)	O
withdrawal	O
or	O
priming	O
protects	O
hematopoietic	O
stem	O
cells	O
from	O
the	O
cytotoxic	O
effects	O
of	O
adjuvant	O
chemotherapy	O
for	O
early-stage	O
breast	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
Serial	O
blood	O
counts	O
were	O
performed	O
in	O
20	O
women	O
with	O
early-stage	O
breast	O
cancer	O
receiving	O
four	O
courses	O
of	O
cyclophosphamide	O
and	O
doxorubicin	O
chemotherapy	O
.	O

By	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
balanced	O
randomization	O
,	O
subjects	O
received	O
GM-CSF	O
priming	O
on	O
days	O
5	O
to	O
1	O
for	O
courses	O
1	O
and	O
3	O
or	O
courses	O
2	O
and	O
4	O
.	O

RESULTS	O
Compared	O
with	O
before	O
priming	O
,	O
after	O
priming	O
the	O
times	O
to	O
neutrophil	O
nadir	O
(	O
12.8	O
+/-	O
2.5	O
days	O
v	O
14.8	O
+/-	O
1.5	O
days	O
,	O
respectively	O
;	O
P	O
=.0001	O
)	O
and	O
platelet	O
nadir	O
(	O
mean	O
+/-	O
SD	O
,	O
10.1	O
+/-	O
1.9	O
days	O
v	O
11.1	O
+/-	O
2.2	O
days	O
,	O
P	O
<	O
.05	O
)	O
were	O
shorter	O
,	O
indicating	O
a	O
shift	O
of	O
cytotoxicity	O
to	O
later	O
progenitors	O
.	O

The	O
neutrophil	O
nadir	O
was	O
similar	O
with	O
and	O
without	O
priming	O
(	O
mean	O
+/-	O
SD	O
,	O
490	O
+/-	O
310/microL	O
v	O
550	O
+/-	O
350/microL	O
,	O
respectively	O
;	O
P	O
=.2	O
)	O
;	O
however	O
,	O
on	O
day	O
16	O
the	O
mean	O
neutrophil	O
count	O
was	O
higher	O
(	O
mean	O
+/-	O
SD	O
,	O
1030	O
+/-	O
580/microL	O
v	O
690	O
+/-	O
370/microL	O
,	O
P	O
=.004	O
)	O
,	O
and	O
the	O
proportion	O
of	O
patients	O
with	O
a	O
neutrophil	O
count	O
less	O
than	O
500/microL	O
was	O
lower	O
after	O
priming	O
than	O
before	O
(	O
six	O
of	O
35	O
or	O
17	O
.	O

1	O
%	O
v	O
12	O
of	O
34	O
or	O
35.3	O
%	O
,	O
respectively	O
;	O
P	O
=.04	O
)	O
.	O

The	O
platelet	O
nadir	O
was	O
higher	O
(	O
mean	O
+/-	O
SD	O
,	O
166,000	O
+/-	O
51,000/microL	O
after	O
priming	O
v	O
151,000	O
+/-	O
45,000/microL	O
before	O
priming	O
,	O
P	O
=.007	O
)	O
,	O
and	O
the	O
duration	O
of	O
thrombocytopenia	O
,	O
ie	O
,	O
a	O
platelet	O
count	O
less	O
than	O
150,000/microL	O
,	O
was	O
shorter	O
(	O
1.5	O
+/-	O
2.1	O
days	O
v	O
2.8	O
+/-	O
2.9	O
days	O
,	O
P	O
=.0025	O
)	O
after	O
priming	O
.	O

Episodes	O
of	O
fever	O
and	O
neutropenia	O
were	O
not	O
observed	O
.	O

CONCLUSIONS	O
GM-CSF	O
priming	O
from	O
days	O
5	O
to	O
1	O
before	O
doxorubicin	O
and	O
cyclophosphamide	O
chemotherapy	O
was	O
associated	O
with	O
an	O
earlier	O
neutrophil	O
and	O
platelet	O
nadir	O
.	O

On	O
day	O
16	O
,	O
a	O
higher	O
mean	O
neutrophil	O
count	O
and	O
a	O
lower	O
proportion	O
of	O
patients	O
with	O
severe	O
(	O
<	O
500/microL	O
)	O
neutropenia	O
were	O
observed	O
.	O

Beneficial	O
effects	O
on	O
the	O
severity	O
and	O
duration	O
of	O
thrombocytopenia	O
were	O
also	O
noted	O
.	O

These	O
observations	O
support	O
the	O
hypothesis	O
that	O
GM-CSF	O
priming	O
protects	O
hematopoietic	O
progenitors	O
from	O
the	O
cytotoxic	O
effects	O
of	O
chemotherapy	O
.	O

A	O
randomized	O
controlled	O
trial	O
of	O
R-salbutamol	O
for	O
topical	O
treatment	O
of	O
discoid	O
lupus	O
erythematosus	O
.	O

BACKGROUND	O
In	O
a	O
recent	O
open	O
pilot	O
trial	O
,	O
R-salbutamol	O
sulphate	O
,	O
a	O
well-known	O
molecule	O
with	O
anti-inflammatory	O
effects	O
,	O
was	O
tested	O
successfully	O
on	O
patients	O
with	O
therapy-resistant	O
discoid	O
lupus	O
erythematosus	O
(	O
DLE	O
)	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
R-salbutamol	O
cream	O
0.5	O
%	O
vs.	O
placebo	O
on	O
DLE	O
lesions	O
in	O
a	O
multicentre	O
,	O
double-blinded	O
,	O
randomized	O
,	O
placebo-controlled	O
phase	O
II	O
trial	O
.	O

METHODS	O
Thirty-seven	O
patients	O
with	O
at	O
least	O
one	O
newly	O
developed	O
DLE	O
lesion	O
were	O
randomized	O
-	O
19	O
to	O
the	O
R-salbutamol	O
cream	O
0.5	O
%	O
and	O
18	O
to	O
placebo	O
-	O
and	O
treated	O
twice	O
daily	O
for	O
8	O
weeks	O
.	O

Efficacy	O
was	O
evaluated	O
through	O
scores	O
of	O
erythema	O
,	O
scaling/hypertrophy	O
and	O
induration	O
as	O
well	O
as	O
pain	O
and	O
itching	O
;	O
general	O
improvement	O
scored	O
by	O
the	O
investigator	O
and	O
global	O
improvement	O
scored	O
by	O
patients	O
'	O
assessment	O
were	O
also	O
evaluated	O
.	O

RESULTS	O
The	O
mean	O
area	O
under	O
the	O
curve	O
of	O
improvement	O
for	O
scaling/hypertrophy	O
,	O
pain	O
,	O
itching	O
and	O
global	O
patient	O
assessment	O
was	O
significantly	O
better	O
for	O
the	O
actively	O
treated	O
patients	O
as	O
compared	O
with	O
placebo	O
(	O
scaling/hypertrophy	O
,	O
P	O
=	O
0.0262	O
;	O
pain	O
,	O
P	O
=	O
0.0238	O
;	O
itching	O
,	O
P	O
=	O
0.0135	O
;	O
global	O
patient	O
assessment	O
,	O
P	O
=	O
0.045	O
)	O
.	O

Moreover	O
,	O
the	O
percentage	O
of	O
patients	O
without	O
induration	O
was	O
significantly	O
higher	O
in	O
the	O
active	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0.013	O
)	O
,	O
and	O
a	O
statistically	O
significantly	O
greater	O
decrease	O
in	O
the	O
size	O
of	O
the	O
lesional	O
area	O
was	O
also	O
seen	O
in	O
the	O
overall	O
analysis	O
of	O
the	O
R-salbutamol-treated	O
patients	O
(	O
P	O
=	O
0.0197	O
)	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
reported	O
.	O

CONCLUSIONS	O
Application	O
of	O
R-salbutamol	O
cream	O
0.5	O
%	O
was	O
safe	O
and	O
well	O
tolerated	O
.	O

Statistically	O
significant	O
effects	O
were	O
seen	O
on	O
scaling/hypertrophy	O
,	O
induration	O
,	O
pain	O
and	O
itching	O
as	O
well	O
as	O
patient	O
global	O
assessment	O
,	O
suggesting	O
that	O
R-salbutamol	O
could	O
be	O
a	O
promising	O
new	O
topical	O
therapy	O
alternative	O
for	O
DLE	O
.	O

Ascaris	O
and	O
growth	O
rates	O
:	O
a	O
randomized	O
trial	O
of	O
treatment	O
.	O

Three	O
hundred	O
forty-one	O
Tanzanian	O
preschool	O
children	O
were	O
randomly	O
assigned	O
to	O
levamisole	O
or	O
placebo	O
treatment	O
given	O
at	O
three-month	O
intervals	O
.	O

Weights	O
and	O
heights	O
were	O
measured	O
at	O
the	O
tri-monthly	O
treatment	O
visits	O
for	O
a	O
period	O
of	O
one	O
year	O
.	O

Among	O
the	O
273	O
children	O
who	O
were	O
seen	O
and	O
weighed	O
at	O
the	O
one-year	O
follow-up	O
visit	O
,	O
the	O
rate	O
of	O
weight	O
gain	O
was	O
8	O
per	O
cent	O
greater	O
for	O
those	O
receiving	O
levamisole	O
than	O
for	O
placebo-treated	O
controls	O
(	O
p	O
=	O
.06	O
)	O
.	O

In	O
78	O
children	O
known	O
to	O
be	O
infected	O
with	O
Ascaris	O
at	O
baseline	O
,	O
the	O
rate	O
of	O
weight	O
gain	O
was	O
21	O
per	O
cent	O
greater	O
in	O
children	O
treated	O
with	O
levamisole	O
than	O
in	O
those	O
receiving	O
placebo	O
(	O
p	O
=	O
.03	O
)	O
.	O

The	O
rate	O
of	O
height	O
gain	O
was	O
no	O
different	O
for	O
treatment	O
and	O
placebo	O
groups	O
.	O

Safety	O
of	O
the	O
combination	O
of	O
valsartan	O
and	O
benazepril	O
in	O
patients	O
with	O
chronic	Condition
renal	Condition
disease	Condition
.	O

European	O
Group	O
for	O
the	O
Investigation	O
of	O
Valsartan	O
in	O
Chronic	O
Renal	O
Disease	O
.	O

OBJECTIVE	O
Several	O
experimental	O
and	O
clinical	O
studies	O
indicate	O
that	O
the	O
renin	O
system	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
progressing	O
renal	O
disease	O
.	O

The	O
combination	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
and	O
an	O
angiotensin	O
receptor	O
blocker	O
could	O
provide	O
a	O
higher	O
degree	O
of	O
blockade	O
of	O
the	O
renin-angiotensin	O
system	O
than	O
either	O
agent	O
alone	O
.	O

Such	O
enhanced	O
suppression	O
might	O
be	O
of	O
benefit	O
for	O
patients	O
exhibiting	O
a	O
progressive	Condition
decline	Condition
in	Condition
renal	Condition
function	Condition
because	O
of	O
chronic	Condition
renal	Condition
disease	Condition
.	O

METHODS	O
A	O
pilot	O
multinational	O
,	O
multicentre	O
,	O
randomized	O
,	O
active-controlled	O
,	O
parallel	O
group	O
open-label	O
study	O
has	O
been	O
conducted	O
in	O
a	O
group	O
of	O
patients	O
with	O
progressive	Condition
chronic	Condition
renal	Condition
failure	Condition
(	O
creatinine	Condition
clearance	Condition
20-45	Condition
ml/min	Condition
)	O
either	O
with	Condition
or	Condition
without	Condition
proteinuria	Condition
and	Condition
hypertension	Condition
.	O

The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
tolerability	O
of	O
the	O
combination	O
of	O
valsartan	O
and	O
benazepril	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
group	O
1	O
received	O
valsartan	O
160	O
mg	O
once	O
daily	O
(	O
n	O
=	O
22	SampleSize
)	O
;	O
group	O
2	O
received	O
valsartan	O
80	O
mg	O
once	O
daily	O
plus	O
benazepril	O
5	O
or	O
10	O
mg	O
once	O
daily	O
(	O
n	O
=	O
42	SampleSize
)	O
;	O
group	O
3	O
received	O
valsartan	O
160	O
mg	O
once	O
daily	O
plus	O
benazepril	O
5	O
or	O
10	O
mg	O
once	O
daily	O
(	O
n	O
=	O
44	SampleSize
)	O
.	O

The	O
study	O
lasted	O
for	O
5	O
weeks	O
,	O
and	O
in	O
groups	O
2	O
and	O
3	O
benazepril	O
was	O
added	O
on	O
top	O
of	O
valsartan	O
after	O
the	O
first	O
week	O
of	O
therapy	O
with	O
the	O
angiotensin	O
receptor	O
blocker	O
.	O

RESULTS	O
Serum	O
creatinine	O
increased	O
in	O
all	O
three	O
groups	O
(	O
mean	O
change	O
within	O
a	O
group	O
:	O
11	O
micromol/l	O
in	O
group	O
1	O
,	O
P=	O
0.045	O
;	O
9	O
micromol/l	O
in	O
group	O
2	O
,	O
P=	O
0.030	O
;	O
15	O
micromol/l	O
in	O
group	O
3	O
,	O
P=	O
0.0006	O
)	O
.	O

Serum	O
potassium	O
also	O
increased	O
in	O
all	O
three	O
groups	O
of	O
patients	O
(	O
mean	O
change	O
within	O
a	O
group	O
:	O
0.28	O
mmol/l	O
in	O
group	O
1	O
,	O
P=	O
0.28	O
;	O
0.48	O
mmol/l	O
in	O
group	O
2	O
,	O
P=	O
0.0008	O
;	O
0.36	O
mmol/l	O
in	O
group	O
3	O
,	O
P=	O
0.02	O
)	O
.	O

After	O
5	O
weeks	O
of	O
treatment	O
,	O
the	O
largest	O
decrease	O
in	O
blood	O
pressure	O
was	O
observed	O
in	O
group	O
3	O
(	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
seated	O
diastolic	O
blood	O
pressure	O
(	O
SDBP	O
)	O
and	O
seated	O
systolic	O
blood	O
pressure	O
(	O
SSBP	O
)	O
,	O
respectively	O
,	O
were	O
:	O
-2.0	O
and	O
-11.5	O
mmHg	O
in	O
group	O
1	O
;	O
-7.6	O
and	O
-15.4	O
mmHg	O
in	O
group	O
2	O
;	O
-12.6	O
and	O
-21.6	O
mmHg	O
in	O
group	O
3	O
)	O
.	O

In	O
addition	O
,	O
both	O
combination	O
treatments	O
resulted	O
in	O
the	O
reduction	O
of	O
proteinuria	O
.	O

The	O
total	O
number	O
of	O
patients	O
with	O
adverse	O
experiences	O
were	O
10	O
(	O
45.5	O
%	O
)	O
,	O
14	O
(	O
33.3	O
%	O
)	O
and	O
11	O
(	O
25	O
%	O
)	O
in	O
groups	O
1,2	O
and	O
3	O
,	O
respectively	O
.	O

In	O
six	O
patients	O
(	O
5.6	O
%	O
)	O
therapy	O
was	O
discontinued	O
as	O
a	O
result	O
of	O
adverse	O
experiences	O
.	O

Only	O
one	O
patient	O
in	O
each	O
of	O
the	O
combined	O
therapy	O
groups	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
hyperkalaemia	O
and	O
no	O
patients	O
were	O
forced	O
to	O
withdraw	O
because	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	O
,	O
acute	O
renal	O
failure	O
or	O
hospitalization	O
.	O

CONCLUSIONS	O
These	O
results	O
indicate	O
that	O
short-term	O
combination	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
and	O
an	O
angiotensin	O
receptor	O
blocker	O
is	O
safe	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
moderate	Condition
chronic	Condition
renal	Condition
failure	Condition
.	O

Family	O
economic	O
empowerment	O
and	O
mental	O
health	O
among	O
AIDS-affected	O
children	O
living	O
in	O
AIDS-impacted	O
communities	O
:	O
evidence	O
from	O
a	O
randomised	O
evaluation	O
in	O
southwestern	O
Uganda	O
.	O

OBJECTIVE	O
The	O
authors	O
examine	O
whether	O
an	O
innovative	O
family	O
economic	O
empowerment	O
intervention	O
addresses	O
mental	O
health	O
functioning	O
of	O
AIDS-affected	O
children	O
in	O
communities	O
heavily	O
impacted	O
by	O
HIV/AIDS	O
in	O
Uganda	O
.	O

METHODS	O
A	O
cluster	O
randomised	O
controlled	O
trial	O
consisting	O
of	O
two	O
study	O
arms	O
,	O
a	O
treatment	O
condition	O
(	O
n=179	O
)	O
and	O
a	O
control	O
condition	O
(	O
n=118	O
)	O
,	O
was	O
used	O
to	O
examine	O
the	O
impact	O
of	O
the	O
family	O
economic	O
empowerment	O
intervention	O
on	O
children	O
's	O
levels	O
of	O
hopelessness	O
and	O
depression	O
.	O

The	O
intervention	O
comprised	O
matched	O
children	O
savings	O
accounts	O
,	O
financial	O
management	O
workshops	O
and	O
mentorship	O
.	O

Data	O
were	O
collected	O
at	O
baseline	O
and	O
12	O
months	O
post-intervention	O
.	O

RESULTS	O
Using	O
multivariate	O
analysis	O
with	O
several	O
socioeconomic	O
controls	O
,	O
the	O
authors	O
find	O
that	O
children	O
in	O
the	O
treatment	O
condition	O
(	O
receiving	O
the	O
intervention	O
)	O
report	O
significant	O
improvement	O
in	O
their	O
mental	O
health	O
functioning	O
.	O

Specifically	O
,	O
the	O
intervention	O
reduces	O
hopelessness	O
and	O
depression	O
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
children	O
in	O
the	O
control	O
condition	O
(	O
not	O
receiving	O
the	O
intervention	O
)	O
report	O
no	O
changes	O
on	O
both	O
measures	O
.	O

CONCLUSIONS	O
The	O
findings	O
indicate	O
that	O
children	O
with	O
poor	O
mental	O
health	O
functioning	O
living	O
in	O
communities	O
affected	O
by	O
HIV/AIDS	O
may	O
benefit	O
from	O
innovative	O
family	O
economic	O
empowerment	O
interventions	O
.	O

As	O
measures	O
of	O
mental	O
health	O
functioning	O
,	O
both	O
hopelessness	O
and	O
depression	O
have	O
long-term	O
negative	O
psychosocial	O
and	O
developmental	O
impacts	O
on	O
children	O
.	O

These	O
findings	O
have	O
implications	O
for	O
public	O
health	O
programmes	O
intended	O
for	O
long-term	O
care	O
and	O
support	O
of	O
children	O
living	O
in	O
resource	O
poor	O
AIDS-impacted	O
communities	O
.	O

Noradrenergic	O
response	O
to	O
intravenous	O
yohimbine	O
in	O
patients	Condition
with	Condition
depression	Condition
and	Condition
comorbidity	Condition
of	Condition
depression	Condition
and	Condition
panic	Condition
.	O

Adrenergic	O
response	O
following	O
infusions	O
of	O
yohimbine	O
or	O
normal	O
saline	O
was	O
evaluated	O
in	O
9	SampleSize
control	O
subjects	O
,	O
8	SampleSize
patients	O
suffering	O
from	O
a	O
major	O
depressive	O
episode	O
(	O
MDE	O
)	O
,	O
and	O
12	SampleSize
patients	O
suffering	O
from	O
concurrent	O
MDE	O
and	O
panic	O
disorder	O
(	O
MDE	O
+	O
P	O
)	O
.	O

Blood	O
was	O
drawn	O
at	O
-20	O
,	O
0	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
45	O
,	O
and	O
90	O
min	O
following	O
the	O
infusions	O
,	O
and	O
assayed	O
for	O
norepinephrine	O
(	O
NE	O
)	O
and	O
3-methoxy-4-hydroxy-phenyl	O
glycol	O
(	O
MHPG	O
)	O
.	O

Although	O
the	O
patient	O
groups	O
exhibited	O
higher	O
baseline	O
NE	O
concentrations	O
,	O
and	O
a	O
greater	O
NE	O
area	O
under	O
the	O
plasma	O
concentration	O
versus	O
time	O
curve	O
(	O
AUC0-90	O
)	O
during	O
the	O
yohimbine	O
infusion	O
,	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

Baseline	O
NE	O
was	O
significantly	O
correlated	O
with	O
the	O
NE	O
AUC0-90	O
in	O
all	O
three	O
groups	O
,	O
suggesting	O
that	O
,	O
although	O
the	O
NE	O
system	O
may	O
be	O
dysregulated	O
in	O
the	O
MDE	O
and	O
MDE	O
+	O
P	O
patients	O
,	O
the	O
NE	O
system	O
still	O
appears	O
to	O
respond	O
somewhat	O
predictably	O
following	O
a	O
challenge	O
,	O
even	O
though	O
the	O
actual	O
magnitude	O
of	O
response	O
may	O
vary	O
.	O

Association	O
of	O
efavirenz	O
hypersusceptibility	O
with	O
virologic	O
response	O
in	O
ACTG	O
368	O
,	O
a	O
randomized	O
trial	O
of	O
abacavir	O
(	O
ABC	O
)	O
in	O
combination	O
with	O
efavirenz	O
(	O
EFV	O
)	O
and	O
indinavir	O
(	O
IDV	O
)	O
in	O
HIV-infected	Condition
subjects	O
with	O
prior	O
nucleoside	O
analog	O
experience	O
.	O

PURPOSE	O
To	O
evaluate	O
the	O
association	O
of	O
efavirenz	O
hypersusceptibility	O
(	O
EFV-HS	O
)	O
with	O
clinical	O
outcome	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
randomized	O
trial	O
of	O
EFV	O
plus	O
indinavir	O
(	O
EFV+IDV	O
)	O
vs.	O
EFV+IDV	O
plus	O
abacavir	O
(	O
ABC	O
)	O
in	O
283	SampleSize
nucleoside-experienced	O
HIV-infected	Condition
patients	O
.	O

METHOD	O
AND	O
RESULTS	O
Rates	O
of	O
virologic	O
failure	O
were	O
similar	O
in	O
the	O
2	O
arms	O
at	O
week	O
16	O
(	O
p	O
=	O
.509	O
)	O
.	O

Treatment	O
discontinuations	O
were	O
more	O
common	O
in	O
the	O
ABC	O
arm	O
(	O
p	O
=	O
.001	O
)	O
.	O

Using	O
logistic	O
regression	O
,	O
there	O
was	O
no	O
association	O
between	O
virologic	O
failure	O
and	O
either	O
baseline	O
ABC	O
resistance	O
or	O
regimen	O
sensitivity	O
score	O
.	O

Using	O
3	O
different	O
genotypic	O
scoring	O
systems	O
,	O
EFV-HS	O
was	O
significantly	O
associated	O
with	O
reduced	O
virologic	O
failure	O
at	O
week	O
16	O
,	O
independent	O
of	O
treatment	O
assignment	O
.	O

In	O
some	O
patients	O
on	O
the	O
nucleoside-sparing	O
arm	O
,	O
the	O
nucleoside-resistance	O
mutation	O
L74V	O
was	O
selected	O
for	O
in	O
combination	O
with	O
the	O
uncommonly	O
occurring	O
EFV-resistance	O
mutations	O
K103N+L100I	O
;	O
L74V	O
was	O
not	O
detected	O
as	O
a	O
minority	O
variant	O
,	O
using	O
clonal	O
sequence	O
analysis	O
,	O
when	O
the	O
nucleoside-sparing	O
regimen	O
was	O
initiated	O
.	O

CONCLUSION	O
Premature	O
treatment	O
discontinuations	O
in	O
the	O
ABC	O
arm	O
and	O
the	O
presence	O
of	O
EFV-HS	O
HIV	O
variants	O
in	O
this	O
patient	O
population	O
likely	O
made	O
it	O
difficult	O
to	O
detect	O
a	O
benefit	O
of	O
adding	O
ABC	O
to	O
EFV+IDV	O
.	O

In	O
addition	O
,	O
L74V	O
,	O
when	O
combined	O
with	O
K103N+L100I	O
,	O
may	O
confer	O
a	O
selective	O
advantage	O
to	O
the	O
virus	O
that	O
is	O
independent	O
of	O
its	O
effects	O
on	O
nucleoside	O
resistance	O
.	O

[	O
Bupivacaine-CO2	O
and	O
bupivacaine-HCl	O
at	O
various	O
injection	O
temperatures	O
in	O
peridural	O
anesthesia	O
for	O
extracorporeal	O
shock	O
wave	O
lithotripsy	O
]	O
.	O

INTRODUCTION	O
The	O
effect	O
of	O
different	O
injection	O
temperatures	O
on	O
carbonated	O
anesthetics	O
has	O
been	O
controversial	O
since	O
1965	O
.	O

The	O
current	O
study	O
was	O
undertaken	O
to	O
determine	O
onset	O
times	O
of	O
sensory	O
and	O
motor	O
blockade	O
after	O
epidural	O
anesthesia	O
with	O
0.5	O
%	O
bupivacaine-CO2	O
and	O
0.5	O
%	O
bupivacaine-HCl	O
at	O
various	O
injection	O
temperatures	O
.	O

MATERIALS	O
AND	O
METHODS	O
The	O
study	O
was	O
performed	O
on	O
90	SampleSize
ASA	Condition
class	Condition
I-II	Condition
urologic	Condition
patients	O
during	O
extracorporeal	O
shock	O
wave	O
lithotripsy	O
.	O

The	O
patients	O
were	O
randomized	O
in	O
six	O
groups	O
to	O
receive	O
either	O
0.5	O
%	O
bupivacaine-CO2	O
or	O
0.5	O
%	O
bupivacaine-HCl	O
at	O
temperatures	O
of	O
4	O
degrees	O
,	O
20	O
degrees	O
,	O
or	O
36	O
degrees	O
C.	O
The	O
six	O
groups	O
were	O
comparable	O
in	O
age	O
,	O
height	O
,	O
and	O
weight	O
.	O

Epidural	O
anesthesia	O
was	O
performed	O
at	O
the	O
L2-3	O
interspace	O
with	O
an	O
18-gauge	O
Tuohy	O
needle	O
using	O
loss	O
of	O
resistance	O
.	O

A	O
catheter	O
was	O
advanced	O
4	O
cm	O
in	O
the	O
epidural	O
space	O
and	O
4	O
ml	O
0.5	O
%	O
bupivacaine	O
with	O
adrenaline	O
1:200,000	O
was	O
given	O
as	O
a	O
test	O
dose	O
.	O

After	O
4	O
min	O
the	O
full	O
anesthetic	O
dose	O
,	O
based	O
on	O
body	O
size	O
,	O
was	O
injected	O
with	O
the	O
patient	O
supine	O
.	O

Sensory	O
blockade	O
was	O
determined	O
by	O
the	O
pinprick	O
method	O
and	O
motor	O
blockade	O
by	O
the	O
Bromage	O
method	O
at	O
2-min	O
intervals	O
for	O
the	O
first	O
20	O
min	O
,	O
at	O
5-min	O
intervals	O
for	O
the	O
next	O
10	O
min	O
,	O
and	O
then	O
every	O
15	O
min	O
to	O
a	O
total	O
of	O
240	O
min	O
.	O

Statistical	O
analysis	O
was	O
done	O
by	O
the	O
Mann-Whitney	O
test	O
,	O
with	O
P	O
less	O
than	O
0.05	O
considered	O
significant	O
.	O

RESULTS	O
Spread	O
of	O
sensory	O
blockade	O
was	O
significantly	O
faster	O
with	O
bupivacaine-CO2	O
and	O
-HCl	O
at	O
a	O
temperature	O
of	O
36	O
degrees	O
C	O
as	O
compared	O
to	O
4	O
degrees	O
or	O
20	O
degrees	O
C	O
(	O
P	O
less	O
than	O
0.05	O
)	O
(	O
Figs	O
.	O

1	O
,	O
2	O
and	O
Table	O
2	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Ambulatory	O
activity	O
of	O
children	O
with	O
cerebral	O
palsy	O
:	O
which	O
characteristics	O
are	O
important	O
?	O
AIM	O
To	O
assess	O
ambulatory	O
activity	O
of	O
children	O
with	O
cerebral	O
palsy	O
(	O
CP	O
)	O
,	O
aged	O
7	O
to	O
13	O
years	O
,	O
and	O
identify	O
associated	O
characteristics	O
.	O

METHOD	O
Sixty-two	O
children	O
with	O
spastic	O
CP	O
(	O
39	O
males	O
,	O
23	O
females	O
;	O
mean	O
age	O
10y	O
1mo	O
,	O
SD	O
1y	O
8mo	O
;	O
age	O
range	O
7-13y	O
)	O
,	O
classified	O
as	O
Gross	O
Motor	O
Function	O
Classification	O
System	O
(	O
GMFCS	O
)	O
levels	O
I	O
to	O
III	O
,	O
participated	O
.	O

Ambulatory	O
activity	O
was	O
measured	O
during	O
1	O
week	O
with	O
a	O
StepWatch	O
activity	O
monitor	O
as	O
steps	O
per	O
day	O
,	O
and	O
time	O
spent	O
at	O
medium	O
and	O
high	O
step	O
rates	O
.	O

Multiple	O
linear	O
regression	O
analyses	O
were	O
performed	O
following	O
a	O
backward	O
selection	O
procedure	O
until	O
only	O
independent	O
variables	O
with	O
p	O
<	O
0.05	O
remained	O
in	O
the	O
model	O
.	O

Ambulatory	O
activity	O
outcome	O
parameters	O
served	O
as	O
dependent	O
variables	O
,	O
and	O
disease	O
,	O
personal	O
,	O
and	O
environmental	O
characteristics	O
as	O
independent	O
variables	O
.	O

Ambulatory	O
activity	O
was	O
corrected	O
for	O
body	O
height	O
.	O

RESULTS	O
Children	O
took	O
more	O
steps	O
during	O
school	O
days	O
(	O
5169	O
steps	O
,	O
SD	O
1641	O
)	O
than	O
during	O
weekend	O
days	O
(	O
4158	O
steps	O
,	O
SD	O
2048	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Higher	O
GMFCS	O
level	O
,	O
bilateral	O
CP	O
,	O
and	O
higher	O
age	O
were	O
associated	O
with	O
lower	O
ambulatory	O
activity	O
on	O
school	O
days	O
(	O
R	O
(	O
2	O
)	O
ranged	O
from	O
43-53	O
%	O
)	O
,	O
whereas	O
bilateral	O
CP	O
,	O
higher	O
age	O
,	O
and	O
no	O
sport	O
club	O
participation	O
were	O
associated	O
with	O
lower	O
ambulatory	O
activity	O
in	O
the	O
weekend	O
(	O
R	O
(	O
2	O
)	O
ranged	O
from	O
21-42	O
%	O
)	O
.	O

Correcting	O
for	O
body	O
height	O
decreased	O
the	O
association	O
with	O
age	O
.	O

INTERPRETATION	O
Interventions	O
should	O
focus	O
at	O
increasing	O
physical	O
activity	O
at	O
the	O
weekend	O
for	O
children	O
with	O
bilateral	O
spastic	O
CP	O
.	O

Xuezhikang	O
,	O
an	O
extract	O
of	O
cholestin	O
,	O
decreases	O
plasma	O
inflammatory	O
markers	O
and	O
endothelin-1	O
,	O
improve	O
exercise-induced	O
ischemia	O
and	O
subjective	O
feelings	O
in	O
patients	O
with	O
cardiac	O
syndrome	O
X	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
Xuezhikang	O
,	O
an	O
extract	O
of	O
cholestin	O
,	O
available	O
from	O
Chinese	O
red	O
yeast	O
rice	O
,	O
could	O
effectively	O
modify	O
lipid	O
profile	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
whether	O
Xuezhikang	O
could	O
modify	O
endothelin-1	O
(	O
ET-1	O
)	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
high-sensitivity	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
and	O
exercise-induced	O
ischemia	O
in	O
patients	O
with	O
cardiac	O
syndrome	O
X	O
(	O
CSX	O
)	O
.	O

Thirty-six	O
patients	O
with	O
CSX	O
were	O
randomly	O
assigned	O
to	O
1200	O
mg/d	O
of	O
Xuezhikang	O
or	O
placebo	O
group	O
(	O
n=18	O
respectively	O
)	O
.	O

Blood	O
samples	O
were	O
drawn	O
at	O
day	O
0	O
and	O
day	O
90	O
for	O
measuring	O
above	O
parameters	O
.	O

The	O
treadmill	O
exercise	O
tests	O
and	O
subjective	O
feelings	O
were	O
also	O
assessed	O
at	O
day	O
0	O
and	O
day	O
90	O
.	O

The	O
data	O
showed	O
that	O
Xuezhikang	O
therapy	O
resulted	O
in	O
significant	O
reductions	O
in	O
total	O
cholesterol	O
(	O
TC	O
,	O
19	O
%	O
)	O
,	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
LDL-C	O
)	O
(	O
26	O
%	O
)	O
,	O
and	O
triglycerides	O
(	O
TG	O
)	O
compared	O
with	O
baseline	O
(	O
16	O
%	O
,	O
p	O
<	O
0.01	O
respectively	O
)	O
.	O

The	O
data	O
also	O
showed	O
that	O
Xuezhikang	O
led	O
significantly	O
to	O
reductions	O
in	O
median	O
and	O
log-CRP	O
levels	O
(	O
38	O
%	O
and	O
44	O
%	O
,	O
p	O
<	O
0.01	O
respectively	O
)	O
,	O
IL-6	O
(	O
20	O
%	O
,	O
p	O
<	O
0.01	O
)	O
,	O
and	O
ET-1	O
(	O
47	O
%	O
,	O
p	O
<	O
0.01	O
)	O
compared	O
with	O
baseline	O
.	O

The	O
exercise	O
duration	O
,	O
and	O
time	O
to	O
1	O
mm	O
ST-segment	O
depression	O
was	O
significantly	O
prolonged	O
after	O
Xuezhikang	O
therapy	O
(	O
9	O
%	O
and	O
6	O
%	O
,	O
p	O
<	O
0.05	O
respectively	O
)	O
accompanied	O
by	O
improvement	O
of	O
subjective	O
feelings	O
.	O

Data	O
suggested	O
that	O
the	O
benefit	O
of	O
Xuezhikang	O
resulted	O
in	O
significant	O
modification	O
vascular	O
function	O
by	O
reduction	O
of	O
ET-1	O
,	O
inflammatory	O
markers	O
and	O
LDL	O
cholesterol	O
,	O
which	O
may	O
be	O
clinically	O
important	O
for	O
patients	O
with	O
CSX	O
.	O

Local	O
contextual	O
processing	O
in	O
major	O
depressive	O
disorder	O
.	O

OBJECTIVE	O
The	O
study	O
investigated	O
local	O
contextual	O
processing	O
in	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

This	O
was	O
defined	O
as	O
the	O
ability	O
to	O
utilize	O
predictive	O
contextual	O
information	O
to	O
facilitate	O
detection	O
of	O
predictable	O
versus	O
random	O
targets	O
.	O

METHOD	O
We	O
recorded	O
EEG	O
in	O
15	O
MDD	O
patients	O
and	O
14	O
age-matched	O
controls	O
.	O

Recording	O
blocks	O
consisted	O
of	O
targets	O
preceded	O
by	O
randomized	O
sequences	O
of	O
standards	O
and	O
by	O
sequences	O
of	O
standards	O
that	O
included	O
a	O
predictive	O
sequence	O
signaling	O
the	O
occurrence	O
of	O
a	O
subsequent	O
target	O
event	O
.	O

RESULTS	O
Both	O
MDD	O
patients	O
and	O
age-matched	O
controls	O
demonstrated	O
a	O
significant	O
reaction	O
time	O
(	O
RT	O
)	O
and	O
P3b	O
latency	O
differences	O
between	O
predicted	O
and	O
random	O
targets	O
.	O

However	O
,	O
patients	O
demonstrated	O
a	O
specific	O
prolongation	O
of	O
these	O
measures	O
during	O
processing	O
of	O
predicted	O
targets	O
,	O
as	O
well	O
as	O
an	O
attenuation	O
of	O
P3b	O
amplitudes	O
for	O
the	O
predictive	O
sequence	O
.	O

In	O
addition	O
,	O
patients	O
target	O
N1	O
amplitudes	O
were	O
attenuated	O
compared	O
with	O
controls	O
.	O

CONCLUSION	O
MDD	O
patients	O
were	O
able	O
to	O
utilize	O
predictive	O
context	O
in	O
order	O
to	O
facilitate	O
processing	O
of	O
deterministic	O
targets	O
,	O
however	O
,	O
this	O
ability	O
was	O
limited	O
compared	O
to	O
controls	O
,	O
as	O
demonstrated	O
by	O
context-dependent	O
P3b	O
deficits	O
.	O

SIGNIFICANCE	O
These	O
findings	O
suggest	O
that	O
patients	O
with	O
major	O
depression	O
have	O
altered	O
processing	O
of	O
local	O
contextual	O
processing	O
.	O

A	O
comparison	O
of	O
albuterol	O
solution	O
nebulized	O
versus	O
albuterol	O
powder	O
given	O
by	O
breath	O
activated	O
metered	O
dose	O
inhaler	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
nebulized	O
vs	O
powdered	O
albuterol	O
in	O
patients	O
with	O
exacerbated	Condition
bronchial	Condition
asthma	Condition
who	Condition
required	Condition
hospitalization	Condition
.	O

From	Condition
January	Condition
to	Condition
May	Condition
1990	Condition
known	O
asthmatics	O
admitted	O
with	O
acute	Condition
exacerbation	Condition
were	O
included	O
by	O
established	O
criteria	O
.	O

Two	O
groups	O
were	O
randomized	O
.	O

Group	O
I	O
for	O
Albuterol	O
powder	O
200	O
micrograms	O
inhaled	O
q	O
4	O
hours	O
.	O

Group	O
II	O
with	O
Albuterol	O
nebulized	O
solution	O
2.5	O
mg	O
inhaled	O
q	O
4	O
hrs	O
.	O

Force	O
Vital	O
Capacity	O
and	O
Force	O
Expiratory	O
Volume	O
in	O
one	O
second	O
were	O
measured	O
with	O
a	O
pressure	O
differential	O
transducer	O
upon	O
admission	O
,	O
30	O
minutes	O
and	O
24-hours	O
following	O
therapies	O
.	O

Absolute	O
FEV1	O
improvement	O
was	O
calculated	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
student	O
's	O
T-Test	O
and	O
Fisher	O
's	O
exact	O
Test	O
with	O
significance	O
established	O
at	O
p	O
>	O
0.01	O
%	O
.	O

Fifteen	SampleSize
patients	O
enrolled	O
in	O
both	O
groups	O
,	O
two	O
patients	O
of	O
group	O
I	O
were	O
excluded	O
from	O
the	O
statistic	O
analysis	O
due	O
to	O
refusal	O
to	O
continue	O
with	O
the	O
therapy	O
.	O

Both	O
groups	O
were	O
comparable	O
with	O
respect	O
to	O
sex	O
,	O
asthma	O
exacerbations/year	O
,	O
smoking	O
history	O
and	O
hospital	O
length	O
of	O
stay	O
.	O

FVC	O
and	O
FEV1	O
were	O
comparable	O
also	O
.	O

In	O
contrast	O
,	O
there	O
were	O
significant	O
difference	O
when	O
the	O
absolute	O
improvement	O
were	O
compared	O
.	O

The	O
mean	O
+/-	O
SE	O
for	O
FEV1	O
absolute	O
improvement	O
at	O
the	O
first	O
30	O
min	O
was	O
0.42	O
+/-	O
0.08	O
lts	O
for	O
the	O
Group	O
I	O
versus	O
0.65	O
+/-	O
0.6	O
lts	O
in	O
the	O
Group	O
II	O
.	O

In	O
the	O
next	O
24	O
hours	O
,	O
Group	O
I	O
was	O
0.16	O
+/-	O
0.2	O
lts	O
versus	O
0.30	O
+/-	O
0.7	O
lts	O
in	O
Group	O
II	O
(	O
p	O
>	O
.01	O
)	O
.	O

We	O
conclude	O
that	O
although	O
the	O
dose	O
equivalence	O
of	O
both	O
delivery	O
systems	O
have	O
not	O
been	O
established	O
in	O
our	O
study	O
,	O
the	O
nebulized	O
solution	O
was	O
more	O
effective	O
during	O
the	O
first	O
24	O
hours	O
of	O
hospitalization	O
than	O
the	O
dry	O
powder	O
.	O

Plasma	O
norepinephrine	O
and	O
mortality	O
.	O

Plasma	O
norepinephrine	O
levels	O
,	O
which	O
reflect	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
are	O
almost	O
universally	O
elevated	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
.	O

This	O
elevation	O
occurs	O
in	O
patients	O
with	O
overt	O
,	O
symptomatic	O
heart	O
failure	O
(	O
HF	O
)	O
and	O
in	O
patients	O
with	O
asymptomatic	O
left	O
ventricular	O
dysfunction	O
.	O

Evidence	O
suggests	O
that	O
the	O
elevation	O
in	O
plasma	O
norepinephrine	O
levels	O
can	O
be	O
at	O
least	O
partly	O
attributed	O
to	O
an	O
increase	O
in	O
sympathetic	O
nervous	O
system	O
activity	O
.	O

It	O
has	O
become	O
evident	O
that	O
elevated	O
plasma	O
norepinephrine	O
levels	O
are	O
directly	O
related	O
to	O
prognosis	O
;	O
patients	O
with	O
levels	O
>	O
900	O
pg/ml	O
have	O
a	O
poor	O
prognosis	O
and	O
shortened	O
life	O
expectancy	O
.	O

However	O
,	O
plasma	O
norepinephrine	O
levels	O
bear	O
little	O
relationship	O
to	O
physiologic	O
and	O
clinical	O
variables	O
observed	O
in	O
HF	O
,	O
including	O
ejection	O
fraction	O
and	O
exercise	O
capacity	O
.	O

Data	O
from	O
the	O
V-HeFT	O
II	O
show	O
that	O
at	O
2-year	O
follow-up	O
,	O
a	O
progressive	O
rise	O
of	O
plasma	O
norepinephrine	O
was	O
observed	O
in	O
both	O
treatment	O
arms	O
,	O
suggesting	O
that	O
disease	O
progresses	O
despite	O
treatment	O
with	O
either	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
,	O
enalapril	O
,	O
or	O
vasodilator	O
therapy	O
with	O
hydralazine/isosorbide	O
dinitrate	O
.	O

It	O
is	O
possible	O
that	O
interventions	O
aimed	O
at	O
the	O
progressive	O
neurohormonal	O
activation	O
that	O
occurs	O
in	O
HF	O
may	O
improve	O
the	O
course	O
of	O
illness	O
.	O

Further	O
study	O
is	O
needed	O
to	O
test	O
this	O
hypothesis	O
.	O

Response	O
to	O
familiar	O
faces	O
,	O
newly	O
familiar	O
faces	O
,	O
and	O
novel	O
faces	O
as	O
assessed	O
by	O
ERPs	O
is	O
intact	O
in	O
adults	Age
with	O
autism	O
spectrum	O
disorders	O
.	O

Individuals	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
have	O
pervasive	O
impairments	O
in	O
social	O
functioning	O
,	O
which	O
may	O
include	O
problems	O
with	O
processing	O
and	O
remembering	O
faces	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
posterior	O
ERP	O
components	O
associated	O
with	O
identity	O
processing	O
(	O
P2	O
,	O
N250	O
and	O
face-N400	O
)	O
and	O
components	O
associated	O
with	O
early-stage	O
face	O
processing	O
(	O
P1	O
and	O
N170	O
)	O
are	O
atypical	O
in	O
ASD	O
.	O

We	O
collected	O
ERP	O
responses	O
to	O
a	O
familiar	O
repeated	O
face	O
(	O
Familiar	O
)	O
,	O
an	O
unfamiliar	O
repeated	O
face	O
(	O
Other	O
)	O
and	O
novel	O
faces	O
(	O
Novels	O
)	O
in	O
29	SampleSize
high-functioning	SampleSize
adults	SampleSize
with	SampleSize
ASD	SampleSize
and	O
matched	O
controls	O
.	O

For	O
both	O
groups	O
,	O
the	O
P2	O
and	O
N250	O
were	O
sensitive	O
to	O
repetition	O
(	O
Other	O
vs.	O
Novels	O
)	O
and	O
personal	O
familiarity	O
(	O
Familiar	O
vs.	O
Other	O
)	O
,	O
and	O
the	O
face-N400	O
was	O
sensitive	O
to	O
repetition	O
.	O

Adults	Age
with	O
ASD	O
did	O
not	O
show	O
significantly	O
atypical	O
processing	O
of	O
facial	O
familiarity	O
and	O
repetition	O
in	O
an	O
ERP	O
paradigm	O
,	O
despite	O
showing	O
significantly	O
poorer	O
performance	O
than	O
controls	O
on	O
a	O
behavioral	O
test	O
of	O
face	O
memory	O
.	O

This	O
study	O
found	O
no	O
evidence	O
that	O
early-stage	O
facial	O
identity	O
processing	O
is	O
a	O
primary	O
contributor	O
to	O
the	O
face	O
recognition	O
deficit	O
in	O
high-functioning	O
ASD	O
.	O

Randomized	O
clinical	O
trial	O
comparing	O
laparoscopic	O
and	O
open	O
surgery	O
in	O
patients	O
with	O
rectal	Condition
cancer	Condition
.	O

BACKGROUND	O
The	O
laparoscopic	O
treatment	O
of	O
rectal	O
cancer	O
is	O
controversial	O
.	O

This	O
study	O
compared	O
surgical	O
outcomes	O
after	O
laparoscopic	O
and	O
open	O
approaches	O
for	O
mid	O
and	O
low	O
rectal	O
cancers	O
.	O

METHODS	O
Some	O
204	SampleSize
patients	O
with	O
mid	Condition
and	Condition
low	Condition
rectal	Condition
adenocarcinomas	Condition
were	O
allocated	O
randomly	O
to	O
open	O
(	O
103	O
)	O
or	O
laparoscopic	O
(	O
101	O
)	O
surgery	O
.	O

The	O
surgical	O
team	O
was	O
the	O
same	O
for	O
both	O
procedures	O
.	O

Most	O
patients	O
had	O
stage	O
II	O
or	O
III	O
disease	O
,	O
and	O
received	O
neoadjuvant	O
therapy	O
with	O
oral	O
capecitabine	O
and	O
50-54	O
Gy	O
external	O
beam	O
radiotherapy	O
.	O

RESULTS	O
Sphincter-preserving	O
surgery	O
was	O
performed	O
in	O
78.6	O
and	O
76.2	O
per	O
cent	O
of	O
patients	O
in	O
the	O
open	O
and	O
laparoscopic	O
groups	O
respectively	O
.	O

Blood	O
loss	O
was	O
significantly	O
greater	O
for	O
open	O
surgery	O
(	O
P	O
<	O
0.001	O
)	O
and	O
operating	O
time	O
was	O
significantly	O
greater	O
for	O
laparoscopic	O
surgery	O
(	O
P	O
=	O
0.020	O
)	O
,	O
and	O
return	O
to	O
diet	O
and	O
hospital	O
stay	O
were	O
longer	O
for	O
open	O
surgery	O
.	O

Complication	O
rates	O
,	O
and	O
involvement	O
of	O
circumferential	O
and	O
radial	O
margins	O
were	O
similar	O
for	O
both	O
procedures	O
,	O
but	O
the	O
number	O
of	O
isolated	O
lymph	O
nodes	O
was	O
greater	O
in	O
the	O
laparoscopic	O
group	O
(	O
mean	O
13.63	O
versus	O
11.57	O
;	O
P	O
=	O
0.026	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
local	O
recurrence	O
,	O
disease-free	O
or	O
overall	O
survival	O
.	O

CONCLUSION	O
Laparoscopic	O
surgery	O
for	O
rectal	O
cancer	O
has	O
a	O
similar	O
complication	O
rate	O
to	O
open	O
surgery	O
,	O
with	O
less	O
blood	O
loss	O
,	O
rapid	O
intestinal	O
recovery	O
,	O
shorter	O
hospital	O
stay	O
,	O
and	O
no	O
compromise	O
of	O
oncological	O
outcomes	O
.	O

Disopyramide-pyridostigmine	O
interaction	O
:	O
selective	O
reversal	O
of	O
anticholinergic	O
symptoms	O
with	O
preservation	O
of	O
antiarrhythmic	O
effect	O
.	O

This	O
double-blind	O
,	O
randomized	O
,	O
placebo	O
crossover	O
study	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
cholinesterase	O
inhibitor	O
--	O
slow-release	O
pyridostigmine	O
(	O
180	O
mg	O
orally	O
every	O
12	O
hours	O
)	O
--	O
on	O
the	O
anticholinergic	O
and	O
antiarrhythmic	O
properties	O
of	O
disopyramide	O
.	O

Quantitative	O
side	O
effects	O
questionnaire	O
scores	O
were	O
used	O
to	O
guide	O
disopyramide	O
administration	O
in	O
20	SampleSize
men	Sex
with	O
ventricular	Condition
tachycardia	Condition
.	O

Disopyramide	O
was	O
given	O
to	O
each	O
patient	O
both	O
with	O
placebo	Condition
and	O
with	O
active	Condition
pyridostigmine	Condition
.	Condition

The	O
maximal	O
administered	O
dose	O
for	O
each	O
regimen	O
was	O
used	O
in	O
conjunction	O
with	O
corresponding	O
questionnaire	O
scores	O
to	O
calculate	O
an	O
index	O
or	O
estimate	O
of	O
the	O
maximal	O
tolerable	O
dose	O
of	O
disopyramide	O
.	O

Additional	O
evaluations	O
performed	O
at	O
baseline	O
and	O
at	O
each	O
maximal	O
administered	O
dose	O
regimen	O
included	O
tear	O
and	O
saliva	O
quantitation	O
,	O
24	O
hour	O
electrocardiogram	O
(	O
ECG	O
)	O
,	O
exercise	O
testing	O
and	O
programmed	O
ventricular	O
stimulation	O
.	O

Results	O
showed	O
that	O
the	O
maximal	O
administered	O
dose	O
of	O
disopyramide	O
was	O
greater	O
with	O
active	O
pyridostigmine	O
than	O
with	O
placebo	O
:	O
295	O
+/-	O
75	O
versus	O
245	O
+/-	O
100	O
mg	O
every	O
6	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
calculated	O
maximal	O
tolerable	O
dose	O
was	O
substantially	O
greater	O
in	O
the	O
presence	O
of	O
pyridostigmine	O
:	O
355	O
+/-	O
90	O
versus	O
260	O
+/-	O
115	O
mg	O
every	O
6	O
hours	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Maximal	O
side	O
effects	O
questionnaire	O
scores	O
also	O
reflected	O
decreased	O
anticholinergic	O
activity	O
in	O
the	O
presence	O
of	O
pyridostigmine	O
compared	O
with	O
placebo	O
:	O
101.9	O
+/-	O
2.2	O
versus	O
104.6	O
+/-	O
2.8	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.005	O
)	O
.	O

Baseline	O
tear	O
and	O
saliva	O
production	O
was	O
significantly	O
reduced	O
during	O
disopyramide	O
therapy	O
,	O
but	O
was	O
restored	O
toward	O
normal	O
by	O
the	O
addition	O
of	O
pyridostigmine	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Sivelestat	O
sodium	O
hydrate	O
improves	O
septic	O
acute	O
lung	O
injury	O
by	O
reducing	O
alveolar	O
dysfunction	O
.	O

Sivelestat	O
sodium	O
hydrate	O
(	O
sivelestat	O
)	O
is	O
a	O
selective	O
inhibitor	O
of	O
polymorphonuclear	O
leukocyte	O
elastase	O
(	O
PMN-E	O
)	O
.	O

We	O
administered	O
sivelestat	O
to	O
patients	O
with	O
septic	Condition
acute	Condition
lung	Condition
injury	Condition
(	Condition
ALI	Condition
)	Condition
to	O
examine	O
its	O
usefulness	O
.	O

The	O
primary	O
endpoints	O
in	O
the	O
study	O
were	O
the	O
duration	O
of	O
artificial	O
ventilation	O
and	O
pulmonary	O
oxygenation	O
ability	O
,	O
and	O
the	O
secondary	O
endpoints	O
were	O
mortality	O
and	O
the	O
concentrations	O
of	O
PMN-E	O
,	O
SP-D	O
,	O
TNF-alpha	O
and	O
IL-8	O
in	O
blood	O
.	O

In	O
the	O
sivelestat	O
group	O
,	O
the	O
duration	O
of	O
artificial	O
ventilation	O
,	O
pulmonary	O
oxygenation	O
ability	O
,	O
and	O
the	O
blood	O
PMN-E	O
,	O
SP-D	O
,	O
TNF-alpha	O
and	O
IL-8	O
concentrations	O
decreased	O
significantly	O
.	O

Administration	O
of	O
sivelestat	O
was	O
found	O
to	O
reduce	O
alveolar	O
dysfunction	O
and	O
improve	O
respiratory	O
function	O
,	O
and	O
it	O
was	O
suggested	O
that	O
early	O
administration	O
might	O
be	O
useful	O
.	O

Predictors	O
of	O
smoking	Condition
cessation	Condition
among	O
cancer	Condition
patients	O
enrolled	O
in	O
a	O
smoking	O
cessation	O
program	O
.	O

UNLABELLED	O
Many	O
cancer	O
patients	O
continue	O
to	O
smoke	O
postdiagnosis	O
,	O
which	O
is	O
associated	O
with	O
poorer	O
clinical	O
outcomes	O
.	O

Identifying	O
prospective	O
predictors	O
of	O
smoking	O
cessation	O
among	O
patients	O
currently	O
receiving	O
smoking	O
cessation	O
treatment	O
can	O
help	O
guide	O
the	O
development	O
and	O
implementation	O
of	O
smoking	O
cessation	O
programs	O
with	O
this	O
population	O
.	O

MATERIAL	O
AND	O
METHODS	O
Data	O
from	O
246	SampleSize
cancer	Condition
patients	O
participating	O
in	O
a	O
randomized	O
placebo-controlled	O
smoking	O
cessation	O
clinical	O
trial	O
were	O
used	O
to	O
examine	O
baseline	O
predictors	O
of	O
end-of-treatment	O
and	O
six-month	O
postbaseline	O
smoking	O
cessation	O
outcomes	O
.	O

Baseline	O
demographic	O
,	O
smoking-related	O
,	O
disease-related	O
,	O
and	O
psychological	O
variables	O
were	O
examined	O
as	O
predictors	O
of	O
biochemically-confirmed	O
point-prevalence	O
abstinence	O
.	O

RESULTS	O
Multivariate	O
analysis	O
indicated	O
that	O
,	O
for	O
end-of-treatment	O
abstinence	O
,	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
quit	O
smoking	O
if	O
they	O
were	O
older	O
(	O
OR	O
=	O
1.06	O
,	O
95	O
%	O
CI	O
:	O
1.03-1.10	O
,	O
p	O
<	O
0.05	O
)	O
and	O
were	O
diagnosed	O
with	O
a	O
non-tobacco	O
related	O
cancer	O
(	O
OR	O
=	O
2.54	O
,	O
95	O
%	O
CI	O
:	O
1.24-5.20	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Likewise	O
,	O
for	O
six-month	O
abstinence	O
,	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
quit	O
smoking	O
if	O
they	O
were	O
older	O
(	O
OR	O
=	O
1.04	O
,	O
95	O
%	O
CI	O
:	O
1.01-1.08	O
,	O
p	O
<	O
0.05	O
)	O
and	O
were	O
significantly	O
less	O
likely	O
to	O
have	O
quit	O
smoking	O
if	O
they	O
were	O
female	O
(	O
OR	O
=	O
0.47	O
,	O
95	O
%	O
CI	O
:	O
0.22-0.97	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Patients	O
with	O
tobacco-related	O
cancers	O
and	O
female	Sex
patients	O
reported	O
significantly	O
higher	O
levels	O
of	O
depression	O
symptoms	O
(	O
p	O
<	O
0.05	O
)	O
,	O
which	O
proved	O
predictive	O
of	O
smoking	O
relapse	O
.	O

CONCLUSIONS	O
Patient	O
age	O
,	O
gender	O
,	O
and	O
cancer-type	O
may	O
be	O
important	O
factors	O
to	O
consider	O
when	O
developing	O
and	O
implementing	O
smoking	O
cessation	O
interventions	O
for	O
cancer	O
patients	O
.	O

Two	O
large	O
preoperative	O
doses	O
of	O
erythropoietin	O
do	O
not	O
reduce	O
the	O
systemic	Condition
inflammatory	Condition
response	Condition
to	Condition
cardiac	Condition
surgery	Condition
.	Condition

OBJECTIVES	O
Cardiac	O
surgery	O
and	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
induce	O
an	O
inflammatory	O
reaction	O
that	O
may	O
lead	O
to	O
tissue	O
injury	O
.	O

Experimental	O
studies	O
suggest	O
that	O
recombinant	O
human	O
erythropoietin	O
(	O
EPO	O
)	O
independent	O
of	O
its	O
erythropoietic	O
effect	O
may	O
be	O
used	O
clinically	O
as	O
an	O
anti-inflammatory	O
drug	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
2	O
large	O
doses	O
of	O
EPO	O
administered	O
shortly	O
before	O
CPB	O
ameliorate	O
the	O
systemic	O
inflammatory	O
response	O
to	O
CPB	O
.	O

DESIGN	O
AND	O
SETTING	O
A	O
prospective	O
,	O
double-blind	O
,	O
placebo-controlled	O
and	O
randomized	O
study	O
at	O
a	O
single	O
tertiary	O
care	O
hospital	O
.	O

PARTICIPANTS	O
Patients	O
scheduled	O
for	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
with	O
CPB	O
.	O

INTERVENTIONS	O
EPO	O
(	O
epoetin	O
alfa	O
,	O
500	O
IU/kg	O
intravenously	O
,	O
n	O
=	O
22	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
was	O
administered	O
12	O
to	O
18	O
hours	O
preoperatively	O
and	O
again	O
at	O
the	O
induction	O
of	O
anesthesia	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
CPB	O
in	O
both	O
groups	O
greatly	O
increased	O
plasma	O
concentrations	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
,	O
interleukin	O
(	O
IL	O
)	O
-1beta	O
,	O
IL-1beta	O
receptor	O
antagonist	O
,	O
IL-6	O
,	O
IL-10	O
,	O
and	O
N-terminal	O
probrain	O
natriuretic	O
peptide	O
(	O
NT-proBNP	O
)	O
.	O

Compared	O
with	O
placebo	O
,	O
EPO	O
at	O
day	O
3	O
after	O
CPB	O
augmented	O
the	O
TNF-alpha	O
response	O
(	O
p	O
<	O
0.05	O
)	O
and	O
at	O
2	O
hours	O
after	O
CPB	O
increased	O
NT-proBNP	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Also	O
,	O
EPO	O
tended	O
to	O
enhance	O
the	O
CPB-induced	O
increase	O
in	O
IL-1beta	O
receptor	O
antagonist	O
(	O
p	O
=	O
0.057	O
)	O
.	O

Otherwise	O
,	O
EPO	O
had	O
no	O
effect	O
on	O
pro-	O
and	O
antiinflammatory	O
mediators	O
compared	O
with	O
placebo	O
.	O

CONCLUSIONS	O
Two	O
large	O
doses	O
of	O
EPO	O
given	O
shortly	O
before	O
CPB	O
do	O
not	O
reduce	O
perioperative	O
release	O
of	O
inflammatory	O
cytokines	O
.	O

In	O
contrast	O
,	O
EPO	O
may	O
augment	O
the	O
TNF-alpha	O
and	O
NT-proBNP	O
response	O
.	O

Although	O
the	O
long-term	O
clinical	O
impact	O
remains	O
unknown	O
,	O
the	O
findings	O
do	O
not	O
support	O
use	O
of	O
EPO	O
as	O
an	O
anti-inflammatory	O
drug	O
in	O
patients	O
undergoing	O
cardiac	O
surgery	O
.	O

MR	O
imaging	O
of	O
pituitary	O
region	O
lesions	O
with	O
gadodiamide	O
injection	O
.	O

Twelve	O
patients	O
with	O
known	O
or	O
suspected	O
pituitary	O
lesions	O
underwent	O
MR	O
imaging	O
with	O
gadodiamide	O
injection	O
at	O
a	O
dose	O
of	O
0.1	O
(	O
n	O
=	O
5	O
)	O
or	O
0.3	O
(	O
n	O
=	O
7	O
)	O
mM/kg	O
.	O

Six	O
of	O
the	O
patients	O
were	O
also	O
studied	O
with	O
0.1	O
mM/kg	O
gadopentetate	O
dimeglumine	O
.	O

Consistent	O
with	O
previous	O
reports	O
gadodiamide	O
injection	O
was	O
found	O
to	O
be	O
a	O
safe	O
and	O
effective	O
contrast	O
medium	O
for	O
MR	O
imaging	O
of	O
the	O
pituitary	O
region	O
.	O

No	O
additional	O
diagnostic	O
information	O
was	O
obtained	O
using	O
0.3	O
mM/kg	O
gadodiamide	O
injection	O
compared	O
to	O
0.1	O
mM/kg	O
gadopentate	O
dimeglumine	O
in	O
the	O
same	O
patients	O
.	O

The	O
high	O
dose	O
(	O
0.3	O
mM/kg	O
)	O
gadodiamide	O
injection	O
in	O
7	O
patients	O
did	O
not	O
shorten	O
the	O
T2	O
value	O
sufficiently	O
to	O
overwhelm	O
the	O
T1	O
shortening	O
and	O
leave	O
pathologic	O
lesions	O
hypointense	O
compared	O
to	O
precontrast	O
studies	O
.	O

With	O
the	O
comparable	O
relaxivities	O
of	O
gadodiamide	O
injection	O
and	O
gadopentetate	O
dimeglumine	O
,	O
similarities	O
in	O
results	O
have	O
to	O
be	O
expected	O
when	O
using	O
these	O
media	O
for	O
MR	O
image	O
enhancement	O
.	O

Intraumbilical	O
vein	O
injection	O
of	O
prostaglandin	O
F2	O
alpha	O
in	O
retained	Condition
placenta	Condition
.	Condition

A	O
randomized	O
protocol	O
was	O
used	O
to	O
study	O
the	O
effect	O
of	O
intraumbilical	O
prostaglandin	O
F2	O
alpha	O
(	O
Hembate	O
,	O
Upjohn	O
)	O
and	O
oxytocin	O
injection	O
in	O
women	Sex
with	O
retained	O
placenta	O
.	O

Prostaglandin	O
F2	O
alpha	O
,	O
20	O
mg	O
,	O
diluted	O
to	O
20	O
ml	O
in	O
normal	O
saline	O
solution	O
(	O
10	SampleSize
women	SampleSize
,	SampleSize
group	O
1	O
)	O
,	O
30	O
IU	O
of	O
oxytocin	O
,	O
diluted	O
to	O
20	O
ml	O
in	O
normal	O
saline	O
solution	O
(	O
11	SampleSize
women	SampleSize
,	O
group	O
2	O
)	O
,	O
or	O
20	O
ml	O
of	O
normal	O
saline	O
solution	O
alone	O
(	O
7	SampleSize
women	SampleSize
,	O
group	O
3	O
)	O
,	O
were	O
injected	O
into	O
the	O
umbilical	O
vein	O
1	O
h	O
after	O
delivery	O
.	O

Nine	SampleSize
women	Sex
(	O
group	O
4	O
,	O
controls	O
)	O
underwent	O
manual	O
removal	O
of	O
the	O
retained	O
placenta	O
.	O

In	O
group	O
1	O
,	O
placental	O
expulsion	O
occurred	O
in	O
all	O
patients	O
and	O
the	O
duration	O
of	O
the	O
placental	O
expulsion	O
after	O
prostaglandin	O
F2	O
alpha	O
injection	O
was	O
6.8	O
+/-	O
1.36	O
(	O
mean	O
+/-	O
SE	O
)	O
min	O
:	O
in	O
group	O
2	O
,	O
six	O
placental	O
expulsions	O
occurred	O
after	O
13.3	O
+/-	O
1.97	O
min	O
(	O
mean	O
+/-	O
SE	O
)	O
;	O
and	O
in	O
group	O
3	O
,	O
no	O
effect	O
was	O
recorded	O
after	O
intraumbilical	O
saline	O
injection	O
.	O

We	O
suggest	O
that	O
intraumbilical	O
vein	O
injection	O
of	O
prostaglandin	O
F2	O
alpha	O
might	O
be	O
a	O
beneficial	O
,	O
non-surgical	O
method	O
for	O
treating	O
retained	O
placenta	O
.	O

Oxytocin	O
might	O
reduce	O
the	O
incidence	O
of	O
manual	O
lysis	O
of	O
the	O
placenta	O
and	O
achieve	O
partial	O
success	O
.	O

Veterans	O
Administration	O
Cooperative	O
Study	O
on	O
antiplatelet	O
agents	O
in	O
diabetic	Condition
patients	O
after	O
amputation	Condition
for	O
gangrene	Condition
:	O
II	O
.	O

Effects	O
of	O
aspirin	O
and	O
dipyridamole	O
on	O
atherosclerotic	O
vascular	O
disease	O
rates	O
.	O

We	O
report	O
the	O
results	O
of	O
a	O
randomized	O
multicenter	O
clinical	O
trial	O
on	O
the	O
effects	O
of	O
aspirin	O
plus	O
dipyridamole	O
versus	O
placebo	O
on	O
major	O
vascular	O
end	O
points	O
in	O
231	SampleSize
non-insulin-dependent	Condition
diabetic	Condition
men	O
with	O
either	O
a	O
recent	O
amputation	O
for	O
gangrene	Condition
or	O
active	O
gangrene	Condition
.	O

Primary	O
end	O
points	O
were	O
death	O
from	O
atherosclerotic	O
vascular	O
disease	O
plus	O
amputation	O
of	O
the	O
opposite	O
extremity	O
for	O
gangrene	O
.	O

There	O
were	O
24	O
atherosclerotic	O
deaths	O
in	O
the	O
drug	O
treatment	O
group	O
(	O
21.8	O
%	O
)	O
and	O
23	O
in	O
the	O
placebo	O
group	O
(	O
19.0	O
%	O
)	O
.	O

There	O
were	O
22	O
patients	O
in	O
the	O
drug	O
treatment	O
group	O
(	O
20.0	O
%	O
)	O
and	O
29	O
patients	O
in	O
the	O
placebo	O
group	O
(	O
24.0	O
%	O
)	O
with	O
opposite-side	O
amputations	O
.	O

Survival	O
curve	O
analyses	O
revealed	O
little	O
difference	O
between	O
these	O
groups	O
for	O
major	O
vascular	O
end	O
points	O
,	O
total	O
mortality	O
,	O
all	O
amputations	O
,	O
or	O
myocardial	O
infarctions	O
.	O

The	O
most	O
noteworthy	O
group	O
difference	O
was	O
observed	O
for	O
cerebrovascular	O
end	O
points	O
(	O
strokes	O
and	O
transient	O
ischemic	O
attacks	O
)	O
,	O
with	O
an	O
incidence	O
of	O
8.2	O
%	O
(	O
9	O
patients	O
)	O
in	O
the	O
drug	O
treatment	O
group	O
and	O
19.0	O
%	O
(	O
23	O
patients	O
)	O
in	O
the	O
placebo	O
group	O
.	O

We	O
conclude	O
from	O
this	O
study	O
that	O
antiplatelet	O
agents	O
have	O
no	O
effect	O
on	O
the	O
primary	O
vascular	O
end	O
points	O
,	O
vascular	O
deaths	O
and/or	O
amputation	O
of	O
the	O
opposite	O
extremity	O
,	O
in	O
this	O
population	O
.	O

Similarly	O
,	O
no	O
effects	O
were	O
seen	O
on	O
secondary	O
vascular	O
end	O
points	O
,	O
except	O
for	O
a	O
suggestion	O
of	O
protection	O
versus	O
strokes	O
and	O
transient	O
ischemic	O
attacks	O
.	O

However	O
,	O
this	O
finding	O
must	O
be	O
interpreted	O
with	O
caution	O
,	O
since	O
it	O
is	O
a	O
secondary	O
end	O
point	O
and	O
was	O
found	O
only	O
after	O
multiple	O
analyses	O
of	O
the	O
data	O
.	O

Diet	O
and	O
vitamin	O
D	O
status	O
among	O
pregnant	Condition
Pakistani	Condition
women	Sex
in	O
Oslo	O
.	O

OBJECTIVES	O
In	O
the	O
present	O
study	O
the	O
diet	O
and	O
the	O
nutritional	O
status	O
of	O
pregnant	Condition
Pakistani	O
immigrant	O
women	Sex
have	O
been	O
compared	O
with	O
a	O
group	O
of	O
Norwegian	Condition
women	Sex
.	O

DESIGN	O
A	O
cross-sectional	O
survey	O
of	O
women	Sex
in	O
the	O
18th	Condition
week	Condition
of	Condition
pregnancy	Condition
.	O

SETTING	O
Women	Sex
referred	O
to	O
routine	O
ultrasound	O
examination	O
at	O
Aker	O
and	O
Ullev?l	O
Hospitals	O
in	O
Norway	O
.	O

SUBJECTS	O
All	O
(	O
58	O
)	O
healthy	O
women	O
of	O
Pakistani	O
origin	O
referred	O
from	O
October	O
of	O
1991	O
to	O
January	O
of	O
1992	O
were	O
included	O
,	O
of	O
whom	O
38	O
(	O
66	O
%	O
)	O
participated	O
.	O

Forty-five	O
Norwegian	O
women	O
were	O
randomly	O
included	O
in	O
the	O
same	O
period	O
and	O
38	O
(	O
84	O
%	O
)	O
of	O
these	O
women	O
participated	O
.	O

RESULTS	O
The	O
serum	O
levels	O
of	O
25-hydroxyvitamin	O
D3	O
were	O
significantly	O
lower	O
in	O
the	O
Pakistanis	O
compared	O
with	O
the	O
Norwegians	O
(	O
median	O
19	O
nmol/l	O
vs	O
55	O
nmol/l	O
,	O
P	O
<	O
0.001	O
)	O
and	O
83	O
%	O
of	O
the	O
Pakistani	O
women	O
had	O
25-hydroxyvitamin	O
D3	O
levels	O
below	O
the	O
reference	O
value	O
(	O
<	O
30	O
nmol/l	O
)	O
.	O

The	O
Pakistanis	O
had	O
higher	O
levels	O
of	O
serum	O
parathyroid	O
hormone	O
(	O
median	O
2.6	O
vs	O
1.6	O
pmol/l	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
Pakistanis	O
also	O
had	O
a	O
lower	O
dietary	O
intake	O
of	O
vitamin	O
D	O
than	O
that	O
of	O
the	O
Norwegians	O
(	O
median	O
2.2	O
vs	O
3.3	O
micrograms/day	O
,	O
P	O
<	O
0.05	O
)	O
,	O
and	O
a	O
lower	O
total	O
intake	O
,	O
including	O
supplements	O
(	O
median	O
2.9	O
vs	O
7.0	O
micrograms/day	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Among	O
the	O
Pakistanis	O
a	O
correlation	O
was	O
found	O
between	O
the	O
dietary	O
intake	O
of	O
margarine	O
,	O
the	O
main	O
source	O
of	O
vitamin	O
D	O
in	O
the	O
diet	O
,	O
and	O
the	O
concentration	O
of	O
25-hydroxyvitamin	O
D3	O
in	O
serum	O
,	O
r	O
=	O
0.48	O
(	O
P	O
=	O
0.01	O
)	O
.	O

In	O
general	O
,	O
the	O
Pakistanis	O
avoided	O
any	O
direct	O
sunshine	O
exposure	O
,	O
and	O
no	O
relation	O
between	O
outdoor	O
activity	O
and	O
serum	O
level	O
of	O
25-hydroxyvitamin	O
D3	O
was	O
found	O
.	O

The	O
Pakistani	O
women	O
had	O
a	O
lower	O
intake	O
of	O
calcium	O
than	O
the	O
Norwegians	O
(	O
median	O
793	O
vs	O
1134	O
mg/day	O
,	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSION	O
This	O
study	O
has	O
shown	O
that	O
Pakistani	O
women	O
living	O
in	O
Oslo	O
are	O
at	O
great	O
risk	O
of	O
developing	O
vitamin	O
D	O
deficiency	O
during	O
pregnancy	O
.	O

The	O
main	O
reasons	O
for	O
this	O
are	O
avoidance	O
of	O
sun	O
exposure	O
,	O
a	O
low	O
dietary	O
intake	O
of	O
vitamin	O
D	O
,	O
and	O
no	O
or	O
little	O
use	O
of	O
supplementation	O
.	O

Pulsed	O
azithromycin	O
treatment	O
is	O
as	O
effective	O
and	O
safe	O
as	O
2-week-longer	O
daily	O
doxycycline	O
treatment	O
of	O
acne	Condition
vulgaris	Condition
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
noninferiority	O
study	O
.	O

Efficacy	O
and	O
safety	O
of	O
azithromycin	O
and	O
doxycycline	O
for	O
the	O
treatment	O
of	O
moderate	Condition
acne	Condition
vulgaris	Condition
were	O
evaluated	O
(	O
240	SampleSize
patients	O
)	O
in	O
both	O
intention-to-treat	O
and	O
per-protocol	O
populations	O
.	O

The	O
evaluation	O
of	O
clinical	O
efficacy	O
was	O
based	O
on	O
the	O
change	O
in	O
the	O
number	O
of	O
facial	O
inflammatory	O
lesions	O
from	O
baseline	O
to	O
the	O
end	O
of	O
treatment	O
,	O
and	O
noninferiority	O
was	O
defined	O
by	O
the	O
upper	O
95	O
%	O
confidence	O
limit	O
of	O
the	O
difference	O
between	O
two	O
treatments	O
being	O
less	O
than	O
9	O
.	O

Reduction	O
in	O
the	O
number	O
of	O
lesions	O
was	O
similar	O
with	O
both	O
azithromycin	O
and	O
doxycycline	O
treatments	O
(	O
27	O
+/-	O
12	O
and	O
30	O
+/-	O
12	O
,	O
respectively	O
)	O
in	O
both	O
groups	O
.	O

Also	O
,	O
the	O
upper	O
95	O
%	O
confidence	O
limit	O
of	O
5	O
inflammatory	O
lesions	O
has	O
satisfied	O
the	O
noninferiority	O
criterion	O
.	O

The	O
incidence	O
of	O
adverse	O
events	O
did	O
not	O
differ	O
between	O
the	O
two	O
treatment	O
groups	O
.	O

The	O
shorter	O
and	O
simpler	O
treatment	O
schedule	O
of	O
azithromycin	O
had	O
similar	O
efficacy	O
and	O
safety	O
as	O
doxycycline	O
in	O
the	O
treatment	O
of	O
moderate	Condition
acne	Condition
vulgaris	Condition
,	O
confirming	O
noninferiority	O
of	O
azithromycin	O
as	O
compared	O
with	O
doxycycline	O
.	O

Outcomes	O
in	O
patients	O
with	O
diabetes	Condition
mellitus	Condition
undergoing	Condition
percutaneous	Condition
coronary	Condition
intervention	Condition
in	O
the	O
current	O
era	O
:	O
a	O
report	O
from	O
the	O
Prevention	O
of	O
REStenosis	O
with	O
Tranilast	O
and	O
its	O
Outcomes	O
(	O
PRESTO	O
)	O
trial	O
.	O

BACKGROUND	O
Diabetes	O
portends	O
an	O
adverse	O
prognosis	O
in	O
patients	O
undergoing	Condition
percutaneous	Condition
coronary	Condition
intervention	Condition
(	O
PCI	Condition
)	O
.	O

Whether	O
improvements	O
in	O
current	O
clinical	O
practice	O
(	O
stents	O
,	O
IIb/IIIa	O
antagonists	O
)	O
have	O
resulted	O
in	O
substantial	O
improvement	O
of	O
these	O
outcomes	O
remains	O
an	O
issue	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
influence	O
of	O
diabetes	O
on	O
9-month	O
outcomes	O
of	O
patients	O
undergoing	Condition
PCI	Condition
in	O
the	O
current	O
era	O
.	O

METHODS	O
AND	O
RESULTS	O
The	O
11	SampleSize
482	SampleSize
patients	O
enrolled	O
in	O
the	O
Prevention	O
of	O
REStenosis	O
with	O
Tranilast	O
and	O
its	O
Outcomes	O
(	O
PRESTO	O
)	O
Trial	O
were	O
stratified	O
according	O
to	O
the	O
presence	O
(	O
n=2694	O
)	O
or	O
absence	O
(	O
n=8798	O
)	O
of	O
diabetes	O
.	O

Diabetic	O
patients	O
were	O
older	O
;	O
were	O
more	O
likely	O
to	O
be	O
female	O
;	O
had	O
a	O
higher	O
proportion	O
of	O
congestive	O
failure	O
,	O
hypertension	O
,	O
prior	O
CABG	O
,	O
and	O
unstable	O
angina	O
;	O
and	O
had	O
higher	O
body	O
mass	O
index	O
and	O
lower	O
ejection	O
fraction	O
than	O
nondiabetic	O
patients	O
(	O
P	O
<	O
0.01	O
for	O
all	O
comparisons	O
)	O
.	O

The	O
degree	O
of	O
multivessel	O
disease	O
was	O
similar	O
between	O
the	O
two	O
groups	O
.	O

American	O
College	O
of	O
Cardiology/American	O
Heart	O
Association	O
type	O
C	O
lesions	O
were	O
more	O
common	O
in	O
diabetic	O
patients	O
(	O
17	O
%	O
versus	O
15	O
%	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Angiographic	O
and	O
procedural	O
success	O
rates	O
and	O
in-hospital	O
events	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

The	O
primary	O
end	O
point	O
of	O
death	O
,	O
myocardial	O
infarction	O
,	O
or	O
target	O
vessel	O
revascularization	O
(	O
TVR	O
)	O
was	O
analyzed	O
as	O
time-to-first	O
event	O
within	O
9	O
months	O
of	O
the	O
index	O
PCI	O
.	O

After	O
adjusting	O
for	O
certain	O
baseline	O
characteristics	O
,	O
diabetes	O
was	O
independently	O
associated	O
with	O
death	O
at	O
9	O
months	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
,	O
1.87	O
;	O
95	O
%	O
CI	O
,	O
1.31	O
to	O
2.68	O
,	O
P	O
<	O
0.01	O
)	O
and	O
with	O
an	O
increased	O
likelihood	O
of	O
TVR	O
(	O
RR	O
,	O
1.27	O
;	O
95	O
%	O
CI	O
,	O
1.14	O
to	O
1.42	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
the	O
composite	O
end	O
point	O
of	O
death/myocardial	O
infarction/TVR	O
(	O
RR	O
,	O
1.26	O
;	O
95	O
%	O
CI	O
,	O
1.13	O
to	O
1.40	O
,	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
Despite	O
advances	O
in	O
interventional	O
techniques	O
,	O
diabetes	O
remains	O
a	O
significant	O
independent	O
predictor	O
of	O
adverse	O
events	O
in	O
the	O
intermediate	O
term	O
after	O
PCI	O
.	O

[	O
Mitomycin	O
C	O
plus	O
HCFU	O
adjuvant	O
chemotherapy	O
for	O
noncuratively	O
resected	O
cases	O
of	O
colorectal	O
carcinoma	O
.	O

(	O
Second	O
report	O
)	O
:	O
5-year	O
survival	O
rate	O
.	O

Cooperative	O
Study	O
Group	O
of	O
Kyushu	O
and	O
Chugoku	O
for	O
HCFU	O
Adjuvant	O
Chemotherapy	O
]	O
.	O

In	O
order	O
to	O
examine	O
the	O
efficacy	O
of	O
adjuvant	O
chemotherapy	O
employing	O
mitomycin	O
C	O
(	O
MMC	O
)	O
and	O
carmofur	O
(	O
HCFU	O
)	O
for	O
patients	O
with	O
noncuratively	Condition
resected	Condition
colorectal	Condition
carcinoma	Condition
,	O
a	O
cooperative	O
study	O
was	O
performed	O
by	O
54	SampleSize
institutions	O
in	O
the	O
Kyushu	O
and	O
Chugoku	O
areas	O
of	O
Japan	O
.	O

The	O
criteria	O
for	O
patient	O
selection	O
were	O
as	O
follows	O
:	O
1	O
)	O
Age	Age
of	Age
75	Age
years	O
or	O
less	O
and	O
not	O
accompanied	O
by	O
any	O
serious	O
disease	O
.	O

2	O
)	O
Macroscopic	O
diagnosis	O
as	O
being	O
noncuratively	O
resected	O
on	O
completion	O
of	O
the	O
surgical	O
procedure	O
.	O

3	O
)	O
Definitive	O
diagnosis	O
of	O
colorectal	O
carcinomas	O
,	O
histologically	O
.	O

4	O
)	O
No	O
synchronous	O
or	O
metachronous	O
double	O
cancer	O
.	O

The	O
prospective	O
randomized	O
controlled	O
study	O
consisted	O
of	O
two	O
groups	O
.	O

In	O
Group	O
A	O
,	O
the	O
MMC	O
group	O
received	O
bolus	O
intravenous	O
injections	O
of	O
20	O
mg	O
MMC	O
on	O
the	O
day	O
of	O
operation	O
and	O
10	O
mg	O
the	O
next	O
day	O
,	O
followed	O
by	O
10	O
mg	O
every	O
4	O
weeks	O
until	O
a	O
total	O
of	O
100	O
mg	O
had	O
been	O
administered	O
.	O

In	O
Group	O
B	O
,	O
the	O
MMC	O
+	O
HCFU	O
group	O
received	O
the	O
same	O
treatment	O
in	O
Group	O
A	O
,	O
but	O
with	O
the	O
addition	O
of	O
600	O
mg/day	O
of	O
HCFU	O
from	O
the	O
second	O
week	O
,	O
orally	O
for	O
at	O
least	O
one	O
year	O
.	O

Concerning	O
the	O
69-month	O
survival	O
rate	O
,	O
a	O
better	O
result	O
was	O
observed	O
in	O
the	O
MMC	O
+	O
HCFU	O
group	O
than	O
in	O
the	O
MMC	O
only	O
group	O
(	O
generalized	O
Wilcoxon	O
test	O
:	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Significantly	O
better	O
survival	O
rates	O
were	O
obtained	O
in	O
those	O
cases	O
with	O
disseminating	O
peritoneal	O
metastasis	O
,	O
hepatic	O
metastasis	O
and	O
stage	O
V	O
cancer	O
in	O
the	O
MMC	O
+	O
HCFU	O
group	O
as	O
when	O
compared	O
with	O
the	O
MMC	O
only	O
group	O
.	O

No	O
significant	O
side	O
effects	O
due	O
to	O
the	O
combined	O
administration	O
of	O
HCFU	O
were	O
recognized	O
.	O

The	O
combined	O
administration	O
of	O
MMC	O
and	O
HCFU	O
was	O
suggested	O
to	O
be	O
a	O
safe	O
and	O
effective	O
adjuvant	O
chemotherapy	O
for	O
noncuratively	O
resected	O
cases	O
of	O
colorectal	O
carcinoma	O
.	O

More	O
is	O
not	O
necessarily	O
better	O
:	O
Examining	O
the	O
nature	O
of	O
the	O
temporal	O
reference	O
memory	O
component	O
in	O
timing	O
.	O

Three	O
experiments	O
compared	O
the	O
timing	O
performance	O
of	O
humans	O
on	O
a	O
modified	O
temporal	O
generalization	O
task	O
with	O
1	O
,	O
3	O
,	O
or	O
5	O
presentations	O
of	O
the	O
standard	O
duration	O
.	O

In	O
all	O
three	O
experiments	O
subjects	O
received	O
presentations	O
of	O
a	O
standard	O
duration	O
at	O
the	O
beginning	O
of	O
a	O
trial	O
block	O
and	O
then	O
had	O
to	O
judge	O
whether	O
each	O
of	O
a	O
number	O
of	O
comparison	O
stimuli	O
was	O
or	O
was	O
not	O
the	O
standard	O
.	O

The	O
duration	O
of	O
the	O
standard	O
changed	O
between	O
blocks	O
.	O

The	O
three	O
experiments	O
varied	O
the	O
experimental	O
design	O
(	O
between	O
or	O
within	O
subjects	O
)	O
,	O
task	O
difficulty	O
(	O
how	O
closely	O
the	O
comparison	O
stimuli	O
were	O
spaced	O
around	O
the	O
standards	O
)	O
,	O
and	O
presence	O
or	O
absence	O
of	O
feedback	O
on	O
performance	O
accuracy	O
.	O

Number	O
of	O
presentations	O
of	O
the	O
standard	O
never	O
affected	O
the	O
proportion	O
of	O
identifications	O
of	O
the	O
standard	O
when	O
it	O
was	O
presented	O
,	O
nor	O
other	O
features	O
of	O
the	O
temporal	O
generalization	O
gradients	O
observed	O
.	O

The	O
implications	O
for	O
the	O
operation	O
of	O
reference	O
memories	O
within	O
the	O
scalar	O
timing	O
system	O
were	O
explored	O
via	O
models	O
that	O
made	O
different	O
assumptions	O
about	O
how	O
the	O
individual	O
presentations	O
of	O
the	O
standard	O
were	O
stored	O
and	O
used	O
.	O

Randomized	O
trial	O
of	O
adoptive	O
transfer	O
of	O
melanoma	O
tumor-infiltrating	O
lymphocytes	O
as	O
adjuvant	O
therapy	O
for	O
stage	Condition
III	Condition
melanoma	Condition
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
interest	O
of	O
using	O
tumor-infiltrating	O
lymphocytes	O
(	O
TIL	O
)	O
as	O
adjuvant	O
therapy	O
for	O
stage	Condition
III	Condition
(	Condition
regional	Condition
lymph	Condition
nodes	Condition
)	Condition
melanoma	Condition
.	O

After	O
lymph	O
node	O
excision	O
,	O
patients	O
without	O
any	O
detectable	O
metastases	Condition
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
TIL	O
plus	O
interleukin-2	O
(	O
IL-2	O
)	O
for	O
2	O
months	O
,	O
or	O
IL-2	O
only	O
.	O

The	O
primary	O
endpoint	O
was	O
determination	O
of	O
the	O
duration	O
of	O
the	O
relapse-free	O
interval	O
.	O

Eighty-eight	SampleSize
patients	O
determined	O
as	O
eligible	O
for	O
treatment	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
46.9	O
months	O
,	O
for	O
the	O
study	O
population	O
the	O
analysis	O
did	O
not	O
show	O
a	O
significant	O
extension	O
of	O
the	O
relapse-free	O
interval	O
or	O
overall	O
survival	O
.	O

However	O
,	O
a	O
significant	O
interaction	O
(	O
P	O
<	O
0.001	O
)	O
was	O
found	O
between	O
the	O
treatment	O
and	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
.	O

In	O
the	O
group	O
with	O
only	O
one	O
invaded	O
lymph	O
node	O
,	O
the	O
estimated	O
relapse	O
rate	O
was	O
significantly	O
lower	O
(	O
P	O
(	O
adjusted	O
)	O
=0.0285	O
)	O
and	O
the	O
overall	O
survival	O
was	O
increased	O
(	O
P	O
(	O
adjusted	O
)	O
=0.039	O
)	O
in	O
the	O
TIL+IL-2	O
arm	O
compared	O
with	O
the	O
IL-2	O
only	O
arm	O
.	O

No	O
differences	O
between	O
the	O
two	O
arms	O
,	O
either	O
as	O
regards	O
the	O
duration	O
of	O
disease-free	O
survival	O
or	O
overall	O
survival	O
,	O
were	O
noted	O
in	O
the	O
group	O
with	O
more	O
than	O
one	O
invaded	O
lymph	O
node	O
whatever	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
.	O

Treatment	O
was	O
compatible	O
with	O
normal	O
daily	O
activity	O
.	O

This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
efficiency	O
of	O
TIL	O
in	O
stage	O
III	O
melanoma	O
(	O
AJCC	O
)	O
is	O
directly	O
related	O
to	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
,	O
indicating	O
that	O
tumor	O
burden	O
might	O
be	O
a	O
crucial	O
factor	O
in	O
the	O
efficacy	O
and/or	O
in	O
vitro	O
expansion	O
of	O
T	O
cells	O
specific	O
for	O
autologous	O
tumor	O
antigen	O
,	O
a	O
finding	O
which	O
could	O
be	O
of	O
value	O
in	O
future	O
vaccine	O
development	O
for	O
the	O
treatment	O
of	O
melanoma	O
.	O

Cardiac	O
and	O
haemodynamic	O
measurements	O
in	O
hypertensive	Condition
pregnancy	Condition
.	O

1	O
.	O

Haemodynamic	O
and	O
left	O
ventricular	O
variables	O
were	O
determined	O
by	O
M-mode	O
echocardiography	O
in	O
21	SampleSize
normotensive	Condition
and	O
36	SampleSize
hypertensive	Condition
patients	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
.	O

2	O
.	O

Blood	O
pressure	O
of	O
hypertensive	Condition
patients	O
was	O
lowered	O
by	O
bed	O
rest	O
only	O
,	O
or	O
by	O
oxprenolol	O
or	O
methyldopa	O
,	O
but	O
remained	O
elevated	O
.	O

3	O
.	O

Cardiac	O
output	O
was	O
raised	O
in	O
the	O
last	O
trimester	O
of	O
pregnancy	O
in	O
both	O
normotensive	Condition
and	O
hypertensive	Condition
patients	O
.	O

4	O
.	O

Left	O
ventricular	O
mass	O
was	O
increased	O
in	O
normal	O
pregnancy	O
,	O
but	O
displayed	O
an	O
exaggerated	O
increase	O
in	O
hypertensive	Condition
patients	O
.	O

5	O
.	O

Total	O
peripheral	O
resistance	O
was	O
inappropriately	O
elevated	O
in	O
hypertensive	O
pregnancy	O
,	O
except	O
in	O
the	O
oxprenolol-treated	O
group	O
.	O

6	O
.	O

There	O
ws	O
no	O
reduction	O
in	O
heart	O
rate	O
or	O
cardiac	O
output	O
in	O
the	O
group	O
treated	O
with	O
beta-adrenoreceptor	O
blocking	O
agents	O
.	O

These	O
factors	O
,	O
in	O
combination	O
with	O
normal	O
peripheral	O
resistance	O
,	O
may	O
contribute	O
to	O
the	O
improvement	O
in	O
foetal	O
outcome	O
described	O
in	O
maternal	O
hypertension	O
of	O
pregnancy	O
treated	O
with	O
oxprenolol	O
.	O

Efficacy	O
and	O
safety	O
of	O
zidovudine	O
and	O
zalcitabine	O
combined	O
with	O
a	O
combination	O
of	O
herbs	O
in	O
the	O
treatment	O
of	O
HIV-infected	Condition
Thai	O
patients	O
.	O

A	O
randomized	O
double	O
blind	O
placebo	O
controlled	O
trial	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
combined-herbs	O
(	O
SH	O
)	O
given	O
with	O
zidovudine	O
(	O
ZDV	O
)	O
and	O
zalcitabine	O
(	O
ddC	O
)	O
for	O
the	O
treatment	O
of	O
HIV	Condition
infection	O
in	O
Thai	Age
adults	Age
was	O
conducted	O
in	O
3	O
hospitals	O
in	O
northern	O
Thailand	O
during	O
2002	O
to	O
2003	O
.	O

The	O
eligible	O
subjects	O
were	O
HIV-infected	Condition
Thai	O
adults	Age
who	O
had	O
never	O
received	O
anti-retrovirals	O
,	O
had	O
a	O
Karnofski	O
Performance	O
Score	O
(	O
KPS	O
)	O
of	O
>	O
or	O
=	O
70	O
,	O
and	O
had	O
no	O
opportunistic	O
infections	O
.	O

The	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
combination	O
of	O
ZDV	O
200	O
mg	O
three	O
times	O
per	O
day	O
,	O
ddC	O
0.75	O
mg	O
three	O
times	O
per	O
day	O
,	O
and	O
SH	O
2.5	O
g	O
three	O
times	O
per	O
day	O
or	O
a	O
combination	O
of	O
ZDV	O
200	O
mg	O
three	O
times	O
per	O
day	O
,	O
ddC	O
0.75	O
mg	O
three	O
times	O
per	O
day	O
,	O
and	O
placebo	O
2.5	O
g	O
three	O
times	O
per	O
day	O
for	O
24	O
weeks	O
.	O

The	O
main	O
outcome	O
measures	O
were	O
HIV-RNA	O
,	O
CD4	O
cells	O
,	O
and	O
blood	O
chemistry	O
profiles	O
prior	O
to	O
the	O
treatment	O
and	O
then	O
every	O
4	O
weeks	O
for	O
24	O
weeks	O
.	O

The	O
baseline	O
characteristics	O
of	O
60	SampleSize
evaluable	SampleSize
subjects	SampleSize
,	O
40	SampleSize
in	O
the	O
SH	O
group	O
and	O
20	SampleSize
in	O
the	O
placebo	O
group	O
,	O
were	O
not	O
significantly	O
different	O
.	O

HIV	O
RNA	O
at	O
week	O
4	O
and	O
thereafter	O
was	O
significantly	O
decreased	O
from	O
the	O
baseline	O
value	O
in	O
both	O
groups	O
(	O
p	O
<	O
0.001	O
)	O
.	O

However	O
,	O
the	O
decline	O
in	O
HIV	O
RNA	O
in	O
the	O
SH	O
group	O
was	O
significantly	O
more	O
than	O
that	O
in	O
the	O
placebo	O
group	O
.	O

The	O
CD4	O
cells	O
in	O
the	O
SH	O
group	O
at	O
week	O
12	O
and	O
thereafter	O
were	O
significantly	O
increased	O
from	O
the	O
baseline	O
value	O
.	O

Serious	O
adverse	O
events	O
in	O
the	O
two	O
groups	O
were	O
not	O
observed	O
.	O

It	O
is	O
concluded	O
that	O
an	O
addition	O
of	O
SH	O
herbs	O
to	O
two	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
has	O
greater	O
antiviral	O
activity	O
than	O
antiretrovirals	O
only	O
.	O

The	O
SH	O
herbs	O
may	O
be	O
an	O
alternative	O
for	O
the	O
third	O
anti-retroviral	O
agent	O
in	O
the	O
triple	O
drug	O
regimen	O
for	O
the	O
treatment	O
of	O
HIV	O
infected	O
patients	O
in	O
countries	O
with	O
limited	O
resources	O
.	O

Influence	O
of	O
lime	O
juice	O
on	O
the	O
severity	O
of	O
sickle	Condition
cell	Condition
anemia	Condition
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
The	O
pain	O
in	O
sickle	O
cell	O
anemia	O
(	O
SCA	O
)	O
is	O
often	O
triggered	O
by	O
dehydration	O
,	O
acidosis	O
,	O
and	O
fever	O
that	O
are	O
usually	O
due	O
to	O
malaria	O
.	O

Intake	O
of	O
lime	O
juice	O
was	O
recently	O
demonstrated	O
to	O
facilitate	O
clearance	O
of	O
the	O
malaria	O
parasite	O
.	O

It	O
was	O
therefore	O
sought	O
to	O
determine	O
whether	O
regular	O
intake	O
of	O
lime	O
juice	O
will	O
ameliorate	O
crisis	O
,	O
especially	O
recurrent	O
bone	O
pain	O
.	O

DESIGN	O
In	O
this	O
preliminary	O
,	O
open-labeled	O
,	O
randomized	O
study	O
,	O
the	O
effects	O
of	O
lime	O
juice	O
on	O
the	O
clinical	O
and	O
some	O
laboratory	O
characteristics	O
of	O
children	Age
with	O
SCA	Condition
were	O
tested	O
.	O

RESULTS	O
Among	O
the	O
113	SampleSize
children	Age
with	O
SCA	Condition
studied	O
in	O
two	O
hospitals	O
,	O
the	O
58	SampleSize
receiving	O
lime	O
treatment	O
had	O
lower	O
rates	O
of	O
significant	O
painful	O
episodes	O
than	O
the	O
55	O
without	O
lime	O
(	O
37	O
versus	O
83	O
crises	O
in	O
6	O
months	O
,	O
and	O
0.64?0.11	O
versus	O
1.51?0.34	O
average	O
rates	O
per	O
child	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Also	O
,	O
fewer	O
subjects	O
than	O
the	O
controls	O
had	O
significant	O
painful	O
episodes	O
(	O
50.0	O
%	O
versus	O
92.7	O
%	O
)	O
;	O
febrile	O
illness	O
(	O
46.6	O
%	O
versus	O
87.3	O
%	O
)	O
and	O
admission	O
rate	O
(	O
3.4	O
%	O
versus	O
34.5	O
%	O
)	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
mean	O
hematocrit	O
of	O
the	O
subjects	O
(	O
26.23?2.03	O
%	O
)	O
at	O
the	O
end	O
of	O
the	O
study	O
was	O
also	O
higher	O
,	O
p	O
<	O
0.001	O
.	O

However	O
,	O
transfusion	O
rate	O
,	O
presence	O
of	O
hepatomegaly	O
,	O
splenomegaly	O
,	O
and	O
jaundice	O
was	O
similar	O
.	O

Treatment	O
with	O
lime	O
did	O
not	O
cause	O
any	O
significant	O
side-effect	O
.	O

CONCLUSIONS	O
Regular	O
intake	O
of	O
lime	O
juice	O
may	O
be	O
of	O
great	O
therapeutic	O
and	O
nutritional	O
relevance	O
in	O
children	Age
with	O
SCA	Condition
.	O

Sequential	O
therapy	O
versus	O
standard	O
triple-drug	O
therapy	O
for	O
Helicobacter	O
pylori	O
eradication	O
:	O
a	O
randomized	O
study	O
.	O

BACKGROUND	O
Antimicrobial	O
resistance	O
has	O
decreased	O
eradication	O
rates	O
for	O
Helicobacter	Condition
pylori	Condition
infection	Condition
worldwide	O
.	O

A	O
sequential	O
treatment	O
schedule	O
has	O
been	O
reported	O
to	O
be	O
effective	O
,	O
but	O
studies	O
published	O
to	O
date	O
were	O
performed	O
in	O
Italy	O
.	O

We	O
undertook	O
this	O
study	O
to	O
determine	O
whether	O
these	O
results	O
could	O
be	O
replicated	O
in	O
India	O
.	O

METHODS	O
A	O
randomized	O
,	O
open-labeled	O
,	O
prospective	O
controlled	O
trial	O
comparing	O
sequential	O
vs.	O
standard	O
triple-drug	O
therapy	O
was	O
carried	O
out	O
at	O
Lokmanya	O
Tilak	O
Municipal	O
General	O
Hospital	O
,	O
Mumbai	O
.	O

Two	O
hundred	O
and	O
thirty-one	O
patients	O
with	O
dyspepsia	O
were	O
randomized	O
to	O
a	O
10-day	O
sequential	O
regimen	O
(	O
40	O
mg	O
of	O
pantoprazole	O
,	O
1	O
g	O
of	O
amoxicillin	O
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
first	O
5	O
days	O
,	O
followed	O
by	O
40	O
mg	O
of	O
pantoprazole	O
,	O
500	O
mg	O
of	O
clarithromycin	O
,	O
and	O
500	O
mg	O
of	O
tinidazole	O
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
remaining	O
5	O
days	O
)	O
or	O
to	O
standard	O
14-day	O
therapy	O
(	O
40	O
mg	O
of	O
pantoprazole	O
,	O
500	O
mg	O
of	O
clarithromycin	O
,	O
and	O
1	O
g	O
of	O
amoxicillin	O
,	O
each	O
administered	O
twice	O
daily	O
)	O
.	O

RESULTS	O
The	O
eradication	O
rate	O
achieved	O
with	O
the	O
sequential	O
regimen	O
was	O
significantly	O
greater	O
than	O
that	O
obtained	O
with	O
the	O
triple	O
therapy	O
.	O

Per-protocol	O
eradication	O
rate	O
of	O
sequential	O
therapy	O
was	O
92.4	O
%	O
(	O
95	O
%	O
CI	O
85.8-96.1	O
%	O
)	O
vs.	O
81.8	O
%	O
(	O
95	O
%	O
CI	O
73.9-87.8	O
%	O
)	O
(	O
p	O
=	O
0.027	O
)	O
for	O
standard	O
drug	O
therapy	O
.	O

Intention-to-treat	O
eradication	O
rates	O
were	O
88.2	O
%	O
(	O
95	O
%	O
CI	O
80.9-93.0	O
%	O
)	O
vs.	O
79.1	O
%	O
(	O
95	O
%	O
CI	O
71.1-85.4	O
%	O
)	O
,	O
p	O
=	O
0.029	O
,	O
respectively	O
.	O

The	O
incidence	O
of	O
major	O
and	O
minor	O
side	O
effects	O
between	O
therapy	O
groups	O
was	O
not	O
significantly	O
different	O
(	O
14.6	O
%	O
in	O
the	O
triple	O
therapy	O
group	O
vs.	O
23.5	O
%	O
in	O
sequential	O
group	O
,	O
p	O
=	O
0.12	O
)	O
.	O

Follow	O
up	O
was	O
incomplete	O
in	O
3.3	O
%	O
and	O
4.7	O
%	O
patients	O
in	O
standard	O
and	O
sequential	O
therapy	O
groups	O
,	O
respectively	O
.	O

Sequential	O
therapy	O
includes	O
one	O
additional	O
antibiotic	O
(	O
tinidazole	O
)	O
that	O
is	O
not	O
contained	O
in	O
standard	O
therapy	O
.	O

CONCLUSIONS	O
Sequential	O
therapy	O
was	O
significantly	O
better	O
than	O
standard	O
therapy	O
for	O
eradicating	O
H.	O
pylori	O
infection	O
.	O

Cisplatin	O
,	O
epirubicin	O
,	O
leucovorin	O
and	O
5-fluorouracil	O
(	O
PELF	O
)	O
is	O
more	O
active	O
than	O
5-fluorouracil	O
,	O
doxorubicin	O
and	O
methotrexate	O
(	O
FAMTX	O
)	O
in	O
advanced	Condition
gastric	Condition
carcinoma	Condition
.	O

BACKGROUND	O
5-Fluorouracil	O
(	O
5-FU	O
)	O
,	O
doxorubicin	O
and	O
methotrexate	O
(	O
FAMTX	O
)	O
and	O
cisplatin	O
,	O
epirubicin	O
,	O
leucovorin	O
and	O
5-FU	O
(	O
PELF	O
)	O
have	O
both	O
been	O
reported	O
to	O
be	O
superior	O
to	O
the	O
combination	O
5-FU	O
,	O
doxorubicin	O
and	O
mitomycin	O
C	O
(	O
FAM	O
)	O
in	O
advanced	Condition
gastric	Condition
carcinoma	Condition
.	O

On	O
the	O
basis	O
of	O
the	O
presence	O
and	O
dose	O
intensity	O
of	O
the	O
included	O
agents	O
,	O
we	O
hypothesised	O
that	O
PELF	O
would	O
be	O
superior	O
to	O
FAMTX	O
.	O

PATIENTS	O
AND	O
METHODS	O
Two	SampleSize
hundred	SampleSize
patients	O
with	O
untreated	Condition
advanced	Condition
gastric	Condition
carcinoma	Condition
were	O
randomised	O
to	O
receive	O
PELF	O
or	O
FAMTX	O
for	O
a	O
maximum	O
of	O
six	O
cycles	O
or	O
until	O
disease	O
progression	O
.	O

RESULTS	O
The	O
complete	O
response	O
(	O
CR	O
)	O
rates	O
to	O
PELF	O
and	O
FAMTX	O
were	O
,	O
respectively	O
,	O
13	O
%	O
[	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
6	O
%	O
to	O
20	O
%	O
]	O
and	O
2	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
to	O
5	O
%	O
;	O
P	O
=	O
0.003	O
)	O
,	O
and	O
the	O
objective	O
response	O
rates	O
[	O
CR	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
rates	O
]	O
39	O
%	O
(	O
95	O
%	O
CI	O
29	O
%	O
to	O
49	O
%	O
)	O
and	O
22	O
%	O
(	O
95	O
%	O
CI	O
13	O
%	O
to	O
30	O
%	O
;	O
P	O
=	O
0.009	O
)	O
,	O
thus	O
significantly	O
favouring	O
the	O
PELF	O
combination	O
.	O

The	O
survival	O
rates	O
after	O
12	O
months	O
(	O
30.8	O
%	O
versus	O
22.4	O
%	O
)	O
and	O
24	O
months	O
(	O
15.7	O
%	O
versus	O
9.5	O
%	O
)	O
were	O
also	O
higher	O
among	O
patients	O
receiving	O
PELF	O
,	O
but	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

The	O
toxicities	O
were	O
qualitatively	O
different	O
but	O
quantitatively	O
similar	O
.	O

Both	O
regimens	O
seem	O
to	O
be	O
feasible	O
provided	O
that	O
careful	O
patient	O
monitoring	O
is	O
assured	O
.	O

CONCLUSIONS	O
PELF	O
is	O
significantly	O
more	O
active	O
than	O
FAMTX	O
and	O
deserves	O
further	O
research	O
in	O
the	O
adjuvant	O
setting	O
.	O

[	O
Gluten-free	O
diet	O
in	O
infantile	O
autism	O
.	O

A	O
therapeutic	O
trial	O
]	O
.	O

It	O
has	O
been	O
postulated	O
that	O
there	O
may	O
be	O
a	O
connection	O
between	O
wheat-gluten/milk-casein	O
and	O
mental	O
disorders	O
such	O
as	O
schizophrenia	O
,	O
hyperactivity	O
and	O
autism	O
.	O

In	O
this	O
study	O
seven	O
patients	O
with	O
infantile	O
autism	O
,	O
three	O
before	O
puberty	O
and	O
four	O
after	O
puberty	O
,	O
were	O
given	O
a	O
gluten-free	O
diet	O
.	O

Three	O
children	O
were	O
provoked	O
with	O
gluten/placebo	O
in	O
a	O
double-blind	O
study	O
.	O

Four	O
young	O
patients	O
participated	O
in	O
an	O
open	O
study	O
and	O
were	O
given	O
a	O
gluten-free	O
diet	O
in	O
six	O
months	O
.	O

Behaviour	O
was	O
registered	O
before	O
,	O
during	O
and	O
after	O
the	O
period	O
with	O
a	O
gluten-free	O
diet	O
.	O

Visual	O
Analogue	O
Scale	O
and	O
Real	O
Life	O
Rating	O
Scale	O
were	O
used	O
to	O
register	O
changes	O
in	O
behaviour	O
.	O

No	O
connection	O
was	O
observed	O
between	O
gluten	O
and	O
behaviour	O
typical	O
for	O
these	O
patients	O
.	O

On	O
the	O
contrary	O
,	O
the	O
gluten-free	O
diet	O
seemed	O
to	O
be	O
another	O
negative	O
factor	O
leading	O
to	O
further	O
social	O
isolation	O
in	O
this	O
group	O
of	O
highly	O
socially	O
handicapped	O
patients	O
and	O
families	O
.	O

Endotracheal	O
cuff	O
pressure	O
and	O
tracheal	O
mucosal	O
blood	O
flow	O
:	O
endoscopic	O
study	O
of	O
effects	O
of	O
four	O
large	O
volume	O
cuffs	O
.	O

Large	O
volume	O
,	O
low	O
pressure	O
endotracheal	O
tube	O
cuffs	O
are	O
claimed	O
to	O
have	O
less	O
deleterious	O
effect	O
on	O
tracheal	O
mucosa	O
than	O
high	O
pressure	O
,	O
low	O
volume	O
cuffs	O
.	O

Low	O
pressure	O
cuffs	O
,	O
however	O
,	O
may	O
easily	O
be	O
overinflated	O
to	O
yield	O
pressures	O
that	O
will	O
exceed	O
capillary	O
perfusion	O
pressure	O
.	O

Various	O
large	O
volume	O
cuffed	O
endotracheal	O
tubes	O
were	O
studied	O
,	O
including	O
Portex	O
Profile	O
,	O
Searle	O
Sensiv	O
,	O
Mallinkrodt	O
Hi-Lo	O
,	O
and	O
Lanz	O
.	O

Tracheal	O
mucosal	O
blood	O
flow	O
in	O
40	SampleSize
patients	Condition
undergoing	Condition
surgery	Condition
was	O
assessed	O
using	O
an	O
endoscopic	O
photographic	O
technique	O
while	O
varying	O
the	O
cuff	O
inflation	O
pressure	O
.	O

It	O
was	O
found	O
that	O
these	O
cuffs	O
when	O
overpressurised	O
impaired	O
mucosal	O
blood	O
flow	O
.	O

This	O
impairment	O
of	O
tracheal	O
mucosal	O
blood	O
flow	O
is	O
an	O
important	O
factor	O
in	O
tracheal	O
morbidity	O
associated	O
with	O
intubation	O
.	O

Hence	O
it	O
is	O
recommended	O
that	O
a	O
cuff	O
inflation	O
pressure	O
of	O
30	O
cm	O
H2O	O
(	O
22	O
mm	O
Hg	O
)	O
should	O
not	O
be	O
exceeded	O
.	O

Diclofenac	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
decreases	O
proteinuria	O
in	O
some	O
glomerular	Condition
diseases	O
:	O
a	O
controlled	O
study	O
.	O

Treatment	O
with	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
was	O
first	O
used	O
in	O
glomerulonephritis	Condition
(	O
GN	O
)	O
in	O
1966	O
but	O
its	O
efficiency	O
is	O
still	O
debated	O
.	O

We	O
studied	O
the	O
antiproteinuric	O
effect	O
of	O
such	O
a	O
treatment	O
in	O
a	O
double-blind	O
study	O
.	O

29	SampleSize
GN	O
patients	O
with	O
normal	Condition
renal	Condition
function	Condition
(	O
17	SampleSize
membranoproliferative	O
GN	O
,	O
12	SampleSize
IgA	O
GN	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
100	O
mg/day	O
of	O
diclofenac	O
or	O
placebo	O
for	O
at	O
least	O
2	O
months	O
.	O

There	O
was	O
a	O
significant	O
antiproteinuric	O
effect	O
of	O
diclofenac	O
versus	O
placebo	O
with	O
a	O
fall	O
of	O
70	O
%	O
in	O
the	O
diclofenac	O
group	O
versus	O
6	O
%	O
in	O
the	O
placebo	O
group	O
(	O
p	O
less	O
than	O
0.001	O
with	O
the	O
Mann-Whitney	O
test	O
)	O
.	O

The	O
median	O
was	O
3	O
mg/min	O
at	O
onset	O
and	O
2.45	O
mg/min	O
after	O
2	O
months	O
treatment	O
with	O
the	O
placebo	O
.	O

In	O
the	O
diclofenac	O
group	O
,	O
it	O
was	O
2.2	O
and	O
0.95	O
mg/min	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Diclofenac	O
did	O
not	O
significantly	O
increase	O
creatinine	O
levels	O
.	O

Gastric	O
irritation	O
was	O
noted	O
only	O
once	O
.	O

This	O
study	O
establishes	O
the	O
short-term	O
antiproteinuric	O
action	O
of	O
diclofenac	O
.	O

Whether	O
this	O
action	O
affects	O
the	O
final	O
outcome	O
is	O
not	O
yet	O
determined	O
.	O

Co-administration	O
of	O
pethidine	O
and	O
clonidine	O
:	O
a	O
spinal	O
anaesthetic	O
technique	O
for	O
total	O
hip	O
replacement	O
.	O

Co-administration	O
of	O
pethidine	O
0.75	O
mg	O
kg-1	O
and	O
clonidine	O
75	O
micrograms	O
intrathecally	O
provided	O
good	O
intraoperative	O
anaesthesia	O
for	O
total	O
hip	O
replacement	O
,	O
similar	O
to	O
that	O
obtained	O
using	O
0.5	O
%	O
isobaric	O
bupivacaine	O
.	O

Sensory	O
and	O
motor	O
block	O
were	O
of	O
shorter	O
duration	O
than	O
that	O
after	O
0.5	O
%	O
isobaric	O
bupivacaine	O
and	O
0.5	O
%	O
isobaric	O
bupivacaine	O
with	O
morphine	O
0.5	O
mg	O
(	O
P	O
<	O
0.001	O
sensory	O
block	O
,	O
P	O
<	O
0.001	O
motor	O
block	O
)	O
.	O

Postoperative	O
morphine	O
consumption	O
,	O
measured	O
using	O
a	O
patient-controlled	O
system	O
,	O
was	O
similar	O
to	O
that	O
in	O
patients	O
in	O
the	O
bupivacaine	O
only	O
group	O
(	O
pethidine-clonidine	O
:	O
median	O
39	O
mg/24	O
h	O
;	O
bupivacaine	O
:	O
median	O
34	O
mg/24	O
h	O
)	O
but	O
greater	O
than	O
that	O
in	O
the	O
bupivacaine-morphine	O
group	O
(	O
median	O
8	O
mg/24	O
h	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Visual	O
analogue	O
pain	O
scores	O
after	O
operation	O
were	O
similar	O
to	O
those	O
with	O
bupivacaine	O
alone	O
at	O
all	O
but	O
one	O
of	O
the	O
recording	O
times	O
but	O
were	O
greater	O
than	O
those	O
in	O
patients	O
who	O
received	O
bupivacaine	O
and	O
morphine	O
at	O
4	O
,	O
6	O
and	O
10	O
h	O
after	O
operation	O
(	O
P	O
<	O
0.001	O
,	O
P	O
<	O
0.04	O
,	O
P	O
<	O
0.02	O
)	O
.	O

The	O
combination	O
did	O
not	O
offer	O
any	O
major	O
advantage	O
over	O
conventional	O
agents	O
.	O

Incidence	O
of	O
puberty	O
in	O
beef	O
heifers	O
fed	O
high-	O
or	O
low-starch	O
diets	O
for	O
different	O
periods	O
before	O
breeding	O
.	O

Spring-born	O
Hereford	O
x	O
Angus	O
heifers	O
(	O
n	O
=	O
206	O
)	O
were	O
used	O
to	O
determine	O
effects	O
of	O
energy	O
supplementation	O
programs	O
and	O
amount	O
of	O
starch	O
in	O
the	O
diet	O
on	O
incidence	O
of	O
puberty	O
.	O

In	O
Exp	O
.	O

1	O
,	O
heifers	O
(	O
205	O
+/-	O
5	O
kg	O
;	O
n	O
=	O
68	O
)	O
grazing	O
dormant	O
native	O
pasture	O
were	O
fed	O
0.9	O
kg/d	O
(	O
as-fed	O
basis	O
)	O
of	O
a	O
42	O
%	O
CP	O
supplement	O
from	O
November	O
until	O
February	O
14	O
.	O

Heifers	O
were	O
stratified	O
by	O
weaning	O
weight	O
and	O
allotted	O
randomly	O
to	O
treatment	O
before	O
breeding	O
(	O
May	O
to	O
July	O
)	O
.	O

Treatments	O
were	O
1	O
)	O
0.9	O
kg	O
(	O
as-fed	O
basis	O
)	O
of	O
a	O
42	O
%	O
CP	O
supplement/d	O
and	O
pasture	O
(	O
control	O
)	O
;	O
2	O
)	O
a	O
high-starch	O
(	O
HS	O
)	O
diet	O
(	O
73	O
%	O
corn	O
;	O
53	O
%	O
starch	O
)	O
fed	O
in	O
a	O
drylot	O
for	O
60	O
d	O
(	O
HS-60	O
)	O
;	O
3	O
)	O
a	O
HS	O
diet	O
fed	O
in	O
drylot	O
for	O
30	O
d	O
(	O
HS-30	O
)	O
;	O
or	O
4	O
)	O
a	O
low-starch	O
(	O
LS	O
)	O
diet	O
(	O
49	O
%	O
corn	O
;	O
37	O
%	O
starch	O
)	O
self-fed	O
on	O
pasture	O
for	O
30	O
d	O
(	O
LS-30	O
)	O
.	O

The	O
HS-60	O
and	O
HS-30	O
heifers	O
were	O
limited-fed	O
to	O
gain	O
0.9	O
kg/d	O
,	O
and	O
the	O
LS-30	O
heifers	O
had	O
ad	O
libitum	O
access	O
to	O
the	O
diet	O
.	O

High-starch-60	O
and	O
LS-30	O
heifers	O
were	O
heavier	O
(	O
P	O
<	O
0.05	O
)	O
than	O
control	O
and	O
HS-30	O
heifers	O
at	O
the	O
beginning	O
of	O
the	O
breeding	O
season	O
.	O

Thirty-one	O
,	O
25	O
,	O
and	O
26	O
%	O
more	O
HS-60	O
heifers	O
were	O
pubertal	O
(	O
P	O
<	O
0.05	O
)	O
on	O
May	O
1	O
compared	O
with	O
LS-30	O
,	O
HS-30	O
,	O
and	O
control	O
heifers	O
,	O
respectively	O
.	O

At	O
puberty	O
,	O
HS-60	O
heifers	O
were	O
24	O
and	O
22	O
d	O
younger	O
(	O
P	O
<	O
0.05	O
)	O
than	O
LS-30	O
and	O
control	O
heifers	O
,	O
and	O
31	O
kg	O
lighter	O
(	O
P	O
<	O
0.01	O
)	O
than	O
LS-30	O
heifers	O
.	O

In	O
Exp	O
.	O

2	O
,	O
heifers	O
grazed	O
dormant	O
pasture	O
and	O
were	O
fed	O
0.9	O
kg	O
(	O
as-fed	O
basis	O
)	O
of	O
a	O
42	O
%	O
CP	O
supplement/d	O
from	O
weaning	O
in	O
October	O
to	O
late	O
February	O
;	O
then	O
heifers	O
were	O
assigned	O
randomly	O
to	O
treatments	O
for	O
60	O
d	O
before	O
the	O
breeding	O
season	O
.	O

In	O
two	O
years	O
,	O
control	O
heifers	O
(	O
n	O
=	O
46	O
)	O
grazed	O
pasture	O
and	O
received	O
0.9	O
kg	O
of	O
SBM	O
supplement/d	O
;	O
LS	O
(	O
n	O
=	O
46	O
)	O
heifers	O
were	O
self-fed	O
a	O
distiller	O
's	O
grain	O
and	O
soybean	O
hull-based	O
diet	O
in	O
drylot	O
;	O
and	O
HS	O
heifers	O
(	O
n	O
=	O
46	O
)	O
were	O
limited-fed	O
a	O
corn-based	O
diet	O
in	O
drylot	O
.	O

During	O
treatment	O
,	O
HS	O
and	O
LS	O
heifers	O
had	O
greater	O
weight	O
gains	O
than	O
control	O
heifers	O
.	O

Pubertal	O
BW	O
(	O
313	O
+/-	O
6	O
kg	O
)	O
was	O
not	O
influenced	O
by	O
treatment	O
,	O
but	O
HS	O
and	O
LS	O
heifers	O
were	O
younger	O
(	O
P	O
<	O
0.03	O
)	O
than	O
control	O
heifers	O
at	O
puberty	O
.	O

During	O
a	O
60-d	O
breeding	O
period	O
,	O
the	O
incidence	O
of	O
puberty	O
was	O
greater	O
(	O
P	O
<	O
0.05	O
)	O
for	O
HS	O
and	O
LS	O
heifers	O
than	O
for	O
control	O
heifers	O
and	O
was	O
greater	O
(	O
P	O
<	O
0.05	O
)	O
in	O
HS	O
than	O
in	O
LS	O
heifers	O
in	O
Year	O
1	O
.	O

Feeding	O
a	O
LS	O
or	O
a	O
HS	O
diet	O
for	O
30	O
d	O
before	O
breeding	O
may	O
be	O
inadequate	O
to	O
stimulate	O
puberty	O
in	O
beef	O
heifers	O
,	O
but	O
feeding	O
a	O
diet	O
with	O
a	O
greater	O
amount	O
of	O
starch	O
for	O
60	O
d	O
before	O
breeding	O
may	O
increase	O
the	O
incidence	O
of	O
puberty	O
during	O
breeding	O
of	O
heifers	O
that	O
have	O
inadequate	O
yearling	O
weight	O
.	O

Does	O
a	O
first	O
trimester	O
dating	O
scan	O
using	O
crown	O
rump	O
length	O
measurement	O
reduce	O
the	O
rate	O
of	O
induction	O
of	O
labour	O
for	O
prolonged	O
pregnancy	O
?	O
An	O
uncompleted	O
randomised	O
controlled	O
trial	O
of	O
463	SampleSize
women	Sex
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
a	O
first	O
trimester	O
ultrasound	O
dating	O
scan	O
on	O
the	O
rate	O
of	O
induction	O
of	O
labour	O
for	O
prolonged	O
pregnancy	O
.	O

DESIGN	O
Randomised	O
controlled	O
trial	O
to	O
include	O
400	SampleSize
women	Sex
in	O
each	O
arm	O
of	O
the	O
trial	O
.	O

SETTING	O
Participating	O
general	O
practices	O
and	O
a	O
district	O
general	O
teaching	O
hospital	O
.	O

POPULATION	O
Women	Sex
attending	O
their	O
general	O
practitioner	O
in	O
the	O
first	Condition
trimester	Condition
to	O
confirm	O
pregnancy	Condition
,	O
in	O
whom	O
a	O
first	O
trimester	O
ultrasound	O
scan	O
was	O
not	O
indicated	O
.	O

METHODS	O
Women	O
randomised	O
to	O
the	O
study	O
group	O
(	O
scan	O
group	O
)	O
underwent	O
an	O
ultrasound	O
dating	O
scan	O
between	O
8	O
and	O
12	O
weeks	O
,	O
measuring	O
crown-rump	O
length	O
.	O

The	O
estimated	O
date	O
of	O
delivery	O
(	O
EDD	O
)	O
was	O
changed	O
if	O
there	O
was	O
a	O
discrepancy	O
of	O
more	O
than	O
5	O
days	O
from	O
the	O
gestation	O
,	O
calculated	O
from	O
the	O
last	O
menstrual	O
period	O
(	O
LMP	O
)	O
.	O

For	O
the	O
remaining	O
women	O
(	O
no-scan	O
group	O
)	O
,	O
gestation	O
was	O
determined	O
using	O
the	O
LMP	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
rate	O
of	O
induction	O
of	O
labour	O
for	O
prolonged	O
pregnancy	O
.	O

RESULTS	O
Due	O
to	O
circumstances	O
beyond	O
the	O
researchers	O
'	O
control	O
,	O
recruitment	O
was	O
abandoned	O
when	O
463	SampleSize
women	Sex
had	O
been	O
enrolled	O
.	O

The	O
EDD	O
was	O
adjusted	O
in	O
13	O
(	O
5.7	O
%	O
)	O
women	O
in	O
the	O
scan	O
group	O
and	O
in	O
2	O
(	O
0.9	O
%	O
)	O
in	O
the	O
no-scan	O
group	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rate	O
of	O
induction	O
for	O
prolonged	O
pregnancy	O
between	O
the	O
scan	O
(	O
19	O
[	O
8.2	O
%	O
]	O
)	O
and	O
the	O
no-scan	O
(	O
17	O
[	O
7.4	O
%	O
]	O
)	O
groups	O
(	O
relative	O
risk	O
1.10	O
;	O
95	O
%	O
CI	O
0.59-2.07	O
)	O
.	O

CONCLUSIONS	O
Acknowledging	O
the	O
reduced	O
numbers	O
recruited	O
for	O
study	O
,	O
it	O
is	O
concluded	O
that	O
there	O
is	O
no	O
evidence	O
that	O
a	O
first	O
trimester	O
ultrasound	O
dating	O
scan	O
reduces	O
the	O
rate	O
of	O
induction	O
of	O
labour	O
for	O
prolonged	O
pregnancy	O
and	O
may	O
result	O
in	O
a	O
more	O
expensive	O
healthcare	O
strategy	O
.	O

Relationship	O
between	O
subjective	O
effects	O
and	O
drug	O
preferences	O
:	O
ethanol	O
and	O
diazepam	O
.	O

The	O
relationship	O
between	O
subjective	O
effects	O
and	O
drug	O
preferences	O
in	O
normal	Condition
volunteers	O
was	O
explored	O
in	O
a	O
meta-analysis	O
of	O
several	O
previously	O
published	O
studies	O
.	O

Subjective	O
effects	O
of	O
,	O
and	O
preference	O
for	O
,	O
ethanol	O
and	O
diazepam	O
vs.	O
placebo	O
were	O
measured	O
using	O
a	O
choice	O
procedure	O
.	O

Subjects	O
were	O
grouped	O
according	O
to	O
their	O
drug	O
choices	O
:	O
'non-choosers	O
'	O
never	O
chose	O
drug	O
,	O
whereas	O
'choosers	O
'	O
always	O
chose	O
drug	O
.	O

The	O
two	O
groups	O
were	O
compared	O
on	O
their	O
subjective	O
responses	O
to	O
drug	O
and	O
on	O
demographic	O
variables	O
.	O

Ethanol	O
decreased	O
Arousal	O
,	O
Elation	O
,	O
Positive	O
Mood	O
and	O
Vigor	O
,	O
and	O
increased	O
Anxiety	O
,	O
Depression	O
and	O
Fatigue	O
in	O
the	O
non-choosers	O
,	O
whereas	O
it	O
increased	O
Arousal	O
and	O
Vigor	O
in	O
the	O
choosers	O
.	O

Ethanol	O
choosers	O
were	O
also	O
more	O
likely	O
to	O
be	O
males	Sex
and/or	O
full-time	O
students	O
than	O
non-choosers	O
.	O

Diazepam	O
produced	O
sedative-like	O
effects	O
in	O
both	O
choosers	O
and	O
non-choosers	O
,	O
but	O
markedly	O
decreased	O
Anxiety	O
and	O
increased	O
Friendliness	O
in	O
choosers	O
only	O
.	O

Diazepam	O
choice	O
was	O
also	O
associated	O
with	O
more	O
frequent	O
recreational	O
use	O
of	O
marijuana	O
and	O
stimulants	O
.	O

Thus	O
,	O
both	O
demographic	O
variables	O
and	O
subjective	O
drug	O
effects	O
were	O
related	O
to	O
drug	O
preference	O
.	O

Lack	O
of	O
benefit	O
of	O
a	O
single	O
dose	O
of	O
synthetic	O
human	O
secretin	O
in	O
the	O
treatment	O
of	O
autism	Condition
and	O
pervasive	Condition
developmental	Condition
disorder	Condition
.	O

BACKGROUND	O
Secretin	O
is	O
a	O
peptide	O
hormone	O
that	O
stimulates	O
pancreatic	O
secretion	O
.	O

After	O
recent	O
publicity	O
about	O
a	O
child	O
with	O
autism	O
whose	O
condition	O
markedly	O
improved	O
after	O
a	O
single	O
dose	O
of	O
secretin	O
,	O
thousands	O
of	O
children	O
with	O
autistic	Condition
disorders	Condition
may	O
have	O
received	O
secretin	O
injections	O
.	O

METHODS	O
We	O
conducted	O
a	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
a	O
single	O
intravenous	O
dose	O
of	O
synthetic	O
human	O
secretin	O
in	O
60	SampleSize
children	Age
(	O
age	O
,	O
3	Age
to	Age
14	Age
years	Age
)	O
with	O
autism	O
or	O
pervasive	O
developmental	O
disorder	O
.	O

The	O
children	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
an	O
intravenous	O
infusion	O
of	O
synthetic	O
human	O
secretin	O
(	O
0.4	O
microg	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
or	O
saline	O
placebo	O
.	O

We	O
used	O
standardized	O
behavioral	O
measures	O
of	O
the	O
primary	O
and	O
secondary	O
features	O
of	O
autism	O
,	O
including	O
the	O
Autism	O
Behavior	O
Checklist	O
,	O
to	O
assess	O
the	O
degree	O
of	O
impairment	O
at	O
base	O
line	O
and	O
over	O
the	O
course	O
of	O
a	O
four-week	O
period	O
after	O
treatment	O
.	O

RESULTS	O
Of	O
the	O
60	O
children	O
,	O
4	O
could	O
not	O
be	O
evaluated	O
-	O
2	O
received	O
secretin	O
outside	O
the	O
study	O
,	O
and	O
2	O
did	O
not	O
return	O
for	O
follow-up	O
.	O

Thus	O
,	O
56	O
children	O
(	O
28	SampleSize
in	O
each	O
group	O
)	O
completed	O
the	O
study	O
.	O

As	O
compared	O
with	O
placebo	O
,	O
secretin	O
treatment	O
was	O
not	O
associated	O
with	O
significant	O
improvements	O
in	O
any	O
of	O
the	O
outcome	O
measures	O
.	O

Among	O
the	O
children	O
in	O
the	O
secretin	O
group	O
,	O
the	O
mean	O
total	O
score	O
on	O
the	O
Autism	O
Behavior	O
Checklist	O
at	O
base	O
line	O
was	O
59.0	O
(	O
range	O
of	O
possible	O
values	O
,	O
0	O
to	O
158	O
,	O
with	O
a	O
larger	O
value	O
corresponding	O
to	O
greater	O
impairment	O
)	O
,	O
and	O
among	O
those	O
in	O
the	O
placebo	O
group	O
it	O
was	O
63.2	O
.	O

The	O
mean	O
decreases	O
in	O
scores	O
over	O
the	O
four-week	O
period	O
were	O
8.9	O
in	O
the	O
secretin	O
group	O
and	O
17.8	O
in	O
the	O
placebo	O
group	O
(	O
mean	O
difference	O
,	O
-8.9	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
-19.4	O
to	O
1.6	O
;	O
P=0.11	O
)	O
.	O

None	O
of	O
the	O
children	O
had	O
treatment-limiting	O
adverse	O
effects	O
.	O

After	O
they	O
were	O
told	O
the	O
results	O
,	O
69	O
percent	O
of	O
the	O
parents	O
of	O
the	O
children	O
in	O
this	O
study	O
said	O
they	O
remained	O
interested	O
in	O
secretin	O
as	O
a	O
treatment	O
for	O
their	O
children	O
.	O

CONCLUSIONS	O
A	O
single	O
dose	O
of	O
synthetic	O
human	O
secretin	O
is	O
not	O
an	O
effective	O
treatment	O
for	O
autism	O
or	O
pervasive	O
developmental	O
disorder	O
.	O

Activator	O
protein-1	O
(	O
AP-1	O
)	O
signalling	O
in	O
human	O
atherosclerosis	Condition
:	O
results	O
of	O
a	O
systematic	O
evaluation	O
and	O
intervention	O
study	O
.	O

Animal	O
studies	O
implicate	O
the	O
AP-1	O
(	O
activator	O
protein-1	O
)	O
pro-inflammatory	O
pathway	O
as	O
a	O
promising	O
target	O
in	O
the	O
treatment	O
of	O
atherosclerotic	Condition
disease	Condition
.	O

It	O
is	O
,	O
however	O
,	O
unclear	O
whether	O
these	O
observations	O
apply	O
to	O
human	O
atherosclerosis	Condition
.	O

Therefore	O
we	O
evaluated	O
the	O
profile	O
of	O
AP-1	O
activation	O
through	O
histological	O
analysis	O
and	O
tested	O
the	O
potential	O
benefit	O
of	O
AP-1	O
inhibition	O
in	O
a	O
clinical	O
trial	O
.	O

AP-1	O
activation	O
was	O
quantified	O
by	O
phospho-c-Jun	O
nuclear	O
translocation	O
(	O
immunohistochemistry	O
)	O
on	O
a	O
biobank	O
of	O
aortic	Condition
wall	Condition
samples	O
from	O
organ	O
donors	O
.	O

The	O
effect	O
of	O
AP-1	O
inhibition	O
on	O
vascular	O
parameters	O
was	O
tested	O
through	O
a	O
double	O
blind	O
placebo-controlled	O
cross-over	O
study	O
of	O
28	O
days	O
doxycycline	O
or	O
placebo	O
in	O
patients	O
with	O
symptomatic	O
peripheral	O
artery	O
disease	O
.	O

Vascular	O
function	O
was	O
assessed	O
by	O
brachial	O
dilation	O
as	O
well	O
as	O
by	O
plasma	O
samples	O
analysed	O
for	O
hs-CRP	O
(	O
high-sensitivity	O
C-reactive	O
protein	O
)	O
,	O
IL-6	O
(	O
interleukin-6	O
)	O
,	O
IL-8	O
,	O
ICAM-1	O
(	O
intercellular	O
adhesion	O
molecule-1	O
)	O
,	O
vWF	O
(	O
von	O
Willebrand	O
factor	O
)	O
,	O
MCP-1	O
(	O
monocyte	O
chemoattractant	O
protein-1	O
)	O
,	O
PAI-1	O
(	O
plasminogen	O
activator	O
inhibitor-1	O
)	O
and	O
fibrinogen	O
.	O

Histological	O
evaluation	O
of	O
human	O
atherosclerosis	O
showed	O
minimal	O
AP-1	O
activation	O
in	O
non-diseased	O
arterial	O
wall	O
(	O
i.e	O
.	O

vessel	O
wall	O
without	O
any	O
signs	O
of	O
atherosclerotic	O
disease	O
)	O
.	O

A	O
gradual	O
increase	O
of	O
AP-1	O
activation	O
was	O
found	O
in	O
non-progressive	O
and	O
progressive	O
phases	O
of	O
atherosclerosis	O
respectively	O
(	O
P	O
<	O
0.044	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
progressive	O
and	O
vulnerable	O
lesions	O
.	O

The	O
expression	O
of	O
phospho-c-Jun	O
diminished	O
as	O
the	O
lesion	O
stabilized	O
(	O
P	O
<	O
0.016	O
)	O
and	O
does	O
not	O
significantly	O
differ	O
from	O
the	O
normal	O
aortic	O
wall	O
(	O
P	O
<	O
0.33	O
)	O
.	O

Evaluation	O
of	O
the	O
doxycycline	O
intervention	O
only	O
revealed	O
a	O
borderline-significant	O
reduction	O
of	O
circulating	O
hs-CRP	O
levels	O
(	O
-0.51	O
?g/ml	O
,	O
P=0.05	O
)	O
and	O
did	O
not	O
affect	O
any	O
of	O
the	O
other	O
markers	O
of	O
systemic	O
inflammation	O
and	O
vascular	O
function	O
.	O

Our	O
studies	O
do	O
not	O
characterize	O
AP-1	O
as	O
a	O
therapeutic	O
target	O
for	O
progressive	O
human	O
atherosclerotic	O
disease	O
.	O

Genital	O
responsiveness	O
in	O
healthy	Condition
women	Sex
with	O
and	O
without	O
sexual	Condition
arousal	Condition
disorder	Condition
.	O

INTRODUCTION	O
Most	O
pharmacological	O
treatments	O
that	O
are	O
currently	O
being	O
developed	O
for	O
women	Sex
with	O
sexual	Condition
arousal	Condition
disorder	Condition
are	O
aimed	O
at	O
remedying	O
a	O
vasculogenic	O
deficit	O
.	O

AIM	O
This	O
study	O
investigated	O
whether	O
pre-	Condition
and	Condition
postmenopausal	Condition
women	Sex
with	O
sexual	Condition
arousal	Condition
disorder	Condition
are	O
less	O
genitally	O
responsive	O
to	O
visual	O
sexual	O
stimuli	O
than	O
pre-	O
and	O
postmenopausal	O
women	O
without	O
sexual	O
problems	O
.	O

METHOD	O
Twenty-nine	SampleSize
medically	O
healthy	Condition
women	Condition
with	O
sexual	Condition
arousal	Condition
disorder	Condition
(	O
15	SampleSize
premenopausal	O
and	O
14	SampleSize
postmenopausal	O
)	O
,	O
diagnosed	O
using	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
4th	O
Edition	O
(	O
DSM-IV	O
)	O
criteria	O
,	O
and	O
30	SampleSize
age-matched	O
women	O
without	O
sexual	O
problems	O
(	O
16	O
premenopausal	O
and	O
14	O
postmenopausal	O
)	O
were	O
shown	O
sexual	O
stimuli	O
depicting	O
cunnilingus	O
and	O
intercourse	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
Genital	O
arousal	O
was	O
assessed	O
as	O
vaginal	O
pulse	O
amplitude	O
(	O
VPA	O
)	O
using	O
vaginal	O
photoplethysmography	O
.	O

RESULTS	O
Results	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
mean	O
and	O
maximum	O
VPA	O
,	O
nor	O
in	O
latency	O
of	O
VPA	O
response	O
.	O

CONCLUSION	O
Women	Sex
with	O
sexual	Condition
arousal	Condition
disorder	Condition
diagnosed	O
according	O
to	O
DSM-IV	O
criteria	O
were	O
not	O
less	O
genitally	O
responsive	O
to	O
visual	O
sexual	O
stimuli	O
than	O
women	O
without	O
such	O
problems	O
.	O

These	O
findings	O
are	O
in	O
line	O
with	O
previous	O
studies	O
.	O

The	O
sexual	O
problems	O
these	O
women	O
report	O
are	O
clearly	O
not	O
related	O
to	O
their	O
potential	O
to	O
become	O
genitally	O
aroused	O
.	O

We	O
argue	O
that	O
the	O
DSM-IV	O
criteria	O
for	O
sexual	O
arousal	O
disorder	O
are	O
in	O
need	O
of	O
revision	O
.	O

In	O
medically	O
healthy	Condition
women	Sex
,	O
impaired	O
genital	O
responsiveness	O
is	O
not	O
a	O
valid	O
diagnostic	O
criterion	O
.	O

The	O
Finnish	O
Diabetes	Condition
Prevention	O
Study	O
.	O

The	O
aim	O
of	O
the	O
Finnish	O
Diabetes	Condition
Prevention	O
Study	O
is	O
to	O
assess	O
the	O
efficacy	O
of	O
an	O
intensive	O
diet-exercise	O
programme	O
in	O
preventing	O
or	O
delaying	O
type	Condition
2	Condition
diabetes	Condition
in	O
individuals	O
with	O
impaired	Condition
glucose	Condition
tolerance	Condition
(	Condition
IGT	Condition
)	Condition
and	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
programme	O
on	O
the	O
risk	O
factors	O
of	O
atherosclerotic	O
vascular	O
diseases	O
and	O
the	O
incidence	O
of	O
cardiovascular	O
events	O
.	O

In	O
this	O
ongoing	O
study	O
,	O
a	O
total	O
of	O
523	SampleSize
overweight	O
subjects	O
with	O
IGT	Condition
based	O
on	O
two	O
oral	O
glucose	O
tolerance	O
tests	O
were	O
randomized	O
to	O
either	O
an	O
intervention	O
group	O
or	O
a	O
control	O
group	O
.	O

The	O
main	O
measure	O
in	O
the	O
intervention	O
group	O
is	O
individual	O
dietary	O
advice	O
aimed	O
at	O
reducing	O
weight	O
and	O
intake	O
of	O
saturated	O
fat	O
and	O
increasing	O
intake	O
of	O
dietary	O
fibre	O
.	O

The	O
intervention	O
subjects	O
are	O
individually	O
guided	O
to	O
increase	O
their	O
level	O
of	O
physical	O
activity	O
.	O

The	O
control	O
group	O
receives	O
general	O
information	O
about	O
the	O
benefits	O
of	O
weight	O
reduction	O
,	O
physical	O
activity	O
and	O
healthy	O
diet	O
in	O
the	O
prevention	O
of	O
diabetes	O
.	O

A	O
pilot	O
study	O
began	O
in	O
1993	O
,	O
and	O
recruitment	O
ended	O
in	O
1998	O
.	O

By	O
the	O
end	O
of	O
April	O
1999	O
there	O
were	O
65	O
new	O
cases	O
of	O
diabetes	O
,	O
34	O
drop-outs	O
and	O
one	O
death	O
.	O

The	O
weight	O
reduction	O
was	O
greater	O
(	O
-4.6	O
kg	O
)	O
at	O
1	O
year	O
in	O
the	O
intervention	O
group	O
(	O
n	O
=	O
152	O
)	O
than	O
in	O
the	O
control	O
group	O
(	O
n	O
=	O
143	O
,	O
-0.9	O
kg	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
this	O
difference	O
was	O
sustained	O
in	O
the	O
second	O
year	O
of	O
follow-up	O
.	O

At	O
1	O
year	O
43.4	O
%	O
and	O
at	O
2	O
years	O
41.8	O
%	O
of	O
the	O
intervention	O
subjects	O
had	O
achieved	O
a	O
weight	O
reduction	O
of	O
at	O
least	O
5	O
kg	O
,	O
while	O
the	O
corresponding	O
figures	O
for	O
the	O
control	O
subjects	O
were	O
14.0	O
and	O
12.0	O
%	O
(	O
P	O
<	O
0.001	O
between	O
the	O
groups	O
)	O
.	O

At	O
1	O
year	O
the	O
intervention	O
group	O
showed	O
significantly	O
greater	O
reductions	O
in	O
2	O
h	O
glucose	O
,	O
fasting	O
and	O
2	O
h	O
insulin	O
,	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
,	O
and	O
serum	O
triglycerides	O
.	O

Most	O
of	O
the	O
beneficial	O
changes	O
in	O
cardiovascular	O
risk	O
factors	O
were	O
sustained	O
for	O
2	O
years	O
.	O

These	O
interim	O
results	O
of	O
the	O
ongoing	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
demonstrate	O
the	O
efficacy	O
and	O
feasibility	O
of	O
the	O
lifestyle	O
intervention	O
programme	O
.	O

Effect	O
of	O
whole	O
body	O
vibration	O
on	O
stereotypy	O
of	O
young	O
children	O
with	O
autism	O
.	O

The	O
objective	O
of	O
this	O
case	O
was	O
report	O
on	O
the	O
effects	O
of	O
acute	O
whole	O
body	O
vibration	O
exposure	O
on	O
stereotyped	O
behaviour	O
of	O
young	O
children	O
with	O
autism	O
.	O

Four	O
young	O
boys	O
(	O
ages	O
4-5	O
years	O
)	O
diagnosed	O
with	O
autism	O
participated	O
.	O

The	O
children	O
were	O
participants	O
in	O
an	O
early	O
intensive	O
behavioural	O
intervention	O
clinic	O
and	O
during	O
downtimes	O
stood	O
on	O
a	O
whole	O
body	O
vibration	O
platform	O
with	O
the	O
machine	O
turned	O
off	O
(	O
control	O
condition	O
)	O
and	O
on	O
(	O
treatment	O
condition	O
)	O
for	O
three	O
to	O
four	O
,	O
30	O
s	O
periods	O
(	O
frequency=28	O
Hz	O
;	O
amplitude	O
0.97	O
mm	O
)	O
.	O

The	O
outcome	O
measure	O
was	O
frequency	O
of	O
stereotypic	O
behaviour	O
,	O
which	O
was	O
evaluated	O
for	O
5	O
min	O
before	O
and	O
after	O
standing	O
on	O
the	O
vibration	O
platform	O
.	O

The	O
results	O
revealed	O
that	O
whole	O
body	O
vibration	O
was	O
not	O
able	O
to	O
uniformly	O
decrease	O
the	O
rates	O
of	O
all	O
types	O
of	O
stereotypy	O
;	O
that	O
is	O
,	O
some	O
stereotypy	O
decreased	O
while	O
others	O
were	O
unchanged	O
.	O

Subjectively	O
,	O
the	O
children	O
enjoyed	O
whole	O
body	O
vibration	O
which	O
was	O
easy	O
to	O
integrate	O
into	O
the	O
behavioural	O
programme	O
.	O

Endoscopic	O
versus	O
operative	O
gastrostomy	Condition
:	O
final	O
results	O
of	O
a	O
prospective	O
randomized	O
trial	O
.	O

This	O
study	O
compared	O
operative	Condition
gastrostomy	Condition
(	Condition
OG	Condition
)	Condition
(	O
by	O
surgeons	O
)	O
with	O
endoscopic	Condition
gastrostomy	Condition
(	Condition
PEG	Condition
)	Condition
(	O
by	O
physicians	O
)	O
in	O
a	O
prospective	O
randomized	O
fashion	O
to	O
determine	O
whether	O
one	O
technique	O
was	O
superior	O
.	O

PEG	O
(	O
Sachs-Vine	O
)	O
and	O
OG	O
(	O
Stamm	O
)	O
were	O
done	O
using	O
local	O
anesthesia	O
.	O

Patients	O
were	O
assessed	O
for	O
complications	O
,	O
mortality	O
,	O
tube	O
function	O
,	O
and	O
cost	O
.	O

Groups	O
were	O
equally	O
matched	O
for	O
indications	O
and	O
underlying	O
disease	O
.	O

Fifty-seven	SampleSize
had	O
OG	Condition
and	O
64	SampleSize
had	O
attempted	O
PEG	Condition
.	O

Complications	O
occurred	O
in	O
26	O
%	O
of	O
OG	O
patients	O
and	O
9	O
%	O
died	O
.	O

Complications	O
occurred	O
in	O
25	O
%	O
of	O
PEG	O
patients	O
and	O
12	O
%	O
died	O
.	O

Tube	O
feeding	O
was	O
initiated	O
in	O
both	O
groups	O
within	O
a	O
mean	O
of	O
29	O
(	O
24	O
to	O
72	O
)	O
hours	O
of	O
the	O
gastrostomy	O
placement	O
.	O

OG	O
cost	O
$	O
1675	O
and	O
PEG	O
$	O
979	O
to	O
perform	O
.	O

Twenty-one	O
PEG	O
patients	O
required	O
endoscopic	O
tube	O
change	O
which	O
raised	O
their	O
total	O
cost	O
to	O
$	O
1574	O
.	O

We	O
conclude	O
there	O
is	O
no	O
difference	O
between	O
OG	O
(	O
using	O
local	O
anesthesia	O
)	O
and	O
PEG	O
with	O
regard	O
to	O
morbidity	O
,	O
mortality	O
,	O
or	O
tube	O
function	O
.	O

The	O
endoscopic	O
technique	O
does	O
appear	O
to	O
have	O
economic	O
advantage	O
.	O

[	O
European	O
topic	O
:	O
liver	O
surgery	O
II	O
--	O
regional	O
chemotherapy	O
]	O
.	O

The	O
most	O
important	O
methods	O
of	O
regional	O
chemotherapy	O
are	O
exemplified	O
by	O
657	O
cases	O
of	O
primary	O
and	O
secondary	O
liver	O
only	O
malignancies	O
.	O

I	O
.	O

Adjuvant	O
portal	O
therapy	O
of	O
the	O
liver	O
with	O
resection	O
of	O
the	O
colorectal	O
primary	O
malignancy	O
seems	O
to	O
be	O
advantageous	O
for	O
advanced	O
tumors	O
.	O

II	O
.	O

It	O
is	O
still	O
unresolved	O
whether	O
survival	O
is	O
prolonged	O
by	O
adjuvant	O
treatment	O
of	O
the	O
liver	O
following	O
curative	O
resection	O
of	O
colorectal	O
liver	O
metastases	O
.	O

III	O
.	O

The	O
median	O
survival	O
time	O
(	O
FUDR	O
,	O
pump	O
)	O
is	O
17	O
months	O
for	O
palliative	O
local	O
chemotherapy	O
of	O
unresectable	O
colorectal	O
liver	O
metastases	O
.	O

IV	O
.	O

Primary	O
non-resectable	O
liver	O
malignancies	O
show	O
the	O
best	O
results	O
after	O
chemoembolisation	O
(	O
Frankfurt	O
method	O
)	O
.	O

Prophylactic	O
amnioinfusion	O
in	O
pregnancies	O
complicated	O
by	O
oligohydramnios	O
:	O
a	O
prospective	O
study	O
.	O

Prophylactic	O
amnioinfusion	O
was	O
assessed	O
in	O
term	O
and	O
post-dates	O
pregnancies	O
with	O
decreased	O
amniotic	O
fluid	O
volume	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
amnioinfusion	O
with	O
warmed	O
saline	O
solution	O
,	O
room-temperature	O
saline	O
,	O
or	O
control	O
.	O

Patients	O
receiving	O
prophylactic	O
amnioinfusion	O
had	O
a	O
significant	O
decrease	O
in	O
both	O
the	O
frequency	O
and	O
severity	O
of	O
variable	O
decelerations	O
in	O
the	O
first	O
stage	O
of	O
labor	O
(	O
P	O
=	O
.006	O
)	O
and	O
in	O
the	O
average	O
total	O
number	O
of	O
variable	O
decelerations	O
in	O
the	O
first	O
and	O
second	O
stages	O
of	O
labor	O
(	O
P	O
=	O
.01	O
)	O
compared	O
with	O
controls	O
.	O

There	O
was	O
no	O
observed	O
effect	O
on	O
newborn	O
serum	O
electrolyte	O
levels	O
with	O
amnioinfusion	O
,	O
nor	O
was	O
there	O
any	O
apparent	O
benefit	O
of	O
infusion	O
of	O
warmed	O
saline	O
compared	O
with	O
room-temperature	O
saline	O
.	O

In	O
contrast	O
to	O
premature	O
gestations	O
with	O
oligohydramnios	O
,	O
prophylactic	O
amnioinfusion	O
was	O
not	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
mean	O
umbilical	O
arterial	O
and	O
venous	O
pH	O
or	O
a	O
significant	O
decrease	O
in	O
cesarean	O
delivery	O
for	O
fetal	O
distress	O
(	O
P	O
=	O
.09	O
)	O
.	O

This	O
is	O
perhaps	O
because	O
the	O
term	O
fetus	O
has	O
an	O
enhanced	O
ability	O
to	O
tolerate	O
recurrent	O
episodes	O
of	O
heart	O
rate	O
decelerations	O
without	O
demonstrating	O
the	O
rapid	O
metabolic	O
changes	O
seen	O
in	O
the	O
premature	O
fetus	O
.	O

Recurrence	O
of	O
condylomata	Condition
acuminata	Condition
following	Condition
cryotherapy	Condition
is	O
not	O
prevented	O
by	O
systemically	O
administered	O
interferon	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
interferon	O
alpha-2a	O
,	O
when	O
utilised	O
as	O
adjuvant	O
chemotherapy	O
following	O
ablation	O
of	O
condylomata	O
acuminata	O
(	O
genital	O
warts	O
)	O
by	O
cryotherapy	O
,	O
is	O
effective	O
in	O
the	O
prevention	O
of	O
recurrences	O
.	O

DESIGN	O
Randomised	O
,	O
placebo-controlled	O
,	O
double-blind	O
study	O
.	O

Statistical	O
analysis	O
was	O
by	O
2-tailed	O
Fisher	O
's	O
Exact	O
Test	O
.	O

PATIENTS	O
97	O
patients	O
with	O
recurrent	O
condylomata	O
acuminata	O
.	Condition

INTERVENTION	O
49	O
patients	O
were	O
treated	O
with	O
cryotherapy	O
plus	O
subcutaneously	O
administered	O
interferon	O
alpha-2a	O
,	O
and	O
48	O
received	O
cryotherapy	O
plus	O
placebo	O
.	O

Of	O
these	O
,	O
36	O
and	O
37	O
patients	O
,	O
respectively	O
,	O
completed	O
the	O
study	O
and	O
were	O
evaluable	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
Clinical	O
eradication	O
of	O
condylomata	O
for	O
six	O
months	O
following	O
adjuvant	O
chemotherapy	O
.	O

RESULTS	O
By	O
completion	O
of	O
the	O
adjuvant	O
chemotherapy	O
,	O
10	O
(	O
28	O
%	O
)	O
interferon	O
recipients	O
and	O
16	O
(	O
43	O
%	O
)	O
placebo	O
recipients	O
experienced	O
recurrences	O
.	O

At	O
six	O
months	O
follow-up	O
,	O
25	O
(	O
69	O
%	O
)	O
interferon	O
and	O
27	O
(	O
73	O
%	O
)	O
placebo	O
recipients	O
experienced	O
recurrences	O
.	O

In	O
the	O
six	O
months	O
following	O
interferon	O
therapy	O
,	O
only	O
31	O
%	O
of	O
interferon	O
and	O
27	O
%	O
of	O
placebo	O
recipients	O
remained	O
free	O
of	O
recurrences	O
(	O
p	O
=	O
0.99	O
)	O
.	O

CONCLUSIONS	O
Interferon	O
alpha-2a	O
administered	O
subcutaneously	O
offers	O
no	O
benefit	O
as	O
a	O
chemotherapeutic	O
adjuvant	O
to	O
cryotherapy	O
when	O
used	O
alone	O
in	O
the	O
therapy	O
of	O
genital	O
warts	O
in	O
this	O
population	O
of	O
patients	O
with	O
recurrent	O
condylomata	O
.	O

The	O
effects	O
of	O
strength	O
training	O
on	O
central	O
arterial	O
compliance	O
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

BACKGROUND	O
Contrary	O
to	O
aerobic	O
exercise	O
,	O
strength	O
training	O
(	O
ST	O
)	O
is	O
associated	O
with	O
decreased	Condition
central	Condition
arterial	Condition
compliance	Condition
in	O
young	O
men	O
.	O

It	O
is	O
unknown	O
whether	O
ST	O
,	O
with	O
or	O
without	O
concurrent	O
endurance	O
training	O
,	O
would	O
have	O
a	O
similar	O
effect	O
in	O
older	O
adults	O
with	O
reduced	Condition
baseline	Condition
arterial	Condition
compliance	Condition
.	O

OBJECTIVE	O
The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
a	O
ST	O
program	O
on	O
central	O
arterial	O
compliance	O
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

DESIGN	O
Randomized	O
,	O
controlled	O
intervention	O
study	O
in	O
which	O
37	SampleSize
healthy	Condition
,	O
sedentary	Condition
men	Sex
and	O
women	Sex
(	O
52+/-2	Age
years	Age
)	O
performed	O
13	O
weeks	O
of	O
ST	O
(	O
n=13	O
)	O
,	O
ST+aerobic	O
exercise	O
(	O
n=12	O
)	O
or	O
stretching	O
exercises	O
as	O
a	O
control	O
group	O
(	O
n=12	O
)	O
.	O

METHODS	O
Participants	O
were	O
rigorously	O
screened	O
for	O
cardiovascular	Condition
disease	Condition
and	O
underwent	O
pre-post	O
testing	O
for	O
carotid	Condition
arterial	Condition
compliance	Condition
(	O
via	O
simultaneous	O
ultrasound	O
and	O
applanation	O
tonometry	O
)	O
,	O
carotid-femoral	O
pulse	O
wave	O
velocity	O
,	O
plasma	O
endothelin-1	O
and	O
angiotensin	O
II	O
concentrations	O
and	O
carotid	O
artery	O
vasoreactivity	O
(	O
cold	O
pressor	O
test	O
)	O
.	O

RESULTS	O
ST	O
performed	O
alone	O
,	O
or	O
in	O
conjunction	O
with	O
aerobic	O
exercise	O
,	O
improved	O
maximal	O
muscle	O
strength	O
and	O
increased	O
total	O
lean	O
body	O
mass	O
(	O
both	O
P	O
<	O
0.01	O
)	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
carotid	O
artery	O
compliance	O
or	O
carotid-femoral	O
pulse	O
wave	O
velocity	O
following	O
ST	O
or	O
ST+aerobic	O
exercise	O
.	O

Carotid	O
artery	O
compliance	O
increased	O
significantly	O
(	O
23	O
%	O
)	O
following	O
stretching	O
which	O
may	O
be	O
attributed	O
to	O
a	O
reduction	O
in	O
carotid	O
pulse	O
pressure	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
plasma	O
vasoconstrictor	O
hormones	O
or	O
carotid	O
artery	O
vasoreactivity	O
following	O
the	O
interventions	O
.	O

CONCLUSION	O
Thirteen	O
weeks	O
of	O
moderate	O
ST	O
two	O
or	O
three	O
times	O
per	O
week	O
does	O
not	O
reduce	O
central	O
arterial	O
compliance	O
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

Bedside	O
ultrasound-guided	O
celiac	O
plexus	O
neurolysis	O
in	O
upper	O
abdominal	O
cancer	O
patients	O
:	O
a	O
randomized	O
,	O
prospective	O
study	O
for	O
comparison	O
of	O
percutaneous	O
bilateral	O
paramedian	O
vs.	O
unilateral	O
paramedian	O
needle-insertion	O
technique	O
.	O

INTRODUCTION	O
Percutaneous	O
anterior	O
abdominal	O
ultrasound	O
guidance	O
for	O
performing	O
celiac	O
plexus	O
neurolysis	O
is	O
a	O
relatively	O
new	O
but	O
more	O
economical	O
,	O
less	O
time-consuming	O
,	O
more	O
comfortable	O
bedside	O
technique	O
for	O
interventional	O
pain	O
management	O
.	O

Paucity	O
of	O
studies	O
evaluating	O
the	O
efficacy	O
of	O
single-site	O
vs.	O
double-site	O
injections	O
at	O
celiac	O
trunk	O
for	O
ultrasound-guided	O
celiac	O
plexus	O
neurolysis	O
(	O
USCPN	O
)	O
prompted	O
us	O
to	O
conduct	O
a	O
prospective	O
,	O
randomized	O
,	O
single-blind	O
clinical	O
trial	O
to	O
compare	O
USCPN	O
using	O
bilateral	O
paramedian	O
(	O
double	O
needle	O
)	O
technique	O
with	O
unilateral	O
paramedian	O
(	O
single	O
needle	O
)	O
technique	O
.	O

METHODS	O
Sixty	O
patients	O
aged	O
18	O
years	O
or	O
older	O
with	O
unresectable	O
upper	O
abdominal	O
cancers	O
were	O
randomized	O
into	O
two	O
groups	O
to	O
receive	O
USCPN	O
.	O

A	O
20-mL	O
mixture	O
of	O
50	O
%	O
ethanol	O
with	O
0.25	O
%	O
bupivacaine	O
was	O
injected	O
either	O
unilaterally	O
(	O
20	O
mL?1	O
site	O
)	O
or	O
bilaterally	O
(	O
10	O
mL?2	O
sites	O
)	O
depending	O
on	O
the	O
randomization	O
group	O
.	O

Subjects	O
were	O
assessed	O
for	O
the	O
pain	O
relief	O
using	O
Numerical	O
rating	O
scale	O
(	O
NRS	O
)	O
to	O
assess	O
their	O
pain	O
relief	O
.	O

RESULTS	O
Baseline	O
parameters	O
being	O
comparable	O
(	O
P	O
>	O
0.05	O
)	O
,	O
the	O
site	O
of	O
drug	O
injections	O
(	O
single	O
or	O
double	O
needle	O
)	O
had	O
no	O
bearing	O
on	O
the	O
onset	O
of	O
pain	O
relief	O
and	O
patient	O
satisfaction	O
scores	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Pain	O
relief	O
during	O
follow-up	O
visits	O
was	O
comparable	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
discomfort	O
score	O
correlated	O
well	O
with	O
the	O
pain	O
relief	O
scoring	O
without	O
any	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
except	O
in	O
the	O
last	O
visit	O
(	O
at	O
3	O
month	O
)	O
.	O

Incidences	O
of	O
the	O
complications	O
were	O
comparable	O
in	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
Ultrasound-guided	O
celiac	O
plexus	O
neurolysis	O
using	O
unilateral	O
paramedian	O
(	O
single	O
needle	O
)	O
needle-insertion	O
technique	O
is	O
comparable	O
with	O
bilateral	O
paramedian	O
(	O
double	O
needle	O
)	O
needle-insertion	O
technique	O
with	O
regard	O
to	O
pain	O
relief	O
and	O
side	O
effects	O
.	O

Inhibition	O
of	O
spontaneous	O
platelet	O
aggregation	O
and	O
adhesion	O
by	O
indobufen	O
(	O
K	O
3920	O
)	O
.	O

A	O
randomized	O
,	O
double-blind	O
crossover	O
study	O
on	O
platelet	O
,	O
coagulation	O
and	O
fibrinolysis	O
function	O
tests	O
.	O

In	O
a	O
randomized	O
double-blind	O
crossover	O
study	O
in	O
12	SampleSize
patients	O
with	O
atherosclerotic	Condition
disease	Condition
,	O
the	O
effect	O
of	O
2	O
dosages	O
(	O
100	O
and	O
200	O
mg	O
twice	O
daily	O
)	O
of	O
indobufen	O
,	O
a	O
new	O
synthetic	O
inhibition	O
of	O
platelet	O
aggregation	O
,	O
on	O
some	O
platelet	O
functions	O
,	O
coagulation	O
and	O
fibrinolysis	O
tests	O
was	O
investigated	O
.	O

Regardless	O
of	O
the	O
dosage	O
used	O
,	O
indobufen	O
was	O
shown	O
to	O
induce	O
a	O
prompt	O
normalization	O
of	O
the	O
enhanced	O
platelet	O
aggregation	O
of	O
these	O
patients	O
.	O

The	O
effect	O
lasted	O
for	O
the	O
entire	O
period	O
of	O
drug	O
administration	O
and	O
in	O
50	O
%	O
of	O
patients	O
a	O
normal	O
platelet	O
aggregation	O
was	O
maintained	O
until	O
the	O
fourth	O
day	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Indobufen	O
was	O
also	O
able	O
to	O
reduce	O
platelet	O
adhesiveness	O
and	O
to	O
lengthen	O
bleeding	O
time	O
,	O
especially	O
when	O
the	O
higher	O
dosage	O
was	O
used	O
.	O

Topical	O
treatment	O
of	O
alopecia	O
areata	O
.	O

It	O
has	O
been	O
shown	O
previously	O
that	O
alopecia	O
areata	O
can	O
be	O
treated	O
with	O
dinitrochlorobenzene	O
(	O
DNCB	O
)	O
and	O
other	O
contact	O
allergens	O
.	O

Whether	O
these	O
agents	O
work	O
by	O
inducing	O
immunologic	O
stimulation	O
or	O
simply	O
a	O
nonspecific	O
inflammatory	O
reaction	O
has	O
not	O
been	O
definitively	O
demonstrated	O
.	O

To	O
test	O
the	O
relative	O
importance	O
of	O
these	O
two	O
mechanisms	O
,	O
we	O
have	O
randomly	O
studied	O
22	O
patients	O
with	O
alopecia	O
areata	O
to	O
whom	O
either	O
DNCB	O
or	O
croton	O
oil	O
was	O
applied	O
topically	O
.	O

Sixty-three	O
percent	O
of	O
patients	O
without	O
spontaneous	O
regrowth	O
of	O
hair	O
regrew	O
hair	O
after	O
DNCB	O
application	O
.	O

None	O
of	O
those	O
treated	O
with	O
croton	O
oil	O
regrew	O
hair	O
when	O
treated	O
later	O
with	O
DNCB	O
.	O

Therefore	O
,	O
a	O
proved	O
contact	O
allergen	O
was	O
shown	O
to	O
be	O
required	O
for	O
therapeutic	O
success	O
.	O

Patient	O
acceptance	O
of	O
the	O
induced	O
contact	O
dermatitis	O
was	O
excellent	O
.	O

In	O
light	O
of	O
recent	O
data	O
on	O
the	O
mutagenicity	O
of	O
DNCB	O
to	O
bacteria	O
,	O
other	O
contact	O
allergens	O
for	O
topical	O
immunotherapy	O
are	O
being	O
sought	O
.	O

Tegaserod	O
,	O
a	O
5-hydroxytryptamine	O
type	O
4	O
receptor	O
partial	O
agonist	O
,	O
is	O
devoid	O
of	O
electrocardiographic	O
effects	O
.	O

OBJECTIVES	O
Certain	O
GI	O
prokinetic	O
agents	O
have	O
been	O
shown	O
to	O
affect	O
cardiac	O
repolarization	O
,	O
which	O
may	O
be	O
associated	O
with	O
life-threatening	O
arrhythmias	O
.	O

The	O
selective	O
5-hydroxytryptamine	O
type	O
4	O
receptor	O
partial	O
agonist	O
tegaserod	O
is	O
a	O
novel	O
promotile	O
agent	O
developed	O
for	O
the	O
treatment	O
of	O
functional	O
motility	O
disorders	O
such	O
as	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
cardiac	O
safety	O
profile	O
of	O
tegaserod	O
through	O
analysis	O
of	O
electrocardiographic	O
data	O
from	O
clinical	O
studies	O
conducted	O
in	O
patients	O
with	O
IBS	Condition
and	O
a	O
study	O
conducted	O
in	O
healthy	Condition
male	Sex
subjects	O
.	O

METHODS	O
In	O
three	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
clinical	O
studies	O
,	O
2516	SampleSize
IBS	Condition
patients	O
with	O
symptoms	O
of	O
abdominal	Condition
pain	Condition
and	O
constipation	Condition
received	O
tegaserod	O
2	O
or	O
6	O
mg	O
b.i.d	O
.	O

(	O
n	O
=	O
1679	O
)	O
or	O
placebo	O
(	O
n	O
=	O
837	O
)	O
for	O
12	O
wk	O
.	O

In	O
an	O
additional	O
study	O
,	O
36	SampleSize
healthy	Condition
male	Sex
subjects	O
received	O
iv	O
.	O

single	O
doses	O
of	O
tegaserod	O
(	O
0.8	O
mg	O
to	O
20	O
mg	O
)	O
or	O
placebo	O
.	O

Standard	O
12-lead	O
electrocardiograms	O
were	O
recorded	O
at	O
baseline	O
and	O
during	O
treatment	O
.	O

Baseline	O
values	O
were	O
compared	O
with	O
data	O
collected	O
during	O
the	O
treatment	O
period	O
.	O

RESULTS	O
The	O
proportion	O
of	O
patients	O
with	O
prolongation	O
of	O
the	O
QTc	O
interval	O
was	O
the	O
same	O
for	O
placebo	O
and	O
tegaserod	O
,	O
as	O
was	O
the	O
frequency	O
of	O
overall	O
electrocardiographic	O
abnormalities	O
.	O

No	O
ventricular	O
or	O
supraventricular	O
tachycardia	O
was	O
observed	O
.	O

Comparable	O
electrocardiographic	O
results	O
were	O
obtained	O
during	O
placebo	O
and	O
tegaserod	O
treatment	O
.	O

In	O
healthy	Condition
volunteers	O
,	O
tegaserod	O
at	O
i.v	O
.	O

doses	O
resulting	O
in	O
plasma	O
concentrations	O
up	O
to	O
100	O
times	O
those	O
measured	O
after	O
therapeutic	O
doses	O
(	O
6	O
mg	O
b.i.d	O
.	O

)	O
did	O
not	O
influence	O
electrocardiographic	O
parameters	O
.	O

CONCLUSIONS	O
Tegaserod	O
is	O
devoid	O
of	O
electrocardiographic	O
effects	O
and	O
is	O
not	O
expected	O
to	O
adversely	O
influence	O
cardiac	O
function	O
.	O

These	O
data	O
confirm	O
preclinical	O
findings	O
.	O

Oxidative	O
DNA	O
damage	O
measured	O
in	O
human	O
lymphocytes	O
:	O
large	O
differences	O
between	O
sexes	O
and	O
between	O
countries	O
,	O
and	O
correlations	O
with	O
heart	O
disease	O
mortality	O
rates	O
.	O

The	O
'antioxidant	O
hypothesis	O
'	O
proposes	O
that	O
vitamin	O
C	O
,	O
vitamin	O
E	O
,	O
carotenoids	O
,	O
and	O
other	O
antioxidants	O
occurring	O
in	O
fruit	O
and	O
vegetables	O
afford	O
protection	O
against	O
heart	O
disease	O
and	O
cancer	O
by	O
preventing	O
oxidative	O
damage	O
to	O
lipids	O
and	O
to	O
DNA	O
,	O
respectively	O
.	O

To	O
test	O
elements	O
of	O
this	O
hypothesis	O
,	O
we	O
have	O
measured	O
blood	O
levels	O
of	O
dietary	O
antioxidants	O
,	O
and	O
8-oxodeoxyguanosine	O
(	O
8-oxo-dG	O
)	O
concentrations	O
in	O
lymphocyte	O
DNA	O
,	O
in	O
healthy	O
men	Sex
and	O
women	Sex
from	O
five	O
European	O
countries	O
:	O
France	O
,	O
Ireland	O
,	O
The	O
Netherlands	O
,	O
Spain	O
,	O
and	O
the	O
U.K	O
.	O

Volunteers	O
,	O
aged	O
25	Age
45	Age
,	O
all	O
nonsmokers	O
,	O
gave	O
blood	O
samples	O
before	O
and	O
after	O
a	O
12-wk	O
carotenoid	O
supplementation	O
regime	O
.	O

Vitamin	O
C	O
was	O
measured	O
in	O
plasma	O
and	O
vitamin	O
E	O
and	O
carotenoids	O
were	O
measured	O
in	O
serum	O
by	O
high-performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
.	O

8-oxo-dG	O
was	O
assayed	O
by	O
HPLC	O
(	O
with	O
coulometric	O
detection	O
)	O
in	O
DNA	O
isolated	O
from	O
lymphocytes	O
from	O
the	O
same	O
blood	O
samples	O
.	O

Mean	O
values	O
were	O
calculated	O
for	O
groups	O
of	O
volunteers	O
at	O
each	O
sampling	O
time	O
according	O
to	O
country	O
,	O
sex	O
,	O
and	O
supplementation	O
(	O
between	O
9	O
and	O
24	O
individual	O
samples	O
contributing	O
to	O
each	O
mean	O
)	O
.	O

We	O
found	O
that	O
8-oxo-dG	O
levels	O
in	O
lymphocyte	O
DNA	O
vary	O
significantly	O
according	O
to	O
sex	O
and	O
country	O
.	O

A	O
low	O
mean	O
8-oxo-dG	O
concentration	O
is	O
seen	O
in	O
DNA	O
of	O
women	O
from	O
all	O
five	O
countries	O
,	O
and	O
of	O
men	O
from	O
France	O
and	O
Spain	O
.	O

8-oxo-dG	O
is	O
significantly	O
higher	O
(	O
up	O
to	O
about	O
threefold	O
)	O
in	O
lymphocyte	O
DNA	O
from	O
men	O
in	O
Ireland	O
and	O
the	O
U.K.	O
Oxidative	O
DNA	O
damage	O
is	O
not	O
significantly	O
affected	O
by	O
carotenoid	O
supplementation	O
;	O
nor	O
is	O
there	O
any	O
association	O
with	O
mean	O
baseline	O
levels	O
of	O
antioxidants	O
,	O
which	O
are	O
generally	O
similar	O
in	O
the	O
five	O
countries	O
.	O

The	O
five	O
countries	O
sampled	O
lie	O
on	O
an	O
axis	O
from	O
northern	O
to	O
southern	O
Europe	O
with	O
a	O
steep	O
gradient	O
in	O
terms	O
of	O
premature	O
heart	O
disease	O
.	O

There	O
is	O
a	O
strong	O
association	O
between	O
premature	O
coronary	O
heart	O
disease	O
mortality	O
in	O
men	O
and	O
the	O
mean	O
levels	O
of	O
8-oxo-dG	O
for	O
the	O
five	O
countries	O
(	O
r	O
=	O
0.95	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Women	O
have	O
low	O
coronary	O
heart	O
disease	O
mortality	O
rates	O
,	O
which	O
do	O
not	O
correlate	O
with	O
8-oxo-dG	O
.	O

In	O
terms	O
of	O
cancer	O
deaths	O
,	O
only	O
colorectal	O
cancer	O
in	O
men	O
shows	O
a	O
significant	O
positive	O
correlation	O
(	O
r	O
=	O
0.91	O
,	O
P	O
<	O
0.05	O
)	O
,	O
and	O
stomach	O
cancer	O
in	O
women	O
is	O
negatively	O
correlated	O
with	O
DNA	O
oxidation	O
(	O
r	O
=	O
-0.92	O
,	O
P	O
=	O
0.01	O
)	O
.	O

Injection	O
pain	O
with	O
propofol	O
.	O

Reduction	O
with	O
aspiration	O
of	O
blood	O
.	O

A	O
randomised	O
,	O
controlled	O
,	O
single-blind	O
study	O
was	O
performed	O
on	O
100	SampleSize
patients	O
to	O
investigate	O
a	O
new	O
method	O
of	O
reducing	O
pain	O
on	O
propofol	O
injection	O
.	O

Aspiration	O
of	O
2	O
ml	O
of	O
the	O
patient	O
's	O
blood	O
into	O
a	O
syringe	O
of	O
propofol	O
immediately	O
before	O
injection	O
was	O
compared	O
with	O
the	O
addition	O
of	O
lignocaine	O
20	O
mg	O
or	O
normal	O
saline	O
2	O
ml	O
to	O
the	O
propofol	O
before	O
injection	O
.	O

The	O
addition	O
of	O
blood	O
was	O
significantly	O
more	O
effective	O
in	O
reducing	O
pain	O
on	O
injection	O
than	O
the	O
addition	O
of	O
saline	O
(	O
p	O
<	O
0.001	O
)	O
,	O
but	O
was	O
not	O
significantly	O
more	O
effective	O
than	O
the	O
addition	O
of	O
lignocaine	O
.	O

Competitive	O
memory	O
training	O
(	O
COMET	O
)	O
for	O
treating	O
low	Condition
self-esteem	Condition
in	O
patients	O
with	O
depressive	Condition
disorders	Condition
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

BACKGROUND	O
Self-esteem	O
is	O
a	O
major	O
concern	O
in	O
mood	O
disorders	O
.	O

Low	O
self-esteem	O
is	O
a	O
symptom	O
of	O
depressive	O
disorders	O
and	O
is	O
considered	O
by	O
some	O
to	O
be	O
a	O
predictor	O
for	O
relapse	O
,	O
whereas	O
high	O
self-esteem	O
seems	O
to	O
buffer	O
against	O
depression	O
.	O

Recently	O
,	O
Competitive	O
Memory	O
Training	O
(	O
COMET	O
)	O
has	O
shown	O
to	O
be	O
effective	O
for	O
the	O
enhancement	O
of	O
self-esteem	O
in	O
several	O
psychopathological	O
conditions	O
.	O

The	O
current	O
study	O
assesses	O
whether	O
COMET	O
is	O
also	O
an	O
effective	O
intervention	O
for	O
patients	O
with	O
depressive	O
disorders	O
.	O

METHODS	O
Sixty-one	SampleSize
patients	O
with	O
depressive	O
disorders	O
who	O
were	O
already	O
in	O
therapy	O
in	O
an	O
outpatient	O
mental	O
health	O
institution	O
were	O
randomly	O
assigned	O
to	O
either	O
eight	O
group	O
sessions	O
of	O
COMET	O
in	O
addition	O
to	O
their	O
regular	O
therapy	O
(	O
COMET	O
+	O
therapy	O
as	O
usual	O
[	O
TAU	O
]	O
:	O
the	O
experimental	O
group	O
)	O
or	O
to	O
8	O
weeks	O
of	O
ongoing	O
regular	O
therapy	O
(	O
TAU	O
only	O
:	O
the	O
control	O
group	O
)	O
.	O

These	O
latter	O
(	O
control	O
)	O
patients	O
received	O
COMET	O
after	O
their	O
TAU	O
only	O
period	O
.	O

All	O
patients	O
in	O
both	O
groups	O
that	O
completed	O
COMET	O
were	O
contacted	O
3	O
and	O
6	O
months	O
later	O
to	O
assess	O
whether	O
the	O
effects	O
of	O
COMET	O
had	O
remained	O
stable	O
.	O

RESULTS	O
Compared	O
to	O
the	O
patients	O
who	O
received	O
TAU	O
only	O
,	O
patients	O
in	O
the	O
COMET	O
+	O
TAU	O
condition	O
showed	O
significant	O
improvement	O
with	O
large	O
effect	O
sizes	O
on	O
indices	O
of	O
self-esteem	O
,	O
depression	O
,	O
and	O
depressive	O
rumination	O
.	O

The	O
therapeutic	O
effects	O
of	O
COMET	O
+	O
TAU	O
remained	O
stable	O
after	O
3	O
and	O
6	O
months	O
on	O
all	O
outcome	O
measures	O
or	O
improved	O
even	O
further	O
.	O

CONCLUSION	O
COMET	O
for	O
low	O
self-esteem	O
seems	O
to	O
be	O
an	O
efficacious	O
trans-diagnostic	O
intervention	O
that	O
can	O
relatively	O
easily	O
be	O
added	O
to	O
the	O
regular	O
treatment	O
of	O
patients	O
with	O
depressive	O
disorders	O
.	O

Hodgkin	Condition
's	Condition
disease	Condition
in	O
childhood	Age
and	O
adolescence	Age
:	O
results	O
of	O
chemotherapy-radiotherapy	O
in	O
clinical	O
stages	O
IA-IIB	O
.	O

From	O
April	O
1972	O
to	O
May	O
1980	O
,	O
72	SampleSize
children	Age
and	O
adolescents	Age
(	O
aged	O
5	O
to	O
19	O
years	O
old	O
,	O
median	O
16	O
)	O
with	O
Hodgkin	Condition
's	Condition
disease	Condition
,	O
clinical	O
stages	O
IA-IIB	O
(	O
IA	O
,	O
18	O
;	O
II2A	O
,	O
two	O
areas	O
involved	O
on	O
the	O
same	O
side	O
of	O
the	O
diaphragm	O
,	O
23	O
;	O
II3+A	O
,	O
three	O
areas	O
or	O
more	O
,	O
16	O
;	O
IIB	O
,	O
15	O
)	O
were	O
prospectively	O
treated	O
in	O
two	O
successive	O
clinical	O
trials	O
(	O
H	O
72	O
and	O
H	O
77	O
)	O
.	O

Clinical	O
stages	O
IA	O
and	O
II2A	O
received	O
three	O
courses	O
of	O
mechlorethamine	O
,	O
Oncovin	O
,	O
procarbazine	O
,	O
and	O
prednisone	O
(	O
MOPP	O
)	O
and	O
supradiaphragmatic	O
radiotherapy	O
(	O
40	O
Gy	O
)	O
,	O
and	O
no	O
laparotomy	O
was	O
performed	O
.	O

Clinical	O
stages	O
II3+A	O
and	O
IIB	O
received	O
either	O
six	O
cycles	O
of	O
MOPP	O
(	O
H	O
72	O
)	O
,	O
three	O
cycles	O
of	O
MOPP	O
,	O
or	O
three	O
cycles	O
of	O
CCNU	O
,	O
vinblastine	O
,	O
procarbazine	O
,	O
and	O
prednisone	O
(	O
CVPP	O
)	O
(	O
H	O
77	O
)	O
and	O
subsequently	O
had	O
a	O
laparotomy	O
followed	O
by	O
supradiaphragmatic	O
radiotherapy	O
and	O
a	O
lumboaortic	O
field	O
if	O
results	O
of	O
laparotomy	O
were	O
positive	O
.	O

Patients	O
without	O
evidence	O
of	O
mediastinal	Condition
involvement	Condition
did	O
not	O
have	O
mediastinal	O
radiotherapy	O
.	O

At	O
the	O
completion	O
of	O
therapy	O
,	O
the	O
disease	O
in	O
70	O
of	O
72	O
patients	O
was	O
in	O
complete	O
remission	O
(	O
one	O
failure	O
,	O
one	O
death	O
during	O
treatment	O
)	O
.	O

Eight	O
patients	O
relapsed	O
(	O
in	O
situ	O
,	O
1	O
;	O
marginal	O
,	O
1	O
;	O
nonirradiated	O
subdiaphragmatic	O
area	O
,	O
6	O
)	O
after	O
three	O
to	O
57	O
months	O
of	O
complete	O
remission	O
(	O
median	O
20	O
months	O
)	O
;	O
one	O
patient	O
died	O
after	O
relapse	O
.	O

There	O
were	O
three	O
deaths	O
after	O
complete	O
remission	O
of	O
the	O
disease	O
(	O
infection	O
,	O
two	O
;	O
acute	O
nonlymphocytic	O
leukemia	O
[	O
ANLL	O
]	O
,	O
one	O
)	O
.	O

As	O
of	O
June	O
1984	O
the	O
median	O
follow-up	O
was	O
82	O
months	O
(	O
range	O
,	O
49	O
to	O
145	O
months	O
)	O
,	O
the	O
actuarial	O
probabilities	O
for	O
survival	O
and	O
freedom	O
from	O
relapse	O
for	O
all	O
patients	O
being	O
91.6	O
%	O
and	O
87.6	O
%	O
,	O
respectively	O
.	O

There	O
was	O
no	O
statistical	O
difference	O
according	O
to	O
clinical	O
stage	O
,	O
age	O
(	O
greater	O
than	O
15	O
or	O
less	O
than	O
15	O
years	O
)	O
,	O
sex	O
,	O
or	O
number	O
of	O
cycles	O
of	O
chemotherapy	O
(	O
six	O
or	O
three	O
)	O
.	O

Bone	O
growth	O
defects	O
related	O
to	O
radiotherapy	O
were	O
reduced	O
particularly	O
in	O
the	O
29	O
patients	O
who	O
did	O
not	O
receive	O
mediastinal	O
radiotherapy	O
.	O

None	O
of	O
these	O
patients	O
had	O
a	O
mediastinal	O
relapse	O
.	O

Azoospermia	O
was	O
the	O
rule	O
for	O
the	O
male	O
patients	O
studied	O
,	O
but	O
young	O
girls	O
and	O
young	O
women	O
retained	O
reproductive	O
integrity	O
.	O

[	O
Therapeutic	O
value	O
of	O
a	O
combination	O
of	O
trimetazidine	O
with	O
a	O
calcium	O
inhibitor	O
in	O
the	O
treatment	O
of	O
chronic	Condition
coronary	Condition
insufficiency	Condition
]	Condition
.	O

This	O
double-blind	O
,	O
placebo-controlled	O
study	O
sought	O
to	O
examine	O
the	O
short-term	O
benefit	O
of	O
adding	O
60	O
mg	O
of	O
trimetazidine	O
to	O
the	O
daily	O
therapeutic	O
regimen	O
of	O
29	SampleSize
male	Sex
patients	O
with	O
coronary	Condition
insufficiency	Condition
who	O
had	O
persistent	Condition
ST	Condition
depression	Condition
on	O
exercise	O
tolerance	O
test	O
(	O
greater	O
than	O
or	O
equal	O
to	O
1	O
mm	O
)	O
,	O
despite	O
treatment	O
with	O
nifedipine	O
40	O
mg	O
per	O
day	O
.	O

As	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
after	O
only	O
14	O
days	O
,	O
the	O
patients	O
treated	O
with	O
trimetazidine	O
showed	O
statistically	O
significant	O
increases	O
in	O
the	O
maximum	O
workload	O
level	O
attained	O
before	O
ST	O
depression	O
occurred	O
(	O
31	O
%	O
versus	O
-	O
6	O
%	O
;	O
P	O
=	O
0.009	O
)	O
,	O
the	O
total	O
work	O
performed	O
(	O
31	O
%	O
versus	O
2	O
%	O
;	O
P	O
=	O
0.024	O
)	O
and	O
a	O
significant	O
decrease	O
in	O
the	O
systolic	O
tension	O
time	O
(	O
double	O
product	O
)	O
/workload	O
ratio	O
(	O
-5	O
%	O
versus	O
+11	O
%	O
;	O
P	O
=	O
0.005	O
)	O
.	O

Throughout	O
the	O
study	O
the	O
clinical	O
acceptability	O
was	O
excellent	O
,	O
with	O
no	O
side	O
effects	O
attributable	O
to	O
trimetazidine	O
being	O
recorded	O
.	O

This	O
study	O
shows	O
that	O
the	O
addition	O
of	O
trimetazidine	O
to	O
a	O
calcium	O
antagonist	O
brings	O
a	O
valuable	O
improvement	O
in	O
therapeutic	O
results	O
.	O

Abdominoperineal	O
resection	O
and	O
anterior	O
resection	O
in	O
the	O
treatment	O
of	O
rectal	Condition
cancer	Condition
:	O
results	O
in	O
relation	O
to	O
adjuvant	O
preoperative	O
radiotherapy	O
.	O

The	O
outcome	O
of	O
patients	O
with	O
rectal	O
cancer	O
treated	O
by	O
abdominoperineal	O
or	O
anterior	O
resection	O
,	O
with	O
or	O
without	O
preoperative	O
radiotherapy	O
,	O
was	O
assessed	O
to	O
detect	O
any	O
differences	O
attributable	O
to	O
the	O
operative	O
method	O
and	O
interactions	O
between	O
radiotherapy	O
and	O
type	O
of	O
surgery	O
.	O

The	O
study	O
was	O
based	O
on	O
1292	SampleSize
patients	O
included	O
in	O
two	O
consecutive	O
controlled	O
randomized	O
trials	O
of	O
preoperative	O
radiotherapy	O
in	O
operable	O
rectal	O
carcinoma	O
.	O

The	O
outcome	O
was	O
not	O
related	O
to	O
surgical	O
method	O
.	O

Radiotherapy	O
increased	O
postoperative	O
mortality	O
and	O
complications	O
and	O
reduced	O
local	O
and	O
distant	O
recurrence	O
,	O
but	O
had	O
no	O
effect	O
on	O
overall	O
survival	O
.	O

Effects	O
of	O
radiotherapy	O
were	O
similar	O
irrespective	O
of	O
the	O
type	O
of	O
surgery	O
,	O
except	O
that	O
the	O
increase	O
in	O
postoperative	O
mortality	O
in	O
irradiated	O
patients	O
was	O
greater	O
in	O
those	O
treated	O
with	O
abdominoperineal	O
resection	O
.	O

Sphincter-saving	O
procedures	O
appear	O
to	O
have	O
no	O
adverse	O
effects	O
on	O
outcome	O
of	O
rectal	O
cancer	O
,	O
but	O
the	O
optimum	O
use	O
of	O
radiotherapy	O
is	O
still	O
to	O
be	O
defined	O
.	O

The	O
effect	O
of	O
oral	O
steroids	O
with	O
and	O
without	O
vitamin	O
D3	O
on	O
early	O
efficacy	O
of	O
immunotherapy	O
in	O
asthmatic	Condition
children	O
.	O

BACKGROUND	O
The	O
possibility	O
of	O
additional	O
strategies	O
to	O
enhance	O
the	O
effectiveness	O
of	O
specific	O
immunotherapy	O
(	O
SIT	O
)	O
is	O
highly	O
attractive	O
.	O

AIM	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
influence	O
of	O
oral	O
corticosteroids	O
and	O
oral	O
corticosteroids	O
combined	O
with	O
vitamin	O
D	O
(	O
3	O
)	O
on	O
the	O
early	O
clinical	O
and	O
immunological	O
effects	O
of	O
SIT	O
.	O

METHODS	O
It	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
conducted	O
in	O
54	SampleSize
asthmatic	Condition
children	O
allergic	Condition
to	Condition
house	Condition
dust	Condition
mites	Condition
.	O

Intervention	O
was	O
based	O
on	O
receiving	O
a	O
single	O
dose	O
of	O
oral	O
steroid	O
,	O
with	O
or	O
without	O
vitamin	O
D	O
(	O
3	O
)	O
,	O
or	O
placebo	O
only	O
on	O
the	O
day	O
of	O
the	O
build-up	O
phase	O
of	O
SIT	O
.	O

RESULTS	O
After	O
12	O
months	O
of	O
SIT	O
,	O
the	O
median	O
daily	O
inhaled	O
corticosteroid	O
(	O
ICS	O
)	O
dose	O
,	O
which	O
controls	O
the	O
symptoms	O
of	O
asthma	O
,	O
was	O
reduced	O
by	O
25	O
%	O
in	O
the	O
steroid	O
group	O
.	O

However	O
,	O
a	O
50	O
%	O
reduction	O
of	O
the	O
median	O
daily	O
ICS	O
dose	O
was	O
observed	O
in	O
the	O
control	O
group	O
.	O

The	O
clinical	O
effects	O
of	O
SIT	O
were	O
not	O
affected	O
in	O
the	O
steroid+D	O
(	O
3	O
)	O
group	O
.	O

Concomitantly	O
,	O
we	O
found	O
that	O
intervention	O
with	O
prednisone	O
significantly	O
impaired	O
the	O
induction	O
of	O
T	O
regulatory	O
lymphocytes	O
.	O

Importantly	O
,	O
the	O
clinical	O
and	O
immunological	O
effects	O
of	O
SIT	O
were	O
not	O
affected	O
by	O
intervention	O
with	O
steroids	O
administered	O
with	O
vitamin	O
D	O
(	O
3	O
)	O
.	O

CONCLUSIONS	O
Our	O
study	O
failed	O
to	O
show	O
a	O
beneficial	O
effect	O
of	O
oral	O
corticosteroids	O
on	O
allergen-specific	O
immunotherapy	O
.	O

We	O
observed	O
that	O
the	O
combined	O
administration	O
of	O
a	O
corticosteroid	O
drug	O
and	O
allergen	O
extract	O
suppressed	O
the	O
early	O
clinical	O
and	O
immunological	O
effects	O
of	O
SIT	O
and	O
that	O
vitamin	O
D	O
(	O
3	O
)	O
prevented	O
this	O
'adverse	O
'	O
influence	O
of	O
steroids	O
.	O

A	O
randomized	O
,	O
dose-escalation	O
study	O
of	O
subconjunctival	O
and	O
intravitreal	O
injections	O
of	O
sirolimus	O
in	O
patients	O
with	O
diabetic	Condition
macular	Condition
edema	Condition
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
a	O
single	O
subconjunctival	O
(	O
SCJ	O
)	O
or	O
intravitreal	O
(	O
IVT	O
)	O
injection	O
of	O
an	O
ophthalmic	O
sirolimus	O
formulation	O
in	O
eyes	O
with	O
diabetic	O
macular	O
edema	O
(	O
DME	O
)	O
.	O

DESIGN	O
Randomized	O
,	O
open-label	O
,	O
dose-escalating	O
phase	O
I	O
study	O
.	O

PARTICIPANTS	O
Fifty	O
eyes	O
among	O
50	O
patients	O
with	O
DME	O
,	O
retinal	O
thickness	O
?	O
300	O
microns	O
and	O
best-corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
20/40	O
to	O
20/200	O
.	O

METHODS	O
A	O
single	O
dose	O
of	O
sirolimus	O
administered	O
SCJ	O
(	O
220	O
,	O
440	O
,	O
880	O
,	O
1320	O
,	O
or	O
1760	O
?g	O
)	O
or	O
IVT	O
(	O
44	O
,	O
110	O
,	O
176	O
,	O
264	O
,	O
or	O
352	O
?g	O
)	O
on	O
day	O
0	O
;	O
observation	O
through	O
day	O
90	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
end	O
points	O
were	O
the	O
frequency	O
and	O
severity	O
of	O
ocular	O
and	O
systemic	O
adverse	O
events	O
.	O

Secondary	O
end	O
points	O
were	O
changes	O
in	O
BCVA	O
and	O
retinal	O
thickness	O
.	O

RESULTS	O
No	O
dose-limiting	O
toxicities	O
were	O
observed	O
and	O
ocular	O
adverse	O
events	O
were	O
mostly	O
mild	O
and	O
transient	O
.	O

Conjunctival	O
hyperemia	O
,	O
hemorrhage	O
,	O
and	O
edema	O
were	O
common	O
after	O
the	O
SCJ	O
injection	O
procedure	O
and	O
conjunctival	O
hemorrhage	O
was	O
common	O
after	O
the	O
IVT	O
injection	O
procedure	O
.	O

Three	O
patients	O
experienced	O
ocular	O
adverse	O
events	O
considered	O
possibly	O
related	O
to	O
study	O
drug	O
:	O
Conjunctival	O
edema	O
and	O
reduced	O
visual	O
acuity	O
were	O
reported	O
in	O
1	O
SCJ	O
patient	O
each	O
and	O
iritis	O
was	O
reported	O
in	O
1	O
IVT	O
patient	O
.	O

No	O
serious	O
ocular	O
adverse	O
events	O
were	O
reported	O
.	O

No	O
nonocular	O
adverse	O
events	O
were	O
considered	O
related	O
to	O
study	O
drug	O
.	O

Systemic	O
exposure	O
to	O
sirolimus	O
was	O
low	O
,	O
with	O
blood	O
concentrations	O
below	O
levels	O
necessary	O
for	O
systemic	O
immunosuppression	O
.	O

For	O
the	O
SCJ	O
group	O
(	O
n	O
=	O
25	O
)	O
,	O
a	O
median	O
increase	O
in	O
BCVA	O
started	O
at	O
day	O
7	O
(	O
5.0	O
letters	O
)	O
and	O
was	O
3.0	O
,	O
4.0	O
,	O
and	O
4.0	O
letters	O
at	O
days	O
14	O
,	O
45	O
and	O
90	O
,	O
respectively	O
.	O

At	O
day	O
45	O
,	O
median	O
decrease	O
in	O
retinal	O
thickness	O
was	O
-23.7	O
?m	O
.	O

For	O
the	O
IVT	O
group	O
(	O
n	O
=	O
25	O
)	O
,	O
the	O
median	O
increase	O
in	O
BCVA	O
was	O
2.0	O
letters	O
at	O
day	O
7	O
;	O
at	O
days	O
14	O
,	O
45	O
,	O
and	O
90	O
,	O
the	O
median	O
increase	O
was	O
maintained	O
(	O
4.0	O
letters	O
)	O
;	O
the	O
median	O
decrease	O
in	O
retinal	O
thickness	O
was	O
-52.0	O
?m	O
at	O
day	O
45	O
.	O

CONCLUSIONS	O
Locally	O
administered	O
sirolimus	O
was	O
well-tolerated	O
with	O
minimal	O
systemic	O
exposure	O
at	O
all	O
doses	O
tested	O
in	O
this	O
small	O
phase	O
I	O
population	O
.	O

These	O
findings	O
support	O
advancing	O
the	O
present	O
sirolimus	O
formulation	O
into	O
phase	O
II	O
studies	O
.	O

FINANCIAL	O
DISCLOSURE	O
(	O
S	O
)	O
Proprietary	O
or	O
commercial	O
disclosure	O
may	O
be	O
found	O
after	O
the	O
references	O
.	O

The	O
immediate	O
efficacy	O
of	O
adjunctive	O
doxycycline	O
in	O
treatment	O
of	O
localized	Condition
juvenile	Condition
periodontitis	Condition
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
on	O
the	O
immediate	O
clinical	O
and	O
microbiological	O
efficacy	O
of	O
doxycycline	O
(	O
100	O
mg	O
for	O
14	O
days	O
)	O
was	O
carried	O
out	O
to	O
determine	O
the	O
benefit	O
of	O
adjunctive	O
medication	O
in	O
16	SampleSize
patients	SampleSize
with	O
localized	Condition
juvenile	Condition
periodontitis	Condition
.	O

Measurements	O
of	O
gingival	O
fluid	O
flow	O
,	O
probing	O
depths	O
,	O
bleeding	O
on	O
probing	O
and	O
suppuration	O
were	O
determined	O
at	O
2	O
periodontal	O
sites	O
with	O
and	O
2	O
without	O
radiographic	O
attachment	O
loss	O
,	O
at	O
weeks	O
0	O
,	O
1	O
,	O
3	O
and	O
8	O
.	O

Subgingival	O
bacterial	O
samples	O
were	O
taken	O
with	O
curettes	O
from	O
the	O
same	O
sites	O
.	O

Spirochaetes	O
were	O
searched	O
for	O
by	O
dark-field	O
microscopy	O
.	O

Actinobacillus	O
actinomycetemcomitans	O
,	O
pigmented	O
and	O
non-pigmented	O
Bacteroides	O
spp.	O
,	O
Capnocytophaga	O
,	O
Fusobacterium	O
and	O
Actinomyces	O
spp	O
.	O

were	O
cultured	O
on	O
various	O
selective	O
and	O
non-selective	O
media	O
.	O

Bacterial	O
species	O
found	O
at	O
least	O
in	O
50	O
%	O
of	O
the	O
patients	O
and	O
comprising	O
on	O
average	O
5	O
%	O
or	O
more	O
of	O
the	O
cultivable	O
flora	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Neither	O
short-term	O
clinical	O
nor	O
microbiological	O
efficacy	O
beyond	O
that	O
of	O
a	O
course	O
of	O
mechanical	O
debridement	O
alone	O
was	O
found	O
by	O
using	O
systemic	O
medication	O
with	O
doxycycline	O
in	O
patients	O
with	O
localized	Condition
juvenile	Condition
periodontitis	Condition
.	O

Allopurinol	O
use	O
yields	O
potentially	O
beneficial	O
effects	O
on	O
inflammatory	O
indices	O
in	O
those	O
with	O
recent	O
ischemic	O
stroke	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Elevated	O
serum	O
uric	O
acid	O
level	O
is	O
associated	O
with	O
poor	O
outcome	O
and	O
increased	O
risk	O
of	O
recurrent	O
events	O
after	O
stroke	O
.	O

The	O
xanthine	O
oxidase	O
inhibitor	O
allopurinol	O
lowers	O
uric	O
acid	O
but	O
also	O
attenuates	O
expression	O
of	O
inflammatory	O
adhesion	O
molecules	O
in	O
murine	O
models	O
,	O
reduces	O
oxidative	O
stress	O
in	O
the	O
vasculature	O
,	O
and	O
improves	O
endothelial	O
function	O
.	O

We	O
sought	O
to	O
investigate	O
whether	O
allopurinol	O
alters	O
expression	O
of	O
inflammatory	O
markers	O
after	O
acute	O
ischemic	O
stroke	O
.	O

METHODS	O
We	O
performed	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
to	O
investigate	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
effect	O
of	O
6	O
weeks	O
'	O
treatment	O
with	O
high-	O
(	O
300	O
mg	O
once	O
a	O
day	O
)	O
or	O
low-	O
(	O
100	O
mg	O
once	O
a	O
day	O
)	O
dose	O
allopurinol	O
on	O
levels	O
of	O
uric	O
acid	O
and	O
circulating	O
inflammatory	O
markers	O
after	O
ischemic	O
stroke	O
.	O

RESULTS	O
We	O
enrolled	O
50	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
(	O
17	O
,	O
17	O
,	O
and	O
16	O
in	O
the	O
high	O
,	O
low	O
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
)	O
.	O

Mean	O
(	O
+/-SD	O
)	O
age	O
was	O
70	O
(	O
+/-13	O
)	O
years	O
.	O

Groups	O
had	O
similar	O
characteristics	O
at	O
baseline	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
events	O
.	O

Uric	O
acid	O
levels	O
were	O
significantly	O
reduced	O
at	O
both	O
7	O
days	O
and	O
6	O
weeks	O
in	O
the	O
high-dose	O
group	O
(	O
by	O
0.14	O
mmol/L	O
at	O
6	O
weeks	O
,	O
P=0.002	O
)	O
.	O

Intercellular	O
adhesion	O
molecule-1	O
concentration	O
(	O
ng/mL	O
)	O
rose	O
by	O
51.2	O
in	O
the	O
placebo	O
group	O
,	O
rose	O
slightly	O
(	O
by	O
10.6	O
)	O
in	O
the	O
low-dose	O
allopurinol	O
group	O
,	O
but	O
fell	O
in	O
the	O
high-dose	O
group	O
(	O
by	O
2.6	O
;	O
difference	O
between	O
groups	O
P=0.012	O
,	O
Kruskal-Wallis	O
test	O
)	O
.	O

CONCLUSIONS	O
Allopurinol	O
treatment	O
is	O
well	O
tolerated	O
and	O
attenuates	O
the	O
rise	O
in	O
intercellular	O
adhesion	O
molecule-1	O
levels	O
seen	O
after	O
stroke	O
.	O

Uric	O
acid	O
levels	O
were	O
lowered	O
with	O
high	O
doses	O
.	O

These	O
findings	O
support	O
further	O
evaluation	O
of	O
allopurinol	O
as	O
a	O
preventive	O
measure	O
after	O
stroke	O
.	O

The	O
effects	O
of	O
prophylactic	O
management	O
and	O
therapeutics	O
on	O
hypertensive	Condition
disease	Condition
in	O
pregnancy	O
:	O
preliminary	O
studies	O
.	O

A	O
controlled	O
prospective	O
evaluation	O
of	O
pregnancy	O
complicated	O
by	O
chronic	O
hypertension	O
is	O
proposed	O
and	O
preliminary	O
data	O
on	O
population	O
selection	O
and	O
pregnancy	O
outcome	O
are	O
presented	O
.	O

Sixty-three	SampleSize
women	Sex
with	O
evidence	O
of	O
underlying	O
hypertensive	Condition
disease	Condition
were	O
followed	O
prospectively	O
throughout	O
pregnancy	O
.	O

Twenty-three	O
patients	O
were	O
followed	O
in	O
a	O
protocol	O
of	O
intensified	O
prenatal	O
care	O
and	O
randomized	O
assignment	O
of	O
antihypertensive	O
agents	O
:	O
placebo	O
,	O
hydralazine	O
,	O
or	O
methyldopa	O
.	O

Forty	SampleSize
patients	O
were	O
followed	O
in	O
the	O
high-risk	O
pregnancy	O
clinics	O
at	O
Duke	O
University	O
.	O

The	O
incidence	O
of	O
preeclampsia	O
in	O
the	O
randomized	O
prophylactic	O
antihypertensive	O
group	O
was	O
statistically	O
lower	O
than	O
that	O
in	O
the	O
nonrandomized	O
group	O
(	O
8.7	O
versus	O
32.5	O
%	O
;	O
P	O
less	O
than	O
.01	O
)	O
.	O

There	O
were	O
no	O
other	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

The	O
63	SampleSize
hypertensive	Condition
women	O
had	O
a	O
high	O
incidence	O
of	O
diabetes	O
mellitus	O
diagnosed	O
during	O
pregnancy	O
(	O
49.2	O
%	O
)	O
as	O
compared	O
to	O
the	O
authors	O
'	O
general	O
obstetric	O
population	O
(	O
8.1	O
%	O
)	O
.	O

Beneficial	O
effects	O
of	O
a	O
diabetes	O
specific	O
formula	O
on	O
insulin	O
sensitivity	O
and	O
free	O
fatty	O
acid	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

BACKGROUND	O
This	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
diabetes	O
specific	O
formula	O
(	O
Diason	O
low	O
energy	O
:	O
313.8	O
kJ/100	O
ml	O
)	O
,	O
compared	O
with	O
a	O
standard	O
formula	O
,	O
on	O
insulin	O
sensitivity	O
,	O
serum	O
C	O
peptide	O
,	O
serum	O
lipids	O
and	O
free	O
fatty	O
acid	O
(	O
FFA	O
)	O
in	O
type	O
2	O
diabetics	O
.	O

METHODS	O
In	O
total	O
of	O
71	O
type	O
2	O
diabetics	O
completed	O
the	O
study	O
.	O

Enteral	O
formulas	O
were	O
given	O
orally	O
as	O
the	O
sole	O
source	O
of	O
nutrition	O
to	O
the	O
subjects	O
for	O
6	O
days	O
.	O

Venous	O
blood	O
samples	O
(	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
hours	O
)	O
were	O
collected	O
at	O
day-7	O
after	O
a	O
75	O
g	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
,	O
day	O
1	O
after	O
a	O
standard	O
test	O
meal	O
(	O
1673.6	O
kJ	O
)	O
and	O
after	O
6	O
days	O
of	O
either	O
the	O
test	O
diabetes	O
specific	O
formula	O
or	O
a	O
standard	O
formula	O
.	O

Plasma	O
glucose	O
,	O
serum	O
insulin	O
,	O
C	O
peptide	O
and	O
lipids	O
were	O
measured	O
.	O

RESULTS	O
After	O
the	O
intervention	O
period	O
,	O
the	O
diabetes	O
specific	O
formula	O
resulted	O
in	O
a	O
significantly	O
lower	O
postprandial	O
rise	O
in	O
blood	O
glucose	O
concentrations	O
at	O
0.5	O
hour	O
(	O
P	O
<	O
0.05	O
)	O
and	O
1	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
;	O
significantly	O
lower	O
peak	O
height	O
of	O
plasma	O
glucose	O
(	O
P	O
=	O
0.05	O
)	O
;	O
significantly	O
lower	O
plasma	O
insulin	O
concentrations	O
at	O
0.5	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
,	O
1	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
and	O
2	O
hours	O
(	O
P	O
<	O
0.01	O
)	O
;	O
and	O
a	O
significantly	O
lower	O
plasma	O
insulin	O
peak	O
compared	O
to	O
controls	O
;	O
both	O
OGTT	O
and	O
a	O
standard	O
test	O
meal	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
glucose	O
and	O
insulin	O
area	O
under	O
the	O
curve	O
after	O
the	O
diabetes	O
specific	O
formula	O
compared	O
to	O
the	O
standard	O
formula	O
were	O
significantly	O
lower	O
.	O

The	O
C	O
peptide	O
level	O
was	O
lower	O
after	O
6	O
days	O
of	O
both	O
nutrition	O
formulas	O
compare	O
to	O
75	O
g	O
OGTT	O
,	O
but	O
not	O
different	O
from	O
the	O
standard	O
mixed	O
meal	O
.	O

Both	O
formulas	O
were	O
well	O
tolerated	O
.	O

CONCLUSIONS	O
In	O
summary	O
the	O
diabetes	O
specific	O
formula	O
with	O
a	O
relatively	O
high	O
monounsaturated	O
fatty	O
acid	O
and	O
high	O
multi	O
fiber	O
proportion	O
significantly	O
improved	O
glycemic	O
control	O
.	O

On	O
top	O
of	O
this	O
,	O
the	O
insulin	O
sensitivity	O
(	O
HOMA-IS	O
)	O
was	O
significantly	O
improved	O
and	O
may	O
therefore	O
directly	O
improve	O
the	O
impact	O
on	O
long	O
term	O
complications	O
.	O

The	O
disease	O
specific	O
formula	O
should	O
therefore	O
be	O
the	O
preferred	O
option	O
to	O
be	O
used	O
by	O
diabetic	O
and	O
hyperglycemic	O
patients	O
in	O
need	O
of	O
nutritional	O
support	O
.	O

Pharmacokinetic	O
study	O
of	O
RU	O
486	O
and	O
its	O
metabolites	O
after	O
oral	O
administration	O
of	O
single	O
doses	O
to	O
pregnant	Condition
and	O
non-pregnant	Condition
women	Sex
.	O

RU	O
486	O
and	O
three	O
of	O
its	O
metabolites	O
(	O
RU	O
42633-monodemethyl	O
,	O
RU	O
42848-didemethyl	O
,	O
and	O
RU	O
42698-hydroxymetabolite	O
)	O
were	O
determined	O
by	O
HPLC	O
in	O
plasma	O
from	O
nine	SampleSize
non-pregnant	Condition
and	O
36	SampleSize
pregnant	Condition
women	Sex
.	O

Each	O
non-pregnant	O
subject	O
took	O
an	O
oral	O
dose	O
of	O
RU	O
486	O
(	O
25	O
,	O
100	O
,	O
400	O
and	O
600	O
mg	O
consecutively	O
)	O
once	O
per	O
menstrual	O
cycle	O
.	O

Six	O
of	O
the	O
nine	O
women	O
also	O
received	O
a	O
dose	O
of	O
200	O
mg	O
.	O

The	O
36	SampleSize
pregnant	Condition
women	Sex
were	O
randomized	O
into	O
four	O
groups	O
which	O
were	O
given	O
a	O
single	O
dose	O
of	O
25	O
,	O
100	O
,	O
400	O
or	O
600	O
mg	O
RU	O
486	O
.	O

Blood	O
samples	O
were	O
taken	O
up	O
to	O
120	O
h	O
after	O
dosing	O
.	O

Peak	O
concentrations	O
of	O
RU	O
486	O
occurred	O
on	O
most	O
occasions	O
within	O
2	O
h.	O
Plasma	O
concentrations	O
at	O
1	O
h	O
and	O
at	O
24	O
h	O
increased	O
in	O
proportion	O
to	O
log	O
dose	O
.	O

There	O
was	O
a	O
wide	O
variability	O
(	O
up	O
to	O
ten-fold	O
)	O
in	O
the	O
pharmacokinetic	O
parameters	O
within	O
each	O
dose	O
group	O
.	O

Plasma	O
concentrations	O
of	O
RU	O
42633	O
were	O
similar	O
to	O
those	O
of	O
RU	O
486	O
but	O
concentrations	O
of	O
RU	O
42848	O
and	O
RU	O
42698	O
were	O
much	O
lower	O
.	O

As	O
with	O
RU	O
486	O
,	O
the	O
plasma	O
concentrations	O
of	O
the	O
metabolites	O
were	O
maintained	O
at	O
high	O
levels	O
for	O
up	O
to	O
48-72	O
h	O
after	O
dosing	O
.	O

The	O
findings	O
were	O
consistent	O
with	O
a	O
rapid	O
metabolism	O
of	O
RU	O
486	O
to	O
RU	O
42633	O
;	O
removal	O
of	O
the	O
second	O
methyl	O
group	O
leading	O
to	O
RU	O
42698	O
occurred	O
much	O
more	O
slowly	O
and	O
to	O
a	O
much	O
less	O
extent	O
than	O
removal	O
of	O
the	O
first	O
.	O

There	O
appeared	O
to	O
be	O
no	O
significant	O
differences	O
between	O
the	O
non-pregnant	Condition
and	O
pregnant	Condition
women	Sex
in	O
either	O
the	O
plasma	O
concentrations	O
or	O
pharmacokinetic	O
parameters	O
of	O
RU	O
486	O
and	O
its	O
metabolites	O
.	O

Effects	O
of	O
strontium	O
on	O
the	O
quality	O
of	O
bone	O
apatite	O
crystals	O
:	O
a	O
paired	O
biopsy	O
study	O
in	O
postmenopausal	Condition
osteoporotic	Condition
women	Sex
.	O

UNLABELLED	O
In	O
paired	O
biopsies	O
of	O
osteoporotic	Condition
women	Sex
treated	O
with	O
either	O
strontium	O
ranelate	O
or	O
a	O
placebo	O
for	O
36	O
months	O
,	O
characteristics	O
of	O
bone	O
apatite	O
crystals	O
were	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
strontium	O
.	O

The	O
mean	O
rate	O
of	O
substitutions	O
of	O
calcium	O
by	O
strontium	O
ions	O
was	O
4.5	O
%	O
.	O

INTRODUCTION	O
The	O
potential	O
effect	O
of	O
strontium	O
(	O
Sr	O
)	O
on	O
bone	O
apatite	O
crystals	O
was	O
investigated	O
in	O
paired	O
biopsies	O
of	O
osteoporotic	Condition
women	Sex
treated	O
with	O
either	O
strontium	O
ranelate	O
(	O
SrRan	O
)	O
or	O
a	O
placebo	O
for	O
36	O
months	O
.	O

METHODS	O
In	O
ten	SampleSize
paired	O
biopsies	O
,	O
crystallinity	O
,	O
apparent	O
length	O
and	O
width/thickness	O
of	O
crystals	O
,	O
interplanar	O
distances	O
,	O
and	O
lattice	O
parameters	O
of	O
unit	O
cells	O
were	O
assessed	O
by	O
X-ray	O
diffraction	O
and	O
selected	O
area	O
electron	O
diffraction	O
.	O

RESULTS	O
All	O
these	O
parameters	O
,	O
reflecting	O
crystal	O
and	O
unit	O
cell	O
characteristics	O
,	O
were	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
Sr	O
and	O
were	O
similar	O
in	O
SrRan	O
and	O
placebo	O
groups	O
after	O
36	O
months	O
of	O
treatment	O
.	O

The	O
mean	O
rate	O
of	O
substitutions	O
of	O
calcium	O
by	O
Sr	O
ions	O
was	O
4.5	O
%	O
.	O

CONCLUSION	O
Overall	O
,	O
the	O
quality	O
of	O
bone	O
apatite	O
crystals	O
was	O
maintained	O
after	O
36	O
months	O
of	O
treatment	O
with	O
SrRan	O
.	O

Multiple	O
sclerosis	O
risk	O
after	O
optic	Condition
neuritis	Condition
:	O
final	O
optic	O
neuritis	O
treatment	O
trial	O
follow-up	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
risk	O
of	O
developing	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
after	O
optic	Condition
neuritis	Condition
and	O
the	O
factors	O
predictive	O
of	O
high	O
and	O
low	O
risk	O
.	O

DESIGN	O
Subjects	O
in	O
the	O
Optic	O
Neuritis	O
Treatment	O
Trial	O
,	O
who	O
were	O
enrolled	O
between	O
July	O
1	O
,	O
1988	O
,	O
and	O
June	O
30	O
,	O
1991	O
,	O
were	O
followed	O
up	O
prospectively	O
for	O
15	O
years	O
,	O
with	O
the	O
final	O
examination	O
in	O
2006	O
.	O

SETTING	O
Neurologic	O
and	O
ophthalmologic	O
examinations	O
at	O
13	O
clinical	O
sites	O
.	O

PARTICIPANTS	O
Three	SampleSize
hundred	SampleSize
eighty-nine	SampleSize
subjects	O
with	O
acute	Condition
optic	Condition
neuritis	Condition
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Development	O
of	O
MS	O
and	O
neurologic	O
disability	O
assessment	O
.	O

RESULTS	O
The	O
cumulative	O
probability	O
of	O
developing	O
MS	O
by	O
15	O
years	O
after	O
onset	O
of	O
optic	O
neuritis	O
was	O
50	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
44	O
%	O
-56	O
%	O
)	O
and	O
strongly	O
related	O
to	O
presence	O
of	O
lesions	O
on	O
a	O
baseline	O
non-contrast-enhanced	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
the	O
brain	O
.	O

Twenty-five	O
percent	O
of	O
patients	O
with	O
no	O
lesions	O
on	O
baseline	O
brain	O
MRI	O
developed	O
MS	O
during	O
follow-up	O
compared	O
with	O
72	O
%	O
of	O
patients	O
with	O
1	O
or	O
more	O
lesions	O
.	O

After	O
10	O
years	O
,	O
the	O
risk	O
of	O
developing	O
MS	O
was	O
very	O
low	O
for	O
patients	O
without	O
baseline	O
lesions	O
but	O
remained	O
substantial	O
for	O
those	O
with	O
lesions	O
.	O

Among	O
patients	O
without	O
lesions	O
on	O
MRI	O
,	O
baseline	O
factors	O
associated	O
with	O
a	O
substantially	O
lower	O
risk	O
for	O
MS	O
included	O
male	O
sex	O
,	O
optic	O
disc	O
swelling	O
,	O
and	O
certain	O
atypical	O
features	O
of	O
optic	O
neuritis	O
.	O

CONCLUSIONS	O
The	O
presence	O
of	O
brain	O
MRI	O
abnormalities	O
at	O
the	O
time	O
of	O
an	O
optic	O
neuritis	O
attack	O
is	O
a	O
strong	O
predictor	O
of	O
the	O
15-year	O
risk	O
of	O
MS	O
.	O

In	O
the	O
absence	O
of	O
MRI-detected	O
lesions	O
,	O
male	O
sex	O
,	O
optic	O
disc	O
swelling	O
,	O
and	O
atypical	O
clinical	O
features	O
of	O
optic	O
neuritis	O
are	O
associated	O
with	O
a	O
low	O
likelihood	O
of	O
developing	O
MS	O
.	O

This	O
natural	O
history	O
information	O
is	O
important	O
when	O
considering	O
prophylactic	O
treatment	O
for	O
MS	O
at	O
the	O
time	O
of	O
a	O
first	O
acute	O
onset	O
of	O
optic	O
neuritis	O
.	O

[	O
New	O
approaches	O
to	O
evaluation	O
of	O
nonspecific	O
inhalation	O
provocation	O
(	O
dose-response	O
relationship	O
)	O
in	O
the	O
comparative	O
evaluation	O
of	O
bronchial	Condition
hyperreactivity	Condition
within	O
the	O
scope	O
of	O
clinical	O
trials	O
]	O
.	O

For	O
the	O
performance	O
of	O
clinical	O
drug	O
trials	O
in	O
the	O
therapy	O
for	O
bronchial	Condition
hyperresponsiveness	Condition
,	O
unspecific	O
inhalatory	O
provocation	O
tests	O
are	O
generally	O
employed	O
to	O
judge	O
therapeutic	O
success	O
.	O

In	O
particular	O
,	O
the	O
parameter-specific	O
provocation	O
doses	O
are	O
considered	O
to	O
be	O
the	O
main	O
target	O
values	O
.	O

However	O
,	O
it	O
must	O
be	O
considered	O
that	O
these	O
provocation	O
doses	O
are	O
not	O
equally	O
calculable	O
for	O
every	O
patient	O
in	O
the	O
same	O
way	O
and	O
at	O
any	O
examination	O
time	O
.	O

This	O
leads	O
to	O
the	O
fact	O
that	O
the	O
number	O
of	O
evaluable	O
case	O
studies	O
is	O
often	O
appreciably	O
lower	O
than	O
the	O
number	O
of	O
test	O
participants	O
and	O
that	O
a	O
meaningful	O
therapy	O
group	O
comparison	O
may	O
even	O
not	O
be	O
possible	O
under	O
certain	O
circumstances	O
.	O

An	O
evaluation	O
model	O
is	O
presented	O
here	O
in	O
order	O
to	O
fully	O
exploit	O
the	O
obtained	O
data	O
;	O
in	O
this	O
the	O
percentile	O
changes	O
of	O
the	O
function	O
parameters	O
(	O
estimated	O
by	O
linear	O
regression	O
)	O
at	O
a	O
defined	O
dose	O
of	O
the	O
provocation	O
substance	O
are	O
analyzed	O
.	O

In	O
analogy	O
,	O
a	O
survival	O
time	O
model	O
and	O
,	O
as	O
a	O
supplement	O
,	O
a	O
best	O
case/worst	O
case	O
analysis	O
are	O
performed	O
for	O
further	O
statistical	O
evaluation	O
.	O

With	O
the	O
present	O
procedure	O
,	O
an	O
evaluation	O
with	O
inclusion	O
of	O
all	O
test	O
participants	O
is	O
possible	O
.	O

In	O
contrast	O
to	O
the	O
previously	O
used	O
evaluation	O
procedures	O
,	O
this	O
allows	O
a	O
reliable	O
statistical	O
confirmation	O
of	O
the	O
results	O
of	O
clinical	O
tests	O
in	O
the	O
therapy	O
for	O
bronchial	Condition
hyperresponsiveness	Condition
.	Condition

Effect	O
of	O
topical	O
rh-TGF-beta	O
1	O
on	O
second	Condition
intention	Condition
wound	Condition
healing	Condition
in	O
horses	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effects	O
on	O
wound	O
healing	O
of	O
transforming	O
growth	O
factor-beta	O
1	O
as	O
a	O
topical	O
treatment	O
to	O
full-thickness	O
,	O
excisional	O
wounds	O
of	O
the	O
distal	O
limb	O
of	O
horses	O
.	O

DESIGN	O
A	O
randomised	O
block	O
study	O
using	O
four	SampleSize
horses	O
,	O
each	O
with	O
wounds	O
assigned	O
to	O
four	O
treatment	O
groups	O
.	O

ANIMALS	O
Four	O
adult	O
Standardbred	O
geldings	O
.	O

PROCEDURE	O
Four	O
,	O
4	O
cm2	O
,	O
full-thickness	O
wounds	O
were	O
created	O
on	O
the	O
dorsomedial	O
and	O
dorsolateral	O
aspect	O
of	O
the	O
metacarpus	O
or	O
metatarsus	O
of	O
each	O
limb	O
of	O
four	O
horses	O
,	O
giving	O
a	O
total	O
of	O
64	O
wounds	O
.	O

For	O
each	O
limb	O
,	O
wounds	O
were	O
randomly	O
assigned	O
to	O
four	O
treatment	O
groups	O
:	O
no	O
treatment	O
(	O
control	O
)	O
,	O
carrier	O
(	O
Methyl	O
Cellulose	O
gel	O
)	O
,	O
50	O
ng/wound	O
rhTGF-beta	O
1	O
in	O
carrier	O
,	O
and	O
500	O
ng/wound	O
rhTGF-beta	O
1	O
in	O
carrier	O
.	O

Wounds	O
were	O
treated	O
on	O
day	O
0	O
and	O
day	O
8	O
.	O

Effects	O
of	O
treatment	O
were	O
evaluated	O
on	O
the	O
basis	O
of	O
the	O
presence	O
of	O
exuberant	O
granulation	O
tissue	O
requiring	O
excision	O
,	O
number	O
of	O
times	O
excision	O
was	O
required	O
,	O
total	O
wound	O
area	O
,	O
area	O
of	O
epithelialisation	O
,	O
area	O
of	O
granulation	O
,	O
and	O
histological	O
evaluation	O
of	O
biopsy	O
samples	O
of	O
wounds	O
on	O
day	O
8	O
and	O
excised	O
wounds	O
on	O
day	O
21	O
.	O

RESULTS	O
Topical	O
application	O
of	O
TGF-beta	O
1	O
at	O
the	O
two	O
concentrations	O
studied	O
had	O
no	O
significant	O
effect	O
on	O
the	O
total	O
area	O
of	O
wounds	O
(	O
P	O
=	O
0.7	O
)	O
,	O
the	O
area	O
of	O
granulation	O
tissue	O
(	O
P	O
=	O
0.78	O
)	O
,	O
the	O
area	O
of	O
epithelialisation	O
(	O
P	O
=	O
0.92	O
)	O
,	O
histological	O
assessment	O
or	O
subjective	O
clinical	O
assessment	O
of	O
wounds	O
.	O

CONCLUSION	O
TGF-beta	O
1	O
had	O
no	O
beneficial	O
effects	O
on	O
wound	O
healing	O
.	O

Additional	O
trials	O
are	O
needed	O
to	O
test	O
if	O
it	O
has	O
value	O
for	O
wound	O
treatment	O
in	O
horses	O
.	O

Cardiopulmonary	O
exercise	O
variables	O
in	O
diastolic	O
versus	O
systolic	O
heart	O
failure	O
.	O

The	O
response	O
to	O
cardiopulmonary	O
exercise	O
(	O
CPX	O
)	O
in	O
patients	O
with	O
heart	O
failure	O
(	O
HF	O
)	O
with	O
normal	O
left	O
ventricular	O
(	O
LV	O
)	O
ejection	O
fractions	O
(	O
EFs	O
)	O
is	O
not	O
well	O
characterized	O
.	O

To	O
determine	O
if	O
CPX	O
testing	O
could	O
distinguish	O
between	O
patients	O
with	O
HF	O
with	O
normal	O
EFs	O
(	O
>	O
50	O
%	O
;	O
i.e.	O
,	O
diastolic	O
HF	O
)	O
and	O
those	O
with	O
decreased	O
EFs	O
(	O
>	O
or	O
=50	O
%	O
;	O
i.e.	O
,	O
systolic	O
HF	O
)	O
,	O
CPX	O
responses	O
were	O
compared	O
between	O
185	O
patients	O
with	O
systolic	O
HF	O
(	O
79	O
%	O
men	O
,	O
mean	O
age	O
62.6	O
+/-	O
10.9	O
years	O
)	O
and	O
43	O
with	O
diastolic	O
HF	O
(	O
54	O
%	O
men	O
,	O
mean	O
age	O
67.4	O
+/-	O
9.8	O
years	O
)	O
enrolled	O
in	O
a	O
phase	O
II	O
multicenter	O
clinical	O
trial	O
.	O

All	O
patients	O
were	O
evaluated	O
with	O
echocardiography	O
and	O
a	O
standardized	O
CPX	O
test	O
as	O
part	O
of	O
the	O
trial	O
.	O

CPX	O
variables	O
,	O
including	O
oxygen	O
uptake	O
at	O
peak	O
exercise	O
(	O
peak	O
VO	O
(	O
2	O
)	O
)	O
and	O
the	O
slope	O
of	O
the	O
ventilation/carbon	O
dioxide	O
production	O
ratio	O
(	O
VE/VCO	O
(	O
2	O
)	O
)	O
,	O
were	O
determined	O
and	O
analyzed	O
by	O
core	O
laboratory	O
personnel	O
.	O

Echocardiographic	O
measurements	O
included	O
the	O
LV	O
EF	O
,	O
the	O
E/A	O
ratio	O
,	O
filling	O
time	O
,	O
cavity	O
volumes	O
,	O
right	O
ventricular	O
function	O
,	O
and	O
mitral	O
regurgitation	O
.	O

Patients	O
in	O
the	O
diastolic	O
HF	O
group	O
tended	O
to	O
be	O
older	O
(	O
p	O
<	O
0.08	O
)	O
,	O
with	O
more	O
women	O
(	O
p	O
<	O
0.006	O
)	O
and	O
with	O
greater	O
body	O
mass	O
indexes	O
(	O
p	O
<	O
0.02	O
)	O
,	O
than	O
those	O
in	O
the	O
systolic	O
HF	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
use	O
of	O
beta	O
blockers	O
or	O
the	O
incidence	O
of	O
coronary	O
artery	O
disease	O
.	O

Patients	O
with	O
diastolic	O
HF	O
had	O
decreased	O
E/A	O
ratios	O
(	O
0.9	O
+/-	O
0.4	O
vs	O
1.4	O
+/-	O
1.1	O
,	O
p	O
<	O
0.02	O
,	O
diastolic	O
HF	O
vs	O
systolic	O
HF	O
)	O
and	O
increased	O
filling	O
times	O
(	O
30.4	O
+/-	O
3.2	O
vs	O
26.5	O
+/-	O
4.7	O
ms	O
,	O
p	O
<	O
0.01	O
,	O
diastolic	O
HF	O
vs	O
systolic	O
HF	O
)	O
.	O

No	O
significant	O
differences	O
in	O
peak	O
VO	O
(	O
2	O
)	O
(	O
14.4	O
+/-	O
1.9	O
vs	O
15.6	O
+/-	O
3.2	O
ml/kg/min	O
,	O
p	O
=	O
0.06	O
,	O
diastolic	O
HF	O
vs	O
systolic	O
HF	O
)	O
were	O
observed	O
.	O

The	O
VE/VCO	O
(	O
2	O
)	O
ratios	O
for	O
the	O
2	O
groups	O
were	O
abnormal	O
and	O
comparable	O
(	O
32	O
2	O
+/-	O
7.5	O
vs	O
34.0	O
+/-	O
8.3	O
,	O
p	O
=	O
0.3	O
,	O
diastolic	O
HF	O
vs	O
systolic	O
HF	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
CPX	O
response	O
in	O
patients	O
with	O
diastolic	O
HF	O
and	O
systolic	O
HF	O
is	O
markedly	O
abnormal	O
and	O
indistinguishable	O
with	O
regard	O
to	O
peak	O
VO	O
(	O
2	O
)	O
and	O
ventilation	O
despite	O
marked	O
differences	O
in	O
the	O
LV	O
EF	O
.	O

Multisensory	O
temporal	O
integration	O
in	O
autism	Condition
spectrum	Condition
disorders	Condition
.	O

The	O
new	O
DSM-5	O
diagnostic	O
criteria	O
for	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
include	O
sensory	O
disturbances	O
in	O
addition	O
to	O
the	O
well-established	O
language	O
,	O
communication	O
,	O
and	O
social	O
deficits	O
.	O

One	O
sensory	O
disturbance	O
seen	O
in	O
ASD	O
is	O
an	O
impaired	O
ability	O
to	O
integrate	O
multisensory	O
information	O
into	O
a	O
unified	O
percept	O
.	O

This	O
may	O
arise	O
from	O
an	O
underlying	O
impairment	O
in	O
which	O
individuals	O
with	O
ASD	O
have	O
difficulty	O
perceiving	O
the	O
temporal	O
relationship	O
between	O
cross-modal	O
inputs	O
,	O
an	O
important	O
cue	O
for	O
multisensory	O
integration	O
.	O

Such	O
impairments	O
in	O
multisensory	O
processing	O
may	O
cascade	O
into	O
higher-level	O
deficits	O
,	O
impairing	O
day-to-day	O
functioning	O
on	O
tasks	O
,	O
such	O
as	O
speech	O
perception	O
.	O

To	O
investigate	O
multisensory	O
temporal	O
processing	O
deficits	O
in	O
ASD	O
and	O
their	O
links	O
to	O
speech	O
processing	O
,	O
the	O
current	O
study	O
mapped	O
performance	O
on	O
a	O
number	O
of	O
multisensory	O
temporal	O
tasks	O
(	O
with	O
both	O
simple	O
and	O
complex	O
stimuli	O
)	O
onto	O
the	O
ability	O
of	O
individuals	O
with	O
ASD	Condition
to	O
perceptually	O
bind	O
audiovisual	O
speech	O
signals	O
.	O

High-functioning	Condition
children	Age
with	O
ASD	Condition
were	O
compared	O
with	O
a	O
group	O
of	O
typically	O
developing	O
children	O
.	O

Performance	O
on	O
the	O
multisensory	O
temporal	O
tasks	O
varied	O
with	O
stimulus	O
complexity	O
for	O
both	O
groups	O
;	O
less	O
precise	O
temporal	O
processing	O
was	O
observed	O
with	O
increasing	O
stimulus	O
complexity	O
.	O

Notably	O
,	O
individuals	O
with	O
ASD	O
showed	O
a	O
speech-specific	O
deficit	O
in	O
multisensory	O
temporal	O
processing	O
.	O

Most	O
importantly	O
,	O
the	O
strength	O
of	O
perceptual	O
binding	O
of	O
audiovisual	O
speech	O
observed	O
in	O
individuals	O
with	O
ASD	O
was	O
strongly	O
related	O
to	O
their	O
low-level	O
multisensory	O
temporal	O
processing	O
abilities	O
.	O

Collectively	O
,	O
the	O
results	O
represent	O
the	O
first	O
to	O
illustrate	O
links	O
between	O
multisensory	O
temporal	O
function	O
and	O
speech	O
processing	O
in	O
ASD	O
,	O
strongly	O
suggesting	O
that	O
deficits	O
in	O
low-level	O
sensory	O
processing	O
may	O
cascade	O
into	O
higher-order	O
domains	O
,	O
such	O
as	O
language	O
and	O
communication	O
.	O

Conservative	O
treatment	O
of	O
plantar	Condition
fasciitis	Condition
.	O

A	O
prospective	O
study	O
.	O

A	O
randomized	O
,	O
prospective	O
study	O
was	O
conducted	O
to	O
compare	O
the	O
individual	O
effectiveness	O
of	O
three	O
types	O
of	O
conservative	O
therapy	O
in	O
the	O
treatment	O
of	O
plantar	O
fasciitis	O
.	O

One	SampleSize
hundred	SampleSize
three	SampleSize
subjects	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
treatment	O
categories	O
:	O
anti-inflammatory	O
,	O
accommodative	O
,	O
or	O
mechanical	O
.	O

Subjects	O
were	O
treated	O
for	O
3	O
months	O
,	O
with	O
follow-up	O
visits	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
weeks	O
.	O

For	O
the	O
85	SampleSize
patients	O
who	O
completed	O
the	O
study	O
,	O
a	O
statistically	O
significant	O
difference	O
was	O
noted	O
between	O
groups	O
,	O
with	O
mechanical	O
treatment	O
with	O
taping	O
and	O
orthoses	O
proving	O
to	O
be	O
more	O
effective	O
than	O
either	O
anti-inflammatory	O
or	O
accommodative	O
modalities	O
.	O

Age-related	O
response	O
to	O
two	O
Haemophilus	O
influenzae	O
type	O
b	O
vaccines	O
.	O

Two	O
types	O
of	O
Hib	O
vaccines	O
were	O
compared	O
for	O
efficacy	O
and	O
safety	O
in	O
71	O
normal	O
children	O
in	O
three	O
age	O
groups	O
:	O
36	O
to	O
72	O
months	O
,	O
15	O
to	O
18	O
months	O
,	O
and	O
6	O
to	O
8	O
months	O
.	O

One	O
vaccine	O
contained	O
the	O
Hib-specific	O
capsular	O
polysaccharide	O
,	O
PRP	O
;	O
the	O
second	O
vaccine	O
contained	O
PRP	O
combined	O
with	O
pertussis	O
vaccine	O
,	O
PRP-P.	O
A	O
third	O
vaccine	O
,	O
DTP	O
,	O
was	O
administered	O
to	O
a	O
control	O
group	O
for	O
each	O
age	O
.	O

Anti-PRP	O
antibody	O
levels	O
were	O
greater	O
after	O
vaccination	O
with	O
PRP-P	O
than	O
after	O
PRP	O
in	O
all	O
three	O
age	O
groups	O
.	O

Immunoresponsiveness	O
to	O
both	O
vaccines	O
increased	O
with	O
age	O
.	O

A	O
lower	O
incidence	O
of	O
side	O
effects	O
was	O
seen	O
with	O
both	O
PRP	O
(	O
15	O
%	O
)	O
and	O
PRP-P	O
(	O
20	O
%	O
)	O
than	O
with	O
DTP	O
(	O
56	O
%	O
)	O
.	O

The	O
results	O
suggest	O
that	O
PRP-P	O
is	O
both	O
well	O
tolerated	O
clinically	O
and	O
has	O
greater	O
immunogenicity	O
than	O
PRP	O
.	O

Comparison	O
of	O
epidural	O
tramadol-ropivacaine	O
and	O
fentanyl-ropivacaine	O
for	O
labor	O
analgesia	O
:	O
a	O
prospective	O
randomized	O
study	O
.	O

BACKGROUND	O
To	O
test	O
the	O
hypothesis	O
that	O
5	O
mg/mL	O
tramadol	O
is	O
superior	O
to	O
3	O
?	O
g/mL	O
fentanyl	O
when	O
combined	O
with	O
0.125	O
%	O
ropivacaine	O
in	O
parturients	O
undergoing	O
labor	O
during	O
epidural	O
analgesia	O
.	O

METHODS	O
Sixty-one	O
parturients	O
undergoing	O
labor	O
selected	O
for	O
delivery	O
with	O
epidural	O
analgesia	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
Group	O
tramadol	O
(	O
0.125	O
%	O
ropivacaine	O
plus	O
tramadol	O
5	O
mg/mL	O
)	O
and	O
Group	O
fentanyl	O
(	O
0.125	O
%	O
ropivacaine	O
plus	O
fentanyl	O
3	O
ug/mL	O
)	O
.	O

Hemodynamics	O
,	O
rate	O
of	O
cesarean	O
delivery	O
,	O
sensory	O
block	O
level	O
,	O
Bromage	O
motor	O
scale	O
scores	O
,	O
instrument-assisted	O
delivery	O
,	O
oxytocin	O
use	O
,	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
scores	O
,	O
Apgar	O
scores	O
,	O
umbilical	O
cord	O
artery	O
gas	O
analysis	O
,	O
and	O
maternal	O
side-effects	O
including	O
nausea	O
,	O
vomiting	O
,	O
pruritus	O
,	O
urinary	O
retention	O
,	O
shivering	O
,	O
hypotension	O
,	O
and	O
respiratory	O
depression	O
were	O
recorded	O
.	O

RESULTS	O
The	O
two	O
groups	O
had	O
no	O
significant	O
differences	O
with	O
respect	O
to	O
maternal	O
hemodynamics	O
,	O
neonatal	O
heart	O
rate	O
,	O
VAS	O
scores	O
,	O
rate	O
of	O
cesarean	O
delivery	O
,	O
sensory	O
block	O
level	O
,	O
Bromage	O
motor	O
scale	O
scores	O
,	O
instrument-assisted	O
delivery	O
,	O
oxytocin	O
use	O
,	O
hypotension	O
,	O
nausea	O
,	O
vomiting	O
,	O
and	O
respiratory	O
depression	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
incidence	O
of	O
pruritus	O
,	O
shivering	O
,	O
and	O
urinary	O
retention	O
were	O
more	O
commonly	O
observed	O
in	O
Group	O
fentanyl	O
despite	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

Umbilical	O
artery	O
pH	O
was	O
significantly	O
lower	O
while	O
PCO	O
(	O
2	O
)	O
was	O
higher	O
in	O
Group	O
fentanyl	O
than	O
Group	O
tramadol	O
(	O
p	O
=	O
0.003	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O

Birth-weight	O
,	O
umbilical	O
artery	O
PO	O
(	O
2	O
)	O
and	O
base	O
deficit	O
,	O
and	O
Apgar	O
scores	O
at	O
1	O
and	O
5	O
min	O
were	O
comparable	O
between	O
the	O
two	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

CONCLUSIONS	O
Our	O
observations	O
suggest	O
that	O
tramadol	O
seems	O
to	O
be	O
a	O
safe	O
alternative	O
to	O
fentanyl	O
for	O
labor	O
analgesia	O
due	O
to	O
its	O
similar	O
analgesic	O
efficacy	O
.	O

Serum	O
bactericidal	O
activities	O
and	O
comparative	O
pharmacokinetics	O
of	O
meropenem	O
and	O
imipenem-cilastatin	O
.	O

The	O
pharmacokinetics	O
and	O
serum	O
bactericidal	O
activities	O
(	O
SBAs	O
)	O
of	O
imipenem	O
and	O
meropenem	O
were	O
investigated	O
in	O
a	O
randomized	O
crossover	O
study	O
.	O

Twelve	O
healthy	O
male	O
volunteers	O
received	O
a	O
constant	O
30-min	O
infusion	O
of	O
either	O
1	O
g	O
of	O
imipenem	O
plus	O
1	O
g	O
of	O
cilastatin	O
or	O
1	O
g	O
of	O
meropenem	O
.	O

The	O
concentrations	O
of	O
the	O
drugs	O
in	O
serum	O
and	O
urine	O
were	O
determined	O
by	O
bioassay	O
and	O
high-pressure	O
liquid	O
chromatography	O
.	O

Pharmacokinetic	O
parameters	O
were	O
based	O
on	O
an	O
open	O
two-compartment	O
model	O
and	O
a	O
noncompartmental	O
technique	O
.	O

At	O
the	O
end	O
of	O
infusion	O
,	O
the	O
mean	O
concentrations	O
of	O
imipenem	O
and	O
meropenem	O
measured	O
in	O
serum	O
were	O
61.2	O
+/-	O
9.8	O
and	O
51.6	O
+/-	O
6.5	O
mg/liter	O
,	O
respectively	O
;	O
urinary	O
recoveries	O
were	O
48.6	O
%	O
+/-	O
8.2	O
%	O
and	O
60.0	O
%	O
+/-	O
6.5	O
%	O
of	O
the	O
dose	O
in	O
12	O
h	O
,	O
respectively	O
;	O
and	O
the	O
areas	O
under	O
the	O
concentration-time	O
curve	O
from	O
time	O
zero	O
to	O
infinity	O
were	O
96.1	O
+/-	O
14.4	O
and	O
70.5	O
+/-	O
10.3	O
mg.h/liter	O
,	O
respectively	O
(	O
P	O
<	O
or	O
=	O
0.02	O
)	O
.	O

Imipenem	O
had	O
a	O
mean	O
half-life	O
of	O
66.7	O
+/-	O
10.4	O
min	O
;	O
that	O
of	O
meropenem	O
was	O
64.4	O
+/-	O
6.9	O
min	O
.	O

The	O
volumes	O
of	O
distribution	O
at	O
steady	O
state	O
of	O
imipenem	O
and	O
meropenem	O
were	O
15.3	O
+/-	O
3.3	O
and	O
18.6	O
+/-	O
3.0	O
liters/70	O
kg	O
,	O
respectively	O
,	O
and	O
the	O
mean	O
renal	O
clearances	O
per	O
1.73	O
m2	O
were	O
85.6	O
+/-	O
17.6	O
and	O
144.6	O
+/-	O
26.0	O
ml/min	O
,	O
respectively	O
.	O

Both	O
antibiotics	O
were	O
well	O
tolerated	O
in	O
this	O
single-dose	O
administration	O
study	O
.	O

The	O
SBAs	O
were	O
measured	O
by	O
the	O
microdilution	O
method	O
of	O
Reller	O
and	O
Stratton	O
(	O
L.	O
B.	O
Reller	O
and	O
C.	O
W.	O
Stratton	O
,	O
J.	O
Infect	O
.	O

Dis	O
.	O

136:196-204	O
,	O
1977	O
)	O
against	O
40	O
clinically	O
isolated	O
strains	O
.	O

Mean	O
reciprocal	O
bactericidal	O
titers	O
were	O
measured	O
1	O
and	O
6	O
h	O
after	O
administration	O
.	O

After	O
1	O
and	O
6	O
h	O
the	O
median	O
SBAs	O
for	O
imipenem	O
and	O
meropenem	O
,	O
were	O
409	O
and	O
34.9	O
and	O
97.9	O
and	O
5.8	O
,	O
respectively	O
,	O
against	O
Staphylococcus	O
aureus	O
,	O
19.9	O
and	O
4.4	O
and	O
19.4	O
and	O
4.8	O
,	O
respectively	O
,	O
against	O
Pseudomonas	O
aeruginosa	O
,	O
34.3	O
and	O
2.2	O
and	O
232	O
and	O
15.5	O
,	O
respectively	O
,	O
against	O
Enterobacter	O
cloacae	O
,	O
and	O
13.4	O
and	O
2.25	O
and	O
90.7	O
and	O
7.9	O
,	O
respectively	O
,	O
against	O
Proteus	O
mirabilis	O
.	O

Both	O
drugs	O
had	O
rather	O
short	O
biological	O
elimination	O
half-lives	O
and	O
a	O
predominantly	O
renal	O
route	O
of	O
elimination	O
.	O

Both	O
carbapenems	O
revealed	O
high	O
SBAs	O
against	O
clinically	O
important	O
pathogens	O
at	O
1	O
h	O
;	O
meropenem	O
had	O
a	O
higher	O
SBA	O
against	O
E.	O
cloacae	O
and	O
P.	O
mirabilis	O
,	O
and	O
the	O
SBA	O
of	O
imipenem	O
against	O
S.	O
aureus	O
was	O
greater	O
than	O
the	O
SBA	O
of	O
meropenem	O
.	O

Continuous	O
event	O
recorders	O
did	O
not	O
affect	O
anxiety	O
or	O
quality	O
of	O
life	O
in	O
patients	O
with	O
palpitations	Condition
.	O

OBJECTIVES	O
Palpitations	O
can	O
generate	O
feelings	O
of	O
anxiety	O
and	O
decrease	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
due	O
to	O
fear	O
of	O
a	O
cardiac	O
abnormality	O
.	O

Continuous	O
event	O
recorders	O
(	O
CERs	O
)	O
have	O
proven	O
to	O
be	O
successful	O
in	O
diagnosing	O
causes	O
of	O
palpitations	O
but	O
may	O
affect	O
patient	O
QoL	O
and	O
anxiety	O
.	O

The	O
aim	O
is	O
to	O
determine	O
anxiety	O
and	O
health-related	O
(	O
HR	O
)	O
-QoL	O
and	O
evaluate	O
the	O
burden	O
of	O
carrying	O
a	O
CER	O
in	O
general	O
practice	O
populations	O
.	O

STUDY	O
DESIGN	O
AND	O
SETTING	O
Patients	O
(	O
n=244	SampleSize
)	O
participated	O
in	O
a	O
randomized	O
trial	O
.	O

One	O
group	O
(	O
n=127	O
)	O
carried	O
a	O
CER	O
during	O
4	O
weeks	O
.	O

One	SampleSize
hundred	SampleSize
and	SampleSize
seventeen	SampleSize
patients	O
formed	O
the	O
usual	O
care	O
(	O
UC	O
)	O
group	O
.	O

State-Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
and	O
the	O
Short	O
Form-36	O
(	O
SF-36	O
)	O
were	O
administered	O
at	O
study	O
inclusion	O
,	O
after	O
1	O
,	O
6	O
months	O
.	O

RESULTS	O
At	O
baseline	O
,	O
patients	O
reported	O
greater	O
anxiety	O
and	O
lower	O
QoL	O
than	O
healthy	O
populations	O
.	O

The	O
CER	O
group	O
had	O
three	O
times	O
more	O
cardiac	O
diagnoses	O
than	O
the	O
UC	O
group	O
.	O

No	O
differences	O
were	O
found	O
between	O
CER	O
group	O
and	O
UC	O
group	O
at	O
6	O
weeks	O
.	O

At	O
6	O
months	O
,	O
the	O
UC	O
group	O
showed	O
QoL	O
improvement	O
and	O
less	O
anxiety	O
compared	O
to	O
the	O
CER	O
group	O
.	O

Type	O
of	O
diagnosis	O
had	O
influence	O
,	O
but	O
did	O
not	O
fully	O
explain	O
these	O
differences	O
.	O

CONCLUSION	O
A	O
CER	O
does	O
not	O
negatively	O
influence	O
anxiety	O
or	O
QoL	O
.	O

Better	O
outcomes	O
in	O
the	O
UC	O
group	O
might	O
be	O
attributed	O
to	O
less	O
cardiac	O
diagnosis	O
and	O
more	O
emphasis	O
on	O
psychological	O
well-being	O
.	O

Preliminary	O
evaluation	O
of	O
psychoeducational	O
support	O
interventions	O
on	O
quality	O
of	O
life	O
in	O
rural	O
breast	Condition
cancer	Condition
survivors	O
after	O
primary	O
treatment	O
.	O

Although	O
most	O
cancer	O
survivors	O
are	O
at	O
risk	O
for	O
being	O
lost	O
in	O
the	O
transition	O
from	O
treatment	O
to	O
survivorship	O
,	O
rural	O
breast	O
cancer	O
survivors	O
face	O
special	O
challenges	O
that	O
might	O
place	O
them	O
at	O
particular	O
risk	O
.	O

This	O
small-scale	O
preliminary	O
study	O
had	O
2	O
specific	O
aims	O
:	O
(	O
aim	O
1	O
)	O
establish	O
the	O
feasibility	O
of	O
rural	O
breast	O
cancer	O
survivors	O
participation	O
in	O
a	O
longitudinal	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
intervention	O
trial	O
and	O
(	O
aim	O
2	O
)	O
determine	O
the	O
effects	O
of	O
the	O
Breast	O
Cancer	O
Education	O
Intervention	O
(	O
BCEI	O
)	O
on	O
overall	O
QOL	O
.	O

Fifty-three	SampleSize
rural	O
breast	O
cancer	O
survivors	O
were	O
randomized	O
to	O
either	O
an	O
experimental	O
(	O
n	O
=	O
27	O
)	O
or	O
a	O
wait-control	O
arm	O
(	O
n	O
=	O
26	O
)	O
.	O

Participants	O
in	O
the	O
experimental	O
arm	O
received	O
the	O
BCEI	O
consisting	O
of	O
3	O
face-to-face	O
education	O
and	O
support	O
sessions	O
and	O
2	O
face-to-face	O
and	O
3	O
telephone	O
follow-up	O
sessions	O
,	O
along	O
with	O
supplemental	O
written	O
and	O
audiotape	O
materials	O
over	O
a	O
6-month	O
period	O
.	O

Breast	O
Cancer	O
Education	O
Intervention	O
modules	O
and	O
interventions	O
are	O
organized	O
within	O
a	O
QOL	O
framework	O
.	O

To	O
address	O
the	O
possible	O
effects	O
of	O
attention	O
,	O
wait-control	O
participants	O
received	O
3	O
face-to-face	O
sessions	O
and	O
3	O
telephone	O
sessions	O
during	O
the	O
first	O
6	O
months	O
of	O
participation	O
in	O
the	O
study	O
,	O
but	O
not	O
the	O
BCEI	O
intervention	O
.	O

Research	O
questions	O
addressing	O
aim	O
1	O
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
can	O
rural	O
breast	O
cancer	O
survivors	O
be	O
recruited	O
into	O
a	O
longitudinal	O
intervention	O
trial	O
,	O
and	O
(	O
b	O
)	O
can	O
their	O
participation	O
be	O
retained	O
.	O

Research	O
questions	O
for	O
aim	O
2	O
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
do	O
participants	O
who	O
received	O
the	O
BCEI	O
show	O
improvement	O
in	O
overall	O
QOL	O
,	O
and	O
(	O
b	O
)	O
is	O
the	O
QOL	O
improvement	O
sustained	O
over	O
time	O
.	O

Data	O
were	O
analyzed	O
using	O
repeated-measures	O
general	O
linear	O
mixed	O
models	O
.	O

Results	O
demonstrated	O
the	O
ability	O
to	O
recruit	O
and	O
retain	O
53	O
rural	O
breast	O
cancer	O
survivors	O
,	O
that	O
the	O
experimental	O
arm	O
showed	O
improvement	O
in	O
overall	O
QOL	O
(	O
P	O
=	O
.013	O
)	O
,	O
and	O
that	O
there	O
were	O
significant	O
differences	O
in	O
overall	O
QOL	O
between	O
the	O
experimental	O
and	O
wait-control	O
groups	O
at	O
both	O
months	O
3	O
and	O
6	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
at	O
least	O
some	O
rural	O
breast	O
cancer	O
survivors	O
can	O
and	O
will	O
participate	O
in	O
a	O
larger	O
trial	O
and	O
will	O
maintain	O
their	O
participation	O
and	O
that	O
those	O
that	O
do	O
participate	O
experience	O
significant	O
QOL	O
benefit	O
.	O

Temporal	O
discounting	O
:	O
the	O
differential	O
effect	O
of	O
proximal	O
and	O
distal	O
consequences	O
on	O
confession	O
decisions	O
.	O

Drawing	O
on	O
the	O
psychological	O
principle	O
that	O
proximal	O
consequences	O
influence	O
behavior	O
more	O
strongly	O
than	O
distal	O
consequences	O
,	O
the	O
authors	O
tested	O
the	O
hypothesis	O
that	O
criminal	O
suspects	O
exhibit	O
a	O
short-sightedness	O
during	O
police	O
interrogation	O
that	O
increases	O
their	O
risk	O
for	O
confession	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
Experiment	O
1	O
showed	O
that	O
participants	O
(	O
N	O
=	O
81	O
)	O
altered	O
how	O
frequently	O
they	O
admitted	O
to	O
criminal	O
and	O
unethical	O
behaviors	O
during	O
an	O
interview	O
to	O
avoid	O
a	O
proximal	O
consequence	O
even	O
though	O
doing	O
so	O
increased	O
their	O
risk	O
of	O
incurring	O
a	O
distal	O
consequence	O
.	O

Experiment	O
2	O
(	O
N	O
=	O
143	O
)	O
yielded	O
the	O
same	O
pattern	O
,	O
but	O
with	O
a	O
procedure	O
that	O
reversed	O
the	O
order	O
of	O
the	O
proximal	O
and	O
distal	O
consequences	O
,	O
thereby	O
ruling	O
out	O
the	O
possibility	O
that	O
it	O
was	O
the	O
unique	O
characteristics	O
of	O
the	O
consequences	O
rather	O
than	O
their	O
proximity	O
that	O
influenced	O
the	O
admission	O
rate	O
.	O

The	O
authors	O
discuss	O
the	O
supported	O
psychological	O
process	O
as	O
a	O
potential	O
explanation	O
for	O
several	O
well-established	O
findings	O
reported	O
in	O
the	O
literature	O
on	O
confessions	O
.	O

Interventional	O
study	O
to	O
strengthen	O
the	O
health	O
promoting	O
behaviours	O
of	O
pregnant	O
women	Sex
to	O
prevent	O
anaemia	O
in	O
southern	Condition
India	Condition
.	O

OBJECTIVES	O
to	O
determine	O
the	O
effectiveness	O
of	O
a	O
health	O
information	O
package	O
in	O
terms	O
of	O
empowering	O
the	O
pregnant	O
women	O
to	O
modify	O
their	O
health-care	O
behaviour	O
and	O
take	O
appropriate	O
action	O
to	O
combat	O
anaemia	O
in	O
pregnancy	O
.	O

DESIGN	O
the	O
study	O
was	O
conceptualized	O
based	O
on	O
Rosenstock	O
and	O
Becker	O
's	O
health	O
belief	O
model	O
.	O

A	O
quasi-experimental	O
pretest-posttest	O
control	O
group	O
design	O
was	O
used	O
.	O

The	O
sample	O
consists	O
of	O
225	O
anaemic	O
pregnant	O
women	O
randomly	O
allocated	O
in	O
experimental	O
(	O
n=75	O
)	O
,	O
control	O
group	O
A	O
(	O
n=75	O
)	O
and	O
control	O
group	O
B	O
(	O
n=75	O
)	O
.	O

The	O
health	O
seeking	O
behaviour	O
outcome	O
measure	O
included	O
knowledge	O
regarding	O
anaemia	O
,	O
food	O
selection	O
ability	O
,	O
increase	O
in	O
haemoglobin	O
level	O
and	O
compliance	O
to	O
iron	O
supplementation	O
.	O

Intervention	O
was	O
a	O
validated	O
planned	O
educational	O
programme	O
with	O
visual	O
aids	O
and	O
iron	O
supplementation	O
.	O

FINDINGS	O
the	O
results	O
show	O
the	O
mean	O
gain	O
of	O
knowledge	O
scores	O
of	O
experimental	O
group	O
was	O
comparatively	O
higher	O
and	O
control	O
groups	O
A	O
and	O
B	O
showed	O
that	O
F	O
ratio	O
was	O
(	O
F	O
(	O
2,190	O
)	O
=11.910	O
,	O
p	O
<	O
0.01	O
)	O
indicating	O
that	O
the	O
pregnant	O
women	O
learned	O
more	O
about	O
anaemia	O
prevention	O
than	O
others	O
.	O

With	O
regard	O
to	O
food	O
selection	O
ability	O
scores	O
of	O
experimental	O
,	O
control	O
groups	O
A	O
and	O
B	O
the	O
F	O
ratio	O
was	O
also	O
significant	O
(	O
F	O
(	O
2,190	O
)	O
=20.92	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Nearly	O
61.2	O
%	O
of	O
the	O
subjects	O
in	O
experimental	O
group	O
became	O
non-anaemic	O
after	O
the	O
intervention	O
when	O
compared	O
to	O
control	O
group	O
A	O
.	O

This	O
indicated	O
that	O
inspite	O
of	O
iron	O
supplementation	O
received	O
by	O
the	O
three	O
groups	O
health	O
education	O
contributed	O
significantly	O
in	O
modifying	O
their	O
health	O
seeking	O
behaviour	O
and	O
their	O
perception	O
about	O
significance	O
of	O
anaemia	O
has	O
a	O
problem	O
.	O

CONCLUSION	O
developing	O
countries	O
still	O
face	O
the	O
critical	O
problem	O
of	O
anaemia	O
in	O
pregnancy	O
.	O

These	O
are	O
the	O
socio-cultural	O
priority	O
problems	O
that	O
demand	O
immediate	O
attention	O
by	O
the	O
policy	O
makers	O
and	O
health	O
professionals	O
.	O

The	O
national	O
anaemia	O
control	O
programme	O
focuses	O
on	O
iron	O
supplementation	O
,	O
but	O
nutritional	O
education	O
and	O
supervision	O
of	O
iron	O
supplementation	O
has	O
failed	O
in	O
different	O
regions	O
.	O

The	O
study	O
implies	O
that	O
economic	O
empowerment	O
;	O
strengthening	O
health	O
literacy	O
through	O
planned	O
educational	O
programs	O
will	O
definitely	O
improve	O
the	O
health	O
behaviour	O
of	O
individual	O
and	O
community	O
at	O
large	O
.	O

Effects	O
of	O
dietary	O
pyridoxine	O
on	O
haemato-immunological	O
responses	O
of	O
Labeo	O
rohita	O
fingerlings	O
reared	O
at	O
higher	O
water	O
temperature	O
.	O

A	O
sixty-day	O
feeding	O
trial	O
was	O
carried	O
out	O
to	O
elucidate	O
the	O
effect	O
of	O
dietary	O
pyridoxine	O
(	O
PN	O
)	O
on	O
hemato-immunological	O
parameters	O
in	O
Labeo	O
rohita	O
fingerlings	O
exposed	O
to	O
an	O
elevated	O
temperature	O
(	O
ET	O
)	O
of	O
33	O
?C	O
.	O

Two	O
hundred	O
and	O
seventy	O
fingerlings	O
(	O
6.71	O
?	O
0.32	O
g	O
)	O
were	O
randomly	O
distributed	O
into	O
six	O
treatments	O
in	O
triplicates	O
(	O
15	O
fish/tank	O
)	O
.	O

Five	O
iso-nitrogenous	O
(	O
356.3	O
?	O
2.7	O
g/kg	O
crude	O
protein	O
)	O
purified	O
diets	O
were	O
prepared	O
with	O
graded	O
levels	O
(	O
0	O
,	O
10	O
,	O
50	O
,	O
100	O
and	O
200	O
mg/kg	O
diet	O
)	O
of	O
PN	O
.	O

Six	O
treatment	O
groups	O
were	O
P10T26	O
(	O
10	O
mg	O
PN	O
+	O
ambient	O
temperature	O
(	O
26	O
?C	O
)	O
,	O
P0T33	O
(	O
0	O
mg	O
PN	O
+	O
ET	O
)	O
,	O
P10T33	O
(	O
10	O
mg	O
PN	O
+	O
ET	O
)	O
,	O
P50T33	O
(	O
50	O
mg	O
PN	O
+	O
ET	O
)	O
,	O
P100T33	O
(	O
100	O
mg	O
PN	O
+	O
ET	O
)	O
and	O
P200T33	O
(	O
200	O
mg	O
PN	O
+	O
ET	O
)	O
.	O

The	O
responses	O
of	O
L.	O
rohita	O
fingerlings	O
to	O
dietary	O
PN	O
were	O
assessed	O
in	O
terms	O
of	O
growth	O
and	O
by	O
analysing	O
some	O
hemato-immunological	O
parameters	O
.	O

When	O
PN	O
supplementation	O
increased	O
from	O
10	O
to	O
200	O
mg/kg	O
diet	O
,	O
a	O
significant	O
improvement	O
in	O
weight	O
gain	O
percentage	O
was	O
observed	O
.	O

Erythrocyte	O
(	O
RBC	O
)	O
count	O
,	O
leucocyte	O
(	O
WBC	O
)	O
count	O
,	O
haemoglobin	O
content	O
and	O
respiratory	O
burst	O
activity	O
were	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
in	O
100	O
mg	O
PN/kg	O
diet-fed	O
group	O
than	O
their	O
non-PN-fed	O
counterpart	O
.	O

Also	O
,	O
serum	O
albumin	O
,	O
globulin	O
and	O
lysozyme	O
activity	O
were	O
found	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
in	O
PN-fed	O
groups	O
.	O

The	O
overall	O
results	O
indicated	O
that	O
dietary	O
PN	O
supplementation	O
at	O
100	O
mg/kg	O
diet	O
may	O
reverse	O
the	O
negative	O
effects	O
caused	O
by	O
ET	O
and	O
may	O
protect	O
the	O
haemato-immunological	O
status	O
of	O
L.	O
rohita	O
fingerlings	O
reared	O
at	O
higher	O
water	O
temperature	O
.	O

Bronchoscopic	O
findings	O
in	O
patients	O
with	O
a	O
complete	O
radiographic	Condition
regression	Condition
of	O
small	O
cell	O
bronchogenic	Condition
carcinoma	Condition
.	O

Fibre-optic	O
bronchoscopy	O
was	O
performed	O
in	O
21	SampleSize
patients	O
with	O
small	Condition
cell	Condition
bronchogenic	Condition
carcinoma	Condition
who	O
demonstrated	O
a	O
complete	O
radiographic	Condition
regression	Condition
of	O
their	O
chest	Condition
lesions	Condition
after	O
3-4	O
months	O
of	O
combination	O
chemotherapy	Condition
.	O

Fifteen	O
patients	O
showed	O
abnormalities	O
at	O
the	O
site	O
of	O
the	O
original	O
tumour	O
consisting	O
of	O
nodular	O
elevations	O
,	O
narrowing	O
of	O
bronchi	O
and/or	O
fibrous	O
strands	O
or	O
membranes	O
.	O

Microscopic	O
evidence	O
of	O
residual	O
cancer	O
was	O
obtained	O
in	O
3	O
cases	O
.	O

In	O
3	O
out	O
of	O
8	O
patients	O
who	O
underwent	O
a	O
further	O
bronchoscopy	O
after	O
18	O
months	O
of	O
treatment	O
,	O
disappearance	O
of	O
nodules	O
was	O
noted	O
at	O
the	O
later	O
examination	O
.	O

Persistent	O
bronchial	O
narrowing	O
was	O
observed	O
in	O
patients	O
who	O
became	O
disease-free	O
2-yr	O
survivors	O
.	O

It	O
is	O
concluded	O
that	O
tumour	O
regression	O
may	O
be	O
accompanied	O
by	O
scar	O
formation	O
,	O
which	O
complicate	O
the	O
interpretation	O
of	O
post-treatment	O
abnormalities	O
,	O
and	O
that	O
further	O
regression	O
of	O
intrabronchial	O
lesions	O
may	O
occur	O
beyond	O
3-4	O
months	O
.	O

Field	O
efficacy	O
of	O
an	O
inactivated	O
bivalent	O
influenza	O
vaccine	O
in	O
a	O
multi-site	O
swine	O
production	O
system	O
during	O
an	O
outbreak	O
of	O
systemic	O
porcine	O
circovirus	O
associated	O
disease	O
.	O

Swine	O
influenza	O
(	O
SI	O
)	O
is	O
a	O
disease	O
of	O
significance	O
for	O
the	O
swine	O
industry	O
,	O
and	O
vaccination	O
is	O
often	O
recommended	O
as	O
a	O
way	O
to	O
reduce	O
its	O
impact	O
on	O
production	O
.	O

The	O
efficacy	O
of	O
SI	O
vaccines	O
is	O
well	O
established	O
under	O
experimental	O
conditions	O
,	O
but	O
information	O
about	O
field	O
efficacy	O
is	O
scarce	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
commercial	O
inactivated	O
bivalent	O
(	O
H1N1/H3N2	O
)	O
vaccine	O
under	O
conditions	O
of	O
natural	O
exposure	O
to	O
a	O
field	O
SI	O
variant	O
.	O

To	O
accomplish	O
our	O
goal	O
we	O
used	O
a	O
randomized	O
,	O
blinded	O
,	O
field	O
trial	O
in	O
2	SampleSize
cohorts	SampleSize
of	O
finisher	Age
pigs	Age
in	O
a	O
multi-site	O
swine	O
production	O
system	O
located	O
in	O
southern	O
Ontario	O
.	O

During	O
the	O
trial	O
,	O
this	O
herd	O
experienced	O
an	O
outbreak	O
of	O
porcine	O
circovirus	O
associated	O
disease	O
(	O
PCVAD	O
)	O
.	O

The	O
efficacy	O
of	O
the	O
SI	O
vaccine	O
was	O
assessed	O
through	O
its	O
effect	O
on	O
average	O
daily	O
weight	O
gain	O
,	O
and	O
serological	O
responses	O
to	O
SI	O
over	O
time	O
.	O

The	O
effect	O
of	O
vaccination	O
on	O
pig	O
growth	O
was	O
different	O
in	O
the	O
2	O
cohorts	O
.	O

Weight	O
gain	O
was	O
higher	O
in	O
vaccinated	O
pigs	O
than	O
in	O
control	O
pigs	O
in	O
Cohort	O
1	O
,	O
but	O
was	O
numerically	O
higher	O
for	O
control	O
pigs	O
than	O
for	O
vaccinated	O
pigs	O
in	O
Cohort	O
2	O
.	O

Vaccination	O
against	O
swine	O
influenza	O
,	O
in	O
a	O
herd	O
experiencing	O
an	O
outbreak	O
of	O
PCVAD	O
,	O
was	O
of	O
questionable	O
value	O
.	O

Effects	O
of	O
ATP	O
infusion	O
on	O
glucose	O
turnover	O
and	O
gluconeogenesis	O
in	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
.	O

Cancer	O
cachexia	O
is	O
associated	O
with	O
elevated	O
lipolysis	O
,	O
proteolysis	O
and	O
gluconeogenesis	O
.	O

ATP	O
infusion	O
has	O
been	O
found	O
to	O
significantly	O
inhibit	O
loss	O
of	O
body	O
weight	O
,	O
fat	O
mass	O
and	O
fat-free	O
mass	O
in	O
patients	O
with	O
advanced	O
lung	O
cancer	O
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
exploring	O
the	O
effects	O
of	O
ATP	O
on	O
whole-body	O
glucose	O
turnover	O
,	O
alanine	O
turnover	O
and	O
gluconeogenesis	O
from	O
alanine	O
.	O

Twelve	SampleSize
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
were	O
studied	O
1	O
week	O
before	O
and	O
during	O
22-24	O
h	O
of	O
continuous	O
ATP	O
infusion	O
.	O

After	O
an	O
overnight	O
fast	O
,	O
turnover	O
rates	O
of	O
glucose	O
and	O
alanine	O
,	O
and	O
gluconeogenesis	O
from	O
alanine	O
,	O
were	O
determined	O
using	O
primed	O
constant	O
infusions	O
of	O
?6	O
,	O
6-	O
(	O
2	O
)	O
H	O
(	O
2	O
)	O
?lucose	O
and	O
?3-	O
(	O
13	O
)	O
C?lanine	O
.	O

Thirteen	O
NSCLC	O
patients	O
and	O
eleven	O
healthy	O
subjects	O
were	O
studied	O
as	O
control	O
groups	O
without	O
ATP	O
infusion	O
.	O

During	O
high-dose	O
ATP	O
infusion	O
(	O
75	O
microg.min	O
(	O
-1	O
)	O
.kg	O
(	O
-1	O
)	O
)	O
,	O
glucose	O
turnover	O
was	O
0.62+/-0.07	O
mmol.h	O
(	O
-1	O
)	O
.kg	O
(	O
-1	O
)	O
,	O
compared	O
with	O
0	O
.	O

44+/-0.13	O
mmol.h	O
(	O
-1	O
)	O
.kg	O
(	O
-1	O
)	O
at	O
baseline	O
(	O
P=0.04	O
)	O
.	O

For	O
gluconeogenesis	O
a	O
similar	O
,	O
but	O
non-significant	O
,	O
trend	O
was	O
observed	O
?baseline	O
,	O
0.30+/-0.16	O
mmol.h	O
(	O
-1	O
)	O
.kg	O
(	O
-1	O
)	O
;	O
during	O
ATP	O
,	O
0.37+/-0.13	O
mmol.h	O
(	O
-1	O
)	O
.kg	O
(	O
-1	O
)	O
(	O
P=0.08	O
)	O
.	O

At	O
lower	O
ATP	O
doses	O
(	O
37-50	O
microg	O
.	O

min	O
(	O
-1	O
)	O
.kg	O
(	O
-1	O
)	O
)	O
these	O
effects	O
were	O
not	O
detected	O
.	O

The	O
relative	O
increase	O
in	O
glucose	O
turnover	O
during	O
ATP	O
infusion	O
compared	O
with	O
baseline	O
showed	O
a	O
significant	O
correlation	O
with	O
the	O
ATP	O
dose	O
(	O
r=0.58	O
,	O
P=0.02	O
)	O
.	O

No	O
change	O
in	O
alanine	O
turnover	O
was	O
observed	O
at	O
any	O
ATP	O
dose	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
an	O
increase	O
in	O
glucose	O
turnover	O
during	O
high-dose	O
ATP	O
infusion	O
compared	O
with	O
baseline	O
levels	O
.	O

During	O
high-dose	O
ATP	O
infusion	O
,	O
glucose	O
turnover	O
was	O
similar	O
to	O
that	O
during	O
low-dose	O
ATP	O
infusion	O
and	O
to	O
that	O
in	O
control	O
NSCLC	O
patients	O
.	O

Between	O
ATP	O
infusions	O
,	O
however	O
,	O
glucose	O
turnover	O
in	O
patients	O
treated	O
with	O
high-dose	O
ATP	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
low-dose	O
and	O
control	O
NSCLC	O
patients	O
(	O
P=0.04	O
and	O
P=0.03	O
respectively	O
)	O
,	O
and	O
similar	O
to	O
that	O
in	O
healthy	O
subjects	O
.	O

This	O
would	O
suggest	O
that	O
repeated	O
high-dose	O
ATP	O
infusions	O
may	O
inhibit	O
glucose	O
turnover	O
between	O
infusion	O
periods	O
.	O

Design	O
,	O
implementation	O
and	O
results	O
of	O
the	O
quality	O
control	O
program	O
for	O
the	O
Australian	O
government	O
's	O
point	O
of	O
care	O
testing	O
in	O
general	O
practice	O
trial	O
.	O

BACKGROUND	O
From	O
2005	O
to	O
2007	O
the	O
Australian	O
Government	O
funded	O
a	O
multicentre	O
,	O
clustered	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
clinical	O
effectiveness	O
,	O
cost-effectiveness	O
,	O
satisfaction	O
and	O
safety	O
of	O
point	O
of	O
care	O
testing	O
(	O
PoCT	O
)	O
in	O
general	O
practice	O
(	O
GP	O
)	O
.	O

PoC	O
tests	O
measured	O
(	O
and	O
devices	O
used	O
)	O
in	O
the	O
trial	O
were	O
haemoglobin	O
A1c	O
and	O
urine	O
albumin	O
:	O
creatinine	O
ratio	O
(	O
DCA	O
2000	O
)	O
,	O
lipids	O
(	O
Cholestech	O
LDX	O
)	O
and	O
international	O
normalized	O
ratio	O
(	O
CoaguChek	O
S	O
)	O
.	O

METHODS	O
An	O
internal	O
quality	O
control	O
(	O
QC	O
)	O
program	O
was	O
developed	O
as	O
part	O
of	O
a	O
quality	O
management	O
framework	O
for	O
the	O
trial	O
.	O

PoCT	O
device	O
operators	O
were	O
provided	O
with	O
a	O
colour-coded	O
QC	O
Result	O
Sheet	O
and	O
QC	O
Action	O
Sheet	O
for	O
on-site	O
recording	O
and	O
interpreting	O
of	O
their	O
results	O
.	O

Within-practice	O
imprecision	O
for	O
QC	O
testing	O
was	O
calculated	O
and	O
compared	O
with	O
the	O
analytical	O
goals	O
for	O
imprecision	O
set	O
prior	O
to	O
the	O
trial	O
.	O

RESULTS	O
The	O
average	O
participation	O
rate	O
for	O
QC	O
testing	O
was	O
91	O
%	O
or	O
greater	O
.	O

Median	O
within-practice	O
imprecision	O
met	O
the	O
analytical	O
goals	O
for	O
all	O
PoC	O
tests	O
,	O
except	O
for	O
high-density	O
lipoprotein-cholesterol	O
(	O
HDL-C	O
)	O
where	O
observed	O
performance	O
was	O
outside	O
the	O
minimum	O
goal	O
for	O
one	O
level	O
and	O
one	O
lot	O
number	O
of	O
QC	O
.	O

Most	O
practices	O
achieved	O
the	O
imprecision	O
goals	O
for	O
all	O
analytes	O
,	O
with	O
the	O
principal	O
exception	O
of	O
HDL-C	O
.	O

CONCLUSIONS	O
Results	O
from	O
QC	O
testing	O
indicate	O
that	O
PoCT	O
in	O
the	O
GP	O
trial	O
met	O
the	O
analytical	O
goals	O
set	O
for	O
the	O
trial	O
,	O
with	O
the	O
exception	O
of	O
HDL-C	O
.	O

Effect	O
of	O
milrinone	O
on	O
short-term	O
outcome	O
of	O
patients	O
with	O
myocardial	Condition
dysfunction	Condition
undergoing	Condition
coronary	Condition
artery	Condition
bypass	Condition
graft	Condition
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Myocardial	O
dysfunction	O
needing	O
inotropic	O
support	O
is	O
a	O
typical	O
complication	O
after	O
on-pump	O
cardiac	O
surgery	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
effect	O
of	O
milrinone	O
on	O
patients	O
with	O
ventricular	Condition
dysfunction	Condition
undergoing	Condition
coronary	Condition
artery	Condition
bypass	Condition
graft	Condition
(	O
CABG	O
)	O
.	O

METHODS	O
Seventy	SampleSize
patients	O
with	O
impaired	Condition
left	Condition
ventricular	Condition
function	Condition
[	Condition
left	Condition
ventricular	Condition
ejection	Condition
fraction	Condition
(	Condition
LVEF	Condition
)	Condition
<	Condition
35	Condition
%	Condition
]	Condition
undergoing	Condition
on-pump	Condition
CABG	Condition
were	O
enrolled	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
an	O
intraoperative	O
bolus	O
of	O
milrinone	O
(	O
50	O
microg/kg	O
)	O
or	O
saline	O
as	O
placebo	O
followed	O
by	O
a	O
24-hour	O
infusion	O
of	O
each	O
agent	O
(	O
0.5	O
microg/kg/min	O
)	O
.	O

Hemodynamic	O
parameters	O
and	O
transthoracic	O
echocardiographic	O
measurement	O
of	O
systolic	O
and	O
diastolic	O
functions	O
were	O
the	O
variables	O
evaluated	O
.	O

RESULTS	O
Serum	O
levels	O
of	O
creatine	O
phosphokinase	O
(	O
CPK	O
)	O
,	O
the	O
MB	O
isoenzyme	O
of	O
creatine	O
kinase	O
(	O
CK-MB	O
)	O
,	O
occurrence	O
of	O
myocardial	O
ischemia	O
or	O
infarction	O
,	O
and	O
mean	O
duration	O
of	O
using	O
inotropic	O
agents	O
were	O
significantly	O
lower	O
in	O
the	O
milrinone	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
regarding	O
the	O
development	O
of	O
ventricular	O
arrhythmia	O
,	O
duration	O
of	O
cardiopulmonary	O
bypass	O
,	O
intra-aortic	O
balloon	O
pump	O
and	O
inotropic	O
support	O
requirement	O
,	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
duration	O
of	O
intensive	O
care	O
unit	O
stay	O
and	O
mortality	O
rate	O
.	O

Although	O
mean	O
pre-operative	O
LVEF	O
was	O
significantly	O
lower	O
in	O
the	O
milrinone	O
group	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
post-operative	O
LVEFs	O
.	O

CONCLUSIONS	O
We	O
suggest	O
that	O
perioperative	O
administration	O
of	O
milrinone	O
in	O
patients	O
undergoing	Condition
on-pump	Condition
CABG	Condition
,	O
especially	O
those	O
with	O
low	O
LVEF	O
,	O
is	O
beneficial	O
.	O

Direct	O
and	O
indirect	O
effects	O
of	O
interdental	O
hygiene	O
in	O
a	O
clinical	O
trial	O
.	O

Many	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
in	O
dental	O
research	O
test	O
the	O
efficacy	O
of	O
interventions	O
on	O
more	O
than	O
one	O
outcome	O
variable	O
.	O

Univariate	O
methods	O
,	O
such	O
as	O
the	O
t	O
test	O
or	O
analysis	O
of	O
covariance	O
,	O
can	O
not	O
evaluate	O
the	O
efficacy	O
of	O
interventions	O
on	O
multiple	O
outcomes	O
simultaneously	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
use	O
structural	O
equation	O
modeling	O
(	O
SEM	O
)	O
to	O
re-analyze	O
a	O
RCT	O
,	O
comparing	O
the	O
effects	O
of	O
pre-curved	O
interdental	O
brushes	O
and	O
flossing	O
on	O
probing	O
pocket	O
depth	O
(	O
PPD	O
)	O
,	O
plaque	O
indices	O
,	O
and	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
measured	O
at	O
baseline	O
,	O
intermediate	O
,	O
and	O
final	O
examinations	O
.	O

Results	O
of	O
SEM	O
showed	O
that	O
the	O
observed	O
greater	O
reduction	O
in	O
PPD	O
and	O
BOP	O
in	O
persons	Condition
using	Condition
interdental	Condition
brushing	Condition
than	Condition
in	Condition
those	Condition
flossing	Condition
is	O
due	O
mainly	O
to	O
the	O
greater	O
efficiency	O
in	O
plaque	O
removal	O
with	O
the	O
interdental	O
brushes	O
(	O
indirect	O
effect	O
)	O
rather	O
than	O
to	O
the	O
compression	O
of	O
the	O
interdental	O
papillae	O
(	O
direct	O
effect	O
)	O
.	O

In	O
contrast	O
,	O
smokers	Condition
showed	O
less	O
BOP	O
at	O
baseline	O
but	O
also	O
less	O
improvement	O
in	O
BOP	O
through	O
direct	O
effects	O
.	O

JobTIPS	O
:	O
a	O
transition	O
to	O
employment	O
program	O
for	O
individuals	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
evaluated	O
the	O
effectiveness	O
of	O
an	O
internet	O
accessed	O
training	O
program	O
that	O
included	O
Theory	O
of	O
Mind-based	O
guidance	O
,	O
video	O
models	O
,	O
visual	O
supports	O
,	O
and	O
virtual	O
reality	O
practice	O
sessions	O
in	O
teaching	O
appropriate	O
job	O
interview	O
skills	O
to	O
individuals	O
with	O
high	O
functioning	O
Autism	O
Spectrum	O
Disorders	O
.	O

In	O
a	O
randomized	O
study	O
,	O
twenty-two	O
youth	O
,	O
ages	O
16-19	O
,	O
were	O
evaluated	O
during	O
two	O
employment	O
interviews	O
.	O

Half	O
received	O
a	O
training	O
intervention	O
following	O
the	O
initial	O
interview	O
and	O
the	O
half	O
who	O
served	O
as	O
a	O
contrast	O
group	O
did	O
not	O
.	O

Their	O
performance	O
pre	O
and	O
post	O
intervention	O
was	O
assessed	O
by	O
four	O
independent	O
raters	O
using	O
a	O
scale	O
that	O
included	O
evaluation	O
of	O
both	O
Content	O
and	O
Delivery	O
.	O

Results	O
suggest	O
that	O
youth	O
who	O
completed	O
the	O
JobTIPS	O
employment	O
program	O
demonstrated	O
significantly	O
more	O
effective	O
verbal	O
content	O
skills	O
than	O
those	O
who	O
did	O
not	O
.	O

Insular	O
and	O
anterior	O
cingulate	O
circuits	O
in	O
smokers	O
with	O
schizophrenia	Condition
.	O

Schizophrenia	Condition
(	O
SZ	Condition
)	O
is	O
associated	O
with	O
high	O
rates	O
of	O
smoking	O
.	O

We	O
previously	O
found	O
that	O
resting	O
state	O
functional	O
connectivity	O
(	O
rsFC	O
)	O
between	O
the	O
dorsal	O
anterior	O
cingulate	O
(	O
dACC	O
)	O
and	O
striatum	O
is	O
independently	O
associated	O
with	O
nicotine	O
addiction	O
and	O
psychiatric	O
illness	O
.	O

Since	O
the	O
insula	O
is	O
implicated	O
in	O
nicotine	O
dependence	O
,	O
we	O
hypothesized	O
that	O
SZ	O
smokers	O
will	O
have	O
greater	O
dysfunction	O
in	O
smoking-related	O
insular	O
and	O
dACC	O
circuits	O
than	O
normal	Condition
control	Condition
smokers	Condition
(	O
NC	O
)	O
independent	O
of	O
smoking	O
severity	O
,	O
consistent	O
with	O
an	O
inherent	O
disease-related	O
weakening	O
of	O
smoking-related	O
circuits	O
.	O

Nicotine	O
challenge	O
was	O
used	O
to	O
demonstrate	O
that	O
decreased	O
rsFC	O
in	O
identified	O
circuits	O
reflects	O
addiction	O
trait	O
and	O
is	O
not	O
affected	O
by	O
pharmacological	O
state	O
.	O

Twenty-four	SampleSize
NC	Condition
smokers	O
and	O
20	SampleSize
smokers	O
with	O
SZ	Condition
matched	O
on	O
nicotine	O
addiction	O
severity	O
participated	O
in	O
a	O
resting	O
state	O
fMRI	O
study	O
and	O
were	O
scanned	O
during	O
two	O
separate	O
sessions	O
while	O
receiving	O
a	O
placebo	O
or	O
nicotine	O
patch	O
,	O
in	O
a	O
randomized	O
,	O
cross-over	O
design	O
.	O

Using	O
individualized	O
,	O
anatomically	O
defined	O
anterior	O
and	O
posterior	O
insula	O
and	O
dACC	O
as	O
regions	O
of	O
interest	O
(	O
ROI	O
)	O
,	O
whole	O
brain	O
rsFC	O
was	O
performed	O
using	O
each	O
ROI	O
as	O
a	O
seed	O
.	O

Significant	O
negative	O
correlations	O
between	O
smoking	O
severity	O
and	O
rsFC	O
between	O
insula	O
,	O
dACC	O
and	O
striatum	O
were	O
found	O
for	O
both	O
groups	O
.	O

Furthermore	O
,	O
smokers	O
with	O
SZ	Condition
demonstrated	O
additive	O
reductions	O
in	O
circuit	O
strength	O
between	O
the	O
dACC	O
and	O
insula	O
compared	O
to	O
NC	O
smokers	O
independent	O
of	O
smoking	O
severity	O
.	O

Nicotine	O
challenge	O
did	O
not	O
significantly	O
alter	O
rsFC	O
in	O
insula-dACC-striatal	O
circuits	O
.	O

Reduced	O
rsFC	O
strength	O
between	O
the	O
insula	O
,	O
dACC	O
and	O
striatum	O
is	O
associated	O
with	O
nicotine	O
addiction	O
severity	O
in	O
both	O
non-psychiatrically	O
ill	O
and	O
in	O
SZ	O
smokers	O
.	O

Decreased	O
insula-dACC	O
rsFC	O
may	O
index	O
overlapping	O
circuitry	O
associated	O
with	O
smoking	O
and	O
SZ	O
.	O

Prospective	O
,	O
randomized	O
trial	O
of	O
diclofenac	O
and	O
ketorolac	O
after	O
refractive	Condition
surgery	Condition
.	O

PURPOSE	O
To	O
compare	O
the	O
effectiveness	O
of	O
diclofenac	O
and	O
ketorolac	O
in	O
relieving	O
corneal	Condition
pain	Condition
after	O
refractive	O
surgery	O
,	O
and	O
determine	O
if	O
there	O
is	O
a	O
difference	O
in	O
stinging	O
on	O
instillation	O
.	O

METHODS	O
Thirty	SampleSize
patients	O
were	O
randomized	O
prospectively	O
to	O
postoperative	O
diclofenac	O
in	O
one	O
eye	O
and	O
ketorolac	O
in	O
the	O
other	O
.	O

Patients	O
and	O
surgeon	O
did	O
not	O
know	O
which	O
medications	O
were	O
used	O
.	O

Ocular	O
postoperative	O
pain	O
and	O
discomfort	O
on	O
instillation	O
of	O
medication	O
were	O
measured	O
after	O
radial	O
keratotomy	O
with	O
a	O
visual	O
analog	O
scale	O
and	O
a	O
questionnaire	O
.	O

RESULTS	O
Both	O
medications	O
were	O
highly	O
effective	O
in	O
relieving	O
pain	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
pain	O
relief	O
,	O
or	O
stinging	O
on	O
instillation	O
(	O
P	O
=	O
.29	O
)	O
.	O

CONCLUSION	O
There	O
was	O
no	O
statistical	O
difference	O
in	O
the	O
effectiveness	O
of	O
the	O
medications	O
on	O
pain	O
relief	O
,	O
or	O
in	O
stinging	O
on	O
instillation	O
.	O

Changes	O
in	O
selected	O
fitness	O
parameters	O
following	O
six	O
weeks	O
of	O
snowshoe	O
training	O
.	O

BACKGROUND	O
Recently	O
,	O
there	O
has	O
been	O
an	O
increase	O
in	O
popularity	O
and	O
participation	O
in	O
the	O
sport	O
of	O
snowshoeing	O
.	O

While	O
the	O
sport	O
has	O
gained	O
considerable	O
recognition	O
,	O
to	O
date	O
there	O
is	O
little	O
or	O
no	O
scientific	O
research	O
regarding	O
training	O
responses	O
to	O
snowshoeing	O
as	O
a	O
form	O
of	O
exercise	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
snowshoe	O
training	O
could	O
improve	O
fitness	O
measures	O
.	O

A	O
further	O
purpose	O
was	O
to	O
compare	O
responses	O
from	O
a	O
snowshoe	O
training	O
program	O
to	O
a	O
similarly	O
designed	O
run	O
training	O
program	O
.	O

METHODS	O
This	O
prospective	O
,	O
comparative	O
study	O
was	O
conducted	O
with	O
healthy	Condition
males	Sex
and	O
females	Sex
between	O
the	O
ages	O
of	O
19	Age
and	Age
24	Age
.	O

These	O
subjects	O
were	O
recruited	O
from	O
the	O
University	O
of	O
Vermont	O
population	O
and	O
surrounding	O
community	O
.	O

Following	O
baseline	O
measurements	O
in	O
VO2max	O
,	O
running	O
time	O
to	O
exhaustion	O
(	O
RTE	O
)	O
,	O
and	O
anthropometry	O
,	O
17	SampleSize
subjects	O
(	O
10	O
snowshoers	O
and	O
7	O
runners	O
)	O
participated	O
in	O
a	O
six	O
week	O
conditioning	O
program	O
.	O

Both	O
groups	O
exercised	O
for	O
30	O
min	O
at	O
75-85	O
%	O
age	O
predicted	O
maximum	O
heart	O
rate	O
,	O
3-4	O
times	O
per	O
week	O
,	O
for	O
a	O
total	O
of	O
18	O
sessions	O
.	O

RESULTS	O
VO2max	O
improved	O
significantly	O
in	O
both	O
running	O
and	O
snowshoeing	O
groups	O
,	O
6.3	O
and	O
8.5	O
%	O
,	O
respectively	O
.	O

Run	O
time	O
to	O
exhaustion	O
also	O
improved	O
significantly	O
in	O
both	O
groups	O
,	O
23.3	O
and	O
33.5	O
%	O
,	O
respectively	O
.	O

There	O
were	O
no	O
changes	O
in	O
anthropometry	O
for	O
either	O
group	O
.	O

With	O
the	O
exception	O
of	O
RTE	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
groups	O
in	O
any	O
other	O
measurements	O
at	O
baseline	O
.	O

CONCLUSIONS	O
These	O
results	O
support	O
the	O
acceptability	O
of	O
snowshoeing	O
as	O
a	O
valid	O
means	O
to	O
improve	O
or	O
maintain	O
cardiovascular	O
endurance	O
.	O

Postoperative	O
dreaming	O
.	O

A	O
comparison	O
of	O
the	O
incidence	O
following	O
pentazocine	O
and	O
morphine	O
premedication	O
.	O

The	O
incidence	O
of	O
postoperative	O
dreaming	O
following	O
the	O
use	O
of	O
morphine	O
and	O
pentazocine	O
as	O
premedicants	O
in	O
an	O
otherwise	O
standard	O
anaesthetic	O
sequence	O
is	O
compared	O
in	O
healthy	Condition
volunteers	Condition
.	Condition

No	O
statistically	O
significant	O
difference	O
was	O
demonstrated	O
between	O
the	O
two	O
drugs	O
.	O

The	O
causes	O
of	O
psychotomimetic	O
problems	O
in	O
the	O
postoperative	O
period	O
and	O
the	O
difficulty	O
of	O
precise	O
definition	O
of	O
hallucinations	O
are	O
discussed	O
.	O

Comparison	O
of	O
ketoconazole	O
and	O
griseofulvin	O
in	O
the	O
treatment	O
of	O
tinea	Condition
pedis	Condition
.	O

Twenty-nine	SampleSize
patients	O
with	O
mycologically	O
proven	O
tinea	Condition
pedis	Condition
were	O
randomly	O
allocated	O
to	O
oral	O
treatment	O
with	O
either	O
ketoconazole	O
200	O
mg	O
daily	O
or	O
griseofulvin	O
1	O
g	O
daily	O
for	O
a	O
period	O
of	O
up	O
to	O
8	O
weeks	O
.	O

Mycological	O
cure	O
rate	O
at	O
4	O
weeks	O
was	O
33	O
%	O
for	O
ketoconazole	O
and	O
29	O
%	O
for	O
griseofulvin	O
,	O
and	O
at	O
8	O
weeks	O
was	O
53	O
%	O
and	O
57	O
%	O
respectively	O
.	O

The	O
efficacy	O
of	O
both	O
drugs	O
in	O
the	O
treatment	O
of	O
interdigital	O
tinea	O
pedis	O
is	O
similar	O
,	O
and	O
is	O
considerably	O
lower	O
than	O
that	O
found	O
with	O
topical	O
imidazole	O
preparations	O
where	O
cure	O
rates	O
of	O
over	O
70	O
%	O
are	O
generally	O
expected	O
.	O

Enoxaparin	O
in	O
the	O
prevention	O
of	O
deep	O
venous	O
thrombosis	O
after	O
major	O
surgery	O
:	O
multicentric	O
study	O
.	O

The	O
Italian	O
Study	O
Group	O
.	O

DVT	O
is	O
a	O
very	O
frequent	O
complication	O
of	O
general	O
surgery	O
.	O

Heparin	O
and	O
,	O
more	O
recently	O
,	O
LMWHs	O
can	O
successfully	O
prevent	O
post	O
surgical	O
thromboembolism	O
.	O

One	SampleSize
thousand	SampleSize
one	SampleSize
hundred	SampleSize
and	SampleSize
twenty-two	SampleSize
patients	SampleSize
(	O
533	SampleSize
males	O
and	O
589	SampleSize
females	O
;	O
mean	Age
age	Age
62.2	Age
+/-	Age
11.4	Age
yrs	Age
)	O
were	O
enrolled	O
in	O
a	O
multicentre	O
controlled	O
study	O
,	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
enoxaparin	O
in	O
comparison	O
to	O
calcium	O
heparin	O
in	O
the	O
prevention	O
of	O
deep	O
venous	O
thrombosis	O
(	O
DVT	O
)	O
following	O
general	O
surgery	O
.	O

Patients	O
assigned	O
to	O
the	O
enoxaparin	O
and	O
the	O
calcium	O
heparin	O
groups	O
received	O
1	O
daily	O
dose	O
of	O
20	O
mg	O
(	O
2000	O
I.U	O
.	O

)	O
and	O
2	O
daily	O
doses	O
of	O
0.2	O
ml	O
(	O
5000	O
I.U	O
.	O

)	O
,	O
respectively	O
starting	O
2	O
hours	O
before	O
the	O
operation	O
.	O

Both	O
drugs	O
were	O
given	O
by	O
subcutaneous	O
route	O
.	O

A	O
Doppler	O
or	O
Duplex	O
Scan	O
diagnosis	O
of	O
DVT	O
was	O
made	O
in	O
3	O
(	O
0.5	O
%	O
)	O
patients	O
in	O
the	O
enoxaparin	O
group	O
(	O
2	O
cases	O
during	O
treatment	O
and	O
1	O
patient	O
at	O
the	O
end	O
of	O
treatment	O
)	O
and	O
in	O
6	O
(	O
1.1	O
%	O
)	O
patients	O
in	O
the	O
calcium	O
heparin	O
group	O
(	O
5	O
cases	O
during	O
treatment	O
and	O
1	O
,	O
bilateral	O
,	O
after	O
the	O
end	O
of	O
treatment	O
)	O
.	O

Pulmonary	O
embolism	O
(	O
PE	O
)	O
was	O
ascertained	O
by	O
angiography	O
in	O
1	O
patient	O
(	O
0.18	O
%	O
)	O
in	O
the	O
enoxaparin	O
group	O
and	O
in	O
2	O
patients	O
(	O
0.36	O
%	O
)	O
in	O
the	O
calcium	O
heparin	O
one	O
.	O

Hemorrhagic	O
complications	O
occurred	O
in	O
29	O
patients	O
(	O
5.2	O
%	O
)	O
in	O
the	O
enoxaparin	O
group	O
and	O
in	O
34	O
(	O
6.1	O
%	O
)	O
in	O
the	O
calcium	O
heparin	O
group	O
.	O

Haematomas	O
located	O
in	O
the	O
injection	O
site	O
were	O
reported	O
in	O
16.1	O
%	O
and	O
25.3	O
%	O
in	O
the	O
enoxaparin	O
and	O
calcium	O
heparin	O
groups	O
respectively	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

Local	O
pain	O
in	O
the	O
injection	O
site	O
at	O
the	O
5th	O
day	O
of	O
treatment	O
was	O
reported	O
in	O
8.4	O
%	O
and	O
16.6	O
%	O
in	O
the	O
enoxaparin	O
and	O
calcium	O
heparin	O
groups	O
respectively	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Analgesic	O
efficacy	O
of	O
low-dose	O
diclofenac	O
versus	O
paracetamol	O
and	O
placebo	O
in	O
postoperative	Condition
dental	Condition
pain	Condition
.	O

AIMS	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
diclofenac-K	O
(	O
12.5	O
mg	O
)	O
vs	O
paracetamol	O
(	O
500	O
mg	O
)	O
and	O
placebo	O
given	O
in	O
a	O
flexible	O
dosage	O
regimen	O
to	O
treat	O
pain	Condition
resulting	O
from	O
extraction	O
of	O
impacted	O
third	O
molar	O
teeth	O
.	O

METHODS	O
This	O
was	O
a	O
2-day	O
,	O
double-blind	O
,	O
double-dummy	O
,	O
randomized	O
,	O
parallel-group	O
,	O
placebo-controlled	O
study	O
of	O
diclofenac-K	O
(	O
12.5	O
mg	O
)	O
tablets	O
vs	O
paracetamol	O
(	O
500	O
mg	O
)	O
tablets	O
and	O
placebo	O
in	O
patients	O
with	O
moderate	Condition
or	Condition
severe	Condition
pain	Condition
within	O
8	O
hours	O
of	O
extraction	O
of	O
impacted	O
third	O
molars	O
.	O

RESULTS	O
After	O
the	O
first	O
2-tablet	O
dose	O
,	O
patients	O
took	O
on	O
average	O
2.5	O
additional	O
tablets	O
of	O
diclofenac-K	O
or	O
2.4	O
tablets	O
of	O
paracetamol	O
,	O
almost	O
all	O
as	O
1-tablet	O
doses	O
.	O

Most	O
placebo	O
patients	O
discontinued	O
by	O
taking	O
rescue	O
medication	O
(	O
ibuprofen	O
200	O
mg	O
)	O
on	O
the	O
first	O
day	O
.	O

Pain	O
relief	O
after	O
the	O
initial	O
dose	O
of	O
diclofenac-K	O
(	O
2	O
x	O
12.5	O
mg	O
)	O
was	O
superior	O
to	O
placebo	O
(	O
P	O
<	O
.01	O
for	O
all	O
efficacy	O
outcomes	O
)	O
and	O
comparable	O
to	O
paracetamol	O
(	O
2	O
x	O
500	O
mg	O
)	O
.	O

About	O
30	O
%	O
of	O
patients	O
in	O
each	O
active	O
treatment	O
group	O
took	O
rescue	O
medication	O
during	O
the	O
study	O
,	O
compared	O
to	O
78	O
%	O
on	O
placebo	O
.	O

About	O
70	O
%	O
in	O
each	O
active	O
treatment	O
group	O
considered	O
the	O
overall	O
pain	O
relief	O
to	O
be	O
some	O
,	O
a	O
lot	O
,	O
or	O
complete	O
compared	O
to	O
only	O
15	O
%	O
on	O
placebo	O
.	O

The	O
incidence	O
of	O
adverse	O
events	O
in	O
each	O
active	O
treatment	O
group	O
was	O
low	O
and	O
comparable	O
between	O
the	O
treatments	O
.	O

CONCLUSION	O
An	O
initial	O
double-dose	O
of	O
diclofenac-K	O
(	O
2	O
x	O
12.5	O
mg	O
)	O
or	O
paracetamol	O
(	O
2	O
x	O
500	O
mg	O
)	O
adequately	O
relieved	O
the	O
most	O
intense	O
postoperative	O
pain	O
,	O
and	O
the	O
flexible	O
multiple	O
dose	O
regimen	O
(	O
1	O
or	O
2	O
tablets	O
)	O
maintained	O
adequate	O
pain	O
relief	O
thereafter	O
.	O

Most	O
patients	O
needed	O
only	O
1-tablet	O
doses	O
following	O
the	O
initial	O
2-tablet	O
dose	O
.	O

Efficacy	O
and	O
safety	O
of	O
timolol/pilocarpine	O
combination	O
drops	O
in	O
glaucoma	O
patients	O
.	O

The	O
aim	O
of	O
this	O
randomized	O
,	O
double-blind	O
study	O
with	O
two	O
parallel	O
groups	O
was	O
to	O
examine	O
the	O
safety	O
,	O
efficacy	O
and	O
tolerability	O
of	O
two	O
combination	O
eye	O
drops	O
containing	O
0.5	O
%	O
timolol	O
and	O
2	O
%	O
pilocarpine	O
(	O
Fotil	O
,	O
Leiras	O
,	O
Finland	O
,	O
and	O
Timpilo	O
,	O
MSD	O
,	O
USA	O
)	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension	O
.	O

Efficacy	O
was	O
determined	O
based	O
on	O
daytime	O
intraocular	O
pressure	O
curve	O
and	O
safety	O
by	O
examining	O
visual	O
fields	O
,	O
visual	O
acuity	O
,	O
optic	O
discs	O
,	O
by	O
determining	O
blood	O
pressure	O
and	O
pulse	O
rate	O
,	O
and	O
by	O
performing	O
Schirmer	O
and	O
fluorescein	O
tests	O
.	O

A	O
total	O
of	O
89	O
patients	O
were	O
enrolled	O
,	O
and	O
71	O
completed	O
the	O
10-week	O
treatment	O
period	O
.	O

This	O
study	O
showed	O
that	O
the	O
two	O
combinations	O
of	O
0.5	O
%	O
timolol	O
maleate	O
and	O
2	O
%	O
pilocarpine	O
HCl	O
compared	O
in	O
this	O
study	O
were	O
equally	O
effective	O
in	O
reducing	O
intraocular	O
pressure	O
.	O

The	O
decrease	O
in	O
mean	O
daily	O
intraocular	O
pressure	O
from	O
0	O
to	O
10	O
weeks	O
was	O
7.48	O
mmHg	O
for	O
Fotil	O
,	O
and	O
6.31	O
for	O
Timpilo	O
.	O

The	O
mean	O
decrease	O
in	O
mean	O
daily	O
intraocular	O
pressure	O
was	O
29.3	O
%	O
for	O
Fotil	O
,	O
and	O
26.0	O
%	O
for	O
Timpilo	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
groups	O
.	O

Adverse	O
event	O
were	O
reported	O
by	O
70	O
out	O
of	O
89	O
patients	O
by	O
the	O
end	O
of	O
2	O
weeks	O
,	O
but	O
were	O
severe	O
enough	O
only	O
in	O
11	O
for	O
the	O
treatment	O
to	O
be	O
discontinued	O
.	O

In	O
all	O
others	O
,	O
adverse	O
events	O
were	O
of	O
transient	O
nature	O
and	O
considered	O
mild	O
.	O

In	O
general	O
,	O
adverse	O
events	O
were	O
similar	O
in	O
both	O
study	O
groups	O
.	O

However	O
,	O
burning	O
was	O
more	O
common	O
in	O
patients	O
on	O
Fotil	O
,	O
and	O
blurring	O
of	O
vision	O
and	O
light	O
sensitivity	O
were	O
more	O
common	O
in	O
patients	O
on	O
Timpilo	O
.	O

In	O
patients	O
with	O
no	O
contraindication	O
to	O
beta-blockers	O
,	O
these	O
drugs	O
appeared	O
to	O
be	O
safe	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Double-blind	O
efficacy	O
study	O
of	O
selenium	O
sulfide	O
in	O
tinea	O
versicolor	O
.	O

Selenium	O
sulfide	O
(	O
2.5	O
%	O
)	O
lotion	O
applied	O
daily	O
for	O
10	O
minutes	O
for	O
7	O
consecutive	O
days	O
was	O
found	O
to	O
be	O
an	O
effective	O
therapeutic	O
agent	O
,	O
significantly	O
superior	O
to	O
the	O
vehicle	O
,	O
in	O
a	O
double-blind	O
study	O
in	O
the	O
treatment	O
of	O
tinea	Condition
versicolor	Condition
.	Condition

Mild	O
transitory	O
contact	O
dermatitis	O
of	O
the	O
primary	O
irritant	O
type	O
occurred	O
in	O
all	O
the	O
treatment	O
groups	O
and	O
was	O
apparently	O
due	O
to	O
the	O
detergent	O
base	O
.	O

Comparison	O
of	O
neodymium-doped	O
yttrium	O
aluminum	O
garnet	O
laser	O
treatment	O
with	O
cold	O
knife	O
endoscopic	O
incision	O
of	O
urethral	O
strictures	O
in	O
male	O
patients	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	O
of	O
visual	O
laser	O
ablation	O
treatment	O
with	O
neodymium-doped	O
yttrium	O
aluminum	O
garnet	O
(	O
Nd	O
:	O
YAG	O
)	O
laser	O
in	O
male	O
patients	O
with	O
urethral	O
strictures	O
and	O
to	O
compare	O
the	O
effects	O
with	O
those	O
obtained	O
in	O
patients	O
treated	O
with	O
Sachse	O
's	O
optical	O
urethrotomy	O
.	O

MATERIALS	O
AND	O
METHODS	O
Fifty	O
patients	O
aged	O
22	O
to	O
83	O
(	O
mean	O
age	O
61.8	O
)	O
with	O
primary	O
(	O
n	O
=	O
26	O
,	O
52	O
%	O
)	O
and	O
recurrent	O
(	O
n	O
=	O
24	O
,	O
48	O
%	O
)	O
urethral	O
strictures	O
0.3	O
to	O
2.4	O
cm	O
long	O
qualified	O
for	O
the	O
study	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
30	O
men	O
treated	O
using	O
visual	O
laser	O
ablation	O
of	O
urethral	O
strictures	O
(	O
VLASU	O
)	O
with	O
Nd	O
:	O
YAGlaser	O
and	O
20	O
men	O
treated	O
by	O
correction	O
of	O
urethral	O
strictures	O
using	O
Sachse	O
's	O
optical	O
urethrotomy	O
.	O

RESULTS	O
At	O
12-month	O
follow-up	O
,	O
seven	O
(	O
35	O
%	O
)	O
patients	O
who	O
underwent	O
optical	O
urethrotomy	O
and	O
21	O
(	O
70	O
%	O
)	O
in	O
the	O
VLASU	O
group	O
did	O
not	O
require	O
repetition	O
of	O
the	O
procedure	O
.	O

The	O
choice	O
of	O
VLASU	O
as	O
a	O
method	O
of	O
treatment	O
significantly	O
decreased	O
the	O
probability	O
of	O
therapeutic	O
failure	O
and	O
recurrence	O
of	O
urethral	O
strictures	O
(	O
p	O
=	O
0.02	O
)	O
.	O

CONCLUSION	O
VLASU	O
can	O
be	O
used	O
as	O
a	O
method	O
of	O
treatment	O
of	O
this	O
disorder	O
.	O

It	O
is	O
an	O
effective	O
,	O
modern	O
,	O
low-invasive	O
,	O
and	O
repeatable	O
technique	O
and	O
is	O
technically	O
simple	O
and	O
easy	O
to	O
master	O
.	O

It	O
can	O
be	O
used	O
in	O
cases	O
in	O
which	O
introduction	O
of	O
a	O
22	O
Char	O
optical	O
urethrotome	O
into	O
the	O
stricture	O
site	O
is	O
impossible	O
,	O
as	O
well	O
as	O
for	O
treatment	O
of	O
multiple	O
strictures	O
during	O
one	O
procedure	O
.	O

[	O
Clinical	O
study	O
on	O
dan	O
shao	O
tang	O
in	O
treating	O
IgA	O
nephropathy	O
of	O
deficiency	O
of	O
yin	O
with	O
damp-heat	O
symptom	O
]	O
.	O

OBJECTIVE	O
To	O
explore	O
the	O
effect	O
of	O
Dan	O
Shao	O
Tang	O
(	O
DST	O
)	O
in	O
treating	O
IgA	O
nephropathy	O
(	O
IgAN	O
)	O
of	O
deficiency	O
of	O
Yin	O
with	O
damp-heat	O
symptom	O
.	O

METHODS	O
90	SampleSize
patients	O
with	O
IgAN	Condition
of	Condition
deficiency	Condition
of	Condition
Yin	Condition
with	O
damp-heat	Condition
symptom	Condition
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

50	O
patients	O
in	O
treatment	O
group	O
were	O
treated	O
with	O
DST	O
and	O
western	O
medicine	O
and	O
40	O
patients	O
in	O
control	O
group	O
were	O
treated	O
only	O
with	O
western	O
medicine	O
.	O

The	O
effects	O
and	O
changes	O
of	O
the	O
indexes	O
including	O
renal	O
function	O
,	O
hematuria	O
,	O
proteinuria	O
,	O
blood	O
IgA	O
before	O
and	O
after	O
treatment	O
were	O
observed	O
.	O

RESULTS	O
After	O
six	O
months	O
treatment	O
,	O
the	O
general	O
effective	O
rate	O
in	O
treatment	O
group	O
was	O
70.00	O
%	O
,	O
which	O
was	O
markedly	O
higher	O
than	O
that	O
in	O
control	O
group	O
(	O
37.50	O
%	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Treatment	O
group	O
is	O
obviously	O
better	O
than	O
control	O
group	O
on	O
decreasing	O
hematuria	O
,	O
proteinuria	O
,	O
blood	O
IgA	O
and	O
improving	O
renal	O
function	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
DST	O
is	O
effective	O
on	O
IgAN	O
of	O
deficiency	O
of	O
Yin	O
with	O
damp-heat	O
symptom	O
.	O

Acustimulation	O
wrist	O
bands	O
are	O
not	O
effective	O
for	O
the	O
control	O
of	O
chemotherapy-induced	O
nausea	O
in	O
women	Sex
with	O
breast	Condition
cancer	Condition
.	O

This	O
experiment	O
examined	O
the	O
efficacy	O
of	O
an	O
acustimulation	O
wrist	O
band	O
for	O
the	O
relief	O
of	O
chemotherapy-induced	O
nausea	O
using	O
a	O
randomized	O
three-arm	O
clinical	O
trial	O
(	O
active	O
acustimulation	O
,	O
sham	O
acustimulation	O
,	O
and	O
no	O
acustimulation	O
)	O
in	O
96	SampleSize
women	Sex
with	O
breast	Condition
cancer	Condition
who	O
experienced	O
nausea	Condition
at	Condition
their	Condition
first	Condition
chemotherapy	Condition
treatment	Condition
.	O

Five	O
outcomes	O
related	O
to	O
wrist	O
band	O
efficacy	O
(	O
acute	O
nausea	O
,	O
delayed	O
nausea	O
,	O
vomiting	O
,	O
QOL	O
,	O
and	O
total	O
amount	O
of	O
antiemetic	O
medication	O
used	O
)	O
were	O
examined	O
.	O

The	O
five	O
outcomes	O
were	O
examined	O
separately	O
using	O
analysis	O
of	O
covariance	O
controlling	O
for	O
age	O
and	O
severity	O
of	O
past	O
nausea	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
any	O
of	O
these	O
study	O
measures	O
among	O
the	O
three	O
treatment	O
conditions	O
(	O
P	O
>	O
0.1	O
for	O
all	O
)	O
.	O

Study	O
results	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
acustimulation	O
bands	O
are	O
efficacious	O
as	O
an	O
adjunct	O
to	O
pharmacological	O
antiemetics	O
for	O
control	O
of	O
chemotherapy-related	O
nausea	O
in	O
female	Sex
breast	Condition
cancer	Condition
patients	O
.	O

Rituximab	O
plus	O
concurrent	O
infusional	O
EPOCH	O
chemotherapy	O
is	O
highly	O
effective	O
in	O
HIV-associated	O
B-cell	Condition
non-Hodgkin	Condition
lymphoma	Condition
.	O

Rituximab	O
plus	O
intravenous	O
bolus	O
chemotherapy	O
is	O
a	O
standard	O
treatment	O
for	O
immunocompetent	O
patients	O
with	O
B-cell	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	Condition
)	O
.	O

Some	O
studies	O
have	O
suggested	O
that	O
rituximab	O
is	O
associated	O
with	O
excessive	O
toxicity	O
in	O
HIV-associated	O
NHL	O
,	O
and	O
that	O
infusional	O
chemotherapy	O
may	O
be	O
more	O
effective	O
.	O

We	O
performed	O
a	O
randomized	O
phase	O
2	O
trial	O
of	O
rituximab	O
(	O
375	O
mg/m	O
(	O
2	O
)	O
)	O
given	O
either	O
concurrently	O
before	O
each	O
infusional	O
etoposide	O
,	O
vincristine	O
,	O
doxorubicin	O
,	O
cyclophosphamide	O
,	O
and	O
prednisone	O
(	O
EPOCH	O
)	O
chemotherapy	O
cycle	O
or	O
sequentially	O
(	O
weekly	O
for	O
6	O
weeks	O
)	O
after	O
completion	O
of	O
all	O
chemotherapy	O
in	O
HIV-associated	Condition
NHL	Condition
.	O

EPOCH	O
consisted	O
of	O
a	O
96-hour	O
intravenous	O
infusion	O
of	O
etoposide	O
,	O
doxorubicin	O
,	O
and	O
vincristine	O
plus	O
oral	O
prednisone	O
followed	O
by	O
intravenous	O
bolus	O
cyclophosphamide	O
given	O
every	O
21	O
days	O
for	O
4	O
to	O
6	O
cycles	O
.	O

In	O
the	O
concurrent	O
arm	O
,	O
35	O
of	O
48	SampleSize
evaluable	O
patients	O
(	O
73	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
58	O
%	O
-85	O
%	O
)	O
had	O
a	O
complete	O
response	O
.	O

In	O
the	O
sequential	O
arm	O
,	O
29	O
of	O
53	SampleSize
evaluable	O
patients	O
(	O
55	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
41	O
%	O
-68	O
%	O
)	O
had	O
a	O
complete	O
response	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
met	O
for	O
the	O
concurrent	O
arm	O
only	O
.	O

Toxicity	O
was	O
comparable	O
in	O
the	O
2	O
arms	O
,	O
although	O
patients	O
with	O
a	O
baseline	O
CD4	O
count	O
less	O
than	O
50/microL	O
had	O
a	O
high	O
infectious	O
death	O
rate	O
in	O
the	O
concurrent	O
arm	O
.	O

We	O
conclude	O
that	O
concurrent	O
rituximab	O
plus	O
infusional	O
EPOCH	O
is	O
an	O
effective	O
regimen	O
for	O
HIV-associated	Condition
lymphoma	Condition
.	O

Osteocalcin	O
in	O
patients	O
with	O
rheumatoid	Condition
arthritis	Condition
.	O

A	O
one-year	O
followup	O
study	O
.	O

OBJECTIVE	O
To	O
analyze	O
clinical	O
,	O
radiological	O
,	O
and	O
drug	O
(	O
disease	O
modifying	O
antirheumatic	O
drug	O
,	O
DMARD	O
)	O
dependent	O
factors	O
influencing	O
bone	O
turnover	O
in	O
patients	O
with	O
rheumatoid	Condition
arthritis	Condition
(	Condition
RA	Condition
)	Condition
.	O

METHODS	O
We	O
investigated	O
in	O
a	O
one-year	O
double	O
blind	O
randomized	O
study	O
comparing	O
intramuscular	O
(	O
im	O
)	O
gold	O
with	O
im	O
methotrexate	O
(	O
MTX	O
)	O
,	O
whether	O
the	O
variation	O
of	O
inflammatory	O
activity	O
or	O
functional	O
capacity	O
,	O
the	O
ascending	O
anatomic	O
stage	O
,	O
or	O
DMARD	O
treatments	O
have	O
an	O
influence	O
on	O
bone	O
formation	O
(	O
osteocalcin	O
)	O
in	O
patients	O
with	O
RA	O
.	O

RESULTS	O
Patients	O
(	O
n	O
=	O
48	SampleSize
)	O
enrolled	O
at	O
the	O
beginning	O
of	O
our	O
study	O
had	O
significantly	O
increased	O
osteocalcin	O
levels	O
(	O
3.45	O
+/-	O
0.93	O
--	O
>	O
4.42	O
+/-	O
1.39	O
ng/ml	O
p	O
<	O
0.02	O
)	O
after	O
one	O
year	O
if	O
inflammatory	O
activity	O
decreased	O
(	O
>	O
or	O
=	O
1	O
SD	O
:	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
26.4	O
mm/h	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
3.8	O
mg/dl	O
)	O
.	O

We	O
found	O
a	O
significant	O
negative	O
correlation	O
of	O
the	O
one-year	O
CRP-	O
(	O
r	O
=	O
-0.44	O
,	O
p	O
<	O
0.001	O
)	O
or	O
ESR	O
differences	O
(	O
r	O
=	O
-0.45	O
,	O
p	O
<	O
0.001	O
)	O
with	O
the	O
corresponding	O
osteocalcin	O
differences	O
.	O

This	O
was	O
also	O
evident	O
if	O
these	O
patients	O
were	O
pooled	O
with	O
15	O
patients	O
excluded	O
from	O
the	O
double	O
blind	O
study	O
as	O
already	O
receiving	O
DMARD	O
treatment	O
(	O
n	O
=	O
63	O
;	O
p	O
<	O
0.01	O
)	O
.	O

Patients	O
with	O
impaired	O
functional	O
capacity	O
also	O
had	O
significantly	O
reduced	O
osteocalcin	O
levels	O
(	O
p	O
<	O
0.01	O
)	O
.	O

In	O
both	O
cases	O
,	O
alkaline	O
phosphatase	O
showed	O
no	O
significant	O
differences	O
.	O

CONCLUSIONS	O
Our	O
data	O
suggest	O
that	O
osteocalcin	O
,	O
a	O
useful	O
followup	O
variable	O
of	O
bone	O
turnover	O
,	O
is	O
changed	O
significantly	O
(	O
p	O
<	O
0.02	O
)	O
in	O
patients	O
with	O
RA	Condition
regarding	O
inflammatory	O
activity	O
and	O
functional	O
capacity	O
.	O

In	O
contrast	O
to	O
alkaline	O
phosphatase	O
,	O
a	O
fall	O
in	O
inflammatory	O
activity	O
stimulated	O
and	O
impairment	O
of	O
functional	O
capacity	O
significantly	O
decreased	O
osteocalcin	O
levels	O
in	O
patients	O
with	O
RA	Condition
.	O

Why	O
the	O
prone	O
position	O
is	O
a	O
risk	O
factor	O
for	O
sudden	O
infant	O
death	O
syndrome	O
.	O

INTRODUCTION	O
The	O
laryngeal	O
chemoreflex	O
may	O
explain	O
why	O
prone	O
sleeping	O
increases	O
the	O
risk	O
of	O
sudden	O
infant	O
death	O
syndrome	O
(	O
SIDS	O
)	O
.	O

Swallowing	O
and	O
arousal	O
are	O
crucial	O
to	O
prevent	O
laryngeal	O
chemoreflex	O
stimulation	O
.	O

Our	O
aim	O
was	O
to	O
examine	O
these	O
reflexes	O
and	O
breathing	O
responses	O
in	O
healthy	Condition
neonates	Age
after	O
pharyngeal	O
infusion	O
of	O
water	O
in	O
the	O
supine	O
versus	O
the	O
prone	O
position	O
,	O
controlling	O
for	O
sleep	O
state	O
.	O

METHODS	O
A	O
total	O
of	O
10	SampleSize
term	O
infants	Age
were	O
recruited	O
after	O
parental	O
consent	O
and	O
ethics	O
approval	O
.	O

Polygraphic	O
recordings	O
included	O
sleep	O
state	O
(	O
active	O
and	O
quiet	O
sleep	O
by	O
electroencephalogram	O
,	O
eye	O
movements	O
,	O
breathing	O
,	O
and	O
behavior	O
)	O
,	O
cardiorespiratory	O
measurements	O
(	O
nasal	O
airflow	O
,	O
chest	O
wall	O
movements	O
,	O
heart	O
rate	O
,	O
and	O
oxygen	O
saturation	O
)	O
,	O
swallowing	O
,	O
and	O
esophageal	O
activity	O
(	O
solid	O
state	O
pressure	O
catheter	O
)	O
.	O

Initial	O
sleeping	O
position	O
was	O
assigned	O
randomly	O
.	O

Measurements	O
were	O
made	O
for	O
1	O
minute	O
before	O
and	O
after	O
0.4	O
mL	O
of	O
water	O
was	O
instilled	O
into	O
the	O
oropharynx	O
.	O

To	O
detect	O
a	O
30	O
%	O
decrease	O
in	O
swallowing	O
,	O
power	O
analysis	O
indicated	O
that	O
>	O
/=10	O
babies	O
were	O
required	O
.	O

Analysis	O
,	O
blinded	O
to	O
position	O
,	O
was	O
made	O
using	O
nonparametric	O
statistics	O
.	O

RESULTS	O
Of	O
the	O
164	O
infusions	O
,	O
the	O
most	O
commonly	O
evoked	O
airway	O
protective	O
responses	O
to	O
pharyngeal	O
infusion	O
were	O
swallowing	O
(	O
95	O
%	O
)	O
and	O
arousal	O
(	O
54	O
%	O
)	O
.	O

After	O
infusion	O
in	O
active	O
sleep	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
swallowing	O
and	O
breathing	O
when	O
the	O
prone	O
position	O
was	O
compared	O
with	O
the	O
supine	O
position	O
(	O
prone	O
:	O
21.3	O
[	O
1.0	O
]	O
swallows/min	O
and	O
-9.6	O
[	O
2.1	O
]	O
breaths/min	O
;	O
and	O
supine	O
:	O
32	O
(	O
2.2	O
)	O
and	O
-2	O
.	O

9	O
(	O
1.5	O
)	O
,	O
respectively	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
occurrence	O
of	O
arousal	O
after	O
water	O
infusion	O
.	O

CONCLUSION	O
These	O
data	O
suggest	O
that	O
airway	O
protection	O
is	O
compromised	O
in	O
the	O
prone	O
sleeping	O
position	O
during	O
active	O
sleep	O
,	O
even	O
in	O
healthy	O
infants	O
exposed	O
to	O
minute	O
pharyngeal	O
fluid	O
volumes	O
of	O
0.4	O
mL	O
.	O

This	O
is	O
because	O
swallowing	O
rate	O
is	O
reduced	O
significantly	O
,	O
and	O
there	O
is	O
no	O
compensatory	O
increase	O
in	O
arousal	O
.	O

The	O
reduction	O
in	O
airway	O
protective	O
reflexes	O
when	O
in	O
the	O
prone	O
position	O
and	O
in	O
active	O
sleep	O
may	O
be	O
the	O
mechanism	O
for	O
the	O
increased	O
risk	O
of	O
SIDS	O
in	O
the	O
prone	O
position	O
.	O

Comparison	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
ebrotidine	O
in	O
the	O
treatment	O
of	O
duodenal	O
ulcer	O
.	O

A	O
multicentre	O
,	O
double-blind	O
,	O
placebo-controlled	O
phase	O
II	O
study	O
.	O

Ebrotidine	O
(	O
N-	O
[	O
(	O
E	O
)	O
-	O
[	O
[	O
2-	O
[	O
[	O
[	O
2-	O
[	O
(	O
diaminomethylene	O
)	O
amino	O
]	O
-4	O
-thiazoly	O
]	O
methyl	O
]	O
thio	O
]	O
ethyl	O
]	O
amino	O
]	O
methylene	O
]	O
-4-bromo-benzenesulfon	O
amide	O
,	O
CAS	O
100981-43-9	O
,	O
FI-3542	O
)	O
is	O
a	O
new	O
H2-receptor	O
antagonist	O
characterized	O
by	O
its	O
high	O
receptor	O
affinity	O
and	O
gastroprotective	O
effect	O
.	O

This	O
Phase	O
II	O
study	O
has	O
been	O
undertaken	O
to	O
establish	O
the	O
efficacy	O
and	O
safety	O
of	O
ebrotidine	O
,	O
administered	O
in	O
four	O
dosages	O
as	O
a	O
single	O
evening	O
dose	O
versus	O
placebo	O
in	O
the	O
treatment	O
of	O
duodenal	O
ulcer	O
.	O

A	O
total	O
of	O
110	O
duodenal	O
ulcer	O
patients	O
were	O
studied	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multicentre	O
clinical	O
trial	O
.	O

The	O
patients	O
were	O
assigned	O
to	O
5	O
groups	O
:	O
placebo	O
,	O
200	O
mg	O
,	O
400	O
mg	O
,	O
600	O
mg	O
and	O
800	O
mg	O
of	O
ebrotidine	O
once	O
daily	O
.	O

Controls	O
were	O
performed	O
at	O
baseline	O
and	O
every	O
two	O
weeks	O
at	O
four	O
follow-up	O
visits	O
unless	O
ulcer	O
healed	O
before	O
.	O

Endoscopic	O
examination	O
was	O
the	O
main	O
parameter	O
for	O
the	O
assessment	O
of	O
treatment	O
efficacy	O
and	O
ulcer	O
healing	O
rate	O
.	O

Vital	O
signs	O
and	O
blood/	O
urine	O
analysis	O
were	O
used	O
to	O
establish	O
safety	O
.	O

The	O
three	O
groups	O
treated	O
with	O
higher	O
dosages	O
(	O
400	O
to	O
800	O
mg	O
of	O
ebrotidine	O
daily	O
)	O
showed	O
an	O
endoscopic	O
ulcer	O
healing	O
rate	O
of	O
90-95	O
%	O
,	O
significantly	O
higher	O
than	O
55	O
%	O
achieved	O
with	O
placebo	O
(	O
p	O
<	O
0.05	O
)	O
,	O
whilst	O
the	O
differences	O
between	O
these	O
three	O
dosages	O
of	O
ebrotidine	O
were	O
not	O
statistically	O
significant	O
.	O

Healing	O
rate	O
in	O
the	O
group	O
treated	O
with	O
200	O
mg	O
of	O
ebrotidine	O
daily	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
the	O
placebo	O
group	O
.	O

The	O
development	O
of	O
symptoms	O
,	O
number	O
of	O
episodes	O
of	O
ulcer-related	O
pain	O
,	O
total	O
ulcerated	O
surface	O
area	O
or	O
subjective	O
ratings	O
by	O
the	O
patients	O
and	O
investigators	O
also	O
differed	O
significantly	O
between	O
ebrotidine	O
(	O
400	O
,	O
600	O
and	O
800	O
mg	O
daily	O
)	O
and	O
placebo	O
,	O
and	O
again	O
,	O
no	O
marked	O
differences	O
were	O
found	O
between	O
these	O
three	O
doses	O
of	O
ebrotidine	O
.	O

As	O
far	O
as	O
tolerance	O
is	O
concerned	O
,	O
no	O
clinically	O
or	O
statistically	O
significant	O
changes	O
were	O
observed	O
in	O
vital	O
signs	O
and	O
analytical	O
parameters	O
.	O

The	O
incidence	O
of	O
side	O
effects	O
was	O
less	O
than	O
that	O
presented	O
by	O
the	O
placebo	O
group	O
,	O
possibly	O
due	O
to	O
a	O
greater	O
consumption	O
of	O
antacids	O
in	O
this	O
group	O
.	O

Results	O
showed	O
that	O
a	O
daily	O
dose	O
of	O
400	O
mg	O
ebrotidine	O
is	O
effective	O
and	O
safe	O
in	O
the	O
treatment	O
of	O
duodenal	O
ulcers	O
.	O

Randomized	O
comparison	O
of	O
two	O
communication	O
interventions	O
for	O
preschoolers	Age
with	O
autism	Condition
spectrum	Condition
disorders	Condition
.	O

This	O
randomized	O
group	O
experiment	O
compared	O
the	O
efficacy	O
of	O
2	O
communication	O
interventions	O
(	O
Responsive	O
Education	O
and	O
Prelinguistic	O
Milieu	O
Teaching	O
[	O
RPMT	O
]	O
and	O
the	O
Picture	O
Exchange	O
Communication	O
System	O
[	O
PECS	O
]	O
)	O
in	O
36	SampleSize
preschoolers	O
with	O
autism	Condition
spectrum	Condition
disorders	Condition
.	Condition

Each	O
treatment	O
was	O
delivered	O
3	O
times	O
per	O
week	O
,	O
in	O
20-min	O
sessions	O
,	O
for	O
6	O
months	O
.	O

The	O
results	O
revealed	O
that	O
the	O
RPMT	O
facilitated	O
the	O
frequency	O
of	O
generalized	O
turn	O
taking	O
and	O
generalized	O
initiating	O
joint	O
attention	O
more	O
than	O
did	O
the	O
PECS	O
.	O

The	O
latter	O
effect	O
occurred	O
only	O
for	O
children	O
who	O
began	O
treatment	O
with	O
at	O
least	O
some	O
initiating	O
joint	O
attention	O
.	O

In	O
contrast	O
,	O
the	O
PECS	O
facilitated	O
generalized	O
requests	O
more	O
than	O
the	O
RPMT	O
in	O
children	O
with	O
very	O
little	O
initiating	O
joint	O
attention	O
prior	O
to	O
treatment	O
.	O

These	O
effect	O
sizes	O
were	O
large	O
.	O

[	O
Preoperative	O
chemotherapy	O
of	O
esophageal	O
cancer	O
]	O
.	O

A	O
series	O
of	O
25	O
patients	O
with	O
advanced	O
esophageal	O
cancer	O
treated	O
from	O
Mar	O
.	O

1981	O
to	O
Sep.	O
1982	O
by	O
preoperative	O
chemotherapy	O
plus	O
surgery	O
is	O
reported	O
.	O

All	O
the	O
patients	O
came	O
from	O
the	O
hospitals	O
of	O
the	O
cooperative	O
research	O
group	O
and	O
were	O
randomized	O
into	O
chemotherapy	O
and	O
control	O
groups	O
.	O

They	O
were	O
proved	O
by	O
X-ray	O
,	O
cytology	O
and	O
histopathology	O
prior	O
to	O
treatment	O
.	O

By	O
histology	O
,	O
22	O
cases	O
were	O
squamous	O
cell	O
carcinoma	O
,	O
1	O
adenocarcinoma	O
and	O
2	O
squamous	O
adenocarcinoma	O
.	O

The	O
COF	O
chemotherapy	O
consisted	O
of	O
Vincristine	O
1	O
mg	O
,	O
cyclophosphamide	O
600	O
mg	O
and	O
5-fluorouracil	O
500	O
mg	O
IV	O
on	O
days	O
1	O
and	O
8	O
with	O
or	O
without	O
the	O
addition	O
of	O
Pingyangmycin	O
,	O
a	O
drug	O
equivalent	O
to	O
Bleomycin	O
A5	O
,	O
at	O
the	O
dose	O
of	O
10	O
mg	O
IM	O
on	O
days	O
1	O
,	O
3	O
,	O
6	O
and	O
8	O
.	O

The	O
interval	O
between	O
the	O
ending	O
of	O
chemotherapy	O
and	O
the	O
surgical	O
resection	O
was	O
5-6	O
days	O
.	O

The	O
results	O
showed	O
that	O
preoperative	O
chemotherapy	O
caused	O
no	O
myelosuppression	O
,	O
but	O
merely	O
mild	O
gastrointestinal	O
symptoms	O
.	O

All	O
patients	O
were	O
operated	O
and	O
resected	O
without	O
difficulty	O
.	O

The	O
subjective	O
improvement	O
in	O
various	O
degrees	O
and	O
the	O
shrinkage	O
of	O
tumor	O
in	O
the	O
X-ray	O
films	O
were	O
present	O
in	O
5/25	O
cases	O
who	O
received	O
preoperative	O
chemotherapy	O
.	O

The	O
histopathological	O
changes	O
in	O
the	O
chemotherapy	O
and	O
control	O
groups	O
(	O
16	O
specimens	O
)	O
were	O
different	O
.	O

In	O
the	O
chemotherapy	O
group	O
,	O
excessive	O
keratinization	O
in	O
the	O
squamous	O
component	O
of	O
the	O
esophageal	O
cancerous	O
tissue	O
appeared	O
in	O
the	O
resected	O
specimens	O
.	O

The	O
incidence	O
of	O
degeneration	O
and	O
necrosis	O
in	O
the	O
squamous	O
epithelium	O
adjacent	O
to	O
carcinoma	O
was	O
higher	O
in	O
the	O
chemotherapy	O
group	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

The	O
results	O
suggested	O
that	O
such	O
combined	O
modality	O
is	O
worth	O
further	O
study	O
.	O

Comparison	O
of	O
fluid	O
types	O
for	O
resuscitation	O
after	O
acute	Condition
blood	Condition
loss	Condition
in	O
mallard	O
ducks	O
(	O
Anas	O
platyrhynchos	O
)	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
LD	O
(	O
50	O
)	O
for	O
acute	Condition
blood	Condition
loss	Condition
in	O
mallard	O
ducks	O
(	O
Anas	O
platyrhynchos	O
)	O
,	O
compare	O
the	O
mortality	O
rate	O
among	O
3	O
fluid	O
resuscitation	O
groups	O
,	O
and	O
determine	O
the	O
time	O
required	O
for	O
a	O
regenerative	O
RBC	O
response	O
.	O

DESIGN	O
Prospective	O
study	O
.	O

SETTING	O
Medical	O
College	O
of	O
Wisconsin	O
Research	O
facility	O
.	O

ANIMALS	O
Eighteen	SampleSize
mallard	O
ducks	O
were	O
included	O
for	O
the	O
LD	O
(	O
50	O
)	O
study	O
and	O
28	SampleSize
for	O
the	O
fluid	O
resuscitation	O
study	O
.	O

INTERVENTIONS	O
Phlebotomy	O
was	O
performed	O
during	O
both	O
the	O
LD	O
(	O
50	O
)	O
and	O
fluid	O
resuscitation	O
studies	O
.	O

Ducks	O
in	O
the	O
fluid	O
resuscitation	O
study	O
received	O
a	O
5	O
mL/kg	O
intravenous	O
bolus	O
of	O
crystalloids	O
,	O
hetastarch	O
(	O
HES	O
)	O
,	O
or	O
a	O
hemoglobin-based	O
oxygen-carrying	O
solution	O
(	O
HBOCS	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
The	O
LD	O
(	O
50	O
)	O
for	O
acute	O
blood	O
loss	O
was	O
60	O
%	O
of	O
total	O
blood	O
volume	O
.	O

This	O
blood	O
volume	O
was	O
removed	O
in	O
the	O
fluid	O
resuscitation	O
study	O
to	O
create	O
a	O
model	O
of	O
acute	O
blood	O
loss	O
.	O

Following	O
fluid	O
administration	O
,	O
6	O
birds	O
in	O
the	O
crystalloid	O
group	O
(	O
66	O
%	O
)	O
,	O
4	O
birds	O
in	O
the	O
HES	O
group	O
(	O
40	O
%	O
)	O
,	O
and	O
2	O
birds	O
in	O
the	O
HBOCS	O
group	O
(	O
20	O
%	O
)	O
died	O
.	O

No	O
statistical	O
difference	O
in	O
mortality	O
rate	O
was	O
seen	O
among	O
the	O
3	O
fluid	O
resuscitation	O
groups	O
.	O

Relative	O
polychromasia	O
evaluated	O
post-phlebotomy	O
demonstrated	O
regeneration	O
starting	O
at	O
24	O
hours	O
and	O
continuing	O
through	O
48	O
hours	O
.	O

CONCLUSIONS	O
The	O
LD	O
(	O
50	O
)	O
for	O
acute	O
blood	O
loss	O
in	O
mallard	O
ducks	O
was	O
60	O
%	O
of	O
their	O
total	O
blood	O
volume	O
.	O

Although	O
no	O
statistical	O
difference	O
in	O
mortality	O
rate	O
was	O
appreciated	O
among	O
the	O
3	O
fluid	O
resuscitation	O
groups	O
,	O
a	O
trend	O
of	O
decreased	O
mortality	O
rate	O
was	O
observed	O
in	O
the	O
HBOCS	O
group	O
.	O

An	O
early	O
regenerative	O
response	O
was	O
apparent	O
following	O
acute	O
blood	O
loss	O
.	O

RCT	O
of	O
a	O
manualized	O
social	O
treatment	O
for	O
high-functioning	O
autism	O
spectrum	O
disorders	O
.	O

This	O
RCT	O
examined	O
the	O
efficacy	O
of	O
a	O
manualized	O
social	O
intervention	O
for	O
children	O
with	O
HFASDs	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
treatment	O
or	O
wait-list	O
conditions	O
.	O

Treatment	O
included	O
instruction	O
and	O
therapeutic	O
activities	O
targeting	O
social	O
skills	O
,	O
face-emotion	O
recognition	O
,	O
interest	O
expansion	O
,	O
and	O
interpretation	O
of	O
non-literal	O
language	O
.	O

A	O
response-cost	O
program	O
was	O
applied	O
to	O
reduce	O
problem	O
behaviors	O
and	O
foster	O
skills	O
acquisition	O
.	O

Significant	O
treatment	O
effects	O
were	O
found	O
for	O
five	O
of	O
seven	O
primary	O
outcome	O
measures	O
(	O
parent	O
ratings	O
and	O
direct	O
child	O
measures	O
)	O
.	O

Secondary	O
measures	O
based	O
on	O
staff	O
ratings	O
(	O
treatment	O
group	O
only	O
)	O
corroborated	O
gains	O
reported	O
by	O
parents	O
.	O

High	O
levels	O
of	O
parent	O
,	O
child	O
and	O
staff	O
satisfaction	O
were	O
reported	O
,	O
along	O
with	O
high	O
levels	O
of	O
treatment	O
fidelity	O
.	O

Standardized	O
effect	O
size	O
estimates	O
were	O
primarily	O
in	O
the	O
medium	O
and	O
large	O
ranges	O
and	O
favored	O
the	O
treatment	O
group	O
.	O

Enhanced	O
baroreceptor	O
control	O
of	O
the	O
cardiovascular	O
system	O
by	O
polyunsaturated	O
Fatty	O
acids	O
in	O
heart	O
failure	O
patients	O
.	O

OBJECTIVES	O
The	O
intention	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
,	O
in	O
heart	O
failure	O
patients	O
,	O
dietary	O
supplementation	O
of	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFA	O
)	O
enhances	O
arterial	O
baroreceptor	O
control	O
of	O
the	O
cardiovascular	O
system	O
.	O

BACKGROUND	O
Administration	O
of	O
PUFA	O
reduces	O
the	O
risk	O
of	O
life-threatening	O
arrhythmias	O
in	O
patients	O
surviving	O
myocardial	O
infarction	O
.	O

This	O
might	O
result	O
from	O
potentiation	O
of	O
arterial	O
baroreflexes	O
,	O
but	O
whether	O
or	O
not	O
PUFA	O
enhance	O
baroreflex	O
function	O
has	O
never	O
been	O
studied	O
in	O
humans	O
.	O

METHODS	O
Patients	O
with	O
post-myocardial	O
infarction	O
left	O
ventricular	O
dysfunction	O
underwent	O
beat-to-beat	O
blood	O
pressure	O
(	O
BP	O
)	O
(	O
Finapres	O
,	O
Ohmeda	O
Inc.	O
,	O
Englewood	O
,	O
Colorado	O
)	O
and	O
R-R	O
interval	O
(	O
electrocardiogram	O
)	O
recording	O
;	O
baroreceptor	O
reflexes	O
were	O
assessed	O
from	O
the	O
bradycardic	O
and	O
depressor	O
responses	O
to	O
graded	O
neck	O
suction	O
(	O
NS	O
)	O
as	O
well	O
as	O
by	O
computation	O
of	O
the	O
alpha	O
spontaneous	O
baroreflex	O
sensitivity	O
index	O
.	O

Assessments	O
were	O
repeated	O
after	O
prolonged	O
treatment	O
with	O
PUFA	O
(	O
2	O
g/die	O
,	O
n	O
=	O
15	O
)	O
or	O
placebo	O
(	O
n	O
=	O
10	O
)	O
.	O

RESULTS	O
Baseline	O
BP	O
and	O
R-R	O
interval	O
were	O
unaffected	O
by	O
PUFA	O
.	O

Both	O
reflex	O
depressor	O
and	O
bradycardic	O
responses	O
to	O
NS	O
increased	O
after	O
PUFA	O
(	O
respectively	O
from	O
-0.09	O
+/-	O
0.01	O
to	O
-0.16	O
+/-	O
0.01	O
mm	O
Hg	O
x	O
mm	O
Hg	O
(	O
-1	O
)	O
,	O
p	O
<	O
0.01	O
,	O
and	O
from	O
1.25	O
+/-	O
0.9	O
to	O
1.76	O
+/-	O
1.1	O
ms	O
x	O
mm	O
Hg	O
(	O
-1	O
)	O
,	O
p	O
<	O
0.04	O
)	O
but	O
not	O
after	O
placebo	O
.	O

The	O
spontaneous	O
baroreflex	O
sensitivity	O
increased	O
in	O
the	O
PUFA	O
(	O
from	O
8.99	O
+/-	O
1.4	O
to	O
12.2	O
+/-	O
1.2	O
ms	O
x	O
mm	O
Hg	O
(	O
-1	O
)	O
,	O
p	O
<	O
0.02	O
)	O
but	O
not	O
in	O
the	O
placebo	O
group	O
.	O

Polyunsaturated	O
fatty	O
acids	O
(	O
but	O
not	O
placebo	O
)	O
treatment	O
also	O
significantly	O
increased	O
R-R	O
interval	O
total	O
variance	O
and	O
low-frequency	O
and	O
high-frequency	O
spectral	O
powers	O
.	O

CONCLUSIONS	O
Dietary	O
PUFA	O
supplementation	O
markedly	O
potentiates	O
baroreflex	O
function	O
and	O
enhances	O
heart	O
rate	O
variability	O
in	O
patients	O
with	O
stable	O
congestive	O
heart	O
failure	O
.	O

Minimal	O
clinically	O
important	O
change	O
for	O
pain	O
intensity	O
,	O
functional	O
status	O
,	O
and	O
general	O
health	O
status	O
in	O
patients	O
with	O
nonspecific	O
low	Condition
back	Condition
pain	Condition
.	O

STUDY	O
DESIGN	O
Cohort	O
study	O
.	O

OBJECTIVES	O
To	O
estimate	O
the	O
Minimal	O
Clinically	O
Important	O
Change	O
(	O
MCIC	O
)	O
of	O
the	O
pain	O
intensity	O
numerical	O
rating	O
scale	O
(	O
PI-NRS	O
)	O
,	O
the	O
Quebec	O
Back	O
Pain	O
Disability	O
Scale	O
(	O
QBPDS	O
)	O
,	O
and	O
the	O
Euroqol	O
(	O
EQ	O
)	O
in	O
patients	O
with	O
low	Condition
back	Condition
pain	Condition
.	O

SUMMARY	O
OF	O
BACKGROUND	O
DATA	O
MCIC	O
can	O
provide	O
valuable	O
information	O
for	O
researchers	O
,	O
healthcare	O
providers	O
,	O
and	O
policymakers	O
.	O

METHODS	O
Data	O
from	O
a	O
randomized	O
controlled	O
trial	O
with	O
442	SampleSize
patients	O
with	O
low	Condition
back	Condition
pain	Condition
were	O
used	O
.	O

The	O
MCIC	O
was	O
estimated	O
over	O
a	O
12-week	O
period	O
,	O
and	O
three	O
different	O
methods	O
were	O
used	O
:	O
1	O
)	O
mean	O
change	O
scores	O
,	O
2	O
)	O
minimal	O
detectable	O
change	O
,	O
and	O
3	O
)	O
optimal	O
cutoff	O
point	O
in	O
receiver	O
operant	O
curves	O
.	O

The	O
global	O
perceived	O
effect	O
scale	O
(	O
GPE	O
)	O
was	O
used	O
as	O
an	O
external	O
criterion	O
.	O

The	O
effect	O
of	O
initial	O
scores	O
on	O
the	O
MCIC	O
was	O
also	O
assessed	O
.	O

RESULTS	O
The	O
MCIC	O
of	O
the	O
PI-NRS	O
ranged	O
from	O
3.5	O
to	O
4.7	O
points	O
in	O
(	O
sub	O
)	O
acute	O
patients	O
and	O
2.5	O
to	O
4.5	O
points	O
in	O
chronic	O
patients	O
with	O
low	O
back	O
pain	O
.	O

The	O
MCIC	O
of	O
the	O
QBPDS	O
was	O
estimated	O
between	O
17.5	O
to	O
32.9	O
points	O
and	O
8.5	O
to	O
24.6	O
points	O
for	O
(	O
sub	O
)	O
acute	O
and	O
chronic	O
patients	O
with	O
low	Condition
back	Condition
pain	Condition
.	O

The	O
MCIC	O
for	O
the	O
EQ	O
ranged	O
from	O
0.07	O
to	O
0.58	O
in	O
(	O
sub	O
)	O
acute	O
patients	O
and	O
0.09	O
to	O
0.28	O
in	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
.	O

CONCLUSION	O
Reporting	O
the	O
percentage	O
of	O
patients	O
who	O
have	O
made	O
a	O
MCIC	O
adds	O
to	O
the	O
interpretability	O
of	O
study	O
results	O
.	O

We	O
present	O
a	O
range	O
of	O
MCIC	O
values	O
and	O
advocate	O
the	O
choice	O
of	O
a	O
single	O
MCIC	O
value	O
according	O
to	O
the	O
specific	O
context	O
.	O

[	O
Postural	O
biofeedback	O
and	O
locomotion	O
reeducation	O
in	Condition
stroke	Condition
patients	Condition
]	Condition
.	O

AIMS	O
To	O
compare	O
,	O
in	O
post-acute	O
hemiparetic	O
patients	O
,	O
gait	O
improvement	O
after	O
conventional	O
physical	O
therapy	O
alone	O
or	O
with	O
a	O
specialised	O
balance	O
retraining	O
program	O
.	O

PATIENTS	O
Twenty-six	O
patients	O
within	O
3	O
months	O
of	O
onset	O
of	O
stroke	O
were	O
randomised	O
to	O
receive	O
physical	O
therapy	O
(	O
control	O
group	O
)	O
or	O
therapy	O
and	O
retraining	O
(	O
experimental	O
group	O
)	O
,	O
most	O
of	O
the	O
patients	O
in	O
both	O
groups	O
with	O
left	O
hemiplegia	O
.	O

The	O
experimental	O
group	O
was	O
significantly	O
older	O
than	O
the	O
control	O
group	O
.	O

METHOD	O
Thirteen	O
patients	O
received	O
early	O
conventional	O
therapy	O
,	O
and	O
13	O
received	O
therapy	O
combined	O
with	O
standing	O
balance	O
training	O
by	O
biofeedback	O
(	O
BPM	O
Monitor	O
)	O
.	O

Clinical	O
measures	O
were	O
collected	O
at	O
entry	O
(	O
J0	O
)	O
,	O
once	O
when	O
subjects	O
began	O
to	O
walk	O
(	O
JM	O
)	O
and	O
30	O
days	O
later	O
(	O
JM	O
+	O
30	O
)	O
.	O

Gait	O
spatiotemporal	O
parameters	O
were	O
collected	O
by	O
use	O
of	O
the	O
Vicon	O
system	O
at	O
JM	O
and	O
JM	O
+	O
30	O
.	O

RESULTS	O
Whatever	O
the	O
method	O
of	O
rehabilitation	O
,	O
the	O
clinical	O
scores	O
improved	O
significantly	O
between	O
J0	O
and	O
JM	O
+	O
30	O
,	O
except	O
for	O
spasticity	O
.	O

The	O
time	O
between	O
stroke	O
and	O
the	O
beginning	O
of	O
walking	O
was	O
not	O
significantly	O
different	O
between	O
both	O
groups	O
.	O

Gait	O
velocity	O
increased	O
significantly	O
between	O
JM	O
and	O
JM	O
+	O
30	O
in	O
both	O
groups	O
,	O
with	O
no	O
difference	O
between	O
groups	O
.	O

The	O
walking	O
pattern	O
was	O
improved	O
for	O
both	O
groups	O
,	O
with	O
a	O
significant	O
increase	O
of	O
the	O
duration	O
of	O
the	O
paretic	O
limb	O
single	O
stance	O
.	O

The	O
experimental	O
group	O
significantly	O
improved	O
the	O
duration	O
of	O
the	O
reception	O
double	O
stance	O
on	O
the	O
paretic	O
limb	O
between	O
JM	O
and	O
JM	O
+	O
30	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O

CONCLUSION	O
Both	O
groups	O
demonstrated	O
improvement	O
in	O
the	O
rehabilitation	O
unit	O
.	O

The	O
benefits	O
of	O
visual	O
biofeedback	O
by	O
forceplate	O
system	O
training	O
suggest	O
particular	O
improvement	O
of	O
anticipation	O
equilibrium	O
with	O
conventional	O
therapy	O
.	O

Evaluation	O
of	O
postural	O
stability	O
by	O
computerised	O
posturography	O
following	O
outpatient	O
paediatric	O
anaesthesia	O
.	O

Comparison	O
of	O
propofol/alfentanil/N2O	O
anaesthesia	O
with	O
thiopentone/halothane/N2O	O
anaesthesia	O
.	O

Simple	O
clinical	O
tests	O
,	O
like	O
Romberg	O
's	O
test	O
or	O
a	O
walking	O
test	O
,	O
have	O
proved	O
to	O
be	O
inadequate	O
guidelines	O
for	O
safe	O
discharge	O
after	O
outpatient	O
anaesthesia	O
.	O

A	O
randomised	O
study	O
was	O
therefore	O
planned	O
to	O
compare	O
postural	O
stability	O
measured	O
by	O
computerised	O
posturography	O
in	O
31	Age
oral	Age
midazolam-atropine	Age
premedicated	Age
children	Age
aged	Age
6.9	Age
(	Age
s.e	Age
.	Age

0.4	O
)	O
years	O
who	O
had	O
been	O
anaesthetised	Condition
with	Condition
either	Condition
propofol/alfentanil/N2O	Condition
or	Condition
thiopentone/halothane/N2O	Condition
.	O

The	O
sway	O
velocity	O
of	O
the	O
children	O
was	O
measured	O
before	O
premedication	O
and	O
1	O
,	O
2	O
and	O
3	O
h	O
after	O
the	O
end	O
of	O
anaesthesia	O
.	O

Results	O
show	O
that	O
sway	O
velocity	O
had	O
returned	O
to	O
baseline	O
values	O
3	O
h	O
after	O
the	O
end	O
of	O
anaesthesia	O
in	O
all	O
children	O
who	O
had	O
received	O
propofol/alfentanil/N2O	O
and	O
in	O
12	O
of	O
the	O
15	O
children	O
who	O
had	O
received	O
thiopentone/halothane/N2O	O
.	O

The	O
quantified	O
version	O
of	O
the	O
Romberg	O
test	O
performed	O
with	O
eyes	O
open	O
or	O
closed	O
was	O
not	O
impaired	O
after	O
anaesthesia	O
,	O
compared	O
with	O
the	O
control	O
values	O
,	O
indicating	O
that	O
in	O
children	O
poor	O
equilibrium	O
is	O
not	O
compensated	O
by	O
vision	O
.	O

The	O
clinical	O
recovery	O
with	O
respect	O
to	O
the	O
times	O
to	O
eye	O
opening	O
,	O
to	O
responding	O
to	O
command	O
or	O
to	O
being	O
fully	O
awake	O
did	O
not	O
differ	O
between	O
the	O
two	O
anaesthesia	O
methods	O
.	O

On	O
the	O
basis	O
of	O
recovery	O
assessed	O
by	O
postural	O
stability	O
,	O
propofol/alfentanil/N2O	O
anaesthesia	O
was	O
not	O
preferable	O
to	O
thiopentone/halothane/N2O	O
anaesthesia	O
after	O
minor	O
paediatric	O
otolaryngological	O
surgery	O
.	O

Transitions	O
during	O
effective	O
treatment	O
for	O
cocaine-abusing	Condition
homeless	O
persons	O
:	O
establishing	O
abstinence	O
,	O
lapse	O
,	O
and	O
relapse	O
,	O
and	O
reestablishing	O
abstinence	O
.	O

Data	O
are	O
reported	O
on	O
drug	O
use	O
among	O
cocaine-dependent	Condition
homeless	O
persons	O
who	O
participated	O
in	O
a	O
clinical	O
trial	O
that	O
compared	O
day	O
treatment	O
only	O
(	O
DT	O
,	O
n	O
=	O
69	SampleSize
)	O
with	O
day	O
treatment	O
plus	O
abstinent-contingent	O
housing	O
and	O
work	O
(	O
DT+	O
,	O
n	O
=	O
72	SampleSize
)	SampleSize
.	O

Drug	O
use	O
was	O
measured	O
with	O
multiple	O
weekly	O
urine	O
toxicologies	O
.	O

Compared	O
with	O
DT	O
participants	O
,	O
more	O
DT+	O
participants	O
established	O
abstinence	O
,	O
maintained	O
abstinence	O
for	O
longer	O
durations	O
,	O
were	O
marginally	O
significantly	O
more	O
likely	O
to	O
lapse	O
,	O
and	O
significantly	O
less	O
likely	O
to	O
relapse	O
.	O

Of	O
all	O
participants	O
who	O
established	O
abstinence	O
and	O
then	O
relapsed	O
,	O
DT+	O
participants	O
relapsed	O
later	O
and	O
were	O
more	O
likely	O
to	O
reestablish	O
abstinence	O
.	O

These	O
analyses	O
yield	O
information	O
on	O
the	O
processes	O
involved	O
in	O
the	O
manner	O
in	O
which	O
drug	O
use	O
changes	O
as	O
a	O
result	O
of	O
abstinent-contingent	O
housing	O
and	O
work	O
.	O

Phase-dependent	O
modulation	O
of	O
the	O
soleus	O
H-reflex	O
during	O
rhythmical	O
arm	O
swing	O
in	O
humans	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
investigate	O
modulation	O
of	O
the	O
soleus	O
H-reflex	O
during	O
rhythmic	O
arm	O
swing	O
in	O
humans	O
.	O

Significant	O
depression	O
of	O
the	O
soleus	O
H-reflex	O
was	O
observed	O
when	O
subjects	O
swung	O
their	O
ipsilateral	O
arms	O
or	O
both	O
arms	O
reciprocally	O
during	O
testing	O
.	O

The	O
degree	O
of	O
soleus	O
H-reflex	O
depression	O
appeared	O
directly	O
proportional	O
to	O
the	O
speed	O
of	O
the	O
arm	O
swing	O
.	O

This	O
depression	O
was	O
observed	O
in	O
the	O
conditioning-testing	O
intervals	O
of	O
400	O
,	O
500	O
,	O
and	O
600	O
msec	O
during	O
the	O
ipsilateral	O
backward	O
arm	O
swing	O
and	O
at	O
the	O
onset	O
of	O
the	O
ipsilateral	O
arm	O
forward	O
swing	O
.	O

This	O
phase	O
of	O
depression	O
partially	O
overlapped	O
the	O
phase	O
of	O
depression	O
of	O
the	O
soleus	O
H-reflex	O
during	O
walking	O
.	O

However	O
,	O
the	O
pattern	O
of	O
modulation	O
during	O
arm	O
swing	O
was	O
not	O
exactly	O
the	O
same	O
as	O
that	O
during	O
walking	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
the	O
ipsilateral	O
arm	O
swing	O
may	O
partially	O
affect	O
the	O
depression	O
of	O
the	O
soleus	O
H-reflex	O
during	O
the	O
arm	O
swing	O
phase	O
of	O
walking	O
but	O
is	O
not	O
responsible	O
for	O
depression	O
of	O
the	O
soleus	O
H-reflex	O
throughout	O
the	O
entire	O
walking	O
cycle	O
.	O

A	O
single	O
dose	O
of	O
gabapentin	O
reduces	O
acute	O
pain	O
and	O
allodynia	O
in	O
patients	O
with	O
herpes	Condition
zoster	Condition
.	O

This	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
measured	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
oral	O
gabapentin	O
(	O
900	O
mg	O
)	O
on	O
pain	O
and	O
allodynia	O
associated	O
with	O
herpes	O
zoster	O
.	O

Pain	O
severity	O
decreased	O
by	O
66	O
%	O
with	O
gabapentin	O
compared	O
to	O
33	O
%	O
with	O
placebo	O
.	O

Reductions	O
in	O
allodynia	O
area	O
and	O
severity	O
,	O
and	O
overall	O
pain	O
relief	O
,	O
were	O
also	O
greater	O
with	O
gabapentin	O
.	O

Randomized	O
,	O
controlled	O
,	O
crossover	O
trial	O
of	O
methylphenidate	O
in	O
pervasive	O
developmental	O
disorders	O
with	O
hyperactivity	O
.	O

CONTEXT	O
Hyperactivity	O
and	O
inattention	O
are	O
common	O
symptoms	O
in	O
children	O
with	O
autistic	O
disorder	O
and	O
related	O
pervasive	O
developmental	O
disorders	O
,	O
but	O
studies	O
of	O
stimulants	O
in	O
these	O
conditions	O
have	O
been	O
inconclusive	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
methylphenidate	O
hydrochloride	O
in	O
children	O
with	O
pervasive	O
developmental	O
disorders	O
and	O
hyperactivity	O
.	O

DESIGN	O
Double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
trial	O
followed	O
by	O
open-label	O
continuation	O
.	O

SETTING	O
Five	O
academic	O
outpatient	O
clinics	O
.	O

PARTICIPANTS	O
Seventy-two	O
drug-free	O
children	O
,	O
aged	O
5	O
to	O
14	O
years	O
,	O
with	O
pervasive	O
developmental	O
disorders	O
accompanied	O
by	O
moderate	O
to	O
severe	O
hyperactivity	O
.	O

INTERVENTIONS	O
Prior	O
to	O
randomization	O
,	O
subjects	O
entered	O
a	O
1-week	O
test-dose	O
phase	O
in	O
which	O
each	O
subject	O
received	O
placebo	O
for	O
1	O
day	O
followed	O
by	O
increasing	O
doses	O
of	O
methylphenidate	O
(	O
low	O
,	O
medium	O
,	O
and	O
high	O
doses	O
)	O
that	O
were	O
each	O
given	O
for	O
2	O
days	O
.	O

The	O
low	O
,	O
medium	O
,	O
and	O
high	O
doses	O
of	O
methylphenidate	O
hydrochloride	O
were	O
based	O
on	O
weight	O
,	O
and	O
they	O
ranged	O
from	O
7.5	O
mg/d	O
to	O
50.0	O
mg/d	O
in	O
divided	O
doses	O
.	O

Subjects	O
who	O
tolerated	O
the	O
test	O
dose	O
(	O
n	O
=	O
66	O
)	O
were	O
assigned	O
to	O
receive	O
placebo	O
for	O
1	O
week	O
and	O
then	O
3	O
methylphenidate	O
doses	O
in	O
random	O
order	O
during	O
a	O
double-blind	O
,	O
crossover	O
phase	O
.	O

Children	O
responding	O
to	O
methylphenidate	O
then	O
entered	O
8	O
weeks	O
of	O
open-label	O
treatment	O
at	O
the	O
individually	O
determined	O
best	O
dose	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
outcome	O
measure	O
was	O
the	O
teacher-rated	O
hyperactivity	O
subscale	O
of	O
the	O
Aberrant	O
Behavior	O
Checklist	O
.	O

Response	O
was	O
defined	O
as	O
much	O
improved	O
or	O
very	O
much	O
improved	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
Improvement	O
item	O
coupled	O
with	O
considerable	O
reductions	O
in	O
the	O
parent-rated	O
and/or	O
teacher-rated	O
Aberrant	O
Behavior	O
Checklist	O
hyperactivity	O
subscale	O
score	O
.	O

RESULTS	O
Methylphenidate	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
primary	O
outcome	O
measure	O
,	O
with	O
effect	O
sizes	O
ranging	O
from	O
0.20	O
to	O
0.54	O
depending	O
on	O
dose	O
and	O
rater	O
.	O

Thirty-five	O
(	O
49	O
%	O
)	O
of	O
72	O
enrolled	O
subjects	O
were	O
classified	O
as	O
methylphenidate	O
responders	O
.	O

Adverse	O
effects	O
led	O
to	O
the	O
discontinuation	O
of	O
study	O
medication	O
in	O
13	O
(	O
18	O
%	O
)	O
of	O
72	O
subjects	O
.	O

CONCLUSIONS	O
Methylphenidate	O
was	O
often	O
efficacious	O
in	O
treating	O
hyperactivity	O
associated	O
with	O
pervasive	O
developmental	O
disorders	O
,	O
but	O
the	O
magnitude	O
of	O
response	O
was	O
less	O
than	O
that	O
seen	O
in	O
typically	O
developing	O
children	O
with	O
attention-deficit/hyperactivity	O
disorder	O
.	O

Adverse	O
effects	O
were	O
more	O
frequent	O
.	O

Pre-exposure	O
studies	O
with	O
purified	O
chick	O
embryo	O
cell	O
culture	O
rabies	O
vaccine	O
and	O
human	O
diploid	O
cell	O
vaccine	O
:	O
serological	O
and	O
clinical	O
responses	O
in	O
man	Sex
.	O

Clinical	O
reactions	O
and	O
neutralizing	O
antibody	O
responses	O
to	O
six	O
pre-exposure	O
regimens	O
of	O
purified	O
chick	O
embryo	O
cell	O
culture	O
rabies	O
vaccine	O
(	O
PCECV	O
)	O
and	O
human	O
diploid	O
cell	O
strain	O
rabies	O
vaccine	O
(	O
HDCSV	O
)	O
were	O
studied	O
in	O
177	SampleSize
volunteers	O
.	O

Antibody	O
kinetics	O
,	O
height	O
of	O
the	O
response	O
and	O
persistence	O
of	O
antibody	O
over	O
two	O
years	O
were	O
virtually	O
identical	O
after	O
PCECV	O
and	O
HDCSV	O
.	O

An	O
antibody	O
response	O
was	O
detected	O
in	O
all	O
subjects	O
on	O
day	O
14	O
when	O
the	O
highest	O
titres	O
were	O
found	O
after	O
two	O
intramuscular	O
(	O
i.m	O
.	O

)	O
1.0	O
ml	O
doses	O
of	O
a	O
schedule	O
of	O
immunization	O
on	O
days	O
0	O
,	O
7	O
and	O
21	O
.	O

In	O
comparison	O
,	O
a	O
schedule	O
of	O
immunization	O
on	O
days	O
0	O
,	O
28	O
and	O
56	O
ultimately	O
evoked	O
the	O
highest	O
titres	O
21	O
days	O
after	O
the	O
final	O
injection	O
,	O
but	O
antibody	O
persisted	O
equally	O
well	O
over	O
two	O
years	O
with	O
either	O
schedule	O
.	O

Neutralizing	O
antibody	O
titres	O
were	O
lower	O
after	O
intradermal	O
(	O
i.d	O
.	O

)	O
vaccination	O
with	O
0.1	O
ml	O
compared	O
to	O
1.0	O
ml	O
i.m	O
.	O

on	O
days	O
0	O
,	O
7	O
and	O
21	O
,	O
but	O
when	O
given	O
on	O
days	O
0	O
,	O
28	O
and	O
56	O
the	O
responses	O
were	O
comparable	O
.	O

Three	O
subjects	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
atopy	O
developed	O
urticarial	O
lesions	O
after	O
PCECV	O
.	O

Both	O
vaccines	O
were	O
otherwise	O
well	O
tolerated	O
.	O

Parietal	O
cell	O
density	O
in	O
duodenal	Condition
ulcer	Condition
patients	O
after	O
short-term	O
treatment	O
with	O
cimetidine	O
and	O
antacids	O
.	O

In	O
a	O
prospective	O
study	O
,	O
20	O
patients	O
with	O
endoscopically	Condition
proven	Condition
duodenal	Condition
ulcers	Condition
were	O
randomised	O
to	O
be	O
treated	O
with	O
cimetidine	O
1	O
g	O
daily	O
or	O
with	O
antacids	O
350	O
mmol	O
daily	O
.	O

The	O
duration	O
of	O
treatment	O
was	O
30	O
days	O
,	O
but	O
this	O
was	O
extended	O
to	O
three	O
months	O
in	O
3	O
patients	O
in	O
the	O
cimetidine	O
group	O
and	O
4	O
patients	O
in	O
the	O
antacid	O
group	O
.	O

A	O
morphological	O
study	O
of	O
biopsies	O
taken	O
via	O
a	O
gastroscope	O
from	O
the	O
corpus	O
mucosa	O
showed	O
no	O
change	O
in	O
mucosal	O
height	O
,	O
parietal	O
cell	O
density	O
per	O
unit	O
volume	O
or	O
changes	O
in	O
cellular	O
infiltration	O
after	O
30	O
and	O
90	O
days	O
treatment	O
in	O
the	O
two	O
groups	O
.	O

Neither	O
H-2	O
receptor	O
blockers	O
nor	O
antacids	O
alter	O
mucosal	O
height	O
or	O
parietal	O
cell	O
density	O
.	O

Treatment	O
was	O
not	O
found	O
to	O
induce	O
gastritic	O
changes	O
in	O
the	O
mucosa	O
.	O

The	O
role	O
of	O
ethnic	O
matching	O
between	O
patient	O
and	O
provider	O
on	O
the	O
effectiveness	O
of	O
brief	O
alcohol	O
interventions	O
with	O
Hispanics	Condition
.	O

BACKGROUND	O
Evaluating	O
the	O
effectiveness	O
of	O
treatments	O
such	O
as	O
brief	O
alcohol	O
interventions	O
among	O
Hispanics	Condition
is	O
essential	O
to	O
effectively	O
addressing	O
their	O
treatment	O
needs	O
.	O

Clinicians	O
of	O
the	O
same	O
ethnicity	O
as	O
the	O
client	O
may	O
be	O
more	O
likely	O
to	O
understand	O
the	O
culture-specific	O
values	O
,	O
norms	O
,	O
and	O
attitudes	O
and	O
,	O
therefore	O
,	O
the	O
intervention	O
may	O
be	O
more	O
effective	O
.	O

Thus	O
,	O
in	O
cases	O
in	O
which	O
Hispanic	Condition
patients	Condition
were	O
provided	O
intervention	O
by	O
a	O
Hispanic	O
clinician	O
improved	O
drinking	O
outcomes	O
were	O
expected	O
.	O

METHODS	O
Patients	O
were	O
recruited	O
from	O
an	O
urban	O
Level	O
I	O
Trauma	O
following	O
screening	O
for	O
an	O
alcohol-related	Condition
injury	Condition
or	O
alcohol	O
problems	O
.	O

Five	SampleSize
hundred	SampleSize
thirty-seven	SampleSize
Hispanics	O
were	O
randomly	O
assigned	O
to	O
brief	O
intervention	O
or	O
treatment	O
as	O
usual	O
.	O

Hierarchical	O
linear	O
modeling	O
was	O
used	O
to	O
determine	O
the	O
effects	O
of	O
ethnic	O
match	O
on	O
drinking	O
outcomes	O
including	O
volume	O
per	O
week	O
,	O
maximum	O
amount	O
,	O
and	O
frequency	O
of	O
5	O
or	O
more	O
drinks	O
per	O
occasion	O
.	O

Analyses	O
controlled	O
for	O
level	O
of	O
acculturation	O
and	O
immigration	O
status	O
.	O

RESULTS	O
For	O
Hispanics	O
who	O
received	O
brief	O
motivational	O
intervention	O
,	O
an	O
ethnic	O
match	O
between	O
patient	O
and	O
provider	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
drinking	O
outcomes	O
at	O
12-month	O
follow-up	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
tendency	O
for	O
ethnic	O
match	O
to	O
be	O
most	O
beneficial	O
to	O
foreign-born	O
Hispanics	O
and	O
less	O
acculturated	O
Hispanics	O
.	O

CONCLUSION	O
As	O
hypothesized	O
,	O
an	O
ethnic	O
match	O
between	O
patient	O
and	O
provider	O
significantly	O
enhanced	O
the	O
effectiveness	O
of	O
brief	O
intervention	O
among	O
Hispanics	O
.	O

Ethnic	O
concordance	O
between	O
patient	O
and	O
provider	O
may	O
have	O
impacted	O
the	O
effectiveness	O
of	O
the	O
intervention	O
through	O
several	O
mechanisms	O
including	O
cultural	O
scripts	O
,	O
ethnic-specific	O
perceptions	O
pertaining	O
to	O
substance	O
abuse	O
,	O
and	O
ethnic-specific	O
preferred	O
channels	O
of	O
communication	O
.	O

Deliberate	O
hypotension	O
in	O
patients	O
with	O
intracranial	Condition
arteriovenous	Condition
malformations	Condition
:	O
esmolol	O
compared	O
with	O
isoflurane	O
and	O
sodium	O
nitroprusside	O
.	O

Thirty	SampleSize
patients	O
undergoing	O
resection	O
of	O
arteriovenous	Condition
malformations	Condition
with	O
deliberate	O
hypotension	O
were	O
randomized	O
to	O
receive	O
1	O
of	O
3	O
hypotensive	O
agents	O
.	O

Anesthesia	O
was	O
maintained	O
with	O
isoflurane	O
and	O
nitrous	O
oxide	O
in	O
all	O
patients	O
.	O

Mean	O
arterial	O
pressure	O
was	O
reduced	O
20	O
%	O
to	O
60-65	O
mm	O
Hg	O
with	O
use	O
of	O
either	O
isoflurane	O
(	O
less	O
than	O
or	O
equal	O
to	O
4	O
%	O
)	O
,	O
sodium	O
nitroprusside	O
(	O
less	O
than	O
or	O
equal	O
to	O
8	O
micrograms.kg-1.min-1	O
)	O
,	O
or	O
esmolol	O
(	O
less	O
than	O
or	O
equal	O
to	O
24	O
mg/min	O
)	O
.	O

Esmolol	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
cardiac	O
output	O
from	O
6.2	O
+/-	O
1.3	O
to	O
3.8	O
+/-	O
0.8	O
L/min	O
,	O
which	O
,	O
because	O
of	O
a	O
22	O
%	O
increase	O
in	O
systemic	O
vascular	O
resistance	O
,	O
far	O
exceeded	O
the	O
reduction	O
in	O
mean	O
arterial	O
pressure	O
.	O

Systemic	O
vascular	O
resistance	O
increased	O
despite	O
a	O
32	O
%	O
decrease	O
in	O
plasma	O
renin	O
activity	O
.	O

In	O
contrast	O
,	O
with	O
sodium	O
nitroprusside	O
or	O
isoflurane	O
,	O
the	O
decrease	O
in	O
mean	O
arterial	O
pressure	O
was	O
associated	O
with	O
decreases	O
in	O
systemic	O
vascular	O
resistance	O
of	O
similar	O
magnitude	O
,	O
with	O
no	O
change	O
in	O
cardiac	O
output	O
.	O

Plasma	O
renin	O
activity	O
levels	O
increased	O
48	O
%	O
with	O
sodium	O
nitroprusside	O
and	O
126	O
%	O
with	O
isoflurane	O
.	O

Heart	O
rate	O
increased	O
13	O
%	O
with	O
sodium	O
nitroprusside	O
,	O
remained	O
unchanged	O
with	O
isoflurane	O
,	O
and	O
decreased	O
23	O
%	O
with	O
esmolol	O
.	O

Although	O
esmolol	O
may	O
be	O
used	O
as	O
a	O
primary	O
hypotensive	O
agent	O
,	O
the	O
potential	O
for	O
marked	O
myocardial	O
depression	O
must	O
be	O
recognized	O
.	O

The	O
differences	O
in	O
pharmacologic	O
properties	O
for	O
the	O
different	O
hypotensive	O
agents	O
suggest	O
that	O
combinations	O
of	O
these	O
agents	O
may	O
provide	O
a	O
pharmacologic	O
profile	O
superior	O
to	O
either	O
agent	O
alone	O
.	O

Effects	O
of	O
fish	O
oil	O
supplementation	O
on	O
markers	O
of	O
the	O
metabolic	O
syndrome	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
fish	O
oil	O
affects	O
cardiovascular	O
risk	O
factors	O
during	O
the	O
adolescent	O
growth	O
spurt	O
.	O

STUDY	O
DESIGN	O
A	O
total	O
of	O
78	O
boys	O
age	O
13-15	O
years	O
with	O
a	O
mean	O
body	O
fat	O
percentage	O
of	O
30	O
%	O
+/-9	O
%	O
were	O
randomly	O
assigned	O
to	O
consume	O
fish	O
oil	O
(	O
providing	O
1.5	O
g	O
of	O
n-3	O
long-chain	O
polyunsaturated	O
fatty	O
acid/day	O
)	O
or	O
vegetable	O
oil	O
(	O
control	O
)	O
for	O
16	O
weeks	O
.	O

The	O
oils	O
were	O
included	O
in	O
bread	O
.	O

RESULTS	O
After	O
the	O
intervention	O
,	O
the	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
content	O
of	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
and	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
were	O
1.2	O
%	O
+/-0.5	O
%	O
and	O
6.7	O
%	O
+/-1.6	O
%	O
,	O
respectively	O
,	O
in	O
the	O
those	O
receiving	O
fish	O
oil	O
(	O
FO	O
group	O
)	O
,	O
compared	O
with	O
0.6	O
%	O
+/-0.3	O
%	O
and	O
4.1	O
%	O
+/-0.9	O
%	O
in	O
the	O
control	O
group	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
3.8+/-1.4	O
mm	O
Hg	O
lower	O
(	O
P	O
<	O
.006	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
was	O
2.6+/-1.1	O
mm	O
Hg	O
lower	O
(	O
P	O
<	O
.01	O
)	O
in	O
the	O
FO	O
group	O
compared	O
with	O
the	O
control	O
group	O
.	O

Plasma	O
triacylglycerol	O
(	O
TAG	O
)	O
concentration	O
and	O
insulin	O
sensitivity	O
were	O
unaffected	O
by	O
either	O
of	O
the	O
treatments	O
.	O

Plasma	O
high-density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
non-HDL	O
cholesterol	O
were	O
increased	O
by	O
5	O
%	O
and	O
7	O
%	O
,	O
respectively	O
,	O
in	O
the	O
FO	O
group	O
,	O
and	O
by	O
2	O
%	O
and	O
0	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
.01-.02	O
)	O
.	O

The	O
changes	O
in	O
RBC	O
EPA	O
content	O
were	O
inversely	O
correlated	O
with	O
the	O
changes	O
in	O
SBP	O
and	O
DBP	O
and	O
directly	O
correlated	O
with	O
the	O
increases	O
in	O
HDL	O
cholesterol	O
and	O
non-HDL	O
cholesterol	O
concentrations	O
.	O

No	O
association	O
was	O
seen	O
between	O
RBC	O
EPA	O
and	O
plasma	O
TAG	O
concentration	O
or	O
insulin	O
sensitivity	O
.	O

CONCLUSION	O
Fish	O
oil	O
improves	O
BP	O
in	O
normotensive	O
and	O
normolipidemic	O
slightly	O
overweight	O
adolescent	O
boys	O
.	O

Postoperative	O
injection	O
of	O
phenylbutazone	O
does	O
not	O
influence	O
fibrinolytic	O
shutdown	O
.	O

Twenty-nine	SampleSize
patients	O
undergoing	O
cholecystectomy	O
because	O
of	O
chronic	Condition
calculous	Condition
cholecystitis	Condition
were	O
randomised	O
to	O
receive	O
phenylbutazone	O
10	O
mg/kg	O
intramuscularly	O
or	O
a	O
control	O
injection	O
(	O
vehicle-containing	O
local	O
anaesthetic	O
)	O
immediately	O
after	O
completion	O
of	O
surgery	O
.	O

Fibrinogen	O
and	O
plasminogen	O
concentrations	O
in	O
plasma	O
,	O
plasminogen	O
activator	O
inhibitor	O
activity	O
in	O
plasma	O
and	O
fibrinolytic	O
activity	O
in	O
concentrated	O
euglobulins	O
were	O
determined	O
before	O
surgery	O
and	O
on	O
the	O
first	O
,	O
third	O
and	O
seventh	O
postoperative	O
days	O
.	O

Phenylbutazone	O
delayed	O
the	O
postoperative	O
rise	O
of	O
fibrinogen	O
concentration	O
and	O
reduced	O
the	O
plasminogen	O
level	O
on	O
the	O
first	O
day	O
after	O
surgery	O
.	O

Fibrinolytic	O
activity	O
in	O
euglobulins	O
was	O
decreased	O
after	O
the	O
operation	O
in	O
both	O
groups	O
.	O

The	O
great	O
dispersion	O
of	O
the	O
results	O
of	O
plasminogen	O
activator	O
inhibitor	O
activity	O
was	O
the	O
plausible	O
cause	O
of	O
the	O
lack	O
of	O
any	O
significant	O
difference	O
in	O
this	O
variable	O
.	O

The	O
postoperative	O
fibrinolytic	O
shutdown	O
,	O
reflected	O
by	O
the	O
decrease	O
of	O
fibrinolytic	O
activity	O
,	O
was	O
unaffected	O
by	O
phenylbutazone	O
.	O

It	O
can	O
be	O
speculated	O
,	O
however	O
,	O
that	O
the	O
decline	O
of	O
plasminogen	O
concentration	O
after	O
surgery	O
in	O
patients	O
receiving	O
this	O
drug	O
was	O
the	O
result	O
of	O
its	O
stimulatory	O
influence	O
on	O
the	O
conversion	O
of	O
plasminogen	O
into	O
plasmin	O
.	O

High-pressure	O
,	O
rapid-inflation	O
pneumatic	O
compression	O
improves	O
venous	O
hemodynamics	O
in	O
healthy	O
volunteers	O
and	O
patients	O
who	O
are	O
post-thrombotic	O
.	O

PURPOSE	O
Deep	O
vein	O
thrombosis	O
(	O
DVT	O
)	O
is	O
a	O
preventable	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
patients	O
who	O
are	O
hospitalized	O
.	O

An	O
important	O
part	O
of	O
the	O
mechanism	O
of	O
DVT	O
prophylaxis	O
with	O
intermittent	O
pneumatic	O
compression	O
(	O
IPC	O
)	O
is	O
reduced	O
venous	O
stasis	O
with	O
increased	O
velocity	O
of	O
venous	O
return	O
.	O

The	O
conventional	O
methods	O
of	O
IPC	O
use	O
low	O
pressure	O
and	O
slow	O
inflation	O
of	O
the	O
air	O
bladder	O
on	O
the	O
leg	O
to	O
augment	O
venous	O
return	O
.	O

Recently	O
,	O
compression	O
devices	O
have	O
been	O
designed	O
that	O
produce	O
high	O
pressure	O
and	O
rapid	O
inflation	O
of	O
air	O
cuffs	O
on	O
the	O
plantar	O
plexus	O
of	O
the	O
foot	O
and	O
the	O
calf	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
venous	O
velocity	O
response	O
to	O
high-pressure	O
,	O
rapid-inflation	O
compression	O
devices	O
versus	O
standard	O
,	O
low-pressure	O
,	O
slow-inflation	O
compression	O
devices	O
in	O
healthy	O
volunteers	O
and	O
patients	O
with	O
severe	O
post-thrombotic	O
venous	O
disease	O
.	O

METHOD	O
Twenty-two	O
lower	O
extremities	O
from	O
healthy	O
volunteers	O
and	O
11	O
lower	O
extremities	O
from	O
patients	O
with	O
class	O
4	O
to	O
class	O
6	O
post-thrombotic	O
chronic	O
venous	O
insufficiency	O
were	O
studied	O
.	O

With	O
duplex	O
ultrasound	O
scanning	O
(	O
ATL-Ultramark	O
9	O
,	O
Advanced	O
Tech	O
Laboratory	O
,	O
Bothell	O
,	O
Wash	O
)	O
,	O
acute	O
DVT	O
was	O
excluded	O
before	O
subject	O
evaluation	O
.	O

Venous	O
velocities	O
were	O
monitored	O
after	O
the	O
application	O
of	O
each	O
of	O
five	O
IPC	O
devices	O
,	O
with	O
all	O
the	O
patients	O
in	O
the	O
supine	O
position	O
.	O

Three	O
high-pressure	O
,	O
rapid-compression	O
devices	O
and	O
two	O
standard	O
,	O
low-pressure	O
,	O
slow-inflation	O
compression	O
devices	O
were	O
applied	O
in	O
a	O
random	O
sequence	O
.	O

Maximal	O
venous	O
velocities	O
were	O
obtained	O
at	O
the	O
common	O
femoral	O
vein	O
and	O
the	O
popliteal	O
vein	O
for	O
all	O
the	O
devices	O
and	O
were	O
recorded	O
as	O
the	O
mean	O
peak	O
velocity	O
of	O
three	O
compression	O
cycles	O
and	O
compared	O
with	O
baseline	O
velocities	O
.	O

RESULTS	O
The	O
baseline	O
venous	O
velocities	O
were	O
higher	O
in	O
the	O
femoral	O
veins	O
than	O
in	O
the	O
popliteal	O
veins	O
in	O
both	O
the	O
volunteers	O
and	O
the	O
post-thrombotic	O
subjects	O
.	O

Standard	O
and	O
high-pressure	O
,	O
rapid-inflation	O
compression	O
significantly	O
increased	O
the	O
popliteal	O
and	O
femoral	O
vein	O
velocities	O
in	O
healthy	O
and	O
post-thrombotic	O
subjects	O
.	O

High-pressure	O
,	O
rapid-inflation	O
compression	O
produced	O
significantly	O
higher	O
maximal	O
venous	O
velocities	O
in	O
the	O
popliteal	O
and	O
femoral	O
veins	O
in	O
both	O
healthy	O
volunteers	O
and	O
patients	O
who	O
were	O
post-thrombotic	O
as	O
compared	O
with	O
standard	O
compression	O
.	O

Compared	O
with	O
the	O
healthy	O
volunteers	O
,	O
the	O
patients	O
who	O
were	O
post-thrombotic	O
had	O
a	O
significantly	O
attenuated	O
velocity	O
response	O
at	O
both	O
the	O
popliteal	O
and	O
the	O
femoral	O
vein	O
levels	O
.	O

CONCLUSION	O
High-pressure	O
,	O
rapid-inflation	O
pneumatic	O
compression	O
increases	O
popliteal	O
and	O
femoral	O
vein	O
velocity	O
as	O
compared	O
with	O
standard	O
,	O
low-pressure	O
,	O
slow-inflation	O
pneumatic	O
compression	O
.	O

Patients	O
with	O
post-thrombotic	O
venous	O
disease	O
have	O
a	O
compromised	O
hemodynamic	O
response	O
to	O
all	O
IPC	O
devices	O
.	O

However	O
,	O
an	O
increased	O
velocity	O
response	O
to	O
the	O
high-pressure	O
,	O
rapid-inflation	O
compression	O
device	O
is	O
preserved	O
.	O

High-pressure	O
,	O
rapid-inflation	O
pneumatic	O
compression	O
may	O
offer	O
additional	O
protection	O
from	O
thrombotic	O
complications	O
on	O
the	O
basis	O
of	O
an	O
improved	O
hemodynamic	O
response	O
,	O
both	O
in	O
healthy	O
volunteers	O
and	O
in	O
patients	O
who	O
were	O
post-thrombotic	O
.	O

Emotional	O
,	O
motivational	O
and	O
interpersonal	O
responsiveness	O
of	O
children	Age
with	O
autism	Condition
in	O
improvisational	O
music	O
therapy	O
.	O

Through	O
behavioural	O
analysis	O
,	O
this	O
study	O
investigated	O
the	O
social-motivational	O
aspects	O
of	O
musical	O
interaction	O
between	O
the	O
child	Age
and	O
the	O
therapist	O
in	O
improvisational	O
music	O
therapy	O
by	O
measuring	O
emotional	O
,	O
motivational	O
and	O
interpersonal	O
responsiveness	O
in	O
children	Age
with	O
autism	Condition
during	O
joint	O
engagement	O
episodes	O
.	O

The	O
randomized	O
controlled	O
study	O
(	O
n	O
=	O
10	SampleSize
)	O
employed	O
a	O
single	O
subject	O
comparison	O
design	O
in	O
two	O
different	O
conditions	O
,	O
improvisational	O
music	O
therapy	O
and	O
toy	O
play	O
sessions	O
,	O
and	O
DVD	O
analysis	O
of	O
sessions	O
.	O

Improvisational	O
music	O
therapy	O
produced	O
markedly	O
more	O
and	O
longer	O
events	O
of	O
'joy	O
'	O
,	O
'emotional	O
synchronicity	O
'	O
and	O
'initiation	O
of	O
engagement	O
'	O
behaviours	O
in	O
the	O
children	O
than	O
toy	O
play	O
sessions	O
.	O

In	O
response	O
to	O
the	O
therapist	O
's	O
interpersonal	O
demands	O
,	O
'compliant	O
(	O
positive	O
)	O
responses	O
'	O
were	O
observed	O
more	O
in	O
music	O
therapy	O
than	O
in	O
toy	O
play	O
sessions	O
,	O
and	O
'no	O
responses	O
'	O
were	O
twice	O
as	O
frequent	O
in	O
toy	O
play	O
sessions	O
as	O
in	O
music	O
therapy	O
.	O

The	O
results	O
of	O
this	O
exploratory	O
study	O
found	O
significant	O
evidence	O
supporting	O
the	O
value	O
of	O
music	O
therapy	O
in	O
promoting	O
social	O
,	O
emotional	O
and	O
motivational	O
development	O
in	O
children	Age
with	O
autism	Condition
.	O

[	O
Pharmacological	O
correction	O
of	O
free	O
radical	O
disturbances	O
and	O
endotoxicosis	O
in	O
patients	O
with	O
diffuse	O
peritonitis	O
at	O
the	O
postoperative	O
period	O
]	O
.	O

The	O
examination	O
and	O
treatment	O
of	O
64	O
patients	O
have	O
shown	O
that	O
inclusion	O
of	O
complex	O
antioxidant	O
cytoflavin	O
in	O
intensive	O
therapy	O
at	O
the	O
postoperative	O
period	O
of	O
diffuse	O
peritonitis	O
allows	O
the	O
hypoxia	O
degree	O
to	O
be	O
decreased	O
that	O
in	O
its	O
turn	O
results	O
in	O
quicker	O
recovery	O
of	O
the	O
antioxidant	O
system	O
and	O
decreased	O
activity	O
of	O
peroxidation	O
and	O
endotoxicosis	O
level	O
.	O

The	O
clinical	O
course	O
of	O
the	O
postoperative	O
period	O
of	O
diffuse	O
peritonitis	O
with	O
cytoflavin	O
included	O
in	O
intensive	O
therapy	O
is	O
characterized	O
by	O
shorter	O
terms	O
of	O
artificial	O
lung	O
ventilation	O
,	O
shorter	O
time	O
of	O
staying	O
in	O
critical	O
condition	O
,	O
more	O
favorable	O
course	O
of	O
complications	O
.	O

Intravenous	O
regional	O
anaesthesia	O
below	O
the	O
knee	O
.	O

A	O
cross-over	O
study	O
with	O
prilocaine	O
in	O
volunteers	O
.	O

The	O
quality	O
of	O
anaesthesia	O
provided	O
by	O
three	O
dosages	O
of	O
prilocaine	O
,	O
40	O
ml	O
0.5	O
%	O
,	O
20	O
ml	O
1	O
%	O
,	O
or	O
40	O
ml	O
1	O
%	O
,	O
administered	O
in	O
random	O
order	O
,	O
for	O
intravenous	O
regional	O
anaesthesia	O
of	O
the	O
lower	O
extremity	O
below	O
the	O
knee	O
was	O
compared	O
in	O
six	SampleSize
volunteers	O
.	O

Limited	O
sensory	O
blockade	O
was	O
achieved	O
in	O
the	O
groups	O
with	O
40	O
ml	O
0.5	O
%	O
and	O
20	O
ml	O
1	O
%	O
during	O
the	O
30-minute	O
test	O
period	O
.	O

One	O
subject	O
was	O
not	O
fully	O
anaesthetised	O
with	O
any	O
of	O
the	O
dosages	O
used	O
.	O

Recovery	O
was	O
rapid	O
(	O
mean	O
12-13	O
minutes	O
)	O
in	O
these	O
two	O
groups	O
.	O

In	O
two	O
subjects	O
given	O
40	O
ml	O
of	O
1	O
%	O
,	O
complete	O
recovery	O
took	O
90	O
minutes	O
.	O

At	O
30	O
minutes	O
,	O
the	O
degree	O
of	O
flexion	O
remaining	O
in	O
the	O
great	O
toe	O
(	O
control	O
100	O
%	O
)	O
was	O
4	O
%	O
in	O
the	O
groups	O
who	O
received	O
40	O
ml	O
of	O
0.5	O
%	O
and	O
1	O
%	O
,	O
but	O
34	O
%	O
in	O
those	O
who	O
received	O
20	O
ml	O
of	O
1	O
%	O
respectively	O
.	O

Full	O
motor	O
recovery	O
was	O
achieved	O
in	O
8-9	O
minutes	O
.	O

Five	O
of	O
six	O
volunteers	O
who	O
received	O
the	O
400-mg	O
dose	O
experienced	O
subjective	O
signs	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
when	O
the	O
cuff	O
was	O
released	O
.	O

In	O
this	O
group	O
,	O
the	O
mean	O
plasma	O
level	O
of	O
prilocaine	O
at	O
2	O
minutes	O
was	O
1.22	O
micrograms/ml	O
,	O
maximum	O
2.12	O
micrograms/ml	O
.	O

In	O
a	O
radiological	O
examination	O
,	O
no	O
leak	O
of	O
contrast	O
medium	O
under	O
the	O
tourniquet	O
cuff	O
(	O
300	O
mmHg	O
)	O
was	O
detected	O
.	O

The	O
development	O
of	O
anaesthesia	O
was	O
fastest	O
following	O
the	O
largest	O
dose	O
,	O
but	O
the	O
large	O
number	O
of	O
central	O
side	O
effects	O
makes	O
that	O
dosage	O
less	O
suitable	O
for	O
clinical	O
work	O
.	O

The	O
GH	O
response	O
to	O
low-dose	O
bolus	O
growth	O
hormone-releasing	O
hormone	O
(	O
GHRH	O
(	O
1-29	O
)	O
NH2	O
)	O
is	O
attenuated	O
in	O
patients	O
with	O
longstanding	Condition
post-irradiation	Condition
GH	Condition
insufficiency	Condition
.	O

OBJECTIVE	O
Previous	O
studies	O
have	O
suggested	O
that	O
post-irradiation	O
GH	O
insufficiency	O
results	O
from	O
a	O
loss	O
of	O
GHRH	O
secretion	O
,	O
since	O
many	O
patients	O
were	O
able	O
to	O
release	O
GH	O
following	O
exogenous	O
GHRH	O
stimulation	O
.	O

However	O
,	O
supramaximal	O
doses	O
of	O
GHRH	O
were	O
used	O
and	O
the	O
response	O
may	O
decline	O
with	O
time	O
after	O
radiotherapy	O
.	O

We	O
re-evaluated	O
the	O
GHRH	O
dose-response	O
curve	O
in	O
patients	O
post	O
cranial	O
irradiation	O
and	O
in	O
controls	O
.	O

DESIGN	O
Randomized	O
controlled	O
study	O
.	O

METHODS	O
Five	SampleSize
adult	Age
male	Sex
long-term	O
survivors	O
of	O
childhood	SampleSize
brain	SampleSize
tumours	SampleSize
(	O
median	O
age	O
21.8	O
years	O
(	O
18.4-26.7	O
)	O
;	O
13.7	O
years	O
(	O
11.4-15.7	O
)	O
post-radiotherapy	O
,	O
>	O
30Gy	O
)	O
and	O
five	SampleSize
matched	O
controls	O
were	O
studied	O
.	O

An	O
intravenous	O
bolus	O
of	O
GHRH	O
(	O
1-29	O
)	O
NH	O
(	O
2	O
)	O
was	O
administered	O
in	O
doses	O
at	O
the	O
lower	O
(	O
0.05	O
microg/kg	O
)	O
and	O
upper	O
(	O
0.15	O
microg/kg	O
)	O
range	O
of	O
the	O
dose-response	O
curves	O
for	O
young	Age
males	O
,	O
as	O
well	O
as	O
the	O
standard	O
supramaximal	O
dose	O
(	O
1	O
.	O

0	O
microg/kg	O
)	O
.	O

GH	O
was	O
measured	O
before	O
stimulation	O
,	O
every	O
2min	O
for	O
the	O
first	O
hour	O
and	O
every	O
5min	O
for	O
the	O
second	O
hour	O
.	O

All	O
studies	O
were	O
conducted	O
in	O
a	O
random	O
fashion	O
.	O

RESULTS	O
Significantly	O
lower	O
peak	O
and	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
GH	O
concentrations	O
occurred	O
in	O
the	O
irradiated	O
group	O
using	O
0.15	O
microg/kg	O
(	O
median	O
peak	O
Irradiated	O
,	O
4	O
.	O

5mU/l	O
vs	O
median	O
Controls	O
,	O
37.4mU/l	O
;	O
P	O
<	O
0.01	O
)	O
and	O
1.0	O
microg/kg	O
(	O
median	O
peak	O
Irradiated	O
,	O
4.8mU/l	O
vs	O
median	O
Controls	O
,	O
15.2mU/l	O
;	O
P	O
<	O
0	O
.	O

05	O
)	O
GHRH	O
(	O
1-29	O
)	O
NH	O
(	O
2	O
)	O
.	O

In	O
irradiated	O
subjects	O
there	O
was	O
an	O
incremental	O
rise	O
in	O
GH	O
output	O
with	O
increasing	O
doses	O
of	O
GHRH	O
(	O
1-29	O
)	O
NH	O
(	O
2	O
)	O
(	O
median	O
AUC	O
:	O
122mU/l.min	O
vs	O
179mU/l.min	O
vs	O
268mU/l.min	O
;	O
P=0.007	O
)	O
reflecting	O
altered	O
pituitary	O
sensitivity	O
and	O
reduced	O
responsiveness	O
.	O

CONCLUSION	O
The	O
GH	O
response	O
to	O
bolus	O
GHRH	O
(	O
1-29	O
)	O
NH	O
(	O
2	O
)	O
is	O
attenuated	O
in	O
adult	Age
long-term	O
survivors	O
of	O
childhood	Condition
brain	Condition
tumours	Condition
.	O

This	O
may	O
reflect	O
direct	O
pituitary	O
damage	O
and/or	O
the	O
loss	O
of	O
the	O
tropic	O
effects	O
of	O
chronic	O
GHRH	O
deficiency	O
.	O

L-arginine	O
and	O
S-nitrosoglutathione	O
reduce	O
embolization	O
in	O
humans	O
.	O

BACKGROUND	O
L-Arginine	O
reduces	O
platelet	O
aggregation	O
and	O
adhesion	O
in	O
ex	O
vivo	O
studies	O
,	O
but	O
there	O
is	O
no	O
evidence	O
as	O
yet	O
that	O
it	O
has	O
a	O
therapeutic	O
effect	O
on	O
clinical	O
end	O
points	O
.	O

Doppler	O
ultrasound	O
can	O
detect	O
cerebral	O
emboli	O
noninvasively	O
.	O

Such	O
embolic	O
signals	O
are	O
common	O
after	O
carotid	O
endarterectomy	O
,	O
and	O
their	O
frequency	O
predicts	O
risk	O
of	O
stroke	O
recurrence	O
.	O

We	O
used	O
this	O
situation	O
to	O
determine	O
the	O
antiplatelet	O
efficacy	O
of	O
L-arginine	O
and	O
S-nitrosoglutathione	O
(	O
GSNO	O
)	O
,	O
a	O
physiological	O
nitric	O
oxide	O
donor	O
with	O
possible	O
platelet	O
specificity	O
.	O

METHODS	O
AND	O
RESULTS	O
Patients	O
undergoing	Condition
carotid	Condition
endarterectomy	Condition
were	O
randomized	O
in	O
a	O
double-blind	O
manner	O
between	O
L-arginine	O
(	O
n=14	O
)	O
,	O
GSNO	O
(	O
n=14	O
)	O
,	O
or	O
placebo	O
(	O
n=14	O
)	O
administered	O
intravenously	O
for	O
90	O
minutes	O
,	O
starting	O
30	O
minutes	O
after	O
skin	O
closure	O
.	O

All	O
patients	O
were	O
pretreated	O
with	O
aspirin	O
and	O
given	O
heparin	O
during	O
surgery	O
.	O

Transcranial	O
Doppler	O
recordings	O
were	O
made	O
from	O
the	O
ipsilateral	O
middle	O
cerebral	O
artery	O
for	O
4	O
hours	O
after	O
surgery	O
,	O
beginning	O
30	O
minutes	O
after	O
skin	O
closure	O
,	O
and	O
also	O
at	O
6	O
and	O
24	O
hours	O
.	O

There	O
were	O
highly	O
significant	O
reductions	O
in	O
the	O
number	O
of	O
Doppler	O
embolic	O
signals	O
in	O
the	O
L-arginine	O
and	O
GSNO	O
groups	O
;	O
first	O
4	O
hours	O
,	O
median	O
(	O
range	O
)	O
number	O
of	O
embolic	O
signals	O
,	O
placebo	O
44.7	O
(	O
6	O
to	O
778	O
)	O
,	O
L-arginine	O
9.5	O
(	O
0	O
to	O
225	O
)	O
,	O
and	O
GSNO	O
0.8	O
(	O
0	O
to	O
8	O
)	O
,	O
both	O
P	O
<	O
0.001	O
versus	O
control	O
values	O
.	O

The	O
reduction	O
in	O
the	O
signals	O
persisted	O
at	O
the	O
24-hour	O
recording	O
.	O

CONCLUSIONS	O
Intravenous	O
L-arginine	O
and	O
GSNO	O
attenuate	O
Doppler	O
embolic	O
signals	O
in	O
humans	O
.	O

Modulation	O
of	O
the	O
NO	O
system	O
with	O
these	O
agents	O
may	O
have	O
applications	O
in	O
the	O
treatment	O
of	O
thromboembolic	Condition
disease	Condition
.	O

This	O
study	O
demonstrates	O
the	O
potential	O
application	O
of	O
ultrasonic	O
embolic	O
signal	O
detection	O
to	O
examine	O
the	O
efficacy	O
of	O
new	O
antiplatelet	O
agents	O
in	O
relatively	O
small	O
numbers	O
of	O
patients	O
.	O

A	O
single	O
nasal	O
allergen	O
challenge	O
increases	O
induced	O
sputum	O
inflammatory	O
markers	O
in	O
non-asthmatic	O
subjects	O
with	O
seasonal	O
allergic	O
rhinitis	O
:	O
correlation	O
with	O
plasma	O
interleukin-5	O
.	O

BACKGROUND	O
Seasonal	O
allergic	O
rhinitis	O
(	O
SAR	O
)	O
is	O
a	O
risk	O
factor	O
for	O
asthma	O
in	O
affected	O
individuals	O
.	O

Nasal	O
allergic	O
inflammation	O
enhances	O
bone-marrow	O
eosinophil	O
production	O
,	O
mainly	O
via	O
IL-5	O
,	O
and	O
rhinitis	O
patients	O
have	O
increased	O
airway	O
inflammation	O
during	O
the	O
pollen	O
season	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
impact	O
of	O
nasal	O
allergy	O
on	O
sputum	O
inflammatory	O
markers	O
.	O

METHODS	O
In	O
an	O
open-labelled	O
,	O
randomized	O
,	O
placebo-controlled	O
cross-over	O
study	O
with	O
16	SampleSize
non-asthmatic	O
SAR	O
patients	O
(	O
median	O
age	O
25	O
years	O
,	O
56	SampleSize
%	SampleSize
males	O
)	O
,	O
the	O
effect	O
of	O
a	O
single	O
nasal	O
allergen	O
challenge	O
performed	O
out	O
of	O
season	O
on	O
induced	O
sputum	O
inflammatory	O
parameters	O
was	O
evaluated	O
.	O

SAR	O
patients	O
were	O
identified	Condition
by	Condition
history	Condition
,	Condition
skin-prick	Condition
test	Condition
and	Condition
specific	Condition
IgE	Condition
.	O

All	O
patients	O
had	O
normal	O
lung	O
function/bronchial	O
hyper-responsiveness	O
out	O
of	O
season	O
and	O
a	O
negative	O
asthma/wheezing	O
history	O
.	O

Sputum	O
cells	O
and	O
supernatant	O
levels	O
of	O
ECP	O
,	O
sICAM	O
,	O
IL-5	O
and	O
IL-10	O
,	O
and	O
plasma	O
levels	O
of	O
IL-5	O
and	O
ECP	O
,	O
were	O
measured	O
before	O
and	O
24	O
h	O
after	O
nasal	O
allergen	O
challenge	O
.	O

After	O
a	O
washout	O
period	O
of	O
at	O
least	O
4	O
weeks	O
,	O
the	O
procedure	O
was	O
repeated	O
with	O
placebo	O
challenge	O
(	O
diluent	O
)	O
.	O

RESULTS	O
Nasal	O
allergen	O
challenge	O
led	O
to	O
an	O
increase	O
in	O
sputum	O
ECP	O
(	O
pre	O
=	O
60	O
+/-	O
12	O
,	O
post	O
=	O
212	O
+/-	O
63	O
micro	O
g/L	O
,	O
P	O
=	O
0.02	O
vs.	O
placebo	O
)	O
,	O
and	O
sICAM	O
(	O
4.8	O
+/-	O
2.7	O
to	O
6.5	O
+/-	O
2.9	O
ng/mL	O
,	O
P	O
=	O
0.02	O
vs.	O
placebo	O
)	O
,	O
whereas	O
IL-10	O
decreased	O
after	O
provocation	O
(	O
44	O
+/-	O
11	O
to	O
29	O
+/-	O
6	O
pg/mL	O
,	O
P	O
=	O
0.06	O
vs.	O
placebo	O
)	O
.	O

Sputum	O
IL-5	O
was	O
undetectable	O
in	O
all	O
patients	O
.	O

The	O
absolute	O
number	O
of	O
blood	O
and	O
sputum	O
eosinophils	O
did	O
not	O
change	O
significantly	O
after	O
allergen	O
or	O
placebo	O
challenge	O
(	O
P	O
>	O
0.07	O
,	O
both	O
comparisons	O
)	O
.	O

Plasma	O
levels	O
of	O
IL-5	O
increased	O
after	O
allergen	O
challenge	O
(	O
8.7	O
+/-	O
2.9	O
to	O
14.5	O
+/-	O
3.9	O
pg/mL	O
,	O
P	O
=	O
0.001	O
)	O
,	O
and	O
the	O
increase	O
in	O
plasma	O
IL-5	O
was	O
positively	O
correlated	O
with	O
the	O
rise	O
in	O
sputum	O
ECP	O
in	O
a	O
subgroup	O
of	O
'responders	O
'	O
(	O
n	O
=	O
12	O
,	O
r	O
=	O
0.71	O
,	O
P	O
=	O
0.01	O
)	O
.	O

CONCLUSIONS	O
A	O
single	O
nasal	O
allergen	O
challenge	O
in	O
SAR	O
patients	O
increased	O
markers	O
of	O
allergic	O
inflammation	O
in	O
the	O
lower	O
respiratory	O
tract	O
,	O
possibly	O
via	O
pronounced	O
activation	O
of	O
inflammatory	O
cells	O
through	O
circulating	O
immediate-type	O
reaction	O
cytokines	O
like	O
IL-5	O
.	O

These	O
findings	O
may	O
provide	O
additional	O
explanatory	O
data	O
for	O
the	O
high	O
susceptibility	O
of	O
SAR	O
patients	O
to	O
incident	O
asthma	O
.	O

Study	O
design	O
and	O
rationale	O
of	O
a	O
dose-ranging	O
trial	O
of	O
LX4211	O
,	O
a	O
dual	O
inhibitor	O
of	O
SGLT1	O
and	O
SGLT2	O
,	O
in	O
type	O
2	O
diabetes	O
inadequately	O
controlled	O
on	O
metformin	O
monotherapy	O
.	O

Sodium-glucose	O
cotransporters	O
1	O
(	O
SGLT1	O
)	O
and	O
2	O
(	O
SGLT2	O
)	O
are	O
the	O
major	O
cellular	O
transporters	O
responsible	O
for	O
gastrointestinal	O
(	O
GI	O
)	O
glucose	O
absorption	O
and	O
renal	O
glucose	O
reabsorption	O
,	O
respectively	O
.	O

LX4211	O
,	O
a	O
dual	O
inhibitor	O
of	O
SGLT1	O
and	O
SGLT2	O
,	O
reduces	O
glucose	O
absorption	O
from	O
the	O
GI	O
tract	O
and	O
enhances	O
urinary	O
glucose	O
excretion	O
.	O

Although	O
several	O
SGLT2-selective	O
inhibitors	O
have	O
been	O
tested	O
in	O
large	O
phase	O
2	O
studies	O
,	O
dual	O
inhibition	O
of	O
SGLT1	O
and	O
SGLT2	O
is	O
novel	O
at	O
this	O
stage	O
of	O
drug	O
development	O
,	O
and	O
it	O
has	O
implications	O
for	O
clinical-trial	O
design	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
design	O
and	O
rationale	O
of	O
a	O
phase	O
2	O
,	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
LX4211	O
in	O
subjects	O
with	O
type	O
2	O
diabetes	O
mellitus	O
who	O
have	O
inadequate	O
glycemic	O
control	O
on	O
metformin	O
monotherapy	O
.	O

The	O
primary	O
endpoint	O
is	O
the	O
change	O
in	O
glycated	O
hemoglobin	O
A1c	O
from	O
baseline	O
to	O
week	O
12	O
.	O

Secondary	O
endpoints	O
include	O
the	O
proportion	O
of	O
subjects	O
achieving	O
a	O
glycated	O
hemoglobin	O
A1c	O
value	O
of	O
<	O
7	O
%	O
,	O
change	O
from	O
baseline	O
in	O
fasting	O
plasma	O
glucose	O
and	O
postprandial	O
glucose	O
(	O
as	O
part	O
of	O
an	O
oral	O
glucose	O
tolerance	O
test	O
)	O
,	O
body	O
weight	O
,	O
and	O
blood	O
pressure	O
.	O

Safety	O
is	O
evaluated	O
with	O
particular	O
focus	O
on	O
hypoglycemia	O
,	O
GI	O
symptoms	O
,	O
and	O
incidence	O
of	O
genitourinary	O
tract	O
infections	O
.	O

The	O
Social	O
Communication	O
Assessment	O
for	O
Toddlers	O
with	O
Autism	O
(	O
SCATA	O
)	O
:	O
an	O
instrument	O
to	O
measure	O
the	O
frequency	O
,	O
form	O
and	O
function	O
of	O
communication	O
in	O
toddlers	O
with	O
autism	O
spectrum	O
disorder	O
.	O

The	O
Social	O
Communication	O
Assessment	O
for	O
Toddlers	O
with	O
Autism	O
(	O
SCATA	O
)	O
was	O
designed	O
to	O
measure	O
non-verbal	O
communication	O
,	O
including	O
early	O
and	O
atypical	O
communication	O
,	O
in	O
young	O
children	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Each	O
communicative	O
act	O
is	O
scored	O
according	O
to	O
its	O
form	O
,	O
function	O
,	O
role	O
and	O
complexity	O
.	O

The	O
SCATA	O
was	O
used	O
to	O
measure	O
communicative	O
ability	O
longitudinally	O
in	O
two	O
samples	O
of	O
toddlers	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Overall	O
frequency	O
of	O
non-verbal	O
communicative	O
acts	O
did	O
not	O
change	O
between	O
the	O
two	O
assessments	O
.	O

However	O
,	O
the	O
form	O
and	O
complexity	O
,	O
the	O
function	O
and	O
the	O
role	O
the	O
child	O
took	O
in	O
the	O
interaction	O
did	O
change	O
with	O
time	O
.	O

Both	O
frequency	O
and	O
function	O
of	O
communicative	O
acts	O
in	O
toddlerhood	O
were	O
positively	O
associated	O
with	O
later	O
language	O
ability	O
:	O
social	O
acts	O
,	O
comments	O
and	O
initiations	O
showed	O
greater	O
predictive	O
association	O
than	O
requests	O
and	O
responses	O
.	O

The	O
addition	O
of	O
amifostine	O
to	O
carboplatin	O
and	O
paclitaxel	O
based	O
chemoradiation	O
in	O
locally	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
:	O
long-term	O
follow-up	O
of	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(	O
RTOG	O
)	O
randomized	O
trial	O
9801	O
.	O

INTRODUCTION	O
We	O
report	O
the	O
long-term	O
results	O
of	O
RTOG	O
9801	O
,	O
a	O
randomized	O
trial	O
investigating	O
the	O
ability	O
of	O
amifostine	O
,	O
a	O
radioprotector	O
,	O
to	O
reduce	O
chemoradiation-induced	O
esophagitis	O
.	O

METHODS	O
Patients	O
with	O
stages	O
II	O
and	O
IIIA/B	O
non-small-cell	O
lung	O
cancer	O
received	O
induction	O
paclitaxel	O
225	O
mg/m2	O
intravenously	O
(	O
IV	O
)	O
and	O
carboplatin	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
6	O
both	O
days	O
1	O
and	O
22	O
,	O
followed	O
by	O
concurrent	O
weekly	O
paclitaxel	O
(	O
50	O
mg/m2	O
)	O
and	O
carboplatin	O
(	O
AUC	O
2	O
)	O
,	O
with	O
hyperfractionated	O
radiation	O
therapy	O
(	O
69.6	O
Gy	O
at	O
1.2	O
Gy	O
BID	O
)	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
amifostine	O
(	O
AM	O
)	O
500	O
mg	O
IV	O
four	O
times	O
per	O
week	O
or	O
no-AM	O
during	O
chemoradiotherapy	O
.	O

Stratification	O
factors	O
included	O
age	O
(	O
<	O
70	O
vs.	O
?70	O
years	O
)	O
,	O
stage	O
and	O
performance	O
status	O
.	O

RESULTS	O
243	O
patients	O
(	O
pts	O
)	O
were	O
enrolled	O
;	O
120	O
received	O
AM	O
,	O
123	O
received	O
no-AM	O
.	O

Two	O
pts	O
on	O
each	O
arm	O
were	O
found	O
ineligible	O
.	O

Overall	O
,	O
85	O
%	O
of	O
patients	O
were	O
?70	O
years	O
;	O
75	O
%	O
had	O
a	O
KPS	O
?90	O
.	O

34	O
%	O
had	O
squamous	O
histology	O
.	O

With	O
median	O
follow-up	O
of	O
96.3	O
months	O
(	O
for	O
patients	O
still	O
alive	O
)	O
,	O
overall	O
survival	O
was	O
identical	O
(	O
hazard	O
ratio	O
1.03	O
(	O
0.79-1.34	O
)	O
,	O
NS	O
)	O
:	O
five-year	O
survival	O
17	O
%	O
in	O
both	O
arms	O
.	O

The	O
incidence	O
of	O
late	O
grade	O
3-5	O
toxicities	O
was	O
16	O
%	O
in	O
the	O
AM	O
arm	O
and	O
19	O
%	O
in	O
the	O
control	O
arm	O
(	O
hazard	O
ratio	O
1.24	O
(	O
0.66-2.32	O
)	O
,	O
NS	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
arms	O
regarding	O
overall	O
survival	O
,	O
disease-free	O
survival	O
or	O
long-term	O
toxicity	O
.	O

CONCLUSION	O
The	O
chemoradiation	O
regimen	O
of	O
carboplatin	O
and	O
paclitaxel	O
produced	O
long-term	O
results	O
in	O
the	O
multi-institutional	O
setting	O
comparable	O
to	O
other	O
regimens	O
.	O

Amifostine	O
did	O
not	O
appear	O
to	O
compromise	O
survival	O
.	O

As	O
done	O
in	O
RTOG	O
9801	O
,	O
more	O
consistent	O
reporting	O
of	O
long	O
term	O
toxicity	O
is	O
needed	O
for	O
comparison	O
of	O
different	O
chemoradiation	O
regimens	O
.	O

Not	O
Now	O
!	O
Supporting	O
interruption	O
management	O
by	O
indicating	O
the	O
modality	O
and	O
urgency	O
of	O
pending	O
tasks	O
.	O

Operators	O
in	O
complex	O
event-driven	O
domains	O
must	O
coordinate	O
competing	O
attentional	O
demands	O
in	O
the	O
form	O
of	O
multiple	O
tasks	O
and	O
interactions	O
.	O

This	O
study	O
examined	O
the	O
extent	O
to	O
which	O
this	O
requirement	O
can	O
be	O
supported	O
more	O
effectively	O
through	O
informative	O
interruption	O
cueing	O
(	O
in	O
this	O
case	O
,	O
partial	O
information	O
about	O
the	O
nature	O
of	O
pending	O
tasks	O
)	O
.	O

The	O
48	SampleSize
participants	O
performed	O
a	O
visually	Condition
demanding	Condition
air	Condition
traffic	Condition
control	Condition
(	Condition
ATC	Condition
)	Condition
task	Condition
.	O

They	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
experimental	O
groups	O
that	O
differed	O
in	O
the	O
availability	O
of	O
information	O
(	O
not	O
available	O
,	O
available	O
upon	O
request	O
,	O
available	O
automatically	O
)	O
about	O
the	O
urgency	O
and	O
modality	O
of	O
pending	O
interruption	O
tasks	O
.	O

Within-subject	O
variables	O
included	O
ATC-related	O
workload	O
and	O
the	O
modality	O
,	O
frequency	O
,	O
and	O
priority	O
of	O
interruption	O
tasks	O
.	O

The	O
results	O
show	O
that	O
advance	O
knowledge	O
about	O
the	O
nature	O
of	O
pending	O
tasks	O
led	O
participants	O
to	O
delay	O
visual	O
interruption	O
tasks	O
the	O
longest	O
,	O
which	O
allowed	O
them	O
to	O
avoid	O
intramodal	O
interference	O
and	O
scanning	O
costs	O
associated	O
with	O
performing	O
these	O
tasks	O
concurrently	O
with	O
ATC	O
tasks	O
.	O

The	O
3	O
experimental	O
groups	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
their	O
interruption	O
task	O
performance	O
;	O
however	O
,	O
the	O
group	O
that	O
automatically	O
received	O
task-related	O
information	O
showed	O
better	O
ATC	O
performance	O
,	O
thus	O
experiencing	O
a	O
net	O
performance	O
gain	O
.	O

Actual	O
or	O
potential	O
applications	O
of	O
this	O
research	O
include	O
the	O
design	O
of	O
interfaces	O
in	O
support	O
of	O
attention	O
and	O
interruption	O
management	O
in	O
a	O
wide	O
range	O
of	O
event-driven	O
environments	O
.	O

The	O
protective	O
effects	O
of	O
angiotensin	O
II	O
blockade	O
with	O
olmesartan	O
medoxomil	O
on	O
resistance	O
vessel	O
remodeling	O
(	O
The	O
VIOS	O
study	O
)	O
:	O
rationale	O
and	O
baseline	O
characteristics	O
.	O

BACKGROUND	O
The	O
VIOS	O
(	O
Vascular	O
Improvement	O
with	O
Olmesartan	O
medoxomil	O
Study	O
)	O
study	O
is	O
a	O
randomized	O
,	O
parallel	O
study	O
to	O
determine	O
the	O
relative	O
effects	O
of	O
suppressing	O
the	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
with	O
the	O
angiotensin	O
receptor	O
antagonist	O
olmesartan	O
medoxomil	O
versus	O
suppressing	O
sympathetic	O
drive	O
with	O
the	O
beta-adrenoceptor	O
antagonist	O
atenolol	O
on	O
remodeling	O
of	O
the	O
subcutaneous	O
small	O
resistance	O
vessel	O
.	O

Remodeling	O
of	O
small	O
resistance	O
vessels	O
may	O
be	O
the	O
earliest	O
pathologic	O
finding	O
associated	O
with	O
hypertension	O
.	O

It	O
may	O
predate	O
the	O
onset	O
of	O
clinically	O
apparent	O
hypertension	O
.	O

METHODS	O
In	O
this	O
study	O
,	O
100	SampleSize
patients	O
with	O
stage	Condition
I	Condition
hypertension	Condition
are	O
characterized	O
at	O
baseline	O
before	O
being	O
treated	O
for	O
1	O
year	O
to	O
obtain	O
a	O
goal	O
BP	O
of	O
less	O
than	O
140/90	O
mm	O
Hg	O
as	O
defined	O
by	O
Joint	O
National	O
Committee	O
(	O
JNC	O
)	O
-7	O
.	O

Resistance	O
vessel	O
remodeling	O
is	O
determined	O
using	O
the	O
gluteal	O
fat	O
biopsy	O
technique	O
in	O
the	O
hypertensive	O
patients	O
and	O
a	O
group	O
of	O
normotensive	O
healthy	O
volunteers	O
.	O

Additionally	O
,	O
efforts	O
will	O
be	O
made	O
to	O
define	O
whether	O
noninvasive	O
hemodynamic	O
parameters	O
,	O
retinal	O
vessel	O
measurement	O
changes	O
,	O
or	O
biologic	O
markers	O
may	O
predict	O
and	O
track	O
the	O
underlying	O
vascular	O
morphologic	O
and	O
physiologic	O
changes	O
induced	O
by	O
either	O
regimen	O
during	O
the	O
12-month	O
treatment	O
period	O
.	O

RESULTS	O
The	O
primary	O
endpoint	O
will	O
be	O
the	O
degree	O
of	O
vascular	O
remodeling	O
as	O
obtained	O
from	O
percutaneous	O
biopsy	O
of	O
gluteal	O
subcutaneous	O
resistance	O
vessels	O
in	O
each	O
of	O
two	O
treatment	O
arms	O
compared	O
with	O
the	O
normal	O
volunteers	O
.	O

The	O
design	O
of	O
the	O
study	O
and	O
the	O
pertinent	O
baseline	O
characteristics	O
of	O
these	O
patients	O
with	O
uncomplicated	O
essential	O
hypertension	O
are	O
presented	O
.	O

CONCLUSION	O
The	O
suppression	O
of	O
the	O
RAS	O
by	O
the	O
blockade	O
of	O
angiotensin	O
II	O
type	O
1	O
(	O
AT	O
(	O
1	O
)	O
)	O
receptors	O
may	O
demonstrate	O
remodeling	O
effects	O
on	O
the	O
ubiquitous	O
small	O
resistance	O
vessels	O
similar	O
to	O
that	O
seen	O
in	O
the	O
myocardium	O
and	O
renal	O
glomeruli	O
,	O
thus	O
affording	O
more	O
complete	O
end-organ	O
protection	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
phase	O
I	O
study	O
of	O
MEDI-545	O
,	O
an	O
anti-interferon-alfa	O
monoclonal	O
antibody	O
,	O
in	O
subjects	O
with	O
chronic	O
psoriasis	O
.	O

BACKGROUND	O
Interferon-alfa	O
(	O
IFN-alpha	O
)	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
psoriasis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
safety	O
profile	O
of	O
MEDI-545	O
,	O
a	O
fully	O
human	O
anti-IFN-alpha	O
monoclonal	O
antibody	O
and	O
to	O
explore	O
its	O
effect	O
on	O
the	O
involvement	O
of	O
type	O
I	O
IFN-alpha	O
activity	O
in	O
the	O
maintenance	O
of	O
established	O
plaque	O
psoriasis	O
.	O

METHODS	O
We	O
conducted	O
an	O
18-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
dose-escalating	O
study	O
in	O
36	O
subjects	O
with	O
chronic	O
plaque	O
psoriasis	O
.	O

Subjects	O
received	O
one	O
intravenous	O
dose	O
of	O
MEDI-545	O
(	O
0.3-30.0	O
mg/kg	O
)	O
or	O
placebo	O
.	O

Study	O
outcomes	O
were	O
safety	O
profile	O
,	O
pharmacokinetics	O
,	O
immunogenicity	O
,	O
and	O
clinical	O
effects	O
.	O

RESULTS	O
There	O
was	O
no	O
difference	O
in	O
adverse	O
events	O
between	O
MEDI-545	O
and	O
placebo	O
.	O

Two	O
serious	O
adverse	O
events	O
were	O
reported	O
;	O
one	O
drug-related	O
hypotensive	O
infusion	O
reaction	O
occurred	O
in	O
one	O
subject	O
in	O
the	O
30.0	O
mg/kg	O
MEDI-545	O
dose	O
group	O
,	O
causing	O
discontinuation	O
of	O
study	O
drug	O
in	O
that	O
subject	O
and	O
study	O
dismissal	O
of	O
the	O
other	O
subjects	O
in	O
the	O
same	O
cohort	O
;	O
and	O
a	O
myocardial	O
infarction	O
occurred	O
in	O
one	O
subject	O
in	O
the	O
10	O
mg/kg	O
MEDI-545	O
dose	O
group	O
,	O
which	O
was	O
considered	O
to	O
be	O
unrelated	O
to	O
treatment	O
.	O

MEDI-545	O
was	O
nonimmunogenic	O
,	O
had	O
a	O
half-life	O
of	O
21	O
days	O
,	O
showed	O
no	O
significant	O
inhibition	O
of	O
the	O
type	O
I	O
IFN	O
gene	O
signature	O
,	O
and	O
had	O
no	O
clinical	O
activity	O
.	O

LIMITATIONS	O
The	O
study	O
addressed	O
only	O
IFN-alpha	O
and	O
chronic	O
psoriatic	O
lesions	O
.	O

CONCLUSION	O
The	O
safety	O
profile	O
of	O
MEDI-545	O
supports	O
further	O
clinical	O
development	O
.	O

IFN-alpha	O
does	O
not	O
appear	O
to	O
be	O
significantly	O
involved	O
in	O
the	O
maintenance	O
of	O
established	O
plaque	O
psoriasis	O
.	O

[	O
The	O
value	O
of	O
local	O
administration	O
of	O
antibiotics	O
in	O
treatment	O
of	O
bone	O
infections	O
]	O
.	O

An	O
open	O
,	O
controlled	O
,	O
randomized	O
clinical	O
investigation	O
was	O
carried	O
out	O
in	O
33	O
patients	O
suffering	O
from	O
osteomyelitis	O
.	O

In	O
the	O
first	O
group	O
,	O
17	O
patients	O
,	O
a	O
through	O
drainage	O
with	O
sterile	O
physiologic	O
solution	O
was	O
applied	O
,	O
while	O
in	O
the	O
second	O
group	O
,	O
16	O
patients	O
,	O
antibiotic	O
was	O
added	O
to	O
the	O
sterile	O
physiologic	O
solution	O
.	O

In	O
all	O
patients	O
values	O
of	O
C	O
reactive	O
protein	O
(	O
CRP	O
)	O
in	O
the	O
blood	O
were	O
examined	O
,	O
and	O
later	O
on	O
every	O
third	O
day	O
after	O
the	O
operation	O
.	O

A	O
significant	O
difference	O
of	O
average	O
values	O
of	O
CRP	O
between	O
the	O
3rd	O
and	O
21st	O
day	O
in	O
both	O
groups	O
of	O
patients	O
was	O
established	O
,	O
as	O
well	O
as	O
the	O
similarity	O
in	O
average	O
values	O
of	O
CRP	O
,	O
which	O
points	O
to	O
the	O
fact	O
that	O
the	O
mechanical	O
effect	O
of	O
through	O
drainage	O
is	O
dominant	O
,	O
speaking	O
about	O
rinsing	O
focus	O
of	O
infection	O
and	O
eliminating	O
necrotic	O
tissues	O
and	O
small	O
sequesters	O
.	O

Rapeseed	O
and	O
soybean	O
products	O
as	O
protein	O
sources	O
for	O
growing	O
turkeys	O
of	O
different	O
ages	O
.	O

(	O
1	O
)	O
Apparent	O
ileal	O
and	O
total	O
tract	O
protein	O
digestibilities	O
of	O
rapeseed	O
meal	O
and	O
cake	O
and	O
soybean	O
meal	O
and	O
cake	O
were	O
assayed	O
in	O
growing	O
turkeys	O
at	O
4	Age
,	Age
8	Age
and	Age
12	Age
weeks	Age
of	O
age	O
.	O

(	O
2	O
)	O
In	O
addition	O
,	O
the	O
effect	O
of	O
killing	O
technique	O
on	O
apparent	O
ileal	O
protein	O
digestibility	O
values	O
obtained	O
by	O
a	O
slaughter	O
method	O
and	O
effect	O
of	O
rapeseed	O
feeding	O
on	O
size	O
of	O
specific	O
organs	O
were	O
studied	O
.	O

(	O
3	O
)	O
Protein	O
digestibility	O
coefficients	O
of	O
rapeseed	O
products	O
were	O
mostly	O
0.10	O
to	O
0.15	O
units	O
lower	O
than	O
those	O
of	O
soybean	O
products	O
.	O

Ileal	O
digestibility	O
of	O
protein	O
increased	O
slightly	O
or	O
remained	O
unchanged	O
from	O
4	O
to	O
8	O
weeks	O
and	O
decreased	O
thereafter	O
.	O

No	O
effect	O
of	O
feed	O
processing	O
method	O
(	O
meal	O
vs	O
cake	O
)	O
on	O
ileal	O
digestibility	O
was	O
observed	O
.	O

(	O
4	O
)	O
Killing	O
the	O
birds	O
by	O
carbon	O
dioxide	O
inhalation	O
and	O
bleeding	O
led	O
to	O
slightly	O
lower	O
ileal	O
digestibility	O
values	O
than	O
mechanical	O
stunning	O
and	O
neck	O
dislocation	O
.	O

(	O
5	O
)	O
Total	O
tract	O
digestibility	O
of	O
protein	O
decreased	O
from	O
4	O
to	O
8	O
weeks	O
of	O
age	O
for	O
soybean	O
meal	O
and	O
rapeseed	O
meal	O
but	O
increased	O
for	O
soybean	O
cake	O
and	O
rapeseed	O
cake	O
.	O

From	O
8	O
to	O
12	O
weeks	O
of	O
age	O
total	O
tract	O
digestibility	O
of	O
protein	O
decreased	O
for	O
all	O
the	O
products	O
tested	O
.	O

(	O
6	O
)	O
Feed	O
containing	O
rapeseed	O
led	O
to	O
enlargement	O
of	O
thyroid	O
glands	O
and	O
hearts	O
,	O
but	O
did	O
not	O
affect	O
liver	O
size	O
or	O
mortality	O
.	O

Phase	O
III	O
trial	O
comparing	O
whole-pelvic	O
versus	O
prostate-only	O
radiotherapy	O
and	O
neoadjuvant	O
versus	O
adjuvant	O
combined	O
androgen	O
suppression	O
:	O
Radiation	O
Therapy	O
Oncology	O
Group	O
9413	O
.	O

PURPOSE	O
This	O
trial	O
tested	O
the	O
hypothesis	O
that	O
combined	O
androgen	O
suppression	O
(	O
CAS	O
)	O
and	O
whole-pelvic	O
(	O
WP	O
)	O
radiotherapy	O
(	O
RT	O
)	O
followed	O
by	O
a	O
boost	O
to	O
the	O
prostate	O
improves	O
progression-free	O
survival	O
(	O
PFS	O
)	O
by	O
10	O
%	O
compared	O
with	O
CAS	O
and	O
prostate-only	O
(	O
PO	O
)	O
RT	O
.	O

This	O
trial	O
also	O
tested	O
the	O
hypothesis	O
that	O
neoadjuvant	O
and	O
concurrent	O
hormonal	O
therapy	O
(	O
NCHT	O
)	O
improves	O
PFS	O
compared	O
with	O
adjuvant	O
hormonal	O
therapy	O
(	O
AHT	O
)	O
by	O
10	O
%	O
.	O

MATERIALS	O
AND	O
METHODS	O
Eligibility	Condition
included	Condition
localized	Condition
prostate	Condition
cancer	Condition
with	Condition
an	Condition
elevated	Condition
prostate-specific	Condition
antigen	Condition
(	Condition
PSA	Condition
)	Condition
<	Condition
or	Condition
=	Condition
100	Condition
ng/mL	Condition
and	Condition
an	Condition
estimated	Condition
risk	Condition
of	Condition
lymph	Condition
node	Condition
(	Condition
LN	Condition
)	Condition
involvement	Condition
of	Condition
15	Condition
%	Condition
.	Condition

Between	O
April	O
1	O
,	O
1995	O
,	O
and	O
June	O
1	O
,	O
1999	O
,	O
1,323	O
patients	O
were	O
accrued	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
WP	O
+	O
NCHT	O
,	O
PO	O
+	O
NCHT	O
,	O
WP	O
+	O
AHT	O
,	O
or	O
PO	O
+	O
AHT	O
.	O

Failure	O
for	O
PFS	O
was	O
defined	O
as	O
the	O
first	O
occurrence	O
of	O
local	O
,	O
regional	O
,	O
or	O
distant	O
disease	O
;	O
PSA	O
failure	O
;	O
or	O
death	O
for	O
any	O
cause	O
.	O

RESULTS	O
With	O
a	O
median	O
follow-up	O
of	O
59.5	O
months	O
,	O
WP	O
RT	O
was	O
associated	O
with	O
a	O
4-year	O
PFS	O
of	O
54	O
%	O
compared	O
with	O
47	O
%	O
in	O
patients	O
treated	O
with	O
PO	O
RT	O
(	O
P	O
=.022	O
)	O
.	O

Patients	O
treated	O
with	O
NCHT	O
experienced	O
a	O
4-year	O
PFS	O
of	O
52	O
%	O
versus	O
49	O
%	O
for	O
AHT	O
(	O
P	O
=.56	O
)	O
.	O

When	O
comparing	O
all	O
four	O
arms	O
,	O
there	O
was	O
a	O
progression-free	O
difference	O
among	O
WP	O
RT	O
+	O
NCHT	O
,	O
PO	O
RT	O
+	O
NCHT	O
,	O
WP	O
RT	O
+	O
AHT	O
,	O
and	O
PO	O
RT	O
+	O
AHT	O
(	O
60	O
%	O
v	O
44	O
%	O
v	O
49	O
%	O
v	O
50	O
%	O
,	O
respectively	O
;	O
P	O
=.008	O
)	O
.	O

No	O
survival	O
advantage	O
has	O
yet	O
been	O
seen	O
.	O

CONCLUSION	O
WP	O
RT	O
+	O
NCHT	O
improves	O
PFS	O
compared	O
with	O
PO	O
RT	O
and	O
NCHT	O
or	O
PO	O
RT	O
and	O
AHT	O
,	O
and	O
compared	O
with	O
WP	O
RT	O
+	O
AHT	O
in	O
patients	O
with	O
a	O
risk	O
of	O
LN	O
involvement	O
of	O
15	O
%	O
.	O

Dietary	O
sodium	O
intake	O
modulates	O
myocardial	Condition
relaxation	Condition
responsiveness	O
to	O
angiotensin	O
II	O
.	O

Dietary	O
sodium	O
alters	O
renovascular	O
responsiveness	O
to	O
angiotensin	O
II	O
(	O
Ang	O
II	O
)	O
in	O
normal	Condition
subjects	Condition
.	O

Evidence	O
supports	O
a	O
connection	O
among	O
dietary	O
sodium	O
,	O
the	O
rennin-angiotensin	O
system	O
,	O
and	O
myocardial	O
function	O
.	O

The	O
authors	O
hypothesized	O
that	O
a	O
similar	O
relationship	O
would	O
exist	O
in	O
the	O
heart	O
,	O
and	O
that	O
the	O
pattern	O
of	O
responses	O
would	O
be	O
qualitatively	O
similar	O
to	O
the	O
renal	O
vasculature	O
.	O

Thirteen	SampleSize
healthy	Condition
volunteers	Condition
(	O
aged	Age
38.6	Age
+/-	Age
4	Age
years	Age
)	O
entered	O
a	O
2	O
week	O
crossover	O
design	O
study	O
(	O
week	O
1	O
,	O
high	O
sodium	O
diet	O
[	O
HS	O
]	O
>	O
200	O
mmol	O
Na/day	O
;	O
week	O
2	O
,	O
low	O
sodium	O
diet	O
[	O
LS	O
]	O
,	O
<	O
10	O
mmol	O
Na/day	O
)	O
to	O
investigate	O
the	O
influence	O
of	O
dietary	O
sodium	O
and	O
Ang	O
II	O
on	O
myocardial	O
relaxation	O
and	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
.	O

At	O
the	O
end	O
of	O
each	O
study	O
week	O
,	O
the	O
authors	O
assessed	O
diastolic	O
function	O
(	O
myocardial	O
relaxation	O
velocities	O
[	O
E	O
'	O
]	O
using	O
tissue	O
Doppler	O
imaging	O
)	O
and	O
RBF	O
(	O
para-aminohippurate	O
clearance	O
)	O
at	O
baseline	O
and	O
after	O
infusion	O
of	O
Ang	O
II	O
(	O
3	O
ng/kg/min	O
x	O
45	O
min	O
)	O
.	O

On	O
HS	O
diet	O
,	O
E	O
'	O
and	O
RBF	O
were	O
higher	O
than	O
on	O
LS	O
diet	O
(	O
E	O
'	O
14.0	O
+/-	O
1.2	O
vs	O
12.6	O
+/-	O
1.0	O
cm/s	O
,	O
P	O
=	O
0.02	O
;	O
RBF	O
596	O
+/-	O
24	O
vs	O
563	O
+/-	O
26	O
mL/min	O
,	O
P	O
=	O
0.02	O
)	O
.	O

Dietary	O
sodium	O
significantly	O
modulated	O
E	O
'	O
and	O
RBF	O
responsiveness	O
to	O
Ang	O
II	O
infusion	O
in	O
like	O
manner	O
.	O

HS	O
was	O
associated	O
with	O
increased	O
responsiveness	O
compared	O
with	O
a	O
blunted	O
LS	O
response	O
(	O
HS	O
DeltaE	O
'	O
-1.4	O
+/-	O
0.4	O
cm/s	O
vs	O
LS	O
DeltaE	O
'	O
-0.1	O
+/-	O
0.3	O
cm/s	O
,	O
P	O
=	O
0.02	O
;	O
HS	O
DeltaRBF	O
-135.2	O
+/-	O
13.2	O
vs	O
LS	O
DeltaRBF	O
-62.5	O
+/-	O
10.1	O
mL/min	O
,	O
P	O
<	O
0.01	O
)	O
.	O

The	O
authors	O
describe	O
for	O
the	O
first	O
time	O
that	O
dietary	O
sodium	O
modulates	O
myocardial	O
relaxation	O
and	O
responsiveness	O
to	O
Ang	O
II	O
.	O

It	O
is	O
important	O
to	O
consider	O
dietary	O
sodium	O
intake	O
when	O
assessing	O
diastolic	O
function	O
.	O

Ang	O
II	O
may	O
play	O
a	O
role	O
in	O
the	O
interaction	O
between	O
dietary	O
sodium	O
and	O
myocardial	O
relaxation	O
.	O

Future	O
research	O
will	O
investigate	O
whether	O
abnormalities	O
in	O
these	O
mechanisms	O
play	O
a	O
role	O
in	O
disorders	O
of	O
diastolic	O
function	O
.	O

Effects	O
of	O
a	O
brief	O
Early	O
Start	O
Denver	O
model	O
(	O
ESDM	O
)	O
-based	O
parent	O
intervention	O
on	O
toddlers	Age
at	O
risk	O
for	O
autism	Condition
spectrum	Condition
disorders	Condition
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
This	O
study	O
was	O
carried	O
out	O
to	O
examine	O
the	O
efficacy	O
of	O
a	O
12-week	O
,	O
low-intensity	O
(	O
1-hour/wk	O
of	O
therapist	O
contact	O
)	O
,	O
parent-delivered	O
intervention	O
for	O
toddlers	O
at	O
risk	O
for	O
autism	Condition
spectrum	Condition
disorders	Condition
(	O
ASD	Condition
)	O
aged	O
14	Age
to	Age
24	Age
months	Age
and	O
their	O
families	O
.	O

METHOD	O
A	O
randomized	O
controlled	O
trial	O
involving	O
98	SampleSize
children	O
and	O
families	O
was	O
carried	O
out	O
in	O
three	O
different	O
sites	O
investigating	O
the	O
efficacy	O
of	O
a	O
parent	O
delivery	O
of	O
the	O
Early	O
Start	O
Denver	O
model	O
(	O
P-ESDM	O
)	O
,	O
which	O
fosters	O
parental	O
use	O
of	O
a	O
child-centered	O
responsive	O
interaction	O
style	O
that	O
embeds	O
many	O
teaching	O
opportunities	O
into	O
play	O
,	O
compared	O
to	O
community	O
treatment	O
as	O
usual	O
.	O

Assessments	O
were	O
completed	O
at	O
baseline	O
and	O
12	O
weeks	O
later	O
,	O
immediately	O
after	O
the	O
end	O
of	O
parent	O
coaching	O
sessions	O
.	O

RESULTS	O
There	O
was	O
no	O
effect	O
of	O
group	O
assignment	O
on	O
parent-child	O
interaction	O
characteristics	O
or	O
on	O
any	O
child	O
outcomes	O
.	O

Both	O
groups	O
of	O
parents	O
improved	O
interaction	O
skills	O
,	O
and	O
both	O
groups	O
of	O
children	O
demonstrated	O
progress	O
.	O

Parents	O
receiving	O
P-ESDM	O
demonstrated	O
significantly	O
stronger	O
working	O
alliances	O
with	O
their	O
therapists	O
than	O
did	O
the	O
community	O
group	O
.	O

Children	O
in	O
the	O
community	O
group	O
received	O
significantly	O
more	O
intervention	O
hours	O
than	O
those	O
in	O
the	O
P-ESDM	O
group	O
.	O

For	O
the	O
group	O
as	O
a	O
whole	O
,	O
both	O
younger	O
child	O
age	O
at	O
the	O
start	O
of	O
intervention	O
and	O
a	O
greater	O
number	O
of	O
intervention	O
hours	O
were	O
positively	O
related	O
to	O
the	O
degree	O
of	O
improvement	O
in	O
children	O
's	O
behavior	O
for	O
most	O
variables	O
.	O

CONCLUSIONS	O
Parent-implemented	O
intervention	O
studies	O
for	O
early	O
ASD	O
thus	O
far	O
have	O
not	O
demonstrated	O
the	O
large	O
effects	O
seen	O
in	O
intensive-treatment	O
studies	O
.	O

Evidence	O
that	O
both	O
younger	O
age	O
and	O
more	O
intervention	O
hours	O
positively	O
affect	O
developmental	O
rates	O
has	O
implications	O
for	O
clinical	O
practice	O
,	O
service	O
delivery	O
,	O
and	O
public	O
policy	O
.	O

Supportive-expressive	O
group	O
therapy	O
for	O
primary	O
breast	O
cancer	O
patients	O
:	O
a	O
randomized	O
prospective	O
multicenter	O
trial	O
.	O

OBJECTIVE	O
The	O
aim	O
is	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
manualized	O
12-week	O
supportive-expressive	O
group	O
therapy	O
program	O
among	O
primary	O
breast	O
cancer	O
patients	O
treated	O
in	O
community	O
settings	O
,	O
to	O
determine	O
whether	O
highly	O
distressed	O
patients	O
were	O
most	O
likely	O
to	O
benefit	O
and	O
whether	O
therapist	O
's	O
training	O
or	O
experience	O
was	O
related	O
to	O
outcome	O
.	O

METHOD	O
Three	O
hundred	O
and	O
fifty-three	O
women	O
within	O
one	O
year	O
of	O
diagnosis	O
with	O
primary	O
breast	O
cancer	O
were	O
randomly	O
assigned	O
to	O
receive	O
supportive-expressive	O
group	O
therapy	O
or	O
to	O
an	O
education	O
control	O
condition	O
.	O

Participants	O
were	O
recruited	O
from	O
two	O
academic	O
centers	O
and	O
nine	O
oncology	O
practices	O
,	O
which	O
were	O
members	O
of	O
NCI	O
's	O
Community	O
Clinical	O
Oncology	O
Program	O
(	O
CCOP	O
)	O
and	O
were	O
followed	O
over	O
2	O
years	O
.	O

RESULTS	O
A	O
2x2x19	O
analysis	O
of	O
variance	O
was	O
conducted	O
with	O
main	O
effects	O
of	O
treatment	O
condition	O
,	O
cohort	O
,	O
and	O
baseline	O
distress	O
and	O
their	O
interactions	O
.	O

There	O
was	O
no	O
main	O
effect	O
for	O
treatment	O
condition	O
after	O
removing	O
one	O
subject	O
with	O
an	O
extreme	O
score	O
.	O

Highly	O
distressed	O
women	O
did	O
not	O
derive	O
a	O
greater	O
benefit	O
from	O
treatment	O
.	O

Therapist	O
training	O
and	O
psychotherapy	O
experience	O
were	O
not	O
associated	O
with	O
a	O
treatment	O
effect	O
.	O

CONCLUSIONS	O
This	O
study	O
provides	O
no	O
evidence	O
of	O
reduction	O
in	O
distress	O
as	O
the	O
result	O
of	O
a	O
brief	O
supportive-expressive	O
intervention	O
for	O
women	O
with	O
primary	O
breast	O
cancer	O
.	O

Future	O
studies	O
might	O
productively	O
focus	O
on	O
women	O
with	O
higher	O
initial	O
levels	O
of	O
distress	O
.	O

Effects	O
of	O
10	O
Hz	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
on	O
clinical	O
global	O
impression	O
in	O
chronic	Condition
schizophrenia	Condition
.	O

UNLABELLED	O
We	O
conducted	O
a	O
randomized	O
,	O
sham-controlled	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
study	O
in	O
chronic	Condition
schizophrenia	Condition
in-patients	O
(	O
n=35	SampleSize
)	O
to	O
evaluate	O
the	O
therapeutic	O
efficacy	O
of	O
10	O
Hz	O
stimulation	O
.	O

Patients	O
,	O
who	O
were	O
on	O
stable	Condition
antipsychotic	Condition
treatment	Condition
,	O
were	O
randomly	O
assigned	O
to	O
the	O
active	O
or	O
sham	O
condition	O
.	O

In	O
the	O
active	O
rTMS	O
group	O
,	O
ten	O
sessions	O
with	O
a	O
total	O
of	O
10,000	O
stimuli	O
were	O
applied	O
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
at	O
110	O
%	O
of	O
motor	O
threshold	O
.	O

The	O
sham	O
group	O
received	O
corresponding	O
sham	O
stimulation	O
.	O

Clinical	O
improvement	O
was	O
measured	O
by	O
the	O
Clinical	O
Global	O
Impression	O
scale	O
(	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
Global	O
Assessment	O
of	O
Functioning	O
Scale	O
(	O
GAF	O
)	O
and	O
the	O
Positive	O
and	O
Negative	O
Symptom	O
Scale	O
(	O
PANSS	O
;	O
secondary	O
outcome	O
measures	O
)	O
.	O

Between-group	O
comparisons	O
revealed	O
no	O
significant	O
differences	O
in	O
clinical	O
outcome	O
variables	O
.	O

Only	O
a	O
subgroup	O
of	O
patients	O
with	O
pronounced	O
negative	O
symptoms	O
developed	O
some	O
clinical	O
improvement	O
as	O
indicated	O
by	O
significant	O
changes	O
in	O
the	O
GAF-scale	O
.	O

Besides	O
there	O
is	O
some	O
evidence	O
for	O
a	O
more	O
favourable	O
clinical	O
outcome	O
within	O
this	O
subgroup	O
after	O
rTMS	O
in	O
the	O
CGI-S	O
and	O
PANSS	O
negative	O
scale	O
,	O
too	O
.	O

In	O
line	O
with	O
earlier	O
investigations	O
,	O
our	O
results	O
suggest	O
a	O
moderate	O
-	O
potentially	O
clinically	O
relevant	O
-	O
treatment	O
effect	O
of	O
prefrontal	O
10	O
Hz	O
rTMS	O
stimulation	O
in	O
chronic	Condition
patients	O
.	O

However	O
,	O
in	O
our	O
study	O
this	O
beneficial	O
effect	O
was	O
restricted	O
to	O
subjects	O
with	O
pronounced	O
negative	O
symptoms	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
INFORMATION	O
ClinicalTrial.gov	O
Identifier	O
:	O
NCT00169689	O
,	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Enhancing	O
antiepileptic	O
drug	O
adherence	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

Suboptimal	O
adherence	O
to	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
treatment	O
is	O
commonplace	O
,	O
and	O
increases	O
the	O
risk	O
of	O
status	O
epilepticus	O
and	O
sudden	O
unexplained	O
death	O
in	O
epilepsy	O
.	O

This	O
randomized	O
controlled	O
trial	O
was	O
designed	O
to	O
demonstrate	O
whether	O
an	O
implementation	O
intention	O
intervention	O
involving	O
the	O
completion	O
of	O
a	O
simple	O
self-administered	O
questionnaire	O
linking	O
the	O
intention	O
of	O
taking	O
medication	O
with	O
a	O
particular	O
time	O
,	O
place	O
,	O
and	O
other	O
activity	O
can	O
improve	O
AED	O
treatment	O
schedule	O
adherence	O
.	O

Of	O
the	O
81	O
patients	O
with	O
epilepsy	O
who	O
were	O
randomized	O
,	O
69	O
completed	O
a	O
1-month	O
monitoring	O
period	O
with	O
an	O
objective	O
measure	O
of	O
tablet	O
taking	O
(	O
electronic	O
registration	O
of	O
pill	O
bottle	O
openings	O
,	O
Medication	O
Event	O
Monitoring	O
System	O
[	O
MEMS	O
]	O
)	O
.	O

Intervention	O
participants	O
showed	O
improved	O
adherence	O
relative	O
to	O
controls	O
on	O
all	O
three	O
outcomes	O
:	O
doses	O
taken	O
in	O
total	O
(	O
93.4	O
%	O
vs.	O
79.1	O
%	O
)	O
,	O
days	O
on	O
which	O
correct	O
dose	O
was	O
taken	O
(	O
88.7	O
%	O
vs.	O
65.3	O
%	O
)	O
,	O
and	O
doses	O
taken	O
on	O
schedule	O
(	O
78.8	O
%	O
vs.	O
55.3	O
%	O
)	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
implementation	O
intention	O
intervention	O
may	O
be	O
an	O
easy-to-administer	O
and	O
effective	O
means	O
of	O
promoting	O
AED	O
adherence	O
.	O

Modest	O
antihypertensive	O
effect	O
of	O
epanolol	O
,	O
a	O
beta	O
1-selective	O
receptor	O
blocker	O
with	O
beta	O
1	O
agonist	O
activity	O
:	O
an	O
acute	O
and	O
long-term	O
hemodynamic	O
study	O
at	O
rest	O
and	O
during	O
exercise	O
and	O
double	O
crossover	O
comparison	O
with	O
atenolol	O
on	O
ambulatory	O
blood	O
pressure	O
.	O

Beta-blockers	O
with	O
less	O
cardiodepressive	O
effect	O
than	O
traditional	O
nonselective	O
beta	O
(	O
1+2	O
)	O
-blocking	O
agents	O
could	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
hypertension	O
,	O
provided	O
the	O
reduction	O
in	O
blood	O
pressure	O
was	O
satisfactory	O
.	O

Epanolol	O
,	O
a	O
selective	O
beta	O
1-receptor	O
blocker	O
with	O
intrinsic	O
sympathomimetic	O
activity	O
,	O
induced	O
a	O
fall	O
in	O
intraarterial	O
pressure	O
of	O
8	O
%	O
at	O
rest	O
sitting	O
and	O
11	O
%	O
during	O
100	O
W	O
bicycle	O
exercise	O
after	O
the	O
first	O
dose	O
of	O
200	O
mg	O
in	O
12	Condition
patients	Condition
with	Condition
essential	Condition
hypertension	Condition
.	Condition

Heart	O
rate	O
,	O
stroke	O
index	O
,	O
and	O
cardiac	O
index	O
initially	O
fell	O
by	O
14	O
%	O
,	O
11	O
%	O
,	O
and	O
23	O
%	O
,	O
respectively	O
.	O

The	O
total	O
peripheral	O
resistance	O
index	O
increased	O
by	O
21	O
%	O
after	O
2	O
hours	O
,	O
and	O
then	O
reverted	O
towards	O
the	O
pretreatment	O
level	O
.	O

After	O
10	O
months	O
of	O
epanolol	O
treatment	O
(	O
mean	O
300	O
mg/day	O
)	O
,	O
the	O
reduction	O
in	O
arterial	O
pressure	O
was	O
5	O
%	O
at	O
rest	O
and	O
10	O
%	O
during	O
exercise	O
.	O

Cardiac	O
index	O
and	O
heart	O
rate	O
were	O
still	O
reduced	O
14-21	O
%	O
,	O
while	O
total	O
peripheral	O
resistance	O
was	O
unchanged	O
or	O
slightly	O
increased	O
(	O
2-10	O
%	O
)	O
.	O

Twenty-four	O
hour	O
ambulatory	O
blood	O
pressure	O
was	O
higher	O
on	O
epanolol	O
(	O
300	O
mg/day	O
)	O
than	O
on	O
atenolol	O
(	O
150	O
mg/day	O
)	O
treatment	O
(	O
137/97	O
vs.	O
128/91	O
mmHg	O
)	O
.	O

Thus	O
,	O
the	O
achieved	O
blood	O
pressure	O
reduction	O
induced	O
by	O
epanolol	O
was	O
moderate	O
,	O
while	O
other	O
characteristics	O
of	O
beta-receptor	O
blockade	O
,	O
in	O
particular	O
,	O
the	O
reduction	O
of	O
heart	O
rate	O
and	O
cardiac	O
output	O
,	O
were	O
maintained	O
.	O

This	O
suggests	O
that	O
the	O
compound	O
may	O
be	O
useful	O
for	O
other	O
cardiovascular	Condition
disorders	Condition
,	O
e.g.	O
,	O
angina	O
pectoris	O
in	O
patients	O
without	O
hypertension	Condition
or	O
cardiac	Condition
arrhythmia	Condition
.	O

Regular	O
replacement	O
of	O
extended	O
wear	O
rigid	O
gas	O
permeable	O
contact	O
lenses	O
.	O

PURPOSE	O
While	O
the	O
benefits	O
of	O
planned	O
replacement	O
of	O
soft	O
contact	O
lenses	O
have	O
been	O
investigated	O
,	O
the	O
question	O
of	O
whether	O
there	O
are	O
any	O
clinical	O
benefits	O
to	O
planned	O
replacement	O
of	O
rigid	O
gas	O
permeable	O
(	O
RGP	O
)	O
lenses	O
does	O
not	O
appear	O
to	O
have	O
been	O
addressed	O
experimentally	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
benefits	O
of	O
regular	O
replacement	O
of	O
extended	O
wear	O
RGP	O
contact	O
lenses	O
.	O

METHODS	O
We	O
conducted	O
a	O
prospective	O
,	O
single-center	O
,	O
controlled	O
,	O
double-masked	O
study	O
of	O
39	O
RGP	O
lens	O
wearers	O
.	O

The	O
subjects	O
were	O
divided	O
into	O
two	O
groups	O
and	O
wore	O
extended	O
wear	O
Quantum	O
2	O
lenses	O
(	O
Dk	O
=	O
120	O
)	O
for	O
12	O
months	O
.	O

Subjects	O
in	O
Group	O
I	O
replaced	O
lenses	O
every	O
3	O
months	O
,	O
whereas	O
those	O
in	O
Group	O
II	O
were	O
not	O
scheduled	O
to	O
replace	O
their	O
lenses	O
.	O

The	O
integrity	O
of	O
the	O
lenses	O
and	O
the	O
ocular	O
responses	O
to	O
lens	O
wear	O
were	O
monitored	O
in	O
both	O
groups	O
every	O
three	O
months	O
.	O

RESULTS	O
Compared	O
to	O
lenses	O
worn	O
by	O
subjects	O
in	O
Group	O
I	O
,	O
lenses	O
worn	O
by	O
Group	O
II	O
subjects	O
showed	O
significantly	O
more	O
mucous	O
coating	O
,	O
lens	O
binding	O
,	O
and	O
corneal	O
staining	O
over	O
time	O
(	O
P	O
<	O
0.05	O
;	O
ANCOVA	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
microcystic	O
or	O
tarsal	O
conjunctiva	O
response	O
,	O
lens	O
comfort	O
,	O
refractive	O
change	O
,	O
or	O
visual	O
acuity	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
We	O
advocate	O
that	O
to	O
maintain	O
optimal	O
lens	O
integrity	O
and	O
ocular	O
health	O
,	O
RGP	O
lenses	O
used	O
for	O
extended	O
wear	O
should	O
be	O
replaced	O
every	O
3	O
to	O
6	O
months	O
.	O

Acute	O
effects	O
of	O
caffeine	O
ingestion	O
on	O
signal-averaged	O
electrocardiograms	O
.	O

BACKGROUND	O
Although	O
moderate	O
caffeine	O
ingestion	O
has	O
not	O
been	O
shown	O
to	O
be	O
arrhythmogenic	O
,	O
caffeine	O
toxicity	O
can	O
cause	O
severe	O
cardiac	O
arrhythmias	O
,	O
including	O
atrial	O
fibrillation	O
and	O
ventricular	O
tachycardia	O
.	O

Atrial	O
fibrillation	O
and	O
ventricular	O
tachycardia	O
have	O
been	O
associated	O
with	O
prolongation	O
of	O
P-wave	O
and	O
QRS	O
complex	O
durations	O
on	O
signal-averaged	O
electrocardiograms	O
.	O

This	O
study	O
investigated	O
acute	O
effects	O
of	O
caffeine	O
ingestion	O
on	O
signal-averaged	O
P-wave	O
and	O
QRS	O
complexes	O
.	O

METHODS	O
AND	O
RESULTS	O
Signal-averaged	O
electrocardiograms	O
were	O
obtained	O
from	O
12	O
normal	O
subjects	O
(	O
6	O
men	O
,	O
6	O
women	O
;	O
ages	O
21	O
to	O
26	O
years	O
)	O
before	O
and	O
after	O
ingestion	O
of	O
caffeine	O
(	O
5	O
mg/kg	O
body	O
weight	O
)	O
or	O
placebo	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
fashion	O
.	O

Electrocardiograms	O
for	O
signal	O
averaging	O
were	O
recorded	O
from	O
electrodes	O
left	O
in	O
a	O
constant	O
location	O
.	O

After	O
bandpass	O
filtering	O
(	O
30	O
to	O
300	O
Hz	O
)	O
and	O
amplification	O
,	O
signals	O
were	O
sampled	O
over	O
7.2	O
minutes	O
at	O
2000	O
Hz	O
.	O

Signal-averaged	O
P-wave	O
and	O
QRS	O
complex	O
durations	O
did	O
not	O
significantly	O
change	O
after	O
placebo	O
ingestion	O
.	O

After	O
caffeine	O
ingestion	O
QRS	O
duration	O
prolonged	O
in	O
9	O
of	O
11	O
subjects	O
at	O
90	O
minutes	O
(	O
mean	O
+/-	O
SEM	O
=	O
0.8+/-0.3	O
ms	O
,	O
P	O
<	O
.02	O
)	O
and	O
in	O
8	O
of	O
9	O
after	O
3	O
hours	O
(	O
1.1+/-0.2	O
ms	O
,	O
P	O
<	O
.001	O
)	O
.	O

No	O
significant	O
change	O
in	O
P-wave	O
duration	O
or	O
heart	O
rate	O
was	O
found	O
after	O
caffeine	O
ingestion	O
at	O
any	O
test	O
interval	O
.	O

Average	O
caffeine	O
level	O
in	O
saliva	O
90	O
minutes	O
after	O
ingestion	O
was	O
6.6+/-1.6	O
(	O
SD	O
)	O
microg/dL	O
.	O

CONCLUSIONS	O
Although	O
probably	O
not	O
arrhythmogenic	O
in	O
normal	O
subjects	O
,	O
moderate	O
caffeine	O
ingestion	O
does	O
produce	O
a	O
small	O
but	O
statistically	O
significant	O
prolongation	O
of	O
signal-averaged	O
QRS	O
complexes	O
.	O

Further	O
prolongation	O
caused	O
by	O
excessive	O
caffeine	O
intake	O
may	O
be	O
a	O
factor	O
in	O
the	O
genesis	O
of	O
arrhythmias	O
associated	O
with	O
caffeine	O
toxicity	O
.	O

Duration	O
of	O
untreated	O
negative	O
and	O
positive	O
symptoms	O
of	O
psychosis	Condition
and	O
cognitive	O
impairment	O
in	O
first	Condition
episode	Condition
psychosis	Condition
.	O

BACKGROUND	O
Duration	O
of	O
untreated	O
psychosis	O
(	O
DUP	O
)	O
has	O
been	O
significantly	O
associated	O
with	O
poor	O
clinical	O
and	O
social	O
outcomes	O
in	O
First	O
Episode	O
Psychosis	O
(	O
FEP	O
)	O
patients	O
,	O
but	O
an	O
association	O
with	O
cognitive	O
outcomes	O
has	O
not	O
been	O
clearly	O
established	O
.	O

METHOD	O
Seventy-seven	SampleSize
consecutively	O
admitted	O
,	O
drug-na?ve	O
patients	O
with	O
FEP	O
were	O
assessed	O
at	O
baseline	O
and	O
at	O
1month	O
and	O
6months	O
.	O

Underlying	O
dimensions	O
of	O
DUP	O
(	O
general	O
prodrome	O
and	O
positive	O
,	O
negative	O
and	O
disorganisation	O
symptoms	O
)	O
were	O
assessed	O
using	O
the	O
Symptom	O
Onset	O
in	O
Schizophrenia	O
(	O
SOS	O
)	O
inventory	O
(	O
Perkins	O
et	O
al.	O
,	O
2000	O
)	O
.	O

To	O
assess	O
the	O
effect	O
of	O
DUP	O
on	O
the	O
neuropsychological	O
status	O
of	O
the	O
patients	O
,	O
a	O
linear	O
mixed-effect	O
model	O
was	O
fitted	O
to	O
each	O
neuropsychological	O
dimension	O
.	O

These	O
models	O
included	O
a	O
dichotomised	O
version	O
of	O
DUP	O
(	O
short	O
versus	O
long	O
duration	O
)	O
as	O
a	O
fixed	O
effect	O
,	O
several	O
adjusting	O
variables	O
to	O
account	O
for	O
patient	O
differences	O
,	O
and	O
a	O
random	O
effect	O
to	O
incorporate	O
the	O
longitudinal	O
structure	O
of	O
the	O
data	O
.	O

RESULTS	O
Patients	O
with	O
a	O
short	O
duration	O
of	O
untreated	O
negative	O
symptoms	O
(	O
DUNS	O
)	O
or	O
a	O
short	O
duration	O
of	O
untreated	O
positive	O
symptoms	O
(	O
DUPS	O
)	O
outperformed	O
patients	O
with	O
a	O
long	O
duration	O
of	O
untreated	O
symptoms	O
on	O
memory	O
tasks	O
and	O
a	O
pre-attentional	O
visual	O
task	O
but	O
not	O
on	O
measures	O
of	O
verbal	O
fluency	O
,	O
attention	O
,	O
reaction	O
time	O
,	O
visual	O
processing	O
and	O
executive	O
functions	O
.	O

CONCLUSIONS	O
This	O
study	O
provides	O
additional	O
support	O
for	O
an	O
early	O
intervention	O
to	O
shorten	O
DUP	O
to	O
facilitate	O
a	O
better	O
outcome	O
in	O
memory	O
and	O
attentional	O
domains	O
of	O
FEP	O
patients	O
.	O

Intravenous	O
levosimendan	O
treatment	O
is	O
cost-effective	O
compared	O
with	O
dobutamine	O
in	O
severe	O
low-output	O
heart	O
failure	O
:	O
an	O
analysis	O
based	O
on	O
the	O
international	O
LIDO	O
trial	O
.	O

BACKGROUND	O
Levosimendan	O
,	O
a	O
novel	O
calcium	O
sensitiser	O
,	O
improves	O
cardiac	O
performance	O
and	O
symptoms	O
without	O
increasing	O
oxygen	O
consumption	O
,	O
and	O
decreases	O
the	O
mortality	O
of	O
patients	O
with	O
low-output	O
heart	O
failure	O
.	O

AIMS	O
To	O
estimate	O
the	O
cost-effectiveness	O
of	O
intravenous	O
treatment	O
with	O
levosimendan	O
compared	O
with	O
dobutamine	O
in	O
patients	O
with	O
severe	O
low-output	O
heart	O
failure	O
.	O

METHODS	O
This	O
economic	O
evaluation	O
was	O
based	O
on	O
a	O
European	O
clinical	O
trial	O
(	O
LIDO	O
)	O
,	O
in	O
which	O
203	O
patients	O
with	O
severe	O
heart	O
failure	O
randomly	O
received	O
a	O
24	O
h	O
infusion	O
with	O
either	O
levosimendan	O
or	O
dobutamine	O
.	O

Survival	O
and	O
resource	O
utilisation	O
data	O
were	O
collected	O
for	O
6	O
months	O
;	O
survival	O
was	O
extrapolated	O
assuming	O
a	O
mean	O
additional	O
lifetime	O
of	O
3	O
years	O
based	O
on	O
data	O
from	O
the	O
Cooperative	O
North	O
Scandinavian	O
Enalapril	O
Survival	O
Study	O
trial	O
.	O

Costs	O
were	O
based	O
on	O
study	O
drug	O
usage	O
and	O
hospitalisation	O
in	O
the	O
6-month	O
follow-up	O
.	O

A	O
sensitivity	O
analysis	O
on	O
dosage	O
of	O
drug	O
and	O
duration	O
of	O
survival	O
was	O
performed	O
.	O

RESULTS	O
The	O
mean	O
survival	O
over	O
6	O
months	O
was	O
157+/-52	O
days	O
in	O
the	O
levosimendan	O
group	O
and	O
139+/-64	O
days	O
in	O
the	O
dobutamine	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

When	O
extrapolated	O
up	O
to	O
3	O
years	O
,	O
the	O
gain	O
in	O
life	O
expectancy	O
was	O
estimated	O
at	O
0.35	O
years	O
(	O
discounted	O
at	O
3	O
%	O
)	O
.	O

Levosimendan	O
increased	O
the	O
mean	O
cost	O
per	O
patient	O
by	O
1108	O
,	O
which	O
was	O
entirely	O
due	O
to	O
the	O
cost	O
of	O
the	O
study	O
drug	O
.	O

The	O
incremental	O
cost	O
per	O
life-year	O
saved	O
(	O
LYS	O
)	O
was	O
3205	O
at	O
the	O
European	O
level	O
;	O
in	O
the	O
individual	O
countries	O
the	O
cost	O
per	O
LYS	O
ranged	O
between	O
3091	O
and	O
3331	O
.	O

The	O
result	O
was	O
robust	O
in	O
the	O
sensitivity	O
analysis	O
.	O

CONCLUSIONS	O
Although	O
the	O
patients	O
in	O
the	O
levosimendan	O
group	O
were	O
alive	O
for	O
more	O
days	O
and	O
thus	O
at	O
risk	O
of	O
hospitalisation	O
for	O
longer	O
,	O
there	O
was	O
no	O
increase	O
in	O
hospitalisation	O
or	O
hospitalisation	O
costs	O
with	O
levosimendan	O
treatment	O
.	O

The	O
cost	O
per	O
LYS	O
using	O
levosimendan	O
compares	O
favourably	O
with	O
other	O
cost-effectiveness	O
analyses	O
in	O
cardiology	O
.	O

Evidence	O
for	O
poorer	O
outcome	O
in	O
patients	O
with	O
severe	O
negative	O
trauma-related	O
cognitions	O
receiving	O
prolonged	O
exposure	O
plus	O
cognitive	O
restructuring	O
:	O
implications	O
for	O
treatment	O
matching	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O

In	O
the	O
current	O
article	O
,	O
we	O
address	O
the	O
existing	O
assumption	O
in	O
the	O
literature	O
on	O
cognitive	O
behavioral	O
treatment	O
of	O
PTSD	O
that	O
patients	O
with	O
severe	O
negative	O
trauma-related	O
cognitions	O
would	O
benefit	O
more	O
from	O
a	O
treatment	O
package	O
that	O
includes	O
exposure	O
and	O
cognitive	O
techniques	O
compared	O
with	O
a	O
treatment	O
that	O
includes	O
exposure	O
only	O
.	O

To	O
test	O
this	O
assumption	O
,	O
54	O
PTSD	O
patients	O
were	O
randomized	O
to	O
prolonged	O
exposure	O
therapy	O
or	O
prolonged	O
exposure	O
therapy	O
plus	O
cognitive	O
restructuring	O
.	O

Contrary	O
to	O
expectations	O
,	O
findings	O
revealed	O
that	O
patients	O
characterized	O
by	O
more	O
severe	O
pretreatment	O
trauma-related	O
cognitions	O
(	O
and	O
more	O
severe	O
pretreatment	O
PTSD	O
symptoms	O
)	O
fared	O
slightly	O
worse	O
in	O
treatment	O
combining	O
exposure	O
and	O
cognitive	O
restructuring	O
.	O

However	O
,	O
there	O
was	O
no	O
relationship	O
between	O
pre-	O
and	O
post-treatment	O
measures	O
of	O
negative	O
cognitions	O
and	O
PTSD	O
symptoms	O
in	O
the	O
exposure	O
alone	O
group	O
.	O

The	O
implications	O
of	O
these	O
findings	O
for	O
examining	O
Person	O
X	O
Treatment	O
interactions	O
and	O
the	O
efficacy	O
of	O
combining	O
treatments	O
for	O
PTSD	O
are	O
discussed	O
.	O

Single-dose	O
tranexamic	O
acid	O
reduces	O
postoperative	O
bleeding	O
after	O
coronary	O
surgery	O
in	O
patients	O
treated	O
with	O
aspirin	O
until	O
surgery	Condition
.	O

UNLABELLED	O
Tranexamic	O
acid	O
reduces	O
postoperative	O
bleeding	O
after	O
coronary	O
artery	O
bypass	O
grafting	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
a	O
single	O
dose	O
of	O
tranexamic	O
acid	O
given	O
immediately	O
before	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
in	O
patients	O
treated	O
with	O
aspirin	O
until	O
the	O
day	O
before	O
surgery	Condition
.	O

The	O
study	O
was	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blinded	O
,	O
placebo-controlled	O
,	O
parallel-group	O
trial	O
.	O

Eighty	SampleSize
patients	SampleSize
were	O
included	O
and	O
divided	O
into	O
two	O
groups	O
:	O
one	O
group	O
received	O
tranexamic	O
acid	O
30	O
mg/kg	O
,	O
and	O
one	O
group	O
received	O
placebo	O
(	O
0.9	O
%	O
NaCl	O
)	O
as	O
a	O
bolus	O
injection	O
before	O
CPB	O
.	O

Postoperative	O
blood	O
loss	O
was	O
recorded	O
for	O
16	O
h.	O
Transfusions	O
of	O
blood	O
products	O
were	O
recorded	O
for	O
the	O
whole	O
hospital	O
stay	O
.	O

Transfusions	O
of	O
packed	O
red	O
cells	O
were	O
given	O
when	O
the	O
hematocrit	O
value	O
was	O
less	O
than	O
20	O
%	O
during	O
CPB	O
and	O
less	O
than	O
25	O
%	O
after	O
surgery	O
.	O

The	SampleSize
patients	SampleSize
in	SampleSize
the	SampleSize
tranexamic	SampleSize
acid	SampleSize
group	SampleSize
had	O
significantly	O
less	O
postoperative	O
bleeding	O
compared	O
with	O
the	SampleSize
patients	SampleSize
in	SampleSize
the	SampleSize
placebo	SampleSize
group	SampleSize
(	O
mean	O
[	O
SD	O
]	O
)	O
(	O
475	O
[	O
274	O
]	O
mL	O
versus	O
713	O
[	O
243	O
]	O
mL	O
;	O
P	O
<	O
0.001	O
)	O
.	O

An	O
effective	O
inhibition	O
of	O
fibrinolysis	O
was	O
found	O
in	O
patients	O
receiving	O
tranexamic	O
acid	O
.	O

Tranexamic	O
acid	O
reduces	O
postoperative	O
bleeding	O
in	O
coronary	O
artery	O
bypass	O
grafting	O
patients	O
treated	O
with	O
aspirin	O
until	O
the	O
day	O
before	O
surgery	O
.	O

IMPLICATIONS	O
Continuation	O
of	O
aspirin	O
medication	O
until	O
the	O
day	O
before	O
coronary	O
artery	O
bypass	O
grafting	O
may	O
increase	O
postoperative	O
bleeding	O
.	O

The	O
administration	O
of	O
a	O
single	O
dose	O
of	O
tranexamic	O
acid	O
(	O
30	O
mg/kg	O
)	O
immediately	O
before	O
cardiopulmonary	O
bypass	O
significantly	O
reduced	O
postoperative	O
bleeding	O
and	O
inhibited	O
fibrinolysis	O
in	O
these	O
patients	O
.	O

Airway	O
responses	O
and	O
inflammation	O
in	O
subjects	O
with	O
asthma	O
after	O
four	O
days	O
of	O
repeated	O
high-single-dose	O
allergen	O
challenge	O
.	O

BACKGROUND	O
Both	O
standard	O
and	O
low-dose	O
allergen	O
provocations	O
are	O
an	O
established	O
tool	O
in	O
asthma	O
research	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
pathophysiological	O
mechanism	O
of	O
allergic	O
asthma	O
.	O

However	O
,	O
clinical	O
symptoms	O
are	O
less	O
likely	O
to	O
be	O
induced	O
.	O

Therefore	O
,	O
we	O
designed	O
a	O
protocol	O
for	O
repetitive	O
high-dose	O
bronchial	O
allergen	O
challenges	O
to	O
generate	O
clinical	O
symptoms	O
and	O
airway	O
inflammation	O
.	O

METHODS	O
A	O
total	O
of	O
27	O
patients	O
aged	O
18	O
to	O
40	O
years	O
with	O
positive	O
skin-prick	O
tests	O
and	O
mild	O
asthma	O
underwent	O
repetitive	O
high-dose	O
allergen	O
challenges	O
with	O
household	O
dust	O
mites	O
for	O
four	O
consecutive	O
days	O
.	O

Pulmonary	O
function	O
and	O
exhaled	O
NO	O
were	O
measured	O
at	O
every	O
visit	O
.	O

Induced	O
sputum	O
was	O
analysed	O
before	O
and	O
after	O
the	O
allergen	O
challenges	O
for	O
cell	O
counts	O
,	O
ECP	O
,	O
IL-5	O
,	O
INF-?	O
,	O
IL-8	O
,	O
and	O
the	O
transcription	O
factor	O
Foxp3	O
.	O

RESULTS	O
We	O
found	O
a	O
significant	O
decrease	O
in	O
pulmonary	O
function	O
,	O
an	O
increased	O
use	O
of	O
salbutamol	O
and	O
the	O
development	O
of	O
a	O
late	O
asthmatic	O
response	O
and	O
bronchial	O
hyperresponsiveness	O
,	O
as	O
well	O
as	O
a	O
significant	O
induction	O
of	O
eNO	O
,	O
eosinophils	O
,	O
and	O
Th-2	O
cytokines	O
.	O

Repeated	O
provocation	O
was	O
feasible	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Two	O
subjects	O
had	O
severe	O
adverse	O
events	O
requiring	O
prednisolone	O
to	O
cope	O
with	O
nocturnal	O
asthma	O
symptoms	O
.	O

CONCLUSIONS	O
Repeated	O
high-dose	O
bronchial	O
allergen	O
challenges	O
resulted	O
in	O
severe	O
asthma	O
symptoms	O
and	O
marked	O
Th-2-mediated	O
allergic	O
airway	O
inflammation	O
.	O

The	O
high-dose	O
challenge	O
model	O
is	O
suitable	O
only	O
in	O
an	O
attenuated	O
form	O
in	O
diseased	O
volunteers	O
for	O
proof-of-concept	O
studies	O
and	O
in	O
clinical	O
settings	O
to	O
reduce	O
the	O
risk	O
of	O
severe	O
asthma	O
exacerbations	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.govNCT00677209	O
.	O

Desmopressin	O
in	O
the	O
treatment	O
of	O
nocturia	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

OBJECTIVES	O
To	O
investigate	O
efficacy	O
,	O
safety	O
,	O
and	O
impact	O
on	O
quality	O
of	O
sleep	O
of	O
desmopressin	O
in	O
the	O
treatment	O
of	O
nocturia	O
.	O

METHODS	O
Adults	O
aged	O
>	O
or	O
=18	O
yr	O
with	O
nocturia	O
(	O
>	O
or	O
=2	O
voids/night	O
)	O
received	O
desmopressin	O
tablets	O
(	O
0.1	O
,	O
0.2	O
,	O
or	O
0.4	O
mg	O
)	O
during	O
a	O
3-wk	O
dose-titration	O
period	O
.	O

Patients	O
should	O
show	O
sufficient	O
response	O
during	O
the	O
dose-titration	O
period	O
(	O
>	O
or	O
=20	O
%	O
reduction	O
in	O
nocturnal	O
diuresis	O
)	O
and	O
a	O
return	O
of	O
nocturnal	O
diuresis	O
to	O
>	O
or	O
=80	O
%	O
of	O
baseline	O
levels	O
during	O
washout	O
.	O

Eligible	O
patients	O
then	O
entered	O
a	O
3-wk	O
double-blind	O
treatment	O
period	O
and	O
received	O
either	O
desmopressin	O
or	O
placebo	O
.	O

RESULTS	O
127	O
patients	O
were	O
randomised	O
to	O
either	O
desmopressin	O
(	O
n=61	O
)	O
or	O
placebo	O
(	O
n=66	O
)	O
.	O

Twenty	O
(	O
33	O
%	O
)	O
desmopressin-treated	O
patients	O
compared	O
with	O
seven	O
(	O
11	O
%	O
)	O
placebo-treated	O
patients	O
showed	O
a	O
clinical	O
response	O
,	O
defined	O
as	O
a	O
>	O
or	O
=50	O
%	O
reduction	O
in	O
the	O
number	O
of	O
nocturnal	O
voids	O
compared	O
with	O
baseline	O
(	O
p=0.0014	O
)	O
.	O

Compared	O
with	O
placebo	O
,	O
desmopressin	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
mean	O
number	O
of	O
nocturnal	O
voids	O
(	O
39	O
%	O
reduction	O
with	O
desmopressin	O
vs.	O
15	O
%	O
with	O
placebo	O
;	O
absolute	O
difference	O
-0.84	O
,	O
p	O
<	O
0.0001	O
)	O
and	O
duration	O
of	O
the	O
first	O
sleep	O
period	O
(	O
prolonged	O
by	O
108	O
min	O
with	O
desmopressin	O
vs.	O
41	O
min	O
with	O
placebo	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Quality	O
of	O
sleep	O
was	O
also	O
improved	O
with	O
desmopressin	O
versus	O
placebo	O
(	O
statistically	O
significant	O
for	O
one	O
of	O
the	O
two	O
parameters	O
evaluated	O
)	O
.	O

Adverse	O
events	O
were	O
mainly	O
mild	O
.	O

CONCLUSIONS	O
Oral	O
desmopressin	O
tablets	O
provide	O
an	O
effective	O
and	O
well-tolerated	O
treatment	O
for	O
nocturia	O
.	O

Compared	O
with	O
placebo	O
,	O
nocturnal	O
voiding	O
frequency	O
is	O
reduced	O
,	O
duration	O
of	O
the	O
first	O
sleep	O
period	O
is	O
increased	O
,	O
and	O
sleep	O
quality	O
may	O
be	O
improved	O
.	O

Clinical	O
evaluation	O
of	O
the	O
WOMAC	O
3.0	O
OA	O
Index	O
in	O
numeric	O
rating	O
scale	O
format	O
using	O
a	O
computerized	O
touch	O
screen	O
version	O
.	O

BACKGROUND	O
The	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
(	O
WOMAC	O
)	O
Osteoarthritis	O
Index	O
is	O
a	O
previously	O
described	O
self-administered	O
questionnaire	O
covering	O
three	O
domains	O
:	O
pain	O
,	O
stiffness	O
and	O
function	O
.	O

It	O
has	O
been	O
validated	O
in	O
patients	O
with	O
osteoarthritis	Condition
(	O
OA	Condition
)	O
of	O
the	O
hip	O
or	O
knee	O
in	O
a	O
paper-based	O
format	O
.	O

AIM	O
To	O
validate	O
the	O
WOMAC	O
3.0	O
using	O
a	O
numerical	O
rating	O
scale	O
in	O
a	O
computerized	O
touch	O
screen	O
format	O
allowing	O
immediate	O
evaluation	O
of	O
the	O
questionnaire	O
.	O

In	O
the	O
computed	O
version	O
cartoons	O
,	O
written	O
and	O
audio	O
instruments	O
were	O
included	O
in	O
order	O
facilitate	O
application	O
.	O

METHODS	O
Fifty	SampleSize
patients	O
,	O
demographically	O
balanced	O
,	O
with	O
radiographically	O
proven	O
primary	O
hip	O
or	O
knee	O
OA	Condition
completed	O
the	O
classical	O
paper	O
and	O
the	O
new	O
computerized	O
WOMAC	O
version	O
.	O

Subjects	O
were	O
randomized	O
either	O
to	O
paper	O
format	O
or	O
computerized	O
format	O
first	O
to	O
balance	O
possible	O
order	O
effects	O
.	O

RESULTS	O
The	O
intra-class	O
correlation	O
coefficients	O
for	O
pain	O
,	O
stiffness	O
and	O
function	O
values	O
were	O
0.915	O
,	O
0.745	O
and	O
0.940	O
,	O
respectively	O
.	O

The	O
Spearman	O
correlation	O
coefficients	O
for	O
pain	O
,	O
stiffness	O
and	O
function	O
were	O
0.88	O
,	O
0.77	O
and	O
0.87	O
,	O
respectively	O
.	O

CONCLUSION	O
These	O
data	O
indicate	O
that	O
the	O
computerized	O
WOMAC	O
OA	O
index	O
3.0	O
is	O
comparable	O
to	O
the	O
paper	O
WOMAC	O
in	O
all	O
three	O
dimensions	O
.	O

The	O
computerized	O
version	O
would	O
allow	O
physicians	O
to	O
get	O
an	O
immediate	O
result	O
and	O
if	O
present	O
a	O
direct	O
comparison	O
with	O
a	O
previous	O
exam	O
.	O

Antioxidant	O
supplementation	O
and	O
exercise-induced	O
oxidative	Condition
stress	Condition
in	O
the	O
60-year-old	Age
as	O
measured	O
by	O
antipyrine	O
hydroxylates	O
.	O

The	O
effects	O
of	O
12	O
weeks	O
of	O
antioxidant	O
supplementation	O
on	O
exercise-induced	O
oxidative	O
stress	O
were	O
investigated	O
in	O
older	O
adults	O
(	O
60	O
(	O
SE	O
1	O
)	O
years	O
;	O
BMI	O
26	O
(	O
SE	O
1	O
)	O
kg/m	O
(	O
2	O
)	O
)	O
.	O

Subjects	O
were	O
randomly	O
divided	O
in	O
two	O
groups	O
:	O
supplementation	O
(	O
n	O
11	O
)	O
with	O
100	O
mg	O
dl-alpha-tocopheryl	O
acetate	O
,	O
200	O
mg	O
ascorbic	O
acid	O
,	O
and	O
2	O
mg	O
beta-carotene	O
,	O
and	O
placebo	O
(	O
n	O
9	O
)	O
.	O

Before	O
and	O
after	O
the	O
12	O
week	O
supplementation	O
period	O
,	O
subjects	O
cycled	O
for	O
45	O
min	O
at	O
submaximal	O
intensity	O
(	O
50	O
%	O
maximal	O
workload	O
capacity	O
)	O
.	O

Antipyrine	O
was	O
used	O
as	O
marker	O
for	O
oxidative	O
stress	O
.	O

Antipyrine	O
reacts	O
quickly	O
with	O
hydroxyl	O
radicals	O
to	O
form	O
para-	O
and	O
ortho-hydroxyantipyrine	O
.	O

The	O
latter	O
metabolite	O
is	O
not	O
formed	O
in	O
man	O
through	O
the	O
mono-oxygenase	O
pathway	O
of	O
cytochrome	O
P450	O
.	O

Daily	O
supplementation	O
significantly	O
increased	O
plasma	O
concentrations	O
of	O
alpha-tocopherol	O
and	O
beta-carotene	O
in	O
the	O
supplemented	O
group	O
(	O
Delta	O
14.4	O
(	O
SE	O
3.2	O
)	O
and	O
0.4	O
(	O
se	O
0.1	O
)	O
micromol/l	O
;	O
P	O
<	O
0.001	O
and	O
P	O
<	O
0.01	O
)	O
.	O

No	O
significant	O
differences	O
,	O
within	O
and	O
between	O
groups	O
,	O
were	O
observed	O
in	O
the	O
exercise-induced	O
increase	O
in	O
the	O
ratios	O
para-	O
and	O
ortho-hydroxyantipyrine	O
to	O
antipyrine	O
.	O

In	O
addition	O
,	O
supplementation	O
did	O
not	O
affect	O
the	O
exercise-induced	O
increase	O
in	O
thiobarbituric	O
acid	O
reactive	O
substances	O
in	O
plasma	O
.	O

In	O
conclusion	O
,	O
in	O
60-year-old	O
subjects	O
antioxidant	O
supplementation	O
had	O
no	O
effect	O
on	O
the	O
exercise-induced	O
increase	O
in	O
oxidative	O
stress	O
as	O
measured	O
by	O
free	O
radical	O
products	O
of	O
antipyrine	O
.	O

Desmopressin	O
has	O
no	O
beneficial	O
effect	O
on	O
excessive	O
postoperative	O
bleeding	Condition
or	O
blood	Condition
product	Condition
requirements	Condition
associated	O
with	O
cardiopulmonary	Condition
bypass	Condition
.	O

Cardiopulmonary	O
bypass	O
during	O
open-heart	O
surgery	O
is	O
sometimes	O
associated	O
with	O
excessive	O
perioperative	O
bleeding	O
.	O

Following	O
a	O
non-randomized	O
study	O
suggesting	O
that	O
desmopressin	O
acetate	O
(	O
desmopressin	O
)	O
reduced	O
blood	O
product	O
requirements	O
in	O
these	O
patients	O
,	O
we	O
conducted	O
a	O
double-blind	O
,	O
placebo-controlled	O
randomized	O
trial	O
of	O
desmopressin	O
(	O
0.3	O
micrograms/kg	O
,	O
i.	O
v.	O
)	O
in	O
92	SampleSize
patients	O
with	O
overt	Condition
bleeding	Condition
and	O
a	O
prolonged	Condition
bleeding	Condition
time	Condition
.	O

Mean	O
blood	O
loss	O
during	O
the	O
first	O
24	O
h	O
post-treatment	O
was	O
similar	O
in	O
the	O
desmopressin	O
and	O
placebo	O
groups	O
(	O
582	O
vs	O
465	O
ml	O
,	O
respectively	O
;	O
p	O
=	O
0.15	O
)	O
.	O

Red-cell	O
(	O
p	O
=	O
0.76	O
)	O
,	O
fresh	O
frozen	O
plasma	O
(	O
r	O
=	O
0.66	O
)	O
and	O
platelet	O
unit	O
(	O
p	O
=	O
0.74	O
)	O
requirements	O
were	O
also	O
similar	O
.	O

The	O
haemostatic	O
effect	O
of	O
desmopressin	O
has	O
been	O
attributed	O
to	O
the	O
release	O
of	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
and	O
a	O
reduced	O
bleeding	O
time	O
.	O

In	O
our	O
study	O
,	O
vWF	O
and	O
factor	O
VIII	O
:	O
C	O
levels	O
increased	O
while	O
the	O
bleeding	O
time	O
decreased	O
significantly	O
at	O
90	O
min	O
and	O
24	O
h	O
in	O
both	O
groups	O
and	O
,	O
although	O
vWF	O
and	O
factor	O
VIII	O
:	O
C	O
levels	O
were	O
slightly	O
higher	O
in	O
desmopressin-treated	O
patients	O
at	O
90	O
min	O
,	O
the	O
difference	O
was	O
not	O
significant	O
.	O

Thrombin-antithrombin	O
III	O
complex	O
,	O
fibrinogen	O
degradation	O
product	O
and	O
tissue	O
plasminogen	O
activator	O
levels	O
,	O
reflecting	O
activation	O
of	O
the	O
coagulation	O
and	O
fibrinolytic	O
systems	O
,	O
respectively	O
,	O
decreased	O
uniformly	O
in	O
both	O
groups	O
.	O

We	O
conclude	O
that	O
desmopressin	O
is	O
not	O
useful	O
in	O
reducing	O
blood	O
loss	O
or	O
blood	O
product	O
requirements	O
in	O
patients	O
with	O
excessive	O
immediate	O
postoperative	Condition
bleeding	Condition
.	O

Efficacy	O
of	O
omeprazole	O
versus	O
high-dose	O
famotidine	O
for	O
prevention	O
of	O
exercise-induced	O
gastritis	O
in	O
racing	O
Alaskan	O
sled	O
dogs	O
.	O

BACKGROUND	O
Omeprazole	O
and	O
famotidine	O
both	O
reduce	O
severity	O
of	O
exercise-induced	O
gastritis	O
,	O
but	O
administering	O
famotidine	O
is	O
easier	O
than	O
administering	O
omeprazole	O
during	O
racing	O
competition	O
.	O

HYPOTHESIS	O
Famotidine	O
is	O
more	O
efficacious	O
than	O
no	O
treatment	O
in	O
reducing	O
severity	O
of	O
exercise-induced	O
gastritis	O
;	O
and	O
high-dose	O
famotidine	O
is	O
more	O
efficacious	O
than	O
omeprazole	O
in	O
reducing	O
severity	O
of	O
exercise-induced	O
gastritis	O
.	O

ANIMALS	O
Experiment	O
1	O
:	O
Randomized	O
placebo-controlled	O
study	O
,	O
36	SampleSize
sled	O
dogs	O
(	O
3-8	O
years	O
)	O
;	O
Experiment	O
2	O
:	O
Randomized	O
positive-control	O
study	O
,	O
52	SampleSize
sled	O
dogs	O
(	O
2-8	O
years	O
)	O
.	O

METHODS	O
Experiment	O
1	O
:	O
Equal	O
numbers	O
of	O
dogs	O
randomly	O
assigned	O
to	O
famotidine	O
(	O
20	O
mg	O
q24h	O
)	O
or	O
no	O
treatment	O
groups	O
.	O

Gastroscopy	O
was	O
performed	O
24	O
hours	O
after	O
the	O
dogs	O
ran	O
330	O
miles	O
.	O

Mucosal	O
appearance	O
was	O
blindly	O
scored	O
by	O
previously	O
described	O
scoring	O
system	O
.	O

Experiment	O
2	O
:	O
Equal	O
numbers	O
of	O
dogs	O
randomly	O
assigned	O
to	O
omeprazole	O
(	O
20	O
mg	O
q24h	O
)	O
or	O
high-dose	O
famotidine	O
(	O
40	O
mg	O
q12h	O
)	O
groups	O
.	O

Gastroscopy	O
was	O
performed	O
48	O
hours	O
before	O
and	O
24	O
hours	O
after	O
the	O
dogs	O
ran	O
300	O
miles	O
.	O

Mucosal	O
appearance	O
was	O
blindly	O
scored	O
by	O
previously	O
described	O
scoring	O
system	O
.	O

RESULTS	O
Famotidine	O
reduced	O
the	O
prevalence	O
of	O
clinically	O
relevant	O
,	O
exercise-induced	O
gastric	O
lesions	O
compared	O
with	O
no	O
treatment	O
(	O
7/16	O
versus	O
11/16	O
,	O
P	O
=	O
.031	O
)	O
.	O

Compared	O
with	O
high-dose	O
famotidine	O
,	O
omeprazole	O
significantly	O
decreased	O
the	O
severity	O
(	O
0.4	O
versus	O
1.2	O
,	O
P	O
=	O
.0002	O
)	O
and	O
prevalence	O
(	O
2/23	O
versus	O
7/21	O
,	O
P	O
=	O
.049	O
)	O
of	O
gastric	O
lesions	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
Although	O
famotidine	O
provides	O
some	O
benefit	O
in	O
the	O
prevention	O
of	O
exercise-induced	O
gastric	O
lesions	O
,	O
omeprazole	O
is	O
superior	O
to	O
famotidine	O
in	O
preventing	O
gastritis	O
in	O
dogs	O
running	O
300	O
miles	O
.	O

Routine	O
administration	O
of	O
omeprazole	O
is	O
recommended	O
to	O
prevent	O
stress-associated	O
gastric	O
disease	O
in	O
exercising	O
and	O
racing	O
Alaskan	O
sled	O
dogs	O
.	O

Analysis	O
of	O
prevention	Condition
program	Condition
effectiveness	O
with	O
clustered	O
data	O
using	O
generalized	O
estimating	O
equations	O
.	O

Experimental	O
studies	O
of	O
prevention	O
programs	O
often	O
randomize	O
clusters	O
of	O
individuals	O
rather	O
than	O
individuals	O
to	O
treatment	O
conditions	O
.	O

When	O
the	O
correlation	O
among	O
individuals	O
within	O
clusters	O
is	O
not	O
accounted	O
for	O
in	O
statistical	O
analysis	O
,	O
the	O
standard	O
errors	O
are	O
biased	O
,	O
potentially	O
resulting	O
in	O
misleading	O
conclusions	O
about	O
the	O
significance	O
of	O
treatment	O
effects	O
.	O

This	O
study	O
demonstrates	O
the	O
generalized	O
estimating	O
equations	O
(	O
GEE	O
)	O
method	O
,	O
focusing	O
specifically	O
on	O
the	O
GEE-independent	O
method	O
,	O
to	O
control	O
for	O
within-cluster	O
correlation	O
in	O
regression	O
models	O
with	O
either	O
continuous	O
or	O
binary	O
outcomes	O
.	O

The	O
GEE-independent	O
method	O
yields	O
consistent	O
and	O
robust	O
variance	O
estimates	O
.	O

Data	O
from	O
project	O
DARE	O
,	O
a	O
youth	O
substance	Condition
abuse	Condition
prevention	O
program	O
,	O
are	O
used	O
for	O
illustration	O
.	O

Comparison	O
of	O
the	O
efficacy	O
of	O
fluoxetine	O
alone	O
vs.	O
fluoxetine	O
plus	O
local	O
lidocaine	O
ointment	O
in	O
the	O
treatment	O
of	O
premature	Condition
ejaculation	Condition
.	O

OBJECTIVE	O
The	O
present	O
study	O
compares	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
fluoxetine	O
alone	O
vs.	O
fluoxetine	O
plus	O
local	O
lidocaine	O
ointment	O
in	O
the	O
treatment	O
of	O
premature	O
ejaculation	O
.	O

METHODS	O
Forty-three	SampleSize
patients	O
suffering	O
from	O
premature	O
ejaculation	O
were	O
studied	O
.	O

The	O
exclusion	O
criteria	O
were	O
erectile	O
dysfunction	O
,	O
loss	O
of	O
libido	O
,	O
alcohol	O
and	O
substance	O
abuse	O
,	O
mental	O
retardation	O
,	O
diabetes	O
mellitus	O
,	O
thyroid	O
disease	O
,	O
hypotension	O
,	O
previous	O
use	O
of	O
these	O
drugs	O
and	O
urogenital	O
infections	O
.	O

The	O
patients	O
'	O
ages	O
ranged	O
from	O
19	Age
to	Age
48	Age
years	Age
(	O
mean	O
age	O
28	Age
+/-	Age
1.6	Age
)	O
.	O

They	O
had	O
regular	O
sexual	O
lives	O
.	O

They	O
had	O
normal	O
psychiatric	O
consultation	O
and	O
the	O
Glombock	O
Rast	O
Sexual	O
Satisfactory	O
Test	O
(	O
GRISS	O
)	O
psychiatric	O
test	O
were	O
in	O
accordance	O
with	O
premature	O
ejaculation	O
.	O

RESULTS	O
The	O
patients	O
were	O
assigned	O
to	O
two	O
groups	O
.	O

Twenty-six	O
patients	O
,	O
aged	O
21	O
to	O
36	O
years	O
(	O
mean	O
age	O
27	O
)	O
,	O
received	O
only	O
fluoxetine	O
20	O
mg/day	O
(	O
1	O
capsule	O
)	O
for	O
a	O
week	O
which	O
was	O
later	O
increased	O
to	O
40	O
mg/day	O
(	O
2	O
capsules	O
)	O
.	O

Seventeen	O
patients	O
,	O
aged	O
19	O
to	O
48	O
years	O
(	O
mean	O
age	O
31	O
)	O
,	O
were	O
given	O
fluoxetine	O
20	O
mg/day	O
plus	O
local	O
application	O
of	O
lidocaine	O
ointment	O
.	O

The	O
patients	O
and	O
partners	O
were	O
re-evaluated	O
8	O
weeks	O
after	O
the	O
treatment	O
.	O

The	O
results	O
were	O
classified	O
as	O
unsuccessful	O
,	O
improvement	O
and	O
cure	O
.	O

The	O
chi-square	O
test	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O

In	O
the	O
fluoxetine	O
group	O
,	O
8	O
(	O
30.8	O
%	O
)	O
patients	O
cured	O
,	O
11	O
(	O
42.2	O
%	O
)	O
showed	O
improvement	O
and	O
there	O
were	O
7	O
failures	O
(	O
26.9	O
%	O
)	O
.	O

In	O
the	O
combination	O
treatment	O
group	O
,	O
9	O
(	O
52.9	O
%	O
)	O
patients	O
cured	O
,	O
improvement	O
was	O
observed	O
in	O
5	O
(	O
29.4	O
%	O
)	O
and	O
failure	O
in	O
3	O
(	O
17.6	O
%	O
)	O
.	O

Side	O
effects	O
in	O
group	O
I	O
were	O
observed	O
in	O
6	O
patients	O
(	O
23	O
%	O
)	O
and	O
in	O
5	O
(	O
29.4	O
%	O
)	O
in	O
group	O
II	O
.	O

There	O
were	O
no	O
statistical	O
differences	O
between	O
the	O
two	O
groups	O
according	O
to	O
the	O
side	O
effects	O
(	O
p	O
>	O
0.01	O
)	O
.	O

No	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
due	O
to	O
side	O
effects	O
.	O

CONCLUSION	O
The	O
combination	O
of	O
fluoxetine	O
plus	O
local	O
application	O
of	O
lidocaine	O
ointment	O
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
fluoxetine	O
alone	O
in	O
the	O
treatment	O
of	O
premature	O
ejaculation	O
.	O

However	O
,	O
the	O
results	O
should	O
be	O
confirmed	O
in	O
further	O
studies	O
with	O
a	O
placebo	O
group	O
to	O
rule	O
out	O
the	O
placebo	O
effect	O
.	O

Teriparatide	O
improves	O
early	O
callus	O
formation	O
in	O
distal	Condition
radial	Condition
fractures	Condition
.	Condition

BACKGROUND	O
Teriparatide	O
(	O
parathyreoid	O
hormone	O
;	O
PTH	O
1-34	O
)	O
increases	O
skeletal	O
mass	O
in	O
humans	O
and	O
improves	O
fracture	O
healing	O
in	O
animals	O
.	O

A	O
recent	O
randomized	O
multicenter	O
trial	O
of	O
nonoperated	O
distal	O
radial	O
fractures	O
showed	O
a	O
moderate	O
shortening	O
of	O
the	O
time	O
to	O
restoration	O
of	O
cortical	O
continuity	O
by	O
treatment	O
with	O
20	O
microg	O
(	O
low-dose	O
)	O
teriparatide	O
per	O
day	O
,	O
but	O
not	O
with	O
40	O
microg	O
(	O
high-dose	O
)	O
.	O

As	O
radiographic	O
cortical	O
continuity	O
appears	O
late	O
in	O
the	O
healing	O
process	O
,	O
perhaps	O
too	O
late	O
for	O
clinical	O
relevance	O
,	O
we	O
studied	O
the	O
qualitative	O
appearance	O
of	O
the	O
callus	O
5	O
weeks	O
after	O
fracture	O
.	O

METHODS	O
One	O
third	O
of	O
the	O
patients	O
of	O
the	O
international	O
trial	O
were	O
treated	O
at	O
Link?ping	O
University	O
Hospital	O
.	O

The	O
multicenter	O
trial	O
did	O
not	O
evaluate	O
early	O
callus	O
formation	O
.	O

We	O
therefore	O
made	O
a	O
blinded	O
qualitative	O
scoring	O
of	O
the	O
callus	O
at	O
5	O
weeks	O
in	O
our	O
27	O
patients	O
.	O

Callus	O
formation	O
was	O
arbitrarily	O
classified	O
as	O
rich	O
,	O
intermediate	O
,	O
or	O
poor	O
.	O

RESULTS	O
9	O
patients	O
were	O
classified	O
as	O
rich	O
(	O
none	O
had	O
received	O
placebo	O
,	O
3	O
low-dose	O
teriparatide	O
,	O
and	O
6	O
high-dose	O
teriparatide	O
)	O
.	O

9	O
patients	O
were	O
classified	O
as	O
intermediate	O
(	O
1	O
had	O
received	O
placebo	O
,	O
5	O
low-dose	O
,	O
and	O
3	O
high-dose	O
)	O
.	O

9	O
patients	O
were	O
classified	O
as	O
poor	O
(	O
7	O
had	O
received	O
placebo	O
,	O
1	O
low-dose	O
,	O
and	O
1	O
high-dose	O
)	O
(	O
p	O
<	O
0.001	O
)	O
.	O

INTERPRETATION	O
This	O
is	O
a	O
post	O
hoc	O
subgroup	O
analysis	O
of	O
an	O
outcome	O
variable	O
,	O
which	O
was	O
not	O
in	O
the	O
official	O
protocol	O
.	O

The	O
results	O
must	O
therefore	O
be	O
interpreted	O
with	O
caution	O
.	O

However	O
,	O
in	O
combination	O
with	O
the	O
results	O
of	O
the	O
larger	O
trial	O
,	O
the	O
data	O
suggest	O
that	O
radiographic	O
quality	O
at	O
an	O
early	O
time	O
point	O
might	O
be	O
a	O
sensitive	O
variable	O
,	O
perhaps	O
better	O
than	O
time	O
to	O
cortical	O
continuity	O
.	O

Moreover	O
,	O
teriparatide	O
appeared	O
to	O
improve	O
early	O
callus	O
formation	O
in	O
distal	O
radial	O
fractures	O
.	O

Effects	O
of	O
low	O
and	O
high	O
protein	O
:	O
carbohydrate	O
ratios	O
in	O
the	O
diet	O
of	O
pregnant	O
gilts	O
on	O
maternal	O
cortisol	O
concentrations	O
and	O
the	O
adrenocortical	O
and	O
sympathoadrenal	O
reactivity	O
in	O
their	O
offspring	O
.	O

Inadequate	O
maternal	O
nutrition	O
during	O
gestation	O
may	O
cause	O
an	O
adverse	O
environment	O
for	O
the	O
fetus	O
leading	O
to	O
alterations	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
and	O
sympatho-adrenomedullary	O
(	O
SAM	O
)	O
systems	O
later	O
in	O
life	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
diets	O
with	O
low	O
and	O
high	O
protein	O
:	O
carbohydrate	O
ratios	O
on	O
cortisol	O
concentrations	O
of	O
pregnant	O
gilts	O
as	O
well	O
as	O
the	O
long-term	O
effects	O
on	O
the	O
function	O
of	O
the	O
HPA	O
and	O
SAM	O
axes	O
in	O
their	O
offspring	O
.	O

Throughout	O
gestation	O
,	O
33	O
German	O
Landrace	O
gilts	O
were	O
fed	O
high	O
(	O
HP	O
,	O
30	O
%	O
)	O
,	O
low	O
(	O
LP	O
,	O
6.5	O
%	O
)	O
,	O
or	O
adequate	O
(	O
AP	O
,	O
12.1	O
%	O
)	O
protein	O
diets	O
,	O
which	O
were	O
made	O
isocaloric	O
by	O
adjusting	O
the	O
carbohydrate	O
content	O
.	O

The	O
salivary	O
cortisol	O
concentrations	O
of	O
the	O
sows	O
were	O
measured	O
in	O
the	O
course	O
of	O
the	O
gestation	O
period	O
.	O

The	O
offspring	O
were	O
cross-fostered	O
,	O
and	O
the	O
plasma	O
cortisol	O
and	O
catecholamine	O
concentrations	O
of	O
the	O
offspring	O
were	O
determined	O
on	O
postnatal	O
d	O
(	O
PND	O
)	O
1	O
and	O
27	O
and	O
under	O
specific	O
challenging	O
conditions	O
:	O
after	O
weaning	O
(	O
PND	O
29	O
)	O
and	O
after	O
ACTH	O
and	O
insulin	O
challenges	O
(	O
PND	O
68	O
and	O
70	O
,	O
respectively	O
)	O
.	O

Glucocorticoid	O
receptor	O
(	O
GR	O
)	O
binding	O
and	O
neurotransmitter	O
concentrations	O
were	O
measured	O
in	O
stress-related	O
brain	O
regions	O
,	O
and	O
histological	O
analyses	O
of	O
the	O
adrenal	O
were	O
performed	O
.	O

Maternal	O
salivary	O
cortisol	O
concentrations	O
increased	O
throughout	O
gestation	O
(	O
P	O
<	O
0.001	O
)	O
and	O
the	O
LP	O
gilts	O
had	O
greater	O
salivary	O
cortisol	O
compared	O
with	O
the	O
AP	O
and	O
HP	O
gilts	O
(	O
P	O
<	O
0.05	O
)	O
.	O

No	O
differences	O
between	O
diets	O
were	O
found	O
for	O
cortisol	O
,	O
corticosteroid-binding	O
globulin	O
,	O
and	O
catecholamine	O
concentrations	O
in	O
plasma	O
and	O
for	O
GR	O
binding	O
in	O
hippocampus	O
and	O
hypothalamus	O
in	O
piglets	O
at	O
PND	O
1	O
and	O
27	O
.	O

However	O
,	O
the	O
cortisol	O
response	O
to	O
weaning	O
was	O
increased	O
in	O
LP	O
piglets	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
in	O
HP	O
offspring	O
the	O
basal	O
plasma	O
noradrenaline	O
concentrations	O
were	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
cortisol	O
response	O
to	O
the	O
ACTH	O
and	O
the	O
insulin	O
challenge	O
did	O
not	O
differ	O
between	O
diets	O
.	O

On	O
PND	O
81	O
,	O
an	O
increased	O
adrenal	O
medulla	O
area	O
was	O
observed	O
in	O
LP	O
offspring	O
compared	O
with	O
the	O
AP	O
offspring	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Our	O
results	O
show	O
that	O
maternal	O
diets	O
with	O
aberrant	O
protein	O
:	O
carbohydrate	O
ratios	O
during	O
gestation	O
have	O
moderate	O
long-term	O
effects	O
on	O
the	O
function	O
of	O
the	O
HPA	O
and	O
SAM	O
system	O
in	O
the	O
offspring	O
,	O
which	O
indicates	O
that	O
pigs	O
show	O
a	O
considerable	O
plasticity	O
to	O
cope	O
with	O
maternal	O
malnutrition	O
.	O

Effects	O
of	O
vitamin	O
A	O
or	O
beta	O
carotene	O
supplementation	O
on	O
pregnancy-related	O
mortality	O
and	O
infant	O
mortality	O
in	O
rural	O
Bangladesh	O
:	O
a	O
cluster	O
randomized	O
trial	O
.	O

CONTEXT	O
Maternal	O
vitamin	O
A	O
deficiency	O
is	O
a	O
public	O
health	O
concern	O
in	O
the	O
developing	O
world	O
.	O

Its	O
prevention	O
may	O
improve	O
maternal	O
and	O
infant	O
survival	O
.	O

OBJECTIVE	O
To	O
assess	O
efficacy	O
of	O
maternal	O
vitamin	O
A	O
or	O
beta	O
carotene	O
supplementation	O
in	O
reducing	O
pregnancy-related	O
and	O
infant	O
mortality	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
Cluster	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
trial	O
among	O
pregnant	O
women	O
13	O
to	O
45	O
years	O
of	O
age	O
and	O
their	O
live-born	O
infants	O
to	O
12	O
weeks	O
(	O
84	O
days	O
)	O
postpartum	O
in	O
rural	O
northern	O
Bangladesh	O
between	O
2001	O
and	O
2007	O
.	O

Interventions	O
Five	O
hundred	O
ninety-six	O
community	O
clusters	O
(	O
study	O
sectors	O
)	O
were	O
randomized	O
for	O
pregnant	O
women	O
to	O
receive	O
weekly	O
,	O
from	O
the	O
first	O
trimester	O
through	O
12	O
weeks	O
postpartum	O
,	O
7000	O
?g	O
of	O
retinol	O
equivalents	O
as	O
retinyl	O
palmitate	O
,	O
42	O
mg	O
of	O
all-trans	O
beta	O
carotene	O
,	O
or	O
placebo	O
.	O

Married	O
women	O
(	O
n	O
=	O
125,257	O
)	O
underwent	O
5-week	O
surveillance	O
for	O
pregnancy	O
,	O
ascertained	O
by	O
a	O
history	O
of	O
amenorrhea	O
and	O
confirmed	O
by	O
urine	O
test	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
participants	O
in	O
32	O
sectors	O
(	O
5	O
%	O
)	O
for	O
biochemical	O
studies	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
All-cause	O
mortality	O
of	O
women	O
related	O
to	O
pregnancy	O
,	O
stillbirth	O
,	O
and	O
infant	O
mortality	O
to	O
12	O
weeks	O
(	O
84	O
days	O
)	O
following	O
pregnancy	O
outcome	O
.	O

RESULTS	O
Groups	O
were	O
comparable	O
across	O
risk	O
factors	O
.	O

For	O
the	O
mortality	O
outcomes	O
,	O
neither	O
of	O
the	O
supplement	O
group	O
outcomes	O
was	O
significantly	O
different	O
from	O
the	O
placebo	O
group	O
outcomes	O
.	O

The	O
numbers	O
of	O
deaths	O
and	O
all-cause	O
,	O
pregnancy-related	O
mortality	O
rates	O
(	O
per	O
100,000	O
pregnancies	O
)	O
were	O
41	O
and	O
206	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
140-273	O
)	O
in	O
the	O
placebo	O
group	O
,	O
47	O
and	O
237	O
(	O
95	O
%	O
CI	O
,	O
166-309	O
)	O
in	O
the	O
vitamin	O
A	O
group	O
,	O
and	O
50	O
and	O
250	O
(	O
95	O
%	O
CI	O
,	O
177-323	O
)	O
in	O
the	O
beta	O
carotene	O
group	O
.	O

Relative	O
risks	O
for	O
mortality	O
in	O
the	O
vitamin	O
A	O
and	O
beta	O
carotene	O
groups	O
were	O
1.15	O
(	O
95	O
%	O
CI	O
,	O
0.75-1.76	O
)	O
and	O
1.21	O
(	O
95	O
%	O
CI	O
,	O
0.81-1.81	O
)	O
,	O
respectively	O
.	O

In	O
the	O
placebo	O
,	O
vitamin	O
A	O
,	O
and	O
beta	O
carotene	O
groups	O
the	O
rates	O
of	O
stillbirth	O
and	O
infant	O
mortality	O
were	O
47.9	O
(	O
95	O
%	O
CI	O
,	O
44.3-51.5	O
)	O
,	O
45.6	O
(	O
95	O
%	O
CI	O
,	O
42.1-49.2	O
)	O
,	O
and	O
51.8	O
(	O
95	O
%	O
CI	O
,	O
48.0-55.6	O
)	O
per	O
1000	O
births	O
and	O
68.1	O
(	O
95	O
%	O
CI	O
,	O
63.7-72.5	O
)	O
,	O
65.0	O
(	O
95	O
%	O
CI	O
,	O
60.7-69.4	O
)	O
,	O
and	O
69.8	O
(	O
95	O
%	O
CI	O
,	O
65.4-72.3	O
)	O
per	O
1000	O
live	O
births	O
,	O
respectively	O
.	O

Vitamin	O
A	O
compared	O
with	O
either	O
placebo	O
or	O
beta	O
carotene	O
supplementation	O
increased	O
plasma	O
retinol	O
concentrations	O
by	O
end	O
of	O
study	O
(	O
1.46	O
[	O
95	O
%	O
CI	O
,	O
1.42-1.50	O
]	O
?mol/L	O
vs	O
1.13	O
[	O
95	O
%	O
CI	O
,	O
1.09-1.17	O
]	O
?mol/L	O
and	O
1.18	O
[	O
95	O
%	O
CI	O
,	O
1.14-1.22	O
]	O
?mol/L	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
and	O
reduced	O
,	O
but	O
did	O
not	O
eliminate	O
,	O
gestational	O
night	O
blindness	O
(	O
7.1	O
%	O
for	O
vitamin	O
A	O
vs	O
9.2	O
%	O
for	O
placebo	O
and	O
8.9	O
%	O
for	O
beta	O
carotene	O
[	O
P	O
<	O
.001	O
for	O
both	O
]	O
)	O
.	O

CONCLUSION	O
Use	O
of	O
weekly	O
vitamin	O
A	O
or	O
beta	O
carotene	O
in	O
pregnant	O
women	O
in	O
Bangladesh	O
,	O
compared	O
with	O
placebo	O
,	O
did	O
not	O
reduce	O
all-cause	O
maternal	O
,	O
fetal	O
,	O
or	O
infant	O
mortality	O
.	O

TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00198822	O
.	O

A	O
prospective	O
randomized	O
study	O
of	O
amoxycillin	O
and	O
omeprazole	O
with	O
and	O
without	O
metronidazole	O
in	O
the	O
eradication	O
treatment	O
of	O
Helicobacter	Condition
pylori	Condition
.	O

A	O
combination	O
of	O
amoxycillin	O
and	O
omeprazole	O
is	O
often	O
used	O
to	O
treat	O
Helicobacter	O
pylori	O
infection	O
.	O

A	O
three-drug	O
regimen	O
comprising	O
metronidazole	O
,	O
amoxycillin	O
and	O
omeprazole	O
has	O
been	O
proposed	O
as	O
an	O
alternative	O
therapy	O
.	O

In	O
a	O
prospective	O
,	O
randomized	O
,	O
comparative	O
study	O
,	O
we	O
evaluated	O
these	O
two	O
regimens	O
with	O
respect	O
to	O
safety	O
and	O
efficacy	O
in	O
patients	O
with	O
H.	O
pylori	O
infection	O
.	O

Sixty	SampleSize
patients	O
with	O
peptic	Condition
ulcer	Condition
(	O
gastric	Condition
,	O
32	SampleSize
patients	O
;	O
duodenal	Condition
,	O
28	SampleSize
patients	O
)	O
who	O
had	O
a	O
history	Condition
of	Condition
ulcer	Condition
recurrence	Condition
were	O
randomly	O
assigned	O
to	O
dual	O
therapy	O
with	O
amoxycillin	O
(	O
500	O
mg	O
three	O
times	O
daily	O
for	O
2	O
weeks	O
)	O
and	O
omeprazole	O
(	O
20	O
mg	O
once	O
daily	O
for	O
8	O
weeks	O
)	O
or	O
to	O
triple	O
therapy	O
with	O
metronidazole	O
(	O
500	O
mg	O
twice	O
daily	O
for	O
2	O
weeks	O
)	O
plus	O
amoxycillin	O
and	O
omeprazole	O
,	O
given	O
in	O
the	O
same	O
dosages	O
as	O
dual	O
therapy	O
.	O

Forty-eight	SampleSize
patients	O
completed	O
the	O
protocol	O
;	O
treatment	O
was	O
discontinued	O
because	O
of	O
side	O
effects	O
in	O
nine	O
patients	O
,	O
and	O
three	O
patients	O
dropped	O
out	O
of	O
the	O
study	O
.	O

On	O
the	O
basis	O
of	O
all	O
patients	O
treated	O
,	O
the	O
rate	O
of	O
H.	O
pylori	O
eradication	O
was	O
significantly	O
higher	O
for	O
triple	O
therapy	O
20/23	O
cases	O
,	O
87.0	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0.664-0.972	O
)	O
than	O
for	O
dual	O
therapy	O
13/25	O
,	O
52.0	O
%	O
;	O
0.313-0.722	O
;	O
P	O
<	O
0.05	O
)	O
.	O

On	O
an	O
intention-to-treat	O
basis	O
,	O
the	O
difference	O
between	O
the	O
groups	O
in	O
the	O
rate	O
of	O
H.	O
pylori	O
eradication	O
was	O
marginally	O
significant	O
(	O
P	O
=	O
0.06	O
[	O
0.028-0.512	O
]	O
)	O
.	O

Side	O
effects	O
were	O
reported	O
by	O
five	O
patients	O
receiving	O
triple	O
therapy	O
(	O
skin	O
rash	O
,	O
one	O
;	O
nausea	O
,	O
two	O
;	O
headache	O
,	O
one	O
;	O
abdominal	O
pain	O
,	O
one	O
)	O
,	O
and	O
four	O
patients	O
receiving	O
dual	O
therapy	O
(	O
skin	O
rash	O
,	O
two	O
;	O
abdominal	O
pain	O
,	O
one	O
;	O
diarrhoea	O
,	O
one	O
)	O
.	O

All	O
side	O
effects	O
resolved	O
spontaneously	O
after	O
termination	O
of	O
treatment	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
safety	O
between	O
the	O
two	O
regimens	O
.	O

Triple	O
therapy	O
with	O
metronidazole	O
,	O
amoxycillin	O
,	O
and	O
omeprazole	O
was	O
significantly	O
more	O
effective	O
for	O
the	O
eradication	O
of	O
H.	O
pylori	O
than	O
dual	O
therapy	O
with	O
amoxycillin	O
and	O
omeprazole	O
alone	O
.	O

The	O
safety	O
of	O
these	O
regimens	O
was	O
similar	O
,	O
and	O
triple	O
therapy	O
was	O
found	O
to	O
be	O
clinically	O
acceptable	O
.	O

Treatment	O
of	O
hypertension	Condition
with	O
ascorbic	O
acid	O
.	O

In	O
a	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
we	O
showed	O
that	O
treatment	O
of	O
hypertensive	Condition
patients	O
with	O
ascorbic	O
acid	O
lowers	O
blood	O
pressure	O
.	O

Further	O
studies	O
of	O
ascorbic	O
acid	O
to	O
treat	O
hypertension	O
,	O
with	O
clinical	O
endpoints	O
,	O
are	O
warranted	O
.	O

Relaxation	O
and	O
imagery	O
and	O
cognitive-behavioral	O
training	O
reduce	O
pain	O
during	O
cancer	O
treatment	O
:	O
a	O
controlled	O
clinical	O
trial	O
.	O

Few	O
controlled	O
clinical	O
trials	O
of	O
psychological	O
interventions	O
for	O
cancer	O
pain	O
relief	O
exist	O
in	O
spite	O
of	O
frequent	O
support	O
for	O
their	O
importance	O
as	O
adjuncts	O
to	O
medical	O
treatment	O
.	O

This	O
study	O
compared	O
oral	O
mucositis	O
pain	O
levels	O
in	O
4	O
groups	O
of	O
cancer	O
patients	O
receiving	O
bone	O
marrow	O
transplants	O
(	O
BMT	O
)	O
:	O
(	O
1	O
)	O
treatment	O
as	O
usual	O
control	O
,	O
(	O
2	O
)	O
therapist	O
support	O
,	O
(	O
3	O
)	O
relaxation	O
and	O
imagery	O
training	O
,	O
and	O
(	O
4	O
)	O
training	O
in	O
a	O
package	O
of	O
cognitive-behavioral	O
coping	O
skills	O
which	O
included	O
relaxation	O
and	O
imagery	O
.	O

A	O
total	O
of	O
94	O
patients	O
completed	O
the	O
study	O
which	O
involved	O
two	O
training	O
sessions	O
prior	O
to	O
treatment	O
and	O
twice	O
a	O
week	O
'booster	O
'	O
sessions	O
during	O
the	O
first	O
5	O
weeks	O
of	O
treatment	O
.	O

Results	O
confirmed	O
our	O
hypothesis	O
that	O
patients	O
who	O
received	O
either	O
relaxation	O
and	O
imagery	O
alone	O
or	O
patients	O
who	O
received	O
the	O
package	O
of	O
cognitive-behavioral	O
coping	O
skills	O
would	O
report	O
less	O
pain	O
than	O
patients	O
in	O
the	O
other	O
2	O
groups	O
.	O

The	O
hypothesis	O
that	O
the	O
cognitive-behavioral	O
skills	O
package	O
would	O
have	O
an	O
additive	O
effect	O
beyond	O
relaxation	O
and	O
imagery	O
alone	O
was	O
not	O
confirmed	O
.	O

Average	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
report	O
of	O
pain	O
within	O
the	O
therapist	O
support	O
group	O
was	O
not	O
significantly	O
lower	O
than	O
the	O
control	O
group	O
(	O
P	O
=	O
0.103	O
)	O
nor	O
significantly	O
higher	O
than	O
the	O
training	O
groups	O
.	O

Patient	O
reports	O
of	O
relative	O
helpfulness	O
of	O
the	O
interventions	O
for	O
managing	O
pain	O
and	O
nausea	O
matched	O
the	O
results	O
of	O
VAS	O
reports	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
relaxation	O
and	O
imagery	O
training	O
reduces	O
cancer	O
treatment-related	O
pain	O
;	O
adding	O
cognitive-behavioral	O
skills	O
to	O
the	O
relaxation	O
with	O
imagery	O
does	O
not	O
,	O
on	O
average	O
,	O
further	O
improve	O
pain	O
relief	O
.	O

Retrograde	O
tracing	O
and	O
electrophysiological	O
findings	O
of	O
collateral	O
sprouting	O
after	Condition
end-to-side	Condition
neurorrhaphy	Condition
.	Condition

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
seek	O
more	O
potent	O
evidences	O
of	O
collateral	O
sprouting	O
for	O
both	O
motor	O
and	O
sensory	O
nerve	O
fibres	O
after	O
end-to-side	O
neurorrhaphy	O
using	O
a	O
modified	O
double-labelling	O
retrograde	O
tracing	O
method	O
and	O
to	O
investigate	O
the	O
function	O
of	O
regenerated	O
motor	O
axons	O
with	O
electrophysiological	O
evaluation	O
.	O

Four	O
groups	O
(	O
n=4	O
for	O
each	O
group	O
)	O
were	O
used	O
:	O
end-to-end	O
coaptation	O
(	O
six	O
months	O
postoperatively	O
)	O
,	O
end-to-side	O
coaptation	O
(	O
four	O
months	O
and	O
six	O
months	O
postoperatively	O
)	O
and	O
normal	O
control	O
.	O

Two	O
fluorescent	O
tracers	O
(	O
true	O
blue	O
and	O
diamidino	O
yellow	O
)	O
were	O
applied	O
to	O
the	O
proximal	O
ends	O
of	O
tibial	O
and	O
common	O
peroneal	O
nerves	O
,	O
respectively	O
after	O
four	O
or	O
six	O
months	O
of	O
nerve	O
coaptation	O
.	O

Five	O
days	O
later	O
,	O
we	O
only	O
found	O
single-labelled	O
motor	O
and	O
sensory	O
neurons	O
in	O
the	O
normal	O
and	O
end-to-end	O
coaptation	O
groups	O
,	O
while	O
some	O
dual-labelled	O
neurons	O
can	O
be	O
identified	O
in	O
end-to-side	O
coaptation	O
groups	O
.	O

Four	O
months	O
after	O
surgery	O
,	O
the	O
motor	O
nerve	O
conduction	O
velocity	O
in	O
end-to-side	O
coaptation	O
was	O
significantly	O
slower	O
than	O
in	O
the	O
normal	O
control	O
.	O

But	O
no	O
difference	O
was	O
found	O
in	O
the	O
sixth	O
month	O
.	O

These	O
results	O
suggest	O
that	O
end-to-side	O
neurorrhaphy	O
can	O
induce	O
the	O
functional	O
collateral	O
sprouting	O
of	O
both	O
motor	O
and	O
sensory	O
axons	O
in	O
the	O
peripheral	O
nerve	O
.	O

Zoledronic	O
acid	O
significantly	O
reduces	O
skeletal	O
complications	O
compared	O
with	O
placebo	O
in	O
Japanese	O
women	Condition
with	O
bone	O
metastases	O
from	O
breast	Condition
cancer	Condition
:	O
a	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O

PURPOSE	O
To	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
zoledronic	O
acid	O
for	O
the	O
treatment	O
of	O
bone	O
metastases	O
from	O
breast	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
Women	O
with	O
bone	O
metastases	O
(	O
N	SampleSize
=	SampleSize
228	SampleSize
)	SampleSize
were	O
randomly	O
assigned	O
to	O
receive	O
4	O
mg	O
zoledronic	O
acid	O
(	O
n	O
=	O
114	O
)	O
or	O
placebo	O
(	O
n	O
=	O
114	O
)	O
via	O
15-minute	O
infusions	O
every	O
4	O
weeks	O
for	O
1	O
year	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	O
skeletal-related	O
event	O
(	O
SRE	O
)	O
rate	O
ratio	O
between	O
treatment	O
groups	O
.	O

An	O
SRE	O
was	O
defined	O
as	O
pathologic	O
fracture	O
,	O
spinal	O
cord	O
compression	O
,	O
and	O
radiation	O
or	O
surgery	O
to	O
bone	O
.	O

Secondary	O
end	O
points	O
included	O
percentage	O
of	O
patients	O
with	O
at	O
least	O
one	O
SRE	O
,	O
time-to-first	O
SRE	O
,	O
and	O
Andersen-Gill	O
multiple-event	O
analysis	O
.	O

RESULTS	O
The	O
SRE	O
rate	O
ratio	O
at	O
1	O
year	O
(	O
excluding	O
HCM	O
and	O
adjusted	O
for	O
prior	O
fracture	O
)	O
was	O
0.61	O
(	O
permutation	O
test	O
;	O
P	O
=	O
.027	O
)	O
,	O
indicating	O
that	O
zoledronic	O
acid	O
reduced	O
the	O
rate	O
of	O
SRE	O
by	O
39	O
%	O
compared	O
with	O
placebo	O
.	O

The	O
percentage	O
of	O
patients	O
with	O
at	O
least	O
one	O
SRE	O
(	O
excluding	O
HCM	O
)	O
was	O
significantly	O
reduced	O
by	O
20	O
%	O
by	O
zoledronic	O
acid	O
(	O
29.8	O
%	O
v	O
49.6	O
%	O
for	O
placebo	O
;	O
P	O
=	O
.003	O
)	O
.	O

Zoledronic	O
acid	O
significantly	O
delayed	O
time-to-first	O
SRE	O
(	O
median	O
not	O
reached	O
v	O
364	O
days	O
;	O
Cox	O
regression	O
;	O
P	O
=	O
.007	O
)	O
and	O
reduced	O
the	O
risk	O
of	O
SREs	O
by	O
41	O
%	O
in	O
multiple	O
event	O
analysis	O
(	O
risk	O
ratio	O
=	O
0.59	O
;	O
P	O
=	O
.019	O
)	O
compared	O
with	O
placebo	O
.	O

Zoledronic	O
acid	O
was	O
well	O
tolerated	O
with	O
a	O
safety	O
profile	O
similar	O
to	O
placebo	O
.	O

No	O
patient	O
treated	O
with	O
zoledronic	O
acid	O
had	O
grade	O
3	O
or	O
4	O
serum	O
creatinine	O
increase	O
.	O

CONCLUSION	O
Zoledronic	O
acid	O
significantly	O
reduced	O
skeletal	O
complications	O
compared	O
with	O
placebo	O
across	O
multiple	O
end	O
points	O
in	O
Japanese	O
women	O
with	O
bone	O
metastases	O
from	O
breast	O
cancer	O
.	O

Etanercept	O
treatment	O
in	O
adults	Age
with	O
established	O
rheumatoid	Condition
arthritis	Condition
:	Condition
7	O
years	O
of	O
clinical	O
experience	O
.	O

OBJECTIVE	O
To	O
evaluate	O
safety	O
and	O
efficacy	O
of	O
longterm	O
etanercept	O
treatment	O
in	O
patients	O
with	O
disease	O
modifying	O
antirheumatic	O
drug	O
(	O
DMARD	O
)	O
refractory	Condition
rheumatoid	Condition
arthritis	Condition
(	Condition
RA	Condition
)	Condition
.	O

METHODS	O
Safety	O
results	O
are	O
reported	O
for	O
714	SampleSize
patients	O
who	O
received	O
etanercept	O
in	O
one	O
of	O
7	O
initial	O
trials	O
or	O
a	O
longterm	O
extension	O
.	O

Efficacy	O
results	O
are	O
reported	O
for	O
581	SampleSize
patients	O
who	O
enrolled	O
in	O
the	O
extension	O
.	O

RESULTS	O
Of	O
the	O
714	SampleSize
patients	O
enrolled	O
in	O
the	O
initial	O
trials	O
,	O
581	SampleSize
(	O
81	O
%	O
)	O
enrolled	O
in	O
the	O
extension	O
,	O
and	O
388	SampleSize
(	O
54	O
%	O
)	O
patients	O
are	O
continuing	O
to	O
receive	O
etanercept	O
therapy	O
.	O

The	O
longest	O
individual	O
treatment	O
was	O
8.2	O
years	O
,	O
with	O
3139	O
total	O
patient-years	O
of	O
etanercept	O
exposure	O
.	O

Rates	O
of	O
serious	O
adverse	O
events	O
(	O
overall	O
rate=14.8	O
events/100	O
patient-yrs	O
)	O
,	O
serious	O
infections	O
(	O
overall	O
rate=4.2	O
events/100	O
patient-yrs	O
)	O
,	O
cancer	O
(	O
overall	O
rate=1.0	O
events/100	O
patient-yrs	O
)	O
,	O
and	O
deaths	O
(	O
overall	O
rate=0.7	O
events/100	O
patient-yrs	O
)	O
were	O
stable	O
each	O
year	O
,	O
through	O
8	O
years	O
of	O
etanercept	O
exposure	O
.	O

For	O
356	SampleSize
patients	O
who	O
completed	O
6	O
years	O
of	O
etanercept	O
treatment	O
,	O
response	O
rates	O
were	O
ACR20=73	O
%	O
,	O
ACR50=52	O
%	O
,	O
ACR70=27	O
%	O
,	O
DAS28	O
CRP	O
good	O
response=52	O
%	O
,	O
and	O
DAS28	O
CRP	O
remission=37	O
%	O
of	O
patients	O
.	O

Similar	O
responses	O
occurred	O
in	O
167	SampleSize
patients	O
who	O
completed	O
Year	O
7	O
.	O

Doses	O
of	O
concomitant	O
methotrexate	O
or	O
corticosteroids	O
were	O
reduced	O
in	O
many	O
patients	O
who	O
maintained	O
clinical	O
responses	O
.	O

CONCLUSION	O
The	O
safety	O
profile	O
of	O
etanercept	O
was	O
consistent	O
over	O
time	O
,	O
with	O
rates	O
of	O
adverse	O
events	O
similar	O
to	O
those	O
reported	O
for	O
patients	O
with	O
RA	Condition
in	O
general	O
.	O

Durable	O
clinical	O
responses	O
were	O
observed	O
in	O
some	O
patients	O
for	O
7	O
years	O
or	O
more	O
.	O

The	O
benefit-to-risk	O
ratio	O
for	O
longterm	O
etanercept	O
treatment	O
remains	O
highly	O
favorable	O
.	O

Selected	O
polymorphisms	O
of	O
GSTP1	O
and	O
TERT	O
were	O
associated	O
with	O
glioma	Condition
risk	Condition
in	O
Han	O
Chinese	O
.	O

BACKGROUND	O
Current	O
evidence	O
suggests	O
that	O
a	O
majority	O
of	O
the	O
inherited	O
risks	O
play	O
a	O
major	O
role	O
in	O
glioma	O
susceptibility	O
,	O
and	O
glioma	O
is	O
due	O
to	O
the	O
co-inheritance	O
of	O
multiple	O
low-risk	O
variants	O
.	O

These	O
variants	O
can	O
be	O
identified	O
through	O
association	O
studies	O
including	O
such	O
as	O
genome-wide	O
association	O
studies	O
(	O
GWAS	O
)	O
,	O
which	O
has	O
led	O
the	O
glioma	O
epidemiology	O
researchers	O
to	O
focus	O
on	O
identifying	O
potential	O
disease-causing	O
factors	O
.	O

METHODS	O
We	O
evaluated	O
and	O
validated	O
10	O
tag	O
single	O
nucleotide	O
polymorphisms	O
(	O
tSNPs	O
)	O
in	O
seven	O
genes	O
associated	O
with	O
glioma	Condition
susceptibility	O
in	O
a	O
Han	O
Chinese	O
population	O
,	O
including	O
301	SampleSize
glioma	O
cases	O
and	O
302	SampleSize
controls	O
,	O
using	O
a	O
multiplexed	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
MassEXTEND	O
assay	O
.	O

We	O
ascertained	O
the	O
genotypic	O
frequencies	O
for	O
each	O
tSNP	O
in	O
control	O
subjects	O
were	O
within	O
Hardy-Weinberg	O
equilibrium	O
(	O
HWE	O
)	O
using	O
an	O
exact	O
test	O
,	O
and	O
then	O
compared	O
the	O
genotype	O
and	O
allele	O
frequencies	O
of	O
glioma	O
patients	O
and	O
control	O
subjects	O
using	O
the	O
?2	O
test	O
.	O

We	O
then	O
applied	O
three	O
genetic	O
models	O
(	O
dominant	O
,	O
recessive	O
,	O
and	O
additive	O
)	O
using	O
PLINK	O
software	O
to	O
assess	O
the	O
association	O
of	O
each	O
tSNP	O
with	O
glioma	O
risk	O
.	O

RESULTS	O
We	O
identified	O
two	O
tSNPs	O
to	O
be	O
associated	O
with	O
glioma	O
susceptibility	O
(	O
rs1695	O
,	O
GSTP1	O
,	O
P	O
=	O
0.019	O
;	O
rs2853676	O
,	O
TERT	O
,	O
P	O
=	O
0.039	O
)	O
,	O
which	O
we	O
confirmed	O
using	O
dominant	O
and	O
additive	O
model	O
analyses	O
.	O

The	O
genotype	O
&	O
ldquo	O
;	O
GA	O
&	O
rdquo	O
;	O
for	O
rs1695	O
was	O
recognized	O
to	O
be	O
a	O
protective	O
genotype	O
for	O
glioma	O
(	O
OR	O
,	O
0.67	O
;	O
95	O
%	O
CI	O
,	O
0.47-0.96	O
;	O
P	O
=	O
0.027	O
)	O
,	O
while	O
the	O
genotype	O
&	O
ldquo	O
;	O
AG	O
&	O
rdquo	O
;	O
for	O
rs2853676	O
was	O
shown	O
to	O
be	O
a	O
risk	O
genotype	O
for	O
glioma	O
(	O
OR	O
,	O
1.50	O
;	O
95	O
%	O
CI	O
,	O
1.05-2.15	O
;	O
P	O
=	O
0.025	O
)	O
.	O

CONCLUSION	O
Our	O
results	O
,	O
and	O
those	O
from	O
previous	O
studies	O
,	O
suggest	O
potential	O
genetic	O
contributes	O
for	O
GSTP1	O
and	O
TERT	O
in	O
glioma	O
development	O
.	O

Scintigraphic	O
evaluation	O
of	O
a	O
new	O
capsule-type	O
colon	O
specific	O
drug	O
delivery	O
system	O
in	O
healthy	Condition
volunteers	Condition
.	Condition

Colonic	O
drug	O
delivery	O
is	O
intended	O
for	O
local	O
or	O
systemic	O
therapies	O
.	O

The	O
lack	O
of	O
predictive	O
in	O
vitro	O
or	O
animal	O
model	O
leads	O
to	O
considerable	O
time	O
delays	O
in	O
colonic	O
product	O
development	O
.	O

The	O
objective	O
of	O
this	O
scintigraphic	O
study	O
was	O
to	O
provide	O
proof	O
of	O
concept	O
for	O
a	O
novel	O
capsule-type	O
colonic	O
delivery	O
system	O
(	O
Colon-Targeted	O
Delivery	O
Capsule	O
)	O
in	O
healthy	O
volunteers	O
.	O

The	O
human	O
data	O
validates	O
the	O
design	O
concept	O
behind	O
the	O
release	O
mechanism	O
,	O
in	O
that	O
capsule	O
disintegration	O
,	O
and	O
hence	O
drug	O
release	O
,	O
did	O
not	O
start	O
until	O
5	O
h	O
after	O
gastric	O
emptying	O
,	O
irrespective	O
of	O
whether	O
the	O
product	O
was	O
administered	O
to	O
fasted	O
or	O
fed	O
subjects	O
.	O

However	O
,	O
the	O
potential	O
for	O
prolonged	O
gastric	O
residence	O
for	O
large	O
enteric	O
coated	O
products	O
intended	O
for	O
intestinal	O
targeting	O
was	O
also	O
observed	O
;	O
overall	O
,	O
the	O
study	O
provides	O
a	O
focus	O
for	O
subsequent	O
product	O
development	O
and	O
highlights	O
the	O
role	O
of	O
scintigraphy	O
in	O
dynamically	O
visualizing	O
the	O
drug	O
delivery	O
process	O
.	O

Effects	O
of	O
telmisartan	O
and	O
enalapril	O
on	O
renoprotection	O
in	O
patients	O
with	O
mild	O
to	O
moderate	O
chronic	Condition
kidney	Condition
disease	Condition
.	O

BACKGROUND	O
Blocking	O
the	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
with	O
angiotensin	O
receptor	O
blockers	O
or	O
angiotensin-converting	O
enzyme	O
inhibitors	O
protects	O
against	O
renal	O
injury	O
in	O
patients	O
with	O
chronic	Condition
kidney	Condition
disease	Condition
(	Condition
CKD	Condition
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
chronic	O
effects	O
of	O
telmisartan	O
and	O
enalapril	O
on	O
proteinuria	O
,	O
urinary	O
liver-type	O
fatty	O
acid-binding	O
protein	O
(	O
L-FABP	O
)	O
and	O
endothelin	O
(	O
ET	O
)	O
-1	O
levels	O
in	O
patients	O
with	O
mild	Condition
CKD	Condition
.	O

MATERIALS	O
AND	O
METHODS	O
Thirty	Condition
CKD	Condition
patients	Condition
with	O
mild	Condition
to	Condition
moderate	Condition
renal	Condition
insufficiency	Condition
(	O
20	Sex
men	Sex
and	O
10	Sex
women	Sex
;	O
mean	O
age	O
,	O
37	Age
years	Age
;	O
estimated	O
glomerular	Condition
filtration	Condition
rate	Condition
(	O
eGFR	O
)	O
>	O
60	O
mL	O
min	O
(	O
-1	O
)	O
and	O
blood	O
pressure	O
>	O
130/85	O
mmHg	O
)	O
were	O
included	O
in	O
the	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
telmisartan	O
at	O
80	O
mg	O
day	O
(	O
-1	O
)	O
(	O
n	O
=	O
15	O
)	O
or	O
enalapril	O
at	O
10	O
mg	O
day	O
(	O
-1	O
)	O
(	O
n	O
=	O
15	O
)	O
.	O

We	O
measured	O
blood	O
pressure	O
,	O
serum	O
creatinine	O
,	O
eGFR	O
,	O
urinary	O
protein	O
,	O
L-FABP	O
and	O
ET-1	O
before	O
the	O
start	O
of	O
treatment	O
and	O
6	O
and	O
12	O
months	O
after	O
the	O
start	O
of	O
treatment	O
.	O

RESULTS	O
The	O
blood	O
pressure	O
reduction	O
rate	O
was	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Urinary	O
protein	O
,	O
L-FABP	O
and	O
ET-1	O
levels	O
were	O
significantly	O
reduced	O
in	O
both	O
groups	O
6	O
and	O
12	O
months	O
(	O
P	O
<	O
0.001	O
)	O
after	O
treatment	O
,	O
but	O
the	O
reduction	O
rates	O
were	O
more	O
pronounced	O
in	O
patients	O
receiving	O
telmisartan	O
than	O
in	O
those	O
receiving	O
enalapril	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Estimated	O
glomerular	O
filtration	O
rate	O
was	O
increased	O
similarly	O
in	O
both	O
groups	O
at	O
12	O
months	O
.	O

CONCLUSIONS	O
The	O
study	O
results	O
suggest	O
that	O
telmisartan	O
results	O
in	O
a	O
greater	O
reduction	O
of	O
urinary	O
markers	O
than	O
does	O
enalapril	O
and	O
that	O
this	O
effect	O
occurs	O
by	O
a	O
mechanism	O
independent	O
of	O
blood	O
pressure	O
reduction	O
.	O

It	O
would	O
be	O
needed	O
to	O
investigate	O
whether	O
the	O
differences	O
may	O
be	O
distinct	O
or	O
not	O
the	O
same	O
when	O
other	O
dosages	O
are	O
used	O
.	O

Comparison	O
of	O
different	O
approaches	O
for	O
assessment	O
of	O
HER2	O
expression	O
on	O
protein	O
and	O
mRNA	O
level	O
:	O
prediction	O
of	O
chemotherapy	O
response	O
in	O
the	O
neoadjuvant	O
GeparTrio	O
trial	O
(	O
NCT00544765	O
)	O
.	O

Human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
testing	O
is	O
an	O
essential	O
part	O
of	O
pathological	O
assessment	O
in	O
breast	Condition
cancer	Condition
patients	O
,	O
as	O
HER2	O
provides	O
not	O
only	O
prognostic	O
but	O
also	O
predictive	O
information	O
on	O
response	O
to	O
targeted	O
therapy	O
.	O

So	O
far	O
,	O
HER2	O
test	O
accuracy	O
of	O
immunohistochemistry/in	O
situ-hybridization	O
techniques	O
is	O
still	O
under	O
debate	O
,	O
and	O
more	O
reliable	O
and	O
robust	O
technologies	O
are	O
needed	O
.	O

To	O
address	O
this	O
issue	O
and	O
to	O
evaluate	O
the	O
predictive	O
value	O
of	O
HER2	O
on	O
chemotherapy	O
,	O
we	O
investigated	O
a	O
cohort	O
of	O
278	O
patients	O
from	O
the	O
GeparTrio	O
trial	O
,	O
a	O
prospective	O
neoadjuvant	O
anthracycline/taxane-based	O
multicenter	O
study	O
.	O

In	O
the	O
GeparTrio	O
trial	O
,	O
patients	O
were	O
not	O
treated	O
with	O
any	O
anti-HER2	O
therapy	O
,	O
as	O
this	O
was	O
not	O
standard	O
therapy	O
at	O
this	O
time	O
.	O

The	O
HER2	O
status	O
was	O
analyzed	O
by	O
three	O
different	O
approaches	O
:	O
local	O
and	O
central	O
evaluation	O
using	O
immunohistochemistry	O
combined	O
with	O
in	O
situ-hybridization	O
as	O
well	O
as	O
evaluation	O
of	O
HER2	O
mRNA	O
expression	O
using	O
kinetic	O
RT-PCR	O
from	O
formalin-fixed	O
,	O
paraffin-embedded	O
(	O
FFPE	O
)	O
tissue	O
samples	O
using	O
a	O
predefined	O
cutoff	O
.	O

HER2	O
overexpression/amplification	O
was	O
observed	O
in	O
37.3	O
%	O
(	O
91/244	O
)	O
and	O
17.9	O
%	O
(	O
41/229	O
)	O
of	O
the	O
informative	O
samples	O
in	O
the	O
local	O
and	O
central	O
evaluations	O
,	O
respectively	O
.	O

Positive	O
HER2	O
mRNA	O
levels	O
were	O
found	O
in	O
19.8	O
%	O
(	O
55/278	O
)	O
.	O

We	O
observed	O
a	O
highly	O
significant	O
correlation	O
between	O
central	O
HER2	O
expression	O
and	O
HER2	O
status	O
measured	O
by	O
kinetic	O
RT-PCR	O
(	O
r	O
=	O
0.856	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
an	O
overall	O
agreement	O
of	O
95.6	O
%	O
(	O
?	O
statistic	O
,	O
0.862	O
,	O
CI	O
0.77-0.94	O
)	O
.	O

Further	O
,	O
central	O
HER2	O
as	O
well	O
as	O
HER2	O
mRNA	O
expression	O
were	O
predictors	O
for	O
a	O
pathological	O
complete	O
response	O
after	O
neoadjuvant	O
anthracycline/taxane-based	O
primary	O
chemotherapy	O
in	O
a	O
univariate	O
binary	O
logistic	O
regression	O
analysis	O
(	O
OR	O
3.29	O
,	O
P	O
=	O
0.002	O
;	O
OR	O
2.65	O
,	O
P	O
=	O
0.004	O
)	O
.	O

The	O
predictive	O
value	O
could	O
be	O
confirmed	O
for	O
the	O
central	O
HER2	O
status	O
by	O
multivariate	O
analysis	O
(	O
OR	O
3.04	O
,	O
P	O
=	O
0.027	O
)	O
.	O

The	O
locally	O
assessed	O
HER2	O
status	O
was	O
not	O
predictive	O
of	O
response	O
to	O
chemotherapy	O
.	O

Our	O
results	O
suggest	O
that	O
standardized	O
methods	O
are	O
preferable	O
for	O
evaluation	O
of	O
HER2	O
status	O
.	O

The	O
kinetic	O
RT-PCR	O
from	O
FFPE	O
tissue	O
might	O
be	O
an	O
additional	O
approach	O
for	O
assessment	O
of	O
this	O
important	O
prognostic	O
and	O
predictive	O
parameter	O
but	O
has	O
to	O
be	O
confirmed	O
by	O
other	O
studies	O
.	O

Randomized	O
trial	O
of	O
recombinant	O
alpha	O
2b-interferon	O
with	O
or	O
without	O
indomethacin	O
in	O
patients	O
with	O
metastatic	Condition
malignant	Condition
melanoma	Condition
.	O

alpha-Interferon	O
has	O
antitumor	O
activity	O
in	O
a	O
variety	O
of	O
malignancies	O
but	O
is	O
frequently	O
associated	O
with	O
unacceptable	O
toxic	O
side-effects	O
.	O

The	O
routine	O
use	O
of	O
agents	O
potentially	O
capable	O
of	O
reducing	O
these	O
side-effects	O
has	O
not	O
been	O
recommended	O
out	O
of	O
concern	O
for	O
possible	O
reductions	O
in	O
the	O
therapeutic	O
activity	O
of	O
interferon	O
.	O

We	O
conducted	O
a	O
prospective	O
randomized	O
trial	O
of	O
alpha-interferon	O
given	O
with	O
or	O
without	O
indomethacin	O
to	O
patients	O
with	O
malignant	Condition
melanoma	Condition
to	O
determine	O
what	O
effect	O
,	O
if	O
any	O
,	O
indomethacin	O
might	O
have	O
on	O
the	O
toxic	O
,	O
immunomodulatory	O
,	O
and	O
therapeutic	O
properties	O
of	O
interferon	O
in	O
this	O
disease	O
.	O

53	SampleSize
patients	O
were	O
stratified	O
according	O
to	O
performance	O
status	O
and	O
randomized	O
to	O
receive	O
alpha	O
2b-interferon	O
,	O
20	O
million	O
units	O
per	O
m2	O
i.v.	O
,	O
5	O
days	O
per	O
week	O
for	O
4	O
weeks	O
followed	O
by	O
10	O
million	O
units	O
per	O
m2	O
s.c.	O
three	O
times	O
per	O
week	O
,	O
either	O
with	O
or	O
without	O
indomethacin	O
,	O
25	O
mg	O
orally	O
three	O
times	O
a	O
day	O
.	O

The	O
overall	O
major	O
response	O
rate	O
was	O
13	O
%	O
(	O
three	O
complete	O
responders	O
and	O
three	O
partial	O
responders	O
among	O
47	O
evaluable	O
patients	O
)	O
and	O
was	O
the	O
same	O
on	O
both	O
arms	O
.	O

The	O
mean	O
maximal	O
temperature	O
elevation	O
induced	O
by	O
interferon	O
was	O
significantly	O
reduced	O
(	O
from	O
102.1	O
to	O
100.7	O
,	O
P	O
=	O
0.0002	O
)	O
by	O
indomethacin	O
,	O
but	O
the	O
incidence	O
and	O
severity	O
of	O
interferon-related	O
fatigue	O
,	O
reduction	O
in	O
performance	O
status	O
,	O
headache	O
,	O
depression	O
,	O
confusion	O
,	O
elevations	O
in	O
liver	O
function	O
tests	O
,	O
and	O
myelosuppression	O
were	O
no	O
different	O
in	O
either	O
arm	O
of	O
the	O
study	O
.	O

Indomethacin	O
did	O
not	O
reduce	O
the	O
frequency	O
of	O
dose	O
reductions	O
for	O
toxic	O
side-effects	O
and	O
did	O
not	O
permit	O
the	O
administration	O
of	O
higher	O
interferon	O
doses	O
.	O

Peripheral	O
blood	O
natural	O
killer	O
activity	O
was	O
significantly	O
enhanced	O
in	O
patients	O
during	O
maintenance	O
therapy	O
whether	O
or	O
not	O
they	O
received	O
indomethacin	O
.	O

Indomethacin	O
appeared	O
to	O
inhibit	O
augmentation	O
of	O
natural	O
killer	O
activity	O
during	O
high	O
dose	O
induction	O
therapy	O
.	O

Immunological	O
changes	O
did	O
not	O
correlate	O
with	O
response	O
status	O
.	O

We	O
conclude	O
that	O
indomethacin	O
can	O
reduce	O
the	O
fever	O
associated	O
with	O
interferon	O
therapy	O
in	O
patients	O
with	O
malignant	Condition
melanoma	Condition
without	O
interfering	O
with	O
its	O
therapeutic	O
or	O
chronic	O
immunomodulatory	O
activities	O
.	O

Since	O
fever	O
is	O
rarely	O
the	O
dose-limiting	O
toxicity	O
of	O
interferon	O
,	O
indomethacin	O
is	O
of	O
marginal	O
benefit	O
to	O
patients	O
with	O
malignant	Condition
melanoma	Condition
receiving	O
interferon	O
at	O
the	O
doses	O
outlined	O
in	O
this	O
study	O
.	O

[	O
Effectiveness	O
of	O
morphine	O
by	O
periarticular	O
injections	O
after	O
shoulder	O
arthroscopy	O
]	O
.	O

Peripheral	O
opioid	O
receptors	O
have	O
been	O
found	O
in	O
inflamed	O
synovia	O
and	O
the	O
analgesic	O
effect	O
of	O
intra-articularly	O
administered	O
morphine	O
after	O
arthroscopic	O
knee	O
surgery	O
has	O
been	O
proven	O
.	O

There	O
is	O
controversy	O
about	O
efficacy	O
of	O
intraarticular	O
morphine	O
after	O
shoulder	O
arthroscopy	O
.	O

Thirty-two	O
patients	O
with	O
impingement	O
syndrome	O
underwent	O
subacromial	O
decompression	O
in	O
the	O
course	O
of	O
arthroscopic	O
shoulder	O
surgery	O
.	O

At	O
the	O
end	O
of	O
the	O
operation	O
morphine	O
(	O
5	O
mg	O
)	O
or	O
saline	O
was	O
injected	O
periarticularly	O
.	O

Pain	O
intensity	O
(	O
rest	O
and	O
passive	O
mobilisation	O
)	O
was	O
recorded	O
after	O
recovery	O
and	O
after	O
1,2,4	O
,	O
and	O
24	O
hours	O
(	O
Numeric	O
Rating	O
Scale	O
)	O
;	O
the	O
use	O
of	O
rescue	O
medication	O
(	O
piritramide	O
by	O
patient	O
controlled	O
analgesia	O
)	O
was	O
noted	O
.	O

No	O
relevant	O
pain	O
reduction	O
was	O
apparent	O
in	O
the	O
morphine	O
group	O
.	O

Piritramide	O
consumption	O
was	O
identical	O
in	O
both	O
groups	O
(	O
19.7	O
+/-	O
16	O
mg	O
vs.	O
19.8	O
+/-	O
19	O
mg	O
)	O
.	O

We	O
conclude	O
that	O
periarticularly	O
administered	O
morphine	O
in	O
arthroscopic	O
subacromial	O
decompression	O
in	O
the	O
dosage	O
applied	O
in	O
this	O
study	O
does	O
exert	O
no	O
relevant	O
analgesic	O
effect	O
.	O

This	O
is	O
possibly	O
due	O
to	O
the	O
fact	O
that	O
either	O
subacromial	O
tissue	O
,	O
despite	O
of	O
chronic	O
inflammation	O
,	O
does	O
not	O
show	O
the	O
same	O
reagibility	O
as	O
synovia	O
or	O
it	O
is	O
a	O
problem	O
of	O
the	O
nearly	O
complete	O
resection	O
of	O
the	O
subacromial	O
bursa	O
.	O

Fifteen-year	O
results	O
of	O
a	O
randomized	O
prospective	O
trial	O
of	O
hyperfractionated	O
chest	O
wall	O
irradiation	O
versus	O
once-daily	O
chest	O
wall	O
irradiation	O
after	O
chemotherapy	O
and	O
mastectomy	O
for	O
patients	O
with	O
locally	O
advanced	Condition
noninflammatory	Condition
breast	Condition
cancer	Condition
.	O

PURPOSE	O
To	O
analyze	O
the	O
results	O
of	O
a	O
Phase	O
III	O
clinical	O
trial	O
that	O
investigated	O
whether	O
a	O
hyperfractionated	O
radiotherapy	O
(	O
RT	O
)	O
schedule	O
could	O
reduce	O
the	O
risk	O
of	O
locoregional	O
recurrence	O
in	O
patients	O
with	O
locally	Condition
advanced	Condition
breast	Condition
cancer	Condition
treated	O
with	O
chemotherapy	O
and	O
mastectomy	O
.	O

METHODS	O
AND	O
MATERIALS	O
Between	O
1985	O
and	O
1989	O
,	O
200	SampleSize
patients	O
with	O
clinical	O
Stage	Condition
III	Condition
noninflammatory	Condition
breast	Condition
cancer	Condition
were	O
enrolled	O
in	O
a	O
prospective	O
study	O
investigating	O
neoadjuvant	O
and	O
adjuvant	O
chemotherapy	O
.	O

Of	O
the	O
179	SampleSize
patients	O
treated	O
with	O
mastectomy	O
after	O
neoadjuvant	O
chemotherapy	O
,	O
108	SampleSize
participated	O
in	O
a	O
randomized	O
component	O
of	O
the	O
trial	O
that	O
compared	O
a	O
dose-escalated	O
,	O
hyperfractionated	O
(	O
twice-daily	O
,	O
b.i.d	O
.	O

)	O
chest	O
wall	O
RT	O
schedule	O
(	O
72	O
Gy	O
in	O
1.2-Gy	O
b.i.d	O
.	O

fractions	O
)	O
with	O
a	O
once-daily	O
(	O
q.d	O
.	O

)	O
schedule	O
(	O
60	O
Gy	O
in	O
2-Gy	O
q.d	O
.	O

fractions	O
)	O
.	O

In	O
both	O
arms	O
of	O
the	O
study	O
,	O
the	O
supraclavicular	O
fossa	O
and	O
axillary	O
apex	O
were	O
treated	O
once	O
daily	O
to	O
50	O
Gy	O
.	O

The	O
median	O
follow-up	O
period	O
was	O
15	O
years	O
.	O

RESULTS	O
The	O
15-year	O
actuarial	O
locoregional	O
recurrence	O
rate	O
was	O
7	O
%	O
for	O
the	O
q.d	O
.	O

arm	O
and	O
12	O
%	O
for	O
the	O
b.i.d	O
.	O

arm	O
(	O
p=0.36	O
)	O
.	O

The	O
rates	O
of	O
severe	O
acute	O
toxicity	O
were	O
similar	O
(	O
4	O
%	O
for	O
q.d	O
.	O

vs.	O
5	O
%	O
for	O
b.i.d	O
.	O

)	O
,	O
but	O
moist	O
desquamation	O
developed	O
in	O
42	O
%	O
of	O
patients	O
in	O
the	O
b.i.d	O
.	O

arm	O
compared	O
with	O
28	O
%	O
of	O
the	O
patients	O
in	O
the	O
q.d	O
.	O

arm	O
(	O
p=0.16	O
)	O
.	O

The	O
15-year	O
actuarial	O
rate	O
of	O
severe	O
late	O
RT	O
complications	O
did	O
not	O
differ	O
between	O
the	O
two	O
arms	O
(	O
6	O
%	O
for	O
q.d	O
.	O

vs.	O
11	O
%	O
for	O
b.i.d.	O
,	O
p=0.54	O
)	O
.	O

CONCLUSION	O
Although	O
the	O
sample	O
size	O
of	O
this	O
study	O
was	O
small	O
,	O
we	O
found	O
no	O
evidence	O
that	O
this	O
hyperfractionation	O
schedule	O
of	O
postmastectomy	O
RT	O
offered	O
a	O
clinical	O
advantage	O
.	O

Therefore	O
,	O
we	O
have	O
concluded	O
that	O
it	O
should	O
not	O
be	O
further	O
studied	O
in	O
this	O
cohort	O
of	O
patients	O
.	O

A	O
randomized	O
phase	O
II	O
trial	O
of	O
two	O
regimens	O
of	O
moderate	O
dose	O
chemoradiation	O
therapy	O
for	O
patients	Condition
with	Condition
non-small	Condition
cell	Condition
lung	Condition
cancer	Condition
not	Condition
suitable	Condition
for	Condition
curative	Condition
therapy	Condition
:	Condition
Trans	O
Tasman	O
Radiation	O
Oncology	O
Study	O
TROG	O
03.07	O
.	O

BACKGROUND	O
There	O
are	O
patients	O
with	O
stage	O
I-III	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
who	O
are	O
not	O
suitable	O
for	O
curative	O
radical	O
chemoradiation	O
therapy	O
.	O

There	O
are	O
patients	O
with	O
an	O
isolated	O
solitary	O
extracranial	O
metastasis	O
who	O
have	O
improved	O
outcomes	O
compared	O
with	O
those	O
with	O
cranial	O
or	O
multiple	O
metastases	O
.	O

Patients	O
of	O
good	O
performance	O
status	O
receiving	O
moderate	O
dose	O
radiation	O
therapy	O
have	O
improved	O
survival	O
.	O

Two	O
regimens	O
of	O
moderate	O
dose	O
chemoradiation	O
therapy	O
for	O
such	O
patients	O
were	O
compared	O
in	O
a	O
randomized	O
phase	O
II	O
trial	O
.	O

METHODS	O
Patients	O
were	O
eligible	O
if	O
they	O
had	O
stage	O
I-IIIB	O
NSCLC	O
,	O
unsuitable	O
for	O
curative	O
therapy	O
,	O
or	O
stage	O
IV	O
with	O
a	O
PET-detected	O
extracranial	O
solitary	O
metastasis	O
.	O

Patients	O
were	O
randomized	O
to	O
the	O
following	O
groups-arm	O
A	O
:	O
40	O
Gy/20	O
fractions/4	O
weeks	O
with	O
concurrent	O
weekly	O
vinorelbine	O
25	O
mg/m	O
+	O
cisplatin	O
20	O
mg/m	O
or	O
arm	O
B	O
:	O
30	O
Gy/15	O
fractions/3	O
weeks	O
with	O
concurrent	O
weekly	O
gemcitabine	O
200	O
mg.	O
Primary	O
end	O
points	O
were	O
feasibility	O
,	O
response	O
rates	O
,	O
and	O
toxicity	O
.	O

Secondary	O
end	O
points	O
were	O
progression-free	O
survival	O
,	O
overall	O
survival	O
,	O
and	O
quality	O
of	O
life	O
.	O

RESULTS	O
Eighty-four	O
patients	O
were	O
randomized	O
.	O

Compliance	O
was	O
above	O
90	O
%	O
for	O
both	O
arms	O
.	O

The	O
overall	O
response	O
rate	O
was	O
51	O
%	O
in	O
arm	O
A	O
and	O
38	O
%	O
in	O
arm	O
B	O
(	O
p	O
=	O
0.147	O
)	O
.	O

Grade	O
3/4	O
toxicity	O
in	O
both	O
arms	O
was	O
acceptable	O
.	O

There	O
was	O
no	O
difference	O
in	O
median	O
progression-free	O
survival	O
between	O
the	O
two	O
arms	O
(	O
5.5	O
versus	O
5.0	O
months	O
,	O
p	O
=	O
0.19	O
)	O
.	O

Patients	O
in	O
arm	O
A	O
had	O
longer	O
median	O
survival	O
but	O
this	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
13.1	O
versus	O
8.3	O
months	O
,	O
p	O
=	O
0.25	O
)	O
.	O

No	O
difference	O
in	O
quality	O
of	O
life	O
was	O
observed	O
.	O

CONCLUSIONS	O
Arm	O
A	O
was	O
chosen	O
for	O
a	O
future	O
phase	O
II	O
comparison	O
with	O
radiation	O
therapy	O
alone	O
as	O
it	O
demonstrated	O
a	O
response	O
rate	O
greater	O
than	O
50	O
%	O
,	O
and	O
data	O
suggested	O
that	O
arm	O
A	O
had	O
superior	O
survival	O
to	O
arm	O
B	O
.	O

Preliminary	O
findings	O
from	O
a	O
prospective	O
,	O
randomized	O
trial	O
of	O
two	O
palatal	O
operations	O
for	O
sleep-disordered	O
breathing	O
.	O

OBJECTIVES	O
We	O
compared	O
the	O
efficacy	O
of	O
2	O
palatal	O
surgical	O
procedures	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
mild	Condition
sleep-disordered	Condition
breathing	Condition
(	Condition
SDB	Condition
)	Condition
.	O

STUDY	O
DESIGN	O
AND	O
SETTING	O
We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
crossover	O
surgical	O
trial	O
at	O
a	O
university	O
hospital	O
.	O

METHODS	O
Twenty	SampleSize
patients	O
with	O
mild	O
SDB	O
for	O
whom	O
conservative	O
treatment	O
failed	O
were	O
identified	O
and	O
consecutively	O
enrolled	O
into	O
an	O
institutional	O
review	O
board-approved	O
surgical	O
protocol	O
.	O

They	O
were	O
randomly	O
assigned	O
to	O
undergo	O
either	O
radiofrequency	O
ablation	O
of	O
the	O
palate	O
(	O
RFAP	O
)	O
for	O
a	O
planned	O
3-stage	O
treatment	O
or	O
laser-assisted	O
uvulopalatoplasty	O
(	O
LAUP	O
)	O
,	O
also	O
for	O
3	O
stages	O
of	O
treatment	O
,	O
using	O
a	O
CO	O
(	O
2	O
)	O
laser	O
.	O

Parameters	O
assessed	O
included	O
severity	O
of	O
SDB	O
(	O
polysomnography	O
)	O
,	O
subjective	O
and	O
objective	O
loudness	O
of	O
snoring	O
(	O
visual	O
analog	O
scale	O
and	O
SNAP	O
recording	O
)	O
,	O
sleepiness	O
(	O
Epworth	O
Sleepiness	O
Scale	O
)	O
,	O
and	O
anatomic	O
changes	O
(	O
upper	O
airway	O
endoscopy	O
)	O
,	O
as	O
well	O
as	O
demographic	O
factors	O
.	O

Patients	O
not	O
achieving	O
satisfactory	O
improvement	O
in	O
their	O
condition	O
were	O
crossed	O
over	O
to	O
the	O
alternative	O
surgical	O
therapy	O
for	O
attempted	O
salvage	O
.	O

RESULTS	O
Seventeen	O
of	O
the	O
enrolled	O
patients	O
have	O
completed	O
the	O
protocol	O
.	O

Ten	O
of	O
these	O
were	O
randomized	O
to	O
the	O
RFAP	O
group	O
,	O
and	O
7	O
to	O
the	O
LAUP	O
group	O
.	O

Six	O
of	O
the	O
RFAP	O
patients	O
(	O
60	O
%	O
)	O
achieved	O
a	O
satisfactory	O
resolution	O
of	O
their	O
snoring	O
,	O
and	O
4	O
failed	O
and	O
were	O
salvaged	O
with	O
LAUP	O
.	O

Six	O
of	O
the	O
LAUP	O
patients	O
(	O
86	O
%	O
)	O
achieved	O
a	O
satisfactory	O
resolution	O
of	O
their	O
snoring	O
,	O
and	O
1	O
patient	O
failed	O
and	O
was	O
salvaged	O
with	O
nasal	O
surgery	O
.	O

One	O
patient	O
who	O
was	O
initially	O
cured	O
had	O
a	O
relapse	O
after	O
9	O
months	O
and	O
was	O
successfully	O
salvaged	O
with	O
RFA	O
.	O

CONCLUSION	O
Prospective	O
,	O
randomized	O
trials	O
of	O
surgery	O
for	O
SDB	O
are	O
possible	O
.	O

Preliminary	O
findings	O
from	O
the	O
current	O
protocol	O
reveal	O
a	O
slight	O
advantage	O
of	O
LAUP	O
over	O
RFAP	O
but	O
with	O
a	O
greater	O
degree	O
of	O
discomfort	O
postoperatively	O
.	O

Epidural	O
analgesia	O
compared	O
with	O
intravenous	O
morphine	O
patient-controlled	O
analgesia	O
:	O
postoperative	O
outcome	O
measures	O
after	O
mastectomy	Condition
with	Condition
immediate	Condition
TRAM	Condition
flap	Condition
breast	Condition
reconstruction	Condition
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Epidural	O
analgesia	O
has	O
been	O
shown	O
to	O
provide	O
superior	O
pain	O
control	O
compared	O
with	O
intravenous	O
(	O
IV	O
)	O
opioids	O
after	O
major	O
surgical	O
procedures	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
effect	O
of	O
epidural	O
analgesia	O
and	O
IV	O
morphine	O
patient-controlled	O
analgesia	O
(	O
PCA	O
)	O
on	O
pain	O
relief	O
,	O
duration	O
of	O
hospitalization	O
,	O
oral	O
nutrition	O
,	O
ambulation	O
,	O
and	O
side	O
effects	O
in	O
patients	O
undergoing	O
a	O
major	O
surgical	O
procedure	O
(	O
i.e.	O
,	O
unilateral	O
mastectomy	O
with	O
immediate	O
transverse	O
rectus	O
abdominis	O
musculocutaneous	O
flap	O
reconstruction	O
)	O
.	O

METHODS	O
Eighteen	SampleSize
patients	O
were	O
prospectively	O
randomized	O
to	O
receive	O
either	O
epidural	O
analgesia	O
or	O
PCA	O
during	O
the	O
postoperative	O
period	O
.	O

The	O
intensity	O
of	O
pain	O
was	O
assessed	O
daily	O
by	O
a	O
100-mm	O
visual	O
analog	O
scale	O
.	O

The	O
total	O
length	O
of	O
hospital	O
stay	O
,	O
time	O
to	O
ambulation	O
,	O
and	O
time	O
to	O
oral	O
nutrition	O
were	O
recorded	O
.	O

RESULTS	O
The	O
epidural	O
group	O
had	O
significantly	O
lower	O
pain	O
scores	O
at	O
3	O
evaluation	O
times	O
through	O
postoperative	O
day	O
number	O
4	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
total	O
length	O
of	O
hospitalization	O
for	O
the	O
epidural	O
group	O
(	O
median	O
,	O
101	O
hours	O
)	O
was	O
significantly	O
less	O
than	O
the	O
PCA	O
group	O
(	O
median	O
,	O
126	O
hours	O
;	O
P	O
=	O
.0498	O
)	O
.	O

The	O
time	O
to	O
first	O
ambulation	O
,	O
time	O
to	O
first	O
bowel	O
sounds	O
,	O
time	O
to	O
tolerating	O
oral	O
nutrition	O
,	O
incidence	O
of	O
nausea/vomiting	O
or	O
pruritus	O
,	O
and	O
time	O
to	O
first	O
flatus	O
were	O
not	O
statistically	O
different	O
between	O
the	O
groups	O
.	O

CONCLUSIONS	O
These	O
results	O
show	O
that	O
epidural	O
analgesia	O
compared	O
with	O
PCA	O
offered	O
improved	O
pain	O
control	O
after	O
breast	O
reconstruction	O
with	O
immediate	O
transverse	O
rectus	O
abdominis	O
musculocutaneous	O
flap	O
reconstruction	O
.	O

It	O
also	O
resulted	O
in	O
a	O
25-hour	O
reduction	O
in	O
time	O
of	O
hospitalization	O
.	O

Comparison	O
of	O
the	O
effects	O
of	O
terazosin	O
and	O
enalapril	O
on	O
laboratory	O
stress	O
testing	O
blood	O
pressure	O
in	O
patients	O
with	O
essential	Condition
hypertension	Condition
.	O

It	O
is	O
the	O
current	O
opinion	O
that	O
an	O
ideal	O
antihypertensive	O
drug	O
should	O
reduce	O
blood	O
pressure	O
(	O
BP	O
)	O
not	O
only	O
at	O
rest	O
but	O
also	O
during	O
stressful	O
situations	O
.	O

The	O
current	O
study	O
was	O
aimed	O
to	O
compare	O
the	O
effects	O
of	O
the	O
selective	O
alpha	O
1-adrenergic	O
blocker	O
terazosin	O
(	O
5	O
mg	O
once	O
daily	O
)	O
and	O
of	O
the	O
angiotensin-converting	O
enzyme	O
inhibitor	O
enalapril	O
(	O
20	O
mg	O
once	O
daily	O
)	O
on	O
cardiovascular	O
response	O
to	O
a	O
set	O
of	O
standardized	O
laboratory	O
stressors	O
,	O
such	O
as	O
mental	O
arithmetic	O
,	O
handgrip	O
test	O
and	O
cycle	O
ergometry	O
,	O
in	O
a	O
group	O
of	O
16	SampleSize
essential	O
hypertensive	O
patients	O
.	O

The	O
study	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
cross-over	O
trial	O
preceded	O
by	O
a	O
placebo	O
run-in	O
period	O
.	O

Terazosin	O
and	O
enalapril	O
had	O
a	O
comparable	O
effect	O
on	O
resting	O
BP	O
,	O
reducing	O
systolic	O
(	O
SBP	O
)	O
and	O
diastolic	O
(	O
DBP	O
)	O
blood	O
pressure	O
from	O
159.5	O
+/-	O
13.9/101.6	O
+/-	O
8.8	O
mm	O
Hg	O
during	O
placebo	O
by	O
7.8	O
%	O
/6.7	O
%	O
and	O
by	O
11.3	O
%	O
/10.2	O
%	O
,	O
respectively	O
.	O

The	O
response	O
rate	O
to	O
the	O
two	O
treatments	O
was	O
approximately	O
the	O
same	O
,	O
being	O
69	O
%	O
and	O
75	O
%	O
after	O
terazosin	O
and	O
enalapril	O
,	O
respectively	O
.	O

During	O
mental	O
arithmetic	O
,	O
from	O
an	O
average	O
of	O
181.6	O
+/-	O
17.8/118.6	O
+/-	O
11.5	O
mm	O
Hg	O
during	O
placebo	O
,	O
BP	O
was	O
reduced	O
by	O
11.5	O
%	O
/7.9	O
%	O
after	O
terazosin	O
and	O
by	O
13.6	O
%	O
/8.5	O
%	O
after	O
enalapril	O
;	O
during	O
handgrip	O
test	O
,	O
BP	O
decreased	O
from	O
207.2	O
+/-	O
22.2/142.2	O
+/-	O
13.6	O
mm	O
Hg	O
by	O
7.3	O
%	O
/8.4	O
%	O
after	O
terazosin	O
and	O
by	O
7.7	O
%	O
/7.1	O
%	O
after	O
enalapril	O
;	O
finally	O
,	O
during	O
cycle	O
ergometry	O
,	O
terazosin	O
and	O
enalapril	O
lowered	O
BP	O
by	O
5.4	O
%	O
/6.7	O
%	O
and	O
7	O
%	O
/3.1	O
%	O
,	O
respectively	O
,	O
from	O
a	O
placebo	O
value	O
of	O
215.5	O
+/-	O
17.3/127.6	O
+/-	O
11.2	O
.	O

No	O
significant	O
difference	O
in	O
antihypertensive	O
efficacy	O
was	O
observed	O
between	O
the	O
two	O
drugs	O
,	O
either	O
at	O
rest	O
and	O
during	O
stress	O
testing	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Comparison	O
of	O
inhaled	O
albuterol	O
powder	O
and	O
aerosol	O
in	O
asthma	Condition
.	O

In	O
this	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
study	O
comparing	O
the	O
efficacy	O
and	O
safety	O
of	O
aerosolized	O
albuterol	O
with	O
the	O
dry	O
powder	O
formulation	O
,	O
231	SampleSize
patients	O
with	O
chronic	Condition
reversible	Condition
obstructive	Condition
airway	Condition
disease	Condition
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
placebo	O
albuterol	O
aerosol	O
followed	O
immediately	O
by	O
active	O
albuterol	O
powder	O
(	O
200	O
micrograms	O
)	O
or	O
active	O
albuterol	O
aerosol	O
(	O
two	O
puffs	O
,	O
180	O
micrograms	O
)	O
followed	O
immediately	O
by	O
placebo	O
lactose	O
powder	O
four	O
times	O
a	O
day	O
for	O
a	O
period	O
of	O
12	O
weeks	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
between	O
the	O
powder	O
and	O
aerosol	O
formulations	O
with	O
respect	O
to	O
pulmonary	O
function	O
,	O
length	O
of	O
time	O
mean	O
FEV1	O
remained	O
greater	O
than	O
or	O
equal	O
to	O
15	O
%	O
above	O
baseline	O
,	O
physicians	O
'	O
assessments	O
of	O
patients	O
'	O
clinical	O
response	O
,	O
or	O
patients	O
'	O
subjective	O
symptom	O
scores	O
.	O

There	O
were	O
also	O
no	O
significant	O
differences	O
between	O
treatment	O
groups	O
in	O
cardiovascular	O
effects	O
,	O
laboratory	O
values	O
,	O
or	O
adverse	O
events	O
.	O

Among	O
patients	O
who	O
expressed	O
a	O
preference	O
for	O
one	O
of	O
the	O
delivery	O
systems	O
,	O
half	SampleSize
preferred	O
using	O
the	O
powder	O
.	O

Results	O
of	O
this	O
study	O
demonstrate	O
that	O
200	O
micrograms	O
of	O
albuterol	O
powder	O
is	O
as	O
safe	O
and	O
effective	O
as	O
180	O
micrograms	O
of	O
albuterol	O
aerosol	O
.	O

Effects	O
of	O
losartan	O
and	O
enalapril	O
on	O
high-sensitivity	O
C-reactive	O
protein	O
and	O
total	O
antioxidant	O
in	O
renal	Condition
transplant	Condition
recipients	O
with	O
Renin-Angiotensin	Condition
system	Condition
polymorphisms	Condition
.	O

BACKGROUND	O
As	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
activity	O
may	O
affect	O
the	O
severity	O
of	O
oxidative	O
stress	O
and	O
inflammatory	O
markers	O
,	O
we	O
assessed	O
the	O
effects	O
of	O
enalapril	O
(	O
E	O
)	O
and/or	O
losartan	O
(	O
L	O
)	O
on	O
these	O
markers	O
in	O
renal	Condition
transplant	Condition
recipients	O
with	O
RAS	Condition
polymorphisms	Condition
.	Condition

PATIENTS	O
AND	O
METHODS	O
After	O
determination	O
by	O
PCR	O
of	O
RAS	O
genotypes	O
,	O
consisting	O
of	O
the	O
angiotensin-converting	O
enzymes	O
(	O
ACE	O
I/D	O
)	O
,	O
angiotensinogens	O
(	O
AGT	O
M235T	O
)	O
and	O
angiotensin	O
II	O
type	O
1	O
receptors	O
(	O
ATR1	O
A1166C	O
)	O
,	O
76	SampleSize
recipients	O
were	O
recruited	O
randomly	O
and	O
assigned	O
4	O
groups	O
.	O

The	O
first	O
(	O
n	O
=	O
17	O
)	O
and	O
second	O
(	O
n	O
=	O
24	O
)	O
groups	O
were	O
treated	O
with	O
E	O
(	O
E	O
(	O
+	O
)	O
:	O
10	O
mg/d	O
)	O
and	O
L	O
(	O
L	O
(	O
+	O
)	O
:	O
50	O
mg/d	O
)	O
alone	O
,	O
respectively	O
.	O

The	O
third	O
positive	O
control	O
group	O
(	O
n	O
=	O
17	O
)	O
received	O
E	O
+	O
L	O
(	O
E	O
(	O
+	O
)	O
L	O
(	O
+	O
)	O
:	O
10	O
mg/d	O
+	O
50	O
mg/d	O
)	O
and	O
the	O
fourth	O
negative	O
control	O
group	O
(	O
n	O
=	O
18	O
)	O
received	O
no	O
medication	O
(	O
E	O
(	O
-	O
)	O
:	O
L	O
(	O
-	O
)	O
)	O
.	O

High-sensitivity	O
C-reactive	O
protein	O
(	O
hs-CRP	O
)	O
and	O
total	O
antioxidant	O
(	O
TA	O
)	O
inflammatory	O
and	O
antioxidative	O
markers	O
were	O
measured	O
after	O
2	O
months	O
.	O

After	O
a	O
2-week	O
washout	O
period	O
,	O
the	O
E	O
(	O
+	O
)	O
group	O
was	O
changed	O
to	O
L	O
(	O
+	O
)	O
and	O
vice	O
versa	O
in	O
a	O
crossover	O
design	O
.	O

They	O
were	O
followed	O
for	O
another	O
8	O
weeks	O
before	O
retesting	O
hs-CRP	O
and	O
TA	O
.	O

A	O
value	O
of	O
P	O
<	O
or	O
=	O
.05	O
was	O
considered	O
significant	O
.	O

RESULTS	O
After	O
2	O
and	O
4	O
months	O
of	O
treatment	O
with	O
the	O
drug	O
regimen	O
,	O
hs-CRP	O
and	O
TA	O
levels	O
were	O
significantly	O
decreased	O
and	O
consequently	O
increased	O
among	O
the	O
E	O
(	O
+	O
)	O
L	O
(	O
+	O
)	O
,	O
L	O
(	O
+	O
)	O
and	O
E	O
(	O
+	O
)	O
groups	O
(	O
P	O
<	O
.05	O
)	O
.	O

On	O
analyzing	O
the	O
relationship	O
between	O
RAS	O
polymorphisms	O
and	O
baseline	O
hs-CRP	O
or	O
TA	O
levels	O
,	O
CC	O
genotype	O
of	O
ATR1	O
showed	O
lower	O
hs-CRP	O
levels	O
(	O
P	O
=	O
.04	O
)	O
.	O

However	O
,	O
none	O
of	O
the	O
RAS	O
polymorphisms	O
predicted	O
the	O
antioxidant	O
and	O
anti-inflammatory	O
response	O
rates	O
to	O
the	O
drugs	O
(	O
P	O
>	O
.05	O
)	O
.	O

CONCLUSION	O
Although	O
hs-CRP	O
was	O
lower	O
in	O
the	O
CC	O
genotype	O
patients	O
of	O
ATR1	O
polymorphisms	O
E	O
and/or	O
L	O
reduced	O
hs-CRP	O
and	O
increased	O
TA	O
regardless	O
of	O
the	O
RAS	O
genotype	O
.	O

Acute	O
prolactin	O
and	O
oxytocin	O
responses	O
and	O
milk	O
yield	O
to	O
infant	O
suckling	O
and	O
artificial	O
methods	O
of	O
expression	O
in	O
lactating	O
women	Sex
.	O

Breast-feeding	O
is	O
today	O
the	O
major	O
form	O
of	O
infant	O
nutrition	O
in	O
the	O
immediate	O
postpartum	O
period	O
.	O

Despite	O
this	O
,	O
recent	O
trends	O
in	O
modern	O
life-styles	O
have	O
raised	O
obstacles	O
to	O
successful	O
lactation	O
.	O

These	O
include	O
infant	O
illness	O
and	O
maternal	O
responsibilities	O
outside	O
the	O
home	O
,	O
both	O
requiring	O
separation	O
from	O
the	O
mother	O
.	O

While	O
the	O
hormonal	O
dynamics	O
of	O
infant	O
suckling	O
are	O
understood	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
artificial	O
methods	O
of	O
milk	O
expression	O
.	O

A	O
variety	O
of	O
breast	O
pumps	O
exist	O
in	O
the	O
current	O
US	O
market	O
which	O
vary	O
considerably	O
in	O
price	O
and	O
effectiveness	O
.	O

To	O
understand	O
better	O
the	O
ability	O
of	O
these	O
pumps	O
to	O
assist	O
women	O
in	O
the	O
maintenance	O
of	O
lactation	O
,	O
the	O
current	O
study	O
was	O
undertaken	O
to	O
evaluate	O
their	O
effects	O
on	O
milk	O
yield	O
and	O
prolactin	O
and	O
oxytocin	O
release	O
when	O
compared	O
to	O
natural	O
infant	O
suckling	O
.	O

Twenty-three	SampleSize
women	O
who	O
were	O
exclusively	O
breast-feeding	O
their	O
infants	O
were	O
randomly	O
assigned	O
to	O
serially	O
use	O
several	O
pumping	O
methods	O
,	O
as	O
well	O
as	O
infant	O
suckling	O
,	O
with	O
blood	O
being	O
taken	O
at	O
10-minute	O
intervals	O
to	O
determine	O
the	O
hormonal	O
responses	O
.	O

The	O
results	O
reveal	O
variability	O
in	O
the	O
prolactin	O
responses	O
to	O
the	O
artificial	O
pumping	O
methods	O
,	O
with	O
the	O
greatest	O
responses	O
found	O
with	O
an	O
electric	O
pulsatile	O
pump	O
;	O
these	O
responses	O
compare	O
favorably	O
with	O
those	O
of	O
natural	O
infant	O
suckling	O
.	O

Other	O
methods	O
were	O
less	O
successful	O
in	O
causing	O
prolactin	O
elevations	O
.	O

No	O
differences	O
were	O
seen	O
among	O
the	O
methods	O
in	O
the	O
oxytocin	O
response	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
striking	O
differences	O
in	O
the	O
ability	O
of	O
breast-pumping	O
methods	O
to	O
produce	O
an	O
acute	O
and	O
sustained	O
prolactin	O
rise	O
in	O
breast-feeding	O
mothers	O
.	O

The	O
large	O
discrepancies	O
found	O
suggest	O
the	O
need	O
for	O
further	O
studies	O
in	O
to	O
enable	O
women	O
and	O
health	O
care	O
providers	O
to	O
choose	O
the	O
most	O
appropriate	O
method	O
for	O
milk	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Letrozole	O
in	O
the	O
neoadjuvant	O
setting	O
:	O
the	O
P024	O
trial	O
.	O

Neoadjuvant	O
chemotherapy	O
trials	O
have	O
consistently	O
reported	O
lower	O
response	O
rates	O
in	O
hormone	O
receptor-positive	O
(	O
HR+	O
)	O
breast	O
cancer	O
when	O
compared	O
with	O
HR-	O
cases	O
.	O

Preoperative	O
endocrine	O
therapy	O
has	O
therefore	O
become	O
a	O
logical	O
alternative	O
and	O
has	O
gained	O
considerable	O
momentum	O
from	O
the	O
finding	O
that	O
aromatase	O
inhibitors	O
(	O
AIs	O
)	O
are	O
more	O
effective	O
than	O
tamoxifen	O
for	O
HR+	O
breast	O
cancer	O
in	O
both	O
the	O
neoadjuvant	O
and	O
adjuvant	O
settings	O
.	O

The	O
most	O
convincing	O
neoadjuvant	O
trial	O
to	O
demonstrate	O
the	O
superiority	O
of	O
an	O
AI	O
versus	O
tamoxifen	O
was	O
the	O
P024	O
study	O
,	O
a	O
large	O
multinational	Age
double-blind	O
trial	O
in	O
postmenopausal	Condition
women	Condition
with	Condition
HR+	Condition
breast	Condition
cancer	Condition
ineligible	Condition
for	Condition
breast-conserving	Condition
surgery	Condition
.	Condition

The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
was	O
55	O
%	O
for	O
letrozole	O
and	O
36	O
%	O
for	O
tamoxifen	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Significantly	O
more	O
letrozole-treated	O
patients	O
underwent	O
breast-conserving	O
surgery	O
(	O
45	O
vs.	O
35	O
%	O
,	O
respectively	O
;	O
P=0.022	O
)	O
.	O

In	O
addition	O
,	O
ORR	O
was	O
significantly	O
higher	O
with	O
letrozole	O
than	O
tamoxifen	O
in	O
the	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
HER1/HER2+	O
subgroup	O
(	O
P=0.0004	O
)	O
.	O

The	O
clinical	O
efficacy	O
of	O
letrozole	O
in	O
HER2+	O
breast	O
cancer	O
was	O
confirmed	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
and	O
was	O
found	O
to	O
be	O
comparable	O
to	O
that	O
of	O
HER2-	O
cases	O
(	O
ORR	O
71	O
%	O
in	O
both	O
subsets	O
)	O
.	O

Biomarker	O
studies	O
confirmed	O
the	O
superiority	O
of	O
letrozole	O
in	O
centrally	O
assessed	O
estrogen	O
receptor-positive	O
(	O
ER+	O
)	O
tumors	O
and	O
found	O
a	O
strong	O
relationship	O
with	O
the	O
degree	O
of	O
ER	O
positivity	O
for	O
both	O
agents	O
.	O

Interestingly	O
,	O
letrozole	O
was	O
effective	O
even	O
in	O
marginally	O
ER+	O
tumors	O
and	O
,	O
unlike	O
tamoxifen	O
,	O
consistently	O
reduced	O
the	O
expression	O
from	O
estrogen-regulated	O
genes	O
(	O
progesterone	O
receptor	O
and	O
trefoil	O
factor	O
1	O
)	O
.	O

Furthermore	O
,	O
when	O
analyzed	O
by	O
Ki67	O
immunohistochemistry	O
,	O
letrozole	O
was	O
significantly	O
more	O
effective	O
than	O
tamoxifen	O
in	O
reducing	O
tumor	O
proliferation	O
(	O
P=0.0009	O
)	O
.	O

Thus	O
,	O
neoadjuvant	O
letrozole	O
is	O
safe	O
and	O
superior	O
to	O
tamoxifen	O
in	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
HR+	O
locally	O
advanced	O
breast	O
cancer	O
.	O

Antibiotic	O
strategy	O
after	O
the	O
empiric	O
phase	O
in	O
patients	O
treated	O
for	O
a	O
hematological	Condition
malignancy	Condition
.	O

Empiric	O
broad-spectrum	O
antibiotic	O
therapy	O
has	O
become	O
a	O
generally	O
accepted	O
strategy	O
in	O
the	O
treatment	O
of	O
febrile	Condition
neutropenic	Condition
patients	O
.	O

Particularly	O
in	O
patients	O
with	O
prolonged	Condition
neutropenia	Condition
,	O
subsequent	O
adaptation	O
of	O
such	O
a	O
regimen	O
will	O
be	O
the	O
rule	O
rather	O
than	O
exception	O
.	O

Since	O
there	O
are	O
no	O
uniformly	O
accepted	O
guidelines	O
for	O
the	O
modification	O
of	O
antibiotic	O
therapy	O
during	O
the	O
post-empiric	O
phase	O
,	O
we	O
assessed	O
the	O
impact	O
of	O
a	O
set	O
of	O
rules	O
that	O
evolved	O
during	O
the	O
first	O
randomized	O
trials	O
.	O

Evaluation	O
of	O
the	O
clinician	O
's	O
compliance	O
with	O
these	O
rules	O
in	O
1951	O
febrile	O
neutropenic	O
episodes	O
was	O
the	O
subject	O
of	O
the	O
present	O
analysis	O
.	O

Treatment	O
was	O
modified	O
in	O
761	O
(	O
39	O
%	O
)	O
cases	O
,	O
and	O
these	O
changes	O
were	O
made	O
according	O
to	O
the	O
rules	O
in	O
76	O
%	O
.	O

For	O
75	O
%	O
of	O
the	O
alterations	O
in	O
treatment	O
during	O
the	O
evening	O
and	O
night	O
shifts	O
,	O
no	O
reasonable	O
explanation	O
was	O
established	O
,	O
while	O
93	O
%	O
of	O
the	O
modifications	O
during	O
the	O
normal	O
working	O
hours	O
were	O
made	O
for	O
objective	O
reasons	O
.	O

The	O
empiric	O
regimen	O
was	O
more	O
frequently	O
changed	O
in	O
patients	O
with	O
a	O
clinical	O
focus	O
of	O
infection	O
at	O
the	O
onset	O
of	O
fever	O
than	O
in	O
patients	O
who	O
showed	O
fever	O
as	O
the	O
only	O
symptom	O
of	O
a	O
possible	O
infection	O
.	O

The	O
perceived	O
need	O
for	O
modification	O
amounted	O
to	O
69	O
%	O
in	O
pulmonary	O
infections	O
,	O
to	O
51	O
%	O
in	O
skin	O
and	O
soft-tissue	O
infections	O
,	O
to	O
44	O
%	O
in	O
patients	O
with	O
abdominal	O
complaints	O
,	O
and	O
to	O
37	O
%	O
in	O
upper	O
respiratory	O
tract	O
infections	O
.	O

Glycopeptides	O
constituted	O
22	O
%	O
of	O
modifications	O
,	O
particularly	O
in	O
patients	O
with	O
a	O
central	O
venous	O
catheter	O
,	O
and	O
systemically	O
active	O
antifungals	O
were	O
administered	O
in	O
16	O
%	O
of	O
cases	O
.	O

Especially	O
inexperienced	O
clinicians	O
tend	O
to	O
adjust	O
antibiotic	O
therapy	O
,	O
in	O
spite	O
of	O
the	O
fact	O
that	O
persistence	O
of	O
fever	O
alone	O
seldom	O
reflects	O
inadequate	O
treatment	O
when	O
the	O
clinical	O
condition	O
of	O
the	O
patient	O
is	O
stable	O
or	O
improving	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
development	O
of	O
subsequent	O
infectious	O
events	O
emphasizes	O
that	O
a	O
genuine	O
need	O
for	O
modification	O
does	O
frequently	O
exist	O
.	O

A	O
randomized	O
trial	O
of	O
etoposide	O
and	O
G-CSF	O
with	O
or	O
without	O
rituximab	O
for	O
PBSC	O
mobilization	O
in	O
B-cell	Condition
non-Hodgkin	Condition
's	Condition
lymphoma	Condition
.	O

Some	O
reports	O
have	O
suggested	O
that	O
rituximab	O
administration	O
before	O
PBSC	O
mobilization	O
may	O
adversely	O
affect	O
PBSC	O
yield	O
.	O

We	O
conducted	O
a	O
prospective	O
randomized	O
trial	O
of	O
PBSC	O
mobilization	O
using	O
etoposide	O
and	O
G-CSF	O
with	O
or	O
without	O
rituximab	O
to	O
determine	O
whether	O
its	O
addition	O
would	O
adversely	O
affect	O
CD34+	O
cell	O
yield	O
in	O
patients	O
with	O
non-Hodgkin	Condition
's	Condition
lymphoma	Condition
.	O

Twenty	Condition
seven	Condition
patients	O
were	O
mobilized	O
with	O
etoposide	O
and	O
G-CSF	O
and	O
28	O
with	O
etoposide	O
,	O
G-CSF	O
and	O
rituximab	O
.	O

There	O
were	O
no	O
adverse	O
consequences	O
of	O
rituximab	O
on	O
CD34+	O
cell	O
yield	O
,	O
or	O
hematopoietic	O
recovery	O
or	O
immunoglobulin	O
levels	O
after	O
transplantation	O
.	O

[	O
Efficacy	O
of	O
naftopidil	O
in	O
patients	O
with	O
overactive	Condition
bladder	Condition
associated	Condition
with	Condition
benign	Condition
prostatic	Condition
hyperplasia	Condition
:	O
prospective	O
randomized	O
controlled	O
study	O
to	O
compare	O
differences	O
in	O
efficacy	O
between	O
morning	O
and	O
evening	O
medication	O
]	O
.	O

A	O
total	O
of	O
100	SampleSize
patients	O
with	O
benign	Condition
prostatic	Condition
hyperplasia	Condition
(	Condition
BPH	Condition
)	Condition
and	Condition
overactive	Condition
bladder	Condition
(	Condition
OAB	Condition
)	Condition
symptoms	O
(	O
BPH/OAB	O
)	O
,	O
enrolled	O
between	O
June	O
2006	O
to	O
March	O
2008	O
,	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
of	O
morning	O
medication	O
(	O
M	O
)	O
and	O
evening	O
medication	O
(	O
E	O
)	O
groups	O
,	O
then	O
50	O
mg	O
of	O
naftopidil	O
was	O
given	O
once	O
a	O
day	O
after	O
breakfast	O
or	O
supper	O
for	O
8	O
weeks	O
.	O

Data	O
were	O
available	O
for	O
efficacy	O
analysis	O
on	O
80	O
patients	O
(	O
M	O
group	O
;	O
43	O
,	O
E	O
group	O
;	O
37	O
)	O
.	O

Naftopidil	O
significantly	O
improved	O
the	O
overall	O
international	O
prostatic	O
symptom	O
score	O
;	O
from	O
19.2?7.9	O
to	O
11.7?5.8	O
in	O
the	O
M	O
group	O
and	O
from	O
19.4?6.4	O
to	O
12.3?6.8	O
in	O
the	O
E	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
,	O
QOL	O
score	O
from	O
4.9?0.8	O
to	O
3.2?1.4	O
in	O
the	O
M	O
group	O
and	O
from	O
5.0?0.8	O
to	O
3.6?1.3	O
in	O
the	O
E	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
OAB	O
symptom	O
score	O
from	O
7.8?2.6	O
to	O
5.0?2.5	O
in	O
the	O
M	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
from	O
8.6?2.9	O
to	O
5.8?	O
3.3	O
in	O
the	O
E	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
adverse	O
effects	O
between	O
the	O
M	O
group	O
(	O
6.1	O
%	O
)	O
and	O
E	O
group	O
(	O
2.2	O
%	O
)	O
.	O

These	O
results	O
suggest	O
that	O
naftopidil	O
improves	O
storage	O
symptoms	O
as	O
well	O
as	O
voiding	O
symptoms	O
regardless	O
of	O
timing	O
of	O
administration	O
.	O

Antibiotic	O
elimination	O
of	O
group-B	O
streptococci	O
in	O
urine	O
in	O
prevention	O
of	O
preterm	Condition
labour	Condition
.	O

The	O
presence	O
of	O
group-B	O
streptococci	O
in	O
the	O
urine	O
of	O
pregnant	Condition
women	Sex
seems	O
to	O
be	O
associated	O
with	O
preterm	O
labour	O
.	O

Urine	O
samples	O
from	O
4122	SampleSize
women	O
at	O
27-31	O
weeks	O
'	O
gestation	O
were	O
examined	O
for	O
bacteria	O
.	O

Group-B	O
streptococci	O
were	O
found	O
in	O
the	O
urine	O
of	O
69	O
women	O
.	O

In	O
a	O
double-blind	O
,	O
controlled	O
study	O
these	O
patients	O
were	O
given	O
either	O
penicillin	O
(	O
10	O
(	O
6	O
)	O
IU	O
three	O
times	O
daily	O
for	O
6	O
days	O
;	O
37	O
patients	O
)	O
or	O
placebo	O
(	O
32	O
patients	O
)	O
.	O

The	O
rates	O
of	O
primary	O
rupture	O
of	O
the	O
membranes	O
(	O
11	O
%	O
v	O
53	O
%	O
;	O
p	O
less	O
than	O
0.001	O
)	O
and	O
preterm	O
labour	O
(	O
5.4	O
%	O
v	O
38	O
%	O
;	O
p	O
less	O
than	O
0.002	O
)	O
were	O
significantly	O
lower	O
in	O
the	O
penicillin	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

These	O
results	O
suggest	O
that	O
treatment	O
and	O
follow-up	O
to	O
prevent	O
recolonisation	O
in	O
pregnant	Condition
women	O
with	O
group-B	Condition
streptococci	Condition
in	O
the	O
urine	O
may	O
reduce	O
the	O
frequency	O
of	O
preterm	O
labour	O
in	O
these	O
patients	O
.	O

Oral	O
sildenafil	O
to	O
control	O
pulmonary	O
hypertension	O
after	O
congenital	O
heart	O
surgery	O
.	O

This	O
study	O
investigates	O
the	O
role	O
of	O
oral	O
sildenafil	O
in	O
decreasing	O
pulmonary	O
pressure	O
after	O
congenital	O
heart	O
surgery	O
.	O

Between	O
September	O
2002	O
and	O
September	O
2004	O
,	O
among	O
a	O
group	O
of	O
postoperative	O
children	O
with	O
large	O
septal	O
defects	O
,	O
moderate	O
to	O
severe	O
pulmonary	O
hypertension	O
[	O
pulmonary	O
artery	O
(	O
PA	O
)	O
to	O
aortic	O
(	O
Ao	O
)	O
pressure	O
ratio	O
of	O
0.76	O
+/-	O
0.17	O
]	O
and	O
systemic	O
desaturation	O
(	O
Ao	O
Sat	O
=	O
0.89	O
+/-	O
0.11	O
)	O
,	O
oral	O
sildenafil	O
(	O
0.3	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
,	O
every	O
3	O
hours	O
)	O
was	O
administered	O
for	O
a	O
period	O
of	O
24-48	O
hours	O
(	O
sildenafil	O
group	O
)	O
.	O

These	O
patients	O
were	O
compared	O
to	O
a	O
group	O
of	O
22	O
children	O
with	O
similar	O
pathologies	O
who	O
did	O
not	O
receive	O
sildenafil	O
(	O
control	O
group	O
)	O
.	O

Postoperative	O
PA	O
pressure	O
(	O
28.61	O
+/-	O
7.80	O
vs	O
39.40	O
+/-	O
10.80	O
mm	O
Hg	O
)	O
and	O
PA/Ao	O
pressure	O
(	O
0.28	O
+/-	O
0.08	O
vs	O
0.41	O
+/-	O
0.11	O
)	O
were	O
significantly	O
lower	O
in	O
the	O
sildenafil	O
group	O
(	O
p	O
=	O
0.001	O
and	O
0.001	O
respectively	O
)	O
.	O

Pulmonary	O
hypertensive	O
crisis	O
was	O
detected	O
in	O
4	O
patients	O
in	O
the	O
control	O
group	O
,	O
but	O
none	O
in	O
the	O
sildenafil	O
group	O
(	O
p	O
=	O
0.02	O
)	O
.	O

There	O
was	O
no	O
significant	O
rise	O
in	O
PA	O
pressure	O
following	O
discontinuation	O
of	O
the	O
drug	O
(	O
26.30	O
+/-	O
6.66	O
vs	O
28.49	O
+/-	O
10.93	O
mm	O
Hg	O
,	O
p	O
=	O
0.366	O
)	O
.	O

No	O
significant	O
complications	O
were	O
noticed	O
regarding	O
sildenafil	O
use	O
.	O

Low	O
doses	O
of	O
oral	O
sildenafil	O
appear	O
to	O
be	O
effective	O
and	O
safe	O
to	O
control	O
postoperative	O
PA	O
pressure	O
in	O
children	O
.	O

Absence	O
of	O
rebound	O
pulmonary	O
hypertension	O
,	O
availability	O
,	O
and	O
low	O
cost	O
of	O
the	O
drug	O
are	O
considered	O
as	O
its	O
major	O
advantages	O
.	O

Safety	O
and	O
pharmacokinetics	O
of	O
a	O
glycoPEGylated	O
recombinant	O
activated	O
factor	O
VII	O
derivative	O
:	O
a	O
randomized	O
first	O
human	O
dose	O
trial	O
in	O
healthy	O
subjects	O
.	O

BACKGROUND	O
Extensive	O
research	O
is	O
currently	O
ongoing	O
to	O
prolong	O
the	O
half-life	O
of	O
coagulation	O
factors	O
.	O

One	O
of	O
these	O
techniques	O
is	O
glycoPEGylation	O
,	O
which	O
has	O
also	O
been	O
applied	O
to	O
recombinant	O
activated	O
factor	O
VII	O
(	O
rFVIIa	O
)	O
,	O
resulting	O
in	O
a	O
rFVIIa	O
derivative	O
(	O
N7-GP	O
)	O
with	O
a	O
prolonged	O
terminal	O
half-life	O
(	O
t	O
(	O
1/2	O
)	O
)	O
.	O

The	O
main	O
clinical	O
purpose	O
of	O
N7-GP	O
is	O
to	O
provide	O
safe	O
and	O
effective	O
prophylaxis	O
to	O
patients	O
with	O
hemophilia	O
and	O
inhibitors	O
.	O

The	O
prolonged	O
t	O
(	O
1/2	O
)	O
of	O
N7-GP	O
can	O
potentially	O
reduce	O
the	O
dosing	O
frequency	O
and	O
thereby	O
facilitate	O
convenience	O
and	O
compliance	O
,	O
which	O
are	O
two	O
significant	O
barriers	O
to	O
effective	O
prophylaxis	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
safety	O
and	O
pharmacokinetics	O
of	O
single	O
doses	O
of	O
N7-GP	O
in	O
healthy	O
men	O
.	O

METHODS	O
A	O
randomized	O
,	O
placebo-controlled	O
,	O
dose-escalation	O
trial	O
with	O
five	O
cohorts	O
(	O
N7-GP	O
dose	O
of	O
12.5-100	O
?g	O
kg	O
(	O
-1	O
)	O
)	O
was	O
performed	O
.	O

In	O
each	O
cohort	O
,	O
eight	O
subjects	O
were	O
randomized	O
to	O
receive	O
N7-GP	O
(	O
n	O
=	O
6	O
)	O
or	O
placebo	O
(	O
n	O
=	O
2	O
)	O
.	O

RESULTS	O
The	O
mean	O
FVIIa	O
activity	O
was	O
measurable	O
for	O
up	O
to	O
at	O
least	O
72	O
h	O
after	O
dosing	O
,	O
and	O
the	O
overall	O
mean	O
t	O
(	O
1/2	O
)	O
for	O
FVIIa	O
activity	O
was	O
15	O
h.	O
The	O
pharmacokinetics	O
of	O
N7-GP	O
appeared	O
to	O
be	O
dose-proportional	O
in	O
the	O
dose	O
range	O
investigated	O
.	O

No	O
serious	O
adverse	O
events	O
(	O
including	O
thromboembolic	O
events	O
)	O
were	O
reported	O
.	O

The	O
frequency	O
of	O
adverse	O
events	O
was	O
similar	O
in	O
both	O
the	O
placebo	O
and	O
N7-GP	O
groups	O
.	O

No	O
neutralizing	O
antibodies	O
against	O
N7-GP	O
were	O
detected	O
.	O

A	O
pharmacologic	O
effect	O
was	O
apparent	O
from	O
a	O
dose-dependent	O
statistically	O
significant	O
decrease	O
in	O
the	O
mean	O
prothrombin	O
time	O
in	O
all	O
N7-GP	O
groups	O
as	O
compared	O
with	O
placebo	O
.	O

CONCLUSIONS	O
N7-GP	O
had	O
a	O
plasma	O
half-life	O
of	O
15	O
h	O
and	O
a	O
profile	O
that	O
makes	O
it	O
a	O
potential	O
candidate	O
for	O
prophylaxis	O
in	O
patients	O
with	O
hemophilia	O
and	O
inhibitors	O
.	O

Use	O
of	O
the	O
electrothermal	O
bipolar	O
vessel	O
system	O
(	O
EBVS	O
)	O
in	O
laparoscopic	O
adrenalectomy	O
:	O
a	O
prospective	O
study	O
.	O

BACKGROUND	O
Since	O
laparoscopic	Condition
adrenalectomy	Condition
(	Condition
LA	Condition
)	Condition
has	O
been	O
adopted	O
as	O
the	O
gold	O
standard	O
for	O
the	O
treatment	O
of	O
adrenal	O
diseases	O
,	O
the	O
development	O
of	O
technology	O
for	O
vascular	O
control	O
and	O
dissection	O
manoeuvres	O
,	O
amongst	O
other	O
things	O
,	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
its	O
further	O
improvement	O
.	O

We	O
report	O
our	O
experience	O
with	O
the	O
electrothermal	O
bipolar	O
vessel	O
sealing	O
(	O
EBVS	O
)	O
device	O
for	O
LA	O
.	O

METHODS	O
From	O
January	O
2004	O
to	O
January	O
2006	O
,	O
50	O
patients	O
(	O
pts	O
)	O
undergoing	O
LA	O
were	O
selected	O
and	O
randomized	O
for	O
use	O
of	O
the	O
EBVS	O
(	O
25	O
pts	O
,	O
group	O
A	O
)	O
versus	O
the	O
UltraSonic	O
Shears	O
(	O
USS	O
)	O
device	O
(	O
25	O
pts	O
,	O
group	O
B	O
)	O
.	O

Age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
previous	O
surgery	O
and	O
associated	O
diseases	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

The	O
main	O
surgical	O
parameters	O
collected	O
for	O
each	O
patient	O
(	O
pt	O
)	O
concerned	O
operative	O
time	O
,	O
major	O
and	O
minor	O
complications	O
,	O
conversion	O
rate	O
,	O
blood	O
loss	O
,	O
hospital	O
stay	O
and	O
histology	O
.	O

RESULTS	O
There	O
was	O
no	O
mortality	O
in	O
either	O
group	O
.	O

The	O
right	O
adrenalectomy	O
mean	O
operative	O
time	O
(	O
OpT	O
)	O
was	O
51.8	O
mins	O
(	O
range	O
40-90	O
mins	O
)	O
and	O
68.6	O
mins	O
(	O
range	O
50-130	O
mins	O
)	O
in	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
P	O
not	O
significant	O
)	O
.	O

The	O
left	O
adrenalectomy	O
mean	O
OpT	O
was	O
72.2	O
mins	O
(	O
range	O
55-100	O
mins	O
)	O
and	O
94	O
mins	O
(	O
range	O
65-140	O
mins	O
)	O
for	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
mean	O
blood	O
loss	O
was	O
83	O
ml	O
(	O
group	O
A	O
)	O
and	O
210	O
ml	O
(	O
group	O
B	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Complications	O
were	O
not	O
different	O
for	O
the	O
two	O
groups	O
.	O

The	O
mean	O
hospital	O
stay	O
was	O
2.9	O
and	O
3.1	O
days	O
in	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
P	O
not	O
significant	O
)	O
.	O

CONCLUSIONS	O
EBVS	O
in	O
LA	O
may	O
provide	O
a	O
significantly	O
short	O
operating	O
time	O
and	O
blood	O
loss	O
.	O

Stapled	O
mucosectomy	O
for	O
acute	O
thrombosed	O
circumferentially	O
prolapsed	O
piles	O
:	O
a	O
prospective	O
randomized	O
comparison	O
with	O
conventional	O
haemorrhoidectomy	O
.	O

OBJECTIVE	O
Stapled	O
mucosectomy	O
has	O
been	O
developed	O
as	O
an	O
alternative	O
to	O
conventional	O
haemorrhoidectomy	O
for	O
the	O
elective	O
treatment	O
of	O
haemorrhoids	O
,	O
but	O
has	O
not	O
been	O
assessed	O
in	O
the	O
emergency	O
setting	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
this	O
technique	O
with	O
a	O
conventional	O
procedure	O
for	O
acute	O
thrombosed	O
circumferential	O
prolapsed	O
haemorrhoids	O
.	O

PATIENTS	O
AND	O
METHODS	O
A	O
prospective	O
randomized	O
comparison	O
of	O
conventional	O
Milligan-Morgan	O
haemorrhoidectomy	O
and	O
stapled	O
mucosectomy	O
was	O
carried	O
out	O
on	O
35	SampleSize
consecutive	O
patients	O
presenting	O
with	O
acute	Condition
thrombosed	Condition
circumferential	Condition
prolapsed	Condition
haemorrhoids	Condition
.	O

Operative	O
data	O
,	O
postoperative	O
stay	O
,	O
pain	O
assessment	O
and	O
persistent	O
symptoms	O
were	O
compared	O
at	O
discharge	O
and	O
at	O
2	O
week	O
and	O
6	O
week	O
review	O
.	O

Additionally	O
at	O
6	O
week	O
review	O
the	O
time	O
to	O
return	O
to	O
work	O
was	O
recorded	O
and	O
an	O
endoanal	O
ultrasound	O
was	O
carried	O
out	O
.	O

RESULTS	O
Thirty	SampleSize
patients	O
were	O
randomized	O
and	O
followed	O
up	O
for	O
six	O
weeks	O
.	O

Although	O
postoperative	O
stay	O
and	O
in-hospital	O
analgesia	O
were	O
the	O
same	O
,	O
patients	O
from	O
the	O
stapled	O
group	O
reported	O
significantly	O
more	O
pain	O
at	O
discharge	O
.	O

However	O
,	O
by	O
2	O
weeks	O
the	O
conventional	O
group	O
reported	O
significantly	O
higher	O
pain	O
scores	O
particularly	O
on	O
passing	O
stool	O
.	O

By	O
this	O
stage	O
over	O
half	O
the	O
stapled	O
group	O
patients	O
reported	O
no	O
pain	O
at	O
all	O
.	O

More	O
patients	O
in	O
the	O
conventional	Condition
group	Condition
complained	O
of	O
persistent	O
symptoms	O
of	O
pain	O
,	O
bleeding	O
and	O
discharge	O
at	O
2	O
week	O
and	O
6	O
week	O
review	O
with	O
20	O
%	O
requiring	O
readmission	O
compared	O
with	O
none	O
in	O
the	O
stapled	O
group	O
.	O

The	O
median	O
return	O
to	O
work	O
was	O
significantly	O
shorter	O
for	O
the	O
stapled	O
group	O
(	O
14	O
days	O
vs	O
28	O
days	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Although	O
all	O
patients	O
claimed	O
to	O
be	O
continent	O
,	O
two	O
patients	O
from	O
each	O
group	O
had	O
ultrasonic	O
evidence	O
of	O
internal	O
sphincter	O
damage	O
.	O

CONCLUSION	O
Stapled	O
mucosectomy	O
for	O
acute	O
thrombosed	O
circumferential	O
piles	O
is	O
feasible	O
and	O
may	O
result	O
in	O
less	O
pain	O
,	O
a	O
more	O
rapid	O
resolution	O
of	O
symptoms	O
and	O
an	O
earlier	O
return	O
to	O
work	O
compared	O
with	O
a	O
conventional	O
procedure	O
.	O

Humoral	O
immunity	O
after	O
kidney	O
transplantation	O
:	O
impact	O
of	O
two	O
randomized	O
immunosuppressive	O
protocols	O
.	O

BACKGROUND	O
Controlling	O
alloimmune	O
humoral	O
response	O
is	O
a	O
challenge	O
in	O
transplantation	O
.	O

Few	O
studies	O
have	O
evaluated	O
the	O
impact	O
of	O
maintenance	O
immunosuppression	O
on	O
blood	O
humoral	O
parameters	O
.	O

MATERIAL/METHODS	O
We	O
performed	O
a	O
post-hoc	O
analysis	O
on	O
307	O
kidney	O
transplant	O
recipients	O
included	O
in	O
a	O
prospective	O
randomized	O
trial	O
comparing	O
tacrolimus/mycophenolate	O
mofetil	O
(	O
Tac/MMF	O
)	O
vs.	O
cyclosporine/azathioprine	O
(	O
CsA/AZA	O
)	O
,	O
both	O
used	O
with	O
antithymocyte	O
globulin	O
induction	O
and	O
steroids	O
.	O

Humoral	O
parameters	O
were	O
analyzed	O
at	O
D0	O
,	O
D15	O
,	O
and	O
M12	O
.	O

RESULTS	O
IgG	O
,	O
IgA	O
,	O
and	O
IgM	O
levels	O
decreased	O
significantly	O
as	O
soon	O
as	O
D15	O
in	O
both	O
groups	O
(	O
?35	O
%	O
,	O
?26	O
%	O
,	O
and	O
?35	O
%	O
respectively	O
,	O
vs.	O
D0	O
)	O
.	O

At	O
M12	O
,	O
although	O
peripheral	O
B-cell	O
counts	O
did	O
not	O
differ	O
between	O
the	O
groups	O
,	O
Tac/MMF	O
regimen	O
was	O
associated	O
with	O
lower	O
IgG	O
,	O
IgA	O
,	O
and	O
IgM	O
levels	O
than	O
CsA/AZA	O
(	O
?5.9	O
%	O
,	O
?14.6	O
%	O
,	O
and	O
?34	O
%	O
,	O
respectively	O
)	O
.	O

Hypogammaglobulinemia	O
at	O
D15	O
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
infections	O
during	O
the	O
first	O
year	O
.	O

The	O
proportion	O
of	O
HLA-sensitized	O
patients	O
decreased	O
in	O
the	O
Tac/MMF	O
group	O
(	O
15.9	O
%	O
at	O
D0	O
and	O
6.7	O
%	O
at	O
M12	O
,	O
p=0.02	O
)	O
and	O
remained	O
stable	O
in	O
the	O
CsA/AZA	O
group	O
(	O
10.3	O
%	O
at	O
D0	O
and	O
8.9	O
%	O
at	O
M12	O
,	O
p=0.5	O
)	O
.	O

More	O
patients	O
sensitized	O
at	O
baseline	O
became	O
non-sensitized	O
at	O
M12	O
with	O
Tac/MMF	O
than	O
with	O
CsA/AZA	O
.	O

CONCLUSIONS	O
Our	O
results	O
suggest	O
humoral	O
immunosuppression	O
is	O
better	O
with	O
Tac/MMF	O
than	O
with	O
CsA/AZA	O
during	O
the	O
first	O
year	O
of	O
kidney	O
transplantation	O
.	O

CD4+FOXP3+	O
regulatory	O
T	O
cell	O
depletion	O
by	O
low-dose	O
cyclophosphamide	O
prevents	O
recurrence	O
in	O
patients	O
with	O
large	O
condylomata	O
acuminata	O
after	O
laser	O
therapy	O
.	O

Condylomata	O
acuminata	O
(	O
CA	O
)	O
caused	O
by	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
is	O
a	O
common	O
sexually	O
transmitted	O
disease	O
with	O
half	O
a	O
million	O
new	O
cases	O
diagnosed	O
in	O
the	O
United	O
States	O
per	O
year	O
and	O
the	O
annual	O
increase	O
in	O
incidence	O
in	O
China	O
.	O

Recurrence	O
is	O
a	O
major	O
challenge	O
for	O
CA	O
treatment	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
FOXP3	O
(	O
+	O
)	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	O
mediate	O
the	O
immunosuppression	O
in	O
large	O
genital	O
warts	O
.	O

Here	O
,	O
we	O
further	O
report	O
that	O
low-dose	O
cyclophosphamide	O
(	O
CY	O
)	O
,	O
a	O
conventional	O
chemotherapy	O
drug	O
,	O
can	O
effectively	O
prevent	O
the	O
recurrence	O
of	O
large	O
CA	O
in	O
clinical	O
patients	O
after	O
laser	O
therapy	O
.	O

Surprisingly	O
,	O
although	O
9	O
out	O
of	O
52	SampleSize
patients	O
recur	O
six	O
weeks	O
after	O
the	O
combination	O
treatment	O
,	O
the	O
re-administration	O
of	O
low-dose	O
CY	O
alone	O
completely	O
eliminates	O
most	O
recurred	O
lesions	O
.	O

We	O
provide	O
evidence	O
that	O
low-dose	O
CY	O
not	O
only	O
depletes	O
patients	O
'	O
Treg	O
cells	O
and	O
enhances	O
function	O
of	O
HPV-specific	O
T	O
cells	O
and	O
NK	O
cells	O
in	O
the	O
periphery	O
,	O
but	O
also	O
ameliorates	O
the	O
immune	O
milieu	O
of	O
the	O
lesion	O
site	O
,	O
leading	O
to	O
the	O
elimination	O
of	O
remnant	O
viruses	O
.	O

These	O
findings	O
have	O
important	O
clinical	O
significance	O
,	O
and	O
potentially	O
lead	O
to	O
a	O
therapeutic	O
breakthrough	O
for	O
the	O
treatment	O
of	O
CA	O
.	O

Creon	O
10,000	O
Minimicrospheres	O
vs.	O
Creon	O
8,000	O
microspheres	O
--	O
an	O
open	O
randomised	O
crossover	O
preference	O
study	O
.	O

Creon	O
10,000	O
Minimicrospherestrade	O
mark	O
(	O
Creon	O
)	O
10,000	O
MMS	O
)	O
is	O
a	O
pancreatic	O
enzyme	O
formulation	O
that	O
contains	O
smaller	O
spheres	O
of	O
pancreatin	O
in	O
a	O
50	O
%	O
smaller	O
capsule	O
than	O
conventional	O
microspheres	O
(	O
Creon	O
)	O
8,000	O
)	O
.	O

This	O
three-centre	Condition
study	Condition
investigated	Condition
the	Condition
preference	Condition
of	Condition
cystic	Condition
fibrosis	Condition
(	Condition
CF	Condition
)	Condition
patients	Condition
for	O
these	O
products	O
.	O

In	O
one	O
centre	O
,	O
72	O
h	O
stool	O
fat	O
excretion	O
and	O
coefficient	O
of	O
fat	O
absorption	O
(	O
CFA	O
)	O
were	O
also	O
compared	O
.	O

Fifty-nine	O
patients	O
with	O
a	O
mean	O
age	O
10	O
years	O
(	O
range	O
3-17	O
)	O
took	O
Creon	O
8,000	O
ms	O
for	O
14	O
days	O
and	O
were	O
then	O
randomised	O
to	O
28	O
days	O
of	O
Creon	O
8,000	O
ms	O
followed	O
by	O
28	O
days	O
of	O
Creon	O
10,000	O
MMS	O
,	O
or	O
vice	O
versa	O
.	O

Dosing	O
was	O
lipase	O
for	O
lipase	O
according	O
to	O
the	O
labelled	O
declaration	O
.	O

At	O
the	O
end	O
of	O
the	O
second	O
treatment	O
period	O
,	O
51	O
of	O
54	O
patients	O
who	O
completed	O
the	O
study	O
expressed	O
a	O
preference	O
,	O
with	O
a	O
statistically	O
significant	O
preference	O
in	O
favour	O
of	O
Creon	O
10,000	O
MMS	O
(	O
47/51	O
;	O
87	O
%	O
)	O
vs.	O
Creon	O
8,000	O
ms	O
(	O
4/51	O
;	O
7.4	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Stool	O
fat	O
(	O
g/day	O
)	O
and	O
CFA	O
(	O
%	O
)	O
were	O
measured	O
in	O
24	O
patients	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
:	O
the	O
products	O
were	O
therapeutically	O
equivalent	O
(	O
Creon	O
10,000	O
:	O
8.4	O
g/day	O
,	O
91.3	O
%	O
CFA	O
;	O
Creon	O
8,000	O
:	O
6.7	O
g/day	O
,	O
93.5	O
%	O
CFA	O
)	O
.	O

Both	O
products	O
were	O
well	O
tolerated	O
.	O

In	O
conclusion	O
,	O
in	O
CF	O
children	O
we	O
found	O
a	O
clear	O
preference	O
for	O
Creon	O
10,000	O
MMS	O
compared	O
with	O
Creon	O
8,000	O
ms	O
with	O
no	O
difference	O
in	O
fat	O
absorption	O
between	O
the	O
two	O
products	O
.	O

Creon	O
10,000s	O
smaller	O
capsules	O
are	O
easier	O
to	O
take	O
and	O
should	O
aid	O
patient	O
compliance	O
.	O

Abnormal	O
cardiac	O
contractility	O
in	O
long-term	O
exogenous	O
subclinical	O
hyperthyroid	O
patients	O
as	O
demonstrated	O
by	O
two-dimensional	O
echocardiography	O
speckle	O
tracking	O
imaging	O
.	O

BACKGROUND	O
Subclinical	O
hyperthyroidism	O
is	O
associated	O
with	O
cardiovascular	O
morbidity	O
.	O

Recent	O
advances	O
in	O
echocardiography	O
imaging	O
have	O
allowed	O
sophisticated	O
evaluation	O
of	O
myocardial	O
tissue	O
properties	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
myocardial	O
effects	O
of	O
long-term	O
exogenous	O
subclinical	O
hyperthyroidism	O
using	O
two-dimensional	O
speckle	O
tracking	O
echocardiography	O
imaging	O
(	O
2D-STE	O
)	O
.	O

DESIGN	O
Prospective	O
,	O
single-blinded	O
,	O
placebo-controlled	O
randomized	O
trial	O
of	O
6	O
months	O
duration	O
with	O
two	O
parallel	O
groups	O
.	O

PATIENTS	O
AND	O
METHODS	O
Totally	O
25	O
patients	O
with	O
a	O
history	O
of	O
differentiated	O
thyroid	O
carcinoma	O
on	O
long-term	O
TSH-suppressive	O
levothyroxine	O
(	O
l-T	O
(	O
4	O
)	O
)	O
substitution	O
were	O
randomized	O
to	O
persistent	O
TSH-suppressive	O
l-T	O
(	O
4	O
)	O
substitution	O
(	O
low-TSH	O
group	O
)	O
or	O
restoration	O
of	O
euthyroidism	O
.	O

Additionally	O
40	O
euthyroid	O
controls	O
were	O
studied	O
.	O

RESULTS	O
(	O
PROPOSAL	O
)	O
:	O
At	O
baseline	O
,	O
the	O
group	O
of	O
patients	O
showed	O
normal	O
left	O
ventricular	O
(	O
LV	O
)	O
systolic	O
function	O
but	O
impaired	O
diastolic	O
function	O
as	O
assessed	O
with	O
conventional	O
echocardiographic	O
parameters	O
.	O

Importantly	O
,	O
2D-STE	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
subclinical	O
LV	O
systolic	O
and	O
diastolic	O
dysfunction	O
with	O
impaired	O
circumferential	O
and	O
longitudinal	O
strain	O
and	O
strain	O
rate	O
at	O
the	O
isovolumic	O
relaxation	O
time	O
.	O

After	O
restoration	O
of	O
euthyroidism	O
,	O
a	O
significant	O
improvement	O
in	O
LV	O
systolic	O
and	O
diastolic	O
function	O
as	O
assessed	O
with	O
2D-STE	O
strain	O
was	O
observed	O
.	O

CONCLUSION	O
Prolonged	O
subclinical	O
hyperthyroidism	O
leads	O
to	O
systolic	O
and	O
diastolic	O
dysfunction	O
,	O
which	O
is	O
reversible	O
after	O
restoration	O
of	O
euthyroidism	O
.	O

2D-STE	O
is	O
a	O
more	O
sensitive	O
technique	O
to	O
evaluate	O
subtle	O
changes	O
in	O
LV	O
performance	O
of	O
these	O
patients	O
.	O

Effect	O
of	O
phenylephrine	O
on	O
the	O
haemodynamic	O
state	O
and	O
cerebral	O
oxygen	O
saturation	O
during	O
anaesthesia	O
in	O
the	O
upright	O
position	O
.	O

BACKGROUND	O
The	O
upright	O
sitting	O
or	O
beachchair	O
position	O
is	O
associated	O
with	O
hypotension	O
,	O
risk	O
of	O
cerebral	O
hypoperfusion	O
,	O
and	O
cerebral	O
injury	O
.	O

We	O
hypothesized	O
that	O
by	O
increasing	O
arterial	O
pressure	O
with	O
phenylephrine	O
administration	O
,	O
cerebral	O
perfusion	O
,	O
and	O
postoperative	O
recovery	O
would	O
be	O
improved	O
.	O

METHODS	O
Thirty-four	SampleSize
patients	O
undergoing	O
elective	Condition
shoulder	Condition
surgery	Condition
were	O
randomized	O
to	O
receive	O
either	O
saline	O
or	O
phenylephrine	O
infusion	O
(	O
PE	O
)	O
5	O
min	O
before	O
being	O
placed	O
in	O
the	O
upright	O
position	O
.	O

Simultaneous	O
measurements	O
of	O
mean	O
arterial	O
pressure	O
,	O
cerebral	O
oxygen	O
saturation	O
,	O
middle	O
cerebral	O
artery	O
velocity	O
,	O
and	O
cardiac	O
function	O
using	O
transthoracic	O
echocardiography	O
were	O
made	O
.	O

Postoperative	O
neurocognitive	O
function	O
was	O
assessed	O
.	O

RESULTS	O
At	O
the	O
commencement	O
of	O
PE	O
,	O
mean	O
(	O
SD	O
)	O
cerebral	O
oxygen	O
saturation	O
significantly	O
decreased	O
from	O
77	O
(	O
10	O
)	O
to	O
67	O
(	O
13	O
)	O
%	O
(	O
P=0.02	O
)	O
,	O
and	O
further	O
to	O
59	O
(	O
11	O
)	O
%	O
on	O
upright	O
positioning	O
.	O

The	O
level	O
of	O
cerebral	O
saturation	O
upright	O
was	O
not	O
significantly	O
different	O
to	O
patients	O
receiving	O
saline	O
(	O
P=0.07	O
)	O
,	O
with	O
values	O
remaining	O
at	O
room-air	O
levels	O
.	O

Middle	O
cerebral	O
artery	O
blood	O
velocity	O
increased	O
by	O
20	O
%	O
(	O
P=0.04	O
)	O
.	O

Phenylephrine	O
prevented	O
hypotension	O
in	O
the	O
upright	O
position	O
primarily	O
by	O
maintaining	O
preload	O
and	O
increasing	O
systemic	O
vascular	O
resistance	O
(	O
P=0.01	O
)	O
,	O
and	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
cardiac	O
output	O
.	O

No	O
postoperative	O
neurocognitive	O
dysfunction	O
was	O
identified	O
.	O

CONCLUSIONS	O
Despite	O
maintaining	O
arterial	O
pressure	O
with	O
phenylephrine	O
,	O
cerebral	O
desaturation	O
occurred	O
with	O
upright	O
positioning	O
.	O

Cerebral	O
oxygen	O
saturation	O
can	O
provide	O
a	O
valuable	O
endpoint	O
when	O
evaluating	O
the	O
effect	O
of	O
vasopressor	O
therapy	O
on	O
cerebral	O
perfusion	O
.	O

Epidural	O
morphine	O
in	O
the	O
elderly	Age
.	O

A	O
controlled	O
trial	O
after	O
upper	O
abdominal	O
surgery	O
.	O

The	O
effectiveness	O
of	O
epidurally	O
administered	O
morphine	O
in	O
the	O
relief	O
of	O
pain	O
after	O
upper	O
abdominal	O
surgery	O
was	O
assessed	O
in	O
a	O
controlled	O
study	O
involving	O
20	O
patients	O
aged	Age
61	Age
to	Age
78	Age
years	Age
.	O

Analgesia	O
provided	O
by	O
epidural	O
morphine	O
was	O
comparable	O
to	O
that	O
obtained	O
in	O
matched	O
patients	O
given	O
an	O
intramuscular	O
regime	O
.	O

The	O
total	O
dose	O
required	O
by	O
the	O
epidural	O
route	O
was	O
less	O
than	O
one-fifth	O
that	O
required	O
intramuscularly	O
,	O
and	O
sedation	O
was	O
correspondingly	O
reduced	O
.	O

Postoperative	O
respiratory	O
mechanics	O
,	O
however	O
,	O
were	O
not	O
significantly	O
improved	O
and	O
delayed	O
respiratory	O
depression	O
was	O
observed	O
in	O
one	O
patient	O
.	O

It	O
is	O
concluded	O
that	O
in	O
elderly	O
patients	O
undergoing	Condition
upper	Condition
abdominal	Condition
surgery	Condition
the	O
risks	O
related	O
to	O
the	O
use	O
of	O
morphine	O
by	O
the	O
epidural	O
route	O
outweigh	O
the	O
marginal	O
advantages	O
it	O
may	O
offer	O
over	O
conventional	O
analgesic	O
techniques	O
.	O

Gefitinib	O
versus	O
placebo	O
in	O
completely	O
resected	O
non-small-cell	O
lung	O
cancer	O
:	O
results	O
of	O
the	O
NCIC	O
CTG	O
BR19	O
study	O
.	O

PURPOSE	O
Survival	O
of	O
patients	O
with	O
completely	Condition
resected	Condition
non-small-cell	Condition
lung	Condition
cancer	Condition
(	Condition
NSCLC	Condition
)	Condition
is	O
unsatisfactory	O
,	O
and	O
in	O
2002	O
,	O
the	O
benefit	O
of	O
adjuvant	O
chemotherapy	O
was	O
not	O
established	O
.	O

This	O
phase	O
III	O
study	O
assessed	O
the	O
impact	O
of	O
postoperative	O
adjuvant	O
gefitinib	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
completely	O
resected	O
(	O
stage	O
IB	O
,	O
II	O
,	O
or	O
IIIA	O
)	O
NSCLC	O
stratified	O
by	O
stage	O
,	O
histology	O
,	O
sex	O
,	O
postoperative	O
radiotherapy	O
,	O
and	O
chemotherapy	O
were	O
randomly	O
assigned	O
(	O
1:1	O
)	O
to	O
receive	O
gefitinib	O
250	O
mg	O
per	O
day	O
or	O
placebo	O
for	O
2	O
years	O
.	O

Study	O
end	O
points	O
were	O
OS	O
,	O
disease-free	O
survival	O
(	O
DFS	O
)	O
,	O
and	O
toxicity	O
.	O

RESULTS	O
As	O
a	O
result	O
of	O
early	O
closure	O
,	O
503	SampleSize
of	SampleSize
1,242	SampleSize
planned	O
patients	O
were	O
randomly	O
assigned	O
(	O
251	O
to	O
gefitinib	O
and	O
252	O
to	O
placebo	O
)	O
.	O

Baseline	O
factors	O
were	O
balanced	O
between	O
the	O
arms	O
.	O

With	O
a	O
median	O
of	O
4.7	O
years	O
of	O
follow-up	O
(	O
range	O
,	O
0.1	O
to	O
6.3	O
years	O
)	O
,	O
there	O
was	O
no	O
difference	O
in	O
OS	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1.24	O
;	O
95	O
%	O
CI	O
,	O
0.94	O
to	O
1.64	O
;	O
P	O
=	O
.14	O
)	O
or	O
DFS	O
(	O
HR	O
,	O
1.22	O
;	O
95	O
%	O
CI	O
,	O
0.93	O
to	O
1.61	O
;	O
P	O
=	O
.15	O
)	O
between	O
the	O
arms	O
.	O

Exploratory	O
analyses	O
demonstrated	O
no	O
DFS	O
(	O
HR	O
,	O
1.28	O
;	O
95	O
%	O
CI	O
,	O
0.92	O
to	O
1.76	O
;	O
P	O
=	O
.14	O
)	O
or	O
OS	O
benefit	O
(	O
HR	O
,	O
1.24	O
;	O
95	O
%	O
CI	O
,	O
0.90	O
to	O
1.71	O
;	O
P	O
=	O
.18	O
)	O
from	O
gefitinib	O
for	O
344	SampleSize
patients	SampleSize
with	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
wild-type	O
tumors	O
.	O

Similarly	O
,	O
there	O
was	O
no	O
DFS	O
(	O
HR	O
,	O
1.84	O
;	O
95	O
%	O
CI	O
,	O
0.44	O
to	O
7.73	O
;	O
P	O
=	O
.395	O
)	O
or	O
OS	O
benefit	O
(	O
HR	O
,	O
3.16	O
;	O
95	O
%	O
CI	O
,	O
0.61	O
to	O
16.45	O
;	O
P	O
=	O
.15	O
)	O
from	O
gefitinib	O
for	O
the	O
15	O
patients	O
with	O
EGFR	O
mutation-positive	O
tumors	O
.	O

Adverse	O
events	O
were	O
those	O
expected	O
with	O
an	O
EGFR	O
inhibitor	O
.	O

Serious	O
adverse	O
events	O
occurred	O
in	O
?	O
5	O
%	O
of	O
patients	O
,	O
except	O
infection	O
,	O
fatigue	O
,	O
and	O
pain	O
.	O

One	O
patient	O
in	O
each	O
arm	O
had	O
fatal	O
pneumonitis	O
.	O

CONCLUSION	O
Although	O
the	O
trial	O
closed	O
prematurely	O
and	O
definitive	O
statements	O
regarding	O
the	O
efficacy	O
of	O
adjuvant	O
gefitinib	O
can	O
not	O
be	O
made	O
,	O
these	O
results	O
indicate	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
of	O
benefit	O
.	O

Eltrombopag	O
for	O
management	O
of	O
chronic	O
immune	O
thrombocytopenia	O
(	O
RAISE	O
)	O
:	O
a	O
6-month	O
,	O
randomised	O
,	O
phase	O
3	O
study	O
.	O

BACKGROUND	O
Eltrombopag	O
is	O
an	O
oral	O
thrombopoietin	O
receptor	O
agonist	O
for	O
the	O
treatment	O
of	O
thrombocytopenia	O
.	O

We	O
aimed	O
to	O
compare	O
the	O
response	O
to	O
once	O
daily	O
eltrombopag	O
versus	O
placebo	O
in	O
patients	O
with	O
chronic	O
immune	O
thrombocytopenia	O
during	O
a	O
6-month	O
period	O
.	O

METHODS	O
We	O
undertook	O
a	O
phase	O
3	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
in	O
adults	O
with	O
previously	O
treated	O
immune	O
thrombocytopenia	O
of	O
more	O
than	O
6	O
months	O
'	O
duration	O
who	O
had	O
baseline	O
platelet	O
counts	O
lower	O
than	O
30,000	O
per	O
?L	O
.	O

Patients	O
were	O
randomly	O
allocated	O
(	O
in	O
a	O
2:1	O
ratio	O
)	O
treatment	O
with	O
local	O
standard	O
of	O
care	O
plus	O
50	O
mg	O
eltrombopag	O
or	O
matching	O
placebo	O
once	O
daily	O
for	O
6	O
months	O
.	O

Randomisation	O
was	O
done	O
centrally	O
with	O
a	O
computer-generated	O
randomisation	O
schedule	O
and	O
was	O
stratified	O
by	O
baseline	O
platelet	O
count	O
(	O
?	O
15,000	O
per	O
?L	O
)	O
,	O
use	O
of	O
treatment	O
for	O
immune	O
thrombocytopenia	O
,	O
and	O
splenectomy	O
status	O
.	O

Patients	O
,	O
investigators	O
,	O
and	O
those	O
assessing	O
data	O
were	O
masked	O
to	O
allocation	O
.	O

Dose	O
modifications	O
were	O
made	O
on	O
the	O
basis	O
of	O
platelet	O
response	O
.	O

Patients	O
were	O
assessed	O
for	O
response	O
to	O
treatment	O
(	O
defined	O
as	O
a	O
platelet	O
count	O
of	O
50,000-400,000	O
per	O
?L	O
)	O
weekly	O
during	O
the	O
first	O
6	O
weeks	O
and	O
at	O
least	O
once	O
every	O
4	O
weeks	O
thereafter	O
;	O
the	O
primary	O
endpoint	O
was	O
the	O
odds	O
of	O
response	O
to	O
eltrombopag	O
versus	O
placebo	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
at	O
ClinicalTrials.gov	O
,	O
number	O
NCT00370331	O
.	O

FINDINGS	O
Between	O
Nov	O
22	O
,	O
2006	O
,	O
and	O
July	O
31	O
,	O
2007	O
,	O
197	O
patients	O
were	O
randomly	O
allocated	O
to	O
treatment	O
groups	O
and	O
were	O
included	O
in	O
the	O
intention-to-treat	O
analysis	O
(	O
135	O
eltrombopag	O
,	O
62	O
placebo	O
)	O
.	O

106	O
(	O
79	O
%	O
)	O
patients	O
in	O
the	O
eltrombopag	O
group	O
responded	O
to	O
treatment	O
at	O
least	O
once	O
during	O
the	O
study	O
,	O
compared	O
with	O
17	O
(	O
28	O
%	O
)	O
patients	O
in	O
the	O
placebo	O
group	O
.	O

The	O
odds	O
of	O
responding	O
were	O
greater	O
in	O
patients	O
in	O
the	O
eltrombopag	O
group	O
compared	O
with	O
those	O
in	O
the	O
placebo	O
group	O
throughout	O
the	O
6-month	O
treatment	O
period	O
(	O
odds	O
ratio	O
8?2	O
,	O
99	O
%	O
CI	O
3?59-18?73	O
;	O
p	O
<	O
0?0001	O
)	O
.	O

37	O
(	O
59	O
%	O
)	O
patients	O
receiving	O
eltrombopag	O
reduced	O
concomitant	O
treatment	O
versus	O
ten	O
(	O
32	O
%	O
)	O
patients	O
receiving	O
placebo	O
(	O
p=0?016	O
)	O
.	O

24	O
(	O
18	O
%	O
)	O
patients	O
receiving	O
eltrombopag	O
needed	O
rescue	O
treatment	O
compared	O
with	O
25	O
(	O
40	O
%	O
)	O
patients	O
receiving	O
placebo	O
(	O
p=0?001	O
)	O
.	O

Three	O
(	O
2	O
%	O
)	O
patients	O
receiving	O
eltrombopag	O
had	O
thromboembolic	O
events	O
compared	O
with	O
none	O
in	O
patients	O
on	O
placebo	O
.	O

Nine	O
(	O
7	O
%	O
)	O
eltrombopag-treated	O
patients	O
and	O
two	O
(	O
3	O
%	O
)	O
in	O
the	O
placebo	O
group	O
had	O
mild	O
increases	O
in	O
alanine	O
aminotransferase	O
concentration	O
,	O
and	O
five	O
(	O
4	O
%	O
)	O
eltrombopag-treated	O
patients	O
(	O
vs	O
none	O
allocated	O
to	O
placebo	O
)	O
had	O
increases	O
in	O
total	O
bilirubin	O
.	O

Four	O
(	O
7	O
%	O
)	O
patients	O
taking	O
placebo	O
had	O
serious	O
bleeding	O
events	O
,	O
compared	O
with	O
one	O
(	O
<	O
1	O
%	O
)	O
patient	O
treated	O
with	O
eltrombopag	O
.	O

INTERPRETATION	O
Eltrombopag	O
is	O
effective	O
for	O
management	O
of	O
chronic	O
immune	O
thrombocytopenia	O
,	O
and	O
could	O
be	O
particularly	O
beneficial	O
for	O
patients	O
who	O
have	O
not	O
responded	O
to	O
splenectomy	O
or	O
previous	O
treatment	O
.	O

These	O
benefits	O
should	O
be	O
balanced	O
with	O
the	O
potential	O
risks	O
associated	O
with	O
eltrombopag	O
treatment	O
.	O

FUNDING	O
GlaxoSmithKline	O
.	O

Controlled-release	O
melatonin	O
,	O
singly	O
and	O
combined	O
with	O
cognitive	O
behavioural	O
therapy	O
,	O
for	O
persistent	O
insomnia	Condition
in	O
children	Age
with	O
autism	Condition
spectrum	Condition
disorders	Condition
:	O
a	O
randomized	O
placebo-controlled	O
trial	O
.	O

Although	O
melatonin	O
and	O
cognitive-behavioural	O
therapy	O
have	O
shown	O
efficacy	O
in	O
treating	O
sleep	O
disorders	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
,	O
little	O
is	O
known	O
about	O
their	O
relative	O
or	O
combined	O
efficacy	O
.	O

One	SampleSize
hundred	SampleSize
and	SampleSize
sixty	SampleSize
children	O
with	O
autism	Condition
spectrum	Condition
disorders	Condition
,	O
aged	Age
4-10	Age
years	Age
,	O
suffering	O
from	O
sleep	Condition
onset	Condition
insomnia	Condition
and	Condition
impaired	Condition
sleep	Condition
maintenance	Condition
,	O
were	O
assigned	O
randomly	O
to	O
either	O
(	O
1	O
)	O
combination	O
of	O
controlled-release	O
melatonin	O
and	O
cognitive-behavioural	O
therapy	O
;	O
(	O
2	O
)	O
controlled-release	O
melatonin	O
;	O
(	O
3	O
)	O
four	O
sessions	O
of	O
cognitive-behavioural	O
therapy	O
;	O
or	O
(	O
4	O
)	O
placebo	O
drug	O
treatment	O
condition	O
for	O
12	O
weeks	O
in	O
a	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
ratio	O
.	O

Children	O
were	O
studied	O
at	O
baseline	O
and	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O

Treatment	O
response	O
was	O
assessed	O
with	O
1-week	O
actigraphic	O
monitoring	O
,	O
sleep	O
diary	O
and	O
sleep	O
questionnaire	O
.	O

Main	O
outcome	O
measures	O
,	O
derived	O
actigraphically	O
,	O
were	O
sleep	O
latency	O
,	O
total	O
sleep	O
time	O
,	O
wake	O
after	O
sleep	O
onset	O
and	O
number	O
of	O
awakenings	O
.	O

The	O
active	O
treatment	O
groups	O
all	O
resulted	O
in	O
improvements	O
across	O
all	O
outcome	O
measures	O
,	O
with	O
moderate-to-large	O
effect	O
sizes	O
from	O
baseline	O
to	O
a	O
12-week	O
assessment	O
.	O

Melatonin	O
treatment	O
was	O
mainly	O
effective	O
in	O
reducing	O
insomnia	O
symptoms	O
,	O
while	O
cognitive-behavioural	O
therapy	O
had	O
a	O
light	O
positive	O
impact	O
mainly	O
on	O
sleep	O
latency	O
,	O
suggesting	O
that	O
some	O
behavioural	O
aspects	O
might	O
play	O
a	O
role	O
in	O
determining	O
initial	O
insomnia	O
.	O

The	O
combination	O
treatment	O
group	O
showed	O
a	O
trend	O
to	O
outperform	O
other	O
active	O
treatment	O
groups	O
,	O
with	O
fewer	O
dropouts	O
and	O
a	O
greater	O
proportion	O
of	O
treatment	O
responders	O
achieving	O
clinically	O
significant	O
changes	O
(	O
63.38	O
%	O
normative	O
sleep	O
efficiency	O
criterion	O
of	O
>	O
85	O
%	O
and	O
84.62	O
%	O
,	O
sleep	O
onset	O
latency	O
<	O
30	O
min	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
adding	O
behavioural	O
intervention	O
to	O
melatonin	O
treatment	O
seems	O
to	O
result	O
in	O
a	O
better	O
treatment	O
response	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O

Effect	O
of	O
shearing	O
on	O
water	O
turnover	O
and	O
thermobiological	O
variables	O
in	O
German	O
Blackhead	O
mutton	O
sheep	O
.	O

Current	O
equations	O
for	O
estimating	O
water	O
requirements	O
in	O
sheep	O
do	O
not	O
differentiate	O
between	O
shorn	O
and	O
unshorn	O
sheep	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
shearing	O
on	O
thermoregulative	O
responses	O
in	O
sheep	O
has	O
not	O
been	O
adequately	O
studied	O
under	O
temperate	O
environmental	O
conditions	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
effect	O
of	O
wool	O
coverage	O
on	O
water	O
turnover	O
in	O
relation	O
to	O
thermoregulation	O
in	O
sheep	O
by	O
using	O
the	O
deuterium	O
dilution	O
technique	O
to	O
predict	O
total	O
water	O
intake	O
before	O
and	O
after	O
shearing	O
.	O

Physiological	O
responses	O
,	O
such	O
as	O
water	O
turnover	O
,	O
surface	O
temperature	O
,	O
and	O
rectal	O
temperature	O
,	O
as	O
well	O
as	O
drinking	O
behavior	O
of	O
sheep	O
were	O
also	O
evaluated	O
.	O

Fourteen	SampleSize
nonlactating	Condition
German	O
Blackhead	O
mutton	O
ewes	O
were	O
randomly	O
allocated	O
into	O
2	O
groups	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
that	O
was	O
already	O
shorn	O
,	O
and	O
a	O
treatment	O
group	O
(	O
n	O
=	O
7	O
)	O
that	O
was	O
left	O
unshorn	O
(	O
wool	O
length	O
:	O
10.6	O
?	O
1.2	O
cm	O
)	O
.	O

Individual	O
feed	O
and	O
water	O
intakes	O
were	O
recorded	O
throughout	O
the	O
experiment	O
(	O
d	O
1	O
to	O
71	O
)	O
.	O

Two	O
weeks	O
after	O
measurements	O
commenced	O
(	O
d	O
15	O
)	O
,	O
treatment	O
sheep	O
were	O
shorn	O
.	O

Water	O
intake	O
was	O
estimated	O
twice	O
for	O
2	O
consecutive	O
weeks	O
by	O
using	O
deuterium	O
dilution	O
techniques	O
(	O
d	O
1	O
to	O
15	O
and	O
d	O
57	O
to	O
71	O
)	O
.	O

Ambient	O
temperature	O
(	O
T	O
(	O
a	O
)	O
)	O
,	O
relative	O
humidity	O
,	O
and	O
respiratory	O
rate	O
were	O
measured	O
daily	O
,	O
whereas	O
BW	O
,	O
rectal	O
and	O
animal	O
surface	O
temperatures	O
(	O
using	O
infrared	O
thermography	O
)	O
,	O
and	O
wool	O
length	O
were	O
measured	O
weekly	O
.	O

In	O
the	O
first	O
2	O
wk	O
,	O
when	O
treatment	O
sheep	O
were	O
unshorn	O
,	O
treatment	O
and	O
control	O
ewes	O
differed	O
(	O
P	O
<	O
0.05	O
)	O
in	O
DMI	O
(	O
52	O
?	O
4	O
vs.	O
59	O
?	O
4	O
g?kg	O
(	O
-0.75	O
)	O
?d	O
(	O
-1	O
)	O
)	O
,	O
water	O
intake	O
(	O
165	O
?	O
17	O
vs.	O
134	O
?	O
18	O
g?kg	O
(	O
-0.75	O
)	O
?d	O
(	O
-1	O
)	O
)	O
,	O
respiratory	O
rate	O
(	O
66	O
?	O
5	O
vs.	O
31	O
?	O
4	O
breath/min	O
)	O
,	O
rectal	O
temperature	O
(	O
39.3	O
?	O
0.2	O
vs.	O
38.8	O
?	O
0.1?C	O
)	O
,	O
and	O
surface	O
temperatures	O
(	O
body	O
side	O
:	O
19.3	O
?	O
0.3	O
vs.	O
24.5	O
?	O
0.6?C	O
;	O
leg	O
:	O
25.8	O
?	O
2.4	O
vs.	O
27.4	O
?	O
1.6?C	O
)	O
.	O

However	O
,	O
after	O
shearing	O
,	O
these	O
differences	O
partly	O
disappeared	O
.	O

The	O
same	O
trend	O
in	O
water	O
intake	O
between	O
groups	O
was	O
confirmed	O
using	O
the	O
isotope	O
dilution	O
technique	O
.	O

We	O
found	O
a	O
significant	O
relationship	O
between	O
T	O
(	O
a	O
)	O
and	O
water	O
intake	O
,	O
respiratory	O
rate	O
,	O
and	O
body	O
surface	O
temperatures	O
.	O

Even	O
under	O
temperate	O
conditions	O
(	O
T	O
(	O
a	O
)	O
<	O
28?C	O
)	O
,	O
shearing	O
significantly	O
reduced	O
core	O
body	O
temperature	O
,	O
water	O
intake	O
,	O
and	O
respiratory	O
rate	O
in	O
German	O
Blackhead	O
mutton	O
sheep	O
,	O
thus	O
indicating	O
heat	O
stress	O
in	O
fleeced	O
animals	O
,	O
which	O
should	O
be	O
considered	O
when	O
determining	O
the	O
optimal	O
shearing	O
time	O
in	O
sheep	O
as	O
well	O
as	O
when	O
estimating	O
water	O
requirements	O
.	O

Schizophrenia	O
.	O

A	O
follow-up	O
study	O
of	O
the	O
results	O
of	O
five	O
forms	O
of	O
treatment	O
.	O

Two	O
hundred	O
twenty-eight	O
first-admission	O
schizophrenic	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
following	O
five	O
treatments	O
:	O
psychotherapy	O
alone	O
,	O
drug	O
alone	O
,	O
psychotherapy	O
plus	O
drug	O
,	O
electroconvulsive	O
therapy	O
(	O
ECT	O
,	O
and	O
milieu	O
.	O

A	O
there-	O
to	O
five-year	O
follow-up	O
examined	O
their	O
course	O
after	O
release	O
from	O
the	O
hospital	O
.	O

The	O
drug	O
alone	O
and	O
ECT	O
groups	O
tended	O
to	O
have	O
the	O
best	O
outcome	O
and	O
the	O
psychotherapy	O
alone	O
group	O
the	O
worst	O
.	O

The	O
positive	O
effect	O
from	O
prior	O
drug	O
treatment	O
began	O
to	O
dissipate	O
after	O
three	O
years	O
postadmission	O
.	O

For	O
the	O
in-hospital	O
treatment	O
successes	O
,	O
the	O
advantage	O
from	O
drug	O
treatment	O
and	O
the	O
disadvantage	O
from	O
psychotherapy	O
were	O
less	O
apparent	O
.	O

Overall	O
,	O
the	O
follow-up	O
outcome	O
is	O
far	O
from	O
reassuring	O
,	O
whatever	O
the	O
type	O
of	O
treatment	O
.	O

Even	O
though	O
a	O
few	O
patients	O
may	O
do	O
well	O
,	O
much	O
remains	O
to	O
be	O
done	O
in	O
and	O
out	O
of	O
the	O
hospital	O
.	O

Virtual	O
reality	O
intervention	O
for	O
older	Age
women	Sex
with	O
breast	Condition
cancer	Condition
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
a	O
virtual	O
reality	O
distraction	O
intervention	O
on	O
chemotherapy-related	O
symptom	O
distress	O
levels	O
in	O
16	SampleSize
women	Condition
aged	O
50	Age
and	Age
older	Age
.	O

A	O
cross-over	O
design	O
was	O
used	O
to	O
answer	O
the	O
following	O
research	O
questions	O
:	O
(	O
1	O
)	O
Is	O
virtual	O
reality	O
an	O
effective	O
distraction	O
intervention	O
for	O
reducing	O
chemotherapy-related	O
symptom	O
distress	O
levels	O
in	O
older	O
women	Condition
with	O
breast	Condition
cancer	Condition
?	O
(	O
2	O
)	O
Does	O
virtual	O
reality	O
have	O
a	O
lasting	O
effect	O
?	O
Chemotherapy	O
treatments	O
are	O
intensive	O
and	O
difficult	O
to	O
endure	O
.	O

One	O
way	O
to	O
cope	O
with	O
chemotherapy-related	O
symptom	O
distress	O
is	O
through	O
the	O
use	O
of	O
distraction	O
.	O

For	O
this	O
study	O
,	O
a	O
head-mounted	O
display	O
(	O
Sony	O
PC	O
Glasstron	O
PLM	O
-	O
S700	O
)	O
was	O
used	O
to	O
display	O
encompassing	O
images	O
and	O
block	O
competing	O
stimuli	O
during	O
chemotherapy	O
infusions	O
.	O

The	O
Symptom	O
Distress	O
Scale	O
(	O
SDS	O
)	O
,	O
Revised	O
Piper	O
Fatigue	O
Scale	O
(	O
PFS	O
)	O
,	O
and	O
the	O
State	O
Anxiety	O
Inventory	O
(	O
SAI	O
)	O
were	O
used	O
to	O
measure	O
symptom	O
distress	O
.	O

For	O
two	O
matched	O
chemotherapy	O
treatments	O
,	O
one	O
pre-test	O
and	O
two	O
post-test	O
measures	O
were	O
employed	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
the	O
VR	O
distraction	O
intervention	O
during	O
one	O
chemotherapy	O
treatment	O
and	O
received	O
no	O
distraction	O
intervention	O
(	O
control	O
condition	O
)	O
during	O
an	O
alternate	O
chemotherapy	O
treatment	O
.	O

Analysis	O
using	O
paired	O
t-tests	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
the	O
SAI	O
(	O
p	O
=	O
0.10	O
)	O
scores	O
immediately	O
following	O
chemotherapy	O
treatments	O
when	O
participants	O
used	O
VR	O
.	O

No	O
significant	O
changes	O
were	O
found	O
in	O
SDS	O
or	O
PFS	O
values	O
.	O

There	O
was	O
a	O
consistent	O
trend	O
toward	O
improved	O
symptoms	O
on	O
all	O
measures	O
48	O
h	O
following	O
completion	O
of	O
chemotherapy	O
.	O

Evaluation	O
of	O
the	O
intervention	O
indicated	O
that	O
women	O
thought	O
the	O
head	O
mounted	O
device	O
was	O
easy	O
to	O
use	O
,	O
they	O
experienced	O
no	O
cybersickness	O
,	O
and	O
100	O
%	O
would	O
use	O
VR	O
again	O
.	O

Regression	O
of	O
left	O
ventricular	O
hypertrophy	O
after	O
stentless	O
versus	O
conventional	O
aortic	Condition
valve	Condition
replacement	Condition
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
analyze	O
regression	O
of	O
left	O
ventricular	O
hypertrophy	O
after	O
randomization	O
to	O
conventional	O
biological	O
versus	O
stentless	O
aortic	O
valve	O
replacement	O
.	O

Stentless	O
(	O
Freestyle	O
,	O
Toronto	O
,	O
n	O
=	O
106	SampleSize
)	O
or	O
conventional	O
biological	O
aortic	O
valves	O
(	O
Carpentier-Edwards	O
,	O
n	O
=	O
74	SampleSize
)	O
were	O
evaluated	O
prospectively	O
.	O

Preoperatively	O
there	O
were	O
no	O
differences	O
with	O
regard	O
to	O
aortic	O
valve	O
pathology	O
,	O
left	O
ventricular	O
function	O
,	O
and	O
pressure	O
gradients	O
between	O
the	O
two	O
patient	O
groups	O
.	O

The	O
patient	O
annulus	O
index	O
(	O
13.55	O
vs.	O
13.46	O
mm	O
;	O
NS	O
)	O
measured	O
intraoperatively	O
was	O
used	O
as	O
baseline	O
for	O
further	O
comparison	O
.	O

Postoperatively	O
,	O
left	O
ventricular	O
mass	O
index	O
was	O
213+/-77	O
g/m2	O
(	O
stentless	O
)	O
compared	O
with	O
202+/-72	O
(	O
conventional	O
group	O
)	O
g/m2	O
(	O
NS	O
)	O
,	O
whereas	O
after	O
6	O
months	O
it	O
was	O
141+/-41	O
g/m2	O
in	O
the	O
stentless	O
and	O
170+/-43	O
g/m2	O
in	O
the	O
conventional	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O

Regression	O
of	O
left	O
ventricular	O
hypertrophy	O
occurs	O
in	O
all	O
patients	O
after	O
aortic	Condition
valve	Condition
replacement	Condition
.	O

Nevertheless	O
,	O
the	O
use	O
of	O
stentless	O
bioprostheses	O
leads	O
to	O
a	O
significant	O
enhancement	O
,	O
which	O
may	O
result	O
in	O
a	O
reduction	O
of	O
the	O
cardiac	O
risk	O
profile	O
for	O
the	O
patient	O
.	O

Endovascular	O
aneurysm	O
repair	O
and	O
outcome	O
in	O
patients	Condition
unfit	Condition
for	Condition
open	Condition
repair	Condition
of	Condition
abdominal	Condition
aortic	Condition
aneurysm	Condition
(	O
EVAR	O
trial	O
2	O
)	O
:	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Endovascular	O
aneurysm	O
repair	O
(	O
EVAR	O
)	O
to	O
exclude	O
abdominal	O
aortic	O
aneurysm	O
(	O
AAA	O
)	O
was	O
introduced	O
for	O
patients	O
of	O
poor	O
health	O
status	O
considered	O
unfit	O
for	O
major	O
surgery	O
.	O

We	O
instigated	O
EVAR	O
trial	O
2	O
to	O
identify	O
whether	O
EVAR	O
improves	O
survival	O
compared	O
with	O
no	O
intervention	O
in	O
patients	O
unfit	O
for	O
open	O
repair	O
of	O
aortic	O
aneurysm	O
.	O

METHODS	O
We	O
did	O
a	O
randomised	O
controlled	O
trial	O
of	O
338	SampleSize
patients	SampleSize
aged	Age
60	Age
years	Age
or	Age
older	Age
who	O
had	O
aneurysms	Condition
of	O
at	O
least	O
5.5	O
cm	O
in	O
diameter	O
and	O
who	O
had	O
been	O
referred	O
to	O
one	O
of	O
31	O
hospitals	O
in	O
the	O
UK	O
.	O

We	O
assigned	O
patients	O
to	O
receive	O
either	O
EVAR	O
(	O
n=166	O
)	O
or	O
no	O
intervention	O
(	O
n=172	O
)	O
.	O

Our	O
primary	O
endpoint	O
was	O
all-cause	O
mortality	O
,	O
with	O
secondary	O
endpoints	O
of	O
aneurysm-related	O
mortality	O
,	O
health-related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
,	O
postoperative	O
complications	O
,	O
and	O
hospital	O
costs	O
.	O

Analyses	O
were	O
by	O
intention	O
to	O
treat	O
.	O

FINDINGS	O
197	O
patients	O
underwent	O
aneurysm	O
repair	O
(	O
47	O
assigned	O
no	O
intervention	O
)	O
and	O
80	O
%	O
of	O
patients	O
adhered	O
to	O
protocol	O
.	O

The	O
30-day	O
operative	O
mortality	O
in	O
the	O
EVAR	O
group	O
was	O
9	O
%	O
(	O
13	O
of	O
150	O
,	O
95	O
%	O
CI	O
5-15	O
)	O
and	O
the	O
no	O
intervention	O
group	O
had	O
a	O
rupture	O
rate	O
of	O
9.0	O
per	O
100	O
person	O
years	O
(	O
95	O
%	O
CI	O
6.0-13.5	O
)	O
.	O

By	O
end	O
of	O
follow	O
up	O
142	O
patients	O
had	O
died	O
,	O
42	O
of	O
aneurysm-related	O
factors	O
;	O
overall	O
mortality	O
after	O
4	O
years	O
was	O
64	O
%	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
EVAR	O
group	O
and	O
the	O
no	O
intervention	O
group	O
for	O
all-cause	O
mortality	O
(	O
hazard	O
ratio	O
1.21	O
,	O
95	O
%	O
CI	O
0.87-1.69	O
,	O
p=0.25	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
aneurysm-related	O
mortality	O
.	O

The	O
mean	O
hospital	O
costs	O
per	O
patient	O
over	O
4	O
years	O
were	O
UK	O
pound	O
sterling	O
13,632	O
in	O
the	O
EVAR	O
group	O
and	O
pound	O
sterling	O
4983	O
in	O
the	O
no	O
intervention	O
group	O
(	O
mean	O
difference	O
pound	O
sterling	O
8649	O
,	O
SE	O
1248	O
)	O
,	O
with	O
no	O
difference	O
in	O
HRQL	O
scores	O
.	O

INTERPRETATION	O
EVAR	O
had	O
a	O
considerable	O
30-day	O
operative	O
mortality	O
in	O
patients	O
already	O
unfit	O
for	O
open	O
repair	O
of	O
their	O
aneurysm	O
.	O

EVAR	O
did	O
not	O
improve	O
survival	O
over	O
no	O
intervention	O
and	O
was	O
associated	O
with	O
a	O
need	O
for	O
continued	O
surveillance	O
and	O
reinterventions	O
,	O
at	O
substantially	O
increased	O
cost	O
.	O

Ongoing	O
follow-up	O
and	O
improved	O
fitness	O
of	O
these	O
patients	O
is	O
a	O
priority	O
.	O

The	O
preparation	O
of	O
patients	O
for	O
cardiac	Condition
surgery	Condition
.	O

This	O
study	O
examines	O
the	O
impact	O
of	O
a	O
preadmission	O
telephone	O
intervention	O
on	O
anxiety	O
,	O
knowledge	O
,	O
and	O
readiness	O
for	O
discharge	O
for	O
patients	O
attending	O
a	O
preadmission	O
teaching	O
program	O
prior	O
to	O
cardiac	Condition
surgery	Condition
.	O

The	O
primary	O
goal	O
of	O
the	O
telephone	O
intervention	O
was	O
to	O
provide	O
support	O
by	O
giving	O
additional	O
information	O
about	O
individual	O
concerns	O
.	O

The	O
telephone	O
intervention	O
did	O
not	O
have	O
an	O
effect	O
on	O
anxiety	O
and	O
knowledge	O
.	O

A	O
significantly	O
higher	O
level	O
of	O
anxiety	O
was	O
found	O
in	O
the	O
experimental	O
group	O
on	O
admission	O
,	O
but	O
this	O
difference	O
became	O
nonsignificant	O
when	O
baseline	O
level	O
and	O
length	O
of	O
waiting	O
time	O
were	O
entered	O
as	O
covariates	O
.	O

The	O
more	O
anxious	O
group	O
rated	O
their	O
perceived	O
knowledge	O
level	O
lower	O
,	O
despite	O
the	O
fact	O
that	O
both	O
groups	O
had	O
similar	O
scores	O
in	O
actual	O
knowledge	O
.	O

Given	O
the	O
potential	O
barrier	O
that	O
anxiety	O
can	O
pose	O
for	O
patient	O
learning	O
,	O
nurses	O
need	O
to	O
adapt	O
their	O
interventions	O
to	O
deal	O
with	O
the	O
patients	O
'	O
feelings	O
of	O
anxiety	O
that	O
accompany	O
cardiac	O
surgery	O
to	O
make	O
the	O
learning	O
process	O
effective	O
.	O

The	O
degrees	O
of	O
UVB-induced	O
erythema	O
and	O
pigmentation	O
correlate	O
linearly	O
and	O
are	O
reduced	O
in	O
a	O
parallel	O
manner	O
by	O
topical	O
anti-inflammatory	O
agents	O
.	O

To	O
examine	O
whether	O
it	O
is	O
possible	O
to	O
evaluate	O
the	O
degree	O
of	O
ultraviolet	O
B	O
(	O
UVB	O
)	O
-induced	O
inflammation	O
by	O
measuring	O
the	O
degree	O
of	O
hyperpigmentation	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
UVB-induced	O
erythema	O
and	O
the	O
subsequent	O
pigmentation	O
quantitatively	O
.	O

At	O
24	O
h	O
and	O
7	O
d	O
after	O
irradiation	O
with	O
erythemogenic	O
doses	O
of	O
UVB	O
to	O
the	O
backs	O
of	O
16	O
Japanese	O
subjects	O
,	O
the	O
degree	O
of	O
induced	O
erythema	O
(	O
delta	O
erythema	O
index	O
)	O
and	O
that	O
of	O
pigmentation	O
(	O
delta	O
melanin	O
index	O
)	O
were	O
examined	O
by	O
an	O
image	O
analytic	O
method	O
using	O
a	O
videomicroscope	O
interfaced	O
with	O
a	O
computer	O
.	O

The	O
relationship	O
between	O
two	O
indices	O
was	O
linear	O
in	O
each	O
subject	O
,	O
and	O
the	O
correlation	O
coefficient	O
was	O
0.83	O
when	O
evaluated	O
using	O
whole	O
data	O
.	O

The	O
slope	O
of	O
the	O
regression	O
line	O
for	O
the	O
delta	O
melanin	O
index	O
against	O
delta	O
erythema	O
index	O
tended	O
to	O
become	O
steeper	O
as	O
non-irradiated	O
skin	O
color	O
became	O
darker	O
(	O
r	O
=	O
0.63	O
)	O
,	O
suggesting	O
that	O
more	O
efficient	O
melanogenesis	O
takes	O
place	O
after	O
the	O
same	O
level	O
of	O
inflammation	O
in	O
the	O
subject	O
with	O
darker	O
skin	O
.	O

Both	O
erythema	O
and	O
hyperpigmentation	O
were	O
suppressed	O
significantly	O
and	O
in	O
a	O
parallel	O
manner	O
by	O
corticosteroids	O
and	O
indomethacin	O
applied	O
topically	O
immediately	O
after	O
UVB	O
irradiation	O
.	O

These	O
results	O
imply	O
that	O
the	O
post-inflammatory	O
hyperpigmentation	O
correlates	O
closely	O
with	O
the	O
severity	O
of	O
the	O
prior	O
inflammation	O
and	O
that	O
chemical	O
mediators	O
released	O
in	O
the	O
inflammatory	O
process	O
have	O
considerable	O
influence	O
on	O
the	O
melanogenesis	O
.	O

We	O
conclude	O
that	O
the	O
measurement	O
of	O
UVB-induced	O
hyperpigmentation	O
can	O
be	O
utilized	O
for	O
the	O
assessment	O
of	O
topical	O
anti-inflammatory	O
agents	O
,	O
unless	O
these	O
have	O
direct	O
actions	O
on	O
the	O
tyrosinase	O
activity	O
of	O
melanocytes	O
.	O

Effects	O
of	O
two	O
combined	O
oral	O
contraceptives	O
containing	O
ethinyl	O
estradiol	O
20	O
microg	O
combined	O
with	O
either	O
drospirenone	O
or	O
desogestrel	O
on	O
lipids	O
,	O
hemostatic	O
parameters	O
and	O
carbohydrate	O
metabolism	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
effect	O
of	O
ethinyl	O
estradiol	O
20	O
microg/drospirenone	O
3	O
mg	O
(	O
EE	O
20	O
microg/DRSP	O
3	O
mg	O
)	O
administered	O
according	O
to	O
a	O
24/4	O
regimen	O
with	O
ethinyl	O
estradiol	O
20	O
microg/desogestrel	O
150	O
microg	O
(	O
EE	O
20	O
microg/DSG	O
150	O
microg	O
)	O
administered	O
according	O
to	O
the	O
conventional	O
21/7	O
regimen	O
on	O
lipid	O
,	O
carbohydrate	O
and	O
hemostatic	O
parameters	O
.	O

STUDY	O
DESIGN	O
In	O
this	O
open-label	O
study	O
,	O
healthy	O
women	Sex
were	O
randomized	O
to	O
EE	O
20	O
microg/DRSP	O
3	O
mg	O
or	O
EE	O
20	O
microg/DSG	O
150	O
microg	O
for	O
seven	O
cycles	O
.	O

Mean	O
differences	O
in	O
high-density	O
lipoprotein	O
(	O
HDL	O
)	O
-	O
and	O
low-density	O
lipoprotein	O
(	O
LDL	O
)	O
-cholesterol	O
levels	O
at	O
cycle	O
7	O
compared	O
to	O
baseline	O
were	O
assessed	O
.	O

Secondary	O
variables	O
included	O
changes	O
in	O
other	O
lipid	O
,	O
hemostatic	O
and	O
carbohydrate	O
parameters	O
.	O

RESULTS	O
Both	O
treatments	O
increased	O
HDL-cholesterol	O
,	O
but	O
decreased	O
LDL-cholesterol	O
by	O
a	O
comparable	O
extent	O
.	O

Although	O
slightly	O
elevated	O
in	O
both	O
groups	O
,	O
blood	O
glucose	O
and	O
C-peptide	O
levels	O
measured	O
during	O
oral	O
glucose	O
tolerance	O
tests	O
were	O
within	O
normal	O
reference	O
ranges	O
at	O
cycle	O
7	O
.	O

Overall	O
,	O
the	O
differences	O
in	O
lipid	O
,	O
hemostatic	O
or	O
carbohydrate	O
parameters	O
were	O
not	O
significant	O
between	O
the	O
two	O
treatments	O
.	O

CONCLUSION	O
EE	O
20	O
microg/DRSP	O
3	O
mg	O
has	O
a	O
good	O
safety	O
profile	O
comparable	O
with	O
EE	O
20	O
microg/DSG	O
150	O
microg	O
.	O

Multicenter	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
to	O
assess	O
the	O
acute	O
prokinetic	O
efficacy	O
of	O
nizatidine-controlled	O
release	O
(	O
150	O
and	O
300	O
mg	O
)	O
in	O
patients	O
with	O
gastroesophageal	Condition
reflux	Condition
disease	Condition
.	O

INTRODUCTION	O
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
test	O
whether	O
nizatidine	O
delivered	O
via	O
a	O
unique	O
bimodal	O
pulsatile-controlled	O
release	O
system	O
,	O
nizatidine	O
controlled	O
release	O
(	O
CR	O
)	O
,	O
accelerates	O
gastric	O
emptying	O
in	O
patients	O
with	O
gastroesophageal	Condition
reflux	Condition
disease	Condition
(	Condition
GERD	Condition
)	Condition
.	Condition

METHODS	O
Combined	O
data	O
were	O
analyzed	O
on	O
39	SampleSize
patients	O
with	O
delayed	Condition
gastric	Condition
emptying	Condition
(	Condition
DGE	Condition
)	Condition
from	O
2	O
studies	O
(	O
n	SampleSize
=	SampleSize
84	SampleSize
)	O
assessing	O
the	O
prokinetic	O
effect	O
of	O
nizatidine	O
CR	O
.	O

A	O
single-blind	O
placebo	O
baseline	O
was	O
followed	O
by	O
double-blind	O
nizatidine	O
CR	O
(	O
150	O
and	O
300	O
mg	O
)	O
in	O
randomized	O
sequence	O
,	O
2	O
to	O
5	O
days	O
apart	O
.	O

Each	O
dose	O
was	O
followed	O
1	O
hour	O
later	O
by	O
an	O
egg-beater	O
meal	O
,	O
labeled	O
with	O
Tc99m	O
.	O

Gamma	O
camera	O
images	O
were	O
obtained	O
at	O
meal	O
completion	O
,	O
1-	O
,	O
2-	O
,	O
3-	O
and	O
4-hour	O
postmeal	O
.	O

All	O
the	O
84	SampleSize
patients	O
were	O
classified	O
at	O
baseline	O
with	O
DGE	Condition
(	O
gastric	O
retention	O
>	O
6.3	O
%	O
at	O
4	O
hours	O
)	O
or	O
normal	Condition
gastric	Condition
emptying	Condition
.	O

RESULTS	O
In	O
the	O
39	O
patients	O
identified	O
with	O
DGE	O
,	O
change	O
from	O
placebo	O
baseline	O
(	O
CFB	O
)	O
for	O
percent	O
gastric	O
retention	O
at	O
4-hour	O
postmeal	O
with	O
nizatidine	O
CR	O
(	O
150	O
and	O
300	O
mg	O
)	O
was	O
each	O
improved	O
and	O
statistically	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
a	O
subgroup	O
of	O
diabetic	Condition
patients	O
with	O
DGE	Condition
(	O
n	O
=	O
10	SampleSize
)	O
,	O
the	O
CFB	O
with	O
nizatidine	O
CR	O
(	O
300	O
mg	O
)	O
was	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
at	O
3-	O
and	O
4-hour	O
postmeal	O
.	O

CONCLUSIONS	O
Nizatidine	O
CR	O
(	O
150	O
and	O
300	O
mg	O
)	O
significantly	O
enhanced	O
gastric	O
emptying	O
of	O
a	O
standard	O
meal	O
in	O
patients	O
with	O
GERD	Condition
with	O
DGE	Condition
.	O

MRI	O
signal	O
hyperintensities	O
and	O
failure	O
to	O
remit	O
following	O
antidepressant	O
treatment	O
.	O

BACKGROUND	O
MRI	O
signal	O
hyperintensities	O
predict	O
poor	O
remission	O
to	O
antidepressant	O
treatment	O
.	O

Previous	O
studies	O
using	O
volumetrics	O
in	O
outpatient	O
samples	O
have	O
relied	O
on	O
total	O
lesion	O
volume	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
remission	O
from	O
geriatric	Condition
depression	Condition
depends	O
on	O
lesion	O
volume	O
by	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
.	O

METHOD	O
Thirty-eight	SampleSize
patients	O
received	O
baseline	O
MRIs	O
as	O
part	O
of	O
a	O
larger	O
12-week	O
,	O
randomized	O
clinical	O
trial	O
comparing	O
sertraline	O
and	O
nortriptyline	O
in	O
the	O
treatment	O
of	O
late-life	Condition
depression	Condition
.	O

MRIcro	O
was	O
used	O
to	O
quantify	O
MRI-hyperintensity	O
volume	O
into	O
total	O
hyperintensity	O
,	O
deep	O
white	O
matter	O
hyperintensity	O
(	O
DWMH	O
)	O
,	O
and	O
periventricular	O
hyperintensity	O
(	O
PVH	O
)	O
volumes	O
.	O

High	O
versus	O
low	O
total	O
,	O
DWMH	O
,	O
and	O
PVH	O
volumes	O
were	O
defined	O
based	O
on	O
the	O
highest	O
quartile	O
of	O
their	O
respective	O
distributions	O
.	O

Remission	O
from	O
depression	O
was	O
defined	O
as	O
a	O
24-item	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
score	O
?	O
7	O
for	O
two	O
consecutive	O
weeks	O
.	O

RESULTS	O
Patients	O
classified	O
as	O
having	O
high	O
DWMH	O
were	O
7.14	O
times	O
more	O
likely	O
not	O
to	O
remit	O
following	O
antidepressant	O
treatment	O
compared	O
to	O
patients	O
classified	O
as	O
having	O
low	O
DWMH	O
(	O
p=0.02	O
)	O
.	O

Similar	O
odds	O
ratios	O
were	O
obtained	O
for	O
PVH	O
(	O
OR=4.17	O
,	O
p=0.16	O
)	O
and	O
total	O
volumes	O
(	O
OR=5.00	O
,	O
p=0.05	O
)	O
.	O

Importantly	O
,	O
adjusting	O
for	O
age	O
did	O
not	O
change	O
the	O
magnitude	O
of	O
these	O
effects	O
.	O

LIMITATIONS	O
A	O
small	O
and	O
predominantly	O
White	O
sample	O
.	O

CONCLUSIONS	O
This	O
is	O
the	O
first	O
study	O
to	O
test	O
whether	O
remission	O
from	O
geriatric	O
depression	O
depends	O
on	O
lesion	O
volume	O
by	O
ROI	O
in	O
an	O
outpatient	O
sample	O
.	O

The	O
pattern	O
of	O
remission	O
rates	O
and	O
odds	O
ratios	O
was	O
similar	O
when	O
patients	O
were	O
classified	O
as	O
having	O
high	O
DWMH	O
,	O
PVH	O
or	O
total	O
volume	O
suggesting	O
that	O
lesion	O
location	O
may	O
not	O
be	O
critical	O
.	O

A	O
placebo-controlled	O
trial	O
of	O
D-cycloserine	O
added	O
to	O
conventional	O
neuroleptics	O
in	O
patients	O
with	O
schizophrenia	Condition
.	O

BACKGROUND	O
In	O
a	O
preliminary	O
dose-finding	O
study	O
,	O
D-cycloserine	O
,	O
a	O
partial	O
agonist	O
at	O
the	O
glycine	O
modulatory	O
site	O
of	O
the	O
glutamatergic	O
N-methyl-D-aspartate	O
(	O
NMDA	O
)	O
receptor	O
,	O
improved	O
negative	O
symptoms	O
and	O
cognitive	O
function	O
when	O
added	O
to	O
conventional	O
neuroleptics	O
at	O
a	O
dose	O
of	O
50	O
mg/d	O
.	O

METHODS	O
Forty-seven	SampleSize
patients	O
with	O
schizophrenia	Condition
meeting	O
criteria	O
for	O
deficit	Condition
syndrome	Condition
were	O
randomized	O
to	O
D-cycloserine	O
,	O
50	O
mg/d	O
(	O
n=23	O
)	O
or	O
placebo	O
(	O
n=24	O
)	O
added	O
to	O
their	O
conventional	O
neuroleptic	O
for	O
an	O
8-week	O
,	O
double-blind	O
trial	O
.	O

Clinical	O
assessments	O
were	O
performed	O
at	O
baseline	O
and	O
at	O
weeks	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
8	O
.	O

Serum	O
concentrations	O
of	O
D-cycloserine	O
,	O
relevant	O
amino	O
acids	O
,	O
and	O
homovanillic	O
acid	O
were	O
assayed	O
at	O
baseline	O
and	O
at	O
weeks	O
4	O
and	O
8	O
.	O

A	O
cognitive	O
battery	O
was	O
performed	O
at	O
baseline	O
and	O
at	O
week	O
8	O
.	O

RESULTS	O
Thirty-nine	SampleSize
patients	O
completed	O
the	O
8-week	O
trial	O
.	O

Seven	O
dropouts	O
occurred	O
in	O
the	O
D-cycloserine	O
group	O
and	O
1	O
in	O
the	O
placebo	O
group	O
.	O

The	O
mean	O
reduction	O
in	O
negative	O
symptoms	O
with	O
D-cycloserine	O
(	O
23	O
%	O
)	O
was	O
significantly	O
greater	O
than	O
with	O
placebo	O
(	O
7	O
%	O
)	O
as	O
calculated	O
by	O
slopes	O
representing	O
Scale	O
for	O
the	O
Assessment	O
of	O
Negative	O
Symptoms	O
(	O
SANS	O
)	O
total	O
scores	O
.	O

Improvement	O
of	O
negative	O
symptoms	O
was	O
predicted	O
by	O
low	O
neuroleptic	O
dose	O
and	O
low	O
baseline	O
SANS	O
total	O
score	O
.	O

No	O
differences	O
were	O
found	O
in	O
performance	O
on	O
any	O
cognitive	O
test	O
between	O
groups	O
or	O
in	O
changes	O
in	O
any	O
other	O
clinical	O
measure	O
.	O

Clinical	O
response	O
did	O
not	O
correlate	O
significantly	O
with	O
serum	O
amino	O
acid	O
concentrations	O
at	O
baseline	O
or	O
with	O
concentrations	O
of	O
D-cycloserine	O
at	O
weeks	O
4	O
and	O
8	O
.	O

CONCLUSION	O
These	O
results	O
support	O
the	O
hypothesis	O
that	O
agents	O
acting	O
at	O
the	O
glycine	O
modulatory	O
site	O
of	O
the	O
NMDA	O
receptor	O
improve	O
primary	O
negative	O
symptoms	O
.	O

Influence	O
of	O
Aloe	O
arborescens	O
Mill	O
.	O

extract	O
on	O
selected	O
parameters	O
of	O
pro-oxidant-antioxidant	O
equilibrium	O
and	O
cytokine	O
synthesis	O
in	O
rowers	O
.	O

This	O
investigation	O
examined	O
the	O
effect	O
of	O
supplementation	O
with	O
Biostimine	O
,	O
extract	O
from	O
Aloe	O
arborescens	O
Mill	O
.	O

leaves	O
,	O
on	O
the	O
levels	O
of	O
pro-oxidant-antioxidant	O
equilibrium	O
markers	O
and	O
anti-	O
and	O
proinflammatory	O
cytokines	O
in	O
rowers	O
subjected	O
to	O
exhaustive	O
exercise	O
.	O

This	O
double-blind	O
study	O
included	O
18	O
members	O
of	O
the	O
Polish	O
Rowing	O
Team	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
the	O
supplemented	O
group	O
(	O
n	O
=	O
9	O
)	O
,	O
which	O
received	O
one	O
ampoule	O
of	O
Biostimine	O
once	O
daily	O
for	O
4	O
weeks	O
,	O
or	O
to	O
the	O
placebo	O
group	O
(	O
n	O
=	O
9	O
)	O
.	O

Subjects	O
performed	O
a	O
2,000-meter-maximum	O
test	O
on	O
a	O
rowing	O
ergometer	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
preparatory	O
camp	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
the	O
antecubital	O
vein	O
before	O
each	O
exercise	O
test	O
,	O
1	O
min	O
after	O
completing	O
the	O
test	O
and	O
after	O
a	O
24-hr	O
recovery	O
period	O
.	O

Superoxide	O
dismutase	O
and	O
glutathione	O
peroxidase	O
activity	O
as	O
well	O
as	O
the	O
concentration	O
of	O
thiobarbituric	O
acid	O
reactive	O
substances	O
(	O
TBARS	O
)	O
were	O
assessed	O
in	O
erythrocytes	O
.	O

In	O
addition	O
,	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
)	O
and	O
creatine	O
kinase	O
activity	O
were	O
measured	O
in	O
plasma	O
samples	O
,	O
and	O
cytokine	O
(	O
IL-6	O
,	O
IL-10	O
)	O
concentrations	O
were	O
determined	O
in	O
the	O
serum	O
.	O

Before	O
and	O
after	O
Biostimine	O
supplementation	O
,	O
exercise	O
significantly	O
increased	O
the	O
values	O
of	O
SOD	O
,	O
IL-6	O
,	O
IL-10	O
,	O
and	O
TBARS	O
in	O
both	O
groups	O
.	O

However	O
,	O
postexercise	O
and	O
recovery	O
levels	O
of	O
TBARS	O
were	O
significantly	O
lower	O
in	O
athletes	O
receiving	O
Biostimine	O
than	O
in	O
controls	O
.	O

After	O
supplementation	O
,	O
TAC	O
was	O
the	O
only	O
variable	O
with	O
the	O
level	O
being	O
significantly	O
higher	O
in	O
the	O
supplemented	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Consequently	O
,	O
we	O
can	O
conclude	O
that	O
Biostimine	O
supplementation	O
reduces	O
the	O
postexercise	O
level	O
of	O
TBARS	O
by	O
increasing	O
the	O
antioxidant	O
activity	O
of	O
plasma	O
but	O
has	O
no	O
effect	O
on	O
inflammatory	O
markers	O
.	O

Feasibility	O
and	O
effects	O
of	O
nurse	O
run	O
clinics	O
for	O
patients	O
with	O
epilepsy	Condition
in	O
general	O
practice	O
:	O
randomised	O
controlled	O
trial	O
.	O

Epilepsy	O
Care	O
Evaluation	O
Group	O
.	O

OBJECTIVE	O
To	O
test	O
the	O
feasibility	O
and	O
effect	O
of	O
nurse	O
run	O
epilepsy	Condition
clinics	O
in	O
primary	O
care	O
.	O

DESIGN	O
A	O
randomised	O
controlled	O
trial	O
of	O
nurse	O
run	O
clinics	O
versus	O
usual	O
care	O
.	O

SETTING	O
Six	O
general	O
practices	O
in	O
the	O
South	O
Thames	O
region	O
.	O

SUBJECTS	O
251	SampleSize
patients	O
aged	O
over	O
15	O
years	O
who	O
were	O
taking	O
anti-epileptic	O
drugs	O
or	O
had	O
a	O
diagnosis	O
of	O
epilepsy	Condition
and	O
an	O
attack	O
in	O
the	O
past	O
two	O
years	O
who	O
met	O
specified	O
inclusion	O
criteria	O
and	O
had	O
responded	O
to	O
a	O
questionnaire	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Questionnaire	O
responses	O
and	O
recording	O
of	O
key	O
variables	O
extracted	O
from	O
the	O
clinical	O
records	O
before	O
and	O
after	O
the	O
intervention	O
.	O

RESULTS	O
127	SampleSize
patients	O
were	O
randomised	O
to	O
a	O
nurse	O
run	O
clinic	O
,	O
of	O
whom	O
106	O
(	O
83	O
%	O
)	O
attended	O
.	O

The	O
nurse	O
wrote	O
28	O
letters	O
to	O
the	O
general	O
practitioners	O
suggesting	O
changes	O
in	O
epilepsy	O
management	O
.	O

For	O
this	O
intervention	O
group	O
compared	O
with	O
the	O
usual	O
care	O
group	O
there	O
was	O
a	O
highly	O
significant	O
improvement	O
in	O
the	O
level	O
of	O
advice	O
recorded	O
as	O
having	O
been	O
given	O
on	O
drug	O
compliance	O
,	O
adverse	O
drug	O
effects	O
,	O
driving	O
,	O
alcohol	O
intake	O
,	O
and	O
self	O
help	O
groups	O
.	O

CONCLUSIONS	O
Nurse	O
run	O
clinics	O
for	O
patients	O
with	O
epilepsy	Condition
were	O
feasible	O
and	O
well	O
attended	O
.	O

Such	O
clinics	O
can	O
significantly	O
improve	O
the	O
level	O
of	O
advice	O
and	O
drug	O
management	O
recorded	O
.	O

The	O
effect	O
of	O
quality	O
and	O
amount	O
of	O
dietary	O
fat	O
on	O
the	O
susceptibility	O
of	O
low	O
density	O
lipoprotein	O
to	O
oxidation	O
in	O
subjects	O
with	O
impaired	Condition
glucose	Condition
tolerance	Condition
.	O

OBJECTIVES	O
We	O
examined	O
the	O
effects	O
of	O
a	O
high	O
fat	O
diet	O
rich	O
in	O
monounsaturated	O
fat	O
(	O
MUFA-diet	O
)	O
and	O
a	O
moderate	O
fat	O
diet	O
rich	O
in	O
polyunsaturated	O
fat	O
(	O
PUFA-diet	O
)	O
on	O
the	O
susceptibility	O
of	O
LDL	O
to	O
oxidation	O
.	O

SUBJECTS	O
29	SampleSize
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
.	O

METHODS	O
After	O
consuming	O
a	O
run-in	O
diet	O
[	O
37	O
%	O
of	O
energy	O
(	O
E	O
%	O
)	O
fat	O
,	O
18	O
E	O
%	O
saturated	O
fat	O
]	O
for	O
three	O
weeks	O
,	O
subjects	O
were	O
randomly	O
assigned	O
either	O
to	O
a	O
MUFA-diet	O
(	O
40	O
E	O
%	O
fat	O
,	O
19	O
E	O
%	O
monounsaturated	O
fatty	O
acids	O
)	O
or	O
a	O
PUFA-diet	O
(	O
34	O
E	O
%	O
fat	O
,	O
10	O
E	O
%	O
polyunsaturated	O
fat	O
)	O
for	O
eight	O
weeks	O
.	O

The	O
susceptibility	O
of	O
LDL	O
to	O
oxidation	O
was	O
measured	O
by	O
challenging	O
LDL	O
with	O
hemin	O
and	O
H2O2	O
and	O
measuring	O
the	O
time	O
for	O
the	O
reaction	O
to	O
reach	O
maximum	O
velocity	O
.	O

Results	O
are	O
expressed	O
as	O
lag	O
time	O
to	O
oxidation	O
in	O
minutes	O
.	O

RESULTS	O
In	O
the	O
PUFA-diet	O
group	O
(	O
n	O
=	O
15	O
)	O
lag	O
time	O
tended	O
to	O
decrease	O
during	O
the	O
experimental	O
diet	O
(	O
97	O
+/-	O
28	O
vs	O
90	O
+/-	O
25	O
min	O
,	O
mean	O
+/-	O
s.d.	O
,	O
P	O
=	O
0.073	O
)	O
,	O
whereas	O
in	O
the	O
MUFA-diet	O
group	O
(	O
n	O
=	O
14	O
)	O
there	O
was	O
no	O
significant	O
change	O
(	O
lag	O
time	O
96	O
+/-	O
24	O
vs	O
100	O
+/-	O
16	O
min	O
,	O
P	O
=	O
0.408	O
)	O
.	O

The	O
mean	O
change	O
in	O
lag	O
time	O
was	O
-7	O
+/-	O
14	O
min	O
(	O
-7.2	O
%	O
)	O
in	O
the	O
PUFA-diet	O
group	O
and	O
+4	O
+/-	O
16	O
min	O
(	O
+4.0	O
%	O
)	O
in	O
the	O
MUFA-diet	O
group	O
(	O
P	O
=	O
0.029	O
,	O
PUFA-diet	O
group	O
vs	O
MUFA-diet	O
group	O
)	O
.	O

The	O
alpha-tocopherol	O
concentration	O
in	O
LDL	O
increased	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
in	O
both	O
diet	O
groups	O
relative	O
to	O
the	O
run-in	O
diet	O
period	O
,	O
but	O
LDL	O
particle	O
score	O
did	O
not	O
change	O
in	O
either	O
of	O
the	O
diet	O
groups	O
during	O
the	O
dietary	O
intervention	O
.	O

In	O
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
a	O
PUFA-rich	O
diet	O
with	O
a	O
moderate	O
amount	O
of	O
fat	O
tended	O
to	O
increase	O
the	O
susceptibility	O
of	O
LDL	O
to	O
oxidation	O
as	O
compared	O
to	O
a	O
higher	O
fat	O
diet	O
rich	O
in	O
MUFA	O
.	O

Furthermore	O
,	O
the	O
negative	O
mean	O
change	O
in	O
lag	O
time	O
to	O
oxidation	O
found	O
in	O
the	O
PUFA-diet	O
group	O
differed	O
significantly	O
from	O
the	O
slightly	O
positive	O
mean	O
change	O
found	O
in	O
the	O
MUFA-diet	O
group	O
.	O

Effect	O
of	O
a	O
ferrule	O
and	O
increased	O
clinical	O
crown	O
length	O
on	O
the	O
in	O
vitro	O
fracture	O
resistance	O
of	O
premolars	O
restored	O
using	O
two	O
dowel-and-core	O
systems	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
a	O
crown-lengthening	O
ferrule	O
on	O
the	O
fracture	O
resistance	O
of	O
endodontically-treated	O
teeth	O
restored	O
with	O
two	O
dowel-core	O
systems	O
.	O

Thirty-two	SampleSize
extracted	O
mandibular	O
first	O
premolars	O
were	O
sectioned	O
perpendicular	O
to	O
the	O
long	O
axis	O
at	O
a	O
point	O
1.0	O
mm	O
occlusal	O
to	O
the	O
buccal	O
cementoenamel	O
junction	O
.	O

Following	O
endodontic	O
treatment	O
,	O
the	O
teeth	O
were	O
randomly	O
assigned	O
to	O
four	O
groups	O
:	O
cast	O
Ni-Cr	O
alloy	O
dowel-core	O
with	O
no	O
ferrule	O
(	O
Group	O
A1	O
)	O
,	O
cast	O
Ni-Cr	O
alloy	O
dowel-core	O
with	O
2.0	O
mm	O
ferrule	O
(	O
Group	O
A2	O
)	O
,	O
prefabricated	O
carbon	O
fiber-reinforced	O
dowel-resin	O
core	O
with	O
no	O
ferrule	O
(	O
Group	O
B1	O
)	O
and	O
carbon	O
fiber-reinforced	O
dowel-resin	O
core	O
with	O
2.0	O
mm	O
ferrule	O
(	O
Group	O
B2	O
)	O
.	O

Each	O
specimen	O
was	O
embedded	O
in	O
a	O
self-cured	O
acrylic	O
resin	O
block	O
from	O
2.0	O
mm	O
apical	O
to	O
the	O
margins	O
of	O
a	O
cast	O
Ni-Cr	O
alloy	O
crown	O
,	O
then	O
loaded	O
at	O
150	O
degrees	O
from	O
the	O
long	O
axis	O
in	O
a	O
universal	O
testing	O
machine	O
at	O
a	O
crosshead	O
speed	O
of	O
1.0	O
mm/minute	O
until	O
fracture	O
.	O

The	O
data	O
were	O
recorded	O
and	O
analyzed	O
using	O
ANOVA	O
and	O
Fisher	O
's	O
exact	O
tests	O
,	O
with	O
alpha	O
=	O
0.05	O
.	O

Mean	O
failure	O
loads	O
(	O
kN	O
)	O
for	O
the	O
A1	O
,	O
A2	O
,	O
B1	O
and	O
B2	O
Groups	O
were	O
:	O
1.46	O
(	O
S.D	O
.	O

0.45	O
)	O
,	O
1.07	O
(	O
0.21	O
)	O
,	O
1.13	O
(	O
0.30	O
)	O
and	O
1.02	O
(	O
0.27	O
)	O
.	O

The	O
teeth	O
restored	O
with	O
cast	O
Ni-Cr	O
dowel-cores	O
and	O
2.0	O
mm	O
ferrules	O
demonstrated	O
significantly	O
lower	O
fracture	O
strengths	O
,	O
p	O
=	O
0.04	O
.	O

There	O
were	O
significant	O
differences	O
in	O
the	O
root	O
fracture	O
patterns	O
between	O
the	O
two	O
dowel	O
systems	O
,	O
with	O
the	O
carbon	O
fiber-reinforced	O
dowel-resin	O
core	O
system	O
,	O
being	O
the	O
less	O
severe	O
p	O
<	O
0.05	O
.	O

Crown	O
lengthening	O
with	O
a	O
2.0	O
mm	O
apical	O
extended	O
ferrule	O
resulted	O
in	O
reduced	O
fracture	O
strengths	O
for	O
endodontically-treated	O
teeth	O
restored	O
using	O
two	O
dowel-core	O
systems	O
and	O
cast	O
metal	O
crowns	O
.	O

The	O
carbon	O
fiber-reinforced	O
dowel-resin	O
core	O
system	O
reduced	O
the	O
severity	O
of	O
the	O
root	Condition
fractures	Condition
.	O

Intravenous	O
pretreatment	O
of	O
hypertonic	O
saline	O
can	O
prevent	O
systemic	O
hypotension	O
induced	O
by	O
spinal	O
anesthesia	O
.	O

BACKGROUND	O
Hypertonic	O
saline	O
improves	O
organ	O
perfusion	O
and	O
patient	O
survival	O
during	O
hemorrhagic	O
shock	O
because	O
it	O
expands	O
plasma	O
volume	O
and	O
increases	O
tissue	O
oxygenation	O
.	O

Its	O
beneficial	O
results	O
have	O
been	O
reported	O
in	O
patients	O
suffering	O
from	O
hypotension	O
during	O
spinal	O
anesthesia	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
influence	O
between	O
prehydration	O
with	O
3	O
%	O
hypertonic	O
saline	O
and	O
with	O
isotonic	O
lactated	O
Ringer	O
's	O
solution	O
on	O
the	O
hemodynamic	O
changes	O
and	O
serum	O
electrolyte	O
concentrations	O
in	O
patients	O
undergoing	O
spinal	O
anesthesia	O
.	O

METHODS	O
Sixty	SampleSize
ASA	O
class	O
I	O
patients	O
scheduled	O
for	O
herniorrhapy	O
under	O
spinal	O
anesthesia	O
were	O
assigned	O
randomly	O
into	O
two	O
groups	O
.	O

Group	O
1	O
=	O
patients	O
were	O
prehydrated	O
with	O
isotonic	O
lactated	O
Ringer	O
's	O
solution	O
at	O
7	O
mg/kg	O
(	O
n	O
=	O
30	O
)	O
;	O
Group	O
2	O
=	O
patients	O
were	O
given	O
prehydration	O
with	O
3	O
%	O
hypertonic	O
saline	O
at	O
7	O
ml/kg	O
(	O
n	O
=	O
30	O
)	O
.	O

Following	O
prehydration	O
,	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
recorded	O
and	O
serum	O
electrolyte	O
concentrations	O
were	O
measured	O
.	O

RESULTS	O
The	O
incidence	O
of	O
hypotension	O
was	O
17/30	O
(	O
57	O
%	O
)	O
in	O
the	O
isotonic	O
lactated	O
Ringer	O
's	O
solution	O
group	O
as	O
against	O
7/30	O
(	O
23	O
%	O
)	O
in	O
the	O
hypertonic	O
saline	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
two	O
groups	O
in	O
relation	O
to	O
the	O
level	O
of	O
anesthesia	O
or	O
maximal	O
heart	O
rate	O
,	O
and	O
electrolyte	O
imbalance	O
did	O
not	O
occur	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
Prior	O
to	O
spinal	O
anesthesia	O
,	O
hydration	O
with	O
small	O
amount	O
of	O
hypertonic	O
saline	O
is	O
effective	O
to	O
minimize	O
hypotension	O
associated	O
with	O
spinal	O
anesthesia	O
.	O

If	O
so	O
administered	O
it	O
would	O
not	O
increase	O
bodily	O
sodium	O
load	O
and	O
unlike	O
isotonic	O
crystalloid	O
solution	O
it	O
dose	O
not	O
cause	O
accumulation	O
of	O
water	O
in	O
the	O
body	O
on	O
equipollent	O
basis	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
risperidone	O
in	O
adults	O
with	O
autistic	Condition
disorder	Condition
and	O
other	O
pervasive	O
developmental	O
disorders	O
.	O

BACKGROUND	O
Neurobiological	O
research	O
has	O
implicated	O
the	O
dopamine	O
and	O
serotonin	O
systems	O
in	O
the	O
pathogenesis	O
of	O
autism	Condition
.	Condition

Open-label	O
reports	O
suggest	O
that	O
the	O
serotonin2A-dopamine	O
D2	O
antagonist	O
risperidone	O
may	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
interfering	O
symptoms	O
of	O
patients	O
with	O
autism	Condition
.	O

METHODS	O
Thirty-one	SampleSize
adults	Age
(	O
age	O
[	O
mean+/-SD	O
]	O
,	O
28.1+/-7.3	O
years	O
)	O
with	O
autistic	Condition
disorder	Condition
(	O
n=17	O
)	O
or	O
pervasive	O
developmental	O
disorder	O
not	O
otherwise	O
specified	O
(	O
n=14	SampleSize
)	O
participated	O
in	O
a	O
12-week	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
risperidone	O
.	O

Patients	O
treated	O
with	O
placebo	O
subsequently	O
received	O
a	O
12-week	O
open-label	O
trial	O
of	O
risperidone	O
.	O

RESULTS	O
For	O
persons	O
completing	O
the	O
study	O
,	O
8	O
(	O
57	O
%	O
)	O
of	O
14	O
patients	O
treated	O
with	O
risperidone	O
were	O
categorized	O
as	O
responders	O
(	O
daily	O
dose	O
[	O
mean+/-SD	O
]	O
,	O
2.9+/-1.4	O
mg	O
)	O
compared	O
with	O
none	O
of	O
16	O
in	O
the	O
placebo	O
group	O
(	O
P	O
<	O
.002	O
)	O
.	O

Risperidone	O
was	O
superior	O
to	O
placebo	O
in	O
reducing	O
repetitive	O
behavior	O
(	O
P	O
<	O
.001	O
)	O
,	O
aggression	O
(	O
P	O
<	O
.001	O
)	O
,	O
anxiety	O
or	O
nervousness	O
(	O
P	O
<	O
.02	O
)	O
,	O
depression	O
(	O
P	O
<	O
.03	O
)	O
,	O
irritability	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
the	O
overall	O
behavioral	O
symptoms	O
of	O
autism	O
(	O
P	O
<	O
.02	O
)	O
.	O

Objective	O
,	O
measurable	O
change	O
in	O
social	O
behavior	O
and	O
language	O
did	O
not	O
occur	O
.	O

Nine	O
(	O
60	O
%	O
)	O
of	O
15	O
patients	O
who	O
received	O
treatment	O
with	O
open-label	O
risperidone	O
following	O
the	O
double-blind	O
placebo	O
phase	O
responded	O
.	O

Other	O
than	O
mild	O
,	O
transient	O
sedation	O
,	O
risperidone	O
was	O
well	O
tolerated	O
,	O
with	O
no	O
evidence	O
of	O
extrapyramidal	O
effects	O
,	O
cardiac	O
events	O
,	O
or	O
seizures	O
.	O

CONCLUSION	O
Risperidone	O
is	O
more	O
effective	O
than	O
placebo	O
in	O
the	O
short-term	O
treatment	O
of	O
symptoms	O
of	O
autism	Condition
in	O
adults	Age
.	O

A	O
double-blind	O
,	O
randomized	O
,	O
controlled	O
,	O
multicenter	O
safety	O
and	O
immunogenicity	O
study	O
of	O
a	O
refrigerator-stable	O
formulation	O
of	O
Zostavax	O
.	O

The	O
vaccine	O
Zostavax	O
has	O
been	O
shown	O
to	O
prevent	O
herpes	O
zoster	O
(	O
HZ	O
)	O
and	O
postherpetic	O
neuralgia	O
and	O
is	O
recommended	O
for	O
individuals	O
>	O
or	O
=60	O
years	O
of	O
age	O
.	O

This	O
study	O
compared	O
the	O
safety	O
and	O
the	O
immunogenicity	O
of	O
a	O
refrigerator-stable	O
formulation	O
(	O
Zostavax	O
refrigerated	O
)	O
with	O
those	O
of	O
the	O
current	O
formulation	O
(	O
Zostavax	O
frozen	O
)	O
in	O
subjects	O
>	O
or	O
=50	O
years	O
of	O
age	O
.	O

Subjects	O
with	O
a	O
negative	O
history	O
for	O
HZ	O
were	O
randomized	O
1:1	O
to	O
receive	O
one	O
dose	O
of	O
either	O
formulation	O
.	O

Enrollment	O
was	O
stratified	O
1:2	O
by	O
age	O
(	O
50	O
to	O
59	O
years	O
and	O
>	O
or	O
=60	O
years	O
)	O
.	O

Safety	O
was	O
evaluated	O
for	O
28	O
days	O
postvaccination	O
.	O

Varicella-zoster	O
virus	O
(	O
VZV	O
)	O
antibody	O
responses	O
were	O
measured	O
by	O
a	O
glycoprotein	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
gpELISA	O
)	O
.	O

The	O
primary	O
endpoints	O
were	O
the	O
VZV	O
antibody	O
geometric	O
mean	O
titer	O
(	O
GMT	O
;	O
day	O
28	O
)	O
,	O
the	O
VZV	O
antibody	O
geometric	O
mean	O
rise	O
(	O
GMR	O
;	O
days	O
1	O
to	O
28	O
)	O
,	O
and	O
the	O
incidence	O
of	O
vaccine-related	O
serious	O
adverse	O
experiences	O
(	O
AEs	O
)	O
over	O
28	O
days	O
.	O

The	O
refrigerated	O
(	O
n	O
=	O
182	O
)	O
and	O
frozen	O
(	O
n	O
=	O
185	O
)	O
formulations	O
induced	O
similar	O
GMTs	O
(	O
727.4	O
and	O
834.4	O
gpELISA	O
units/ml	O
,	O
respectively	O
)	O
;	O
the	O
estimated	O
GMT	O
ratio	O
(	O
refrigerated	O
formulation/frozen	O
formulation	O
)	O
was	O
0.87	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.71	O
to	O
1.07	O
)	O
.	O

The	O
GMRs	O
were	O
2.6-	O
and	O
2.9-fold	O
,	O
respectively	O
.	O

No	O
vaccine-related	O
serious	O
AEs	O
were	O
reported	O
in	O
either	O
group	O
,	O
and	O
the	O
safety	O
profiles	O
of	O
the	O
formulations	O
were	O
generally	O
similar	O
.	O

The	O
frequencies	O
of	O
injection-site	O
AEs	O
during	O
follow-up	O
were	O
35.6	O
%	O
and	O
46.4	O
%	O
in	O
the	O
refrigerated	O
and	O
the	O
frozen	O
formulation	O
groups	O
,	O
respectively	O
,	O
and	O
were	O
generally	O
mild	O
.	O

The	O
frequencies	O
of	O
systemic	O
AEs	O
were	O
similar	O
in	O
the	O
two	O
groups	O
,	O
and	O
those	O
of	O
vaccine-related	O
AEs	O
were	O
approximately	O
6	O
%	O
in	O
both	O
groups	O
.	O

The	O
refrigerator-stable	O
formulation	O
of	O
Zostavax	O
has	O
an	O
acceptable	O
safety	O
profile	O
and	O
is	O
as	O
immunogenic	O
as	O
the	O
frozen	O
formulation	O
;	O
thus	O
,	O
the	O
vaccine	O
may	O
be	O
used	O
in	O
clinical	O
settings	O
where	O
freezer	O
availability	O
is	O
limited	O
.	O

Clinical	O
and	O
microbial	O
evaluation	O
of	O
a	O
histatin-containing	O
mouthrinse	O
in	O
humans	O
with	O
experimental	O
gingivitis	O
.	O

OBJECTIVE	O
P-113	O
,	O
a	O
12	O
amino	O
acid	O
histatin-based	O
peptide	O
,	O
was	O
evaluated	O
in	O
a	O
mouthrinse	O
formulation	O
for	O
safety	O
,	O
prevention	O
of	O
the	O
development	O
of	O
experimental	O
gingivitis	O
,	O
and	O
for	O
its	O
effects	O
on	O
periodontal	O
flora	O
.	O

METHOD	O
159	O
periodontally	O
healthy	O
subjects	O
abstained	O
from	O
oral	O
hygiene	O
procedures	O
and	O
self-administered	O
either	O
0.005	O
%	O
,	O
0.01	O
%	O
,	O
0.05	O
%	O
P-113	O
or	O
placebo	O
mouthrinse	O
formulations	O
twice	O
daily	O
over	O
a	O
four	O
week	O
treatment	O
period	O
.	O

During	O
this	O
time	O
,	O
the	O
safety	O
,	O
anti-plaque	O
,	O
and	O
anti-gingivitis	O
effects	O
of	O
P-113	O
were	O
evaluated	O
.	O

RESULTS	O
There	O
was	O
a	O
significant	O
reduction	O
in	O
plaque	O
(	O
p=0.046	O
)	O
and	O
a	O
reduction	O
in	O
gingivitis	O
(	O
p=0.086	O
)	O
for	O
subjects	O
using	O
0.01	O
%	O
P-113	O
mouthrinse	O
.	O

Significantly	O
more	O
subjects	O
in	O
the	O
0.01	O
%	O
and	O
0.05	O
%	O
treatment	O
groups	O
showed	O
a	O
small	O
increase	O
in	O
plaque	O
index	O
of	O
<	O
0.25	O
as	O
compared	O
to	O
the	O
placebo	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Similar	O
trends	O
were	O
noted	O
for	O
changes	O
in	O
the	O
%	O
of	O
sites	O
with	O
bleeding	O
on	O
probing	O
in	O
the	O
0.01	O
%	O
P-113	O
group	O
.	O

There	O
were	O
no	O
treatment-related	O
adverse	O
events	O
,	O
and	O
there	O
were	O
no	O
adverse	O
shifts	O
in	O
supragingival	O
microflora	O
during	O
the	O
study	O
.	O

CONCLUSION	O
These	O
data	O
suggest	O
that	O
P-113	O
mouthrinse	O
is	O
safe	O
and	O
reduces	O
plaque	O
,	O
gingivitis	O
and	O
gingival	O
bleeding	O
in	O
the	O
human	O
experimental	O
gingivitis	O
model	O
.	O

Unpacking	O
attitude	O
certainty	O
:	O
attitude	O
clarity	O
and	O
attitude	O
correctness	O
.	O

Attitude	O
certainty	O
has	O
been	O
the	O
subject	O
of	O
considerable	O
attention	O
in	O
the	O
attitudes	O
and	O
persuasion	O
literature	O
.	O

The	O
present	O
research	O
identifies	O
2	O
aspects	O
of	O
attitude	O
certainty	O
and	O
provides	O
evidence	O
for	O
the	O
distinctness	O
of	O
the	O
constructs	O
.	O

Specifically	O
,	O
it	O
is	O
proposed	O
that	O
attitude	O
certainty	O
can	O
be	O
conceptualized	O
,	O
and	O
empirically	O
separated	O
,	O
in	O
terms	O
of	O
attitude	O
clarity	O
(	O
the	O
subjective	O
sense	O
that	O
one	O
knows	O
what	O
one	O
's	O
attitude	O
is	O
)	O
and	O
attitude	O
correctness	O
(	O
the	O
subjective	O
sense	O
that	O
one	O
's	O
attitude	O
is	O
correct	O
or	O
valid	O
)	O
.	O

Experiment	O
1	O
uses	O
factor	O
analysis	O
and	O
correlational	O
data	O
to	O
provide	O
evidence	O
for	O
viewing	O
attitude	O
clarity	O
and	O
attitude	O
correctness	O
as	O
separate	O
constructs	O
.	O

Experiments	O
2	O
and	O
3	O
demonstrate	O
that	O
attitude	O
clarity	O
and	O
attitude	O
correctness	O
can	O
have	O
distinct	O
antecedents	O
(	O
repeated	O
expression	O
and	O
consensus	O
feedback	O
,	O
respectively	O
)	O
.	O

Experiment	O
4	O
reveals	O
that	O
these	O
constructs	O
each	O
play	O
an	O
independent	O
role	O
in	O
persuasion	O
and	O
resistance	O
situations	O
.	O

As	O
clarity	O
and	O
correctness	O
increase	O
,	O
attitudes	O
become	O
more	O
resistant	O
to	O
counterattitudinal	O
persuasive	O
messages	O
.	O

These	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
existing	O
attitude	O
strength	O
literature	O
.	O

[	O
A	O
comparison	O
of	O
2	O
methods	O
of	O
plastic	O
cast	O
fixation	O
in	O
treatment	O
of	O
loco	Condition
classico	Condition
radius	Condition
fracture	Condition
.	Condition

A	O
prospective	O
,	O
randomized	O
study	O
]	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
functional	O
and	O
radiological	O
result	O
of	O
two	O
different	O
positions	O
of	O
the	O
wrist	O
in	O
a	O
plaster	O
cast	O
following	O
Colles	O
'	O
fracture	O
.	O

For	O
this	O
prospective	O
study	O
,	O
each	O
of	O
50	O
patients	O
with	O
type	O
A	O
2.2	O
,	O
A	O
3.3	O
,	O
C	O
1.2	O
or	O
C	O
2.2	O
(	O
AO	O
classification	O
)	O
fractures	O
of	O
the	O
radius	O
was	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
.	O

Both	O
groups	O
were	O
treated	O
in	O
the	O
same	O
way	O
as	O
far	O
as	O
anaesthesia	O
and	O
reduction	O
were	O
concerned	O
.	O

The	O
only	O
difference	O
in	O
treatment	O
lay	O
in	O
the	O
position	O
of	O
fixation	O
in	O
plaster	O
.	O

In	O
group	O
1	O
the	O
wrist	O
was	O
immobilized	O
in	O
neutral	O
flexion-extension	O
.	O

In	O
group	O
2	O
the	O
wrist	O
was	O
dorsiflexed	O
20	O
degrees	O
,	O
while	O
the	O
carpus	O
was	O
pushed	O
in	O
a	O
volar	O
direction	O
by	O
an	O
impression	O
in	O
the	O
plaster	O
cast	O
.	O

At	O
review	O
2-7	O
years	O
after	O
the	O
accidents	O
,	O
the	O
two	O
groups	O
were	O
compared	O
with	O
reference	O
to	O
symptoms	O
,	O
range	O
of	O
motion	O
at	O
the	O
wrist	O
,	O
power	O
of	O
first	O
closure	O
and	O
radiographic	O
appearance	O
.	O

In	O
group	O
1	O
there	O
were	O
5	O
patients	O
with	O
significant	O
disability	O
,	O
compared	O
with	O
only	O
1	O
in	O
group	O
2	O
.	O

A	O
significant	O
difference	O
was	O
found	O
in	O
the	O
range	O
of	O
movement	O
between	O
the	O
two	O
groups	O
for	O
flexion	O
and	O
ulnar	O
abduction	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
loss	O
of	O
power	O
of	O
first	O
clenching	O
(	O
difference	O
between	O
injured	O
and	O
healthy	O
hand	O
)	O
was	O
6.2	O
mmHg	O
for	O
group	O
1	O
and	O
3.8	O
mmHg	O
for	O
group	O
2	O
(	O
not	O
significant	O
)	O
.	O

The	O
radiographic	O
examination	O
showed	O
significant	O
differences	O
both	O
in	O
sagittal	O
inclination	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
radial	O
shortening	O
(	O
p	O
<	O
0.05	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Comparison	O
of	O
chemotherapy	O
with	O
chemohormonal	O
therapy	O
as	O
first-line	O
therapy	O
for	O
metastatic	Condition
,	Condition
hormone-sensitive	Condition
breast	Condition
cancer	Condition
:	O
An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
.	O

PURPOSE	O
Although	O
hormonal	O
therapy	O
represents	O
standard	O
therapy	O
for	O
metastatic	O
hormone-sensitive	O
disease	O
,	O
many	O
patients	O
receive	O
initial	O
chemotherapy	O
because	O
of	O
the	O
location	O
,	O
bulk	O
,	O
or	O
aggressiveness	O
of	O
their	O
disease	O
.	O

It	O
is	O
uncertain	O
whether	O
simultaneous	O
hormonal	O
therapy	O
provides	O
additional	O
benefit	O
compared	O
with	O
chemotherapy	O
alone	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
trial	O
E3186	O
was	O
initiated	O
to	O
explore	O
this	O
question	O
.	O

PATIENTS	O
AND	O
METHODS	O
Between	O
January	O
1988	O
and	O
December	O
1992	O
,	O
231	SampleSize
patients	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-positive	O
or	O
ER-unknown	O
metastatic	O
breast	O
cancer	O
were	O
randomized	O
to	O
receive	O
either	O
chemotherapy	O
(	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
fluorouracil	O
?CAF	O
)	O
or	O
chemohormonal	O
therapy	O
(	O
CAF	O
plus	O
tamoxifen	O
and	O
Halotestin	O
?fluoxymesterone	O
;	O
Pharmacia-Upjohn	O
,	O
Kalamazoo	O
,	O
MI	O
?CAFTH	O
)	O
as	O
front-line	O
therapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O

Patients	O
who	O
experienced	O
a	O
complete	O
response	O
to	O
induction	O
therapy	O
either	O
received	O
or	O
did	O
not	O
receive	O
maintenance	O
cyclophosphamide	O
,	O
methotrexate	O
,	O
fluorouracil	O
,	O
prednisone	O
,	O
and	O
TH	O
as	O
a	O
secondary	O
randomization	O
.	O

RESULTS	O
The	O
response	O
rates	O
(	O
complete	O
response	O
and	O
partial	O
response	O
)	O
of	O
patients	O
who	O
received	O
CAF	O
and	O
CAFTH	O
were	O
similar	O
(	O
69.2	O
%	O
v	O
68.9	O
%	O
,	O
respectively	O
;	O
P	O
=.99	O
)	O
.	O

Time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
was	O
slightly	O
longer	O
for	O
patients	O
who	O
received	O
chemohormonal	O
therapy	O
compared	O
with	O
chemotherapy	O
alone	O
patients	O
(	O
13.4	O
months	O
v	O
10.3	O
months	O
,	O
respectively	O
;	O
P	O
=.087	O
)	O
,	O
and	O
TTF	O
was	O
significantly	O
longer	O
in	O
ER-positive	O
compared	O
with	O
ER-negative	O
patients	O
(	O
17.4	O
months	O
v	O
10.3	O
months	O
,	O
respectively	O
;	O
P	O
=.048	O
)	O
.	O

However	O
,	O
ER	O
status	O
had	O
no	O
effect	O
on	O
overall	O
survival	O
(	O
30.0	O
months	O
for	O
CAF	O
v	O
29.3	O
months	O
for	O
CAFTH	O
)	O
.	O

CONCLUSION	O
In	O
patients	O
with	O
potentially	O
hormone-sensitive	O
metastatic	O
breast	O
cancer	O
,	O
chemohormonal	O
therapy	O
prolongs	O
TTF	O
for	O
ER-positive	O
patients	O
without	O
improving	O
overall	O
survival	O
.	O

[	O
Antazoline/tetryzoline	O
eyedrops	O
in	O
comparison	O
with	O
levocabastine	O
eyedrops	O
in	O
acute	O
allergic	Condition
conjunctivitis	Condition
]	O
.	O

BACKGROUND	O
Allergic	Condition
conjunctivitis	Condition
is	O
one	O
of	O
the	O
most	O
frequent	O
allergic	O
diseases	O
of	O
the	O
anterior	O
eye	O
segment	O
.	O

METHODS	O
This	O
multicentre	O
,	O
clinical	O
trial	O
was	O
an	O
investigation	O
to	O
compare	O
the	O
antiallergic	O
efficacy	O
,	O
local	O
tolerance	O
and	O
safety	O
of	O
Antazolin/Tetryzolin	O
eye	O
drops	O
and	O
Levocabastine	O
eye	O
drops	O
.	O

69	SampleSize
patients	O
were	O
treated	O
over	O
a	O
2	O
weeks	O
course	O
of	O
therapy	O
.	O

The	O
subjective	O
and	O
objective	O
ocular	O
symptoms	O
were	O
documented	O
over	O
the	O
treatment	O
period	O
.	O

RESULTS	O
Both	O
eye	O
drops	O
reduced	O
subjective	O
and	O
objective	O
ocular	O
symptoms	O
effective	O
.	O

The	O
difference	O
between	O
the	O
treatments	O
(	O
p	O
=	O
0.0395	O
)	O
was	O
the	O
faster	O
onset	O
of	O
action	O
of	O
Antazolin/Tetryzolin	O
30	O
minutes	O
after	O
administration	O
of	O
the	O
first	O
drop	O
of	O
trial	O
medication	O
.	O

CONCLUSION	O
A	O
fast	O
and	O
effective	O
onset	O
of	O
action	O
is	O
of	O
high	O
clinical	O
relevance	O
.	O

Therefore	O
the	O
benefits	O
of	O
using	O
Antazolin/Tetryzolin	O
eye	O
drops	O
was	O
clearly	O
outweigh	O
.	O

Effects	O
of	O
an	O
Internet-based	O
intervention	O
on	O
plasma	O
glucose	O
levels	O
in	O
patients	O
with	O
type	Condition
2	Condition
diabetes	Condition
.	O

This	O
study	O
applied	O
a	O
12-week	O
educational	O
intervention	O
that	O
used	O
both	O
the	O
cellular	O
phone	O
and	O
the	O
Internet	O
to	O
send	O
short	O
message	O
service	O
.	O

Forty-two	SampleSize
diabetic	Condition
patients	O
were	O
asked	O
to	O
access	O
a	O
Web	O
site	O
by	O
using	O
a	O
cellular	O
phone	O
or	O
wire	O
Internet	O
and	O
input	O
their	O
blood	O
glucose	O
levels	O
every	O
day	O
.	O

Patients	O
were	O
sent	O
the	O
optimal	O
recommendations	O
by	O
both	O
the	O
cellular	O
phone	O
and	O
the	O
Internet	O
.	O

After	O
12	O
weeks	O
,	O
the	O
patients	O
had	O
a	O
mean	O
decrease	O
of	O
28.6	O
mg/dL	O
in	O
fasting	O
plasma	O
glucose	O
and	O
78.4	O
mg/dL	O
in	O
2-hour	O
postprandial	O
blood	O
sugar	O
levels	O
and	O
a	O
mean	O
increase	O
in	O
the	O
care	O
satisfaction	O
score	O
.	O

Serotonergic	O
control	O
of	O
TSH	O
and	O
PRL	O
secretion	O
in	O
obese	Condition
men	Sex
.	O

To	O
evaluate	O
whether	O
the	O
inhibitory	O
control	O
of	O
TSH	O
and	O
the	O
stimulatory	O
control	O
of	O
prolactin	O
(	O
PRL	O
)	O
secretion	O
exerted	O
by	O
endogenous	O
serotonin	O
was	O
altered	O
in	O
obesity	O
,	O
22	SampleSize
obese	Condition
men	Sex
and	O
10	SampleSize
normal	Condition
controls	O
were	O
tested	O
with	O
TRH	O
(	O
200	O
micrograms	O
IV	O
bolus	O
)	O
in	O
the	O
presence	O
(	O
experimental	O
test	O
)	O
and	O
absence	O
(	O
control	O
test	O
)	O
of	O
the	O
serotonergic	O
agonist	O
fenfluramine	O
(	O
60	O
mg	O
PO	O
90	O
min	O
before	O
TRH	O
)	O
.	O

Control	O
and	O
experimental	O
tests	O
were	O
also	O
performed	O
in	O
seven	O
male	O
patients	O
with	O
subclinical	Condition
hypothyroidism	Condition
and	O
were	O
repeated	O
in	O
the	O
same	O
obese	Condition
subjects	O
after	O
substantial	O
weight	O
loss	O
.	O

Basal	O
TSH	O
levels	O
were	O
similar	O
in	O
control	O
and	O
obese	Condition
men	O
.	O

Normal	O
TSH	O
responses	O
to	O
TRH	O
(	O
peak	O
less	O
than	O
or	O
equal	O
to	O
14	O
mU/L	O
)	O
were	O
observed	O
in	O
all	O
normal	O
controls	O
(	O
mean	O
peak	O
+/-	O
SE	O
9.8	O
+/-	O
0.6	O
mU/L	O
)	O
.	O

In	O
contrast	O
,	O
obese	Condition
men	O
were	O
divided	O
into	O
two	O
groups	O
:	O
nine	O
in	O
whom	O
the	O
TRH-induced	O
TSH	O
rise	O
was	O
higher	O
than	O
normal	O
(	O
group	O
I	O
:	O
mean	O
peak	O
=	O
16.5	O
+/-	O
0.5	O
mU/L	O
)	O
and	O
13	O
in	O
whom	O
it	O
was	O
normal	O
(	O
group	O
II	O
:	O
mean	O
peak	O
=	O
10.6	O
+/-	O
0.7	O
mU/L	O
)	O
.	O

The	O
hypothyroid	Condition
men	O
all	O
had	O
elevated	O
basal	O
and	O
TRH-stimulated	O
TSH	O
levels	O
.	O

Basal	O
PRL	O
concentrations	O
were	O
similar	O
in	O
the	O
normal	O
controls	O
and	O
both	O
groups	O
of	O
obese	Condition
subjects	O
.	O

The	O
PRL	O
response	O
to	O
TRH	O
was	O
lower	O
in	O
both	O
group	O
I	O
and	O
group	O
II	O
obese	O
men	O
than	O
in	O
normal	O
controls	O
and	O
was	O
similar	O
between	O
group	O
I	O
and	O
group	O
II	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Intra-luminal	O
nicotine	O
reduces	O
smooth	O
muscle	O
tone	O
and	O
contractile	O
activity	O
in	O
the	O
distal	O
large	O
bowel	O
.	O

BACKGROUND	O
Nicotine	O
may	O
be	O
of	O
therapeutic	O
value	O
in	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
,	O
although	O
its	O
mechanism	O
of	O
action	O
has	O
not	O
been	O
established	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
effect	O
of	O
a	O
solution	O
of	O
nicotine	O
on	O
sustained	O
resting	O
pressure	O
(	O
tone	O
)	O
and	O
contractile	O
activity	O
in	O
the	O
human	O
colon	O
.	O

METHODS	O
Ten	O
healthy	O
volunteers	O
,	O
and	O
seven	O
with	O
UC	O
in	O
symptomatic	O
remission	O
took	O
part	O
;	O
all	O
were	O
non-smokers	O
.	O

All	O
17	O
subjects	O
were	O
given	O
nicotine	O
or	O
placebo	O
solution	O
on	O
two	O
separate	O
occasions	O
in	O
a	O
randomized	O
sequence	O
.	O

A	O
water-perfused	O
manometry	O
catheter	O
,	O
with	O
openings	O
at	O
5	O
,	O
10	O
and	O
15	O
cm	O
from	O
the	O
tip	O
,	O
was	O
placed	O
by	O
rigid	O
sigmoidoscopy	O
in	O
the	O
recto-sigmoid	O
region	O
.	O

Baseline	O
tone	O
and	O
activity	O
were	O
measured	O
for	O
15	O
min	O
prior	O
to	O
instillation	O
of	O
20	O
ml	O
of	O
saline	O
alone	O
or	O
with	O
nicotine	O
,	O
1.2	O
mg	O
,	O
at	O
pH	O
4.5	O
.	O

Observations	O
were	O
made	O
over	O
the	O
subsequent	O
15-20	O
min	O
.	O

RESULTS	O
Baseline	O
spontaneous	O
activity	O
in	O
all	O
subjects	O
showed	O
both	O
high-	O
and	O
low-frequency	O
components	O
;	O
in	O
three	O
patients	O
with	O
UC	O
,	O
the	O
low-frequency	O
activity	O
was	O
of	O
high	O
amplitude	O
.	O

The	O
nicotine	O
reduced	O
both	O
tone	O
and	O
activity	O
in	O
all	O
subjects	O
,	O
with	O
reduction	O
or	O
abolition	O
of	O
the	O
large	O
contractions	O
in	O
UC	O
.	O

Tone	O
in	O
all	O
17	O
subjects	O
was	O
reduced	O
significantly	O
at	O
3	O
min	O
after	O
nicotine	O
(	O
P	O
=	O
0.000015	O
,	O
sign	O
test	O
)	O
;	O
the	O
rate	O
of	O
recovery	O
varied	O
in	O
individuals	O
.	O

Results	O
from	O
normals	O
and	O
UC	O
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
.	O

No	O
significant	O
change	O
in	O
tone	O
or	O
activity	O
was	O
observed	O
with	O
the	O
saline	O
solution	O
.	O

CONCLUSION	O
Intra-luminal	O
nicotine	O
significantly	O
reduces	O
both	O
smooth	O
muscle	O
tone	O
and	O
contractile	O
activity	O
in	O
the	O
recto-sigmoid	O
colon	O
in	O
both	O
normal	O
subjects	O
and	O
patients	O
with	O
UC	O
.	O

Rett	O
syndrome	O
:	O
randomized	O
controlled	O
trial	O
of	O
L-carnitine	O
.	O

Rett	O
syndrome	O
is	O
a	O
severe	O
neurodevelopmental	O
disorder	O
of	O
unknown	O
etiology	O
,	O
occurring	O
almost	O
exclusively	O
in	O
female	O
patients	O
.	O

The	O
etiology	O
and	O
functional	O
significance	O
of	O
plasma	O
carnitine	O
deficiency	O
seen	O
in	O
some	O
patients	O
with	O
Rett	O
syndrome	O
is	O
unknown	O
.	O

To	O
investigate	O
whether	O
L-carnitine	O
might	O
be	O
of	O
benefit	O
in	O
Rett	O
syndrome	O
,	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
crossover	O
trial	O
of	O
L-carnitine	O
has	O
been	O
completed	O
in	O
35	O
subjects	O
.	O

Eight-week	O
treatment	O
phases	O
were	O
completed	O
for	O
both	O
a	O
placebo	O
and	O
L-carnitine	O
.	O

Outcome	O
was	O
measured	O
by	O
parents/caregivers	O
and	O
at	O
medical	O
follow-up	O
using	O
three	O
established	O
tools	O
:	O
the	O
Rett	O
Syndrome	O
Motor	O
Behavioral	O
Assessment	O
,	O
the	O
Hand	O
Apraxia	O
Scale	O
,	O
and	O
the	O
Patient	O
Well-Being	O
Index	O
.	O

Analysis	O
comparing	O
change	O
between	O
baseline	O
and	O
week	O
8	O
of	O
treatment	O
for	O
L-carnitine	O
and	O
the	O
placebo	O
showed	O
that	O
both	O
parents/caregivers	O
and	O
medical	O
follow-up	O
detected	O
improvements	O
in	O
the	O
subjects	O
'	O
well-being	O
.	O

In	O
addition	O
,	O
medical	O
review	O
showed	O
an	O
improvement	O
on	O
the	O
Hand	O
Apraxia	O
Scale	O
for	O
a	O
higher	O
proportion	O
of	O
girls	O
on	O
L-carnitine	O
.	O

Identification	O
of	O
predictors	O
of	O
clinical	O
improvement	O
has	O
been	O
limited	O
by	O
the	O
power	O
of	O
the	O
study	O
.	O

These	O
findings	O
suggest	O
that	O
L-carnitine	O
is	O
of	O
benefit	O
in	O
some	O
patients	O
with	O
Rett	O
syndrome	O
.	O

While	O
L-carnitine	O
did	O
not	O
lead	O
to	O
major	O
functional	O
changes	O
in	O
ability	O
,	O
the	O
type	O
of	O
changes	O
reported	O
could	O
still	O
have	O
a	O
substantial	O
impact	O
on	O
the	O
girls	O
and	O
their	O
families	O
.	O

Information	O
is	O
still	O
needed	O
,	O
however	O
,	O
to	O
determine	O
if	O
only	O
subgroups	O
of	O
girls	O
with	O
the	O
disorder	O
are	O
responsive	O
to	O
L-carnitine	O
and	O
the	O
appropriate	O
duration	O
of	O
therapy	O
.	O

Comparison	O
of	O
tocainide	O
and	O
prajmalium	O
bitartrate	O
for	O
the	O
treatment	O
of	O
ventricular	Condition
arrhythmias	Condition
.	O

The	O
antiarrhythmic	O
efficacy	O
of	O
tocainide	O
,	O
a	O
new	O
antiarrhythmic	O
substance	O
,	O
has	O
been	O
compared	O
with	O
that	O
of	O
prajmalium	O
bitartrate	O
,	O
a	O
drug	O
in	O
clinical	O
use	O
for	O
many	O
years	O
in	O
the	O
German	O
speaking	O
countries	O
.	O

The	O
investigation	O
was	O
performed	O
as	O
a	O
double-blind	O
cross-over	O
study	O
in	O
20	SampleSize
patients	O
with	O
ventricular	Condition
arrhythmias	Condition
(	O
VA	Condition
)	O
of	O
various	O
origin	O
.	O

The	O
efficacy	O
was	O
assessed	O
by	O
serial	O
Holter	O
monitoring	O
.	O

Plasma	O
levels	O
were	O
measured	O
to	O
study	O
the	O
dose-effect	O
relationship	O
.	O

Applying	O
to	O
the	O
criterion	O
of	O
a	O
reduction	O
of	O
VA	O
of	O
more	O
than	O
75	O
%	O
or	O
an	O
improvement	O
according	O
to	O
the	O
Lown	O
grading	O
8	O
pts	O
.	O

under	O
tocainide	O
and	O
7	O
under	O
prajmalium	O
bitartrate	O
were	O
responders	O
.	O

Side	O
effects	O
were	O
few	O
and	O
under	O
tocainide	O
only	O
2	O
pts	O
.	O

had	O
to	O
discontinue	O
the	O
therapy	O
.	O

From	O
the	O
present	O
findings	O
tocainide	O
and	O
prajmalium	O
bitartrate	O
have	O
the	O
same	O
efficient	O
antiarrhythmic	O
effects	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Oral	O
sucrose	O
as	O
an	O
analgesic	O
drug	O
for	O
procedural	O
pain	O
in	O
newborn	O
infants	Age
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Many	O
infants	Age
admitted	O
to	O
hospital	O
undergo	O
repeated	O
invasive	O
procedures	O
.	O

Oral	O
sucrose	O
is	O
frequently	O
given	O
to	O
relieve	O
procedural	O
pain	O
in	O
neonates	Age
on	O
the	O
basis	O
of	O
its	O
effect	O
on	O
behavioural	O
and	O
physiological	O
pain	O
scores	O
.	O

We	O
assessed	O
whether	O
sucrose	O
administration	O
reduces	O
pain-specific	O
brain	O
and	O
spinal	O
cord	O
activity	O
after	O
an	O
acute	Condition
noxious	Condition
procedure	O
in	O
newborn	Condition
infants	Age
.	O

METHODS	O
In	O
this	O
double-blind	O
,	O
randomised	O
controlled	O
trial	O
,	O
59	O
newborn	Condition
infants	Age
at	O
University	O
College	O
Hospital	O
(	O
London	O
,	O
UK	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
0?5	O
mL	O
24	O
%	O
sucrose	O
solution	O
or	O
0?5	O
mL	O
sterile	O
water	O
2	O
min	O
before	O
undergoing	O
a	O
clinically	O
required	O
heel	O
lance	O
.	O

Randomisation	O
was	O
by	O
a	O
computer-generated	O
randomisation	O
code	O
,	O
and	O
researchers	O
,	O
clinicians	O
,	O
participants	O
,	O
and	O
parents	O
were	O
masked	O
to	O
the	O
identity	O
of	O
the	O
solutions	O
.	O

The	O
primary	O
outcome	O
was	O
pain-specific	O
brain	O
activity	O
evoked	O
by	O
one	O
time-locked	O
heel	O
lance	O
,	O
recorded	O
with	O
electroencephalography	O
and	O
identified	O
by	O
principal	O
component	O
analysis	O
.	O

Secondary	O
measures	O
were	O
baseline	O
behavioural	O
and	O
physiological	O
measures	O
,	O
observational	O
pain	O
scores	O
(	O
PIPP	O
)	O
,	O
and	O
spinal	O
nociceptive	O
reflex	O
withdrawal	O
activity	O
.	O

Data	O
were	O
analysed	O
per	O
protocol	O
.	O

This	O
study	O
is	O
registered	O
,	O
number	O
ISRCTN78390996	O
.	O

FINDINGS	O
29	O
infants	O
were	O
assigned	O
to	O
receive	O
sucrose	O
and	O
30	O
to	O
sterilised	O
water	O
;	O
20	O
and	O
24	O
infants	O
,	O
respectively	O
,	O
were	O
included	O
in	O
the	O
analysis	O
of	O
the	O
primary	O
outcome	O
measure	O
.	O

Nociceptive	O
brain	O
activity	O
after	O
the	O
noxious	O
heel	O
lance	O
did	O
not	O
differ	O
significantly	O
between	O
infants	O
who	O
received	O
sucrose	O
and	O
those	O
who	O
received	O
sterile	O
water	O
(	O
sucrose	O
:	O
mean	O
0?10	O
,	O
95	O
%	O
CI	O
0?04-0?16	O
;	O
sterile	O
water	O
:	O
mean	O
0?08	O
,	O
0?04-0?12	O
;	O
p=0?46	O
)	O
.	O

No	O
significant	O
difference	O
was	O
recorded	O
between	O
the	O
sucrose	O
and	O
sterile	O
water	O
groups	O
in	O
the	O
magnitude	O
or	O
latency	O
of	O
the	O
spinal	O
nociceptive	O
reflex	O
withdrawal	O
recorded	O
from	O
the	O
biceps	O
femoris	O
of	O
the	O
stimulated	O
leg	O
.	O

The	O
PIPP	O
score	O
was	O
significantly	O
lower	O
in	O
infants	O
given	O
sucrose	O
than	O
in	O
those	O
given	O
sterile	O
water	O
(	O
mean	O
5?8	O
,	O
95	O
%	O
CI	O
3?7-7?8	O
vs	O
8?5	O
,	O
7?3-9?8	O
;	O
p=0?02	O
)	O
and	O
significantly	O
more	O
infants	O
had	O
no	O
change	O
in	O
facial	O
expression	O
after	O
sucrose	O
administration	O
(	O
seven	O
of	O
20	O
[	O
35	O
%	O
]	O
vs	O
none	O
of	O
24	O
;	O
p	O
<	O
0?0001	O
)	O
.	O

INTERPRETATION	O
Our	O
data	O
suggest	O
that	O
oral	O
sucrose	O
does	O
not	O
significantly	O
affect	O
activity	O
in	O
neonatal	O
brain	O
or	O
spinal	O
cord	O
nociceptive	O
circuits	O
,	O
and	O
therefore	O
might	O
not	O
be	O
an	O
effective	O
analgesic	O
drug	O
.	O

The	O
ability	O
of	O
sucrose	O
to	O
reduce	O
clinical	O
observational	O
scores	O
after	O
noxious	O
events	O
in	O
newborn	O
infants	O
should	O
not	O
be	O
interpreted	O
as	O
pain	O
relief	O
.	O

FUNDING	O
Medical	O
Research	O
Council	O
.	O

Randomized	O
study	O
of	O
six	O
umbilical	O
cord	O
care	O
regimens	O
.	O

Comparing	O
length	O
of	O
attachment	O
,	O
microbial	O
control	O
,	O
and	O
satisfaction	O
.	O

Two	O
hundred	O
and	O
seventy	O
one	O
infants	O
were	O
enrolled	O
in	O
a	O
study	O
to	O
compare	O
six	O
different	O
methods	O
of	O
treating	O
the	O
umbilical	O
cord	O
.	O

Antimicrobial	O
control	O
was	O
equal	O
for	O
all	O
methods	O
.	O

Repeated	O
triple	O
dye	O
application	O
was	O
considered	O
least	O
acceptable	O
by	O
staff	O
and	O
parents	O
and	O
had	O
the	O
longest	O
attachment	O
time	O
.	O

Povidone-iodine	O
was	O
associated	O
with	O
the	O
shortest	O
attachment	O
time	O
and	O
was	O
most	O
liked	O
.	O

If	O
there	O
is	O
no	O
special	O
need	O
to	O
treat	O
a	O
specific	O
nosocomial	O
outbreak	O
,	O
duration	O
of	O
cord	O
attachment	O
and	O
satisfaction	O
of	O
staff	O
and	O
parents	O
can	O
help	O
clinicians	O
decide	O
on	O
a	O
cord	O
care	O
regimen	O
.	O

A	O
comparison	O
of	O
sclerotherapy	O
with	O
staple	O
transection	O
of	O
the	O
esophagus	O
for	O
the	O
emergency	O
control	O
of	O
bleeding	Condition
from	Condition
esophageal	Condition
varices	Condition
.	O

We	O
compared	O
two	O
procedures	O
for	O
the	O
emergency	O
treatment	O
of	O
bleeding	Condition
esophageal	Condition
varices	Condition
in	Condition
patients	Condition
who	Condition
did	Condition
not	Condition
respond	Condition
to	Condition
blood	Condition
transfusion	Condition
and	Condition
vasoactive	Condition
drugs	Condition
.	O

We	O
randomly	O
assigned	O
101	O
patients	O
with	Condition
cirrhosis	Condition
of	Condition
the	Condition
liver	Condition
and	Condition
bleeding	Condition
esophageal	Condition
varices	Condition
to	O
undergo	O
either	O
emergency	O
sclerotherapy	O
(	O
n	O
=	O
50	O
)	O
or	O
staple	O
transection	O
of	O
the	O
esophagus	O
(	O
n	O
=	O
51	O
)	O
.	O

Four	O
patients	O
assigned	O
to	O
sclerotherapy	O
and	O
12	O
assigned	O
to	O
staple	O
transection	O
did	O
not	O
actually	O
undergo	O
those	O
procedures	O
,	O
but	O
all	O
analyses	O
were	O
made	O
on	O
an	O
intention-to-treat	O
basis	O
.	O

Total	O
mortality	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
;	O
the	O
relative	O
risk	O
of	O
death	O
for	O
staple	O
transection	O
as	O
compared	O
with	O
sclerotherapy	O
was	O
0.88	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.51	O
to	O
1.54	O
)	O
.	O

Mortality	O
at	O
six	O
weeks	O
was	O
44	O
percent	O
among	O
those	O
assigned	O
to	O
sclerotherapy	O
and	O
35	O
percent	O
among	O
those	O
assigned	O
to	O
staple	O
transection	O
.	O

Complication	O
rates	O
were	O
similar	O
for	O
the	O
two	O
groups	O
.	O

An	O
interval	O
of	O
five	O
days	O
without	O
bleeding	O
was	O
achieved	O
in	O
88	O
percent	O
of	O
those	O
assigned	O
to	O
staple	O
transection	O
and	O
in	O
62	O
percent	O
of	O
those	O
assigned	O
to	O
sclerotherapy	O
after	O
a	O
single	O
injection	O
(	O
P	O
less	O
than	O
0.01	O
)	O
and	O
82	O
percent	O
after	O
three	O
injections	O
.	O

In	O
only	O
2	O
of	O
the	O
11	O
patients	O
who	O
received	O
a	O
third	O
sclerotherapy	O
injection	O
was	O
bleeding	O
controlled	O
for	O
more	O
than	O
five	O
days	O
,	O
and	O
9	O
died	O
.	O

We	O
conclude	O
that	O
staple	O
transection	O
of	O
the	O
esophagus	O
is	O
as	O
safe	O
as	O
sclerotherapy	O
for	O
the	O
emergency	O
treatment	O
of	O
bleeding	O
esophageal	O
varices	O
and	O
that	O
it	O
is	O
more	O
effective	O
than	O
a	O
single	O
sclerotherapy	O
procedure	O
.	O

We	O
currently	O
recommend	O
surgery	O
after	O
two	O
injection	O
treatments	O
have	O
failed	O
.	O

Efficacy	O
and	O
safety	O
of	O
bexarotene	O
combined	O
with	O
psoralen-ultraviolet	O
A	O
(	O
PUVA	O
)	O
compared	O
with	O
PUVA	O
treatment	O
alone	O
in	O
stage	O
IB-IIA	O
mycosis	O
fungoides	O
:	O
final	O
results	O
from	O
the	O
EORTC	O
Cutaneous	Condition
Lymphoma	Condition
Task	O
Force	O
phase	O
III	O
randomized	O
clinical	O
trial	O
(	O
NCT00056056	O
)	O
.	O

BACKGROUND	O
Psoralen	O
plus	O
ultraviolet	O
A	O
(	O
PUVA	O
)	O
is	O
the	O
standard	O
treatment	O
for	O
early	O
stages	O
of	O
mycosis	Condition
fungoides	Condition
.	O

There	O
have	O
been	O
no	O
adequate	O
randomized	O
controlled	O
trials	O
with	O
sufficient	O
power	O
comparing	O
this	O
modality	O
with	O
other	O
therapies	O
.	O

OBJECTIVE	O
To	O
assess	O
disease	O
response	O
and	O
to	O
compare	O
the	O
response	O
rates	O
of	O
patients	O
treated	O
with	O
PUVA	O
alone	O
or	O
PUVA	O
and	O
bexarotene	O
.	O

METHODS	O
EORTC	O
21011	O
(	O
NCT	O
00056056	O
)	O
was	O
a	O
randomized	O
phase	O
III	O
study	O
comparing	O
combined	O
bexarotene	O
(	O
Targretin	O
(	O
?	O
)	O
)	O
and	O
PUVA	O
vs.	O
PUVA	O
alone	O
in	O
patients	O
with	O
stage	O
IB	O
and	O
IIA	O
mycosis	O
fungoides	O
(	O
MF	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
overall	O
response	O
rate	O
[	O
complete	O
clinical	O
response	O
(	O
CCR	O
)	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
]	O
.	O

RESULTS	O
The	O
study	O
was	O
prematurely	O
closed	O
due	O
to	O
low	O
accrual	O
after	O
93	O
of	O
145	O
required	O
patients	O
(	O
65	O
%	O
)	O
were	O
randomized	O
.	O

Of	O
the	O
93	O
randomized	O
patients	O
,	O
87	O
started	O
treatment	O
,	O
41	O
received	O
PUVA	O
and	O
46	O
received	O
PUVA	O
+	O
bexarotene	O
.	O

Total	O
UVA	O
doses	O
received	O
were	O
107	O
J	O
cm	O
(	O
-2	O
)	O
(	O
range	O
1?4-489?9	O
)	O
in	O
the	O
PUVA	O
arm	O
vs.	O
101?7	O
J	O
cm	O
(	O
-2	O
)	O
(	O
0?2-529?9	O
)	O
in	O
the	O
combination	O
arm	O
.	O

The	O
safety	O
profile	O
was	O
acceptable	O
with	O
few	O
grade	O
3-4	O
toxicities	O
observed	O
in	O
either	O
arm	O
.	O

More	O
drop-outs	O
due	O
to	O
toxicity	O
were	O
observed	O
in	O
the	O
combination	O
arm	O
compared	O
with	O
the	O
PUVA-alone	O
arm	O
.	O

The	O
best	O
overall	O
response	O
(	O
CCR	O
+	O
PR	O
)	O
rate	O
was	O
71	O
%	O
for	O
PUVA	O
alone	O
and	O
77	O
%	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	O
0?57	O
)	O
.	O

The	O
median	O
duration	O
of	O
response	O
was	O
9?7	O
months	O
for	O
PUVA	O
vs.	O
5?8	O
months	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	O
0?33	O
)	O
.	O

CCR	O
was	O
seen	O
in	O
25	O
patients	O
of	O
whom	O
10	O
received	O
PUVA	O
alone	O
(	O
CCR	O
22	O
%	O
)	O
and	O
15	O
received	O
combination	O
therapy	O
(	O
CCR	O
31	O
%	O
)	O
(	O
P	O
=	O
0?45	O
)	O
.	O

CCR	O
was	O
sustained	O
in	O
25	O
%	O
of	O
patients	O
regardless	O
of	O
therapy	O
.	O

There	O
was	O
a	O
trend	O
towards	O
fewer	O
PUVA	O
sessions	O
needed	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
22	O
)	O
compared	O
with	O
the	O
PUVA	O
arm	O
(	O
median	O
27?5	O
)	O
(	O
P	O
=	O
0?11	O
)	O
.	O

Similarly	O
,	O
a	O
trend	O
towards	O
lower	O
UVA	O
dose	O
required	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
55?8	O
J	O
cm	O
(	O
-2	O
)	O
)	O
compared	O
with	O
the	O
PUVA	O
arm	O
alone	O
(	O
median	O
117?5	O
J	O
cm	O
(	O
-2	O
)	O
)	O
(	O
P	O
=	O
0?5	O
)	O
was	O
observed	O
.	O

CONCLUSIONS	O
No	O
significant	O
difference	O
in	O
response	O
rate	O
or	O
response	O
duration	O
was	O
observed	O
in	O
this	O
study	O
.	O

However	O
,	O
there	O
was	O
a	O
trend	O
towards	O
fewer	O
PUVA	O
sessions	O
and	O
lower	O
UVA	O
dose	O
required	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
PUVA	O
+	O
bexarotene	O
)	O
but	O
this	O
did	O
not	O
achieve	O
statistical	O
significance	O
due	O
to	O
insufficient	O
power	O
.	O

Cycle	O
control	O
with	O
oral	O
contraceptives	O
containing	O
20	O
micrograms	O
of	O
ethinyl	O
estradiol	O
.	O

A	O
multicenter	O
,	O
randomized	O
comparison	O
of	O
levonorgestrel/ethinyl	O
estradiol	O
(	O
100	O
micrograms/20	O
micrograms	O
)	O
and	O
norethindrone/ethinyl	O
estradiol	O
(	O
1000	O
micrograms/20	O
micrograms	O
)	O
.	O

A	O
randomized	O
,	O
open-label	O
,	O
multicenter	O
study	O
was	O
undertaken	O
to	O
compare	O
the	O
effects	O
of	O
oral	O
contraceptives	O
(	O
OC	O
)	O
containing	O
100	O
micrograms	O
levonorgestrel	O
(	O
LNG	O
)	O
/20	O
micrograms	O
ethinyl	O
estradiol	O
(	O
EE	O
)	O
(	O
Aless/Loette	O
)	O
and	O
1000	O
micrograms	O
norethindrone	O
acetate	O
(	O
NETA	O
)	O
/20	O
micrograms	O
EE	O
(	O
Loestrin	O
Fe	O
1/20	O
)	O
on	O
menstrual	O
cycle	O
control	O
over	O
four	O
cycles	O
of	O
use	O
.	O

A	O
total	O
of	O
84	O
evaluable	O
women	Sex
provided	O
274	O
cycles	O
of	O
exposure	O
in	O
the	O
LNG/EE	O
group	O
,	O
and	O
89	O
women	O
provided	O
289	O
cycles	O
of	O
exposure	O
in	O
the	O
NETA/EE	O
group	O
.	O

Overall	O
,	O
the	O
LNG/EE	O
group	O
achieved	O
a	O
consistently	O
higher	O
percentage	O
of	O
normal	O
menstrual	O
cycles	O
as	O
well	O
as	O
a	O
lower	O
rate	O
of	O
intermenstrual	O
bleeding	O
and	O
amenorrhea	O
than	O
the	O
NETA/EE	O
group	O
.	O

In	O
cycle	O
4	O
,	O
63.8	O
%	O
of	O
cycles	O
were	O
normal	O
in	O
the	O
LNG/EE	O
group	O
compared	O
with	O
41.9	O
%	O
in	O
the	O
NETA/EE	O
group	O
(	O
p	O
<	O
0.005	O
)	O
.	O

Of	O
the	O
total	O
cycles	O
in	O
the	O
NETA/EE	O
group	O
,	O
10	O
%	O
were	O
amenorrheic	O
,	O
compared	O
with	O
1.1	O
%	O
in	O
the	O
LNG/EE	O
group	O
.	O

The	O
occurrence	O
of	O
bleeding	O
and/or	O
spotting	O
was	O
significantly	O
lower	O
in	O
cycles	O
2	O
and	O
3	O
in	O
the	O
LNG/EE	O
group	O
(	O
41.7	O
%	O
and	O
34.8	O
%	O
,	O
respectively	O
)	O
compared	O
with	O
the	O
NETA/EE	O
group	O
(	O
62.3	O
%	O
and	O
56.3	O
%	O
;	O
p	O
<	O
0.05	O
)	O
.	O

Other	O
cycle	O
variables	O
were	O
generally	O
similar	O
between	O
groups	O
,	O
as	O
was	O
the	O
incidence	O
of	O
adverse	O
events	O
.	O

These	O
results	O
demonstrate	O
that	O
good	O
cycle	O
control	O
was	O
achieved	O
with	O
an	O
OC	O
containing	O
20	O
micrograms	O
EE	O
and	O
that	O
100	O
micrograms	O
LNG/20	O
micrograms	O
EE	O
produces	O
better	O
cycle	O
control	O
than	O
1000	O
micrograms	O
NETA/20	O
micrograms	O
EE	O
.	O

A	O
comparison	O
of	O
laparoscopically	O
assisted	O
and	O
open	O
colectomy	O
for	O
colon	Condition
cancer	Condition
.	O

BACKGROUND	O
Minimally	O
invasive	O
,	O
laparoscopically	O
assisted	O
surgery	O
was	O
first	O
considered	O
in	O
1990	O
for	O
patients	O
undergoing	O
colectomy	O
for	O
cancer	O
.	O

Concern	O
that	O
this	O
approach	O
would	O
compromise	O
survival	O
by	O
failing	O
to	O
achieve	O
a	O
proper	O
oncologic	O
resection	O
or	O
adequate	O
staging	O
or	O
by	O
altering	O
patterns	O
of	O
recurrence	O
(	O
based	O
on	O
frequent	O
reports	O
of	O
tumor	O
recurrences	O
within	O
surgical	O
wounds	O
)	O
prompted	O
a	O
controlled	O
trial	O
evaluation	O
.	O

METHODS	O
We	O
conducted	O
a	O
noninferiority	O
trial	O
at	O
48	O
institutions	O
and	O
randomly	O
assigned	O
872	SampleSize
patients	O
with	O
adenocarcinoma	Condition
of	Condition
the	Condition
colon	Condition
to	O
undergo	O
open	O
or	O
laparoscopically	O
assisted	O
colectomy	O
performed	O
by	O
credentialed	O
surgeons	O
.	O

The	O
median	O
follow-up	O
was	O
4.4	O
years	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
time	O
to	O
tumor	O
recurrence	O
.	O

RESULTS	O
At	O
three	O
years	O
,	O
the	O
rates	O
of	O
recurrence	O
were	O
similar	O
in	O
the	O
two	O
groups	O
--	O
16	O
percent	O
among	O
patients	O
in	O
the	O
group	O
that	O
underwent	O
laparoscopically	O
assisted	O
surgery	O
and	O
18	O
percent	O
among	O
patients	O
in	O
the	O
open-colectomy	O
group	O
(	O
two-sided	O
P=0.32	O
;	O
hazard	O
ratio	O
for	O
recurrence	O
,	O
0.86	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.63	O
to	O
1.17	O
)	O
.	O

Recurrence	O
rates	O
in	O
surgical	O
wounds	O
were	O
less	O
than	O
1	O
percent	O
in	O
both	O
groups	O
(	O
P=0.50	O
)	O
.	O

The	O
overall	O
survival	O
rate	O
at	O
three	O
years	O
was	O
also	O
very	O
similar	O
in	O
the	O
two	O
groups	O
(	O
86	O
percent	O
in	O
the	O
laparoscopic-surgery	O
group	O
and	O
85	O
percent	O
in	O
the	O
open-colectomy	O
group	O
;	O
P=0.51	O
;	O
hazard	O
ratio	O
for	O
death	O
in	O
the	O
laparoscopic-surgery	O
group	O
,	O
0.91	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.68	O
to	O
1.21	O
)	O
,	O
with	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
time	O
to	O
recurrence	O
or	O
overall	O
survival	O
for	O
patients	O
with	O
any	O
stage	O
of	O
cancer	O
.	O

Perioperative	O
recovery	O
was	O
faster	O
in	O
the	O
laparoscopic-surgery	O
group	O
than	O
in	O
the	O
open-colectomy	O
group	O
,	O
as	O
reflected	O
by	O
a	O
shorter	O
median	O
hospital	O
stay	O
(	O
five	O
days	O
vs.	O
six	O
days	O
,	O
P	O
<	O
0.001	O
)	O
and	O
briefer	O
use	O
of	O
parenteral	O
narcotics	O
(	O
three	O
days	O
vs.	O
four	O
days	O
,	O
P	O
<	O
0.001	O
)	O
and	O
oral	O
analgesics	O
(	O
one	O
day	O
vs.	O
two	O
days	O
,	O
P=0.02	O
)	O
.	O

The	O
rates	O
of	O
intraoperative	O
complications	O
,	O
30-day	O
postoperative	O
mortality	O
,	O
complications	O
at	O
discharge	O
and	O
60	O
days	O
,	O
hospital	O
readmission	O
,	O
and	O
reoperation	O
were	O
very	O
similar	O
between	O
groups	O
.	O

CONCLUSIONS	O
In	O
this	O
multi-institutional	O
study	O
,	O
the	O
rates	O
of	O
recurrent	O
cancer	O
were	O
similar	O
after	O
laparoscopically	O
assisted	O
colectomy	O
and	O
open	O
colectomy	O
,	O
suggesting	O
that	O
the	O
laparoscopic	O
approach	O
is	O
an	O
acceptable	O
alternative	O
to	O
open	O
surgery	O
for	O
colon	O
cancer	O
.	O

Alkalinized	O
lidocaine	O
and	O
heparin	O
provide	O
immediate	O
relief	O
of	O
pain	O
and	O
urgency	O
in	O
patients	O
with	O
interstitial	Condition
cystitis	Condition
.	O

INTRODUCTION	O
It	O
has	O
been	O
reported	O
in	O
an	O
open-label	O
study	O
that	O
the	O
combination	O
of	O
alkalinized	O
lidocaine	O
and	O
heparin	O
can	O
immediately	O
relieve	O
the	O
symptoms	O
of	O
urinary	O
urgency	O
,	O
frequency	O
,	O
and	O
pain	O
associated	O
with	O
interstitial	O
cystitis	O
(	O
IC	O
)	O
.	O

This	O
combination	O
has	O
also	O
been	O
reported	O
to	O
relieve	O
pain	O
associated	O
with	O
sex	O
in	O
patients	O
with	O
IC	Condition
.	O

AIM	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
corroborate	O
these	O
findings	O
in	O
a	O
multicenter	O
setting	O
.	O

METHODS	O
The	O
study	O
design	O
was	O
a	O
multicenter	O
prospective	O
,	O
double-blind	O
,	O
crossover	O
,	O
placebo-controlled	O
trial	O
.	O

Each	O
participant	O
met	O
all	O
of	O
the	O
clinical	O
National	O
Institute	O
of	O
Diabetes	Condition
and	O
Digestive	O
and	O
Kidney	Condition
Diseases	Condition
criteria	O
(	O
excluding	O
cystoscopy	O
)	O
for	O
IC	O
.	O

Each	O
patient	O
received	O
drug	O
and	O
control	O
,	O
in	O
random	O
order	O
,	O
within	O
48	O
hours	O
of	O
enrolling	O
in	O
the	O
study	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
outcome	O
measure	O
was	O
percent	O
change	O
in	O
pain	O
score	O
(	O
11-point	O
analog	O
pain	O
scale	O
)	O
12	O
hours	O
after	O
receiving	O
the	O
drug	O
or	O
control	O
.	O

Secondary	O
measures	O
were	O
the	O
global	O
assessment	O
response	O
(	O
GAR	O
)	O
of	O
symptoms	O
and	O
12-hour	O
average	O
urgency	O
reduction	O
determined	O
from	O
11-point	O
urgency	O
scales	O
.	O

RESULTS	O
Eighteen	O
(	O
18	SampleSize
)	O
patients	O
completed	O
the	O
trial	O
.	O

The	O
average	O
reduction	O
of	O
pain	O
over	O
12	O
hours	O
was	O
21	O
%	O
for	O
control	O
and	O
42	O
%	O
for	O
active	O
drug	O
(	O
P	O
=	O
0.0363	O
)	O
.	O

GAR	O
was	O
13	O
%	O
for	O
control	O
and	O
50	O
%	O
for	O
drug	O
(	O
P	O
=	O
0.0137	O
)	O
.	O

Average	O
urgency	O
reduction	O
was	O
13	O
%	O
for	O
control	O
and	O
35	O
%	O
for	O
drug	O
(	O
P	O
=	O
0.0328	O
)	O
.	O

CONCLUSIONS	O
The	O
combination	O
of	O
alkalinized	O
lidocaine	O
and	O
heparin	O
provides	O
up	O
to	O
12	O
hours	O
of	O
relief	O
from	O
urgency	O
and	O
pain	O
associated	O
with	O
IC	O
.	O

This	O
combination	O
provides	O
significant	O
immediate	O
relief	O
of	O
symptoms	O
for	O
patients	O
with	O
IC	O
.	O

Clozapine	O
versus	O
placebo	O
in	O
Huntington	Condition
's	Condition
disease	Condition
:	O
a	O
double	O
blind	O
randomised	O
comparative	O
study	O
.	O

OBJECTIVES	O
To	O
establish	O
the	O
effect	O
of	O
the	O
atypical	O
neuroleptic	O
clozapine	O
on	O
chorea	O
,	O
voluntary	O
motor	O
performance	O
,	O
and	O
functional	O
disability	O
in	O
patients	O
with	O
Huntington	O
's	O
disease	O
.	O

METHODS	O
Thirty	SampleSize
three	SampleSize
patients	O
with	O
Huntington	O
's	O
disease	O
participated	O
in	O
a	O
double	O
blind	O
randomised	O
trial	O
.	O

A	O
maximum	O
of	O
150	O
mg/day	O
clozapine	O
or	O
placebo	O
equivalent	O
was	O
given	O
for	O
a	O
period	O
of	O
31	O
days	O
.	O

Assessments	O
were	O
performed	O
in	O
the	O
week	O
before	O
and	O
at	O
the	O
last	O
day	O
of	O
the	O
trial	O
.	O

Chorea	O
was	O
scored	O
using	O
the	O
abnormal	O
involuntary	O
movement	O
scale	O
(	O
AIMS	O
)	O
,	O
the	O
chorea	O
score	O
of	O
the	O
unified	O
Huntington	O
's	O
disease	O
rating	O
scale	O
(	O
UHDRS	O
)	O
,	O
and	O
judgement	O
of	O
video	O
recordings	O
.	O

Voluntary	O
motor	O
performance	O
was	O
assessed	O
using	O
the	O
UHDRS	O
motor	O
scale	O
.	O

Patients	O
and	O
their	O
partners	O
completed	O
a	O
questionnaire	O
regarding	O
functional	O
disability	O
.	O

Twelve	O
patients	O
already	O
used	O
other	O
neuroleptic	O
medication	O
,	O
which	O
was	O
kept	O
unchanged	O
during	O
the	O
trial	O
period	O
.	O

Results	O
of	O
neuroleptic	O
naive	O
and	O
neuroleptic	O
treated	O
patients	O
were	O
analysed	O
separately	O
.	O

RESULTS	O
Clozapine	O
tended	O
to	O
reduce	O
chorea	O
in	O
neuroleptic	O
naive	O
patients	O
only	O
(	O
AIMS	O
)	O
;	O
improvement	O
seemed	O
more	O
pronounced	O
in	O
patients	O
receiving	O
higher	O
doses	O
of	O
clozapine	O
.	O

Other	O
measures	O
of	O
chorea	O
(	O
UHDRS	O
chorea	O
score	O
,	O
video	O
ratings	O
)	O
showed	O
no	O
improvement	O
.	O

Clozapine	O
had	O
no	O
beneficial	O
effect	O
on	O
chorea	O
in	O
patients	O
already	O
receiving	O
neuroleptic	O
medication	O
.	O

Voluntary	O
motor	O
performance	O
did	O
not	O
improve	O
with	O
clozapine	O
.	O

Neuroleptic	O
naive	O
patients	O
reported	O
aggravation	O
of	O
functional	O
disability	O
,	O
possibly	O
reflecting	O
the	O
frequent	O
occurrence	O
of	O
side	O
effects	O
.	O

Adverse	O
reactions	O
forced	O
trial	O
termination	O
in	O
six	O
patients	O
and	O
dose	O
reduction	O
in	O
another	O
eight	O
,	O
and	O
consisted	O
mainly	O
of	O
drowsiness	O
,	O
fatigue	O
,	O
anticholinergic	O
symptoms	O
,	O
and	O
walking	O
difficulties	O
.	O

CONCLUSIONS	O
Clozapine	O
has	O
little	O
beneficial	O
effect	O
in	O
patients	O
with	O
Huntington	O
's	O
disease	O
,	O
although	O
individual	O
patients	O
may	O
tolerate	O
doses	O
high	O
enough	O
to	O
reduce	O
chorea	O
.	O

Because	O
adverse	O
reactions	O
are	O
often	O
encountered	O
,	O
clozapine	O
should	O
be	O
used	O
with	O
restraint	O
in	O
this	O
patient	O
group	O
.	O

Neuropsychological	O
outcomes	O
after	O
psychosocial	O
intervention	O
for	O
depression	O
in	O
Parkinson	O
's	O
disease	O
.	O

The	O
authors	O
describe	O
neuropsychological	O
outcomes	O
in	O
people	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
after	O
their	O
participation	O
in	O
an	O
NIH-sponsored	O
,	O
randomized	O
,	O
controlled	O
trial	O
of	O
cognitive-behavioral	O
treatment	O
for	O
depression	O
.	O

Improvements	O
in	O
mood	O
were	O
associated	O
with	O
modest	O
gains	O
in	O
verbal	O
memory	O
and	O
executive	O
functioning	O
over	O
the	O
10-week	O
treatment	O
period	O
and	O
accounted	O
for	O
greater	O
variance	O
in	O
neuropsychological	O
outcomes	O
at	O
the	O
end	O
of	O
treatment	O
than	O
other	O
known	O
correlates	O
of	O
cognitive	O
functioning	O
in	O
PD	O
,	O
such	O
as	O
disease	O
severity	O
,	O
age	O
,	O
and	O
education	O
.	O

Baseline	O
working	O
memory	O
and	O
executive	O
skills	O
were	O
also	O
associated	O
with	O
depression	O
improvement	O
over	O
time	O
.	O

Mortality	O
in	O
patients	O
with	O
small	O
choroidal	O
melanoma	O
.	O

COMS	O
report	O
no	O
.	O

4	O
.	O

The	O
Collaborative	O
Ocular	O
Melanoma	O
Study	O
Group	O
.	O

OBJECTIVE	O
To	O
describe	O
the	O
clinical	O
characteristics	O
and	O
survival	O
experience	O
of	O
a	O
prospectively	O
followed	O
up	O
group	O
of	O
patients	O
with	O
small	O
choroidal	O
melanoma	O
.	O

METHODS	O
The	O
Collaborative	O
Ocular	O
Melanoma	O
Study	O
(	O
COMS	O
)	O
is	O
a	O
set	O
of	O
clinical	O
trials	O
designed	O
to	O
compare	O
the	O
role	O
of	O
radiotherapy	O
and	O
enucleation	O
in	O
the	O
treatment	O
of	O
medium	O
and	O
large-size	O
choroidal	O
melanoma	O
.	O

From	O
December	O
1986	O
to	O
August	O
1989	O
,	O
patients	O
with	O
small	O
choroidal	O
melanoma	O
,	O
not	O
large	O
enough	O
to	O
be	O
eligible	O
for	O
the	O
COMS	O
clinical	O
trials	O
,	O
were	O
offered	O
participation	O
in	O
a	O
nonrandomized	O
prospective	O
follow-up	O
study	O
.	O

Small	O
choroidal	O
melanomas	O
were	O
defined	O
as	O
1.0	O
to	O
3.0	O
mm	O
in	O
apical	O
height	O
and	O
at	O
least	O
5.0	O
mm	O
in	O
basal	O
diameter	O
.	O

A	O
total	O
of	O
204	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Patients	O
were	O
followed	O
up	O
annually	O
through	O
August	O
1989	O
.	O

Two	O
additional	O
assessments	O
of	O
treatment	O
status	O
and	O
mortality	O
were	O
conducted	O
in	O
1993-1994	O
and	O
1995-1996	O
.	O

The	O
median	O
length	O
of	O
follow-up	O
was	O
92	O
months	O
.	O

Eight	O
percent	O
of	O
patients	O
were	O
treated	O
at	O
the	O
time	O
of	O
study	O
enrollment	O
and	O
an	O
additional	O
33	O
%	O
were	O
treated	O
during	O
follow-up	O
.	O

RESULTS	O
Twenty-seven	O
patients	O
have	O
died	O
;	O
6	O
deaths	O
were	O
reported	O
by	O
the	O
clinical	O
center	O
as	O
due	O
to	O
metastatic	O
melanoma	O
.	O

The	O
Kaplan-Meier	O
estimate	O
of	O
5-year	O
all-cause	O
mortality	O
was	O
6.0	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
2.7	O
%	O
-9.3	O
%	O
)	O
and	O
8-year	O
all-cause	O
mortality	O
was	O
14.9	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
9.6	O
%	O
-20.2	O
%	O
)	O
.	O

CONCLUSIONS	O
Otherwise	O
healthy	O
patients	O
,	O
average	O
age	O
of	O
60	O
years	O
,	O
without	O
a	O
previous	O
diagnosis	O
of	O
malignant	O
disease	O
who	O
have	O
small	O
choroidal	O
lesions	O
judged	O
to	O
be	O
melanoma	O
have	O
a	O
low	O
risk	O
of	O
dying	O
within	O
5	O
years	O
.	O

Low-dose	O
,	O
vaginally	O
administered	O
estrogens	O
may	O
enhance	O
local	O
benefits	O
of	O
systemic	O
therapy	O
in	O
the	O
treatment	O
of	O
urogenital	Condition
atrophy	Condition
in	O
postmenopausal	Condition
women	SampleSize
on	Condition
hormone	Condition
therapy	Condition
.	O

BACKGROUND	O
When	O
genital	O
atrophy	O
exists	O
,	O
systemic	O
hormone	O
therapy	O
(	O
HT	O
)	O
has	O
a	O
timing	O
until	O
to	O
induce	O
vaginal	O
proliferation	O
and	O
symptomatic	O
relieve	O
.	O

Thus	O
,	O
in	O
order	O
to	O
obtain	O
a	O
prompt	O
improvement	O
,	O
the	O
association	O
of	O
local	O
therapy	O
acting	O
on	O
the	O
genital	O
epithelium	O
to	O
the	O
systemic	O
treatment	O
should	O
be	O
considered	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
a	O
combined	O
therapy	O
consisting	O
of	O
vaginal	O
estriol	O
with	O
transdermal	O
17-beta-estradiol	O
(	O
50	O
microg/day	O
)	O
plus	O
medroxyprogesterone	O
acetate	O
(	O
5	O
mg/day	O
)	O
per	O
os	O
in	O
shortening	O
the	O
period	O
of	O
uro-genital	O
symptoms	O
.	O

SUBJECTS	O
AND	O
METHODS	O
In	O
a	O
randomized	O
,	O
double	O
blind	O
,	O
controlled	O
with	O
placebo	O
study	O
,	O
27	SampleSize
women	SampleSize
with	O
climacteric	Condition
symptoms	Condition
and	O
atrophic	Condition
vaginitis	Condition
were	O
treated	O
for	O
4	O
months	O
with	O
HT	O
plus	O
vaginal	O
estriol	O
0.5	O
mg/day	O
(	O
group	O
E	O
)	O
or	O
placebo	O
(	O
group	O
P	O
)	O
.	O

Patients	O
use	O
the	O
local	O
medication	O
daily	O
for	O
the	O
first	O
3	O
weeks	O
and	O
twice-weekly	O
thereafter	O
.	O

Before	O
entering	O
in	O
the	O
study	O
,	O
patients	O
were	O
asked	O
about	O
HT	O
and	O
selected	O
for	O
inclusion	O
.	O

In	O
the	O
first	O
visit	O
,	O
electible	O
patients	O
after	O
written	O
informed	O
consent	O
were	O
randomized	O
to	O
receive	O
HT	O
plus	O
local	O
estriol	O
or	O
placebo	O
.	O

All	O
the	O
subjects	O
had	O
baseline	O
studies	O
,	O
including	O
medical	O
history	O
,	O
physical	O
examination	O
,	O
blood	O
and	O
urine	O
analysis	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
effect	O
of	O
local	O
treatment	O
on	O
urinary	O
and	O
genital	O
symptoms	O
,	O
a	O
score	O
for	O
genital	O
,	O
urinary	O
and	O
colposcopic	O
complaints	O
(	O
0	O
minimum-100	O
maximum	O
)	O
was	O
developed	O
.	O

This	O
score	O
and	O
Blatt-Kuperman	O
were	O
recorded	O
and	O
performed	O
in	O
every	O
control	O
.	O

RESULTS	O
There	O
were	O
no	O
differences	O
on	O
climacteric	O
symptoms	O
relief	O
between	O
the	O
two	O
groups	O
.	O

Additionally	O
,	O
the	O
improvement	O
in	O
urinary	O
symptoms	O
at	O
the	O
end	O
of	O
the	O
study	O
was	O
similar	O
for	O
both	O
groups	O
(	O
from	O
16.5	O
+/-	O
6.1	O
to	O
8.5	O
+/-	O
2.4	O
for	O
E	O
group	O
and	O
from	O
15.8	O
+/-	O
7.8	O
to	O
8.8	O
+/-	O
2.7	O
for	O
P	O
group	O
;	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
;	O
however	O
,	O
those	O
women	O
in	O
group	O
E	O
reached	O
significant	O
improvement	O
on	O
urinary	O
complaints	O
since	O
the	O
first	O
month	O
of	O
treatment	O
.	O

Additionally	O
,	O
a	O
significant	O
difference	O
between	O
E	O
and	O
P	O
was	O
observed	O
at	O
months	O
2	O
and	O
3	O
,	O
although	O
no	O
differences	O
were	O
detected	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Papanicolaou	O
smear	O
showed	O
reactive	O
or	O
reparative	O
changes	O
and	O
karyopyknotic	O
index	O
exhibited	O
a	O
significant	O
increase	O
in	O
superficial	O
cells	O
in	O
both	O
groups	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

CONCLUSIONS	O
Adding	O
vaginal	O
estriol	O
to	O
HRT	O
may	O
shorten	O
the	O
latency	O
period	O
for	O
urinary	O
symptoms	O
.	O

Antipyrine	O
clearance	O
and	O
response	O
to	O
interferon	O
treatment	O
in	O
patients	O
with	O
chronic	Condition
active	Condition
hepatitis	Condition
C.	Condition
To	O
determine	O
whether	O
hepatic	O
metabolic	O
function	O
affects	O
the	O
response	O
to	O
interferon	O
treatment	O
,	O
we	O
measured	O
antipyrine	O
clearance	O
(	O
APC	O
)	O
in	O
85	SampleSize
patients	O
with	O
chronic	Condition
active	Condition
hepatitis	Condition
C	Condition
and	O
compared	O
the	O
results	O
with	O
treatment	O
outcome	O
.	O

Among	O
55	SampleSize
patients	O
who	O
responded	O
to	O
interferon	O
by	O
normalization	O
of	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
,	O
median	O
APC	O
before	O
treatment	O
was	O
0.47	O
(	O
range	O
,	O
0.12	O
to	O
0.98	O
;	O
normal	O
range	O
,	O
0.34	O
to	O
1.02	O
mL/min/kg	O
body	O
wt	O
)	O
,	O
a	O
value	O
that	O
was	O
significantly	O
greater	O
than	O
in	O
30	O
nonresponders	O
(	O
0.23	O
;	O
0.08	O
to	O
0.67	O
mL/min/kg	O
body	O
wt	O
,	O
P	O
<	O
.001	O
)	O
.	O

APC	O
was	O
closely	O
associated	O
with	O
response	O
to	O
interferon	O
.	O

The	O
response	O
rate	O
among	O
cases	O
with	O
values	O
>	O
0.25	O
mL/min/kg	O
body	O
weight	O
was	O
79	O
%	O
,	O
the	O
same	O
as	O
in	O
cases	O
without	O
cirrhosis	O
.	O

Cases	O
without	O
cirrhosis	O
and	O
with	O
APC	O
of	O
>	O
0.25	O
mL/min/kg	O
body	O
weight	O
had	O
an	O
85	O
%	O
chance	O
of	O
responding	O
to	O
interferon	O
;	O
this	O
was	O
unlikely	O
a	O
simple	O
reflection	O
of	O
histological	O
activity	O
,	O
because	O
the	O
correlation	O
with	O
Scheuer	O
score	O
was	O
poor	O
in	O
this	O
subgroup	O
(	O
r	O
=	O
-.31	O
,	O
P	O
<	O
.05	O
)	O
.	O

A	O
second	O
,	O
independent	O
group	O
of	O
43	SampleSize
patients	O
was	O
used	O
to	O
test	O
the	O
predictive	O
value	O
of	O
APC	O
(	O
using	O
0.25	O
mL/min/kg	O
body	O
wt	O
as	O
a	O
cut-off	O
)	O
for	O
response	O
to	O
interferon	O
treatment	O
.	O

In	O
this	O
group	O
,	O
APC	O
correctly	O
predicted	O
positive	O
response	O
to	O
interferon	O
in	O
75	O
%	O
of	O
cases	O
.	O

APC	O
was	O
also	O
used	O
to	O
measure	O
the	O
effects	O
of	O
treatment	O
on	O
hepatic	O
metabolic	O
function	O
.	O

Regardless	O
of	O
outcome	O
,	O
there	O
was	O
no	O
change	O
in	O
APC	O
at	O
the	O
end	O
of	O
a	O
6-month	O
course	O
of	O
interferon	O
treatment	O
.	O

Six	O
months	O
later	O
,	O
however	O
,	O
improvement	O
in	O
APC	O
(	O
14	O
%	O
;	O
P	O
<	O
.05	O
)	O
was	O
evident	O
among	O
responders	O
but	O
not	O
in	O
those	O
who	O
had	O
failed	O
to	O
respond	O
to	O
interferon	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Playing	O
on	O
the	O
typewriter	O
,	O
typing	O
on	O
the	O
piano	O
:	O
manipulation	O
knowledge	O
of	O
objects	O
.	O

Two	O
experiments	O
investigated	O
sensory/motor-based	O
functional	O
knowledge	O
of	O
man-made	O
objects	O
:	O
manipulation	O
features	O
associated	O
with	O
the	O
actual	O
usage	O
of	O
objects	O
.	O

In	O
Experiment	O
1	O
,	O
a	O
series	O
of	O
prime-target	O
pairs	O
was	O
presented	O
auditorily	O
,	O
and	O
participants	O
were	O
asked	O
to	O
make	O
a	O
lexical	O
decision	O
on	O
the	O
target	O
word	O
.	O

Participants	O
made	O
a	O
significantly	O
faster	O
decision	O
about	O
the	O
target	O
word	O
(	O
e.g	O
.	O

'typewriter	O
'	O
)	O
following	O
a	O
related	O
prime	O
that	O
shared	O
manipulation	O
features	O
with	O
the	O
target	O
(	O
e.g	O
.	O

'piano	O
'	O
)	O
than	O
an	O
unrelated	O
prime	O
(	O
e.g	O
.	O

'blanket	O
'	O
)	O
.	O

In	O
Experiment	O
2	O
,	O
participants	O
'	O
eye	O
movements	O
were	O
monitored	O
when	O
they	O
viewed	O
a	O
visual	O
display	O
on	O
a	O
computer	O
screen	O
while	O
listening	O
to	O
a	O
concurrent	O
auditory	O
input	O
.	O

Participants	O
were	O
instructed	O
to	O
simply	O
identify	O
the	O
auditory	O
input	O
and	O
touch	O
the	O
corresponding	O
object	O
on	O
the	O
computer	O
display	O
.	O

Participants	O
fixated	O
an	O
object	O
picture	O
(	O
e.g	O
.	O

typewriter	O
)	O
related	O
to	O
a	O
target	O
word	O
(	O
e.g	O
.	O

'piano	O
'	O
)	O
significantly	O
more	O
often	O
than	O
an	O
unrelated	O
object	O
picture	O
(	O
e.g	O
.	O

bucket	O
)	O
as	O
well	O
as	O
a	O
visually	O
matched	O
control	O
(	O
e.g	O
.	O

couch	O
)	O
.	O

Results	O
of	O
the	O
two	O
experiments	O
suggest	O
that	O
manipulation	O
knowledge	O
of	O
words	O
is	O
retrieved	O
without	O
conscious	O
effort	O
and	O
that	O
manipulation	O
knowledge	O
constitutes	O
a	O
part	O
of	O
the	O
lexical-semantic	O
representation	O
of	O
objects	O
.	O

A	O
prospective	O
double-blind	O
,	O
randomized	O
clinical	O
trial	O
of	O
levocarnitine	O
to	O
treat	O
autism	O
spectrum	O
disorders	O
.	O

BACKGROUND	O
L-carnitine	O
was	O
proposed	O
as	O
a	O
potential	O
treatment	O
for	O
patients	O
diagnosed	O
with	O
an	O
autism	O
spectrum	O
disorder	O
to	O
improve	O
mitochondrial	O
dysfunction	O
,	O
but	O
no	O
prior	O
randomized	O
controlled	O
trials	O
have	O
been	O
conducted	O
.	O

MATERIAL/METHODS	O
Thirty	O
subjects	O
diagnosed	O
with	O
an	O
ASD	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
standardized	O
regimen	O
(	O
50	O
mg	O
L-carnitine/kg	O
bodyweight/day	O
)	O
of	O
liquid	O
L-carnitine	O
(	O
n=19	O
)	O
or	O
placebo	O
(	O
n=11	O
)	O
for	O
3-months	O
.	O

Measures	O
included	O
changes	O
in	O
professionally	O
completed	O
Childhood	O
Autism	O
Rating	O
Scale	O
(	O
CARS	O
)	O
,	O
hand	O
muscle	O
testing	O
,	O
and	O
modified	O
clinical	O
global	O
impression	O
(	O
CGI	O
)	O
forms	O
;	O
parent	O
completed	O
Autism	O
Treatment	O
Evaluation	O
Checklist	O
(	O
ATEC	O
)	O
,	O
treatment	O
adherence	O
measurement	O
(	O
TAM	O
)	O
,	O
frequency	O
and	O
intensity	O
of	O
side	O
effect	O
rating	O
(	O
FISER	O
)	O
/global	O
rating	O
of	O
side	O
effect	O
burden	O
(	O
GRSEB	O
)	O
/patient	O
report	O
of	O
incidence	O
of	O
side	O
effects	O
(	O
PRISE	O
)	O
forms	O
;	O
and	O
lab	O
testing	O
.	O

RESULTS	O
Significant	O
improvements	O
were	O
observed	O
in	O
CARS	O
(	O
-2.03	O
,	O
95	O
%	O
CI=-3.7	O
to	O
-0.31	O
)	O
,	O
CGI	O
(	O
-0.69	O
,	O
95	O
%	O
CI=-1.1	O
to	O
-0.06	O
)	O
,	O
and	O
ATEC	O
scores	O
.	O

Significant	O
correlations	O
between	O
changes	O
in	O
serum	O
free-carnitine	O
levels	O
and	O
positive	O
clinical	O
changes	O
were	O
observed	O
for	O
hand	O
muscle	O
strength	O
(	O
R2=0.23	O
,	O
P=0.046	O
)	O
,	O
cognitive	O
scores	O
(	O
R2=0.27	O
,	O
P=0.019	O
)	O
,	O
and	O
CARS	O
scores	O
(	O
R2=0.20	O
,	O
P=0.047	O
)	O
.	O

Study	O
subjects	O
were	O
protocol-compliant	O
(	O
average	O
adherence	O
was	O
>	O
85	O
%	O
)	O
and	O
generally	O
well-tolerated	O
the	O
L-carnitine	O
therapy	O
given	O
.	O

CONCLUSIONS	O
L-carnitine	O
therapy	O
(	O
50	O
mg/kilogram-bodyweight/day	O
)	O
administered	O
for	O
3-months	O
significantly	O
improved	O
several	O
clinical	O
measurements	O
of	O
ASD	O
severity	O
,	O
but	O
subsequent	O
studies	O
are	O
recommended	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
as	O
immunomodulating	O
factor	O
together	O
with	O
influenza	O
vaccination	O
in	O
stem	Condition
cell	Condition
transplant	Condition
patients	O
.	O

The	O
effect	O
of	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
on	O
the	O
serological	O
response	O
at	O
influenza	O
vaccination	O
was	O
studied	O
in	O
117	SampleSize
patients	O
who	O
had	O
undergone	Condition
stem	Condition
cell	Condition
transplantation	Condition
(	O
SCT	Condition
)	O
.	O

The	O
vaccine	O
response	O
was	O
evaluated	O
as	O
significant	O
increases	O
in	O
levels	O
of	O
influenza	O
hemagglutination-inhibition	O
(	O
HAI	O
)	O
antibodies	O
and	O
of	O
IgG	O
antibodies	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
antibody	O
response	O
to	O
either	O
influenza	O
A	O
or	O
B	O
in	O
64	O
patients	O
who	O
received	O
GM-CSF	O
at	O
vaccination	O
,	O
compared	O
with	O
the	O
53	O
who	O
did	O
not	O
.	O

In	O
the	O
subgroup	O
of	O
allogeneic	Condition
SCT	Condition
patients	Condition
,	O
HAI	O
showed	O
that	O
the	O
response	O
rate	O
to	O
the	O
influenza	O
B	O
vaccine	O
was	O
significantly	O
higher	O
in	O
the	O
treatment	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O

ELISA	O
showed	O
that	O
autologous	Condition
SCT	Condition
patients	Condition
with	Condition
breast	Condition
cancer	Condition
who	O
received	O
GM-CSF	O
had	O
a	O
better	O
response	O
to	O
influenza	O
A	O
(	O
P	O
<	O
.05	O
)	O
and	O
B	O
(	O
P	O
<	O
.01	O
)	O
.	O

At	O
early	O
vaccination	O
,	O
4-12	O
months	O
after	O
stem	O
cell	O
transplantation	O
,	O
these	O
responses	O
were	O
more	O
pronounced	O
.	O

GM-CSF	O
appears	O
to	O
improve	O
the	O
response	O
to	O
influenza	O
vaccination	O
in	O
some	O
groups	O
of	O
SCT	Condition
patients	Condition
,	O
but	O
only	O
to	O
a	O
limited	O
extent	O
.	O

Iron	O
intake	O
and	O
iron	O
nutritional	O
status	O
of	O
infants	O
fed	O
iron-fortified	O
beikost	O
with	O
meat	O
.	O

We	O
compared	O
iron	O
intake	O
and	O
iron	O
nutritional	O
status	O
of	O
two	O
groups	O
of	O
healthy	O
term	O
infants	O
who	O
received	O
meat-containing	O
baby	O
foods	O
fortified	O
with	O
ferrous	O
sulphate	O
(	O
2	O
mg	O
Fe/100	O
g	O
)	O
.	O

One	O
group	O
received	O
an	O
Fe-fortified	O
formula	O
(	O
1.6	O
mg	O
Fe/100	O
kcal	O
)	O
and	O
the	O
other	O
a	O
nonfortified	O
formula	O
.	O

Fe	O
intake	O
of	O
the	O
group	O
fed	O
the	O
nonfortified	O
formula	O
was	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

These	O
infants	O
received	O
Fe	O
mainly	O
from	O
fortification	O
Fe	O
with	O
beikost	O
(	O
75-86	O
%	O
)	O
and	O
less	O
than	O
10	O
%	O
met	O
the	O
recommended	O
intake	O
of	O
1	O
mg.kg-1.d-1	O
;	O
whereas	O
80-85	O
%	O
of	O
the	O
infants	O
fed	O
the	O
Fe-fortified	O
formula	O
did	O
.	O

Hb	O
,	O
Hct	O
,	O
FEP	O
,	O
and	O
ferritin	O
were	O
similar	O
in	O
both	O
groups	O
with	O
the	O
exception	O
of	O
lower	O
ferritin	O
values	O
at	O
age	O
365	O
d	O
(	O
p	O
less	O
than	O
0.05	O
)	O
in	O
the	O
group	O
fed	O
the	O
nonfortified	O
formula	O
.	O

No	O
infant	O
had	O
hemoglobin	O
less	O
than	O
100	O
g/L	O
.	O

We	O
conclude	O
that	O
regular	O
consumption	O
of	O
commercially	O
prepared	O
Fe-fortified	O
beikost	O
with	O
meat	O
prevents	O
most	O
healthy	O
term	O
infants	O
from	O
Fe	O
deficiency	O
even	O
if	O
Fe	O
intake	O
is	O
substantially	O
below	O
the	O
recommended	O
intake	O
.	O

Intervention	O
for	O
ineffective	O
airway	O
clearance	O
in	O
asthmatic	O
children	O
:	O
a	O
controlled	O
and	O
randomized	O
clinical	O
trial	O
.	O

This	O
study	O
aimed	O
to	O
analyse	O
the	O
effectiveness	O
of	O
an	O
intervention	O
for	O
the	O
nursing	O
diagnosis	O
of	O
ineffective	O
airway	O
clearance	O
in	O
asthmatic	O
children	O
.	O

A	O
blinded	O
,	O
randomized	O
and	O
controlled	O
clinical	O
trial	O
was	O
developed	O
in	O
a	O
paediatric	O
hospital	O
located	O
on	O
northeast	O
of	O
Brazil	O
with	O
42	O
asthmatic	O
children	O
aged	O
?	O
36	O
months	O
.	O

The	O
children	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
(	O
intervention	O
and	O
control	O
)	O
by	O
means	O
of	O
a	O
simple	O
drawing	O
.	O

The	O
applied	O
intervention	O
included	O
actions	O
related	O
to	O
change	O
of	O
positioning	O
and	O
stimulation	O
of	O
cough	O
.	O

The	O
main	O
findings	O
of	O
this	O
study	O
show	O
that	O
before	O
the	O
intervention	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
health	O
status	O
of	O
the	O
children	O
.	O

After	O
the	O
intervention	O
,	O
the	O
indicators	O
of	O
choking	O
(	O
16.83	O
vs.	O
26.17	O
,	O
P	O
=	O
0.007	O
)	O
and	O
adventitious	O
breath	O
sounds	O
(	O
16.4	O
vs.	O
26.6	O
,	O
P	O
=	O
0.005	O
)	O
were	O
higher	O
,	O
on	O
average	O
,	O
in	O
the	O
intervention	O
group	O
.	O

It	O
was	O
observed	O
an	O
improvement	O
in	O
obstructive	O
symptoms	O
in	O
children	O
who	O
received	O
the	O
intervention	O
proposed	O
.	O

Why	O
distinctive	O
information	O
reduces	O
false	O
memories	O
:	O
evidence	O
for	O
both	O
impoverished	Condition
relational-encoding	Condition
and	O
distinctiveness	Condition
heuristic	Condition
accounts	Condition
.	O

Two	O
accounts	O
explain	O
why	O
studying	O
pictures	O
reduces	O
false	O
memories	O
within	O
the	O
Deese-Roediger-McDermott	O
paradigm	O
(	O
J.	O
Deese	O
,	O
1959	O
;	O
H.	O
L.	O
Roediger	O
&	O
K.	O
B.	O
McDermott	O
,	O
1995	O
)	O
.	O

The	O
impoverished	O
relational-encoding	O
account	O
suggests	O
that	O
studying	O
pictures	O
interferes	O
with	O
the	O
encoding	O
of	O
relational	O
information	O
,	O
which	O
is	O
the	O
primary	O
basis	O
for	O
false	O
memories	O
in	O
this	O
paradigm	O
.	O

Alternatively	O
,	O
the	O
distinctiveness	O
heuristic	O
assumes	O
that	O
critical	O
lures	O
are	O
actively	O
withheld	O
by	O
the	O
use	O
of	O
a	O
retrieval	O
strategy	O
.	O

When	O
participants	O
were	O
given	O
inclusion	Condition
recall	Condition
instructions	Condition
to	O
report	O
studied	O
items	O
as	O
well	O
as	O
related	O
items	O
,	O
they	O
still	O
reported	O
critical	O
lures	O
less	O
often	O
after	O
picture	O
encoding	O
than	O
they	O
did	O
after	O
word	O
encoding	O
.	O

As	O
the	O
impoverished	O
relational-encoding	O
account	O
suggests	O
,	O
critical	O
lures	O
appear	O
less	O
likely	O
to	O
come	O
to	O
mind	O
after	O
picture	O
encoding	O
than	O
they	O
do	O
after	O
word	O
encoding	O
.	O

However	O
,	O
the	O
results	O
from	O
a	O
postrecall	O
recognition	O
test	O
provide	O
evidence	O
in	O
favor	O
of	O
the	O
distinctiveness	O
heuristic	O
.	O

Additive	O
IOP-reducing	O
effect	O
of	O
latanoprost	O
in	O
patients	O
insufficiently	Condition
controlled	Condition
on	O
timolol	O
.	O

PURPOSE	O
To	O
evaluate	O
the	O
effect	O
on	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
of	O
switching	O
from	O
timolol	O
to	O
latanoprost	O
or	O
adding	O
latanoprost	O
to	O
timolol	O
in	O
patients	O
with	O
open	O
angle	Condition
glaucoma	Condition
or	Condition
ocular	Condition
hypertension	Condition
where	O
IOP	O
is	O
not	O
adequately	O
controlled	O
with	O
timolol	O
.	O

METHODS	O
This	O
was	O
a	O
6-week	O
,	O
double-masked	O
,	O
randomised	O
multi-centre	O
study	O
.	O

53	SampleSize
patients	O
with	O
primary	Condition
open	Condition
angle	Condition
glaucoma	Condition
,	O
capsular	Condition
glaucoma	Condition
,	O
or	O
ocular	Condition
hypertension	Condition
with	O
an	O
IOP	O
of	O
at	O
least	O
21	O
mmHg	O
on	O
current	O
therapy	O
were	O
recruited	O
.	O

After	O
a	O
run-in	O
period	O
of	O
at	O
least	O
2	O
weeks	O
on	O
timolol	O
,	O
5	O
mg/ml	O
twice	O
daily	O
,	O
patients	O
were	O
randomised	O
to	O
one	O
of	O
three	O
groups	O
.	O

One	O
group	O
continued	O
on	O
timolol	O
,	O
one	O
switched	O
from	O
timolol	O
to	O
latanoprost	O
,	O
50	O
microg/ml	O
once	O
daily	O
,	O
and	O
a	O
third	O
group	O
received	O
latanoprost	O
in	O
addition	O
to	O
timolol	O
.	O

The	O
efficacy	O
was	O
evaluated	O
by	O
comparing	O
IOP	O
at	O
9	O
AM	O
at	O
baseline	O
and	O
after	O
6	O
weeks	O
of	O
treatment	O
.	O

RESULTS	O
IOP	O
at	O
baseline	O
and	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
mean	O
+/-	O
SEM	O
)	O
were	O
24.2	O
+/-	O
0.9	O
and	O
23.8	O
+/-	O
1.0	O
mmHg	O
(	O
n	O
=	O
16	O
)	O
for	O
patients	O
continuing	O
on	O
timolol	O
,	O
26.3	O
+/-	O
1.2	O
and	O
19.6	O
+/-	O
1.1	O
mmHg	O
(	O
n	O
=	O
17	O
)	O
for	O
patients	O
switching	O
to	O
latanoprost	O
,	O
and	O
23.2	O
+/-	O
1.0	O
and	O
17.5	O
+/-	O
0.8	O
mmHg	O
(	O
n	O
=	O
17	O
)	O
for	O
patients	O
with	O
combined	O
treatment	O
.	O

Adding	O
latanoprost	O
to	O
timolol	O
reduced	O
IOP	O
with	O
5.9	O
+/-	O
0.9	O
mmHg	O
(	O
p	O
<	O
0.001	O
)	O
and	O
switching	O
from	O
timolol	O
to	O
latanoprost	O
reduced	O
IOP	O
with	O
5.0	O
+/-	O
0.9	O
mmHg	O
(	O
p	O
<	O
0.001	O
)	O
,	O
which	O
caused	O
in	O
each	O
group	O
a	O
significant	O
IOP	O
reduction	O
of	O
about	O
25	O
%	O
.	O

CONCLUSIONS	O
The	O
effect	O
of	O
latanoprost	O
was	O
additive	O
to	O
that	O
of	O
timolol	O
,	O
and	O
a	O
good	O
effect	O
on	O
IOP	O
reduction	O
was	O
also	O
achieved	O
by	O
switching	O
from	O
timolol	O
to	O
latanoprost	O
,	O
suggesting	O
that	O
a	O
switch	O
in	O
many	O
patients	O
is	O
an	O
effective	O
alternative	O
to	O
combination	O
treatment	O
.	O

Are	O
prenatal	O
ultrasound	O
scans	O
associated	O
with	O
the	O
autism	O
phenotype	O
?	O
Follow-up	O
of	O
a	O
randomised	O
controlled	O
trial	O
.	O

An	O
existing	O
randomised	O
controlled	O
trial	O
was	O
used	O
to	O
investigate	O
whether	O
multiple	O
ultrasound	O
scans	O
may	O
be	O
associated	O
with	O
the	O
autism	O
phenotype	O
.	O

From	O
2,834	O
single	O
pregnancies	O
,	O
1,415	O
were	O
selected	O
at	O
random	O
to	O
receive	O
ultrasound	O
imaging	O
and	O
continuous	O
wave	O
Doppler	O
flow	O
studies	O
at	O
five	O
points	O
throughout	O
pregnancy	O
(	O
Intensive	O
)	O
and	O
1,419	O
to	O
receive	O
a	O
single	O
imaging	O
scan	O
at	O
18	O
weeks	O
(	O
Regular	O
)	O
,	O
with	O
further	O
scans	O
only	O
as	O
indicated	O
on	O
clinical	O
grounds	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	O
of	O
Autism	O
Spectrum	O
Disorder	O
between	O
the	O
Regular	O
(	O
9/1,125	O
,	O
0.8	O
%	O
)	O
and	O
Intensive	O
(	O
7/1,167	O
,	O
0.6	O
%	O
)	O
groups	O
,	O
nor	O
a	O
difference	O
between	O
groups	O
in	O
the	O
level	O
of	O
autistic-like	O
traits	O
in	O
early	O
adulthood	O
.	O

There	O
is	O
no	O
clear	O
link	O
between	O
the	O
frequency	O
and	O
timing	O
of	O
prenatal	O
ultrasound	O
scans	O
and	O
the	O
autism	O
phenotype	O
.	O

Profound	O
luteinizing	O
hormone	O
suppression	O
after	O
stopping	O
the	O
gonadotropin-releasing	O
hormone-agonist	O
leuprolide	O
acetate	O
.	O

OBJECTIVE	O
To	O
compare	O
levels	O
of	O
serum	O
LH	O
during	O
continued	O
use	O
of	O
leuprolide	O
acetate	O
(	O
LA	O
)	O
with	O
levels	O
during	O
the	O
first	O
week	O
after	O
discontinuing	O
LA	O
.	O

DESIGN	O
Prospective	O
controlled	O
study	O
.	O

SETTING	O
Clinical	O
assisted	O
conception	O
program	O
.	O

PATIENTS	O
Women	Condition
undergoing	O
controlled	O
ovarian	Condition
stimulation	Condition
for	O
assisted	O
conception	O
were	O
randomized	O
to	O
receive	O
LA	O
according	O
to	O
short	O
or	O
ultrashort	O
protocols	O
.	O

The	O
alternative	O
protocol	O
was	O
used	O
then	O
in	O
a	O
second	O
cycle	O
.	O

Each	O
patient	O
was	O
thus	O
her	O
own	O
control	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Serum	O
LH	O
over	O
time	O
.	O

RESULTS	O
When	O
LA	O
was	O
stopped	O
after	O
5	O
days	O
of	O
administration	O
,	O
LH	O
levels	O
fell	O
profoundly	O
when	O
compared	O
with	O
levels	O
when	O
LA	O
was	O
continued	O
.	O

CONCLUSION	O
Loss	O
of	O
LH	O
after	O
stopping	O
LA	O
is	O
likely	O
to	O
be	O
clinically	O
important	O
in	O
ovarian	O
stimulation	O
regimens	O
that	O
use	O
pure	O
FSH	O
with	O
LA	O
in	O
ultrashort	O
protocols	O
.	O

The	O
fall	O
in	O
LH	O
lasts	O
at	O
least	O
1	O
week	O
and	O
may	O
be	O
explainable	O
by	O
persistent	O
suppression	O
of	O
endogenous	O
GnRH	O
by	O
LA	O
during	O
this	O
time	O
.	O

Physical	O
health	O
--	O
a	O
cluster	O
randomized	O
controlled	O
lifestyle	O
intervention	O
among	O
persons	O
with	O
a	O
psychiatric	O
disability	O
and	O
their	O
staff	O
.	O

The	O
objective	O
was	O
to	O
explore	O
the	O
impact	O
on	O
physical	O
health	O
of	O
a	O
lifestyle	O
programme	O
among	O
persons	O
with	O
psychiatric	O
disabilities	O
,	O
and	O
their	O
caregivers	O
.	O

Their	O
satisfaction	O
with	O
the	O
intervention	O
was	O
also	O
assessed	O
.	O

Somatic	O
comorbidity	O
and	O
an	O
increased	O
mortality	O
related	O
to	O
the	O
lifestyle	O
among	O
persons	O
with	O
psychiatric	O
disabilities	O
are	O
well	O
known	O
.	O

Few	O
randomized	O
controlled	O
trials	O
have	O
been	O
aimed	O
specifically	O
at	O
lifestyle	O
issues	O
among	O
persons	O
with	O
a	O
psychiatric	O
disability	O
.	O

This	O
trial	O
includes	O
clients	O
with	O
psychiatric	O
disabilities	O
living	O
in	O
supported	O
housing	O
and	O
their	O
staff	O
.	O

Forty-one	O
persons	O
with	O
a	O
DSM-	O
?	O
V	O
diagnosis	O
of	O
severe	O
mental	O
illness	O
from	O
psychiatric	O
disability	O
from	O
10	O
supported	O
housing	O
facilities	O
and	O
41	O
of	O
their	O
caregivers	O
participated	O
in	O
this	O
12-month	O
study	O
during	O
2005-2006	O
in	O
Sweden	O
.	O

The	O
supported	O
housing	O
facilities	O
with	O
residents	O
and	O
staff	O
were	O
randomly	O
assigned	O
to	O
either	O
a	O
health	O
intervention	O
programme	O
or	O
a	O
control	O
programme	O
with	O
an	O
aesthetic	O
content	O
.	O

The	O
presence	O
of	O
metabolic	O
syndrome	O
and	O
changes	O
in	O
the	O
mean	O
of	O
physiological	O
parameters	O
such	O
as	O
Hba1c	O
,	O
P-glucose	O
,	O
P-insulin	O
,	O
lipids	O
,	O
blood	O
pressure	O
,	O
physical	O
working	O
capacity	O
,	O
body	O
mass	O
index	O
,	O
Heart	O
Score	O
were	O
investigated	O
and	O
participants	O
'	O
satisfaction	O
assessed	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
mean	O
of	O
metabolic	O
syndrome	O
criteria	O
in	O
the	O
intervention	O
group	O
compared	O
with	O
the	O
control	O
group	O
at	O
the	O
follow-up	O
.	O

The	O
participants	O
expressed	O
satisfaction	O
with	O
the	O
programme	O
.	O

The	O
results	O
indicate	O
that	O
health	O
interventions	O
on	O
lifestyle	O
issues	O
when	O
involving	O
carers	O
are	O
appreciated	O
,	O
feasible	O
and	O
could	O
be	O
successful	O
in	O
reducing	O
some	O
health-related	O
risk	O
factors	O
among	O
persons	O
with	O
psychiatric	O
disabilities	O
.	O

A	O
randomized	O
controlled	O
trial	O
of	O
nonlinear	O
frequency	O
compression	O
versus	O
conventional	O
processing	O
in	O
hearing	O
aids	O
:	O
speech	O
and	O
language	O
of	O
children	Age
at	Age
three	Age
years	Age
of	Age
age	Age
.	Age

OBJECTIVE	O
To	O
determine	O
the	O
effect	O
of	O
nonlinear	O
frequency	O
compression	O
(	O
NLFC	O
)	O
on	O
children	O
's	O
development	O
of	O
speech	O
and	O
language	O
at	O
three	O
years	O
of	O
age	O
.	O

DESIGN	O
A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
as	O
part	O
of	O
the	O
population-based	O
longitudinal	O
study	O
on	O
outcomes	O
of	O
children	O
with	O
hearing	O
impairment	O
(	O
LOCHI	O
)	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
fitting	O
with	O
NLFC	O
(	O
Phonak	O
Naida	O
V	O
SP	O
or	O
UP	O
)	O
or	O
with	O
conventional	O
processing	O
in	O
hearing	O
aids	O
,	O
prescribed	O
by	O
using	O
either	O
the	O
NAL	O
or	O
the	O
DSL	O
formula	O
.	O

Standardized	O
tests	O
of	O
speech	O
production	O
,	O
receptive	O
and	O
expressive	O
language	O
were	O
administered	O
,	O
and	O
parent	O
ratings	O
were	O
collected	O
.	O

All	O
assessments	O
were	O
double-blinded	O
.	O

STUDY	O
SAMPLE	O
Participants	O
were	O
44	O
of	O
the	O
450	O
children	O
in	O
the	O
LOCHI	O
cohort	O
.	O

RESULTS	O
Compared	O
to	O
children	O
using	O
conventional	O
processing	O
,	O
receptive	O
and	O
expressive	O
language	O
was	O
higher	O
but	O
receptive	O
vocabulary	O
and	O
consonant	O
articulation	O
scores	O
were	O
lower	O
for	O
children	O
who	O
use	O
NLFC	O
.	O

There	O
was	O
increased	O
substitution	O
of	O
affricates	O
by	O
fricatives	O
for	O
children	O
using	O
NLFC	O
,	O
compared	O
to	O
children	O
using	O
conventional	O
amplification	O
.	O

After	O
allowing	O
for	O
the	O
effect	O
of	O
multiple	O
demographic	O
variables	O
,	O
the	O
difference	O
in	O
global	O
language	O
scores	O
between	O
groups	O
was	O
not	O
significant	O
(	O
effect	O
:	O
0.8	O
[	O
95	O
%	O
confidence	O
interval	O
:	O
-	O
6.7	O
,	O
8.3	O
]	O
)	O
.	O

CONCLUSIONS	O
There	O
is	O
insufficient	O
evidence	O
to	O
indicate	O
a	O
difference	O
in	O
language	O
ability	O
between	O
children	O
using	O
NLFC	O
and	O
those	O
using	O
conventional	O
amplification	O
.	O

Randomized	O
trial	O
of	O
the	O
effects	O
of	O
risedronate	O
on	O
vertebral	O
fractures	O
in	O
women	Sex
with	O
established	O
postmenopausal	Condition
osteoporosis	Condition
.	O

Vertebral	O
Efficacy	O
with	O
Risedronate	O
Therapy	O
(	O
VERT	O
)	O
Study	O
Group	O
.	O

The	O
purpose	O
of	O
this	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
risedronate	O
in	O
the	O
prevention	O
of	O
vertebral	O
fractures	O
in	O
postmenopausal	O
women	O
with	O
established	Condition
osteoporosis	Condition
.	O

The	O
study	O
was	O
conducted	O
at	O
80	O
study	O
centers	O
in	O
Europe	O
and	O
Australia	O
.	O

Postmenopausal	O
women	O
(	O
n	O
=	O
1226	O
)	O
with	O
two	Condition
or	Condition
more	Condition
prevalent	Condition
vertebral	Condition
fractures	Condition
received	O
risedronate	O
2.5	O
or	O
5	O
mg/day	O
or	O
placebo	O
;	O
all	O
subjects	O
also	O
received	O
elemental	O
calcium	O
1000	O
mg/day	O
,	O
and	O
up	O
to	O
500	O
IU/day	O
vitamin	O
D	O
if	O
baseline	O
levels	O
were	O
low	O
.	O

The	O
study	O
duration	O
was	O
3	O
years	O
;	O
however	O
,	O
the	O
2.5	O
mg	O
group	O
was	O
discontinued	O
by	O
protocol	O
amendment	O
after	O
2	O
years	O
.	O

Lateral	O
spinal	O
radiographs	O
were	O
taken	O
annually	O
for	O
assessment	O
of	O
vertebral	O
fractures	O
,	O
and	O
bone	O
mineral	O
density	O
was	O
measured	O
by	O
dual-energy	O
X-ray	O
absorptiometry	O
at	O
6-month	O
intervals	O
.	O

Risedronate	O
5	O
mg	O
reduced	O
the	O
risk	O
of	O
new	O
vertebral	O
fractures	O
by	O
49	O
%	O
over	O
3	O
years	O
compared	O
with	O
control	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
significant	O
reduction	O
of	O
61	O
%	O
was	O
seen	O
within	O
the	O
first	O
year	O
(	O
p	O
=	O
0.001	O
)	O
.	O

The	O
fracture	O
reduction	O
with	O
risedronate	O
2.5	O
mg	O
was	O
similar	O
to	O
that	O
in	O
the	O
5	O
mg	O
group	O
over	O
2	O
years	O
.	O

The	O
risk	O
of	O
nonvertebral	O
fractures	O
was	O
reduced	O
by	O
33	O
%	O
compared	O
with	O
control	O
over	O
3	O
years	O
(	O
p	O
=	O
0.06	O
)	O
.	O

Risedronate	O
significantly	O
increased	O
bone	O
mineral	O
density	O
at	O
the	O
spine	O
and	O
hip	O
within	O
6	O
months	O
.	O

The	O
adverse-event	O
profile	O
of	O
risedronate	O
,	O
including	O
gastrointestinal	O
adverse	O
events	O
,	O
was	O
similar	O
to	O
that	O
of	O
control	O
.	O

Risedronate	O
5	O
mg	O
provides	O
effective	O
and	O
well-tolerated	O
therapy	O
for	O
severe	Condition
postmenopausal	Condition
osteoporosis	Condition
,	O
reducing	O
the	O
incidence	O
of	O
vertebral	O
fractures	O
and	O
improving	O
bone	O
density	O
in	O
women	O
with	O
established	Condition
disease	Condition
.	O

Fulvestrant	O
versus	O
anastrozole	O
for	O
the	O
treatment	O
of	O
advanced	O
breast	O
carcinoma	O
:	O
a	O
prospectively	O
planned	O
combined	O
survival	O
analysis	O
of	O
two	O
multicenter	O
trials	O
.	O

BACKGROUND	O
Fulvestrant	O
is	O
an	O
estrogen	O
receptor	O
antagonist	O
with	O
no	O
agonist	O
effects	O
.	O

In	O
the	O
second-line	O
treatment	O
of	O
advanced	O
breast	O
carcinoma	O
,	O
fulvestrant	O
was	O
shown	O
previously	O
to	O
be	O
as	O
effective	O
as	O
the	O
third-generation	O
aromatase	O
inhibitor	O
,	O
anastrozole	O
,	O
in	O
terms	O
of	O
time	O
to	O
disease	O
progression	O
and	O
objective	O
response	O
rates	O
.	O

The	O
authors	O
reported	O
the	O
overall	O
survival	O
results	O
from	O
these	O
studies	O
.	O

METHODS	O
A	O
prospectively	O
planned	O
,	O
combined	O
,	O
overall	O
survival	O
analysis	O
was	O
performed	O
,	O
including	O
data	O
from	O
two	O
Phase	O
III	O
trials	O
that	O
compared	O
the	O
efficacy	O
and	O
tolerability	O
of	O
fulvestrant	O
(	O
250	O
mg	O
monthly	O
;	O
n	O
=	O
428	O
)	O
with	O
anastrozole	O
(	O
1	O
mg	O
daily	O
;	O
n	O
=	O
423	O
)	O
in	O
the	O
treatment	O
of	O
postmenopausal	Condition
women	Sex
with	O
advanced	Condition
breast	Condition
carcinoma	Condition
who	O
had	O
disease	O
progression	O
after	O
receipt	O
of	O
previous	O
endocrine	O
treatment	O
.	O

RESULTS	O
At	O
an	O
extended	O
median	O
follow-up	O
of	O
27.0	O
months	O
(	O
range	O
,	O
0-66.9	O
months	O
)	O
,	O
319	SampleSize
(	O
74.5	O
%	O
)	O
patients	O
in	O
the	O
fulvestrant	O
group	O
and	O
322	SampleSize
(	O
76.1	O
%	O
)	O
patients	O
in	O
the	O
anastrozole	O
group	O
had	O
died	O
.	O

Prolonged	O
survival	O
was	O
observed	O
with	O
both	O
drugs	O
,	O
with	O
10-20	O
%	O
of	O
patients	O
still	O
alive	O
>	O
5	O
years	O
after	O
randomization	O
.	O

The	O
median	O
overall	O
survival	O
was	O
similar	O
between	O
treatments	O
,	O
being	O
27.4	O
months	O
and	O
27.7	O
months	O
in	O
fulvestrant	O
and	O
anastrozole-treated	O
patients	O
,	O
respectively	O
(	O
hazards	O
ratio	O
,	O
0.98	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.84-1.15	O
;	O
P	O
=	O
0.809	O
)	O
.	O

Fulvestrant	O
continued	O
to	O
be	O
well	O
tolerated	O
,	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
incidence	O
of	O
joint	O
disorders	O
compared	O
with	O
anastrozole	O
(	O
P	O
=	O
0.0234	O
)	O
.	O

CONCLUSIONS	O
The	O
current	O
analysis	O
showed	O
that	O
fulvestrant	O
was	O
similar	O
to	O
anastrozole	O
with	O
respect	O
to	O
overall	O
survival	O
in	O
the	O
second-line	O
treatment	O
of	O
postmenopausal	Condition
women	Sex
with	O
advanced	Condition
breast	Condition
carcinoma	Condition
.	O

A	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
parallel	O
study	O
of	O
loteprednol	O
etabonate	O
0.2	O
%	O
in	O
patients	O
with	O
seasonal	Condition
allergic	Condition
conjunctivitis	Condition
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
loteprednol	O
etabonate	O
(	O
LE	O
)	O
0.2	O
%	O
in	O
reducing	O
the	O
signs	O
and	O
symptoms	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

DESIGN	O
Randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
multicenter	O
study	O
of	O
6	O
weeks	O
duration	O
.	O

PARTICIPANTS	O
A	O
total	O
of	O
135	SampleSize
patients	O
with	O
signs	O
and	O
symptoms	O
of	O
seasonal	Condition
allergic	Condition
conjunctivitis	Condition
participated	O
.	O

INTERVENTION	O
All	O
patients	O
received	O
either	O
LE	O
0.2	O
%	O
or	O
placebo	O
(	O
vehicle	O
)	O
four	O
times	O
a	O
day	O
in	O
both	O
eyes	O
for	O
42	O
days	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Bulbar	O
conjunctival	O
injection	O
(	O
primary	O
sign	O
)	O
and	O
itching	O
(	O
primary	O
symptom	O
)	O
over	O
the	O
first	O
2	O
weeks	O
of	O
treatment	O
was	O
measured	O
.	O

RESULTS	O
A	O
reduction	O
in	O
severity	O
was	O
seen	O
in	O
both	O
LE	O
and	O
placebo	O
groups	O
for	O
bulbar	O
conjunctival	O
injection	O
(	O
1.5	O
vs.	O
1.0	O
units	O
on	O
a	O
0-3	O
scale	O
)	O
and	O
itching	O
(	O
3.4	O
vs.	O
3.0	O
units	O
on	O
a	O
0-4	O
scale	O
)	O
over	O
the	O
first	O
2	O
weeks	O
.	O

The	O
treatment	O
effect	O
by	O
these	O
measures	O
was	O
-0.5	O
and	O
-0.4	O
units	O
in	O
favor	O
of	O
LE	O
(	O
P	O
<	O
or	O
=	O
0.008	O
)	O
.	O

Resolution	O
(	O
i.e.	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
signs	O
or	O
symptoms	O
no	O
longer	O
present	O
)	O
at	O
day	O
14	O
strongly	O
favored	O
LE-treated	O
patients	O
(	O
36	O
%	O
and	O
15	O
%	O
;	O
58	O
%	O
and	O
38	O
%	O
,	O
for	O
injection	O
and	O
itching	O
,	O
respectively	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

One	O
patient	O
in	O
each	O
treatment	O
group	O
(	O
1	O
of	O
67	O
and	O
1	O
of	O
68	O
,	O
respectively	O
)	O
had	O
an	O
elevation	O
of	O
intraocular	O
pressure	O
of	O
10	O
mmHg	O
or	O
greater	O
during	O
the	O
6	O
weeks	O
of	O
treatment	O
.	O

CONCLUSIONS	O
Loteprednol	O
etabonate	O
0.2	O
%	O
was	O
more	O
effective	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

Loteprednol	O
etabonate	O
0.2	O
%	O
had	O
a	O
safety	O
profile	O
comparable	O
to	O
placebo	O
.	O

The	O
relationship	O
between	O
repetitive	O
behaviors	O
and	O
growth	O
hormone	O
response	O
to	O
sumatriptan	O
challenge	O
in	O
adult	Age
autistic	Condition
disorder	Condition
.	O

Autism	O
is	O
heterogeneous	O
with	O
respect	O
to	O
clinical	O
symptoms	O
and	O
etiology	O
.	O

To	O
sort	O
out	O
this	O
heterogeneity	O
in	O
autism	O
,	O
we	O
investigated	O
whether	O
specific	O
neurobiological	O
markers	O
vary	O
in	O
parallel	O
to	O
core	O
symptomatology	O
.	O

Specifically	O
,	O
we	O
assessed	O
growth	O
hormone	O
response	O
to	O
the	O
5-HT	O
1d	O
agonist	O
,	O
sumatriptan	O
,	O
and	O
linked	O
this	O
measure	O
of	O
serotonergic	O
function	O
to	O
the	O
severity	O
of	O
repetitive	O
behaviors	O
in	O
adult	Age
autistic	Condition
patients	O
.	O

Eleven	SampleSize
adult	Age
patients	O
with	O
autism	Condition
or	O
Asperger	Condition
's	Condition
disorder	Condition
were	O
randomized	O
to	O
single	O
dose	O
sumatriptan	O
(	O
6	O
mg	O
SQ	O
)	O
and	O
placebo	O
challenges	O
,	O
separated	O
by	O
a	O
one-week	O
interval	O
.	O

In	O
adult	O
autistic	O
disorders	O
,	O
severity	O
of	O
repetitive	O
behaviors	O
at	O
baseline	O
,	O
as	O
measured	O
by	O
YBOCS-compulsion	O
score	O
,	O
significantly	O
positively	O
correlated	O
with	O
both	O
peak	O
delta	O
growth	O
hormone	O
response	O
and	O
area	O
under	O
the	O
curve	O
growth	O
hormone	O
response	O
to	O
sumatriptan	O
.	O

Thus	O
,	O
the	O
severity	O
of	O
a	O
specific	O
behavioral	O
dimension	O
in	O
autism	O
(	O
repetitive	O
behaviors	O
)	O
parallels	O
the	O
sensitivity	O
of	O
the	O
5-HT	O
1d	O
receptor	O
,	O
as	O
manifest	O
by	O
sumatriptan	O
elicited	O
GH	O
response	O
.	O

Comparing	O
microvascular	O
alterations	O
during	O
minimal	O
extracorporeal	O
circulation	O
and	O
conventional	O
cardiopulmonary	O
bypass	O
in	O
coronary	Condition
artery	Condition
bypass	Condition
graft	O
surgery	O
:	O
a	O
prospective	O
,	O
randomized	O
study	O
.	O

OBJECTIVES	O
Minimal	O
extracorporeal	O
circulation	O
(	O
MECC	O
)	O
has	O
been	O
introduced	O
in	O
coronary	O
artery	O
bypass	O
graft	O
(	O
CABG	O
)	O
surgery	O
,	O
offering	O
clinical	O
benefits	O
owing	O
to	O
reduced	O
hemodilution	O
and	O
no	O
blood-air	O
interface	O
.	O

Yet	O
,	O
the	O
effects	O
of	O
MECC	O
on	O
the	O
intraoperative	O
microvascular	O
perfusion	O
in	O
comparison	O
with	O
conventional	O
extracorporeal	O
circulation	O
(	O
CECC	O
)	O
have	O
not	O
been	O
studied	O
so	O
far	O
.	O

METHODS	O
The	O
current	O
study	O
aimed	O
to	O
analyze	O
alterations	O
in	O
microvascular	O
perfusion	O
at	O
4	O
predefined	O
time	O
points	O
(	O
T1-T4	O
)	O
during	O
on-pump	O
CABG	O
using	O
orthogonal	O
polarization	O
spectral	O
imaging	O
.	O

Forty	SampleSize
patients	O
were	O
randomized	O
for	O
being	O
operated	O
on	O
with	O
either	O
MECC	O
or	O
CECC	O
.	O

Changes	O
in	O
functional	O
capillary	O
density	O
(	O
FCD	O
)	O
,	O
blood	O
flow	O
velocity	O
,	O
and	O
vessel	O
diameter	O
were	O
analyzed	O
by	O
a	O
blinded	O
investigator	O
.	O

RESULTS	O
After	O
start	O
of	O
extracorporeal	O
circulation	O
(	O
ECC	O
)	O
and	O
aortic	O
crossclamping	O
(	O
T2	O
)	O
,	O
both	O
groups	O
showed	O
a	O
significant	O
drop	O
of	O
FCD	O
,	O
with	O
a	O
significantly	O
higher	O
FCD	O
in	O
the	O
MECC	O
group	O
(	O
206.8	O
?	O
33.6	O
cm/cm?	O
in	O
CECC	O
group	O
versus	O
217.8	O
?	O
35.3	O
cm/cm?	O
in	O
MECC	O
group	O
;	O
P	O
=	O
.034	O
)	O
.	O

In	O
the	O
late	O
phase	O
of	O
the	O
ECC	O
(	O
T3	O
)	O
,	O
FCD	O
in	O
the	O
MECC	O
group	O
was	O
already	O
recovered	O
,	O
whereas	O
FCD	O
in	O
the	O
CECC	O
group	O
was	O
still	O
significantly	O
depressed	O
(	O
223.1	O
?	O
35.6	O
cm/cm?	O
in	O
MECC	O
group	O
;	O
P	O
=	O
.100	O
vs	O
T1	O
;	O
211.1	O
?	O
36.9	O
cm/cm?	O
in	O
CECC	O
group	O
;	O
P	O
=	O
.017	O
vs	O
T1	O
)	O
.	O

After	O
termination	O
of	O
ECC	O
(	O
T4	O
)	O
,	O
FCD	O
recovered	O
in	O
both	O
groups	O
to	O
baseline	O
.	O

Blood	O
flow	O
velocity	O
tended	O
to	O
be	O
higher	O
in	O
the	O
MECC	O
group	O
,	O
with	O
a	O
significant	O
intergroup	O
difference	O
after	O
aortic	O
crossclamping	O
(	O
T2	O
)	O
.	O

CONCLUSIONS	O
Orthogonal	O
polarization	O
spectral	O
imaging	O
data	O
reveal	O
an	O
impairment	O
of	O
microvascular	O
perfusion	O
during	O
on-pump	O
CABG	O
.	O

Changes	O
in	O
FCD	O
indicate	O
a	O
faster	O
recovery	O
of	O
the	O
microvascular	O
perfusion	O
in	O
MECC	O
during	O
the	O
reperfusion	O
period	O
.	O

Beneficial	O
recovery	O
of	O
microvascular	O
organ	O
perfusion	O
could	O
partly	O
explain	O
the	O
perioperative	O
advantages	O
reported	O
for	O
MECC	O
.	O

Supplemental	O
perioperative	O
oxygen	O
and	O
the	O
risk	O
of	O
surgical	O
wound	O
infection	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

CONTEXT	O
Supplemental	O
perioperative	O
oxygen	O
has	O
been	O
variously	O
reported	O
to	O
halve	O
or	O
double	O
the	O
risk	O
of	O
surgical	O
wound	O
infection	O
.	O

OBJECTIVE	O
To	O
test	O
the	O
hypothesis	O
that	O
supplemental	O
oxygen	O
reduces	O
infection	O
risk	O
in	O
patients	O
following	O
colorectal	O
surgery	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
A	O
double-blind	O
,	O
randomized	O
controlled	O
trial	O
of	O
300	O
patients	O
aged	O
18	O
to	O
80	O
years	O
who	O
underwent	O
elective	O
colorectal	O
surgery	O
in	O
14	O
Spanish	O
hospitals	O
from	O
March	O
1	O
,	O
2003	O
,	O
to	O
October	O
31	O
,	O
2004	O
.	O

Wound	O
infections	O
were	O
diagnosed	O
by	O
blinded	O
investigators	O
using	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
criteria	O
.	O

Baseline	O
patient	O
characteristics	O
,	O
anesthetic	O
treatment	O
,	O
and	O
potential	O
confounding	O
factors	O
were	O
recorded	O
.	O

INTERVENTIONS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
either	O
30	O
%	O
or	O
80	O
%	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FIO2	O
)	O
intraoperatively	O
and	O
for	O
6	O
hours	O
after	O
surgery	O
.	O

Anesthetic	O
treatment	O
and	O
antibiotic	O
administration	O
were	O
standardized	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Any	O
surgical	O
site	O
infection	O
(	O
SSI	O
)	O
;	O
secondary	O
outcomes	O
included	O
return	O
of	O
bowel	O
function	O
and	O
ability	O
to	O
tolerate	O
solid	O
food	O
,	O
ambulation	O
,	O
suture	O
removal	O
,	O
and	O
duration	O
of	O
hospitalization	O
.	O

RESULTS	O
A	O
total	O
of	O
143	O
patients	O
received	O
30	O
%	O
perioperative	O
oxygen	O
and	O
148	O
received	O
80	O
%	O
perioperative	O
oxygen	O
.	O

Surgical	O
site	O
infection	O
occurred	O
in	O
35	O
patients	O
(	O
24.4	O
%	O
)	O
administered	O
30	O
%	O
FIO2	O
and	O
in	O
22	O
patients	O
(	O
14.9	O
%	O
)	O
administered	O
80	O
%	O
FIO2	O
(	O
P=.04	O
)	O
.	O

The	O
risk	O
of	O
SSI	O
was	O
39	O
%	O
lower	O
in	O
the	O
80	O
%	O
FIO2	O
group	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
,	O
0.61	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.38-0.98	O
)	O
vs	O
the	O
30	O
%	O
FIO2	O
group	O
.	O

After	O
adjustment	O
for	O
important	O
covariates	O
,	O
the	O
RR	O
of	O
infection	O
in	O
patients	O
administered	O
supplemental	O
oxygen	O
was	O
0.46	O
(	O
95	O
%	O
CI	O
,	O
0.22-0.95	O
;	O
P	O
=	O
.04	O
)	O
.	O

None	O
of	O
the	O
secondary	O
outcomes	O
varied	O
significantly	O
between	O
the	O
2	O
treatment	O
groups	O
.	O

CONCLUSIONS	O
Patients	O
receiving	O
supplemental	O
inspired	O
oxygen	O
had	O
a	O
significant	O
reduction	O
in	O
the	O
risk	O
of	O
wound	O
infection	O
.	O

Supplemental	O
oxygen	O
appears	O
to	O
be	O
an	O
effective	O
intervention	O
to	O
reduce	O
SSI	O
in	O
patients	O
undergoing	O
colon	O
or	O
rectal	O
surgery	O
.	O

Trial	O
Registration	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00235456	O
.	O

Comparison	O
of	O
a	O
biopsychosocial	O
therapy	O
(	O
BT	O
)	O
with	O
a	O
conventional	O
biomedical	O
therapy	O
(	O
MT	O
)	O
of	O
subacute	O
low	O
back	O
pain	O
in	O
the	O
first	O
episode	O
of	O
sick	O
leave	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

This	O
randomized	O
controlled	O
clinical	O
trial	O
compares	O
the	O
effectiveness	O
of	O
a	O
biopsychosocial	O
treatment	O
with	O
a	O
solely	O
conventional	O
biomedical	O
therapy	O
in	O
patients	O
with	O
subacute	O
low	O
back	O
pain	O
using	O
parameters	O
for	O
pain	O
intensity	O
,	O
functional	O
status	O
,	O
depressive	O
dysfunction	O
and	O
work	O
performance	O
.	O

Sixty-four	SampleSize
patients	O
with	O
a	O
first-time	O
sick	O
leave	O
between	O
3	O
and	O
12	O
weeks	O
due	O
to	O
low	Condition
back	Condition
pain	Condition
were	O
randomly	O
assigned	O
to	O
either	O
a	O
conventional	O
biomedical	O
therapy	O
(	O
MT	O
;	O
n=33	O
)	O
group	O
,	O
or	O
a	O
biopsychosocial	O
therapy	O
(	O
BT	O
;	O
n=31	O
)	O
group	O
including	O
a	O
psychotherapeutic	O
module	O
;	O
both	O
in	O
accordance	O
with	O
a	O
standardized	O
3	O
weeks	O
inpatient	O
treatment	O
.	O

Pain	O
intensity	O
,	O
functional	O
back	O
capacity	O
,	O
clinical	O
parameters	O
and	O
depressive	O
dysfunction	O
revealed	O
significant	O
improvement	O
in	O
both	O
treatment	O
groups	O
at	O
end	O
of	O
3	O
weeks	O
therapy	O
(	O
T1	O
)	O
.	O

However	O
,	O
at	O
6	O
months	O
(	O
T2	O
)	O
,	O
analysis	O
revealed	O
significant	O
better	O
results	O
for	O
nearly	O
all	O
parameters	O
in	O
the	O
BT	O
group	O
that	O
showed	O
further	O
improvement	O
from	O
T1	O
to	O
T2	O
,	O
whereas	O
the	O
values	O
in	O
the	O
MT	O
group	O
deteriorated	O
from	O
T1	O
back	O
to	O
the	O
baseline	O
values	O
.	O

During	O
the	O
2-year	O
period	O
after	O
therapy	O
,	O
10	O
%	O
in	O
MT	O
and	O
59	O
%	O
in	O
BT	O
required	O
no	O
further	O
sick	O
leave	O
due	O
to	O
low	O
back	O
pain	O
.	O

The	O
results	O
of	O
the	O
study	O
indicate	O
that	O
a	O
psychotherapeutic	O
element	O
in	O
the	O
treatment	O
of	O
low	O
back	O
pain	O
appears	O
to	O
positively	O
influence	O
pain	O
,	O
functional	O
status	O
and	O
work	O
performance	O
when	O
conducted	O
at	O
an	O
early	O
stage	O
of	O
chronification	O
and	O
helps	O
in	O
the	O
achievement	O
of	O
a	O
better	O
outcome	O
.	O

Evaluation	O
of	O
a	O
new	O
wound	O
closure	O
device	O
for	O
linear	O
surgical	O
incisions	O
:	O
3M	O
Steri-Strip	O
S	O
Surgical	O
Skin	O
Closure	O
versus	O
subcuticular	O
closure	O
.	O

BACKGROUND	O
Technological	O
innovations	O
are	O
often	O
adopted	O
before	O
scientific	O
comparison	O
to	O
an	O
accepted	O
standard	O
.	O

The	O
authors	O
'	O
study	O
compared	O
suture	O
with	O
a	O
new	O
coaptive	O
film	O
device	O
,	O
3M	O
Steri-Strip	O
S	O
Surgical	O
Skin	O
Closure	O
,	O
on	O
linear	O
incisions	O
.	O

METHODS	O
Patients	O
undergoing	O
Wise-pattern	Condition
breast	Condition
reduction	Condition
or	Condition
abdominal	Condition
procedures	Condition
had	O
paired	O
incisions	O
randomly	O
assigned	O
to	O
Steri-Strip	O
S	O
or	O
suture	O
closure	O
.	O

Key	O
outcome	O
measures	O
were	O
closure	O
time	O
,	O
patient	O
comfort	O
,	O
and	O
scar	O
quality	O
at	O
6	O
months	O
by	O
patients	O
and	O
surgeons	O
using	O
a	O
new	O
scar	O
evaluation	O
tool	O
,	O
visual	O
assessment	O
of	O
linear	O
scars	O
.	O

Statistical	O
differences	O
between	O
the	O
two	O
closure	O
techniques	O
were	O
assessed	O
by	O
Wilcoxon	O
signed	O
rank	O
test	O
.	O

RESULTS	O
Of	O
59	SampleSize
patients	O
,	O
eight	O
were	O
excluded	O
from	O
randomization	O
(	O
a	O
surgeon	O
judged	O
Steri-Strip	O
S	O
to	O
be	O
a	O
nonviable	O
closure	O
technique	O
for	O
mismatched	O
wound	O
edges	O
)	O
.	O

Fifty-one	SampleSize
patients	O
(	O
breast	O
,	O
n	O
=	O
24	O
;	O
abdomen	O
,	O
n	O
=	O
27	O
)	O
were	O
randomized	O
.	O

Operative	O
time	O
with	O
Steri-Strip	O
S	O
for	O
breast	O
was	O
2.0	O
minutes	O
(	O
SD	O
=	O
1.1	O
)	O
versus	O
suture	O
closure	O
at	O
4.6	O
minutes	O
(	O
SD	O
=	O
1.5	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Similarly	O
,	O
Steri-Strip	O
S	O
versus	O
suture	O
for	O
the	O
abdomen	O
was	O
faster	O
(	O
p	O
<	O
0.001	O
;	O
4.9	O
minutes	O
,	O
SD	O
=	O
2.3	O
versus	O
10.1	O
minutes	O
,	O
SD	O
=	O
3.4	O
)	O
.	O

Comfort	O
scores	O
did	O
not	O
differ	O
between	O
closures	O
[	O
5.8	O
(	O
SD	O
=	O
2.7	O
)	O
versus	O
6.9	O
(	O
SD	O
=	O
2.0	O
)	O
,	O
respectively	O
,	O
on	O
breast	O
(	O
p	O
=	O
0.142	O
)	O
and	O
7.7	O
(	O
SD	O
=	O
1.8	O
)	O
versus	O
7.7	O
(	O
SD	O
=	O
2.3	O
)	O
on	O
abdomen	O
(	O
p	O
=	O
0.903	O
)	O
]	O
.	O

Complication	O
rates	O
did	O
not	O
differ	O
between	O
closure	O
types	O
.	O

Patients	O
'	O
visual	O
assessment	O
of	O
linear	O
scars	O
rating	O
of	O
breasts	O
was	O
3.8	O
(	O
SD	O
=	O
2.9	O
)	O
for	O
Steri-Strip	O
S	O
and	O
better	O
at	O
2.6	O
(	O
SD	O
=	O
2.9	O
)	O
for	O
suture	O
(	O
p	O
=	O
0.008	O
)	O
.	O

One	O
surgeon	O
rated	O
breast	O
Steri-Strip	O
S	O
scars	O
worse	O
than	O
suture	O
scars	O
(	O
4.3	O
versus	O
3.7	O
;	O
p	O
=	O
0.014	O
)	O
.	O

For	O
abdominal	O
scars	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
patient	O
or	O
surgeon	O
ratings	O
.	O

CONCLUSIONS	O
Steri-Strip	O
S	O
permits	O
faster	O
wound	O
closure	O
than	O
suture	O
.	O

On	O
the	O
basis	O
of	O
patient	O
reports	O
of	O
comfort	O
and	O
scar	O
quality	O
,	O
surgeons	O
increase	O
efficiency	O
and	O
maintain	O
quality	O
with	O
the	O
use	O
of	O
Steri-Strip	O
S	O
on	O
abdominal	O
wounds	O
but	O
not	O
on	O
breast	O
wounds	O
.	O

The	O
effect	O
of	O
an	O
early	O
education	O
program	O
on	O
adult	O
health	O
:	O
the	O
Carolina	O
Abecedarian	O
Project	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVES	O
We	O
explored	O
whether	O
a	O
successful	O
randomized	O
controlled	O
trial	O
of	O
early	O
education	O
,	O
the	O
Carolina	O
Abecedarian	O
Project	O
(	O
ABC	O
)	O
,	O
which	O
enrolled	O
infants	O
from	O
1972	O
to	O
1977	O
at	O
the	O
Frank	O
Porter	O
Graham	O
Child	O
Development	O
Institute	O
in	O
Chapel	O
Hill	O
,	O
North	O
Carolina	O
,	O
improved	O
health	O
outcomes	O
and	O
behaviors	O
by	O
21	O
years	O
of	O
age	O
.	O

METHODS	O
ABC	O
randomized	O
111	O
infants	O
to	O
receive	O
an	O
intensive	O
early	O
education	O
program	O
or	O
nutritional	O
supplements	O
and	O
parental	O
counseling	O
alone	O
;	O
participants	O
have	O
been	O
followed	O
to	O
the	O
present	O
day	O
.	O

We	O
examined	O
the	O
effect	O
of	O
ABC	O
on	O
health	O
outcomes	O
and	O
behavioral	O
risk	O
factors	O
when	O
participants	O
were	O
aged	O
21	O
years	O
,	O
and	O
then	O
explored	O
the	O
mediators	O
of	O
this	O
relationship	O
.	O

RESULTS	O
Relative	O
to	O
the	O
control	O
group	O
,	O
the	O
ABC	O
treatment	O
group	O
was	O
previously	O
found	O
to	O
have	O
improved	O
cognition	O
and	O
educational	O
attainment	O
.	O

We	O
found	O
that	O
the	O
intervention	O
also	O
improved	O
heath	O
(	O
P	O
=	O
.05	O
)	O
and	O
health	O
behaviors	O
(	O
P	O
=	O
.03	O
)	O
when	O
participants	O
were	O
aged	O
21	O
years	O
.	O

These	O
improvements	O
in	O
behaviors	O
were	O
not	O
mediated	O
by	O
IQ	O
,	O
math	O
and	O
reading	O
scores	O
at	O
15	O
years	O
of	O
age	O
,	O
educational	O
attainment	O
,	O
or	O
health	O
insurance	O
.	O

CONCLUSIONS	O
Effective	O
early	O
education	O
programs	O
may	O
improve	O
health	O
and	O
reduce	O
risky	O
health	O
behaviors	O
in	O
adulthood	O
.	O

[	O
Pharmacokinetics	O
of	O
theophylline	O
in	O
sustained-release	O
formulation	O
in	O
young	Condition
asthmatics	Condition
]	Condition
.	O

Pharmacokinetics	O
of	O
two	O
theophylline	O
(	O
CAS	O
58-55-9	O
)	O
sustained	O
release	O
preparations	O
(	O
T	O
:	O
Bronchoretard	O
Capsules/R	O
:	O
Capsule	O
formulation	O
from	O
the	O
US	O
market	O
)	O
were	O
investigated	O
in	O
an	O
open	O
randomised	O
two-way	O
crossover	O
design	O
.	O

The	O
capsules	O
of	O
the	O
test	O
formulation	O
were	O
opened	O
and	O
administered	O
on	O
a	O
tablespoonful	O
of	O
apple	O
sauce	O
.	O

Nineteen	O
asthmatics	O
aged	O
6	O
to	O
12	O
years	O
participated	O
in	O
this	O
study	O
.	O

Following	O
individual	O
dosing	O
of	O
100-300	O
mg	O
theophylline	O
twice	O
a	O
day	O
,	O
a	O
pharmacokinetic	O
profile	O
for	O
24	O
h	O
was	O
derived	O
after	O
seven	O
days	O
of	O
multiple	O
dosing	O
.	O

All	O
relevant	O
parameters	O
for	O
rate	O
(	O
Cmax	O
ss	O
,	O
Cmin	O
ss	O
,	O
Cav	O
ss	O
,	O
plateau	O
time	O
,	O
peak-trough	O
fluctuation	O
,	O
nocturnal	O
excess	O
,	O
tmax	O
ss	O
)	O
and	O
extent	O
of	O
absorption	O
(	O
AUCss	O
)	O
were	O
calculated	O
for	O
both	O
formulations	O
.	O

With	O
long	O
plateau	O
times	O
(	O
T	O
:	O
17.3	O
h	O
)	O
and	O
small	O
peak-trough	O
fluctuations	O
(	O
T	O
:	O
49.0	O
%	O
)	O
,	O
established	O
quality	O
criteria	O
for	O
high	O
quality	O
theophylline	O
preparations	O
were	O
fulfilled	O
by	O
the	O
test	O
formulation	O
.	O

Furthermore	O
,	O
symmetrical	O
peaks	O
resulted	O
after	O
morning	O
and	O
evening	O
administration	O
of	O
the	O
test	O
formulation	O
.	O

In	O
conclusion	O
,	O
smooth	O
and	O
predictable	O
concentration/time	O
profiles	O
were	O
achieved	O
,	O
enabling	O
an	O
efficacious	O
and	O
safe	O
therapy	O
of	O
asthma	O
.	O

This	O
individual	O
mode	O
of	O
administration	O
allows	O
not	O
only	O
a	O
perfect	O
dose	O
titration	O
in	O
young	O
asthmatics	O
,	O
but	O
is	O
also	O
helpful	O
to	O
patients	O
who	O
have	O
difficulty	O
in	O
swallowing	O
large	O
dosage	O
forms	O
.	O

Measuring	O
the	O
impact	O
of	O
patient	O
counseling	O
in	O
the	O
outpatient	O
pharmacy	O
setting	O
:	O
the	O
research	O
design	O
of	O
the	O
Kaiser	O
Permanente/USC	O
patient	O
consultation	O
study	O
.	O

This	O
article	O
describes	O
the	O
research	O
method	O
used	O
to	O
measure	O
the	O
impact	O
of	O
three	O
alternative	O
models	O
of	O
patient	O
counseling	O
in	O
the	O
outpatient	O
pharmacy	O
setting	O
.	O

The	O
study	O
was	O
conducted	O
in	O
pharmacies	O
operated	O
by	O
the	O
Southern	O
California	O
region	O
Kaiser	O
Permanente	O
Medical	O
Care	O
Program	O
.	O

Both	O
random	O
assignment	O
and	O
large-scale	O
geographic	O
area	O
research	O
designs	O
were	O
used	O
.	O

The	O
presentation	O
of	O
the	O
research	O
design	O
includes	O
discussions	O
of	O
data	O
collection	O
and	O
patient	O
sampling	O
methods	O
;	O
the	O
measurement	O
of	O
patient	O
outcomes	O
,	O
including	O
measures	O
of	O
health	O
care	O
costs	O
and	O
utilization	O
,	O
patient	O
functional	O
status	O
,	O
and	O
quality	O
of	O
life	O
.	O

Demographic	O
data	O
are	O
presented	O
for	O
the	O
study	O
population	O
,	O
including	O
an	O
analysis	O
of	O
potential	O
biased	O
selection	O
of	O
patients	O
electing	O
to	O
participate	O
in	O
random	O
assignment	O
.	O

Data	O
are	O
also	O
presented	O
documenting	O
potential	O
selection	O
bias	O
across	O
geographically	O
determined	O
treatment	O
groups	O
in	O
the	O
geographic	O
area	O
design	O
arm	O
.	O

Finally	O
,	O
the	O
article	O
presents	O
the	O
analysis	O
plan	O
for	O
the	O
study	O
and	O
discusses	O
study	O
limitations	O
.	O

Recombinant	O
human	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
ameliorates	O
zidovudine-induced	O
neutropenia	O
in	O
patients	O
with	O
acquired	Condition
immunodeficiency	Condition
syndrome	Condition
(	Condition
AIDS	Condition
)	Condition
/AIDS-related	Condition
complex	Condition
.	O

To	O
evaluate	O
the	O
effect	O
of	O
recombinant	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
on	O
patients	O
with	O
acquired	Condition
immunodeficiency	Condition
syndrome	Condition
(	Condition
AIDS	Condition
)	O
or	O
AIDS-related	Condition
complex	Condition
(	Condition
ARC	Condition
)	Condition
who	O
were	O
intolerant	O
to	O
zidovudine	O
because	O
of	O
neutropenia	Condition
,	O
we	O
performed	O
a	O
randomized	O
,	O
open-label	O
study	O
in	O
which	O
patients	O
were	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
.	O

Zidovudine	O
was	O
discontinued	O
in	O
group	O
A	O
patients	O
before	O
instituting	O
GM-CSF	O
treatment	O
and	O
was	O
restarted	O
in	O
a	O
graduated	O
fashion	O
over	O
4	O
weeks	O
.	O

Group	O
B	O
patients	O
continued	O
on	O
full-dose	O
(	O
1,200	O
mg/d	O
)	O
zidovudine	O
therapy	O
while	O
beginning	O
GM-CSF	O
therapy	O
.	O

A	O
total	O
of	O
17	SampleSize
patients	O
were	O
entered	O
,	O
eight	O
in	O
group	O
A	O
and	O
nine	O
in	O
group	O
B	O
.	O

Five	SampleSize
of	O
eight	SampleSize
patients	O
in	O
group	O
A	O
and	O
seven	SampleSize
of	O
nine	SampleSize
in	O
group	O
B	O
had	O
a	O
history	O
of	O
Pneumocystis	Condition
carinii	Condition
pneumonia	Condition
(	Condition
PCP	Condition
)	Condition
.	O

All	O
were	O
homosexual	O
males	Sex
,	O
except	O
one	SampleSize
female	Sex
in	O
group	O
A	O
who	O
was	O
the	O
sex	O
partner	O
of	O
a	O
bisexual	O
male	O
with	O
AIDS	Condition
.	O

All	O
patients	O
had	O
neutropenia	Condition
(	O
absolute	O
neutrophil	O
count	O
[	O
ANC	O
]	O
less	O
than	O
1,000/microL	O
)	O
while	O
taking	O
full-dose	O
zidovudine	O
.	O

The	O
mean	O
CD4	O
(	O
+/-	O
SD	O
)	O
lymphocyte	O
level	O
was	O
37	O
(	O
+/-	O
29	O
)	O
/microL	O
and	O
39	O
(	O
+/-	O
44	O
)	O
/microL	O
in	O
groups	O
A	O
and	O
B	O
,	O
respectively	O
.	O

After	O
randomization	O
,	O
patients	O
were	O
begun	O
on	O
subcutaneous	O
GM-CSF	O
at	O
a	O
dose	O
of	O
1.0	O
microgram/kg/d	O
.	O

Patients	O
in	O
group	O
A	O
received	O
2	O
weeks	O
of	O
daily	O
GM-CSF	O
,	O
at	O
which	O
time	O
zidovudine	O
was	O
restarted	O
if	O
the	O
ANC	O
was	O
greater	O
than	O
1,000/microL	O
;	O
if	O
the	O
ANC	O
was	O
less	O
than	O
1,000/microL	O
,	O
the	O
dose	O
of	O
GM-CSF	O
was	O
increased	O
to	O
3.0	O
micrograms/kg	O
,	O
and	O
at	O
2-week	O
intervals	O
either	O
zidovudine	O
was	O
restarted	O
or	O
the	O
dose	O
of	O
GM-CSF	O
was	O
increased	O
to	O
5	O
micrograms/kg	O
and	O
then	O
10	O
micrograms/kg	O
,	O
to	O
maintain	O
the	O
ANC	O
greater	O
than	O
1,000/microL	O
.	O

Group	O
B	O
patients	O
received	O
full-dose	O
zidovudine	O
concurrently	O
with	O
GM-CSF	O
administration	O
.	O

The	O
dose	O
of	O
GM-CSF	O
was	O
increased	O
every	O
2	O
weeks	O
if	O
necessary	O
to	O
keep	O
the	O
ANC	O
greater	O
than	O
1,000/microL	O
while	O
maintaining	O
full-dose	O
zidovudine	O
therapy	O
.	O

Patients	O
in	O
each	O
group	O
showed	O
an	O
increase	O
in	O
total	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
.	O

Neutrophils	O
and	O
eosinophils	O
were	O
responsible	O
for	O
the	O
majority	O
of	O
this	O
increase	O
.	O

Patients	O
in	O
group	O
A	O
had	O
a	O
more	O
rapid	O
increase	O
in	O
WBC	O
than	O
those	O
in	O
group	O
B	O
;	O
however	O
,	O
by	O
week	O
8	O
,	O
the	O
WBC	O
in	O
each	O
group	O
was	O
essentially	O
equal	O
.	O

Viral	O
replication	O
as	O
measured	O
by	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
p24	O
antigen	O
(	O
Ag	O
)	O
was	O
decreased	O
in	O
four	O
patients	O
in	O
each	O
group	O
,	O
increased	O
in	O
one	O
patient	O
in	O
each	O
group	O
,	O
and	O
remained	O
unchanged	O
in	O
the	O
remainder	O
.	O

The	O
ability	O
to	O
culture	O
virus	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
was	O
not	O
changed	O
by	O
the	O
regimen	O
.	O

The	O
major	O
toxicities	O
of	O
the	O
regimen	O
were	O
fever	O
and	O
malaise	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Determining	O
the	O
trough-to-peak	O
ratio	O
in	O
parallel-group	O
trials	O
.	O

Systolic	O
Hypertension	O
in	O
Europe	O
(	O
SYST-EUR	O
)	O
Trial	O
Investigators	O
.	O

We	O
explored	O
how	O
in	O
parallel-group	O
trials	O
interindividual	O
variability	O
,	O
correction	O
for	O
placebo	O
effects	O
,	O
and	O
smoothing	O
of	O
blood	O
pressure	O
profiles	O
can	O
be	O
handled	O
in	O
measuring	O
the	O
trough-to-peak	O
ratio	O
in	O
244	SampleSize
individuals	O
with	O
isolated	Condition
systolic	Condition
hypertension	Condition
(	O
>	Age
or	Age
=	Age
60	Age
years	Age
)	Age
enrolled	O
in	O
the	O
placebo-controlled	O
Systolic	Condition
Hypertension	Condition
in	O
europe	O
Trial	O
.	O

Net	O
treatment	O
effects	O
were	O
computed	O
by	O
subtracting	O
the	O
mean	O
changes	O
from	O
baseline	O
during	O
placebo	O
(	O
n	O
=	O
133	O
)	O
from	O
those	O
during	O
active	O
treatment	O
(	O
n	O
=	O
111	O
)	O
.	O

At	O
entry	O
,	O
systolic/diastolic	O
pressures	O
averaged	O
176/86	O
mm	O
Hg	O
in	O
the	O
clinic	O
and	O
149/80	O
mm	O
Hg	O
on	O
24-hour	O
ambulatory	O
monitoring	O
.	O

With	O
corrections	O
applied	O
for	O
baseline	O
and	O
placebo	O
,	O
nitrendipine	O
(	O
10	O
to	O
40	O
mg/d	O
)	O
,	O
with	O
the	O
possible	O
addition	O
of	O
enalapril	O
(	O
5	O
to	O
20	O
mg/d	O
)	O
and/or	O
hydrochlorothiazide	O
(	O
12.5	O
to	O
25	O
mg/d	O
)	O
,	O
reduced	O
(	O
P	O
<	O
.001	O
)	O
these	O
blood	O
pressure	O
values	O
by	O
16.6/7.3	O
and	O
9.8/4.7	O
mm	O
Hg	O
,	O
respectively	O
.	O

The	O
net	O
trough-to-peak	O
ratios	O
were	O
first	O
determined	O
from	O
blood	O
pressure	O
profiles	O
(	O
12	O
hours	O
)	O
with	O
1-hour	O
precision	O
,	O
synchronized	O
by	O
the	O
morning	O
and	O
evening	O
doses	O
of	O
the	O
double-blind	O
medication	O
.	O

According	O
to	O
the	O
usual	O
approach	O
,	O
disregarding	O
interindividual	O
variability	O
,	O
the	O
systolic/diastolic	O
net	O
trough-to-peak	O
ratios	O
were	O
0.46/0.40	O
in	O
the	O
morning	O
and	O
0.77/0.99	O
in	O
the	O
evening	O
.	O

In	O
individual	O
subjects	O
,	O
the	O
baseline-adjusted	O
trough-to-peak	O
ratios	O
were	O
nonnormally	O
distributed	O
.	O

We	O
therefore	O
used	O
a	O
nonparametric	O
technique	O
to	O
calculate	O
the	O
net	O
trough-to-peak	O
ratios	O
from	O
the	O
results	O
in	O
individual	O
subjects	O
.	O

In	O
the	O
morning	O
,	O
these	O
ratios	O
averaged	O
0.25	O
systolic	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.09	O
to	O
0.41	O
)	O
and	O
0.15	O
diastolic	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.00	O
to	O
0.31	O
)	O
and	O
in	O
the	O
evening	O
,	O
0.19	O
and	O
0.36	O
(	O
95	O
%	O
confidence	O
intervals	O
,	O
0.00	O
to	O
0.38	O
and	O
0.14	O
to	O
0.56	O
)	O
,	O
respectively	O
.	O

When	O
the	O
blood	O
pressure	O
profiles	O
were	O
smoothed	O
by	O
substituting	O
the	O
1-hour	O
averages	O
by	O
moving	O
or	O
fixed	O
2-hour	O
averages	O
or	O
by	O
Fourier	O
modeling	O
,	O
the	O
trough-to-peak	O
ratios	O
remained	O
unchanged	O
after	O
the	O
morning	O
dose	O
(	O
0.20/0.13	O
,	O
0.20/0.14	O
,	O
and	O
0.16/0.21	O
,	O
respectively	O
)	O
but	O
tended	O
to	O
increase	O
in	O
the	O
evening	O
(	O
0.32/0.38	O
,	O
0.28/0.40	O
,	O
and	O
0.48/0.49	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
parallel-group	O
analysis	O
proposed	O
makes	O
it	O
possible	O
for	O
one	O
to	O
correct	O
the	O
trough-to-peak	O
ratio	O
for	O
baseline	O
as	O
well	O
as	O
placebo	O
,	O
to	O
account	O
for	O
interindividual	O
variability	O
,	O
and	O
to	O
calculate	O
a	O
confidence	O
interval	O
for	O
the	O
net	O
trough-to-peak	O
ratio	O
.	O

Accounting	O
for	O
interindividual	O
variability	O
reduces	O
the	O
trough-to-peak	O
ratio	O
.	O

Smoothing	O
affects	O
the	O
individualized	O
net	O
trough-to-peak	O
ratios	O
in	O
an	O
unpredictable	O
way	O
and	O
should	O
therefore	O
be	O
avoided	O
.	O

Effect	O
of	O
L-arginine	O
or	O
L-citrulline	O
oral	O
supplementation	O
on	O
blood	O
pressure	O
and	O
right	O
ventricular	O
function	O
in	O
heart	Condition
failure	Condition
patients	O
with	O
preserved	Condition
ejection	Condition
fraction	Condition
.	O

BACKGROUND	O
The	O
effect	O
of	O
L-arginine	O
and	O
L-citrulline	O
on	O
blood	O
pressure	O
and	O
right	O
ventricular	O
function	O
in	O
heart	Condition
failure	Condition
patients	Condition
with	Condition
preserved	Condition
ejection	Condition
fraction	Condition
(	Condition
HFpEF	Condition
)	O
is	O
unknown	O
.	O

We	O
have	O
therefore	O
evaluated	O
,	O
in	O
a	O
randomized	O
clinical	O
trial	O
,	O
the	O
effect	O
of	O
these	O
aminoacids	O
in	O
chronic	O
outstanding	O
and	O
stable	O
patients	O
with	O
HFpEF	Condition
.	O

METHODS	O
AND	O
RESULTS	O
All	O
patients	O
underwent	O
an	O
echocardiogram	O
and	O
radioisotopic	O
ventriculography	O
rest/exercise	O
,	O
and	O
were	O
randomized	O
in	O
a	O
consecutive	O
manner	O
to	O
the	O
L-arginine	O
group	O
(	O
n	O
=	O
15	O
;	O
8	O
g/day	O
)	O
;	O
and	O
the	O
citrulline	O
malate	O
group	O
(	O
n	O
=	O
15	O
;	O
3	O
g/day	O
)	O
.	O

The	O
duration	O
of	O
follow-up	O
was	O
two	O
months	O
.	O

The	O
principal	O
echocardiographic	O
finding	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
pulmonary	O
artery	O
pressure	O
in	O
the	O
L-arginine	O
(	O
56.3	O
?	O
10	O
vs	O
44	O
?	O
16.5	O
mm	O
Hg	O
,	O
p	O
<	O
0.05	O
)	O
and	O
the	O
citrulline	O
(	O
56.67	O
?	O
7.96	O
vs	O
47.67	O
?	O
8.59	O
mm	O
Hg	O
,	O
p	O
<	O
0.05	O
)	O
groups	O
.	O

Duration	O
on	O
treadmill	O
and	O
right	O
ventricular	O
ejection	O
fraction	O
post	O
exercise	O
increased	O
,	O
while	O
diastolic	O
and	O
systolic	O
artery	O
pressure	O
decreased	O
significantly	O
in	O
both	O
groups	O
.	O

There	O
were	O
no	O
other	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

CONCLUSIONS	O
Administration	O
of	O
L-arginine	O
and	O
citrulline	O
to	O
patients	O
with	O
HFpEF	O
improved	O
right	O
ventricular	O
function	O
by	O
increasing	O
right	O
ventricular	O
ejection	O
fraction	O
,	O
and	O
probably	O
decreasing	O
systolic	O
pulmonary	O
artery	O
pressure	O
.	O

Women	Condition
's	Condition
responses	Condition
to	Condition
information	Condition
on	Condition
mammographic	Condition
breast	Condition
density	Condition
.	Condition

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
negative	O
and	O
positive	O
outcomes	O
of	O
providing	O
mammographic	O
breast	O
density	O
(	O
MBD	O
)	O
information	O
to	O
participants	Condition
of	Condition
a	Condition
screening	Condition
program	Condition
.	Condition

A	O
randomized	O
experiment	O
was	O
conducted	O
with	O
a	O
sample	O
of	O
618	O
women	O
50	O
years	O
or	O
older	O
with	O
MBD	O
greater	O
than	O
50	O
%	O
of	O
breast	O
volume	O
.	O

The	O
intervention	O
consisted	O
of	O
reporting	O
the	O
presence	O
of	O
MBD	O
in	O
the	O
screening	O
mammography	O
results	O
letter	O
that	O
was	O
sent	O
along	O
with	O
an	O
information	O
pamphlet	O
.	O

Compared	O
to	O
the	O
controls	O
,	O
more	O
women	O
in	O
the	O
intervention	O
group	O
described	O
the	O
term	O
breast	O
density	O
correctly	O
and	O
recognized	O
it	O
as	O
a	O
risk	O
factor	O
for	O
breast	O
cancer	O
.	O

Although	O
at	O
the	O
4-week	O
follow-up	O
the	O
intervention	O
group	O
indicated	O
that	O
they	O
were	O
very	O
likely	O
to	O
have	O
an	O
annual	O
clinical	O
breast	O
examination	O
more	O
frequently	O
than	O
controls	O
,	O
no	O
differences	O
were	O
detected	O
at	O
6	O
months	O
.	O

There	O
were	O
no	O
significant	O
differences	O
on	O
other	O
behavioural	O
or	O
psychological	O
measures	O
,	O
although	O
at	O
the	O
4-week	O
follow-up	O
the	O
control	O
group	O
perceived	O
their	O
risk	O
for	O
breast	O
cancer	O
,	O
relative	O
to	O
other	O
women	O
their	O
age	O
,	O
as	O
a	O
lot	O
lower	O
than	O
did	O
women	O
in	O
the	O
intervention	O
group	O
.	O

The	O
results	O
demonstrate	O
a	O
feasible	O
and	O
non-threatening	O
way	O
to	O
provide	O
women	O
with	O
important	O
personalized	O
information	O
about	O
breast	O
cancer	O
risk	O
.	O

Investigation	O
of	O
erosion	O
and	O
abrasion	O
on	O
enamel	O
and	O
dentine	O
:	O
a	O
model	O
in	O
situ	O
using	O
toothpastes	O
of	O
different	O
abrasivity	O
.	O

BACKGROUND	O
Studies	O
in	O
vitro	O
suggest	O
that	O
abrasion	O
and	O
erosion	O
may	O
act	O
synergistically	O
to	O
produce	O
wear	O
of	O
enamel	O
and	O
dentine	O
.	O

Methods	O
in	O
situ	O
are	O
recently	O
available	O
to	O
study	O
separately	O
erosion	O
and	O
abrasion	O
of	O
dental	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
combine	O
two	O
in	O
situ	O
protocols	O
to	O
study	O
the	O
interplay	O
between	O
erosion	O
and	O
abrasion	O
of	O
enamel	O
and	O
dentine	O
.	O

METHOD	O
The	O
study	O
was	O
a	O
single-blind	O
,	O
randomised	O
,	O
five-treatment	O
cross-over	O
design	O
involving	O
15	SampleSize
healthy	O
volunteers	O
.	O

During	O
each	O
10-day	O
study	O
period	O
,	O
subjects	O
wore	O
from	O
0900	O
to	O
1700	O
h	O
an	O
upper	O
removable	O
acrylic	O
appliance	O
holding	O
one	O
polished	O
enamel	O
and	O
one	O
polished	O
dentine	O
specimen	O
.	O

The	O
specimen	O
treatment	O
regimens	O
were	O
:	O
1	O
.	O

Drinking	O
water	O
and	O
brushing	O
with	O
toothpaste	O
A	O
.	O

2	O
.	O

Drinking	O
water	O
and	O
brushing	O
with	O
toothpaste	O
B	O
.	O

3	O
.	O

Drinking	O
orange	O
juice	O
.	O

4	O
.	O

Drinking	O
orange	O
juice	O
and	O
brushing	O
with	O
toothpaste	O
A	O
.	O

5	O
.	O

Drinking	O
orange	O
juice	O
and	O
brushing	O
with	O
toothpaste	O
B	O
.	O

Drinking	O
and	O
brushing	O
times	O
were	O
around	O
0900	O
,	O
1100	O
,	O
1300	O
and	O
1500	O
h.	O
Drinks	O
were	O
consumed	O
as	O
250	O
ml	O
over	O
10	O
min	O
and	O
brushing	O
ex	O
vivo	O
for	O
1	O
min	O
to	O
each	O
specimen	O
.	O

Measurement	O
of	O
tissue	O
loss	O
was	O
made	O
on	O
days	O
5	O
and	O
10	O
of	O
each	O
period	O
using	O
a	O
profilometer	O
.	O

RESULTS	O
All	O
treatments	O
produced	O
increasing	O
tissue	O
loss	O
over	O
time	O
,	O
which	O
was	O
considerably	O
greater	O
for	O
dentine	O
than	O
enamel	O
.	O

For	O
enamel	O
,	O
the	O
data	O
at	O
days	O
5	O
and	O
10	O
showed	O
a	O
significant	O
effect	O
for	O
erosion	O
(	O
i.e	O
.	O

orange	O
juice	O
was	O
significantly	O
more	O
erosive	O
than	O
water	O
)	O
,	O
but	O
no	O
significant	O
effect	O
for	O
abrasion	O
(	O
i.e	O
.	O

no	O
significant	O
difference	O
between	O
the	O
two	O
toothpaste	O
treatments	O
)	O
.	O

The	O
combined	O
orange	O
juice	O
and	O
toothpaste	O
effects	O
were	O
directional	O
for	O
synergy	O
but	O
did	O
not	O
reach	O
significance	O
.	O

For	O
dentine	O
at	O
day	O
10	O
,	O
many	O
specimens	O
exceeded	O
the	O
50	O
microm	O
set	O
limit	O
of	O
the	O
profilometer	O
and	O
only	O
day	O
5	O
data	O
were	O
considered	O
.	O

There	O
were	O
significant	O
effects	O
for	O
erosion	O
(	O
orange	O
juice	O
produced	O
significantly	O
more	O
erosion	O
than	O
water	O
)	O
and	O
for	O
abrasion	O
(	O
paste	O
A	O
was	O
significantly	O
more	O
abrasive	O
to	O
dentine	O
than	O
paste	O
B	O
)	O
.	O

The	O
synergy	O
effect	O
could	O
not	O
be	O
examined	O
for	O
dentine	O
due	O
to	O
the	O
truncation	O
effect	O
as	O
the	O
set	O
limit	O
of	O
the	O
profilometer	O
was	O
exceeded	O
.	O

CONCLUSIONS	O
Erosion	O
increases	O
the	O
susceptibility	O
of	O
enamel	O
to	O
toothpaste	O
abrasion	O
.	O

Dentine	O
is	O
considerably	O
more	O
susceptible	O
than	O
enamel	O
to	O
erosion	O
and	O
abrasion	O
alone	O
or	O
combined	O
.	O

Dentine	O
loss	O
appears	O
to	O
correlate	O
with	O
toothpaste	O
abrasivity	O
(	O
RDA	O
value	O
)	O
.	O

Comparison	O
of	O
arch	O
dimension	O
changes	O
in	O
1-phase	O
vs	O
2-phase	O
treatment	O
of	O
Class	O
II	O
malocclusion	O
.	O

INTRODUCTION	O
We	O
compared	O
arch	O
dimension	O
changes	O
in	O
1-phase	O
and	O
2-phase	O
treatment	O
of	O
Class	O
II	O
malocclusion	O
.	O

This	O
was	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
conducted	O
in	O
the	O
Department	O
of	O
Orthodontics	O
at	O
the	O
University	O
of	O
Florida	O
between	O
1990	O
and	O
2003	O
.	O

METHODS	O
During	O
phase	O
1	O
treatment	O
,	O
86	O
subjects	O
were	O
treated	O
with	O
a	O
bionator	O
,	O
93	O
were	O
treated	O
with	O
headgear/biteplane	O
,	O
and	O
81	O
served	O
as	O
the	O
observation	O
group	O
.	O

For	O
phase	O
2	O
,	O
all	O
subjects	O
were	O
then	O
treated	O
with	O
full	O
orthodontic	O
appliances	O
.	O

Arch	O
dimensions	O
were	O
followed	O
;	O
maxillary	O
and	O
mandibular	O
alginate	O
impressions	O
were	O
taken	O
at	O
baseline	O
,	O
end	O
of	O
early	O
Class	O
II	O
treatment	O
or	O
observation	O
,	O
beginning	O
of	O
fixed	O
appliance	O
treatment	O
,	O
end	O
of	O
orthodontic	O
treatment	O
,	O
and	O
approximately	O
3	O
years	O
posttreatment	O
.	O

Alginate	O
impressions	O
were	O
taken	O
of	O
each	O
dental	O
arch	O
at	O
each	O
data	O
collection	O
point	O
.	O

These	O
were	O
poured	O
in	O
orthodontic	O
stone	O
,	O
trimmed	O
,	O
and	O
photocopied	O
from	O
the	O
occlusal	O
aspect	O
.	O

These	O
images	O
were	O
then	O
scanned	O
and	O
measured	O
.	O

RESULTS	O
Although	O
differences	O
between	O
the	O
treatment	O
groups	O
were	O
found	O
in	O
both	O
the	O
maxillary	O
and	O
mandibular	O
arches	O
after	O
phase	O
1	O
,	O
these	O
differences	O
were	O
no	O
longer	O
evident	O
by	O
the	O
end	O
of	O
full	O
orthodontic	O
treatment	O
or	O
after	O
posttreatment	O
retention	O
.	O

CONCLUSIONS	O
There	O
were	O
no	O
differences	O
in	O
arch	O
dimensions	O
after	O
1-phase	O
or	O
2-phase	O
treatment	O
of	O
Class	O
II	O
malocclusion	O
.	O

The	O
additive	O
analgesic	O
efficacy	O
of	O
acetaminophen	O
,	O
1000	O
mg	O
,	O
and	O
codeine	O
,	O
60	O
mg	O
,	O
in	O
dental	Condition
pain	Condition
.	O

In	O
a	O
double-blind	O
,	O
randomized	O
,	O
single-dose	O
trial	O
the	O
analgesic	O
contribution	O
of	O
acetaminophen	O
,	O
1000	O
mg	O
,	O
and	O
codeine	O
,	O
60	O
mg	O
,	O
was	O
determined	O
.	O

The	O
study	O
was	O
a	O
2	O
X	O
2	O
factorial	O
experiment	O
in	O
which	O
120	SampleSize
patients	O
suffering	O
from	O
pain	O
as	O
a	O
result	O
of	O
oral	O
surgery	O
rated	O
their	O
pain	O
intensity	O
and	O
pain	O
relief	O
for	O
up	O
to	O
5	O
hours	O
after	O
a	O
single	O
dose	O
of	O
one	O
of	O
:	O
1000	O
mg	O
acetaminophen	O
,	O
60	O
mg	O
codeine	O
,	O
1000	O
mg	O
acetaminophen	O
plus	O
60	O
mg	O
codeine	O
,	O
or	O
placebo	O
.	O

The	O
factorial	O
analysis	O
showed	O
that	O
both	O
1000	O
mg	O
acetaminophen	O
and	O
60	O
mg	O
codeine	O
made	O
a	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0.05	O
)	O
contribution	O
to	O
the	O
analgesic	O
effectiveness	O
of	O
the	O
combination	O
on	O
all	O
measures	O
of	O
efficacy	O
(	O
sum	O
of	O
pain	O
intensity	O
differences	O
,	O
largest	O
pain	O
intensity	O
difference	O
,	O
total	O
pain	O
relief	O
,	O
largest	O
pain	O
relief	O
,	O
and	O
time	O
to	O
remedication	O
)	O
.	O

The	O
incidence	O
of	O
adverse	O
effects	O
did	O
not	O
appear	O
to	O
differ	O
among	O
the	O
treatments	O
,	O
including	O
placebo	O
.	O

The	O
effects	O
of	O
candesartan	O
on	O
diabetes	O
glomerulopathy	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

Our	O
objective	O
was	O
to	O
study	O
the	O
effects	O
of	O
candesartan	O
on	O
diabetic	O
glomerulopathy	O
in	O
young	O
normoalbuminuric	O
and	O
normotensive	O
patients	O
with	O
type	O
1	O
diabetes	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

In	O
13	O
patients	O
aged	O
24	O
years	O
at	O
baseline	O
,	O
we	O
evaluated	O
blood	O
pressure	O
,	O
kidney	O
biopsies	O
and	O
kidney	O
function	O
tests	O
at	O
baseline	O
and	O
after	O
5	O
years	O
of	O
treatment	O
.	O

Kidney	O
biopsies	O
were	O
examined	O
with	O
light	O
and	O
electron	O
microscopy	O
,	O
glomerular	O
filtration	O
rate	O
and	O
effective	O
renal	O
plasma	O
flow	O
determined	O
with	O
inulin	O
and	O
para-aminohippuric	O
acid	O
clearances	O
.	O

Two	O
patients	O
in	O
the	O
placebo	O
group	O
needed	O
antihypertensive	O
treatment	O
because	O
they	O
developed	O
microalbuminuria	O
and/or	O
hypertension	O
,	O
but	O
no	O
patient	O
in	O
the	O
candesartan	O
group	O
did	O
.	O

A	O
significant	O
reduction	O
in	O
mesangial	O
matrix	O
volume	O
and	O
mesangial	O
volume	O
occurred	O
in	O
the	O
candesartan	O
group	O
,	O
although	O
changes	O
in	O
morphological	O
parameters	O
were	O
similar	O
between	O
groups	O
.	O

Office	O
blood	O
pressure	O
was	O
significantly	O
lower	O
in	O
the	O
candesartan	O
group	O
at	O
follow-up	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Deterioration	O
in	O
morphological	O
parameters	O
observed	O
in	O
earlier	O
studies	O
of	O
our	O
patients	O
did	O
not	O
become	O
worse	O
during	O
treatment	O
with	O
candesartan	O
or	O
placebo	O
.	O

The	O
effects	O
of	O
candesartan	O
,	O
with	O
reduction	O
in	O
morphological	O
parameters	O
and	O
lowering	O
of	O
blood	O
pressure	O
,	O
might	O
influence	O
future	O
treatment	O
of	O
glomerulopathy	O
in	O
type	O
1	O
diabetes	O
patients	O
.	O

[	O
Evaluation	O
of	O
Stepping	O
Stones	O
Triple	O
P	O
:	O
Interims	O
analysis	O
of	O
the	O
Stepping-Stones-SPC-Multicentric	O
Study	O
]	O
.	O

Stepping	O
Stones	O
Triple	O
P	O
is	O
a	O
behavioural	O
parenting	O
training	O
for	O
families	O
with	O
a	O
handicapped	Condition
child	Age
,	O
which	O
has	O
already	O
been	O
successfully	O
evaluated	O
in	O
its	O
country	O
of	O
origin	O
,	O
Australia	O
.	O

Within	O
a	O
multicentric	O
study	O
of	O
several	O
Social	O
Pediatric	O
Centers	O
(	O
SPCs	O
)	O
and	O
further	O
clinics/institutions	O
in	O
Germany	O
,	O
it	O
has	O
been	O
established	O
as	O
a	O
group	O
parenting	O
training	O
(	O
3-7	O
families	O
per	O
training	O
)	O
.	O

Statistical	O
analysis	O
proved	O
significant	O
effects	O
concerning	O
dysfunctional	O
parenting	O
,	O
parental	O
stress	O
and	O
child	O
behaviour	O
problems	O
as	O
well	O
as	O
little	O
side	O
effects	O
and	O
a	O
positive	O
acceptance	O
of	O
stepping	O
stones	O
by	O
the	O
families	O
.	O

Oxytocin	O
infusion	O
reduces	O
repetitive	O
behaviors	O
in	O
adults	Age
with	O
autistic	Condition
and	Condition
Asperger	Condition
's	Condition
disorders	Condition
.	O

Autism	O
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
dysfunction	O
in	O
three	O
core	O
behavioral	O
domains	O
:	O
repetitive	O
behaviors	O
,	O
social	O
deficits	O
,	O
and	O
language	O
abnormalities	O
.	O

There	O
is	O
evidence	O
that	O
abnormalities	O
exist	O
in	O
peptide	O
systems	O
,	O
particularly	O
the	O
oxytocin	O
system	O
,	O
in	O
autism	Condition
spectrum	Condition
patients	O
.	O

Furthermore	O
,	O
oxytocin	O
and	O
the	O
closely	O
related	O
peptide	O
vasopressin	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
social	O
and	O
repetitive	O
behaviors	O
.	O

This	O
study	O
examined	O
the	O
impact	O
of	O
oxytocin	O
on	O
repetitive	O
behaviors	O
in	O
15	O
adults	O
with	O
autism	O
or	O
Asperger	O
's	O
disorder	O
via	O
randomized	O
double-blind	O
oxytocin	O
and	O
placebo	O
challenges	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
an	O
instrument	O
rating	O
six	O
repetitive	O
behaviors	O
:	O
need	O
to	O
know	O
,	O
repeating	O
,	O
ordering	O
,	O
need	O
to	O
tell/ask	O
,	O
self-injury	O
,	O
and	O
touching	O
.	O

Patients	O
with	O
autism	O
spectrum	O
disorders	O
showed	O
a	O
significant	O
reduction	O
in	O
repetitive	O
behaviors	O
following	O
oxytocin	O
infusion	O
in	O
comparison	O
to	O
placebo	O
infusion	O
.	O

Repetitive	O
behavior	O
in	O
autism	O
spectrum	O
disorders	O
may	O
be	O
related	O
to	O
abnormalities	O
in	O
the	O
oxytocin	O
system	O
,	O
and	O
may	O
be	O
partially	O
ameliorated	O
by	O
synthetic	O
oxytocin	O
infusion	O
.	O

Effect	O
of	O
negative	O
air	O
ionization	O
on	O
hyperactive	Condition
and	O
autistic	Condition
children	Age
.	O

Twenty-one	SampleSize
attention	Condition
deficit	Condition
disorder	Condition
with	O
hyperactivity	Condition
and	O
seven	SampleSize
autistic	Condition
children	Age
were	O
randomly	O
exposed	O
to	O
negatively	O
ionized	O
and	O
ambient	O
atmospheres	O
under	O
rigorously	O
controlled	O
experimental	O
conditions	O
.	O

The	O
negatively	O
ionized	O
condition	O
did	O
not	O
significantly	O
affect	O
measurements	O
of	O
activity	O
level	O
,	O
impulsivity	O
,	O
reality	O
orientation	O
,	O
destructive/constructiveness	O
,	O
attention	O
,	O
or	O
task	O
performance	O
.	O

Significant	O
results	O
might	O
be	O
obtained	O
if	O
subgroups	O
of	O
known	O
hyperserotoninemic	Condition
autistic	Condition
and	O
attention	Condition
deficit	Condition
disorder	Condition
children	Age
were	O
exposed	O
to	O
negatively	O
ionized	O
conditions	O
.	O

[	O
Improving	O
wound	Condition
healing	Condition
after	Condition
nose	Condition
surgery	Condition
by	O
combined	O
administration	O
of	O
xylometazoline	O
and	O
dexpanthenol	O
]	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
examination	O
of	O
efficacy	O
and	O
tolerability	O
of	O
an	O
application-form	O
of	O
the	O
new	O
combination	O
of	O
Xylometazoline	O
with	O
Dexpanthenol	O
(	O
Nasic	O
)	O
versus	O
Xylometazoline	O
alone	O
.	O

PATIENTS	O
AND	O
METHODS	O
Randomized	O
verum	O
controlled	O
parallel-group-comparison	O
of	O
two	O
weeks	O
treatment	O
of	O
a	O
nasal-spray	O
.	O

61	O
inpatients	O
with	O
the	O
diagnosis	O
Rhinitis	O
following	O
nasal	O
operation	O
were	O
included	O
in	O
this	O
study	O
and	O
30	O
patients	O
were	O
treated	O
with	O
verum	O
and	O
placebo	O
each	O
.	O

The	O
assessment	O
of	O
nasal-breathing-resistance	O
according	O
to	O
scores	O
was	O
defined	O
as	O
target-parameter	O
.	O

Confirmatory	O
statistical	O
analysis	O
was	O
carried	O
out	O
according	O
to	O
Wilcoxon-Mann-Whitney-U	O
two-sided	O
at	O
alpha	O
<	O
or	O
=	O
0.05	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
The	O
superiority	O
of	O
the	O
combination	O
of	O
Xylometazoline-Dexpanthenol	O
nasal-spray	O
versus	O
Xylometazoline	O
nasal	O
spray	O
could	O
be	O
proven	O
for	O
the	O
target-parameter	O
as	O
clinically	O
relevant	O
and	O
statistically	O
significant	O
.	O

The	O
clinically	O
proven	O
efficacy	O
is	O
emphasized	O
by	O
good	O
tolerability	O
of	O
both	O
treatments	O
.	O

Due	O
to	O
easy	O
handling	O
of	O
the	O
nasal-spray	O
a	O
good	O
compliance	O
was	O
confirmed	O
.	O

CONCLUSION	O
Distinct	O
improvement	O
of	O
symptoms	O
in	O
patients	O
following	O
nasal	O
operations	O
underlines	O
the	O
efficacy	O
of	O
both	O
medications	O
.	O

With	O
respect	O
to	O
the	O
tolerability	O
therapy	O
with	O
the	O
combination	O
is	O
more	O
beneficial	O
in	O
comparison	O
to	O
the	O
alternative	O
therapy	O
.	O

The	O
result	O
of	O
this	O
controlled	O
clinical	O
study	O
confirms	O
that	O
the	O
combination	O
Xylometazoline-Dexpanthenol	O
is	O
an	O
enlargement	O
and	O
improvement	O
of	O
effective	O
medicinal	O
treatment	O
of	O
rhinitis	O
following	O
nasal	O
operation	O
in	O
comparison	O
to	O
therapy	O
with	O
Xylometazoline	O
alone	O
.	O

Oral	O
6-mercaptopurine	O
versus	O
oral	O
6-thioguanine	O
and	O
veno-occlusive	O
disease	O
in	O
children	Age
with	O
standard-risk	Condition
acute	Condition
lymphoblastic	Condition
leukemia	Condition
:	O
report	O
of	O
the	O
Children	O
's	O
Oncology	O
Group	O
CCG-1952	O
clinical	O
trial	O
.	O

The	O
Children	O
's	O
Cancer	O
Group	O
1952	O
(	O
CCG-1952	O
)	O
clinical	O
trial	O
studied	O
the	O
substitution	O
of	O
oral	O
6-thioguanine	O
(	O
TG	O
)	O
for	O
6-mercaptopurine	O
(	O
MP	O
)	O
and	O
triple	O
intrathecal	O
therapy	O
(	O
ITT	O
)	O
for	O
intrathecal	O
methotrexate	O
(	O
IT-MTX	O
)	O
in	O
the	O
treatment	O
of	O
standard-risk	Condition
acute	Condition
lymphoblastic	Condition
leukemia	Condition
.	O

After	O
remission	O
induction	O
,	O
2027	SampleSize
patients	O
were	O
randomized	O
to	O
receive	O
MP	O
(	O
n	O
=	O
1010	O
)	O
or	O
TG	O
(	O
n	O
=	O
1017	O
)	O
and	O
IT-MTX	O
(	O
n	O
=	O
1018	O
)	O
or	O
ITT	O
(	O
n	O
=	O
1009	O
)	O
.	O

The	O
results	O
of	O
the	O
thiopurine	O
comparison	O
are	O
as	O
follows	O
.	O

The	O
estimated	O
7-year	O
event-free	O
survival	O
(	O
EFS	O
)	O
for	O
subjects	O
randomized	O
to	O
TG	O
was	O
84.1	O
%	O
(	O
+/-	O
1.8	O
%	O
)	O
and	O
to	O
MP	O
was	O
79.0	O
%	O
(	O
+/-	O
2.1	O
%	O
;	O
P	O
=	O
.004	O
log	O
rank	O
)	O
,	O
although	O
overall	O
survival	O
was	O
91.9	O
%	O
(	O
+/-	O
1.4	O
%	O
)	O
and	O
91.2	O
%	O
(	O
+/-	O
1.5	O
%	O
)	O
,	O
respectively	O
(	O
P	O
=	O
.6	O
log	O
rank	O
)	O
.	O

The	O
TG	O
starting	O
dose	O
was	O
reduced	O
from	O
60	O
to	O
50	O
mg/m	O
(	O
2	O
)	O
per	O
day	O
after	O
recognition	O
of	O
hepatic	O
veno-occlusive	O
disease	O
(	O
VOD	O
)	O
.	O

A	O
total	O
of	O
257	SampleSize
patients	O
on	O
TG	O
(	O
25	O
%	O
)	O
developed	O
VOD	O
or	O
disproportionate	O
thrombocytopenia	O
and	O
switched	O
to	O
MP	O
.	O

Once	O
portal	O
hypertension	O
occurred	O
,	O
all	O
subjects	O
on	O
TG	O
were	O
changed	O
to	O
MP	O
.	O

The	O
benefit	O
of	O
randomization	O
to	O
TG	O
over	O
MP	O
,	O
as	O
measured	O
by	O
EFS	O
,	O
was	O
evident	O
primarily	O
in	O
boys	O
who	O
began	O
TG	O
at	O
60	O
mg/m	O
(	O
2	O
)	O
(	O
relative	O
hazard	O
rate	O
[	O
RHR	O
]	O
0.65	O
,	O
P	O
=	O
.002	O
)	O
.	O

The	O
toxicities	O
of	O
TG	O
preclude	O
its	O
protracted	O
use	O
as	O
given	O
in	O
this	O
study	O
.	O

This	O
study	O
is	O
registered	O
at	O
http	O
:	O
//clinicaltrials.gov	O
as	O
NCT00002744	O
.	O

[	O
Treatment	O
of	O
autism	Condition
children	Condition
:	Condition
observation	O
on	O
efficacy	O
of	O
behavior	O
training	O
with	O
retention	O
of	O
needles	O
on	O
head	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
the	O
effect	O
difference	O
of	O
behavior	O
training	O
with	O
head	O
needling	O
retention	O
and	O
behavior	O
training	O
after	O
acupuncture	O
for	O
autism	O
children	O
.	O

METHODS	O
Sixty	O
qualified	O
autism	O
children	O
were	O
divided	O
randomly	O
into	O
simultaneous	O
head	O
needling	O
retention	O
and	O
behavior	O
training	O
group	O
(	O
trial	O
group	O
)	O
and	O
behavior	O
training	O
after	O
acupuncture	O
treatment	O
group	O
(	O
control	O
group	O
)	O
with	O
30	O
case	O
in	O
each	O
group	O
.	O

Retention	O
needles	O
on	O
the	O
head	O
with	O
simultaneous	O
behavior	O
training	O
was	O
applied	O
for	O
the	O
trial	O
group	O
.	O

The	O
main	O
acupoints	O
included	O
Sishen	O
Xue	O
,	O
Dingshen	O
Sanxue	O
(	O
3	O
points	O
for	O
mental	O
tranquilization	O
)	O
,	O
Nao	O
Sanxue	O
(	O
3	O
points	O
for	O
the	O
function	O
of	O
brain	O
)	O
,	O
Shou	O
Zhisanxue	O
(	O
3	O
points	O
for	O
mental	O
activities	O
on	O
hand	O
)	O
and	O
Zozhi	O
Sonxue	O
(	O
3	O
points	O
for	O
mental	O
activities	O
on	O
foot	O
)	O
.	O

Other	O
points	O
were	O
combined	O
according	O
to	O
conditions	O
of	O
patients	O
.	O

Needles	O
on	O
the	O
4	O
extremities	O
were	O
withdrawn	O
first	O
after	O
30	O
minutes	O
,	O
needles	O
on	O
head	O
were	O
remained	O
during	O
behavior	O
training	O
.	O

While	O
behavior	O
training	O
was	O
applied	O
to	O
the	O
control	O
group	O
when	O
acupuncture	O
treatment	O
was	O
completely	O
accomplished	O
.	O

Treatments	O
were	O
applied	O
once	O
a	O
day	O
to	O
both	O
groups	O
.	O

And	O
3	O
months	O
was	O
taken	O
as	O
one	O
observation	O
cycle	O
.	O

Estimation	O
was	O
made	O
on	O
therapeutic	O
effect	O
and	O
developing	O
level	O
of	O
autism	O
children	O
with	O
CARS	O
and	O
PEP	O
.	O

RESULTS	O
The	O
total	O
effective	O
rate	O
of	O
the	O
trial	O
group	O
was	O
83.3	O
%	O
(	O
25/30	O
)	O
,	O
better	O
than	O
66.7	O
%	O
(	O
20/30	O
)	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
CARS	O
scores	O
of	O
both	O
groups	O
declined	O
after	O
the	O
treatment	O
.	O

And	O
the	O
score	O
of	O
trail	O
group	O
was	O
lower	O
than	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

While	O
the	O
PEP	O
scores	O
of	O
both	O
groups	O
increased	O
,	O
and	O
the	O
score	O
of	O
trail	O
group	O
was	O
higher	O
than	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

The	O
increasing	O
level	O
of	O
scores	O
of	O
cognitive	O
understanding	O
and	O
cognitive	O
expression	O
were	O
all	O
better	O
than	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
The	O
effect	O
of	O
behavior	O
training	O
with	O
head	O
needle	O
retention	O
on	O
autism	O
children	O
is	O
better	O
than	O
behavior	O
training	O
after	O
acupuncture	O
treatment	O
,	O
especially	O
in	O
enhancing	O
cognition	O
understanding	O
and	O
cognition	O
expression	O
.	O

Multiple	O
doses	O
of	O
secretin	O
in	O
the	O
treatment	O
of	O
autism	Condition
:	O
a	O
controlled	O
study	O
.	O

UNLABELLED	O
Dramatic	O
effects	O
on	O
autistic	O
behaviour	O
after	O
repeated	O
injections	O
of	O
the	O
gastrointestinal	O
hormone	O
secretin	O
have	O
been	O
referred	O
in	O
a	O
number	O
of	O
case	O
reports	O
.	O

In	O
the	O
absence	O
of	O
curative	O
and	O
effective	O
treatments	O
for	O
this	O
disabling	O
condition	O
,	O
this	O
information	O
has	O
created	O
new	O
hope	O
among	O
parents	O
.	O

Although	O
controlled	O
studies	O
on	O
the	O
effect	O
of	O
mainly	O
one	O
single	O
dose	O
have	O
not	O
documented	O
any	O
effect	O
,	O
many	O
children	Age
still	O
continue	O
to	O
receive	O
secretin	O
.	O

Six	SampleSize
children	O
enrolled	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
in	O
which	O
each	O
child	O
was	O
its	O
own	O
control	O
.	O

Human	O
synthetic	O
secretin	O
,	O
mean	O
dose	O
3.4	O
clinical	O
units	O
,	O
and	O
placebo	O
were	O
administered	O
intravenously	O
in	O
randomized	O
order	O
every	O
4th	O
wk	O
,	O
on	O
three	O
occasions	O
each	O
.	O

The	O
measurement	O
instruments	O
were	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
the	O
aberrant	O
behaviour	O
checklist	O
(	O
ABC	O
)	O
.	O

Statistically	O
significant	O
differences	O
were	O
found	O
for	O
placebo	O
in	O
3	O
out	O
of	O
6	O
children	Age
and	O
for	O
secretin	O
in	O
one	O
child	O
,	O
using	O
parental	O
ratings	O
only	O
(	O
VAS	O
scores	O
)	O
.	O

Differences	O
were	O
small	O
and	O
lacked	O
clinical	O
significance	O
,	O
which	O
was	O
in	O
accordance	O
with	O
the	O
overall	O
impression	O
of	O
the	O
parents	O
and	O
teachers	O
and	O
visual	O
inspection	O
of	O
graphs	O
.	O

CONCLUSION	O
In	O
this	O
placebo-controlled	O
study	O
,	O
multiple	O
doses	O
of	O
secretin	O
did	O
not	O
produce	O
any	O
symptomatic	O
improvement	O
.	O

Effects	O
of	O
parecoxib	O
on	O
morphine	O
analgesia	O
after	O
gynecology	O
tumor	O
operation	O
:	O
a	O
randomized	O
trial	O
of	O
parecoxib	O
used	O
in	O
postsurgical	O
pain	O
management	O
.	O

BACKGROUND	O
The	O
analgesic	O
efficacy	O
of	O
parecoxib	O
in	O
postsurgical	O
pain	O
management	O
has	O
been	O
confirmed	O
in	O
minimally	O
invasive	O
surgery	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
its	O
effects	O
used	O
in	O
combination	O
with	O
opioids	O
and	O
about	O
its	O
potential	O
for	O
opioid-sparing	O
effects	O
in	O
complex	O
operations	O
.	O

This	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
influence	O
of	O
parecoxib	O
on	O
morphine	O
analgesia	O
after	O
gynecological	O
tumor	O
surgery	O
.	O

METHODS	O
Eighty	O
patients	O
undergoing	O
gynecological	O
tumor	O
resection	O
were	O
randomized	O
to	O
receive	O
either	O
intravenous	O
parecoxib	O
at	O
a	O
dose	O
of	O
40	O
mg	O
(	O
Group	O
P	O
,	O
n	O
=	O
40	O
)	O
followed	O
by	O
40	O
mg	O
every	O
12	O
h	O
for	O
48	O
h	O
or	O
saline	O
as	O
a	O
control	O
(	O
Group	O
C	O
,	O
n	O
=	O
40	O
)	O
30	O
min	O
before	O
induction	O
of	O
anesthesia	O
,	O
followed	O
by	O
saline	O
at	O
the	O
same	O
time	O
points	O
after	O
the	O
operation	O
.	O

All	O
patients	O
had	O
access	O
to	O
patient-controlled	O
analgesia	O
with	O
intravenous	O
morphine	O
.	O

Patients	O
were	O
assessed	O
with	O
respect	O
to	O
pain	O
score	O
(	O
visual	O
analog	O
scale	O
from	O
0-10	O
)	O
,	O
cumulative	O
morphine	O
requirement	O
,	O
satisfaction	O
score	O
,	O
and	O
side	O
effects	O
at	O
2	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
48	O
h	O
after	O
surgery	O
.	O

RESULTS	O
A	O
total	O
of	O
79	O
patients	O
were	O
evaluated	O
.	O

The	O
cumulative	O
dose	O
of	O
morphine	O
administered	O
at	O
each	O
time	O
point	O
was	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C	O
(	O
P	O
<	O
0.05	O
)	O
,	O
at	O
2	O
h	O
(	O
3.81	O
?	O
0.35	O
versus	O
4.13	O
?	O
0.45	O
;	O
P	O
=	O
0.01	O
)	O
,	O
6	O
h	O
(	O
16.20	O
?	O
1.49	O
versus	O
19.60	O
?	O
0.35	O
;	O
P	O
<	O
0.001	O
)	O
,	O
12	O
h	O
(	O
26.29	O
?	O
2.75	O
versus	O
32.49	O
?	O
2.42	O
;	O
P	O
<	O
0.001	O
)	O
,	O
24	O
h	O
(	O
41.72	O
?	O
2.70	O
versus	O
49.97	O
?	O
4.53	O
;	O
P	O
<	O
0.001	O
)	O
,	O
and	O
48	O
h	O
(	O
60.06	O
?	O
4.00	O
versus	O
65.68	O
?	O
3.23	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Compared	O
with	O
Group	O
C	O
,	O
Group	O
P	O
had	O
significantly	O
lower	O
visual	O
analog	O
scale	O
scores	O
at	O
rest	O
and	O
with	O
movement	O
,	O
respectively	O
,	O
at	O
2	O
h	O
(	O
4.2	O
,	O
P	O
<	O
0.001	O
and	O
5.0	O
,	O
P	O
<	O
0.001	O
)	O
,	O
6	O
h	O
(	O
3.6	O
,	O
P	O
<	O
0.001	O
and	O
4.5	O
,	O
P	O
<	O
0.001	O
)	O
,	O
12	O
h	O
(	O
3.0	O
,	O
P	O
=	O
0.017	O
and	O
4.0	O
,	O
P	O
<	O
0.001	O
)	O
,	O
24	O
h	O
(	O
2.1	O
,	O
P	O
<	O
0.001	O
and	O
3.4	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
48	O
h	O
(	O
1.8	O
,	O
P	O
<	O
0.001	O
and	O
2.6	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
satisfaction	O
score	O
was	O
higher	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C	O
(	O
8.6	O
?	O
0.3	O
versus	O
6.8	O
?	O
0.7	O
,	O
P	O
<	O
0.001	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
side	O
effects	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSIONS	O
The	O
use	O
of	O
parecoxib	O
with	O
patient-controlled	O
analgesic	O
morphine	O
in	O
postoperative	O
analgesia	O
resulted	O
in	O
comprehensive	O
enhancement	O
of	O
the	O
analgesic	O
efficacy	O
,	O
reducing	O
the	O
opioid	O
requirement	O
and	O
increasing	O
patient	O
satisfaction	O
after	O
gynecological	O
tumor	O
surgery	O
.	O

Spotty	O
calcification	O
as	O
a	O
marker	O
of	O
accelerated	O
progression	O
of	O
coronary	O
atherosclerosis	O
:	O
insights	O
from	O
serial	O
intravascular	O
ultrasound	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
atheroma	Condition
progression	O
in	O
patients	O
with	O
spotty	O
calcification	O
.	O

BACKGROUND	O
Although	O
extensively	O
calcified	O
atherosclerotic	O
lesions	O
have	O
been	O
proposed	O
to	O
be	O
clinically	O
quiescent	O
,	O
the	O
presence	O
of	O
spotty	O
calcification	O
within	O
plaque	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
ischemic	O
cardiovascular	O
events	O
.	O

The	O
relationship	O
between	O
spotty	O
calcification	O
and	O
disease	O
progression	O
has	O
not	O
been	O
investigated	O
.	O

METHODS	O
A	O
total	O
of	O
1,347	SampleSize
stable	O
patients	O
with	O
angiographic	O
coronary	O
artery	O
disease	O
underwent	O
serial	O
evaluation	O
of	O
atheroma	O
burden	O
with	O
intravascular	O
ultrasound	O
imaging	O
.	O

Patients	O
with	O
spotty	O
calcification	O
were	O
identified	O
based	O
on	O
the	O
presence	O
of	O
lesions	O
(	O
1	O
to	O
4	O
mm	O
in	O
length	O
)	O
containing	O
an	O
arc	O
of	O
calcification	O
of	O
<	O
90?	O
.	O

Clinical	O
characteristics	O
and	O
disease	O
progression	O
were	O
compared	O
between	O
patients	O
with	O
spotty	O
calcification	O
(	O
n	O
=	O
922	O
)	O
and	O
those	O
with	O
no	O
calcification	O
(	O
n	O
=	O
425	O
)	O
.	O

RESULTS	O
Patients	O
with	O
spotty	O
calcification	O
were	O
older	O
(	O
age	O
56	O
years	O
vs.	O
54	O
years	O
;	O
p	O
=	O
0.001	O
)	O
,	O
more	O
likely	O
to	O
be	O
male	O
(	O
68	O
%	O
vs.	O
54	O
%	O
;	O
p	O
=	O
0.01	O
)	O
,	O
and	O
have	O
a	O
history	O
of	O
diabetes	O
mellitus	O
(	O
30	O
%	O
vs.	O
24	O
%	O
;	O
p	O
=	O
0.01	O
)	O
and	O
myocardial	O
infarction	O
(	O
28	O
%	O
vs.	O
20	O
%	O
;	O
p	O
=	O
0.004	O
)	O
,	O
and	O
have	O
lower	O
on-treatment	O
high-density	O
lipoprotein	O
cholesterol	O
levels	O
(	O
48	O
?	O
16	O
mg/dl	O
vs.	O
51	O
?	O
17	O
mg/dl	O
;	O
p	O
=	O
0.001	O
)	O
.	O

Patients	O
with	O
spotty	O
calcification	O
demonstrated	O
a	O
greater	O
percent	O
atheroma	O
volume	O
(	O
PAV	O
)	O
(	O
36.0	O
?	O
7.6	O
%	O
vs.	O
29.0	O
?	O
8.5	O
%	O
;	O
p	O
<	O
0.001	O
)	O
and	O
total	O
atheroma	O
volume	O
(	O
174.6	O
?	O
71.9	O
mm	O
(	O
3	O
)	O
vs.	O
133.9	O
?	O
64.9	O
mm	O
(	O
3	O
)	O
;	O
p	O
<	O
0.001	O
)	O
.	O

On	O
serial	O
evaluation	O
,	O
spotty	O
calcification	O
was	O
associated	O
with	O
greater	O
progression	O
of	O
PAV	O
(	O
+0.43	O
?	O
0.07	O
%	O
vs.	O
+0.02	O
?	O
0.11	O
%	O
;	O
p	O
=	O
0.002	O
)	O
.	O

Although	O
intensive	O
low-density	O
lipoprotein	O
cholesterol	O
and	O
blood	O
pressure	O
lowering	O
therapy	O
slowed	O
disease	O
progression	O
,	O
these	O
efficacies	O
were	O
attenuated	O
in	O
patients	O
with	O
spotty	O
calcification	O
.	O

CONCLUSIONS	O
The	O
presence	O
of	O
spotty	O
calcification	O
is	O
associated	O
with	O
more	O
extensive	O
and	O
diffuse	O
coronary	O
atherosclerosis	O
and	O
accelerated	O
disease	O
progression	O
despite	O
use	O
of	O
medical	O
therapies	O
.	O

A	O
randomised	O
,	O
controlled	O
study	O
of	O
dietary	O
intervention	O
in	O
autistic	Condition
syndromes	Condition
.	Condition

Impaired	O
social	O
interaction	O
,	O
communication	O
and	O
imaginative	O
skills	O
characterize	O
autistic	O
syndromes	O
.	O

In	O
these	O
syndromes	O
urinary	O
peptide	O
abnormalities	O
,	O
derived	O
from	O
gluten	O
,	O
gliadin	O
,	O
and	O
casein	O
,	O
are	O
reported	O
.	O

They	O
reflect	O
processes	O
with	O
opioid	O
effect	O
.	O

The	O
aim	O
of	O
this	O
single	O
blind	O
study	O
was	O
to	O
evaluate	O
effect	O
of	O
gluten	O
and	O
casein-free	O
diet	O
for	O
children	Age
with	O
autistic	Condition
syndromes	Condition
and	O
urinary	Condition
peptide	Condition
abnormalities	Condition
.	Condition

A	O
randomly	O
selected	O
diet	O
and	O
control	O
group	O
with	O
10	SampleSize
children	Age
in	O
each	O
group	O
participated	O
.	O

Observations	O
and	O
tests	O
were	O
done	O
before	O
and	O
after	O
a	O
period	O
of	O
1	O
year	O
.	O

The	O
development	O
for	O
the	O
group	O
of	O
children	O
on	O
diet	O
was	O
significantly	O
better	O
than	O
for	O
the	O
controls	O
.	O

Transcutaneous	O
electrical	O
nerve	O
stimulation	O
after	O
thoracotomy	O
.	O

Pain	O
relief	O
and	O
peak	O
expiratory	O
flow	O
rate	O
--	O
a	O
trial	O
of	O
transcutaneous	O
electrical	O
nerve	O
stimulation	O
.	O

Forty	SampleSize
patients	O
scheduled	O
to	O
undergo	O
thoracotomy	Condition
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
transcutaneous	O
electrical	O
nerve	O
stimulation	O
with	O
intramuscular	O
papaveretum	O
(	O
20	O
patients	O
)	O
or	O
intramuscular	O
papaveretum	O
alone	O
(	O
20	O
patients	O
)	O
for	O
postoperative	O
pain	O
relief	O
.	O

Total	O
intramuscular	O
analgesic	O
requirements	O
in	O
the	O
first	O
24	O
hours	O
,	O
time	O
to	O
satisfactory	O
transfer	O
to	O
oral	O
analgesia	O
,	O
antiemetic	O
requirements	O
and	O
length	O
of	O
stay	O
in	O
hospital	O
postoperatively	O
were	O
noted	O
.	O

Peak	O
expiratory	O
flow	O
rate	O
was	O
compared	O
pre-	O
and	O
postoperatively	O
in	O
the	O
two	O
groups	O
.	O

Use	O
of	O
nerve	O
stimulation	O
did	O
not	O
significantly	O
alter	O
the	O
requirements	O
for	O
analgesia	O
although	O
there	O
was	O
a	O
reduction	O
in	O
postoperative	O
nausea	O
and	O
vomiting	O
in	O
the	O
nerve	O
stimulation	O
group	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
changes	O
in	O
peak	O
expiratory	O
flow	O
rate	O
.	O

The	O
A-V	O
Impulse	O
System	O
reduces	O
deep-vein	Condition
thrombosis	Condition
and	O
swelling	O
after	O
hemiarthroplasty	Condition
for	Condition
hip	Condition
fracture	Condition
.	O

We	O
performed	O
a	O
prospective	O
randomised	O
controlled	O
trial	O
of	O
the	O
A-V	O
Impulse	O
System	O
in	O
82	SampleSize
patients	O
treated	Condition
by	Condition
hemiarthroplasty	Condition
for	Condition
subcapital	Condition
fracture	Condition
of	Condition
the	Condition
femoral	Condition
neck	Condition
.	O

The	O
incidence	O
of	O
proximal	O
deep-vein	O
thrombosis	O
as	O
assessed	O
by	O
Doppler	O
ultrasonography	O
was	O
23	O
%	O
in	O
the	O
control	O
group	O
and	O
0	O
%	O
in	O
those	O
using	O
the	O
device	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Calf	O
and	O
thigh	O
circumferences	O
were	O
measured	O
in	O
both	O
groups	O
at	O
seven	O
to	O
ten	O
days	O
after	O
operation	O
.	O

In	O
the	O
treatment	O
group	O
there	O
was	O
a	O
mean	O
relative	O
reduction	O
of	O
postoperative	O
swelling	O
of	O
the	O
thigh	O
by	O
3.27	O
cm	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
of	O
the	O
calf	O
by	O
1.55	O
cm	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

The	O
A-V	O
Impulse	O
System	O
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
method	O
of	O
reducing	O
the	O
incidence	O
of	O
proximal	O
deep-vein	O
thrombosis	O
,	O
and	O
of	O
postoperative	O
swelling	O
.	O

Long-term	O
exposure	O
to	O
belatacept	O
in	O
recipients	O
of	O
extended	O
criteria	O
donor	O
kidneys	O
.	O

Patients	O
in	O
the	O
BENEFIT-EXT	O
study	O
received	O
extended	O
criteria	O
donor	O
kidneys	O
and	O
a	O
more	O
intensive	O
(	O
MI	O
)	O
or	O
less	O
intensive	O
(	O
LI	O
)	O
belatacept	O
immunosuppression	O
regimen	O
,	O
or	O
cyclosporine	O
A	O
(	O
CsA	O
)	O
.	O

Patients	O
who	O
remained	O
on	O
assigned	O
therapy	O
through	O
year	O
3	O
were	O
eligible	O
to	O
enter	O
a	O
long-term	O
extension	O
(	O
LTE	O
)	O
study	O
.	O

Three	O
hundred	O
four	O
patients	O
entered	O
the	O
LTE	O
(	O
n	O
=	O
104	O
MI	O
;	O
n	O
=	O
113	O
LI	O
;	O
n	O
=	O
87	O
CsA	O
)	O
,	O
and	O
260	O
continued	O
treatment	O
through	O
year	O
5	O
(	O
n	O
=	O
91	O
MI	O
;	O
n	O
=	O
100	O
LI	O
;	O
n	O
=	O
69	O
CsA	O
)	O
.	O

Twenty	O
patients	O
died	O
during	O
the	O
LTE	O
(	O
n	O
=	O
5	O
MI	O
;	O
n	O
=	O
9	O
LI	O
;	O
n	O
=	O
6	O
CsA	O
)	O
,	O
and	O
eight	O
experienced	O
graft	O
loss	O
(	O
n	O
=	O
2	O
MI	O
;	O
n	O
=	O
1	O
LI	O
;	O
n	O
=	O
5	O
CsA	O
)	O
.	O

Three	O
patients	O
experienced	O
an	O
acute	O
rejection	O
episode	O
(	O
n	O
=	O
2	O
MI	O
;	O
n	O
=	O
1	O
LI	O
)	O
.	O

The	O
incidence	O
rate	O
of	O
serious	O
adverse	O
events	O
,	O
viral	O
infections	O
and	O
fungal	O
infections	O
was	O
similar	O
across	O
groups	O
during	O
the	O
LTE	O
.	O

There	O
were	O
four	O
cases	O
of	O
posttransplant	O
lymphoproliferative	O
disorder	O
(	O
PTLD	O
)	O
from	O
the	O
beginning	O
of	O
the	O
LTE	O
to	O
year	O
5	O
(	O
n	O
=	O
3	O
LI	O
;	O
n	O
=	O
1	O
CsA	O
)	O
;	O
two	O
of	O
three	O
PTLD	O
cases	O
in	O
the	O
LI	O
group	O
were	O
in	O
patients	O
who	O
were	O
seronegative	O
for	O
Epstein-Barr	O
virus	O
(	O
EBV	O
(	O
-	O
)	O
)	O
at	O
transplantation	O
.	O

Mean	O
?	O
SD	O
calculated	O
GFR	O
at	O
year	O
5	O
was	O
55.9	O
?	O
17.5	O
(	O
MI	O
)	O
,	O
59.0	O
?	O
29.1	O
(	O
LI	O
)	O
and	O
44.6	O
?	O
16.4	O
(	O
CsA	O
)	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
.	O

Continued	O
treatment	O
with	O
belatacept	O
was	O
associated	O
with	O
a	O
consistent	O
safety	O
profile	O
and	O
sustained	O
improvement	O
in	O
renal	O
function	O
versus	O
CsA	O
over	O
time	O
.	O

The	O
effect	O
of	O
iron	O
in	O
formula	O
milk	O
after	O
6	O
months	O
of	O
age	O
.	O

Ninety	SampleSize
two	SampleSize
normal	Condition
birthweight	Condition
infants	Age
aged	O
6	Age
months	Age
entered	O
a	O
double	O
blind	O
controlled	O
trial	O
which	O
compared	O
a	O
follow	O
on	O
formula	O
milk	O
with	O
no	O
added	O
iron	O
against	O
the	O
same	O
formula	O
milk	O
containing	O
1.2	O
mg	O
of	O
iron	O
per	O
100	O
ml	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
social	O
class	O
or	O
demographic	O
characteristics	O
of	O
the	O
two	O
treatment	O
groups	O
or	O
in	O
the	O
proportion	O
of	O
each	O
group	O
completing	O
the	O
trial	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
two	O
groups	O
in	O
the	O
quantity	O
of	O
milk	O
taken	O
but	O
the	O
amounts	O
taken	O
lessened	O
between	O
6	O
and	O
18	O
months	O
of	O
age	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
mean	O
haemoglobin	O
and	O
median	O
serum	O
ferritin	O
at	O
6	O
,	O
9	O
,	O
12	O
,	O
15	O
,	O
and	O
18	O
months	O
of	O
age	O
.	O

Very	O
few	O
infants	O
developed	O
iron	O
deficiency	O
anaemia	O
in	O
either	O
group	O
but	O
there	O
was	O
a	O
tendency	O
for	O
serum	O
ferritin	O
levels	O
to	O
fall	O
between	O
6	O
and	O
18	O
months	O
of	O
age	O
in	O
both	O
groups	O
.	O

The	O
results	O
suggest	O
that	O
iron	O
added	O
to	O
follow	O
on	O
milk	O
was	O
not	O
an	O
important	O
source	O
of	O
dietary	O
iron	O
in	O
the	O
infants	O
studied	O
.	O

Phase	O
III	O
study	O
of	O
two	O
different	O
dosing	O
schedules	O
of	O
erythropoietin	O
in	O
anemic	Condition
patients	Condition
with	Condition
cancer	Condition
.	O

PURPOSE	O
To	O
compare	O
maintenance	O
epoetin	O
alfa	O
administered	O
once	O
every	O
3	O
weeks	O
with	O
continued	O
weekly	O
epoetin	O
alfa	O
for	O
patients	O
with	O
cancer-associated	Condition
anemia	Condition
.	O

PATIENTS	O
AND	O
METHODS	O
Eligible	O
patients	O
were	O
randomly	O
assigned	O
at	O
enrollment	O
to	O
receive	O
three	O
weekly	O
doses	O
of	O
epoetin	O
alfa	O
40,000	O
U	O
subcutaneously	O
(	O
SC	O
)	O
,	O
followed	O
by	O
either	O
standard	O
weekly	O
epoetin	O
alfa	O
(	O
40K	O
arm	O
)	O
or	O
120,000	O
U	O
of	O
epoetin	O
alfa	O
(	O
120K	O
arm	O
)	O
SC	O
every	O
3	O
weeks	O
for	O
18	O
additional	O
weeks	O
.	O

RESULTS	O
Three	SampleSize
hundred	SampleSize
sixty-five	SampleSize
patients	SampleSize
were	O
enrolled	O
.	O

One	O
hundred	O
eighty-three	O
patients	O
were	O
assigned	O
to	O
the	O
40K	O
arm	O
,	O
and	O
182	O
were	O
assigned	O
to	O
the	O
120K	O
arm	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
proportion	O
of	O
patients	O
requiring	O
transfusions	O
during	O
the	O
study	O
(	O
23	O
%	O
in	O
40K	O
arm	O
and	O
18	O
%	O
in	O
120K	O
arm	O
,	O
P	O
=	O
.22	O
)	O
or	O
specifically	O
during	O
the	O
maintenance	O
phase	O
(	O
13	O
%	O
in	O
40K	O
arm	O
v	O
15	O
%	O
in	O
120K	O
arm	O
,	O
P	O
=	O
.58	O
)	O
.	O

Patients	O
randomly	O
assigned	O
to	O
the	O
40K	O
arm	O
were	O
more	O
likely	O
to	O
have	O
a	O
>	O
or	O
=	O
2	O
or	O
>	O
or	O
=	O
3	O
g/dL	O
hemoglobin	O
(	O
Hb	O
)	O
increment	O
,	O
were	O
more	O
likely	O
to	O
have	O
a	O
drug	O
dose	O
held	O
because	O
of	O
high	O
Hb	O
,	O
and	O
had	O
higher	O
mean	O
end-of-study	O
Hb	O
levels	O
.	O

Toxicities	O
,	O
including	O
thromboembolism	O
,	O
and	O
overall	O
survival	O
were	O
similar	O
.	O

Patients	O
in	O
the	O
40K	O
arm	O
had	O
a	O
higher	O
global	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
at	O
baseline	O
for	O
unclear	O
reasons	O
,	O
whereas	O
patients	O
in	O
the	O
120K	O
arm	O
had	O
a	O
greater	O
global	O
QOL	O
improvement	O
during	O
the	O
study	O
,	O
so	O
end-of-study	O
QOL	O
was	O
equivalent	O
.	O

CONCLUSION	O
After	O
three	O
weekly	O
doses	O
of	O
epoetin	O
alfa	O
40,000	O
U	O
,	O
a	O
dose	O
of	O
120,000	O
U	O
can	O
be	O
administered	O
safely	O
once	O
every	O
3	O
weeks	O
without	O
increasing	O
transfusion	O
needs	O
or	O
sacrificing	O
QOL	O
.	O

The	O
Hb	O
increment	O
is	O
somewhat	O
greater	O
with	O
continued	O
weekly	O
epoetin	O
alfa	O
.	O

Lack	O
of	O
blinding	O
as	O
a	O
result	O
of	O
different	O
treatment	O
schedules	O
may	O
have	O
confounded	O
results	O
.	O

Should	O
insertion	O
of	O
intramedullary	O
nails	O
for	O
tibial	O
fractures	O
be	O
with	O
or	O
without	O
reaming	O
?	O
A	O
prospective	O
,	O
randomized	O
study	O
with	O
3.8	O
years	O
'	O
follow-up	O
.	O

OBJECTIVE	O
To	O
determine	O
if	O
any	O
differences	O
exist	O
in	O
healing	O
and	O
complications	O
between	O
reamed	O
and	O
unreamed	O
nailing	O
in	O
patients	O
with	O
tibial	O
shaft	O
fractures	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
.	O

SETTING	O
Level	O
1	O
trauma	O
center	O
.	O

PATIENTS	O
Forty-five	O
patients	O
with	O
displaced	O
closed	O
and	O
open	O
Gustilo	O
type	O
I-IIIA	O
fractures	O
of	O
the	O
central	O
two	O
thirds	O
of	O
the	O
tibia	O
.	O

INTERVENTION	O
Stabilization	O
of	O
tibial	O
fractures	O
either	O
with	O
a	O
slotted	O
,	O
stainless	O
steel	O
reamed	O
nail	O
or	O
a	O
solid	O
,	O
titanium	O
unreamed	O
nail	O
.	O

MAIN	O
OUTCOME	O
MEASUREMENTS	O
Nonunions	O
,	O
time	O
to	O
fracture	O
healing	O
,	O
and	O
rate	O
of	O
malunions	O
.	O

RESULTS	O
The	O
average	O
time	O
to	O
fracture	O
healing	O
was	O
16.7	O
weeks	O
in	O
the	O
reamed	O
group	O
and	O
25.7	O
weeks	O
in	O
the	O
unreamed	O
group	O
.	O

The	O
difference	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
0.004	O
)	O
.	O

There	O
were	O
three	O
nonunions	O
,	O
all	O
in	O
the	O
unreamed	O
nail	O
group	O
.	O

Two	O
of	O
these	O
fractures	O
healed	O
after	O
dynamization	O
by	O
removing	O
static	O
interlocking	O
screws	O
.	O

The	O
third	O
nonunion	O
did	O
not	O
heal	O
despite	O
exchange	O
reamed	O
nailing	O
2	O
years	O
after	O
the	O
primary	O
surgery	O
and	O
dynamization	O
with	O
a	O
fibular	O
osteotomy	O
after	O
an	O
additional	O
1	O
year	O
.	O

There	O
were	O
two	O
malunions	O
in	O
the	O
reamed	O
group	O
and	O
four	O
malunions	O
in	O
the	O
unreamed	O
group	O
.	O

There	O
were	O
no	O
differences	O
for	O
all	O
other	O
outcome	O
measurements	O
.	O

CONCLUSION	O
Unreamed	O
nailing	O
in	O
patients	O
with	O
tibial	O
shaft	O
fractures	O
may	O
be	O
associated	O
with	O
higher	O
rates	O
of	O
secondary	O
operations	O
and	O
malunions	O
compared	O
with	O
reamed	O
nailing	O
.	O

The	O
time	O
to	O
fracture	O
healing	O
was	O
significantly	O
longer	O
with	O
unreamed	O
nails	O
.	O

Randomized	O
trial	O
of	O
liberal	O
versus	O
restrictive	O
guidelines	O
for	O
red	O
blood	O
cell	O
transfusion	O
in	O
preterm	O
infants	O
.	O

OBJECTIVE	O
Although	O
many	O
centers	O
have	O
introduced	O
more	O
restrictive	O
transfusion	O
policies	O
for	O
preterm	O
infants	O
in	O
recent	O
years	O
,	O
the	O
benefits	O
and	O
adverse	O
consequences	O
of	O
allowing	O
lower	O
hematocrit	O
levels	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
restrictive	O
guidelines	O
for	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
transfusions	O
for	O
preterm	O
infants	O
can	O
reduce	O
the	O
number	O
of	O
transfusions	O
without	O
adverse	O
consequences	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
We	O
enrolled	O
100	O
hospitalized	O
preterm	O
infants	O
with	O
birth	O
weights	O
of	O
500	O
to	O
1300	O
g	O
into	O
a	O
randomized	O
clinical	O
trial	O
comparing	O
2	O
levels	O
of	O
hematocrit	O
threshold	O
for	O
RBC	O
transfusion	O
.	O

INTERVENTION	O
The	O
infants	O
were	O
assigned	O
randomly	O
to	O
either	O
the	O
liberal-	O
or	O
the	O
restrictive-transfusion	O
group	O
.	O

For	O
each	O
group	O
,	O
transfusions	O
were	O
given	O
only	O
when	O
the	O
hematocrit	O
level	O
fell	O
below	O
the	O
assigned	O
value	O
.	O

In	O
each	O
group	O
,	O
the	O
transfusion	O
threshold	O
levels	O
decreased	O
with	O
improving	O
clinical	O
status	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
We	O
recorded	O
the	O
number	O
of	O
transfusions	O
,	O
the	O
number	O
of	O
donor	O
exposures	O
,	O
and	O
various	O
clinical	O
and	O
physiologic	O
outcomes	O
.	O

RESULTS	O
Infants	O
in	O
the	O
liberal-transfusion	O
group	O
received	O
more	O
RBC	O
transfusions	O
(	O
5.2	O
+/-	O
4.5	O
[	O
mean	O
+/-	O
SD	O
]	O
vs	O
3.3	O
+/-	O
2.9	O
in	O
the	O
restrictive-transfusion	O
group	O
)	O
.	O

However	O
,	O
the	O
number	O
of	O
donors	O
to	O
whom	O
the	O
infants	O
were	O
exposed	O
was	O
not	O
significantly	O
different	O
(	O
2.8	O
+/-	O
2.5	O
vs	O
2.2	O
+/-	O
2.0	O
)	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
groups	O
in	O
the	O
percentage	O
of	O
infants	O
who	O
avoided	O
transfusions	O
altogether	O
(	O
12	O
%	O
in	O
the	O
liberal-transfusion	O
group	O
versus	O
10	O
%	O
in	O
the	O
restrictive-transfusion	O
group	O
)	O
.	O

Infants	O
in	O
the	O
restrictive-transfusion	O
group	O
were	O
more	O
likely	O
to	O
have	O
intraparenchymal	O
brain	O
hemorrhage	O
or	O
periventricular	O
leukomalacia	O
,	O
and	O
they	O
had	O
more	O
frequent	O
episodes	O
of	O
apnea	O
,	O
including	O
both	O
mild	O
and	O
severe	O
episodes	O
.	O

CONCLUSIONS	O
Although	O
both	O
transfusion	O
programs	O
were	O
well	O
tolerated	O
,	O
our	O
finding	O
of	O
more	O
frequent	O
major	O
adverse	O
neurologic	O
events	O
in	O
the	O
restrictive	O
RBC-transfusion	O
group	O
suggests	O
that	O
the	O
practice	O
of	O
restrictive	O
transfusions	O
may	O
be	O
harmful	O
to	O
preterm	O
infants	O
.	O

Continuous	O
chemotherapy	O
in	O
responsive	O
metastatic	Condition
breast	Condition
cancer	Condition
:	O
a	O
role	O
for	O
tumour	O
markers	O
?	O
A	O
biochemical	O
response	O
index	O
comprising	O
ESR	O
,	O
CEA	O
and	O
CA	O
15.3	O
was	O
evaluated	O
in	O
67	SampleSize
patients	O
with	O
systemic	Condition
breast	Condition
cancer	Condition
treated	Condition
by	Condition
chemotherapy	Condition
;	O
55	SampleSize
were	O
assessable	Condition
by	Condition
UICC	Condition
criteria	Condition
and	O
the	O
response	O
index	O
(	O
96	O
%	O
of	O
all	O
UICC	O
assessable	O
patients	O
)	O
.	O

Marker	O
changes	O
at	O
2	O
and	O
4	O
months	O
showed	O
a	O
highly	O
significant	O
correlation	O
with	O
the	O
UICC	O
assessed	O
response	O
at	O
3	O
and	O
6	O
months	O
(	O
P	O
<	O
0.001	O
)	O
;	O
sensitivity	O
100	O
%	O
,	O
specificity	O
87	O
%	O
;	O
positive	O
predictive	O
value	O
85	O
%	O
;	O
negative	O
predictive	O
value	O
100	O
%	O
.	O

This	O
index	O
was	O
then	O
used	O
to	O
select	O
out	O
truly	O
responsive	O
patients	O
and	O
to	O
prospectively	O
direct	O
their	O
chemotherapy	O
.	O

Twenty-six	O
responding	O
(	O
biochemical/clinical	O
)	O
patients	O
were	O
randomised	O
to	O
discontinue	O
cytotoxics	O
after	O
6	O
months	O
and	O
move	O
to	O
maintenance	O
hormones	O
(	O
n	O
=	O
13	O
)	O
or	O
continue	O
chemotherapy	O
whilst	O
the	O
biochemical	O
markers	O
kept	O
falling	O
or	O
remained	O
within	O
the	O
normal	O
range	O
.	O

Biochemical	O
progression	O
prompted	O
a	O
change	O
of	O
chemotherapy	O
.	O

Continuous	O
chemotherapy	O
in	O
biochemically	O
defined	O
responders	O
was	O
associated	O
with	O
a	O
significant	O
lengthening	O
of	O
remission	O
duration	O
and	O
an	O
improved	O
quality	O
of	O
life	O
and	O
survival	O
.	O

We	O
are	O
now	O
using	O
the	O
index	O
to	O
routinely	O
direct	O
chemotherapy	O
and	O
select	O
out	O
true	O
responders	O
for	O
maintenance	O
chemotherapy	O
.	O

A	O
double	O
blind	O
randomized	O
trial	O
to	O
compare	O
the	O
effects	O
of	O
eprosartan	O
and	O
enalapril	O
on	O
blood	O
pressure	O
,	O
platelets	O
,	O
and	O
endothelium	O
function	O
in	O
patients	O
with	O
essential	Condition
hypertension	Condition
.	O

The	O
renin-angiotensin	O
system	O
is	O
the	O
major	O
contributor	O
to	O
development	O
of	O
hypertension	O
,	O
atherosclerosis	O
,	O
and	O
many	O
other	O
cardiovascular	O
diseases	O
.	O

Angiotensin	O
II	O
,	O
one	O
of	O
the	O
main	O
effectors	O
of	O
this	O
system	O
,	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
hypertension	O
and	O
plays	O
an	O
important	O
role	O
in	O
monocyte	O
,	O
platelet	O
,	O
and	O
endothelium	O
interactions	O
.	O

The	O
effects	O
on	O
platelet	O
and	O
endothelial	O
function	O
,	O
either	O
by	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	O
receptor	O
antagonists	O
,	O
are	O
still	O
not	O
well	O
understood	O
.	O

A	O
double-blind	O
,	O
randomized	O
,	O
prospective	O
trial	O
of	O
either	O
enalapril	O
(	O
10-20	O
mg	O
daily	O
)	O
or	O
eprosartan	O
(	O
400-800	O
mg	O
daily	O
)	O
over	O
a	O
10-week	O
period	O
was	O
conducted	O
in	O
42	SampleSize
patients	O
(	O
27	SampleSize
males	Sex
,	O
15	SampleSize
females	Sex
)	O
.	O

Platelet	O
activation	O
was	O
evaluated	O
by	O
measuring	O
platelet	O
factor	O
4	O
(	O
PF-4	O
)	O
,	O
beta-thromboglobulin	O
(	O
beta-TG	O
)	O
,	O
the	O
ratio	O
of	O
platelet	O
factor	O
4	O
to	O
beta-thromboglobulin	O
,	O
and	O
endothelial	O
function	O
by	O
measuring	O
total	O
plasma	O
nitrate	O
levels	O
,	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
levels	O
,	O
and	O
blood	O
flow	O
using	O
venous	O
occlusive	O
plethysmography	O
.	O

After	O
a	O
10-week	O
treatment	O
with	O
enalapril	O
or	O
eprosartan	O
,	O
the	O
sitting	O
blood	O
pressure	O
in	O
both	O
the	O
enalapril	O
group	O
(	O
from	O
152.2	O
+/-	O
18.7	O
mmHg	O
to	O
141.9	O
+/-	O
23.5	O
mmHg	O
,	O
P	O
<	O
0.05	O
)	O
and	O
eprosartan	O
group	O
(	O
from	O
151	O
+/-	O
10.0	O
mmHg	O
to	O
142.3	O
+/-	O
12.9	O
mmHg	O
,	O
P	O
<	O
0.05	O
)	O
was	O
significantly	O
reduced	O
.	O

Significant	O
diastolic	O
blood	O
pressure	O
(	O
DPB	O
)	O
reduction	O
(	O
from	O
94	O
+/-	O
8.7	O
to	O
84.5	O
+/-	O
9.6	O
mmHg	O
,	O
P	O
<	O
0.05	O
)	O
and	O
a	O
greater	O
DBP	O
reduction	O
response	O
were	O
found	O
in	O
the	O
eprosartan	O
group	O
(	O
63	O
%	O
in	O
eprosartan	O
versus	O
25	O
%	O
in	O
enalapril	O
)	O
.	O

Additionally	O
,	O
dose-dependent	O
reductions	O
in	O
the	O
indices	O
of	O
platelet	O
activation	O
and	O
endothelial	O
dysfunction	O
were	O
observed	O
in	O
patients	O
administered	O
high	O
dose	O
treatments	O
of	O
eprosartan	O
and	O
enalapril	O
,	O
and	O
the	O
beneficial	O
effects	O
of	O
these	O
agents	O
were	O
not	O
correlated	O
with	O
the	O
reduction	O
of	O
blood	O
pressure	O
using	O
both	O
agents	O
.	O

Eprosartan	O
is	O
effective	O
and	O
well-tolerated	O
in	O
the	O
treatment	O
of	O
mid-to-moderate	O
hypertension	O
,	O
and	O
the	O
DBP	O
response	O
reduction	O
to	O
eprosartin	O
was	O
better	O
than	O
that	O
to	O
enalapril	O
.	O

A	O
high	O
dose	O
of	O
either	O
eprosartan	O
or	O
enalapril	O
significantly	O
decreased	O
the	O
indices	O
of	O
platelet	O
activation	O
and	O
endothelial	O
dysfunction	O
in	O
hypertensive	Condition
patients	O
.	O

The	O
benefits	O
of	O
both	O
agents	O
can	O
not	O
be	O
explained	O
solely	O
by	O
their	O
antihypertensive	O
effects	O
and	O
possibly	O
may	O
be	O
mediated	O
through	O
their	O
unique	O
effect	O
on	O
angiotensin	O
blockade	O
.	O

Phase	O
II	O
trial	O
of	O
nab-paclitaxel	O
compared	O
with	O
docetaxel	O
as	O
first-line	O
chemotherapy	O
in	O
patients	O
with	O
metastatic	Condition
breast	Condition
cancer	Condition
:	O
final	O
analysis	O
of	O
overall	O
survival	O
.	O

BACKGROUND	O
A	O
randomized	O
phase	O
II	O
study	O
in	O
first-line	O
MBC	O
demonstrated	O
superior	O
efficacy	O
and	O
safety	O
of	O
weekly	O
nab-paclitaxel	O
compared	O
with	O
docetaxel	O
.	O

Final	O
survival	O
analyses	O
and	O
updated	O
safety	O
results	O
are	O
reported	O
.	O

PATIENTS	O
AND	O
METHODS	O
Three	SampleSize
hundred	SampleSize
two	SampleSize
patients	O
with	Condition
no	Condition
previous	Condition
chemotherapy	Condition
for	O
MBC	Condition
were	O
randomized	O
to	O
receive	O
nab-paclitaxel	O
300	O
mg/m	O
(	O
2	O
)	O
q3w	O
,	O
nab-paclitaxel	O
100	O
mg/m	O
(	O
2	O
)	O
or	O
150	O
mg/m	O
(	O
2	O
)	O
the	O
first	O
3	O
of	O
4	O
weeks	O
(	O
qw	O
3/4	O
)	O
,	O
or	O
docetaxel	O
100	O
mg/m	O
(	O
2	O
)	O
q3w	O
.	O

The	O
trial	O
was	O
powered	O
for	O
analyses	O
of	O
antitumor	O
activity	O
and	O
safety	O
.	O

RESULTS	O
Treatment	O
with	O
nab-paclitaxel	O
150	O
mg/m	O
(	O
2	O
)	O
qw	O
3/4	O
resulted	O
in	O
a	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
33.8	O
months	O
compared	O
with	O
22.2	O
,	O
27.7	O
,	O
and	O
26.6	O
months	O
for	O
nab-paclitaxel	O
100	O
mg/m	O
(	O
2	O
)	O
qw	O
3/4	O
,	O
nab-paclitaxel	O
300	O
mg/m	O
(	O
2	O
)	O
q3w	O
,	O
and	O
docetaxel	O
,	O
respectively	O
(	O
overall	O
P	O
=	O
.047	O
)	O
.	O

Patients	O
receiving	O
150	O
mg/m	O
(	O
2	O
)	O
nab-paclitaxel	O
had	O
prolonged	O
median	O
OS	O
compared	O
with	O
those	O
in	O
the	O
100	O
mg/m	O
(	O
2	O
)	O
nab-paclitaxel	O
arm	O
(	O
hazard	O
ratio	O
,	O
0.575	O
;	O
P	O
=	O
.008	O
)	O
.	O

A	O
trend	O
toward	O
a	O
longer	O
OS	O
was	O
noted	O
in	O
the	O
150	O
mg/m	O
(	O
2	O
)	O
nab-paclitaxel	O
arm	O
versus	O
docetaxel	O
arm	O
(	O
hazard	O
ratio	O
,	O
0.688	O
)	O
.	O

Grade	O
3	O
or	O
4	O
fatigue	O
,	O
neutropenia	O
,	O
and	O
febrile	O
neutropenia	O
were	O
less	O
frequent	O
in	O
all	O
nab-paclitaxel	O
arms	O
compared	O
with	O
docetaxel	O
.	O

CONCLUSIONS	O
Consistent	O
with	O
previously	O
published	O
efficacy	O
results	O
,	O
these	O
data	O
suggest	O
that	O
150	O
mg/m	O
(	O
2	O
)	O
qw	O
3/4	O
may	O
represent	O
the	O
most	O
clinically	O
efficacious	O
nab-paclitaxel	O
dosing	O
regimen	O
for	O
patients	O
with	O
no	O
previous	O
chemotherapy	O
for	O
MBC	O
.	O

A	O
phase	O
III	O
trial	O
confirming	O
these	O
results	O
would	O
be	O
necessary	O
and	O
prudent	O
before	O
widespread	O
adoption	O
of	O
the	O
150	O
mg/m	O
(	O
2	O
)	O
dose	O
in	O
clinical	O
practice	O
.	O

A	O
hybrid	O
technique	O
using	O
bipolar	O
energy	O
in	O
transurethral	O
prostate	O
surgery	O
:	O
a	O
prospective	O
,	O
randomized	O
comparison	O
.	O

PURPOSE	O
We	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
transurethral	O
resection	O
and	O
vaporization	O
with	O
bipolar	O
PlasmaKinetic	O
energy	O
.	O

MATERIALS	O
AND	O
METHODS	O
During	O
a	O
2-year	O
period	O
101	SampleSize
men	Sex
with	O
benign	Condition
prostatic	Condition
hyperplasia	Condition
were	O
randomly	O
assigned	O
to	O
PlasmaKinetic	O
surgery	O
or	O
standard	O
transurethral	O
prostate	O
resection	O
(	O
TURP	O
)	O
.	O

Patient	O
demographics	O
,	O
indications	O
for	O
surgery	O
,	O
preoperative	O
and	O
postoperative	O
International	O
Prostate	O
Symptom	O
Score	O
,	O
uroflowmetry	O
scores	O
,	O
operative	O
time	O
,	O
catheterization	O
duration	O
,	O
hospital	O
stay	O
and	O
complication	O
rates	O
were	O
compared	O
.	O

RESULTS	O
Complete	O
data	O
on	O
96	SampleSize
patients	O
with	O
a	O
mean	Age
age	Age
+/-	Age
SD	Age
of	Age
69.1	Age
+/-	Age
6.1	Age
years	Age
was	O
available	O
at	O
a	O
mean	O
followup	O
of	O
18.3	O
+/-	O
6.7	O
months	O
(	O
range	O
12	O
to	O
23	O
)	O
.	O

In	O
the	O
PlasmaKinetic	O
and	O
TURP	O
groups	O
mean	O
operative	O
time	O
was	O
40.3	O
+/-	O
11.4	O
(	O
range	O
30	O
to	O
60	O
)	O
and	O
57.8	O
+/-	O
13.4	O
minutes	O
(	O
range	O
45	O
to	O
75	O
)	O
,	O
respectively	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
mean	O
volume	O
of	O
saline	O
irrigation	O
during	O
the	O
PlasmaKinetic	O
procedure	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
hyperosmolar	O
solution	O
irrigation	O
during	O
TURP	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Patients	O
in	O
the	O
PlasmaKinetic	O
and	O
TURP	O
groups	O
were	O
catheterized	O
a	O
mean	O
of	O
2.3	O
+/-	O
0.7	O
(	O
range	O
2	O
to	O
4	O
)	O
and	O
3.8	O
+/-	O
0.7	O
days	O
(	O
range	O
3	O
to	O
5	O
)	O
,	O
respectively	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
mean	O
improvement	O
rate	O
from	O
baseline	O
at	O
month	O
12	O
in	O
International	O
Prostate	O
Symptom	O
Score	O
and	O
the	O
maximal	O
urinary	O
flow	O
rate	O
was	O
similar	O
in	O
the	O
2	O
groups	O
.	O

Severe	O
irritative	O
symptoms	O
were	O
the	O
most	O
common	O
complaints	O
after	O
PlasmaKinetic	O
surgery	O
,	O
as	O
observed	O
in	O
6	O
cases	O
(	O
12.2	O
%	O
)	O
.	O

Recatheterization	O
was	O
necessary	O
in	O
3	O
cases	O
(	O
6.1	O
%	O
)	O
cases	O
in	O
the	O
PlasmaKinetic	O
group	O
and	O
in	O
1	O
(	O
2.1	O
%	O
)	O
in	O
the	O
TURP	O
group	O
.	O

During	O
followup	O
urethral	O
stricture	O
formation	O
was	O
observed	O
in	O
3	O
patients	O
(	O
6.1	O
%	O
)	O
cases	O
in	O
the	O
former	O
group	O
and	O
in	O
1	O
(	O
2.1	O
%	O
)	O
in	O
the	O
latter	O
group	O
(	O
p	O
=	O
0.002	O
)	O
.	O

Reoperation	O
was	O
required	O
in	O
2	O
(	O
4.1	O
%	O
)	O
and	O
1	O
(	O
2.1	O
%	O
)	O
cases	O
in	O
the	O
PlasmaKinetic	O
and	O
TURP	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Transurethral	O
surgery	O
with	O
PlasmaKinetic	O
bipolar	O
energy	O
seems	O
to	O
be	O
a	O
promising	O
alternative	O
to	O
prostatic	O
tissue	O
removal	O
with	O
shorter	O
operative	O
,	O
catheterization	O
and	O
hospitalization	O
times	O
,	O
although	O
increased	O
rates	O
of	O
postoperative	O
irritative	O
symptoms	O
and	O
urethral	O
stricture	O
formation	O
must	O
be	O
further	O
evaluated	O
.	O

CT	O
and	O
MRI	O
measurements	O
of	O
tibial	O
tubercle-trochlear	O
groove	O
distances	O
are	O
not	O
equivalent	O
in	O
patients	O
with	O
patellar	Condition
instability	Condition
.	O

BACKGROUND	O
Tibial	O
tubercle-trochlear	O
groove	O
distance	O
(	O
TT-TG	O
)	O
is	O
a	O
commonly	O
used	O
measurement	O
for	O
surgical	O
decision	O
making	O
in	O
patients	O
with	O
patellofemoral	Condition
malalignment	Condition
and	Condition
instability	Condition
.	O

This	O
measurement	O
has	O
historically	O
been	O
performed	O
utilizing	O
axial	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O

More	O
recently	O
,	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
has	O
been	O
proposed	O
as	O
an	O
equivalent	O
method	O
,	O
but	O
this	O
has	O
not	O
yet	O
been	O
fully	O
validated	O
.	O

PURPOSE	O
To	O
determine	O
the	O
reliability	O
of	O
TT-TG	O
distance	O
measurements	O
on	O
both	O
MRI	O
and	O
CT	O
and	O
to	O
determine	O
whether	O
the	O
measurements	O
are	O
interchangeable	O
with	O
one	O
another	O
.	O

STUDY	O
DESIGN	O
Cohort	O
study	O
(	O
diagnosis	O
)	O
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O

METHODS	O
All	O
patients	O
with	O
patellar	Condition
instability	Condition
who	O
underwent	O
both	O
CT	O
and	O
MRI	O
of	O
the	O
knee	O
from	O
2003	O
to	O
2011	O
were	O
included	O
(	O
n	O
=	O
59	O
knees	O
in	O
54	SampleSize
patients	O
)	O
.	O

Two	O
fellowship-trained	O
musculoskeletal	O
radiologists	O
measured	O
the	O
TT-TG	O
distances	O
for	O
each	O
patient	O
by	O
CT	O
and	O
MRI	O
in	O
a	O
randomized	O
,	O
blinded	O
fashion	O
.	O

Interobserver	O
reliability	O
was	O
calculated	O
between	O
radiologists	O
for	O
both	O
imaging	O
modalities	O
,	O
and	O
intermethod	O
reliability	O
was	O
calculated	O
between	O
the	O
2	O
imaging	O
modalities	O
.	O

The	O
results	O
are	O
reported	O
using	O
intraclass	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
and	O
Bland-Altman	O
analysis	O
.	O

RESULTS	O
The	O
59	O
knees	O
had	O
a	O
mean	O
TT-TG	O
distance	O
of	O
16.9	O
mm	O
(	O
range	O
,	O
8.3-25.8	O
mm	O
)	O
by	O
CT	O
and	O
14.7	O
mm	O
(	O
range	O
,	O
1.5-25.1	O
mm	O
)	O
by	O
MRI	O
.	O

Interobserver	O
reliability	O
between	O
the	O
radiologists	O
was	O
considered	O
excellent	O
for	O
both	O
CT	O
and	O
MRI	O
(	O
ICC	O
=	O
0.777	O
and	O
0.843	O
,	O
respectively	O
)	O
.	O

When	O
comparing	O
CT	O
to	O
MRI	O
,	O
the	O
ICC	O
was	O
considered	O
only	O
fair	O
for	O
each	O
of	O
the	O
raters	O
(	O
0.532	O
and	O
0.539	O
)	O
.	O

Eleven	O
patients	O
(	O
19	O
%	O
)	O
had	O
a	O
TT-TG	O
distance	O
of	O
?20	O
mm	O
on	O
CT	O
preoperatively	O
and	O
underwent	O
distal	O
realignment	O
by	O
tibial	O
tubercle	O
osteotomy	O
.	O

In	O
this	O
surgical	O
subgroup	O
,	O
the	O
mean	O
TT-TG	O
distance	O
was	O
22.5	O
mm	O
(	O
range	O
,	O
19.8-25.8	O
mm	O
)	O
by	O
CT	O
and	O
only	O
18.7	O
mm	O
(	O
range	O
,	O
14.4-22.8	O
mm	O
)	O
by	O
MRI	O
for	O
a	O
mean	O
difference	O
of	O
3.80	O
mm	O
(	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSION	O
The	O
TT-TG	O
distance	O
can	O
be	O
measured	O
with	O
excellent	O
interrater	O
reliability	O
on	O
both	O
MRI	O
and	O
CT	O
;	O
however	O
,	O
the	O
values	O
derived	O
from	O
these	O
2	O
tests	O
may	O
not	O
be	O
interchangeable	O
.	O

This	O
observation	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
MRI	O
is	O
used	O
for	O
surgical	O
planning	O
because	O
MRI	O
may	O
underestimate	O
the	O
TT-TG	O
distance	O
when	O
compared	O
with	O
CT	O
.	O

A	O
prospective	O
randomized	O
study	O
concerning	O
the	O
point	O
A	O
dose	O
in	O
high-dose	O
rate	O
intracavitary	O
therapy	O
for	O
carcinoma	Condition
of	Condition
the	Condition
uterine	Condition
cervix	Condition
.	O

The	O
final	O
results	O
.	O

PURPOSE	O
High-dose	O
rate	O
(	O
HDR	O
)	O
remote	O
afterloading	O
intracavitary	O
therapy	O
has	O
been	O
recognized	O
as	O
an	O
effective	O
and	O
safe	O
treatment	O
modality	O
for	O
carcinoma	Condition
of	Condition
the	Condition
uterine	Condition
cervix	Condition
.	O

Since	O
1983	O
,	O
a	O
prospective	O
randomized	O
study	O
was	O
started	O
in	O
order	O
to	O
investigate	O
the	O
more	O
advantageous	O
treatment	O
schedule	O
with	O
keeping	O
the	O
local	O
control	O
rate	O
.	O

This	O
paper	O
reports	O
the	O
final	O
results	O
in	O
terms	O
of	O
survival	O
,	O
local	O
control	O
and	O
complications	O
.	O

PATIENTS	O
AND	O
METHODS	O
Between	O
January	O
1983	O
and	O
February	O
1989	O
,	O
a	O
total	O
of	O
165	SampleSize
patients	O
with	O
carcinoma	Condition
of	Condition
the	Condition
uterine	Condition
cervix	Condition
was	O
entered	O
in	O
a	O
prospective	O
randomized	O
study	O
concerning	O
the	O
point	O
A	O
dose	O
of	O
HDR	O
therapy	O
(	O
6	O
Gy/fraction	O
vs	O
7.5	O
Gy/fraction	O
)	O
and	O
external	O
irradiation	O
dose	O
at	O
Department	O
of	O
Radiation	O
Therapy	O
,	O
The	O
Center	O
for	O
Adult	O
Diseases	O
,	O
Osaka	O
.	O

UICC	O
[	O
20	O
]	O
stage	O
distribution	O
of	O
patients	O
was	O
as	O
follows	O
:	O
stage	O
IA	O
=	O
4	SampleSize
,	O
stage	O
IB	O
=	O
33	SampleSize
,	O
stage	O
IIA	O
=	O
18	SampleSize
,	O
stage	O
IIB	O
=	O
38	SampleSize
,	O
stage	O
III	O
=	O
57	SampleSize
,	O
stage	O
IV	O
=	O
15	SampleSize
.	O

RESULTS	O
Overall	O
5-year	O
cause	O
specific	O
survivals	O
were	O
as	O
follows	O
:	O
stage	O
IA	O
=	O
100	O
%	O
,	O
stage	O
IB	O
=	O
96	O
%	O
,	O
stage	O
IIA	O
=	O
92	O
%	O
,	O
stage	O
IIB	O
=	O
79	O
%	O
,	O
stage	O
III	O
=	O
57	O
%	O
,	O
stage	O
IV	O
=	O
27	O
%	O
.	O

In	O
each	O
stage	O
,	O
5-year	O
survival	O
rates	O
in	O
groups	O
A	O
and	O
B	O
were	O
100	O
%	O
,	O
93	O
%	O
in	O
stage	O
I	O
,	O
82	O
%	O
and	O
85	O
%	O
in	O
stage	O
II	O
,	O
62	O
%	O
and	O
52	O
%	O
in	O
stage	O
II	O
and	O
22	O
%	O
and	O
31	O
%	O
in	O
stage	O
IV	O
,	O
respectively	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
among	O
these	O
survival	O
curves	O
in	O
each	O
stage	O
.	O

Five-year	O
local	O
failure	O
rates	O
were	O
16	O
%	O
in	O
group	O
A	O
and	O
16	O
%	O
in	O
group	O
B	O
(	O
p	O
=	O
0.9096	O
)	O
,	O
and	O
corresponding	O
distant	O
failure	O
rates	O
were	O
23	O
%	O
in	O
group	O
A	O
and	O
19	O
%	O
in	O
group	O
B	O
(	O
p	O
=	O
0.2955	O
)	O
.	O

Moderate-to-severe	O
complications	O
requiring	O
treatment	O
(	O
Kottmeier	O
's	O
grade	O
2	O
or	O
more	O
)	O
were	O
noted	O
in	O
6	O
patients	O
(	O
7	O
%	O
)	O
in	O
group	O
A	O
and	O
6	O
patients	O
(	O
7	O
%	O
)	O
in	O
group	O
B	O
.	O

All	O
of	O
the	O
bladder	O
and	O
rectal	O
complications	O
needed	O
medical	O
treatment	O
(	O
Kottmeier	O
's	O
grade	O
2	O
)	O
.	O

Severe	O
complications	O
receiving	O
surgery	O
were	O
noted	O
in	O
4	O
patients	O
(	O
A	O
:	O
1	O
;	O
B	O
:	O
3	O
)	O
,	O
i.e.	O
,	O
small	O
intestine	O
3	O
and	O
sigmoid	O
colon	O
1	O
patient	O
.	O

Another	O
1	O
patient	O
(	O
A	O
)	O
was	O
dead	O
of	O
ileus	O
.	O

CONCLUSIONS	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
2	O
treatment	O
schedules	O
in	O
survival	O
rates	O
,	O
failure	O
patterns	O
and	O
complications	O
rates	O
.	O

This	O
fact	O
suggests	O
that	O
small	O
number	O
of	O
fractions	O
(	O
7.5	O
Gy/fraction	O
)	O
may	O
be	O
advantageous	O
because	O
of	O
short	O
duration	O
and	O
a	O
low	O
load	O
of	O
treatment	O
.	O

Effects	O
of	O
ursodeoxycholic	O
acid	O
on	O
serum	O
liver	O
enzymes	O
in	O
patients	O
with	O
hepatitis	Condition
C	Condition
virus-related	Condition
chronic	Condition
liver	Condition
disease	Condition
.	O

OBJECTIVE	O
To	O
study	O
the	O
effect	O
of	O
ursodeoxycholic	O
acid	O
(	O
UDCA	O
)	O
on	O
serum	O
liver	O
enzyme	O
levels	O
[	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
gamma-glutamyl	O
transferase	O
(	O
GGT	O
)	O
]	O
in	O
101	SampleSize
patients	O
with	O
hepatitis	Condition
C	Condition
virus-related	Condition
chronic	Condition
liver	Condition
disease	Condition
.	O

METHODS	O
Forty-nine	O
patients	O
were	O
assigned	O
to	O
receive	O
UDCA	O
(	O
450	O
mg/day	O
)	O
over	O
a	O
period	O
of	O
6	O
months	O
and	O
52	O
to	O
receive	O
no	O
treatment	O
.	O

RESULTS	O
In	O
the	O
UDCA	O
group	O
,	O
serum	O
ALT	O
and	O
GGT	O
levels	O
significantly	O
improved	O
.	O

ALT	O
values	O
decreased	O
from	O
pre-treatment	O
levels	O
of	O
157.0	O
+/-	O
62.6	O
IU/l	O
to	O
82.5	O
+/-	O
46.4	O
IU/l	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
GGT	O
fell	O
from	O
141.3	O
+/-	O
86.2	O
IU/l	O
to	O
66.0	O
+/-	O
49.5	O
IU/l	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
change	O
occurred	O
in	O
the	O
mean	O
ALT	O
and	O
GGT	O
levels	O
in	O
the	O
control	O
group	O
.	O

CONCLUSION	O
Although	O
our	O
encouraging	O
preliminary	O
results	O
must	O
be	O
validated	O
by	O
double-blind	O
histological	O
trials	O
,	O
UDCA	O
may	O
be	O
an	O
alternative	O
treatment	O
for	O
patients	O
who	O
fail	O
to	O
respond	O
to	O
interferon	O
therapy	O
.	O

The	O
SPEM	O
(	O
Studio	O
Policentrico	O
Elettrocateteri	O
Membrane	O
)	O
:	O
a	O
multicenter	O
study	O
on	O
membrane	Condition
leads	Condition
.	O

SPEM	O
is	O
a	O
multicenter	O
randomized	O
double-blind	O
study	O
performed	O
to	O
test	O
the	O
acute	O
and	O
chronic	O
electrophysiological	O
behavior	O
of	O
three	O
different	O
ventricular	Condition
leads	Condition
:	O
(	O
1	O
)	O
an	O
ion	O
exchange	O
membrane	O
with	O
30-microgram	O
dexamethasone	O
elution	O
in	O
a	O
contoured	O
activated	O
carbon	O
tip	O
lead	O
(	O
Membrane	O
1400T	O
,	O
30	O
patients	O
)	O
;	O
(	O
2	O
)	O
the	O
same	O
lead	O
design	O
without	O
steroid	O
(	O
Membrane	O
1401T	O
,	O
24	O
patients	O
)	O
;	O
and	O
(	O
3	O
)	O
the	O
same	O
lead	O
design	O
without	O
steroid	O
or	O
membrane	O
(	O
control	O
group	O
,	O
27	O
patients	O
)	O
.	O

Twenty-three	SampleSize
of	O
the	O
81	SampleSize
patients	O
were	O
women	Sex
;	O
the	O
mean	O
age	O
for	O
all	O
patients	O
was	O
74	Age
+/-	Age
10	Age
years	Age
.	O

Parameters	O
are	O
calculated	O
both	O
in	O
uni-	O
and	O
bipolar	O
configuration	O
at	O
implant	O
and	O
at	O
follow-up	O
after	O
1	O
,	O
5	O
,	O
15	O
,	O
30	O
,	O
90	O
,	O
180	O
,	O
and	O
360	O
days	O
.	O

Implant	O
threshold	O
(	O
chronaxie	O
=	O
0.413	O
+/-	O
0.280	O
ms	O
,	O
rheobase	O
=	O
0.264	O
+/-	O
0.099	O
V	O
)	O
,	O
signal	O
amplitude	O
(	O
13.45	O
+/-	O
5.87	O
mV	O
)	O
,	O
and	O
slew	O
rate	O
(	O
2.05	O
+/-	O
1.38	O
V/s	O
)	O
reveal	O
no	O
significant	O
differences	O
.	O

Pacing	O
impedance	O
values	O
both	O
at	O
implant	O
(	O
unipolar	O
571	O
+/-	O
165	O
omega	O
;	O
bipolar	O
605	O
+/-	O
123	O
omega	O
)	O
and	O
at	O
follow-ups	O
(	O
unipolar	O
480	O
+/-	O
72	O
omega	O
;	O
bipolar	O
518	O
+/-	O
75	O
omega	O
)	O
are	O
slightly	O
lower	O
in	O
the	O
unipolar	O
configuration	O
.	O

At	O
15	O
and	O
30-day	O
follow-ups	O
,	O
control	O
group	O
and	O
nonsteroid	O
leads	O
show	O
a	O
higher	O
threshold	O
value	O
growth	O
(	O
in	O
unipolar	O
from	O
0.16	O
+/-	O
0.11	O
to	O
1.19	O
+/-	O
0.85	O
microJ	O
;	O
in	O
bipolar	O
from	O
0.18	O
+/-	O
0.13	O
to	O
1.24	O
+/-	O
0.88	O
microJ	O
)	O
than	O
the	O
membrane	O
steroid	O
leads	O
(	O
in	O
unipolar	O
from	O
0.13	O
+/-	O
0.11	O
to	O
0.70	O
+/-	O
0.39	O
microJ	O
;	O
in	O
bipolar	O
from	O
0.23	O
+/-	O
0.32	O
to	O
0.76	O
+/-	O
0.36	O
microJ	O
)	O
;	O
the	O
threshold	O
of	O
nonsteroid	O
leads	O
decreases	O
after	O
1-3	O
months	O
and	O
it	O
settles	O
at	O
the	O
same	O
threshold	O
level	O
of	O
the	O
leads	O
with	O
membrane	O
and	O
steroid	O
(	O
in	O
unipolar	O
0.60	O
+/-	O
0.33	O
microJ	O
;	O
in	O
bipolar	O
0.55	O
+/-	O
0.26	O
microJ	O
)	O
,	O
which	O
has	O
been	O
stable	O
since	O
the	O
first	O
month	O
.	O

The	O
ion	O
exchange	O
membrane	O
is	O
effective	O
in	O
reducing	O
the	O
chronic	O
pacing	O
threshold	O
like	O
acute	O
steroid	O
elution	O
at	O
low	O
doses	O
,	O
but	O
membrane	O
alone	O
does	O
not	O
prevent	O
an	O
acute	O
pacing	O
threshold	O
increase	O
through	O
the	O
first	O
month	O
postimplant	O
.	O

The	O
effects	O
of	O
amantadine	O
and	O
pemoline	O
on	O
cognitive	O
functioning	O
in	O
multiple	O
sclerosis	O
.	O

BACKGROUND	O
Amantadine	O
hydrochloride	O
and	O
pemoline	O
,	O
both	O
frequently	O
used	O
to	O
treat	O
the	O
fatigue	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
may	O
also	O
improve	O
attention	O
and	O
other	O
cognitive	O
functions	O
in	O
MS.	O
To	O
our	O
knowledge	O
,	O
these	O
agents	O
have	O
never	O
been	O
compared	O
in	O
a	O
placebo-controlled	O
trial	O
of	O
patients	O
with	O
MS	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
amantadine	O
and	O
pemoline	O
on	O
cognitive	O
functioning	O
in	O
MS.	O
METHODS	O
A	O
total	O
of	O
45	O
ambulatory	O
patients	O
with	O
MS	O
and	O
severe	O
fatigue	O
were	O
treated	O
for	O
6	O
weeks	O
with	O
amantadine	O
,	O
pemoline	O
,	O
or	O
placebo	O
using	O
a	O
parallel	O
group	O
design	O
.	O

They	O
underwent	O
comprehensive	O
neuropsychological	O
testing	O
to	O
determine	O
treatment	O
effects	O
on	O
cognitive	O
functioning	O
.	O

Primary	O
outcome	O
measures	O
were	O
tests	O
of	O
attention	O
(	O
Digit	O
Span	O
,	O
Trail	O
Making	O
Test	O
,	O
and	O
Symbol	O
Digit	O
Modalities	O
Test	O
)	O
,	O
verbal	O
memory	O
(	O
Selective	O
Reminding	O
Test	O
)	O
,	O
nonverbal	O
memory	O
(	O
Benton	O
Visual	O
Retention	O
Test	O
)	O
,	O
and	O
motor	O
speed	O
(	O
Finger	O
Tapping	O
Test	O
)	O
.	O

RESULTS	O
Fatigue	O
did	O
not	O
significantly	O
correlate	O
with	O
any	O
of	O
the	O
neuropsychological	O
outcome	O
measures	O
at	O
baseline	O
or	O
after	O
treatment	O
.	O

All	O
three	O
treatment	O
groups	O
improved	O
on	O
tests	O
of	O
attention	O
(	O
P	O
<	O
.003	O
)	O
,	O
verbal	O
memory	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
motor	O
speed	O
(	O
P	O
<	O
.002	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
amantadine	O
,	O
pemoline	O
,	O
and	O
placebo	O
.	O

CONCLUSIONS	O
Cognitive	O
functioning	O
in	O
MS	O
is	O
independent	O
of	O
fatigue	O
.	O

Neither	O
amantadine	O
nor	O
pemoline	O
enhances	O
cognitive	O
performance	O
in	O
MS	O
compared	O
with	O
placebo	O
.	O

[	O
Simvastatin	O
versus	O
gemfibrozil	O
in	O
the	O
treatment	O
of	O
primary	Condition
hypercholesterolemia	Condition
in	O
hypertensive	Condition
patients	O
treated	Condition
with	Condition
hydrochlorothiazide	Condition
]	O
.	O

Recent	O
pharmacological	O
studies	O
confirmed	O
the	O
role	O
of	O
hypercholesterolemia	O
in	O
the	O
pathogenesis	O
of	O
coronary	O
atherosclerosis	O
.	O

A	O
10	O
%	O
reduction	O
in	O
cholesterol	O
levels	O
can	O
reduce	O
the	O
risk	O
of	O
coronary	O
heart	O
disease	O
by	O
15	O
%	O
.	O

However	O
many	O
hypercholesterolemic	O
patients	O
often	O
suffer	O
from	O
arterial	O
hypertension	O
and	O
drugs	O
such	O
as	O
thiazide	O
diuretics	O
cause	O
an	O
imbalance	O
in	O
lipid	O
metabolism	O
.	O

The	O
efficacy	O
and	O
the	O
tolerability	O
of	O
simvastatin	O
(	O
a	O
inhibitor	O
of	O
HGM-CoA	O
reductase	O
)	O
with	O
that	O
of	O
gemfibrozil	O
(	O
a	O
fibric	O
acid	O
derivative	O
,	O
which	O
can	O
reduce	O
the	O
VLDL	O
level	O
)	O
were	O
compared	O
in	O
a	O
placebo-controlled	O
study	O
in	O
2	O
groups	O
of	O
patients	O
with	O
primary	O
hypercholesterolemia	O
and	O
mild-to-moderate	O
essential	O
hypertension	O
treated	O
with	O
hydrochlorothiazide	O
.	O

After	Condition
10	Condition
weeks	Condition
standard	Condition
hypolipidemic	Condition
diet	Condition
and	Condition
hydrochlorothiazide	Condition
(	Condition
25	Condition
mg	Condition
od	Condition
)	Condition
therapy	Condition
,	O
30	SampleSize
patients	O
whose	O
cholesterol	Condition
levels	Condition
were	Condition
still	Condition
greater	Condition
than	Condition
or	Condition
equal	Condition
to	Condition
250	Condition
mg/100	Condition
ml	Condition
and	Condition
whose	Condition
diastolic	Condition
blood	Condition
pressure	Condition
was	Condition
less	Condition
than	Condition
95	Condition
mmHg	Condition
were	O
randomized	O
to	O
one	O
of	O
the	O
following	O
treatments	O
:	O
simvastatin	O
,	O
20	O
mg	O
od	O
,	O
gemfibrozil	O
,	O
600	O
mg	O
bid	O
or	O
placebo	O
,	O
while	O
continuing	O
dietetic	O
and	O
diuretic	O
treatment	O
.	O

After	O
24	O
weeks	O
treatment	O
,	O
simvastatin	O
induced	O
a	O
37	O
%	O
reduction	O
in	O
cholesterol	O
plasma	O
levels	O
,	O
a	O
9	O
%	O
increase	O
of	O
HDL	O
and	O
a	O
16	O
%	O
reduction	O
of	O
LDL	O
.	O

APO-A1	O
showed	O
a	O
4	O
%	O
increase	O
,	O
while	O
APO-B	O
showed	O
a	O
3	O
%	O
reduction	O
.	O

Gemfibrozil	O
induced	O
a	O
20	O
%	O
reduction	O
in	O
plasma	O
triglycerides	O
and	O
a	O
13	O
%	O
decrease	O
in	O
plasma	O
cholesterol	O
,	O
with	O
a	O
significant	O
19	O
%	O
increase	O
in	O
HDL	O
and	O
a	O
11	O
%	O
reduction	O
in	O
LDL	O
.	O

No	O
significant	O
variations	O
in	O
any	O
of	O
the	O
lipid	O
parameters	O
monitored	O
were	O
observed	O
in	O
the	O
placebo	O
group	O
.	O

Treatment	O
with	O
simvastatin	O
or	O
gemfibrozil	O
in	O
hypertensive	O
patients	O
in	O
hydrochlorothiazide	O
monotherapy	O
can	O
reduce	O
total	O
cholesterol	O
and	O
LDL-cholesterol	O
plasma	O
levels	O
,	O
while	O
significantly	O
increasing	O
HDL	O
plasma	O
levels	O
compared	O
to	O
placebo	O
.	O

Simvastatin	O
,	O
however	O
,	O
resulted	O
more	O
efficient	O
than	O
gemfibrozil	O
on	O
total	O
cholesterol	O
or	O
cholesterol	O
fractions	O
.	O

Treatment	O
of	O
duodenal	Condition
ulcer	Condition
with	O
low-dose	O
antacids	O
.	O

The	O
aim	O
of	O
the	O
present	O
investigation	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
a	O
low-dose	O
antacid	O
(	O
Maalox	O
70	O
,	O
280	O
mmol/day	O
)	O
with	O
that	O
of	O
the	O
H2-receptor	O
antagonist	O
cimetidine	O
(	O
Tagamet	O
,	O
200	O
mg	O
three	O
times	O
daily	O
and	O
400	O
mg/day	O
)	O
after	O
14	O
and	O
28	O
days	O
in	O
the	O
treatment	O
of	O
duodenal	Condition
ulcer	Condition
.	O

The	O
prospective	O
multicentre	O
study	O
included	O
171	SampleSize
patients	O
with	O
endoscopically	O
confirmed	O
duodenal	Condition
ulcers	Condition
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
treatment	O
groups	O
with	O
antacid	O
containing	O
Mg	O
and	O
Al	O
hydroxide	O
(	O
M	O
)	O
(	O
4	O
X	O
70	O
mmol/day	O
;	O
n	O
=	O
86	O
)	O
or	O
to	O
the	O
group	O
receiving	O
cimetidine	O
(	O
T	O
)	O
(	O
1000	O
mg/day	O
;	O
n	O
=	O
85	O
)	O
.	O

The	O
two	O
treatment	O
groups	O
were	O
matched	O
for	O
age	O
,	O
sex	O
,	O
drinking	O
and	O
smoking	O
habits	O
,	O
and	O
drug	O
use	O
.	O

Endoscopic	O
examinations	O
were	O
carried	O
out	O
before	O
the	O
start	O
of	O
treatment	O
and	O
14	O
days	O
later	O
.	O

If	O
the	O
ulcer	O
was	O
still	O
present	O
at	O
this	O
time	O
,	O
the	O
second	O
endoscopic	O
examination	O
was	O
done	O
after	O
a	O
further	O
14	O
days	O
.	O

Endoscopically	O
,	O
the	O
ulcer	O
had	O
healed	O
at	O
14	O
days	O
in	O
38.8	O
%	O
(	O
M	O
)	O
and	O
in	O
34.9	O
%	O
(	O
T	O
)	O
and	O
at	O
28	O
days	O
in	O
80.0	O
%	O
(	O
M	O
)	O
and	O
74.7	O
%	O
(	O
T	O
)	O
,	O
respectively	O
.	O

The	O
healing	O
rate	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
treatment	O
groups	O
.	O

Complaints	O
,	O
measured	O
as	O
percentage	O
of	O
days	O
per	O
week	O
with	O
upper	O
abdominal	O
pain	O
,	O
were	O
significantly	O
reduced	O
in	O
both	O
groups	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
regard	O
to	O
pain	O
relief	O
or	O
side	O
effects	O
.	O

Treatment	O
had	O
to	O
be	O
abandoned	O
in	O
one	O
patient	O
receiving	O
antacid	O
because	O
of	O
diarrhoea	O
and	O
in	O
one	O
patient	O
receiving	O
cimetidine	O
because	O
of	O
the	O
absence	O
of	O
any	O
response	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
home	O
visiting	O
asthma	O
education	O
program	O
:	O
challenges	O
to	O
program	O
implementation	O
.	O

This	O
study	O
describes	O
the	O
implementation	O
of	O
a	O
nurse	O
home	O
visiting	O
asthma	O
education	O
program	O
for	O
low-income	O
African	O
American	O
families	O
of	O
young	O
children	Age
with	O
asthma	Condition
.	O

Of	O
55	SampleSize
families	O
,	O
71	SampleSize
%	SampleSize
completed	O
the	O
program	O
consisting	O
of	O
eight	O
lessons	O
.	O

The	O
achievement	O
of	O
learning	O
objectives	O
was	O
predicted	O
by	O
caregiver	O
factors	O
,	O
such	O
as	O
education	O
,	O
presence	O
of	O
father	O
or	O
surrogate	O
father	O
in	O
the	O
household	O
,	O
and	O
safety	O
of	O
the	O
neighborhood	O
,	O
but	O
not	O
by	O
child	O
factors	O
,	O
such	O
as	O
age	O
or	O
severity	O
of	O
asthma	O
as	O
implied	O
by	O
the	O
prescribed	O
asthma	O
medication	O
regimen	O
.	O

Incompatibility	O
between	O
the	O
scheduling	O
needs	O
of	O
the	O
families	O
and	O
the	O
nurse	O
home	O
visitors	O
was	O
a	O
major	O
obstacle	O
in	O
delivering	O
the	O
program	O
on	O
time	O
,	O
despite	O
the	O
flexibility	O
of	O
the	O
nurse	O
home	O
visitors	O
.	O

The	O
authors	O
suggest	O
that	O
future	O
home-based	O
asthma	O
education	O
programs	O
contain	O
a	O
more	O
limited	O
number	O
of	O
home	O
visits	O
but	O
add	O
telephone	O
follow-ups	O
and	O
address	O
the	O
broader	O
needs	O
of	O
low-income	O
families	O
that	O
most	O
likely	O
function	O
as	O
barriers	O
to	O
program	O
success	O
.	O

Effects	O
of	O
individualized	O
breast	O
cancer	O
risk	O
counseling	O
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
Studies	O
have	O
shown	O
that	O
a	O
majority	O
of	O
women	Sex
with	O
a	O
family	O
history	O
of	O
breast	Condition
cancer	Condition
have	O
exaggerated	O
perceptions	O
of	O
their	O
own	O
risk	O
of	O
this	O
disease	O
and	O
experience	O
excessive	O
anxiety	O
.	O

In	O
response	O
to	O
the	O
need	O
to	O
communicate	O
more	O
accurate	O
risk	O
information	O
to	O
these	O
women	O
,	O
specialized	O
programs	O
for	O
breast	O
cancer	O
risk	O
counseling	O
have	O
been	O
initiated	O
in	O
medical	O
centers	O
across	O
the	O
United	O
States	O
.	O

PURPOSE	O
Our	O
purpose	O
was	O
1	O
)	O
to	O
evaluate	O
the	O
impact	O
of	O
a	O
standardized	O
protocol	O
for	O
individualized	O
breast	O
cancer	O
risk	O
counseling	O
on	O
comprehension	O
of	O
personal	O
risk	O
among	O
first-degree	O
relatives	O
of	O
index	O
breast	O
cancer	O
patients	O
and	O
2	O
)	O
to	O
identify	O
women	O
most	O
and	O
least	O
likely	O
to	O
benefit	O
from	O
such	O
counseling	O
.	O

METHODS	O
This	O
study	O
is	O
a	O
prospective	O
randomized	O
trial	O
comparing	O
individualized	O
breast	O
cancer	O
risk	O
counseling	O
to	O
general	O
health	O
counseling	O
(	O
control	O
)	O
.	O

We	O
studied	O
200	SampleSize
women	O
aged	O
35	Age
years	Age
and	O
older	O
who	O
had	O
a	O
family	O
history	O
of	O
breast	O
cancer	O
in	O
a	O
first-degree	O
relative	O
.	O

Women	O
with	O
a	O
personal	O
history	O
of	O
cancer	O
were	O
excluded	O
.	O

Risk	O
comprehension	O
was	O
assessed	O
as	O
the	O
concordance	O
between	O
perceived	O
subjective	O
lifetime	O
breast	O
cancer	O
risk	O
and	O
estimated	O
objective	O
lifetime	O
risk	O
.	O

RESULTS	O
The	O
results	O
of	O
logistic	O
regression	O
analysis	O
showed	O
that	O
women	O
who	O
received	O
risk	O
counseling	O
were	O
significantly	O
more	O
likely	O
to	O
improve	O
their	O
risk	O
comprehension	O
,	O
compared	O
with	O
women	O
in	O
the	O
control	O
condition	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
3.5	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1.3-9.5	O
;	O
P	O
=	O
.01	O
)	O
.	O

However	O
,	O
in	O
both	O
groups	O
,	O
about	O
two	O
thirds	O
of	O
women	O
continued	O
to	O
overestimate	O
their	O
lifetime	O
risks	O
substantially	O
following	O
counseling	O
.	O

Examination	O
of	O
subjects	O
by	O
treatment	O
interaction	O
effects	O
indicated	O
that	O
risk	O
counseling	O
did	O
not	O
produce	O
improved	O
comprehension	O
among	O
the	O
large	O
proportion	O
of	O
women	O
who	O
had	O
high	O
levels	O
of	O
anxious	O
preoccupation	O
with	O
breast	O
cancer	O
at	O
base	O
line	O
(	O
P	O
=	O
.02	O
)	O
.	O

In	O
addition	O
,	O
white	O
women	O
were	O
less	O
likely	O
to	O
benefit	O
than	O
African-American	O
women	O
(	O
OR	O
=	O
0.34	O
;	O
95	O
%	O
CI	O
=	O
0.11-0.99	O
;	O
P	O
=	O
.05	O
)	O
.	O

CONCLUSION	O
Efforts	O
to	O
counsel	O
women	O
about	O
their	O
breast	O
cancer	O
risks	O
are	O
not	O
likely	O
to	O
be	O
effective	O
unless	O
their	O
breast	O
cancer	O
anxieties	O
are	O
also	O
addressed	O
.	O

IMPLICATIONS	O
Attention	O
to	O
the	O
psychological	O
aspects	O
of	O
breast	O
cancer	O
risk	O
will	O
be	O
critical	O
in	O
the	O
development	O
of	O
risk-counseling	O
programs	O
that	O
incorporate	O
testing	O
for	O
the	O
recently	O
cloned	O
breast	O
cancer	O
susceptibility	O
gene	O
,	O
BRCA1	O
(	O
and	O
BRCA2	O
when	O
that	O
gene	O
has	O
also	O
been	O
cloned	O
)	O
.	O

The	O
effect	O
of	O
calcium	O
supplementation	O
on	O
bone	O
density	O
in	O
premenarcheal	O
females	O
:	O
a	O
co-twin	O
approach	O
.	O

The	O
age	O
and	O
developmental	O
stage	O
at	O
which	O
calcium	O
supplementation	O
produces	O
the	O
greatest	O
bone	O
effects	O
remain	O
controversial	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
calcium	O
supplementation	O
may	O
improve	O
bone	O
accrual	O
in	O
premenarcheal	O
females	O
.	O

Fifty-one	O
pairs	O
of	O
premenarcheal	O
female	O
twins	O
(	O
27	O
monozygotic	O
and	O
24	O
dizygotic	O
;	O
mean	O
+/-	O
sd	O
age	O
,	O
10.3	O
+/-	O
1.5	O
yr	O
)	O
participated	O
in	O
a	O
randomized	O
,	O
single-blind	O
,	O
placebo-controlled	O
trial	O
with	O
one	O
twin	O
of	O
each	O
pair	O
receiving	O
a	O
1200-mg	O
calcium	O
carbonate	O
(	O
Caltrate	O
)	O
supplement	O
.	O

Areal	O
bone	O
mineral	O
density	O
(	O
aBMD	O
)	O
was	O
measured	O
at	O
baseline	O
and	O
6	O
,	O
12	O
,	O
18	O
and	O
24	O
months	O
.	O

There	O
were	O
no	O
within-pair	O
differences	O
in	O
height	O
,	O
weight	O
,	O
or	O
calcium	O
intake	O
at	O
baseline	O
.	O

Calcium	O
supplementation	O
was	O
associated	O
(	O
P	O
<	O
0.05	O
)	O
with	O
increased	O
aBMD	O
compared	O
with	O
placebo	O
,	O
adjusted	O
for	O
age	O
,	O
height	O
,	O
and	O
weight	O
at	O
the	O
following	O
time	O
points	O
from	O
baseline	O
:	O
total	O
hip	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
,	O
12	O
months	O
(	O
1.6	O
%	O
)	O
,	O
and	O
18	O
months	O
(	O
2.4	O
%	O
)	O
;	O
lumbar	O
spine	O
,	O
12	O
months	O
(	O
1.0	O
%	O
)	O
;	O
femoral	O
neck	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
.	O

Adjusted	O
total	O
body	O
bone	O
mineral	O
content	O
was	O
higher	O
in	O
the	O
calcium	O
group	O
at	O
6	O
months	O
(	O
2.0	O
%	O
)	O
,	O
12	O
months	O
(	O
2.5	O
%	O
)	O
,	O
18	O
months	O
(	O
4.6	O
%	O
)	O
,	O
and	O
24	O
months	O
(	O
3.7	O
%	O
)	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O

Calcium	O
supplementation	O
was	O
effective	O
in	O
increasing	O
aBMD	O
at	O
regional	O
sites	O
over	O
the	O
first	O
12-18	O
months	O
,	O
but	O
these	O
gains	O
were	O
not	O
maintained	O
to	O
24	O
months	O
.	O

Randomised	O
controlled	O
trial	O
of	O
improvisational	O
music	O
therapy	O
's	O
effectiveness	O
for	O
children	Age
with	O
autism	Condition
spectrum	Condition
disorders	Condition
(	O
TIME-A	O
)	O
:	O
study	O
protocol	O
.	O

BACKGROUND	O
Previous	O
research	O
has	O
suggested	O
that	O
music	O
therapy	O
may	O
facilitate	O
skills	O
in	O
areas	O
typically	O
affected	O
by	O
autism	Condition
spectrum	Condition
disorders	Condition
such	O
as	O
social	O
interaction	O
and	O
communication	O
.	O

However	O
,	O
generalisability	O
of	O
previous	O
findings	O
has	O
been	O
restricted	O
,	O
as	O
studies	O
were	O
limited	O
in	O
either	O
methodological	O
accuracy	O
or	O
the	O
clinical	O
relevance	O
of	O
their	O
approach	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
effects	O
of	O
improvisational	O
music	O
therapy	O
on	O
social	O
communication	O
skills	O
of	O
children	Age
with	O
autism	Condition
spectrum	Condition
disorders	Condition
.	O

An	O
additional	O
aim	O
of	O
the	O
study	O
is	O
to	O
examine	O
if	O
variation	O
in	O
dose	O
of	O
treatment	O
(	O
i.e.	O
,	O
number	O
of	O
music	O
therapy	O
sessions	O
per	O
week	O
)	O
affects	O
outcome	O
of	O
therapy	O
,	O
and	O
to	O
determine	O
cost-effectiveness	O
.	O

METHODS/DESIGN	O
Children	Age
aged	O
between	O
4	Age
;	Age
0	Age
and	Age
6	Age
;	Age
11	Age
years	Age
who	O
are	O
diagnosed	O
with	O
autism	Condition
spectrum	Condition
disorder	Condition
will	O
be	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
conditions	O
.	O

Parents	O
of	O
all	O
participants	O
will	O
receive	O
three	O
sessions	O
of	O
parent	O
counselling	O
(	O
at	O
0	O
,	O
2	O
,	O
and	O
5	O
months	O
)	O
.	O

In	O
addition	O
,	O
children	O
randomised	O
to	O
the	O
two	O
intervention	O
groups	O
will	O
be	O
offered	O
individual	O
,	O
improvisational	O
music	O
therapy	O
over	O
a	O
period	O
of	O
five	O
months	O
,	O
either	O
one	O
session	O
(	O
low-intensity	O
)	O
or	O
three	O
sessions	O
(	O
high-intensity	O
)	O
per	O
week	O
.	O

Generalised	O
effects	O
of	O
music	O
therapy	O
will	O
be	O
measured	O
using	O
standardised	O
scales	O
completed	O
by	O
blinded	O
assessors	O
(	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
,	O
ADOS	O
)	O
and	O
parents	O
(	O
Social	O
Responsiveness	O
Scale	O
,	O
SRS	O
)	O
before	O
and	O
2	O
,	O
5	O
,	O
and	O
12	O
months	O
after	O
randomisation	O
.	O

Cost	O
effectiveness	O
will	O
be	O
calculated	O
as	O
man	O
years	O
.	O

A	O
group	O
sequential	O
design	O
with	O
first	O
interim	O
look	O
at	O
N	O
=	O
235	O
will	O
ensure	O
both	O
power	O
and	O
efficiency	O
.	O

DISCUSSION	O
Responding	O
to	O
the	O
need	O
for	O
more	O
rigorously	O
designed	O
trials	O
examining	O
the	O
effectiveness	O
of	O
music	O
therapy	O
in	O
autism	Condition
spectrum	Condition
disorders	Condition
,	O
this	O
pragmatic	O
trial	O
sets	O
out	O
to	O
generate	O
findings	O
that	O
will	O
be	O
well	O
generalisable	O
to	O
clinical	O
practice	O
.	O

Addressing	O
the	O
issue	O
of	O
dose	O
variation	O
,	O
this	O
study	O
's	O
results	O
will	O
also	O
provide	O
information	O
on	O
the	O
relevance	O
of	O
session	O
frequency	O
for	O
therapy	O
outcome	O
.	O

TRIAL	O
REGISTRATION	O
Current	O
Controlled	O
Trials	O
ISRCTN78923965	O
.	O

Can	O
incentives	O
undermine	O
intrinsic	O
motivation	O
to	O
participate	O
in	O
epidemiologic	O
surveys	O
?	O
Response	O
rates	O
to	O
surveys	O
are	O
decreasing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
use	O
of	O
lottery	O
tickets	O
as	O
incentives	O
in	O
an	O
epidemiologic	O
control	O
group	O
.	O

A	O
self-administered	O
questionnaire	O
was	O
sent	O
to	O
parents	O
in	O
the	O
municipality	O
of	O
Stockholm	O
,	O
Sweden	O
,	O
who	O
were	O
to	O
be	O
used	O
as	O
a	O
control	O
group	O
in	O
a	O
study	O
addressing	O
stress	O
in	O
parents	O
of	O
children	Age
with	O
cancer	Condition
.	O

A	O
stratified	O
random	O
sample	O
of	O
450	SampleSize
parents	O
were	O
randomized	O
into	O
three	O
incentive	O
groups	O
:	O
(	O
a	O
)	O
no	O
incentive	O
;	O
(	O
b	O
)	O
a	O
promised	O
incentive	O
of	O
one	O
lottery	O
ticket	O
to	O
be	O
received	O
upon	O
reply	O
;	O
(	O
c	O
)	O
a	O
promised	O
incentive	O
of	O
one	O
lottery	O
ticket	O
to	O
be	O
received	O
upon	O
reply	O
and	O
an	O
additional	O
lottery	O
ticket	O
upon	O
reply	O
within	O
1	O
week	O
.	O

The	O
overall	O
response	O
rate	O
across	O
the	O
three	O
groups	O
was	O
65.3	O
%	O
.	O

The	O
response	O
rate	O
was	O
highest	O
in	O
the	O
no	O
incentive	O
group	O
(	O
69.3	O
%	O
)	O
and	O
lowest	O
in	O
the	O
one	O
plus	O
one	O
lottery	O
ticket	O
group	O
(	O
62.0	O
%	O
)	O
.	O

In	O
a	O
survival	O
analysis	O
,	O
the	O
difference	O
between	O
the	O
two	O
response	O
curves	O
was	O
significant	O
by	O
the	O
log-rank	O
test	O
(	O
P	O
=	O
0.04	O
)	O
,	O
with	O
the	O
no	O
incentive	O
group	O
having	O
a	O
shorter	O
time	O
to	O
response	O
than	O
the	O
incentive	O
group	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
use	O
of	O
lottery	O
tickets	O
as	O
incentives	O
to	O
increase	O
participation	O
in	O
a	O
mail	O
questionnaire	O
among	O
parents	O
may	O
be	O
less	O
valuable	O
or	O
even	O
harmful	O
.	O

Incentives	O
may	O
undermine	O
motivation	O
in	O
studies	O
in	O
which	O
the	O
intrinsic	O
motivation	O
of	O
the	O
respondents	O
is	O
already	O
high	O
.	O

Evaluation	O
of	O
rapid	Condition
radiation	Condition
treatment	Condition
schedules	O
utilizing	O
two	O
treatment	O
sessions	O
per	O
day	O
.	O

The	O
authors	O
studied	O
normal	O
human	O
skin	O
reactions	O
to	O
two	O
different	O
rapid	O
radiotherapy	O
schedules	O
of	O
2	O
sessions	O
per	O
day	O
and	O
evaluated	O
their	O
effectiveness	O
in	O
relief	O
of	O
pain	O
and	O
local	O
tumor	O
control	O
.	O

Patients	O
were	O
randomized	O
to	O
three	O
treatment	O
groups	O
:	O
SCHEDULE	O
A	O
(	O
control	O
)	O
:	O
conventional	O
one	O
treatment	O
per	O
day	O
regimen	O
totalling	O
3,760	O
rads	O
in	O
22-23	O
days	O
;	O
SCHEDULE	O
B	O
:	O
2	O
sessions	O
per	O
day	O
totalling	O
3,440	O
rads	O
in	O
10-11	O
days	O
;	O
and	O
SCHEDULE	O
C	O
:	O
2	O
sessions	O
per	O
day	O
totalling	O
3,568	O
rads	O
in	O
10-11	O
days	O
.	O

The	O
pattern	O
and	O
magnitude	O
of	O
skin	O
reactions	O
in	O
the	O
three	O
schedules	O
are	O
nearly	O
identical	O
but	O
tumor	O
regression	O
and	O
pain	O
relief	O
were	O
achieved	O
faster	O
in	O
the	O
rapid	O
fractionation	O
schedules	O
.	O

Hypotensive	O
effects	O
and	O
influence	O
on	O
serum	O
lipids	O
of	O
SQ29,852	O
,	O
a	O
new	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
in	O
patients	O
with	O
essential	O
hypertension	O
:	O
a	O
comparison	O
with	O
atenolol	O
.	O

The	O
effects	O
of	O
SQ29,852	O
(	O
n	O
=	O
24	O
)	O
,	O
a	O
new	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
and	O
atenolol	O
(	O
n	O
=	O
22	O
)	O
,	O
monotherapies	O
were	O
compared	O
in	O
46	O
patients	O
with	O
mild	O
to	O
moderate	O
essential	O
hypertension	O
.	O

Both	O
SQ29,852	O
(	O
mean	O
dose	O
15.0	O
+/-	O
5.1	O
mg/day	O
)	O
and	O
atenolol	O
(	O
mean	O
dose	O
37.5	O
+/-	O
18.5	O
mg/day	O
)	O
significantly	O
decreased	O
both	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
serum	O
lipids	O
,	O
apolipoproteins	O
,	O
lipoproteins	O
or	O
atherosclerotic	O
indices	O
after	O
both	O
SQ29,852	O
and	O
atenolol	O
.	O

There	O
were	O
also	O
no	O
significant	O
inter-group	O
differences	O
.	O

There	O
were	O
no	O
serious	O
side	O
effects	O
or	O
abnormal	O
laboratory	O
tests	O
in	O
both	O
treatment	O
groups	O
.	O

It	O
is	O
concluded	O
that	O
SQ29,852	O
is	O
an	O
effective	O
antihypertensive	O
drug	O
without	O
adverse	O
effect	O
on	O
lipid	O
metabolism	O
.	O

A	O
home-based	O
exercise	O
program	O
to	O
improve	O
function	O
,	O
fatigue	O
,	O
and	O
sleep	O
quality	O
in	O
patients	O
with	O
Stage	O
IV	O
lung	O
and	O
colorectal	O
cancer	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

CONTEXT	O
Exercise	O
benefits	O
patients	O
with	O
cancer	O
,	O
but	O
studies	O
of	O
home-based	O
approaches	O
,	O
particularly	O
among	O
those	O
with	O
Stage	O
IV	O
disease	O
,	O
remain	O
small	O
and	O
exploratory	O
.	O

OBJECTIVES	O
To	O
conduct	O
an	O
adequately	O
powered	O
trial	O
of	O
a	O
home-based	O
exercise	O
intervention	O
that	O
can	O
be	O
facilely	O
integrated	O
into	O
established	O
delivery	O
and	O
reimbursement	O
structures	O
.	O

METHODS	O
Sixty-six	O
adults	O
with	O
Stage	O
IV	O
lung	O
or	O
colorectal	O
cancer	O
were	O
randomized	O
,	O
in	O
an	O
eight-week	O
trial	O
,	O
to	O
usual	O
care	O
or	O
incremental	O
walking	O
and	O
home-based	O
strength	O
training	O
.	O

The	O
exercising	O
participants	O
were	O
instructed	O
during	O
a	O
single	O
physiotherapy	O
visit	O
and	O
subsequently	O
exercised	O
four	O
days	O
or	O
more	O
per	O
week	O
;	O
training	O
and	O
step-count	O
goals	O
were	O
advanced	O
during	O
bimonthly	O
telephone	O
calls	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
mobility	O
assessed	O
with	O
the	O
Ambulatory	O
Post	O
Acute	O
Care	O
Basic	O
Mobility	O
Short	O
Form	O
.	O

Secondary	O
outcomes	O
included	O
ratings	O
of	O
pain	O
and	O
sleep	O
quality	O
as	O
well	O
as	O
the	O
ability	O
to	O
perform	O
daily	O
activities	O
(	O
Ambulatory	O
Post	O
Acute	O
Care	O
Daily	O
Activities	O
Short	O
Form	O
)	O
,	O
quality	O
of	O
life	O
(	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-General	O
)	O
,	O
and	O
fatigue	O
(	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Fatigue	O
)	O
.	O

RESULTS	O
Three	O
participants	O
dropped	O
out	O
and	O
seven	O
died	O
(	O
five	O
in	O
the	O
intervention	O
and	O
two	O
in	O
the	O
control	O
group	O
,	O
P=0.28	O
)	O
.	O

At	O
Week	O
8	O
,	O
the	O
intervention	O
group	O
reported	O
improved	O
mobility	O
(	O
P=0.01	O
)	O
,	O
fatigue	O
(	O
P=0.02	O
)	O
,	O
and	O
sleep	O
quality	O
(	O
P=0.05	O
)	O
compared	O
with	O
the	O
usual	O
care	O
group	O
,	O
but	O
did	O
not	O
differ	O
on	O
the	O
other	O
measures	O
.	O

CONCLUSION	O
A	O
home-based	O
exercise	O
program	O
seems	O
capable	O
of	O
improving	O
the	O
mobility	O
,	O
fatigue	O
,	O
and	O
sleep	O
quality	O
of	O
patients	O
with	O
Stage	O
IV	O
lung	O
and	O
colorectal	O
cancer	O
.	O

Clinical	O
outcome	O
of	O
postoperative	O
adjuvant	O
immunochemotherapy	O
with	O
sizofiran	O
for	O
patients	O
with	O
resectable	O
gastric	O
cancer	O
:	O
a	O
randomised	O
controlled	O
study	O
.	O

Adjuvant	O
immunochemotherapy	O
using	O
the	O
antitumour	O
polysaccharide	O
sizofiran	O
(	O
SPG	O
)	O
,	O
an	O
extract	O
from	O
the	O
culture	O
broth	O
of	O
Schizophyllum	O
commune	O
Fries	O
,	O
was	O
prescribed	O
randomly	O
for	O
386	O
Japanese	O
patients	O
with	O
resectable	O
gastric	O
cancer	O
.	O

Although	O
the	O
overall	O
survival	O
probability	O
for	O
5	O
years	O
did	O
not	O
differ	O
between	O
the	O
SPG	O
and	O
control	O
groups	O
,	O
in	O
264	O
patients	O
with	O
curatively	O
resected	O
cancer	O
,	O
the	O
probability	O
to	O
5	O
year	O
survival	O
and	O
to	O
recurrence	O
in	O
the	O
sizofiran-administered	O
patients	O
was	O
better	O
than	O
in	O
the	O
controls	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
four	O
of	O
six	O
prognostic	O
factors	O
correlated	O
with	O
the	O
prognosis	O
of	O
the	O
264	O
patients	O
who	O
underwent	O
curative	O
surgery	O
,	O
that	O
is	O
,	O
nodal	O
involvement	O
(	O
chi	O
2	O
=	O
21.426	O
,	O
P	O
=	O
less	O
than	O
0.0001	O
)	O
,	O
age	O
distribution	O
(	O
chi	O
2	O
=	O
9.262	O
,	O
P	O
=	O
0.010	O
)	O
,	O
sizofiran	O
administration	O
(	O
chi	O
2	O
=	O
6.507	O
,	O
P	O
=	O
0.011	O
)	O
,	O
and	O
primary	O
tumour	O
size	O
(	O
chi	O
2	O
=	O
9.345	O
,	O
P	O
=	O
0.025	O
)	O
.	O

Thus	O
,	O
patients	O
with	O
a	O
curatively	O
resected	O
gastric	O
cancer	O
had	O
a	O
better	O
prognosis	O
when	O
sizofiran	O
was	O
prescribed	O
in	O
combination	O
with	O
antitumour	O
drugs	O
.	O

Randomized	O
clinical	O
trial	O
of	O
radiofrequency	O
ablation	O
or	O
conventional	O
high	O
ligation	O
and	O
stripping	O
for	O
great	Condition
saphenous	Condition
varicose	Condition
veins	Condition
.	O

BACKGROUND	O
This	O
randomized	O
clinical	O
trial	O
compared	O
early	O
outcomes	O
after	O
radiofrequency	O
ablation	O
(	O
RFA	O
)	O
and	O
conventional	O
surgery	O
for	O
varicose	O
veins	O
.	O

METHODS	O
Consecutive	O
patients	O
with	O
symptomatic	Condition
varicose	Condition
veins	Condition
due	Condition
to	Condition
isolated	Condition
great	Condition
saphenous	Condition
vein	Condition
(	Condition
GSV	Condition
)	Condition
incompetence	Condition
and	O
suitable	O
for	O
RFA	O
were	O
randomized	O
to	O
either	O
RFA	O
or	O
conventional	O
surgery	O
(	O
saphenofemoral	O
disconnection	O
and	O
stripping	O
)	O
.	O

Clinical	O
,	O
radiological	O
and	O
patient-based	O
outcomes	O
were	O
recorded	O
at	O
1	O
and	O
5	O
weeks	O
after	O
intervention	O
.	O

RESULTS	O
RFA	O
resulted	O
in	O
successful	O
obliteration	O
of	O
the	O
GSV	O
in	O
all	O
47	Condition
patients	O
.	O

Complete	O
above-knee	O
stripping	O
was	O
unsuccessful	O
in	O
seven	O
of	O
41	O
patients	O
.	O

RFA	O
took	O
longer	O
than	O
conventional	O
surgery	O
:	O
median	O
interquartile	O
range	O
76	O
(	O
67-84	O
)	O
versus	O
48	O
(	O
39-54	O
)	O
min	O
;	O
P	O
<	O
0.001	O
.	O

Patients	O
returned	O
to	O
their	O
normal	O
activities	O
significantly	O
earlier	O
after	O
RFA	O
(	O
median	O
3	O
(	O
2-5	O
)	O
versus	O
12.5	O
(	O
4-21	O
)	O
days	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Postoperative	O
pain	O
was	O
significantly	O
less	O
after	O
RFA	O
(	O
median	O
score	O
on	O
visual	O
analogue	O
scale	O
1.70	O
(	O
0.50-4.30	O
)	O
versus	O
4.0	O
(	O
2.35-6.05	O
)	O
;	O
P	O
=	O
0.001	O
)	O
.	O

Patient	O
satisfaction	O
,	O
quality	O
of	O
life	O
improvement	O
and	O
analgesic	O
requirements	O
significantly	O
favoured	O
RFA	O
.	O

CONCLUSION	O
RFA	O
took	O
longer	O
to	O
perform	O
but	O
resulted	O
in	O
a	O
significantly	O
better	O
early	O
outcome	O
than	O
conventional	O
surgery	O
in	O
suitable	O
patients	O
with	O
great	Condition
saphenous	Condition
varicose	Condition
veins	Condition
.	O

Comparative	O
study	O
for	O
the	O
effect	O
of	O
photodynamic	O
therapy	O
,	O
imiquimod	O
immunotherapy	O
and	O
combination	O
of	O
both	O
therapies	O
on	O
40	O
lesions	O
of	O
actinic	Condition
keratosis	Condition
in	O
Japanese	O
patients	O
.	O

We	O
treated	O
12	O
,	O
15	O
and	O
13	O
Japanese	O
actinic	Condition
keratosis	Condition
(	Condition
AK	Condition
)	Condition
lesions	O
with	O
5-aminolevulinic	O
acid	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
,	O
5	O
%	O
imiquimod	O
cream	O
and	O
combination	O
of	O
both	O
therapies	O
,	O
respectively	O
,	O
and	O
compared	O
the	O
effects	O
.	O

Patients	O
underwent	O
the	O
second	O
course	O
,	O
when	O
AK	O
lesions	O
remained	O
after	O
the	O
first	O
course	O
.	O

Efficacy	O
was	O
evaluated	O
1	O
month	O
after	O
each	O
treatment	O
.	O

Combination	O
therapy	O
cleared	O
all	O
AK	O
lesions	O
only	O
after	O
the	O
first	O
course	O
,	O
while	O
PDT	O
and	O
imiquimod	O
therapy	O
cleared	O
41.7	O
%	O
and	O
66.7	O
%	O
of	O
AK	O
lesions	O
after	O
the	O
first	O
course	O
,	O
respectively	O
.	O

All	O
residual	O
AK	O
lesions	O
after	O
the	O
first	O
course	O
were	O
cleared	O
by	O
the	O
second	O
courses	O
of	O
PDT	O
or	O
imiquimod	O
therapy	O
.	O

During	O
the	O
course	O
,	O
erosion	O
and	O
crust	O
developed	O
significantly	O
more	O
frequently	O
in	O
combination	O
therapy	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Most	O
Japanese	O
AK	O
lesions	O
can	O
be	O
satisfactorily	O
treated	O
with	O
either	O
PDT	O
or	O
imiquimod	O
monotherapy	O
.	O

However	O
,	O
only	O
severe	O
cases	O
may	O
better	O
be	O
treated	O
with	O
combination	O
therapy	O
,	O
which	O
show	O
higher	O
efficacy	O
even	O
though	O
adverse	O
events	O
occur	O
frequently	O
.	O

A	O
30-month	O
longitudinal	O
study	O
of	O
the	O
effects	O
of	O
some	O
oral	O
hygiene	O
measures	O
on	O
Streptococcus	O
mutans	O
and	O
approximal	O
dental	O
caries	O
.	O

The	O
effects	O
of	O
some	O
oral	O
hygiene	O
measures	O
on	O
Streptococcus	O
mutants	O
and	O
approximal	O
dental	O
caries	O
were	O
evaluated	O
.	O

One	O
hundred	O
and	O
eighty-seven	O
13-year-old	O
individuals	O
with	O
high	O
levels	O
of	O
salivary	O
S.	O
mutans	O
(	O
greater	O
than	O
10	O
(	O
6	O
)	O
/mL	O
)	O
were	O
selected	O
.	O

They	O
were	O
randomly	O
distributed	O
into	O
three	O
groups	O
.	O

Group	O
I	O
initially	O
received	O
professional	O
mechanical	O
tooth-cleaning	O
,	O
tongue-scraping	O
,	O
chlorhexidine	O
treatment	O
,	O
and	O
oral	O
hygiene	O
instructions	O
concentrated	O
on	O
the	O
approximal	O
surfaces	O
most	O
colonized	O
by	O
S.	O
mutans	O
.	O

The	O
treatment	O
was	O
given	O
four	O
times	O
with	O
intervals	O
of	O
two	O
days	O
,	O
followed	O
by	O
one	O
single	O
treatment	O
every	O
six	O
months	O
throughout	O
the	O
experimental	O
period	O
.	O

The	O
initial	O
treatment	O
period	O
for	O
group	O
II	O
,	O
also	O
consisting	O
of	O
four	O
visits	O
,	O
included	O
the	O
same	O
oral	O
hygiene	O
instructions	O
as	O
for	O
group	O
I	O
.	O

The	O
instructions	O
were	O
repeated	O
every	O
six	O
months	O
.	O

Group	O
III	O
was	O
maintained	O
in	O
the	O
preventive	O
program	O
provided	O
by	O
the	O
local	O
Dental	O
Health	O
Office	O
,	O
based	O
on	O
mechanical	O
plaque	O
control	O
and	O
topical	O
use	O
of	O
fluorides	O
and	O
chlorhexidine	O
at	O
individualized	O
intervals	O
.	O

Group	O
I	O
showed	O
a	O
significant	O
immediate	O
reduction	O
of	O
S.	O
mutans	O
in	O
saliva	O
as	O
well	O
as	O
an	O
approximal	O
tooth	O
surfaces	O
.	O

After	O
six	O
months	O
,	O
there	O
were	O
no	O
differences	O
among	O
the	O
three	O
groups	O
regarding	O
these	O
variables	O
.	O

Compared	O
with	O
baseline	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
of	O
S.	O
mutans	O
in	O
all	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
caries	O
progression	O
among	O
the	O
three	O
groups	O
.	O

However	O
,	O
the	O
selected	O
high-risk	O
individuals	O
in	O
group	O
I	O
developed	O
0.25	O
new	O
manifest	O
caries	O
lesions	O
approximally/year	O
,	O
compared	O
with	O
0.27	O
for	O
all	O
children	O
of	O
the	O
same	O
age	O
group	O
in	O
the	O
area	O
.	O

Seventeen	O
individuals	O
had	O
approximal	O
surfaces	O
with	O
consistently	O
high	O
or	O
consistently	O
low	O
S.	O
mutans	O
levels	O
.	O

Forty-six	O
percent	O
of	O
the	O
surfaces	O
with	O
high	O
values	O
developed	O
new	O
or	O
progressive	O
caries	O
,	O
compared	O
with	O
2	O
%	O
of	O
the	O
surfaces	O
with	O
low	O
values	O
.	O

Further	O
validation	O
of	O
the	O
alcohol	O
dependence	O
scale	O
as	O
an	O
index	O
of	O
severity	O
.	O

OBJECTIVE	O
The	O
Alcohol	O
Dependence	O
Scale	O
(	O
ADS	O
)	O
yields	O
continuous	O
scores	O
purported	O
to	O
reflect	O
the	O
severity	O
of	O
the	O
dependence	O
syndrome	O
.	O

We	O
evaluated	O
the	O
concurrent	O
validity	O
of	O
the	O
ADS	O
as	O
a	O
general	O
measure	O
of	O
severity	O
and	O
the	O
screening	O
accuracy	O
of	O
the	O
total	O
score	O
and	O
subscales	O
to	O
detect	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
(	O
DSM-IV	O
)	O
,	O
physiological	O
dependence	O
.	O

METHOD	O
Treatment-seeking	O
,	O
alcohol-dependent	Condition
individuals	O
entering	O
the	O
Combining	O
Pharmacotherapies	O
and	O
Behavioral	O
Interventions	O
for	O
Alcohol	O
Dependence	O
(	O
COMBINE	O
)	O
Study	O
(	O
N	O
=	O
1,372	SampleSize
;	O
69	SampleSize
%	SampleSize
men	O
)	O
completed	O
the	O
ADS	O
,	O
diagnostic	O
interviews	O
,	O
and	O
other	O
measures	O
before	O
randomization	O
.	O

Analyses	O
of	O
variance	O
tested	O
differences	O
between	O
ADS	O
quartiles	O
on	O
alcohol-	O
related	O
measures	O
.	O

Areas	O
under	O
the	O
receiver	O
operating	O
characteristic	O
(	O
AUROC	O
)	O
curve	O
assessed	O
screening	O
accuracy	O
for	O
DSM-IV	O
physiological	O
dependence	O
(	O
tolerance	O
or	O
withdrawal	O
)	O
or	O
withdrawal	O
alone	O
.	O

RESULTS	O
ADS	O
quartiles	O
differed	O
on	O
age	O
,	O
other	O
demographics	O
,	O
and	O
prior	O
treatment	O
episodes	O
.	O

Linear	O
correlation	O
showed	O
moderate	O
to	O
large	O
magnitude	O
associations	O
with	O
alcohol-related	O
self-report	O
measures	O
and	O
most	O
indices	O
of	O
consumption	O
.	O

ADS	O
quartiles	O
differed	O
significantly	O
on	O
proportion	O
with	O
DSM-IV	O
physiological	O
dependence	O
,	O
but	O
AUROC	O
curves	O
indicated	O
that	O
the	O
ADS	O
had	O
limited	O
accuracy	O
as	O
a	O
continuous	O
measure	O
to	O
detect	O
DSMIV	O
physiological	O
dependence	O
(	O
AUROC	O
=	O
.75	O
[	O
95	O
%	O
confidence	O
interval	O
{	O
CI	O
}	O
:	O
.70-.79	O
]	O
and	O
.67	O
[	O
95	O
%	O
CI	O
:	O
.60-.74	O
]	O
for	O
men	O
and	O
women	O
,	O
respectively	O
;	O
p	O
=	O
.08	O
)	O
or	O
withdrawal	O
alone	O
(	O
AUROC	O
=	O
.77	O
[	O
95	O
%	O
CI	O
:	O
.74-.80	O
]	O
and	O
.74	O
[	O
95	O
%	O
CI	O
:	O
.69-.79	O
]	O
for	O
men	O
and	O
women	O
,	O
respectively	O
;	O
p	O
=	O
.30	O
)	O
.	O

Screening	O
accuracy	O
was	O
comparably	O
limited	O
based	O
on	O
ADS	O
subscales	O
reflecting	O
psychoperceptual	O
or	O
psychophysical	O
withdrawal	O
.	O

CONCLUSIONS	O
The	O
ADS	O
reflected	O
variation	O
in	O
symptom	O
severity	O
but	O
did	O
not	O
adequately	O
identify	O
physiological	O
dependence	O
or	O
withdrawal	O
in	O
treatment-seeking	O
individuals	O
with	O
DSM-IV	O
alcohol	O
dependence	O
.	O

Intermediate-term	O
mortality	O
and	O
cardiac	O
transplantation	O
in	O
infants	Age
with	O
single-ventricle	Condition
lesions	Condition
:	O
risk	O
factors	O
and	O
their	O
interaction	O
with	O
shunt	O
type	O
.	O

OBJECTIVE	O
The	O
study	O
objective	O
was	O
to	O
identify	O
factors	O
associated	O
with	O
death	O
and	O
cardiac	O
transplantation	O
in	O
infants	Age
undergoing	Condition
the	Condition
Norwood	Condition
procedure	Condition
and	O
to	O
determine	O
differences	O
in	O
associations	O
that	O
might	O
favor	O
the	O
modified	O
Blalock-Taussig	O
shunt	O
or	O
a	O
right	O
ventricle-to-pulmonary	O
artery	O
shunt	O
.	O

METHODS	O
We	O
used	O
competing	O
risks	O
methodology	O
to	O
analyze	O
death	O
without	O
transplantation	O
,	O
cardiac	O
transplantation	O
,	O
and	O
survival	O
without	O
transplantation	O
.	O

Parametric	O
time-to-event	O
modeling	O
and	O
bootstrapping	O
were	O
used	O
to	O
identify	O
independent	O
predictors	O
.	O

RESULTS	O
Data	O
from	O
549	O
subjects	O
(	O
follow-up	O
,	O
2.7	O
?	O
0.9	O
years	O
)	O
were	O
analyzed	O
.	O

Mortality	O
risk	O
was	O
characterized	O
by	O
early	O
and	O
constant	O
phases	O
;	O
transplant	O
was	O
characterized	O
by	O
only	O
a	O
constant	O
phase	O
.	O

Early	O
phase	O
factors	O
associated	O
with	O
death	O
included	O
lower	O
socioeconomic	O
status	O
(	O
P	O
=	O
.01	O
)	O
,	O
obstructed	O
pulmonary	O
venous	O
return	O
(	O
P	O
<	O
.001	O
)	O
,	O
smaller	O
ascending	O
aorta	O
(	O
P	O
=	O
.02	O
)	O
,	O
and	O
anatomic	O
subtype	O
.	O

Constant	O
phase	O
factors	O
associated	O
with	O
death	O
included	O
genetic	O
syndrome	O
(	O
P	O
<	O
.001	O
)	O
and	O
lower	O
gestational	O
age	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
right	O
ventricle-to-pulmonary	O
artery	O
shunt	O
demonstrated	O
better	O
survival	O
in	O
the	O
51	O
%	O
of	O
subjects	O
who	O
were	O
full	O
term	O
with	O
aortic	O
atresia	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
modified	O
Blalock-Taussig	O
shunt	O
was	O
better	O
among	O
the	O
4	O
%	O
of	O
subjects	O
who	O
were	O
preterm	O
with	O
a	O
patent	O
aortic	O
valve	O
(	O
P	O
=	O
.003	O
)	O
.	O

Lower	O
pre-Norwood	O
right	O
ventricular	O
fractional	O
area	O
change	O
,	O
pre-Norwood	O
surgery	O
,	O
and	O
anatomy	O
other	O
than	O
hypoplastic	O
left	O
heart	O
syndrome	O
were	O
independently	O
associated	O
with	O
transplantation	O
(	O
all	O
P	O
<	O
.03	O
)	O
,	O
but	O
shunt	O
type	O
was	O
not	O
(	O
P	O
=	O
.43	O
)	O
.	O

CONCLUSIONS	O
Independent	O
risk	O
factors	O
for	O
intermediate-term	O
mortality	O
include	O
lower	O
socioeconomic	O
status	O
,	O
anatomy	O
,	O
genetic	O
syndrome	O
,	O
and	O
lower	O
gestational	O
age	O
.	O

Term	O
infants	O
with	O
aortic	O
atresia	O
benefited	O
from	O
a	O
right	O
ventricle-to-pulmonary	O
artery	O
shunt	O
,	O
and	O
preterm	O
infants	O
with	O
a	O
patent	O
aortic	O
valve	O
benefited	O
from	O
a	O
modified	O
Blalock-Taussig	O
shunt	O
.	O

Right	O
ventricular	O
function	O
and	O
anatomy	O
,	O
but	O
not	O
shunt	O
type	O
,	O
were	O
associated	O
with	O
transplantation	O
.	O

Randomized	O
controlled	O
trial	O
of	O
the	O
focus	O
parent	O
training	O
for	O
toddlers	Age
with	O
autism	Condition
:	O
1-year	O
outcome	O
.	O

This	O
randomized	O
controlled	O
trial	O
compared	O
results	O
obtained	O
after	O
12	O
months	O
of	O
nonintensive	O
parent	O
training	O
plus	O
care-as-usual	O
and	O
care-as-usual	O
alone	O
.	O

The	O
training	O
focused	O
on	O
stimulating	O
joint	O
attention	O
and	O
language	O
skills	O
and	O
was	O
based	O
on	O
the	O
intervention	O
described	O
by	O
Drew	O
et	O
al	O
.	O

(	O
Eur	O
Child	O
Adolesc	O
Psychiatr	O
11:266-272	O
,	O
2002	O
)	O
.	O

Seventy-five	O
toddlers	O
with	O
autism	O
spectrum	O
disorder	O
(	O
65	O
autism	O
,	O
10	O
PDD-NOS	O
,	O
mean	O
age	O
=	O
34.4	O
months	O
,	O
SD	O
=	O
6.2	O
)	O
were	O
enrolled	O
.	O

Analyses	O
were	O
conducted	O
on	O
a	O
final	O
sample	O
of	O
67	O
children	O
(	O
lost	O
to	O
follow-up	O
=	O
8	O
)	O
.	O

No	O
significant	O
intervention	O
effects	O
were	O
found	O
for	O
any	O
of	O
the	O
primary	O
(	O
language	O
)	O
,	O
secondary	O
(	O
global	O
clinical	O
improvement	O
)	O
,	O
or	O
mediating	O
(	O
child	O
engagement	O
,	O
early	O
precursors	O
of	O
social	O
communication	O
,	O
or	O
parental	O
skills	O
)	O
outcome	O
variables	O
,	O
suggesting	O
that	O
the	O
'Focus	O
parent	O
training	O
'	O
was	O
not	O
of	O
additional	O
value	O
to	O
the	O
more	O
general	O
care-as-usual	O
.	O

Comparison	O
of	O
meloxicam	O
and	O
a	O
glucosamine-chondroitin	O
supplement	O
in	O
management	O
of	O
feline	Condition
osteoarthritis	Condition
.	O

A	O
double-blind	O
randomised	O
,	O
placebo-controlled	O
,	O
prospective	O
trial	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
meloxicam	O
and	O
a	O
glucosamine-chondroitin	O
(	O
Glu-Ch	O
)	O
supplement	O
in	O
the	O
management	O
of	O
feline	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

METHODS	O
Prospective	O
,	O
blinded	O
,	O
randomized	O
clinical	O
trial	O
.	O

Cats	Age
over	Age
eight	Age
years	Age
of	Age
age	Age
with	O
clinical	Condition
signs	Condition
of	Condition
chronic	Condition
OA	Condition
were	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
and	O
Glu-Ch	O
or	O
meloxicam	O
was	O
administered	O
orally	O
for	O
70	O
days	O
,	O
followed	O
by	O
a	O
placebo	O
until	O
day	O
98	O
.	O

Cats	O
were	O
assessed	O
by	O
a	O
veterinarian	O
on	O
five	O
occasions	O
and	O
the	O
owner	O
completed	O
an	O
assessment	O
form	O
at	O
the	O
same	O
time	O
.	O

RESULTS	O
Data	O
were	O
collected	O
from	O
thirty	O
cats	O
.	O

Pre-treatment	O
disease	O
scores	O
were	O
significantly	O
higher	O
in	O
the	O
meloxicam	O
group	O
for	O
owner	O
mobility	O
(	O
p=0.01	O
)	O
and	O
veterinary	O
lameness	O
(	O
p=0.02	O
)	O
.	O

Owner	O
mobility	O
scores	O
at	O
day	O
14	O
(	O
p=0.01	O
)	O
and	O
day	O
42	O
(	O
p=0.002	O
)	O
were	O
significantly	O
improved	O
compared	O
to	O
pre-treatment	O
scores	O
for	O
the	O
meloxicam	O
group	O
.	O

When	O
meloxicam	O
and	O
Glu-Ch	O
were	O
discontinued	O
and	O
the	O
placebo	O
commenced	O
,	O
a	O
significant	O
proportion	O
of	O
the	O
meloxicam	O
group	O
showed	O
worsening	O
of	O
all	O
the	O
owner-assessed	O
scores	O
between	O
day	O
70	O
and	O
day	O
98	O
,	O
when	O
compared	O
to	O
the	O
Glu-Ch	O
group	O
(	O
mobility	O
p=0.01	O
;	O
activity	O
p=0.02	O
;	O
temperament	O
p=0.04	O
;	O
lifestyle	O
p=0.01	O
)	O
.	O

CONCLUSIONS	O
Treatment	O
with	O
meloxicam	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
mobility	O
and	O
activity	O
levels	O
of	O
cats	O
with	O
OA	O
until	O
the	O
placebo	O
was	O
introduced	O
.	O

A	O
greater	O
proportion	O
of	O
cats	O
receiving	O
meloxicam	O
medication	O
showed	O
a	O
significant	O
worsening	O
of	O
owner	O
assessment	O
scores	O
once	O
the	O
placed	O
was	O
introduced	O
,	O
when	O
compared	O
to	O
the	O
Glu-Ch	O
group	O
.	O

Evaluation	O
of	O
lidocaine	O
in	O
human	Condition
inferior	Condition
alveolar	Condition
nerve	Condition
block	Condition
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
measure	O
the	O
degree	O
of	O
anesthesia	O
following	O
the	O
administration	O
of	O
3.6	O
ml	O
of	O
2	O
%	O
lidocaine	O
solutions	O
with	O
either	O
1:50,000	O
,	O
1:80,000	O
,	O
or	O
1:100,000	O
for	O
inferior	O
alveolar	O
nerve	O
block	O
and	O
to	O
compare	O
the	O
results	O
with	O
those	O
obtained	O
following	O
the	O
administration	O
of	O
1.8	O
ml	O
of	O
the	O
same	O
solutions	O
(	O
1	O
)	O
.	O

With	O
the	O
use	O
of	O
a	O
repeated	O
measures	O
design	O
,	O
30	SampleSize
subjects	O
randomly	O
received	O
an	O
inferior	O
alveolar	O
injection	O
at	O
three	O
successive	O
appointments	O
.	O

The	O
first	O
molar	O
,	O
first	O
premolar	O
,	O
lateral	O
incisor	O
,	O
and	O
contralateral	O
canine	O
(	O
control	O
)	O
were	O
blindly	O
tested	O
with	O
an	O
Analytic	O
Technology	O
pulp	O
tester	O
at	O
3-min	O
cycles	O
for	O
50	O
min	O
.	O

The	O
degree	O
of	O
anesthesia	O
was	O
comparable	O
for	O
the	O
three	O
solutions	O
following	O
the	O
administration	O
of	O
3.6	O
ml	O
of	O
each	O
solution	O
.	O

Retrospective	O
evaluation	O
showed	O
that	O
the	O
volume	O
of	O
the	O
solution	O
influenced	O
the	O
degree	O
of	O
anesthesia	O
.	O

Anxiety	O
disorders	O
in	O
typically	O
developing	O
youth	O
:	O
autism	O
spectrum	O
symptoms	O
as	O
a	O
predictor	O
of	O
cognitive-behavioral	O
treatment	O
.	O

Symptoms	O
of	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
were	O
assessed	O
(	O
Social	O
Responsiveness	O
Scale-Parent	O
(	O
SRS-P	O
)	O
;	O
coded	O
in-session	O
behavior	O
)	O
in	O
typically-developing	O
,	O
anxiety-disordered	O
children	O
(	O
N	O
=	O
50	O
)	O
treated	O
with	O
cognitive-behavioral	O
therapy	O
(	O
CBT	O
)	O
.	O

Study	O
1	O
:	O
children	O
with	O
moderate	O
autistic	O
symptomology	O
(	O
per	O
SRS-P	O
)	O
were	O
significantly	O
more	O
likely	O
to	O
improve	O
from	O
family	O
CBT	O
(	O
FCBT	O
)	O
than	O
individual	O
CBT	O
(	O
ICBT	O
;	O
OR	O
=	O
8.67	O
)	O
.	O

Coded	O
behavior	O
did	O
not	O
predict	O
outcome	O
.	O

Study	O
2	O
:	O
CBT	O
components	O
were	O
compared	O
by	O
treatment	O
and	O
ASD	O
symptom	O
status	O
.	O

At-home	O
exposure	O
completion	O
was	O
greater	O
in	O
FCBT	O
and	O
there	O
was	O
an	O
interaction	O
in	O
child	O
involvement	O
for	O
treatment	O
and	O
ASD	O
status	O
.	O

Though	O
both	O
treatments	O
reduced	O
anxiety	O
,	O
FCBT	O
outperformed	O
ICBT	O
for	O
children	O
with	O
moderate	O
ASD	O
symptoms	O
,	O
a	O
benefit	O
potentially	O
linked	O
to	O
more	O
at-home	O
exposures	O
and	O
greater	O
child	O
involvement	O
in	O
FCBT	O
.	O

Comparative	O
bioavailability	O
of	O
two	O
formulations	O
of	O
terbinafine	O
.	O

Data	O
from	O
a	O
cross-over	O
,	O
randomised	O
,	O
open-label	O
bioequivalence	O
study	O
in	O
healthy	Condition
volunteers	O
.	O

An	O
open-label	O
,	O
randomised	O
,	O
cross-over	O
single	O
dose	O
study	O
,	O
using	O
2	O
periods	O
x	O
2	O
sequences	O
,	O
with	O
a	O
minimum	O
washout	O
period	O
of	O
21	O
days	O
,	O
was	O
conducted	O
in	O
order	O
to	O
assess	O
the	O
comparative	O
bioavailability	O
of	O
two	O
formulations	O
of	O
terbinafine	O
(	O
CAS	O
78628-80-5	O
)	O
250	O
mg	O
tablets	O
.	O

Plasma	O
samples	O
were	O
obtained	O
at	O
baseline	O
,	O
+0.333	O
;	O
0.667	O
;	O
1.00	O
;	O
1.33	O
;	O
1.67	O
;	O
2.00	O
;	O
2.33	O
;	O
2.67	O
;	O
3.00	O
;	O
3.50	O
;	O
4.00	O
;	O
6.00	O
;	O
8.00	O
;	O
12.0	O
;	O
24.0	O
;	O
36.0	O
;	O
48.0	O
and	O
72.0	O
h	O
post-administration	O
.	O

Terbinafine	O
levels	O
were	O
determined	O
by	O
high	O
pressure	O
liquid	O
chromatography	O
with	O
tandem	O
mass	O
detection	O
(	O
HPLC-MS/MS	O
)	O
and	O
the	O
lower	O
limit	O
of	O
quantification	O
was	O
set	O
at	O
9.99	O
ng/mL	O
.	O

The	O
pharmacokinetic	O
parameters	O
used	O
for	O
the	O
bioequivalence	O
assessment	O
(	O
AUClast	O
,	O
AUCinf	O
and	O
Cmax	O
)	O
were	O
determined	O
from	O
the	O
terbinafine	O
concentration	O
data	O
using	O
non-compartmental	O
analysis	O
.	O

Classical	O
90	O
%	O
confidence	O
intervals	O
(	O
90CI	O
)	O
were	O
calculated	O
for	O
the	O
overall	O
sample	O
,	O
and	O
for	O
males	Sex
and	O
females	Sex
separately	O
,	O
and	O
gender	O
effects	O
were	O
investigated	O
using	O
an	O
appropriate	O
model	O
.	O

The	O
results	O
showed	O
that	O
overall	O
classical	O
90CI	O
were	O
96.08-105.40	O
%	O
for	O
AUCinf	O
,	O
95.68-105.33	O
for	O
AUClast	O
and	O
88.24-112.83	O
for	O
Cmax	O
,	O
that	O
is	O
,	O
all	O
within	O
the	O
predefined	O
ranges	O
for	O
bioequivalence	O
acceptance	O
.	O

Separate	O
gender	O
analysis	O
showed	O
very	O
similar	O
results	O
for	O
males	Sex
and	O
females	Sex
when	O
analysed	O
independently	O
,	O
and	O
no	O
gender	O
effects	O
were	O
detected	O
(	O
p	O
>	O
0.05	O
for	O
all	O
of	O
the	O
tested	O
model	O
effects	O
)	O
.	O

It	O
may	O
be	O
therefore	O
concluded	O
that	O
the	O
evaluated	O
formulations	O
are	O
bioequivalent	O
in	O
terms	O
of	O
rate	O
and	O
extent	O
of	O
absorption	O
.	O

Improvement	O
of	O
pain	O
related	O
self	O
management	O
for	O
oncologic	O
patients	O
through	O
a	O
trans	O
institutional	O
modular	O
nursing	O
intervention	O
:	O
protocol	O
of	O
a	O
cluster	O
randomized	O
multicenter	O
trial	O
.	O

BACKGROUND	O
Pain	O
is	O
one	O
of	O
the	O
most	O
frequent	O
and	O
distressing	O
symptoms	O
in	O
cancer	O
patients	O
.	O

For	O
the	O
majority	O
of	O
the	O
patients	O
,	O
sufficient	O
pain	O
relief	O
can	O
be	O
obtained	O
if	O
adequate	O
treatment	O
is	O
provided	O
.	O

However	O
,	O
pain	O
remains	O
often	O
undertreated	O
due	O
to	O
institutional	O
,	O
health	O
care	O
professional	O
and	O
patient	O
related	O
barriers	O
.	O

Patients	O
self	O
management	O
skills	O
are	O
affected	O
by	O
the	O
patients	O
'	O
knowledge	O
,	O
activities	O
and	O
attitude	O
to	O
pain	O
management	O
.	O

This	O
trial	O
protocol	O
is	O
aimed	O
to	O
test	O
the	O
SCION-PAIN	O
program	O
,	O
a	O
multi	O
modular	O
structured	O
intervention	O
to	O
improve	O
self	O
management	O
in	O
cancer	O
patients	O
with	O
pain	O
.	O

METHODS	O
240	O
patients	O
with	O
diagnosed	O
malignancy	O
and	O
pain	O
>	O
3	O
days	O
and	O
average	O
pain	O
>	O
or=	O
3/10	O
will	O
participate	O
in	O
a	O
cluster	O
randomized	O
trial	O
on	O
18	O
wards	O
in	O
2	O
German	O
university	O
hospitals	O
.	O

Patients	O
from	O
the	O
intervention	O
wards	O
will	O
receive	O
,	O
additionally	O
to	O
standard	O
pain	O
treatment	O
,	O
the	O
SCION-PAIN	O
program	O
consisting	O
of	O
3	O
modules	O
:	O
pharmacologic	O
pain	O
management	O
,	O
nonpharmacologic	O
pain	O
management	O
and	O
discharge	O
management	O
.	O

The	O
intervention	O
will	O
be	O
conducted	O
by	O
specially	O
trained	O
oncology	O
nurses	O
and	O
includes	O
components	O
of	O
patient	O
education	O
,	O
skills	O
training	O
and	O
counseling	O
to	O
improve	O
self	O
care	O
regarding	O
pain	O
management	O
beginning	O
with	O
admission	O
followed	O
by	O
booster	O
session	O
every	O
3rd	O
day	O
and	O
one	O
follow	O
up	O
telephone	O
counseling	O
within	O
2	O
to	O
3	O
days	O
after	O
discharge	O
.	O

Patients	O
in	O
the	O
control	O
group	O
will	O
receive	O
standard	O
care	O
.	O

Primary	O
endpoint	O
is	O
the	O
group	O
difference	O
in	O
patient	O
related	O
barriers	O
to	O
management	O
of	O
cancer	O
pain	O
(	O
BQII	O
)	O
,	O
7	O
days	O
after	O
discharge	O
.	O

Secondary	O
endpoints	O
are	O
:	O
pain	O
intensity	O
&	O
interference	O
,	O
adherence	O
,	O
coping	O
and	O
HRQoL	O
.	O

DISCUSSION	O
The	O
study	O
will	O
determine	O
if	O
the	O
acquired	O
self	O
management	O
skills	O
of	O
the	O
patients	O
continue	O
to	O
be	O
used	O
after	O
discharge	O
from	O
hospital	O
.	O

It	O
is	O
hypothesized	O
that	O
patients	O
who	O
receive	O
the	O
multi	O
modular	O
structured	O
intervention	O
will	O
have	O
less	O
patient	O
related	O
barriers	O
and	O
a	O
better	O
self	O
management	O
of	O
cancer	O
pain	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials	O
NCT00779597	O
.	O

Home	O
blood	O
pressure	O
monitoring	O
:	O
advantages	O
and	O
limitations	O
.	O

Home	O
blood	O
pressure	O
monitoring	O
is	O
a	O
useful	O
tool	O
for	O
clinical	O
management	O
of	O
patients	O
with	O
hypertension	Condition
.	O

Its	O
major	O
advantages	O
are	O
the	O
ease	O
with	O
which	O
the	O
techniques	O
can	O
be	O
learned	O
,	O
reproducibility	O
of	O
values	O
,	O
sensitivity	O
of	O
measurement	O
and	O
availability	O
of	O
normotensive	O
data	O
.	O

In	O
spite	O
of	O
the	O
ability	O
to	O
tell	O
whether	O
a	O
subject	O
has	O
normal	O
or	O
abnormal	O
values	O
,	O
because	O
of	O
the	O
lack	O
of	O
prospective	O
mortality/morbidity	O
data	O
,	O
home	O
blood	O
pressure	O
monitoring	O
can	O
not	O
be	O
used	O
to	O
decide	O
whether	O
treatment	O
is	O
indicated	O
.	O

The	O
treatment	O
decision	O
must	O
be	O
based	O
on	O
repeated	O
clinic	O
blood	O
pressure	O
readings	O
.	O

After	O
that	O
the	O
home	O
blood	O
pressure	O
monitoring	O
can	O
be	O
used	O
to	O
exclude	O
individuals	O
who	O
are	O
at	O
risk	O
for	O
side	O
effects	O
due	O
to	O
low	O
out-of-office	O
blood	O
pressure	O
readings	O
and	O
to	O
precisely	O
monitor	O
the	O
blood	O
pressure	O
response	O
to	O
therapy	O
.	O

Home	O
blood	O
pressure	O
monitoring	O
is	O
frequently	O
used	O
to	O
find	O
subjects	O
with	O
'white-coat	O
'	O
hypertension	O
.	O

In	O
our	O
study	O
of	O
borderline	Condition
hypertension	Condition
in	O
Tecumseh	O
,	O
white-coat	O
hypertension	O
is	O
present	O
in	O
7.1	O
%	O
of	O
the	O
whole	O
population	O
and	O
in	O
58	O
%	O
of	O
all	O
subjects	O
with	O
elevated	O
blood	O
pressures	O
in	O
the	O
clinic	O
.	O

Subjects	O
with	O
white-coat	O
hypertension	O
in	O
Tecumseh	O
appear	O
to	O
be	O
at	O
an	O
increased	O
risk	O
for	O
coronary	O
heart	O
disease	O
:	O
they	O
show	O
repeated	O
elevated	O
clinic	O
readings	O
throughout	O
their	O
life	O
time	O
,	O
their	O
parents	O
have	O
higher	O
blood	O
pressure	O
,	O
their	O
high-density	O
lipoprotein	O
is	O
decreased	O
and	O
insulin	O
,	O
cholesterol	O
and	O
triglycerides	O
are	O
elevated	O
.	O

Whereas	O
subjects	O
with	O
white-coat	O
hypertension	O
should	O
not	O
be	O
treated	O
with	O
antihypertensive	O
agents	O
,	O
they	O
must	O
be	O
followed	O
and	O
managed	O
through	O
non-pharmacologic	O
means	O
.	O

Efficacy	O
of	O
ebrotidine	O
and	O
ranitidine	O
combined	O
with	O
amoxicillin	O
and	O
metronidazole	O
in	O
the	O
eradication	O
of	O
Helicobacter	O
pylori	O
in	O
patients	O
with	O
duodenal	Condition
ulcer	Condition
.	O

This	O
double-blind	O
,	O
randomized	O
,	O
phase	O
III	O
clinical	O
trial	O
was	O
carried	O
out	O
in	O
two	O
parallel	O
groups	O
to	O
assess	O
the	O
efficacy	O
of	O
ebrotidine	O
(	O
N-	O
[	O
(	O
E	O
)	O
-	O
[	O
[	O
2-	O
[	O
[	O
[	O
2-	O
[	O
(	O
diaminomethylene	O
)	O
amino	O
]	O
-4-thiazolyl	O
]	O
methyl	O
]	O
thio	O
]	O
ethyl	O
]	O
amino	O
]	O
methylene	O
]	O
-4-bromo-benzenesulfonamide	O
,	O
CAS	O
100981-43-9	O
,	O
FI-3542	O
)	O
400	O
mg	O
and	O
ranitidine	O
300	O
mg	O
given	O
in	O
single	O
evening	O
dose	O
,	O
combined	O
with	O
amoxicillin	O
750	O
mg	O
and	O
metronidazole	O
500	O
mg	O
three	O
times	O
daily	O
for	O
14	O
days	O
,	O
in	O
the	O
eradication	O
of	O
Helicobacter	O
pylori	O
in	O
patients	O
with	O
duodenal	O
ulcer	O
.	O

Thirty	O
patients	O
were	O
included	O
,	O
divided	O
into	O
two	SampleSize
groups	SampleSize
of	SampleSize
15	SampleSize
,	O
to	O
whom	O
one	O
of	O
the	O
study	O
therapies	O
was	O
administered	O
based	O
on	O
a	O
randomization	O
code	O
.	O

Clinical	O
and	O
endoscopic	O
controls	O
were	O
performed	O
4	O
,	O
6	O
and	O
8	O
weeks	O
after	O
the	O
onset	O
of	O
the	O
treatment	O
.	O

No	O
differences	O
were	O
seen	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
regard	O
to	O
demographic	O
parameters	O
and	O
clinical	O
histories	O
.	O

They	O
were	O
both	O
perfectly	O
homogeneous	O
.	O

There	O
were	O
no	O
differences	O
between	O
the	O
eradication	O
of	O
both	O
therapies	O
in	O
both	O
the	O
antrum	O
and	O
gastric	O
body	O
samples	O
(	O
over	O
80	O
%	O
eradication	O
)	O
,	O
allowing	O
the	O
results	O
to	O
be	O
classified	O
as	O
satisfactory	O
.	O

Moreover	O
,	O
perfect	O
control	O
was	O
achieved	O
through	O
the	O
study	O
of	O
clinical	O
symptoms	O
,	O
which	O
even	O
disappeared	O
in	O
some	O
cases	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
healing	O
rate	O
of	O
the	O
duodenal	O
ulcer	O
after	O
four	O
weeks	O
,	O
86.7	O
%	O
being	O
achieved	O
for	O
both	O
groups	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
energy	O
metabolism	O
and	O
food	O
intake	O
in	O
humans	O
.	O

The	O
effect	O
of	O
glucocorticoid	O
administration	O
on	O
energy	O
metabolism	O
and	O
food	O
intake	O
was	O
studied	O
in	O
20	O
healthy	O
,	O
nondiabetic	O
Caucasian	O
male	O
volunteers	O
[	O
27	O
+/-	O
5	O
(	O
SD	O
)	O
yr	O
,	O
72	O
+/-	O
9	O
kg	O
,	O
20	O
+/-	O
7	O
%	O
body	O
fat	O
]	O
randomly	O
and	O
blindly	O
assigned	O
to	O
glucocorticoid	O
(	O
methylprednisolone	O
,	O
METH	O
;	O
n	O
=	O
10	O
)	O
or	O
placebo	O
(	O
PLAC	O
;	O
n	O
=	O
10	O
)	O
treatment	O
.	O

Each	O
subject	O
was	O
studied	O
twice	O
:	O
during	O
a	O
weight	O
maintenance	O
diet	O
and	O
during	O
ad	O
libitum	O
food	O
intake	O
.	O

Energy	O
metabolism	O
was	O
measured	O
by	O
indirect	O
calorimetry	O
and	O
food	O
intake	O
by	O
an	O
automated	O
food-selection	O
system	O
.	O

Twenty-four-hour	O
urinary	O
norepinephrine	O
excretion	O
(	O
24-h	O
NE	O
)	O
was	O
used	O
as	O
an	O
estimate	O
of	O
sympathetic	O
nervous	O
system	O
activity	O
.	O

During	O
weight	O
maintenance	O
,	O
METH	O
intravenous	O
infusion	O
(	O
125	O
mg/30	O
min	O
)	O
increased	O
energy	O
expenditure	O
compared	O
with	O
PLAC	O
,	O
and	O
after	O
4	O
days	O
of	O
oral	O
therapy	O
,	O
METH	O
(	O
40	O
mg/day	O
)	O
decreased	O
24-h	O
NE	O
and	O
increased	O
energy	O
expenditure	O
compared	O
with	O
PLAC	O
.	O

During	O
ad	O
libitum	O
food	O
intake	O
,	O
after	O
4	O
days	O
of	O
METH	O
(	O
40	O
mg/day	O
)	O
or	O
PLAC	O
oral	O
therapy	O
,	O
both	O
groups	O
increased	O
their	O
energy	O
intake	O
over	O
weight	O
maintenance	O
,	O
but	O
the	O
increase	O
was	O
significantly	O
larger	O
in	O
the	O
METH	O
group	O
compared	O
with	O
the	O
PLAC	O
group	O
(	O
4,554	O
+/-	O
1,857	O
vs.	O
2,867	O
+/-	O
846	O
kcal/day	O
;	O
P	O
=	O
0.04	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
therapeutic	O
doses	O
of	O
glucocorticoids	O
induce	O
obesity	O
mostly	O
by	O
increasing	O
energy	O
intake	O
,	O
an	O
effect	O
which	O
may	O
be	O
related	O
to	O
the	O
ability	O
of	O
glucocorticoids	O
to	O
act	O
directly	O
or	O
indirectly	O
on	O
the	O
central	O
regulation	O
of	O
appetite	O
.	O

Effects	O
of	O
flumazenil	O
on	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
consumption	O
after	O
midazolam	O
anaesthesia	O
for	O
craniotomy	O
.	O

Cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	O
(	O
CMRO2	O
)	O
were	O
measured	O
by	O
a	O
modification	O
of	O
the	O
Kety-Schmidt	O
technique	O
using	O
i.v	O
.	O

xenon-133	O
in	O
20	O
patients	O
undergoing	O
craniotomy	O
for	O
supratentorial	O
cerebral	O
tumours	O
.	O

Anaesthesia	O
was	O
induced	O
and	O
maintained	O
with	O
midazolam	O
,	O
fentanyl	O
and	O
nitrous	O
oxide	O
.	O

Pancuronium	O
was	O
given	O
for	O
neuromuscular	O
block	O
.	O

The	O
lungs	O
were	O
ventilated	O
to	O
normocapnia	O
.	O

The	O
first	O
flow	O
measurements	O
were	O
performed	O
approximately	O
1	O
h	O
after	O
induction	O
of	O
anaesthesia	O
.	O

At	O
the	O
end	O
of	O
operation	O
the	O
patients	O
were	O
allocated	O
to	O
two	O
groups	O
.	O

Ten	O
patients	O
were	O
given	O
flumazenil	O
0.01	O
mg	O
kg-1	O
and	O
5	O
min	O
later	O
the	O
second	O
flow	O
measurement	O
was	O
performed	O
.	O

In	O
the	O
other	O
10	O
patients	O
the	O
second	O
flow	O
measurement	O
was	O
performed	O
before	O
the	O
administration	O
of	O
flumazenil	O
.	O

Plasma	O
concentrations	O
of	O
midazolam	O
were	O
measured	O
at	O
the	O
time	O
of	O
each	O
measurement	O
of	O
CBF	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
groups	O
in	O
plasma	O
concentration	O
of	O
midazolam	O
,	O
CBF	O
or	O
CMRO2	O
.	O

Flumazenil	O
had	O
no	O
effect	O
on	O
CBF	O
and	O
CMRO2	O
.	O

Use	O
of	O
ketorolac	O
is	O
associated	O
with	O
decreased	O
pneumonia	O
following	O
rib	Condition
fractures	Condition
.	O

BACKGROUND	O
The	O
effectiveness	O
of	O
the	O
nonsteroidal	O
anti-inflammatory	O
drug	O
ketorolac	O
in	O
reducing	O
pulmonary	Condition
morbidity	Condition
after	O
rib	Condition
fractures	Condition
remains	O
largely	O
unknown	O
.	O

METHODS	O
A	O
retrospective	O
cohort	O
study	O
was	O
conducted	O
spanning	O
January	O
2003	O
to	O
June	O
2011	O
assessing	O
pneumonia	O
within	O
30	O
days	O
and	O
potential	O
adverse	O
effects	O
of	O
ketorolac	O
among	O
all	O
patients	O
with	O
rib	Condition
fractures	Condition
who	O
received	O
ketorolac	O
<	O
4	O
days	O
after	O
injury	O
compared	O
with	O
a	O
random	O
sample	O
of	O
those	O
who	O
did	O
not	O
.	O

RESULTS	O
Among	O
202	SampleSize
patients	O
who	O
received	O
ketorolac	O
and	O
417	SampleSize
who	O
did	O
not	O
,	O
ketorolac	O
use	O
was	O
associated	O
with	O
decreased	O
pneumonia	O
(	O
odds	O
ratio	O
,	O
.14	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
.04	O
to	O
.46	O
)	O
and	O
increased	O
ventilator-free	O
days	O
(	O
difference	O
,	O
1.8	O
days	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.1	O
to	O
2.5	O
)	O
and	O
intensive	O
care	O
unit-free	O
days	O
(	O
difference	O
,	O
2.1	O
days	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.3	O
to	O
3.0	O
)	O
within	O
30	O
days	O
.	O

The	O
rates	O
of	O
acute	O
kidney	O
injury	O
,	O
gastrointestinal	O
hemorrhage	O
,	O
and	O
fracture	O
nonunion	O
were	O
not	O
different	O
.	O

CONCLUSIONS	O
Early	O
administration	O
of	O
ketorolac	O
to	O
patients	O
with	O
rib	Condition
fractures	Condition
is	O
associated	O
with	O
a	O
decreased	O
likelihood	O
of	O
pneumonia	O
,	O
without	O
apparent	O
risks	O
.	O

Psychosocial	O
nursing	O
therapy	O
following	O
sudden	O
cardiac	Condition
arrest	Condition
:	O
impact	O
on	O
two-year	O
survival	O
.	O

BACKGROUND	O
Although	O
psychosocial	O
therapy	O
has	O
been	O
shown	O
to	O
reduce	O
mortality	O
after	O
myocardial	O
infarction	O
,	O
it	O
is	O
unknown	O
whether	O
the	O
benefits	O
of	O
psychosocial	O
therapy	O
on	O
mortality	O
reduction	O
extend	O
to	O
out-of-hospital	O
sudden	O
cardiac	O
arrest	O
,	O
a	O
main	O
cause	O
of	O
cardiovascular	O
mortality	O
.	O

OBJECTIVE	O
Describe	O
efficacy	O
of	O
psychosocial	O
therapy	O
on	O
two-year	O
cardiovascular	O
mortality	O
in	O
sudden	O
cardiac	O
arrest	O
survivors	O
.	O

METHOD	O
Survivors	O
of	O
out-of-hospital	O
ventricular	O
fibrillation	O
or	O
asystole	O
(	O
N	O
=	O
129	SampleSize
)	O
,	O
documented	O
by	O
electrocardiograms	O
from	O
registries	O
of	O
a	O
citywide	O
Medic	O
One	O
unit	O
and	O
two	O
countywide	O
emergency	O
units	O
,	O
were	O
randomized	O
into	O
a	O
two	O
group	O
,	O
experimental	O
,	O
longitudinal	O
design	O
.	O

The	O
intervention	O
consisted	O
of	O
11	O
individual	O
sessions	O
,	O
implementing	O
three	O
components	O
:	O
physiologic	O
relaxation	O
with	O
biofeedback	O
training	O
focused	O
on	O
altering	O
autonomic	O
tone	O
;	O
cognitive	O
behavioral	O
therapy	O
aimed	O
at	O
self-management	O
and	O
coping	O
strategies	O
for	O
depression	O
,	O
anxiety	O
,	O
and	O
anger	O
;	O
and	O
cardiovascular	O
health	O
education	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
cardiovascular	O
mortality	O
.	O

RESULTS	O
Risk	O
of	O
cardiovascular	O
death	O
was	O
significantly	O
reduced	O
86	O
%	O
by	O
psychosocial	O
therapy	O
,	O
p	O
=	O
.03	O
.	O

Six	O
of	O
the	O
seven	O
cardiovascular	O
deaths	O
in	O
the	O
control	O
group	O
were	O
caused	O
by	O
ventricular	O
arrhythmias	O
.	O

The	O
cardiovascular	O
death	O
in	O
the	O
therapy	O
group	O
was	O
due	O
to	O
stroke	O
.	O

Controlling	O
for	O
depression	O
,	O
previous	O
myocardial	O
infarction	O
,	O
low	O
ejection	O
fraction	O
,	O
decreased	O
heart	O
rate	O
variability	O
,	O
and	O
ventricular	O
ectopic	O
beats	O
had	O
little	O
impact	O
on	O
estimated	O
treatment	O
effect	O
.	O

The	O
risk	O
of	O
all-cause	O
mortality	O
was	O
reduced	O
by	O
62	O
%	O
in	O
the	O
therapy	O
group	O
,	O
p	O
=	O
.13	O
.	O

There	O
were	O
a	O
total	O
of	O
three	O
deaths	O
in	O
the	O
therapy	O
group	O
and	O
eight	O
deaths	O
in	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
Psychosocial	O
therapy	O
significantly	O
reduced	O
the	O
risk	O
of	O
cardiovascular	O
death	O
in	O
sudden	O
cardiac	O
arrest	O
survivors	O
.	O

A	O
preliminary	O
study	O
of	O
the	O
optimal	O
anesthesia	O
positioning	O
for	O
the	O
morbidly	O
obese	O
patient	O
.	O

BACKGROUND	O
Hypoxemia	O
during	O
the	O
induction	O
of	O
general	O
anesthesia	O
for	O
the	O
morbidly	O
obese	O
patient	O
is	O
a	O
major	O
concern	O
of	O
anesthesiologists	O
.	O

The	O
etiology	O
of	O
this	O
pathophysiological	O
problem	O
is	O
multifactorial	O
,	O
and	O
patient	O
positioning	O
may	O
be	O
a	O
contributing	O
factor	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
identify	O
optimal	O
patient	O
positioning	O
for	O
the	O
induction	O
of	O
general	O
anesthesia	O
that	O
minimizes	O
the	O
risk	O
of	O
hypoxemia	O
in	O
these	O
patients	O
.	O

METHODS	O
26	O
morbidly	O
obese	O
patients	O
(	O
body	O
mass	O
index-BMI	O
56	O
+/-	O
3	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
positions	O
for	O
induction	O
of	O
anesthesia	O
:	O
1	O
)	O
30	O
degrees	O
Reverse	O
Trendelenburg	O
;	O
2	O
)	O
Supine-Horizontal	O
;	O
3	O
)	O
30	O
degrees	O
Back	O
Up	O
Fowler	O
.	O

Mask	O
ventilation	O
,	O
full	O
neuromuscular	O
paralysis	O
and	O
direct	O
laryngoscopy	O
were	O
performed	O
.	O

Any	O
airway	O
difficulties	O
were	O
noted	O
.	O

After	O
endotracheal	O
tube	O
placement	O
,	O
subjects	O
were	O
ventilated	O
for	O
5	O
minutes	O
with	O
1	O
%	O
isoflurane	O
in	O
a	O
mixture	O
of	O
50	O
%	O
oxygen/50	O
%	O
air	O
and	O
then	O
disconnected	O
from	O
the	O
ventilation	O
circuit	O
.	O

The	O
time	O
required	O
for	O
capillary	O
oxygen	O
saturation	O
(	O
SaO2	O
)	O
,	O
as	O
measured	O
by	O
pulse	O
oximeter	O
,	O
to	O
decline	O
from	O
100	O
%	O
to	O
92	O
%	O
was	O
noted	O
and	O
identified	O
as	O
the	O
safe	O
apnea	O
period	O
(	O
SAP	O
)	O
.	O

Ventilation	O
was	O
then	O
immediately	O
re-established	O
.	O

The	O
lowest	O
SaO2	O
after	O
resuming	O
ventilation	O
and	O
the	O
time	O
from	O
that	O
nadir	O
to	O
an	O
SaO2	O
of	O
97	O
%	O
were	O
also	O
recorded	O
.	O

RESULTS	O
BMI	O
and	O
hip-waist	O
ratios	O
of	O
patients	O
in	O
groups	O
1	O
,	O
2	O
and	O
3	O
did	O
not	O
significantly	O
differ	O
.	O

There	O
were	O
no	O
differences	O
in	O
airway	O
difficulties	O
between	O
the	O
different	O
groups	O
.	O

The	O
SAP	O
in	O
groups	O
1	O
,	O
2	O
and	O
3	O
was	O
178	O
+/-	O
55	O
,	O
123	O
+/-	O
24	O
and	O
153	O
+/-	O
63	O
seconds	O
,	O
respectively	O
.	O

The	O
SaO2	O
of	O
patients	O
in	O
the	O
reverse	O
Trendelenburg	O
position	O
dropped	O
the	O
least	O
and	O
took	O
the	O
shortest	O
time	O
to	O
recover	O
to	O
97	O
%	O
.	O

CONCLUSIONS	O
In	O
morbidly	O
obese	O
patients	O
,	O
the	O
30	O
degrees	O
Reverse	O
Trendelenburg	O
position	O
provided	O
the	O
longest	O
SAP	O
when	O
compared	O
to	O
the	O
30	O
degrees	O
Back	O
Up	O
Fowler	O
and	O
Horizontal-Supine	O
positions	O
.	O

Since	O
on	O
induction	O
of	O
general	O
anesthesia	O
morbidly	O
obese	O
patients	O
may	O
be	O
difficult	O
to	O
mask	O
ventilate	O
and/or	O
intubate	O
,	O
this	O
extra	O
time	O
may	O
preclude	O
adverse	O
sequelae	O
resulting	O
from	O
hypoxemia	O
.	O

Therefore	O
,	O
Reverse	O
Trendelenburg	O
is	O
recommended	O
as	O
the	O
optimal	O
position	O
for	O
induction	O
.	O

[	O
Rehabilitation	O
of	O
the	O
patients	O
presenting	O
with	O
combined	O
pathology	O
:	O
dyscirculatory	O
encephalopathy	O
and	O
climacteric	O
syndrome	O
]	O
.	O

The	O
present	O
paper	O
reports	O
the	O
data	O
on	O
rehabilitation	O
of	O
women	O
presenting	O
with	O
combined	O
pathology	O
:	O
dyscirculatory	O
encephalopathy	O
and	O
climacteric	O
syndrome	O
.	O

It	O
is	O
shown	O
that	O
the	O
introduction	O
of	O
ozonotherapy	O
and	O
klimadynon	O
,	O
a	O
herbal	O
medicine	O
possessed	O
of	O
the	O
estrogen-like	O
action	O
,	O
into	O
combined	O
rehabilitative	O
treatment	O
ensures	O
the	O
significant	O
improvement	O
of	O
the	O
parameters	O
of	O
interest	O
,	O
such	O
as	O
climacteric	O
symptoms	O
,	O
short-term	O
memory	O
,	O
lipid	O
profile	O
,	O
endothelial	O
function	O
,	O
cerebral	O
circulation	O
,	O
and	O
quality	O
of	O
life	O
.	O

Pain	O
relief	O
can	O
reduce	O
hypoxemia	O
in	O
distressed	Condition
neonates	O
during	O
routine	O
treatment	O
procedures	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
the	O
use	O
of	O
opioids	O
could	O
reduce	O
the	O
hypoxemia	O
and	O
hemodynamic	O
instability	O
associated	O
with	O
routine	O
intensive	O
care	O
procedures	O
in	O
neonates	Age
with	O
respiratory	Condition
distress	Condition
.	Condition

DESIGN	O
Randomized	O
and	O
placebo-controlled	O
study	O
.	O

METHODS	O
Physiological	O
,	O
plasma	O
beta-endorphin	O
,	O
cortisol	O
,	O
and	O
glucose	O
responses	O
to	O
routine	O
treatment	O
procedures	O
were	O
studied	O
in	O
84	SampleSize
mechanically	Condition
ventilated	Condition
distressed	Condition
neonates	O
randomized	O
into	O
groups	O
receiving	O
1	O
mg/kg	O
meperidine	O
or	O
0.9	O
%	O
saline	O
15	O
minutes	O
before	O
tracheal	O
suction	O
or	O
routine	O
nursing	O
care	O
.	O

RESULTS	O
The	O
duration	O
of	O
hypoxemia	O
(	O
transcutaneous	O
partial	O
pressure	O
of	O
O2	O
<	O
6.6	O
kPa	O
(	O
<	O
50	O
mm	O
Hg	O
)	O
and/or	O
arterial	O
blood	O
oxygen	O
saturation	O
<	O
80	O
%	O
)	O
during	O
treatment	O
procedures	O
was	O
significantly	O
longer	O
in	O
the	O
saline	O
group	O
(	O
mean	O
82	O
vs	O
36	O
seconds	O
,	O
P	O
=	O
.001	O
)	O
and	O
distress	O
quantified	O
by	O
a	O
novel	O
behavioral	O
scoring	O
method	O
was	O
much	O
higher	O
.	O

Changes	O
in	O
arterial	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
or	O
plasma	O
beta-endorphin	O
,	O
cortisol	O
,	O
and	O
glucose	O
concentration	O
did	O
not	O
show	O
any	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

CONCLUSION	O
Newborns	Age
with	O
respiratory	Condition
difficulties	Condition
often	O
suffer	O
from	O
hypoxemia	O
during	O
essential	O
treatment	O
procedures	O
.	O

The	O
use	O
of	O
opioid	O
analgesia	O
may	O
reduce	O
the	O
duration	O
of	O
hypoxemia	O
and	O
the	O
associated	O
distress	O
and	O
,	O
therefore	O
,	O
may	O
improve	O
the	O
long-term	O
results	O
of	O
neonatal	O
intensive	O
care	O
.	O

Hypertension	Condition
and	O
non-insulin-dependent	Condition
diabetes	Condition
.	O

A	O
comparison	O
between	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
and	O
a	O
calcium	O
antagonist	O
.	O

The	O
effects	O
of	O
the	O
angiotensin-converting	O
enzyme	O
lisinopril	O
were	O
compared	O
with	O
those	O
of	O
the	O
calcium	O
antagonist	O
nifedipine	O
in	O
162	SampleSize
non-insulin-dependent	Condition
diabetic	Condition
hypertensive	Condition
patients	O
for	O
a	O
24-week	O
period	O
.	O

In	O
83	O
and	O
79	O
patients	O
,	O
respectively	O
,	O
lisinopril	O
and	O
slow-release	O
nifedipine	O
produced	O
similar	O
reductions	O
in	O
blood	O
pressure	O
(	O
systolic/diastolic	O
:	O
-16/-13	O
mmHg	O
supine	O
and	O
-14/-11	O
mmHg	O
standing	O
after	O
lisinopril	O
;	O
-15/-12	O
mmHg	O
supine	O
and	O
-14/-11	O
mmHg	O
standing	O
nifedipine	O
)	O
.	O

Fasting	O
and	O
post-prandial	O
plasma	O
glucose	O
,	O
glycosylated	O
haemoglobin	O
and	O
plasma	O
lipids	O
appeared	O
to	O
be	O
unaffected	O
by	O
either	O
agent	O
.	O

Also	O
,	O
28	O
%	O
of	O
the	O
patients	O
on	O
lisinopril	O
and	O
30	O
%	O
of	O
those	O
on	O
nifedipine	O
presented	O
microalbuminuria	O
.	O

Both	O
drugs	O
induced	O
a	O
reduction	O
in	O
the	O
albumin	O
excretion	O
rate	O
(	O
AER	O
)	O
.	O

The	O
geometric	O
mean	O
x	O
:	O
tolerance	O
factor	O
of	O
the	O
reduction	O
in	O
AER	O
among	O
the	O
23	O
microalbuminuric	O
patients	O
on	O
lisinopril	O
(	O
-10.0	O
x:1.3	O
micrograms/min	O
)	O
was	O
greater	O
,	O
though	O
not	O
significantly	O
so	O
,	O
than	O
that	O
observed	O
in	O
the	O
26	O
on	O
nifedipine	O
(	O
-0.9	O
x	O
1.2	O
micrograms/min	O
)	O
.	O

Moreover	O
,	O
lisinopril	O
appeared	O
to	O
be	O
better	O
tolerated	O
than	O
nifedipine	O
in	O
our	O
study	O
population	O
.	O

Microalbuminuria	O
is	O
an	O
important	O
risk	O
factor	O
for	O
cardiovascular	O
mortality	O
in	O
non-insulin-dependent	Condition
diabetic	Condition
patients	O
as	O
well	O
as	O
in	O
the	O
general	O
population	O
.	O

To	O
what	O
extent	O
a	O
reduction	O
in	O
the	O
AER	O
could	O
ameliorate	O
diabetic	O
patients	O
is	O
,	O
at	O
present	O
,	O
unknown	O
.	O

Finally	O
,	O
both	O
lisinopril	O
and	O
nifedipine	O
showed	O
a	O
similar	O
antihypertensive	O
effect	O
in	O
these	O
patients	O
which	O
was	O
not	O
associated	O
with	O
significant	O
differences	O
in	O
plasma	O
glucose	O
,	O
insulin	O
or	O
lipid	O
concentrations	O
.	O

The	O
clinical	O
consequences	O
of	O
the	O
insignificant	O
differences	O
in	O
AER	O
remain	O
unclear	O
.	O

Effectiveness	O
of	O
the	O
school	O
dental	O
screening	O
programme	O
in	O
stimulating	O
dental	O
attendance	O
for	O
children	Age
in	O
need	O
of	O
treatment	O
in	O
Northern	O
Ireland	O
.	O

UNLABELLED	O
The	O
school	O
dental	O
screening	O
programme	O
has	O
been	O
in	O
existence	O
from	O
the	O
beginning	O
of	O
the	O
20th	O
century	O
yet	O
its	O
value	O
in	O
encouraging	O
attendance	O
among	O
children	O
with	O
a	O
dental	Condition
health	Condition
need	O
is	O
not	O
fully	O
established	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
school	O
dental	O
screening	O
in	O
promoting	O
dental	O
attendance	O
among	O
children	Age
with	O
a	O
treatment	O
need	O
and	O
to	O
examine	O
the	O
relative	O
importance	O
of	O
screening	O
,	O
social	O
class	O
and	O
other	O
factors	O
in	O
dental	O
attendance	O
.	O

METHODS	O
Sixty-four	SampleSize
participating	O
schools	O
were	O
assigned	O
to	O
study	O
and	O
control	O
groups	O
using	O
a	O
stratified	O
,	O
blocked	O
randomisation	O
technique	O
.	O

The	O
study	O
group	O
children	O
received	O
the	O
standard	O
school	O
dental	O
screening	O
and	O
the	O
dental	O
attendance	O
of	O
those	O
with	O
a	O
positive	O
screening	O
result	O
was	O
assessed	O
after	O
2	O
months	O
by	O
means	O
of	O
a	O
questionnaire	O
issued	O
to	O
the	O
children	O
's	O
parents	O
.	O

The	O
control	O
group	O
children	O
were	O
not	O
,	O
at	O
this	O
stage	O
,	O
screened	O
,	O
yet	O
their	O
parents	O
received	O
the	O
same	O
questionnaire	O
assessing	O
dental	O
attendance	O
over	O
the	O
2-month	O
period	O
.	O

However	O
,	O
only	O
questionnaires	O
from	O
control	O
group	O
children	O
who	O
had	O
a	O
positive	O
result	O
at	O
a	O
subsequent	O
screening	O
were	O
retained	O
for	O
analysis	O
.	O

RESULTS	O
A	O
total	O
of	O
2,321	SampleSize
children	SampleSize
were	O
screened	O
,	O
with	O
980	SampleSize
having	O
a	O
positive	O
result	O
.	O

The	O
mean	O
dmft	O
of	O
those	O
screening	O
positive	O
was	O
4.85	O
.	O

In	O
all	O
,	O
664	SampleSize
completed	O
questionnaires	O
were	O
returned	O
,	O
giving	O
a	O
response	O
rate	O
of	O
67.8	O
%	O
.	O

Dental	O
attendance	O
was	O
reported	O
among	O
45.5	O
%	O
of	O
the	O
study	O
group	O
(	O
n=352	O
)	O
in	O
the	O
2	O
months	O
following	O
screening	O
.	O

In	O
the	O
same	O
period	O
,	O
27.6	O
%	O
of	O
the	O
control	O
group	O
(	O
n=312	O
)	O
claimed	O
attendance	O
.	O

The	O
effect	O
was	O
found	O
to	O
be	O
significant	O
among	O
the	O
high	O
employed	O
group	O
(	O
P	O
<	O
0.01	O
)	O
and	O
the	O
unemployed	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
School	O
dental	O
screening	O
was	O
capable	O
of	O
stimulating	O
dental	O
attendance	O
.	O

The	O
strong	O
effect	O
among	O
the	O
lowest	O
socio-economic	O
group	O
shows	O
that	O
school	O
dental	O
screening	O
may	O
be	O
used	O
to	O
decrease	O
dental	O
health	O
inequalities	O
.	O

Parent	O
satisfaction	O
in	O
a	O
multi-site	O
acute	O
trial	O
of	O
risperidone	O
in	O
children	O
with	O
autism	O
:	O
a	O
social	O
validity	O
study	O
.	O

RATIONALE	O
Subjects	O
who	O
view	O
experimental	O
procedures	O
as	O
worthwhile	O
are	O
more	O
likely	O
to	O
participate	O
in	O
clinical	O
trials	O
and	O
comply	O
with	O
study	O
procedures	O
.	O

Designing	O
studies	O
that	O
consider	O
the	O
consumer	O
's	O
perspective	O
will	O
help	O
to	O
forge	O
a	O
better	O
alliance	O
between	O
participants	O
and	O
researchers	O
.	O

OBJECTIVE	O
Participant	O
satisfaction	O
is	O
seldom	O
assessed	O
in	O
pharmacological	O
research	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
on	O
parent	O
satisfaction	O
in	O
a	O
randomized	O
clinical	O
trial	O
in	O
children	Age
with	O
autistic	Condition
disorder	Condition
and	Condition
severely	Condition
disruptive	Condition
behavior	Condition
.	O

METHOD	O
Parents	O
of	O
101	SampleSize
children	Condition
with	O
autism	Condition
who	O
had	O
participated	O
in	O
a	O
multi-site	O
8-week	O
double-blind	O
clinical	O
trial	O
of	O
risperidone	O
were	O
given	O
a	O
questionnaire	O
at	O
the	O
end	O
to	O
elicit	O
their	O
perceptions	O
of	O
the	O
appropriateness	O
and	O
acceptability	O
of	O
clinical	O
trial	O
procedures	O
.	O

RESULTS	O
Ninety-six	O
(	O
95.0	O
%	O
)	O
parents	O
returned	O
the	O
questionnaire	O
.	O

Of	O
these	O
,	O
80.0	O
to	O
96.8	O
%	O
,	O
depending	O
on	O
the	O
question	O
,	O
expressed	O
satisfaction	O
with	O
their	O
child	O
's	O
research	O
participation	O
regardless	O
of	O
treatment	O
outcome	O
or	O
assignment	O
to	O
active	O
drug	O
or	O
placebo	O
.	O

In	O
all	O
,	O
90.5	O
%	O
of	O
parents	O
indicated	O
that	O
they	O
would	O
definitely	O
recommend	O
the	O
clinical	O
trial	O
to	O
other	O
families	O
with	O
similar	O
children	O
.	O

A	O
total	O
of	O
92.7	O
%	O
indicated	O
that	O
they	O
would	O
rejoin	O
the	O
clinical	O
trial	O
if	O
they	O
had	O
to	O
do	O
it	O
all	O
over	O
again	O
.	O

Ethnic	O
minority	O
subjects	O
were	O
more	O
satisfied	O
than	O
white	O
participants	O
with	O
the	O
use	O
of	O
learning	O
tests	O
.	O

CONCLUSIONS	O
Parents	O
of	O
children	O
participating	O
in	O
this	O
trial	O
were	O
highly	O
satisfied	O
and	O
supportive	O
of	O
the	O
clinical	O
trial	O
procedures	O
.	O

Random	O
assignment	O
to	O
drug	O
or	O
placebo	O
and	O
the	O
clinical	O
response	O
of	O
their	O
children	O
did	O
not	O
appear	O
to	O
influence	O
their	O
views	O
.	O

Further	O
satisfaction	O
studies	O
of	O
this	O
sort	O
are	O
encouraged	O
.	O

Final	O
report	O
of	O
a	O
randomized	O
controlled	O
study	O
with	O
streptococcal	O
preparation	O
OK-432	O
as	O
a	O
supplementary	O
immunopotentiator	O
for	O
laryngeal	O
cancer	O
.	O

We	O
conducted	O
a	O
randomized	O
controlled	O
study	O
of	O
streptococcal	O
preparation	O
OK-432	O
on	O
120	O
newly	O
identified	O
cases	O
of	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
who	O
were	O
registered	O
at	O
10	O
participating	O
institutions	O
between	O
November	O
1984	O
and	O
October	O
1989	O
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
those	O
in	O
early	O
stages	O
(	O
stage	O
I	O
or	O
II	O
)	O
and	O
those	O
in	O
advanced	O
stages	O
(	O
stage	O
III	O
or	O
IV	O
)	O
;	O
these	O
groups	O
were	O
further	O
subdivided	O
into	O
an	O
immunotherapy	O
group	O
(	O
receiving	O
OK-432	O
)	O
and	O
a	O
control	O
group	O
(	O
who	O
did	O
not	O
receive	O
OK-432	O
)	O
.	O

The	O
usefulness	O
of	O
OK-432	O
was	O
studied	O
using	O
the	O
sealed	O
envelope	O
method	O
.	O

The	O
basic	O
therapy	O
for	O
all	O
cases	O
was	O
radiotherapy	O
and	O
,	O
when	O
required	O
,	O
surgery	O
.	O

As	O
adjuvant	O
therapy	O
,	O
5Fu	O
or	O
derivatives	O
were	O
administered	O
to	O
all	O
cases	O
from	O
the	O
beginning	O
of	O
the	O
treatment	O
period	O
to	O
one	O
year	O
after	O
the	O
basic	O
therapy	O
,	O
with	O
the	O
exception	O
of	O
cases	O
in	O
whom	O
side	O
effects	O
were	O
serious	O
enough	O
to	O
contraindicate	O
use	O
of	O
the	O
drug	O
.	O

The	O
target	O
administration	O
period	O
was	O
5	O
years	O
.	O

Of	O
the	O
initial	O
120	O
cases	O
,	O
11	O
cases	O
were	O
disqualified	O
(	O
3	O
cases	O
of	O
double	O
cancer	O
and	O
8	O
of	O
incomplete	O
primary	O
therapy	O
)	O
and	O
the	O
remaining	O
109	O
were	O
used	O
for	O
evaluation	O
.	O

The	O
5-year	O
survival	O
rate	O
and	O
the	O
5-year	O
recurrence-free	O
rate	O
were	O
76	O
%	O
and	O
84	O
%	O
,	O
respectively	O
,	O
in	O
the	O
immunized	O
groups	O
(	O
both	O
the	O
early	O
and	O
advanced	O
groups	O
)	O
,	O
whereas	O
the	O
same	O
rates	O
for	O
the	O
control	O
groups	O
were	O
78	O
%	O
and	O
75	O
%	O
.	O

There	O
was	O
a	O
tendency	O
for	O
the	O
immunized	O
groups	O
to	O
enjoy	O
a	O
slightly	O
longer	O
recurrence-free	O
period	O
.	O

Over	O
a	O
24-month	O
observation	O
period	O
the	O
immunized	O
group	O
always	O
had	O
higher	O
levels	O
of	O
peripheral	O
leukocytes	O
and	O
peripheral	O
lymphocytes	O
;	O
this	O
difference	O
was	O
significant	O
for	O
the	O
first	O
21	O
months	O
.	O

Inhibition	O
of	O
bone	O
marrow	O
function	O
is	O
sometimes	O
observed	O
with	O
radiotherapy	O
.	O

It	O
is	O
hoped	O
that	O
,	O
if	O
this	O
inhibition	O
can	O
be	O
mitigated	O
,	O
it	O
will	O
be	O
possible	O
to	O
assist	O
the	O
compromised	O
immune	O
system	O
and	O
maintain	O
a	O
certain	O
level	O
of	O
immune	O
performance	O
which	O
will	O
prevent	O
recurrence	O
and	O
improve	O
survival	O
rate	O
.	O

In	O
the	O
present	O
study	O
we	O
observed	O
a	O
tendency	O
of	O
the	O
lower	O
recurrence	O
rate	O
in	O
the	O
immunized	O
group	O
,	O
and	O
we	O
hypothesize	O
that	O
OK-432	O
is	O
effective	O
in	O
extending	O
the	O
recurrence-free	O
period	O
.	O

Mefloquine	O
kinetics	O
in	O
cured	O
and	O
recrudescent	O
patients	O
with	O
acute	O
falciparum	O
malaria	O
and	O
in	O
healthy	O
volunteers	O
.	O

Mefloquine	O
pharmacokinetics	O
were	O
compared	O
in	O
a	O
randomized	O
clinical	O
trial	O
in	O
Thailand	O
among	O
patients	O
with	O
malaria	O
and	O
healthy	O
volunteers	O
.	O

A	O
single	O
oral	O
dose	O
of	O
1500	O
mg	O
mefloquine	O
hydrochloride	O
was	O
administered	O
to	O
11	O
patients	O
and	O
5	O
volunteers	O
and	O
750	O
mg	O
was	O
given	O
to	O
16	O
patients	O
and	O
5	O
volunteers	O
.	O

Efficacy	O
was	O
82	O
%	O
for	O
1500	O
mg	O
and	O
63	O
%	O
for	O
750	O
mg	O
.	O

In	O
cured	O
patients	O
taking	O
750	O
mg	O
mefloquine	O
,	O
peak	O
plasma	O
drug	O
concentration	O
(	O
Cmax	O
)	O
and	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
were	O
significantly	O
greater	O
than	O
in	O
the	O
patients	O
for	O
whom	O
treatment	O
failed	O
(	O
p	O
less	O
than	O
0.0005	O
and	O
p	O
less	O
than	O
0.01	O
,	O
respectively	O
)	O
,	O
and	O
plasma	O
mefloquine	O
levels	O
were	O
significantly	O
higher	O
from	O
8	O
hours	O
to	O
18	O
days	O
after	O
treatment	O
.	O

Mefloquine	O
AUC	O
was	O
reduced	O
and	O
variable	O
in	O
the	O
presence	O
of	O
diarrhea	O
.	O

Compared	O
with	O
noninfected	O
volunteers	O
,	O
clinically	O
ill	O
patients	O
displayed	O
a	O
delayed	O
time	O
to	O
reach	O
peak	O
concentration	O
(	O
p	O
less	O
than	O
0.01	O
)	O
and	O
significantly	O
higher	O
mefloquine	O
plasma	O
levels	O
in	O
the	O
first	O
2	O
days	O
after	O
administration	O
of	O
either	O
the	O
750	O
mg	O
or	O
the	O
1500	O
mg	O
dose	O
.	O

Mefloquine	O
AUC	O
was	O
similar	O
in	O
patients	O
with	O
malaria	O
and	O
healthy	O
volunteers	O
.	O

Because	O
plasma	O
levels	O
increased	O
in	O
temporal	O
relationship	O
with	O
clinical	O
illness	O
,	O
mefloquine	O
volume	O
of	O
distribution	O
or	O
clearance	O
(	O
or	O
both	O
)	O
was	O
reduced	O
during	O
the	O
acute	O
phase	O
of	O
illness	O
.	O

Efficacy	O
and	O
safety	O
of	O
de	O
novo	O
or	O
early	O
everolimus	O
with	O
low	O
cyclosporine	O
in	O
deceased-donor	O
kidney	O
transplant	O
recipients	O
at	O
specified	O
risk	O
of	O
delayed	O
graft	O
function	O
:	O
12-month	O
results	O
of	O
a	O
randomized	O
,	O
multicenter	O
trial	O
.	O

Immediate	O
or	O
early	O
use	O
of	O
proliferation	O
signal	O
inhibitor	O
(	O
PSI	O
)	O
/mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitor	O
therapy	O
can	O
avoid	O
high	O
exposure	O
to	O
calcineurin	O
inhibitors	O
but	O
concerns	O
exist	O
relating	O
to	O
the	O
risk	O
of	O
delayed	O
graft	O
function	O
(	O
DGF	O
)	O
and	O
impaired	O
wound	O
healing	O
with	O
the	O
mTOR	O
sirolimus	O
.	O

CALLISTO	O
was	O
a	O
12-month	O
,	O
prospective	O
,	O
multicenter	O
,	O
open-label	O
study	O
.	O

Deceased-donor	O
kidney	O
transplant	O
patients	O
at	O
protocol-specified	O
risk	O
of	O
DGF	O
were	O
randomized	O
to	O
start	O
everolimus	O
on	O
day	O
1	O
(	O
immediate	O
everolimus	O
,	O
IE	O
;	O
n	O
=	O
65	O
)	O
or	O
week	O
5	O
(	O
delayed	O
everolimus	O
,	O
DE	O
;	O
n	O
=	O
74	O
)	O
.	O

Incidence	O
of	O
the	O
primary	O
endpoint	O
(	O
biopsy-proven	O
acute	O
rejection	O
,	O
BPAR	O
;	O
graft	O
loss	O
,	O
death	O
,	O
DGF	O
,	O
wound	O
healing	O
complications	O
related	O
to	O
transplant	O
surgery	O
or	O
loss	O
to	O
follow-up	O
)	O
was	O
64.6	O
%	O
and	O
66.2	O
%	O
in	O
the	O
IE	O
and	O
DE	O
groups	O
,	O
respectively	O
,	O
at	O
month	O
12	O
(	O
P	O
=	O
0.860	O
)	O
.	O

The	O
overall	O
incidence	O
of	O
BPAR	O
was	O
20.1	O
%	O
.	O

Median	O
estimated	O
glomerular	O
filtration	O
rate	O
was	O
48	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
and	O
49	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
in	O
the	O
IE	O
and	O
DE	O
groups	O
,	O
respectively	O
,	O
at	O
month	O
12	O
.	O

DGF	O
and	O
wound	O
healing	O
complications	O
were	O
similar	O
between	O
groups	O
.	O

Adverse	O
events	O
led	O
to	O
study	O
drug	O
discontinuation	O
in	O
17	O
IE	O
patients	O
(	O
26.2	O
%	O
)	O
and	O
28	O
DE	O
patients	O
(	O
37.8	O
%	O
)	O
(	O
NS	O
)	O
.	O

In	O
conclusion	O
,	O
introduction	O
of	O
everolimus	O
immediately	O
or	O
early	O
posttransplant	O
in	O
DGF-risk	O
patients	O
is	O
associated	O
with	O
good	O
efficacy	O
,	O
renal	O
function	O
and	O
safety	O
profile	O
.	O

There	O
seems	O
no	O
benefit	O
in	O
delaying	O
initiation	O
of	O
everolimus	O
.	O

Amisulpride	O
versus	O
bromocriptine	O
in	O
infantile	Condition
autism	Condition
:	O
a	O
controlled	O
crossover	O
comparative	O
study	O
of	O
two	O
drugs	O
with	O
opposite	O
effects	O
on	O
dopaminergic	O
function	O
.	O

An	O
alteration	O
of	O
dopaminergic	O
(	O
DA	O
)	O
function	O
much	O
more	O
complex	O
than	O
simple	O
hyperactivity	O
has	O
been	O
evoked	O
in	O
infantile	Condition
autism	Condition
.	O

We	O
therefore	O
compared	O
the	O
clinical	O
efficacy	O
of	O
a	O
DA	O
antagonist	O
(	O
amisulpride	O
)	O
and	O
a	O
DA	O
agonist	O
(	O
bromocriptine	O
)	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
trial	O
in	O
9	SampleSize
children	Age
with	O
autism	Condition
,	O
likely	O
severely	O
mentally	Condition
retarded	Condition
.	O

Amisulpride	O
acts	O
preferentially	O
on	O
specific	O
autistic	O
symptoms	O
whereas	O
bromocriptine	O
acts	O
more	O
on	O
motor	O
hyperactivity	O
and	O
attention	O
symptoms	O
.	O

These	O
findings	O
raise	O
the	O
specificity	O
of	O
these	O
two	O
drugs	O
which	O
appear	O
to	O
act	O
preferentially	O
on	O
some	O
target	O
symptoms	O
and	O
are	O
consistent	O
with	O
some	O
clinical	O
and	O
pharmacological	O
observations	O
showing	O
a	O
sedative	O
effect	O
with	O
low	O
doses	O
of	O
DA	O
agonists	O
and	O
a	O
stimulant	O
effect	O
with	O
low	O
doses	O
of	O
DA	O
antagonists	O
such	O
as	O
the	O
benzamides	O
.	O

Herpes	O
simplex	O
virus	O
vaccine	O
in	O
recurrent	O
herpetic	O
ocular	O
infection	O
.	O

PURPOSE	O
To	O
evaluate	O
the	O
efficacy	O
of	O
an	O
antiherpetic	O
vaccine	O
in	O
recurrent	O
herpetic	O
ocular	O
infections	O
.	O

METHODS	O
Twenty	O
patients	O
with	O
herpes	O
simplex	O
virus	O
1-related	O
recurrent	O
keratitis/keratouveitis	O
were	O
prospectively	O
enrolled	O
and	O
randomly	O
assigned	O
to	O
receive	O
either	O
a	O
specific	O
vaccination	O
with	O
heat	O
shock-inactivated	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
10	O
patients	O
)	O
or	O
to	O
be	O
observed	O
as	O
controls	O
(	O
10	O
patients	O
)	O
.	O

The	O
number	O
,	O
duration	O
,	O
and	O
anatomic	O
localization	O
of	O
relapses	O
were	O
recorded	O
in	O
all	O
the	O
patients	O
for	O
12	O
months	O
before	O
inclusion	O
in	O
the	O
study	O
and	O
for	O
a	O
similar	O
period	O
after	O
the	O
assignment	O
of	O
each	O
subject	O
to	O
vaccine	O
or	O
control	O
group	O
.	O

RESULTS	O
In	O
the	O
vaccine	O
group	O
,	O
we	O
observed	O
a	O
reduction	O
both	O
in	O
the	O
number	O
(	O
p	O
=	O
0.016	O
)	O
and	O
average	O
duration	O
(	O
p	O
=	O
0.050	O
)	O
of	O
recurrences	O
,	O
whereas	O
in	O
the	O
control	O
group	O
,	O
no	O
significant	O
change	O
was	O
found	O
comparing	O
a	O
12-month	O
period	O
before	O
and	O
after	O
inclusion	O
in	O
the	O
study	O
.	O

The	O
comparison	O
between	O
the	O
two	O
groups	O
highlighted	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
(	O
p	O
=	O
0.013	O
)	O
and	O
average	O
duration	O
(	O
p	O
=	O
0.051	O
)	O
of	O
relapses	O
in	O
treated	O
subjects	O
,	O
who	O
did	O
not	O
show	O
any	O
significant	O
vaccine-induced	O
side	O
effects	O
.	O

CONCLUSION	O
The	O
use	O
of	O
a	O
vaccination	O
with	O
heat	O
shock-inactivated	O
herpes	O
simplex	O
virus	O
1	O
seems	O
to	O
be	O
able	O
to	O
reduce	O
the	O
number	O
and	O
duration	O
of	O
relapses	O
in	O
herpes	O
simplex	O
virus	O
1-related	O
keratitis/keratouveitis	O
.	O

Effectiveness	O
of	O
norgestimate	O
and	O
ethinyl	O
estradiol	O
in	O
treating	O
moderate	Condition
acne	Condition
vulgaris	Condition
.	O

BACKGROUND	O
An	O
excess	O
of	O
androgen	O
is	O
believed	O
to	O
contribute	O
to	O
development	O
of	O
acne	O
in	O
some	O
patients	O
.	O

Because	O
oral	O
contraceptives	O
(	O
OCs	O
)	O
may	O
reduce	O
the	O
active	O
androgen	O
level	O
,	O
hormonal	O
therapy	O
with	O
OCs	O
has	O
been	O
used	O
successfully	O
to	O
treat	O
patients	O
with	O
acne	Condition
,	O
although	O
this	O
treatment	O
has	O
previously	O
not	O
been	O
studied	O
in	O
placebo-controlled	O
trials	O
.	O

OBJECTIVE	O
Our	O
purpose	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
triphasic	O
,	O
combination	O
OC	O
(	O
ORTHO	O
TRI-CYCLEN	O
[	O
Ortho-McNeil	O
Pharmaceutical	O
,	O
Raritan	O
,	O
N.J.	O
]	O
,	O
norgestimate/ethinyl	O
estradiol	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
treatment	O
of	O
moderate	O
acne	O
vulgaris	O
.	O

METHODS	O
Two	SampleSize
hundred	SampleSize
fifty-seven	SampleSize
healthy	Condition
female	Sex
subjects	O
,	O
15	Age
to	Age
49	Age
years	Age
of	O
age	O
with	O
moderate	Condition
acne	Condition
vulgaris	Condition
,	O
were	O
enrolled	O
in	O
a	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O

Each	O
month	O
for	O
6	O
months	O
,	O
subjects	O
received	O
either	O
3	O
consecutive	O
weeks	O
of	O
the	O
OC	O
(	O
i.e.	O
,	O
tablets	O
containing	O
a	O
fixed	O
dose	O
of	O
ethinyl	O
estradiol	O
[	O
0.035	O
mg	O
]	O
and	O
increasing	O
doses	O
of	O
norgestimate	O
[	O
0.180	O
mg	O
,	O
0.215	O
mg	O
,	O
0.250	O
mg	O
]	O
)	O
followed	O
by	O
7	O
days	O
of	O
inactive	O
drug	O
or	O
placebo	O
(	O
color-matched	O
tablets	O
)	O
.	O

Efficacy	O
was	O
assessed	O
by	O
facial	O
acne	O
lesion	O
counts	O
,	O
an	O
investigator	O
's	O
global	O
assessment	O
,	O
a	O
subject	O
's	O
self-assessment	O
,	O
and	O
an	O
analysis	O
of	O
within-cycle	O
variation	O
(	O
cycle	O
6	O
)	O
in	O
lesion	O
counts	O
.	O

RESULTS	O
Of	O
the	O
160	SampleSize
subjects	O
in	O
whom	O
efficacy	O
could	O
be	O
evaluated	O
,	O
the	O
OC	O
group	O
showed	O
a	O
statistically	O
significantly	O
greater	O
improvement	O
than	O
the	O
placebo	O
group	O
for	O
all	O
primary	O
efficacy	O
measures	O
.	O

The	O
mean	O
decrease	O
in	O
inflammatory	O
lesion	O
count	O
from	O
baseline	O
to	O
cycle	O
6	O
was	O
11.8	O
(	O
62.0	O
%	O
)	O
versus	O
7.6	O
(	O
38.6	O
%	O
)	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
and	O
the	O
mean	O
decrease	O
in	O
total	O
lesion	O
count	O
was	O
29.1	O
(	O
53.1	O
%	O
)	O
versus	O
14.1	O
(	O
26.8	O
%	O
)	O
(	O
p	O
=	O
0.0001	O
)	O
in	O
the	O
OC	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

In	O
the	O
investigator	O
's	O
global	O
assessment	O
,	O
93.7	O
%	O
of	O
the	O
active	O
treatment	O
group	O
versus	O
65.4	O
%	O
of	O
the	O
placebo	O
group	O
were	O
rated	O
as	O
improved	O
at	O
the	O
end	O
of	O
the	O
study	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Six	O
of	O
the	O
seven	O
secondary	O
efficacy	O
measures	O
(	O
total	O
comedones	O
,	O
open	O
comedones	O
,	O
closed	O
comedones	O
,	O
papules	O
,	O
pustules	O
,	O
and	O
the	O
subject	O
's	O
self-assessment	O
of	O
study	O
treatment	O
)	O
were	O
also	O
significantly	O
more	O
favorable	O
in	O
the	O
OC	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

CONCLUSION	O
An	O
OC	O
containing	O
0.035	O
mg	O
of	O
ethinyl	O
estradiol	O
combined	O
with	O
the	O
triphasic	O
regimen	O
of	O
norgestimate	O
is	O
a	O
safe	O
and	O
effective	O
treatment	O
of	O
moderate	O
acne	O
vulgaris	O
in	O
women	Sex
with	O
no	O
known	O
contraindication	O
to	O
OC	O
therapy	O
.	O

The	O
effect	O
of	O
visual	O
supports	O
on	O
performance	O
of	O
the	O
TGMD-2	O
for	O
children	Age
with	O
autism	Condition
spectrum	Condition
disorder	Condition
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
visual	O
supports	O
on	O
the	O
performance	O
of	O
the	O
Test	O
of	O
Gross	O
Motor	O
Development	O
(	O
TGMD-2	O
)	O
for	O
children	Age
with	O
autism	Condition
spectrum	Condition
disorder	Condition
(	Condition
ASD	Condition
)	Condition
.	O

Participants	O
(	O
N	O
=	O
22	SampleSize
)	O
performed	O
the	O
TGMD-2	O
under	O
three	O
different	O
protocols	O
(	O
traditional	O
protocol	O
,	O
picture	O
task	O
card	O
protocol	O
,	O
and	O
picture	O
activity	O
schedule	O
protocol	O
)	O
.	O

Gross	O
motor	O
quotient	O
scores	O
on	O
the	O
TGMD-2	O
were	O
measured	O
and	O
statistically	O
analyzed	O
using	O
a	O
within-subjects	O
repeated-measures	O
ANOVA	O
.	O

Results	O
indicated	O
statistically	O
significant	O
differences	O
between	O
protocols	O
,	O
while	O
post	O
hoc	O
tests	O
indicated	O
that	O
the	O
picture	O
task	O
card	O
condition	O
produced	O
significantly	O
higher	O
gross	O
motor	O
quotient	O
scores	O
than	O
the	O
traditional	O
protocol	O
and	O
the	O
picture	O
activity	O
schedule	O
.	O

The	O
results	O
suggest	O
that	O
more	O
accurate	O
gross	O
motor	O
quotient	O
scores	O
on	O
the	O
TGMD-2	O
by	O
children	Age
with	O
ASD	Condition
can	O
be	O
elicited	O
using	O
the	O
picture	O
task	O
card	O
protocol	O
.	O

The	O
efficacy	O
of	O
melatonin	O
for	O
sleep	O
problems	O
in	O
children	O
with	O
autism	O
,	O
fragile	O
X	O
syndrome	O
,	O
or	O
autism	O
and	O
fragile	O
X	O
syndrome	O
.	O

STUDY	O
OBJECTIVE	O
To	O
determine	O
the	O
efficacy	O
of	O
melatonin	O
on	O
sleep	Condition
problems	Condition
in	O
children	O
with	O
autistic	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
and	O
fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
.	O

METHODS	O
A	O
4-week	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
crossover	O
design	O
was	O
conducted	O
following	O
a	O
1-week	O
baseline	O
period	O
.	O

Either	O
melatonin	O
,	O
3	O
mg	O
,	O
or	O
placebo	O
was	O
given	O
to	O
participants	O
for	O
2	O
weeks	O
and	O
then	O
alternated	O
for	O
another	O
2	O
weeks	O
.	O

Sleep	O
variables	O
,	O
including	O
sleep	O
duration	O
,	O
sleep-onset	O
time	O
,	O
sleep-onset	O
latency	O
time	O
,	O
and	O
the	O
number	O
of	O
night	O
awakenings	O
,	O
were	O
recorded	O
using	O
an	O
Actiwatch	O
and	O
from	O
sleep	O
diaries	O
completed	O
by	O
parents	O
.	O

All	O
participants	O
had	O
been	O
thoroughly	O
assessed	O
for	O
ASD	O
and	O
also	O
had	O
DNA	O
testing	O
for	O
the	O
diagnosis	O
of	O
FXS	O
.	O

RESULTS	O
Data	O
were	O
successfully	O
obtained	O
from	O
the	O
12	Condition
of	O
18	Condition
subjects	O
who	O
completed	O
the	O
study	O
(	O
11	Condition
males	O
,	O
age	O
range	O
2	O
to	O
15.25	O
years	O
,	O
mean	O
5.47	O
,	O
SD	O
3.6	O
)	O
.	O

Five	Condition
participants	O
met	O
diagnostic	O
criteria	O
for	O
ASD	O
,	O
3	O
for	O
FXS	O
alone	O
,	O
3	O
for	O
FXS	O
and	O
ASD	O
,	O
and	O
1	O
for	O
fragile	O
X	O
premutation	O
.	O

Eight	Condition
out	O
of	O
12	Condition
had	O
melatonin	O
first	O
.	O

The	O
conclusions	O
from	O
a	O
nonparametric	O
repeated-measures	O
technique	O
indicate	O
that	O
mean	O
night	O
sleep	O
duration	O
was	O
longer	O
on	O
melatonin	O
than	O
placebo	O
by	O
21	O
minutes	O
(	O
p	O
=	O
.02	O
)	O
,	O
mean	O
sleep-onset	O
latency	O
was	O
shorter	O
by	O
28	O
minutes	O
(	O
p	O
=	O
.0001	O
)	O
,	O
and	O
mean	O
sleep-onset	O
time	O
was	O
earlier	O
by	O
42	O
minutes	O
(	O
p	O
=	O
.02	O
)	O
.	O

CONCLUSION	O
The	O
results	O
of	O
this	O
study	O
support	O
the	O
efficacy	O
and	O
tolerability	O
of	O
melatonin	O
treatment	O
for	O
sleep	O
problems	O
in	O
children	O
with	O
ASD	O
and	O
FXS	O
.	O

Evaluation	O
of	O
an	O
aquatics	O
programme	O
on	O
fitness	O
parameters	O
of	O
individuals	O
with	O
a	O
brain	Condition
injury	Condition
.	O

The	O
primary	O
objective	O
was	O
to	O
determine	O
the	O
effect	O
of	O
an	O
aquatic	O
exercise	O
programme	O
on	O
the	O
physical	O
fitness	O
of	O
people	O
with	O
a	O
brain	Condition
injury	Condition
.	O

A	O
pre-test-post-test	O
randomized-groups	O
design	O
was	O
conducted	O
.	O

Sixteen	SampleSize
outpatients	O
with	O
a	O
brain	Condition
injury	Condition
were	O
included	O
in	O
the	O
study	O
.	O

Eight	O
participants	O
were	O
assigned	O
to	O
an	O
aquatic	O
exercise	O
group	O
and	O
eight	O
to	O
a	O
control	O
group	O
.	O

The	O
components	O
of	O
physical	O
fitness	O
measured	O
included	O
cardiovascular	O
endurance	O
,	O
body	O
composition	O
,	O
muscular	O
strength	O
and	O
endurance	O
and	O
flexibility	O
.	O

Measurements	O
were	O
taken	O
pre-	O
and	O
post-programme	O
.	O

Results	O
indicated	O
an	O
increase	O
in	O
components	O
of	O
physical	O
fitness	O
for	O
the	O
experimental	O
group	O
but	O
not	O
the	O
control	O
group	O
.	O

Increases	O
in	O
fitness	O
were	O
reported	O
as	O
having	O
a	O
positive	O
impact	O
on	O
the	O
functional	O
capacity	O
of	O
individuals	O
in	O
the	O
exercise	O
group	O
as	O
well	O
as	O
enhancing	O
the	O
individual	O
's	O
ability	O
to	O
complete	O
activities	O
of	O
daily	O
living	O
successfully	O
.	O

Results	O
indicate	O
that	O
aquatic	O
exercise	O
may	O
positively	O
impact	O
the	O
primary	O
and	O
secondary	O
physical	O
injuries	O
caused	O
by	O
a	O
brain	O
injury	O
.	O

Chemotherapy	O
for	O
operable	Condition
gastric	Condition
cancer	Condition
:	Condition
results	O
of	O
the	O
Dutch	O
randomised	O
FAMTX	O
trial	O
.	O

The	O
Dutch	Condition
Gastric	O
Cancer	O
Group	O
(	O
DGCG	O
)	O
.	O

The	O
aim	O
of	O
this	O
trial	O
was	O
to	O
investigate	O
whether	O
pre-operative	O
chemotherapy	O
leads	O
to	O
a	O
15	O
%	O
higher	O
curative	O
resectability	O
rate	O
in	O
patients	O
with	O
operable	O
gastric	O
cancer	O
.	O

In	O
this	O
randomised	O
trial	O
,	O
patients	O
were	O
allocated	O
to	O
receive	O
either	O
four	O
courses	O
of	O
chemotherapy	O
using	O
5-fluorouracil	O
,	O
doxorubicin	O
and	O
methotrexate	O
(	O
FAMTX	O
)	O
prior	O
to	O
surgery	O
or	O
to	O
undergo	O
surgery	O
only	O
.	O

Patients	O
younger	O
than	O
75	O
years	O
of	O
age	O
with	O
a	O
good	O
physical	O
and	O
mental	O
condition	O
and	O
a	O
histologically	O
proven	O
adenocarcinoma	O
of	O
the	O
stomach	O
without	O
clinical	O
or	O
radiographic	O
(	O
computed	O
tomography	O
scan	O
)	O
evidence	O
of	O
distant	O
metastases	O
were	O
eligible	O
for	O
this	O
trial	O
.	O

Early	O
gastric	O
cancer	O
or	O
cardia	O
carcinoma	O
were	O
excluded	O
.	O

The	O
response	O
to	O
chemotherapy	O
was	O
evaluated	O
after	O
two	O
and	O
four	O
courses	O
.	O

In	O
case	O
of	O
progressive	O
disease	O
(	O
PD	O
)	O
after	O
two	O
courses	O
,	O
patients	O
were	O
operated	O
upon	O
as	O
soon	O
as	O
possible	O
.	O

Otherwise	O
complete	O
response	O
(	O
CR	O
)	O
partial	O
response	O
(	O
PR	O
)	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
two	O
more	O
courses	O
were	O
scheduled	O
.	O

The	O
standard	O
surgical	O
procedure	O
was	O
a	O
limited	O
lymphadenectomy	O
(	O
D1	O
)	O
with	O
staging	O
biopsy	O
of	O
the	O
para-aortic	O
lymph	O
nodes	O
.	O

Between	O
September	O
1993	O
and	O
February	O
1996	O
,	O
56	O
eligible	O
and	O
evaluable	O
patients	O
were	O
entered	O
:	O
27	O
were	O
randomised	O
to	O
receive	O
FAMTX	O
before	O
surgery	O
and	O
29	O
to	O
undergo	O
surgery	O
only	O
.	O

In	O
the	O
FAMTX	O
+	O
surgery	O
treatment	O
group	O
,	O
15/27	O
(	O
56	O
%	O
)	O
had	O
curative	O
resections	O
versus	O
18/29	O
(	O
62	O
%	O
)	O
in	O
the	O
surgery	O
only	O
arm	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
frequency	O
of	O
TNM	O
stages	O
I	O
+	O
II	O
in	O
both	O
treatment	O
arms	O
:	O
15/27	O
versus	O
15/29	O
.	O

Due	O
to	O
PD	O
and/or	O
toxicity	O
,	O
12	O
patients	O
(	O
44	O
%	O
)	O
could	O
not	O
complete	O
the	O
planned	O
four	O
courses	O
of	O
FAMTX	O
.	O

Response	O
evaluation	O
after	O
chemotherapy	O
was	O
possible	O
in	O
25	O
patients	O
:	O
2	O
CR	O
,	O
6	O
PR	O
,	O
8	O
SD	O
and	O
9	O
PD	O
.	O

The	O
difference	O
in	O
curative	O
resectability	O
rate	O
was	O
6.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
-32	O
to	O
+19	O
%	O
)	O
in	O
favour	O
of	O
surgery	O
only	O
.	O

Downstaging	O
for	O
stages	O
I	O
+	O
II	O
did	O
not	O
occur	O
.	O

PD	O
was	O
more	O
often	O
the	O
reason	O
for	O
not	O
completing	O
the	O
planned	O
four	O
courses	O
than	O
toxicity	O
.	O

More	O
active	O
regimens	O
than	O
FAMTX	O
are	O
required	O
for	O
future	O
randomised	O
trials	O
.	O

Argon	O
laser	O
trabeculoplasty	O
in	O
primary	Condition
open-angle	Condition
glaucoma	Condition
--	O
results	O
in	O
black	O
Jamaican	O
population	O
.	O

A	O
controlled	O
,	O
randomised	O
,	O
prospective	O
trial	O
of	O
Argon	O
laser	O
trabeculoplasty	O
(	O
ALT	O
)	O
was	O
carried	O
out	O
on	O
48	O
eyes	O
of	O
30	SampleSize
black	O
Jamaican	O
patients	O
with	O
primary	Condition
open-angle	Condition
glaucoma	Condition
.	O

All	O
eyes	O
had	O
uncontrolled	Condition
intra-ocular	Condition
pressures	Condition
(	Condition
greater	Condition
than	Condition
or	Condition
equal	Condition
to	Condition
22	Condition
mm	Condition
Hg	Condition
)	Condition
despite	O
medical	O
therapy	O
.	O

Treatment	O
was	O
successful	O
in	O
controlling	O
intraocular	O
pressure	O
in	O
68	O
%	O
of	O
eyes	O
after	O
12	O
months	O
follow-up	O
(	O
p	O
=	O
0.004	O
)	O
.	O

The	O
average	O
drop	O
in	O
intraocular	O
pressure	O
attributable	O
to	O
ALT	O
was	O
6.6	O
mmHg	O
.	O

Argon	O
laser	O
trabeculoplasty	O
is	O
an	O
effective	O
adjunct	O
in	O
managing	O
to	O
control	O
intraocular	O
pressure	O
in	O
black	O
Jamaican	O
glaucoma	Condition
patients	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
fluvoxamine	O
in	O
adults	Age
with	O
autistic	Condition
disorder	O
.	O

BACKGROUND	O
Autistic	O
disorder	O
is	O
characterized	O
by	O
a	O
fundamental	O
disturbance	O
in	O
social	O
interaction	O
,	O
impairments	O
in	O
communication	O
,	O
and	O
a	O
markedly	O
restricted	O
repertoire	O
of	O
activities	O
and	O
interests	O
.	O

Abnormalities	O
in	O
the	O
serotonin	O
neurotransmitter	O
system	O
have	O
been	O
identified	O
in	O
some	O
persons	O
with	O
autism	O
.	O

No	O
consistently	O
effective	O
and	O
safe	O
drugs	O
have	O
been	O
developed	O
for	O
treating	O
the	O
symptoms	O
of	O
autism	O
.	O

METHODS	O
Thirty	SampleSize
adults	O
with	O
autistic	Condition
disorder	Condition
completed	O
a	O
12-week	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
the	O
potent	O
and	O
selective	O
serotonin	O
uptake	O
inhibitor	O
fluvoxamine	O
maleate	O
.	O

Behavioral	O
ratings	O
were	O
obtained	O
at	O
baseline	O
and	O
after	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
of	O
treatment	O
.	O

RESULTS	O
Eight	O
(	O
53	O
%	O
)	O
of	O
15	SampleSize
patients	O
in	O
the	O
fluvoxamine-treated	O
group	O
were	O
categorized	O
as	O
responders	O
compared	O
with	O
none	O
of	O
15	SampleSize
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
.001	O
)	O
.	O

Fluvoxamine	O
was	O
superior	O
to	O
placebo	O
in	O
reducing	O
repetitive	O
thoughts	O
and	O
behavior	O
(	O
P	O
<	O
.001	O
)	O
,	O
maladaptive	O
behavior	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
aggression	O
(	O
P	O
<	O
.03	O
)	O
,	O
and	O
in	O
improving	O
some	O
aspects	O
of	O
social	O
relatedness	O
(	O
P	O
<	O
.04	O
)	O
,	O
especially	O
language	O
usage	O
(	O
P	O
<	O
.008	O
)	O
.	O

Treatment	O
response	O
was	O
not	O
correlated	O
with	O
age	O
level	O
of	O
autistic	O
behavior	O
,	O
or	O
full-scale	O
IQ	O
.	O

Other	O
than	O
mild	O
sedation	O
and	O
nausea	O
in	O
a	O
few	O
patients	O
,	O
fluvoxamine	O
was	O
well	O
tolerated	O
.	O

No	O
dyskinesias	O
,	O
adverse	O
cardiovascular	O
events	O
,	O
or	O
seizures	O
occurred	O
.	O

CONCLUSIONS	O
Fluvoxamine	O
is	O
more	O
effective	O
than	O
placebo	O
in	O
the	O
short-term	O
treatment	O
of	O
the	O
symptoms	O
of	O
autistic	O
disorder	O
in	O
adults	O
.	O

Controlled	O
studies	O
of	O
fluvoxamine	O
and	O
other	O
potent	O
and	O
selective	O
serotonin	O
uptake	O
inhibitors	O
seem	O
warranted	O
in	O
children	O
and	O
adolescents	O
with	O
autism	O
.	O

Safety	O
and	O
efficacy	O
of	O
donepezil	O
in	O
children	O
and	O
adolescents	O
with	O
autism	O
:	O
neuropsychological	O
measures	O
.	O

OBJECTIVE	O
There	O
has	O
been	O
recent	O
interest	O
in	O
the	O
use	O
of	O
cognitive	O
enhancing	O
drugs	O
,	O
such	O
as	O
cholinesterase	O
inhibitors	O
,	O
as	O
a	O
possible	O
treatment	O
for	O
executive	O
functioning	O
(	O
EF	O
)	O
deficits	O
in	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
tolerability	O
,	O
safety	O
,	O
and	O
efficacy	O
of	O
donepezil	O
on	O
EF	O
in	O
a	O
sample	O
of	O
children	O
and	O
adolescents	O
with	O
ASD	O
.	O

METHOD	O
Thirty-four	O
children	O
and	O
adolescents	O
with	O
ASD	O
(	O
age	O
range	O
8-17	O
years	O
;	O
IQ	O
>	O
75	O
)	O
were	O
enrolled	O
in	O
a	O
10-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
donepezil	O
(	O
doses	O
of	O
5	O
and	O
10	O
mg	O
)	O
,	O
followed	O
by	O
a	O
10-week	O
open	O
label	O
trial	O
for	O
placebo	O
nonresponders	O
.	O

RESULTS	O
The	O
effect	O
of	O
donepezil	O
treatment	O
on	O
EF	O
was	O
examined	O
.	O

Despite	O
improvement	O
on	O
a	O
number	O
of	O
EF	O
measures	O
,	O
no	O
statistically	O
significant	O
between-group	O
differences	O
were	O
found	O
(	O
with	O
gains	O
observed	O
for	O
both	O
the	O
placebo	O
and	O
donepezil	O
groups	O
)	O
.	O

CONCLUSIONS	O
The	O
results	O
suggest	O
that	O
short-term	O
treatment	O
with	O
donepezil	O
may	O
have	O
limited	O
impact	O
on	O
cognitive	O
functioning	O
in	O
ASD	O
.	O

Future	O
controlled	O
trials	O
may	O
need	O
to	O
consider	O
a	O
longer	O
treatment	O
period	O
to	O
detect	O
significant	O
gains	O
on	O
EF	O
measures	O
.	O

Levels	O
of	O
opioid	Condition
physical	Condition
dependence	Condition
in	O
heroin	Condition
addicts	Condition
.	O

The	O
levels	O
of	O
opioid	O
physical	O
dependence	O
in	O
a	O
group	O
of	O
long-term	O
heroin	Condition
addicts	Condition
were	O
ascertained	O
by	O
measuring	O
the	O
severity	O
of	O
the	O
opioid	O
withdrawal	O
syndrome	O
before	O
and	O
after	O
pharmacological	O
challenge	O
with	O
either	O
0.4	O
mg	O
naloxone	O
or	O
placebo	O
.	O

Prior	O
to	O
challenge	O
,	O
patients	O
manifested	O
some	O
subjective	O
symptoms	O
but	O
few	O
objective	O
signs	O
of	O
opioid	O
withdrawal	O
.	O

Patients	O
who	O
received	O
placebo	O
(	O
n	O
=	O
18	SampleSize
)	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
score	O
on	O
one	O
of	O
three	O
rating	O
scales	O
used	O
to	O
assess	O
opioid	O
withdrawal	O
.	O

Patients	O
who	O
received	O
naloxone	O
(	O
n	O
=	O
58	SampleSize
)	O
showed	O
significant	O
increases	O
in	O
mean	O
scores	O
on	O
all	O
three	O
rating	O
scales	O
,	O
but	O
this	O
was	O
due	O
primarily	O
to	O
increases	O
observed	O
in	O
a	O
minority	O
of	O
patients	O
.	O

Sixty-one	O
percent	O
of	O
patients	O
failed	O
to	O
manifest	O
clinically	O
significant	O
changes	O
in	O
subjective	O
symptoms	O
,	O
and	O
74	O
%	O
of	O
patients	O
failed	O
to	O
manifest	O
clinically	O
significant	O
changes	O
in	O
objective	O
signs	O
of	O
opioid	O
withdrawal	O
following	O
naloxone	O
administration	O
.	O

The	O
results	O
suggest	O
that	O
a	O
substantial	O
subgroup	O
of	O
heroin	O
addicts	O
are	O
able	O
to	O
use	O
opioids	O
regularly	O
while	O
maintaining	O
relatively	O
low	O
levels	O
of	O
physical	O
dependence	O
.	O

Low	O
body	O
mass	O
index	O
and	O
dyslipidemia	O
in	O
dialysis	Condition
patients	Condition
linked	O
to	O
elevated	O
plasma	O
fibroblast	O
growth	O
factor	O
23	O
.	O

BACKGROUND	O
Fibroblast	O
growth	O
factor	O
23	O
(	O
FGF23	O
)	O
has	O
been	O
associated	O
with	O
death	O
in	O
dialysis	O
patients	O
.	O

Since	O
FGF23	O
shares	O
structural	O
features	O
with	O
FGF19	O
subfamily	O
members	O
that	O
exert	O
hormonal	O
control	O
of	O
fat	O
mass	O
,	O
we	O
hypothesized	O
that	O
high	O
circulating	O
FGF23	O
concentrations	O
would	O
be	O
associated	O
with	O
the	O
development	O
of	O
a	O
uremic	O
lipid	O
profile	O
and	O
lower	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

METHODS	O
This	O
study	O
was	O
conducted	O
among	O
654	O
patients	O
receiving	O
chronic	O
hemodialysis	O
.	O

C-terminal	O
FGF23	O
concentrations	O
were	O
measured	O
in	O
stored	O
plasma	O
samples	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
examine	O
the	O
cross-sectional	O
associations	O
of	O
plasma	O
FGF23	O
concentrations	O
with	O
BMI	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
low-density	O
lipoprotein-cholesterol	O
(	O
LDL-C	O
)	O
,	O
high-density	O
lipoprotein-cholesterol	O
(	O
HDL-C	O
)	O
and	O
triglycerides	O
.	O

Cox	O
proportional	O
hazard	O
models	O
were	O
used	O
to	O
examine	O
the	O
association	O
between	O
FGF23	O
concentrations	O
and	O
all-cause	O
mortality	O
.	O

RESULTS	O
Participants	O
had	O
a	O
mean	O
age	O
of	O
60	O
?	O
11	O
years	O
and	O
a	O
median	O
(	O
IQR	O
)	O
FGF23	O
concentration	O
of	O
4,212	O
(	O
1,411-13,816	O
)	O
RU/ml	O
.	O

An	O
increase	O
per	O
SD	O
in	O
log10	O
FGF23	O
was	O
associated	O
with	O
lower	O
BMI	O
(	O
?	O
=	O
-1.11	O
;	O
p	O
=	O
0.008	O
)	O
,	O
TC	O
(	O
?	O
=	O
-6.46	O
;	O
p	O
=	O
0.02	O
)	O
,	O
LDL-C	O
(	O
?	O
=	O
-4.73	O
;	O
p	O
=	O
0.04	O
)	O
and	O
HDL-C	O
(	O
?	O
=	O
-2.14	O
;	O
p	O
=	O
0.03	O
)	O
;	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
race	O
,	O
cardiovascular	O
risk	O
factors	O
,	O
serum	O
albumin	O
,	O
markers	O
of	O
mineral	O
metabolism	O
,	O
and	O
use	O
of	O
lipid-lowering	O
drugs	O
.	O

The	O
association	O
of	O
FGF23	O
with	O
death	O
was	O
attenuated	O
after	O
adjustment	O
for	O
HDL-C	O
(	O
HR	O
of	O
highest	O
quartile	O
1.53	O
,	O
95	O
%	O
CI	O
1.06-2.20	O
compared	O
to	O
lowest	O
quartile	O
)	O
.	O

CONCLUSION	O
These	O
results	O
indicate	O
that	O
higher	O
plasma	O
FGF23	O
levels	O
are	O
associated	O
with	O
lower	O
BMI	O
and	O
dyslipidemia	O
in	O
dialysis	O
patients	O
.	O

The	O
association	O
between	O
FGF23	O
and	O
death	O
may	O
be	O
mediated	O
through	O
unexplored	O
metabolic	O
risk	O
factors	O
unrelated	O
to	O
mineral	O
metabolism	O
.	O

Improving	O
the	O
immunogenicity	O
of	O
pneumococcal	O
conjugate	O
vaccine	O
in	O
HIV-infected	O
adults	O
with	O
a	O
toll-like	O
receptor	O
9	O
agonist	O
adjuvant	O
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

BACKGROUND	O
Persons	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
are	O
often	O
hyporesponsive	O
to	O
immunization	O
,	O
including	O
pneumococcal	O
vaccines	O
.	O

We	O
hypothesized	O
that	O
adding	O
CPG	O
7909	O
,	O
a	O
toll-like	O
receptor	O
9	O
(	O
TLR9	O
)	O
agonist	O
and	O
vaccine	O
adjuvant	O
,	O
to	O
7-valent	O
pneumococcal	O
conjugate	O
vaccine	O
(	O
7vPnC	O
)	O
would	O
increase	O
its	O
immunogenicity	O
in	O
HIV-infected	O
adults	O
.	O

METHODS	O
We	O
performed	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
phase	O
1b/2a	O
trial	O
randomizing	O
HIV-positive	O
patients	O
to	O
receive	O
double	O
doses	O
of	O
7vPnC	O
(	O
Prevnar	O
)	O
at	O
0	O
and	O
3	O
months	O
and	O
1	O
dose	O
of	O
23-valent	O
pneumococcal	O
polysaccharide	O
vaccine	O
(	O
PPV-23	O
;	O
Pneumo	O
Novum	O
)	O
at	O
9	O
months	O
,	O
with	O
experimental	O
patients	O
receiving	O
1	O
mg	O
of	O
CPG	O
7909	O
added	O
to	O
each	O
of	O
their	O
3	O
vaccine	O
doses	O
;	O
control	O
patients	O
had	O
phosphate-buffered	O
saline	O
added	O
instead	O
.	O

Immunogenicity	O
and	O
safety	O
were	O
evaluated	O
for	O
up	O
to	O
10	O
months	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
vaccine	O
high	O
responders	O
at	O
9	O
months	O
,	O
defined	O
as	O
a	O
2-fold	O
increase	O
in	O
IgG	O
levels	O
to	O
>	O
or	O
=	O
1	O
microg/mL	O
for	O
at	O
least	O
5	O
of	O
7	O
of	O
the	O
7vPnC	O
serotypes	O
.	O

RESULTS	O
Ninety-seven	O
participants	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
proportion	O
of	O
vaccine	O
high	O
responders	O
was	O
higher	O
in	O
the	O
experimental	O
group	O
(	O
n	O
=	O
48	O
)	O
than	O
among	O
controls	O
(	O
n	O
=	O
49	O
;	O
48.8	O
%	O
vs	O
25.0	O
%	O
;	O
P	O
=	O
.02	O
)	O
at	O
9	O
months	O
.	O

Greater	O
proportions	O
of	O
high	O
responders	O
were	O
also	O
observed	O
at	O
3	O
(	O
51.1	O
%	O
vs	O
39.6	O
%	O
;	O
P	O
=	O
.26	O
)	O
,	O
4	O
(	O
77.3	O
%	O
vs	O
56.3	O
%	O
;	O
P	O
=	O
.03	O
)	O
,	O
and	O
10	O
months	O
(	O
87.8	O
%	O
vs	O
51.1	O
%	O
;	O
P	O
<	O
.001	O
)	O
.	O

Mild	O
systemic	O
and	O
injection	O
site	O
reactions	O
to	O
7vPnC	O
were	O
more	O
common	O
in	O
the	O
experimental	O
group	O
than	O
the	O
control	O
group	O
(	O
100	O
%	O
vs	O
81.3	O
%	O
;	O
P	O
=	O
.002	O
)	O
.	O

CPG	O
7909	O
did	O
not	O
increase	O
non-7vPnC	O
IgG	O
levels	O
after	O
PPV-23	O
immunization	O
.	O

No	O
adverse	O
effects	O
on	O
CD4	O
(	O
+	O
)	O
cell	O
count	O
or	O
organ	O
functions	O
occurred	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
The	O
addition	O
of	O
a	O
TLR9	O
agonist	O
to	O
7vPnC	O
significantly	O
enhanced	O
the	O
proportion	O
of	O
vaccine	O
high	O
responders	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT00562939	O
.	O

Oral	O
rizatriptan	O
versus	O
oral	O
sumatriptan	O
:	O
a	O
direct	O
comparative	O
study	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	O
.	O

Rizatriptan	O
030	O
Study	O
Group	O
.	O

Rizatriptan	O
is	O
a	O
potent	O
,	O
oral	O
,	O
5-HT1B/1D	O
agonist	O
with	O
more	O
rapid	O
absorption	O
and	O
higher	O
bioavailability	O
than	O
oral	O
sumatriptan	O
.	O

It	O
was	O
postulated	O
that	O
this	O
would	O
result	O
in	O
more	O
rapid	O
onset	O
of	O
effect	O
.	O

This	O
randomized	O
,	O
double-blind	O
,	O
triple-dummy	O
,	O
parallel-groups	O
study	O
compared	O
rizatriptan	O
5	O
mg	O
,	O
rizatriptan	O
10	O
mg	O
,	O
sumatriptan	O
100	O
mg	O
,	O
and	O
placebo	O
in	O
1268	O
outpatients	O
treating	O
a	O
single	O
migraine	O
attack	O
.	O

Headache	O
relief	O
rates	O
after	O
rizatriptan	O
10	O
mg	O
were	O
consistently	O
higher	O
than	O
sumatriptan	O
at	O
all	O
time	O
points	O
up	O
to	O
2	O
hours	O
,	O
with	O
significance	O
at	O
1	O
hour	O
(	O
37	O
%	O
versus	O
28	O
%	O
,	O
P	O
=	O
0.010	O
)	O
.	O

All	O
active	O
agents	O
were	O
significantly	O
superior	O
to	O
placebo	O
with	O
regard	O
to	O
headache	O
relief	O
and	O
pain	O
freedom	O
at	O
2	O
hours	O
(	O
P	O
<	O
or	O
=	O
0.001	O
)	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
of	O
time	O
to	O
pain	O
relief	O
through	O
2	O
hours	O
demonstrated	O
that	O
,	O
after	O
adjustment	O
for	O
age	O
imbalance	O
,	O
rizatriptan	O
10	O
mg	O
had	O
earlier	O
onset	O
than	O
sumatriptan	O
100	O
mg	O
(	O
P	O
=	O
0.032	O
;	O
hazard	O
ratio	O
1.21	O
)	O
.	O

Rizatriptan	O
10	O
mg	O
was	O
also	O
superior	O
to	O
sumatriptan	O
on	O
pain-free	O
response	O
(	O
P	O
=	O
0.032	O
)	O
,	O
reduction	O
in	O
functional	O
disability	O
(	O
P	O
=	O
0.015	O
)	O
,	O
and	O
relief	O
of	O
nausea	O
at	O
2	O
hours	O
(	O
P	O
=	O
0.010	O
)	O
.	O

Significantly	O
fewer	O
drug-related	O
clinical	O
adverse	O
events	O
were	O
reported	O
after	O
rizatriptan	O
10	O
mg	O
(	O
33	O
%	O
,	O
P	O
=	O
0.014	O
)	O
compared	O
with	O
sumatriptan	O
100	O
mg	O
(	O
41	O
%	O
)	O
.	O

We	O
conclude	O
that	O
rizatriptan	O
10	O
mg	O
has	O
a	O
rapid	O
onset	O
of	O
action	O
and	O
relieves	O
headache	O
and	O
associated	O
symptoms	O
more	O
effectively	O
than	O
sumatriptan	O
100	O
mg	O
.	O

Prospective	O
randomised	O
multicentre	O
trial	O
with	O
the	O
birth	O
trainer	O
EPI-NO	O
for	O
the	O
prevention	O
of	O
perineal	Condition
trauma	Condition
.	Condition

BACKGROUND	O
In	O
several	O
non-randomised	O
trials	O
training	O
with	O
EPI-NO	O
increased	O
the	O
rate	O
of	O
intact	O
perineum	O
and	O
decreased	O
episiotomy	O
rates	O
,	O
shortened	O
the	O
second	O
stage	O
of	O
labour	O
and	O
lowered	O
use	O
of	O
pain	O
killers	O
.	O

AIMS	O
To	O
verify	O
the	O
preliminary	O
results	O
with	O
EPI-NO	O
in	O
a	O
prospective	O
randomised	O
trial	O
.	O

METHODS	O
Randomised	O
,	O
single-blind	Condition
multicentre	O
trial	O
in	O
four	O
university	O
hospitals	O
in	O
Germany	O
including	O
276	SampleSize
primigravidae	O
.	O

RESULTS	O
After	O
training	O
with	O
EPI-NO	O
we	O
observed	O
a	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
intact	O
perineum	O
(	O
37.4	O
%	O
vs	O
25.7	O
%	O
;	O
P	O
=	O
0.05	O
)	O
and	O
a	O
tendency	O
towards	O
lower	O
episiotomy	O
rates	O
(	O
41.9	O
%	O
vs	O
50.5	O
%	O
;	O
P	O
=	O
0.11	O
)	O
.	O

We	O
found	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
regarding	O
incidence	O
of	O
perineal	O
tears	O
,	O
duration	O
of	O
second	O
stage	O
of	O
labour	O
,	O
use	O
of	O
pain	O
relief	O
and	O
rate	O
of	O
vaginal	O
infection	O
.	O

CONCLUSIONS	O
Training	O
with	O
EPI-NO	O
increases	O
significantly	O
the	O
likelihood	O
of	O
having	O
an	O
intact	O
perineum	O
and	O
reduces	O
the	O
episiotomy	O
rate	O
.	O

Double-blind	O
,	O
placebo-controlled	O
,	O
dose-ranging	O
study	O
of	O
new	O
recombinant	O
hypoallergenic	O
Bet	O
v	O
1	O
in	O
an	O
environmental	O
exposure	O
chamber	O
.	O

BACKGROUND	O
Recombinant	O
allergens	O
offer	O
a	O
tool	O
for	O
improving	O
specific	O
immunotherapy	O
(	O
SIT	O
)	O
.	O

OBJECTIVE	O
To	O
find	O
the	O
optimal	O
dose	O
of	O
a	O
new	O
hypoallergenic	O
folding	O
variant	O
of	O
recombinant	O
Bet	O
v	O
1	O
(	O
rBet	O
v	O
1-FV	O
)	O
as	O
SIT	O
for	O
patients	O
with	O
birch	Condition
pollen	Condition
allergy	Condition
.	O

METHODS	O
Before	O
SIT	O
,	O
thirty-seven	O
adult	O
patients	O
were	O
exposed	O
for	O
eight	O
hours	O
in	O
an	O
environmental	O
exposure	O
chamber	O
(	O
EEC	O
)	O
to	O
birch	O
pollen	O
at	O
an	O
average	O
concentration	O
of	O
3500	O
?	O
500	O
grains/m	O
(	O
3	O
)	O
,	O
then	O
randomized	O
to	O
four	O
maintenance	O
dose	O
groups	O
of	O
rBet	O
v	O
1-FV	O
and	O
one	O
placebo	O
group	O
:	O
20	O
?g	O
(	O
n	O
=	O
7	O
)	O
,	O
80	O
?g	O
(	O
n	O
=	O
8	O
)	O
,	O
160	O
?g	O
(	O
n	O
=	O
7	O
)	O
,	O
320	O
?g	O
(	O
n	O
=	O
8	O
)	O
,	O
and	O
placebo	O
(	O
n	O
=	O
7	O
)	O
.	O

Patients	O
were	O
treated	O
for	O
10	O
weeks	O
with	O
weekly	O
injections	O
and	O
then	O
re-exposed	O
in	O
the	O
EEC	O
.	O

The	O
optimal	O
dose	O
for	O
SIT	O
was	O
assessed	O
using	O
efficacy	O
results	O
from	O
the	O
EEC	O
,	O
IgG	O
responses	O
,	O
and	O
tolerability	O
.	O

RESULTS	O
Thirty-six	O
patients	O
were	O
evaluable	O
for	O
efficacy	O
assessment	O
.	O

The	O
total	O
symptom	O
score	O
significantly	O
decreased	O
in	O
all	O
active	O
groups	O
compared	O
with	O
placebo	O
(	O
-18.8	O
%	O
for	O
placebo	O
patients	O
;	O
-71.9	O
%	O
,	O
P	O
=	O
0.0022	O
for	O
20	O
?g	O
;	O
-75.6	O
%	O
,	O
P	O
=	O
0.0007	O
for	O
80	O
?g	O
;	O
-81.8	O
%	O
,	O
P	O
=	O
0.0009	O
for	O
160	O
?g	O
;	O
-78.3	O
%	O
,	O
P	O
=	O
0.0003	O
for	O
320	O
?g	O
)	O
.	O

IgG1	O
increased	O
significantly	O
in	O
all	O
active	O
groups	O
compared	O
to	O
placebo	O
.	O

All	O
four	O
active	O
doses	O
were	O
well	O
tolerated	O
,	O
no	O
serious	O
adverse	O
event	O
occurred	O
;	O
two	O
Grade	O
II	O
reactions	O
,	O
according	O
to	O
EAACI	O
classification	O
,	O
were	O
observed	O
,	O
one	O
in	O
each	O
of	O
the	O
160-	O
and	O
320-?g	O
groups	O
.	O

CONCLUSIONS	O
Considering	O
efficacy	O
,	O
immunological	O
response	O
,	O
and	O
tolerability	O
,	O
a	O
maintenance	O
dose	O
of	O
80	O
?g	O
of	O
rBet	O
v	O
1-FV	O
appears	O
to	O
be	O
the	O
ideal	O
dose	O
for	O
allergen	O
immunotherapy	O
in	O
birch	O
pollen	O
allergic	O
patients	O
.	O

A	O
replication	O
and	O
extension	O
of	O
the	O
PEERS	O
intervention	O
:	O
examining	O
effects	O
on	O
social	O
skills	O
and	O
social	O
anxiety	O
in	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
Program	O
for	O
the	O
Education	O
and	O
Enrichment	O
of	O
Relational	O
Skills	O
(	O
PEERS	O
:	O
Laugeson	O
et	O
al	O
.	O

in	O
J	O
Autism	O
Dev	O
Disord	O
39	O
(	O
4	O
)	O
:596-606	O
,	O
2009	O
)	O
.	O

PEERS	O
focuses	O
on	O
improving	O
friendship	O
quality	O
and	O
social	O
skills	O
among	O
adolescents	Age
with	Age
higher-functioning	Age
ASD	Age
.	Age

58	O
participants	O
aged	O
11-16	O
years-old	O
were	O
randomly	O
assigned	O
to	O
either	O
an	O
immediate	O
treatment	O
or	O
waitlist	O
comparison	O
group	O
.	O

Results	O
revealed	O
,	O
in	O
comparison	O
to	O
the	O
waitlist	O
group	O
,	O
that	O
the	O
experimental	O
treatment	O
group	O
significantly	O
improved	O
their	O
knowledge	O
of	O
PEERS	O
concepts	O
and	O
friendship	O
skills	O
,	O
increased	O
in	O
their	O
amount	O
of	O
get-togethers	O
,	O
and	O
decreased	O
in	O
their	O
levels	O
of	O
social	O
anxiety	O
,	O
core	O
autistic	O
symptoms	O
,	O
and	O
problem	O
behaviors	O
from	O
pre-to	O
post-PEERS	O
.	O

This	O
study	O
provides	O
the	O
first	O
independent	O
replication	O
and	O
extension	O
of	O
the	O
empirically-supported	O
PEERS	O
social	O
skills	O
intervention	O
for	O
adolescents	Age
with	Age
ASD	Age
.	Age

Effects	O
of	O
maternal	O
and	O
dietary	O
selenium	O
(	O
Se-enriched	O
yeast	O
)	O
on	O
the	O
expression	O
of	O
p34	O
(	O
cdc2	O
)	O
and	O
CyclinB1	O
of	O
germ	O
cells	O
of	O
their	O
offspring	O
in	O
goats	Condition
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
selenium	O
on	O
the	O
expression	O
of	O
p34	O
(	O
cdc2	O
)	O
and	O
CyclinB1	O
(	O
two	O
components	O
of	O
MPF	O
regulating	O
cell	O
cycle	O
)	O
of	O
germ	O
cells	O
of	O
their	O
offspring	O
in	O
goats	O
.	O

A	O
herd	O
of	O
119	SampleSize
Taihang	O
Black	O
Goats	O
,	O
which	O
was	O
randomly	O
divided	O
into	O
4	O
treatments	O
,	O
received	O
experimental	O
diet	O
with	O
different	O
Se	O
levels	O
(	O
from	O
Se-enriched	O
yeast	O
)	O
for	O
174d	O
.	O

The	O
four	O
treatments	O
,	O
fed	O
with	O
a	O
basal	O
diet	O
,	O
were	O
supplemented	O
with	O
0	O
(	O
control	O
)	O
,	O
0.5	O
,	O
2	O
and	O
4	O
mgkg??	O
DM	O
Se	O
.	O

Testis	O
samples	O
were	O
collected	O
from	O
the	O
young	O
male	O
goats	O
of	O
each	O
treatment	O
group	O
at	O
the	O
end	O
of	O
the	O
study	O
(	O
30d	O
after	O
weaning	O
)	O
for	O
mRNA	O
expression	O
using	O
real-time	O
PCR	O
and	O
for	O
protein	O
expression	O
by	O
immunohistochemistry	O
assay	O
.	O

Results	O
show	O
that	O
a	O
significant	O
decrease	O
was	O
observed	O
in	O
mRNA	O
expression	O
of	O
p34	O
(	O
cdc2	O
)	O
and	O
CyclinB1	O
in	O
the	O
testis	O
of	O
Se-deficient	O
(	O
Group	O
1	O
)	O
and	O
Se-excess	O
(	O
Group	O
4	O
)	O
animals	O
compared	O
with	O
that	O
in	O
Groups	O
2	O
and	O
3	O
.	O

However	O
,	O
no	O
significant	O
changes	O
were	O
found	O
in	O
mRNA	O
expression	O
of	O
p34	O
(	O
cdc2	O
)	O
between	O
Se-deficient	O
(	O
Group	O
1	O
)	O
and	O
Se-excess	O
(	O
Group	O
4	O
)	O
.	O

Also	O
the	O
immunohistochemistry	O
assay	O
detected	O
similar	O
results	O
of	O
protein	O
expression	O
of	O
these	O
two	O
genes	O
.	O

These	O
results	O
suggest	O
,	O
that	O
maternal	O
and	O
dietary	O
Se-induced	O
oxidative	O
stress	O
can	O
modulate	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
the	O
cell	O
cycle	O
related	O
genes	O
(	O
p34	O
(	O
cdc2	O
)	O
and	O
CyclinB1	O
)	O
in	O
the	O
testis	O
of	O
their	O
offspring	O
.	O

In	O
addition	O
,	O
Se	O
deficiency	O
and	O
Se	O
excess	O
could	O
prevent	O
the	O
completion	O
of	O
the	O
cell	O
cycle	O
.	O

Use	O
of	O
an	O
Internet	O
portal	O
to	O
improve	O
community-based	O
pediatric	Age
ADHD	Condition
care	O
:	O
a	O
cluster	O
randomized	O
trial	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
effectiveness	O
of	O
a	O
quality	O
improvement	O
program	O
to	O
improve	O
pediatricians	O
'	O
adherence	O
to	O
existing	O
,	O
evidence-based	O
,	O
attention-deficit/hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
practice	O
guidelines	O
.	O

METHODS	O
Forty-nine	SampleSize
community-based	O
pediatricians	O
at	O
8	O
practices	O
participated	O
in	O
a	O
cluster-randomized	O
trial	O
.	O

Practices	O
were	O
matched	O
according	O
to	O
the	O
numbers	O
of	O
pediatricians	O
and	O
the	O
proportions	O
of	O
patients	O
receiving	O
Medicaid	O
.	O

The	O
medical	O
charts	O
for	O
a	O
random	O
sample	O
of	O
patients	O
with	O
ADHD	O
for	O
each	O
of	O
the	O
participating	O
pediatricians	O
were	O
examined	O
at	O
baseline	O
and	O
6	O
months	O
.	O

All	O
practices	O
participated	O
in	O
4	O
sessions	O
of	O
training	O
,	O
including	O
didactic	O
lectures	O
and	O
office	O
flow	O
modification	O
workshops	O
.	O

Practices	O
were	O
then	O
given	O
access	O
to	O
an	O
ADHD	O
Internet	O
portal	O
that	O
allowed	O
parents	O
,	O
teachers	O
,	O
and	O
pediatricians	O
to	O
input	O
information	O
(	O
eg	O
,	O
rating	O
scales	O
)	O
about	O
patients	O
,	O
after	O
which	O
information	O
was	O
scored	O
,	O
interpreted	O
,	O
and	O
formatted	O
in	O
a	O
report	O
style	O
that	O
was	O
helpful	O
for	O
assessment	O
and	O
treatment	O
of	O
patients	O
with	O
ADHD	O
.	O

Physicians	O
evaluated	O
their	O
practice	O
behaviors	O
quarterly	O
and	O
addressed	O
underperforming	O
areas	O
.	O

RESULTS	O
Pediatricians	O
in	O
the	O
intervention	O
group	O
,	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
,	O
demonstrated	O
significantly	O
higher	O
rates	O
of	O
many	O
American	O
Academy	O
of	O
Pediatrics-recommended	O
ADHD	O
care	O
practices	O
,	O
including	O
collection	O
of	O
parent	O
(	O
Cohen	O
's	O
d	O
=	O
0.69	O
)	O
and	O
teacher	O
(	O
d	O
=	O
0.68	O
)	O
rating	O
scales	O
for	O
assessment	O
of	O
children	O
with	O
ADHD	O
,	O
use	O
of	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
,	O
criteria	O
(	O
d	O
=	O
0.85	O
)	O
,	O
and	O
use	O
of	O
teacher	O
rating	O
scales	O
to	O
monitor	O
treatment	O
responses	O
(	O
d	O
=	O
1.01	O
)	O
.	O

CONCLUSION	O
A	O
quality	O
improvement	O
intervention	O
that	O
can	O
be	O
widely	O
disseminated	O
by	O
using	O
Internet-based	O
information	O
technology	O
significantly	O
improved	O
the	O
quality	O
of	O
ADHD	O
care	O
in	O
community-based	O
pediatric	O
settings	O
.	O

[	O
Clinical	O
application	O
of	O
irradiated	O
drug-containing	O
porcine-cornea	O
to	O
patients	O
with	O
ocular	Condition
burns	Condition
]	O
.	O

OBJECTIVE	O
To	O
explore	O
a	O
new	O
method	O
for	O
the	O
management	O
of	O
patients	O
with	O
ocular	Condition
burns	Condition
.	O

METHODS	O
Fifty-five	SampleSize
cases	O
of	O
patients	O
with	O
ocular	Condition
burns	Condition
(	O
in	O
88	SampleSize
eyes	O
)	O
were	O
randomly	O
divided	O
into	O
treatment	O
and	O
control	O
groups	O
.	O

Thirty	O
cases	O
in	O
treatment	O
group	O
with	O
49	O
eyes	O
were	O
transplanted	O
with	O
irradiated	O
drug-containing	O
(	O
ofloxacin	O
,	O
acetyl	O
cysteine	O
and	O
reduced	O
glutathione	O
)	O
porcine-cornea	O
.	O

25	O
cases	O
in	O
control	O
group	O
with	O
39	O
eyes	O
were	O
treated	O
with	O
routine	O
program	O
.	O

RESULTS	O
Thirty-two	O
eyes	O
were	O
rescued	O
in	O
treatment	O
group	O
with	O
the	O
cure	O
rate	O
of	O
65.3	O
%	O
.	O

But	O
only	O
17	O
eyes	O
were	O
saved	O
in	O
control	O
group	O
with	O
the	O
cure	O
rate	O
of	O
43.59	O
%	O
,	O
indicating	O
significant	O
difference	O
of	O
the	O
cure	O
rate	O
between	O
the	O
two	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
Irradiated	O
drug-containing	O
porcine-cornea	O
might	O
well	O
be	O
an	O
ideal	O
therapeutic	O
material	O
for	O
the	O
management	O
of	O
patients	O
with	O
ocular	Condition
burns	Condition
.	O

Outcomes	O
of	O
early	O
endovascular	O
versus	O
surgical	O
treatment	O
of	O
ruptured	Condition
cerebral	Condition
aneurysms	Condition
.	O

A	O
prospective	O
randomized	O
study	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
This	O
prospective	O
study	O
was	O
conducted	O
to	O
compare	O
the	O
outcomes	O
of	O
surgical	O
clipping	O
and	O
endovascular	O
treatment	O
in	O
acute	Condition
(	Condition
<	Condition
72	Condition
hours	Condition
)	Condition
aneurysmal	Condition
subarachnoid	Condition
hemorrhage	Condition
(	Condition
SAH	Condition
)	Condition
.	O

METHODS	O
One	SampleSize
hundred	SampleSize
nine	SampleSize
consecutive	Condition
patients	Condition
were	O
randomly	Condition
assigned	Condition
to	O
either	O
surgical	O
(	O
n=57	O
)	O
or	O
endovascular	O
(	O
n=52	O
)	O
treatment	O
.	O

Clinical	O
and	O
neuropsychological	O
outcome	O
was	O
assessed	O
at	O
3	O
and	O
12	O
months	O
after	O
treatment	O
;	O
MRI	O
of	O
the	O
brain	O
was	O
performed	O
at	O
12	O
months	O
.	O

Follow-up	O
angiography	O
was	O
scheduled	O
after	O
clipping	O
and	O
3	O
and	O
12	O
months	O
after	O
endovascular	O
treatment	O
.	O

RESULTS	O
One	O
year	O
postoperatively	O
,	O
43/41	O
(	O
surgical/endovascular	O
)	O
patients	O
had	O
good	O
or	O
moderate	O
recovery	O
,	O
5/4	O
had	O
severe	O
disability	O
or	O
were	O
in	O
a	O
vegetative	O
state	O
,	O
and	O
9/7	O
had	O
died	O
(	O
NS	O
)	O
according	O
to	O
intention	O
to	O
treat	O
.	O

Patients	O
with	O
good	O
clinical	O
recovery	O
did	O
not	O
differ	O
in	O
their	O
neuropsychological	O
test	O
scores	O
.	O

Symptomatic	O
vasospasm	O
(	O
OR	O
2.47	O
;	O
95	O
%	O
CI	O
1.45	O
to	O
4.19	O
;	O
P	O
<	O
0.001	O
)	O
,	O
poorer	O
Hunt	O
and	O
Hess	O
grade	O
(	O
OR	O
2.50	O
;	O
95	O
%	O
CI	O
1.31	O
to	O
4.75	O
;	O
P=0.005	O
)	O
,	O
need	O
for	O
permanent	O
shunt	O
(	O
OR	O
8.90	O
;	O
95	O
%	O
CI	O
1.80	O
to	O
44.15	O
;	O
P=0.008	O
)	O
,	O
and	O
larger	O
size	O
of	O
the	O
aneurysm	O
(	O
OR	O
1	O
.	O

22	O
;	O
95	O
%	O
CI	O
1.02	O
to	O
1.45	O
;	O
P=0.032	O
)	O
independently	O
predicted	O
worsened	O
clinical	O
outcome	O
regardless	O
of	O
the	O
treatment	O
modality	O
.	O

In	O
MRI	O
,	O
superficial	O
brain	O
retraction	O
deficits	O
(	O
P	O
<	O
0.001	O
)	O
and	O
ischemic	O
lesions	O
in	O
the	O
territory	O
of	O
the	O
ruptured	O
aneurysm	O
(	O
P=0.025	O
)	O
were	O
more	O
frequent	O
in	O
the	O
surgical	O
group	O
.	O

Kaplan-Meier	O
analysis	O
(	O
mean+/-SD	O
follow-up	O
39+/-18	O
months	O
)	O
revealed	O
equal	O
survival	O
in	O
both	O
treatment	O
groups	O
.	O

No	O
late	O
rebleedings	O
have	O
occurred	O
.	O

CONCLUSIONS	O
One-year	O
clinical	O
and	O
neuropsychological	O
outcomes	O
seem	O
comparable	O
after	O
early	O
surgical	O
and	O
endovascular	O
treatment	O
of	O
ruptured	O
intracranial	O
aneurysms	O
.	O

The	O
long-term	O
efficacy	O
of	O
endovascular	O
treatment	O
in	O
preventing	O
rebleeding	O
remains	O
open	O
.	O

Stapled	O
hemorrhoidopexy	O
vs.	O
Harmonic	O
Scalpel	O
hemorrhoidectomy	O
:	O
a	O
randomized	O
trial	O
.	O

PURPOSE	O
A	O
randomized	O
trial	O
was	O
undertaken	O
to	O
evaluate	O
and	O
compare	O
stapled	O
hemorrhoidopexy	O
with	O
excisional	O
hemorrhoidectomy	O
in	O
which	O
the	O
Harmonic	O
Scalpel	O
was	O
used	O
.	O

METHODS	O
Patients	O
with	O
Grade	O
III	O
hemorrhoids	O
who	O
were	O
employed	O
during	O
the	O
trial	O
period	O
were	O
recruited	O
and	O
randomized	O
into	O
two	O
groups	O
:	O
(	O
1	O
)	O
Harmonic	O
Scalpel	O
hemorrhoidectomy	O
,	O
and	O
(	O
2	O
)	O
stapled	O
hemorrhoidopexy	O
.	O

All	O
operations	O
were	O
performed	O
by	O
a	O
single	O
surgeon	O
.	O

In	O
the	O
stapled	O
group	O
,	O
the	O
doughnut	O
obtained	O
was	O
sent	O
for	O
histopathologic	O
examination	O
to	O
determine	O
whether	O
smooth	O
muscles	O
were	O
included	O
in	O
the	O
specimen	O
.	O

Operative	O
data	O
and	O
complications	O
were	O
recorded	O
,	O
and	O
patients	O
were	O
followed	O
up	O
through	O
a	O
structured	O
pro	O
forma	O
protocol	O
.	O

An	O
independent	O
assessor	O
was	O
assigned	O
to	O
obtain	O
postoperative	O
pain	O
scores	O
and	O
satisfaction	O
scores	O
at	O
six-month	O
follow-up	O
.	O

Patients	O
were	O
also	O
administered	O
a	O
simple	O
questionnaire	O
at	O
follow-up	O
to	O
assess	O
continence	O
functions	O
.	O

RESULTS	O
Over	O
a	O
20-month	O
period	O
,	O
88	O
patients	O
were	O
recruited	O
.	O

The	O
two	O
groups	O
were	O
matched	O
for	O
age	O
and	O
gender	O
distribution	O
.	O

No	O
significant	O
difference	O
was	O
identified	O
between	O
the	O
two	O
groups	O
in	O
terms	O
of	O
operation	O
time	O
,	O
blood	O
loss	O
,	O
day	O
of	O
first	O
bowel	O
movement	O
after	O
surgery	O
,	O
and	O
complication	O
rates	O
.	O

Despite	O
a	O
similar	O
parenteral	O
and	O
oral	O
analgesic	O
requirement	O
,	O
the	O
stapled	O
group	O
had	O
a	O
significantly	O
better	O
pain	O
score	O
(	O
P	O
=	O
0.002	O
)	O
;	O
these	O
patients	O
also	O
had	O
a	O
significantly	O
shorter	O
length	O
of	O
stay	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
on	O
average	O
resumed	O
work	O
nine	O
days	O
earlier	O
than	O
the	O
group	O
treated	O
with	O
the	O
Harmonic	O
Scalpel	O
(	O
6.7	O
vs.	O
15.6	O
,	O
P	O
=	O
0.002	O
)	O
.	O

Although	O
88	O
percent	O
of	O
doughnuts	O
obtained	O
in	O
the	O
stapled	O
group	O
contained	O
some	O
smooth	O
muscle	O
fibers	O
,	O
no	O
association	O
was	O
found	O
between	O
smooth	O
muscle	O
incorporation	O
and	O
postoperative	O
continence	O
function	O
,	O
and	O
as	O
a	O
whole	O
the	O
continence	O
outcomes	O
of	O
the	O
stapled	O
group	O
were	O
similar	O
to	O
those	O
after	O
Harmonic	O
Scalpel	O
hemorrhoidectomy	O
.	O

Finally	O
,	O
at	O
six-month	O
follow-up	O
,	O
patients	O
who	O
underwent	O
the	O
stapled	O
procedure	O
had	O
significantly	O
better	O
satisfaction	O
scores	O
(	O
P	O
=	O
0.001	O
)	O
.	O

CONCLUSION	O
Stapled	O
hemorrhoidopexy	O
is	O
a	O
safe	O
and	O
effective	O
procedure	O
for	O
Grade	O
III	O
hemorrhoidal	O
disease	O
.	O

Patients	O
derive	O
greater	O
short-term	O
benefits	O
of	O
reduced	O
pain	O
,	O
shorter	O
length	O
of	O
stay	O
,	O
and	O
earlier	O
resumption	O
to	O
work	O
.	O

Long-term	O
follow-up	O
is	O
necessary	O
to	O
determine	O
whether	O
these	O
initial	O
results	O
are	O
lasting	O
.	O

Oral	O
ondansetron	O
in	O
the	O
prevention	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
.	O

The	O
effect	O
of	O
three	O
times	O
daily	O
oral	O
ondansetron	O
in	O
preventing	O
postoperative	O
nausea	O
and	O
vomiting	O
was	O
investigated	O
in	O
two	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multi-centre	O
studies	O
.	O

The	O
first	O
study	O
compared	O
ondansetron	O
1	O
,	O
8	O
and	O
16	O
mg	O
to	O
placebo	O
,	O
and	O
the	O
second	O
study	O
compared	O
8	O
mg	O
ondansetron	O
to	O
placebo	O
.	O

Both	O
studies	O
included	O
ASA	Condition
Class	Condition
I-III	Condition
female	Sex
patients	Condition
about	Condition
to	Condition
undergo	Condition
major	Condition
abdominal	Condition
gynaecological	Condition
surgery	Condition
or	Condition
vaginal	Condition
hysterectomy	Condition
.	O

In	O
the	O
first	O
study	O
,	O
the	O
8	O
and	O
16	O
mg	O
ondansetron	O
groups	O
had	O
a	O
significantly	O
lower	O
incidence	O
of	O
nausea	O
and	O
vomiting	O
in	O
the	O
0-24	O
h	O
period	O
following	O
recovery	O
from	O
anaesthesia	O
than	O
the	O
placebo	O
group	O
.	O

Ondansetron	O
8	O
mg	O
three	O
times	O
daily	O
was	O
also	O
significantly	O
better	O
than	O
placebo	O
in	O
the	O
second	O
study	O
.	O

Side-effects	O
mainly	O
consisted	O
of	O
constipation	O
,	O
headache	O
,	O
and	O
asymptomatic	O
elevation	O
of	O
liver	O
enzymes	O
.	O

The	O
incidence	O
of	O
side-effects	O
was	O
similar	O
in	O
ondansetron-	O
and	O
placebo-treated	O
patients	O
.	O

There	O
appeared	O
to	O
be	O
no	O
clinically	O
important	O
benefit	O
of	O
the	O
16	O
mg	O
three	O
times	O
daily	O
ondansetron	O
regimen	O
over	O
the	O
8	O
mg	O
three	O
times	O
daily	O
dose	O
,	O
therefore	O
8	O
mg	O
three	O
times	O
daily	O
is	O
recommended	O
as	O
the	O
optimal	O
oral	O
dose	O
in	O
the	O
prevention	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
.	O

Capsaicin	O
jelly	O
against	O
migraine	Condition
pain	O
.	O

OBJECTIVE	O
Recent	O
studies	O
support	O
the	O
role	O
of	O
extracranial	O
perivascular	O
afferents	O
in	O
a	O
substantial	O
percentage	O
of	O
migraineurs	O
.	O

Perivascular	O
afferent	O
fibres	O
of	O
the	O
superficial	O
temporal	O
artery	O
contain	O
peptides	O
,	O
like	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
and	O
substance	O
P	O
(	O
SP	O
)	O
.	O

CGRP	O
and	O
SP	O
are	O
considered	O
relevant	O
in	O
the	O
genesis	O
of	O
migraine	O
pain	O
.	O

Capsaicin	O
is	O
an	O
agonist	O
of	O
the	O
transient	O
receptor	O
potential	O
vanilloid	O
type	O
1	O
.	O

It	O
causes	O
membrane	O
depolarisation	O
of	O
sensory	O
neurons	O
,	O
which	O
release	O
CGRP	O
,	O
SP	O
and	O
other	O
pain	O
peptides	O
;	O
excitation	O
is	O
followed	O
by	O
a	O
refractory	O
state	O
,	O
causing	O
inactivation	O
.	O

Topical	O
capsaicin	O
has	O
been	O
found	O
to	O
be	O
efficacious	O
in	O
several	O
types	O
of	O
neuropathic	O
pain	O
.	O

We	O
attempted	O
to	O
verify	O
whether	O
topical	O
periarterial	O
capsaicin	O
could	O
ameliorate	O
pain	O
in	O
absence	O
of	O
and	O
during	O
a	O
migraine	O
attack	O
.	O

METHODS	O
On	O
23	Condition
migraineurs	O
showing	O
pain	O
at	O
pressure	O
on	O
scalp	O
arteries	O
,	O
we	O
administered	O
topical	O
capsaicin	O
0.1	O
%	O
or	O
vaseline	O
jelly	O
on	O
painful	O
arteries	O
in	O
absence	O
of	O
migraine	O
attack	O
.	O

In	O
those	O
having	O
pain	O
reduction	O
>	O
50	O
%	O
,	O
we	O
made	O
the	O
same	O
comparison	O
during	O
a	O
migraine	O
attack	O
.	O

RESULTS	O
Topical	O
capsaicin	O
caused	O
>	O
50	O
%	O
reduction	O
of	O
arterial	O
pain	O
in	O
absence	O
of	O
attack	O
in	O
17/23	O
patients	O
,	O
as	O
opposed	O
to	O
two	O
with	O
vaseline	O
.	O

During	O
attacks	O
of	O
mild-	O
to	O
moderate-intensity	O
,	O
>	O
50	O
%	O
improvement	O
was	O
obtained	O
in	O
11/17	O
with	O
capsaicin	O
and	O
in	O
one	O
with	O
vaseline	O
.	O

CONCLUSIONS	O
Although	O
referring	O
to	O
a	O
small	O
number	O
of	O
patients	O
,	O
our	O
data	O
show	O
that	O
topical	O
capsaicin	O
may	O
relieve	O
arterial	O
pain	O
in	O
absence	O
of	O
and	O
during	O
a	O
migraine	O
attack	O
in	O
a	O
substantial	O
number	O
of	O
patients	O
experiencing	O
scalp	O
arterial	O
tenderness	O
.	O

More	O
active	O
capsacinoids	O
might	O
be	O
tried	O
in	O
the	O
future	O
and	O
could	O
provide	O
a	O
new	O
method	O
for	O
treating	O
migraine	O
attacks	O
.	O

Efficacy	O
of	O
intramuscular	O
oxytetracycline	O
as	O
a	O
dry	O
cow	O
treatment	O
for	O
Staphylococcus	O
aureus	O
mastitis	O
.	O

To	O
determine	O
the	O
efficacy	O
of	O
intramuscular	O
oxytetracycline	O
as	O
a	O
supplemental	O
dry	O
cow	O
treatment	O
for	O
Staphylococcus	O
aureus	O
mastitis	O
,	O
37	O
Holstein	O
cows	O
were	O
randomly	O
assigned	O
to	O
two	O
treatment	O
groups	O
:	O
intracisternal	O
infusion	O
with	O
a	O
commercial	O
preparation	O
of	O
cephapirin	O
benzathine	O
at	O
drying	O
off	O
(	O
20	O
cows	O
)	O
and	O
infusion	O
with	O
cephapirin	O
benzathine	O
at	O
drying	O
off	O
and	O
intramuscular	O
oxytetracycline	O
at	O
11	O
mg/kg	O
once	O
daily	O
on	O
d	O
7	O
,	O
8	O
,	O
9	O
,	O
and	O
10	O
after	O
drying	O
off	O
(	O
17	O
cows	O
)	O
.	O

Milk	O
samples	O
collected	O
7	O
,	O
14	O
,	O
30	O
,	O
and	O
60	O
d	O
after	O
calving	O
were	O
plated	O
for	O
bacterial	O
isolation	O
within	O
24	O
h	O
after	O
collection	O
and	O
after	O
24	O
to	O
72	O
h	O
of	O
storage	O
at	O
-20	O
degrees	O
C.	O
Quarters	O
were	O
defined	O
as	O
infected	O
if	O
S.	O
aureus	O
was	O
isolated	O
from	O
the	O
fresh	O
and	O
frozen	O
cultures	O
from	O
any	O
one	O
sample	O
collected	O
before	O
drying	O
off	O
.	O

An	O
infected	O
quarter	O
was	O
defined	O
as	O
cured	O
if	O
S.	O
aureus	O
was	O
not	O
isolated	O
from	O
the	O
fresh	O
or	O
frozen	O
culture	O
from	O
milk	O
samples	O
obtained	O
following	O
calving	O
.	O

The	O
rate	O
of	O
cure	O
by	O
30	O
d	O
after	O
calving	O
for	O
systemic	O
oxytetracycline	O
(	O
in	O
combination	O
with	O
cephapirin	O
treatment	O
)	O
was	O
29.4	O
%	O
for	O
infected	O
quarters	O
and	O
29.4	O
%	O
for	O
infected	O
cows	O
,	O
compared	O
with	O
27.5	O
and	O
25.0	O
%	O
,	O
respectively	O
,	O
for	O
the	O
cephapirin	O
treatment	O
only	O
.	O

Results	O
including	O
the	O
culture	O
at	O
60	O
d	O
after	O
calving	O
were	O
21.2	O
and	O
22.5	O
%	O
,	O
respectively	O
,	O
for	O
combination	O
therapy	O
and	O
cephapirin	O
therapy	O
only	O
.	O

Systemic	O
oxytetracycline	O
,	O
in	O
combination	O
with	O
intramammary	O
dry	O
cow	O
treatment	O
,	O
did	O
not	O
improve	O
the	O
rate	O
of	O
cure	O
for	O
S.	O
aureus	O
mastitis	O
.	O

Lower	O
relapse	O
rates	O
after	O
neighbourhood	O
injection	O
of	O
Corynebacterium	O
parvum	O
in	O
operable	O
cervix	O
carcinoma	O
.	O

The	O
effect	O
of	O
adjuvant	O
immunotherapy	O
with	O
a	O
single	O
neighbourhood	O
injection	O
of	O
2	O
mg	O
C.	O
parvum	O
(	O
CP	O
)	O
was	O
investigated	O
in	O
a	O
randomized	O
study	O
involving	O
43	O
patients	O
with	O
carcinoma	O
of	O
the	O
cervix	O
uteri	O
,	O
all	O
of	O
whom	O
were	O
treated	O
by	O
radical	O
surgery	O
.	O

All	O
patients	O
had	O
carcinoma	O
confined	O
to	O
the	O
cervix	O
,	O
the	O
upper	O
part	O
of	O
the	O
vagina	O
or	O
the	O
parametrial	O
region	O
.	O

When	O
the	O
malignancy	O
had	O
spread	O
to	O
the	O
parametrial	O
region	O
,	O
additional	O
postoperative	O
radiotherapy	O
was	O
given	O
.	O

22	O
patients	O
received	O
immunotherapy	O
10	O
days	O
before	O
surgery	O
,	O
whereas	O
the	O
remaining	O
21	O
control	O
patients	O
received	O
no	O
immune	O
stimulation	O
.	O

Only	O
minor	O
side	O
effects	O
of	O
CP	O
were	O
encountered	O
.	O

Follow-up	O
shows	O
a	O
relapse	O
rate	O
of	O
5	O
%	O
in	O
the	O
CP	O
treated	O
group	O
and	O
of	O
29	O
%	O
in	O
the	O
controls	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

A	O
further	O
15	O
patients	O
with	O
more	O
advanced	O
malignancies	O
were	O
added	O
to	O
our	O
studies	O
.	O

In	O
these	O
,	O
CP	O
stimulation	O
had	O
no	O
effect	O
on	O
relapse	O
rates	O
,	O
but	O
the	O
relapse-free	O
intervals	O
were	O
longer	O
after	O
immune	O
stimulation	O
:	O
control	O
3.5	O
months	O
(	O
mean	O
)	O
+/-	O
1.5	O
(	O
s.d	O
.	O

)	O
,	O
CP	O
13.0	O
months	O
+/-	O
7.0	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
number	O
of	O
peripheral	O
T	O
cells	O
and	O
the	O
ability	O
to	O
become	O
sensitized	O
to	O
DNCB	O
were	O
increased	O
after	O
CP	O
stimulation	O
.	O

A	O
decrease	O
was	O
found	O
in	O
the	O
number	O
of	O
blood	O
monocytes	O
and	O
the	O
number	O
of	O
monocytes	O
capable	O
of	O
transforming	O
into	O
active	O
macrophages	O
,	O
indicating	O
a	O
possible	O
sequestration	O
of	O
these	O
cells	O
in	O
the	O
tissues	O
.	O

[	O
Effect	O
analysis	O
on	O
non-and-low	O
response	O
infants	Age
after	O
revaccinated	O
hepatitis	O
B	O
vaccine	O
]	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
booster	O
immunization	O
effect	O
to	O
non-and-low	O
response	O
children	O
after	O
3	O
doses	O
HepB	O
immunization	O
.	O

METHODS	O
Non-and-low	O
response	O
infants	Age
born	O
in	O
2004	Age
2005	Age
administered	O
3	O
doses	O
of	O
HepB	O
at	O
0	O
,	O
1	O
,	O
6	O
months	O
in	O
Guangzhou	O
,	O
Beijing	O
and	O
Zhejiang	O
were	O
divided	O
into	O
4	O
groups	O
randomly	O
,	O
and	O
boosted	O
3	O
dose	O
of	O
4	O
different	O
types	O
of	O
HepB	O
at	O
0	O
,	O
1	O
,	O
6	O
months	O
.	O

RESULTS	O
The	O
GMC	O
of	O
non-and-low	O
response	O
children	O
in	O
group	O
A	O
(	O
before	O
booster	O
)	O
,	O
group	O
B	O
(	O
after	O
1	O
dose	O
booster	O
)	O
and	O
group	O
C	O
(	O
after	O
3	O
dose	O
booster	O
)	O
were	O
18.66	O
mIUml	O
,	O
88.82	O
mIU/ml	O
,	O
178.24	O
mIU/ml	O
respectively	O
;	O
the	O
proportion	O
of	O
non-responders	O
in	O
three	O
groups	O
were	O
20.4	O
%	O
,	O
9.1	O
%	O
,	O
1.9	O
%	O
respectively	O
.	O

In	O
103	SampleSize
non-and-low	O
response	O
children	Age
,	O
proportion	O
of	O
titers	O
of	O
more	O
than	O
100	O
mIU/ml	O
of	O
group	O
B	O
and	O
group	O
C	O
were	O
61.2	O
%	O
and	O
84.5	O
%	O
,	O
and	O
there	O
was	O
statistical	O
significant	O
difference	O
(	O
chi2	O
=	O
14.13	O
,	O
P	O
<	O
0.01	O
)	O
.	O

The	O
GMC	O
after	O
3	O
doses	O
revaccination	O
with	O
four	O
kinds	O
of	O
HepB	O
,	O
included	O
5	O
microg	O
HepB-Y	O
,	O
10	O
microg	O
HepB-Y	O
,	O
l0	O
microg	O
HepB-CHO	O
,	O
10	O
microg	O
HepB-HY	O
were	O
168.8	O
mJU/ml	O
,	O
174.7	O
mIU/ml	O
,	O
184.9	O
mIU/ml	O
,	O
182.9	O
mIU/ml	O
respectively	O
.	O

Proportion	O
of	O
titers	O
of	O
more	O
than	O
100	O
mIU/ml	O
for	O
four	O
kinds	O
HepB	O
were	O
79.0	O
%	O
,	O
85.7	O
%	O
,	O
88.2	O
%	O
and	O
84.6	O
%	O
respectively	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
(	O
chi2	O
=	O
0.75	O
,	O
0.05	O
)	O
.	O

CONCLUSION	O
There	O
were	O
no	O
different	O
of	O
seroconversion	O
rate	O
between	O
study	O
population	O
received	O
1	O
dose	O
and	O
3	O
dose	O
booster	O
(	O
P	O
>	O
0.05	O
)	O
,	O
but	O
high	O
titer	O
was	O
observed	O
after	O
3	O
dose	O
booster	O
.	O

The	O
four	O
kinds	O
of	O
HepB	O
,	O
including	O
5	O
microg	O
HepB-Y,10	O
microg	O
HepB-Y	O
,	O
10	O
microg	O
HepB-CHO	O
,	O
10	O
microg	O
HepB-HY	O
had	O
the	O
same	O
immunization	O
effect	O
after	O
3	O
doses	O
revaccination	O
at	O
0	O
,	O
1	O
,	O
6	O
months	O
to	O
non-and-low	O
response	O
children	O
.	O

Folate	O
and	O
arsenic	O
metabolism	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
folic	O
acid-supplementation	O
trial	O
in	O
Bangladesh	O
.	O

BACKGROUND	O
Populations	O
in	O
South	O
and	O
East	O
Asia	O
and	O
many	O
other	O
regions	O
of	O
the	O
world	O
are	O
chronically	Condition
exposed	Condition
to	Condition
arsenic-contaminated	Condition
drinking	Condition
water	Condition
.	O

To	O
various	O
degrees	O
,	O
ingested	O
inorganic	O
arsenic	O
(	O
InAs	O
)	O
is	O
methylated	O
to	O
monomethylarsonic	O
acid	O
(	O
MMA	O
)	O
and	O
dimethylarsinic	O
acid	O
(	O
DMA	O
)	O
via	O
folate-dependent	O
one-carbon	O
metabolism	O
;	O
impaired	O
methylation	O
is	O
associated	O
with	O
adverse	O
health	O
outcomes	O
.	O

Consequently	O
,	O
folate	O
nutritional	O
status	O
may	O
influence	O
arsenic	O
methylation	O
and	O
toxicity	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
folic	O
acid	O
supplementation	O
of	O
arsenic-exposed	O
adults	O
would	O
increase	O
arsenic	O
methylation	O
.	O

DESIGN	O
Two	SampleSize
hundred	SampleSize
adults	O
in	O
a	O
rural	O
region	O
of	O
Bangladesh	O
,	O
previously	O
found	O
to	O
have	O
low	Condition
plasma	Condition
concentrations	Condition
of	Condition
folate	Condition
(	Condition
<	Condition
/=9	Condition
nmol/L	Condition
)	Condition
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
folic	O
acid-supplementation	O
trial	O
.	O

Plasma	O
concentrations	O
of	O
folate	O
and	O
homocysteine	O
and	O
urinary	O
concentrations	O
of	O
arsenic	O
metabolites	O
were	O
analyzed	O
at	O
baseline	O
and	O
after	O
12	O
wk	O
of	O
supplementation	O
with	O
folic	O
acid	O
at	O
a	O
dose	O
of	O
400	O
microg/d	O
or	O
placebo	O
.	O

RESULTS	O
The	O
increase	O
in	O
the	O
proportion	O
of	O
total	O
urinary	O
arsenic	O
excreted	O
as	O
DMA	O
in	O
the	O
folic	O
acid	O
group	O
(	O
72	O
%	O
before	O
and	O
79	O
%	O
after	O
supplementation	O
)	O
was	O
significantly	O
(	O
P	O
<	O
0.0001	O
)	O
greater	O
than	O
that	O
in	O
the	O
placebo	O
group	O
,	O
as	O
was	O
the	O
reduction	O
in	O
the	O
proportions	O
of	O
total	O
urinary	O
arsenic	O
excreted	O
as	O
MMA	O
(	O
13	O
%	O
and	O
10	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
as	O
InAs	O
(	O
15	O
%	O
and	O
11	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
These	O
data	O
indicate	O
that	O
folic	O
acid	O
supplementation	O
to	O
participants	O
with	O
low	Condition
plasma	Condition
folate	Condition
enhances	O
arsenic	O
methylation	O
.	O

Because	O
persons	O
whose	O
urine	O
contains	O
low	O
proportions	O
of	O
DMA	O
and	O
high	O
proportions	O
of	O
MMA	O
and	O
InAs	O
have	O
been	O
reported	O
to	O
be	O
at	O
greater	O
risk	O
of	O
skin	O
and	O
bladder	O
cancers	O
and	O
peripheral	O
vascular	O
disease	O
,	O
these	O
results	O
suggest	O
that	O
folic	O
acid	O
supplementation	O
may	O
reduce	O
the	O
risk	O
of	O
arsenic-related	O
health	O
outcomes	O
.	O

Impact	O
of	O
angiotensin	O
II	O
receptor	O
blocker	O
therapy	O
(	O
olmesartan	O
or	O
valsartan	O
)	O
on	O
coronary	O
atherosclerotic	O
plaque	O
volume	O
measured	O
by	O
intravascular	O
ultrasound	O
in	O
patients	O
with	O
stable	Condition
angina	Condition
pectoris	Condition
.	O

Coronary	O
plaques	O
can	O
be	O
reduced	O
by	O
some	O
medications	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
2	O
angiotensin	O
II	O
receptor	O
blockers	O
(	O
olmesartan	O
at	O
20	O
mg/day	O
or	O
valsartan	O
at	O
80	O
mg/day	O
)	O
on	O
coronary	O
plaque	O
by	O
coronary	O
intravascular	O
ultrasound	O
.	O

One	SampleSize
hundred	SampleSize
hypertensive	Condition
patients	O
with	O
stable	Condition
angina	Condition
pectoris	Condition
who	O
underwent	O
elective	O
percutaneous	O
coronary	O
intervention	O
were	O
randomly	O
selected	O
to	O
receive	O
1	O
of	O
the	O
2	O
angiotensin	O
II	O
receptor	O
blockers	O
after	O
coronary	O
intervention	O
.	O

Nontarget	O
coronary	O
lesions	O
with	O
mild	O
to	O
moderate	O
stenosis	O
were	O
measured	O
by	O
volumetric	O
intravascular	O
ultrasound	O
at	O
baseline	O
and	O
after	O
6	O
months	O
.	O

After	O
6	O
months	O
,	O
both	O
the	O
olmesartan	O
and	O
the	O
valsartan	O
groups	O
showed	O
significant	O
reduction	O
of	O
the	O
examined	O
coronary	O
plaque	O
volume	O
(	O
46.2	O
?	O
24.1	O
mm?	O
at	O
baseline	O
vs	O
41.6	O
?	O
21.1	O
mm?	O
at	O
6	O
months	O
:	O
4.7	O
%	O
decrease	O
,	O
p	O
=	O
0.0002	O
;	O
and	O
47.2	O
?	O
32.7	O
mm?	O
at	O
baseline	O
vs	O
42.5	O
?	O
30.2	O
mm?	O
at	O
6	O
months	O
:	O
4.8	O
%	O
decrease	O
,	O
p	O
=	O
0.002	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
of	O
plaque	O
regression	O
between	O
the	O
2	O
groups	O
(	O
p	O
=	O
0.96	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
from	O
baseline	O
in	O
the	O
coronary	O
plaque	O
volume	O
in	O
patients	O
with	O
stable	O
angina	O
pectoris	O
who	O
received	O
olmesartan	O
or	O
valsartan	O
for	O
6	O
months	O
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
reduction	O
of	O
plaque	O
volume	O
achieved	O
by	O
these	O
2	O
medications	O
.	O

A	O
randomised	O
comparison	O
of	O
three	O
drainage	O
systems	O
following	O
cholecystectomy	O
.	O

The	O
efficacy	O
of	O
low	O
pressure	O
,	O
high	O
pressure	O
and	O
passive	O
drainage	O
systems	O
have	O
been	O
compared	O
after	O
cholecystectomy	O
.	O

Symptoms	O
of	O
pain	O
,	O
discomfort	O
and	O
nausea	O
were	O
compared	O
using	O
linear	O
analogue	O
scales	O
and	O
spirometry	O
was	O
used	O
to	O
examine	O
pre-operative	O
and	O
postoperative	O
respiratory	O
function	O
.	O

The	O
low	O
pressure	O
suction	O
drain	O
removed	O
an	O
intraperitoneal	O
marker	O
,	O
gentamicin	O
,	O
more	O
effectively	O
than	O
the	O
high	O
pressure	O
suction	O
drain	O
,	O
but	O
not	O
more	O
effectively	O
than	O
the	O
passive	O
drain	O
.	O

There	O
were	O
no	O
differences	O
in	O
postoperative	O
respiratory	O
function	O
nor	O
in	O
the	O
amount	O
of	O
pain	O
or	O
discomfort	O
between	O
the	O
groups	O
.	O

The	O
passive	O
drain	O
group	O
reported	O
less	O
nausea	O
than	O
the	O
suction	O
drain	O
groups	O
.	O

If	O
a	O
negative	O
pressure	O
drainage	O
system	O
is	O
to	O
be	O
used	O
,	O
a	O
low	O
pressure	O
suction	O
drain	O
should	O
be	O
used	O
in	O
preference	O
to	O
a	O
high	O
pressure	O
system	O
.	O

Hysteroscopic	O
morcellation	O
compared	O
with	O
electrical	O
resection	O
of	O
endometrial	O
polyps	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
evaluate	O
whether	O
hysteroscopic	O
morcellation	O
or	O
bipolar	O
electrosurgical	O
resection	O
is	O
more	O
favorable	O
for	O
removing	O
endometrial	O
polyps	O
in	O
an	O
office	O
setting	O
in	O
terms	O
of	O
feasibility	O
,	O
speed	O
,	O
pain	O
,	O
and	O
acceptability	O
.	O

METHODS	O
A	O
multicenter	O
,	O
single-blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
of	O
office	O
hysteroscopic	O
morcellation	O
compared	O
with	O
electrosurgical	O
resection	O
was	O
conducted	O
.	O

A	O
total	O
of	O
121	O
women	O
were	O
randomly	O
allocated	O
to	O
polyp	O
removal	O
by	O
one	O
of	O
the	O
two	O
methods	O
in	O
an	O
office	O
setting	O
.	O

The	O
outcomes	O
assessed	O
were	O
time	O
taken	O
to	O
complete	O
the	O
endometrial	O
polypectomy	O
,	O
defined	O
as	O
the	O
time	O
from	O
insertion	O
to	O
removal	O
of	O
vaginal	O
instrumentation	O
,	O
completeness	O
of	O
polyp	O
removal	O
,	O
acceptability	O
,	O
and	O
pain	O
measured	O
on	O
a	O
100-mm	O
visual	O
analog	O
scale	O
.	O

RESULTS	O
The	O
median	O
time	O
taken	O
to	O
complete	O
the	O
procedure	O
was	O
5	O
minutes	O
and	O
28	O
seconds	O
for	O
morcellation	O
compared	O
with	O
10	O
minutes	O
and	O
12	O
seconds	O
for	O
electrosurgical	O
resection	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
polyps	O
were	O
completely	O
removed	O
in	O
61	O
out	O
of	O
62	O
(	O
98	O
%	O
)	O
women	O
assigned	O
to	O
morcellation	O
compared	O
with	O
49	O
out	O
of	O
59	O
(	O
83	O
%	O
)	O
women	O
treated	O
with	O
electrosurgical	O
resection	O
(	O
odds	O
ratio	O
12.5	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.5-100.6	O
;	O
P=.02	O
)	O
.	O

The	O
mean	O
pain	O
scores	O
during	O
the	O
procedure	O
favored	O
morcellation	O
by	O
16.1	O
points	O
on	O
average	O
(	O
35.9	O
compared	O
with	O
52.0	O
;	O
95	O
%	O
CI	O
for	O
difference	O
,	O
-24.7	O
to	O
-7.6	O
;	O
P	O
<	O
.001	O
)	O
.	O

Overall	O
,	O
99	O
%	O
of	O
women	O
found	O
office	O
polypectomy	O
to	O
be	O
acceptable	O
,	O
with	O
only	O
one	O
woman	O
in	O
the	O
electrosurgical	O
resection	O
group	O
considering	O
the	O
procedure	O
unacceptable	O
.	O

CONCLUSION	O
In	O
comparison	O
to	O
electrosurgical	O
resection	O
during	O
hysteroscopic	O
polypectomy	O
,	O
morcellation	O
was	O
significantly	O
quicker	O
,	O
less	O
painful	O
,	O
more	O
acceptable	O
to	O
women	O
,	O
and	O
more	O
likely	O
to	O
completely	O
remove	O
endometrial	O
polyps	O
compared	O
with	O
electrosurgical	O
resection	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
,	O
www.clinicaltrials.gov	O
,	O
NCT01509313	O
.	O

Plasma	O
Epstein-Barr	O
virus	O
DNA	O
predicts	O
outcome	O
in	O
advanced	Condition
Hodgkin	Condition
lymphoma	Condition
:	O
correlative	O
analysis	O
from	O
a	O
large	O
North	O
American	O
cooperative	O
group	O
trial	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
associated	O
with	O
Hodgkin	O
lymphoma	O
(	O
HL	O
)	O
and	O
can	O
be	O
detected	O
by	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
of	O
viral	O
nucleic	O
acid	O
(	O
EBER	O
)	O
in	O
tumor	O
cells	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
plasma	O
EBV-DNA	O
could	O
serve	O
as	O
a	O
surrogate	O
for	O
EBER-ISH	O
and	O
to	O
explore	O
its	O
prognostic	O
utility	O
in	O
HL	O
.	O

Specimens	O
from	O
the	O
Cancer	O
Cooperative	O
Intergroup	O
Trial	O
E2496	O
were	O
used	O
to	O
compare	O
pretreatment	O
plasma	O
EBV-DNA	O
quantification	O
with	O
EBV	O
tumor	O
status	O
by	O
EBER-ISH	O
.	O

A	O
cutoff	O
of	O
>	O
60	O
viral	O
copies/100	O
?L	O
plasma	O
yielded	O
96	O
%	O
concordance	O
with	O
EBER-ISH	O
.	O

Pretreatment	O
and	O
month	O
6	O
plasma	O
specimens	O
were	O
designated	O
EBV	O
(	O
-	O
)	O
or	O
EBV	O
(	O
+	O
)	O
by	O
this	O
cutoff	O
.	O

Patients	O
with	O
pretreatment	O
EBV	O
(	O
+	O
)	O
plasma	O
(	O
n	O
=	O
54	O
)	O
had	O
inferior	O
failure-free	O
survival	O
(	O
FFS	O
)	O
compared	O
with	O
those	O
with	O
pretreatment	O
EBV	O
(	O
-	O
)	O
plasma	O
(	O
n	O
=	O
274	O
)	O
,	O
log-rank	O
P	O
=	O
.009	O
.	O

By	O
contrast	O
,	O
no	O
difference	O
in	O
FFS	O
was	O
observed	O
when	O
patients	O
were	O
stratified	O
by	O
EBER-ISH	O
.	O

Pretreatment	O
plasma	O
EBV	O
positivity	O
was	O
an	O
independent	O
predictor	O
of	O
treatment	O
failure	O
on	O
multivariate	O
analyses	O
.	O

At	O
month	O
6	O
,	O
plasma	O
EBV	O
(	O
+	O
)	O
patients	O
(	O
n	O
=	O
7	O
)	O
had	O
inferior	O
FFS	O
compared	O
with	O
plasma	O
EBV	O
(	O
-	O
)	O
patients	O
(	O
n	O
=	O
125	O
)	O
,	O
log-rank	O
P	O
=	O
.007	O
.	O

These	O
results	O
confirm	O
that	O
plasma	O
EBV-DNA	O
is	O
highly	O
concordant	O
with	O
EBER-ISH	O
in	O
HL	O
and	O
suggest	O
that	O
it	O
may	O
have	O
prognostic	O
utility	O
both	O
at	O
baseline	O
and	O
after	O
therapy	O
.	O

This	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT00003389	O
.	O

A	O
sensory	O
integration	O
therapy	O
program	O
on	O
sensory	Condition
problems	Condition
for	O
children	O
with	O
autism	Condition
.	O

The	O
study	O
was	O
planned	O
to	O
investigate	O
the	O
effect	O
of	O
a	O
sensory	O
integration	O
therapy	O
program	O
on	O
sensory	O
problems	O
of	O
children	O
with	O
autism	Condition
.	O

This	O
study	O
was	O
conducted	O
at	O
the	O
Trakya	O
University	O
Training	O
and	O
Research	O
Center	O
for	O
Mentally	O
and	O
Physically	O
Handicapped	O
Children	O
in	O
Turkey	O
.	O

The	O
children	O
were	O
separated	O
into	O
two	O
groups	O
,	O
each	O
comprising	O
15	SampleSize
children	O
between	O
7	O
and	O
11	O
years	O
of	O
age	O
with	O
autism	Condition
,	O
according	O
to	O
DSM-IV	O
criteria	O
.	O

The	O
children	O
in	O
each	O
group	O
were	O
assessed	O
initially	O
on	O
a	O
checklist	O
,	O
Sensory	O
Evaluation	O
Form	O
for	O
Children	O
with	O
Autism	O
,	O
developed	O
to	O
evaluate	O
sensory	O
characteristics	O
of	O
children	O
with	O
autism	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
participants	O
were	O
assessed	O
again	O
on	O
the	O
checklist	O
.	O

Statistically	O
significant	O
differences	O
between	O
groups	O
indicated	O
that	O
the	O
sensory	O
integration	O
therapy	O
program	O
positively	O
affected	O
treated	O
children	O
.	O

Long-term	O
survival	O
in	O
a	O
phase	O
III	O
,	O
randomised	O
study	O
of	O
topotecan	O
versus	O
paclitaxel	O
in	O
advanced	O
epithelial	O
ovarian	O
carcinoma	O
.	O

BACKGROUND	O
We	O
have	O
continued	O
to	O
monitor	O
the	O
survival	O
of	O
patients	O
randomised	O
in	O
a	O
previously	O
reported	O
multicentre	O
phase	O
III	O
study	O
of	O
topotecan	O
versus	O
paclitaxel	O
in	O
patients	O
with	O
advanced	O
epithelial	O
ovarian	O
cancer	O
who	O
had	O
failed	O
one	O
prior	O
platinum-based	O
regimen	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
bidimensionally	O
measurable	O
disease	O
were	O
randomised	O
to	O
topotecan	O
(	O
1.5	O
mg/m	O
(	O
2	O
)	O
/day	O
for	O
5	O
days	O
)	O
or	O
paclitaxel	O
(	O
175	O
mg/m	O
(	O
2	O
)	O
/day	O
as	O
a	O
3-h	O
infusion	O
)	O
every	O
21	O
days	O
.	O

Patients	O
were	O
eligible	O
for	O
treatment	O
with	O
the	O
alternate	O
therapy	O
at	O
third	O
line	O
.	O

The	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
(	O
EORTC	O
QOL	O
)	O
-C30	O
questionnaire	O
was	O
also	O
used	O
to	O
measure	O
eight	O
symptoms	O
at	O
baseline	O
and	O
during	O
each	O
course	O
(	O
pain	O
,	O
anorexia	O
,	O
diarrhoea	O
,	O
fatigue	O
,	O
nausea	O
and	O
vomiting	O
,	O
dyspnea	O
,	O
constipation	O
and	O
insomnia	O
)	O
.	O

RESULTS	O
A	O
total	O
of	O
226	O
patients	O
were	O
evaluable	O
for	O
response	O
.	O

Demographic	O
characteristics	O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
,	O
as	O
were	O
results	O
of	O
the	O
EORTC	O
QOL-30	O
questionnaire	O
.	O

For	O
the	O
topotecan	O
group	O
,	O
median	O
time	O
to	O
progression	O
was	O
18.9	O
weeks	O
(	O
range	O
<	O
1	O
to	O
92.6+	O
weeks	O
;	O
25	O
%	O
censored	O
)	O
,	O
and	O
,	O
for	O
paclitaxel	O
,	O
14.7	O
weeks	O
(	O
range	O
<	O
1	O
to	O
137.3+	O
weeks	O
;	O
12.3	O
%	O
censored	O
)	O
;	O
P	O
=	O
0.076	O
.	O

At	O
4	O
years	O
post-randomisation	O
,	O
median	O
survival	O
in	O
the	O
topotecan	O
group	O
was	O
63.0	O
weeks	O
(	O
range	O
<	O
1	O
to	O
238.4+	O
weeks	O
;	O
20.5	O
%	O
censored	O
)	O
and	O
,	O
for	O
paclitaxel	O
,	O
53.0	O
weeks	O
(	O
range	O
<	O
1	O
to	O
226.3+	O
weeks	O
;	O
12.3	O
%	O
censored	O
)	O
;	O
P	O
=	O
0.44	O
.	O

CONCLUSION	O
Topotecan	O
continues	O
to	O
demonstrate	O
comparable	O
efficacy	O
and	O
survival	O
to	O
paclitaxel	O
with	O
manageable	O
and	O
non-cumulative	O
haematological	O
toxicity	O
.	O

Non-haematological	O
toxicity	O
was	O
generally	O
mild	O
for	O
both	O
groups	O
.	O

The	O
long-term	O
survival	O
rate	O
indicates	O
substantial	O
therapeutic	O
benefit	O
for	O
this	O
group	O
of	O
patients	O
receiving	O
topotecan	O
at	O
relapse	O
of	O
ovarian	O
cancer	O
.	O

Double	O
blind	O
,	O
placebo	O
controlled	O
study	O
of	O
metronidazole	Condition
as	Condition
a	Condition
disease	Condition
modifying	Condition
agent	Condition
in	Condition
the	Condition
treatment	Condition
of	Condition
rheumatoid	Condition
arthritis	Condition
.	Condition

Anecdotal	O
reports	O
suggest	O
that	O
metronidazole	O
may	O
have	O
disease	O
modifying	O
activity	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

To	O
assess	O
possible	O
beneficial	O
effects	O
a	O
double	O
blind	O
,	O
comparative	O
trial	O
of	O
metronidazole	O
and	O
placebo	O
was	O
performed	O
.	O

Fifty	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	O
were	O
randomly	O
allocated	O
to	O
receive	O
active	O
drug	O
(	O
n	O
=	O
24	O
)	O
or	O
placebo	O
(	O
n	O
=	O
26	O
)	O
and	O
reviewed	O
at	O
weeks	O
0	O
,	O
1	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
and	O
24	O
.	O

Detailed	O
assessment	O
of	O
drug	O
safety	O
,	O
biochemical	O
and	O
haematological	O
parameters	O
,	O
and	O
efficacy	O
was	O
made	O
at	O
these	O
dates	O
.	O

Dose	O
regimen	O
was	O
400	O
mg	O
twice	O
daily	O
from	O
weeks	O
0	O
to	O
eight	O
,	O
increasing	O
to	O
400	O
mg	O
three	O
times	O
a	O
day	O
from	O
weeks	O
nine	O
to	O
24	O
provided	O
that	O
no	O
adverse	O
effects	O
were	O
recorded	O
.	O

Most	O
patients	O
were	O
unable	O
to	O
tolerate	O
metronidazole	O
because	O
of	O
side	O
effects	O
or	O
lack	O
of	O
efficacy	O
,	O
with	O
only	O
five	O
(	O
21	O
%	O
)	O
continuing	O
to	O
take	O
the	O
drug	O
at	O
24	O
weeks	O
.	O

For	O
those	O
patients	O
attaining	O
12	O
weeks	O
of	O
treatment	O
an	O
overall	O
improvement	O
in	O
articular	O
index	O
and	O
morning	O
stiffness	O
was	O
found	O
.	O

No	O
improvement	O
in	O
laboratory	O
indices	O
of	O
disease	O
activity	O
was	O
seen	O
,	O
however	O
.	O

In	O
this	O
study	O
metronidazole	O
did	O
not	O
have	O
disease	O
modifying	O
properties	O
and	O
was	O
unacceptably	O
toxic	O
.	O

The	O
role	O
of	O
the	O
MA-sensitive	O
leukocyte	O
chemotaxis	O
in	O
rheumatoid	Condition
arthritis	Condition
.	O

A	O
randomized	O
double-blind	O
clinical	O
trial	O
of	O
griseofulvin	O
treatment	O
.	O

Polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
chemotaxis	O
is	O
thought	O
to	O
play	O
an	O
essential	O
role	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O

PMN	O
chemotaxis	O
is	O
in	O
part	O
sensitive	O
to	O
microtubule	O
antagonists	O
(	O
MAs	O
)	O
,	O
e.g	O
.	O

colchicine	O
.	O

The	O
antimycotic	O
antibiotic	O
griseofulvin	O
inhibits	O
the	O
MA-sensitive	O
PMN	O
chemotaxis	O
in	O
vitro	O
in	O
concentrations	O
far	O
below	O
those	O
obtained	O
in	O
serum	O
during	O
antimycotic	O
therapy	O
.	O

The	O
role	O
of	O
the	O
MA-sensitive	O
chemotaxis	O
in	O
rheumatoid	O
arthritis	O
could	O
thus	O
be	O
elucidated	O
by	O
a	O
clinical	O
trial	O
of	O
griseofulvin	O
treatment	O
.	O

Griseofulvin	O
(	O
n	O
=	O
20	SampleSize
)	O
was	O
tested	O
in	O
a	O
randomized	O
double-blind	O
study	O
versus	O
placebo	O
(	O
m	O
=	O
19	SampleSize
)	O
during	O
one	O
year	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
of	O
mild-moderate	O
activity	O
.	O

No	O
beneficial	O
effect	O
of	O
griseofulvin	O
treatment	O
was	O
noted	O
on	O
clinical	O
symptoms	O
or	O
laboratory	O
parameters	O
of	O
rheumatoid	O
arthritis	O
.	O

Moreover	O
,	O
the	O
placebo-treated	O
patients	O
showed	O
more	O
improvement	O
than	O
the	O
griseofulvin-treated	O
patients	O
.	O

It	O
is	O
therefore	O
suggested	O
that	O
the	O
MA-sensitive	O
chemotaxis	O
plays	O
a	O
reparative	O
role	O
in	O
the	O
inflammatory	O
lesions	O
of	O
rheumatoid	O
arthritis	O
.	O

The	O
effect	O
of	O
prethrombolytic	O
cyclosporine-A	O
injection	O
on	O
clinical	O
outcome	O
of	O
acute	O
anterior	O
ST-elevation	O
myocardial	O
infarction	O
.	O

INTRODUCTION	O
Reperfusion	O
injury	O
reduces	O
the	O
benefits	O
of	O
early	O
reperfusion	O
therapies	O
after	O
acute	O
ST-elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
.	O

Cyclosporine-A	O
(	O
CsA	O
)	O
is	O
a	O
potent	O
inhibitor	O
of	O
opening	O
of	O
the	O
mitochondrial	O
permeability	O
transition	O
pore	O
,	O
which	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
myocardial	O
reperfusion	O
injury	O
.	O

The	O
impact	O
of	O
this	O
treatment	O
on	O
clinical	O
outcomes	O
of	O
acute	O
STEMI	O
remains	O
unknown	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
clinical	O
outcomes	O
of	O
using	O
this	O
drug	O
in	O
patients	O
with	O
acute	O
anterior	O
STEMI	O
receiving	O
thrombolytic	O
treatment	O
(	O
TLT	O
)	O
.	O

METHODS	O
In	O
this	O
double-blinded	O
randomized	O
clinical	O
trial	O
,	O
101	O
patients	O
with	O
acute	O
anterior	O
STEMI	O
who	O
were	O
candidate	O
for	O
TLT	O
,	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
into	O
treatment	O
or	O
control	O
groups	O
.	O

Patients	O
in	O
the	O
treatment	O
group	O
received	O
an	O
intravenous	O
bolus	O
injection	O
of	O
2.5	O
mg/kg	O
of	O
CsA	O
immediately	O
before	O
TLT	O
.	O

The	O
patients	O
in	O
the	O
control	O
group	O
received	O
an	O
equivalent	O
volume	O
of	O
normal	O
saline	O
.	O

Infarct	O
size	O
,	O
occurrence	O
of	O
major	O
arrhythmias	O
,	O
heart	O
failure	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
TLT-related	O
complications	O
,	O
in-hospital	O
and	O
6-month	O
mortality	O
rates	O
were	O
investigated	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
demographics	O
,	O
myocardial	O
enzyme	O
release	O
,	O
occurrence	O
of	O
major	O
arrhythmias	O
[	O
9	O
(	O
18	O
%	O
)	O
vs.	O
12	O
(	O
23.5	O
%	O
)	O
,	O
P	O
=	O
0.80	O
]	O
,	O
heart	O
failure	O
[	O
18	O
(	O
36	O
%	O
)	O
vs.	O
19	O
(	O
38.3	O
%	O
)	O
,	O
P	O
=	O
0.83	O
]	O
,	O
LVEF	O
at	O
first	O
day	O
[	O
34.7	O
?	O
9.9	O
%	O
vs.	O
33.5	O
?	O
8.1	O
%	O
,	O
P	O
=	O
0.50	O
]	O
or	O
at	O
discharge	O
[	O
37.7	O
?	O
10	O
%	O
vs.	O
36.1	O
?	O
8.2	O
%	O
,	O
P	O
=	O
0.43	O
]	O
,	O
and	O
in-hospital	O
[	O
4	O
(	O
8	O
%	O
)	O
vs.	O
6	O
(	O
11.8	O
%	O
)	O
,	O
P	O
=	O
0.74	O
]	O
or	O
6-month	O
mortality	O
rates	O
[	O
9	O
(	O
18	O
%	O
)	O
vs.	O
10	O
(	O
19.6	O
%	O
)	O
,	O
P	O
=	O
0.99	O
]	O
between	O
the	O
CsA	O
vs.	O
the	O
control	O
group	O
.	O

CONCLUSION	O
In	O
this	O
study	O
,	O
the	O
prethrombolytic	O
administration	O
of	O
CsA	O
was	O
not	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
infarct	O
size	O
or	O
any	O
improvement	O
in	O
clinical	O
outcomes	O
.	O

A	O
randomized	O
crossover	O
study	O
comparing	O
patient	O
preference	O
for	O
tamsulosin	O
and	O
silodosin	O
in	O
patients	O
with	O
lower	Condition
urinary	Condition
tract	Condition
symptoms	Condition
associated	O
with	O
benign	Condition
prostatic	Condition
hyperplasia	Condition
.	O

Patient	O
preference	O
for	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
treatment	O
with	O
the	O
?	O
(	O
1	O
)	O
-blockers	O
,	O
tamsulosin	O
or	O
silodosin	O
,	O
was	O
compared	O
using	O
patient-reported	O
outcomes	O
.	O

Japanese	O
patients	O
with	O
lower	Condition
urinary	Condition
tract	Condition
symptoms	O
associated	O
with	O
BPH	O
were	O
randomly	O
allocated	O
to	O
either	O
the	O
T-S	O
group	O
(	O
tamsulosin	O
0.2	O
mg	O
orally	O
once	O
daily	O
for	O
4	O
weeks	O
then	O
silodosin	O
4	O
mg	O
orally	O
twice	O
daily	O
for	O
4	O
weeks	O
)	O
or	O
the	O
S-T	O
group	O
(	O
silodosin	O
4	O
mg	O
orally	O
twice	O
daily	O
for	O
4	O
weeks	O
then	O
tamsulosin	O
0.2	O
mg	O
orally	O
once	O
daily	O
for	O
4	O
weeks	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
preferred	O
drug	O
for	O
treatment	O
continuation	O
at	O
8	O
weeks	O
,	O
determined	O
by	O
a	O
patient-reported	O
questionnaire	O
.	O

In	O
total	O
,	O
102	O
patients	O
(	O
mean	Age
age	Age
70.3	Age
years	Age
)	O
were	O
enrolled	O
and	O
84	O
(	O
n	O
=	O
42	O
per	O
group	O
)	O
completed	O
the	O
study	O
.	O

A	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
proportion	O
of	O
patients	O
who	O
preferred	O
tamsulosin	O
(	O
59/84	O
patients	O
;	O
70.2	O
%	O
)	O
and	O
those	O
who	O
preferred	O
silodosin	O
(	O
18/84	O
patients	O
;	O
21.4	O
%	O
)	O
.	O

A	O
major	O
reason	O
for	O
preference	O
of	O
either	O
drug	O
was	O
'good	O
efficacy	O
'	O
.	O

Incidence	O
of	O
adverse	O
effects	O
was	O
significantly	O
lower	O
with	O
tamsulosin	O
(	O
3/91	O
patients	O
;	O
3.3	O
%	O
)	O
than	O
with	O
silodosin	O
(	O
25/88	O
patients	O
;	O
28.4	O
%	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
tamsulosin	O
is	O
very	O
effective	O
for	O
BPH	O
,	O
has	O
few	O
adverse	O
effects	O
and	O
that	O
patients	O
want	O
to	O
continue	O
to	O
use	O
it	O
.	O

Role	O
of	O
diltiazem	O
in	O
the	O
treatment	O
of	O
silent	O
myocardial	O
ischemia	O
.	O

Silent	O
myocardial	O
ischemia	O
is	O
a	O
frequent	O
finding	O
when	O
Holter	O
monitoring	O
is	O
done	O
in	O
patients	O
with	O
advanced	Condition
coronary	Condition
disease	Condition
.	O

Silent	O
ischemia	O
is	O
associated	O
with	O
a	O
worse	O
prognosis	O
in	O
patients	O
with	O
stable	O
or	O
unstable	O
angina	O
,	O
survivors	O
of	O
myocardial	O
infarction	O
,	O
and	O
populations	O
at	O
risk	O
for	O
coronary	O
disease	O
.	O

Whether	O
medical	O
therapy	O
for	O
silent	O
ischemia	O
improves	O
prognosis	O
is	O
not	O
known	O
.	O

In	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
multicenter	O
trial	O
of	O
60	SampleSize
patients	O
with	O
documented	O
coronary	Condition
disease	Condition
,	Condition
positive	O
exercise	O
tests	O
,	O
and	O
ischemic	O
episodes	O
on	O
Holter	O
monitoring	O
,	O
long-acting	O
diltiazem	O
reduced	O
ischemic	O
episodes	O
by	O
50	O
%	O
compared	O
to	O
placebo	O
,	O
from	O
a	O
mean	O
of	O
5.6	O
to	O
2.8	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

Efficacy	O
was	O
maintained	O
over	O
24	O
h	O
and	O
diltiazem	O
also	O
significantly	O
improved	O
exercise	O
test	O
parameters	O
.	O

Three	O
smaller	O
studies	O
also	O
demonstrated	O
that	O
diltiazem	O
effectively	O
reduces	O
ambulatory	O
ischemia	O
;	O
however	O
,	O
results	O
with	O
nifedipine	O
are	O
conflicting	O
,	O
with	O
several	O
studies	O
showing	O
no	O
benefit	O
.	O

In	O
contrast	O
,	O
beta-blockers	O
reliably	O
reduce	O
ischemic	O
episodes	O
.	O

The	O
role	O
of	O
medical	O
therapy	O
for	O
silent	O
ischemia	O
will	O
be	O
clarified	O
only	O
when	O
its	O
effect	O
upon	O
morbidity	O
and	O
mortality	O
are	O
determined	O
.	O

Clinical	O
trial	O
:	O
marine	O
lipid	O
suppositories	O
as	O
laxatives	O
.	O

UNLABELLED	O
Cod-liver	O
oil	O
and	O
other	O
marine	O
products	O
containing	O
polyunsaturated	O
fatty	O
acids	O
have	O
anti-inflammatory	O
,	O
anti-bacterial	O
and	O
anti-viral	O
effects	O
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
inflammatory	O
and	O
infectious	O
diseases	O
.	O

We	O
developed	O
suppositories	O
and	O
ointment	O
with	O
30	O
%	O
free	O
fatty	O
acid	O
(	O
FFA	O
)	O
extract	O
from	O
omega-3	O
fish	O
oil	O
.	O

Our	O
purpose	O
was	O
to	O
evaluate	O
the	O
safety	O
of	O
marine	O
lipid	O
suppositories	O
and	O
ointment	O
in	O
healthy	Condition
volunteers	Condition
and	O
to	O
explore	O
the	O
laxative	O
effect	O
of	O
the	O
suppositories	O
.	O

Thirty	O
healthy	O
volunteers	O
were	O
randomized	O
either	O
to	O
a	O
study	O
group	O
administrating	O
30	O
%	O
FFA	O
suppositories	O
and	O
applying	O
30	O
%	O
FFA	O
ointment	O
to	O
the	O
perianal	O
region	O
twice	O
per	O
day	O
for	O
two	O
weeks	O
,	O
or	O
to	O
a	O
control	O
group	O
using	O
placebo	O
suppositories	O
and	O
ointment	O
in	O
a	O
double	O
blinded	O
manner	O
.	O

RESULTS	O
No	O
serious	O
toxic	O
effects	O
or	O
irritation	O
were	O
observed	O
.	O

In	O
the	O
study	O
group	O
93	O
%	O
felt	O
the	O
urge	O
to	O
defecate	O
after	O
administration	O
of	O
the	O
suppositories	O
as	O
compared	O
to	O
37	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0.001	O
)	O
.	O

Subsequently	O
90	O
%	O
in	O
the	O
study	O
group	O
defecated	O
,	O
compared	O
to	O
33	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0.001	O
)	O
.	O

CONCLUSION	O
The	O
marine	O
lipid	O
suppositories	O
and	O
ointment	O
were	O
well	O
tolerated	O
with	O
no	O
significant	O
toxic	O
side	O
effects	O
observed	O
during	O
the	O
study	O
period	O
.	O

The	O
suppositories	O
have	O
a	O
distinct	O
laxative	O
effect	O
and	O
we	O
aim	O
to	O
explore	O
this	O
effect	O
in	O
further	O
clinical	O
trials	O
.	O

The	O
IDvIP	O
trial	O
:	O
a	O
two-centre	O
randomised	O
double-blind	O
controlled	O
trial	O
comparing	O
intramuscular	O
diamorphine	O
and	O
intramuscular	O
pethidine	O
for	O
labour	O
analgesia	O
.	O

BACKGROUND	O
Intramuscular	O
pethidine	O
is	O
routinely	O
used	O
throughout	O
the	O
UK	O
for	O
labour	O
analgesia	O
.	O

Studies	O
have	O
suggested	O
that	O
pethidine	O
provides	O
little	O
pain	O
relief	O
in	O
labour	O
and	O
has	O
a	O
number	O
of	O
side	O
effects	O
affecting	O
mother	O
and	O
neonate	O
.	O

It	O
can	O
cause	O
nausea	O
,	O
vomiting	O
and	O
dysphoria	O
in	O
mothers	O
and	O
can	O
cause	O
reduced	O
fetal	O
heart	O
rate	O
variability	O
and	O
accelerations	O
.	O

Neonatal	O
effects	O
include	O
respiratory	O
depression	O
and	O
impaired	O
feeding	O
.	O

There	O
are	O
few	O
large	O
studies	O
comparing	O
the	O
relative	O
side	O
effects	O
and	O
efficacy	O
of	O
different	O
opioids	O
in	O
labour	O
.	O

A	O
small	O
trial	O
comparing	O
intramuscular	O
pethidine	O
with	O
diamorphine	O
,	O
showed	O
diamorphine	O
to	O
have	O
some	O
benefits	O
over	O
pethidine	O
when	O
used	O
for	O
labour	O
analgesia	O
but	O
the	O
study	O
did	O
not	O
investigate	O
the	O
adverse	O
effects	O
of	O
either	O
opioid	O
.	O

METHODS	O
The	O
Intramuscular	O
Diamorphine	O
versus	O
Intramuscular	O
Pethidine	O
(	O
IDvIP	O
)	O
trial	O
is	O
a	O
randomised	O
double-blind	O
two	O
centre	O
controlled	O
trial	O
comparing	O
intramuscular	O
diamorphine	O
and	O
pethidine	O
regarding	O
their	O
analgesic	O
efficacy	O
in	O
labour	O
and	O
their	O
side	O
effects	O
in	O
mother	O
,	O
fetus	O
and	O
neonate	O
.	O

Information	O
about	O
the	O
trial	O
will	O
be	O
provided	O
to	O
women	O
in	O
the	O
antenatal	O
period	O
or	O
in	O
early	O
labour	O
.	O

Consent	O
and	O
recruitment	O
to	O
the	O
trial	O
will	O
be	O
obtained	O
when	O
the	O
mother	O
requests	O
opioid	O
analgesia	O
.	O

The	O
sample	O
size	O
requirement	O
is	O
406	O
women	O
with	O
data	O
on	O
primary	O
outcomes	O
.	O

The	O
maternal	O
primary	O
outcomes	O
are	O
pain	O
relief	O
during	O
the	O
first	O
3	O
hours	O
after	O
trial	O
analgesia	O
and	O
specifically	O
pain	O
relief	O
after	O
60	O
minutes	O
.	O

The	O
neonatal	O
primary	O
outcomes	O
are	O
need	O
for	O
resuscitation	O
and	O
Apgar	O
Score	O
<	O
7	O
at	O
1	O
minute	O
.	O

The	O
secondary	O
outcomes	O
are	O
an	O
additional	O
measure	O
of	O
pain	O
relief	O
,	O
maternal	O
sedation	O
,	O
nausea	O
and	O
vomiting	O
,	O
maternal	O
oxygen	O
saturation	O
,	O
satisfaction	O
with	O
analgesia	O
,	O
whether	O
method	O
of	O
analgesia	O
would	O
be	O
used	O
again	O
,	O
use	O
of	O
Entonox	O
,	O
umbilical	O
arterial	O
and	O
venous	O
pH	O
,	O
fetal	O
heart	O
rate	O
,	O
meconium	O
staining	O
,	O
time	O
from	O
delivery	O
to	O
first	O
breath	O
,	O
Apgar	O
scores	O
at	O
5	O
mins	O
,	O
naloxone	O
requirement	O
,	O
transfer	O
to	O
neonatal	O
intensive	O
care	O
unit	O
,	O
neonatal	O
haemoglobin	O
oxygen	O
saturation	O
at	O
30	O
,	O
60	O
,	O
90	O
,	O
and	O
120	O
mins	O
after	O
delivery	O
,	O
and	O
neonatal	O
sedation	O
and	O
feeding	O
behaviour	O
during	O
first	O
2	O
hours	O
.	O

DISCUSSION	O
If	O
the	O
trial	O
demonstrates	O
that	O
diamorphine	O
provides	O
better	O
analgesia	O
with	O
fewer	O
side	O
effects	O
in	O
mother	O
and	O
neonate	O
this	O
could	O
lead	O
to	O
a	O
change	O
in	O
national	O
practice	O
and	O
result	O
in	O
diamorphine	O
becoming	O
the	O
preferred	O
intramuscular	O
opioid	O
for	O
analgesia	O
in	O
labour	O
.	O

TRIAL	O
REGISTRATION	O
ISRCTN14898678Eudra	O
No	O
:	O
2006-003250-18	O
,	O
REC	O
Reference	O
No	O
:	O
06/Q1702/95	O
,	O
MHRA	O
Authorisation	O
No	O
:	O
1443/0001/001-0001	O
,	O
NIHR	O
UKCRN	O
reference	O
6895	O
,	O
RfPB	O
grant	O
PB-PG-0407-13170_IR5	O
.	O

Social	O
competence	O
and	O
social	O
skills	O
training	O
and	O
intervention	O
for	O
children	O
with	O
Autism	Condition
Spectrum	Condition
Disorders	Condition
.	O

This	O
study	O
examined	O
the	O
effectiveness	O
of	O
a	O
30	O
week	O
social	O
competence	O
and	O
social	O
skills	O
group	O
intervention	O
program	O
with	O
children	O
,	O
ages	O
7-11	O
,	O
diagnosed	Condition
with	Condition
Autism	Condition
Spectrum	Condition
Disorders	Condition
(	Condition
ASD	Condition
)	Condition
.	O

Eighteen	Condition
children	Condition
with	O
ASD	Condition
were	O
assessed	O
with	O
pretreatment	O
and	O
posttreatment	O
measures	O
on	O
the	O
Walker-McConnell	O
Scale	O
(	O
WMS	O
)	O
and	O
the	O
MGH	O
YouthCare	O
Social	O
Competence	O
Development	O
Scale	O
.	O

Each	O
received	O
the	O
30-week	O
intervention	O
program	O
.	O

For	O
comparison	O
,	O
a	O
matched	O
sample	O
of	O
ten	Condition
non-ASD	O
children	O
was	O
also	O
assessed	O
,	O
but	O
received	O
no	O
treatment	O
.	O

The	O
findings	O
indicated	O
that	O
each	O
ASD	O
intervention	O
group	O
demonstrated	O
significant	O
gains	O
on	O
the	O
WMS	O
and	O
significant	O
improvement	O
in	O
the	O
areas	O
of	O
anxiety	O
management	O
,	O
joint	O
attention	O
,	O
and	O
flexibility/transitions	O
.	O

Results	O
suggest	O
that	O
this	O
approach	O
can	O
be	O
effective	O
in	O
improving	O
core	O
social	O
deficits	O
in	O
individuals	O
with	O
ASD	O
.	O

Radiotherapy	O
and	O
CCNU	O
in	O
the	O
treatment	O
of	O
high-grade	O
supratentorial	O
astrocytomas	O
.	O

Forty-one	SampleSize
consecutive	O
patients	O
with	O
supratentorial	Condition
primary	Condition
brain	Condition
tumors	Condition
(	O
38	SampleSize
Grade	Condition
III	Condition
and	Condition
IV	Condition
astrocytomas	Condition
,	O
one	SampleSize
giant-cell	Condition
astrocytoma	Condition
,	O
and	O
two	SampleSize
cases	O
with	O
insufficient	O
tissue	O
for	O
diagnosis	O
)	O
were	O
randomly	O
allocated	O
within	O
2	O
weeks	O
of	O
surgery	O
to	O
one	O
of	O
three	O
therapeutic	O
groups	O
.	O

Group	O
1	O
(	O
15	O
patients	O
)	O
received	O
radiation	O
therapy	O
totaling	O
4000	O
to	O
4500	O
rads	O
in	O
4	O
to	O
5	O
weeks	O
.	O

Group	O
2	O
(	O
13	O
patients	O
)	O
received	O
1-	O
(	O
2-chloroethyl	O
)	O
-3-cyclohexyl-1-nitrosourea	O
CCNU	O
)	O
130	O
mg/sq	O
m	O
orally	O
every	O
6	O
weeks	O
.	O

Group	O
3	O
(	O
13	O
patients	O
)	O
received	O
radiation	O
therapy	O
plus	O
CCNU	O
as	O
for	O
Groups	O
1	O
and	O
2	O
.	O

When	O
the	O
disease	O
progressed	O
,	O
patients	O
in	O
Groups	O
1	O
and	O
2	O
were	O
crossed	O
over	O
to	O
receive	O
CCNU	O
and	O
irradiation	O
respectively	O
.	O

The	O
median	O
survival	O
time	O
in	O
these	O
groups	O
was	O
188	O
,	O
259	O
,	O
and	O
252	O
days	O
,	O
and	O
the	O
mean	O
survival	O
263	O
,	O
262	O
,	O
and	O
329	O
days	O
.	O

The	O
median	O
time	O
from	O
diagnosis	O
to	O
crossover	O
(	O
Groups	O
1	O
and	O
2	O
)	O
or	O
to	O
progression	O
(	O
Group	O
3	O
)	O
was	O
163	O
,	O
99	O
,	O
and	O
220	O
days	O
,	O
and	O
the	O
mean	O
time	O
was	O
172	O
,	O
108	O
,	O
and	O
231	O
days	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
means	O
or	O
medians	O
in	O
any	O
of	O
these	O
situations	O
.	O

The	O
effect	O
of	O
eradication	O
of	O
Helicobacter	O
pylori	O
upon	O
the	O
duodenal	O
ulcer	O
recurrence	O
--	O
a	O
24	O
month	O
follow-up	O
study	O
.	O

OBJECTIVES	O
To	O
evaluate	O
the	O
effect	O
of	O
eradication	O
of	O
Helicobacter	O
pylori	O
(	O
H.pylori	O
)	O
in	O
the	O
patients	O
with	O
duodenal	Condition
ulcer	Condition
(	Condition
Du	Condition
)	Condition
upon	O
the	O
DU	O
recurrence	O
.	O

METHODS	O
This	O
study	O
was	O
performed	O
for	O
190	SampleSize
patients	O
with	O
DU	Condition
.	O

Four	O
different	O
methods-microscopy	O
of	O
Gram	O
stained	O
mucosal	O
smear	O
,	O
specific	O
culture	O
,	O
biopsy	O
urease	O
test	O
,	O
histology	O
of	O
H	O
&	O
E	O
staining-were	O
taken	O
for	O
identifying	O
colonization	O
of	O
H.	O
pylori	O
before	O
treatment	O
,	O
and	O
for	O
finding	O
the	O
eradication	O
of	O
H.	O
pylori	O
4	O
weeks	O
after	O
completion	O
of	O
therapy	O
in	O
each	O
treatment	O
group	O
(	O
cometidine	O
,	O
omeprazole	O
,	O
colloidal	O
bismuth	O
subcitrate	O
(	O
CBS	O
)	O
,	O
CBS	O
and	O
metronidazole	O
double	O
therapy	O
,	O
CBS	O
,	O
metronidazole	O
and	O
amoxicillin	O
triple	O
therapy	O
)	O
.	O

To	O
detect	O
DU	O
recurrence	O
,	O
the	O
gastroscopy	O
was	O
performed	O
at	O
6	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
months	O
after	O
therapy	O
.	O

RESULTS	O
The	O
eradication	O
rate	O
of	O
the	O
cimetidine	O
group	O
the	O
omeprazole	O
group	O
,	O
and	O
the	O
CBS	O
group	O
were	O
0	O
%	O
,	O
7.7	O
%	O
,	O
0	O
%	O
,	O
respectively	O
,	O
and	O
that	O
of	O
the	O
double	O
therapy	O
group	O
and	O
the	O
triple	O
therapy	O
group	O
were	O
44.4	O
%	O
and	O
89.3	O
%	O
,	O
respectively	O
.	O

Seventy	SampleSize
three	SampleSize
patients	O
who	O
were	O
followed	O
up	O
for	O
2	O
years	O
were	O
categorized	O
into	O
two	O
groups	O
according	O
to	O
the	O
eradication	O
of	O
H.	O
pylori	O
.	O

The	O
recurrence	O
rate	O
was	O
3.2	O
%	O
both	O
in	O
1	O
year	O
and	O
2	O
years	O
later	O
in	O
the	O
former	O
group-one	O
consisting	O
of	O
31	SampleSize
patients	O
with	O
H.	O
pylori	O
eradicated	O
,	O
while	O
the	O
recurrence	O
rate	O
was	O
57.1	O
%	O
in	O
1	O
year	O
and	O
78.6	O
%	O
in	O
2	O
years	O
later	O
,	O
in	O
the	O
latter	O
group-the	O
other	O
of	O
42	SampleSize
patients	O
with	O
H.	O
pylori	O
not	O
eradicated	O
.	O

CONCLUSION	O
The	O
eradication	O
of	O
H.	O
pylori	O
in	O
patients	O
with	O
DU	Condition
reduces	O
the	O
recurrence	O
of	O
DU	O
.	O

Safety	O
and	O
immunogenicity	O
of	O
a	O
combined	O
pentavalent	O
diphtheria	O
,	O
tetanus	O
,	O
acellular	O
pertussis	O
,	O
inactivated	O
poliovirus	O
and	O
Haemophilus	O
influenzae	O
type	O
b-tetanus	O
conjugate	O
vaccine	O
in	O
infants	Age
,	O
compared	O
with	O
a	O
whole	O
cell	O
pertussis	O
pentavalent	O
vaccine	O
.	O

BACKGROUND	O
We	O
compared	O
the	O
safety	O
and	O
immunogenicity	O
of	O
two	O
combined	O
diphtheria-tetanus-pertussis-inactivated	O
poliovirus	O
vaccines	O
containing	O
either	O
acellular	O
(	O
Pa	O
,	O
SmithKline	O
Beecham	O
Biologicals	O
)	O
or	O
whole	O
cell	O
(	O
Pw	O
,	O
Pasteur	O
Merieux	O
Connaught	O
)	O
pertussis	O
components	O
,	O
mixed	O
with	O
a	O
Haemophilus	O
influenzae	O
type	O
b	O
polysaccharide	O
polyribosylribitol	O
phosphate-tetanus	O
conjugate	O
vaccine	O
in	O
an	O
open	O
,	O
randomized	O
study	O
in	O
healthy	Condition
infants	Age
.	O

DESIGN	O
The	O
combined	O
vaccines	O
were	O
given	O
at	O
2	O
,	O
4	O
,	O
6	O
and	O
12	O
months	O
of	O
age	O
,	O
and	O
serum	O
samples	O
were	O
obtained	O
at	O
ages	O
2	O
,	O
6	O
,	O
7	O
,	O
12	O
and	O
13	O
months	O
.	O

Adverse	O
events	O
were	O
obtained	O
by	O
diary	O
cards	O
.	O

RESULTS	O
The	O
Pa	O
group	O
(	O
n	O
=	O
101	SampleSize
)	O
had	O
a	O
clearly	O
lower	O
incidence	O
of	O
both	O
local	Condition
and	Condition
systemic	Condition
adverse	Condition
events	Condition
than	O
the	O
Pw	O
group	O
(	O
n	O
=	O
100	SampleSize
)	O
.	O

Immunogenicity	O
was	O
comparable	O
for	O
the	O
diphtheria	O
and	O
tetanus	O
components	O
,	O
but	O
significantly	O
superior	O
for	O
pertussis	O
toxin	O
,	O
filamentous	O
hemagglutinin	O
,	O
pertactin	O
and	O
polioviruses	O
1	O
,	O
2	O
and	O
3	O
in	O
the	O
Pa	O
group	O
.	O

Both	O
groups	O
had	O
an	O
appropriate	O
response	O
with	O
regard	O
to	O
H.	O
influenzae	O
type	O
b	O
polysaccharide	O
polyribosylribitol	O
phosphate	O
,	O
but	O
the	O
dynamics	O
of	O
the	O
response	O
were	O
significantly	O
different	O
:	O
geometric	O
mean	O
concentrations	O
(	O
micrograms	O
per	O
ml	O
)	O
after	O
the	O
second	O
,	O
third	O
and	O
booster	O
doses	O
were	O
1.27	O
,	O
5.06	O
and	O
23.12	O
in	O
the	O
Pa	O
group	O
and	O
2.72	O
,	O
6.66	O
and	O
13.59	O
in	O
the	O
Pw	O
group	O
,	O
respectively	O
(	O
P	O
=	O
0.0002	O
after	O
second	O
dose	O
;	O
P	O
=	O
0.0005	O
after	O
booster	O
)	O
.	O

CONCLUSION	O
The	O
presently	O
studied	O
diphtheria	O
,	O
tetanus	O
,	O
acellular	O
pertussis-H.	O
influenzae	O
b	O
vaccine	O
conjugated	O
to	O
tetanus	O
toxoid	O
combination	O
was	O
at	O
least	O
as	O
immunogenic	O
as	O
the	O
diphtheria	O
,	O
tetanus	O
,	O
whole	O
cell	O
pertussis-H.	O
influenzae	O
b	O
vaccine	O
conjugated	O
to	O
tetanus	O
toxoid	O
combination	O
,	O
with	O
a	O
significantly	O
better	O
safety	O
profile	O
.	O

This	O
is	O
of	O
obvious	O
importance	O
in	O
countries	O
where	O
inactivated	O
poliovirus	O
vaccine	O
is	O
part	O
of	O
the	O
routine	O
infant	O
immunization	O
programs	O
.	O

Syncope	Condition
Evaluation	O
in	O
the	O
Emergency	O
Department	O
Study	O
(	O
SEEDS	O
)	O
:	O
a	O
multidisciplinary	O
approach	O
to	O
syncope	O
management	O
.	O

BACKGROUND	O
The	O
primary	O
aim	O
and	O
central	O
hypothesis	O
of	O
the	O
study	O
are	O
that	O
a	O
designated	O
syncope	O
unit	O
in	O
the	O
emergency	O
department	O
improves	O
diagnostic	O
yield	O
and	O
reduces	O
hospital	O
admission	O
for	O
patients	O
with	O
syncope	O
who	O
are	O
at	O
intermediate	O
risk	O
for	O
an	O
adverse	O
cardiovascular	O
outcome	O
.	O

METHODS	O
AND	O
RESULTS	O
In	O
this	O
prospective	O
,	O
randomized	O
,	O
single-center	O
study	O
,	O
patients	O
were	O
randomly	O
allocated	O
to	O
2	O
treatment	O
arms	O
:	O
syncope	O
unit	O
evaluation	O
and	O
standard	O
care	O
.	O

The	O
2	O
groups	O
were	O
compared	O
with	O
chi2	O
test	O
for	O
independence	O
of	O
categorical	O
variables	O
.	O

Wilcoxon	O
rank	O
sum	O
test	O
was	O
used	O
for	O
continuous	O
variables	O
.	O

Survival	O
was	O
estimated	O
with	O
the	O
Kaplan-Meier	O
method	O
.	O

One	O
hundred	O
three	O
consecutive	O
patients	O
(	O
53	O
women	O
;	O
mean	O
age	O
64+/-17	O
years	O
)	O
entered	O
the	O
study	O
.	O

Fifty-one	O
patients	O
were	O
randomized	O
to	O
the	O
syncope	O
unit	O
.	O

For	O
the	O
syncope	O
unit	O
and	O
standard	O
care	O
patients	O
,	O
the	O
presumptive	O
diagnosis	O
was	O
established	O
in	O
34	O
(	O
67	O
%	O
)	O
and	O
5	O
(	O
10	O
%	O
)	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
hospital	O
admission	O
was	O
required	O
for	O
22	O
(	O
43	O
%	O
)	O
and	O
51	O
(	O
98	O
%	O
)	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
total	O
patient-hospital	O
days	O
were	O
reduced	O
from	O
140	O
to	O
64	O
.	O

Actuarial	O
survival	O
was	O
97	O
%	O
and	O
90	O
%	O
(	O
P=0.30	O
)	O
,	O
and	O
survival	O
free	O
from	O
recurrent	O
syncope	O
was	O
88	O
%	O
and	O
89	O
%	O
(	O
P=0.72	O
)	O
at	O
2	O
years	O
for	O
the	O
syncope	O
unit	O
and	O
standard	O
care	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
The	O
novel	O
syncope	O
unit	O
designed	O
for	O
this	O
study	O
significantly	O
improved	O
diagnostic	O
yield	O
in	O
the	O
emergency	O
department	O
and	O
reduced	O
hospital	O
admission	O
and	O
total	O
length	O
of	O
hospital	O
stay	O
without	O
affecting	O
recurrent	O
syncope	O
and	O
all-cause	O
mortality	O
among	O
intermediate-risk	O
patients	O
.	O

Observations	O
from	O
the	O
present	O
study	O
provide	O
benchmark	O
data	O
for	O
improving	O
patient	O
care	O
and	O
effectively	O
utilizing	O
healthcare	O
resources	O
.	O

Hydrogen	O
peroxide	O
mouth	O
rinse	O
:	O
an	O
analgesic	O
post-tonsillectomy	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
analgesic	O
efficacy	O
of	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
mouth	O
rinse	O
with	O
control	O
for	O
post-tonsillectomy	O
pain	O
management	O
.	O

DESIGN	O
Double-blinded	O
,	O
prospective	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

PATIENTS	O
AND	O
METHODS	O
Thirty-seven	O
patients	O
from	O
5	O
to	O
14	O
years	O
old	O
undergoing	O
electrocautery	O
tonsillectomy	O
were	O
randomized	O
to	O
either	O
the	O
H2O2	O
mouth	O
rinse	O
or	O
the	O
water	O
rinse	O
(	O
control	O
)	O
group	O
.	O

For	O
14	O
days	O
,	O
patients	O
recorded	O
pain	O
levels	O
twice	O
daily	O
using	O
a	O
visual	O
analogue	O
scale	O
.	O

Analgesic	O
uses	O
,	O
as	O
well	O
as	O
any	O
complications	O
,	O
were	O
also	O
noted	O
by	O
the	O
patients	O
.	O

RESULTS	O
Thirty-seven	O
patients	O
completed	O
the	O
study	O
,	O
21	O
in	O
the	O
treatment	O
group	O
and	O
16	O
in	O
the	O
control	O
group	O
.	O

Mean	O
postoperative	O
days	O
of	O
pain	O
were	O
10.3	O
and	O
8.3	O
,	O
respectively	O
,	O
and	O
differed	O
significantly	O
(	O
p	O
=	O
.008	O
)	O
.	O

Mean	O
postoperative	O
days	O
of	O
analgesic	O
use	O
were	O
9.0	O
and	O
6.7	O
,	O
respectively	O
,	O
and	O
differed	O
significantly	O
(	O
p	O
=	O
.005	O
)	O
.	O

Only	O
one	O
incidence	O
of	O
postoperative	O
hemorrhage	O
occurred	O
in	O
the	O
study	O
group	O
.	O

CONCLUSION	O
In	O
our	O
study	O
,	O
the	O
H2O2	O
mouth	O
rinse	O
does	O
not	O
provide	O
a	O
better	O
analgesic	O
effect	O
than	O
the	O
water	O
rinse	O
for	O
post-tonsillectomy	O
pain	O
relief	O
.	O

Oral	O
estrogen	O
antagonizes	O
the	O
metabolic	O
actions	O
of	O
growth	O
hormone	O
in	O
growth	O
hormone-deficient	O
women	O
.	O

We	O
have	O
determined	O
whether	O
oral	O
estrogen	O
reduces	O
the	O
biological	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
in	O
GH-deficient	O
(	O
GHD	O
)	O
women	O
compared	O
with	O
transdermal	O
estrogen	O
treatment	O
.	O

In	O
two	O
separate	O
studies	O
,	O
eight	O
GHD	O
women	O
randomly	O
received	O
either	O
oral	O
or	O
transdermal	O
estrogen	O
for	O
8	O
wk	O
before	O
crossing	O
over	O
to	O
the	O
alternate	O
route	O
of	O
administration	O
.	O

The	O
first	O
study	O
assessed	O
the	O
effects	O
of	O
incremental	O
doses	O
of	O
GH	O
(	O
0.5	O
,	O
1.0	O
,	O
2.0	O
IU/day	O
for	O
1	O
wk	O
each	O
)	O
on	O
insulin-like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
levels	O
during	O
each	O
estrogen	O
treatment	O
phase	O
.	O

The	O
second	O
study	O
assessed	O
the	O
effects	O
of	O
GH	O
(	O
2	O
IU/day	O
)	O
on	O
lipid	O
oxidation	O
and	O
on	O
protein	O
metabolism	O
using	O
the	O
whole	O
body	O
leucine	O
turnover	O
technique	O
.	O

Mean	O
IGF-I	O
level	O
was	O
significantly	O
lower	O
during	O
oral	O
estrogen	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
and	O
rose	O
dose	O
dependently	O
during	O
GH	O
administration	O
by	O
a	O
lesser	O
magnitude	O
(	O
P	O
<	O
0.05	O
)	O
compared	O
with	O
transdermal	O
treatment	O
.	O

Postprandial	O
lipid	O
oxidation	O
was	O
significantly	O
lower	O
with	O
oral	O
estrogen	O
treatment	O
,	O
both	O
before	O
(	O
P	O
<	O
0.05	O
)	O
and	O
during	O
(	O
P	O
<	O
0.05	O
)	O
GH	O
administration	O
,	O
compared	O
with	O
transdermal	O
treatment	O
.	O

Protein	O
synthesis	O
was	O
lower	O
during	O
oral	O
estrogen	O
both	O
before	O
and	O
during	O
GH	O
administration	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Oral	O
estrogen	O
antagonizes	O
several	O
of	O
the	O
metabolic	O
actions	O
of	O
GH	O
.	O

It	O
may	O
aggravate	O
body	O
composition	O
abnormalities	O
already	O
present	O
in	O
GHD	O
women	O
and	O
attenuate	O
the	O
beneficial	O
effects	O
of	O
GH	O
therapy	O
.	O

Estrogen	O
replacement	O
in	O
GHD	O
women	O
should	O
be	O
administered	O
by	O
a	O
nonoral	O
route	O
.	O

Double-blind	O
comparison	O
of	O
liquid	O
antacid	O
and	O
placebo	O
in	O
the	O
treatment	O
of	O
symptomatic	Condition
reflux	Condition
esophagitis	Condition
.	O

Although	O
antacids	O
have	O
been	O
the	O
mainstay	O
of	O
pharmacologic	O
therapy	O
for	O
reflux	O
esophagitis	O
,	O
their	O
effectiveness	O
has	O
not	O
been	O
tested	O
in	O
a	O
placebo-controlled	O
double-blind	O
trial	O
.	O

We	O
report	O
a	O
double-blind	O
comparison	O
of	O
liquid	O
antacid	O
vs	O
placebo	O
in	O
the	O
treatment	O
of	O
reflux	O
esophagitis	O
in	O
32	SampleSize
patients	O
with	O
chronic	Condition
heartburn	Condition
.	O

Entry	O
criteria	O
included	O
the	O
presence	O
of	O
symptomatic	O
gastroesophageal	O
reflux	O
confirmed	O
by	O
both	O
an	O
acid	O
perfusion	O
(	O
Bernstein	O
)	O
test	O
and	O
by	O
intraesophageal	O
pH	O
probe	O
.	O

Drug	O
treatment	O
consisted	O
of	O
15	O
ml	O
(	O
80	O
mEq	O
)	O
doses	O
of	O
antacid	O
(	O
Maalox	O
Therapeutic	O
Concentration	O
,	O
William	O
H.	O
Rorer	O
)	O
or	O
placebo	O
taken	O
7	O
times	O
daily	O
,	O
ie	O
,	O
1	O
and	O
3	O
hr	O
after	O
meals	O
and	O
at	O
bedtime	O
.	O

Both	O
groups	O
showed	O
significant	O
improvement	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
both	O
frequency	O
and	O
severity	O
of	O
heartburn	O
.	O

The	O
time	O
to	O
reproduce	O
heartburn	O
with	O
the	O
timed	O
Bernstein	O
test	O
was	O
increased	O
with	O
both	O
active	O
drug	O
and	O
placebo	O
therapy	O
.	O

The	O
mean	O
increase	O
was	O
402	O
%	O
(	O
41	O
+/-	O
20	O
sec	O
to	O
169	O
+/-	O
66	O
sec	O
)	O
for	O
the	O
placebo	O
group	O
and	O
286	O
%	O
(	O
42	O
+/-	O
16	O
to	O
120	O
+/-	O
57	O
sec	O
)	O
in	O
the	O
antacid	O
group	O
.	O

Both	O
the	O
antacid	O
and	O
placebo	O
groups	O
showed	O
improvement	O
in	O
the	O
degree	O
of	O
esophagitis	O
as	O
assessed	O
endoscopically	O
.	O

The	O
current	O
study	O
asked	O
:	O
does	O
regular	O
antacid	O
therapy	O
have	O
a	O
favorable	O
influence	O
on	O
the	O
natural	O
history	O
of	O
symptomatic	O
reflux	O
esophagitis	O
,	O
ie	O
,	O
does	O
therapy	O
heal	O
or	O
otherwise	O
change	O
esophagitis	O
so	O
that	O
painful	O
episodes	O
are	O
either	O
less	O
frequent	O
,	O
less	O
severe	O
,	O
or	O
both	O
?	O
We	O
found	O
that	O
the	O
natural	O
history	O
of	O
symptomatic	O
reflux	O
esophagitis	O
was	O
to	O
improve	O
with	O
either	O
antacid	O
or	O
placebo	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
antacid	O
or	O
placebo	O
on	O
the	O
(	O
short-term	O
)	O
natural	O
history	O
of	O
the	O
disease	O
.	O

[	O
Prevention	O
of	O
stress	O
ulcers	O
with	O
synthetic	O
depot	O
secretin	O
]	O
.	O

The	O
pathogenesis	O
of	O
stress	O
ulcers	O
is	O
still	O
far	O
from	O
being	O
understood	O
.	O

It	O
is	O
reported	O
about	O
a	O
synthetic	O
secretin	O
(	O
Hoe	O
069	O
+	O
depot	O
component	O
)	O
given	O
prophylactically	O
to	O
100	O
patients	O
postoperatively	O
.	O

It	O
eliminated	O
or	O
ameliorated	O
stress	O
ulcers	O
.	O

The	O
result	O
,	O
confirmed	O
by	O
gastroscopy	O
,	O
demonstrates	O
the	O
treatment	O
with	O
secretin	O
plus	O
depot	O
component	O
as	O
a	O
highly	O
recommendable	O
prophylaxis	O
in	O
the	O
postsurgical	O
intensive	O
care	O
treatment	O
.	O

A	O
double	O
blind	O
randomized	O
study	O
of	O
oral	O
clodronate	O
in	O
the	O
treatment	O
of	O
bone	Condition
metastases	Condition
from	Condition
tumors	Condition
poorly	Condition
responsive	Condition
to	Condition
chemotherapy	Condition
.	O

Bisphosphonates	O
are	O
used	O
in	O
oncology	O
as	O
a	O
means	O
of	O
decreasing	O
complications	O
due	O
to	O
bone	O
metastases	O
,	O
in	O
association	O
with	O
anticancer	O
treatment	O
,	O
especially	O
in	O
patients	O
with	O
breast	O
cancer	O
,	O
prostate	O
cancer	O
and	O
myeloma	O
.	O

Little	O
is	O
known	O
about	O
the	O
effects	O
of	O
bisphosphonates	O
on	O
bone	O
metastases	O
from	O
other	O
tumors	O
and	O
in	O
particular	O
from	O
tumors	O
for	O
which	O
no	O
effective	O
treatment	O
is	O
available	O
.	O

We	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
placebo-controlled	O
trial	O
of	O
oral	O
clodronate	O
in	O
patients	O
with	O
bone	Condition
metastases	Condition
from	Condition
tumors	Condition
poorly	Condition
responsive	Condition
to	Condition
chemotherapy	Condition
,	O
with	O
the	O
aims	O
of	O
evaluating	O
the	O
effects	O
of	O
this	O
drug	O
on	O
symptoms	O
control	O
and	O
bone	O
metastases	O
evolution	O
.	O

Sixty-six	SampleSize
patients	O
with	O
poorly	Condition
responsive	Condition
tumors	Condition
such	Condition
as	Condition
non-small	Condition
cell	Condition
lung	Condition
cancer	Condition
(	Condition
NSCLC	Condition
)	Condition
,	Condition
bladder	Condition
cancer	Condition
,	Condition
gastrointestinal	Condition
cancers	Condition
,	Condition
kidney	Condition
cancer	Condition
,	Condition
melanoma	Condition
and	Condition
metastatic	Condition
carcinoma	Condition
of	Condition
unknown	Condition
origin	Condition
entered	O
the	O
study	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
clodronate	O
1,600	O
mg/day	O
for	O
one	O
year	O
or	O
identical	O
placebo-containing	O
tablets	O
.	O

Various	O
parameters	O
such	O
as	O
Karnofsky	O
performance	O
status	O
,	O
pain	O
score	O
(	O
measured	O
by	O
a	O
visual-analogue	O
scale	O
)	O
and	O
analgesic	O
requirement	O
were	O
recorded	O
at	O
monthly	O
intervals	O
.	O

Of	O
the	O
66	O
patients	O
enrolled	O
,	O
9	O
were	O
observed	O
for	O
one	O
month	O
or	O
less	O
;	O
7	O
were	O
followed	O
for	O
two	O
months	O
;	O
only	O
50	O
patients	O
were	O
followed	O
for	O
more	O
than	O
2	O
months	O
and	O
could	O
be	O
adequately	O
evaluated	O
.	O

At	O
3	O
months	O
both	O
clodronate	O
and	O
placebo-treated	O
patients	O
had	O
a	O
decrease	O
in	O
Karnofsky	O
performance	O
status	O
,	O
with	O
the	O
decrease	O
being	O
more	O
evident	O
in	O
the	O
placebo	O
group	O
.	O

Mean	O
pain	O
scores	O
showed	O
an	O
increase	O
of	O
pain	O
in	O
patients	O
receiving	O
placebo	O
and	O
a	O
decrease	O
of	O
pain	O
in	O
patients	O
receiving	O
clodronate	O
,	O
although	O
the	O
difference	O
failed	O
to	O
be	O
statistically	O
significant	O
.	O

Analgesics	O
requirement	O
increased	O
in	O
both	O
groups	O
,	O
but	O
significantly	O
more	O
in	O
patients	O
receiving	O
placebo	O
(	O
p	O
=	O
0.042	O
)	O
,	O
in	O
whom	O
increase	O
in	O
opioid	O
requirements	O
was	O
particularly	O
evident	O
.	O

Toxicity	O
was	O
low	O
,	O
with	O
occasional	O
gastroenteric	O
discomfort	O
in	O
both	O
groups	O
.	O

The	O
main	O
problem	O
of	O
this	O
study	O
was	O
the	O
difficulty	O
in	O
recruiting	O
an	O
adequate	O
number	O
of	O
patients	O
and	O
following	O
them	O
for	O
a	O
sufficient	O
period	O
of	O
time	O
:	O
general	O
conditions	O
rapidly	O
deteriorated	O
in	O
many	O
patients	O
,	O
and	O
approximately	O
25	O
%	O
of	O
the	O
66	O
enrolled	O
were	O
not	O
considered	O
evaluable	O
;	O
few	O
patients	O
survived	O
for	O
the	O
length	O
of	O
the	O
study	O
,	O
one	O
year	O
.	O

This	O
might	O
partly	O
account	O
for	O
the	O
lack	O
of	O
significance	O
of	O
some	O
of	O
the	O
parameters	O
under	O
study	O
.	O

With	O
these	O
limits	O
,	O
oral	O
clodronate	O
demonstrated	O
some	O
efficacy	O
in	O
symptom	O
control	O
and	O
in	O
reducing	O
the	O
need	O
for	O
analgesics	O
.	O

Randomized	O
trial	O
of	O
an	O
allogeneic	O
melanoma	O
lysate	O
vaccine	O
with	O
low-dose	O
interferon	O
Alfa-2b	O
compared	O
with	O
high-dose	O
interferon	O
Alfa-2b	O
for	O
Resected	O
stage	O
III	O
cutaneous	O
melanoma	O
.	O

PURPOSE	O
To	O
compare	O
the	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
with	O
resected	O
stage	O
III	O
melanoma	O
administered	O
active	O
specific	O
immunotherapy	O
and	O
low-dose	O
interferon	O
alfa-2b	O
(	O
IFN-alpha-2b	O
)	O
with	O
the	O
OS	O
achieved	O
using	O
high-dose	O
IFN-alpha-2b	O
.	O

PATIENTS	O
AND	O
METHODS	O
An	O
Ad	O
Hoc	O
Melanoma	O
Working	O
Group	O
of	O
25	O
investigators	O
treated	O
604	O
patients	O
from	O
April	O
1997	O
to	O
January	O
2003	O
.	O

Patients	O
were	O
stratified	O
by	O
sex	O
and	O
number	O
of	O
nodes	O
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
2	O
years	O
of	O
treatment	O
with	O
active	O
specific	O
immunotherapy	O
with	O
allogeneic	O
melanoma	O
lysates	O
and	O
low-dose	O
IFN-alpha-2b	O
(	O
arm	O
1	O
)	O
or	O
high-dose	O
IFN-alpha-2b	O
alone	O
for	O
1	O
year	O
(	O
arm	O
2	O
)	O
.	O

Active	O
specific	O
immunotherapy	O
was	O
injected	O
subcutaneously	O
(	O
SC	O
)	O
weekly	O
for	O
4	O
weeks	O
,	O
at	O
week	O
8	O
,	O
and	O
bimonthly	O
thereafter	O
.	O

IFN-alpha-2b	O
SC	O
was	O
begun	O
on	O
week	O
4	O
and	O
continued	O
thrice	O
weekly	O
at	O
5	O
MU/m2	O
for	O
2	O
years	O
.	O

IFN-alpha-2b	O
in	O
arm	O
2	O
was	O
administered	O
according	O
to	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
1684	O
study	O
regimen	O
.	O

RESULTS	O
Median	O
follow-up	O
time	O
was	O
32	O
months	O
for	O
all	O
patients	O
and	O
42	O
months	O
for	O
surviving	O
patients	O
.	O

Median	O
OS	O
time	O
exceeds	O
84	O
months	O
in	O
arm	O
1	O
and	O
is	O
83	O
months	O
in	O
arm	O
2	O
(	O
P	O
=	O
.56	O
)	O
.	O

Five-year	O
OS	O
rate	O
is	O
61	O
%	O
in	O
arm	O
1	O
and	O
57	O
%	O
in	O
arm	O
2	O
.	O

Estimated	O
5-year	O
relapse-free	O
survival	O
(	O
RFS	O
)	O
rate	O
is	O
50	O
%	O
in	O
arm	O
1	O
and	O
48	O
%	O
in	O
arm	O
2	O
,	O
with	O
median	O
RFS	O
times	O
of	O
58	O
and	O
50	O
months	O
,	O
respectively	O
.	O

The	O
incidence	O
of	O
serious	O
adverse	O
events	O
as	O
a	O
result	O
of	O
treatment	O
was	O
the	O
same	O
in	O
both	O
arms	O
,	O
but	O
more	O
severe	O
neuropsychiatric	O
toxicity	O
was	O
seen	O
in	O
arm	O
2	O
.	O

CONCLUSION	O
OS	O
and	O
RFS	O
achieved	O
by	O
active	O
specific	O
immunotherapy	O
and	O
low-dose	O
IFN-alpha-2b	O
were	O
indistinguishable	O
from	O
those	O
achieved	O
by	O
high-dose	O
IFN-alpha-2b	O
.	O

Long	O
RFS	O
and	O
OS	O
times	O
were	O
observed	O
in	O
both	O
treatment	O
arms	O
.	O

Randomized	O
study	O
of	O
continuous	O
infusion	O
fluorouracil	O
versus	O
fluorouracil	O
plus	O
cisplatin	O
in	O
patients	O
with	O
metastatic	Condition
colorectal	Condition
cancer	Condition
.	O

One	SampleSize
hundred	SampleSize
twenty-two	SampleSize
chemotherapy-naive	O
patients	O
with	O
histologically	O
confirmed	O
colorectal	Condition
adenocarcinoma	Condition
were	O
entered	O
into	O
a	O
randomized	O
trial	O
comparing	O
infusional	O
fluorouracil	O
(	O
FU	O
)	O
versus	O
cisplatin	O
(	O
CDDP	O
)	O
and	O
FU	O
.	O

In	O
both	O
groups	O
,	O
patients	O
received	O
continuous	O
infusion	O
FU	O
1,000	O
mg/m2/d	O
for	O
5	O
consecutive	O
days	O
every	O
4	O
weeks	O
.	O

Patients	O
randomized	O
to	O
CDDP/FU	O
also	O
received	O
CDDP	O
20	O
mg/m2	O
intravenous	O
(	O
IV	O
)	O
bolus	O
on	O
days	O
1	O
to	O
5	O
of	O
each	O
cycle	O
.	O

Patients	O
were	O
comparable	O
in	O
terms	O
of	O
age	O
,	O
performance	O
status	O
,	O
baseline	O
laboratory	O
values	O
,	O
dominant	O
sites	O
of	O
measurable	O
disease	O
,	O
and	O
percent	O
of	O
liver	O
involvement	O
.	O

The	O
partial	O
response	O
rate	O
was	O
significantly	O
greater	O
in	O
patients	O
who	O
received	O
CDDP/FU	O
versus	O
FU	O
alone	O
(	O
25	O
%	O
v	O
3	O
%	O
,	O
P	O
=	O
.001	O
)	O
.	O

Patients	O
who	O
received	O
CDDP/FU	O
experienced	O
significantly	O
greater	O
toxicity	O
compared	O
with	O
FU	O
alone	O
:	O
grades	O
3	O
and	O
4	O
hematologic	O
toxicity	O
occurred	O
in	O
22	O
%	O
and	O
0	O
%	O
of	O
patients	O
,	O
respectively	O
(	O
P	O
=	O
.0001	O
)	O
;	O
grades	O
2	O
to	O
4	O
nausea	O
and	O
vomiting	O
occurred	O
in	O
80	O
%	O
and	O
15	O
%	O
of	O
patients	O
,	O
respectively	O
(	O
P	O
=	O
.0001	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
either	O
the	O
duration	O
of	O
response	O
(	O
median	O
,	O
6	O
and	O
4.7	O
months	O
for	O
CDDP/FU	O
and	O
FU	O
groups	O
,	O
respectively	O
)	O
or	O
survival	O
(	O
median	O
10	O
,	O
and	O
12	O
months	O
,	O
respectively	O
)	O
.	O

Compared	O
with	O
infusional	O
FU	O
alone	O
,	O
CDDP/FU	O
provided	O
a	O
significantly	O
greater	O
partial	O
response	O
rate	O
with	O
increased	O
toxicity	O
,	O
but	O
it	O
did	O
not	O
improve	O
overall	O
survival	O
in	O
patients	O
with	O
advanced	Condition
colorectal	Condition
carcinoma	Condition
.	O

Therefore	O
,	O
the	O
use	O
of	O
CDDP/FU	O
as	O
routine	O
therapy	O
for	O
the	O
treatment	O
of	O
colorectal	O
carcinoma	O
can	O
not	O
be	O
recommended	O
.	O

Piperacillin/tazobactam	O
plus	O
tobramycin	O
versus	O
ceftazidime	O
plus	O
tobramycin	O
as	O
empiric	O
therapy	O
for	O
fever	O
in	O
severely	O
neutropenic	O
patients	O
.	O

The	O
objective	O
of	O
this	O
trial	O
was	O
to	O
evaluate	O
the	O
potential	O
advantages	O
of	O
the	O
combination	O
of	O
piperacillin	O
and	O
tazobactam	O
in	O
the	O
control	O
of	O
fever	O
in	O
neutropenic	O
patients	O
.	O

In	O
this	O
single-center	O
study	O
,	O
patients	O
who	O
experienced	O
a	O
total	O
of	O
247	O
febrile	O
episodes	O
were	O
prospectively	O
randomized	O
to	O
receive	O
either	O
our	O
standard	O
regimen	O
,	O
ceftazidime	O
3	O
g/day	O
(	O
1	O
g	O
t.i.d	O
.	O

)	O
plus	O
tobramycin	O
3	O
mg/kg	O
per	O
day	O
(	O
1.5	O
mg/kg	O
b.i.d	O
.	O

)	O
,	O
or	O
piperacillin	O
12	O
g/day	O
plus	O
tazobactam	O
1.5	O
g/day	O
(	O
4	O
g+0.5	O
g	O
t.i.d	O
.	O

)	O
plus	O
tobramycin	O
3	O
mg/kg	O
per	O
day	O
(	O
1.5	O
mg/kg	O
b.i.d.	O
)	O
.	O

Vancomycin	O
was	O
added	O
in	O
all	O
cases	O
of	O
persistent	O
fever	O
in	O
the	O
ceftazidime	O
arm	O
,	O
but	O
only	O
when	O
there	O
was	O
microbiologically	O
documented	O
resistance	O
in	O
the	O
piperacillin/tazobactam	O
arm	O
.	O

All	O
247	O
episodes	O
were	O
evaluable	O
by	O
intent-to-treat	O
analysis	O
.	O

The	O
two	O
populations	O
were	O
well	O
matched	O
in	O
terms	O
of	O
age	O
,	O
gender	O
,	O
underlying	O
disease	O
,	O
chemotherapy	O
received	O
,	O
oral	O
decontamination	O
,	O
clinical	O
and	O
bacterial	O
documentation	O
,	O
and	O
severity	O
and	O
duration	O
of	O
neutropenia	O
.	O

Initial	O
antibacterial	O
therapy	O
was	O
successful	O
(	O
apyrexia	O
at	O
72	O
h	O
,	O
without	O
antibiotic	O
change	O
)	O
more	O
frequently	O
(	O
P	O
=	O
0.008	O
)	O
with	O
the	O
regimen	O
containing	O
piperacillin/tazobactam	O
(	O
54.4	O
%	O
)	O
than	O
with	O
the	O
one	O
including	O
ceftazidime	O
(	O
37.6	O
%	O
)	O
.	O

Fewer	O
(	O
P	O
=	O
0.02	O
)	O
major	O
infectious	O
events	O
(	O
infectious	O
death	O
or	O
delay	O
in	O
treatment	O
of	O
underlying	O
disease	O
due	O
to	O
infection	O
)	O
were	O
observed	O
during	O
piperacillin/	O
tazobactam	O
treatment	O
(	O
2.6	O
%	O
)	O
than	O
with	O
the	O
ceftazidime	O
regimen	O
(	O
11.3	O
%	O
)	O
,	O
despite	O
a	O
lower	O
frequency	O
of	O
glycopeptide	O
addition	O
when	O
piperacillin/tazobactam	O
was	O
used	O
(	O
54.4	O
%	O
versus	O
77.4	O
%	O
)	O
according	O
to	O
the	O
rules	O
adopted	O
.	O

This	O
trial	O
confirmed	O
the	O
efficacy	O
of	O
the	O
piperacillin/tazobactam	O
combination	O
for	O
empirical	O
treatment	O
of	O
febrile	O
neutropenic	O
patients	O
.	O

This	O
antibiotic	O
combination	O
permitted	O
a	O
dramatic	O
decrease	O
in	O
empiric	O
glycopeptide	O
antibiotic	O
administration	O
in	O
such	O
patients	O
.	O

Automatic	O
detection	O
of	O
red	O
lesions	O
in	O
digital	O
color	O
fundus	O
photographs	O
.	O

The	O
robust	O
detection	O
of	O
red	O
lesions	O
in	O
digital	O
color	O
fundus	O
photographs	O
is	O
a	O
critical	O
step	O
in	O
the	O
development	O
of	O
automated	O
screening	O
systems	O
for	O
diabetic	Condition
retinopathy	O
.	O

In	O
this	O
paper	O
,	O
a	O
novel	O
red	O
lesion	O
detection	O
method	O
is	O
presented	O
based	O
on	O
a	O
hybrid	O
approach	O
,	O
combining	O
prior	O
works	O
by	O
Spencer	O
et	O
al	O
.	O

(	O
1996	O
)	O
and	O
Frame	O
et	O
al	O
.	O

(	O
1998	O
)	O
with	O
two	O
important	O
new	O
contributions	O
.	O

The	O
first	O
contribution	O
is	O
a	O
new	O
red	O
lesion	O
candidate	O
detection	O
system	O
based	O
on	O
pixel	O
classification	O
.	O

Using	O
this	O
technique	O
,	O
vasculature	O
and	O
red	O
lesions	O
are	O
separated	O
from	O
the	O
background	O
of	O
the	O
image	O
.	O

After	O
removal	O
of	O
the	O
connected	O
vasculature	O
the	O
remaining	O
objects	O
are	O
considered	O
possible	O
red	O
lesions	O
.	O

Second	O
,	O
an	O
extensive	O
number	O
of	O
new	O
features	O
are	O
added	O
to	O
those	O
proposed	O
by	O
Spencer-Frame	O
.	O

The	O
detected	O
candidate	O
objects	O
are	O
classified	O
using	O
all	O
features	O
and	O
a	O
k-nearest	O
neighbor	O
classifier	O
.	O

An	O
extensive	O
evaluation	O
was	O
performed	O
on	O
a	O
test	O
set	O
composed	O
of	O
images	O
representative	O
of	O
those	O
normally	O
found	O
in	O
a	O
screening	O
set	O
.	O

When	O
determining	O
whether	O
an	O
image	O
contains	O
red	O
lesions	O
the	O
system	O
achieves	O
a	O
sensitivity	O
of	O
100	O
%	O
at	O
a	O
specificity	O
of	O
87	O
%	O
.	O

The	O
method	O
is	O
compared	O
with	O
several	O
different	O
automatic	O
systems	O
and	O
is	O
shown	O
to	O
outperform	O
them	O
all	O
.	O

Performance	O
is	O
close	O
to	O
that	O
of	O
a	O
human	O
expert	O
examining	O
the	O
images	O
for	O
the	O
presence	O
of	O
red	O
lesions	O
.	O

Naltrexone	O
and	O
communication	O
skills	O
in	O
young	Sex
children	Sex
with	O
autism	Condition
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
naltrexone	O
on	O
communication	O
skills	O
of	O
young	Age
children	Age
with	O
autism	Condition
.	O

METHOD	O
Twenty-four	SampleSize
children	Age
with	O
autism	Condition
,	O
3.0	Age
to	Age
8.3	Age
years	Age
old	Age
(	O
mean	O
5.1	Age
)	O
who	O
were	O
living	O
at	O
home	O
and	O
attending	O
appropriate	O
school	O
programs	O
,	O
participated	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
trial	O
.	O

Naltrexone	O
,	O
1.0	O
mg/kg	O
,	O
or	O
placebo	O
was	O
administered	O
daily	O
for	O
2	O
weeks	O
.	O

Communication	O
was	O
evaluated	O
from	O
videotaped	O
samples	O
of	O
seminaturalistic	O
parent-child	O
interaction	O
.	O

Child	O
and	O
parent	O
language	O
were	O
assessed	O
using	O
similar	O
measures	O
.	O

RESULTS	O
In	O
this	O
heterogeneous	O
sample	O
,	O
the	O
median	O
number	O
of	O
words	O
the	O
child	O
produced	O
on	O
placebo	O
was	O
9.5	O
(	O
range	O
0-124	O
)	O
.	O

The	O
median	O
proportion	O
of	O
utterances	O
with	O
echolalia	O
was	O
0.16	O
.	O

No	O
differences	O
were	O
found	O
between	O
the	O
naltrexone	O
and	O
placebo	O
conditions	O
in	O
any	O
of	O
the	O
measures	O
of	O
children	O
or	O
parents	O
'	O
communication	O
.	O

Significant	O
correlations	O
were	O
found	O
between	O
the	O
child	O
's	O
number	O
of	O
words	O
and	O
developmental	O
quotient	O
(	O
Spearman	O
rho	O
=	O
0.58	O
,	O
p	O
=	O
.003	O
)	O
and	O
between	O
the	O
child	O
's	O
and	O
parent	O
's	O
number	O
of	O
words	O
(	O
rho	O
=	O
0.55	O
,	O
p	O
=	O
.005	O
)	O
.	O

CONCLUSIONS	O
Previous	O
studies	O
showed	O
that	O
naltrexone	O
was	O
associated	O
with	O
modest	O
reduction	O
in	O
hyperactivity	O
and	O
restlessness	O
in	O
this	O
group	O
of	O
children	O
with	O
autism	O
.	O

In	O
this	O
short-term	O
study	O
,	O
the	O
medication	O
did	O
not	O
lead	O
to	O
improvement	O
in	O
communication	O
,	O
a	O
core	O
deficit	O
of	O
autism	O
.	O

A	O
randomized	O
placebo-controlled	O
prevention	O
trial	O
of	O
aspirin	O
and/or	O
resistant	O
starch	O
in	O
young	Age
people	O
with	O
familial	Condition
adenomatous	Condition
polyposis	Condition
.	O

Evidence	O
supporting	O
aspirin	O
and	O
resistant	O
starch	O
(	O
RS	O
)	O
for	O
colorectal	Condition
cancer	Condition
prevention	O
comes	O
from	O
epidemiologic	O
and	O
laboratory	O
studies	O
(	O
aspirin	O
and	O
RS	O
)	O
and	O
randomized	O
controlled	O
clinical	O
trials	O
(	O
aspirin	O
)	O
.	O

Familial	Condition
adenomatous	Condition
polyposis	Condition
(	O
FAP	Condition
)	O
strikes	O
young	O
people	O
and	O
,	O
untreated	O
,	O
confers	O
virtually	O
a	O
100	O
%	O
risk	O
of	O
colorectal	O
cancer	O
and	O
early	O
death	O
.	O

We	O
conducted	O
an	O
international	O
,	O
multicenter	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
of	O
aspirin	O
(	O
600	O
mg/d	O
)	O
and/or	O
RS	O
(	O
30	O
g/d	O
)	O
for	O
from	O
1	O
to	O
12	O
years	O
to	O
prevent	O
disease	O
progression	O
in	O
FAP	Condition
patients	O
from	O
10	Age
to	Age
21	Age
years	Age
of	O
age	O
.	O

In	O
a	O
2	O
?	O
2	O
factorial	O
design	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
following	O
four	O
study	O
arms	O
:	O
aspirin	O
plus	O
RS	O
placebo	O
;	O
RS	O
plus	O
aspirin	O
placebo	O
;	O
aspirin	O
plus	O
RS	O
;	O
RS	O
placebo	O
plus	O
aspirin	O
placebo	O
;	O
they	O
were	O
followed	O
with	O
standard	O
annual	O
clinical	O
examinations	O
including	O
endoscopy	O
.	O

The	O
primary	O
endpoint	O
was	O
polyp	O
number	O
in	O
the	O
rectum	O
and	O
sigmoid	O
colon	O
(	O
at	O
the	O
end	O
of	O
intervention	O
)	O
,	O
and	O
the	O
major	O
secondary	O
endpoint	O
was	O
size	O
of	O
the	O
largest	O
polyp	O
.	O

A	O
total	O
of	O
206	O
randomized	O
FAP	O
patients	O
commenced	O
intervention	O
,	O
of	O
whom	O
133	O
had	O
at	O
least	O
one	O
follow-up	O
endoscopy	O
and	O
were	O
therefore	O
included	O
in	O
the	O
primary	O
analysis	O
.	O

Neither	O
intervention	O
significantly	O
reduced	O
polyp	O
count	O
in	O
the	O
rectum	O
and	O
sigmoid	O
colon	O
:	O
aspirin	O
relative	O
risk	O
=	O
0.77	O
(	O
95	O
%	O
CI	O
,	O
0.54-1.10	O
;	O
versus	O
nonaspirin	O
arms	O
)	O
;	O
RS	O
relative	O
risk	O
=	O
1.05	O
(	O
95	O
%	O
CI	O
,	O
0.73-1.49	O
;	O
versus	O
non-RS	O
arms	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
a	O
smaller	O
size	O
of	O
largest	O
polyp	O
in	O
patients	O
treated	O
with	O
aspirin	O
versus	O
nonaspirin	O
--	O
mean	O
3.8	O
mm	O
versus	O
5.5	O
mm	O
for	O
patients	O
treated	O
1	O
or	O
more	O
years	O
(	O
adjusted	O
P	O
=	O
0.09	O
)	O
and	O
mean	O
3.0	O
mm	O
versus	O
6.0	O
mm	O
for	O
patients	O
treated	O
more	O
than	O
1	O
year	O
(	O
P	O
=	O
0.02	O
)	O
;	O
there	O
were	O
similar	O
weaker	O
trends	O
with	O
RS	O
versus	O
non-RS	O
.	O

Exploratory	O
translational	O
endpoints	O
included	O
crypt	O
length	O
(	O
which	O
was	O
significantly	O
shorter	O
in	O
normal-appearing	O
mucosa	O
in	O
the	O
RS	O
group	O
over	O
time	O
)	O
and	O
laboratory	O
measures	O
of	O
proliferation	O
(	O
including	O
Ki67	O
)	O
.	O

This	O
clinical	O
trial	O
is	O
the	O
largest	O
ever	O
conducted	O
in	O
the	O
setting	O
of	O
FAP	O
and	O
found	O
a	O
trend	O
of	O
reduced	O
polyp	O
load	O
(	O
number	O
and	O
size	O
)	O
with	O
600	O
mg	O
of	O
aspirin	O
daily	O
.	O

RS	O
had	O
no	O
clinical	O
effect	O
on	O
adenomas	O
.	O

Fake	O
bad	O
test	O
response	O
bias	O
effects	O
on	O
the	O
test	O
of	O
variables	O
of	O
attention	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
faking	O
bad	O
(	O
FB	O
)	O
on	O
the	O
Test	O
of	O
Variables	O
of	O
Attention	O
(	O
TOVA	O
)	O
using	O
subjects	O
randomly	O
placed	O
into	O
two	O
groups	O
.	O

Subjects	O
in	O
Group	O
1	O
took	O
the	O
TOVA	O
under	O
normal	O
conditions	O
(	O
NC	O
)	O
first	O
;	O
they	O
were	O
then	O
requested	O
to	O
subtly	O
fake	O
bad	O
.	O

Group	O
2	O
subjects	O
took	O
the	O
TOVA	O
under	O
the	O
same	O
fake	O
bad	O
instructions	O
first	O
,	O
then	O
took	O
the	O
test	O
under	O
normal	O
conditions	O
the	O
second	O
time	O
.	O

An	O
analysis	O
of	O
the	O
effects	O
of	O
test	O
order	O
yielded	O
non-significant	O
differences	O
for	O
basic	O
TOVA	O
variables	O
across	O
all	O
four	O
quarters	O
,	O
both	O
halves	O
and	O
the	O
total	O
score	O
.	O

An	O
analysis	O
for	O
group	O
mean	O
differences	O
between	O
the	O
NC	O
and	O
the	O
FB	O
instructions	O
yielded	O
significant	O
differences	O
across	O
the	O
basic	O
TOVA	O
variables	O
across	O
the	O
four	O
quarters	O
,	O
two	O
halves	O
and	O
total	O
score	O
.	O

The	O
FB	O
group	O
had	O
excessive	O
amounts	O
of	O
omission	O
and	O
commission	O
errors	O
,	O
a	O
greater	O
response	O
time	O
mean	O
(	O
i.e.	O
,	O
slower	O
to	O
respond	O
)	O
and	O
had	O
greater	O
variance	O
around	O
their	O
mean	O
response	O
time	O
.	O

The	O
study	O
affirms	O
that	O
the	O
professional	O
using	O
the	O
TOVA	O
needs	O
to	O
carefully	O
eliminate	O
a	O
fake	O
bad	O
test-taking	O
bias	O
when	O
subjects	O
produce	O
excessive	O
test	O
results	O
.	O

Prefrontal	O
neuromodulation	O
using	O
rTMS	O
improves	O
error	O
monitoring	O
and	O
correction	O
function	O
in	O
autism	O
.	O

One	O
important	O
executive	O
function	O
known	O
to	O
be	O
compromised	O
in	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
is	O
related	O
to	O
response	O
error	O
monitoring	O
and	O
post-error	O
response	O
correction	O
.	O

Several	O
reports	O
indicate	O
that	O
children	O
with	O
ASD	O
show	O
reduced	O
error	O
processing	O
and	O
deficient	O
behavioral	O
correction	O
after	O
an	O
error	O
is	O
committed	O
.	O

Error	O
sensitivity	O
can	O
be	O
readily	O
examined	O
by	O
measuring	O
event-related	O
potentials	O
(	O
ERP	O
)	O
associated	O
with	O
responses	O
to	O
errors	O
,	O
the	O
fronto-central	O
error-related	O
negativity	O
(	O
ERN	O
)	O
,	O
and	O
the	O
error-related	O
positivity	O
(	O
Pe	O
)	O
.	O

The	O
goal	O
of	O
our	O
study	O
was	O
to	O
investigate	O
whether	O
reaction	O
time	O
(	O
RT	O
)	O
,	O
error	O
rate	O
,	O
post-error	O
RT	O
change	O
,	O
ERN	O
,	O
and	O
Pe	O
will	O
show	O
positive	O
changes	O
following	O
12-week	O
long	O
slow	O
frequency	O
repetitive	O
TMS	O
(	O
rTMS	O
)	O
over	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLPFC	O
)	O
in	O
high	O
functioning	O
children	O
with	O
ASD	O
.	O

We	O
hypothesized	O
that	O
12	O
sessions	O
of	O
1	O
Hz	O
rTMS	O
bilaterally	O
applied	O
over	O
the	O
DLPFC	O
will	O
result	O
in	O
improvements	O
reflected	O
in	O
both	O
behavioral	O
and	O
ERP	O
measures	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
either	O
active	O
rTMS	O
treatment	O
or	O
wait-list	O
(	O
WTL	O
)	O
groups	O
.	O

Baseline	O
and	O
post-TMS/or	O
WTL	O
EEG	O
was	O
collected	O
using	O
128	O
channel	O
EEG	O
system	O
.	O

The	O
task	O
involved	O
the	O
recognition	O
of	O
a	O
specific	O
illusory	O
shape	O
,	O
in	O
this	O
case	O
a	O
square	O
or	O
triangle	O
,	O
created	O
by	O
three	O
or	O
four	O
inducer	O
disks	O
.	O

ERN	O
in	O
TMS	O
treatment	O
group	O
became	O
significantly	O
more	O
negative	O
.	O

The	O
number	O
of	O
omission	O
errors	O
decreased	O
post-TMS	O
.	O

The	O
RT	O
did	O
not	O
change	O
,	O
but	O
post-error	O
RT	O
became	O
slower	O
.	O

There	O
were	O
no	O
changes	O
in	O
RT	O
,	O
error	O
rate	O
,	O
post-error	O
RT	O
slowing	O
,	O
nor	O
in	O
ERN/Pe	O
measures	O
in	O
the	O
wait-list	O
group	O
.	O

Our	O
results	O
show	O
significant	O
post-TMS	O
differences	O
in	O
the	O
response-locked	O
ERP	O
such	O
as	O
ERN	O
,	O
as	O
well	O
as	O
behavioral	O
response	O
monitoring	O
measures	O
indicative	O
of	O
improved	O
error	O
monitoring	O
and	O
correction	O
function	O
.	O

The	O
ERN	O
and	O
Pe	O
,	O
along	O
with	O
behavioral	O
performance	O
measures	O
,	O
can	O
be	O
used	O
as	O
functional	O
outcome	O
measures	O
to	O
assess	O
the	O
effectiveness	O
of	O
neuromodulation	O
(	O
e.g.	O
,	O
rTMS	O
)	O
in	O
children	O
with	O
autism	O
and	O
thus	O
may	O
have	O
important	O
practical	O
implications	O
.	O

A	O
comparison	O
of	O
a	O
short	O
nurse-based	O
and	O
a	O
long	O
multidisciplinary	O
version	O
of	O
structured	O
patient	O
education	O
in	O
irritable	O
bowel	O
syndrome	O
.	O

OBJECTIVE	O
Structured	O
multidisciplinary	O
patient	O
group	O
education	O
has	O
positive	O
effects	O
on	O
symptoms	O
,	O
health-related	O
quality	O
of	O
life	O
,	O
and	O
disease-related	O
knowledge	O
in	O
patients	O
with	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
but	O
few	O
studies	O
comparing	O
different	O
forms	O
of	O
educational	O
interventions	O
are	O
available	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
effects	O
of	O
long	O
multidisciplinary	O
group	O
education	O
with	O
a	O
short	O
nurse-based	O
group	O
education	O
with	O
regard	O
to	O
symptoms	O
,	O
knowledge	O
,	O
quality	O
of	O
life	O
,	O
and	O
satisfaction	O
with	O
the	O
intervention	O
in	O
IBS	O
patients	O
.	O

METHODS	O
Patients	O
with	O
IBS	O
according	O
to	O
the	O
Rome	O
II	O
criteria	O
were	O
randomized	O
to	O
either	O
short	O
nurse-based	O
or	O
a	O
long	O
multidisciplinary-based	O
education	O
.	O

The	O
effects	O
were	O
evaluated	O
by	O
self-administered	O
questionnaires	O
at	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
baseline	O
,	O
and	O
compared	O
between	O
the	O
groups	O
.	O

RESULTS	O
No	O
differences	O
in	O
effects	O
were	O
detected	O
in	O
the	O
between-group	O
comparisons	O
at	O
any	O
of	O
the	O
follow-up	O
assessments	O
.	O

However	O
,	O
positive	O
effects	O
on	O
symptoms	O
,	O
knowledge	O
,	O
quality	O
of	O
life	O
,	O
and	O
satisfaction	O
with	O
the	O
intervention	O
were	O
found	O
in	O
both	O
the	O
short	O
and	O
the	O
long	O
version	O
.	O

CONCLUSION	O
A	O
short	O
,	O
nurse-based	O
educational	O
intervention	O
seems	O
to	O
be	O
as	O
efficacious	O
as	O
a	O
longer	O
multidisciplinary	O
version	O
.	O

In	O
both	O
groups	O
,	O
positive	O
effects	O
on	O
patients	O
'	O
well-being	O
were	O
found	O
to	O
a	O
similar	O
extent	O
.	O

This	O
is	O
an	O
important	O
finding	O
that	O
,	O
from	O
a	O
cost-effective	O
perspective	O
,	O
could	O
contribute	O
toward	O
an	O
optimized	O
management	O
of	O
patients	O
with	O
IBS	O
.	O

Caudal	O
neostigmine	O
with	O
bupivacaine	O
produces	O
a	O
dose-independent	O
analgesic	O
effect	O
in	O
children	Age
.	O

PURPOSE	O
To	O
evaluate	O
the	O
analgesic	O
efficacy	O
and	O
duration	O
of	O
varying	O
doses	O
of	O
caudal	O
neostigmine	O
with	O
plain	O
bupivacaine	O
and	O
its	O
side	O
effects	O
in	O
children	Age
undergoing	O
genito-urinary	Condition
surgery	Condition
.	O

METHODS	O
In	O
a	O
randomized	O
double-blind	O
prospective	O
study	O
80	SampleSize
boys	Sex
aged	O
two	Age
to	Age
eight	Age
years	O
scheduled	O
for	O
surgical	O
repair	O
of	O
hypospadias	Condition
were	O
allocated	O
randomly	O
to	O
one	O
of	O
four	O
groups	O
(	O
n	O
=	O
20	O
each	O
)	O
and	O
received	O
either	O
only	O
caudal	O
0.25	O
%	O
plain	O
bupivacaine	O
0.5	O
mL.kg	O
(	O
-1	O
)	O
(	O
Group	O
I	O
)	O
or	O
0.25	O
%	O
plain	O
bupivacaine	O
0.5	O
mL.kg	O
(	O
-1	O
)	O
with	O
neostigmine	O
(	O
Groups	O
II-IV	O
)	O
in	O
doses	O
of	O
2	O
,	O
3	O
and	O
4	O
microg.kg	O
(	O
-1	O
)	O
respectively	O
.	O

Postoperative	O
pain	O
was	O
assessed	O
for	O
24	O
hr	O
using	O
an	O
objective	O
pain	O
score	O
.	O

Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
oxygen	O
saturation	O
,	O
total	O
amount	O
of	O
analgesic	O
consumed	O
and	O
adverse	O
effects	O
were	O
also	O
recorded	O
.	O

RESULTS	O
The	O
duration	O
of	O
postoperative	O
analgesia	O
in	O
Group	O
I	O
(	O
5.1	O
+/-	O
2.3	O
hr	O
)	O
was	O
significantly	O
shorter	O
than	O
in	O
the	O
other	O
three	O
groups	O
(	O
II	O
-16.6	O
+/-	O
4.9	O
hr	O
;	O
III	O
-	O
17.2	O
+/-	O
5.5	O
hr	O
;	O
IV	O
-	O
17.0	O
+/-	O
5.8	O
hr	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Total	O
analgesic	O
(	O
paracetamol	O
)	O
consumption	O
was	O
significantly	O
more	O
in	O
Group	O
I	O
(	O
697.6	O
+/-	O
240.7	O
mg	O
)	O
than	O
in	O
the	O
groups	O
receiving	O
caudal	O
neostigmine	O
(	O
II	O
-	O
248.0	O
+/-	O
178.4	O
;	O
III	O
-	O
270.2	O
+/-	O
180.8	O
and	O
IV	O
-230.6	O
+/-	O
166.9	O
mg	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Groups	O
II	O
,	O
III	O
and	O
IV	O
were	O
comparable	O
with	O
regards	O
to	O
duration	O
of	O
postoperative	O
analgesia	O
and	O
total	O
analgesic	O
consumption	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Incidence	O
of	O
nausea	O
and	O
vomiting	O
were	O
comparable	O
in	O
all	O
four	O
groups	O
.	O

No	O
significant	O
alteration	O
in	O
vital	O
signs	O
or	O
any	O
other	O
adverse	O
effects	O
were	O
observed	O
.	O

CONCLUSIONS	O
Caudal	O
neostigmine	O
(	O
2	O
,	O
3	O
and	O
4	O
microg.kg	O
(	O
-1	O
)	O
)	O
with	O
bupivacaine	O
produces	O
a	O
dose-independent	O
analgesic	O
effect	O
(	O
approximately	O
16-17	O
hr	O
)	O
in	O
children	O
as	O
compared	O
to	O
those	O
receiving	O
caudal	O
bupivacaine	O
alone	O
(	O
approximately	O
five	O
hours	O
)	O
and	O
a	O
reduction	O
in	O
postoperative	O
rescue	O
analgesic	O
consumption	O
without	O
increasing	O
the	O
incidence	O
of	O
adverse	O
effects	O
.	O

Thrombolysis	O
is	O
superior	O
to	O
heparin	O
for	O
non-obstructive	O
mitral	O
mechanical	O
valve	O
thrombosis	O
.	O

BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY	O
Non-obstructive	O
prosthetic	Condition
valve	Condition
thrombosis	Condition
(	Condition
PVT	Condition
)	Condition
is	O
a	O
unique	O
subset	O
that	O
features	O
clinical	O
presentation	O
without	O
heart	O
failure	O
,	O
and	O
may	O
be	O
asymptomatic	O
.	O

Thrombolysis	O
has	O
been	O
accepted	O
for	O
obstructive	O
PVT	O
,	O
but	O
treatment	O
strategies	O
of	O
non-obstructive	O
PVT	O
are	O
controversial	O
.	O

This	O
study	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
thrombolysis	O
and	O
heparin	O
treatment	O
in	O
these	O
patients	O
.	O

METHODS	O
Between	O
1993	O
and	O
1998	O
,	O
20	SampleSize
consecutive	O
patients	O
were	O
found	O
by	O
multiplane	O
transesophageal	O
echocardiography	O
(	O
TEE	O
)	O
to	O
have	O
non-obstructive	Condition
PVT	Condition
.	Condition

TEE	O
was	O
performed	O
for	O
peripheral	O
embolism	O
in	O
two	O
patients	O
,	O
stroke	O
or	O
transient	O
ischemic	O
attack	O
in	O
six	O
,	O
stroke	O
and	O
fever	O
in	O
two	O
,	O
fever	O
in	O
one	O
patient	O
,	O
as	O
a	O
routine	O
postoperative	O
examination	O
in	O
two	O
patients	O
,	O
and	O
for	O
other	O
reasons	O
in	O
seven	O
.	O

Patients	O
were	O
allocated	O
to	O
two	O
groups	O
:	O
group	O
I	O
(	O
n	O
=	O
8	O
)	O
received	O
streptokinase-mediated	O
fibrinolysis	O
;	O
group	O
II	O
(	O
n	O
=	O
12	O
)	O
received	O
intravenous	O
heparin	O
by	O
infusion	O
.	O

Treatment	O
was	O
monitored	O
using	O
TEE	O
.	O

RESULTS	O
There	O
was	O
no	O
difference	O
between	O
patient	O
groups	O
with	O
regard	O
to	O
sex	O
,	O
age	O
,	O
type	O
of	O
prosthesis	O
and	O
time	O
since	O
operation	O
,	O
though	O
anticoagulant	O
status	O
was	O
more	O
often	O
inadequate	O
in	O
group	O
II	O
.	O

By	O
TEE	O
,	O
valve	O
motion	O
was	O
normal	O
in	O
all	O
patients	O
.	O

In	O
group	O
I	O
,	O
all	O
thrombi	O
were	O
mobile	O
and	O
5-13	O
mm	O
in	O
diameter	O
;	O
in	O
group	O
II	O
,	O
all	O
thrombi	O
but	O
three	O
were	O
mobile	O
and	O
3-18	O
mm	O
in	O
diameter	O
.	O

In	O
group	O
I	O
,	O
thrombolysis	O
was	O
successful	O
in	O
all	O
patients	O
,	O
without	O
complications	O
,	O
within	O
6-72	O
h.	O
In	O
group	O
II	O
,	O
heparin	O
treatment	O
was	O
successful	O
in	O
six	O
patients	O
in	O
3-32	O
days	O
.	O

In	O
one	O
patient	O
,	O
seven	O
days	O
'	O
of	O
unsuccessful	O
heparin	O
was	O
followed	O
by	O
two	O
months	O
'	O
successful	O
coumarin	O
therapy	O
.	O

Among	O
five	O
unsuccessful	O
cases	O
,	O
the	O
thrombus	O
size	O
increased	O
in	O
four	O
(	O
three	O
became	O
obstructive	O
in	O
7-35	O
days	O
)	O
;	O
all	O
four	O
patients	O
were	O
switched	O
to	O
fibrinolysis	O
,	O
which	O
was	O
successful	O
without	O
complications	O
in	O
12-60	O
h.	O
The	O
fifth	O
patient	O
developed	O
a	O
stroke	O
after	O
nine	O
days	O
of	O
heparin	O
treatment	O
and	O
was	O
subsequently	O
operated	O
on	O
.	O

CONCLUSIONS	O
Non-obstructive	O
PVT	O
may	O
be	O
asymptomatic	O
in	O
one-third	O
of	O
patients	O
.	O

Thrombolysis	O
is	O
an	O
efficient	O
and	O
safe	O
treatment	O
,	O
and	O
may	O
be	O
first-line	O
therapy	O
if	O
there	O
is	O
no	O
contraindication	O
.	O

Heparin	O
treatment	O
was	O
successful	O
in	O
about	O
one-half	O
of	O
our	O
cases	O
in	O
the	O
presence	O
of	O
sessile	O
or	O
small	O
thrombi	O
and	O
inadequate	O
anticoagulant	O
status	O
.	O

In	O
unsuccessful	O
cases	O
,	O
thrombi	O
became	O
obstructive	O
or	O
caused	O
stroke	O
during	O
heparin	O
therapy	O
,	O
the	O
adequate	O
duration	O
of	O
which	O
remains	O
unclear	O
.	O

Onset	O
of	O
action	O
of	O
ciclesonide	O
once	O
daily	O
in	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
rhinitis	O
.	O

Ciclesonide	O
is	O
an	O
intranasal	O
corticosteroid	O
approved	O
for	O
the	O
treatment	O
of	O
allergic	O
rhinitis	O
.	O

We	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
placebo-controlled	O
study	O
to	O
evaluate	O
the	O
time	O
to	O
onset	O
of	O
action	O
of	O
ciclesonide	O
200	O
microg	O
once	O
daily	O
in	O
502	SampleSize
adults	O
with	O
seasonal	Condition
allergic	Condition
rhinitis	Condition
of	O
at	O
least	O
2	O
years	O
'	O
duration	O
.	O

To	O
trigger	O
immunologic	O
priming	O
,	O
patients	O
underwent	O
between	O
one	O
and	O
five	O
priming	O
sessions	O
with	O
exposure	O
to	O
3,500	O
grains/m	O
(	O
3	O
)	O
(	O
+/-500	O
)	O
of	O
ragweed	O
pollen	O
in	O
an	O
environmental	O
exposure	O
chamber	O
.	O

The	O
criteria	O
for	O
a	O
successful	O
priming	O
session	O
were	O
a	O
patient-assessed	O
instantaneous	O
total	O
nasal	O
symptom	O
score	O
of	O
at	O
least	O
6	O
(	O
of	O
a	O
possible	O
12	O
)	O
and	O
a	O
nasal	O
congestion	O
or	O
rhinorrhea	O
score	O
of	O
at	O
least	O
2	O
(	O
of	O
a	O
possible	O
3	O
)	O
90	O
minutes	O
after	O
allergen	O
exposure	O
during	O
at	O
least	O
two	O
consecutive	O
priming	O
sessions	O
.	O

Patients	O
were	O
then	O
randomly	O
assigned	O
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
ciclesonide	O
200	O
microg	O
(	O
n	O
=	O
251	O
)	O
or	O
placebo	O
(	O
n	O
=	O
251	O
)	O
administered	O
intranasally	O
.	O

The	O
difference	O
in	O
the	O
change	O
from	O
baseline	O
total	O
nasal	O
symptom	O
scores	O
in	O
the	O
two	O
groups	O
was	O
assessed	O
hourly	O
for	O
12	O
hours	O
after	O
administration	O
.	O

Onset	O
of	O
action	O
was	O
determined	O
to	O
have	O
taken	O
place	O
the	O
first	O
time	O
that	O
the	O
effects	O
of	O
ciclesonide	O
,	O
as	O
reflected	O
in	O
the	O
total	O
nasal	O
symptom	O
score	O
,	O
were	O
significantly	O
greater	O
than	O
those	O
of	O
placebo	O
at	O
a	O
particular	O
hourly	O
assessment	O
,	O
provided	O
that	O
the	O
subsequent	O
hourly	O
assessment	O
also	O
showed	O
a	O
statistically	O
significant	O
difference	O
.	O

The	O
onset	O
of	O
action	O
of	O
ciclesonide	O
occurred	O
within	O
1	O
hour	O
of	O
administration	O
(	O
p	O
=	O
0.01	O
vs.	O
placebo	O
)	O
,	O
and	O
the	O
significant	O
difference	O
in	O
total	O
nasal	O
symptom	O
scores	O
between	O
ciclesonide	O
and	O
placebo	O
was	O
maintained	O
through	O
post-treatment	O
hour	O
12	O
(	O
p	O
=	O
0.018	O
)	O
.	O

[	O
Tocolysis	O
with	O
hexoprenalin	O
and	O
salbutamol	O
in	O
a	O
clinical	O
comparison	O
]	O
.	O

140	O
patients	O
with	O
a	O
threatening	O
premature	O
birth	O
at	O
the	O
greater	O
than	O
or	O
equal	O
to	O
24-less	O
than	O
37	O
week	O
of	O
gestation	O
were	O
in	O
this	O
study	O
randomly	O
treated	O
with	O
hexoprenalin	O
or	O
salbutamol	O
.	O

In	O
77	O
%	O
in	O
the	O
hexoprenalin	O
and	O
in	O
74	O
%	O
in	O
the	O
salbutamol	O
group	O
the	O
weight	O
of	O
the	O
newborn	O
was	O
greater	O
than	O
or	O
equal	O
to	O
2500	O
g.	O
In	O
66	O
%	O
in	O
both	O
study	O
groups	O
the	O
birth	O
occurred	O
after	O
the	O
completed	O
37	O
weeks	O
of	O
gestation	O
.	O

During	O
infusion	O
of	O
hexoprenalin	O
tachycardia	O
in	O
mothers	O
occurred	O
statistically	O
highly	O
significantly	O
less	O
than	O
during	O
salbutamol	O
.	O

11	O
%	O
of	O
the	O
mothers	O
in	O
the	O
hexoprenalin	O
group	O
had	O
side-effects	O
during	O
infusion	O
compared	O
to	O
30	O
%	O
in	O
the	O
salbutamol	O
group	O
.	O

The	O
correlation	O
between	O
the	O
tocolysis-index	O
(	O
Baumgarten	O
)	O
and	O
the	O
prolongation-index	O
(	O
Richter	O
)	O
given	O
by	O
the	O
regression	O
lines	O
facilitates	O
in	O
some	O
measure	O
the	O
comparison	O
of	O
different	O
tocolytic	O
drugs	O
concerning	O
its	O
tocolytic	O
effect	O
.	O

Theory-driven	O
intervention	O
improves	O
calcium	O
intake	O
,	O
osteoporosis	O
knowledge	O
,	O
and	O
self-efficacy	O
in	O
community-dwelling	Condition
older	Age
Black	Condition
adults	Age
.	O

OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	O
of	O
an	O
osteoporosis	O
education	O
program	O
to	O
improve	O
calcium	O
intake	O
,	O
knowledge	O
,	O
and	O
self-efficacy	O
in	O
community-dwelling	Condition
older	Age
Black	Condition
adults	Age
.	O

DESIGN	O
Randomized	O
repeated	O
measures	O
experimental	O
design	O
.	O

SETTING	O
Churches	O
and	O
community-based	O
organizations	O
.	O

PARTICIPANTS	O
Men	O
and	O
women	O
(	O
n	O
=	O
110	SampleSize
)	O
50	Age
years	Age
old	Age
and	Age
older	Age
from	Condition
3	Condition
south	Condition
Florida	Condition
counties	Condition
.	O

INTERVENTION	O
Participants	O
randomly	O
assigned	O
to	O
either	O
of	O
2	O
groups	O
:	O
Group	O
1	O
(	O
experimental	O
group	O
)	O
or	O
Group	O
2	O
(	O
wait-list	O
control	O
group	O
)	O
.	O

Group	O
1	O
participated	O
in	O
6	O
weekly	O
education	O
program	O
sessions	O
immediately	O
following	O
baseline	O
assessment	O
,	O
and	O
Group	O
2	O
started	O
the	O
program	O
following	O
Group	O
1	O
's	O
program	O
completion	O
.	O

A	O
tested	O
curriculum	O
was	O
adapted	O
to	O
meet	O
the	O
needs	O
of	O
the	O
target	O
population	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Dietary	O
calcium	O
intake	O
,	O
osteoporosis	O
knowledge	O
,	O
health	O
beliefs	O
,	O
and	O
self-efficacy	O
.	O

ANALYSIS	O
Descriptive	O
and	O
summary	O
statistics	O
,	O
repeated	O
measures	O
analysis	O
of	O
variance	O
,	O
and	O
regression	O
analysis	O
.	O

RESULTS	O
Of	O
the	O
total	O
participants	O
,	O
84.6	O
%	O
completed	O
the	O
study	O
(	O
mean	O
age	O
=	O
70.2	O
years	O
)	O
.	O

Overall	O
,	O
an	O
educational	O
program	O
developed	O
with	O
a	O
theoretical	O
background	O
was	O
associated	O
with	O
improvement	O
in	O
calcium	O
intake	O
,	O
knowledge	O
,	O
and	O
self-efficacy	O
,	O
with	O
no	O
effect	O
on	O
most	O
health	O
belief	O
subscales	O
.	O

Assigned	O
group	O
was	O
the	O
major	O
predictor	O
of	O
change	O
in	O
calcium	O
intake	O
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
A	O
theory-driven	O
approach	O
is	O
valuable	O
in	O
improving	O
behavior	O
to	O
promote	O
bone	O
health	O
in	O
this	O
population	O
.	O

Health	O
professionals	O
should	O
consider	O
using	O
more	O
theory-driven	O
approaches	O
in	O
intervention	O
studies	O
.	O

Comparison	O
of	O
coronary	O
bypass	O
surgery	O
with	O
angioplasty	O
in	O
patients	O
with	O
multivessel	O
disease	O
.	O

The	O
Bypass	O
Angioplasty	O
Revascularization	O
Investigation	O
(	O
BARI	O
)	O
Investigators	O
.	O

BACKGROUND	O
Coronary-artery	O
bypass	O
grafting	O
(	O
CABG	O
)	O
and	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
are	O
alternative	O
methods	O
of	O
revascularization	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
in	O
selected	O
patients	O
with	O
multivessel	O
disease	O
suitable	O
for	O
treatment	O
with	O
either	O
procedure	O
,	O
an	O
initial	O
strategy	O
of	O
PTCA	O
does	O
not	O
result	O
in	O
a	O
poorer	O
five-year	O
clinical	O
outcome	O
than	O
CABG	O
.	O

METHODS	O
Patients	O
with	O
multivessel	O
disease	O
were	O
randomly	O
assigned	O
to	O
an	O
initial	O
treatment	O
strategy	O
of	O
CABG	O
(	O
n	O
=	O
914	O
)	O
or	O
PTCA	O
(	O
n	O
=	O
915	O
)	O
and	O
were	O
followed	O
for	O
an	O
average	O
of	O
5.4	O
years	O
.	O

Analysis	O
of	O
outcome	O
events	O
was	O
performed	O
according	O
to	O
the	O
intention	O
to	O
treat	O
.	O

RESULTS	O
The	O
respective	O
in-hospital	O
event	O
rates	O
for	O
CABG	O
and	O
PTCA	O
were	O
1.3	O
percent	O
and	O
1.1	O
percent	O
for	O
mortality	O
,	O
4.6	O
percent	O
and	O
2.1	O
percent	O
for	O
Q-wave	O
myocardial	O
infarction	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
0.8	O
percent	O
and	O
0.2	O
percent	O
for	O
stroke	O
.	O

The	O
five-year	O
survival	O
rate	O
was	O
89.3	O
percent	O
for	O
those	O
assigned	O
to	O
CABG	O
and	O
86.3	O
percent	O
for	O
those	O
assigned	O
to	O
PTCA	O
(	O
P	O
=	O
0.19	O
;	O
95	O
percent	O
confidence	O
interval	O
of	O
the	O
difference	O
in	O
survival	O
,	O
-0.2	O
percent	O
to	O
6.0	O
percent	O
)	O
.	O

The	O
respective	O
five-year	O
survival	O
rates	O
free	O
from	O
Q-wave	O
myocardial	O
infarction	O
were	O
80.4	O
percent	O
and	O
78.7	O
percent	O
.	O

By	O
five	O
years	O
after	O
study	O
entry	O
,	O
8	O
percent	O
of	O
the	O
patients	O
assigned	O
to	O
CABG	O
had	O
undergone	O
additional	O
revascularization	O
procedures	O
,	O
as	O
compared	O
with	O
54	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
;	O
69	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
did	O
not	O
subsequently	O
undergo	O
CABG	O
.	O

Among	O
diabetic	O
patients	O
who	O
were	O
being	O
treated	O
with	O
insulin	O
or	O
oral	O
hypoglycemic	O
agents	O
at	O
base	O
line	O
,	O
a	O
subgroup	O
not	O
specified	O
by	O
the	O
protocol	O
,	O
five-year	O
survival	O
was	O
80.6	O
percent	O
for	O
the	O
CABG	O
group	O
as	O
compared	O
with	O
65.5	O
percent	O
for	O
the	O
PTCA	O
group	O
(	O
P	O
=	O
0.003	O
)	O
.	O

CONCLUSIONS	O
As	O
compared	O
with	O
CABG	O
,	O
an	O
initial	O
strategy	O
of	O
PTCA	O
did	O
not	O
significantly	O
compromise	O
five-year	O
survival	O
in	O
patients	O
with	O
multivessel	O
disease	O
,	O
although	O
subsequent	O
revascularization	O
was	O
required	O
more	O
often	O
with	O
this	O
strategy	O
.	O

For	O
treated	O
diabetics	O
,	O
five-year	O
survival	O
was	O
significantly	O
better	O
after	O
CABG	O
than	O
after	O
PTCA	O
.	O

Paracetamol	O
reduces	O
postoperative	O
pain	O
and	O
rescue	O
analgesic	O
demand	O
after	O
robot-assisted	O
endoscopic	O
thyroidectomy	O
by	O
the	O
transaxillary	O
approach	O
.	O

BACKGROUND	O
Postoperative	Condition
pain	Condition
following	Condition
endoscopic	Condition
thyroidectomy	Condition
,	O
although	O
less	O
severe	O
than	O
after	O
open	O
methods	O
,	O
is	O
still	O
a	O
source	O
of	O
marked	O
discomfort	O
and	O
surgical	O
stress	O
.	O

This	O
clinical	O
trial	O
was	O
conducted	O
to	O
determine	O
if	O
repeated	O
intravenous	O
paracetamol	O
could	O
decrease	O
postoperative	O
pain	O
and	O
rescue	O
analgesic	O
requirements	O
after	O
robot-assisted	O
endoscopic	O
thyroidectomy	O
via	O
the	O
transaxillary	O
approach	O
.	O

MATERIALS	O
AND	O
METHODS	O
This	O
prospective	O
,	O
randomized	O
,	O
double-blinded	O
,	O
and	O
placebo-controlled	O
study	O
enrolled	O
124	SampleSize
women	SampleSize
21-60	O
years	O
of	O
age	O
who	O
were	O
scheduled	O
for	O
elective	O
gasless	O
robot-assisted	O
endoscopic	O
thyroidectomy	O
via	O
the	O
transaxillary	O
approach	O
.	O

The	O
patients	O
were	O
given	O
placebo	O
or	O
1	O
g	O
of	O
paracetamol	O
as	O
a	O
100	O
ml	O
solution	O
infused	O
over	O
15	O
min	O
1	O
h	O
before	O
the	O
induction	O
of	O
anesthesia	O
,	O
and	O
then	O
at	O
6-h	O
intervals	O
for	O
the	O
following	O
24	O
h.	O
RESULTS	O
Postoperative	O
pain	O
scores	O
were	O
significantly	O
lower	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
and	O
24	O
h	O
after	O
surgery	O
in	O
the	O
paracetamol	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Significantly	O
fewer	O
patients	O
in	O
the	O
paracetamol	O
group	O
received	O
rescue	O
analgesics	O
compared	O
to	O
the	O
placebo	O
group	O
(	O
9.5	O
%	O
vs.	O
65.6	O
%	O
,	O
respectively	O
)	O
.	O

First	O
analgesic	O
time	O
was	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Postoperative	O
nausea	O
(	O
44.3	O
%	O
vs.	O
22.2	O
%	O
)	O
and	O
vomiting	O
(	O
21.3	O
%	O
vs.	O
6.3	O
%	O
)	O
were	O
more	O
frequent	O
in	O
the	O
placebo	O
group	O
than	O
in	O
the	O
paracetamol	O
group	O
.	O

Other	O
postoperative	O
side	O
effects	O
,	O
including	O
sedation	O
,	O
confusion	O
,	O
and	O
pruritus	O
,	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
We	O
concluded	O
that	O
repeated	O
administration	O
of	O
1	O
g	O
of	O
intravenous	O
paracetamol	O
over	O
24	O
h	O
is	O
easy	O
,	O
effective	O
,	O
safe	O
,	O
and	O
well	O
tolerated	O
for	O
pain	O
management	O
in	O
patients	O
with	O
moderate	Condition
to	Condition
severe	Condition
postoperative	Condition
pain	Condition
after	O
gasless	O
robot-assisted	O
endoscopic	O
thyroidectomy	O
performed	O
via	O
the	O
transaxillary	O
approach	O
.	O

Effect	O
of	O
extradural	O
analgesia	O
on	O
stress	O
responses	O
to	O
abdominal	O
surgery	O
in	O
infants	O
.	O

We	O
studied	O
40	O
children	O
younger	O
than	O
4	O
yr	O
having	O
elective	O
abdominal	O
surgery	O
under	O
general	O
anaesthesia	O
supplemented	O
with	O
either	O
systemic	O
opioids	O
or	O
extradural	O
bupivacaine	O
.	O

Venous	O
blood	O
samples	O
were	O
obtained	O
before	O
tracheal	O
intubation	O
to	O
measure	O
baseline	O
concentrations	O
of	O
adrenaline	O
,	O
noradrenaline	O
,	O
glucose	O
,	O
ACTH	O
and	O
cortisol	O
.	O

Additional	O
samples	O
were	O
obtained	O
45	O
min	O
after	O
the	O
start	O
of	O
surgery	O
,	O
at	O
the	O
end	O
of	O
surgery	O
,	O
1	O
h	O
and	O
24	O
h	O
after	O
the	O
end	O
of	O
surgery	O
.	O

Plasma	O
concentrations	O
of	O
bupivacaine	O
were	O
measured	O
also	O
in	O
the	O
extradural	O
group	O
at	O
each	O
sampling	O
time	O
.	O

Both	O
techniques	O
provided	O
acceptable	O
analgesia	O
,	O
but	O
the	O
perioperative	O
increases	O
in	O
adrenaline	O
,	O
glucose	O
and	O
ACTH	O
were	O
significantly	O
greater	O
in	O
the	O
opioid	O
group	O
.	O

Noradrenaline	O
concentrations	O
decreased	O
to	O
less	O
than	O
baseline	O
values	O
in	O
the	O
extradural	O
group	O
and	O
were	O
significantly	O
less	O
than	O
in	O
the	O
opioid	O
group	O
.	O

The	O
perioperative	O
increase	O
in	O
cortisol	O
was	O
similar	O
in	O
the	O
two	O
groups	O
,	O
despite	O
the	O
differences	O
in	O
ACTH	O
responses	O
.	O

Most	O
responses	O
returned	O
to	O
the	O
baseline	O
values	O
within	O
24	O
h.	O
Plasma	O
bupivacaine	O
concentrations	O
remained	O
within	O
safe	O
limits	O
during	O
the	O
study	O
,	O
but	O
systemic	O
concentrations	O
increased	O
in	O
some	O
of	O
the	O
patients	O
during	O
postoperative	O
infusion	O
with	O
0.125	O
%	O
bupivacaine	O
.	O

Prevention	O
of	O
subsequent	O
exercise-induced	O
periinfarct	O
ischemia	O
by	O
emergency	O
coronary	O
angioplasty	O
in	O
acute	Condition
myocardial	Condition
infarction	Condition
:	O
comparison	O
with	O
intracoronary	O
streptokinase	O
.	O

To	O
compare	O
the	O
efficacy	O
of	O
emergency	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
and	O
intracoronary	O
streptokinase	O
in	O
preventing	O
exercise-induced	O
periinfarct	O
ischemia	O
,	O
28	O
patients	O
presenting	O
within	O
12	O
hours	O
of	O
the	O
onset	O
of	O
symptoms	O
of	O
acute	Condition
myocardial	Condition
infarction	Condition
were	O
prospectively	O
randomized	O
.	O

Of	O
these	O
,	O
14	O
patients	O
were	O
treated	O
with	O
emergency	O
angioplasty	O
and	O
14	O
patients	O
received	O
intracoronary	O
streptokinase	O
.	O

Recatheterization	O
and	O
submaximal	O
exercise	O
thallium-201	O
single	O
photon	O
emission	O
computed	O
tomography	O
were	O
performed	O
before	O
hospital	O
discharge	O
.	O

Periinfarct	O
ischemia	O
was	O
defined	O
as	O
a	O
reversible	O
thallium	O
defect	O
adjacent	O
to	O
a	O
fixed	O
defect	O
assessed	O
qualitatively	O
.	O

Successful	O
reperfusion	O
was	O
achieved	O
in	O
86	O
%	O
of	O
patients	O
treated	O
with	O
emergency	O
angioplasty	O
and	O
86	O
%	O
of	O
patients	O
treated	O
with	O
intracoronary	O
streptokinase	O
(	O
p	O
=	O
NS	O
)	O
.	O

Residual	O
stenosis	O
of	O
the	O
infarct-related	O
coronary	O
artery	O
shown	O
at	O
predischarge	O
angiography	O
was	O
43.8	O
+/-	O
31.4	O
%	O
for	O
the	O
angioplasty	O
group	O
and	O
75.0	O
+/-	O
15.6	O
%	O
for	O
the	O
streptokinase	O
group	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Of	O
the	O
angioplasty	O
group	O
,	O
9	O
%	O
developed	O
exercise-induced	O
periinfarct	O
ischemia	O
compared	O
with	O
60	O
%	O
of	O
the	O
streptokinase	O
group	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Thus	O
,	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
treated	O
with	O
emergency	O
angioplasty	O
had	O
significantly	O
less	O
severe	O
residual	O
coronary	O
stenosis	O
and	O
exercise-induced	O
periinfarct	O
ischemia	O
than	O
did	O
those	O
treated	O
with	O
intracoronary	O
streptokinase	O
.	O

These	O
results	O
suggest	O
further	O
application	O
of	O
coronary	O
angioplasty	O
in	O
the	O
management	O
of	O
acute	O
myocardial	O
infarction	O
.	O

The	O
effectiveness	O
of	O
educational	O
interventions	O
to	O
enhance	O
the	O
adoption	O
of	O
fee-based	O
arsenic	O
testing	O
in	O
Bangladesh	Condition
:	O
a	O
cluster	O
randomized	O
controlled	O
trial	O
.	O

Arsenic	O
(	O
As	O
)	O
testing	O
could	O
help	O
22	O
million	O
people	O
,	O
using	O
drinking	O
water	O
sources	O
that	O
exceed	O
the	O
Bangladesh	O
As	O
standard	O
,	O
to	O
identify	O
safe	O
sources	O
.	O

A	O
cluster	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
household	O
education	O
and	O
local	O
media	O
in	O
the	O
increasing	O
demand	O
for	O
fee-based	O
As	O
testing	O
.	O

Randomly	O
selected	O
households	O
(	O
N	O
=	O
452	SampleSize
)	O
were	O
divided	O
into	O
three	O
interventions	O
implemented	O
by	O
community	O
workers	O
:	O
1	O
)	O
fee-based	O
As	O
testing	O
with	O
household	O
education	O
(	O
HE	O
)	O
;	O
2	O
)	O
fee-based	O
As	O
testing	O
with	O
household	O
education	O
and	O
a	O
local	O
media	O
campaign	O
(	O
HELM	O
)	O
;	O
and	O
3	O
)	O
fee-based	O
As	O
testing	O
alone	O
(	O
Control	O
)	O
.	O

The	O
fee	O
for	O
the	O
As	O
test	O
was	O
US	O
$	O
0.28	O
,	O
higher	O
than	O
the	O
cost	O
of	O
the	O
test	O
(	O
US	O
$	O
0.16	O
)	O
.	O

Of	O
households	O
with	O
untested	O
wells	O
,	O
93	O
%	O
in	O
both	O
intervention	O
groups	O
HE	O
and	O
HELM	O
purchased	O
an	O
As	O
test	O
,	O
whereas	O
only	O
53	O
%	O
in	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
fee-based	O
As	O
testing	O
with	O
household	O
education	O
is	O
effective	O
in	O
the	O
increasing	O
demand	O
for	O
As	O
testing	O
in	O
rural	Condition
Bangladesh	Condition
.	O

Mediastinal	O
lymphadenectomy	O
in	O
non-small	O
cell	O
lung	O
cancer	O
:	O
effectiveness	O
in	O
patients	O
with	O
or	O
without	O
nodal	O
micrometastases	O
-	O
results	O
of	O
a	O
preliminary	O
study	O
.	O

OBJECTIVES	O
So	O
far	O
it	O
has	O
not	O
clearly	O
been	O
demonstrated	O
that	O
systematic	O
mediastinal	O
lymphadenectomy	O
improves	O
survival	O
in	O
patients	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

One	O
explanation	O
might	O
be	O
that	O
in	O
some	O
patients	O
an	O
early	O
spread	O
of	O
tumor	O
cells	O
has	O
occurred	O
which	O
might	O
not	O
be	O
curable	O
by	O
surgical	O
means	O
.	O

To	O
test	O
this	O
hypothesis	O
lymph	O
nodes	O
of	O
patients	O
which	O
were	O
treated	O
either	O
by	O
lymph	O
node	O
sampling	O
or	O
systematic	O
lymphadenectomy	O
were	O
screened	O
for	O
micrometastatic	O
spread	O
of	O
tumor	O
cells	O
and	O
the	O
influence	O
of	O
nodal	O
micrometastases	O
on	O
the	O
efficacy	O
of	O
lymphadenectomy	O
was	O
analyzed	O
.	O

METHODS	O
Lymph	O
nodes	O
from	O
patients	O
(	O
n=94	O
)	O
which	O
were	O
included	O
in	O
a	O
randomized	O
trial	O
of	O
lymph	O
node	O
sampling	O
(	O
LS	O
,	O
n=41	O
)	O
versus	O
radical	O
systematic	O
lymphadenectomy	O
(	O
LA	O
,	O
n=53	O
)	O
were	O
screened	O
by	O
immunohistochemistry	O
for	O
disseminated	O
tumor	O
cells	O
using	O
the	O
antibody	O
Ber-Ep4	O
.	O

The	O
median	O
observation	O
time	O
was	O
longer	O
than	O
5	O
years	O
and	O
follow-up	O
data	O
were	O
available	O
from	O
all	O
94	O
patients	O
.	O

Kaplan-Meier	O
curves	O
were	O
calculated	O
and	O
tested	O
for	O
statistical	O
significance	O
using	O
the	O
log-rank	O
test	O
.	O

RESULTS	O
Standard	O
histopathological	O
analysis	O
revealed	O
no	O
lymph	O
node	O
involvement	O
(	O
pN0	O
)	O
in	O
61	O
patients	O
,	O
pN1	O
disease	O
in	O
13	O
patients	O
and	O
pN2	O
disease	O
in	O
20	O
patients	O
without	O
significant	O
differences	O
between	O
LA	O
and	O
LS	O
with	O
respect	O
to	O
T-stage	O
,	O
N-stage	O
or	O
age	O
and	O
sex	O
of	O
the	O
patients	O
.	O

By	O
immunohistochemistry	O
a	O
minimal	O
nodal	O
spread	O
of	O
tumor	O
cells	O
was	O
detected	O
in	O
21	O
out	O
of	O
94	O
patients	O
(	O
LS	O
,	O
n=10	O
(	O
24	O
%	O
)	O
;	O
LA	O
,	O
n=11	O
(	O
21	O
%	O
)	O
)	O
.	O

Similar	O
to	O
the	O
entire	O
group	O
of	O
patients	O
also	O
in	O
the	O
subset	O
of	O
patients	O
with	O
nodal	O
micrometastases	O
the	O
type	O
of	O
lymphadenectomy	O
did	O
not	O
significantly	O
influence	O
the	O
long-term	O
survival	O
(	O
P=0.27	O
and	O
P=0.39	O
,	O
respectively	O
)	O
.	O

In	O
contrast	O
,	O
in	O
patients	O
with	O
a	O
negative	O
immunohistochemical	O
analysis	O
systematic	O
lymphadenectomy	O
resulted	O
in	O
an	O
improved	O
overall	O
survival	O
(	O
P=0.044	O
)	O
.	O

CONCLUSIONS	O
Our	O
data	O
provide	O
some	O
evidence	O
that	O
systematic	O
lymphadenectomy	O
improves	O
survival	O
in	O
patients	O
without	O
an	O
early	O
locoregional	O
spread	O
of	O
cancer	O
cells	O
.	O

As	O
long	O
as	O
these	O
patients	O
can	O
not	O
be	O
identified	O
preoperatively	O
all	O
patients	O
should	O
undergo	O
a	O
systematic	O
mediastinal	O
lymphadenectomy	O
.	O

Ciprofloxacin	O
,	O
lomefloxacin	O
,	O
or	O
levofloxacin	O
as	O
treatment	O
for	O
chronic	Condition
osteomyelitis	Condition
.	O

The	O
efficacy	O
and	O
safety	O
of	O
three	O
oral	O
fluoroquinolones	O
(	O
lomefloxacin	O
,	O
levofloxacin	O
,	O
and	O
ciprofloxacin	O
)	O
for	O
the	O
treatment	O
of	O
chronic	O
osteomyelitis	O
were	O
analyzed	O
.	O

Twenty-seven	SampleSize
patients	O
had	O
documented	O
infections	Condition
with	Condition
quinolone-sensitive	Condition
organisms	Condition
and	O
received	O
either	O
lomefloxacin	O
,	O
levofloxacin	O
,	O
or	O
ciprofloxacin	O
.	O

Levofloxacin	O
was	O
effective	O
therapy	O
for	O
9	O
of	O
15	O
(	O
60	O
%	O
)	O
patients	O
.	O

Lomefloxacin	O
was	O
effective	O
therapy	O
for	O
five	O
of	O
seven	O
(	O
71	O
%	O
)	O
patients	O
,	O
and	O
ciprofloxacin	O
was	O
effective	O
therapy	O
for	O
two	O
of	O
five	O
patients	O
(	O
40	O
%	O
)	O
.	O

Average	O
follow-up	O
was	O
11.8	O
months	O
for	O
patients	O
who	O
completed	O
the	O
course	O
of	O
therapy	O
,	O
and	O
the	O
average	O
duration	O
of	O
therapy	O
was	O
60.6	O
days	O
.	O

Gram-positive	O
bacteria	O
were	O
isolated	O
from	O
18	O
patients	O
,	O
and	O
11	O
patients	O
were	O
cured	O
.	O

Oral	O
fluoroquinolones	O
can	O
be	O
safe	O
,	O
effective	O
therapy	O
if	O
they	O
are	O
given	O
for	O
a	O
prolonged	O
course	O
as	O
treatment	O
for	O
infections	O
caused	O
by	O
susceptible	O
gram-positive	O
as	O
well	O
as	O
gram-negative	O
organisms	O
and	O
in	O
combination	O
with	O
adequate	O
surgical	O
debridement	O
.	O

Aerobic	O
exercise	O
improves	O
self-reported	O
sleep	O
and	O
quality	O
of	O
life	O
in	O
older	Age
adults	Age
with	O
insomnia	Condition
.	O

OBJECTIVE	O
To	O
assess	O
the	O
efficacy	O
of	O
moderate	O
aerobic	O
physical	O
activity	O
with	O
sleep	O
hygiene	O
education	O
to	O
improve	O
sleep	O
,	O
mood	O
and	O
quality	O
of	O
life	O
in	O
older	O
adults	O
with	O
chronic	O
insomnia	O
.	O

METHODS	O
Seventeen	O
sedentary	O
adults	O
aged	O
>	Age
or=55	Age
years	Age
with	O
insomnia	O
(	O
mean	O
age	O
61.6	O
[	O
SD?4.3	O
]	O
years	O
;	O
16	O
female	O
)	O
participated	O
in	O
a	O
randomized	O
controlled	O
trial	O
comparing	O
16	O
weeks	O
of	O
aerobic	O
physical	O
activity	O
plus	O
sleep	O
hygiene	O
to	O
non-physical	O
activity	O
plus	O
sleep	O
hygiene	O
.	O

Eligibility	O
included	O
primary	O
insomnia	O
for	O
at	O
least	O
3	O
months	O
,	O
habitual	O
sleep	O
duration	O
<	O
6.5h	O
and	O
a	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
(	O
PSQI	O
)	O
score	O
>	O
5	O
.	O

Outcomes	O
included	O
sleep	O
quality	O
,	O
mood	O
and	O
quality	O
of	O
life	O
questionnaires	O
(	O
PSQI	O
,	O
Epworth	O
Sleepiness	O
Scale	O
[	O
ESS	O
]	O
,	O
Short-form	O
36	O
[	O
SF-36	O
]	O
,	O
Center	O
for	O
Epidemiological	O
Studies	O
Depression	O
Scale	O
[	O
CES-D	O
]	O
)	O
.	O

RESULTS	O
The	O
physical	O
activity	O
group	O
improved	O
in	O
sleep	O
quality	O
on	O
the	O
global	O
PSQI	O
(	O
p	O
<	O
.0001	O
)	O
,	O
sleep	O
latency	O
(	O
p=.049	O
)	O
,	O
sleep	O
duration	O
(	O
p=.04	O
)	O
,	O
daytime	O
dysfunction	O
(	O
p=.027	O
)	O
,	O
and	O
sleep	O
efficiency	O
(	O
p=.036	O
)	O
PSQI	O
sub-scores	O
compared	O
to	O
the	O
control	O
group	O
.	O

The	O
physical	O
activity	O
group	O
also	O
had	O
reductions	O
in	O
depressive	O
symptoms	O
(	O
p=.044	O
)	O
,	O
daytime	O
sleepiness	O
(	O
p=.02	O
)	O
and	O
improvements	O
in	O
vitality	O
(	O
p=.017	O
)	O
compared	O
to	O
baseline	O
scores	O
.	O

CONCLUSION	O
Aerobic	O
physical	O
activity	O
with	O
sleep	O
hygiene	O
education	O
is	O
an	O
effective	O
treatment	O
approach	O
to	O
improve	O
sleep	O
quality	O
,	O
mood	O
and	O
quality	O
of	O
life	O
in	O
older	Age
adults	Age
with	O
chronic	O
insomnia	O
.	O

Delineation	O
of	O
cryptogenic	O
Lennox-Gastaut	O
syndrome	O
and	O
myoclonic	O
astatic	O
epilepsy	O
using	O
multiple	O
correspondence	O
analysis	O
.	O

PURPOSE	O
To	O
distinguish	O
various	O
types	O
of	O
childhood	Condition
severe	Condition
cryptogenic/idiopathic	Condition
generalised	Condition
epilepsy	Condition
on	O
the	O
basis	O
of	O
reproducible	O
diagnostic	O
criteria	O
,	O
using	O
multiple	O
correspondence	O
analysis	O
(	O
MCA	O
)	O
.	O

METHODS	O
We	O
applied	O
MCA	O
to	O
a	O
series	O
of	O
72	O
children	O
with	O
no	O
evidence	O
of	O
brain	O
damage	O
,	O
starting	O
epilepsy	O
between	O
1	O
and	O
10	O
years	O
,	O
with	O
two	O
or	O
more	O
types	O
of	O
generalised	O
seizures	O
.	O

We	O
excluded	O
patients	O
with	O
infantile	O
spasms	O
or	O
typical	O
absences	O
.	O

MCA	O
was	O
performed	O
on	O
all	O
clinical	O
and	O
EEG	O
parameters	O
,	O
first	O
throughout	O
follow-up	O
,	O
then	O
restricted	O
to	O
the	O
first	O
year	O
of	O
the	O
disease	O
.	O

RESULTS	O
When	O
including	O
all	O
follow-up	O
variables	O
,	O
there	O
were	O
three	O
groups	O
:	O
(	O
1	O
)	O
Thirty-seven	O
children	O
with	O
male	O
predominance	O
,	O
familial	O
history	O
of	O
epilepsy	O
,	O
simple	O
febrile	O
convulsions	O
,	O
massive	O
myoclonus	O
,	O
tonic-clonic	O
fits	O
.	O

Outcome	O
was	O
favourable	O
,	O
with	O
no	O
seizures	O
and	O
mildly	O
affected	O
cognitive	O
functions	O
.	O

Interictal	O
EEG	O
showed	O
short	O
sequences	O
of	O
irregular	O
3-Hz	O
spike-waves	O
.	O

(	O
2	O
)	O
In	O
18	O
children	O
,	O
clinical	O
characteristics	O
were	O
similar	O
to	O
those	O
of	O
the	O
first	O
group	O
at	O
the	O
early	O
stage	O
,	O
but	O
95	O
%	O
exhibited	O
myoclonic	O
status	O
and	O
vibratory	O
tonic	O
seizures	O
,	O
with	O
persisting	O
seizures	O
on	O
follow-up	O
.	O

EEG	O
showed	O
long	O
sequences	O
of	O
generalised	O
irregular	O
spike	O
and	O
slow	O
waves	O
.	O

Those	O
two	O
groups	O
meet	O
the	O
characteristics	O
of	O
childhood	O
onset	O
myoclonic-astatic	O
epilepsy	O
(	O
MAE	O
)	O
with	O
respectively	O
,	O
favourable	O
and	O
unfavourable	O
outcome	O
.	O

(	O
3	O
)	O
Eleven	O
children	O
had	O
later	O
onset	O
,	O
atypical	O
absences	O
,	O
tonic	O
and	O
partial	O
seizures	O
,	O
and	O
no	O
myoclonus	O
,	O
or	O
vibratory	O
tonic	O
seizures	O
.	O

All	O
had	O
mental	O
retardation	O
and	O
persisting	O
seizures	O
.	O

EEG	O
showed	O
long	O
sequences	O
of	O
slow	O
spike-wave	O
activity	O
and	O
half	O
the	O
patients	O
had	O
spike	O
and	O
slow	O
wave	O
foci	O
.	O

These	O
patients	O
met	O
the	O
major	O
characteristics	O
of	O
Lennox-Gastaut	O
syndrome	O
.	O

Initial	O
parameters	O
failed	O
to	O
distinguish	O
the	O
first	O
two	O
groups	O
,	O
but	O
Lennox-Gastaut	O
syndrome	O
(	O
the	O
third	O
group	O
)	O
was	O
distinct	O
from	O
both	O
groups	O
of	O
myoclonic	O
astatic	O
epilepsy	O
from	O
the	O
onset	O
.	O

Within	O
MAE	O
groups	O
combined	O
,	O
clinical	O
and	O
EEG	O
risk	O
factors	O
for	O
mental	O
retardation	O
could	O
be	O
identified	O
.	O

CONCLUSION	O
It	O
is	O
possible	O
to	O
validate	O
statistically	O
the	O
distinction	O
between	O
discrete	O
epileptic	O
syndromes	O
.	O

Myoclonic	O
astatic	O
epilepsy	O
is	O
therefore	O
distinct	O
from	O
Lennox-Gastaut	O
syndrome	O
,	O
and	O
the	O
distinction	O
appears	O
from	O
the	O
first	O
year	O
of	O
the	O
disorder	O
.	O

A	O
proof	O
of	O
concept	O
study	O
to	O
evaluate	O
putative	O
benefits	O
of	O
montelukast	O
in	O
moderate	Condition
persistent	Condition
asthmatics	Condition
.	O

AIMS	O
Whether	O
chronic	O
dosing	O
with	O
montelukast	O
confers	O
benefit	O
in	O
patients	O
with	O
moderate	Condition
to	Condition
severe	Condition
asthma	Condition
remains	O
to	O
be	O
fully	O
established	O
.	O

A	O
proof	O
of	O
concept	O
study	O
was	O
performed	O
evaluating	O
putative	O
benefits	O
with	O
montelukast	O
in	O
moderate	O
persistent	O
asthmatics	O
who	O
were	O
taken	O
off	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
and	O
switched	O
to	O
salmeterol	O
.	O

The	O
latter	O
was	O
done	O
to	O
dissociate	O
the	O
effects	O
of	O
montelukast	O
from	O
ICS	O
.	O

METHODS	O
Twenty	SampleSize
moderate	Condition
to	Condition
severe	Condition
persistent	Condition
asthmatics	Condition
completed	O
a	O
randomized	O
double-blind	O
crossover	O
study	O
.	O

Subjects	O
received	O
montelukast	O
10	O
mg	O
daily	O
or	O
placebo	O
for	O
2	O
weeks	O
each	O
.	O

This	O
was	O
preceded	O
by	O
a	O
2-week	O
run-in	O
when	O
ICS	O
were	O
discontinued	O
and	O
salmeterol	O
started	O
,	O
and	O
used	O
on	O
a	O
regular	O
basis	O
throughout	O
the	O
study	O
.	O

Measurements	O
were	O
made	O
after	O
run-in	O
and	O
after	O
both	O
randomized	O
treatments	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
sequence	O
effects	O
for	O
responses	O
as	O
to	O
whether	O
placebo	O
or	O
montelukast	O
were	O
given	O
first	O
or	O
second	O
.	O

Methacholine	O
PD20	O
values	O
after	O
run-in	O
,	O
first	O
and	O
second	O
placebo	O
were	O
63	O
micro	O
g	O
,	O
60	O
micro	O
g	O
and	O
64	O
micro	O
g	O
,	O
respectively	O
(	O
corresponding	O
to	O
2	O
,	O
4	O
and	O
6	O
weeks	O
of	O
ICS	O
washout	O
,	O
respectively	O
)	O
.	O

Lung	O
function	O
deteriorated	O
pre	O
vs	O
post	O
run-in	O
,	O
which	O
was	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
for	O
FEF25-75	O
%	O
predicted	O
.	O

Montelukast	O
conferred	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
improvements	O
as	O
change	O
from	O
post	O
run-in	O
compared	O
with	O
placebo	O
in	O
methacholine	O
PD20	O
,	O
FEV1	O
%	O
predicted	O
,	O
FEF25-75	O
%	O
predicted	O
,	O
diurnal	O
peak	O
expiratory	O
flow	O
,	O
symptoms	O
and	O
salbutamol	O
use	O
.	O

For	O
the	O
primary	O
outcome	O
of	O
methacholine	O
PD20	O
,	O
this	O
amounted	O
to	O
a	O
1.6-fold	O
difference	O
(	O
95	O
%	O
CI	O
1.1	O
,	O
2.5	O
)	O
.	O

CONCLUSIONS	O
In	O
moderate	O
persistent	O
asthmatics	O
switched	O
from	O
taking	O
ICS	O
to	O
salmeterol	O
alone	O
,	O
adding	O
montelukast	O
conferred	O
significant	O
benefits	O
on	O
all	O
parameters	O
of	O
asthma	O
control	O
.	O

Further	O
studies	O
are	O
indicated	O
to	O
evaluate	O
whether	O
montelukast	O
exhibits	O
additive	O
effects	O
to	O
ICS/long-acting	O
beta2-adrenoceptor	O
agonist	O
combination	O
inhalers	O
upon	O
clinically	O
important	O
outcomes	O
.	O

Dalteparin	O
low	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
in	O
ovarian	Condition
cancer	Condition
:	O
a	O
phase	O
II	O
randomized	O
study	O
.	O

OBJECTIVE	O
Low	O
molecular	O
weight	O
heparin	O
reduces	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
and	O
may	O
have	O
antineoplastic	O
effects	O
by	O
interfering	O
with	O
angiogenesis	O
and	O
with	O
tumor	O
growth	O
and	O
metastasis	O
.	O

A	O
multicentre	O
phase	O
II	O
randomized	O
trial	O
was	O
done	O
to	O
evaluate	O
the	O
antineoplastic	O
potential	O
of	O
dalteparin	O
in	O
ovarian	O
cancer	O
(	O
OC	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
Women	Sex
with	O
newly-diagnosed	Condition
epithelial	Condition
OC	Condition
were	O
randomized	O
to	O
receive	O
standard	O
chemotherapy	O
(	O
CT	O
)	O
and	O
one	O
of	O
3	O
doses	O
of	O
dalteparin	O
(	O
50	O
IU/kg	O
,	O
100	O
IU/kg	O
,	O
or	O
150	O
IU/kg	O
)	O
subcutaneously	O
once	O
daily	O
during	O
the	O
first	O
3	O
of	O
6	O
cycles	O
of	O
3-weekly	O
CT	O
.	O

Blood	O
was	O
drawn	O
on	O
day	O
1	O
of	O
each	O
cycle	O
for	O
CA125	O
and	O
,	O
in	O
a	O
substudy	O
of	O
randomized	O
patients	O
,	O
for	O
markers	O
of	O
coagulation	O
activation	O
and	O
angiogenesis	O
.	O

The	O
primary	O
outcome	O
was	O
tumor	O
response	O
defined	O
by	O
?	O
50	O
%	O
reduction	O
in	O
serum	O
CA125	O
from	O
baseline	O
sustained	O
for	O
at	O
least	O
28	O
days	O
.	O

Patients	O
were	O
followed	O
until	O
the	O
end	O
of	O
CT	O
.	O

RESULTS	O
The	O
study	O
was	O
terminated	O
early	O
due	O
to	O
poor	O
recruitment	O
.	O

Seventy-seven	O
women	Sex
were	O
evaluable	O
for	O
the	O
primary	O
outcome	O
.	O

A	O
50	O
%	O
drop	O
in	O
CA125	O
at	O
the	O
end	O
of	O
cycle	O
3	O
was	O
seen	O
in	O
85	O
%	O
of	O
the	O
50	O
IU/kg	O
group	O
,	O
92	O
%	O
of	O
the	O
100	O
IU/kg	O
group	O
,	O
and	O
85	O
%	O
of	O
the	O
150	O
IU/kg	O
group	O
.	O

There	O
were	O
no	O
symptomatic	O
VTE	O
or	O
major	O
bleeding	O
events	O
while	O
on	O
dalteparin	O
.	O

Two	O
patients	O
experienced	O
VTE	O
several	O
days	O
after	O
discontinuing	O
study	O
drug	O
.	O

Women	O
on	O
dalteparin	O
had	O
lower	O
levels	O
of	O
D-dimer	O
and	O
thrombin-antithrombin	O
,	O
and	O
higher	O
levels	O
of	O
tissue	O
factor	O
pathway	O
inhibitor	O
,	O
relative	O
to	O
baseline	O
.	O

CONCLUSION	O
Dalteparin	O
is	O
safe	O
and	O
well	O
tolerated	O
in	O
women	O
receiving	O
CT	O
for	O
newly-diagnosed	O
epithelial	O
OC	O
.	O

A	O
dose-response	O
effect	O
was	O
not	O
identified	O
.	O

The	O
lack	O
of	O
control	O
group	O
precluded	O
any	O
inference	O
on	O
the	O
antineoplastic	O
effect	O
of	O
dalteparin	O
.	O

A	O
comparison	O
of	O
the	O
recovery	O
times	O
of	O
desflurane	O
and	O
isoflurane	O
in	O
outpatient	Condition
anesthesia	Condition
.	O

The	O
low	O
solubility	O
of	O
desflurane	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
faster	O
awakening	O
from	O
anesthesia	O
when	O
compared	O
with	O
other	O
anesthetics	O
in	O
common	O
use	O
.	O

However	O
,	O
research	O
has	O
failed	O
to	O
consistently	O
demonstrate	O
faster	O
discharge	O
times	O
from	O
the	O
postanesthesia	O
care	O
unit	O
following	O
the	O
use	O
of	O
desflurane	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
compare	O
the	O
recovery	O
and	O
discharge	O
times	O
of	O
outpatients	O
undergoing	O
procedures	Condition
greater	Condition
than	Condition
2	Condition
hours	Condition
in	Condition
length	Condition
.	O

Thirty-three	SampleSize
patients	O
aged	O
18	Age
to	Age
70	Age
years	O
were	O
randomized	O
to	O
receive	O
either	O
desflurane	O
or	O
isoflurane	O
following	O
a	O
standard	O
intravenous	O
induction	O
with	O
propofol	O
.	O

Patients	O
received	O
premedication	O
and	O
opioids	O
consistent	O
with	O
institutional	O
practice	O
,	O
and	O
inhalation	O
agents	O
were	O
titrated	O
to	O
effect	O
during	O
anesthetic	O
maintenance	O
.	O

Following	O
surgery	O
,	O
patients	O
were	O
evaluated	O
for	O
time	O
to	O
emergence	O
and	O
time	O
to	O
meeting	O
discharge	O
criteria	O
.	O

The	O
results	O
demonstrated	O
no	O
differences	O
between	O
the	O
emergence	O
or	O
discharge	O
times	O
following	O
desflurane	O
or	O
isoflurane	O
.	O

In	O
addition	O
,	O
measured	O
parameters	O
,	O
such	O
as	O
intraoperative	O
vital	O
signs	O
and	O
postoperative	O
emesis	O
and	O
opioid	O
requirements	O
,	O
were	O
not	O
different	O
between	O
the	O
groups	O
.	O

The	O
use	O
of	O
desflurane	O
as	O
part	O
of	O
a	O
balanced	O
anesthetic	O
technique	O
did	O
not	O
speed	O
the	O
emergence	O
or	O
discharge	O
time	O
when	O
compared	O
with	O
isoflurane	O
.	O

Preoperative	O
small-dose	O
ketamine	O
has	O
no	O
preemptive	O
analgesic	O
effect	O
in	O
patients	O
undergoing	O
total	O
mastectomy	O
.	O

UNLABELLED	O
We	O
evaluated	O
the	O
preemptive	O
analgesic	O
effect	O
of	O
a	O
small	O
dose	O
of	O
ketamine	O
given	O
before	O
or	O
immediately	O
after	O
surgery	O
in	O
a	O
randomized	O
,	O
double-blinded	O
study	O
performed	O
in	O
128	SampleSize
women	O
undergoing	Condition
total	Condition
mastectomy	Condition
.	O

Group	O
1	O
patients	O
received	O
ketamine	O
0.15	O
mg/kg	O
as	O
a	O
5-mL	O
i.v	O
.	O

injection	O
5	O
min	O
before	O
surgery	O
and	O
isotonic	O
saline	O
5	O
mL	O
i.v	O
.	O

at	O
the	O
time	O
of	O
skin	O
closure	O
.	O

Group	O
2	O
received	O
5	O
mL	O
i.v	O
.	O

of	O
isotonic	O
saline	O
,	O
then	O
0.15	O
mg/kg	O
i.v	O
.	O

ketamine	O
.	O

A	O
standard	O
general	O
anesthesia	O
procedure	O
including	O
sufentanil	O
was	O
used	O
.	O

In	O
the	O
recovery	O
room	O
,	O
patient-controlled	O
analgesia	O
i.v	O
.	O

morphine	O
was	O
used	O
for	O
postoperative	O
analgesia	O
.	O

Postoperative	O
pain	O
was	O
assessed	O
by	O
measuring	O
morphine	O
consumption	O
and	O
visual	O
analog	O
scale	O
pain	O
scores	O
.	O

No	O
significant	O
intergroup	O
differences	O
were	O
seen	O
in	O
the	O
pain	O
scores	O
.	O

Patient-controlled	O
analgesia	O
morphine	O
consumption	O
was	O
lower	O
during	O
the	O
first	O
2	O
h	O
after	O
surgery	O
in	O
patients	O
given	O
ketamine	O
at	O
the	O
time	O
of	O
skin	O
closure	O
.	O

No	O
patient	O
complained	O
of	O
hallucinations	O
or	O
nightmares	O
.	O

The	O
incidence	O
of	O
adverse	O
effects	O
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

In	O
conclusion	O
,	O
administering	O
ketamine	O
at	O
the	O
end	O
of	O
surgery	O
is	O
more	O
effective	O
in	O
reducing	O
morphine	O
consumption	O
than	O
it	O
is	O
when	O
given	O
before	O
surgery	O
.	O

IMPLICATIONS	O
We	O
administered	O
the	O
same	O
small	O
dose	O
of	O
ketamine	O
before	O
or	O
after	O
surgery	O
.	O

The	O
preoperative	O
administration	O
of	O
0.15	O
mg/kg	O
ketamine	O
in	O
patients	O
undergoing	Condition
total	Condition
mastectomy	Condition
did	O
not	O
elicit	O
a	O
preemptive	O
analgesic	O
effect	O
.	O

Ketamine	O
given	O
at	O
closure	O
reduced	O
the	O
patient-controlled	O
analgesia	O
morphine	O
requirement	O
in	O
the	O
first	O
2	O
h	O
after	O
surgery	O
.	O

A	O
prospective	O
randomized	O
trial	O
of	O
topical	O
pimecrolimus	O
for	O
cetuximab-associated	Condition
acnelike	Condition
eruption	Condition
.	O

BACKGROUND	O
Clinical	O
trials	O
addressing	O
the	O
acneiform	O
rash	O
associated	O
with	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitors	O
are	O
lacking	O
.	O

OBJECTIVE	O
We	O
evaluated	O
the	O
ability	O
of	O
topical	O
pimecrolimus	O
to	O
reduce	O
the	O
severity	O
of	O
cetuximab-related	Condition
facial	Condition
rash	Condition
.	Condition

METHODS	O
In	O
all	O
,	O
24	SampleSize
patients	O
with	O
metastatic	Condition
colorectal	Condition
cancer	Condition
with	Condition
cetuximab	Condition
facial	Condition
rash	Condition
received	O
twice	O
daily	O
pimecrolimus	O
application	O
for	O
5	O
weeks	O
to	O
half	O
of	O
the	O
face	O
.	O

At	O
baseline	O
,	O
week	O
2	O
,	O
and	O
week	O
5	O
,	O
a	O
dermatologist	O
performed	O
facial	O
lesion	O
counts	O
,	O
patients	O
reported	O
perceived	O
severity	O
of	O
rash-related	O
symptoms	O
,	O
and	O
standardized	O
facial	O
photographs	O
were	O
obtained	O
for	O
blinded	O
evaluation	O
of	O
global	O
rash	O
severity	O
.	O

RESULTS	O
Treatment	O
sides	O
had	O
greater	O
decrease	O
in	O
lesion	O
counts	O
than	O
observation	O
sides	O
of	O
face	O
at	O
weeks	O
2	O
(	O
P	O
<	O
.001	O
)	O
and	O
5	O
(	O
P	O
=	O
.02	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
patients	O
'	O
assessment	O
of	O
symptoms	O
and	O
in	O
review	O
of	O
facial	O
photographs	O
for	O
rash	O
severity	O
between	O
treatment	O
and	O
observation	O
sides	O
.	O

LIMITATIONS	O
This	O
study	O
was	O
not	O
placebo	O
controlled	O
.	O

CONCLUSIONS	O
Pimecrolimus	O
application	O
did	O
not	O
translate	O
into	O
clinically	O
meaningful	O
benefit	O
for	O
patients	O
with	O
cetuximab-related	Condition
facial	Condition
rash	Condition
.	O

The	O
radial	O
forearm	O
flap	O
:	O
a	O
biomechanical	O
study	O
of	O
donor-site	O
morbidity	O
utilizing	O
sheep	O
tibia	O
.	O

The	O
use	O
of	O
vascularized	O
bone	O
grafts	O
to	O
reconstruct	O
extremity	O
and	O
mandibular	O
defects	O
is	O
now	O
commonplace	O
in	O
reconstructive	O
surgery	O
.	O

Fibula	O
,	O
scapula	O
,	O
iliac	O
crest	O
,	O
rib	O
,	O
and	O
metatarsal	O
as	O
well	O
as	O
the	O
radial	O
forearm	O
osseocutaneous	O
flaps	O
have	O
all	O
been	O
utilized	O
for	O
this	O
purpose	O
.	O

Troublesome	O
spiral	O
fractures	O
of	O
the	O
distal	O
radius	O
are	O
the	O
most	O
common	O
fractures	O
associated	O
with	O
the	O
use	O
of	O
the	O
distal	O
radius	O
as	O
a	O
vascularized	O
bone-graft	O
donor	O
site	O
.	O

This	O
study	O
was	O
proposed	O
to	O
investigate	O
the	O
effect	O
of	O
donor-site	O
bone	O
loss	O
on	O
the	O
strength	O
of	O
the	O
radius	O
under	O
torsional	O
(	O
rotational	O
)	O
loading	O
.	O

Previous	O
clinical	O
series	O
and	O
experimental	O
studies	O
have	O
not	O
examined	O
this	O
aspect	O
of	O
distal	O
radius	O
loading	O
after	O
harvesting	O
the	O
bone	O
graft	O
.	O

Fifty	SampleSize
pairs	O
of	O
sheep	O
tibiae	O
were	O
utilized	O
in	O
the	O
experiment	O
.	O

Five	SampleSize
pairs	O
were	O
used	O
in	O
a	O
pilot	O
study	O
and	O
45	SampleSize
pairs	O
were	O
used	O
in	O
the	O
main	O
experiment	O
.	O

Five	SampleSize
pairs	O
of	O
human	O
radii	O
were	O
used	O
for	O
the	O
control	O
in	O
the	O
pilot	O
study	O
.	O

The	O
pilot	O
study	O
attempted	O
to	O
make	O
a	O
comparison	O
between	O
the	O
human	O
radius	O
and	O
the	O
sheep	O
tibia	O
for	O
experimental	O
purposes	O
.	O

For	O
the	O
biomechanical	O
study	O
of	O
donor-site	O
defects	O
,	O
four	O
study	O
groups	O
were	O
examined	O
with	O
random	O
assignment	O
and	O
matched	O
pairs	O
.	O

The	O
control	O
group	O
(	O
group	O
1	O
)	O
had	O
no	O
alteration	O
to	O
the	O
bone	O
.	O

Each	O
test	O
condition	O
included	O
five	O
matched	O
pairs	O
of	O
sheep	O
tibiae	O
.	O

Experiment	O
1	O
compared	O
the	O
difference	O
in	O
the	O
depth	O
of	O
the	O
osteotomy	O
defect	O
.	O

In	O
doing	O
this	O
,	O
one-third	O
of	O
the	O
total	O
length	O
of	O
the	O
bone	O
was	O
removed	O
in	O
each	O
of	O
the	O
following	O
specimens	O
to	O
include	O
(	O
1a	O
)	O
30	O
percent	O
of	O
the	O
cross-sectional	O
area	O
of	O
the	O
total	O
bone	O
,	O
(	O
1b	O
)	O
37	O
percent	O
of	O
the	O
cross-sectional	O
area	O
of	O
the	O
total	O
bone	O
,	O
and	O
(	O
1c	O
)	O
50	O
percent	O
of	O
the	O
cross-sectional	O
area	O
of	O
the	O
total	O
bone	O
.	O

In	O
experiment	O
2	O
,	O
the	O
osteotomy	O
shape	O
was	O
varied	O
.	O

Instead	O
of	O
the	O
ends	O
of	O
the	O
cuts	O
being	O
squared	O
,	O
the	O
ends	O
were	O
beveled	O
or	O
rounded	O
.	O

Experiment	O
3	O
compared	O
different	O
lengths	O
of	O
bone	O
removed	O
in	O
the	O
osteotomy	O
defect	O
and	O
included	O
the	O
following	O
:	O
In	O
experiment	O
3a	O
the	O
diameter	O
of	O
the	O
sheep	O
tibia	O
was	O
measured	O
at	O
the	O
incisura	O
fibularis	O
.	O

This	O
dimension	O
was	O
one	O
diameter	O
of	O
bone	O
,	O
and	O
a	O
one-diameter	O
length	O
of	O
bone	O
was	O
removed	O
.	O

In	O
experiment	O
3b	O
,	O
a	O
two-diameter	O
length	O
of	O
bone	O
was	O
removed	O
.	O

In	O
experiment	O
3c	O
,	O
a	O
three-diameter	O
length	O
of	O
bone	O
was	O
removed	O
.	O

In	O
experiment	O
3d	O
,	O
a	O
four-diameter	O
length	O
of	O
bone	O
was	O
removed	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Transdermal	O
nitroglycerin	O
in	O
angina	Condition
pectoris	Condition
:	O
efficacy	O
of	O
intermittent	O
application	O
.	O

Continuous	O
application	O
of	O
transdermal	O
nitroglycerin	O
appears	O
to	O
result	O
in	O
tolerance	O
to	O
the	O
antianginal	O
effect	O
.	O

In	O
a	O
double-blind	O
study	O
the	O
effects	O
of	O
continuous	O
(	O
24	O
h/day	O
)	O
and	O
intermittent	O
(	O
16	O
h/day	O
)	O
application	O
of	O
transdermal	O
nitroglycerin	O
in	O
a	O
dosage	O
of	O
10	O
mg/day	O
were	O
compared	O
with	O
the	O
effects	O
of	O
placebo	O
in	O
12	SampleSize
patients	O
with	O
chronic	O
stable	O
angina	O
receiving	O
treatment	O
with	O
beta-adrenergic	O
blocking	O
or	O
calcium	O
channel	O
blocking	O
agents	O
.	O

Exercise	O
performance	O
was	O
assessed	O
2	O
to	O
4	O
hours	O
after	O
initial	O
application	O
and	O
after	O
1	O
week	O
of	O
each	O
treatment	O
given	O
in	O
random	O
order	O
with	O
a	O
3	O
day	O
interval	O
between	O
treatments	O
.	O

Exercise	O
time	O
to	O
onset	O
of	O
angina	O
,	O
total	O
exercise	O
duration	O
and	O
time	O
to	O
1	O
mm	O
ST	O
segment	O
depression	O
were	O
all	O
significantly	O
increased	O
after	O
initial	O
application	O
during	O
the	O
continuous	O
and	O
intermittent	O
treatment	O
periods	O
.	O

These	O
increases	O
were	O
maintained	O
after	O
1	O
week	O
of	O
intermittent	O
but	O
not	O
continuous	O
treatment	O
.	O

Thus	O
the	O
benefit	O
of	O
initial	O
application	O
of	O
transdermal	O
nitroglycerin	O
is	O
maintained	O
with	O
intermittent	O
treatment	O
and	O
a	O
daily	O
nitrate-free	O
interval	O
,	O
whereas	O
tolerance	O
to	O
antianginal	O
effect	O
occurs	O
with	O
continuous	O
treatment	O
.	O

Seven-star	O
needle	O
stimulation	O
improves	O
language	O
and	O
social	O
interaction	O
of	O
children	Age
with	O
autistic	Condition
spectrum	Condition
disorders	Condition
.	O

This	O
is	O
a	O
randomized	O
controlled	O
trial	O
that	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
Seven-star	O
Needle	O
Stimulation	O
treatment	O
on	O
children	Age
with	O
Autistic	O
Spectrum	O
Disorders	O
(	O
ASD	Condition
)	O
.	O

Thirty-two	SampleSize
children	Age
with	O
ASD	Condition
were	O
assigned	O
randomly	O
into	O
the	O
treatment	O
and	O
control	O
groups	O
.	O

Children	O
in	O
the	O
treatment	O
group	O
underwent	O
30	O
sessions	O
of	O
stimulation	O
over	O
6	O
weeks	O
,	O
while	O
children	O
in	O
the	O
control	O
group	O
were	O
on	O
a	O
waiting	O
list	O
and	O
did	O
not	O
receive	O
treatment	O
during	O
this	O
period	O
of	O
time	O
.	O

Intervention	O
consisted	O
of	O
a	O
treatment	O
regime	O
comprising	O
of	O
30	O
sessions	O
of	O
Seven-star	O
Needle	O
Stimulation	O
,	O
delivered	O
over	O
6	O
weeks	O
.	O

Each	O
session	O
lasted	O
5	O
to	O
10	O
min	O
,	O
children	O
in	O
the	O
treatment	O
group	O
were	O
stimulated	O
at	O
the	O
front	O
and	O
back	O
sides	O
of	O
their	O
body	O
and	O
the	O
head	O
by	O
using	O
Seven-star	O
Needles	O
.	O

The	O
change	O
in	O
the	O
children	O
's	O
behavior	O
was	O
evaluated	O
using	O
parents	O
'	O
report	O
and	O
neurophysiological	O
changes	O
were	O
measured	O
by	O
quantitative	O
EEG	O
(	O
qEEG	O
)	O
.	O

Results	O
showed	O
that	O
the	O
treatment	O
group	O
demonstrated	O
significant	O
improvement	O
in	O
language	O
and	O
social	O
interaction	O
,	O
but	O
not	O
in	O
stereotyped	O
behavior	O
or	O
motor	O
function	O
,	O
compared	O
to	O
the	O
control	O
group	O
.	O

qEEG	O
spectral	O
amplitudes	O
in	O
the	O
treatment	O
,	O
but	O
not	O
in	O
the	O
control	O
group	O
,	O
were	O
also	O
reduced	O
significantly	O
.	O

The	O
results	O
suggested	O
that	O
Seven-star	O
Needle	O
Stimulation	O
might	O
be	O
an	O
effective	O
intervention	O
to	O
improve	O
language	O
and	O
social	O
functioning	O
of	O
children	Age
with	O
ASD	Condition
.	O

Effect	O
of	O
systemic	O
penicillin	O
on	O
pain	O
in	O
untreated	Condition
irreversible	Condition
pulpitis	Condition
.	Condition

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
penicillin	O
on	O
pain	O
in	O
untreated	O
teeth	O
diagnosed	O
with	O
irreversible	O
pulpitis	O
.	O

STUDY	O
DESIGN	O
Forty	SampleSize
emergency	O
patients	O
participated	O
,	O
and	O
each	O
had	O
a	O
clinical	O
diagnosis	O
of	O
an	O
irreversible	O
pulpitis	O
.	O

Patients	O
randomly	O
received	O
a	O
7-day	O
oral	O
dose	O
(	O
28	O
capsules	O
,	O
500	O
mg	O
each	O
,	O
to	O
be	O
taken	O
every	O
6	O
hours	O
)	O
of	O
either	O
penicillin	O
or	O
a	O
placebo	O
control	O
in	O
a	O
double-blind	O
manner	O
.	O

No	O
endodontic	O
treatment	O
was	O
performed	O
.	O

Each	O
patient	O
also	O
received	O
ibuprofen	O
;	O
acetaminophen	O
with	O
codeine	O
(	O
30	O
mg	O
)	O
;	O
and	O
a	O
7-day	O
diary	O
to	O
record	O
pain	O
,	O
percussion	O
pain	O
,	O
and	O
number	O
and	O
type	O
of	O
pain	O
medication	O
taken	O
.	O

RESULTS	O
The	O
administration	O
of	O
penicillin	O
did	O
not	O
significantly	O
(	O
P	O
>	O
.05	O
)	O
reduce	O
pain	O
,	O
percussion	O
pain	O
,	O
or	O
the	O
number	O
of	O
analgesic	O
medications	O
taken	O
by	O
patients	O
with	O
untreated	O
irreversible	O
pulpitis	O
.	O

The	O
majority	O
of	O
patients	O
with	O
untreated	O
irreversible	O
pulpitis	O
had	O
significant	O
pain	O
and	O
required	O
analgesics	O
to	O
manage	O
this	O
pain	O
.	O

CONCLUSION	O
Penicillin	O
should	O
not	O
be	O
prescribed	O
for	O
untreated	O
irreversible	O
pulpitis	O
because	O
penicillin	O
is	O
ineffective	O
for	O
pain	O
relief	O
.	O

Biventricular	O
pacing	O
improves	O
cardiac	O
function	O
and	O
prevents	O
further	O
left	O
atrial	O
remodeling	O
in	O
patients	O
with	O
symptomatic	Condition
atrial	Condition
fibrillation	Condition
after	O
atrioventricular	O
node	O
ablation	O
.	O

BACKGROUND	O
Randomized	O
trials	O
have	O
demonstrated	O
benefits	O
of	O
biventricular	O
(	O
BiV	O
)	O
pacing	O
in	O
patients	O
with	O
advanced	Condition
heart	Condition
failure	Condition
,	O
intraventricular	Condition
conduction	Condition
delay	Condition
,	Condition
and	O
atrial	Condition
fibrillation	Condition
(	Condition
AF	Condition
)	Condition
post-atrioventricular	Condition
(	Condition
AV	Condition
)	Condition
node	Condition
ablation	Condition
.	O

The	O
AV	O
Node	O
Ablation	O
with	O
CLS	O
and	O
CRT	O
Pacing	O
Therapies	O
for	O
Treatment	O
of	O
AF	O
trial	O
(	O
AVAIL	O
CLS/CRT	O
)	O
was	O
designed	O
to	O
demonstrate	O
superiority	O
of	O
BiV	O
pacing	O
in	O
patients	O
with	O
AF	O
after	O
AV	O
node	O
ablation	O
,	O
to	O
evaluate	O
its	O
effects	O
on	O
cardiac	O
structure	O
and	O
function	O
,	O
and	O
to	O
investigate	O
additional	O
benefits	O
of	O
Closed	O
Loop	O
Stimulation	O
(	O
CLS	O
)	O
(	O
BIOTRONIK	O
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

METHODS	O
Patients	O
with	O
refractory	O
AF	Condition
underwent	O
AV	O
node	O
ablation	O
and	O
were	O
randomized	O
(	O
2:2:1	O
)	O
to	O
BiV	O
pacing	O
with	O
CLS	O
,	O
BiV	O
pacing	O
with	O
accelerometer	O
,	O
or	O
right	O
ventricular	O
(	O
RV	O
)	O
pacing	O
.	O

Echocardiography	O
was	O
performed	O
at	O
baseline	O
and	O
6	O
months	O
,	O
with	O
paired	O
data	O
available	O
for	O
108	SampleSize
patients	O
.	O

RESULTS	O
The	O
RV	O
pacing	O
contributed	O
to	O
significant	O
increase	O
in	O
left	O
atrial	O
volume	O
,	O
left	O
ventricular	O
(	O
LV	O
)	O
end-systolic	O
volume	O
,	O
and	O
LV	O
mass	O
compared	O
to	O
BiV	O
pacing	O
.	O

Ejection	O
fraction	O
decreased	O
insignificantly	O
with	O
RV	O
pacing	O
compared	O
to	O
significant	O
increase	O
with	O
BiV	O
pacing	O
.	O

Interventricular	O
dyssynchrony	O
significantly	O
decreased	O
with	O
BiV	O
compared	O
with	O
RV	O
pacing	O
.	O

Closed	O
Loop	O
Stimulation	O
did	O
not	O
result	O
in	O
additional	O
echocardiographic	O
changes	O
;	O
heart	O
rate	O
distribution	O
was	O
significantly	O
wider	O
with	O
CLS	O
.	O

All	O
groups	O
showed	O
significant	O
improvement	O
in	O
6-minute	O
walk	O
distance	O
,	O
quality-of-life	O
score	O
,	O
and	O
New	O
York	O
Heart	O
Association	O
class	O
.	O

CONCLUSION	O
In	O
conclusion	O
,	O
RV	O
pacing	O
results	O
in	O
significant	O
increase	O
in	O
left	O
atrial	O
volume	O
,	O
LV	O
mass	O
,	O
and	O
worsening	O
of	O
LV	O
contractility	O
compared	O
to	O
patients	O
receiving	O
BiV	O
pacing	O
post-AV	O
node	O
ablation	O
for	O
refractory	O
AF	O
.	O

Closed	O
Loop	O
Stimulation	O
was	O
not	O
associated	O
with	O
additional	O
structural	O
changes	O
but	O
resulted	O
in	O
significantly	O
wider	O
heart	O
rate	O
distribution	O
.	O

Aztreonam	O
versus	O
gentamicin	O
for	O
short-term	O
prophylaxis	O
in	O
biliary	O
and	O
gastric	O
surgery	O
.	O

Short-term	O
antibiotic	O
prophylaxis	O
was	O
studied	O
in	O
80	SampleSize
patients	O
undergoing	O
biliary	O
or	O
gastric	O
surgery	O
.	O

The	O
patients	O
were	O
randomized	O
to	O
receive	O
1	O
g	O
of	O
aztreonam	O
or	O
80	O
mg	O
of	O
gentamicin	O
intravenously	O
30	O
minutes	O
before	O
surgery	O
and	O
8	O
and	O
16	O
hours	O
after	O
surgery	O
.	O

Of	O
samples	O
taken	O
from	O
the	O
abdominal	O
cavity	O
for	O
bacteriologic	O
study	O
,	O
53	O
%	O
were	O
culture	O
positive	O
.	O

Wound	O
infections	O
developed	O
in	O
two	O
(	O
4.5	O
%	O
)	O
of	O
44	O
patients	O
receiving	O
aztreonam	O
and	O
in	O
seven	O
(	O
19.4	O
%	O
)	O
of	O
36	O
patients	O
treated	O
with	O
gentamicin	O
.	O

Staphylococcus	O
epidermidis	O
and	O
Enterobacter	O
species	O
were	O
isolated	O
from	O
sites	O
of	O
wound	O
infection	O
in	O
the	O
aztreonam	O
group	O
;	O
Escherichia	O
coli	O
(	O
two	O
isolates	O
)	O
,	O
Pseudomonas	O
aeruginosa	O
(	O
two	O
isolates	O
)	O
,	O
Enterobacter	O
species	O
,	O
Klebsiella	O
species	O
,	O
Enterococcus	O
faecalis	O
,	O
and	O
Aeromonas	O
hydrophila	O
were	O
isolated	O
from	O
the	O
gentamicin	O
group	O
.	O

Our	O
data	O
indicate	O
that	O
aztreonam	O
is	O
safe	O
and	O
effective	O
for	O
the	O
prevention	O
of	O
infections	O
following	O
biliary	O
and	O
gastric	O
surgery	O
.	O

Hypericum	O
treatment	O
of	O
mild	O
depressions	O
with	O
somatic	O
symptoms	O
.	O

In	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
study	O
,	O
39	O
patients	O
with	O
depression	O
with	O
somatic	O
symptoms	O
were	O
treated	O
with	O
hypericum	O
extract	O
LI	O
160	O
.	O

The	O
therapy	O
lasted	O
for	O
4	O
weeks	O
;	O
the	O
dosage	O
was	O
300	O
mg	O
three	O
times	O
daily	O
.	O

At	O
the	O
onset	O
of	O
the	O
study	O
as	O
well	O
as	O
after	O
2	O
and	O
4	O
weeks	O
,	O
the	O
following	O
criteria	O
were	O
analyzed	O
:	O
HAMD	O
,	O
B-L	O
,	O
CGI	O
,	O
and	O
vegetative	O
symptoms	O
.	O

The	O
results	O
show	O
a	O
significant	O
improvement	O
in	O
the	O
active	O
treatment	O
group	O
at	O
the	O
5	O
%	O
level	O
as	O
compared	O
to	O
placebo	O
.	O

Seventy	O
percent	O
of	O
the	O
patients	O
treated	O
with	O
LI	O
160	O
were	O
free	O
of	O
symptoms	O
after	O
4	O
weeks	O
.	O

Typical	O
symptoms	O
of	O
the	O
depression	O
such	O
as	O
lack	O
of	O
activity	O
,	O
tiredness	O
,	O
fatigue	O
,	O
and	O
disturbed	O
sleep	O
,	O
were	O
especially	O
responsive	O
.	O

In	O
no	O
case	O
were	O
any	O
undesirable	O
side	O
effects	O
observed	O
.	O

Oscillatory	Condition
potentials	O
,	O
retinopathy	Condition
,	O
and	O
long-term	O
glucose	O
control	O
in	O
insulin-dependent	Condition
diabetes	Condition
.	O

The	O
main	O
objective	O
of	O
the	O
study	O
was	O
to	O
assess	O
effects	O
of	O
long-term	O
lowering	O
of	O
glucosylated	O
hemoglobin	O
(	O
HbA1	O
%	O
)	O
on	O
neurosensory	O
function	O
in	O
insulin-dependent	O
diabetes	O
.	O

Individual	O
(	O
OP-1	O
,	O
OP-2	O
,	O
OP-3	O
)	O
and	O
summed	O
(	O
OP-sum	O
)	O
amplitudes	O
of	O
oscillatory	O
potentials	O
(	O
OPs	O
)	O
of	O
electroretinography	O
were	O
recorded	O
at	O
study	O
start	O
and	O
7-years	O
later	O
in	O
45	SampleSize
patients	O
(	O
the	O
Oslo	O
study	O
)	O
.	O

As	O
an	O
overall	O
7-year	O
change	O
,	O
amplitudes	O
of	O
OP-2	O
,	O
OP-3	O
and	O
OP-sum	O
were	O
reduced	O
(	O
p	O
<	O
0.0001-0.01	O
)	O
,	O
retinopathy	O
worsened	O
(	O
p	O
=	O
0.005	O
)	O
,	O
intraocular	O
pressure	O
decreased	O
(	O
p	O
<	O
0.001	O
)	O
,	O
systolic	O
blood	O
pressure	O
increased	O
(	O
p	O
<	O
0.0002	O
)	O
,	O
and	O
glycemic	O
control	O
improved	O
from	O
HbA1	O
of	O
11.2	O
+/-	O
2.2	O
%	O
at	O
study	O
start	O
to	O
a	O
7-year	O
cumulative	O
mean	O
of	O
9.5	O
+/-	O
1.5	O
%	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Multiple	O
regression	O
analysis	O
did	O
not	O
identify	O
any	O
independent	O
relations	O
between	O
change	O
in	O
OP-1	O
,	O
OP-2	O
,	O
OP-3	O
,	O
OP-sum	O
and	O
change	O
in	O
glycemic	O
control	O
or	O
background	O
variables	O
,	O
including	O
change	O
in	O
age	O
and	O
duration	O
of	O
diabetes	O
.	O

However	O
,	O
cross-sectional	O
observations	O
at	O
7	O
years	O
showed	O
negative	O
correlations	O
between	O
all	O
OPs	O
and	O
age	O
(	O
p	O
<	O
0.0001-0.003	O
)	O
,	O
and	O
between	O
OP-3	O
and	O
duration	O
(	O
p	O
=	O
0.003	O
)	O
and	O
counts	O
of	O
microaneurysms	O
(	O
p	O
=	O
0.02	O
)	O
.	O

The	O
data	O
suggest	O
that	O
various	O
clinical	O
background	O
variables	O
may	O
influence	O
individual	O
and	O
summed	O
amplitudes	O
of	O
OPs	O
differently	O
.	O

Reduced	O
neurosensory	O
retinal	O
function	O
(	O
OPs	O
)	O
seemed	O
to	O
appear	O
after	O
7-years	O
,	O
independently	O
of	O
vascular	O
defects	O
of	O
retinopathy	O
and	O
long-term	O
improvement	O
in	O
glucose	O
control	O
.	O

Effectiveness	O
of	O
sensory	O
integration	O
interventions	O
in	O
children	Age
with	O
autism	Condition
spectrum	Condition
disorders	Condition
:	O
a	O
pilot	O
study	O
.	O

The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
establish	O
a	O
model	O
for	O
randomized	O
controlled	O
trial	O
research	O
,	O
identify	O
appropriate	O
outcome	O
measures	O
,	O
and	O
address	O
the	O
effectiveness	O
of	O
sensory	O
integration	O
(	O
SI	O
)	O
interventions	O
in	O
children	Age
with	O
autism	Condition
spectrum	Condition
disorders	Condition
(	O
ASD	Condition
)	O
.	O

Children	Age
ages	Age
6-12	Age
with	Age
ASD	O
were	O
randomly	O
assigned	O
to	O
a	O
fine	O
motor	O
or	O
SI	O
treatment	O
group	O
.	O

Pretests	O
and	O
posttests	O
measured	O
social	O
responsiveness	O
,	O
sensory	O
processing	O
,	O
functional	O
motor	O
skills	O
,	O
and	O
social-emotional	O
factors	O
.	O

Results	O
identified	O
significant	O
positive	O
changes	O
in	O
Goal	O
Attainment	O
Scaling	O
scores	O
for	O
both	O
groups	O
;	O
more	O
significant	O
changes	O
occurred	O
in	O
the	O
SI	O
group	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
autistic	O
mannerisms	O
occurred	O
in	O
the	O
SI	O
group	O
.	O

No	O
other	O
results	O
were	O
significant	O
.	O

The	O
study	O
discusses	O
considerations	O
for	O
designing	O
future	O
outcome	O
studies	O
for	O
children	Age
with	O
ASD	Condition
.	O

Toxicity	O
and	O
efficacy	O
of	O
6-thioguanine	O
versus	O
6-mercaptopurine	O
in	O
childhood	Age
lymphoblastic	Condition
leukaemia	Condition
:	O
a	O
randomised	O
trial	O
.	O

BACKGROUND	O
6-mercaptopurine	O
has	O
been	O
a	O
standard	O
component	O
of	O
long-term	O
continuing	O
treatment	O
for	O
childhood	Age
lymphoblastic	Condition
leukaemia	Condition
,	O
whereas	O
6-thioguanine	O
has	O
been	O
mainly	O
used	O
for	O
intensification	O
courses	O
.	O

Since	O
preliminary	O
data	O
have	O
shown	O
that	O
6-thioguanine	O
is	O
more	O
effective	O
than	O
6-mercaptopurine	O
,	O
we	O
compared	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
two	O
drugs	O
for	O
childhood	O
lymphoblastic	O
leukaemia	O
.	O

METHODS	O
Consecutive	O
children	Age
with	O
lymphoblastic	Condition
leukaemia	O
diagnosed	O
in	O
the	O
UK	O
and	O
Ireland	O
between	O
April	O
,	O
1997	O
,	O
and	O
June	O
,	O
2002	O
,	O
were	O
randomly	O
assigned	O
either	O
6-thioguanine	O
(	O
750	O
patients	O
)	O
or	O
6-mercaptopurine	O
(	O
748	O
patients	O
)	O
during	O
interim	O
maintenance	O
and	O
continuing	O
therapy	O
.	O

All	O
patients	O
received	O
6-thioguanine	O
during	O
intensification	O
courses	O
.	O

We	O
analysed	O
event-free	O
and	O
overall	O
survival	O
on	O
an	O
intention-to-treat	O
basis	O
.	O

We	O
obtained	O
toxicity	O
data	O
using	O
an	O
adverse-event	O
reporting	O
system	O
,	O
with	O
follow-up	O
questionnaires	O
to	O
seek	O
detailed	O
information	O
for	O
specific	O
toxicities	O
.	O

This	O
trial	O
is	O
registered	O
with	O
the	O
International	O
Standard	O
Randomised	O
Controlled	O
Number	O
26727615	O
with	O
the	O
name	O
ALL97	O
.	O

FINDINGS	O
After	O
a	O
median	O
follow	O
up	O
of	O
6	O
years	O
,	O
there	O
was	O
no	O
difference	O
in	O
event-free	O
or	O
overall	O
survival	O
between	O
the	O
two	O
treatment	O
groups	O
.	O

Although	O
6-thioguanine	O
conferred	O
a	O
significantly	O
lower	O
risk	O
of	O
isolated	O
CNS	O
relapse	O
than	O
did	O
6-mercaptopurine	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.53	O
,	O
95	O
%	O
CI	O
0.30-0.92	O
,	O
p=0.02	O
)	O
,	O
the	O
benefit	O
was	O
offset	O
by	O
an	O
increased	O
risk	O
of	O
death	O
in	O
remission	O
(	O
2.22	O
,	O
1.20-4.14	O
,	O
p=0.01	O
)	O
,	O
mainly	O
due	O
to	O
infections	O
during	O
continuing	O
therapy	O
.	O

Additionally	O
,	O
95	O
patients	O
developed	O
veno-occlusive	O
disease	O
of	O
the	O
liver	O
.	O

Of	O
these	O
,	O
82	O
were	O
randomly	O
assigned	O
6-thioguanine	O
,	O
representing	O
11	O
%	O
of	O
all	O
6-thioguanine	O
recipients	O
.	O

On	O
long-term	O
follow-up	O
,	O
about	O
5	O
%	O
of	O
6-thioguanine	O
recipients	O
have	O
evidence	O
of	O
non-cirrhotic	O
portal	O
hypertension	O
due	O
to	O
periportal	O
liver	O
fibrosis	O
or	O
nodular	O
regenerative	O
hyperplasia	O
.	O

INTERPRETATION	O
Compared	O
with	O
6-mercaptopurine	O
,	O
6-thioguanine	O
causes	O
excess	O
toxicity	O
without	O
an	O
overall	O
benefit	O
.	O

6-mercaptopurine	O
should	O
remain	O
the	O
thiopurine	O
of	O
choice	O
for	O
continuing	O
therapy	O
of	O
childhood	O
lymphoblastic	O
leukaemia	O
.	O

Minocycline	O
safety	O
and	O
tolerability	O
in	O
Huntington	Condition
disease	Condition
.	O

Minocycline	O
is	O
an	O
antibiotic	O
with	O
anti-inflammatory	O
and	O
antiapoptotic	O
properties	O
that	O
prolongs	O
survival	O
in	O
a	O
transgenic	O
Huntington	Condition
disease	Condition
(	O
HD	Condition
)	O
mouse	O
model	O
.	O

In	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
study	O
of	O
minocycline	O
in	O
60	SampleSize
HD	Condition
patients	O
,	O
the	O
authors	O
determined	O
that	O
over	O
8	O
weeks	O
,	O
minocycline	O
at	O
100	O
and	O
200	O
mg/day	O
was	O
well	O
tolerated	O
and	O
safe	O
in	O
HD	Condition
patients	O
.	O

Tolerability	O
and	O
adverse	O
event	O
frequency	O
were	O
similar	O
between	O
treatment	O
and	O
placebo	O
groups	O
.	O

Montelukast	O
treatment	O
of	O
moderate	O
to	O
severe	Condition
atopic	Condition
dermatitis	Condition
in	Condition
adults	Condition
:	Condition
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
4-week	O
trial	O
,	O
59	Condition
patients	Condition
with	Condition
moderate	Condition
to	Condition
severe	Condition
atopic	Condition
dermatitis	Condition
were	O
treated	O
orally	O
with	O
10	O
mg	O
of	O
the	O
leukotriene	O
antagonist	O
montelukast	O
.	O

Forty-seven	Condition
patients	Condition
completed	Condition
the	Condition
study	Condition
.	Condition

No	O
difference	O
in	O
efficacy	O
was	O
seen	O
among	O
patients	O
who	O
received	O
montelukast	O
and	O
the	O
group	O
given	O
a	O
placebo	O
.	O

Prediction	O
of	O
the	O
response	O
to	O
citalopram	O
and	O
reboxetine	O
in	O
post-stroke	Condition
depressed	Condition
patients	O
.	O

RATIONALE	O
AND	O
OBJECTIVE	O
Depression	O
is	O
a	O
significant	O
complication	O
of	O
stroke	O
.	O

The	O
effectiveness	O
of	O
antidepressant	O
drugs	O
in	O
the	O
management	O
of	O
post-stroke	O
depression	O
(	O
PSD	O
)	O
has	O
been	O
widely	O
investigated	O
.	O

However	O
,	O
the	O
choice	O
of	O
antidepressant	O
drug	O
is	O
critically	O
influenced	O
by	O
its	O
safety	O
and	O
tolerability	O
and	O
by	O
its	O
effect	O
on	O
concurrent	O
pathologies	O
.	O

Here	O
we	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
,	O
citalopram	O
,	O
and	O
a	O
noradrenaline	O
reuptake	O
inhibitor	O
(	O
NARI	O
)	O
,	O
reboxetine	O
,	O
in	O
post-stroke	O
patients	O
affected	O
by	O
anxious	Condition
depression	Condition
or	O
retarded	Condition
depression	Condition
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
double-blind	O
study	O
.	O

Seventy-four	SampleSize
post-stroke	Condition
depressed	Condition
patients	O
were	O
diagnosed	O
as	O
affected	O
by	O
anxious	O
or	O
retarded	O
depression	O
by	O
using	O
a	O
synoptic	O
table	O
.	O

Randomisation	O
was	O
planned	O
so	O
that	O
50	O
%	O
of	O
the	O
patients	O
in	O
each	O
subgroup	O
were	O
assigned	O
for	O
16	O
weeks	O
to	O
treatment	O
with	O
citalopram	O
and	O
the	O
remaining	O
50	O
%	O
were	O
assigned	O
to	O
treatment	O
with	O
reboxetine	O
.	O

The	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
)	O
,	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HDRS	O
)	O
and	O
a	O
synoptic	O
table	O
were	O
used	O
to	O
score	O
depressive	O
symptoms	O
.	O

RESULTS	O
Both	O
citalopram	O
and	O
reboxetine	O
showed	O
good	O
safety	O
and	O
tolerability	O
.	O

Citalopram	O
exhibited	O
greater	O
efficacy	O
in	O
anxious	O
depressed	O
patients	O
,	O
while	O
reboxetine	O
was	O
more	O
effective	O
in	O
retarded	O
depressed	O
patients	O
.	O

CONCLUSIONS	O
Citalopram	O
or	O
other	O
SSRIs	O
and	O
reboxetine	O
may	O
be	O
of	O
first	O
choice	O
treatment	O
in	O
PSD	O
because	O
of	O
their	O
good	O
efficacy	O
and	O
lack	O
of	O
severe	O
side	O
effects	O
.	O

In	O
addition	O
,	O
PSD	Condition
patients	O
should	O
be	O
classified	O
according	O
to	O
their	O
clinical	O
profile	O
(	O
similarly	O
to	O
patients	O
affected	O
by	O
primary	O
depression	O
)	O
for	O
the	O
selection	O
of	O
SSRIs	O
or	O
reboxetine	O
as	O
drugs	O
of	O
choice	O
in	O
particular	O
subgroups	O
of	O
patients	O
.	O

Evaluating	O
the	O
impact	O
of	O
peer	O
,	O
nurse	O
case-managed	O
,	O
and	O
standard	O
HIV	O
risk-reduction	O
programs	O
on	O
psychosocial	O
and	O
health-promoting	O
behavioral	O
outcomes	O
among	O
homeless	O
women	Sex
.	O

Investigators	O
examined	O
the	O
6-month	O
impact	O
of	O
three	O
cognitive-behavioral	O
HIV	O
risk-reduction	O
programs	O
on	O
behavioral	O
factors	O
(	O
substance	O
use	O
and	O
sexual	O
risk	O
behaviors	O
)	O
and	O
cognitive	O
and	O
psychological	O
resources	O
of	O
325	SampleSize
women	Sex
who	O
resided	O
in	O
emergency	O
or	O
sober-living	O
shelters	O
and	O
their	O
308	SampleSize
intimate	O
sexual	O
partners	O
.	O

Participants	O
were	O
randomized	O
by	O
shelter	O
to	O
a	O
peer-mentored	O
,	O
a	O
nurse	O
case-managed	O
,	O
or	O
a	O
standard	O
care	O
HIV	O
risk-reduction	O
program	O
.	O

Significant	O
improvements	O
were	O
observed	O
in	O
all	O
groups	O
in	O
all	O
behavioral	O
factors	O
and	O
cognitive	O
and	O
psychological	O
resources	O
except	O
for	O
self-esteem	O
.	O

Participants	O
in	O
the	O
peer-mentored	O
and	O
nurse	O
case-managed	O
groups	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
standard	O
group	O
in	O
self-esteem	O
,	O
life	O
satisfaction	O
,	O
psychological	O
well-being	O
,	O
use	O
of	O
noninjection	O
drugs	O
,	O
sex	O
with	O
multiple	O
partners	O
,	O
and	O
unprotected	O
sex	O
at	O
6	O
months	O
(	O
n	O
=	O
633	O
)	O
.	O

It	O
was	O
concluded	O
that	O
a	O
standard	O
approach	O
by	O
health	O
care	O
professionals	O
appears	O
to	O
effectively	O
modify	O
HIV	O
risk	O
behaviors	O
for	O
a	O
majority	O
of	O
homeless	Condition
participants	O
and	O
may	O
have	O
important	O
economic	O
and	O
policy	O
implications	O
.	O

Further	O
,	O
the	O
impact	O
of	O
short-term	O
programs	O
that	O
address	O
psychological	O
vulnerabilities	O
of	O
impoverished	Condition
populations	O
needs	O
to	O
be	O
studied	O
further	O
.	O

Engagement	O
with	O
electronic	O
screen	O
media	O
among	O
students	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
investigated	O
the	O
relative	O
engagement	O
potential	O
of	O
four	O
types	O
of	O
electronic	O
screen	O
media	O
(	O
ESM	O
)	O
:	O
animated	O
video	O
,	O
video	O
of	O
self	O
,	O
video	O
of	O
a	O
familiar	O
person	O
engaged	O
with	O
an	O
immersive	O
virtual	O
reality	O
(	O
VR	O
)	O
game	O
,	O
and	O
immersion	O
of	O
self	O
in	O
the	O
VR	O
game	O
.	O

Forty-two	O
students	O
with	O
autism	O
,	O
varying	O
in	O
age	O
and	O
expressive	O
communication	O
ability	O
,	O
were	O
randomly	O
assigned	O
to	O
the	O
experimental	O
conditions	O
.	O

Gaze	O
duration	O
and	O
vocalization	O
served	O
as	O
dependent	O
measures	O
of	O
engagement	O
.	O

The	O
results	O
reveal	O
differential	O
responding	O
across	O
ESM	O
,	O
with	O
some	O
variation	O
related	O
to	O
the	O
engagement	O
metric	O
employed	O
.	O

Preferences	O
for	O
seeing	O
themselves	O
on	O
the	O
screen	O
,	O
as	O
well	O
as	O
for	O
viewing	O
the	O
VR	O
scenarios	O
,	O
emerged	O
from	O
the	O
data	O
.	O

While	O
the	O
study	O
did	O
not	O
yield	O
definitive	O
data	O
about	O
the	O
relative	O
engagement	O
potential	O
of	O
ESM	O
alternatives	O
,	O
it	O
does	O
provide	O
a	O
foundation	O
for	O
future	O
research	O
,	O
including	O
guidance	O
related	O
to	O
participant	O
profiles	O
,	O
stimulus	O
characteristics	O
,	O
and	O
data	O
coding	O
challenges	O
.	O

[	O
Effects	O
of	O
an	O
intensive	O
therapy	O
program	O
for	O
behaviorally	Condition
disordered	Condition
mentally	Condition
handicapped	Condition
patients	O
on	O
staff	O
personnel	O
in	O
residential	O
care	O
]	O
.	O

This	O
study	O
evaluates	O
the	O
effects	O
of	O
an	O
intensive	O
therapy	O
program	O
designed	O
for	O
mentally	Condition
handicapped	Condition
persons	O
with	O
severely	O
disturbed	O
or	O
autistic	Condition
behavior	Condition
on	O
their	O
staff	O
personal	O
which	O
had	O
an	O
active	O
role	O
in	O
the	O
program	O
.	O

The	O
staff	O
members	O
rated	O
their	O
professional	O
competence	O
,	O
quality	O
of	O
interaction	O
with	O
the	O
client	O
,	O
team	O
culture	O
and	O
work	O
satisfaction	O
before	O
and	O
after	O
being	O
engaged	O
in	O
the	O
program	O
,	O
with	O
additional	O
ratings	O
of	O
their	O
personal	O
aims	O
at	O
the	O
beginning	O
of	O
the	O
program	O
.	O

Three	O
sets	O
of	O
data	O
were	O
obtained	O
with	O
the	O
program	O
being	O
conducted	O
three	O
times	O
in	O
a	O
row	O
.	O

The	O
testings	O
of	O
the	O
related	O
as	O
well	O
as	O
the	O
independent	O
samples	O
show	O
differentiated	O
program	O
effects	O
.	O

The	O
main	O
effect	O
is	O
an	O
increase	O
of	O
the	O
professional	O
competence	O
and	O
quality	O
of	O
interaction	O
,	O
especially	O
by	O
the	O
qualified	O
staff	O
members	O
.	O

Trainees	O
put	O
emphasis	O
on	O
the	O
development	O
of	O
their	O
personal	O
relationship	O
with	O
the	O
client	O
.	O

The	O
results	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
impact	O
of	O
learning	O
processes	O
specific	O
to	O
the	O
roles	O
of	O
the	O
staff	O
members	O
and	O
motivational	O
factors	O
on	O
learning	O
and	O
therapy	O
outcome	O
,	O
along	O
with	O
institutional	O
conditions	O
influencing	O
successful	O
learning	O
.	O

Thus	O
the	O
program	O
facilitates	O
the	O
professional	O
and	O
interpersonal	O
learning	O
process	O
of	O
staff	O
members	O
in	O
a	O
specific	O
way	O
with	O
success	O
as	O
well	O
as	O
with	O
limitations	O
.	O

Neuroendocrine	O
effects	O
of	O
sumatriptan	O
.	O

The	O
neuroendocrine	O
effects	O
of	O
the	O
5-HT	O
receptor	O
agonist	O
,	O
sumatriptan	O
(	O
6	O
mg	O
subcutaneously	O
)	O
,	O
were	O
studied	O
in	O
11	O
healthy	O
male	O
subjects	O
using	O
a	O
placebo-controlled	O
,	O
cross-over	O
design	O
.	O

Compared	O
to	O
placebo	O
,	O
sumatriptan	O
significantly	O
lowered	O
levels	O
of	O
plasma	O
prolactin	O
but	O
increased	O
those	O
of	O
plasma	O
growth	O
hormone	O
.	O

There	O
was	O
no	O
effect	O
on	O
plasma	O
cortisol	O
concentrations	O
.	O

The	O
neuroendocrine	O
effects	O
of	O
sumatriptan	O
differ	O
from	O
those	O
of	O
previously	O
described	O
5-HT-receptor	O
agonists	O
,	O
and	O
may	O
be	O
a	O
consequence	O
of	O
selective	O
activation	O
of	O
5-HT1D	O
or	O
5-HT1B	O
receptors	O
.	O

However	O
,	O
the	O
present	O
data	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
the	O
neuroendocrine	O
changes	O
reflect	O
nonspecific	O
stress	O
responses	O
or	O
changes	O
in	O
pituitary	O
blood	O
flow	O
.	O

Emotion	O
regulation	O
strategies	O
that	O
promote	O
learning	O
:	O
reappraisal	O
enhances	O
children	Condition
's	Condition
memory	O
for	O
educational	O
information	O
.	O

The	O
link	O
between	O
emotion	O
regulation	O
and	O
academic	O
achievement	O
is	O
well	O
documented	O
.	O

Less	O
is	O
known	O
about	O
specific	O
emotion	O
regulation	O
strategies	O
that	O
promote	O
learning	O
.	O

Six-	O
to	O
13-year-olds	O
(	O
N	O
=	O
126	O
)	O
viewed	O
a	O
sad	O
film	O
and	O
were	O
instructed	O
to	O
reappraise	O
the	O
importance	O
,	O
reappraise	O
the	O
outcome	O
,	O
or	O
ruminate	O
about	O
the	O
sad	O
events	O
;	O
another	O
group	O
received	O
no	O
regulation	O
instructions	O
.	O

Children	Condition
viewed	O
an	O
educational	O
film	O
,	O
and	O
memory	O
for	O
this	O
was	O
later	O
assessed	O
.	O

As	O
predicted	O
,	O
reappraisal	O
strategies	O
more	O
effectively	O
attenuated	O
children	O
's	O
self-reported	O
emotional	O
processing	O
.	O

Reappraisal	O
enhanced	O
memory	O
for	O
educational	O
details	O
relative	O
to	O
no	O
instructions	O
.	O

Rumination	O
did	O
not	O
lead	O
to	O
differences	O
in	O
memory	O
from	O
the	O
other	O
instructions	O
.	O

Memory	O
benefits	O
of	O
effective	O
instructions	O
were	O
pronounced	O
for	O
children	O
with	O
poorer	O
emotion	O
regulation	O
skill	O
,	O
suggesting	O
the	O
utility	O
of	O
reappraisal	O
in	O
learning	O
contexts	O
.	O

[	O
Long-term	O
treatment	O
of	O
cerebrovascular	O
changes	O
in	O
the	O
elderly	O
(	O
author	O
's	O
transl	O
)	O
]	O
.	O

A	O
prospective	O
study	O
over	O
15	O
months	O
in	O
100	O
elderly	O
patients	O
with	O
signs	O
of	O
cerebro-vascular	O
impairment	O
demonstrated	O
by	O
psychometric	O
testing	O
that	O
Hydergine	O
(	O
an	O
ergot	O
alkaloid	O
preparation	O
:	O
4.5	O
mg	O
daily	O
)	O
compensated	O
the	O
signs	O
of	O
dementia	O
,	O
present	O
in	O
the	O
placebo	O
group	O
,	O
and	O
in	O
some	O
patients	O
actually	O
brought	O
about	O
a	O
significant	O
improvement	O
in	O
mental	O
activity	O
.	O

Similar	O
compensatory	O
effect	O
was	O
also	O
demonstrable	O
in	O
cerebral	O
haemodynamics	O
:	O
in	O
the	O
placebo	O
group	O
there	O
was	O
a	O
progressive	O
increase	O
in	O
cerebral	O
circulation	O
time	O
,	O
an	O
expression	O
of	O
decreased	O
cerebral	O
blood	O
flow	O
,	O
while	O
with	O
Hydergine	O
cerebral	O
circulation	O
time	O
was	O
shortened	O
and	O
stabilized	O
.	O

Serial	O
EEGs	O
,	O
obtained	O
in	O
parallel	O
with	O
psychometric	O
and	O
circulation	O
time	O
tests	O
,	O
demonstrated	O
a	O
marked	O
increase	O
in	O
the	O
8-10	O
Hz	O
pattern	O
which	O
corresponds	O
to	O
the	O
physiological	O
alpha	O
activity	O
in	O
this	O
age	O
group	O
.	O

Furthermore	O
,	O
there	O
was	O
a	O
diminished	O
variability	O
in	O
performance	O
in	O
the	O
tested	O
frequency	O
bands	O
with	O
Hydergine	O
,	O
the	O
opposite	O
tendency	O
being	O
obtained	O
in	O
the	O
placebo	O
group	O
.	O

[	O
Local	O
treatment	O
of	O
periarthropathies	Condition
with	O
the	O
5-HT3-receptor-antagonist	O
tropisetron	O
]	O
.	O

All	O
substances	O
used	O
in	O
the	O
local	O
treatment	O
for	O
periarthropathies	Condition
,	O
such	O
as	O
local	O
anesthetics	O
,	O
corticosteroids	O
or	O
botulinum	O
toxin	O
A	O
,	O
possess	O
certain	O
disadvantages	O
.	O

Finding	O
alternatives	O
to	O
these	O
agents	O
in	O
the	O
local	O
treatment	O
of	O
the	O
disease	O
therefore	O
seems	O
desirable	O
.	O

Comparative	O
studies	O
proved	O
a	O
local	O
injection	O
of	O
the	O
5-HT3	O
receptor	O
antagonist	O
,	O
tropisetron	O
(	O
Navoban	O
(	O
R	O
)	O
)	O
,	O
to	O
be	O
more	O
effective	O
than	O
an	O
injection	O
of	O
the	O
local	O
anesthetic	O
prilocaine	O
in	O
treating	O
periarthropathies	Condition
of	O
different	O
localizations	O
.	O

A	O
comparison	O
between	O
the	O
local	O
injection	O
of	O
10	O
mg	O
of	O
depot	O
dexamethasone	O
combined	O
with	O
60	O
mg	O
of	O
lidocaine	O
and	O
5	O
mg	O
of	O
tropisetron	O
showed	O
that	O
the	O
two	O
regimens	O
had	O
the	O
same	O
effect	O
.	O

These	O
findings	O
demonstrate	O
that	O
a	O
local	O
injection	O
of	O
5	O
mg	O
tropisetron	O
does	O
represent	O
an	O
alternative	O
to	O
the	O
local	O
treatment	O
with	O
corticosteriods	O
plus	O
local	O
anesthetics	O
.	O

However	O
,	O
these	O
results	O
should	O
be	O
corroborated	O
by	O
additional	O
studies	O
.	O

Clinical	O
evaluation	O
of	O
the	O
antihypertensive	O
effect	O
of	O
metoprolol	O
in	O
combination	O
with	O
hydrochlorothiazide	O
and	O
hydralazine	O
in	O
an	O
unselected	O
hypertensive	Condition
population	O
.	O

One	SampleSize
hundred	SampleSize
nineteen	SampleSize
patients	O
with	O
essential	Condition
hypertension	Condition
(	O
96	SampleSize
completing	O
six	O
months	O
and	O
92	SampleSize
a	O
one	O
year	O
study	O
period	O
)	O
were	O
randomized	O
into	O
four	O
parallel	O
groups	O
and	O
treated	O
with	O
one	O
of	O
four	O
programs	O
:	O
200	O
mg	O
of	O
metoprolol	O
plus	O
placebo	O
;	O
200	O
mg	O
of	O
metoprolol	O
plus	O
25	O
mg	O
of	O
hydrochlorothiazide	O
;	O
200	O
mg	O
of	O
metoprolol	O
plus	O
50	O
mg	O
hydrochlorothiazide	O
,	O
or	O
;	O
200	O
mg	O
metoprolol	O
plus	O
50	O
mg	O
of	O
hydralazine	O
.	O

Blood	O
pressure	O
reduction	O
was	O
significant	O
in	O
these	O
all	O
groups	O
and	O
no	O
differences	O
were	O
observed	O
in	O
blood	O
pressure	O
reduction	O
among	O
the	O
groups	O
.	O

During	O
the	O
one	O
year	O
therapy	O
the	O
levels	O
of	O
serum	O
bilirubin	O
,	O
uric	O
acid	O
and	O
triglycerides	O
were	O
significantly	O
increased	O
in	O
all	O
groups	O
but	O
the	O
group	O
treated	O
with	O
metoprolol	O
and	O
hydralazine	O
.	O

Serum	O
cholesterol	O
level	O
did	O
not	O
increase	O
in	O
any	O
group	O
during	O
the	O
one	O
year	O
therapy	O
.	O

The	O
results	O
indicate	O
that	O
the	O
combination	O
therapy	O
in	O
mild	O
to	O
moderate	O
hypertension	O
should	O
not	O
be	O
initiated	O
before	O
individual	O
response	O
to	O
single	O
drug	O
therapy	O
is	O
evaluated	O
.	O

Antihypertensive	O
drug	O
treatment	O
may	O
cause	O
some	O
biochemical	O
changes	O
and	O
those	O
changes	O
seem	O
to	O
be	O
smallest	O
patients	O
treated	O
with	O
combination	O
of	O
beta-blocker	O
and	O
hydralazine	O
.	O

Safety	O
and	O
acceptability	O
of	O
cellulose	O
sulfate	O
as	O
a	O
vaginal	O
microbicide	O
in	O
HIV-infected	O
women	O
.	O

OBJECTIVES	O
Few	O
studies	O
of	O
topical	O
microbicides	O
have	O
assessed	O
their	O
safety	O
in	O
HIV-infected	O
women	O
.	O

We	O
conducted	O
this	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
acceptability	O
of	O
6	O
%	O
cellulose	O
sulfate	O
(	O
CS	O
)	O
gel	O
as	O
a	O
vaginal	O
microbicide	O
in	O
sexually	O
abstinent	O
and	O
active	O
HIV-infected	O
women	O
.	O

METHODS	O
Fifty-nine	O
HIV-infected	O
women	O
were	O
enrolled	O
in	O
a	O
randomized	O
double-blind	O
placebo-controlled	O
study	O
comparing	O
6	O
%	O
CS	O
to	O
placebo	O
gel	O
used	O
for	O
14	O
days	O
.	O

Sexually	O
abstinent	O
women	O
applied	O
gel	O
once	O
or	O
twice	O
daily	O
and	O
sexually	O
active	O
women	O
used	O
gel	O
once	O
daily	O
.	O

RESULTS	O
CS	O
gel	O
was	O
safe	O
with	O
no	O
reported	O
severe	O
or	O
life-threatening	O
adverse	O
events	O
(	O
AE	O
)	O
.	O

Thirty-nine	O
(	O
66	O
%	O
)	O
of	O
the	O
participants	O
experienced	O
urogenital	O
AE	O
judged	O
as	O
probably	O
or	O
possibly	O
related	O
to	O
gel	O
.	O

The	O
majority	O
(	O
51	O
%	O
)	O
of	O
these	O
participants	O
reported	O
only	O
mild	O
events	O
.	O

Fewer	O
women	O
(	O
62	O
%	O
)	O
who	O
used	O
CS	O
experienced	O
urogenital	O
AE	O
than	O
those	O
assigned	O
to	O
placebo	O
gel	O
(	O
70	O
%	O
)	O
(	O
P	O
=	O
0.59	O
)	O
.	O

Eleven	O
(	O
19	O
%	O
)	O
women	O
experienced	O
intermenstrual	O
bleeding	O
judged	O
to	O
be	O
probably	O
or	O
possibly	O
related	O
to	O
gel	O
use	O
(	O
four	O
in	O
the	O
CS	O
and	O
seven	O
in	O
the	O
placebo	O
gel	O
group	O
)	O
.	O

There	O
was	O
no	O
increase	O
in	O
AE	O
by	O
frequency	O
of	O
gel	O
use	O
or	O
sexual	O
activity	O
with	O
the	O
exception	O
of	O
abdominal/pelvic	O
pain	O
which	O
was	O
noted	O
more	O
frequently	O
with	O
twice	O
daily	O
use	O
among	O
sexually	O
abstinent	O
women	O
.	O

Women	O
and	O
men	O
found	O
the	O
gel	O
highly	O
acceptable	O
.	O

CONCLUSIONS	O
This	O
Phase	O
I	O
study	O
demonstrated	O
that	O
CS	O
vaginal	O
gel	O
was	O
safe	O
,	O
well	O
tolerated	O
and	O
acceptable	O
by	O
HIV-infected	O
women	O
and	O
their	O
male	O
partners	O
.	O

Thus	O
,	O
further	O
development	O
of	O
CS	O
is	O
warranted	O
as	O
a	O
potential	O
method	O
to	O
prevent	O
HIV	O
transmission	O
and	O
acquisition	O
.	O

Extracorporeal	O
shock	O
wave	O
therapy	O
(	O
ESWT	O
)	O
in	O
patients	O
with	O
chronic	O
proximal	O
plantar	O
fasciitis	O
:	O
a	O
2-year	O
follow-up	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
extracorporeal	O
shock	O
wave	O
therapy	O
(	O
ESWT	O
)	O
in	O
patients	O
with	O
chronically	O
painful	O
proximal	O
plantar	O
fasciitis	O
with	O
a	O
further	O
conventional	O
conservative	O
treatment	O
.	O

Forty-seven	O
patients	O
(	O
49	O
feet	O
)	O
with	O
a	O
previously	O
unsuccessful	O
nonsurgical	O
treatment	O
of	O
at	O
least	O
6	O
months	O
were	O
randomized	O
to	O
two	O
groups	O
.	O

Heel	O
cups	O
had	O
to	O
be	O
worn	O
throughout	O
the	O
study	O
.	O

Group	O
1	O
(	O
25	O
heels	O
)	O
was	O
treated	O
immediately	O
with	O
three	O
sessions	O
of	O
ESWT	O
(	O
3000	O
shock	O
waves/session	O
of	O
0.2	O
mJ/mm2	O
)	O
at	O
weekly	O
intervals	O
.	O

The	O
patients	O
of	O
group	O
2	O
(	O
24	O
heels	O
)	O
continued	O
nonsurgical	O
treatment	O
(	O
iontophoresis	O
with	O
diclofenac	O
and	O
an	O
oral	O
nonsteroidal	O
anti-inflammatory	O
drug	O
)	O
for	O
12	O
weeks	O
.	O

After	O
this	O
period	O
they	O
were	O
treated	O
using	O
the	O
protocol	O
of	O
group	O
1	O
.	O

No	O
significant	O
difference	O
of	O
pain	O
and	O
walking	O
time	O
after	O
further	O
nonsurgical	O
treatment	O
(	O
3	O
months	O
)	O
was	O
seen	O
in	O
group	O
2	O
.	O

At	O
12	O
weeks	O
after	O
ESWT	O
,	O
the	O
pain	O
estimation	O
on	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
for	O
activities	O
of	O
daily	O
living	O
diminished	O
significantly	O
by	O
62.9	O
%	O
in	O
group	O
1	O
and	O
by	O
63.0	O
%	O
in	O
group	O
2	O
.	O

The	O
comfortable	O
walking	O
time	O
had	O
increased	O
significantly	O
in	O
both	O
groups	O
.	O

Two	O
years	O
after	O
ESWT	O
,	O
pain	O
during	O
activities	O
of	O
daily	O
living	O
decreased	O
by	O
94	O
%	O
in	O
group	O
1	O
and	O
by	O
90	O
%	O
in	O
group	O
2	O
on	O
the	O
VAS	O
and	O
the	O
comfortable	O
walking	O
time	O
had	O
increased	O
significantly	O
in	O
both	O
groups	O
.	O

Efficacy	O
and	O
safety	O
of	O
oral	O
conivaptan	O
:	O
a	O
V1A/V2	O
vasopressin	O
receptor	O
antagonist	O
,	O
assessed	O
in	O
a	O
randomized	O
,	O
placebo-controlled	O
trial	O
in	O
patients	O
with	O
euvolemic	Condition
or	Condition
hypervolemic	Condition
hyponatremia	Condition
.	O

CONTEXT	O
Hyponatremia	O
[	O
serum	O
sodium	O
concentration	O
(	O
[	O
Na	O
(	O
+	O
)	O
]	O
)	O
,	O
<	O
135	O
mEq/liter	O
]	O
is	O
the	O
most	O
common	O
fluid	O
and	O
electrolyte	O
abnormality	O
among	O
hospitalized	Condition
patients	Condition
.	O

It	O
is	O
frequently	O
caused	O
by	O
the	O
inappropriate	O
release	O
of	O
arginine	O
vasopressin	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
oral	O
conivaptan	O
,	O
a	O
vasopressin	O
V	O
(	O
1A	O
)	O
/V	O
(	O
2	O
)	O
receptor	O
antagonist	O
,	O
in	O
patients	O
with	O
euvolemic	Condition
or	O
hypervolemic	Condition
hyponatremia	Condition
.	O

DESIGN	O
The	O
study	O
design	O
was	O
a	O
5-d	O
placebo-controlled	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

SETTING	O
The	O
study	O
was	O
performed	O
at	O
a	O
hospital	O
.	O

INTERVENTION	O
Oral	O
conivaptan	O
(	O
40	O
or	O
80	O
mg/d	O
)	O
or	O
placebo	O
was	O
given	O
in	O
two	O
divided	O
doses	O
.	O

PATIENTS	O
Seventy-four	SampleSize
patients	O
(	O
average	O
baseline	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
,	O
115	O
to	O
<	O
130	O
mEq/liter	O
)	O
were	O
studied	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
The	O
main	O
outcome	O
measure	O
was	O
the	O
change	O
from	O
baseline	O
in	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
area	O
under	O
the	O
curve	O
.	O

RESULTS	O
The	O
least-squares	O
mean	O
change	O
from	O
baseline	O
in	O
the	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
area	O
under	O
the	O
curve	O
with	O
conivaptan	O
(	O
40	O
and	O
80	O
mg/d	O
)	O
was	O
2.0-fold	O
(	O
P	O
=	O
0.03	O
)	O
and	O
2.5-fold	O
(	O
P	O
<	O
0.001	O
)	O
greater	O
,	O
respectively	O
,	O
than	O
that	O
with	O
placebo	O
.	O

The	O
median	O
time	O
to	O
achieve	O
a	O
confirmed	O
increase	O
in	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
of	O
4	O
mEq/liter	O
or	O
more	O
from	O
baseline	O
was	O
71.7	O
h	O
for	O
placebo	O
,	O
27.5	O
h	O
for	O
40	O
mg/d	O
conivaptan	O
(	O
P	O
=	O
0.044	O
)	O
,	O
and	O
12.1	O
h	O
for	O
80	O
mg/d	O
conivaptan	O
(	O
P	O
=	O
0.002	O
)	O
.	O

The	O
mean	O
total	O
times	O
during	O
which	O
patients	O
had	O
a	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
level	O
of	O
4	O
mEq/liter	O
or	O
more	O
above	O
baseline	O
were	O
46.5	O
,	O
69.8	O
,	O
and	O
88.8	O
h	O
(	O
P	O
=	O
0.001	O
)	O
,	O
respectively	O
.	O

The	O
least-squares	O
mean	O
change	O
in	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
from	O
baseline	O
to	O
end	O
of	O
treatment	O
was	O
3.4	O
mEq/liter	O
for	O
placebo	O
,	O
6.4	O
mEq/liter	O
for	O
40	O
mg/d	O
conivaptan	O
,	O
and	O
8.2	O
mEq/liter	O
for	O
80	O
mg/d	O
conivaptan	O
(	O
P	O
=	O
0.002	O
)	O
.	O

A	O
confirmed	O
normal	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
(	O
>	O
/=135	O
mEq/liter	O
)	O
or	O
increase	O
of	O
6	O
mEq/liter	O
or	O
more	O
was	O
observed	O
in	O
48	O
%	O
of	O
patients	O
given	O
placebo	O
,	O
71	O
%	O
given	O
40	O
mg/d	O
conivaptan	O
,	O
and	O
82	O
%	O
given	O
80	O
mg/d	O
conivaptan	O
(	O
P	O
=	O
0.014	O
)	O
.	O

Headache	O
,	O
hypotension	O
,	O
nausea	O
,	O
constipation	O
,	O
and	O
postural	O
hypotension	O
were	O
the	O
most	O
common	O
adverse	O
events	O
.	O

CONCLUSION	O
Oral	O
conivaptan	O
(	O
40	O
and	O
80	O
mg/d	O
)	O
was	O
well	O
tolerated	O
and	O
efficacious	O
in	O
correcting	O
serum	O
[	O
Na	O
(	O
+	O
)	O
]	O
in	O
hyponatremia	O
.	O

Topical	O
anti-inflammatory	O
drugs	O
in	O
the	O
treatment	O
of	O
allergic	O
pollinosic	O
conjunctivitis	O
:	O
a	O
comparative	O
double-blind	O
study	O
.	O

Anti-inflammatory	O
drugs	O
,	O
i.e	O
.	O

glucocorticosteroids	O
and	O
NSAIDs	O
(	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
)	O
,	O
are	O
often	O
included	O
in	O
the	O
treatment	O
of	O
allergic	O
conjunctivitis	O
.	O

The	O
present	O
study	O
compares	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
topical	O
hydrocortisone	O
,	O
acetylsalicylic	O
acid	O
(	O
ASA	O
)	O
and	O
piroxicam	O
compared	O
to	O
placebo	O
.	O

The	O
trial	O
,	O
designed	O
as	O
a	O
double-blind	O
,	O
randomized	O
and	O
parallel-group	O
treatment	O
,	O
was	O
carried	O
out	O
in	O
a	O
group	O
of	O
40	O
patients	O
suffering	O
from	O
seasonal	O
allergic	O
conjunctivitis	O
due	O
to	O
Parietaria	O
pollen	O
,	O
during	O
the	O
pollen	O
season	O
(	O
June-July	O
,	O
1990	O
)	O
.	O

Patients	O
received	O
hydrocortisone	O
0.1	O
%	O
solution	O
,	O
ASA	O
1	O
%	O
solution	O
,	O
piroxicam	O
0.5	O
%	O
solution	O
or	O
placebo	O
as	O
eye	O
drops	O
,	O
all	O
one	O
drop	O
in	O
each	O
eye	O
q.i.d	O
.	O

for	O
14	O
days	O
.	O

The	O
symptoms	O
were	O
evaluated	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
treatment	O
by	O
the	O
clinician	O
and	O
by	O
patients	O
on	O
a	O
diary	O
card	O
.	O

The	O
hydrocortisone	O
group	O
showed	O
a	O
rapid	O
and	O
significant	O
improvement	O
during	O
the	O
first	O
week	O
of	O
treatment	O
,	O
while	O
ASA	O
and	O
piroxicam	O
reduced	O
symptomatology	O
during	O
the	O
second	O
week	O
of	O
treatment	O
;	O
this	O
difference	O
was	O
statistically	O
significant	O
.	O

At	O
the	O
end	O
of	O
the	O
trial	O
,	O
the	O
active	O
drugs	O
were	O
comparable	O
with	O
regard	O
to	O
clinical	O
efficacy	O
.	O

A	O
statistically	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
active	O
drugs	O
and	O
placebo	O
,	O
while	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
among	O
the	O
three	O
drugs	O
.	O

No	O
serious	O
side-effects	O
were	O
observed	O
.	O

The	O
results	O
demonstrate	O
the	O
clinical	O
efficacy	O
of	O
anti-inflammatory	O
drugs	O
in	O
the	O
treatment	O
of	O
pollen-induced	O
allergic	O
conjunctivitis	O
;	O
they	O
also	O
suggest	O
the	O
use	O
of	O
NSAIDs	O
in	O
long-term	O
treatment	O
,	O
as	O
their	O
efficacy	O
has	O
been	O
shown	O
to	O
be	O
closely	O
comparable	O
to	O
that	O
of	O
steroids	O
,	O
while	O
avoiding	O
the	O
well-known	O
side-effects	O
of	O
the	O
latter	O
in	O
prolonged	O
treatment	O
.	O

The	O
effects	O
of	O
moderate	O
to	O
vigorous	O
aerobic	O
exercise	O
on	O
the	O
sleep	O
need	O
of	O
sedentary	O
young	O
adults	O
.	O

Exercise	O
has	O
been	O
recommended	O
for	O
enhancing	O
sleep	O
;	O
a	O
claim	O
linked	O
to	O
the	O
belief	O
that	O
sleep	O
need	O
-	O
defined	O
by	O
sleep	O
duration	O
and	O
depth	O
-	O
is	O
increased	O
post-exercise	O
to	O
allow	O
tissue	O
recovery	O
.	O

Objective	O
studies	O
investigating	O
exercise-sleep	O
responses	O
have	O
produced	O
mixed	O
outcomes	O
,	O
and	O
the	O
disparity	O
in	O
results	O
between	O
studies	O
may	O
be	O
due	O
to	O
differences	O
in	O
individual	O
characteristics	O
and/or	O
exercise	O
protocol	O
,	O
emphasising	O
the	O
importance	O
of	O
carefully	O
controlled	O
trials	O
.	O

We	O
investigated	O
the	O
role	O
of	O
exercise	O
on	O
the	O
sleep	O
need	O
of	O
sedentary	O
adults	O
,	O
after	O
controlling	O
for	O
exercise	O
mode	O
,	O
timing	O
and	O
duration	O
.	O

Twelve	O
healthy	O
volunteers	O
(	O
25.2	O
?	O
4.0	O
years	O
,	O
9	O
females	O
,	O
[	O
Vdot	O
]	O
O	O
(	O
2	O
)	O
max	O
35.4	O
?	O
8.8	O
ml?	O
kg	O
(	O
-1	O
)	O
?	O
min	O
(	O
-1	O
)	O
)	O
were	O
randomised	O
to	O
no-exercise	O
or	O
to	O
a	O
bout	O
of	O
treadmill	O
exercise	O
at	O
45	O
%	O
,	O
55	O
%	O
,	O
65	O
%	O
or	O
75	O
%	O
[	O
Vdot	O
]	O
O	O
(	O
2	O
)	O
max	O
in	O
a	O
crossover	O
design	O
.	O

Sleep	O
on	O
no-exercise	O
and	O
exercise	O
nights	O
were	O
assessed	O
by	O
polysomnography	O
.	O

Participants	O
spent	O
a	O
greater	O
proportion	O
of	O
sleep	O
in	O
light	O
sleep	O
(	O
stage	O
1	O
+	O
stage	O
2	O
)	O
after	O
exercise	O
at	O
both	O
65	O
%	O
and	O
75	O
%	O
[	O
Vdot	O
]	O
O	O
(	O
2	O
)	O
max	O
(	O
P	O
<	O
0.05	O
)	O
than	O
the	O
no-exercise	O
condition	O
.	O

There	O
was	O
a	O
trend	O
of	O
a	O
reduced	O
proportion	O
of	O
rapid	O
eye	O
movement	O
sleep	O
with	O
increased	O
exercise	O
intensity	O
(	O
P	O
=	O
0.067	O
)	O
.	O

No	O
other	O
changes	O
were	O
observed	O
in	O
any	O
other	O
sleep	O
variables	O
.	O

Two	O
findings	O
emerged	O
:	O
vigorous	O
exercise	O
did	O
not	O
increase	O
sleep	O
need	O
;	O
however	O
,	O
this	O
level	O
of	O
exercise	O
increased	O
light	O
sleep	O
.	O

The	O
Randomised	O
Intervention	O
Treatment	O
of	O
Angina	O
(	O
RITA	O
)	O
Trial	O
protocol	O
:	O
a	O
long	O
term	O
study	O
of	O
coronary	O
angioplasty	O
and	O
coronary	O
artery	O
bypass	O
surgery	O
in	O
patients	O
with	O
angina	Condition
.	O

The	O
Randomised	O
Intervention	O
Treatment	O
of	O
Angina	O
(	O
RITA	O
)	O
Trial	O
is	O
a	O
prospective	O
,	O
randomised	O
study	O
to	O
compare	O
the	O
short	O
term	O
and	O
long	O
term	O
effects	O
of	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
and	O
coronary	O
artery	O
bypass	O
surgery	O
.	O

During	O
the	O
study	O
a	O
register	O
of	O
patients	O
undergoing	O
coronary	Condition
arteriography	Condition
at	O
the	O
fourteen	O
participating	O
centres	O
is	O
being	O
maintained	O
to	O
assess	O
the	O
overall	O
context	O
of	O
patient	O
recruitment	O
.	O

Patients	O
with	O
arteriographically	Condition
proven	Condition
coronary	Condition
artery	Condition
disease	Condition
are	O
considered	O
for	O
the	O
trial	O
if	O
the	O
participating	O
cardiologist	O
and	O
surgeon	O
agree	O
that	O
equivalent	O
revascularisation	O
could	O
be	O
achieved	O
by	O
either	O
treatment	O
method	O
.	O

Patients	O
who	O
satisfy	O
the	O
trial	O
entry	O
criteria	O
are	O
randomised	O
to	O
treatment	O
by	O
coronary	O
angioplasty	O
or	O
coronary	O
artery	O
bypass	O
surgery	O
,	O
with	O
prospective	O
stratification	O
into	O
groups	O
with	O
one	O
,	O
two	O
,	O
or	O
three	O
treatment	O
vessels	O
.	O

Randomisation	O
implies	O
an	O
intention	O
to	O
treat	O
the	O
patient	O
by	O
the	O
assigned	O
procedure	O
and	O
the	O
analysis	O
of	O
long	O
term	O
results	O
will	O
include	O
all	O
randomised	O
cases	O
.	O

The	O
trial	O
will	O
recruit	O
at	O
least	O
1000	SampleSize
patients	O
who	O
will	O
be	O
followed	O
for	O
five	O
years	O
.	O

The	O
major	O
trial	O
end	O
points	O
include	O
death	O
,	O
new	O
myocardial	O
infarction	O
,	O
and	O
new	O
coronary	O
angioplasty	O
or	O
coronary	O
artery	O
bypass	O
procedures	O
.	O

Other	O
outcome	O
measures	O
include	O
symptom	O
and	O
employment	O
status	O
,	O
quality	O
of	O
life	O
,	O
exercise	O
tolerance	O
,	O
and	O
left	O
ventricular	O
function	O
.	O

A	O
randomized	O
trial	O
of	O
an	O
interim	O
methadone	O
maintenance	O
clinic	O
.	O

BACKGROUND	O
Interim	O
methadone	O
maintenance	O
has	O
been	O
proposed	O
as	O
a	O
method	O
of	O
providing	O
clinically	O
effective	O
services	O
to	O
heroin	Condition
addicts	Condition
waiting	O
for	O
treatment	O
in	O
standard	O
comprehensive	O
methadone	O
maintenance	O
programs	O
.	O

METHODS	O
A	O
clinic	O
that	O
provided	O
initial	O
medical	O
evaluation	O
,	O
methadone	O
medication	O
,	O
and	O
AIDS	O
education	O
,	O
but	O
did	O
not	O
include	O
formal	O
drug	O
abuse	O
counseling	O
or	O
other	O
social	O
support	O
services	O
was	O
established	O
in	O
New	O
York	O
City	O
.	O

A	O
sample	O
of	O
301	SampleSize
volunteer	O
subjects	O
recruited	O
from	O
the	O
waiting	O
list	O
for	O
treatment	O
in	O
the	O
Beth	O
Israel	O
methadone	O
program	O
were	O
randomly	O
assigned	O
to	O
immediate	O
entry	O
into	O
the	O
interim	O
clinic	O
or	O
a	O
control	O
group	O
.	O

RESULTS	O
There	O
were	O
no	O
differences	O
in	O
initial	O
levels	O
of	O
illicit	O
drug	O
use	O
across	O
the	O
experimental	O
and	O
control	O
groups	O
.	O

One-month	O
urinalysis	O
follow-up	O
data	O
showed	O
a	O
significant	O
reduction	O
in	O
heroin	O
use	O
in	O
the	O
experimental	O
group	O
(	O
from	O
63	O
%	O
positive	O
at	O
intake	O
to	O
29	O
%	O
positive	O
)	O
with	O
no	O
change	O
in	O
the	O
control	O
group	O
(	O
62	O
%	O
to	O
60	O
%	O
positive	O
)	O
.	O

No	O
significant	O
change	O
was	O
observed	O
in	O
cocaine	O
urinalyses	O
(	O
approximately	O
70	O
%	O
positive	O
for	O
both	O
groups	O
at	O
intake	O
and	O
follow-up	O
)	O
.	O

A	O
higher	O
percentage	O
of	O
the	O
experimental	O
group	O
were	O
in	O
treatment	O
at	O
16-month	O
follow-up	O
(	O
72	O
%	O
vs	O
56	O
%	O
)	O
.	O

CONCLUSIONS	O
Limited	O
services	O
interim	O
methadone	O
maintenance	O
can	O
reduce	O
heroin	O
use	O
among	O
persons	O
awaiting	O
entry	O
into	O
comprehensive	O
treatment	O
and	O
increase	O
the	O
percentage	O
entering	O
treatment	O
.	O

The	O
Toronto	O
prehospital	O
hypertonic	O
resuscitation	Condition
--	Condition
head	Condition
injury	O
and	O
multiorgan	O
dysfunction	O
trial	O
:	O
feasibility	O
study	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
of	O
a	O
prehospital	O
trial	O
comparing	O
hypertonic	O
saline	O
and	O
dextran	O
(	O
HSD	O
)	O
with	O
normal	O
saline	O
(	O
NS	O
)	O
in	O
blunt	O
head	O
injury	O
patients	O
.	O

DESIGN	O
The	O
study	O
used	O
a	O
double	O
blind	O
randomized	O
trial	O
.	O

SETTING	O
The	O
study	O
was	O
conducted	O
in	O
air	O
and	O
land	O
emergency	O
medical	O
services	O
and	O
2	O
trauma	O
centers	O
serving	O
a	O
population	O
of	O
4	SampleSize
million	SampleSize
people	SampleSize
.	SampleSize

PATIENTS	O
The	O
study	O
population	O
consisted	O
of	O
head	O
injured	O
,	O
blunt	O
trauma	O
adult	Condition
patients	O
with	O
a	O
Glasgow	Condition
Coma	Condition
Scale	O
of	O
lower	O
than	O
9	O
.	O

INTERVENTIONS	O
We	O
used	O
250	O
mL	O
of	O
HSD	O
vs	O
NS	O
given	O
within	O
4	O
hours	O
of	O
the	O
accident	O
.	O

MEASUREMENTS	O
The	O
specific	O
objectives	O
were	O
to	O
assess	O
protocol-related	O
logistical	O
issues	O
,	O
randomization	O
,	O
HSD	O
safety	O
,	O
and	O
follow	O
up	O
rates	O
and	O
to	O
obtain	O
survival	O
and	O
neurocognitive	O
end	O
point	O
estimates	O
.	O

MAIN	O
RESULTS	O
Of	O
132	SampleSize
eligible	SampleSize
patients	SampleSize
,	O
113	SampleSize
were	O
randomized	O
.	O

Nineteen	O
eligible	O
patients	O
were	O
missed	O
because	O
of	O
lack	O
of	O
time	O
(	O
9	O
[	O
22	O
%	O
]	O
)	O
,	O
paramedic	O
discretion	O
(	O
3	O
[	O
7	O
%	O
]	O
)	O
,	O
the	O
paramedic	O
forgot	O
(	O
6	O
[	O
15	O
%	O
]	O
)	O
,	O
and	O
the	O
paramedic	O
refused	O
(	O
1	O
[	O
2	O
%	O
]	O
)	O
.	O

Randomization	O
compliance	O
was	O
96	O
%	O
(	O
109/113	O
)	O
.	O

Four	O
randomized	O
cases	O
met	O
exclusion	O
criteria	O
:	O
penetrating	O
trauma	O
(	O
1	O
)	O
,	O
cardiac	O
arrest	O
(	O
2	O
)	O
,	O
and	O
fall	O
from	O
standing	O
(	O
1	O
)	O
.	O

Three	O
randomized	O
patients	O
were	O
excluded	O
from	O
the	O
final	O
analysis	O
:	O
2	O
patients	O
received	O
less	O
than	O
50	O
mL	O
of	O
study	O
solution	O
due	O
to	O
an	O
interstitial	O
intravenous	O
line	O
and	O
1	O
lost	O
randomization	O
identification	O
.	O

Fifty	O
patients	O
(	O
47	O
%	O
)	O
were	O
randomized	O
to	O
HSD	O
and	O
56	O
(	O
53	O
%	O
)	O
to	O
NS	O
.	O

Mean	O
injury	O
severity	O
score	O
was	O
32.7	O
for	O
HSD	O
and	O
32.6	O
for	O
NS	O
.	O

There	O
was	O
no	O
difference	O
in	O
length	O
of	O
stay	O
,	O
Sequential	O
Organ	O
Failure	O
Assessment	O
maximum	O
,	O
Multiple	O
Organ	O
Dysfunction	O
Score	O
maximum	O
,	O
delta	O
Multiple	O
Organ	O
Dysfunction	O
Score	O
,	O
or	O
Apache	O
scores	O
.	O

Initial	O
head	O
scans	O
scored	O
3	O
or	O
higher	O
by	O
Marshall	O
classification	O
for	O
12	O
HSD	O
and	O
11	O
NS	O
patients	O
.	O

Zero	O
adverse	O
events	O
occurred	O
,	O
and	O
follow-up	O
for	O
the	O
primary	O
outcome	O
was	O
100	O
%	O
.	O

Alive	O
at	O
30	O
days	O
for	O
HSD	O
and	O
NS	O
,	O
respectively	O
,	O
was	O
70	O
%	O
(	O
35/50	O
)	O
and	O
75	O
%	O
(	O
42/56	O
)	O
and	O
at	O
discharge	O
was	O
68	O
%	O
(	O
34/50	O
)	O
and	O
73	O
%	O
(	O
41/56	O
)	O
.	O

Only	O
49.3	O
%	O
(	O
37/77	O
)	O
of	O
surviving	O
patients	O
consented	O
to	O
follow-up	O
at	O
4	O
months	O
and	O
89	O
%	O
(	O
33/37	O
)	O
completed	O
the	O
assessment	O
.	O

Disability	O
rating	O
scale	O
(	O
median	O
,	O
interquartile	O
range	O
)	O
was	O
3	O
(	O
0	O
,	O
6	O
)	O
for	O
HSD	O
and	O
was	O
0	O
(	O
0	O
,	O
6	O
)	O
for	O
NS	O
.	O

Glasgow	O
Outcome	O
Scale	O
Evaluation	O
was	O
higher	O
than	O
4	O
for	O
HSD	O
(	O
12/12	O
[	O
100	O
%	O
]	O
)	O
and	O
NS	O
(	O
15/21	O
[	O
72	O
%	O
]	O
)	O
.	O

Functional	O
Independence	O
Measure	O
(	O
mean	O
,	O
SD	O
)	O
was	O
62	O
(	O
37	O
)	O
for	O
HSD	O
and	O
80	O
(	O
32	O
)	O
for	O
NS	O
.	O

CONCLUSIONS	O
It	O
is	O
feasible	O
to	O
conduct	O
a	O
prehospital	O
randomized	O
controlled	O
trial	O
with	O
HSD	O
for	O
treatment	O
of	O
blunt	Condition
trauma	Condition
patients	Condition
with	Condition
head	Condition
injuries	Condition
;	Condition
however	O
,	O
consent	O
for	O
neurofunctional	O
outcomes	O
in	O
this	O
cohort	O
is	O
problematic	O
and	O
threatens	O
the	O
feasibility	O
of	O
definitive	O
trials	O
using	O
these	O
potentially	O
meaningful	O
end	O
points	O
.	O

American	O
College	O
of	O
Cardiology/European	O
Society	O
of	O
Cardiology	O
International	O
Study	O
of	O
Angiographic	O
Data	O
Compression	O
Phase	O
I	O
:	O
The	O
effect	O
of	O
lossy	O
data	O
compression	O
on	O
recognition	O
of	O
diagnostic	O
features	O
in	O
digital	Condition
coronary	Condition
angiography	Condition
.	O

OBJECTIVES	O
This	O
study	O
intended	O
to	O
determine	O
the	O
effect	O
of	O
varying	O
degrees	O
of	O
lossy	O
Joint	O
Photographic	O
Experts	O
Group	O
(	O
JPEG	O
)	O
compression	O
on	O
detection	O
of	O
coronary	O
angiographic	O
features	O
.	O

BACKGROUND	O
Compression	O
of	O
digital	O
coronary	O
angiograms	O
facilitates	O
playback	O
of	O
images	O
and	O
decreases	O
cost	O
.	O

There	O
are	O
little	O
data	O
on	O
the	O
effect	O
of	O
compression	O
on	O
the	O
accuracy	O
of	O
coronary	O
angiography	O
.	O

METHODS	O
At	O
six	O
centers	O
,	O
71	SampleSize
angiographers	O
each	O
reviewed	O
a	O
set	O
of	O
100	O
angiographic	O
sequences	O
.	O

The	O
100	O
sequences	O
were	O
divided	O
into	O
four	O
,	O
25-sequence	O
subsets	O
.	O

Each	O
subset	O
of	O
25	O
was	O
displayed	O
either	O
as	O
original	O
images	O
or	O
at	O
one	O
of	O
three	O
compression	O
ratios	O
(	O
CRs	O
)	O
(	O
6:1	O
,	O
10:1	O
or	O
16:1	O
)	O
.	O

The	O
effect	O
of	O
lossy	O
compression	O
on	O
the	O
sensitivity	O
and	O
specificity	O
for	O
detection	O
of	O
diagnostic	O
features	O
was	O
determined	O
.	O

The	O
effect	O
of	O
compression	O
on	O
subjective	O
measures	O
of	O
image	O
quality	O
graded	O
by	O
the	O
angiographers	O
was	O
also	O
examined	O
.	O

RESULTS	O
Lossy	O
compression	O
at	O
a	O
ratio	O
of	O
16:1	O
decreased	O
the	O
sensitivity	O
for	O
the	O
detection	O
of	O
diagnostic	O
features	O
(	O
76	O
%	O
vs.	O
80	O
%	O
p	O
=	O
0.004	O
)	O
.	O

The	O
largest	O
effect	O
was	O
in	O
the	O
detection	O
of	O
calcification	O
(	O
52	O
%	O
vs.	O
63	O
%	O
at	O
16:1	O
compression	O
vs.	O
original	O
images	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Subjective	O
indicators	O
of	O
image	O
quality	O
indicated	O
a	O
reduction	O
in	O
confidence	O
in	O
interpretation	O
at	O
CRs	O
of	O
10:1	O
and	O
16:1	O
.	O

CONCLUSIONS	O
With	O
increased	O
ratios	O
of	O
lossy	O
compression	O
,	O
a	O
degradation	O
of	O
digital	O
coronary	O
angiograms	O
occurs	O
that	O
results	O
in	O
decreased	O
diagnostic	O
accuracy	O
.	O

The	O
sensitivity	O
for	O
detection	O
of	O
common	O
diagnostic	O
features	O
was	O
decreased	O
,	O
and	O
subjective	O
assessment	O
of	O
image	O
quality	O
was	O
impaired	O
.	O

Caution	O
is	O
warranted	O
in	O
the	O
interpretation	O
of	O
coronary	O
angiograms	O
that	O
have	O
been	O
subjected	O
to	O
lossy	O
JPEG	O
compression	O
beyond	O
a	O
ratio	O
of	O
6:1	O
.	O

A	O
preliminary	O
trial	O
of	O
ascorbic	O
acid	O
as	O
supplemental	O
therapy	O
for	O
autism	Condition
.	Condition

1	O
.	O

This	O
study	O
presents	O
the	O
results	O
of	O
a	O
30-week	O
double-blind	O
,	O
placebo-controlled	O
trial	O
exploring	O
the	O
effectiveness	O
of	O
ascorbic	O
acid	O
(	O
8g/70kg/day	O
)	O
as	O
a	O
supplemental	O
pharmacological	O
treatment	O
for	O
autistic	O
children	O
in	O
residential	O
treatment	O
.	O

2	O
.	O

Residential	O
school	O
children	O
(	O
N	O
=	O
18	O
)	O
were	O
randomly	O
assigned	O
to	O
either	O
ascorbate-ascorbate-placebo	O
treatment	O
order	O
group	O
or	O
ascorbate-placebo-ascorbate	O
treatment	O
order	O
group	O
.	O

Each	O
treatment	O
phase	O
lasted	O
10	O
weeks	O
and	O
behaviors	O
were	O
rated	O
weekly	O
using	O
the	O
Ritvo-Freeman	O
scale	O
.	O

3	O
.	O

Significant	O
group	O
by	O
phase	O
interactions	O
were	O
found	O
for	O
total	O
scores	O
and	O
also	O
sensory	O
motor	O
scores	O
indicating	O
a	O
reduction	O
in	O
symptom	O
severity	O
associated	O
with	O
the	O
ascorbic	O
acid	O
treatment	O
.	O

4	O
.	O

These	O
results	O
were	O
consistent	O
with	O
a	O
hypothesized	O
dopaminergic	O
mechanism	O
of	O
action	O
of	O
ascorbic	O
acid	O
.	O

Cophenylcaine	O
spray	O
vs.	O
placebo	O
in	O
flexible	O
nasendoscopy	O
:	O
a	O
prospective	O
double-blind	O
randomised	O
controlled	O
trial	O
.	O

Practices	O
vary	O
across	O
the	O
UK	O
on	O
the	O
use	O
of	O
topical	O
preparation	O
prior	O
to	O
flexible	O
fibreoptic	O
nasendoscopy	O
.	O

In	O
this	O
double-blind	O
study	O
,	O
we	O
randomised	O
98	SampleSize
patients	O
to	O
receive	O
cophenylcaine	O
or	O
placebo	O
nasal	O
spray	O
before	O
flexible	O
nasendoscopy	O
.	O

A	O
visual	O
analogue	O
scale	O
(	O
1-100	O
)	O
was	O
used	O
to	O
record	O
pain	O
,	O
unpleasantness	O
of	O
taste	O
and	O
overall	O
discomfort	O
experienced	O
.	O

Overall	O
,	O
the	O
procedure	O
was	O
associated	O
with	O
minimal	O
pain	O
and	O
discomfort	O
in	O
both	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
pain	O
or	O
overall	O
discomfort	O
experienced	O
between	O
the	O
two	O
groups	O
;	O
however	O
,	O
the	O
sensation	O
of	O
bad	O
taste	O
was	O
significantly	O
worse	O
in	O
the	O
cophenylcaine	O
group	O
.	O

In	O
linear	O
regression	O
,	O
factors	O
that	O
predicted	O
the	O
overall	O
unpleasantness	O
of	O
the	O
experience	O
were	O
primarily	O
pain	O
experienced	O
and	O
secondarily	O
unpleasantness	O
of	O
taste	O
.	O

We	O
conclude	O
that	O
the	O
routine	O
use	O
of	O
cophenylcaine	O
for	O
nasal	O
preparation	O
is	O
not	O
justified	O
before	O
flexible	O
nasendoscopy	O
.	O

A	O
comparative	O
study	O
of	O
ofloxacin	O
and	O
cefixime	O
for	O
treatment	O
of	O
typhoid	Condition
fever	Condition
in	O
children	Age
.	O

The	O
Dong	O
Nai	O
Pediatric	O
Center	O
Typhoid	O
Study	O
Group	O
.	O

BACKGROUND	O
Despite	O
concerns	O
about	O
safety	O
in	O
children	O
,	O
fluoroquinolone	O
antibiotics	O
have	O
become	O
the	O
treatment	O
of	O
choice	O
in	O
patients	O
with	O
multidrug-resistant	Condition
typhoid	Condition
fever	Condition
in	O
Vietnam	O
.	O

However	O
,	O
quinolone-resistant	O
strains	O
of	O
Salmonella	O
typhi	O
have	O
recently	O
been	O
reported	O
from	O
Vietnam	O
;	O
and	O
if	O
quinolone	O
resistance	O
becomes	O
established	O
,	O
alternative	O
oral	O
treatment	O
options	O
will	O
be	O
needed	O
.	O

OBJECTIVE	O
Cefixime	O
,	O
an	O
orally	O
administered	O
third	O
generation	O
cephalosporin	O
,	O
was	O
compared	O
with	O
ofloxacin	O
for	O
the	O
treatment	O
of	O
uncomplicated	O
typhoid	O
fever	O
in	O
children	O
.	O

METHODS	O
In	O
an	O
open	O
trial	O
children	Age
with	O
suspected	O
typhoid	Condition
fever	Condition
were	O
randomized	O
to	O
receive	O
either	O
ofloxacin	O
(	O
10	O
mg/kg/day	O
in	O
two	O
divided	O
doses	O
)	O
for	O
5	O
days	O
or	O
cefixime	O
(	O
20	O
mg/kg/day	O
in	O
two	O
divided	O
doses	O
)	O
for	O
7	O
days	O
.	O

RESULTS	O
S.	O
typhi	O
was	O
isolated	O
from	O
82	SampleSize
patients	O
(	O
44	O
in	O
the	O
cefixime	O
group	O
,	O
38	O
in	O
the	O
ofloxacin	O
group	O
)	O
and	O
70	SampleSize
(	O
85	O
%	O
)	O
of	O
the	O
isolates	O
were	O
multidrug-resistant	O
.	O

Median	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
range	O
)	O
fever	O
clearance	O
times	O
were	O
4.4	O
(	O
4	O
to	O
5.2	O
,	O
0.2	O
to	O
9.9	O
)	O
days	O
for	O
ofloxacin	O
recipients	O
and	O
8.5	O
(	O
4.2	O
to	O
9	O
,	O
1.8	O
to	O
15.2	O
)	O
days	O
for	O
cefixime-treated	O
patients	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

There	O
were	O
11	O
treatment	O
failures	O
(	O
10	O
acute	O
and	O
one	O
relapse	O
)	O
in	O
the	O
cefixime	O
group	O
and	O
1	O
acute	O
treatment	O
failure	O
in	O
the	O
ofloxacin	O
group	O
(	O
mean	O
difference	O
,	O
22	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
9	O
to	O
36	O
%	O
)	O
.	O

CONCLUSION	O
Short	O
course	O
treatment	O
with	O
cefixime	O
may	O
provide	O
a	O
useful	O
alternative	O
treatment	O
in	O
cases	O
of	O
uncomplicated	Condition
typhoid	Condition
fever	Condition
in	O
children	Age
,	O
but	O
it	O
is	O
less	O
effective	O
than	O
short	O
course	O
treatment	O
with	O
ofloxacin	O
.	O

Pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
six	O
epoetin	O
alfa	O
dosing	O
regimens	O
in	O
anemic	O
critically	O
ill	O
patients	O
without	O
acute	O
blood	O
loss	O
.	O

OBJECTIVE	O
To	O
describe	O
the	O
pharmacokinetic	O
profiles	O
of	O
six	O
different	O
dosing	O
regimens	O
for	O
epoetin	O
alfa	O
,	O
and	O
whether	O
more	O
rapid	O
and	O
robust	O
reticulocytosis	O
can	O
be	O
elicited	O
with	O
more	O
frequent	O
administration	O
of	O
epoetin	O
alfa	O
in	O
anemic	O
critically	O
ill	O
patients	O
.	O

DESIGN	O
Randomized	O
,	O
open-label	O
,	O
multicenter	O
,	O
28-day	O
clinical	O
trial	O
.	O

SETTING	O
Ten	O
centers	O
in	O
the	O
United	O
States	O
.	O

PATIENTS	O
Adult	O
(	O
age	O
>	O
or=18	O
years	O
)	O
critically	O
ill	O
patients	O
with	O
hemoglobin	O
<	O
or=12	O
g/dL	O
,	O
expected	O
hospitalization	O
of	O
>	O
or=7	O
days	O
,	O
with	O
no	O
ongoing	O
acute	O
blood	O
loss	O
.	O

INTERVENTIONS	O
One	O
of	O
six	O
dosing	O
epoetin	O
alfa	O
regimens	O
for	O
15	O
days	O
,	O
as	O
follows	O
:	O
40,000	O
IU	O
once	O
weekly	O
,	O
subcutaneously	O
(	O
group	O
A	O
)	O
or	O
intravenously	O
(	O
IV	O
)	O
(	O
group	O
B	O
)	O
;	O
15,000	O
IU	O
every	O
other	O
day	O
,	O
subcutaneously	O
(	O
group	O
C	O
)	O
or	O
IV	O
(	O
group	O
D	O
)	O
;	O
or	O
40,000	O
IU	O
day	O
1	O
and	O
3	O
,	O
subcutaneously	O
(	O
group	O
E	O
)	O
or	O
IV	O
(	O
group	O
F	O
)	O
,	O
followed	O
by	O
15,000	O
IU	O
once	O
every	O
other	O
day	O
on	O
[	O
corrected	O
]	O
days	O
5-15	O
[	O
corrected	O
]	O
MEASUREMENTS	O
Serum	O
erythropoietin	O
concentration	O
,	O
absolute	O
reticulocyte	O
count	O
,	O
and	O
adverse	O
events	O
.	O

MAIN	O
RESULTS	O
Of	O
the	O
60	O
patients	O
who	O
were	O
enrolled	O
(	O
60	O
%	O
men	O
,	O
mean	O
age	O
53	O
years	O
,	O
mean	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
,	O
19.5	O
)	O
,	O
30	O
were	O
evaluable	O
for	O
both	O
pharmacokinetics	O
and	O
pharmacodynamics	O
(	O
50	O
%	O
)	O
.	O

Erythropoietin	O
exposure	O
was	O
approximately	O
ten	O
times	O
greater	O
for	O
IV	O
dosing	O
than	O
for	O
subcutaneous	O
dosing	O
.	O

Mean	O
absolute	O
reticulocyte	O
count	O
peaked	O
at	O
day	O
11	O
or	O
15	O
in	O
each	O
group	O
and	O
appeared	O
to	O
be	O
greater	O
for	O
subcutaneous	O
dosing	O
(	O
mean	O
peak	O
response	O
149-169	O
x	O
10	O
(	O
9	O
)	O
/L	O
)	O
compared	O
with	O
IV	O
dosing	O
(	O
mean	O
peak	O
response	O
138-147	O
x	O
10	O
(	O
9	O
)	O
/L	O
)	O
at	O
most	O
visits	O
.	O

The	O
most	O
frequently	O
reported	O
adverse	O
events	O
were	O
pyrexia	O
(	O
18	O
%	O
)	O
,	O
hypokalemia	O
(	O
15	O
%	O
)	O
,	O
and	O
hypophosphatemia	O
(	O
15	O
%	O
)	O
.	O

CONCLUSIONS	O
In	O
this	O
study	O
of	O
anemic	O
critically	O
ill	O
patients	O
treated	O
with	O
epoetin	O
alfa	O
,	O
all	O
dosing	O
regimens	O
were	O
well	O
tolerated	O
and	O
appeared	O
to	O
effect	O
reticulocytosis	O
,	O
with	O
a	O
peak	O
at	O
day	O
11	O
or	O
15	O
in	O
most	O
patients	O
.	O

The	O
pharmacokinetics	O
of	O
epoetin	O
alfa	O
did	O
not	O
predict	O
pharmacodynamic	O
response	O
in	O
anemic	O
critically	O
ill	O
patients	O
.	O

A	O
comparison	O
of	O
single-dose	O
versus	O
conventional-dose	O
antibiotic	O
treatment	O
of	O
bacteriuria	Condition
in	Condition
elderly	Condition
women	Condition
.	Condition

The	O
efficacy	O
of	O
single-dose	O
antibiotic	O
therapy	O
for	O
the	O
treatment	O
of	O
bacteriuria	O
in	O
a	O
group	O
of	O
non-catheterized	O
elderly	O
women	O
was	O
compared	O
with	O
that	O
of	O
conventional	O
7-10	O
day	O
courses	O
of	O
antibiotic	O
therapy	O
.	O

Thirty-one	O
women	O
received	O
single-dose	O
treatment	O
and	O
22	O
conventional-dose	O
treatment	O
.	O

The	O
cure	O
rates	O
at	O
1	O
and	O
6	O
weeks	O
for	O
the	O
single-dose	O
treatments	O
were	O
52	O
%	O
and	O
38	O
%	O
,	O
respectively	O
,	O
and	O
the	O
cure	O
rates	O
for	O
the	O
conventional-dose	O
treatments	O
at	O
1	O
and	O
6	O
weeks	O
were	O
59	O
%	O
and	O
52	O
%	O
,	O
respectively	O
.	O

It	O
is	O
concluded	O
that	O
there	O
may	O
be	O
a	O
place	O
for	O
the	O
use	O
of	O
single-dose	O
antibiotic	O
therapy	O
for	O
the	O
treatment	O
of	O
selected	O
elderly	O
women	O
with	O
bacteriuria	O
,	O
but	O
larger	O
studies	O
are	O
needed	O
.	O

A	O
controlled	O
trial	O
of	O
cisapride	O
in	O
anorexia	Condition
nervosa	Condition
.	O

To	O
determine	O
the	O
efficacy	O
of	O
cisapride	O
,	O
10	O
mg	O
three	O
times	O
daily	O
,	O
in	O
improving	O
gastric	O
emptying	O
,	O
reducing	O
distress	O
during	O
meals	O
,	O
and	O
facilitating	O
weight	O
gain	O
in	O
anorexia	Condition
nervosa	Condition
,	O
we	O
conducted	O
an	O
8-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
on	O
29	SampleSize
inpatients	O
.	O

Measures	O
included	O
scintigraphic	O
gastric	O
emptying	O
studies	O
at	O
0	O
,	O
2	O
,	O
4	O
,	O
and	O
8	O
weeks	O
;	O
subjective	O
distress	O
during	O
meals	O
measured	O
by	O
visual	O
analogue	O
scales	O
;	O
self-rating	O
of	O
degree	O
of	O
global	O
improvement	O
in	O
symptoms	O
associated	O
with	O
eating	O
at	O
end	O
of	O
study	O
;	O
and	O
weight	O
measured	O
weekly	O
.	O

Gastric	O
emptying	O
improved	O
significantly	O
but	O
equally	O
in	O
both	Condition
groups	O
over	O
the	O
study	O
period	O
.	O

Yet	O
subjective	O
measures	O
were	O
better	O
in	O
the	O
cisapride	SampleSize
group	O
;	O
they	O
rated	O
themselves	O
as	O
more	O
hungry	O
(	O
p	O
=	O
.02	O
)	O
and	O
more	O
improved	O
on	O
the	O
global	O
measure	O
of	O
change	O
in	O
symptoms	O
(	O
p	O
=	O
.02	O
)	O
.	O

Even	O
so	O
,	O
the	O
cisapride	Condition
group	O
did	O
not	O
gain	O
more	O
weight	O
.	O

The	O
correlation	O
between	O
gastric	O
emptying	O
and	O
weight	O
gain	O
was	O
modest	O
(	O
r	O
=	O
.30	O
;	O
p	O
=	O
.11	O
)	O
,	O
and	O
between	O
gastric	O
emptying	O
and	O
the	O
subjective	O
measures	O
,	O
virtually	O
absent	O
.	O

A	O
randomized	O
prospective	O
controlled	O
trial	O
of	O
oral	O
ganciclovir	O
versus	O
oral	O
valacyclovir	O
for	O
prophylaxis	O
of	O
cytomegalovirus	O
disease	O
after	O
renal	Condition
transplantation	Condition
.	Condition

Oral	O
ganciclovir	O
and	O
valacyclovir	O
reduce	O
the	O
incidence	O
of	O
cytomegalovirus	O
(	O
CMV	O
)	O
disease	O
after	O
renal	O
transplantation	O
(	O
RTx	O
)	O
.	O

Our	O
study	O
was	O
designed	O
to	O
compare	O
the	O
efficacy	O
,	O
costs	O
,	O
and	O
safety	O
of	O
oral	O
ganciclovir	O
and	O
valacyclovir	O
in	O
the	O
prophylaxis	O
of	O
CMV	O
disease	O
over	O
the	O
first	O
6	O
months	O
after	O
RTx	O
.	O

A	O
total	O
of	O
38	O
patients	O
was	O
randomized	O
to	O
3-month	O
treatment	O
with	O
either	O
oral	O
ganciclovir	O
(	O
1	O
g	O
t.i.d.	O
,	O
n=14	O
,	O
GAN	O
group	O
)	O
or	O
oral	O
valacyclovir	O
(	O
2	O
g	O
q.i.d.	O
,	O
n=12	O
,	O
VAL	O
group	O
)	O
.	O

A	O
third	O
group	O
(	O
C	O
,	O
n=12	O
)	O
received	O
no	O
prophylaxis	O
.	O

The	O
patients	O
were	O
monitored	O
by	O
CMV-nested	O
PCR	O
in	O
whole	O
blood	O
.	O

No	O
differences	O
were	O
found	O
between	O
the	O
groups	O
in	O
their	O
demographic	O
characteristics	O
,	O
immunosuppressive	O
protocols	O
,	O
or	O
donor	O
and	O
recipient	O
CMV	O
serology	O
.	O

Thirty-six	O
out	O
of	O
38	O
(	O
94.7	O
%	O
)	O
recipients	O
were	O
CMV-seropositive	O
.	O

Over	O
the	O
6-month	O
post-RTx	O
period	O
,	O
there	O
were	O
13	O
episodes	O
of	O
CMV	O
disease	O
in	O
eight	O
(	O
66.7	O
%	O
)	O
patients	O
of	O
the	O
C	O
group	O
compared	O
with	O
none	O
in	O
the	O
GAN	O
and	O
VAL	O
groups	O
(	O
P=0.0005	O
,	O
GAN	O
vs	O
C	O
;	O
P=0.001	O
,	O
VAL	O
vs	O
C	O
)	O
.	O

The	O
incidence	O
of	O
CMV	O
viremia	O
was	O
30.8	O
%	O
,	O
50.0	O
%	O
,	O
and	O
91.7	O
%	O
in	O
the	O
GAN	O
,	O
VAL	O
,	O
and	O
C	O
groups	O
,	O
respectively	O
(	O
P=0.004	O
,	O
GAN	O
vs	O
C	O
;	O
P=0.07	O
,	O
VAL	O
vs	O
C	O
;	O
P=NS	O
,	O
GAN	O
vs	O
VAL	O
)	O
.	O

Treatment	O
failure	O
(	O
death	O
,	O
graft	O
loss	O
,	O
CMV	O
disease	O
,	O
or	O
withdrawal	O
from	O
study	O
)	O
occurred	O
in	O
14.3	O
%	O
,	O
0	O
%	O
and	O
66.7	O
%	O
in	O
the	O
GAN	O
,	O
VAL	O
,	O
and	O
C	O
groups	O
,	O
respectively	O
(	O
P=0.014	O
,	O
GAN	O
vs	O
C	O
;	O
P=0.001	O
,	O
VAL	O
vs	O
C	O
;	O
P=NS	O
,	O
GAN	O
vs	O
VAL	O
)	O
.	O

The	O
average	O
CMV-associated	O
costs	O
per	O
patient	O
(	O
in	O
2001	O
euros	O
)	O
were	O
2,449+/-1,178	O
,	O
2,485+/-581	O
,	O
and	O
4,259+/-4,616	O
in	O
the	O
GAN	O
,	O
VAL	O
,	O
and	O
C	O
groups	O
,	O
respectively	O
.	O

Ganciclovir	O
and	O
valacyclovir	O
were	O
well	O
tolerated	O
,	O
with	O
ganciclovir	O
having	O
had	O
to	O
be	O
withdrawn	O
shortly	O
in	O
one	O
patient	O
only	O
because	O
of	O
thrombocytopenia	O
.	O

In	O
conclusion	O
,	O
oral	O
ganciclovir	O
and	O
valacyclovir	O
are	O
equally	O
safe	O
and	O
effective	O
in	O
the	O
prophylaxis	O
of	O
CMV	O
disease	O
after	O
RTx	O
.	O

Both	O
are	O
cost-effective	O
and	O
help	O
reduce	O
CMV-associated	O
costs	O
by	O
some	O
40	O
%	O
compared	O
with	O
patients	O
without	O
prophylaxis	O
.	O

[	O
Rapidity	O
of	O
pain	O
relief	O
,	O
medication	O
requirement	O
and	O
patient	O
satisfaction	O
with	O
reflux	O
treatment	O
in	O
the	O
physician	O
's	O
office	O
]	O
.	O

Treatment	O
of	O
gastroesophageal	Condition
reflux	Condition
disease	Condition
(	O
GERD	Condition
)	O
with	O
proton	O
pump	O
inhibitors	O
was	O
investigated	O
in	O
three	O
controlled	O
prospective	O
,	O
randomized	O
open	O
studies	O
.	O

Lansoprazole	O
,	O
omeprazole	O
MUPS	O
and	O
esomeprazole	O
were	O
compared	O
under	O
doctor	O
's	O
office	O
conditions	O
.	O

The	O
outcomes	O
of	O
interest	O
were	O
the	O
rapidity	O
of	O
pain	O
relief	O
achieved	O
with	O
a	O
single	O
dose	O
,	O
effectiveness	O
and	O
patient	O
satisfaction	O
with	O
on	O
demand	O
therapy	O
.	O

In	O
the	O
first	O
study	O
,	O
180	SampleSize
patients	O
with	O
chronic	Condition
and	Condition
prolonged	Condition
episodes	Condition
of	Condition
reflux	Condition
were	O
investigated	O
.	O

Time	O
to	O
pain	O
relief	O
following	O
a	O
single	O
dose	O
was	O
1.1	O
+/-	O
0.8	O
hours	O
with	O
30	O
mg	O
lansoprazole	O
,	O
3.0	O
+/-	O
2.5	O
hours	O
with	O
20	O
mgomeprazole	O
MUPS	O
and	O
2.1	O
+/-	O
1.2	O
hours	O
with	O
40	O
mg	O
esomeprazole	O
.	O

Studies	O
2	O
and	O
3	O
were	O
designed	O
as	O
cross-over	O
studies	O
intended	O
to	O
investigate	O
drug	O
consumption	O
.	O

In	O
study	O
2	O
,	O
the	O
amount	O
of	O
lansoprazole	O
consumed	O
was	O
approximately	O
50	O
%	O
less	O
than	O
that	O
of	O
omeprazole	O
,	O
and	O
this	O
translated	O
to	O
81	O
%	O
patient	O
satisfaction	O
with	O
lansoprazole	O
compared	O
with	O
only	O
9.5	O
%	O
for	O
omeprazole	O
.	O

In	O
study	O
3	O
comparing	O
lansoprazole	O
and	O
esomeprazole	O
,	O
consumption	O
of	O
the	O
former	O
was	O
85	O
%	O
that	O
of	O
the	O
latter	O
.	O

58	O
%	O
of	O
the	O
patients	O
opted	O
to	O
continuetreatment	O
with	O
lansoprazole	O
,	O
compared	O
with	O
only	O
25	O
%	O
in	O
the	O
case	O
of	O
esomeprazole	O
.	O

The	O
appreciably	O
greater	O
patient	O
satisfaction	O
with	O
lansoprazole	O
was	O
due	O
tothe	O
faster	O
pain	O
relief	O
achieved	O
with	O
this	O
drug	O
.	O

Assessment	O
of	O
response	O
to	O
induction	O
therapy	O
and	O
its	O
influence	O
on	O
5-year	O
failure-free	O
survival	O
in	O
group	O
III	O
rhabdomyosarcoma	O
:	O
the	O
Intergroup	O
Rhabdomyosarcoma	O
Study-IV	O
experience	O
--	O
a	O
report	O
from	O
the	O
Soft	O
Tissue	O
Sarcoma	O
Committee	O
of	O
the	O
Children	O
's	O
Oncology	O
Group	O
.	O

PURPOSE	O
Initial	O
response	O
to	O
induction	O
chemotherapy	O
predicts	O
failure-free	O
survival	O
(	O
FFS	O
)	O
in	O
osteosarcoma	O
and	O
Ewing	O
's	O
sarcoma	O
.	O

For	O
Intergroup	O
Rhabdomyosarcoma	O
Study	O
(	O
IRS	O
)	O
IV	O
patients	O
with	O
group	O
III	O
rhabdomyosarcoma	O
,	O
we	O
assessed	O
whether	O
reported	O
response	O
assessed	O
by	O
anatomic	O
imaging	O
at	O
week	O
8	O
predicted	O
FFS	O
.	O

PATIENTS	O
AND	O
METHODS	O
We	O
studied	O
444	O
group	O
III	O
patients	O
who	O
received	O
induction	O
therapy	O
,	O
had	O
response	O
assessed	O
at	O
week	O
8	O
by	O
anatomic	O
imaging	O
,	O
and	O
continued	O
with	O
protocol	O
therapy	O
.	O

Induction	O
chemotherapy	O
was	O
generally	O
followed	O
by	O
radiation	O
therapy	O
(	O
RT	O
)	O
starting	O
after	O
week	O
9	O
.	O

Response	O
to	O
induction	O
therapy	O
was	O
determined	O
at	O
weeks	O
0	O
and	O
8	O
.	O

Local	O
institutions	O
coded	O
response	O
.	O

RESULTS	O
Response	O
rate	O
for	O
the	O
entire	O
cohort	O
at	O
week	O
8	O
was	O
77	O
%	O
(	O
95	O
%	O
CI	O
,	O
73	O
%	O
to	O
81	O
%	O
;	O
complete	O
response	O
[	O
CR	O
]	O
,	O
21	O
%	O
;	O
partial	O
response	O
[	O
PR	O
]	O
,	O
56	O
%	O
)	O
but	O
response	O
had	O
no	O
influence	O
on	O
FFS	O
(	O
P	O
=	O
.57	O
)	O
.	O

Two	O
hundred	O
seventy-two	O
patients	O
received	O
standard-timing	O
RT	O
at	O
week	O
9	O
and	O
thus	O
only	O
chemotherapy	O
during	O
induction	O
.	O

Response	O
rate	O
was	O
81	O
%	O
(	O
95	O
%	O
CI	O
,	O
76	O
%	O
to	O
86	O
%	O
;	O
CR	O
,	O
22	O
%	O
;	O
PR	O
,	O
59	O
%	O
)	O
.	O

In	O
these	O
patients	O
,	O
response	O
did	O
not	O
influence	O
FFS	O
except	O
for	O
those	O
with	O
alveolar	O
histology	O
.	O

One	O
hundred	O
thirty-two	O
other	O
patients	O
received	O
chemotherapy	O
and	O
RT	O
during	O
induction	O
(	O
up-front	O
RT	O
)	O
.	O

Response	O
rate	O
was	O
65	O
%	O
(	O
95	O
%	O
CI	O
,	O
57	O
%	O
to	O
73	O
%	O
;	O
CR	O
,	O
12	O
%	O
;	O
PR	O
,	O
53	O
%	O
)	O
,	O
but	O
response	O
had	O
no	O
influence	O
on	O
FFS	O
(	O
P	O
=	O
.69	O
)	O
.	O

Forty	O
patients	O
received	O
no	O
RT	O
at	O
all	O
(	O
protocol	O
violation	O
)	O
and	O
response	O
to	O
induction	O
therapy	O
had	O
no	O
effect	O
on	O
FFS	O
.	O

CONCLUSION	O
In	O
IRS-IV	O
,	O
response	O
rate	O
to	O
induction	O
therapy	O
was	O
77	O
%	O
in	O
group	O
III	O
patients	O
,	O
was	O
independent	O
of	O
histology	O
,	O
and	O
had	O
no	O
influence	O
on	O
FFS	O
overall	O
.	O

Predicting	O
the	O
effect	O
of	O
anthelmintic	O
treatment	O
on	O
milk	O
production	O
of	O
dairy	O
cattle	O
in	O
Canada	O
using	O
an	O
Ostertagia	O
ostertagi	O
ELISA	O
from	O
individual	O
milk	O
samples	O
.	O

Gastrointestinal	Condition
nematodes	Condition
,	O
such	O
as	O
Ostertagia	Condition
ostertagi	Condition
and	O
several	Condition
species	Condition
of	Condition
Cooperia	Condition
,	O
are	O
ubiquitous	O
in	O
temperate	O
climates	O
and	O
have	O
been	O
shown	O
to	O
have	O
detrimental	O
effects	O
on	O
production	O
in	O
adult	O
dairy	O
cattle	O
.	O

A	O
published	O
meta-analysis	O
demonstrated	O
that	O
overall	O
,	O
producers	O
lose	O
approximately	O
0.35	O
kg	O
of	O
milk	O
per	O
parasitized	O
cow	O
per	O
day	O
.	O

Enzyme-linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
have	O
the	O
ability	O
to	O
quantify	O
nematode	O
infections	O
in	O
cattle	O
,	O
and	O
thus	O
,	O
could	O
be	O
used	O
to	O
estimate	O
the	O
amount	O
of	O
milk	O
production	O
loss	O
due	O
to	O
differing	O
levels	O
of	O
parasitism	O
at	O
the	O
individual	O
cow	O
level	O
.	O

ELISA	O
results	O
from	O
individual	O
cow	O
milk	O
samples	O
were	O
used	O
to	O
predict	O
milk	O
production	O
response	O
following	O
a	O
randomized	O
anthelmintic	O
treatment	O
in	O
a	O
large	O
field	O
trial	O
.	O

To	O
increase	O
statistical	O
power	O
,	O
the	O
data	O
collected	O
from	O
this	O
field	O
trial	O
was	O
pooled	O
with	O
data	O
from	O
two	O
other	O
published	O
field	O
trials	O
to	O
form	O
an	O
individual	O
patient	O
data	O
meta-analysis	O
(	O
IPDMA	O
)	O
.	O

The	O
ability	O
to	O
predict	O
the	O
effect	O
of	O
anthelmintic	O
treatment	O
on	O
milk	O
production	O
depends	O
on	O
the	O
level	O
of	O
parasitism	O
quantified	O
by	O
an	O
ELISA	O
measuring	O
milk	O
antibodies	O
against	O
O.	O
ostertagi	O
,	O
and	O
reported	O
as	O
optical	O
density	O
ratios	O
(	O
ODRs	O
)	O
.	O

Therefore	O
,	O
the	O
estimates	O
from	O
the	O
interaction	O
between	O
ODR	O
and	O
treatment	O
on	O
milk	O
production	O
were	O
used	O
to	O
determine	O
how	O
well	O
the	O
ODR	O
predicted	O
the	O
response	O
of	O
the	O
treatment	O
.	O

It	O
was	O
anticipated	O
that	O
the	O
relationship	O
between	O
milk	O
production	O
and	O
ODR	O
was	O
unlikely	O
to	O
be	O
linear	O
,	O
so	O
fractional	O
polynomials	O
were	O
applied	O
to	O
the	O
continuous	O
ODR	O
values	O
.	O

The	O
interaction	O
in	O
the	O
field	O
trial	O
showed	O
a	O
trend	O
(	O
p=0.138	O
)	O
toward	O
a	O
beneficial	O
treatment	O
effect	O
when	O
the	O
individual	O
ODR	O
values	O
,	O
measured	O
in	O
late	O
lactation	O
and	O
using	O
Svanovir	O
(	O
?	O
)	O
,	O
were	O
greater	O
than	O
0.12	O
.	O

When	O
individual	O
data	O
from	O
two	O
other	O
similar	O
studies	O
were	O
included	O
in	O
an	O
IPDMA	O
,	O
the	O
interaction	O
terms	O
became	O
statistically	O
significant	O
(	O
p=0.009	O
)	O
indicating	O
that	O
there	O
is	O
a	O
beneficial	O
treatment	O
effect	O
when	O
ODR	O
values	O
are	O
slightly	O
elevated	O
.	O

A	O
graph	O
was	O
used	O
to	O
demonstrate	O
the	O
treatment	O
effect	O
(	O
the	O
estimated	O
difference	O
of	O
kg/cow/day	O
of	O
milk	O
yield	O
between	O
the	O
treated	O
and	O
placebo	O
cows	O
)	O
,	O
with	O
95	O
%	O
confidence	O
intervals	O
,	O
as	O
the	O
ODR	O
values	O
increase	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
methods	O
of	O
quantifying	O
the	O
ODR	O
values	O
differed	O
between	O
the	O
three	O
studies	O
in	O
the	O
IPDMA	O
,	O
therefore	O
some	O
caution	O
should	O
be	O
used	O
when	O
using	O
these	O
final	O
estimated	O
values	O
.	O

However	O
,	O
the	O
shape	O
and	O
magnitude	O
of	O
the	O
treatment	O
effects	O
,	O
as	O
well	O
as	O
the	O
other	O
fixed	O
model	O
estimates	O
,	O
were	O
very	O
similar	O
between	O
the	O
field	O
trial	O
and	O
the	O
IPDMA	O
suggesting	O
that	O
any	O
bias	O
would	O
likely	O
be	O
minimal	O
.	O

Prediction	O
of	O
metabolic	O
and	O
cardiopulmonary	O
responses	O
to	O
maximum	O
cycle	O
ergometry	O
:	O
a	O
randomised	O
study	O
.	O

All	O
of	O
the	O
most	O
widely-cited	O
studies	O
for	O
the	O
prediction	O
of	O
maximum	O
exercise	O
responses	O
have	O
utilized	O
either	O
volunteers	O
or	O
referred	O
subjects	O
.	O

Therefore	O
,	O
selection	O
bias	O
,	O
with	O
overestimation	O
of	O
the	O
reference	O
values	O
,	O
is	O
a	O
likely	O
consequence	O
.	O

In	O
order	O
to	O
establish	O
a	O
set	O
of	O
predictive	O
equations	O
for	O
the	O
gas	O
exchange	O
,	O
ventilatory	O
and	O
cardiovascular	O
responses	O
to	O
maximum	O
ramp-incremental	O
cycle	O
ergometry	O
,	O
this	O
study	O
prospectively	O
evaluated	O
120	SampleSize
sedentary	O
individuals	O
(	O
60	SampleSize
males	Sex
,	O
60	SampleSize
females	Sex
,	O
aged	Age
20-80	Age
)	O
,	O
randomly-selected	O
from	O
>	O
8,000	O
subjects	O
.	O

Regular	O
physical	O
activity	O
pattern	O
by	O
questionnaire	O
,	O
body	O
composition	O
by	O
anthropometry	O
and	O
dual	O
energy	O
X-ray	O
absorptiometry	O
(	O
n	O
=	O
75	O
)	O
and	O
knee	O
strength	O
by	O
isokinetic	O
dynamometry	O
were	O
also	O
assessed	O
.	O

Previously	O
reported	O
equations	O
typically	O
overestimated	O
the	O
subjects	O
'	O
peak	O
oxygen	O
uptake	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Prediction	O
linear	O
equations	O
for	O
the	O
main	O
variables	O
of	O
clinical	O
interest	O
were	O
established	O
by	O
backward	O
stepwise	O
regression	O
analysis	O
including	O
:	O
sex	O
,	O
age	O
,	O
knee	O
extensor	O
peak	O
torque	O
,	O
bone-free	O
lean	O
leg	O
mass	O
,	O
total	O
and	O
lean	O
body	O
mass	O
,	O
height	O
,	O
and	O
physical	O
activity	O
scores	O
.	O

Reference	O
intervals	O
(	O
95	O
%	O
confidence	O
limits	O
)	O
were	O
calculated	O
:	O
some	O
of	O
these	O
values	O
differed	O
markedly	O
from	O
those	O
formerly	O
recommended	O
.	O

The	O
results	O
therefore	O
might	O
provide	O
a	O
more	O
appropriate	O
frame	O
of	O
reference	O
for	O
interpretation	O
of	O
the	O
responses	O
to	O
symptom-limited	O
ramp	O
incremental	O
cycle	O
ergometry	O
in	O
sedentary	O
subjects	O
;	O
i.e	O
.	O

those	O
usually	O
referred	O
for	O
clinical	O
cardiopulmonary	O
exercise	O
tests	O
.	O

Controlled	O
trial	O
of	O
induction	O
of	O
labor	O
by	O
vaginal	O
suppositories	O
containing	O
prostaglandin	O
E2	O
.	O

A	O
group	O
of	O
84	O
women	O
at	O
39-43	O
weeks	O
of	O
pregnancy	O
were	O
randomly	O
allocated	O
to	O
a	O
blind	O
trial	O
of	O
induction	O
of	O
labor	O
with	O
vaginal	O
suppositories	O
containing	O
inert	O
material	O
or	O
either	O
0.2	O
mg	O
or	O
0.4	O
mg	O
of	O
prostaglandin	O
E2	O
.	O

The	O
suppositories	O
were	O
self-administered	O
every	O
two	O
hours	O
during	O
waking	O
hours	O
on	O
two	O
successive	O
days	O
until	O
labor	O
started	O
or	O
15	O
had	O
been	O
used	O
.	O

Side-effects	O
were	O
absent	O
.	O

Labor	O
was	O
established	O
within	O
48	O
hr	O
of	O
insertion	O
of	O
the	O
first	O
suppository	O
in	O
9.3	O
%	O
of	O
control	O
patients	O
,	O
65.4	O
%	O
of	O
those	O
treated	O
with	O
0.2	O
mg	O
PGE2	O
and	O
85.7	O
%	O
of	O
those	O
treated	O
with	O
0.4	O
mg	O
PGE2	O
.	O

The	O
mean	O
Apgar	O
scores	O
in	O
the	O
three	O
groups	O
were	O
the	O
same	O
.	O

The	O
mean	O
total	O
dose	O
of	O
PGE2	O
were	O
2.0	O
mg	O
(	O
0.2	O
mg	O
group	O
)	O
and	O
2.3	O
mg	O
(	O
0.4	O
mg	O
group	O
)	O
.	O

It	O
is	O
concluded	O
that	O
vaginal	O
PGE2	O
is	O
an	O
effective	O
and	O
acceptable	O
method	O
of	O
inducing	O
labor	O
at	O
term	O
.	O

Double-blind	O
placebo-controlled	O
trial	O
of	O
aprindine	O
and	O
digoxin	O
for	O
the	O
prevention	O
of	O
symptomatic	Condition
atrial	Condition
fibrillation	Condition
.	O

A	O
multicenter	O
,	O
placebo-controlled	O
,	O
randomized	O
,	O
double-blind	O
trial	O
compared	O
the	O
preventive	O
effect	O
of	O
aprindine	O
and	O
digoxin	O
on	O
the	O
recurrence	O
of	O
atrial	Condition
fibrillation	Condition
(	Condition
AF	Condition
)	O
with	O
placebo	O
,	O
and	O
also	O
compare	O
the	O
effectiveness	O
of	O
these	O
2	O
drugs	O
in	O
the	O
prevention	O
of	O
AF	O
.	O

Patients	O
with	O
symptomatic	Condition
paroxysmal	Condition
or	O
persistent	Condition
AF	Condition
who	O
had	O
converted	O
to	O
sinus	Condition
rhythm	Condition
(	Condition
SR	Condition
)	O
were	O
randomly	O
assigned	O
aprindine	O
(	O
40	O
mg/day	O
)	O
,	O
digoxin	O
(	O
0.25	O
mg/day	O
)	O
or	O
placebo	O
and	O
followed	O
up	O
on	O
an	O
outpatient	O
basis	O
every	O
2	O
weeks	O
for	O
6	O
months	O
.	O

Of	O
the	O
141	SampleSize
patients	O
from	O
36	SampleSize
participating	O
centers	O
,	O
47	SampleSize
were	SampleSize
given	SampleSize
aprindine	SampleSize
,	O
47	SampleSize
digoxin	SampleSize
,	O
and	O
47	SampleSize
were	SampleSize
on	SampleSize
placebo	SampleSize
.	O

After	O
the	O
6-month	O
follow-up	O
,	O
the	O
Kaplan-Meier	O
estimates	O
of	O
the	O
percentage	O
of	O
patients	O
remaining	O
free	O
of	O
recurrent	O
symptomatic	O
AF	O
on	O
aprindine	O
,	O
digoxin	O
and	O
placebo	O
were	O
33.3	O
%	O
,	O
29.2	O
%	O
and	O
21.5	O
%	O
,	O
respectively	O
.	O

In	O
patients	O
remaining	O
in	O
SR	O
for	O
15	O
days	O
after	O
from	O
the	O
start	O
of	O
follow-up	O
,	O
freedom	O
from	O
recurrence	O
was	O
significantly	O
more	O
prevalent	O
in	O
the	O
aprindine	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
p=0.0414	O
)	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
digoxin	O
and	O
placebo	O
groups	O
.	O

The	O
rate	O
of	O
adverse	O
events	O
was	O
similar	O
in	O
the	O
3	O
groups	O
.	O

In	O
conclusion	O
,	O
neither	O
aprindine	O
nor	O
digoxin	O
had	O
a	O
significant	O
effect	O
on	O
preventing	O
relapse	O
of	O
symptomatic	O
AF	O
;	O
however	O
,	O
recurrence	O
of	O
AF	O
occurred	O
later	O
with	O
aprindine	O
than	O
with	O
placebo	O
or	O
digoxin	O
.	O

Theta	O
burst	O
stimulation	O
in	O
the	O
rehabilitation	O
of	O
the	O
upper	O
limb	O
:	O
a	O
semirandomized	O
,	O
placebo-controlled	O
trial	O
in	O
chronic	O
stroke	O
patients	O
.	O

BACKGROUND	O
Noninvasive	O
cortical	O
stimulation	O
could	O
represent	O
an	O
add-on	O
treatment	O
to	O
enhance	O
motor	O
recovery	O
after	O
stroke	O
.	O

However	O
,	O
its	O
clinical	O
value	O
,	O
including	O
anticipated	O
size	O
and	O
duration	O
of	O
the	O
treatment	O
effects	O
,	O
remains	O
largely	O
unknown	O
.	O

OBJECTIVE	O
The	O
authors	O
designed	O
a	O
small	O
semi-randomized	O
clinical	O
trial	O
to	O
explore	O
whether	O
long-lasting	O
clinically	O
important	O
gains	O
can	O
be	O
achieved	O
by	O
adding	O
theta	O
burst	O
stimulation	O
(	O
TBS	O
)	O
,	O
a	O
form	O
of	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
TMS	O
)	O
,	O
to	O
a	O
rehabilitation	O
program	O
for	O
the	O
hand	O
.	O

METHODS	O
A	O
total	O
of	O
41	O
chronic	O
stroke	O
patients	O
received	O
excitatory	O
TBS	O
to	O
the	O
ipsilesional	O
hemisphere	O
or	O
inhibitory	O
TBS	O
to	O
the	O
contralesional	O
hemisphere	O
in	O
2	O
centers	O
;	O
each	O
active	O
group	O
was	O
compared	O
with	O
a	O
group	O
receiving	O
sham	O
TBS	O
.	O

TBS	O
was	O
followed	O
by	O
physical	O
therapy	O
for	O
10	O
working	O
days	O
.	O

Patients	O
and	O
therapists	O
were	O
blinded	O
to	O
the	O
type	O
of	O
TBS	O
.	O

Primary	O
outcome	O
measures	O
(	O
9-hole	O
Peg	O
Test	O
[	O
9HPT	O
]	O
,	O
Jebsen	O
Taylor	O
Test	O
[	O
JTT	O
]	O
,	O
and	O
grip	O
and	O
pinch-grip	O
dynamometry	O
)	O
were	O
assessed	O
4	O
,	O
30	O
,	O
and	O
90	O
days	O
post	O
treatment	O
.	O

The	O
clinically	O
important	O
difference	O
was	O
defined	O
as	O
10	O
%	O
of	O
the	O
maximum	O
score	O
.	O

RESULTS	O
There	O
were	O
no	O
differences	O
between	O
the	O
active	O
treatment	O
and	O
sham	O
groups	O
in	O
any	O
of	O
the	O
outcome	O
measures	O
.	O

All	O
patients	O
achieved	O
small	O
sustainable	O
improvements	O
--	O
9HPT	O
,	O
5	O
%	O
of	O
maximum	O
(	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
3	O
%	O
-7	O
%	O
)	O
;	O
JTT	O
,	O
5.7	O
%	O
(	O
CI	O
=	O
3	O
%	O
-8	O
%	O
)	O
;	O
and	O
grip	O
strength	O
,	O
6	O
%	O
(	O
CI	O
=	O
2	O
%	O
-10	O
%	O
)	O
--	O
all	O
below	O
the	O
defined	O
clinically	O
important	O
level	O
.	O

CONCLUSIONS	O
Cortical	O
stimulation	O
did	O
not	O
augment	O
the	O
gains	O
from	O
a	O
late	O
rehabilitation	O
program	O
.	O

The	O
effect	O
size	O
anticipated	O
by	O
the	O
authors	O
was	O
overestimated	O
.	O

These	O
results	O
can	O
improve	O
the	O
design	O
of	O
future	O
work	O
on	O
therapeutic	O
uses	O
of	O
TMS	O
.	O

[	O
Prevention	O
of	O
vascular	O
complications	O
following	O
cerebral	O
ischemia	O
of	O
arterial	O
origin	O
;	O
the	O
ESPRIT	O
trial	O
:	O
mild	O
anticoagulant	O
therapy	O
,	O
combination	O
treatment	O
with	O
acetylsalicylic	O
acid	O
plus	O
dipyridamole	O
or	O
treatment	O
with	O
acetylsalicylic	O
acid	O
alone	O
?	O
]	O
.	O

The	O
European	O
and	O
Australian	O
Stroke	O
Prevention	O
in	O
Reversible	O
Ischaemia	O
Trial	O
(	O
ESPRIT	O
)	O
is	O
a	O
randomised	O
clinical	O
trial	O
in	O
which	O
patients	Condition
with	Condition
cerebral	Condition
ischaemia	Condition
of	Condition
arterial	Condition
origin	Condition
will	O
be	O
randomised	O
between	O
oral	O
anticoagulation	O
(	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
:	O
2.0-3.0	O
)	O
,	O
the	O
combination	O
of	O
acetylsalicylic	O
acid	O
(	O
in	O
any	O
dose	O
between	O
30	O
and	O
325	O
mg	O
per	O
day	O
)	O
plus	O
dipyridamole	O
(	O
400	O
mg	O
daily	O
)	O
and	O
acetylsalicylic	O
acid	O
only	O
(	O
in	O
any	O
dose	O
between	O
30	O
and	O
325	O
mg	O
per	O
day	O
)	O
.	O

It	O
is	O
planned	O
to	O
enroll	O
4500	O
patients	O
with	O
a	O
mean	O
follow-up	O
of	O
three	O
years	O
.	O

Primary	O
outcome	O
is	O
the	O
composite	O
event	O
of	O
vascular	O
death	O
,	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
or	O
major	O
bleeding	O
complication	O
;	O
outcome	O
assessment	O
will	O
be	O
blinded	O
.	O

ESPRIT	O
is	O
an	O
international	O
,	O
multicentre	O
study	O
in	O
which	O
60-80	O
hospitals	O
in	O
the	O
Netherlands	O
and	O
other	O
countries	O
in	O
Europe	O
and	O
Australia	O
will	O
participate	O
.	O

An	O
open	O
,	O
parallel	O
group	O
comparison	O
of	O
quinapril	O
and	O
captopril	O
,	O
when	O
added	O
to	O
diuretic	O
therapy	O
,	O
in	O
the	O
treatment	O
of	O
elderly	O
patients	O
with	O
heart	O
failure	O
.	O

This	O
study	O
aimed	O
to	O
compare	O
the	O
efficacy	O
,	O
tolerability	O
and	O
first-dose	O
blood-pressure	O
response	O
of	O
once-daily	O
quinapril	O
and	O
twice-daily	O
captopril	O
when	O
added	O
to	O
diuretic	O
therapy	O
in	O
elderly	O
patients	O
with	O
heart	O
failure	O
.	O

The	O
study	O
was	O
performed	O
at	O
a	O
single	O
centre	O
as	O
an	O
open	O
randomised	O
parallel-group	O
study	O
,	O
patients	O
being	O
selected	O
for	O
inclusion	O
from	O
the	O
outpatient	O
population	O
.	O

Following	O
a	O
starting	O
dose	O
of	O
either	O
2.5	O
mg	O
once-daily	O
quinapril	O
,	O
or	O
6.25	O
mg	O
twice-daily	O
captopril	O
,	O
patients	O
were	O
reviewed	O
at	O
two-weekly	O
intervals	O
,	O
and	O
following	O
clinical	O
assessment	O
a	O
decision	O
was	O
made	O
either	O
to	O
titrate	O
up	O
to	O
the	O
next	O
medication	O
stage	O
or	O
to	O
enter	O
the	O
patient	O
into	O
the	O
16-week	O
maintenance	O
phase	O
.	O

Efficacy	O
was	O
assessed	O
using	O
a	O
six-minute	O
walking	O
test	O
,	O
the	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
class	O
,	O
a	O
functional	O
lifescale	O
(	O
FLS	O
)	O
questionnaire	O
and	O
the	O
cardiothoracic	O
ratio	O
(	O
CTR	O
)	O
-at	O
study	O
entry	O
and	O
at	O
the	O
end	O
of	O
the	O
maintenance	O
phase	O
.	O

Blood	O
pressure	O
was	O
measured	O
for	O
5	O
h	O
post-first-dose	O
of	O
medication	O
.	O

Sixty-one	O
patients	O
were	O
randomised	O
to	O
treatment	O
:	O
30	O
to	O
quinapril	O
and	O
31	O
to	O
captopril	O
.	O

Following	O
withdrawals	O
,	O
data	O
from	O
36	O
patients	O
(	O
20	O
on	O
quinapril	O
,	O
16	O
on	O
captopril	O
)	O
were	O
available	O
for	O
analysis	O
.	O

The	O
distance	O
walked	O
during	O
the	O
six-minute	O
walking	O
test	O
improved	O
in	O
both	O
groups	O
;	O
the	O
difference	O
between	O
the	O
treatment	O
groups	O
was	O
not	O
statistically	O
significant	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
FLS	O
or	O
CTR	O
.	O

An	O
analysis	O
of	O
change	O
in	O
the	O
NYHA	O
status	O
from	O
study	O
entry	O
to	O
study	O
end	O
showed	O
a	O
statistically	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
p	O
=	O
0.02	O
)	O
in	O
favour	O
of	O
quinapril	O
.	O

Five	O
patients	O
in	O
each	O
group	O
experienced	O
hypotension	O
during	O
the	O
5	O
h	O
following	O
the	O
first	O
dose	O
of	O
medication	O
.	O

This	O
study	O
has	O
shown	O
heart	O
failure	O
to	O
be	O
as	O
well	O
controlled	O
by	O
once-daily	O
quinapril	O
as	O
by	O
twice-daily	O
captopril	O
,	O
with	O
comparable	O
effects	O
on	O
first-dose	O
blood-pressure	O
response	O
.	O

Racial	O
differences	O
in	O
primary	O
and	O
repeat	O
lower	O
extremity	O
amputation	O
:	O
results	O
from	O
a	O
multihospital	O
study	O
.	O

OBJECTIVE	O
African	O
Americans	O
have	O
a	O
much	O
higher	O
risk	O
of	O
major	O
(	O
above-	O
or	O
below-knee	O
)	O
lower	O
extremity	O
amputation	O
and	O
a	O
lower	O
rate	O
of	O
limb-preserving	O
vascular	O
surgery	O
or	O
angioplasty	O
than	O
white	O
patients	O
.	O

This	O
article	O
analyzes	O
two	O
potential	O
pathways	O
for	O
racial	O
disparities	O
:	O
primary	O
amputation	O
,	O
defined	O
as	O
a	O
major	O
amputation	O
performed	O
without	O
any	O
prior	O
attempt	O
at	O
revascularization	O
,	O
and	O
repeat	O
amputation	O
,	O
defined	O
as	O
a	O
major	O
amputation	O
subsequent	O
to	O
a	O
previous	O
through-foot	O
or	O
major	O
amputation	O
.	O

METHODS	O
Randomly	O
selected	O
medical	O
records	O
were	O
reviewed	O
for	O
248	O
African	O
American	O
,	O
30	O
Hispanic	O
,	O
and	O
235	O
white	O
or	O
other-race	O
patients	O
undergoing	Condition
above-	Condition
or	Condition
below-knee	Condition
amputation	Condition
between	O
1995	O
and	O
2003	O
at	O
three	O
Chicago	O
teaching	O
hospitals	O
.	O

Chronic	O
disease	O
prevalence	O
and	O
severity	O
,	O
preadmission	O
functional	O
status	O
,	O
clinical	O
presentation	O
,	O
and	O
vascular	O
history	O
were	O
used	O
to	O
test	O
the	O
risk-adjusted	O
effect	O
of	O
race	O
and	O
ethnicity	O
on	O
rates	O
of	O
primary	O
and	O
repeat	O
amputation	O
.	O

RESULTS	O
Controlling	O
for	O
demographic	O
,	O
functional	O
,	O
chronic	O
disease	O
,	O
and	O
clinical	O
characteristics	O
,	O
African	O
American	O
patients	O
were	O
1.7	O
times	O
more	O
likely	O
to	O
have	O
undergone	O
both	O
primary	O
(	O
P	O
=	O
.01	O
)	O
and	O
repeat	O
(	O
P	O
=	O
.03	O
)	O
amputation	O
than	O
white	O
or	O
other-race	O
amputees	O
.	O

Race	O
remained	O
a	O
significant	O
independent	O
risk	O
factor	O
even	O
after	O
controlling	O
for	O
the	O
higher	O
severity	O
of	O
illness	O
,	O
greater	O
disability	O
,	O
and	O
more	O
complex	O
presentation	O
of	O
African	O
American	O
amputees	O
.	O

CONCLUSIONS	O
Higher	O
rates	O
of	O
primary	O
and	O
repeat	O
amputation	O
for	O
African	O
American	O
patients	O
at	O
study	O
hospitals	O
,	O
which	O
all	O
have	O
significant	O
vascular	O
surgery	O
capacity	O
and	O
an	O
aggressive	O
policy	O
of	O
limb	O
salvage	O
,	O
suggest	O
that	O
these	O
rates	O
may	O
be	O
even	O
higher	O
at	O
less	O
well	O
equipped	O
institutions	O
.	O

Improving	O
access	O
to	O
primary	O
and	O
preventive	O
care	O
for	O
lower-income	O
patients	O
could	O
reduce	O
amputation	O
rates	O
among	O
African	O
Americans	O
.	O

Position	O
of	O
anterior	O
capsulorhexis	O
and	O
posterior	O
capsule	O
opacification	O
.	O

PURPOSE	O
To	O
evaluate	O
whether	O
the	O
position	O
of	O
the	O
anterior	O
continuous	O
curvilinear	O
capsulorhexis	O
influences	O
the	O
rate	O
of	O
posterior	O
capsule	O
opacification	O
(	O
PCO	O
)	O
.	O

METHODS	O
A	O
total	O
of	O
119	SampleSize
patients	Condition
,	O
aged	O
61-86	Age
years	Age
,	O
underwent	O
cataract	Condition
surgery	Condition
with	O
phacoemulsification	O
performed	O
by	O
a	O
single	O
surgeon	O
.	O

The	O
patients	O
were	O
randomized	O
to	O
implantation	O
with	O
either	O
a	O
silicone	O
intraocular	O
lens	O
(	O
IOL	O
)	O
(	O
SI40NB	O
,	O
Allergan	O
)	O
or	O
an	O
AcrySof	O
IOL	O
(	O
MA60BM	O
,	O
Alcon	O
)	O
.	O

Three	O
years	O
after	O
surgery	O
,	O
the	O
rate	O
of	O
PCO	O
was	O
analysed	O
using	O
the	O
evaluation	O
of	O
posterior	O
capsule	O
opacification	O
computer	O
software	O
(	O
EPCO	O
)	O
.	O

The	O
results	O
were	O
related	O
to	O
the	O
capsulorhexis	O
position	O
,	O
which	O
was	O
assessed	O
with	O
a	O
retroillumination	O
photograph	O
.	O

RESULTS	O
If	O
the	O
capsulorhexis	O
was	O
located	O
partially	O
or	O
completely	O
off	O
the	O
optics	O
of	O
the	O
IOL	O
,	O
compared	O
to	O
totally	O
on	O
the	O
IOL	O
,	O
significantly	O
more	O
PCO	O
was	O
found	O
(	O
p	O
=	O
0.0014	O
)	O
.	O

When	O
comparing	O
within	O
each	O
IOL	O
type	O
,	O
patients	O
with	O
AcrySof	O
IOLs	O
were	O
found	O
to	O
have	O
significantly	O
less	O
PCO	O
when	O
the	O
capsulorhexis	O
was	O
totally	O
on	O
the	O
optic	O
(	O
p	O
=	O
0.0048	O
)	O
.	O

This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
silicone	O
group	O
(	O
p	O
=	O
0.041	O
)	O
.	O

CONCLUSION	O
A	O
relatively	O
small	O
and	O
central	O
capsulorhexis	O
allowing	O
for	O
the	O
complete	O
covering	O
of	O
the	O
IOL	O
optics	O
by	O
the	O
rhexis	O
edges	O
seems	O
to	O
protect	O
against	O
PCO	O
in	O
cataract	O
surgery	O
,	O
with	O
both	O
round-edged	O
silicone	O
IOLs	O
and	O
sharp-edged	O
hydrophobic	O
acrylic	O
IOLs	O
.	O

[	O
The	O
comparison	O
of	O
the	O
effect	O
of	O
enalapril	O
and	O
indapamide	O
on	O
the	O
peripheral	O
blood	O
pressure	O
and	O
central	O
blood	O
pressure	O
through	O
pulse	O
wave	O
analysis	O
]	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
the	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
enalapril	O
and	O
diuretic	O
indapamide	O
on	O
the	O
peripheral	O
blood	O
pressure	O
and	O
the	O
central	O
blood	O
pressure	O
in	O
Chinese	O
patients	O
with	O
essential	O
hypertension	O
.	O

METHODS	O
This	O
study	O
was	O
a	O
double	O
blind	O
,	O
randomized	O
study	O
.	O

Informed	O
consent	O
were	O
given	O
by	O
all	O
patients	O
.	O

After	O
2	O
weeks	O
of	O
placebo	O
run-in	O
period	O
,	O
105	O
patients	O
with	O
mild	O
or	O
moderate	O
essential	O
hypertension	O
were	O
randomized	O
to	O
receive	O
either	O
enalapril	O
(	O
10	O
mg	O
per	O
day	O
)	O
or	O
indapamide	O
(	O
2.5	O
mg	O
per	O
day	O
)	O
for	O
8	O
weeks	O
.	O

Radial	O
pulse	O
wave	O
recordings	O
were	O
performed	O
in	O
all	O
the	O
patients	O
before	O
the	O
active	O
treatments	O
were	O
given	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Only	O
those	O
patients	O
who	O
have	O
finished	O
8	O
weeks	O
of	O
active	O
treatment	O
in	O
both	O
groups	O
were	O
included	O
into	O
the	O
final	O
analysis	O
.	O

RESULTS	O
One	O
hundred	O
one	O
patients	O
(	O
51	O
in	O
enalapril	O
group	O
and	O
50	O
in	O
indapamide	O
group	O
)	O
completed	O
the	O
study	O
.	O

No	O
significant	O
difference	O
(	O
all	O
P	O
values	O
>	O
0.05	O
)	O
was	O
found	O
in	O
baseline	O
data	O
between	O
the	O
two	O
groups	O
.	O

After	O
8	O
weeks	O
of	O
treatment	O
,	O
all	O
the	O
parameters	O
of	O
pulse	O
wave	O
(	O
except	O
heart	O
rates	O
in	O
both	O
groups	O
and	O
augmentation	O
index	O
in	O
indapamide	O
group	O
)	O
decreased	O
significantly	O
.	O

Comparison	O
of	O
the	O
2	O
groups	O
showed	O
that	O
there	O
were	O
no	O
significant	O
differences	O
(	O
all	O
P	O
values	O
>	O
0.05	O
)	O
in	O
all	O
the	O
parameters	O
of	O
pulse	O
wave	O
except	O
that	O
the	O
central	O
systolic	O
blood	O
pressure	O
,	O
augmentation	O
and	O
augmentation	O
index	O
were	O
significantly	O
lower	O
in	O
enalapril	O
group	O
than	O
in	O
indapamide	O
group	O
.	O

In	O
enalapril	O
group	O
,	O
the	O
reduced	O
values	O
of	O
systolic	O
blood	O
pressure	O
and	O
pulse	O
pressure	O
in	O
central	O
aorta	O
were	O
significantly	O
larger	O
than	O
those	O
in	O
brachial	O
artery	O
.	O

However	O
,	O
the	O
difference	O
was	O
not	O
observed	O
in	O
indapamide	O
group	O
.	O

CONCLUSIONS	O
Enalapril	O
and	O
indapamide	O
are	O
both	O
similarly	O
effective	O
in	O
reducing	O
peripheral	O
arterial	O
blood	O
pressure	O
.	O

Moreover	O
,	O
enalapril	O
is	O
more	O
effective	O
in	O
reducing	O
central	O
systolic	O
pressure	O
and	O
augmentation	O
index	O
than	O
indapamide	O
.	O

The	O
difference	O
is	O
probably	O
due	O
to	O
the	O
reduction	O
of	O
wave	O
reflection	O
caused	O
by	O
enalapril	O
.	O

Biochemical	O
and	O
functional	O
effects	O
of	O
creatine	O
phosphate	O
in	O
cardioplegic	O
solution	O
during	O
aortic	O
valve	O
surgery	O
--	O
a	O
clinical	O
study	O
.	O

During	O
myocardial	O
ischemia	O
there	O
is	O
a	O
drop	O
in	O
high-energy	O
phosphates	O
in	O
the	O
myocardium	O
.	O

Cold	O
potassium	O
cardioplegia	O
decreases	O
but	O
does	O
not	O
altogether	O
prevent	O
this	O
reduction	O
.	O

Supplementation	O
of	O
cardioplegic	O
solutions	O
with	O
the	O
high-energy	O
compound	O
creatine	O
phosphate	O
(	O
10	O
mmol/L	O
)	O
compared	O
to	O
plain	O
cardioplegic	O
solutions	O
was	O
investigated	O
in	O
this	O
study	O
.	O

Thirty	O
patients	O
scheduled	O
for	O
aortic	O
valve	O
replacement	O
were	O
included	O
.	O

The	O
patients	O
were	O
randomized	O
to	O
group	O
I	O
(	O
creatine	O
phosphate	O
)	O
or	O
group	O
II	O
(	O
control	O
)	O
.	O

Postoperative	O
hemodynamic	O
evaluation	O
revealed	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

However	O
,	O
group	O
I	O
exhibited	O
a	O
tendency	O
toward	O
a	O
better	O
stroke-work	O
index	O
(	O
135	O
+/-	O
18	O
%	O
vs.	O
102	O
+/-	O
5	O
%	O
recovery	O
15	O
minutes	O
after	O
bypass	O
and	O
145	O
+/-	O
16	O
%	O
vs.	O
119	O
+/-	O
11	O
%	O
recovery	O
105	O
min	O
after	O
bypass	O
)	O
.	O

There	O
were	O
fewer	O
patients	O
in	O
group	O
I	O
(	O
5/15	O
)	O
needing	O
inotropic	O
support	O
compared	O
to	O
group	O
II	O
(	O
9/14	O
)	O
.	O

The	O
myocardial	O
content	O
of	O
ATP	O
and	O
creatine	O
phosphate	O
showed	O
no	O
significant	O
differences	O
during	O
ischemia	O
and	O
reperfusion	O
.	O

It	O
is	O
concluded	O
that	O
the	O
myocardial	O
protection	O
during	O
ischemia	O
was	O
sufficient	O
to	O
prevent	O
significant	O
reductions	O
of	O
myocardial	O
ATP	O
and	O
creatine	O
phosphate	O
irrespective	O
of	O
supplementation	O
with	O
CP	O
.	O

[	O
Intra-uterine	O
insemination	O
with	O
controlled	O
ovarian	O
hyperstimulation	O
compared	O
to	O
an	O
expectant	O
management	O
in	O
couples	O
with	O
unexplained	Condition
subfertility	Condition
and	O
an	O
intermediate	O
prognosis	O
:	O
a	O
randomised	O
study	O
]	O
.	O

OBJECTIVE	O
Intrauterine	O
insemination	O
(	O
IUI	O
)	O
with	O
controlled	O
ovarian	O
hyperstimulation	O
(	O
COH	O
)	O
is	O
commonly	O
used	O
as	O
treatment	O
of	O
first	O
choice	O
in	O
couples	O
with	O
unexplained	Condition
subfertility	Condition
.	O

This	O
treatment	O
should	O
only	O
be	O
applied	O
when	O
there	O
is	O
a	O
realistic	O
increase	O
in	O
chance	O
of	O
pregnancy	O
,	O
particularly	O
because	O
it	O
carries	O
the	O
increased	O
risk	O
of	O
multiple	O
pregnancies	O
.	O

We	O
evaluated	O
the	O
effectiveness	O
of	O
IUI	O
with	O
COH	O
relative	O
to	O
expectant	O
management	O
in	O
couples	O
with	O
unexplained	Condition
subfertility	Condition
and	O
an	O
intermediate	O
prognosis	O
of	O
a	O
spontaneous	O
ongoing	O
pregnancy	O
.	O

DESIGN	O
Multicentre	O
randomised	O
clinical	O
study	O
.	O

METHOD	O
253	SampleSize
couples	O
with	O
unexplained	Condition
subfertility	Condition
and	O
a	O
probability	O
of	O
a	O
spontaneous	O
ongoing	O
pregnancy	O
of	O
30	O
%	O
to	O
40	O
%	O
within	O
12	O
months	O
,	O
were	O
randomly	O
assigned	O
to	O
IUI	O
with	O
COH	O
for	O
6	O
months	O
or	O
expectant	O
management	O
for	O
6	O
months	O
.	O

The	O
primary	O
endpoint	O
of	O
our	O
study	O
was	O
ongoing	O
pregnancy	O
within	O
6	O
months	O
.	O

Analysis	O
was	O
carried	O
out	O
according	O
to	O
the	O
intention	O
to	O
treat	O
principle	O
.	O

This	O
study	O
was	O
registered	O
with	O
the	O
Dutch	O
Trial	O
Register	O
and	O
has	O
the	O
International	O
Standard	O
Randomised	O
Clinical	O
Trial	O
number	O
ISRCTN72675518	O
.	O

RESULTS	O
Of	O
the	O
253	O
couples	O
included	O
,	O
127	O
couples	O
were	O
allocated	O
to	O
IUI	O
with	O
COH	O
and	O
126	O
to	O
expectant	O
management	O
.	O

In	O
the	O
intervention	O
group	O
,	O
42	O
women	O
(	O
33	O
%	O
)	O
conceived	O
,	O
of	O
which	O
29	O
pregnancies	O
were	O
ongoing	O
(	O
23	O
%	O
)	O
.	O

In	O
the	O
expectant	O
management	O
group	O
,	O
40	O
women	O
(	O
32	O
%	O
)	O
conceived	O
,	O
of	O
which	O
34	O
pregnancies	O
were	O
ongoing	O
(	O
27	O
%	O
)	O
(	O
relative	O
risk	O
:	O
0.85	O
;	O
95	O
%	O
CI	O
:	O
0.63-1.1	O
)	O
.	O

In	O
the	O
expectant	O
management	O
group	O
one	O
twin	O
pregnancy	O
occurred	O
and	O
in	O
the	O
intervention	O
group	O
one	O
woman	O
conceived	O
twins	O
and	O
one	O
a	O
triplet	O
.	O

CONCLUSION	O
A	O
substantial	O
beneficial	O
effect	O
of	O
IUI	O
with	O
COH	O
in	O
couples	O
with	O
unexplained	O
subfertility	O
and	O
an	O
intermediate	O
prognosis	O
can	O
be	O
excluded	O
.	O

Expectant	O
management	O
for	O
a	O
period	O
of	O
6	O
months	O
therefore	O
appears	O
justified	O
in	O
these	O
couples	O
.	O

[	O
Diphtheria	O
antitoxin	O
level	O
2	O
years	O
after	O
booster	O
vaccination	O
]	O
.	O

In	O
a	O
prospective	O
,	O
controlled	O
,	O
randomized	O
,	O
multicenter	O
study	O
the	O
immunogenicity	O
of	O
a	O
single	O
(	O
day	O
0	O
)	O
and	O
two	O
(	O
day	O
0	O
,	O
28	O
)	O
booster	O
vaccination	O
against	O
diphtheria	O
were	O
compared	O
in	O
subjects	Condition
who	Condition
had	Condition
received	Condition
their	Condition
last	Condition
diphtheria	Condition
vaccination	Condition
more	Condition
than	Condition
10	Condition
years	Condition
ago	Condition
.	Condition

Both	O
short-term	O
and	O
long-term	O
immunogenicity	O
was	O
assessed	O
by	O
determining	O
diphtheria	O
antitoxin	O
levels	O
four	O
weeks	O
after	O
vaccination	O
and	O
after	O
one	O
and	O
two	O
years	O
.	O

102	O
subjects	O
received	O
the	O
first	O
booster	O
vaccination	O
,	O
and	O
83	O
were	O
vaccinated	O
twice	O
.	O

Prior	O
to	O
the	O
first	O
vaccination	O
27	O
%	O
of	O
the	O
subjects	O
had	O
a	O
diphtheria	O
antitoxin	O
level	O
below	O
0.01	O
I.U./ml	O
;	O
after	O
the	O
first	O
booster	O
only	O
5	O
%	O
were	O
unprotected	O
.	O

The	O
second	O
booster	O
did	O
not	O
show	O
a	O
significant	O
effect	O
,	O
however	O
,	O
in	O
1	O
of	O
the	O
5	O
subjects	O
who	O
were	O
still	O
unprotected	O
after	O
the	O
first	O
booster	O
the	O
second	O
elicited	O
an	O
antitoxin	O
level	O
of	O
more	O
than	O
0.01	O
I.U./ml	O
.	O

After	O
one	O
and	O
two	O
years	O
7	O
%	O
and	O
8	O
%	O
of	O
the	O
subjects	O
had	O
diphtheria	O
antitoxin	O
level	O
below	O
0.01	O
I.U./ml	O
.	O

A	O
serological	O
effect	O
of	O
a	O
second	O
booster	O
vaccination	O
four	O
weeks	O
after	O
the	O
first	O
one	O
could	O
not	O
be	O
demonstrated	O
neither	O
after	O
one	O
nor	O
after	O
two	O
years	O
.	O

Randomised	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
study	O
of	O
fluticasone	O
propionate	O
in	O
patients	O
with	O
moderate	Condition
to	Condition
severe	Condition
chronic	Condition
obstructive	Condition
pulmonary	Condition
disease	Condition
:	O
the	O
ISOLDE	O
trial	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
effect	O
of	O
long	O
term	O
inhaled	O
corticosteroids	O
on	O
lung	O
function	O
,	O
exacerbations	O
,	O
and	O
health	O
status	O
in	O
patients	O
with	O
moderate	Condition
to	Condition
severe	Condition
chronic	Condition
obstructive	Condition
pulmonary	Condition
disease	Condition
.	O

DESIGN	O
Double	O
blind	O
,	O
placebo	O
controlled	O
study	O
.	O

SETTING	O
Eighteen	O
UK	O
hospitals	O
.	O

PARTICIPANTS	O
751	Condition
men	Sex
and	O
women	Sex
aged	O
between	O
40	O
and	O
75	O
years	O
with	O
mean	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV	O
(	O
1	O
)	O
)	O
50	O
%	O
of	O
predicted	O
normal	O
.	O

INTERVENTIONS	O
Inhaled	O
fluticasone	O
propionate	O
500	O
microgram	O
twice	O
daily	O
from	O
a	O
metered	O
dose	O
inhaler	O
or	O
identical	O
placebo	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Efficacy	O
measures	O
:	O
rate	O
of	O
decline	O
in	O
FEV	O
(	O
1	O
)	O
after	O
the	O
bronchodilator	O
and	O
in	O
health	O
status	O
,	O
frequency	O
of	O
exacerbations	O
,	O
respiratory	O
withdrawals	O
.	O

Safety	O
measures	O
:	O
morning	O
serum	O
cortisol	O
concentration	O
,	O
incidence	O
of	O
adverse	O
events	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
annual	O
rate	O
of	O
decline	O
in	O
FEV	O
(	O
1	O
)	O
(	O
P=0.16	O
)	O
.	O

Mean	O
FEV	O
(	O
1	O
)	O
after	O
bronchodilator	O
remained	O
significantly	O
higher	O
throughout	O
the	O
study	O
with	O
fluticasone	O
propionate	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Median	O
exacerbation	O
rate	O
was	O
reduced	O
by	O
25	O
%	O
from	O
1.32	O
a	O
year	O
on	O
placebo	O
to	O
0.99	O
a	O
year	O
on	O
with	O
fluticasone	O
propionate	O
(	O
P=0.026	O
)	O
.	O

Health	O
status	O
deteriorated	O
by	O
3.2	O
units	O
a	O
year	O
on	O
placebo	O
and	O
2.0	O
units	O
a	O
year	O
on	O
fluticasone	O
propionate	O
(	O
P=0.0043	O
)	O
.	O

Withdrawals	O
because	O
of	O
respiratory	O
disease	O
not	O
related	O
to	O
malignancy	O
were	O
higher	O
in	O
the	O
placebo	O
group	O
(	O
25	O
%	O
v	O
19	O
%	O
,	O
P=0.034	O
)	O
.	O

CONCLUSIONS	O
Fluticasone	O
propionate	O
500	O
microgram	O
twice	O
daily	O
did	O
not	O
affect	O
the	O
rate	O
of	O
decline	O
in	O
FEV	O
(	O
1	O
)	O
but	O
did	O
produce	O
a	O
small	O
increase	O
in	O
FEV	O
(	O
1	O
)	O
.	O

Patients	O
on	O
fluticasone	O
propionate	O
had	O
fewer	O
exacerbations	O
and	O
a	O
slower	O
decline	O
in	O
health	O
status	O
.	O

These	O
improvements	O
in	O
clinical	O
outcomes	O
support	O
the	O
use	O
of	O
this	O
treatment	O
in	O
patients	O
with	O
moderate	Condition
to	Condition
severe	Condition
chronic	Condition
obstructive	Condition
pulmonary	Condition
disease	Condition
.	O

Effects	O
of	O
large	O
doses	O
of	O
arachidonic	O
acid	O
added	O
to	O
docosahexaenoic	O
acid	O
on	O
social	Condition
impairment	Condition
in	Condition
individuals	Condition
with	Condition
autism	Condition
spectrum	Condition
disorders	Condition
:	Condition
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
randomized	O
trial	O
.	O

Autism	O
spectrum	O
disorders	O
are	O
a	O
neurodevelopmental	O
disorders	O
with	O
reduced	O
cortical	O
functional	O
connectivity	O
relating	O
to	O
social	O
cognition	O
.	O

Polyunsaturated	O
fatty	O
acids	O
arachidonic	O
acid	O
(	O
ARA	O
)	O
and	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
may	O
have	O
key	O
role	O
in	O
brain	O
network	O
maturation	O
.	O

In	O
particularly	O
,	O
ARA	O
is	O
important	O
in	O
signal	O
transduction	O
related	O
to	O
neuronal	O
maturation	O
.	O

Supplementation	O
with	O
larger	O
ARA	O
doses	O
added	O
to	O
DHA	O
may	O
therefore	O
mitigate	O
social	O
impairment	O
.	O

In	O
a	O
16-week	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
,	O
we	O
evaluated	O
the	O
efficacy	O
of	O
supplementation	O
with	O
large	O
doses	O
of	O
ARA	O
added	O
to	O
DHA	O
(	O
n	O
=	O
7	O
)	O
or	O
placebo	O
(	O
n	O
=	O
6	O
)	O
in	O
13	O
participants	O
(	O
mean	O
age	O
,	O
14.6	O
[	O
SD	O
,	O
5.9	O
]	O
years	O
)	O
.	O

To	O
examine	O
underlying	O
mechanisms	O
underlying	O
the	O
effect	O
of	O
our	O
supplementation	O
regimen	O
,	O
we	O
examined	O
plasma	O
levels	O
of	O
antioxidants	O
transferrin	O
and	O
superoxide	O
dismutase	O
,	O
which	O
are	O
useful	O
markers	O
of	O
signal	O
transduction	O
.	O

The	O
outcome	O
measures	O
were	O
the	O
Social	O
Responsiveness	O
Scale	O
and	O
the	O
Aberrant	O
Behavior	O
Checklist-Community	O
.	O

Repeated-measures	O
analysis	O
of	O
variance	O
revealed	O
that	O
our	O
supplementation	O
regimen	O
significantly	O
improved	O
Aberrant	O
Behavior	O
Checklist-Community-measured	O
social	O
withdrawal	O
and	O
Social	O
Responsiveness	O
Scale-measured	O
communication	O
.	O

Treatment	O
effect	O
sizes	O
were	O
more	O
favorable	O
for	O
the	O
treatment	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
communication	O
:	O
treatment	O
groups	O
,	O
0.87	O
vs	O
,	O
placebo	O
,	O
0.44	O
;	O
social	O
withdrawal	O
:	O
treatment	O
groups	O
,	O
0.88	O
,	O
vs	O
placebo	O
,	O
0.54	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
change	O
in	O
plasma	O
transferrin	O
levels	O
and	O
a	O
trend	O
toward	O
a	O
significant	O
difference	O
in	O
the	O
change	O
in	O
plasma	O
superoxide	O
dismutase	O
levels	O
between	O
the	O
2	O
groups	O
.	O

This	O
preliminary	O
study	O
suggests	O
that	O
supplementation	O
with	O
larger	O
ARA	O
doses	O
added	O
to	O
DHA	O
improves	O
impaired	O
social	O
interaction	O
in	O
individuals	O
with	O
autism	O
spectrum	O
disorder	O
by	O
up-regulating	O
signal	O
transduction	O
.	O

Prevalence	O
and	O
treatment	O
outcome	O
of	O
cervicitis	Condition
of	O
unknown	O
etiology	O
.	O

BACKGROUND	O
Mucopurulent	O
cervicitis	O
(	O
MPC	O
)	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
mucopurulent	O
discharge	O
from	O
the	O
cervix	O
and	O
other	O
signs	O
of	O
inflammation	O
.	O

This	O
was	O
a	O
phase	O
III	O
,	O
multicenter	O
study	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
placebo	O
versus	O
empiric	O
antibiotic	O
treatment	O
for	O
clinical	O
cure	O
of	O
MPC	O
of	O
unknown	O
etiology	O
at	O
2-month	O
follow-up	O
.	O

Unfortunately	O
,	O
enrollment	O
was	O
terminated	O
because	O
of	O
low	O
accrual	O
of	O
women	O
with	O
cervicitis	O
of	O
unknown	O
etiology	O
,	O
but	O
important	O
prevalence	O
and	O
outcome	O
data	O
were	O
obtained	O
.	O

METHODS	O
Five	SampleSize
hundred	SampleSize
seventy-seven	SampleSize
women	O
were	O
screened	O
for	O
MPC	Condition
.	Condition

Women	O
with	O
MPC	O
were	O
randomized	O
to	O
the	O
treatment	O
or	O
placebo	O
arm	O
of	O
the	O
study	O
,	O
and	O
the	O
2	O
arms	O
were	O
evaluated	O
based	O
on	O
the	O
etiology	O
,	O
clinical	O
cure	O
rates	O
,	O
adverse	O
events	O
(	O
AEs	O
)	O
,	O
and	O
rates	O
of	O
pelvic	O
inflammatory	O
disease	O
.	O

RESULTS	O
One	SampleSize
hundred	SampleSize
thirty-one	SampleSize
(	O
23	O
%	O
[	O
131/577	O
]	O
)	O
screened	O
women	O
were	O
found	O
to	O
have	O
MPC	O
.	O

Eighty-seven	SampleSize
were	O
enrolled	O
and	O
randomized	O
.	O

After	O
excluding	O
women	O
with	O
sexually	O
transmitted	O
infections	O
and	O
other	O
exclusions	O
,	O
61	O
%	O
(	O
53/87	O
)	O
had	O
cervicitis	O
of	O
unknown	O
etiology	O
.	O

The	O
overall	O
clinical	O
failure	O
rate	O
was	O
30	O
%	O
(	O
10/33	O
)	O
,	O
and	O
the	O
clinical	O
cure	O
rate	O
was	O
only	O
24	O
%	O
(	O
8/33	O
)	O
.	O

Rates	O
were	O
not	O
significantly	O
different	O
between	O
the	O
arms	O
.	O

There	O
were	O
24	O
gastrointestinal	O
AEs	O
in	O
the	O
treatment	O
arm	O
compared	O
with	O
1	O
AE	O
in	O
the	O
placebo	O
arm	O
.	O

CONCLUSIONS	O
More	O
than	O
half	O
of	O
the	O
cases	O
of	O
MPC	O
were	O
of	O
unknown	O
etiology	O
.	O

Clinical	O
cure	O
rates	O
for	O
the	O
placebo	O
and	O
treatment	O
arms	O
were	O
extremely	O
low	O
,	O
with	O
most	O
women	O
concluding	O
the	O
study	O
with	O
a	O
partial	O
response	O
.	O

Gastrointestinal	O
AEs	O
were	O
higher	O
in	O
the	O
treatment	O
arm	O
.	O

Evaluation	O
of	O
three	O
dosage-prediction	O
methods	O
for	O
initial	O
in-hospital	O
stabilization	O
of	O
warfarin	O
therapy	O
.	O

Three	O
dosage-prediction	O
methods	O
for	O
initial	O
in-hospital	O
stabilization	O
of	O
warfarin	O
therapy	O
were	O
evaluated	O
.	O

Adult	O
inpatients	O
who	O
had	O
received	O
warfarin	O
sodium	O
10	O
mg	O
daily	O
for	O
less	O
than	O
three	O
days	O
were	O
eligible	O
for	O
the	O
study	O
.	O

After	O
receiving	O
their	O
third	O
warfarin	O
dose	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
have	O
their	O
warfarin	O
dosages	O
adjusted	O
using	O
one	O
of	O
three	O
dosage-prediction	O
methods	O
:	O
by	O
analog	O
computer	O
(	O
n	O
=	O
31	O
)	O
,	O
linear	O
regression	O
(	O
n	O
=	O
22	O
)	O
,	O
or	O
empiric	O
dosing	O
by	O
the	O
physician	O
(	O
n	O
=	O
34	O
)	O
.	O

A	O
prothrombin	O
time	O
(	O
PT	O
)	O
ratio	O
(	O
patient	O
PT	O
divided	O
by	O
control	O
PT	O
)	O
between	O
1.3	O
and	O
2.5	O
was	O
considered	O
to	O
be	O
in	O
the	O
therapeutic	O
range	O
.	O

For	O
patients	O
who	O
achieved	O
a	O
stable	O
PT	O
ratio	O
(	O
defined	O
as	O
a	O
PT	O
ratio	O
between	O
1.3	O
and	O
2.5	O
that	O
varied	O
by	O
less	O
than	O
0.05	O
on	O
two	O
consecutive	O
days	O
or	O
by	O
less	O
than	O
0.1	O
on	O
three	O
consecutive	O
days	O
without	O
a	O
dosage	O
change	O
)	O
before	O
discharge	O
,	O
the	O
number	O
of	O
days	O
(	O
time	O
to	O
stabilization	O
)	O
from	O
administration	O
of	O
the	O
first	O
warfarin	O
dose	O
to	O
achievement	O
of	O
the	O
warfarin	O
dosage	O
that	O
produced	O
a	O
stable	O
PT	O
ratio	O
(	O
stabilization	O
dosage	O
)	O
was	O
compared	O
.	O

A	O
total	O
of	O
54	O
patients	O
met	O
the	O
study	O
criteria	O
for	O
a	O
stable	O
PT	O
ratio	O
before	O
hospital	O
discharge	O
(	O
analog	O
computer	O
,	O
n	O
=	O
20	O
;	O
linear	O
regression	O
,	O
n	O
=	O
15	O
;	O
empiric	O
dosing	O
,	O
n	O
=	O
19	O
)	O
.	O

The	O
mean	O
times	O
to	O
stabilization	O
were	O
6.8	O
days	O
in	O
the	O
analog-computer	O
group	O
,	O
7.3	O
days	O
in	O
the	O
linear-regression	O
group	O
,	O
and	O
8.4	O
days	O
in	O
the	O
empiric-dosing	O
group	O
;	O
these	O
times	O
were	O
not	O
significantly	O
different	O
.	O

All	O
20	O
stabilized	O
patients	O
in	O
the	O
analog-computer	O
group	O
achieved	O
a	O
stable	O
PT	O
ratio	O
by	O
the	O
fourth	O
dosage	O
prediction	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Slotted	O
versus	O
non-slotted	O
locked	O
intramedullary	O
nailing	O
for	O
femoral	O
shaft	O
fractures	O
.	O

Experimentally	O
,	O
two	O
slotted	O
nails	O
,	O
the	O
Grosse-Kempf	O
nail	O
and	O
the	O
AO/ASIF	O
universal	O
femoral	O
nail	O
,	O
were	O
compared	O
to	O
the	O
non-slotted	O
Grosse-Kempf	O
nail	O
and	O
control	O
bone	O
using	O
a	O
cadaver	Condition
femoral	Condition
osteotomy	Condition
.	O

The	O
stiffnesses	O
and	O
strengths	O
of	O
the	O
osteotomies	O
fixed	O
with	O
slotted	O
nails	O
in	O
10-30	O
degrees	O
torsion	O
were	O
6-8	O
%	O
and	O
the	O
values	O
of	O
non-slotted	O
nails	O
40	O
%	O
of	O
control	O
bone	O
.	O

The	O
maximal	O
moments	O
were	O
14-18	O
%	O
and	O
48	O
%	O
,	O
respectively	O
.	O

In	O
the	O
clinical	O
range	O
of	O
torsion	O
,	O
the	O
implant-bone	O
construct	O
never	O
failed	O
or	O
was	O
deformed	O
.	O

Clinically	O
,	O
46	SampleSize
femoral	Condition
shaft	Condition
fractures	Condition
were	O
randomized	O
to	O
treatment	O
with	O
Gross-Kempf	O
nails	O
,	O
24	SampleSize
with	O
slotted	Condition
nails	Condition
and	O
22	SampleSize
with	O
non-slotted	Condition
nails	Condition
.	O

Four	O
complications	O
in	O
the	O
slotted	O
nail	O
group	O
and	O
three	O
in	O
the	O
non-slotted	O
nail	O
group	O
were	O
considered	O
to	O
be	O
independent	O
of	O
the	O
choice	O
of	O
nail	O
and	O
did	O
not	O
affect	O
the	O
end	O
result	O
.	O

Three	O
splinterings	O
of	O
the	O
distal	O
fragment	O
,	O
one	O
resulting	O
in	O
a	O
change	O
of	O
the	O
osteosynthesis	O
implant	O
to	O
a	O
condylar	O
plate	O
,	O
were	O
considered	O
to	O
result	O
from	O
the	O
high	O
stiffness	O
of	O
the	O
non-slotted	O
nail	O
.	O

Osteosynthesis	O
of	O
femoral	O
shaft	O
fractures	O
using	O
slotted	O
nails	O
has	O
not	O
resulted	O
in	O
healing	O
disturbances	O
,	O
which	O
could	O
be	O
accounted	O
for	O
by	O
the	O
high	O
torsional	O
elasticity	O
of	O
the	O
nail	O
;	O
there	O
seems	O
to	O
be	O
no	O
indication	O
for	O
high-stiffness	O
nails	O
in	O
femoral	Condition
fractures	Condition
.	O

Effects	O
of	O
pyridostigmine	O
and	O
naloxone	O
on	O
the	O
abnormal	O
TSH	O
response	O
to	O
TRH	O
during	O
starvation	O
in	O
humans	O
.	O

BACKGROUND	O
Starvation	O
is	O
associated	O
with	O
a	O
blunted	O
TSH	O
response	O
to	O
thyrotropin-releasing	O
hormone	O
(	O
TRH	O
)	O
(	O
peak	O
minus	O
baseline	O
<	O
5	O
mIU/L	O
)	O
,	O
despite	O
basal	O
TSH	O
and	O
thyroid	O
hormone	O
levels	O
within	O
the	O
normal	O
range	O
.	O

In	O
light	O
of	O
the	O
inhibitory	O
effect	O
of	O
somatostatin	O
on	O
TSH	O
secretion	O
,	O
we	O
examined	O
whether	O
this	O
condition	O
is	O
caused	O
by	O
an	O
increased	O
hypothalamic	O
somatostatinergic	O
tone	O
in	O
starving	Condition
subjects	Condition
.	O

The	O
possible	O
involvement	O
of	O
endogenous	O
opioids	O
in	O
the	O
mechanism	O
underlying	O
the	O
abnormal	O
TSH	O
response	O
to	O
TRH	O
was	O
also	O
evaluated	O
.	O

METHODS	O
The	O
TSH	O
response	O
to	O
TRH	O
(	O
25	O
micrograms	O
in	O
an	O
intravenous	O
bolus	O
)	O
,	O
serum	O
total	O
and	O
free	O
T4	O
and	O
T3	O
levels	O
,	O
and	O
24-hour	O
urinary-free	O
cortisol	O
levels	O
were	O
measured	O
in	O
28	O
normal	Condition
men	O
(	O
age	O
27-35	O
years	O
)	O
within	O
10	O
%	O
of	O
their	O
ideal	O
body	O
weight	O
.	O

They	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
of	O
7	O
.	O

In	O
21	O
subjects	O
(	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
,	O
TRH	O
tests	O
were	O
performed	O
after	O
an	O
overnight	O
(	O
8	O
hours	O
)	O
fast	O
,	O
placebo	O
administrations	O
(	O
control	O
test	O
)	O
,	O
and	O
after	O
prolonged	O
(	O
56	O
hours	O
)	O
starvation	O
.	O

TRH	O
tests	O
after	O
prolonged	O
starvation	O
were	O
performed	O
either	O
after	O
placebos	O
(	O
in	O
all	O
subjects	O
)	O
or	O
the	O
administration	O
of	O
pyridostigmine	O
(	O
180	O
mg	O
orally	O
)	O
(	O
in	O
7	O
subjects	O
,	O
group	O
1	O
)	O
;	O
naloxone	O
(	O
0.8	O
mg	O
in	O
an	O
i.v	O
.	O

bolus	O
injection	O
)	O
(	O
in	O
7	O
subjects	O
,	O
group	O
2	O
)	O
;	O
or	O
the	O
combination	O
of	O
pyridostigmine	O
and	O
naloxone	O
(	O
in	O
7	O
subjects	O
,	O
group	O
3	O
)	O
.	O

The	O
remaining	O
7	O
subjects	O
(	O
group	O
4	O
)	O
were	O
tested	O
at	O
weekly	O
intervals	O
with	O
TRH	O
plus	O
placebo	O
,	O
TRH	O
plus	O
naloxone	O
,	O
TRH	O
plus	O
pyridostigmine	O
,	O
and	O
TRH	O
plus	O
naloxone	O
plus	O
pyridostigmine	O
after	O
a	O
fasting	O
period	O
of	O
8	O
hours	O
.	O

RESULTS	O
In	O
all	O
subjects	O
of	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
TRH-induced	O
TSH	O
rise	O
was	O
significantly	O
lower	O
after	O
prolonged	O
starvation	O
than	O
after	O
overnight	O
fast	O
.	O

Neither	O
pyridostigmine	O
nor	O
naloxone	O
,	O
given	O
alone	O
,	O
changed	O
the	O
basal	O
levels	O
of	O
TSH	O
and	O
the	O
TSH	O
response	O
to	O
TRH	O
after	O
prolonged	O
starvation	O
.	O

In	O
contrast	O
,	O
the	O
concomitant	O
administration	O
of	O
naloxone	O
and	O
pyridostigmine	O
significantly	O
enhanced	O
the	O
TRH-induced	O
TSH	O
rise	O
.	O

After	O
overnight	O
fasting	O
,	O
naloxone	O
administration	O
in	O
group	O
4	O
subjects	O
did	O
not	O
change	O
the	O
TSH	O
response	O
to	O
TRH	O
,	O
whereas	O
pyridostigmine	O
significantly	O
enhanced	O
the	O
TSH	O
response	O
to	O
TRH	O
.	O

When	O
naloxone	O
was	O
given	O
together	O
with	O
pyridostigmine	O
and	O
TRH	O
the	O
TSH	O
response	O
was	O
similar	O
to	O
that	O
observed	O
in	O
the	O
TRH	O
plus	O
pyridostigmine	O
test	O
.	O

CONCLUSIONS	O
These	O
data	O
indicate	O
that	O
naloxone-sensitive	O
endogenous	O
opioids	O
exert	O
an	O
inhibitory	O
effect	O
on	O
the	O
cholinergic	O
stimulatory	O
control	O
of	O
TSH	O
secretion	O
during	O
prolonged	O
starvation	O
.	O

This	O
suggests	O
that	O
an	O
enhanced	O
hypothalamic	O
somatostatinergic	O
activity	O
is	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
reduced	O
TSH	O
response	O
to	O
TRH	O
.	O

Blockade	O
of	O
cytotoxic	O
T-lymphocyte	O
antigen-4	O
by	O
ipilimumab	O
results	O
in	O
dysregulation	O
of	O
gastrointestinal	O
immunity	O
in	O
patients	O
with	O
advanced	O
melanoma	Condition
.	O

Blockade	O
of	O
cytotoxic	O
T-lymphocyte	O
antigen-4	O
(	O
CTLA-4	O
)	O
by	O
ipilimumab	O
leads	O
to	O
immune-mediated	O
tumor	O
regression	O
and	O
immune-related	O
adverse	O
events	O
(	O
irAEs	O
)	O
,	O
including	O
diarrhea	O
and	O
colitis	O
.	O

The	O
current	O
analyses	O
were	O
undertaken	O
to	O
promote	O
an	O
understanding	O
of	O
the	O
underlying	O
mechanism	O
of	O
action	O
and	O
to	O
identify	O
potential	O
biomarkers	O
that	O
could	O
help	O
in	O
the	O
prediction	O
and	O
management	O
of	O
ipilimumab-induced	O
gastrointestinal	O
irAEs	O
.	O

Treatment-na?ve	O
or	O
previously	O
treated	O
patients	O
with	O
unresectable	O
stage	O
III/IV	O
melanoma	O
(	O
n	O
=	O
115	O
)	O
received	O
open-label	O
ipilimumab	O
(	O
10	O
mg/kg	O
every	O
3	O
weeks	O
for	O
four	O
doses	O
)	O
and	O
were	O
randomized	O
to	O
receive	O
concomitant	O
blinded	O
prophylactic	O
oral	O
budesonide	O
(	O
9	O
mg/d	O
with	O
gradual	O
taper	O
through	O
week	O
16	O
)	O
or	O
placebo	O
.	O

Outcome	O
measures	O
included	O
histologic	O
assessment	O
of	O
bowel	O
biopsies	O
and	O
assessment	O
of	O
serologic	O
markers	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
,	O
fecal	O
calprotectin	O
levels	O
,	O
and	O
polymorphisms	O
in	O
immune-related	O
genes	O
.	O

Ipilimumab	O
resulted	O
in	O
dysregulation	O
of	O
gastrointestinal	O
mucosal	O
immunity	O
as	O
evidenced	O
by	O
altered	O
antibody	O
levels	O
to	O
enteric	O
flora	O
,	O
inflammatory	O
cell	O
infiltration	O
into	O
gastrointestinal	O
mucosa	O
,	O
and	O
increased	O
fecal	O
calprotectin	O
associated	O
with	O
diarrhea	O
and	O
clinical	O
evidence	O
of	O
colitis	O
.	O

The	O
pattern	O
of	O
ipilimumab-induced	O
antibody	O
titers	O
to	O
microbial	O
flora	O
and	O
the	O
histologic	O
features	O
and	O
location	O
of	O
the	O
inflammation	O
were	O
distinct	O
from	O
classic	O
IBD	O
.	O

Prophylactic	O
budesonide	O
did	O
not	O
prevent	O
ipilimumab-induced	O
bowel	O
inflammation	O
.	O

Despite	O
an	O
observed	O
association	O
between	O
colonic	O
inflammation	O
and	O
grade	O
2	O
or	O
higher	O
diarrhea	O
,	O
no	O
baseline	O
biomarkers	O
could	O
reliably	O
predict	O
development	O
of	O
gastrointestinal	O
toxicity	O
.	O

Although	O
classic	O
IBD	O
and	O
ipilimumab-related	O
gastrointestinal	O
toxicity	O
are	O
both	O
immune	O
mediated	O
,	O
the	O
observed	O
pattern	O
of	O
biomarkers	O
suggests	O
ipilimumab-related	O
gastrointestinal	O
toxicity	O
may	O
be	O
a	O
distinct	O
clinicopathologic	O
entity	O
.	O

Carbenicillin-trimethoprim/sulfamethoxazole	O
versus	O
carbenicillin-gentamicin	O
as	O
empiric	O
therapy	O
of	O
infection	O
in	O
granulocytopenic	Condition
patients	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

The	O
results	O
of	O
therapy	O
with	O
carbenicillin	O
plus	O
trimethoprim-sulfamethoxazole	O
(	O
C-T/S	O
)	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
carbenicillin	O
plus	O
gentamicin	O
(	O
C-G	O
)	O
in	O
a	O
prospective	O
double-blind	O
study	O
of	O
empiric	O
antibiotic	O
therapy	O
in	O
granulocytopenic	Condition
patients	O
.	O

Patients	O
were	O
stratified	O
into	O
two	SampleSize
groups	O
:	O
favorable-prognosis	O
,	O
group	SampleSize
1	SampleSize
(	O
carcinoma	Condition
,	O
lymphoma	Condition
,	O
multiple	Condition
myeloma	Condition
)	O
,	O
or	O
unfavorable-prognosis	O
,	O
group	SampleSize
2	SampleSize
(	O
acute	Condition
leukemia	Condition
,	O
bone	Condition
marrow	Condition
transplantation	Condition
)	O
,	O
based	O
on	O
anticipated	O
duration	O
of	O
granulocytopenia	Condition
.	O

Over-all	O
,	O
empiric	O
antibiotic	O
trials	O
were	O
more	O
often	O
successful	O
(	O
P	O
=	O
0.004	O
)	O
in	O
group	O
1	O
(	O
55	O
of	O
62	O
patients	O
or	O
89	O
per	O
cent	O
)	O
than	O
in	O
group	O
2	O
(	O
42	O
of	O
64	O
patients	O
,	O
66	O
per	O
cent	O
)	O
mwithin	O
group	O
1	O
,	O
there	O
was	O
a	O
favorable	O
outcome	O
in	O
30	O
of	O
32	O
(	O
94	O
per	O
cent	O
)	O
C-T/S	O
trials	O
and	O
in	O
25	O
of	O
30	O
(	O
83	O
per	O
cent	O
)	O
C-G	O
trials	O
(	O
P	O
=	O
0.25	O
)	O
;	O
within	O
group	O
2	O
,	O
there	O
was	O
a	O
favorable	O
outcome	O
in	O
23	O
of	O
30	O
(	O
77	O
per	O
cent	O
)	O
C-T/S	O
trials	O
and	O
in	O
19	O
of	O
34	O
(	O
56	O
per	O
cent	O
)	O
C-G	O
trials	O
(	O
P	O
=	O
0.14	O
)	O
,	O
Combined	O
results	O
in	O
both	O
groups	O
indicated	O
a	O
higher	O
proportion	O
of	O
favorable	O
outcome	O
in	O
C-T/S	O
trials	O
(	O
53	O
of	O
62	O
,	O
85	O
per	O
cent	O
)	O
than	O
in	O
C-G	O
trials	O
(	O
44	O
of	O
64	O
,	O
69	O
per	O
cent	O
)	O
.	O

Further	O
analysis	O
(	O
Manetl-Naenszel	O
test	O
)	O
showed	O
the	O
over-all	O
difference	O
in	O
outcome	O
to	O
be	O
significant	O
(	O
P	O
=	O
0.049	O
)	O
,	O
but	O
the	O
general	O
applicability	O
of	O
this	O
result	O
may	O
be	O
limited	O
by	O
the	O
rather	O
low	O
incidence	O
of	O
gram-negative	O
bacterial	O
infections	O
in	O
this	O
study	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
treatment	O
regimens	O
in	O
antibiotic	O
toxicity	O
,	O
and	O
serious	O
superinfection	O
occurred	O
only	O
in	O
group	O
2	O
patients	O
(	O
21	O
per	O
cent	O
of	O
trials	O
)	O
,	O
equally	O
divided	O
between	O
treatment	O
arms	O
.	O

Initial	O
protocol	O
dosing	O
achieved	O
target	O
plasma	O
levels	O
of	O
trimethoprim	O
(	O
3	O
to	O
8	O
micrograms/ml	O
)	O
or	O
gentamicin	O
(	O
4	O
to	O
10	O
micrograms/ml	O
)	O
in	O
57	O
of	O
68	O
(	O
84	O
per	O
cent	O
)	O
C-T/S	O
trials	O
compared	O
to	O
21	O
of	O
60	O
(	O
35	O
per	O
cent	O
)	O
C-G	O
trials	O
.	O

Cimetidine	O
as	O
an	O
immunomodulator	O
in	O
the	O
treatment	O
of	O
herpes	O
zoster	O
.	O

As	O
there	O
is	O
evidence	O
of	O
a	O
possible	O
immunoregulatory	O
role	O
for	O
H2-histamine	O
receptor	O
antagonists	O
,	O
we	O
carried	O
out	O
a	O
prospective	O
randomized	O
trial	O
to	O
evaluate	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
effect	O
of	O
cimetidine	O
,	O
an	O
H2-blocker	O
,	O
in	O
the	O
treatment	O
of	O
herpes	O
zoster	O
infection	O
.	O

Cimetidine	O
treatment	O
shortened	O
the	O
median	O
interval	O
until	O
the	O
first	O
decrease	O
in	O
pain	O
,	O
the	O
median	O
interval	O
until	O
the	O
complete	O
resolution	O
of	O
pain	O
and	O
promoted	O
faster	O
complete	O
healing	O
of	O
skin	O
lesions	O
than	O
symptomatic	O
treatment	O
.	O

The	O
immunological	O
trends	O
observed	O
in	O
vitro	O
support	O
an	O
important	O
role	O
for	O
histamine	O
in	O
the	O
induction	O
of	O
immunosuppression	O
,	O
as	O
measured	O
by	O
the	O
response	O
to	O
the	O
mitogen	O
phytohemagglutinin	O
.	O

This	O
effect	O
of	O
histamine	O
was	O
antagonized	O
by	O
cimetidine	O
.	O

Double-blind	O
placebo-controlled	O
trial	O
of	O
secretin	O
:	O
effects	O
on	O
aberrant	O
behavior	O
in	O
children	O
with	O
autism	O
.	O

Secretin	O
has	O
been	O
proposed	O
as	O
a	O
treatment	O
alternative	O
for	O
autistic	O
spectrum	O
disorders	O
,	O
but	O
empirical	O
support	O
is	O
lacking	O
.	O

A	O
double-blind	O
placebo-controlled	O
study	O
examined	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
synthetic	O
human	O
secretin	O
on	O
aberrant	O
behavior	O
.	O

Parent	O
and	O
teacher	O
data	O
from	O
the	O
Aberrant	O
Behavior	O
Checklist	O
for	O
eight	O
male	O
children	O
were	O
analyzed	O
for	O
reliable	O
change	O
in	O
a	O
clinical	O
replication	O
series	O
.	O

By	O
parent	O
and	O
teacher	O
report	O
,	O
the	O
majority	O
of	O
change	O
occurred	O
either	O
on	O
the	O
placebo	O
trial	O
or	O
reflected	O
deterioration	O
subsequent	O
to	O
secretin	O
infusion	O
.	O

Repeated-measures	O
multivariate	O
analysis	O
of	O
variance	O
results	O
were	O
similar	O
.	O

Results	O
are	O
consistent	O
with	O
other	O
studies	O
,	O
suggesting	O
that	O
secretin	O
may	O
not	O
be	O
an	O
effective	O
treatment	O
option	O
.	O

Adjuvant	O
subcutaneous	O
interleukin-2	O
in	O
patients	O
with	O
resected	O
renal	O
cell	O
carcinoma	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
A	O
pilot	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
toxicity	O
and	O
tolerance	O
to	O
low-dose	O
subcutaneous	O
interleukin-2	O
(	O
IL-2	O
)	O
for	O
patients	O
with	O
resected	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
at	O
high	O
risk	O
for	O
recurrent	O
disease	O
(	O
TNM	O
stages	O
III	O
and	O
IV	O
resected	O
distant	O
metastases	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
surgically	O
resected	O
locally	O
advanced	O
(	O
T3-4	O
or	O
N1-2	O
)	O
or	O
metastatic	O
RCC	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
4	O
treatment	O
groups	O
that	O
received	O
different	O
dose	O
levels	O
and	O
schedules	O
of	O
subcutaneous	O
IL-2	O
as	O
follows	O
:	O
dose	O
level	O
1	O
,	O
4	O
MIU/m2	O
per	O
day	O
,	O
every	O
other	O
week	O
for	O
24	O
weeks	O
(	O
n	O
=	O
10	O
)	O
;	O
dose	O
level	O
2	O
,	O
8	O
MIU/m2	O
per	O
day	O
,	O
every	O
other	O
week	O
for	O
24	O
weeks	O
(	O
n	O
=	O
9	O
)	O
;	O
dose	O
level	O
3	O
,	O
4	O
MIU/m2	O
per	O
day	O
,	O
weeks	O
1-4	O
,	O
9-12	O
,	O
and	O
17-20	O
(	O
n	O
=	O
11	O
)	O
;	O
and	O
dose	O
level	O
4	O
,	O
8	O
MIU/m2	O
per	O
day	O
,	O
weeks	O
1-4	O
,	O
9-12	O
,	O
and	O
17-20	O
(	O
n	O
=	O
10	O
)	O
.	O

Interleukin-2	O
was	O
administered	O
in	O
2	O
daily	O
doses	O
on	O
days	O
1-5	O
of	O
each	O
week	O
indicated	O
.	O

A	O
dose	O
level	O
was	O
considered	O
tolerable	O
if	O
no	O
more	O
than	O
2	O
patients	O
experienced	O
grade	O
3/4	O
toxicity	O
.	O

RESULTS	O
Forty-one	O
patients	O
were	O
entered	O
in	O
the	O
study	O
and	O
40	O
were	O
evaluable	O
for	O
toxicity	O
.	O

Therapy	O
was	O
well	O
tolerated	O
at	O
all	O
dose	O
levels	O
and	O
schedules	O
,	O
with	O
most	O
patients	O
(	O
98	O
%	O
)	O
experiencing	O
mild-to-moderate	O
constitutional	O
symptoms	O
.	O

Grade	O
3/4	O
toxicity	O
was	O
seen	O
in	O
8	O
patients	O
(	O
20	O
%	O
)	O
.	O

Interleukin-2	O
dose	O
reductions	O
were	O
required	O
in	O
7	O
patients	O
,	O
and	O
no	O
patient	O
discontinued	O
therapy	O
secondary	O
to	O
toxicity	O
.	O

Of	O
39	O
patients	O
evaluable	O
for	O
efficacy	O
,	O
31	O
have	O
experienced	O
relapse	O
(	O
79	O
%	O
)	O
,	O
and	O
15	O
have	O
died	O
(	O
38	O
%	O
)	O
.	O

Median	O
survival	O
was	O
1.4	O
years	O
,	O
and	O
the	O
3-year	O
disease-free	O
survival	O
rate	O
was	O
33	O
%	O
.	O

Median	O
overall	O
survival	O
has	O
not	O
been	O
reached	O
;	O
however	O
,	O
the	O
3-year	O
survival	O
rate	O
was	O
70	O
%	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
any	O
of	O
the	O
treatment	O
arms	O
with	O
respect	O
to	O
disease-free	O
survival	O
or	O
3-year	O
survival	O
(	O
P	O
>	O
0.54	O
and	O
P	O
>	O
or=	O
0.09	O
for	O
all	O
pairwise	O
comparisons	O
)	O
,	O
schedules	O
(	O
dose	O
level	O
1/2	O
vs.	O
3/4	O
;	O
P	O
=	O
0.46	O
and	O
P	O
=	O
0.5	O
)	O
,	O
or	O
dose	O
of	O
IL-2	O
administered	O
(	O
dose	O
level	O
1/3	O
vs.	O
2/4	O
;	O
P	O
=	O
0.99	O
and	O
P	O
=	O
0.1	O
)	O
.	O

CONCLUSION	O
Subcutaneous	O
IL-2	O
was	O
well	O
tolerated	O
for	O
6	O
months	O
in	O
patients	O
with	O
surgically	O
resected	O
RCC	O
at	O
high	O
risk	O
of	O
recurrence	O
.	O

Future	O
adjuvant	O
trials	O
in	O
this	O
setting	O
are	O
not	O
likely	O
to	O
include	O
IL-2	O
in	O
view	O
of	O
the	O
clinical	O
efficacy	O
and	O
favorable	O
toxicity	O
profiles	O
of	O
selected	O
multitargeted	O
kinase	O
inhibitors	O
.	O

Monotherapy	O
of	O
mild	Condition
hypertension	Condition
with	O
nifedipine	O
.	O

The	O
effectiveness	O
of	O
nifedipine	O
as	O
first-line	O
monotherapy	O
for	O
mild	Condition
diastolic	Condition
hypertension	Condition
(	O
range	O
:	O
95	O
to	O
105	O
mm	O
Hg	O
)	O
was	O
tested	O
in	O
this	O
placebo-controlled	O
,	O
double-blind	O
,	O
randomized	O
trial	O
.	O

Fifty-six	SampleSize
patients	O
were	O
enrolled	O
and	O
,	O
after	O
titration	O
of	O
the	O
placebo	O
or	O
active	O
drug	O
,	O
they	O
were	O
followed	O
for	O
12	O
weeks	O
.	O

Significant	O
declines	O
in	O
the	O
sitting	O
systolic	O
and	O
diastolic	O
pressures	O
of	O
-19	O
+/-	O
4	O
mm	O
Hg	O
(	O
standard	O
error	O
)	O
and	O
-13	O
+/-	O
2	O
mm	O
Hg	O
,	O
respectively	O
,	O
were	O
observed	O
during	O
this	O
follow-up	O
period	O
.	O

Overall	O
,	O
75	O
percent	O
of	O
patients	O
receiving	O
active	O
drug	O
had	O
diastolic	O
pressures	O
less	O
than	O
or	O
equal	O
to	O
90	O
mm	O
Hg	O
at	O
the	O
last	O
treatment	O
visit	O
.	O

Heart	O
rate	O
was	O
not	O
significantly	O
changed	O
in	O
the	O
sitting	O
position	O
during	O
the	O
treatment	O
period	O
,	O
and	O
the	O
majority	O
of	O
patients	O
(	O
75	O
percent	O
)	O
showed	O
a	O
response	O
to	O
nifedipine	O
doses	O
of	O
10	O
or	O
20	O
mg	O
orally	O
three	O
times	O
daily	O
in	O
the	O
capsule	O
form	O
.	O

The	O
levels	O
of	O
the	O
systolic	O
and	O
diastolic	O
pressures	O
at	O
entry	O
were	O
not	O
predictive	O
of	O
the	O
dose	O
of	O
nifedipine	O
required	O
for	O
effective	O
blood	O
pressure	O
control	O
.	O

Biochemical	O
markers	O
as	O
predictors	O
of	O
bone	O
mineral	O
density	O
changes	O
after	O
GnRH	O
agonist	O
treatment	O
.	O

To	O
evaluate	O
bone	O
biochemical	O
markers	O
as	O
predictors	O
of	O
the	O
efficacy	O
of	O
a	O
hormone	O
replacement	O
therapy	O
(	O
HRT	O
)	O
,	O
we	O
studied	O
the	O
bone	O
changes	O
induced	O
by	O
the	O
cessation	O
and	O
return	O
of	O
ovarian	O
function	O
in	O
28	O
patients	O
treated	O
for	O
6	O
months	O
with	O
a	O
GnRH	O
agonist	O
.	O

This	O
model	O
reproduced	O
the	O
effects	O
observed	O
in	O
postmenopausal	O
women	O
with	O
high	O
bone	O
turnover	O
treated	O
with	O
HRT	O
.	O

At	O
the	O
end	O
of	O
the	O
treatment	O
,	O
Z	O
scores	O
were	O
1.8	O
+/-	O
0.3	O
for	O
Crosslaps	O
(	O
CTx	O
)	O
and	O
deoxypyridinoline	O
(	O
D-Pyr	O
)	O
,	O
and	O
1.1	O
+/-	O
0.2	O
for	O
bone	O
alkaline	O
phosphatase	O
(	O
B-ALP	O
)	O
and	O
osteocalcin	O
(	O
OC	O
)	O
.	O

This	O
indicated	O
an	O
imbalance	O
in	O
bone	O
remodeling	O
with	O
a	O
high	O
bone	O
resorption	O
.	O

Bone	O
mineral	O
density	O
(	O
BMD	O
)	O
fell	O
by	O
4.2	O
+/-	O
2.5	O
%	O
.	O

The	O
changes	O
in	O
BMD	O
between	O
the	O
6th	O
and	O
12th	O
months	O
were	O
0	O
.	O

34	O
+/-	O
2.24	O
and	O
-1.73	O
+/-	O
3.25	O
%	O
at	O
the	O
lumbar	O
spine	O
and	O
the	O
femoral	O
neck	O
,	O
respectively	O
.	O

Biochemical	O
markers	O
except	O
urinary	O
calcium	O
and	O
hydroxyproline	O
measured	O
at	O
6	O
months	O
were	O
positively	O
correlated	O
with	O
the	O
BMD	O
changes	O
at	O
the	O
lumbar	O
spine	O
.	O

After	O
the	O
resumption	O
of	O
menstruation	O
,	O
13	O
of	O
28	O
women	O
displayed	O
positive	O
spine	O
BMD	O
changes	O
between	O
the	O
6th	O
and	O
12th	O
months	O
;	O
in	O
this	O
group	O
,	O
bone	O
biochemical	O
markers	O
measured	O
at	O
6	O
months	O
were	O
significantly	O
higher	O
(	O
P	O
=	O
0.02	O
)	O
.	O

Stepwise	O
regression	O
analysis	O
showed	O
that	O
the	O
association	O
of	O
B-ALP	O
and	O
D-Pyr	O
measured	O
at	O
6	O
months	O
explained	O
40	O
%	O
of	O
BMD	O
variance	O
and	O
the	O
association	O
of	O
B-ALP	O
,	O
PTH	O
,	O
and	O
estradiol	O
56	O
%	O
.	O

We	O
conclude	O
that	O
measuring	O
individual	O
biochemical	O
bone	O
markers	O
can	O
help	O
to	O
predict	O
the	O
bone	O
effect	O
of	O
an	O
increase	O
in	O
the	O
circulating	O
estradiol	O
in	O
women	O
with	O
ovarian	O
deficiency	O
.	O

Evaluation	O
of	O
hypertensive	Condition
patients	O
after	O
care	O
provided	O
by	O
community	O
pharmacists	O
in	O
a	O
rural	O
setting	O
.	O

We	O
evaluated	O
blood	O
pressure	O
control	O
,	O
quality	O
of	O
life	O
,	O
quality	O
of	O
care	O
,	O
and	O
satisfaction	O
of	O
patients	O
who	O
were	O
monitored	O
by	O
specially	O
trained	O
community	O
pharmacists	O
in	O
a	O
group	O
medical	O
practice	O
.	O

After	O
participating	O
in	O
an	O
intensive	O
skill	O
development	O
program	O
,	O
pharmacists	O
performed	O
in	O
an	O
interdisciplinary	O
team	O
in	O
a	O
rural	O
clinic	O
.	O

The	O
primary	O
objective	O
was	O
assessed	O
by	O
evaluating	O
outcome	O
variables	O
at	O
6	O
months	O
compared	O
with	O
baseline	O
in	O
25	SampleSize
patients	O
randomly	O
assigned	O
to	O
a	O
study	O
group	O
.	O

A	O
control	O
group	O
of	O
26	SampleSize
patients	O
was	O
also	O
evaluated	O
to	O
determine	O
if	O
outcome	O
variables	O
remained	O
constant	O
from	O
baseline	O
to	O
6	O
months	O
.	O

Systolic	O
blood	O
pressure	O
was	O
reduced	O
in	O
the	O
study	O
group	O
(	O
151	O
mm	O
Hg	O
baseline	O
,	O
140	O
mm	O
Hg	O
at	O
6	O
mo	O
,	O
p	O
<	O
0.001	O
)	O
and	O
diastolic	O
blood	O
pressure	O
was	O
significantly	O
lower	O
at	O
2	O
,	O
4	O
,	O
and	O
5	O
months	O
compared	O
with	O
baseline	O
.	O

Ratings	O
from	O
a	O
blinded	O
peer	O
review	O
panel	O
indicated	O
significant	O
improvement	O
in	O
the	O
appropriateness	O
of	O
the	O
blood	O
pressure	O
regimen	O
,	O
going	O
from	O
8.7	O
+/-	O
4.7	O
to	O
10.9	O
+/-	O
4.5	O
in	O
the	O
study	O
group	O
(	O
p	O
<	O
0.01	O
)	O
,	O
but	O
they	O
did	O
not	O
change	O
in	O
the	O
control	O
group	O
.	O

Several	O
quality	O
of	O
life	O
scores	O
improved	O
significantly	O
in	O
the	O
study	O
group	O
after	O
6	O
months	O
(	O
p	O
<	O
0.05	O
)	O
.	O

These	O
included	O
physical	O
functioning	O
(	O
61.6	O
vs	O
70.7	O
)	O
,	O
physical	O
role	O
limitations	O
(	O
56.8	O
vs	O
72.8	O
)	O
,	O
and	O
bodily	O
pain	O
(	O
60.0	O
vs	O
71.7	O
)	O
at	O
baseline	O
and	O
6	O
months	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
control	O
group	O
.	O

Patient	O
satisfaction	O
scores	O
were	O
consistently	O
higher	O
in	O
the	O
study	O
group	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Our	O
results	O
indicate	O
that	O
when	O
community	O
pharmacists	O
in	O
a	O
clinic	O
setting	O
are	O
trained	O
and	O
included	O
as	O
members	O
of	O
the	O
primary	O
care	O
team	O
,	O
significant	O
improvements	O
in	O
blood	O
pressure	O
control	O
,	O
quality	O
of	O
life	O
,	O
and	O
patient	O
satisfaction	O
can	O
be	O
achieved	O
.	O

Dofequidar	O
fumarate	O
(	O
MS-209	O
)	O
in	O
combination	O
with	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
fluorouracil	O
for	O
patients	O
with	O
advanced	Condition
or	Condition
recurrent	Condition
breast	Condition
cancer	Condition
.	O

PURPOSE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
dofequidar	O
plus	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
fluorouracil	O
(	O
CAF	O
)	O
therapy	O
in	O
comparison	O
with	O
CAF	O
alone	O
,	O
in	O
patients	O
with	O
advanced	Condition
or	Condition
recurrent	Condition
breast	Condition
cancer	Condition
.	O

Dofequidar	O
is	O
a	O
novel	O
,	O
orally	O
active	O
quinoline	O
derivative	O
that	O
reverses	O
multidrug	O
resistance	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
this	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
,	O
patients	O
were	O
treated	O
with	O
six	O
cycles	O
of	O
CAF	O
therapy	O
:	O
28	O
days/cycle	O
,	O
with	O
doxorubicin	O
(	O
25	O
mg/m2	O
)	O
and	O
fluorouracil	O
(	O
500	O
mg/m2	O
)	O
administered	O
on	O
days	O
1	O
and	O
8	O
and	O
cyclophosphamide	O
(	O
100	O
mg	O
orally	O
[	O
PO	O
]	O
)	O
administered	O
on	O
day	O
1	O
through	O
14	O
.	O

Patients	O
received	O
dofequidar	O
(	O
900	O
mg	O
PO	O
)	O
30	O
minutes	O
before	O
each	O
dose	O
of	O
doxorubicin	O
.	O

Primary	O
end	O
point	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
;	O
partial	O
or	O
complete	O
response	O
)	O
.	O

In	O
total	O
,	O
221	SampleSize
patients	O
were	O
assessable	O
.	O

RESULTS	O
ORR	O
was	O
42.6	O
%	O
for	O
CAF	O
compared	O
with	O
53.1	O
%	O
for	O
dofequidar	O
+	O
CAF	O
,	O
a	O
24.6	O
%	O
relative	O
improvement	O
and	O
10.5	O
%	O
absolute	O
increase	O
(	O
P	O
=	O
.077	O
)	O
.	O

There	O
was	O
a	O
trend	O
for	O
prolonged	O
progression-free	O
survival	O
(	O
PFS	O
;	O
median	O
241	O
days	O
for	O
CAF	O
v	O
366	O
days	O
for	O
dofequidar	O
+	O
CAF	O
;	O
P	O
=	O
.145	O
)	O
.	O

In	O
retrospectively	O
defined	O
subgroups	O
,	O
significant	O
improvement	O
in	O
PFS	O
in	O
favor	O
of	O
dofequidar	O
was	O
observed	O
in	O
patients	O
who	O
were	O
premenopausal	Condition
,	O
had	O
no	Condition
prior	Condition
therapy	Condition
,	O
and	O
were	O
stage	O
IV	O
at	O
diagnosis	O
with	O
an	O
intact	Condition
primary	Condition
tumor	Condition
.	O

Except	O
for	O
neutropenia	O
and	O
leukopenia	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
excess	O
of	O
grade	O
3/4	O
adverse	O
events	O
compared	O
with	O
CAF	O
.	O

Treatment	O
with	O
dofequidar	O
did	O
not	O
affect	O
the	O
plasma	O
concentration	O
of	O
doxorubicin	O
.	O

CONCLUSION	O
Dofequidar	O
+	O
CAF	O
was	O
well	O
tolerated	O
and	O
is	O
suggested	O
to	O
have	O
efficacy	O
in	O
patients	O
who	O
had	O
not	Condition
received	Condition
prior	Condition
therapy	Condition
.	O

Evaluation	O
of	O
a	O
preventive	O
intervention	O
for	O
child	Age
anxiety	Condition
in	O
two	O
randomized	O
attention-control	O
school	O
trials	O
.	O

The	O
present	O
research	O
examined	O
the	O
effectiveness	O
of	O
a	O
cognitive-behavioral	O
therapy	O
(	O
CBT	O
)	O
based	O
intervention	O
program	O
,	O
FRIENDS	O
,	O
for	O
children	Age
from	O
grades	O
4	O
to	O
6	O
,	O
using	O
random	O
assignment	O
at	O
the	O
school-level	O
and	O
an	O
attention-control	O
design	O
in	O
two	O
longitudinal	O
studies	O
.	O

The	O
first	O
study	O
targeted	O
children	Age
with	O
anxiety	Condition
symptoms	O
(	O
N=191	SampleSize
,	O
mean	O
age=10.1	Age
)	O
as	O
screened	O
with	O
self	O
,	O
parent	O
,	O
and	O
teacher-reports	O
;	O
the	O
second	O
study	O
took	O
a	O
universal	O
approach	O
with	O
full	O
classrooms	O
of	O
children	O
participating	O
(	O
N=253	SampleSize
,	O
mean	O
age=9.8	Age
)	O
.	O

The	O
results	O
showed	O
no	O
intervention	O
effect	O
in	O
both	O
studies	O
,	O
with	O
children	O
's	O
anxiety	O
symptoms	O
decreasing	O
over	O
time	O
regardless	O
of	O
whether	O
they	O
were	O
in	O
the	O
story-reading	O
(	O
attention	O
control	O
)	O
or	O
FRIENDS	O
condition	O
.	O

The	O
findings	O
also	O
indicated	O
that	O
girls	O
reported	O
a	O
higher	O
level	O
of	O
anxiety	O
than	O
boys	O
and	O
children	O
in	O
higher	O
grades	O
reported	O
lower	O
anxiety	O
relative	O
to	O
younger	O
children	O
in	O
both	O
studies	O
.	O

In	O
addition	O
,	O
similar	O
patterns	O
were	O
found	O
using	O
a	O
subgroup	O
of	O
children	O
with	O
high-anxiety	O
symptoms	O
from	O
both	O
studies	O
.	O

Utilization	O
of	O
health	O
care	O
services	O
by	O
patients	O
with	O
chronic	Condition
obstructive	Condition
pulmonary	Condition
disease	Condition
.	O

In	O
order	O
to	O
identify	O
healthcare	O
resource	O
use	O
patterns	O
associated	O
with	O
chronic	Condition
obstructive	Condition
pulmonary	Condition
disease	Condition
(	O
COPD	Condition
)	O
,	O
resource	O
utilization	O
(	O
RU	O
)	O
data	O
collection	O
was	O
integrated	O
into	O
a	O
randomized	O
,	O
double-blind	O
placebo-controlled	O
study	O
of	O
Viozan	O
(	O
sibenadet	O
HCl	O
)	O
.	O

This	O
study	O
enrolled	O
patients	O
with	O
symptomatic	Condition
,	Condition
smoking-related	Condition
COPD	Condition
,	O
randomized	O
to	O
receive	O
sibenadet	O
or	O
placebo	O
for	O
a	O
52-week	O
treatment	O
period	O
.	O

A	O
questionnaire	O
establishing	O
typical	O
pre-trial	O
,	O
COPD-related	O
RU	O
was	O
completed	O
by	O
each	O
patient	O
.	O

Subsequent	O
data	O
were	O
collected	O
by	O
means	O
of	O
an	O
Interactive	O
Voice	O
Response	O
System	O
(	O
IVRS	O
)	O
at	O
30-day	O
intervals	O
(	O
14	O
time	O
points	O
)	O
during	O
the	O
study	O
and	O
in	O
the	O
follow-up	O
period	O
.	O

The	O
IVRS	O
system	O
facilitated	O
data	O
collection	O
and	O
minimized	O
inconvenience	O
to	O
the	O
patient	O
.	O

Compliance	O
with	O
the	O
requirement	O
to	O
record	O
details	O
of	O
the	O
healthcare	O
services	O
during	O
the	O
year-long	O
study	O
was	O
high	O
.	O

No	O
overall	O
trend	O
for	O
lower	O
RU	O
was	O
associated	O
with	O
sibenadet	O
therapy	O
,	O
which	O
correlates	O
with	O
the	O
lack	O
of	O
sustained	O
clinical	O
effect	O
seen	O
in	O
studies	O
conducted	O
concurrently	O
.	O

These	O
data	O
do	O
,	O
however	O
,	O
provide	O
valuable	O
information	O
on	O
RU	O
associated	O
with	O
COPD	O
and	O
insights	O
into	O
adjustments	O
associated	O
with	O
changes	O
in	O
disease	O
course	O
.	O

Physicians	O
were	O
seen	O
to	O
be	O
the	O
most	O
common	O
source	O
of	O
care	O
for	O
patients	O
with	O
COPD	O
and	O
more	O
of	O
the	O
patients	O
with	O
severe	Condition
COPD	Condition
(	Condition
stage	Condition
III	Condition
)	Condition
than	O
mild	Condition
(	Condition
stage	Condition
I	Condition
)	Condition
were	O
seen	O
to	O
utilize	O
the	O
most	O
expensive	O
resources	O
(	O
e.g	O
.	O

inpatient	O
hospital	O
care	O
)	O
.	O

For	O
those	O
patients	O
who	O
experienced	O
an	O
exacerbation	O
during	O
the	O
trial	O
(	O
irrespective	O
of	O
treatment	O
group	O
)	O
,	O
resource	O
use	O
was	O
increased	O
during	O
the	O
periods	O
when	O
an	O
exacerbation	O
was	O
reported	O
when	O
compared	O
with	O
the	O
periods	O
before	O
or	O
after	O
an	O
exacerbation	O
.	O

The	O
proportion	O
of	O
cases	O
attending	O
the	O
physician	O
doubled	O
and	O
with	O
a	O
trip	O
to	O
the	O
Emergency	O
Room	O
(	O
ER	O
)	O
increased	O
approximately	O
ninefold	O
during	O
the	O
reporting	O
period	O
in	O
which	O
the	O
exacerbation	O
occurred	O
compared	O
with	O
the	O
previous	O
month	O
.	O

This	O
study	O
has	O
shown	O
that	O
use	O
of	O
an	O
IVRS	O
,	O
even	O
in	O
elderly	Age
patients	O
,	O
is	O
an	O
effective	O
means	O
of	O
gathering	O
RU	O
data	O
over	O
long	O
periods	O
.	O

The	O
study	O
findings	O
suggest	O
that	O
the	O
advent	O
of	O
effective	O
therapeutic	O
interventions	O
,	O
particularly	O
any	O
with	O
the	O
ability	O
to	O
minimize	O
exacerbations	O
and	O
limit	O
disease	O
progression	O
,	O
could	O
impact	O
on	O
the	O
health	O
care	O
services	O
used	O
and	O
potentially	O
reduce	O
associated	O
costs	O
.	O

Effect	O
of	O
gemfibrozil	O
on	O
change	O
in	O
renal	O
function	O
in	O
men	Sex
with	O
moderate	Condition
chronic	Condition
renal	Condition
insufficiency	Condition
and	O
coronary	Condition
disease	Condition
.	O

BACKGROUND	O
Limited	O
data	O
suggest	O
that	O
low	O
levels	O
of	O
serum	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
)	O
and	O
high	O
levels	O
of	O
triglyceride-rich	O
lipoproteins	O
may	O
be	O
associated	O
with	O
more	O
rapid	O
rates	O
of	O
kidney	O
function	O
loss	O
in	O
individuals	O
with	O
chronic	Condition
renal	Condition
insufficiency	Condition
(	Condition
CRI	Condition
)	Condition
.	O

Although	O
fibric	O
acid	O
derivatives	O
increase	O
serum	O
HDL-C	O
levels	O
and	O
decrease	O
triglyceride	O
levels	O
,	O
their	O
effects	O
on	O
renal	O
function	O
are	O
largely	O
unknown	O
.	O

We	O
conducted	O
this	O
study	O
to	O
determine	O
whether	O
gemfibrozil	O
reduced	O
rates	O
of	O
renal	O
function	O
loss	O
in	O
people	O
with	O
moderate	Condition
CRI	Condition
.	O

METHODS	O
This	O
was	O
a	O
post	O
hoc	O
subgroup	O
analysis	O
in	O
the	O
Veterans	O
Affairs	O
High-Density	O
Lipoprotein	O
Intervention	O
Trial	O
,	O
a	O
randomized	O
double-blind	O
trial	O
of	O
gemfibrozil	O
versus	O
placebo	O
in	O
2,531	SampleSize
men	Sex
with	O
coronary	Condition
disease	Condition
,	O
HDL-C	O
levels	O
of	O
40	O
mg/dL	O
or	O
less	O
(	O
<	O
or	O
=1.0	O
mmol/L	O
)	O
,	O
low-density	O
lipoprotein	O
cholesterol	O
levels	O
of	O
140	O
mg/dL	O
or	O
less	O
(	O
<	O
or	O
=3.6	O
mmol/L	O
)	O
,	O
and	O
a	O
range	O
of	O
triglyceride	O
values	O
.	O

Moderate	O
CRI	O
is	O
defined	O
as	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
of	O
30	O
to	O
59.9	O
mL/min/1.73	O
m2	O
at	O
baseline	O
.	O

Multivariate	O
regression	O
was	O
used	O
to	O
calculate	O
rates	O
of	O
decline	O
in	O
estimated	O
GFR	O
for	O
individuals	O
administered	O
gemfibrozil	O
or	O
placebo	O
,	O
controlling	O
for	O
prospectively	O
determined	O
potential	O
confounders	O
.	O

RESULTS	O
Change	O
in	O
renal	O
function	O
could	O
be	O
calculated	O
in	O
1,981	SampleSize
individuals	O
,	O
of	O
whom	O
399	SampleSize
individuals	O
(	O
20.2	O
%	O
)	O
were	O
eligible	O
for	O
inclusion	O
.	O

Among	O
399	SampleSize
study	O
subjects	O
,	O
the	O
rate	O
of	O
change	O
in	O
renal	O
function	O
in	O
the	O
gemfibrozil	O
group	O
during	O
a	O
median	O
of	O
61	O
months	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
the	O
placebo	O
group	O
(	O
0.49	O
mL/min/1.73	O
m2/y	O
faster	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.09	O
slower	O
to	O
1.09	O
faster	O
;	O
P	O
=	O
0.10	O
)	O
.	O

No	O
clinically	O
relevant	O
effect	O
of	O
gemfibrozil	O
on	O
renal	O
function	O
was	O
observed	O
in	O
groups	O
defined	O
by	O
baseline	O
lipid	O
levels	O
,	O
kidney	O
function	O
,	O
diabetic	O
status	O
,	O
or	O
other	O
components	O
of	O
the	O
metabolic	O
syndrome	O
.	O

The	O
incidence	O
of	O
transient	O
(	O
10	O
%	O
versus	O
4	O
%	O
;	O
P	O
=	O
0.01	O
)	O
,	O
but	O
not	O
sustained	O
(	O
9	O
%	O
versus	O
4	O
%	O
;	O
P	O
=	O
0.07	O
)	O
,	O
increases	O
in	O
serum	O
creatinine	O
levels	O
of	O
0.5	O
mg/dL	O
or	O
greater	O
(	O
>	O
or	O
=44	O
micromol/L	O
)	O
was	O
significantly	O
greater	O
in	O
the	O
gemfibrozil	O
group	O
.	O

However	O
,	O
in	O
5	O
subjects	O
with	O
acute	O
increases	O
in	O
serum	O
creatinine	O
levels	O
,	O
serum	O
creatine	O
kinase	O
levels	O
were	O
significantly	O
elevated	O
as	O
well	O
,	O
suggesting	O
that	O
myocyte	O
toxicity	O
may	O
have	O
been	O
responsible	O
.	O

Even	O
when	O
these	O
individuals	O
were	O
excluded	O
,	O
no	O
clinically	O
significant	O
effect	O
of	O
gemfibrozil	O
on	O
kidney	O
function	O
was	O
observed	O
.	O

CONCLUSION	O
Gemfibrozil	O
does	O
not	O
appear	O
to	O
exert	O
a	O
clinically	O
relevant	O
effect	O
on	O
rates	O
of	O
kidney	O
function	O
loss	O
in	O
individuals	O
with	O
moderate	Condition
CRI	Condition
,	O
low	Condition
HDL-C	Condition
levels	Condition
,	O
and	O
concomitant	O
coronary	Condition
disease	Condition
.	O

Impact	O
of	O
antioxidants	O
,	O
zinc	O
,	O
and	O
copper	O
on	O
cognition	O
in	O
the	O
elderly	O
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

Participants	O
in	O
the	O
Age-Related	O
Eye	O
Disease	O
Study	O
were	O
randomly	O
assigned	O
to	O
receive	O
daily	O
antioxidants	O
(	O
vitamin	O
C	O
,	O
500	O
mg	O
;	O
vitamin	O
E	O
,	O
400	O
IU	O
;	O
beta	O
carotene	O
,	O
15	O
mg	O
)	O
,	O
zinc	O
and	O
copper	O
(	O
zinc	O
,	O
80	O
mg	O
;	O
cupric	O
oxide	O
,	O
2	O
mg	O
)	O
,	O
antioxidants	O
plus	O
zinc	O
and	O
copper	O
,	O
or	O
placebo	O
.	O

A	O
cognitive	O
battery	O
was	O
administered	O
to	O
2,166	O
elderly	O
persons	O
after	O
a	O
median	O
of	O
6.9	O
years	O
of	O
treatment	O
.	O

Treatment	O
groups	O
did	O
not	O
differ	O
on	O
any	O
of	O
the	O
six	O
cognitive	O
tests	O
(	O
p	O
>	O
0.05	O
for	O
all	O
)	O
.	O

These	O
results	O
do	O
not	O
support	O
a	O
beneficial	O
or	O
harmful	O
effect	O
of	O
antioxidants	O
or	O
zinc	O
and	O
copper	O
on	O
cognition	O
in	O
older	O
adults	O
.	O

Service	O
variation	O
in	O
baseline	O
variables	O
and	O
prediction	O
of	O
risk	O
in	O
a	O
randomised	O
controlled	O
trial	O
of	O
psychological	O
treatment	O
in	O
repeated	O
parasuicide	O
:	O
the	O
POPMACT	O
Study	O
.	O

The	O
treatment	O
protocol	O
and	O
baseline	O
characteristics	O
of	O
480	O
subjects	O
with	O
a	O
history	O
of	O
repeated	O
parasuicide	O
recruited	O
in	O
five	O
centres	O
to	O
a	O
randomised	O
therapeutic	O
trial	O
of	O
manual	O
assisted	O
cognitive-behaviour	O
therapy	O
(	O
MACT	O
)	O
and	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
are	O
described	O
.	O

Most	O
patients	O
had	O
significant	O
anxiety	O
and	O
depressive	O
disturbance	O
with	O
42	O
%	O
having	O
a	O
personality	O
disorder	O
.	O

Variation	O
in	O
service	O
policies	O
influenced	O
recruitment	O
,	O
with	O
earlier	O
assessment	O
centres	O
seeing	O
people	O
with	O
more	O
frequent	O
episodes	O
of	O
self-harm	O
and	O
greater	O
parasuicide	O
risk	O
than	O
later	O
ones	O
.	O

Parasuicide	O
risk	O
was	O
also	O
significantly	O
greater	O
in	O
those	O
with	O
their	O
first	O
parasuicide	O
episode	O
at	O
an	O
earlier	O
age	O
and	O
in	O
those	O
with	O
a	O
more	O
recent	O
latest	O
episode	O
.	O

Rate-modulated	O
cardiac	O
pacing	O
based	O
on	O
transthoracic	O
impedance	O
measurements	O
of	O
minute	O
ventilation	O
:	O
correlation	O
with	O
exercise	O
gas	O
exchange	O
.	O

The	O
relation	O
of	O
pacing	O
rate	O
to	O
physiologic	O
variables	O
of	O
metabolic	O
demand	O
was	O
examined	O
in	O
10	SampleSize
consecutive	O
patients	O
with	O
a	O
minute	O
ventilation-sensing	O
,	O
rate-modulating	O
ventricular	O
pacemaker	O
implanted	O
for	O
complete	O
heart	O
block	O
.	O

All	O
patients	O
had	O
paroxysmal	Condition
(	O
seven	SampleSize
patients	O
)	O
or	O
chronic	O
(	O
three	SampleSize
patients	O
)	O
atrial	Condition
fibrillation	Condition
and	O
were	O
referred	O
for	O
catheter	O
ablation	O
of	O
the	O
atrioventricular	O
junction	O
.	O

Treadmill	O
exercise	O
testing	O
with	O
measurement	O
of	O
expired	O
gas	O
exchange	O
and	O
respiratory	O
flow	O
was	O
performed	O
before	O
ablation	O
and	O
4	O
weeks	O
after	O
pacemaker	O
implantation	O
,	O
with	O
the	O
pacemaker	O
programmed	O
to	O
both	O
the	O
fixed-rate	O
VVI	O
and	O
rate-modulating	O
minute	O
ventilation	O
VVIR	O
pacing	O
modes	O
in	O
random	O
sequence	O
.	O

The	O
relation	O
of	O
pacing	O
rate	O
to	O
oxygen	O
consumption	O
(	O
VO2	O
)	O
,	O
expired	O
carbon	O
dioxide	O
concentration	O
(	O
VCO2	O
)	O
,	O
respiratory	O
quotient	O
,	O
tidal	O
volume	O
,	O
respiratory	O
rate	O
and	O
minute	O
ventilation	O
was	O
determined	O
during	O
exercise	O
in	O
the	O
rate-modulating	O
minute	O
ventilation	O
pacing	O
mode	O
.	O

Pacing	O
rate	O
was	O
highly	O
correlated	O
with	O
minute	O
ventilation	O
(	O
r	O
=	O
0.89	O
)	O
,	O
respiratory	O
quotient	O
(	O
r	O
=	O
0.89	O
)	O
,	O
VCO2	O
(	O
r	O
=	O
0.87	O
)	O
,	O
tidal	O
volume	O
(	O
r	O
=	O
0.87	O
)	O
,	O
VO2	O
(	O
r	O
=	O
0.84	O
)	O
and	O
respiratory	O
rate	O
(	O
r	O
=	O
0.84	O
)	O
.	O

The	O
mean	O
exercise	O
duration	O
increased	O
from	O
8.3	O
+/-	O
2.8	O
min	O
in	O
the	O
fixed	O
rate	O
pacing	O
mode	O
to	O
10.2	O
+/-	O
3.4	O
min	O
in	O
the	O
rate-modulating	O
,	O
minute	O
ventilation	O
mode	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
maximal	O
VO2	O
increased	O
from	O
13.4	O
+/-	O
3.4	O
to	O
16.3	O
+/-	O
4.1	O
cc/kg	O
per	O
min	O
(	O
p	O
=	O
0.0004	O
)	O
.	O

The	O
maximal	O
heart	O
rate	O
achieved	O
in	O
the	O
minute	O
ventilation	O
pacing	O
mode	O
was	O
136	O
+/-	O
9.7	O
beats/min	O
,	O
similar	O
to	O
that	O
observed	O
in	O
the	O
patient	O
's	O
intrinsic	O
cardiac	O
rhythm	O
before	O
ablation	O
(	O
134.9	O
+/-	O
30.1	O
beats/min	O
,	O
p	O
=	O
NS	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Radiation-induced	O
brachial	O
plexopathy	O
:	O
neurological	O
follow-up	O
in	O
161	SampleSize
recurrence-free	Condition
breast	Condition
cancer	Condition
patients	O
.	O

PURPOSE	O
The	O
purpose	O
was	O
to	O
assess	O
the	O
incidence	O
and	O
clinical	O
manifestations	O
of	O
radiation-induced	O
brachial	O
plexopathy	O
in	O
breast	O
cancer	O
patients	O
,	O
treated	O
according	O
to	O
the	O
Danish	O
Breast	O
Cancer	O
Cooperative	O
Group	O
protocols	O
.	O

METHODS	O
AND	O
MATERIALS	O
One	SampleSize
hundred	SampleSize
and	SampleSize
sixty-one	SampleSize
recurrence-free	O
breast	O
cancer	O
patients	O
were	O
examined	O
for	O
radiation-induced	O
brachial	O
plexopathy	O
after	O
a	O
median	O
follow-up	O
period	O
of	O
50	O
months	O
(	O
13-99	O
months	O
)	O
.	O

After	O
total	O
mastectomy	O
and	O
axillary	O
node	O
sampling	O
,	O
high-risk	O
patients	O
were	O
randomized	O
to	O
adjuvant	O
therapy	O
.	O

One	O
hundred	O
twenty-eight	O
patients	O
were	O
treated	O
with	O
postoperative	O
radiotherapy	O
with	O
50	O
Gy	O
in	O
25	O
daily	O
fractions	O
over	O
5	O
weeks	O
.	O

In	O
addition	O
,	O
82	O
of	O
these	O
patients	O
received	O
cytotoxic	O
therapy	O
(	O
cyclophosphamide	O
,	O
methotrexate	O
,	O
and	O
5-fluorouracil	O
)	O
and	O
46	O
received	O
tamoxifen	O
.	O

RESULTS	O
Five	O
percent	O
and	O
9	O
%	O
of	O
the	O
patients	O
receiving	O
radiotherapy	O
had	O
disabling	O
and	O
mild	O
radiation-induced	O
brachial	O
plexopathy	O
,	O
respectively	O
.	O

Radiation-induced	O
brachial	O
plexopathy	O
was	O
more	O
frequent	O
in	O
patients	O
receiving	O
cytotoxic	O
therapy	O
(	O
p	O
=	O
0.04	O
)	O
and	O
in	O
younger	O
patients	O
(	O
p	O
=	O
0.04	O
)	O
.	O

The	O
clinical	O
manifestations	O
were	O
paraesthesia	O
(	O
100	O
%	O
)	O
,	O
hypaesthesia	O
(	O
74	O
%	O
)	O
,	O
weakness	O
(	O
58	O
%	O
)	O
,	O
decreased	O
muscle	O
stretch	O
reflexes	O
(	O
47	O
%	O
)	O
,	O
and	O
pain	O
(	O
47	O
%	O
)	O
.	O

CONCLUSION	O
The	O
brachial	O
plexus	O
is	O
more	O
vulnerable	O
to	O
large	O
fraction	O
size	O
.	O

Fractions	O
of	O
2	O
Gy	O
or	O
less	O
are	O
advisable	O
.	O

Cytotoxic	O
therapy	O
adds	O
to	O
the	O
damaging	O
effect	O
of	O
radiotherapy	O
.	O

Peripheral	O
nerves	O
in	O
younger	Age
patients	O
seems	O
more	O
vulnerable	O
.	O

Radiation-induced	O
brachial	O
plexopathy	O
occurs	O
mainly	O
as	O
diffuse	O
damage	O
to	O
the	O
brachial	O
plexus	O
.	O

Closure	O
of	O
the	O
femoral	O
artery	O
after	O
cardiac	O
catheterization	O
:	O
a	O
comparison	O
of	O
Angio-Seal	O
,	O
StarClose	O
,	O
and	O
manual	O
compression	O
.	O

OBJECTIVES	O
To	O
compare	O
Angio-Seal	O
(	O
AS	O
)	O
and	O
StarClose	O
(	O
SC	O
)	O
and	O
manual	O
compression	O
(	O
MC	O
)	O
on	O
efficacy	O
of	O
hemostasis	O
,	O
complication	O
rate	O
,	O
safety	O
of	O
early	O
mobilization	O
,	O
and	O
patient	O
comfort	O
.	O

BACKGROUND	O
Closure	O
of	O
the	O
femoral	O
artery	O
after	O
cardiac	O
catheterization	O
can	O
be	O
obtained	O
through	O
different	O
methods	O
.	O

Today	O
,	O
physicians	O
can	O
choose	O
from	O
a	O
number	O
of	O
different	O
devices	O
to	O
achieve	O
arterial	O
closure	O
.	O

METHODS	O
In	O
a	O
prospective	O
trial	O
450	O
patients	O
were	O
randomized	O
to	O
AS	O
,	O
SC	O
,	O
or	O
MC	O
.	O

Patients	O
were	O
mobilized	O
1	O
to	O
2	O
hr	O
after	O
device	O
placement	O
,	O
and	O
6	O
hr	O
after	O
MC	O
.	O

Data	O
were	O
collected	O
during	O
hospital	O
admission	O
and	O
by	O
telephone	O
at	O
one	O
month	O
after	O
hospital	O
discharge	O
.	O

RESULTS	O
Devices	O
were	O
used	O
in	O
138/150	O
allocated	O
to	O
AS	O
and	O
124/150	O
allocated	O
to	O
SC	O
patients	O
(	O
92	O
%	O
vs.	O
83	O
%	O
,	O
P	O
=	O
0.015	O
)	O
Patients	O
with	O
MC	O
experienced	O
more	O
pain	O
during	O
sheath	O
removal	O
than	O
patients	O
receiving	O
a	O
device	O
,	O
and	O
rated	O
their	O
period	O
of	O
bed	O
rest	O
as	O
less	O
comfortable	O
.	O

Oozing	O
and	O
need	O
for	O
pressure	O
bandage	O
at	O
the	O
puncture	O
site	O
were	O
observed	O
in	O
37	O
AS	O
patients	O
and	O
57	O
SC	O
patients	O
(	O
25	O
%	O
vs.	O
38	O
%	O
,	O
P	O
=	O
0.002	O
)	O
.	O

Hematoma	O
occurred	O
in	O
15	O
AS	O
patients	O
,	O
in	O
17	O
SC	O
patients	O
,	O
and	O
in	O
14	O
MC	O
patients	O
(	O
11	O
vs.	O
14	O
vs.	O
9	O
%	O
,	O
ns	O
)	O
.	O

CONCLUSION	O
There	O
is	O
no	O
difference	O
in	O
safety	O
between	O
the	O
three	O
methods	O
of	O
arterial	O
closure	O
.	O

SC	O
was	O
more	O
often	O
not	O
used	O
or	O
successfully	O
deployed	O
.	O

SC	O
patients	O
more	O
often	O
had	O
continuing	O
oozing	O
.	O

On	O
patient	O
comfort	O
,	O
closure	O
devices	O
performed	O
better	O
than	O
MC	O
.	O

Early	O
ambulation	O
in	O
patients	O
with	O
a	O
closure	O
device	O
is	O
safe	O
.	O

AS	O
is	O
the	O
preferred	O
method	O
of	O
arterial	O
closure	O
after	O
cardiac	O
catheterization	O
.	O

Topical	O
treatment	O
of	O
tinea	O
pedis	O
using	O
6	O
%	O
coriander	O
oil	O
in	O
unguentum	O
leniens	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
comparative	O
pilot	O
study	O
.	O

BACKGROUND	O
The	O
antifungal	O
activity	O
of	O
coriander	O
oil	O
has	O
already	O
been	O
demonstrated	O
in	O
vitro	O
.	O

OBJECTIVE	O
Evaluation	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
6	O
%	O
coriander	O
oil	O
in	O
unguentum	O
leniens	O
in	O
the	O
treatment	O
of	O
interdigital	O
tinea	O
pedis	O
.	O

METHODS	O
Half-side	O
comparative	O
pilot	O
study	Condition
on	Condition
subjects	Condition
with	Condition
symmetric	Condition
,	Condition
bilateral	Condition
interdigital	Condition
tinea	Condition
pedis	Condition
.	Condition

Active	O
drug	O
and	O
placebo	O
control	O
were	O
applied	O
twice	O
daily	O
on	O
the	O
affected	O
areas	O
,	O
and	O
follow-up	O
visits	O
were	O
performed	O
on	O
days	O
14	O
and	O
28	O
.	O

RESULTS	O
40	O
participants	O
(	O
mean	O
age	O
52.5	O
years	O
,	O
60	O
%	O
male	O
)	O
were	O
included	O
in	O
the	O
study	O
.	O

For	O
6	O
%	O
coriander	O
oil	O
in	O
unguentum	O
leniens	O
,	O
a	O
highly	O
significant	O
improvement	O
of	O
the	O
clinical	O
signs	O
(	O
p	O
<	O
0.0001	O
)	O
was	O
observed	O
during	O
the	O
entire	O
observation	O
period	O
;	O
the	O
number	O
of	O
positive	O
fungal	O
cultures	O
also	O
tended	O
to	O
decrease	O
(	O
p	O
=	O
0.0654	O
)	O
.	O

The	O
tolerability	O
of	O
the	O
tested	O
substances	O
was	O
good	O
.	O

CONCLUSION	O
Coriander	O
oil	O
is	O
effective	O
and	O
well	O
tolerated	O
in	O
the	O
treatment	O
of	O
interdigital	O
tinea	O
pedis	O
.	O

Translucency	O
of	O
zirconia	Condition
copings	Condition
made	O
with	O
different	O
CAD/CAM	O
systems	O
.	O

STATEMENT	O
OF	O
PROBLEM	O
Zirconia	O
cores	O
are	O
reported	O
to	O
be	O
less	O
translucent	O
than	O
glass	O
,	O
lithium	O
disilicate	O
,	O
or	O
alumina	O
cores	O
.	O

This	O
could	O
affect	O
the	O
esthetic	O
appearance	O
and	O
the	O
clinical	O
choices	O
made	O
when	O
using	O
zirconia-based	O
restorations	O
.	O

PURPOSE	O
The	O
purpose	O
of	O
this	O
in	O
vitro	O
study	O
was	O
to	O
evaluate	O
the	O
translucency	O
of	O
zirconia	O
copings	O
for	O
single	O
crowns	O
fabricated	O
using	O
different	O
CAD/CAM	O
systems	O
,	O
using	O
lithium	O
disilicate	O
glass	O
ceramic	O
as	O
a	O
control	O
.	O

MATERIAL	O
AND	O
METHODS	O
Using	O
impressions	O
made	O
from	O
a	O
stainless	O
steel	O
complete-crown	O
master	O
die	O
,	O
9	SampleSize
stone	O
cast	O
replicas	O
were	O
fabricated	O
,	O
numbered	O
,	O
and	O
distributed	O
into	O
8	O
ceramic	O
ZrO	O
(	O
2	O
)	O
CAD/CAM	O
system	O
groups	O
(	O
Lava	O
Frame	O
0.3	O
and	O
0.5	O
,	O
IPS	O
e.max	O
ZirCAD	O
,	O
VITA	O
YZ	O
,	O
Procera	O
AllZircon	O
,	O
Digizon	O
,	O
DC	O
Zircon	O
,	O
and	O
Cercon	O
Base	O
)	O
and	O
to	O
a	O
lithium	O
disilicate	O
glass-ceramic	O
control	O
group	O
(	O
IPS	O
e.max	O
Press	O
)	O
using	O
a	O
simple	O
computer-generated	O
randomization	O
method	O
.	O

From	O
each	O
die	O
,	O
the	O
manufacturer	O
's	O
authorized	O
milling	O
centers	O
supplied	O
5	O
copings	O
per	O
group	O
without	O
applying	O
any	O
dying	O
technique	O
to	O
the	O
ceramic	O
base	O
material	O
.	O

The	O
copings	O
were	O
prepared	O
to	O
allow	O
for	O
a	O
40-mum	O
cement	O
layer	O
and	O
were	O
of	O
different	O
thicknesses	O
according	O
to	O
system	O
specifications	O
.	O

Translucency	O
was	O
measured	O
by	O
the	O
direct	O
transmission	O
method	O
with	O
a	O
digital	O
photoradiometer	O
mounted	O
in	O
a	O
dark	O
chamber	O
.	O

The	O
light	O
source	O
was	O
a	O
150-W	O
halogen	O
lamp	O
beam	O
.	O

Measurements	O
were	O
repeated	O
3	O
times	O
for	O
each	O
specimen	O
.	O

Data	O
obtained	O
were	O
analyzed	O
using	O
1-way	O
ANOVA	O
and	O
the	O
Bonferroni	O
multiple	O
comparison	O
test	O
(	O
alpha=.05	O
)	O
.	O

RESULTS	O
Among	O
ZrO	O
(	O
2	O
)	O
copings	O
,	O
Lava	O
(	O
0.3	O
mm	O
and	O
0.5	O
mm	O
thick	O
)	O
showed	O
the	O
highest	O
(	O
P	O
<	O
.05	O
)	O
values	O
of	O
translucency	O
measured	O
as	O
light	O
flow	O
units	O
(	O
3.572	O
+	O
or	O
-	O
018	O
x	O
10	O
(	O
3	O
)	O
lx	O
and	O
3.181	O
+	O
or	O
-	O
0.13	O
x	O
10	O
(	O
3	O
)	O
lx	O
,	O
respectively	O
)	O
.	O

These	O
values	O
represent	O
71.7	O
%	O
and	O
63.9	O
%	O
,	O
respectively	O
,	O
of	O
the	O
glass-ceramic	O
control	O
group	O
(	O
4.98	O
x	O
10	O
(	O
3	O
)	O
lx	O
)	O
.	O

CONCLUSIONS	O
All	O
ZrO	O
(	O
2	O
)	O
copings	O
demonstrated	O
different	O
levels	O
of	O
light	O
transmission	O
,	O
with	O
the	O
2	O
Lava	O
specimens	O
showing	O
the	O
highest	O
values	O
.	O

Translucency	O
of	O
zirconia	O
copings	O
was	O
significantly	O
lower	O
(	O
P=.001	O
)	O
than	O
that	O
of	O
the	O
lithium	O
disilicate	O
glass-ceramic	O
control	O
.	O

Parenting	Condition
stress	Condition
in	O
the	O
infant	O
aphakia	O
treatment	O
study	O
.	O

OBJECTIVE	O
To	O
evaluate	O
parenting	Condition
stress	Condition
following	O
infants	Age
'	O
cataract	O
extraction	O
surgery	O
,	O
and	O
to	O
determine	O
if	O
levels	O
of	O
stress	O
differ	O
between	O
2	O
treatments	O
for	O
unilateral	O
congenital	O
cataract	O
in	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
At	O
surgery	O
,	O
an	O
intraocular	O
lens	O
(	O
IOL	O
)	O
was	O
implanted	O
or	O
children	O
were	O
left	O
aphakic	O
,	O
treated	O
with	O
contact	O
lens	O
(	O
CL	O
)	O
.	O

Stress	O
measures	O
were	O
administered	O
3	O
months	O
after	O
surgery	O
and	O
at	O
the	O
first	O
visit	O
after	O
the	O
visual	O
acuity	O
(	O
VA	O
)	O
assessment	O
done	O
at	O
12	O
months	O
of	O
age	O
.	O

RESULTS	O
Caregivers	O
in	O
the	O
IOL	O
group	O
reported	O
higher	O
levels	O
of	O
stress	O
than	O
those	O
in	O
the	O
CL	O
group	O
3	O
months	O
after	O
surgery	O
,	O
but	O
there	O
were	O
no	O
group	O
differences	O
in	O
stress	O
scores	O
at	O
the	O
post-VA	O
assessment	O
.	O

Stress	O
scores	O
did	O
not	O
change	O
differentially	O
for	O
participants	O
assigned	O
to	O
IOL	O
versus	O
CL	O
treatments	O
.	O

CONCLUSIONS	O
Treatment	O
assignment	O
did	O
not	O
have	O
a	O
significant	O
impact	O
on	O
caregiver	O
stress	O
during	O
infancy	Age
or	O
on	O
the	O
change	O
in	O
stress	O
during	O
the	O
child	O
's	O
first	O
2	O
years	O
of	O
life	O
.	O

Evaluation	O
of	O
the	O
pharmacodynamics	O
of	O
acetylsalicylic	O
acid	O
81	O
mg	O
with	O
or	O
without	O
esomeprazole	O
20	O
mg	O
in	O
healthy	Condition
volunteers	Condition
.	Condition

BACKGROUND	O
The	O
absence	O
of	O
a	O
pharmacokinetic	O
interaction	O
between	O
the	O
proton	O
pump	O
inhibitor	O
esomeprazole	O
(	O
40	O
mg	O
)	O
and	O
acetylsalicylic	O
acid	O
(	O
aspirin	O
,	O
ASA	O
;	O
325	O
mg	O
)	O
has	O
previously	O
been	O
established	O
.	O

OBJECTIVE	O
This	O
study	O
set	O
out	O
to	O
investigate	O
the	O
potential	O
for	O
pharmacodynamic	O
interaction	O
between	O
low-dose	O
ASA	O
and	O
esomeprazole	O
in	O
healthy	O
volunteers	O
,	O
by	O
measuring	O
ASA	O
antiplatelet	O
activity	O
.	O

STUDY	O
DESIGN	O
This	O
was	O
a	O
single-center	O
,	O
open-label	O
,	O
two-period	O
,	O
randomized	O
crossover	O
study	O
.	O

PARTICIPANTS	O
Healthy	O
male	O
and	O
female	O
volunteers	O
aged	O
18-75	O
years	O
were	O
included	O
.	O

All	O
volunteers	O
received	O
ASA	O
81	O
mg	O
once	O
daily	O
for	O
5	O
days	O
prior	O
to	O
the	O
study	O
(	O
pre-screen	O
)	O
.	O

Subjects	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
had	O
aspirin	O
reactivity	O
units	O
(	O
ARU	O
,	O
as	O
measured	O
by	O
the	O
VerifyNow	O
ASA	O
assay	O
)	O
of	O
<	O
550	O
on	O
Day	O
6	O
.	O

INTERVENTION	O
After	O
pre-screening	O
and	O
a	O
washout	O
period	O
of	O
at	O
least	O
14	O
days	O
,	O
eligible	O
volunteers	O
received	O
ASA	O
81	O
mg	O
with	O
or	O
without	O
esomeprazole	O
20	O
mg	O
once	O
daily	O
for	O
5	O
days	O
in	O
randomized	O
order	O
,	O
with	O
a	O
14-day	O
washout	O
between	O
treatments	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
The	O
main	O
outcome	O
measure	O
was	O
the	O
antiplatelet	O
activity	O
of	O
ASA	O
,	O
as	O
assessed	O
by	O
ARU	O
ratio	O
relative	O
to	O
baseline	O
in	O
the	O
VerifyNow	O
ASA	O
assay	O
;	O
suppression	O
of	O
serum	O
thromboxane	O
B	O
(	O
2	O
)	O
(	O
TXB	O
(	O
2	O
)	O
)	O
was	O
a	O
secondary	O
endpoint	O
.	O

Statistical	O
comparisons	O
were	O
made	O
using	O
linear	O
mixed	O
models	O
.	O

RESULTS	O
A	O
total	O
of	O
29	O
volunteers	O
(	O
19	O
aged	O
?50	O
years	O
;	O
8	O
women	O
;	O
21	O
men	O
)	O
were	O
evaluable	O
for	O
pharmacodynamic	O
analysis	O
(	O
per	O
protocol	O
)	O
.	O

All	O
volunteers	O
on	O
both	O
treatments	O
achieved	O
ARU	O
<	O
550	O
at	O
Day	O
6	O
.	O

The	O
geometric	O
mean	O
ratio	O
of	O
Day	O
6	O
to	O
Day	O
1	O
(	O
baseline	O
)	O
platelet	O
aggregation	O
was	O
0.70	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.68	O
,	O
0.72	O
)	O
with	O
ASA	O
alone	O
and	O
0.71	O
(	O
95	O
%	O
CI	O
0.69	O
,	O
0.74	O
)	O
with	O
ASA	O
+	O
esomeprazole	O
.	O

The	O
ratio	O
of	O
platelet	O
aggregation	O
(	O
ASA	O
+	O
esomeprazole/ASA	O
)	O
was	O
1.02	O
(	O
95	O
%	O
CI	O
0.99	O
,	O
1.05	O
)	O
.	O

ASA	O
administered	O
alone	O
or	O
with	O
esomeprazole	O
reduced	O
serum	O
TXB	O
(	O
2	O
)	O
by	O
more	O
than	O
99.5	O
%	O
.	O

The	O
ratio	O
of	O
suppression	O
of	O
serum	O
TXB	O
(	O
2	O
)	O
levels	O
(	O
ASA	O
+	O
esomeprazole/ASA	O
)	O
was	O
1.06	O
(	O
95	O
%	O
CI	O
0.88	O
,	O
1.29	O
)	O
.	O

The	O
combination	O
of	O
ASA	O
and	O
esomeprazole	O
was	O
well	O
tolerated	O
.	O

CONCLUSION	O
No	O
pharmacodynamic	O
interaction	O
between	O
low-dose	O
ASA	O
and	O
esomeprazole	O
was	O
found	O
with	O
regard	O
to	O
platelet	O
function	O
.	O

TRIAL	O
REGISTRATION	O
Registered	O
at	O
ClinicalTrials	O
.	O

gov	O
as	O
NCT01199328	O
.	O

Measuring	O
adherence	O
in	O
a	O
hypertension	Condition
clinical	O
trial	O
.	O

BACKGROUND	O
Non-adherence	O
in	O
hypertension	O
is	O
a	O
global	O
problem	O
and	O
promoting	O
adherence	O
is	O
necessary	O
to	O
decrease	O
cardiovascular	O
mortality	O
.	O

AIMS	O
The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
examine	O
the	O
measurement	O
of	O
adherence	O
to	O
medication	O
taking	O
in	O
hypertensive	Condition
patients	O
.	O

Adherence	O
was	O
evaluated	O
primarily	O
by	O
means	O
of	O
MEMS	O
(	O
Medication	O
Event	O
Monitoring	O
System	O
,	O
Aprex	O
Corporation	O
,	O
Fremont	O
,	O
California	O
)	O
an	O
electronic	O
system	O
that	O
records	O
the	O
date	O
and	O
time	O
of	O
opening	O
of	O
the	O
study	O
medication	O
container	O
.	O

Additional	O
measurements	O
such	O
as	O
change	O
in	O
urinary	O
potassium	O
level	O
,	O
capsule	O
count	O
,	O
client	O
self	O
report	O
and	O
physician	O
estimate	O
of	O
adherence	O
were	O
recorded	O
.	O

METHODS	O
A	O
randomised	O
clinical	O
trial	O
was	O
used	O
to	O
assign	O
patients	O
to	O
receive	O
the	O
study	O
medication	O
(	O
potassium	O
)	O
or	O
placebo	O
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
answer	O
the	O
research	O
questions	O
.	O

Frequency	O
and	O
percentage	O
of	O
responses	O
to	O
different	O
measures	O
of	O
adherence	O
were	O
carried	O
out	O
as	O
well	O
as	O
correlation	O
between	O
the	O
measures	O
.	O

RESULTS	O
One	SampleSize
hundred	SampleSize
and	SampleSize
seven	SampleSize
subjects	O
between	O
the	O
ages	O
of	O
26	Age
and	Age
80	Age
participated	O
in	O
the	O
clinical	O
trial	O
.	O

The	O
results	O
showed	O
that	O
adherence	O
measures	O
varied	O
with	O
lowest	O
adherence	O
from	O
two	O
items	O
of	O
self-report	O
related	O
to	O
forgetfulness	O
(	O
46	O
and	O
55	O
%	O
)	O
and	O
stringent	O
electronic	O
monitoring	O
with	O
the	O
MEMS	O
(	O
58	O
%	O
)	O
to	O
percentages	O
in	O
the	O
80-90	O
range	O
for	O
other	O
self-report	O
items	O
and	O
the	O
general	O
adherence	O
scale	O
.	O

Electronic	O
monitoring	O
correlated	O
best	O
with	O
capsule	O
count	O
at	O
visit	O
5	O
.	O

Implications	O
for	O
health	O
care	O
providers	O
are	O
discussed	O
.	O

Development	O
of	O
autistic	Condition
children	Condition
based	O
on	O
maternal	O
responses	O
to	O
the	O
Autism	O
Behavior	O
Checklist	O
.	O

BACKGROUND	O
language	O
and	O
speech-language	O
intervention	O
.	O

AIM	O
to	O
evaluate	O
the	O
development	O
process	O
of	O
autistic	O
children	O
,	O
in	O
a	O
direct	O
and	O
indirect	O
intervention	O
context	O
based	O
on	O
the	O
responses	O
of	O
mothers	O
to	O
the	O
Autism	O
Behavior	O
Checklist	O
.	O

METHOD	O
the	O
research	O
sample	O
consisted	O
of	O
11	O
mothers	O
of	O
children	O
diagnosed	O
,	O
according	O
to	O
the	O
criteria	O
established	O
by	O
the	O
DSM	O
IVtr	O
(	O
APA	O
,	O
2002	O
)	O
,	O
with	O
autism	O
(	O
six	O
)	O
and	O
with	O
Asperger	O
Syndrome	O
(	O
five	O
)	O
and	O
who	O
were	O
seen	O
at	O
the	O
Investigation	O
Laboratory	O
of	O
Global	O
Developmental	O
Disorders	O
of	O
the	O
Federal	O
University	O
of	O
S?o	O
Paulo	O
.	O

These	O
children	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
Six	O
were	O
receiving	O
both	O
direct	O
and	O
indirect	O
intervention	O
(	O
TG	O
)	O
,	O
and	O
five	O
were	O
receiving	O
indirect	O
intervention	O
exclusively	O
(	O
OG	O
)	O
.	O

The	O
Autism	O
Behavior	O
Checklist	O
(	O
Krug	O
et	O
al.	O
,	O
1993	O
)	O
was	O
used	O
,	O
adapted	O
to	O
the	O
Portuguese	O
language	O
by	O
Marteleto	O
(	O
2003	O
)	O
.	O

This	O
behavior	O
checklist	O
(	O
57	O
items	O
)	O
allows	O
the	O
detailed	O
description	O
of	O
non-adaptable	O
characteristics	O
regarding	O
the	O
following	O
areas	O
:	O
sensory	O
,	O
use	O
of	O
the	O
body	O
and	O
object	O
,	O
Language	O
,	O
Psycho-social	O
and	O
Relational	O
.	O

The	O
questionnaire	O
was	O
filled	O
in	O
during	O
an	O
interview	O
on	O
three	O
occasions	O
:	O
at	O
the	O
beginning	O
of	O
intervention	O
,	O
after	O
six	O
months	O
and	O
at	O
the	O
end	O
of	O
12	O
months	O
.	O

RESULTS	O
after	O
statistical	O
analysis	O
it	O
was	O
observed	O
that	O
there	O
was	O
a	O
greater	O
development	O
in	O
the	O
total	O
scores	O
and	O
in	O
the	O
areas	O
of	O
language	O
,	O
psycho-social	O
and	O
relational	O
for	O
the	O
TG	O
.	O

This	O
suggests	O
a	O
greater	O
development	O
pattern	O
during	O
the	O
studied	O
period	O
for	O
this	O
group	O
.	O

CONCLUSION	O
the	O
mothers	O
of	O
both	O
groups	O
observed	O
behavioral	O
changes	O
.	O

The	O
better	O
scores	O
observed	O
for	O
the	O
TG	O
is	O
probably	O
related	O
to	O
the	O
effectiveness	O
of	O
direct	O
intervention	O
,	O
and	O
not	O
to	O
the	O
lack	O
of	O
attention	O
of	O
parents	O
in	O
the	O
OG	O
in	O
recognizing	O
behavioral	O
changes	O
in	O
their	O
children	O
.	O

[	O
Clinical	O
observation	O
on	O
acupuncture	O
combined	O
with	O
Yizhi	O
Jiannao	O
granules	O
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
clinical	O
therapeutic	O
effect	O
of	O
acupuncture	O
combined	O
with	O
Yizhi	O
Jiannao	O
Granules	O
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
its	O
effects	O
on	O
intelligence	O
,	O
daily	O
life	O
and	O
social	O
activity	O
ability	O
.	O

METHODS	O
Eighty-four	SampleSize
cases	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
,	O
28	SampleSize
cases	O
in	O
each	O
group	O
.	O

The	O
combined	O
acupuncture	O
and	O
medication	O
group	O
was	O
treated	O
with	O
acupuncture	O
at	O
Baihui	O
(	O
GV	O
20	O
)	O
,	O
Sishencong	O
(	O
EX-HN	O
1	O
)	O
,	O
Dazhui	O
(	O
GV	O
14	O
)	O
,	O
Guanyuan	O
(	O
CV	O
4	O
)	O
,	O
etc	O
.	O

and	O
oral	O
administration	O
of	O
Yizhi	O
Jiannao	O
Granules	O
;	O
the	O
Chinese	O
herb	O
group	O
was	O
treated	O
with	O
Yizhi	O
Jiannao	O
Granules	O
,	O
and	O
the	O
western	O
medicine	O
group	O
with	O
oral	O
administration	O
of	O
Aricept	O
.	O

The	O
scores	O
for	O
the	O
Mini-Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
,	O
Ability	O
of	O
Daily	O
Life	O
(	O
ADL	O
)	O
and	O
the	O
therapeutic	O
effects	O
were	O
assessed	O
and	O
compared	O
before	O
treatment	O
and	O
after	O
treatment	O
for	O
12	O
weeks	O
among	O
the	O
groups	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
scores	O
for	O
MMSE	O
and	O
ADL	O
were	O
improved	O
in	O
the	O
combined	O
acupuncture	O
and	O
medication	O
group	O
,	O
the	O
Chinese	O
herb	O
group	O
and	O
the	O
western	O
medicine	O
group	O
,	O
which	O
were	O
better	O
in	O
the	O
combined	O
acupuncture	O
and	O
medication	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
total	O
effective	O
rate	O
of	O
85.7	O
%	O
in	O
the	O
combined	O
acupuncture	O
and	O
medication	O
group	O
was	O
better	O
than	O
71.4	O
%	O
in	O
the	O
Chinese	O
herb	O
group	O
and	O
67.9	O
%	O
in	O
the	O
western	O
medicine	O
group	O
.	O

CONCLUSION	O
Acupuncture	O
combined	O
with	O
Yizhi	O
Jiannao	O
Granules	O
has	O
a	O
significant	O
therapeutic	O
effect	O
on	O
Alzheimer	O
's	O
disease	O
,	O
which	O
is	O
better	O
than	O
that	O
of	O
Yizhi	O
Jiannao	O
Granules	O
or	O
Aricept	O
.	O

Specific	O
exercises	O
to	O
treat	O
pregnancy-related	O
low	O
back	O
pain	O
in	O
a	O
South	O
African	O
population	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effect	O
of	O
an	O
exercise	O
program	O
,	O
including	O
specific	O
stabilizing	O
exercises	O
,	O
on	O
pain	O
intensity	O
and	O
functional	O
ability	O
in	O
women	Sex
with	O
pregnancy-related	Condition
low	Condition
back	Condition
pain	Condition
.	O

METHODS	O
Fifty	SampleSize
women	O
between	O
16	O
and	O
24	O
weeks	O
of	O
pregnancy	O
were	O
recruited	O
at	O
Tygerberg	O
and	O
Paarl	O
Hospitals	O
,	O
Western	O
Cape	O
,	O
South	O
Africa	O
.	O

Twenty-six	SampleSize
women	O
were	O
randomized	O
to	O
a	O
10-week	O
exercise	O
program	O
and	O
24	O
were	O
randomized	O
as	O
controls	O
.	O

RESULTS	O
Overall	O
,	O
the	O
most	O
frequent	O
type	O
of	O
back	O
pain	O
experienced	O
was	O
lumbar	O
pain	O
(	O
36	O
[	O
72.0	O
%	O
]	O
)	O
.	O

Pain	O
intensity	O
(	O
P=0.76	O
)	O
and	O
functional	O
ability	O
(	O
P=0.29	O
)	O
were	O
comparable	O
between	O
the	O
groups	O
on	O
study	O
entry	O
.	O

In	O
the	O
study	O
group	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
pain	O
intensity	O
(	O
P	O
<	O
0.01	O
)	O
and	O
an	O
improvement	O
in	O
functional	O
ability	O
(	O
P=0.06	O
)	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

In	O
the	O
control	O
group	O
,	O
there	O
were	O
no	O
significant	O
changes	O
in	O
pain	O
intensity	O
(	O
P=0.89	O
)	O
or	O
functional	O
ability	O
(	O
P=0.70	O
)	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

CONCLUSION	O
A	O
specific	O
exercise	O
program	O
decreased	O
back	O
pain	O
intensity	O
and	O
increased	O
functional	O
ability	O
during	O
pregnancy	O
in	O
South	O
African	O
women	O
with	O
lumbar	Condition
and	Condition
pelvic	Condition
girdle	Condition
pain	Condition
.	O

Simvastatin	O
blunts	O
endotoxin-induced	O
tissue	O
factor	O
in	O
vivo	O
.	O

BACKGROUND	O
Beyond	O
lipid	O
lowering	O
,	O
various	O
antiinflammatory	O
properties	O
have	O
been	O
ascribed	O
to	O
statins	O
.	O

Moreover	O
,	O
in	O
vitro	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
anticoagulant	O
effects	O
of	O
3-hydroxy-3-methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitors	O
,	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
monocyte	O
tissue	O
factor	O
(	O
TF	O
)	O
was	O
suppressed	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
statins	O
in	O
experimental	O
endotoxemia	Condition
on	O
inflammatory	O
and	O
procoagulant	O
responses	O
in	O
vivo	O
.	O

METHODS	O
AND	O
RESULTS	O
In	O
this	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel-group	O
study	O
,	O
20	SampleSize
healthy	Condition
,	O
male	Sex
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
simvastatin	O
(	O
80	O
mg/d	O
)	O
or	O
placebo	O
for	O
4	O
days	O
before	O
intravenous	O
administration	O
of	O
LPS	O
(	O
20	O
IU/kg	O
IV	O
)	O
.	O

Plasma	O
high-sensitive	O
C-reactive	O
protein	O
(	O
hsCRP	O
)	O
,	O
monocyte	O
chemoattractant	O
protein	O
(	O
MCP-1	O
)	O
,	O
sCD40L	O
,	O
sCD40	O
,	O
and	O
prothrombin	O
fragment	O
F1+2	O
(	O
F1.2	O
)	O
were	O
determined	O
by	O
ELISAs	O
at	O
baseline	O
and	O
at	O
4	O
and	O
8	O
hours	O
after	O
LPS	O
administration	O
.	O

Monocyte	O
TF	O
expression	O
and	O
monocyte-platelet	O
aggregates	O
were	O
measured	O
by	O
whole-blood	O
flow	O
cytometry	O
over	O
the	O
same	O
time	O
course	O
.	O

The	O
increases	O
in	O
hsCRP	O
and	O
MCP-1	O
,	O
both	O
known	O
inducers	O
of	O
TF	O
,	O
were	O
significantly	O
suppressed	O
by	O
statin	O
treatment	O
after	O
LPS	O
challenge	O
.	O

Statin	O
premedication	O
blunted	O
the	O
increase	O
of	O
monocyte	O
TF	O
expression	O
in	O
response	O
to	O
LPS	O
.	O

In	O
parallel	O
,	O
endotoxin-induced	O
formation	O
of	O
F1.2	O
was	O
significantly	O
reduced	O
by	O
simvastatin	O
after	O
4	O
and	O
8	O
hours	O
.	O

LPS	O
infusion	O
affected	O
neither	O
the	O
formation	O
and	O
activation	O
of	O
monocyte-platelet	O
aggregates	O
nor	O
plasma	O
levels	O
of	O
sCD40	O
and	O
sCD40L	O
.	O

CONCLUSIONS	O
Simvastatin	O
suppresses	O
the	O
inflammatory	O
response	O
to	O
endotoxin	O
and	O
blunts	O
monocyte	O
TF	O
expression	O
but	O
does	O
not	O
affect	O
platelet	O
activation	O
.	O

Preschool	O
based	O
JASPER	O
intervention	O
in	O
minimally	O
verbal	O
children	O
with	O
autism	O
:	O
pilot	O
RCT	O
.	O

In	O
this	O
pilot	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
a	O
novel	O
intervention	O
(	O
JASPER	O
,	O
Joint	O
Attention	O
Symbolic	O
Play	O
Engagement	O
and	O
Regulation	O
)	O
on	O
3	O
to	O
5	O
year	O
old	O
,	O
minimally	O
verbal	O
children	O
with	O
autism	O
who	O
were	O
attending	O
a	O
non-public	O
preschool	O
.	O

Participants	O
were	O
randomized	O
to	O
a	O
control	O
group	O
(	O
treatment	O
as	O
usual	O
,	O
30	O
h	O
of	O
ABA-based	O
therapy	O
per	O
week	O
)	O
or	O
a	O
treatment	O
group	O
(	O
substitution	O
of	O
30	O
min	O
of	O
JASPER	O
treatment	O
,	O
twice	O
weekly	O
during	O
their	O
regular	O
program	O
)	O
.	O

A	O
baseline	O
of	O
12	O
weeks	O
in	O
which	O
no	O
changes	O
were	O
noted	O
in	O
core	O
deficits	O
was	O
followed	O
by	O
12	O
weeks	O
of	O
intervention	O
for	O
children	O
randomized	O
to	O
the	O
JASPER	O
treatment	O
.	O

Participants	O
in	O
the	O
treatment	O
group	O
demonstrated	O
greater	O
play	O
diversity	O
on	O
a	O
standardized	O
assessment	O
.	O

Effects	O
also	O
generalized	O
to	O
the	O
classroom	O
,	O
where	O
participants	O
in	O
the	O
treatment	O
group	O
initiated	O
more	O
gestures	O
and	O
spent	O
less	O
time	O
unengaged	O
.	O

These	O
results	O
provide	O
further	O
support	O
that	O
even	O
brief	O
,	O
targeted	O
interventions	O
on	O
joint	O
attention	O
and	O
play	O
can	O
improve	O
core	O
deficits	O
in	O
minimally	O
verbal	O
children	O
with	O
ASD	O
.	O

Tramadol	O
suppository	O
versus	O
placebo	O
for	O
the	O
relief	O
of	O
perineal	Condition
pain	Condition
after	O
perineorrhaphy	O
:	O
a	O
randomized	O
controlled	O
trial	O
in	O
Thailand	O
.	O

OBJECTIVE	O
This	O
randomized	O
double-blinded	O
control	O
trial	O
was	O
conducted	O
to	O
compare	O
the	O
effectiveness	O
of	O
tramodol	O
and	O
placebo	O
rectal	O
suppository	O
for	O
the	O
management	O
of	O
postpartum	O
perineal	O
pain	O
after	O
perineorrhaphy	O
.	O

MATERIAL	O
AND	O
METHOD	O
One	O
hundred	O
women	Age
who	O
gave	O
birth	O
vaginally	O
with	O
episiotomy	O
and	O
a	O
second-	Condition
or	Condition
third-degree	Condition
tear	Condition
,	O
were	O
randomly	O
assign	O
to	O
receive	O
two	O
tablets	O
oftramadol	O
50	O
mg	O
or	O
two	O
tablets	O
ofplacebo	O
,	O
the	O
pill	O
were	O
physically	O
similar	O
to	O
the	O
real	O
drug	O
.	O

Pain	O
ratings	O
were	O
recorded	O
immediately	O
after	O
perineorrhaphy	O
,	O
30	O
minutes	O
,	O
and	O
1	O
,	O
2	O
,	O
6	O
,	O
12	O
and	O
24	O
hours	O
after	O
first	O
dose	O
on	O
a	O
10-cm	O
visual	O
analogue	O
scale	O
.	O

Side	O
effects	O
and	O
overall	O
opinion	O
were	O
assessed	O
.	O

RESULTS	O
Tramadol	O
and	O
placebo	O
had	O
no	O
statistical	O
significances	O
in	O
analgesic	O
properties	O
,	O
assessed	O
by	O
the	O
means	O
of	O
pain	O
rating	O
at	O
the	O
different	O
time	O
intervals	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
events	O
reported	O
.	O

CONCLUSION	O
No	O
differences	O
were	O
found	O
in	O
between	O
Tramadol	O
and	O
placebo	O
in	O
relief	O
perineal	O
pain	O
after	O
perineorrhaphy	O
Effect	O
of	O
antacids	O
on	O
intragastric	O
pH	O
in	O
healthy	O
subjects	O
and	O
duodenal	Condition
ulcer	Condition
patients	O
.	O

Influence	O
of	O
the	O
size	O
of	O
the	O
antacid	O
dose	O
and	O
of	O
anticholinergics	O
.	O

Different	O
doses	O
of	O
two	O
liquid	O
antacids	O
,	O
alone	O
and	O
combined	O
with	O
an	O
anticholinergic	O
agent	O
,	O
were	O
studied	O
with	O
respect	O
to	O
the	O
duration	O
of	O
antacid	O
action	O
.	O

The	O
studies	O
were	O
performed	O
in	O
healthy	O
subjects	O
with	O
MAO	O
less	O
than	O
30	O
mmol/h	O
and	O
in	O
duodenal	Condition
ulcer	Condition
patients	O
with	O
MAO	O
greater	O
than	O
35	O
mmol/h	O
.	O

Gastric	O
pH	O
was	O
recorded	O
using	O
radiotelemetric	O
technique	O
(	O
Heidelberg	O
capsule	O
)	O
.	O

In	O
the	O
healthy	O
subjects	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
duration	O
of	O
action	O
with	O
the	O
different	O
doses	O
but	O
in	O
duodenal	Condition
ulcer	Condition
patients	O
a	O
tenfold	O
increase	O
of	O
the	O
antacid	O
dose	O
resulted	O
in	O
a	O
doubling	O
of	O
the	O
duration	O
of	O
action	O
.	O

Combined	O
treatment	O
with	O
an	O
anticholinergic	O
and	O
antacids	O
enhanced	O
the	O
antacid	O
effects	O
in	O
both	O
groups	O
.	O

It	O
is	O
concluded	O
that	O
an	O
antacid	O
dose	O
should	O
be	O
so	O
great	O
that	O
it	O
binds	O
secreted	O
acid	O
before	O
the	O
dose	O
leaves	O
the	O
stomach	O
.	O

Further	O
increase	O
of	O
the	O
dose	O
will	O
not	O
increase	O
the	O
duration	O
.	O

Concomitant	O
use	O
of	O
an	O
anticholinergic	O
agent	O
increases	O
the	O
duration	O
of	O
antacid	O
action	O
.	O

Probiotics	O
in	O
the	O
management	O
of	O
atopic	O
eczema	O
.	O

BACKGROUND	O
Over	O
the	O
last	O
two	O
decades	O
the	O
incidence	O
of	O
allergic	O
diseases	O
has	O
increased	O
in	O
industrialized	O
countries	O
,	O
and	O
consequently	O
new	O
approaches	O
have	O
to	O
be	O
explored	O
.	O

OBJECTIVE	O
The	O
potential	O
of	O
probiotics	O
to	O
control	O
allergic	O
inflammation	O
at	O
an	O
early	O
age	O
was	O
assessed	O
in	O
a	O
randomized	O
double-blind	O
placebo-controlled	O
study	O
.	O

METHODS	O
A	O
total	O
of	O
27	O
infants	O
,	O
mean	O
age	O
4.6	O
months	O
,	O
who	O
manifested	O
atopic	O
eczema	O
during	O
exclusive	O
breast-feeding	O
and	O
who	O
have	O
had	O
no	O
exposure	O
to	O
any	O
infant	O
or	O
substitute	O
formula	O
were	O
weaned	O
to	O
probiotic-supplemented	O
,	O
Bifidobacterium	O
lactis	O
Bb-12	O
or	O
Lactobacillus	O
strain	O
GG	O
(	O
ATCC	O
53103	O
)	O
,	O
extensively	O
hydrolysed	O
whey	O
formulas	O
or	O
to	O
the	O
same	O
formula	O
without	O
probiotics	O
.	O

The	O
extent	O
and	O
severity	O
of	O
atopic	O
eczema	O
,	O
the	O
growth	O
and	O
nutrition	O
of	O
infants	O
,	O
and	O
concentrations	O
of	O
circulating	O
cytokines/chemokines	O
and	O
soluble	O
cell	O
surface	O
adhesion	O
molecules	O
in	O
serum	O
and	O
methyl-histamine	O
and	O
eosinophilic	O
protein	O
X	O
in	O
urine	O
were	O
determined	O
.	O

RESULTS	O
The	O
SCORAD	O
score	O
reflecting	O
the	O
extent	O
and	O
severity	O
of	O
atopic	O
eczema	O
was	O
16	O
(	O
7-25	O
)	O
during	O
breast-feeding	O
,	O
median	O
(	O
interquartile	O
range	O
)	O
.	O

After	O
2	O
months	O
,	O
a	O
significant	O
improvement	O
in	O
skin	O
condition	O
occurred	O
in	O
patients	O
given	O
probiotic-supplemented	O
formulas	O
,	O
as	O
compared	O
to	O
the	O
unsupplemented	O
group	O
;	O
chi	O
(	O
2	O
)	O
=	O
12.27	O
,	O
P	O
=	O
0.002	O
.	O

SCORAD	O
decreased	O
in	O
the	O
Bifidobacterium	O
lactis	O
Bb-12	O
group	O
to	O
0	O
(	O
0-3.8	O
)	O
,	O
and	O
in	O
the	O
Lactobacillus	O
GG	O
group	O
to	O
1	O
(	O
0.1-8.7	O
)	O
,	O
vs	O
unsupplemented	O
13.4	O
(	O
4.5-18.2	O
)	O
,	O
median	O
(	O
interquartile	O
range	O
)	O
,	O
in	O
parallel	O
with	O
a	O
reduction	O
in	O
the	O
concentration	O
of	O
soluble	O
CD4	O
in	O
serum	O
and	O
eosinophilic	O
protein	O
X	O
in	O
urine	O
.	O

CONCLUSION	O
The	O
results	O
provide	O
the	O
first	O
clinical	O
demonstration	O
of	O
specific	O
probiotic	O
strains	O
modifying	O
the	O
changes	O
related	O
to	O
allergic	O
inflammation	O
.	O

The	O
data	O
further	O
indicate	O
that	O
probiotics	O
may	O
counteract	O
inflammatory	O
responses	O
beyond	O
the	O
intestinal	O
milieu	O
.	O

The	O
combined	O
effects	O
of	O
these	O
probiotic	O
strains	O
will	O
guide	O
infants	O
through	O
the	O
weaning	O
period	O
,	O
when	O
sensitization	O
to	O
newly	O
encountered	O
antigens	O
is	O
initiated	O
.	O

The	O
probiotic	O
approach	O
may	O
thus	O
offer	O
a	O
new	O
direction	O
in	O
the	O
search	O
for	O
future	O
foods	O
for	O
allergy	O
treatment	O
and	O
prevention	O
strategies	O
.	O

Adult	Age
height	O
in	O
short	O
children	Age
born	O
SGA	Condition
treated	O
with	O
growth	O
hormone	O
and	O
gonadotropin	O
releasing	O
hormone	O
analog	O
:	O
results	O
of	O
a	O
randomized	O
,	O
dose-response	O
GH	O
trial	O
.	O

CONTEXT	O
GH	O
treatment	O
is	O
effective	O
in	O
improving	O
height	O
in	O
short	Condition
children	Condition
born	Condition
small	Condition
for	Condition
gestational	Condition
age	Condition
(	Condition
SGA	Condition
)	Condition
.	O

GH	O
is	O
thought	O
to	O
have	O
limited	O
effect	O
when	O
started	O
during	O
adolescence	O
.	O

OBJECTIVE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
GH	O
treatment	O
efficacy	O
in	O
short	O
SGA	O
children	O
when	O
treatment	O
was	O
started	O
during	O
adolescence	O
;	O
to	O
assess	O
whether	O
GH	O
2	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
during	O
puberty	O
improves	O
adult	O
height	O
(	O
AH	O
)	O
compared	O
with	O
1	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
;	O
and	O
to	O
assess	O
whether	O
an	O
additional	O
2-yr	O
postponement	O
of	O
puberty	O
by	O
GnRH	O
analog	O
(	O
GnRHa	O
)	O
improves	O
AH	O
in	O
children	O
who	O
are	O
short	O
at	O
the	O
start	O
of	O
puberty	O
(	O
<	O
140	O
cm	O
)	O
,	O
with	O
a	O
poor	O
AH	O
expectation	O
.	O

PATIENTS	O
AND	O
DESIGN	O
In	O
this	O
longitudinal	O
,	O
randomized	O
,	O
dose-response	O
GH	O
trial	O
,	O
we	O
included	O
121	O
short	O
SGA	O
children	O
(	O
60	O
boys	O
)	O
at	O
least	O
8	O
yr	O
of	O
age	O
.	O

We	O
performed	O
intention-to-treat	O
analyses	O
on	O
all	O
children	O
and	O
uncensored	O
case	O
analyses	O
on	O
84	O
children	O
who	O
reached	O
AH	O
.	O

Besides	O
,	O
we	O
evaluated	O
growth	O
during	O
2	O
yr	O
of	O
combined	O
GH/GnRHa	O
and	O
subsequent	O
GH	O
treatment	O
until	O
AH	O
in	O
a	O
subgroup	O
of	O
40	O
pubertal	O
children	O
with	O
a	O
height	O
of	O
less	O
than	O
140	O
cm	O
at	O
the	O
start	O
.	O

RESULTS	O
Short	O
SGA	O
children	O
started	O
treatment	O
at	O
a	O
median	O
age	O
of	O
11.2	O
yr	O
,	O
when	O
46	O
%	O
had	O
already	O
started	O
puberty	O
.	O

Median	O
height	O
increased	O
from	O
-2.9	O
at	O
start	O
to	O
-1.7	O
sd	O
score	O
(	O
SDS	O
)	O
at	O
AH	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Treatment	O
with	O
GH	O
2	O
vs.	O
1	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
during	O
puberty	O
resulted	O
in	O
significantly	O
better	O
AH	O
(	O
P	O
=	O
0.001	O
)	O
,	O
also	O
after	O
correction	O
for	O
gender	O
,	O
age	O
at	O
start	O
,	O
height	O
SDS	O
at	O
start	O
,	O
treatment	O
years	O
before	O
puberty	O
,	O
and	O
target	O
height	O
SDS	O
.	O

AH	O
was	O
similar	O
in	O
children	O
who	O
started	O
puberty	O
at	O
less	O
than	O
140	O
cm	O
and	O
received	O
GH/GnRHa	O
,	O
compared	O
with	O
children	O
who	O
started	O
puberty	O
greater	O
than	O
140	O
cm	O
and	O
received	O
GH	O
only	O
(	O
P	O
=	O
0.795	O
)	O
.	O

CONCLUSION	O
When	O
started	O
in	O
adolescence	O
,	O
GH	O
treatment	O
significantly	O
improves	O
AH	O
in	O
short	O
SGA	O
children	O
,	O
particularly	O
with	O
GH	O
2	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
during	O
puberty	O
.	O

When	O
SGA	O
children	O
are	O
short	O
at	O
the	O
start	O
of	O
puberty	O
,	O
they	O
can	O
benefit	O
from	O
combined	O
GH/GnRHa	O
treatment	O
.	O

Paracervical	O
anesthesia	O
for	O
outpatient	O
hysteroscopy	O
.	O

One	SampleSize
hundred	SampleSize
seventy-seven	SampleSize
women	Sex
aged	O
41	Age
+/-	Age
8	Age
(	O
mean	O
+/-	O
SD	O
)	O
years	O
,	O
referred	O
for	O
evaluation	O
of	O
excessive	Condition
uterine	Condition
bleeding	Condition
,	O
were	O
enrolled	O
in	O
an	O
open-label	O
randomized	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
local	O
anesthesia	O
before	O
hysteroscopy	O
in	O
an	O
outpatient	O
population	O
.	O

The	O
patients	O
underwent	O
hysteroscopy	O
and	O
endometrial	O
biopsy	O
with	O
paracervical	O
block	O
by	O
10	O
mL	O
of	O
1	O
%	O
mepivacaine	O
hydrochloride	O
solution	O
(	O
n	O
=	O
87	O
)	O
or	O
no	O
local	O
anesthesia	O
(	O
n	O
=	O
90	O
)	O
and	O
assessed	O
lower	O
abdominal	O
and	O
pelvic	O
pain	O
according	O
to	O
a	O
10-point	O
linear	O
analog	O
scale	O
.	O

The	O
mean	O
+/-	O
SD	O
pain	O
score	O
was	O
4.5	O
+/-	O
2.0	O
at	O
hysteroscopy	O
and	O
5.2	O
+/-	O
2.1	O
at	O
endometrial	O
biopsy	O
in	O
the	O
87	O
subjects	O
given	O
a	O
paracervical	O
block	O
versus	O
4.9	O
+/-	O
2.2	O
and	O
5.7	O
+/-	O
2.4	O
in	O
the	O
90	O
women	O
not	O
given	O
local	O
anesthesia	O
,	O
without	O
statistically	O
significant	O
differences	O
.	O

Paracervical	O
anesthesia	O
for	O
routine	O
outpatient	O
hysteroscopy	O
in	O
premenopausal	Age
women	O
may	O
be	O
superfluous	O
.	O

Methotrexate	O
in	O
the	O
treatment	O
of	O
steroid-dependent	Condition
asthma	Condition
.	O

A	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
was	O
designed	O
to	O
compare	O
steroid	O
requirements	O
between	O
placebo	O
and	O
methotrexate	O
(	O
MTX	O
)	O
treatment	O
in	O
subjects	O
with	O
corticosteroid-requiring	O
asthma	Condition
.	O

Subjects	O
began	O
with	O
a	O
steroid	O
taper	O
and	O
then	O
were	O
randomized	O
to	O
a	O
3-month	O
trial	O
of	O
drug	O
or	O
placebo	O
therapy	O
.	O

Subjects	O
received	O
15	O
mg	O
of	O
MTX	O
a	O
week	O
or	O
identical	O
placebo	O
.	O

A	O
1-month	O
washout	O
period	O
was	O
completed	O
before	O
the	O
crossover	O
trial	O
.	O

Symptom	O
scores	O
,	O
peak	O
flow	O
rates	O
,	O
spirometry	O
,	O
and	O
beta-agonist	O
frequency	O
were	O
closely	O
monitored	O
.	O

Ten	SampleSize
subjects	SampleSize
completed	O
the	O
study	O
.	O

The	O
average	O
dose	O
of	O
prednisone	O
during	O
the	O
placebo-treatment	O
period	O
was	O
11.97	O
mg/day	O
compared	O
to	O
8.37	O
mg/day	O
while	O
subjects	O
were	O
taking	O
MTX	O
.	O

This	O
was	O
a	O
30	O
%	O
reduction	O
in	O
daily	O
steroid	O
requirement	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Symptom	O
scores	O
and	O
spirometry	O
did	O
not	O
differ	O
between	O
the	O
crossover	O
trials	O
,	O
and	O
overall	O
clinical	O
status	O
was	O
not	O
altered	O
.	O

Complications	O
from	O
MTX	O
were	O
mild	O
and	O
included	O
anorexia	O
,	O
alopecia	O
,	O
and	O
stomatitis	O
.	O

All	O
complications	O
resolved	O
with	O
dose	O
reduction	O
or	O
when	O
MTX	O
was	O
stopped	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

No	O
subjects	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
MTX	O
complications	O
.	O

Low-dose	O
MTX	O
significantly	O
reduced	O
the	O
steroid	O
requirement	O
in	O
this	O
group	O
of	O
subjects	O
with	O
steroid-dependent	O
asthma	Condition
.	O

This	O
reduction	O
in	O
steroid	O
requirement	O
was	O
obtained	O
without	O
altering	O
clinical	O
status	O
and	O
without	O
significant	O
complication	O
.	O

Successful	O
treatment	O
of	O
blepharitis	Condition
with	O
bibrocathol	O
(	O
Posiformin?	O
2	O
%	O
)	O
.	O

BACKGROUND	O
Bibrocathol	O
is	O
a	O
well-established	O
antiseptic	O
drug	O
for	O
the	O
treatment	O
of	O
acute	O
eyelid	O
diseases	O
like	O
blepharitis	O
.	O

Despite	O
its	O
frequent	O
use	O
in	O
clinical	O
practice	O
,	O
no	O
controlled	O
clinical	O
trial	O
on	O
the	O
efficacy	O
of	O
bibrocathol	O
2	O
%	O
eye	O
ointment	O
has	O
been	O
performed	O
until	O
now	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
efficacy	O
,	O
safety	O
and	O
tolerability	O
of	O
bibrocathol	O
(	O
Posiformin?	O
2	O
%	O
)	O
eye	O
ointment	O
in	O
patients	O
diagnosed	O
with	O
blepharitis	O
.	O

METHODS	O
In	O
this	O
multi-center	O
,	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
parallel-group	O
comparison	O
,	O
the	O
change	O
of	O
signs	O
and	O
symptoms	O
(	O
sum	O
score	O
)	O
of	O
blepharitis	O
in	O
197	O
patients	O
(	O
ITT	O
(	O
intention-to-treat-group	O
)	O
;	O
mean	O
age	O
56	O
?	O
18	O
years	O
,	O
56	O
%	O
female	O
,	O
active	O
drug	O
:	O
vehicle	O
=	O
97:100	O
)	O
over	O
2	O
weeks	O
treatment	O
with	O
bibrocathol	O
2	O
%	O
eye	O
ointment	O
was	O
evaluated	O
.	O

RESULTS	O
Patients	O
receiving	O
bibrocathol	O
2	O
%	O
showed	O
greater	O
improvement	O
in	O
the	O
sum	O
score	O
than	O
the	O
placebo	O
patients	O
(	O
p	O
<	O
0.0001	O
,	O
Cohen	O
's	O
effect	O
size	O
d	O
=	O
0.73	O
)	O
.	O

Also	O
,	O
the	O
results	O
from	O
further	O
efficacy	O
assessments	O
improvement	O
of	O
single	O
symptoms	O
and	O
ocular	O
discomfort	O
measured	O
by	O
a	O
VAS	O
(	O
visual	O
analogue	O
scale	O
)	O
supported	O
treatment	O
with	O
bibrocathol	O
.	O

Patients	O
and	O
investigators	O
provided	O
favorable	O
tolerability	O
ratings	O
preferring	O
bibrocathol	O
over	O
placebo	O
.	O

No	O
safety	O
issues	O
were	O
observed	O
with	O
regard	O
to	O
intraocular	O
pressure	O
,	O
visual	O
acuity	O
,	O
or	O
occurrence	O
of	O
adverse	O
events	O
.	O

CONCLUSIONS	O
Blepharitis	O
therapy	O
with	O
the	O
antiseptic	O
bibrocathol	O
2	O
%	O
in	O
this	O
trial	O
was	O
highly	O
efficacious	O
and	O
safe	O
.	O

Effects	O
of	O
nifedipine	O
on	O
gastric	Condition
acid	Condition
secretion	Condition
and	O
gastrin	Condition
release	Condition
in	O
man	Sex
.	O

As	O
calcium	O
is	O
important	O
in	O
the	O
regulation	O
of	O
gastric	O
acid	O
secretion	O
and	O
gastrin	O
release	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
calcium	O
antagonist	O
nifedipine	O
on	O
these	O
processes	O
in	O
man	O
.	O

Nifedipine	O
30	O
mg	O
orally	O
inhibited	O
basal	O
acid	O
output	O
by	O
37	O
%	O
(	O
p	O
less	O
than	O
0.025	O
)	O
and	O
that	O
stimulated	O
by	O
low	O
infusion	O
rates	O
of	O
pentagastrin	O
--	O
that	O
is	O
,	O
0.031	O
and	O
0.062	O
microgram/kg/h	O
by	O
44	O
%	O
(	O
p	O
=	O
0.05	O
)	O
and	O
39	O
%	O
(	O
p	O
less	O
than	O
0.02	O
)	O
respectively	O
.	O

On	O
increasing	O
the	O
pentagastrin	O
infusion	O
rate	O
the	O
inhibition	O
was	O
surmounted	O
suggesting	O
it	O
was	O
competitive	O
in	O
type	O
.	O

Nifedipine	O
did	O
not	O
affect	O
basal	O
or	O
Oxo	O
meal	O
stimulated	O
gastrin	O
concentrations	O
in	O
normal	O
volunteers	O
nor	O
did	O
it	O
affect	O
resting	O
serum	O
gastrin	O
or	O
calcium	O
stimulated	O
increase	O
in	O
gastrin	O
in	O
a	O
single	O
patient	O
with	O
Zollinger-Ellison	Condition
syndrome	Condition
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
transmembrane	O
flux	O
of	O
calcium	O
ions	O
being	O
involved	O
in	O
basal	O
and	O
pentagastrin	Condition
stimulated	Condition
acid	Condition
secretion	Condition
in	O
man	O
.	O

Effect	O
of	O
esomeprazole	O
triple	O
therapy	O
on	O
eradication	O
rates	O
of	O
Helicobacter	O
pylori	O
,	O
gastric	O
ulcer	O
healing	O
and	O
prevention	O
of	O
relapse	O
in	O
gastric	Condition
ulcer	Condition
patients	O
.	O

OBJECTIVES	O
To	O
compare	O
esomeprazole-based	O
triple	O
therapy	O
with	O
esomeprazole	O
alone	O
for	O
the	O
eradication	O
of	O
Helicobacter	O
pylori	O
(	O
H.	O
pylori	O
)	O
,	O
healing	O
of	O
ulcer	O
and	O
prevention	O
of	O
relapse	O
in	O
H.	O
pylori-related	O
gastric	O
ulcer	O
(	O
GU	O
)	O
diseases	O
.	O

METHODS	O
In	O
this	O
double-blind	O
study	O
,	O
401	SampleSize
H.	O
pylori-positive	O
patients	O
with	O
more	O
than	O
or	O
equal	O
to	O
two	O
GUs	O
were	O
randomized	O
to	O
:	O
esomeprazole	O
(	O
20	O
mg	O
)	O
twice	O
daily	O
(	O
bid	O
)	O
and	O
amoxicillin	O
(	O
1000	O
mg	O
)	O
bid	O
and	O
clarithromycin	O
(	O
500	O
mg	O
)	O
bid	O
(	O
EAC	O
)	O
for	O
1	O
week	O
,	O
followed	O
by	O
placebo	O
for	O
3	O
weeks	O
(	O
EAC	O
and	O
placebo	O
)	O
;	O
EAC	O
for	O
1	O
week	O
,	O
followed	O
by	O
esomeprazole	O
(	O
20	O
mg	O
)	O
once	O
daily	O
(	O
E20	O
)	O
for	O
3	O
weeks	O
(	O
EAC	O
and	O
E20	O
)	O
;	O
or	O
esomeprazole	O
(	O
20	O
mg	O
)	O
bid	O
and	O
placebo	O
antimicrobials	O
for	O
1	O
week	O
,	O
followed	O
by	O
E20	O
for	O
3	O
weeks	O
(	O
E20	O
bid	O
and	O
E20	O
)	O
.	O

Patients	O
with	O
unhealed	O
GUs	O
at	O
4	O
weeks	O
received	O
E20	O
for	O
an	O
additional	O
4	O
weeks	O
.	O

Healed	O
patients	O
were	O
followed	O
up	O
for	O
12	O
months	O
.	O

RESULTS	O
Eradication	O
rates	O
at	O
4	O
weeks	O
or	O
8	O
weeks	O
were	O
82	O
%	O
for	O
EAC	O
and	O
E20	O
,	O
77	O
%	O
for	O
EAC	O
and	O
placebo	O
and	O
9.5	O
%	O
for	O
E20	O
bid	O
and	O
E20	O
(	O
intention-to-treat	O
analysis	O
)	O
.	O

Significantly	O
more	O
patients	O
receiving	O
EAC	O
than	O
those	O
receiving	O
esomeprazole	O
alone	O
remained	O
free	O
of	O
GUs	O
during	O
follow-up	O
[	O
EAC	O
and	O
E20	O
,	O
90	O
%	O
;	O
EAC	O
and	O
placebo	O
,	O
87	O
%	O
;	O
P=0.0005	O
for	O
combined	O
group	O
vs.	O
esomeprazole	O
alone	O
[	O
E20	O
bid	O
and	O
E20	O
(	O
74	O
%	O
)	O
]	O
.	O

All	O
treatments	O
were	O
well	O
tolerated	O
.	O

CONCLUSION	O
Esomeprazole-based	O
triple	O
therapy	O
is	O
effective	O
for	O
the	O
eradication	O
of	O
H.	O
pylori	O
,	O
healing	O
of	O
GU	O
and	O
prevention	O
of	O
relapse	O
.	O

Esomeprazole	O
monotherapy	O
for	O
3	O
weeks	O
after	O
triple	O
therapy	O
may	O
be	O
beneficial	O
in	O
terms	O
of	O
healing	O
.	O

Inhibin	O
A	O
is	O
down-regulated	O
during	O
chemotherapy	O
in	O
patients	O
with	O
breast	Condition
cancer	Condition
.	O

BACKGROUND	O
Inhibins	O
are	O
dimeric	O
glycoproteins	O
,	O
composed	O
of	O
an	O
alpha-subunit	O
(	O
INH-?	O
)	O
and	O
one	O
of	O
two	O
possible	O
beta-subunits	O
(	O
?A	O
or	O
?B	O
)	O
,	O
with	O
substantial	O
roles	O
in	O
human	O
reproduction	O
and	O
in	O
endocrine-responsive	O
tumours	O
.	O

Aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
serological	O
measurement	O
of	O
inhibin	O
A	O
(	O
?-?A	O
)	O
in	O
breast	Condition
cancer	Condition
patients	O
during	O
chemotherapy	O
.	O

PATIENTS	O
AND	O
METHODS	O
A	O
series	O
of	O
30	SampleSize
breast	Condition
cancer	Condition
patients	O
who	O
underwent	O
standardised	O
chemotherapy	O
were	O
prospectively	O
evaluated	O
before	O
chemotherapeutic	O
treatment	O
as	O
well	O
as	O
four	O
weeks	O
after	O
chemotherapy	O
and	O
two	O
years	O
after	O
chemotherapy	O
for	O
the	O
serological	O
expression	O
of	O
inhibin	O
A	O
.	O

For	O
statistical	O
analysis	O
the	O
Wilcoxon	O
rank	O
sum	O
test	O
was	O
used	O
for	O
paired	O
samples	O
.	O

Statistical	O
significance	O
was	O
assumed	O
at	O
p	O
<	O
0.05	O
.	O

RESULTS	O
The	O
concentration	O
of	O
inhibin	O
A	O
showed	O
a	O
significant	O
decrease	O
between	O
data	O
obtained	O
before	O
chemotherapy	O
and	O
after	O
chemotherapy	O
(	O
p	O
<	O
0.005	O
)	O
and	O
two-year	O
follow-up	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Interestingly	O
,	O
there	O
were	O
no	O
differences	O
in	O
inhibin	O
A	O
concentrations	O
between	O
the	O
four-week	O
and	O
two-year	O
follow-up	O
(	O
p=0.744	O
)	O
.	O

DISCUSSION	O
Chemotherapy	O
significantly	O
decreases	O
inhibin	O
A	O
concentration	O
during	O
chemotherapy	O
.	O

This	O
might	O
reflect	O
a	O
suppression	O
of	O
ovarian	O
function	O
,	O
being	O
also	O
a	O
marker	O
for	O
chemotherapy-induced	O
amenorrhoea	O
.	O

Moreover	O
,	O
it	O
has	O
been	O
suggested	O
that	O
inhibin	O
A	O
might	O
be	O
a	O
tumour	O
marker	O
for	O
breast	O
cancer	O
,	O
and	O
therefore	O
a	O
sudden	O
increase	O
in	O
its	O
concentration	O
might	O
be	O
indicative	O
of	O
breast	O
cancer	O
recurrence	O
.	O

Treatment	O
of	O
severe	O
aplastic	O
anemia	O
with	O
antilymphocyte	O
globulin	O
,	O
cyclosporine	O
and	O
two	O
different	O
granulocyte	O
colony-stimulating	O
factor	O
regimens	O
:	O
a	O
GITMO	O
prospective	O
randomized	O
study	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
In	O
a	O
previous	O
study	O
we	O
showed	O
that	O
patients	Condition
with	Condition
severe	Condition
aplastic	Condition
anemia	Condition
(	Condition
SAA	Condition
)	Condition
treated	Condition
with	Condition
anti-lymphocyte	Condition
globulin	Condition
(	Condition
ALG	Condition
)	Condition
,	Condition
cyclosporin	Condition
(	Condition
CyA	Condition
)	Condition
and	Condition
granulocyte	Condition
colony-stimulating	Condition
factor	Condition
(	Condition
G-CSF	Condition
)	Condition
5	O
micro	O
g/kg/day	O
had	O
an	O
encouraging	O
outcome	O
.	O

However	O
,	O
failure	O
to	O
respond	O
,	O
delayed	O
responses	O
,	O
partial	O
responses	O
,	O
relapses	O
and	O
early	O
deaths	O
remain	O
significant	O
problems	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
whether	O
a	O
higher	O
dose	O
of	O
G-CSF	O
(	O
10	O
micro	O
g/kg/day	O
)	O
would	O
reduce	O
these	O
complications	O
.	O

DESIGN	O
AND	O
METHODS	O
This	O
was	O
a	O
multicenter	O
prospective	O
trial	O
in	O
77	O
SAA	O
patients	O
treated	O
with	O
horse	O
ALG	O
(	O
15	O
mg/kg/day	O
day1-5	O
)	O
and	O
CyA	O
(	O
5	O
mg/kg/day	O
day	O
1-180	O
)	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
G-CSF	O
5	O
micro	O
g/kg/day	O
(	O
n=38	O
,	O
group	O
A	O
)	O
or	O
10	O
micro	O
g/kg/day	O
(	O
n=39	O
,	O
group	O
B	O
)	O
from	O
day	O
+1	O
to	O
day	O
+30	O
.	O

All	O
patients	O
then	O
received	O
G-CSF	O
5	O
micro	O
g/kg/day	O
from	O
day	O
+31	O
to	O
day	O
+90	O
.	O

The	O
primary	O
end	O
point	O
of	O
this	O
study	O
was	O
response	O
at	O
day	O
+120	O
.	O

Secondary	O
end	O
points	O
were	O
early	O
deaths	O
,	O
blood	O
counts	O
at	O
day	O
+120	O
,	O
and	O
survival	O
.	O

RESULTS	O
At	O
day	O
+120	O
responses	O
were	O
classified	O
as	O
absent	O
,	O
partial	O
,	O
and	O
complete	O
in	O
12	O
,	O
22	O
,	O
and	O
4	O
patients	O
in	O
group	O
A	O
and	O
in	O
23	O
,	O
7	O
,	O
and	O
9	O
patients	O
in	O
group	O
B	O
(	O
p=0.001	O
)	O
.	O

At	O
last	O
follow-up	O
these	O
figures	O
were	O
respectively	O
9	O
,	O
12	O
,	O
and	O
17	O
vs	O
19	O
,	O
2	O
,	O
and	O
18	O
(	O
p=0.004	O
)	O
.	O

Thirteen	O
patients	O
(	O
5	O
in	O
group	O
A	O
and	O
8	O
in	O
group	O
B	O
)	O
died	O
before	O
day	O
120	O
(	O
p=0.3	O
)	O
.	O

Median	O
peripheral	O
blood	O
counts	O
on	O
day	O
120	O
were	O
comparable	O
in	O
the	O
two	O
groups	O
:	O
Hb	O
10.5	O
and	O
9.5	O
g/dL	O
in	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
p=0.6	O
)	O
,	O
Neutrophil	O
counts	O
were	O
2.4	O
vs	O
1.9x10	O
(	O
9	O
)	O
/L	O
in	O
groups	O
A	O
and	O
B	O
(	O
p=0.4	O
)	O
and	O
platelet	O
counts	O
were	O
,	O
respectively	O
,	O
42	O
vs	O
36x10	O
(	O
9	O
)	O
/L	O
(	O
p=0.3	O
)	O
.	O

The	O
actuarial	O
survival	O
at	O
4	O
years	O
is	O
72	O
%	O
in	O
group	O
A	O
and	O
67	O
%	O
in	O
group	O
B	O
(	O
p=0.3	O
)	O
.	O

INTERPRETATION	O
AND	O
CONCLUSIONS	O
Increasing	O
the	O
dose	O
of	O
G-CSF	O
does	O
not	O
appear	O
to	O
reduce	O
early	O
deaths	O
,	O
does	O
not	O
improve	O
peripheral	O
blood	O
counts	O
nor	O
survival	O
,	O
and	O
may	O
reduce	O
the	O
response	O
rate	O
in	O
patients	O
with	O
SAA	O
receiving	O
ALG	O
and	O
CyA	O
.	O

Correlates	O
of	O
cognitive	O
deficits	O
in	O
first	Condition
episode	Condition
schizophrenia	Condition
.	O

OBJECTIVE	O
The	O
presence	O
of	O
cognitive	O
dysfunction	O
in	O
schizophrenia	Condition
has	O
been	O
well	O
documented	O
,	O
but	O
questions	O
remain	O
about	O
whether	O
there	O
are	O
relationships	O
between	O
this	O
dysfunction	O
and	O
clinical	O
symptomatology	O
.	O

If	O
present	O
,	O
such	O
relationships	O
should	O
be	O
most	O
clearly	O
observable	O
in	O
patients	O
with	O
first	Condition
episode	Condition
schizophrenia	Condition
;	O
that	O
is	O
,	O
before	O
the	O
effects	O
of	O
chronic	Condition
illness	Condition
,	O
institutionalization	O
,	O
or	O
treatment	O
might	O
confound	O
them	O
.	O

METHOD	O
307	SampleSize
schizophrenia	Condition
subjects	O
in	O
their	O
first	Condition
episode	Condition
of	Condition
illness	Condition
were	O
recruited	O
to	O
participate	O
in	O
a	O
clinical	O
trial	O
comparing	O
the	O
long-term	O
efficacy	O
of	O
haloperidol	O
and	O
risperidone	O
.	O

The	O
psychopathology	O
,	O
cognitive	O
functioning	O
,	O
early	O
treatment	O
history	O
,	O
and	O
duration	O
of	O
untreated	O
psychosis	O
of	O
these	O
subjects	O
were	O
assessed	O
prior	O
to	O
their	O
assignment	O
to	O
randomized	O
,	O
double-blind	O
treatment	O
.	O

Approximately	O
two-thirds	SampleSize
of	O
the	O
subjects	O
were	O
receiving	O
antipsychotic	O
treatment	O
at	O
the	O
time	O
of	O
assessment	O
;	O
however	O
,	O
the	O
duration	O
of	O
treatment	O
was	O
limited	O
to	O
12	O
weeks	O
or	O
less	O
.	O

RESULTS	O
The	O
severity	O
of	O
negative	O
symptoms	O
at	O
the	O
time	O
of	O
assessment	O
was	O
associated	O
with	O
deficits	O
in	O
memory	O
,	O
verbal	O
fluency	O
,	O
psychomotor	O
speed	O
and	O
executive	O
function	O
.	O

Positive	O
symptoms	O
were	O
not	O
associated	O
with	O
cognitive	O
deficits	O
.	O

Also	O
,	O
the	O
duration	O
of	O
untreated	O
illness	O
(	O
DUI	O
)	O
prior	O
to	O
assessment	O
was	O
not	O
significantly	O
associated	O
with	O
cognitive	O
impairment	O
.	O

CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
of	O
first	Condition
episode	Condition
schizophrenia	Condition
patients	O
suggest	O
that	O
a	O
relationship	O
exists	O
between	O
negative	O
symptoms	O
and	O
cognitive	O
dysfunction	O
.	O

However	O
,	O
that	O
relationship	O
accounts	O
for	O
only	O
a	O
minor	O
portion	O
of	O
the	O
variance	O
(	O
i.e.	O
,	O
10-15	O
%	O
)	O
in	O
the	O
severity	O
of	O
cognitive	O
dysfunction	O
after	O
controlling	O
for	O
a	O
number	O
of	O
potentially	O
confounding	O
factors	O
.	O

This	O
finding	O
provides	O
support	O
for	O
the	O
theory	O
that	O
the	O
neurobiological	O
processes	O
that	O
give	O
rise	O
to	O
symptomatology	O
and	O
cognitive	O
dysfunction	O
in	O
schizophrenia	Condition
are	O
partially	O
overlapping	O
.	O

Peripheral	O
intravenous	O
line	O
survival	O
and	O
phlebitis	O
prevention	O
in	O
patients	O
receiving	O
intravenous	O
antibiotics	O
:	O
heparin/hydrocortisone	O
versus	O
in-line	O
filters	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
use	O
of	O
in-line	O
filtration	O
with	O
the	O
addition	O
of	O
heparin/hydrocortisone	O
(	O
hep/hc	O
)	O
to	O
the	O
infusate	O
for	O
both	O
phlebitis	O
prevention	O
and	O
intravenous	O
(	O
i.v	O
.	O

)	O
line	O
survival	O
in	O
peripheral	O
i.v	O
.	O

catheters	O
.	O

This	O
study	O
was	O
specific	O
for	O
a	O
patient	SampleSize
group	SampleSize
receiving	O
prolonged	O
courses	O
of	O
i.v	O
.	O

antibiotics	O
.	O

Analysis	O
of	O
the	O
two	O
endpoints	O
for	O
conventional	O
short	O
i.v	O
.	O

catheters	O
(	O
short	O
lines	O
)	O
versus	O
long	O
(	O
30	O
cm	O
)	O
i.v	O
.	O

catheters	O
(	O
long	O
lines	O
)	O
was	O
also	O
performed	O
.	O

METHODS	O
Patients	O
with	O
cystic	O
fibrosis	O
receiving	O
intermittent	O
i.v	O
.	O

antibiotics	O
were	O
randomly	O
allocated	O
to	O
receive	O
their	O
drugs	O
either	O
through	O
an	O
in-line	O
filter	O
using	O
a	O
drug-free	O
infusate	O
or	O
with	O
no	O
filter	O
and	O
an	O
infusate	O
containing	O
heparin	O
500	O
units	O
and	O
hydrocortisone	O
10	O
mg/L	O
.	O

Infusion	O
sites	O
were	O
assessed	O
daily	O
.	O

RESULTS	O
Both	O
the	O
hep/hc	O
and	O
filter	O
groups	O
were	O
similar	O
in	O
terms	O
of	O
phlebitis	O
incidence	O
and	O
i.v	O
.	O

line	O
survival	O
when	O
analyzed	O
separately	O
for	O
both	O
short	O
and	O
long	O
lines	O
.	O

Long	O
lines	O
displayed	O
markedly	O
prolonged	O
survival	O
times	O
and	O
reduced	O
phlebitis	O
compared	O
with	O
short	O
lines	O
.	O

CONCLUSIONS	O
The	O
effectiveness	O
of	O
i.v	O
.	O

filters	O
in	O
excluding	O
the	O
large	O
particle	O
load	O
introduced	O
by	O
i.v	O
.	O

antibiotics	O
and	O
hence	O
in	O
reducing	O
the	O
subsequent	O
phlebitis	O
makes	O
them	O
a	O
useful	O
alternative	O
to	O
the	O
use	O
of	O
hep/hc	O
.	O

The	O
use	O
of	O
filters	O
in	O
this	O
patient	O
group	O
may	O
offer	O
advantages	O
in	O
terms	O
of	O
ease	O
of	O
use	O
and	O
a	O
possible	O
decrease	O
in	O
hep/hc-related	O
problems	O
.	O

Long	O
lines	O
offer	O
practical	O
advantages	O
over	O
short	O
lines	O
for	O
patients	O
requiring	O
longer	O
term	O
i.v	O
.	O

access	O
.	O

Brief	O
Report	O
:	O
social	O
disability	O
in	O
autism	O
spectrum	O
disorder	O
:	O
results	O
from	O
Research	O
Units	O
on	O
Pediatric	O
Psychopharmacology	O
(	O
RUPP	O
)	O
Autism	O
Network	O
trials	O
.	O

There	O
is	O
growing	O
interest	O
in	O
measuring	O
social	O
disability	O
as	O
a	O
core	O
element	O
of	O
autism	O
spectrum	O
disorders	O
in	O
medication	O
trials	O
.	O

We	O
conducted	O
a	O
secondary	O
analysis	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
Social	O
Withdrawal	O
subscale	O
using	O
data	O
from	O
two	O
federally-funded	O
,	O
multi-site	O
,	O
randomized	O
trials	O
with	O
risperidone	O
.	O

Study	O
1	O
included	O
52	O
subjects	O
assigned	O
to	O
placebo	O
and	O
49	O
subjects	O
to	O
risperidone	O
under	O
double-blind	O
conditions	O
.	O

Study	O
2	O
included	O
49	O
subjects	O
assigned	O
to	O
risperidone	O
only	O
and	O
75	O
subjects	O
assigned	O
to	O
risperidone	O
plus	O
parent	O
training	O
.	O

After	O
8	O
weeks	O
of	O
treatment	O
,	O
all	O
active	O
treatments	O
were	O
superior	O
to	O
placebo	O
(	O
effect	O
sizes	O
ranging	O
from	O
0.42	O
to	O
0.65	O
)	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
Social	O
Withdrawal	O
subscale	O
may	O
be	O
a	O
useful	O
measure	O
of	O
social	O
disability	O
in	O
acute	O
treatment	O
trials	O
.	O

Pre-medication	O
with	O
pronase	O
reduces	O
artefacts	O
during	O
endoscopic	O
ultrasonography	O
.	O

BACKGROUND	O
Gastric	O
mucus	O
usually	O
induces	O
artefacts	O
during	O
endoscopic	O
ultrasonography	O
.	O

AIM	O
To	O
investigate	O
the	O
effectiveness	O
of	O
pre-medication	O
with	O
the	O
proteolytic	O
enzyme	O
,	O
pronase	O
,	O
before	O
endoscopic	O
ultrasonography	O
.	O

METHODS	O
Out-patients	O
scheduled	O
for	O
endoscopic	O
ultrasonography	O
were	O
randomly	O
assigned	O
to	O
oral	O
pre-medication	O
with	O
the	O
anti-foam	O
agent	O
,	O
dimethylpolysiloxane	O
,	O
alone	O
(	O
treatment	O
A	O
;	O
n	O
=	O
29	O
)	O
,	O
with	O
dimethylpolysiloxane	O
plus	O
sodium	O
bicarbonate	O
(	O
treatment	O
B	O
;	O
n	O
=	O
29	O
)	O
or	O
with	O
dimethylpolysiloxane	O
,	O
sodium	O
bicarbonate	O
and	O
pronase	O
(	O
treatment	O
C	O
;	O
n	O
=	O
29	O
)	O
.	O

All	O
drinks	O
were	O
given	O
about	O
10	O
min	O
before	O
the	O
start	O
of	O
the	O
procedure	O
.	O

After	O
insertion	O
of	O
the	O
endoscope	O
,	O
endoscopists	O
recorded	O
visibility	O
scores	O
before	O
the	O
procedure	O
,	O
imaging	O
scores	O
at	O
endoscopic	O
ultrasonography	O
and	O
the	O
numbers	O
of	O
high-echo	O
spots	O
in	O
the	O
gastric	O
cavity	O
and	O
on	O
the	O
gastric	O
wall	O
surface	O
after	O
the	O
procedure	O
.	O

RESULTS	O
Pre-medication	O
with	O
pronase	O
(	O
treatment	O
C	O
)	O
significantly	O
reduced	O
(	O
both	O
at	O
P	O
<	O
0.05	O
)	O
the	O
visibility	O
score	O
(	O
score	O
4	O
,	O
46	O
%	O
)	O
in	O
comparison	O
with	O
that	O
obtained	O
for	O
pre-medication	O
without	O
pronase	O
(	O
10	O
%	O
for	O
both	O
treatments	O
A	O
and	O
B	O
)	O
.	O

Treatment	O
with	O
pronase	O
significantly	O
reduced	O
(	O
both	O
at	O
P	O
<	O
0.05	O
)	O
the	O
endoscopic	O
ultrasonography	O
score	O
in	O
the	O
gastric	O
cavity	O
(	O
score	O
4	O
,	O
34	O
%	O
)	O
in	O
comparison	O
with	O
that	O
found	O
for	O
treatments	O
A	O
(	O
7	O
%	O
)	O
and	O
B	O
(	O
0	O
%	O
)	O
.	O

It	O
also	O
significantly	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
the	O
endoscopic	O
ultrasonography	O
score	O
on	O
the	O
gastric	O
wall	O
surface	O
(	O
score	O
4	O
,	O
14	O
%	O
)	O
in	O
comparison	O
with	O
that	O
observed	O
for	O
treatment	O
A	O
(	O
3	O
%	O
)	O
.	O

The	O
numbers	O
of	O
high-echo	O
spots	O
in	O
the	O
gastric	O
cavity	O
and	O
on	O
the	O
gastric	O
wall	O
surface	O
were	O
significantly	O
less	O
(	O
both	O
at	O
P	O
<	O
0.001	O
)	O
for	O
pre-medication	O
with	O
pronase	O
(	O
treatment	O
C	O
)	O
than	O
for	O
pre-medication	O
with	O
treatments	O
A	O
and	O
B	O
.	O

There	O
were	O
no	O
complications	O
associated	O
with	O
the	O
solutions	O
.	O

CONCLUSIONS	O
Pre-treatment	O
with	O
pronase	O
reduced	O
the	O
artefacts	O
during	O
endoscopic	O
ultrasonography	O
.	O

Standardized	O
preoperative	O
corticosteroid	O
treatment	O
in	O
neonates	O
undergoing	O
cardiac	O
surgery	O
:	O
results	O
from	O
a	O
randomized	O
trial	O
.	O

OBJECTIVE	O
A	O
heightened	O
inflammatory	O
response	O
occurs	O
after	O
cardiac	O
surgery	O
.	O

The	O
perioperative	O
use	O
of	O
glucocorticoids	O
has	O
been	O
advocated	O
as	O
a	O
method	O
to	O
improve	O
postoperative	O
outcomes	O
.	O

Randomized	O
prospective	O
studies	O
to	O
quantify	O
the	O
effect	O
of	O
methylprednisolone	O
on	O
perioperative	O
outcomes	O
in	O
neonatal	O
cardiac	O
surgery	O
have	O
not	O
been	O
performed	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
preoperative	O
methylprednisolone	O
would	O
improve	O
postoperative	O
recovery	O
in	O
neonates	O
requiring	O
cardiac	O
surgery	O
.	O

METHODS	O
Neonates	O
scheduled	O
for	O
cardiac	O
surgery	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
2-dose	O
(	O
8	O
hours	O
preoperatively	O
and	O
operatively	O
,	O
n	O
=	O
39	O
)	O
or	O
single-dose	O
(	O
operatively	O
,	O
n	O
=	O
37	O
)	O
methylprednisolone	O
(	O
30	O
mg/kg	O
per	O
dose	O
)	O
in	O
a	O
prospective	O
double-blind	O
trial	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
incidence	O
of	O
low	O
cardiac	O
output	O
syndrome	O
(	O
standardized	O
score	O
)	O
or	O
death	O
36	O
hours	O
postoperatively	O
.	O

Secondary	O
outcomes	O
were	O
death	O
at	O
30	O
days	O
,	O
interleukin-6	O
levels	O
,	O
inotropic	O
score	O
,	O
fluid	O
balance	O
,	O
serum	O
creatinine	O
,	O
and	O
intensive	O
care	O
unit	O
and	O
hospital	O
stay	O
.	O

RESULTS	O
Preoperative	O
plasma	O
levels	O
of	O
the	O
inflammatory	O
cytokine	O
interleukin-6	O
were	O
reduced	O
by	O
2-fold	O
(	O
P	O
<	O
.001	O
)	O
in	O
the	O
2-dose	O
methylprednisolone	O
group	O
,	O
consistent	O
with	O
the	O
anti-inflammatory	O
effects	O
of	O
methylprednisolone	O
.	O

However	O
,	O
the	O
incidence	O
of	O
low	O
cardiac	O
output	O
syndrome	O
was	O
46	O
%	O
(	O
17/37	O
)	O
in	O
the	O
single-dose	O
and	O
38	O
%	O
(	O
15/39	O
)	O
in	O
the	O
2-dose	O
methylprednisolone	O
groups	O
(	O
P	O
=	O
.51	O
)	O
.	O

Two-dose	O
methylprednisolone	O
was	O
associated	O
with	O
a	O
higher	O
serum	O
creatinine	O
(	O
0.61	O
?	O
0.18	O
mg/dL	O
vs	O
0.53	O
?	O
0.12	O
mg/dL	O
,	O
P	O
=	O
.03	O
)	O
and	O
poorer	O
postoperative	O
diuresis	O
(	O
-96	O
?	O
49	O
mL	O
,	O
P	O
=	O
.05	O
)	O
.	O

Inotropic	O
requirement	O
,	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
intensive	O
care	O
unit	O
,	O
and	O
hospital	O
stay	O
did	O
not	O
differ	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
Combined	O
preoperative	O
and	O
intraoperative	O
use	O
of	O
glucocorticoids	O
in	O
neonatal	O
cardiac	O
surgery	O
does	O
not	O
favorably	O
affect	O
early	O
clinical	O
outcomes	O
and	O
may	O
exacerbate	O
perioperative	O
renal	O
dysfunction	O
.	O

Efficacy	O
of	O
primaquine	O
regimens	O
for	O
primaquine-resistant	O
Plasmodium	O
vivax	O
malaria	O
in	O
Thailand	Condition
.	Condition

To	O
define	O
the	O
current	O
efficacy	O
of	O
Fansidar	O
(	O
F.	O
Hoffmann-La	O
Roche	O
Ltd.	O
,	O
Basel	O
Switzerland	O
)	O
(	O
pyrimethamine	O
and	O
sulfadoxine	O
)	O
,	O
primaquine	O
in	O
a	O
high	O
dose	O
,	O
and	O
artesunate	O
for	O
treating	O
acute	O
Plasmodium	O
vivax	O
malaria	O
,	O
we	O
conducted	O
a	O
comparative	O
clinical	O
trial	O
of	O
these	O
3	O
drugs	O
in	O
an	O
open-label	O
study	O
.	O

Patients	O
(	O
15-65	O
years	O
old	O
)	O
were	O
assigned	O
to	O
1	O
of	O
4	O
treatments	O
regimens	O
in	O
a	O
serial	O
order	O
.	O

Ninety	O
percent	O
of	O
the	O
patients	O
were	O
infected	O
at	O
Thailand-Myanmar	O
border	O
.	O

Patients	O
in	O
group	O
I	O
(	O
n	O
=	O
23	O
)	O
received	O
Fansidar	O
(	O
3	O
tablets	O
,	O
75	O
mg	O
of	O
pyrimethamine	O
and	O
1,500	O
mg	O
of	O
sulfadoxine	O
,	O
a	O
single	O
dose	O
on	O
the	O
first	O
day	O
)	O
,	O
group	O
II	O
(	O
n	O
=	O
23	O
)	O
received	O
Fansidar	O
(	O
3	O
tablets	O
,	O
75	O
mg	O
of	O
pyrimethamine	O
and	O
1,500	O
mg	O
of	O
sulfadoxine	O
,	O
a	O
single	O
dose	O
on	O
the	O
first	O
day	O
)	O
and	O
then	O
received	O
primaquine	O
(	O
30	O
mg	O
a	O
day	O
for	O
14	O
days	O
)	O
,	O
group	O
III	O
(	O
n	O
=	O
23	O
)	O
received	O
primaquine	O
(	O
30	O
mg	O
a	O
day	O
for	O
14	O
days	O
)	O
,	O
and	O
group	O
IV	O
(	O
n	O
=	O
23	O
)	O
received	O
artesunate	O
(	O
200	O
mg	O
once	O
a	O
day	O
for	O
3	O
days	O
)	O
and	O
then	O
primaquine	O
(	O
30	O
mg	O
a	O
day	O
for	O
14	O
days	O
)	O
.	O

Cure	O
rates	O
on	O
day	O
28	O
of	O
follow-up	O
were	O
40	O
%	O
,	O
100	O
%	O
,	O
100	O
%	O
,	O
and	O
100	O
%	O
in	O
groups	O
I	O
,	O
II	O
,	O
II	O
,	O
and	O
IV	O
,	O
respectively	O
.	O

There	O
were	O
4	O
and	O
5	O
patients	O
in	O
group	O
I	O
showing	O
post-treatment	O
reappearance	O
of	O
parasitemia	O
at	O
<	O
or	O
=	O
16	O
days	O
and	O
between	O
17	O
and	O
28	O
days	O
,	O
respectively	O
.	O

Patients	O
in	O
the	O
other	O
3	O
groups	O
showed	O
negative	O
parasitemias	O
within	O
7	O
days	O
after	O
treatment	O
.	O

Artesunate	O
plus	O
primaquine	O
(	O
group	O
IV	O
)	O
cleared	O
parasitemia	O
faster	O
than	O
the	O
other	O
3	O
regimens	O
.	O

There	O
is	O
a	O
high	O
proportion	O
of	O
ineffectiveness	O
of	O
Fansidar	O
for	O
treatment	O
of	O
P.	O
vivax	O
malaria	O
and	O
it	O
should	O
be	O
no	O
longer	O
used	O
for	O
treatment	O
of	O
P.	O
vivax	O
malaria	O
acquired	O
at	O
the	O
Thailand-Myanmar	O
border	O
.	O

A	O
high	O
dose	O
of	O
primaquine	O
is	O
safe	O
and	O
effective	O
in	O
the	O
treatment	O
of	O
P.	O
vivax	O
malaria	O
during	O
the	O
28-day	O
follow-up	O
period	O
.	O

Cardiovascular	O
effects	O
of	O
tamoxifen	O
in	O
women	O
with	O
and	O
without	O
heart	O
disease	O
:	O
breast	O
cancer	O
prevention	O
trial	O
.	O

National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
Breast	O
Cancer	O
Prevention	O
Trial	O
Investigators	O
.	O

BACKGROUND	O
The	O
overall	O
effect	O
of	O
prophylactic	O
tamoxifen	O
in	O
women	O
depends	O
on	O
the	O
balance	O
between	O
the	O
effects	O
of	O
the	O
drug	O
,	O
which	O
include	O
preventing	O
breast	O
cancer	O
and	O
altering	O
cardiovascular	O
risk	O
.	O

In	O
a	O
recent	O
clinical	O
trial	O
,	O
postmenopausal	O
estrogen-progestin	O
therapy	O
was	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
early	O
cardiovascular	O
events	O
among	O
women	O
with	O
a	O
history	O
of	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
.	O

The	O
cardiovascular	O
effects	O
of	O
tamoxifen	O
in	O
women	O
with	O
and	O
without	O
CHD	O
are	O
not	O
known	O
.	O

The	O
National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
Breast	O
Cancer	O
Prevention	O
Trial	O
(	O
BCPT	O
)	O
is	O
the	O
only	O
clinical	O
trial	O
that	O
provides	O
data	O
to	O
assess	O
the	O
cardiovascular	O
effects	O
of	O
tamoxifen	O
in	O
women	O
with	O
and	O
without	O
CHD	O
.	O

METHODS	O
A	O
total	O
of	O
13	O
388	O
women	O
at	O
increased	O
risk	O
for	O
breast	O
cancer	O
were	O
randomly	O
assigned	O
in	O
the	O
BCPT	O
to	O
receive	O
either	O
tamoxifen	O
(	O
20	O
mg/day	O
)	O
or	O
placebo	O
.	O

Cardiovascular	O
follow-up	O
was	O
available	O
for	O
13	O
194	O
women	O
,	O
1048	O
of	O
whom	O
had	O
prior	O
clinical	O
CHD	O
.	O

Fatal	O
and	O
nonfatal	O
myocardial	O
infarction	O
,	O
unstable	O
angina	O
,	O
and	O
severe	O
angina	O
were	O
tabulated	O
(	O
mean	O
follow-up	O
:	O
49	O
months	O
)	O
.	O

All	O
statistical	O
tests	O
were	O
two-sided	O
.	O

RESULTS	O
Cardiovascular	O
event	O
rates	O
were	O
not	O
statistically	O
significantly	O
different	O
between	O
women	O
assigned	O
to	O
receive	O
tamoxifen	O
and	O
those	O
assigned	O
to	O
receive	O
placebo	O
,	O
independent	O
of	O
pre-existing	O
CHD	O
.	O

Among	O
women	O
without	O
CHD	O
(	O
6074	O
on	O
tamoxifen	O
versus	O
6072	O
on	O
placebo	O
)	O
,	O
risk	O
ratios	O
(	O
95	O
%	O
confidence	O
intervals	O
[	O
CIs	O
]	O
)	O
for	O
tamoxifen	O
users	O
were	O
1.75	O
(	O
0.44	O
to	O
8.13	O
)	O
for	O
fatal	O
myocardial	O
infarction	O
,	O
1.11	O
(	O
0.55	O
to	O
2.28	O
)	O
for	O
nonfatal	O
myocardial	O
infarction	O
,	O
0.69	O
(	O
0.29	O
to	O
1.57	O
)	O
for	O
unstable	O
angina	O
,	O
and	O
0.83	O
(	O
0.32	O
to	O
2.10	O
)	O
for	O
severe	O
angina	O
.	O

In	O
women	O
with	O
CHD	O
(	O
516	O
on	O
tamoxifen	O
versus	O
532	O
on	O
placebo	O
)	O
,	O
risk	O
ratios	O
(	O
95	O
%	O
CIs	O
)	O
for	O
tamoxifen	O
users	O
were	O
0.00	O
(	O
0	O
to	O
1.58	O
)	O
for	O
fatal	O
myocardial	O
infarction	O
,	O
1.25	O
(	O
0.32	O
to	O
5.18	O
)	O
for	O
nonfatal	O
myocardial	O
infarction	O
,	O
2.26	O
(	O
0.87	O
to	O
6.55	O
)	O
for	O
unstable	O
angina	O
,	O
and	O
1.39	O
(	O
0.23	O
to	O
9.47	O
)	O
for	O
severe	O
angina	O
.	O

There	O
was	O
no	O
evidence	O
that	O
the	O
lack	O
of	O
association	O
between	O
tamoxifen	O
and	O
cardiovascular	O
events	O
was	O
related	O
to	O
an	O
early	O
increase	O
in	O
risk	O
that	O
may	O
have	O
been	O
offset	O
by	O
a	O
late	O
decrease	O
in	O
risk	O
.	O

CONCLUSION	O
When	O
used	O
for	O
breast	O
cancer	O
prevention	O
in	O
women	O
with	O
or	O
without	O
heart	O
disease	O
,	O
tamoxifen	O
is	O
not	O
associated	O
with	O
beneficial	O
or	O
adverse	O
cardiovascular	O
effects	O
.	O

Chemotherapy	O
for	O
patients	O
with	O
non-small	O
cell	O
lung	Condition
cancer	Condition
:	O
the	O
surgical	O
setting	O
of	O
the	O
Big	O
Lung	O
Trial	O
.	O

OBJECTIVES	O
The	O
non-small	O
cell	O
lung	Condition
cancer	Condition
(	O
NSCLC	O
)	O
meta-analysis	O
suggested	O
a	O
survival	O
benefit	O
for	O
cisplatin-based	O
chemotherapy	O
when	O
given	O
in	O
addition	O
to	O
surgery	O
,	O
radical	O
radiotherapy	O
or	O
'best	O
supportive	O
care	O
'	O
.	O

However	O
,	O
it	O
included	O
many	O
small	O
trials	O
and	O
trials	O
with	O
differing	O
eligibility	O
criteria	O
and	O
chemotherapy	O
regimens	O
.	O

The	O
aim	O
of	O
the	O
Big	O
Lung	O
Trial	O
was	O
therefore	O
to	O
run	O
a	O
large	O
pragmatic	O
trial	O
to	O
confirm	O
the	O
survival	O
benefits	O
seen	O
in	O
the	O
meta-analysis	O
.	O

METHODS	O
In	O
the	O
surgery	O
setting	O
,	O
a	O
total	O
of	O
381	SampleSize
patients	O
were	O
randomised	O
to	O
chemotherapy	O
(	O
C	O
,	O
192	SampleSize
patients	O
)	O
or	O
no	O
chemotherapy	O
(	O
NoC	O
,	O
189	SampleSize
patients	O
)	O
.	O

C	O
was	O
three	O
3-weekly	O
cycles	O
of	O
cisplatin/vindesine	O
,	O
mitomycin/ifosfamide/cisplatin	O
,	O
mitomycin/vinblastine/cisplatin	O
or	O
vinorelbine/cisplatin	O
.	O

RESULTS	O
Chemotherapy	O
was	O
given	O
before	O
surgery	O
in	O
3	O
%	O
of	O
patients	O
whilst	O
97	O
%	O
received	O
adjuvant	O
chemotherapy	O
.	O

Baseline	O
characteristics	O
were	O
:	O
median	O
age	O
61	O
years	O
,	O
69	O
%	O
male	O
,	O
48	O
%	O
squamous	O
cell	O
,	O
93	O
%	O
WHO	O
PS	O
0-1	O
,	O
27	O
%	O
stage	O
I	O
,	O
38	O
%	O
stage	O
II	O
,	O
and	O
34	O
%	O
stage	O
III	O
.	O

Complete	O
resection	O
was	O
achieved	O
in	O
approximately	O
95	O
%	O
of	O
patients	O
.	O

In	O
the	O
C	O
group	O
,	O
13	O
%	O
received	O
no	O
chemotherapy	O
,	O
21	O
%	O
one	O
or	O
two	O
cycles	O
,	O
and	O
64	O
%	O
all	O
three	O
cycles	O
of	O
their	O
prescribed	O
chemotherapy	O
(	O
60	O
%	O
of	O
the	O
latter	O
with	O
no	O
delays	O
or	O
modification	O
)	O
.	O

30	O
%	O
had	O
grade	O
3/4	O
toxicity	O
,	O
mainly	O
haematological	O
,	O
nausea/vomiting	O
and	O
neutropenic	O
fever	O
,	O
and	O
six	O
patients	O
were	O
reported	O
as	O
having	O
a	O
treatment-related	O
death	O
.	O

198	O
(	O
52	O
%	O
)	O
of	O
patients	O
have	O
died	O
,	O
but	O
there	O
is	O
currently	O
no	O
evidence	O
of	O
a	O
benefit	O
in	O
overall	O
survival	O
to	O
the	O
C	O
group	O
:	O
HR	O
1.02	O
(	O
95	O
%	O
CI	O
0.77-1.35	O
)	O
,	O
P	O
=	O
0.90	O
)	O
.	O

CONCLUSIONS	O
This	O
trial	O
has	O
failed	O
to	O
observe	O
a	O
survival	O
benefit	O
with	O
adjuvant	O
chemotherapy	O
following	O
complete	O
resection	O
of	O
stage	O
I-III	O
NSCLC	O
.	O

However	O
,	O
the	O
hazard	O
ratio	O
and	O
95	O
%	O
confidence	O
intervals	O
are	O
consistent	O
with	O
the	O
previously	O
reported	O
meta-analysis	O
and	O
two	O
large	O
recently	O
reported	O
trials	O
,	O
which	O
suggest	O
a	O
small	O
survival	O
benefit	O
with	O
cisplatin-based	O
chemotherapy	O
.	O

Dynamic	O
surface	O
electromyographic	O
responses	O
in	O
chronic	O
low	O
back	O
pain	O
treated	O
by	O
traditional	O
bone	O
setting	O
and	O
conventional	O
physical	O
therapy	O
.	O

OBJECTIVE	O
This	O
study	O
compared	O
the	O
dynamic	O
surface	O
electromyographic	O
(	O
EMG	O
)	O
activities	O
of	O
back	O
muscles	O
and	O
pain	O
before	O
and	O
after	O
traditional	O
bone	O
setting	O
and	O
physical	O
therapy	O
.	O

METHODS	O
This	O
study	O
was	O
a	O
prospective	O
clinical	O
trial	O
that	O
compared	O
surface	O
EMG	O
dynamic	O
activities	O
after	O
traditional	O
bone	O
setting	O
and	O
physical	O
therapy	O
.	O

Sixty-one	O
patients	O
(	O
mean	O
age	O
,	O
41	O
years	O
)	O
with	O
nonspecific	O
low	O
back	O
pain	O
were	O
randomized	O
into	O
two	O
subgroups	O
by	O
treatment	O
.	O

The	O
patients	O
underwent	O
a	O
dynamic	O
EMG	O
evaluation	O
for	O
which	O
they	O
were	O
asked	O
to	O
stand	O
and	O
then	O
bend	O
forward	O
as	O
far	O
as	O
possible	O
,	O
stay	O
fully	O
flexed	O
,	O
and	O
return	O
to	O
standing	O
.	O

A	O
flexion-relaxation	O
ratio	O
was	O
calculated	O
by	O
comparing	O
maximal	O
EMG	O
activity	O
while	O
flexing	O
with	O
the	O
average	O
EMG	O
activity	O
in	O
full	O
flexion	O
.	O

Concentric	O
(	O
maximal	O
EMG	O
activity	O
during	O
extension	O
)	O
and	O
eccentric	O
(	O
maximal	O
EMG	O
activity	O
during	O
flexion	O
)	O
ratios	O
were	O
also	O
used	O
in	O
the	O
analyses	O
.	O

RESULTS	O
Disability	O
,	O
depression	O
,	O
and	O
visual	O
analog	O
scale	O
scores	O
decreased	O
significantly	O
after	O
both	O
treatments	O
.	O

The	O
concentric	O
ratio	O
increased	O
statistically	O
in	O
both	O
groups	O
after	O
the	O
treatments	O
.	O

The	O
study	O
failed	O
to	O
show	O
a	O
significant	O
association	O
between	O
experienced	O
back	O
pain	O
and	O
EMG	O
parameters	O
.	O

CONCLUSIONS	O
Both	O
treatments	O
seem	O
to	O
have	O
a	O
positive	O
influence	O
on	O
back	O
muscle	O
function	O
by	O
improving	O
muscle	O
symmetry	O
;	O
however	O
,	O
the	O
treatments	O
had	O
no	O
effect	O
on	O
the	O
flexion-relaxation	O
phenomenon	O
after	O
1	O
month	O
.	O

Active	O
back	O
exercise	O
at	O
home	O
together	O
with	O
rehabilitation	O
treatments	O
might	O
be	O
effective	O
and	O
improve	O
function	O
for	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
.	O

Dose-response	O
comparison	O
of	O
RRR-alpha-tocopherol	O
and	O
all-racemic	O
alpha-tocopherol	O
on	O
LDL	O
oxidation	O
.	O

Much	O
data	O
have	O
accrued	O
in	O
support	O
of	O
the	O
concept	O
that	O
oxidation	O
of	O
LDL	O
is	O
a	O
key	O
early	O
step	O
in	O
atherogenesis	O
.	O

The	O
most	O
consistent	O
data	O
with	O
respect	O
to	O
micronutrient	O
antioxidants	O
and	O
atherosclerosis	O
appear	O
to	O
relate	O
to	O
alpha-tocopherol	O
(	O
AT	O
)	O
,	O
the	O
predominant	O
lipid-soluble	O
antioxidant	O
in	O
LDL	O
.	O

There	O
are	O
scant	O
data	O
on	O
the	O
direct	O
comparison	O
of	O
RRR-AT	O
and	O
all-racemic	O
(	O
rac	O
)	O
-AT	O
on	O
LDL	O
oxidizability	O
.	O

Hence	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
relative	O
effects	O
of	O
RRR-AT	O
and	O
all-rac-AT	O
on	O
plasma	O
antioxidant	O
levels	O
and	O
LDL	O
oxidation	O
in	O
healthy	O
persons	O
in	O
a	O
dose-response	O
study	O
.	O

The	O
effect	O
of	O
RRR-AT	O
and	O
all-rac-AT	O
at	O
doses	O
of	O
100	O
,	O
200	O
,	O
400	O
,	O
and	O
800	O
IU/d	O
on	O
plasma	O
and	O
LDL	O
AT	O
levels	O
and	O
LDL	O
oxidation	O
was	O
tested	O
in	O
a	O
randomized	O
,	O
placebo-controlled	O
study	O
of	O
79	O
healthy	O
subjects	O
.	O

Copper-catalyzed	O
oxidation	O
of	O
LDL	O
was	O
monitored	O
by	O
measuring	O
the	O
formation	O
of	O
conjugated	O
dienes	O
and	O
lipid	O
peroxides	O
over	O
an	O
8-hour	O
time	O
course	O
at	O
baseline	O
and	O
again	O
after	O
8	O
weeks	O
.	O

Plasma	O
AT	O
,	O
lipid-standardized	O
AT	O
,	O
and	O
LDL	O
AT	O
levels	O
rose	O
in	O
a	O
dose-dependent	O
fashion	O
in	O
both	O
the	O
RRR-AT	O
and	O
all-rac-AT	O
groups	O
compared	O
with	O
baseline	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
plasma	O
,	O
lipid-standardized	O
,	O
and	O
LDL	O
AT	O
levels	O
between	O
RRR-AT	O
and	O
all-rac-AT	O
supplementation	O
at	O
any	O
dose	O
comparison	O
.	O

The	O
lag	O
phases	O
of	O
oxidation	O
were	O
significantly	O
prolonged	O
with	O
doses	O
>	O
or	O
=	O
400	O
IU/d	O
of	O
RRR-AT	O
and	O
all-rac-AT	O
,	O
as	O
measured	O
by	O
conjugated-dienes	O
assay	O
and	O
at	O
400	O
IU/d	O
of	O
RRR-AT	O
and	O
800	O
IU/d	O
of	O
both	O
forms	O
of	O
AT	O
by	O
lipid	O
peroxide	O
assay	O
.	O

Again	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
lag	O
phase	O
of	O
oxidation	O
at	O
each	O
dose	O
for	O
RRR-AT	O
when	O
compared	O
with	O
all-rac-AT	O
.	O

Also	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
LDL	O
oxidation	O
after	O
in	O
vitro	O
enrichment	O
of	O
LDL	O
with	O
RRR-AT	O
and	O
all-rac-AT	O
.	O

Thus	O
,	O
supplementation	O
with	O
either	O
RRR-AT	O
or	O
all-rac-AT	O
resulted	O
in	O
similar	O
increases	O
in	O
plasma	O
and	O
LDL	O
AT	O
levels	O
at	O
equivalent	O
IU	O
doses	O
,	O
and	O
the	O
degree	O
of	O
protection	O
against	O
copper-catalyzed	O
LDL	O
oxidation	O
was	O
only	O
evident	O
at	O
doses	O
>	O
or	O
=	O
400	O
IU/d	O
for	O
both	O
forms	O
.	O

[	O
Effect	O
of	O
zengjing	O
no	O
.	O

1	O
capsule	O
on	O
morphology	O
and	O
motility	O
of	O
sperm	O
in	O
patients	O
with	O
oligospermia	O
]	O
.	O

OBJECTIVE	O
To	O
explore	O
the	O
effect	O
of	O
Zengjing	O
Capsule	O
No	O
.	O

1	O
(	O
ZJC1	O
)	O
on	O
morphology	O
and	O
motility	O
of	O
sperm	O
in	O
patients	O
with	O
oligospermia	O
(	O
OSM	O
)	O
.	O

METHODS	O
Seventy-two	O
OSM	O
patients	O
were	O
assigned	O
to	O
2	O
groups	O
by	O
a	O
randomizing	O
digital	O
table	O
,	O
the	O
treated	O
group	O
and	O
the	O
control	O
group	O
,	O
they	O
were	O
treated	O
respectively	O
by	O
ZJC1	O
and	O
Wuzi	O
Yanzong	O
Pill	O
(	O
WYP	O
)	O
.	O

The	O
changes	O
of	O
density	O
,	O
motility	O
and	O
morphology	O
of	O
sperm	O
in	O
patients	O
before	O
and	O
after	O
3-month	O
treatment	O
were	O
examined	O
using	O
computerized	O
WLJY-9000	O
colour	O
semen	O
analysis	O
system	O
with	O
refined	O
Papanicolaou	O
's	O
stain	O
.	O

RESULTS	O
The	O
density	O
,	O
motility	O
and	O
morphology	O
of	O
sperm	O
were	O
improved	O
and	O
sperm	O
deformity	O
rate	O
was	O
significantly	O
decreased	O
after	O
treatment	O
in	O
both	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
the	O
effects	O
in	O
the	O
treated	O
group	O
were	O
better	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
ZJC1	O
can	O
enhance	O
the	O
density	O
and	O
motility	O
of	O
sperm	O
and	O
reduce	O
the	O
sperm	O
deformity	O
rate	O
in	O
patients	O
with	O
OSM	O
.	O

Treatment	O
of	O
hypertensive	O
and	O
hypercholesterolaemic	O
patients	O
in	O
general	O
practice	O
.	O

The	O
effect	O
of	O
captopril	O
,	O
atenolol	O
and	O
pravastatin	O
combined	O
with	O
life	O
style	O
intervention	O
.	O

OBJECTIVE	O
To	O
elucidate	O
the	O
effect	O
on	O
blood	O
pressure	O
and	O
blood	O
lipids	O
of	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
(	O
captopril	O
)	O
,	O
and	O
a	O
beta-receptor	O
blocking	O
agent	O
(	O
atenolol	O
)	O
,	O
given	O
alone	O
or	O
in	O
combination	O
with	O
a	O
cholesterol	O
reducing	O
drug	O
,	O
the	O
beta-hydroxy-methylglutaryl-coenzyme	O
A	O
reductase	O
inhibitor	O
pravastatin	O
,	O
in	O
patients	O
who	O
were	O
also	O
encouraged	O
to	O
improve	O
their	O
lifestyle	O
.	O

DESIGN	O
A	O
longitudinal	O
study	O
consisting	O
of	O
three	O
phases	O
.	O

I	O
:	O
Lifestyle	O
intervention	O
alone	O
.	O

II	O
:	O
Continued	O
lifestyle	O
intervention	O
combined	O
with	O
captopril	O
or	O
atenolol	O
.	O

III	O
:	O
Continued	O
lifestyle	O
intervention	O
combined	O
with	O
the	O
same	O
drugs	O
as	O
in	O
phase	O
II	O
and	O
in	O
addition	O
pravastatin	O
or	O
placebo	O
.	O

SETTING	O
Fifty-four	O
general	O
practice	O
surgeries	O
in	O
Norway	O
.	O

PARTICIPANTS	O
Hypertensive	O
patients	O
,	O
210	O
females	O
and	O
160	O
males	O
,	O
treated	O
or	O
untreated	O
with	O
antihypertensive	O
drugs	O
with	O
a	O
sitting	O
diastolic	O
blood	O
pressure	O
between	O
95	O
and	O
115	O
mmHg	O
and	O
a	O
serum	O
total	O
cholesterol	O
between	O
6.5	O
mmol/l	O
(	O
7.0	O
for	O
those	O
age	O
60-67	O
years	O
)	O
and	O
9.0	O
mmol/l	O
.	O

RESULTS	O
The	O
antihypertensive	O
effect	O
of	O
captopril	O
and	O
atenolol	O
was	O
not	O
influenced	O
by	O
concurrent	O
administration	O
of	O
pravastatin	O
.	O

The	O
effect	O
of	O
pravastatin	O
was	O
not	O
limited	O
by	O
concurrent	O
medication	O
with	O
captopril	O
or	O
atenolol	O
.	O

Improvement	O
in	O
lifestyle	O
seemed	O
to	O
reduce	O
the	O
need	O
for	O
supplementary	O
treatment	O
with	O
diuretics	O
.	O

CONCLUSION	O
Pravastatin	O
can	O
be	O
used	O
in	O
combination	O
with	O
captopril	O
or	O
atenolol	O
in	O
the	O
treatment	O
of	O
hypertensive	O
and	O
hypercholesterolaemic	O
patients	O
.	O

[	O
Hepatoprotective	O
activity	O
of	O
remaxol	O
in	O
patients	O
with	O
chronic	O
hepatic	O
disorders	O
]	O
.	O

This	O
milticentre	O
randomized	O
clinical	O
study	O
of	O
the	O
efficiency	O
of	O
remaxol	O
infusion	O
solution	O
(	O
hepatoprotective	O
medicine	O
for	O
chronic	O
liver	O
dysfunction	O
)	O
included	O
494	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
and	O
C.	O
294	O
of	O
them	O
staying	O
in	O
7	O
clinics	O
were	O
given	O
remaxol	O
and	O
200	O
ones	O
received	O
placebo	O
.	O

Randomization	O
was	O
achieved	O
by	O
the	O
envelope	O
method	O
.	O

A	O
detailed	O
description	O
of	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
the	O
diseases	O
is	O
presented	O
.	O

Effects	O
of	O
remaxol	O
vs	O
placebo	O
on	O
the	O
functional	O
activity	O
of	O
affected	O
liver	O
are	O
discussed	O
.	O

Results	O
of	O
laboratory	O
and	O
clinical	O
analysis	O
indicate	O
that	O
mechanism	O
of	O
remaxol	O
action	O
is	O
based	O
on	O
hepatoprotective	O
,	O
antioxidative	O
,	O
and	O
anticholestatic	O
activities	O
of	O
the	O
drug	O
.	O

Effect	O
of	O
postural	O
supports	O
on	O
neuromotor	O
function	O
in	O
very	O
preterm	Condition
infants	Age
to	O
term	O
equivalent	O
age	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
effect	O
of	O
a	O
postural	O
support	O
nappy	O
and/or	O
a	O
postural	O
support	O
roll	O
on	O
neuromotor	O
function	O
in	O
very	O
preterm	O
infants	Age
when	O
nursed	O
prone	O
to	O
term	O
equivalent	O
age	O
.	O

METHODS	O
A	O
randomized	O
observer	O
blind	O
controlled	O
trial	O
of	O
123	SampleSize
very	O
preterm	Condition
infants	Age
was	O
conducted	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
of	O
the	O
sole	O
tertiary	O
referral	O
centre	O
in	O
Western	O
Australia	O
.	O

Infants	Age
were	O
stratified	O
by	O
gestational	O
age	O
(	O
<	O
29	Age
weeks	Age
or	Age
29-30	Age
weeks	Age
)	O
,	O
then	O
randomized	O
into	O
one	O
of	O
three	O
intervention	O
groups	O
:	O
postural	O
support	O
nappy	O
,	O
postural	O
support	O
nappy	O
and	O
postural	O
support	O
roll	O
,	O
or	O
disposable	O
nappy	O
and	O
postural	O
support	O
roll	O
.	O

Interventions	O
started	O
when	O
infants	O
were	O
stable	O
and	O
ceased	O
when	O
routine	O
side-lying	O
commenced	O
.	O

Measurements	O
of	O
shoulder	O
and	O
hip	O
posture	O
were	O
performed	O
pre-intervention	O
,	O
5	O
weeks	O
post-intervention	O
and	O
term	O
postmenstrual	O
age	O
.	O

RESULTS	O
Infants	O
nursed	O
with	O
a	O
postural	O
support	O
roll	O
and	O
a	O
postural	O
support	O
nappy	O
demonstrated	O
improved	O
hip	O
posture	O
to	O
term	O
equivalent	O
age	O
compared	O
with	O
infants	O
nursed	O
with	O
either	O
a	O
postural	O
support	O
roll	O
only	O
,	O
or	O
a	O
postural	O
support	O
nappy	O
only	O
.	O

Infants	O
nursed	O
with	O
a	O
postural	O
support	O
roll	O
either	O
with	O
or	O
without	O
a	O
postural	O
support	O
nappy	O
demonstrated	O
improved	O
shoulder	O
posture	O
to	O
term	O
equivalent	O
age	O
.	O

CONCLUSIONS	O
Combined	O
use	O
of	O
a	O
postural	O
support	O
roll	O
and	O
a	O
postural	O
support	O
nappy	O
while	O
very	O
preterm	O
infants	O
are	O
nursed	O
prone	O
improves	O
hip	O
posture	O
up	O
to	O
term	O
postmenstrual	O
age	O
.	O

Use	O
of	O
a	O
postural	O
support	O
roll	O
improves	O
shoulder	O
posture	O
up	O
to	O
term	O
equivalent	O
age	O
.	O

A	O
study	O
of	O
a	O
Self-Care	O
Rehabilitation	O
Program	O
in	O
pediatric	O
asthma	Condition
.	O

The	O
Self-Care	O
Rehabilitation	O
in	O
Pediatric	O
Asthma	O
(	O
SCRPA	O
)	O
project	O
was	O
designed	O
to	O
ascertain	O
the	O
level	O
to	O
which	O
children	O
with	O
asthma	Condition
are	O
able	O
to	O
acquire	O
the	O
asthma	Condition
knowledge	O
and	O
skills	O
presented	O
in	O
a	O
self-management	O
training	O
program	O
conducted	O
by	O
the	O
American	O
Lung	O
Association	O
of	O
Utah	O
and	O
the	O
effect	O
of	O
such	O
training	O
on	O
the	O
asthma	O
experience	O
.	O

The	O
preschool	O
SCRPA	O
Curriculum	O
(	O
ages	O
2-5	O
)	O
consisted	O
of	O
six	O
1-hour	O
classes	O
scheduled	O
twice	O
a	O
week	O
for	O
3	O
weeks	O
.	O

The	O
first	O
and	O
last	O
classes	O
were	O
for	O
one	O
or	O
both	O
parents	O
only	O
,	O
and	O
the	O
middle	O
four	O
sessions	O
were	O
for	O
the	O
child	O
and	O
parent	O
(	O
s	O
)	O
.	O

The	O
school-age	O
SCRPA	O
curriculum	O
(	O
ages	O
6-14	O
)	O
consisted	O
of	O
eight	O
90-minute	O
classes	O
for	O
both	O
child	O
and	O
parent	O
(	O
s	O
)	O
scheduled	O
twice	O
a	O
week	O
for	O
4	O
weeks	O
.	O

Private	O
physicians	O
referred	O
21	SampleSize
preschool	O
children	O
and	O
38	O
school-age	O
children	O
into	O
the	O
program	O
.	O

The	O
school-age	O
children	O
were	O
randomly	O
assigned	O
to	O
a	O
study	O
or	O
control	O
group	O
,	O
and	O
the	O
preschool	O
children	O
served	O
as	O
their	O
own	O
controls	O
.	O

A	O
comparison	O
of	O
asthma	O
episodes	O
during	O
the	O
3	O
months	O
before	O
and	O
after	O
training	O
showed	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
number	O
of	O
episodes	O
but	O
no	O
change	O
in	O
severity	O
in	O
the	O
preschool	O
,	O
school	O
study	O
,	O
and	O
school	O
control	O
groups	O
.	O

The	O
decrease	O
in	O
episodes	O
for	O
the	O
control	O
groups	O
suggest	O
that	O
the	O
family	O
record	O
keeping	O
required	O
of	O
all	O
subjects	O
may	O
have	O
a	O
beneficial	O
effect	O
,	O
a	O
phenomenon	O
worth	O
further	O
investigation	O
.	O

Also	O
,	O
the	O
school-age	O
group	O
,	O
in	O
pre-	O
and	O
posttesting	O
,	O
demonstrated	O
that	O
the	O
SCRPA	O
curriculum	O
increased	O
knowledge	O
and	O
skills	O
in	O
the	O
study	O
group	O
,	O
changes	O
not	O
found	O
in	O
the	O
control	O
group	O
.	O

Group-based	O
HIV	O
risk	O
reduction	O
intervention	O
for	O
adolescent	O
girls	O
:	O
evidence	O
of	O
feasibility	O
and	O
efficacy	O
.	O

The	O
purposes	O
of	O
this	O
pilot	O
study	O
were	O
(	O
a	O
)	O
to	O
assess	O
the	O
feasibility	O
of	O
a	O
community-based	O
,	O
small	O
group	O
HIV	O
risk	O
reduction	O
intervention	O
with	O
adolescent	O
girls	O
,	O
and	O
(	O
b	O
)	O
to	O
obtain	O
preliminary	O
evidence	O
of	O
the	O
efficacy	O
of	O
this	O
theoretically-guided	O
intervention	O
using	O
a	O
controlled	O
design	O
.	O

The	O
feasibility	O
of	O
the	O
intervention	O
was	O
demonstrated	O
by	O
successfully	O
implementing	O
it	O
with	O
33	O
sexually-active	O
,	O
single	O
girls	O
.	O

Preliminary	O
evidence	O
of	O
the	O
efficacy	O
of	O
the	O
intervention	O
was	O
obtained	O
using	O
a	O
randomized	O
trial	O
with	O
62	O
sexually-active	O
,	O
single	O
girls	O
.	O

Data	O
obtained	O
at	O
a	O
3-month	O
follow-up	O
assessment	O
showed	O
that	O
girls	O
who	O
received	O
the	O
HIV-related	O
intervention	O
improved	O
their	O
HIV-related	O
knowledge	O
and	O
enhanced	O
their	O
motivation	O
for	O
risk	O
reduction	O
compared	O
to	O
girls	O
who	O
received	O
a	O
control	O
(	O
health	O
promotion	O
)	O
intervention	O
.	O

Effect	O
sizes	O
suggest	O
that	O
the	O
HIV	O
intervention	O
also	O
reduced	O
several	O
risk	O
behaviors	O
(	O
e.g.	O
,	O
vaginal	O
sex	O
without	O
a	O
condom	O
,	O
giving	O
oral	O
sex	O
,	O
and	O
alcohol	O
and	O
drug	O
use	O
before	O
sex	O
)	O
.	O

Challenges	O
to	O
implementation	O
and	O
suggestions	O
for	O
intervention	O
enhancement	O
are	O
discussed	O
.	O

A	O
limited	O
sampling	O
method	O
for	O
the	O
estimation	O
of	O
flunarizine	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
and	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
.	O

A	O
limited	O
sampling	O
model	O
has	O
been	O
developed	O
for	O
flunarizine	O
following	O
a	O
30	O
mg	O
oral	O
dose	O
in	O
epileptic	Condition
patients	Condition
who	O
were	O
receiving	Condition
phenytoin	Condition
or	Condition
carbamazepine	Condition
or	Condition
both	Condition
,	O
to	O
estimate	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
and	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
.	O

The	O
model	O
was	O
developed	O
using	O
training	O
data	O
sets	O
from	O
30	O
,	O
20	O
,	O
15	O
,	O
or	O
10	O
patients	O
at	O
one	O
or	O
two	O
time	O
points	O
.	O

The	O
equations	O
describing	O
the	O
models	O
for	O
AUC	O
using	O
two	O
time	O
points	O
(	O
3	O
and	O
24h	O
)	O
and	O
Cmax	O
for	O
the	O
training	O
data	O
set	O
of	O
30	O
subjects	O
were	O
AUCpredicted	O
=	O
11.1	O
C3h	O
+	O
121.4	O
C24h	O
-	O
157	O
(	O
r	O
=	O
0.80	O
)	O
Cmax	O
(	O
predicted	O
)	O
=	O
0.036	O
AUC	O
+	O
42.9	O
(	O
r	O
=	O
0.74	O
)	O
The	O
model	O
was	O
validated	O
on	O
64	SampleSize
patients	O
who	O
received	O
flunarizine	O
orally	O
.	O

The	O
model	O
provided	O
reasonably	O
good	O
estimates	O
for	O
both	O
AUC	O
and	O
Cmax	O
.	O

The	O
mean	O
predicted	O
AUC	O
of	O
flunarizine	O
was	O
1230	O
+/-	O
717	O
ng	O
h	O
mL-1	O
,	O
whereas	O
the	O
observed	O
AUC	O
was	O
1203	O
+/-	O
900	O
ng	O
h	O
mL-1	O
.	O

The	O
bias	O
of	O
the	O
prediction	O
was	O
2	O
%	O
and	O
precision	O
was	O
28	O
%	O
.	O

The	O
mean	O
predicted	O
Cmax	O
of	O
flunarizine	O
was	O
86	O
+/-	O
32	O
ng	O
mL-1	O
as	O
compared	O
to	O
an	O
observed	O
mean	O
Cmax	O
of	O
90	O
+/-	O
42	O
ng	O
mL-1	O
.	O

The	O
bias	O
and	O
precision	O
of	O
the	O
prediction	O
were	O
4	O
%	O
and	O
24	O
%	O
,	O
respectively	O
.	O

The	O
method	O
described	O
here	O
may	O
be	O
used	O
to	O
estimate	O
AUC	O
and	O
Cmax	O
for	O
flunarizine	O
without	O
detailed	O
pharmacokinetic	O
studies	O
.	O

Comparison	O
of	O
5-aminosalicylic	O
acid	O
(	O
3	O
g	O
)	O
and	O
prednisolone	O
phosphate	O
sodium	O
enemas	O
(	O
30	O
mg	O
)	O
in	O
the	O
treatment	O
of	O
distal	Condition
ulcerative	Condition
colitis	Condition
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
trial	O
.	O

Twenty-nine	SampleSize
patients	SampleSize
with	O
attacks	Condition
of	Condition
distal	Condition
ulcerative	Condition
colitis	Condition
were	O
treated	O
randomly	O
with	O
3	O
g	O
5-aminosalicylic	O
acid	O
(	O
5-ASA	O
)	O
or	O
30	O
mg	O
of	O
prednisolone	O
phosphate	O
sodium	O
(	O
PP	O
)	O
enemas	O
(	O
40	O
ml	O
)	O
.	O

Endoscopic	O
,	O
clinical	O
,	O
and	O
histologic	O
improvement	O
were	O
comparable	O
in	O
the	O
two	O
treatment	O
groups	O
.	O

Our	O
study	O
showed	O
that	O
topical	O
treatment	O
with	O
5-ASA	O
is	O
as	O
efficacious	O
as	O
PP	O
in	O
improving	O
distal	Condition
ulcerative	Condition
colitis	Condition
.	O

Impacts	O
of	O
a	O
disease	O
management	O
program	O
for	O
dually	O
eligible	O
beneficiaries	O
.	O

The	O
LifeMasters	O
Supported	O
SelfCare	O
demonstration	O
program	O
provides	O
disease	O
management	O
(	O
DM	O
)	O
services	O
to	O
Florida	O
Medicare	O
beneficiaries	O
who	O
are	O
also	O
enrolled	O
in	O
Medicaid	O
and	O
have	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
,	O
diabetes	O
,	O
or	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

The	O
population-based	O
program	O
provides	O
primarily	O
telephonic	O
patient	O
education	O
and	O
monitoring	O
services	O
.	O

Findings	O
from	O
the	O
randomized	O
,	O
intent-to-treat	O
design	O
over	O
the	O
first	O
18	O
months	O
of	O
operations	O
show	O
virtually	O
no	O
overall	O
impacts	O
on	O
hospital	O
or	O
emergency	O
room	O
(	O
ER	O
)	O
use	O
,	O
Medicare	O
expenditures	O
,	O
quality	O
of	O
care	O
,	O
or	O
prescription	O
drug	O
use	O
for	O
the	O
33,000	O
enrollees	O
.	O

However	O
,	O
for	O
beneficiaries	O
with	O
CHF	O
who	O
resided	O
in	O
high-cost	O
South	O
Florida	O
counties	O
,	O
the	O
program	O
reduced	O
Medicare	O
expenditures	O
by	O
9.6	O
percent	O
.	O

Dexamethasone	O
therapy	O
and	O
cortisol	O
excretion	O
in	O
severe	Condition
pediatric	Condition
head	Condition
injury	Condition
.	Condition

Glucocorticoids	O
are	O
used	O
in	O
an	O
attempt	O
to	O
reduce	O
brain	O
edema	O
secondary	O
to	O
head	O
injury	O
.	O

Nevertheless	O
,	O
their	O
usefulness	O
remains	O
uncertain	O
and	O
contradictory	O
.	O

In	O
a	O
randomized	O
study	O
of	O
24	O
children	O
with	O
severe	O
head	O
injury	O
,	O
urinary	O
free	O
cortisol	O
was	O
measured	O
by	O
radioimmunoassay	O
.	O

Twelve	O
patients	O
(	O
group	O
1	O
)	O
received	O
dexamethasone	O
and	O
12	O
(	O
group	O
2	O
)	O
did	O
not	O
.	O

All	O
patients	O
were	O
treated	O
with	O
a	O
standardized	O
regimen	O
.	O

In	O
group	O
1	O
there	O
was	O
complete	O
suppression	O
of	O
endogenous	O
cortisol	O
production	O
.	O

In	O
group	O
2	O
free	O
cortisol	O
was	O
up	O
to	O
20-fold	O
higher	O
than	O
under	O
basal	O
conditions	O
and	O
reached	O
maximum	O
values	O
on	O
days	O
1-3	O
.	O

Since	O
the	O
excretion	O
of	O
cortisol	O
in	O
urine	O
reflects	O
the	O
production	O
rate	O
closely	O
and	O
is	O
not	O
influenced	O
by	O
liver	O
function	O
and	O
barbiturates	O
,	O
the	O
results	O
in	O
group	O
2	O
show	O
that	O
the	O
endogenous	O
production	O
of	O
steroids	O
is	O
an	O
adequate	O
reaction	O
to	O
severe	O
head	O
injury	O
.	O

Exogenous	O
glucocorticoids	O
are	O
thus	O
unlikely	O
to	O
have	O
any	O
more	O
beneficial	O
effects	O
than	O
endogenous	O
cortisol	O
.	O

Effect	O
of	O
nitazoxanide	O
on	O
morbidity	O
and	O
mortality	O
in	O
Zambian	Condition
children	Age
with	O
cryptosporidiosis	Condition
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Cryptosporidiosis	Condition
in	O
children	Age
in	O
developing	Condition
countries	Condition
causes	O
persistent	O
diarrhoea	O
and	O
malnutrition	O
and	O
is	O
associated	O
with	O
increased	O
mortality	O
,	O
but	O
there	O
is	O
no	O
effective	O
treatment	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
nitazoxanide-a	O
new	O
broad-spectrum	O
antiparasitic	O
drug-on	O
morbidity	O
and	O
mortality	O
in	O
Zambian	Condition
children	Age
with	O
diarrhoea	Condition
due	Condition
to	Condition
Cryptosporidium	Condition
parvum	Condition
.	O

METHODS	O
Children	Age
with	O
cryptosporidial	Condition
diarrhoea	Condition
who	O
were	O
admitted	O
to	O
the	O
University	O
Teaching	O
Hospital	O
,	O
Lusaka	O
,	O
Zambia	O
,	O
between	O
November	O
,	O
2000	O
,	O
and	O
July	O
,	O
2001	O
,	O
and	O
whose	O
parents	O
consented	O
to	O
their	O
having	O
an	O
HIV	O
test	O
were	O
randomly	O
assigned	O
nitazoxanide	O
(	O
100	O
mg	O
twice	O
daily	O
orally	O
for	O
3	O
days	O
)	O
or	O
placebo	O
.	O

The	O
primary	O
endpoint	O
was	O
clinical	O
response	O
on	O
day	O
7	O
after	O
the	O
start	O
of	O
treatment	O
.	O

Secondary	O
endpoints	O
included	O
parasitological	O
response	O
by	O
day	O
10	O
and	O
mortality	O
at	O
day	O
8	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
,	O
with	O
exclusion	O
of	O
patients	O
subsequently	O
found	O
to	O
be	O
negative	O
for	O
C	Condition
parvum	Condition
or	O
co-infected	O
at	O
baseline	O
.	O

The	O
trial	O
was	O
stratified	O
by	O
HIV	O
serology	O
.	O

FINDINGS	O
50	SampleSize
HIV-seropositive	O
and	O
50	SampleSize
HIV-seronegative	O
children	Age
were	O
recruited	O
for	O
the	O
study	O
,	O
four	O
of	O
whom	O
were	O
subsequently	O
excluded	O
.	O

In	O
HIV-seronegative	O
children	O
,	O
diarrhoea	O
resolved	O
in	O
14	O
(	O
56	O
%	O
)	O
of	O
25	O
receiving	O
nitazoxanide	O
and	O
5	O
(	O
23	O
%	O
)	O
of	O
22	O
receiving	O
placebo	O
(	O
difference	O
33	O
%	O
,	O
95	O
%	O
CI	O
7-59	O
;	O
p=0.037	O
)	O
.	O

C	O
parvum	O
was	O
eradicated	O
from	O
stool	O
in	O
13	O
(	O
52	O
%	O
)	O
of	O
25	O
receiving	O
nitazoxanide	O
and	O
three	O
(	O
14	O
%	O
)	O
of	O
22	O
receiving	O
placebo	O
(	O
38	O
%	O
,	O
95	O
%	O
CI	O
14-63	O
;	O
p=0.007	O
)	O
.	O

Four	O
children	O
(	O
18	O
%	O
)	O
of	O
22	O
in	O
the	O
placebo	O
group	O
had	O
died	O
by	O
day	O
8	O
,	O
compared	O
with	O
none	O
of	O
25	O
in	O
the	O
nitazoxanide	O
group	O
(	O
-18	O
%	O
,	O
-34	O
to	O
2	O
;	O
p=0.041	O
)	O
.	O

HIV-seropositive	O
children	O
did	O
not	O
benefit	O
from	O
nitazoxanide	O
.	O

Nitazoxanide	O
was	O
not	O
significantly	O
associated	O
with	O
adverse	O
events	O
in	O
either	O
stratum	O
.	O

INTERPRETATION	O
A	O
3-day	O
course	O
of	O
nitazoxanide	O
significantly	O
improved	O
the	O
resolution	O
of	O
diarrhoea	O
,	O
parasitological	O
eradication	O
,	O
and	O
mortality	O
in	O
HIV-seronegative	O
,	O
but	O
not	O
HIV-seropositive	O
,	O
children	O
.	O

Effect	O
of	O
gravity	O
on	O
robot-assisted	O
motor	O
training	O
after	O
chronic	Condition
stroke	Condition
:	O
a	O
randomized	O
trial	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
efficacy	O
of	O
2	O
distinct	O
6-week	O
robot-assisted	O
reaching	O
programs	O
compared	O
with	O
an	O
intensive	O
conventional	O
arm	O
exercise	O
program	O
(	O
ICAE	O
)	O
for	O
chronic	O
,	O
stroke-related	O
upper-extremity	O
(	O
UE	O
)	O
impairment	O
.	O

To	O
examine	O
whether	O
the	O
addition	O
of	O
robot-assisted	O
training	O
out	O
of	O
the	O
horizontal	O
plane	O
leads	O
to	O
improved	O
outcomes	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
,	O
single-blinded	O
,	O
with	O
12-week	O
follow-up	O
.	O

SETTING	O
Research	O
setting	O
in	O
a	O
large	O
medical	O
center	O
.	O

PARTICIPANTS	O
Adults	Age
(	O
N=62	SampleSize
)	O
with	O
chronic	Condition
,	Condition
stroke-related	Condition
arm	Condition
weakness	Condition
stratified	O
by	O
impairment	O
severity	O
using	O
baseline	O
UE	O
motor	O
assessments	O
.	O

INTERVENTIONS	O
Sixty	O
minutes	O
,	O
3	O
times	O
a	O
week	O
for	O
6	O
weeks	O
of	O
robot-assisted	O
planar	O
reaching	O
(	O
gravity	O
compensated	O
)	O
,	O
combined	O
planar	O
with	O
vertical	O
robot-assisted	O
reaching	O
,	O
or	O
intensive	O
conventional	O
arm	O
exercise	O
program	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
UE	O
Fugl-Meyer	O
Assessment	O
(	O
FMA	O
)	O
mean	O
change	O
from	O
baseline	O
to	O
final	O
training	O
.	O

RESULTS	O
All	O
groups	O
showed	O
modest	O
gains	O
in	O
the	O
FMA	O
from	O
baseline	O
to	O
final	O
with	O
no	O
significant	O
between	O
group	O
differences	O
.	O

Most	O
change	O
occurred	O
in	O
the	O
planar	O
robot	O
group	O
(	O
mean	O
change	O
?	O
SD	O
,	O
2.94	O
?	O
0.77	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.40-4.47	O
)	O
.	O

Participants	O
with	O
greater	O
motor	O
impairment	O
(	O
n=41	O
)	O
demonstrated	O
a	O
larger	O
difference	O
in	O
response	O
(	O
mean	O
change	O
?	O
SD	O
,	O
2.29	O
?	O
0.72	O
;	O
95	O
%	O
CI	O
,	O
0.85-3.72	O
)	O
for	O
planar	O
robot-assisted	O
exercise	O
compared	O
with	O
the	O
intensive	O
conventional	O
arm	O
exercise	O
program	O
(	O
mean	O
change	O
?	O
SD	O
,	O
0.43	O
?	O
0.72	O
;	O
95	O
%	O
CI	O
,	O
-1.00	O
to	O
1.86	O
)	O
.	O

CONCLUSIONS	O
Chronic	O
UE	O
deficits	O
because	O
of	O
stroke	O
are	O
responsive	O
to	O
intensive	O
motor	O
task	O
training	O
.	O

However	O
,	O
training	O
outside	O
the	O
horizontal	O
plane	O
in	O
a	O
gravity	O
present	O
environment	O
using	O
a	O
combination	O
of	O
vertical	O
with	O
planar	O
robots	O
was	O
not	O
superior	O
to	O
training	O
with	O
the	O
planar	O
robot	O
alone	O
.	O

The	O
NORwegian	O
study	O
on	O
DIstrict	O
treatment	O
of	O
ST-elevation	O
myocardial	O
infarction	O
(	O
NORDISTEMI	O
)	O
.	O

OBJECTIVES	O
Thrombolysis	O
is	O
the	O
treatment	O
of	O
choice	O
for	O
patients	O
with	O
ST-elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
living	O
in	O
rural	O
areas	O
with	O
long	O
transfer	O
delays	O
to	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

This	O
trial	O
compares	O
two	O
different	O
strategies	O
following	O
thrombolysis	O
:	O
to	O
transfer	O
all	O
patients	O
for	O
immediate	O
coronary	O
angiography	O
and	O
intervention	O
,	O
or	O
to	O
manage	O
the	O
patients	O
more	O
conservatively	O
.	O

DESIGN	O
The	O
NORwegian	O
study	O
on	O
DIstrict	O
treatment	O
of	O
STEMI	O
(	O
NORDISTEMI	O
)	O
is	O
an	O
open	O
,	O
prospective	O
,	O
randomized	O
controlled	O
trial	O
in	O
patients	O
with	O
STEMI	O
of	O
less	O
than	O
6	O
hours	O
of	O
duration	O
and	O
more	O
than	O
90	O
minutes	O
expected	O
time	O
delay	O
to	O
PCI	O
.	O

A	O
total	O
of	O
266	O
patients	O
will	O
receive	O
full-dose	O
thrombolysis	O
,	O
preferably	O
pre-hospital	O
,	O
and	O
then	O
be	O
randomized	O
to	O
either	O
strategy	O
.	O

Our	O
primary	O
endpoint	O
is	O
the	O
one	O
year	O
combined	O
incidence	O
of	O
death	O
,	O
reinfarction	O
,	O
stroke	O
or	O
new	O
myocardial	O
ischaemia	O
.	O

The	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT00161005	O
.	O

RESULTS	O
By	O
April	O
2006	O
,	O
109	O
patients	O
have	O
been	O
randomized	O
.	O

Thrombolysis	O
has	O
been	O
given	O
pre-hospital	O
to	O
52	O
%	O
of	O
patients	O
.	O

The	O
median	O
transport	O
distance	O
from	O
first	O
medical	O
contact	O
to	O
catheterization	O
laboratory	O
was	O
155	O
km	O
(	O
range	O
90-396	O
km	O
)	O
.	O

Results	O
of	O
the	O
study	O
are	O
expected	O
in	O
2008	O
.	O

Equivalent	O
efficacy	O
of	O
mitomycin	O
C	O
plus	O
doxorubicin	O
instillation	O
to	O
bacillus	O
Calmette-Guerin	O
therapy	O
for	O
carcinoma	O
in	O
situ	O
of	O
the	O
bladder	O
.	O

BACKGROUND	O
To	O
elucidate	O
the	O
most	O
efficient	O
topical	O
therapy	O
for	O
carcinoma	O
in	O
situ	O
of	O
the	O
bladder	O
,	O
the	O
efficacy	O
of	O
intravesical	O
mitomycin	O
C	O
plus	O
doxorubicin	O
therapy	O
was	O
compared	O
with	O
bacillus	O
Calmette-Guerin	O
(	O
BCG	O
)	O
therapy	O
.	O

The	O
clinical	O
behavior	O
of	O
the	O
tumor	O
was	O
analysed	O
according	O
to	O
the	O
histological	O
grade	O
.	O

METHODS	O
Forty-two	O
patients	O
with	O
carcinoma	O
in	O
situ	O
of	O
the	O
bladder	O
were	O
randomized	O
to	O
intravesical	O
BCG	O
(	O
21	O
patients	O
)	O
or	O
mitomycin	O
C	O
plus	O
doxorubicin	O
sequential	O
therapy	O
(	O
21	O
patients	O
)	O
as	O
first	O
line	O
treatment	O
.	O

The	O
non-responders	O
underwent	O
the	O
subsequent	O
instillation	O
of	O
the	O
other	O
intravesical	O
therapy	O
alternately	O
.	O

Of	O
the	O
patients	O
,	O
27	O
had	O
grade	O
2	O
and	O
15	O
had	O
grade	O
3	O
cancer	O
.	O

RESULTS	O
Both	O
topical	O
therapies	O
were	O
equally	O
effective	O
with	O
initial	O
response	O
rates	O
of	O
86	O
%	O
(	O
18/21	O
)	O
for	O
BCG	O
and	O
81	O
%	O
(	O
17/21	O
)	O
for	O
mitomycin	O
C	O
plus	O
doxorubicin	O
,	O
irrespective	O
of	O
the	O
tumor	O
grade	O
.	O

Of	O
seven	O
initial	O
non-responders	O
,	O
five	O
patients	O
achieved	O
a	O
complete	O
response	O
by	O
subsequent	O
instillation	O
,	O
resulting	O
in	O
a	O
total	O
response	O
rate	O
of	O
95	O
%	O
.	O

After	O
a	O
mean	O
follow-up	O
of	O
47	O
months	O
,	O
five	O
patients	O
(	O
12	O
%	O
)	O
developed	O
disease	O
progression	O
.	O

The	O
progression	O
rates	O
were	O
not	O
different	O
between	O
the	O
topical	O
therapies	O
,	O
but	O
were	O
significantly	O
higher	O
in	O
grade	O
3	O
than	O
in	O
grade	O
2	O
cases	O
.	O

CONCLUSION	O
It	O
appears	O
likely	O
that	O
mitomycin	O
C	O
plus	O
doxorubicin	O
instillation	O
has	O
an	O
equivalent	O
efficacy	O
to	O
BCG	O
as	O
the	O
initial	O
therapy	O
of	O
carcinoma	O
in	O
situ	O
and	O
the	O
combination	O
of	O
them	O
would	O
be	O
the	O
most	O
efficient	O
treatment	O
for	O
the	O
disease	O
.	O

Moreover	O
,	O
histological	O
grading	O
would	O
be	O
clinically	O
useful	O
in	O
defining	O
the	O
tumor	O
characteristics	O
and	O
behavior	O
of	O
carcinoma	O
in	O
situ	O
of	O
the	O
bladder	O
.	O

Nonspecific	O
and	O
selective	O
stimulation	O
of	O
the	O
immune	O
system	O
in	O
the	O
treatment	O
of	O
carcinoma	O
in	O
humans	O
.	O

The	O
experience	O
of	O
the	O
Toronto	O
General	O
Hospital	O
in	O
the	O
use	O
of	O
nonspecific	O
stimulation	O
of	O
the	O
immune	O
system	O
with	O
bacille	O
Calmette-Gu?rin	O
(	O
BCG	O
)	O
for	O
the	O
treatment	O
of	O
cancer	O
of	O
the	O
gastrointestinal	O
tract	O
,	O
malignant	O
melanoma	O
and	O
breast	O
cancer	O
is	O
described	O
.	O

The	O
results	O
are	O
presented	O
in	O
terms	O
of	O
survival	O
curves	O
.	O

The	O
use	O
of	O
BCG	O
administered	O
intraperitoneally	O
in	O
a	O
randomized	O
study	O
of	O
patients	O
with	O
gastric	O
,	O
pancreatic	O
and	O
colorectal	O
cancer	O
proved	O
of	O
no	O
benefit	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
BCG	O
was	O
given	O
orally	O
in	O
a	O
randomized	O
study	O
of	O
patients	O
with	O
resectable	O
cancer	O
of	O
the	O
colon	O
and	O
in	O
nonrandomized	O
consecutive	O
studies	O
of	O
patients	O
with	O
malignant	O
melanoma	O
and	O
stage	O
IV	O
carcinoma	O
of	O
the	O
breast	O
survival	O
was	O
increased	O
.	O

In	O
a	O
group	O
of	O
patients	O
with	O
advanced	O
gastrointestinal	O
cancer	O
selective	O
stimulation	O
of	O
the	O
immune	O
system	O
with	O
NED	O
137	O
produced	O
a	O
significant	O
increase	O
in	O
survival	O
when	O
compared	O
with	O
the	O
survival	O
of	O
historical	O
controls	O
(	O
the	O
patients	O
given	O
BCG	O
intraperitoneally	O
along	O
with	O
5-fluorouracil	O
for	O
gastrointestinal	O
cancer	O
)	O
.	O

The	O
results	O
of	O
these	O
studies	O
suggest	O
the	O
need	O
for	O
a	O
more	O
rational	O
approach	O
in	O
manipulating	O
the	O
immune	O
response	O
that	O
would	O
combine	O
chemotherapy	O
with	O
selective	O
stimulation	O
of	O
the	O
immune	O
system	O
.	O

Assessing	O
the	O
benefit	O
of	O
a	O
personalized	O
EHR-generated	O
informed	O
consent	O
in	O
a	O
dental	O
school	O
setting	O
.	O

Informed	O
consents	O
are	O
routinely	O
used	O
as	O
an	O
important	O
source	O
of	O
information	O
to	O
help	O
patients	O
make	O
appropriate	O
clinical	O
decisions	O
.	O

However	O
,	O
current	O
standard	O
consent	O
forms	O
may	O
not	O
accomplish	O
their	O
intended	O
purpose	O
due	O
to	O
the	O
variety	O
of	O
patient	O
literacy	O
and	O
experiences	O
and	O
,	O
in	O
the	O
dental	O
school	O
setting	O
,	O
the	O
developing	O
competence	O
of	O
students	O
.	O

The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
test	O
the	O
efficacy	O
of	O
a	O
personalized	O
informed	O
consent	O
generated	O
through	O
an	O
electronic	O
health	O
record	O
(	O
EHR	O
)	O
at	O
one	O
dental	O
school	O
and	O
its	O
role	O
in	O
patient	O
decision	O
making	O
.	O

In	O
the	O
study	O
,	O
a	O
set	O
of	O
informed	O
consents	O
,	O
or	O
SmartConsents	O
,	O
were	O
developed	O
for	O
specific	O
diagnoses	O
and	O
procedures	O
,	O
enhanced	O
with	O
graphics	O
,	O
and	O
delivered	O
through	O
the	O
school	O
's	O
EHR	O
.	O

Fifty	SampleSize
patients	O
were	O
recruited	O
in	O
the	O
school	O
's	O
Urgent	O
Care	O
Clinic	O
and	O
divided	O
evenly	O
into	O
two	O
groups	O
:	O
one	O
(	O
control	O
)	O
receiving	O
the	O
standard	O
consent	O
,	O
with	O
the	O
second	O
receiving	O
a	O
SmartConsent	O
.	O

Following	O
treatment	O
,	O
patients	O
were	O
assessed	O
based	O
on	O
demographics	O
,	O
decisional	O
conflict	O
,	O
satisfaction	O
,	O
health	O
literacy	O
,	O
and	O
knowledge	O
.	O

Overall	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
main	O
effects	O
between	O
SmartConsent	O
and	O
standard	O
informed	O
consents	O
for	O
decisional	O
conflict	O
and	O
satisfaction	O
,	O
although	O
significant	O
differences	O
were	O
identified	O
during	O
secondary	O
analysis	O
of	O
satisfaction	O
,	O
gender	O
,	O
and	O
ethnicity	O
.	O

The	O
study	O
also	O
demonstrated	O
the	O
potential	O
for	O
consents	O
to	O
aid	O
the	O
student	O
provider	O
in	O
better	O
communicating	O
with	O
patients	O
.	O

Effectiveness	O
of	O
initiating	O
treatment	O
with	O
valsartan/hydrochlorothiazide	O
in	O
patients	O
with	O
stage-1	O
or	O
stage-2	O
hypertension	Condition
.	O

This	O
prospective	O
,	O
6-week	O
,	O
multicenter	O
,	O
double-blind	O
study	O
examined	O
the	O
benefits	O
of	O
initiating	O
treatment	O
with	O
combination	O
valsartan/hydrochlorothiazide	O
(	O
HCTZ	O
)	O
compared	O
with	O
initial	O
valsartan	O
monotherapy	O
for	O
648	Condition
patients	O
with	O
stage-1	O
or	O
stage-2	O
hypertension	O
(	O
age=52.6+/-10	Age
years	Age
;	O
54	O
%	O
male	Age
;	O
baseline	O
blood	O
pressure	O
(	O
BP	O
)	O
=161/98	O
mm	O
Hg	O
,	O
32	O
%	O
stage	O
1	O
)	O
.	O

Patients	O
were	O
randomized	O
to	O
valsartan	O
80	O
mg	O
(	O
V-low	O
)	O
,	O
valsartan	O
160	O
mg	O
(	O
V-high	O
)	O
or	O
valsartan/HCTZ	O
160/12.5	O
mg	O
(	O
V/HCTZ	O
)	O
,	O
and	O
electively	O
titrated	O
after	O
weeks	O
2	O
and	O
4	O
to	O
the	O
next	O
dosage	O
level	O
(	O
maximum	O
dose	O
valsartan/HCTZ	O
160/25	O
mg	O
)	O
if	O
BP	O
remained	O
>	O
140/90	O
mm	O
Hg	O
.	O

At	O
end	O
of	O
the	O
study	O
,	O
patients	O
initiated	O
with	O
V/HCTZ	O
required	O
less	O
titration	O
steps	O
compared	O
with	O
the	O
initial	O
valsartan	O
monotherapy	O
groups	O
(	O
63	O
vs	O
86	O
%	O
required	O
titration	O
by	O
study	O
end	O
,	O
respectively	O
)	O
and	O
reached	O
the	O
target	O
BP	O
goal	O
of	O
<	O
140/90	O
mm	O
Hg	O
in	O
a	O
shorter	O
period	O
of	O
time	O
(	O
2.8	O
weeks	O
)	O
(	O
P	O
<	O
0.0001	O
)	O
vs	O
V-low	O
(	O
4.3	O
weeks	O
)	O
and	O
V-high	O
(	O
3.9	O
weeks	O
)	O
.	O

Initial	O
combination	O
therapy	O
was	O
also	O
associated	O
with	O
higher	O
BP	O
control	O
rates	O
and	O
greater	O
reductions	O
in	O
both	O
systolic	O
and	O
diastolic	O
BP	O
from	O
baseline	O
(	O
63	O
%	O
,	O
-27.7+/-13/-15.1+/-8	O
mm	O
Hg	O
)	O
compared	O
with	O
V-low	O
(	O
46	O
%	O
,	O
-21.2+/-13/-11.4+/-8	O
mm	O
Hg	O
,	O
P	O
<	O
0.0001	O
)	O
or	O
V-high	O
(	O
51	O
%	O
,	O
-24.0+/-13/-12.0+/-10	O
mm	O
Hg	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Overall	O
and	O
drug-related	O
AEs	O
were	O
mild	O
to	O
moderate	O
and	O
were	O
similar	O
between	O
V/HCTZ	O
(	O
53.1	O
and	O
14.1	O
%	O
,	O
respectively	O
)	O
and	O
the	O
two	O
monotherapy	O
groups	O
,	O
V-low	O
(	O
50.5	O
and	O
13.8	O
%	O
)	O
and	O
V-high	O
(	O
50.7	O
and	O
11.8	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
initiating	O
therapy	O
with	O
a	O
combination	O
of	O
valsartan	O
and	O
low-dose	O
HCTZ	O
results	O
in	O
early	O
,	O
improved	O
BP	O
efficacy	O
with	O
similar	O
tolerability	O
as	O
compared	O
with	O
starting	O
treatment	O
with	O
a	O
low	O
or	O
higher	O
dose	O
of	O
valsartan	O
for	O
patients	O
with	O
stage-1	O
and	O
stage-2	O
hypertension	O
.	O

A	O
phase	O
III	O
study	O
of	O
belatacept-based	O
immunosuppression	O
regimens	O
versus	O
cyclosporine	O
in	O
renal	Condition
transplant	Condition
recipients	Condition
(	O
BENEFIT	O
study	O
)	O
.	O

Belatacept	O
,	O
a	O
costimulation	O
blocker	O
,	O
may	O
preserve	O
renal	O
function	O
and	O
improve	O
long-term	O
outcomes	O
versus	O
calcineurin	O
inhibitors	O
in	O
kidney	O
transplantation	O
.	O

This	O
Phase	O
III	O
study	O
(	O
Belatacept	O
Evaluation	O
of	O
Nephroprotection	O
and	O
Efficacy	O
as	O
First-line	O
Immunosuppression	O
Trial	O
)	O
assessed	O
a	O
more	O
intensive	O
(	O
MI	O
)	O
or	O
less	O
intensive	O
(	O
LI	O
)	O
regimen	O
of	O
belatacept	O
versus	O
cyclosporine	O
in	O
adults	Age
receiving	O
a	O
kidney	Condition
transplant	Condition
from	O
living	O
or	O
standard	O
criteria	O
deceased	O
donors	O
.	O

The	O
co-primary	O
endpoints	O
at	O
12	O
months	O
were	O
patient/graft	O
survival	O
,	O
a	O
composite	O
renal	O
impairment	O
endpoint	O
(	O
percent	O
with	O
a	O
measured	O
glomerular	O
filtration	O
rate	O
(	O
mGFR	O
)	O
<	O
60	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
at	O
Month	O
12	O
or	O
a	O
decrease	O
in	O
mGFR	O
>	O
or	O
=10	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
Month	O
3-Month	O
12	O
)	O
and	O
the	O
incidence	O
of	O
acute	O
rejection	O
.	O

At	O
Month	O
12	O
,	O
both	O
belatacept	O
regimens	O
had	O
similar	O
patient/graft	O
survival	O
versus	O
cyclosporine	O
(	O
MI	O
:	O
95	O
%	O
,	O
LI	O
:	O
97	O
%	O
and	O
cyclosporine	O
:	O
93	O
%	O
)	O
,	O
and	O
were	O
associated	O
with	O
superior	O
renal	O
function	O
as	O
measured	O
by	O
the	O
composite	O
renal	O
impairment	O
endpoint	O
(	O
MI	O
:	O
55	O
%	O
;	O
LI	O
:	O
54	O
%	O
and	O
cyclosporine	O
:	O
78	O
%	O
;	O
p	O
<	O
or	O
=	O
0.001	O
MI	O
or	O
LI	O
versus	O
cyclosporine	O
)	O
and	O
by	O
the	O
mGFR	O
(	O
65	O
,	O
63	O
and	O
50	O
mL/min	O
for	O
MI	O
,	O
LI	O
and	O
cyclosporine	O
;	O
p	O
<	O
or	O
=	O
0.001	O
MI	O
or	O
LI	O
versus	O
cyclosporine	O
)	O
.	O

Belatacept	O
patients	O
experienced	O
a	O
higher	O
incidence	O
(	O
MI	O
:	O
22	O
%	O
,	O
LI	O
:	O
17	O
%	O
and	O
cyclosporine	O
:	O
7	O
%	O
)	O
and	O
grade	O
of	O
acute	O
rejection	O
episodes	O
.	O

Safety	O
was	O
generally	O
similar	O
between	O
groups	O
,	O
but	O
posttransplant	O
lymphoproliferative	O
disorder	O
was	O
more	O
common	O
in	O
the	O
belatacept	O
groups	O
.	O

Belatacept	O
was	O
associated	O
with	O
superior	O
renal	O
function	O
and	O
similar	O
patient/graft	O
survival	O
versus	O
cyclosporine	O
at	O
1	O
year	O
posttransplant	O
,	O
despite	O
a	O
higher	O
rate	O
of	O
early	O
acute	O
rejection	O
.	O

Improved	O
responsiveness	O
of	O
PCOS	O
patients	O
to	O
clomiphene	O
after	O
CYP17a	O
inhibitor	O
.	O

PURPOSE	O
To	O
study	O
the	O
effect	O
of	O
CYP17a	O
inhibitor	O
,	O
ketoconazole	O
,	O
on	O
clomiphene	O
responsiveness	O
in	O
PCOS	O
patients	O
.	O

METHODS	O
Prospective	O
analysis	O
was	O
employed	O
with	O
the	O
setup	O
at	O
Alexandria	O
IVF/ICSI	O
center	O
.	O

Ninety-seven	O
insulin-resistant	O
PCOS	O
patients	O
undergoing	O
ovulation	O
induction	O
using	O
clomiphene	O
citrate	O
were	O
randomly	O
divided	O
,	O
by	O
random	O
number	O
table	O
,	O
into	O
two	O
groups	O
.	O

The	O
first	O
group	O
(	O
n	O
=	O
49	O
)	O
received	O
ketoconazole	O
(	O
400	O
mg	O
daily	O
)	O
till	O
correction	O
of	O
metabolic	O
syndrome	O
followed	O
by	O
clomiphene	O
(	O
100	O
mg/day	O
)	O
;	O
the	O
second	O
group	O
(	O
n	O
=	O
48	O
)	O
receiving	O
clomiphene	O
without	O
ketoconazole	O
pretreatment	O
.	O

Main	O
outcome	O
measures	O
were	O
incidence	O
of	O
clomiphene	O
resistance	O
,	O
monofollicular	O
response	O
,	O
fasting	O
insulin/glucose	O
ratio	O
,	O
serum	O
testosterone	O
,	O
and	O
pregnancy	O
rates	O
.	O

RESULTS	O
The	O
ketoconazole	O
group	O
showed	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
incidence	O
of	O
monofollicular	O
response	O
(	O
38	O
%	O
)	O
,	O
higher	O
pregnancy	O
rates	O
,	O
and	O
significantly	O
less	O
marked	O
antiestrogenic	O
manifestations	O
than	O
did	O
the	O
control	O
group	O
.	O

They	O
also	O
had	O
significantly	O
lower	O
incidence	O
of	O
clomiphene	O
resistance	O
(	O
11.6	O
%	O
)	O
,	O
lower	O
serum	O
testosterone	O
levels	O
,	O
less	O
hyperinsulinaemia	O
,	O
than	O
did	O
the	O
control	O
group	O
.	O

CONCLUSION	O
Ketoconazole	O
improved	O
clomiphene	O
responsivenss	O
in	O
PCOS	O
patients	O
and	O
attenuated	O
its	O
untoward	O
biological	O
effects	O
.	O

Improved	O
survival	O
with	O
early	O
intensification	O
:	O
combined	O
results	O
from	O
the	O
Medical	O
Research	O
Council	O
childhood	O
ALL	O
randomised	O
trials	O
,	O
UKALL	O
X	O
and	O
UKALL	O
XI	O
.	O

Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Childhood	O
Leukaemia	O
.	O

The	O
Medical	O
Research	O
Council	O
(	O
MRC	O
)	O
United	O
Kingdom	O
trial	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
UKALL	O
X	O
)	O
randomised	O
patients	O
aged	O
0-14	O
years	O
inclusive	O
with	O
an	O
initial	O
white	O
blood	O
count	O
of	O
less	O
than	O
100	O
x	O
10	O
(	O
9	O
)	O
/l	O
to	O
receive	O
an	O
early	O
intensification	O
block	O
,	O
a	O
late	O
intensification	O
block	O
,	O
both	O
,	O
or	O
neither	O
.	O

The	O
next	O
trial	O
,	O
UKALL	O
XI	O
,	O
for	O
children	O
aged	O
1-14	O
years	O
,	O
randomised	O
between	O
different	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
directed	O
therapies	O
.	O

At	O
the	O
beginning	O
of	O
the	O
trial	O
,	O
all	O
patients	O
were	O
also	O
randomised	O
between	O
late	O
intensification	O
alone	O
and	O
both	O
early	O
plus	O
late	O
blocks	O
.	O

The	O
effects	O
of	O
both	O
the	O
early	O
and	O
the	O
late	O
block	O
in	O
UKALL	O
X	O
alone	O
have	O
been	O
reported	O
previously	O
.	O

This	O
paper	O
examines	O
the	O
effect	O
of	O
the	O
addition	O
of	O
the	O
early	O
intensification	O
block	O
to	O
treatment	O
which	O
included	O
late	O
intensification	O
,	O
combining	O
the	O
data	O
from	O
UKALL	O
X	O
and	O
the	O
first	O
part	O
of	O
UKALL	O
XI	O
.	O

Early	O
intensification	O
was	O
associated	O
with	O
fewer	O
bone	O
marrow	O
relapses	O
and	O
a	O
reduction	O
in	O
the	O
odds	O
of	O
death	O
of	O
0.63	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
0.46-0.87	O
)	O
.	O

Survival	O
was	O
significantly	O
improved	O
with	O
an	O
increase	O
at	O
5	O
years	O
of	O
8	O
%	O
,	O
from	O
79	O
to	O
87	O
%	O
.	O

Following	O
this	O
demonstration	O
that	O
early	O
intensification	O
improves	O
survival	O
,	O
the	O
effect	O
of	O
a	O
third	O
intensification	O
block	O
is	O
under	O
investigation	O
.	O

[	O
Prevention	O
of	O
migraine	Condition
with	O
flunarizine	O
and	O
acetylsalicylic	O
acid	O
.	O

A	O
double-blind	O
study	O
]	O
.	O

UNLABELLED	O
30	SampleSize
children	Age
between	Age
7	Age
and	Age
17	Age
years	O
suffering	O
from	O
at	O
least	O
2	O
attacks/month	O
of	O
common	Condition
or	Condition
classical	Condition
migraine	Condition
since	O
more	O
than	O
1	O
year	O
were	O
studied	O
.	O

After	O
clinical	O
exclusion	O
of	O
symptomatic	O
headache	O
4	O
weeks	O
were	O
documented	O
by	O
means	O
of	O
a	O
migraine	O
diary	O
.	O

Prophylaxis	O
with	O
Calcium	O
entry	O
blocker	O
Flunarizine	O
(	O
Sibelium	O
)	O
or	O
Thromboxane	O
A	O
inhibitor	O
Acetylsalicylic	O
acid	O
(	O
ASS	O
)	O
was	O
carried	O
out	O
in	O
a	O
double	O
blind	O
design	O
for	O
3	O
months	O
.	O

Medication	O
was	O
given	O
as	O
one	O
dosage	O
in	O
the	O
evening	O
:	O
2-5	O
mg/kg	O
KG	O
ASS	O
or	O
5-10	O
mg	O
Flunarizine	O
.	O

Documented	O
attack	O
frequency	O
and	O
duration	O
were	O
controlled	O
at	O
monthly	O
physical	O
examinations	O
.	O

Final	O
results	O
showed	O
no	O
differences	O
in	O
significant	O
reduction	O
of	O
attack	O
frequency	O
or	O
symptoms	O
between	O
both	O
different	O
therapeutic	O
principals	O
.	O

72.4	O
%	O
(	O
ASS	O
73.3	O
%	O
;	O
Flunarizine	O
71.4	O
%	O
)	O
of	O
patients	O
were	O
attack-free	O
or	O
had	O
at	O
least	O
a	O
50	O
%	O
reduction	O
.	O

Migraine	O
frequency	O
of	O
initially	O
7-8	O
was	O
reduced	O
to	O
1-2	O
attacks/month	O
.	O

Duration	O
remained	O
constant	O
in	O
both	O
groups	O
(	O
1-3	O
h	O
)	O
.	O

Side	O
effects	O
were	O
slight	O
body	O
weight	O
gain	O
or	O
abdominal	O
pain	O
after	O
intake	O
,	O
prophylaxis	O
had	O
not	O
to	O
be	O
interrupted	O
therefore	O
.	O

Longtime	O
prognosis	O
is	O
not	O
yet	O
possible	O
because	O
the	O
time	O
of	O
observation	O
is	O
too	O
short	O
so	O
far	O
.	O

CONCLUSION	O
Both	O
substances	O
are	O
definitely	O
useful	O
and	O
have	O
few	O
side	O
effects	O
in	O
childhood	Condition
migraine	Condition
.	Condition

If	O
the	O
response	O
to	O
one	O
is	O
insufficient	O
the	O
other	O
substance	O
should	O
be	O
tried	O
.	O

Control	O
of	O
the	O
lumbar	O
neutral	O
zone	O
decreases	O
low	Condition
back	Condition
pain	Condition
and	O
improves	O
self-evaluated	O
work	O
ability	O
:	O
a	O
12-month	O
randomized	O
controlled	O
study	O
.	O

STUDY	O
DESIGN	O
A	O
randomized	O
controlled	O
study	O
with	O
12	O
months	O
intervention	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
effectiveness	O
of	O
a	O
training	O
intervention	O
with	O
emphases	O
on	O
the	O
control	O
of	O
lumbar	O
neutral	O
zone	O
(	O
NZ	O
)	O
and	O
behavior	O
modeling	O
as	O
secondary	O
prevention	O
of	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
and	O
disability	O
.	O

SUMMARY	O
OF	O
BACKGROUND	O
DATA	O
Improving	O
the	O
control	O
of	O
lumbar	O
NZ	O
and	O
enhancing	O
muscle	O
activation	O
patterns	O
ensuring	O
spinal	O
stability	O
have	O
been	O
proposed	O
as	O
means	O
for	O
secondary	O
prevention	O
of	O
LBP	O
and	O
disability	O
.	O

In	O
addition	O
,	O
cognitive	O
behavior	O
interventions	O
have	O
been	O
shown	O
to	O
lower	O
the	O
risk	O
of	O
recurrence	O
of	O
LBP	O
and	O
long-term	O
disability	O
.	O

METHODS	O
Middle-aged	O
working	O
men	O
with	O
recent	O
LBP	O
but	O
without	O
severe	O
disability	O
were	O
randomly	O
allocated	O
to	O
either	O
a	O
training	O
(	O
TG	O
,	O
n	O
=	O
52	O
)	O
or	O
control	O
group	O
(	O
CG	O
,	O
n	O
=	O
54	O
)	O
.	O

The	O
aim	O
was	O
to	O
exercise	O
twice	O
a	O
week	O
for	O
12	O
months	O
,	O
once	O
guided	O
and	O
once	O
independently	O
.	O

The	O
outcome	O
measures	O
were	O
the	O
changes	O
in	O
intensity	O
of	O
LBP	O
,	O
disability	O
,	O
self-evaluated	O
future	O
work	O
ability	O
,	O
and	O
neuromuscular	O
fitness	O
.	O

RESULTS	O
The	O
intensity	O
of	O
LBP	O
decreased	O
significantly	O
more	O
(	O
39	O
%	O
)	O
in	O
the	O
TG	O
than	O
in	O
CG	O
at	O
12	O
months	O
.	O

The	O
proportion	O
of	O
subjects	O
with	O
negative	O
expectations	O
about	O
their	O
future	O
work	O
ability	O
decreased	O
in	O
both	O
groups	O
at	O
6	O
and	O
12	O
months	O
;	O
however	O
,	O
the	O
proportion	O
was	O
significantly	O
bigger	O
in	O
TG	O
compared	O
with	O
CG	O
(	O
P	O
=	O
0.028	O
)	O
.	O

There	O
effects	O
on	O
disability	O
indexes	O
and	O
fitness	O
were	O
not	O
statistically	O
significant	O
.	O

CONCLUSIONS	O
Controlling	O
lumbar	O
NZ	O
is	O
a	O
specific	O
form	O
of	O
exercise	O
and	O
daily	O
self-care	O
with	O
potential	O
for	O
prevention	O
of	O
recurrent	O
nonspecific	O
LBP	O
and	O
disability	O
among	O
middle	O
aged	O
working	O
men	O
.	O

Yoga	O
effects	O
on	O
mood	O
and	O
quality	O
of	O
life	O
in	O
Chinese	O
women	Sex
undergoing	O
heroin	Condition
detoxification	Condition
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Yoga	O
,	O
as	O
a	O
mind-body	O
therapy	O
,	O
is	O
effective	O
in	O
improving	O
quality	O
of	O
life	O
for	O
patients	O
with	O
chronic	O
diseases	O
,	O
yet	O
little	O
is	O
known	O
about	O
its	O
effectiveness	O
in	O
female	O
heroin	O
addicts	O
.	O

OBJECTIVES	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
yoga	O
on	O
mood	O
status	O
and	O
quality	O
of	O
life	O
among	O
women	O
undergoing	O
detoxification	O
for	O
heroin	O
dependence	O
in	O
China	O
.	O

METHOD	O
This	O
study	O
was	O
a	O
randomized	O
controlled	O
trial	O
.	O

Seventy-five	SampleSize
women	O
aged	O
20-37	Age
years	Age
undergoing	O
detoxification	O
for	O
heroin	O
dependence	O
at	O
AnKang	O
Hospital	O
were	O
allocated	O
randomly	O
into	O
an	O
intervention	O
or	O
a	O
control	O
group	O
.	O

Women	O
in	O
the	O
intervention	O
group	O
received	O
a	O
6-month	O
yoga	O
intervention	O
in	O
addition	O
to	O
hospital	O
routine	O
care	O
,	O
and	O
women	O
in	O
the	O
control	O
group	O
received	O
hospital	O
routine	O
care	O
only	O
.	O

Mood	O
status	O
and	O
quality	O
of	O
life	O
were	O
assessed	O
using	O
the	O
Profile	O
of	O
Mood	O
States	O
and	O
Medical	O
Outcomes	O
Study	O
36-item	O
Short-Form	O
Health	O
Survey	O
at	O
baseline	O
and	O
following	O
3	O
and	O
6	O
months	O
of	O
treatment	O
.	O

Repeated-measures	O
analysis	O
of	O
variance	O
was	O
used	O
to	O
evaluate	O
treatment	O
and	O
time	O
effects	O
on	O
mood	O
and	O
quality	O
of	O
life	O
.	O

RESULTS	O
Most	O
female	Sex
heroin	Condition
addicts	Condition
were	O
young	O
and	O
single	O
,	O
with	O
a	O
low	O
education	O
level	O
.	O

Most	O
had	O
used	O
heroin	O
by	O
injection	O
.	O

Mood	O
state	O
and	O
quality	O
of	O
life	O
of	O
female	O
heroin	O
addicts	O
were	O
poor	O
.	O

The	O
intervention	O
group	O
showed	O
a	O
significant	O
improvement	O
in	O
mood	O
status	O
and	O
quality	O
of	O
life	O
over	O
time	O
compared	O
with	O
their	O
counterparts	O
in	O
the	O
control	O
group	O
.	O

CONCLUSION	O
Yoga	O
may	O
improve	O
mood	O
status	O
and	O
quality	O
of	O
life	O
for	O
women	O
undergoing	O
detoxification	O
for	O
heroin	O
dependence	O
.	O

Yoga	O
can	O
be	O
used	O
as	O
an	O
auxiliary	O
treatment	O
with	O
traditional	O
hospital	O
routine	O
care	O
for	O
these	O
women	O
.	O

DTkid	O
:	O
interactive	O
simulation	O
software	O
for	O
training	O
tutors	O
of	O
children	Age
with	O
autism	Condition
.	O

Discrete-trial	O
training	O
(	O
DTT	O
)	O
relies	O
critically	O
on	O
implementation	O
by	O
trained	O
tutors	O
.	O

We	O
report	O
three	O
experiments	O
carried	O
out	O
in	O
the	O
development	O
of	O
DTkid	O
--	O
interactive	O
computer	O
simulation	O
software	O
that	O
presents	O
SIMon	O
,	O
a	O
realistic	O
virtual	O
child	O
with	O
whom	O
novice	O
tutors	O
can	O
learn	O
and	O
practise	O
DTT	O
techniques	O
.	O

Experiments	O
1	O
and	O
2	O
exposed	O
groups	O
of	O
participants	O
either	O
to	O
DTkid	O
training	O
or	O
to	O
a	O
control	O
task	O
.	O

Participants	O
in	O
the	O
former	O
groups	O
demonstrated	O
significantly	O
greater	O
procedural	O
and	O
declarative	O
knowledge	O
of	O
DTT	O
.	O

Experiment	O
3	O
confirmed	O
this	O
finding	O
,	O
further	O
demonstrating	O
that	O
observation	O
of	O
DTkid	O
training	O
trials	O
alone	O
was	O
sufficient	O
to	O
enhance	O
participants	O
'	O
declarative	O
and	O
procedural	O
knowledge	O
of	O
DTT	O
.	O

Results	O
indicate	O
that	O
DTkid	O
offers	O
the	O
potential	O
for	O
an	O
effective	O
means	O
of	O
teaching	O
DTT	O
skills	O
to	O
novice	O
tutors	O
of	O
children	Age
with	O
autism	Condition
.	O

Effectiveness	O
of	O
nonpharmacologic	O
treatments	O
for	O
acute	Condition
seasonal	Condition
allergic	Condition
conjunctivitis	Condition
.	Condition

OBJECTIVE	O
To	O
investigate	O
whether	O
artificial	O
tears	O
and	O
cold	O
compress	O
alone	O
or	O
in	O
combination	O
provide	O
a	O
treatment	O
benefit	O
and	O
whether	O
they	O
were	O
as	O
effective	O
as	O
or	O
could	O
enhance	O
topical	O
antiallergic	O
medication	O
.	O

DESIGN	O
Randomized	O
,	O
masked	O
clinical	O
trial	O
.	O

PARTICIPANTS	O
Eighteen	O
subjects	O
(	O
mean	O
age	O
,	O
29.5?11.0	O
years	O
)	O
allergic	O
to	O
grass	O
pollen	O
.	O

INTERVENTION	O
Controlled	O
exposure	O
to	O
grass	O
pollen	O
using	O
an	O
environmental	O
chamber	O
to	O
stimulate	O
an	O
ocular	O
allergic	O
reaction	O
followed	O
by	O
application	O
of	O
artificial	O
tears	O
(	O
ATs	O
)	O
,	O
5	O
minutes	O
of	O
cold	O
compress	O
(	O
CC	O
)	O
,	O
ATs	O
combined	O
with	O
CC	O
,	O
or	O
no	O
treatment	O
applied	O
at	O
each	O
separate	O
visit	O
in	O
random	O
order	O
.	O

A	O
subset	O
of	O
11	O
subjects	O
also	O
had	O
epinastine	O
hydrochloride	O
(	O
EH	O
)	O
applied	O
alone	O
and	O
combined	O
with	O
CC	O
in	O
random	O
order	O
or	O
instillation	O
of	O
a	O
volume-matched	O
saline	O
control	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Bulbar	O
conjunctival	O
hyperemia	O
,	O
ocular	O
surface	O
temperature	O
,	O
and	O
ocular	O
symptoms	O
repeated	O
before	O
and	O
every	O
10	O
minutes	O
after	O
treatment	O
for	O
1	O
hour	O
.	O

RESULTS	O
Bulbar	O
conjunctival	O
hyperemia	O
and	O
ocular	O
symptoms	O
decreased	O
and	O
temperature	O
recovered	O
to	O
baseline	O
faster	O
with	O
nonpharmaceutical	O
treatments	O
compared	O
with	O
no	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Artificial	O
tears	O
combined	O
with	O
CC	O
reduced	O
hyperemia	O
more	O
than	O
other	O
treatments	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
treatment	O
effect	O
of	O
EH	O
was	O
enhanced	O
by	O
combining	O
it	O
with	O
a	O
CC	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Cold	O
compress	O
combined	O
with	O
ATs	O
or	O
EH	O
lowered	O
the	O
antigen-raised	O
ocular	O
surface	O
temperature	O
to	O
less	O
than	O
the	O
pre-exposure	O
baseline	O
.	O

Artificial	O
tear	O
instillation	O
alone	O
or	O
CC	O
combined	O
with	O
ATs	O
or	O
EH	O
significantly	O
reduced	O
the	O
temperature	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Cold	O
compress	O
combined	O
with	O
ATs	O
or	O
EH	O
had	O
a	O
similar	O
cooling	O
effect	O
(	O
P	O
>	O
0.05	O
)	O
.	O

At	O
all	O
measurement	O
intervals	O
,	O
symptoms	O
were	O
reduced	O
for	O
both	O
EH	O
and	O
EH	O
combined	O
with	O
CC	O
than	O
CC	O
or	O
ATs	O
alone	O
or	O
in	O
combination	O
(	O
P	O
<	O
0.014	O
)	O
.	O

CONCLUSIONS	O
After	O
controlled	O
exposure	O
to	O
grass	O
pollen	O
,	O
CC	O
and	O
AT	O
treatment	O
showed	O
a	O
therapeutic	O
effect	O
on	O
the	O
signs	O
and	O
symptoms	O
of	O
allergic	O
conjunctivitis	O
.	O

A	O
CC	O
enhanced	O
the	O
use	O
of	O
EH	O
alone	O
and	O
was	O
the	O
only	O
treatment	O
to	O
reduce	O
symptoms	O
to	O
baseline	O
within	O
1	O
hour	O
of	O
antigenic	O
challenge	O
.	O

Signs	O
of	O
allergic	O
conjunctivitis	O
generally	O
were	O
reduced	O
most	O
by	O
a	O
combination	O
of	O
a	O
CC	O
in	O
combination	O
with	O
ATs	O
or	O
EH	O
.	O

The	O
efficacy	O
of	O
intramammary	O
tilmicosin	O
at	O
drying-off	O
,	O
and	O
other	O
risk	O
factors	O
for	O
the	O
prevention	O
of	O
new	O
intramammary	O
infections	O
during	O
the	O
dry	O
period	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
an	O
intramammary	O
infusion	O
,	O
containing	O
tilmicosin	O
phosphate	O
,	O
to	O
an	O
infusion	O
of	O
a	O
negative	O
control	O
intramammary	O
placebo	O
for	O
preventing	O
new	O
intramammary	O
infections	O
(	O
IMI	O
)	O
during	O
the	O
dry	O
period	O
.	O

Cows	Condition
were	O
enrolled	O
from	O
24	O
dairy	O
herds	O
from	O
three	O
geographical	O
regions	O
of	O
Canada	O
.	O

Data	O
from	O
248	SampleSize
cows	O
and	O
938	O
bacteriologically	O
negative	O
quarters	O
at	O
drying-off	O
are	O
summarized	O
.	O

Overall	O
,	O
the	O
rate	O
of	O
new	O
IMI	O
during	O
the	O
dry	O
period	O
was	O
16.7	O
%	O
of	O
quarters	O
.	O

The	O
new	O
infection	O
rates	O
for	O
quarters	O
that	O
received	O
intramammary	O
tilmicosin	O
compared	O
with	O
the	O
intramammary	O
placebo	O
were	O
14.4	O
and	O
19.4	O
%	O
,	O
respectively	O
.	O

The	O
majority	O
of	O
new	O
IMI	O
was	O
caused	O
by	O
coagulase-negative	O
staphylococci	O
(	O
49	O
%	O
)	O
and	O
environmental	O
streptococcal	O
organisms	O
(	O
26.8	O
%	O
)	O
.	O

The	O
probability	O
for	O
quarters	O
to	O
develop	O
new	O
IMI	O
in	O
the	O
dry	O
period	O
was	O
significantly	O
increased	O
when	O
cows	O
had	O
higher	O
milk	O
production	O
before	O
drying-off	O
(	O
P	O
=	O
0.04	O
)	O
,	O
when	O
cows	O
had	O
longer	O
dry	O
periods	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
when	O
dry	O
cows	O
were	O
housed	O
in	O
tie-stall	O
barns	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Higher	O
parity	O
cows	O
and	O
those	O
that	O
had	O
a	O
linear	O
score	O
somatic	O
cell	O
count	O
(	O
SCC	O
)	O
above	O
4	O
on	O
the	O
last	O
DHI	O
test	O
were	O
also	O
at	O
increased	O
risk	O
for	O
new	O
IMI	O
(	O
P	O
<	O
0.10	O
)	O
.	O

Administration	O
of	O
intramammary	O
tilmicosin	O
appears	O
to	O
be	O
an	O
efficacious	O
therapy	O
for	O
prevention	O
of	O
new	O
IMI	O
;	O
however	O
,	O
there	O
is	O
currently	O
no	O
approved	O
intramammary	O
formulation	O
of	O
this	O
product	O
available	O
.	O

Use	O
of	O
blanket	O
dry	O
cow	O
antibiotic	O
therapy	O
compared	O
to	O
selective	O
dry	O
cow	O
therapy	O
,	O
as	O
well	O
as	O
the	O
importance	O
of	O
identifying	O
risk	O
factors	O
and	O
managing	O
the	O
environment	O
of	O
dry	O
cows	O
are	O
discussed	O
.	O

Effect	O
of	O
soy	O
protein	O
containing	O
isoflavones	O
on	O
blood	O
lipids	O
in	O
moderately	O
hypercholesterolemic	Condition
adults	Age
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Dietary	O
intake	O
of	O
soy	O
protein	O
with	O
isoflavones	O
may	O
be	O
associated	O
with	O
reductions	O
in	O
serum	O
cholesterol	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
effects	O
of	O
a	O
water-washed	O
soy	O
protein	O
concentrate	O
with	O
a	O
milk-protein	O
based	O
control	O
on	O
blood	O
lipid	O
levels	O
in	O
hyperlipidemic	Condition
men	Sex
and	O
women	Sex
.	Sex

METHODS	O
A	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
clinical	O
trial	O
including	O
159	SampleSize
subjects	O
.	O

After	O
a	O
3-week	O
run-in	O
period	O
during	O
which	O
all	O
subjects	O
consumed	O
a	O
milk	O
protein-based	O
supplement	O
,	O
participants	O
were	O
randomized	O
into	O
one	O
of	O
two	O
groups	O
:	O
a	O
control	O
group	O
(	O
continued	O
milk	O
protein	O
)	O
and	O
an	O
intervention	O
group	O
(	O
soy	O
protein	O
)	O
for	O
a	O
five-week	O
period	O
.	O

Fasting	O
venous	O
blood	O
draws	O
for	O
lipid	O
measurement	O
were	O
obtained	O
at	O
baseline	O
,	O
towards	O
the	O
end	O
of	O
the	O
run-in	O
period	O
and	O
at	O
the	O
end	O
of	O
the	O
intervention	O
.	O

Blood	O
isoflavone	O
concentrations	O
were	O
measured	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

RESULTS	O
Blood	O
lipid	O
levels	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
at	O
any	O
point	O
in	O
time	O
;	O
and	O
there	O
were	O
no	O
significant	O
associations	O
between	O
blood	O
isoflavones	O
and	O
lipid	O
levels	O
.	O

Significant	O
decreases	O
in	O
total	O
cholesterol	O
(	O
19	O
mg/dL	O
)	O
,	O
and	O
LDL-cholesterol	O
(	O
11	O
mg/dL	O
)	O
,	O
were	O
observed	O
during	O
the	O
run-in	O
period	O
,	O
with	O
no	O
further	O
decreases	O
in	O
lipids	O
during	O
the	O
intervention	O
period	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
These	O
results	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
water-washed	O
soy	O
protein	O
has	O
an	O
effect	O
on	O
blood	O
lipids	O
.	O

Several	O
hypotheses	O
are	O
discussed	O
,	O
highlighting	O
the	O
selective	O
nature	O
of	O
the	O
effect	O
of	O
soy	O
consumption	O
in	O
the	O
population	O
.	O

The	O
cholesterol-lowering	O
effect	O
during	O
the	O
run-in	O
period	O
may	O
be	O
explained	O
by	O
the	O
regression	O
to	O
the	O
mean	O
effect	O
and	O
by	O
other	O
factors	O
related	O
to	O
study	O
participation	O
,	O
mainly	O
nutrient	O
displacement	O
induced	O
by	O
the	O
protein	O
supplement	O
.	O

Early	O
reperfusion	O
and	O
late	O
clinical	O
outcomes	O
in	O
patients	O
presenting	O
with	O
acute	Condition
myocardial	Condition
infarction	Condition
randomly	O
assigned	O
to	O
primary	O
percutaneous	O
coronary	O
intervention	O
or	O
streptokinase	O
.	O

BACKGROUND	O
Primary	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
has	O
become	O
an	O
alternative	O
to	O
thrombolytic	O
therapy	O
as	O
a	O
reperfusion	O
strategy	O
for	O
ST-elevation	O
acute	O
myocardial	O
infarction	O
(	O
AMI	Condition
)	O
.	O

METHODS	O
The	O
main	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
PCI	O
and	O
thrombolytic	O
therapy	O
achieve	O
comparable	O
reperfusion	O
rates	O
,	O
as	O
evidenced	O
by	O
ST-segment	O
resolution	O
.	O

Secondary	O
end	O
points	O
included	O
infarct	O
vessel	O
patency	O
rates	O
before	O
hospital	O
discharge	O
and	O
short-	O
and	O
long-term	O
outcomes	O
.	O

Patients	O
with	O
ischemic	Condition
chest	Condition
pain	Condition
with	O
duration	O
<	O
or	O
=12	O
hours	O
and	O
no	O
contraindication	O
for	O
thrombolytic	O
therapy	O
were	O
included	O
.	O

RESULTS	O
Between	O
October	O
1993	O
and	O
August	O
1995	O
,	O
58	SampleSize
patients	O
were	O
randomly	O
assigned	O
to	O
streptokinase	O
(	O
SK	O
)	O
and	O
54	SampleSize
patients	O
to	O
primary	O
PCI	O
.	O

Baseline	O
clinical	O
characteristics	O
and	O
infarct	O
location	O
were	O
well	O
balanced	O
in	O
both	O
groups	O
.	O

Median	O
age	O
(	O
interquartile	O
range	O
)	O
was	O
68	Age
(	O
58	O
,	O
75	O
)	O
years	O
,	O
29	O
%	O
were	O
women	Sex
,	O
and	O
78	O
%	O
of	O
the	O
patients	O
met	O
at	O
least	O
one	O
criterion	O
for	O
not	O
low	O
risk	O
AMI	O
(	O
anterior	O
location	O
,	O
age	O
>	Age
70	Age
years	Age
old	O
,	O
previous	O
MI	O
,	O
systolic	O
blood	O
pressure	O
<	O
100	O
mm	O
Hg	O
,	O
and/or	O
heart	O
rate	O
>	O
100	O
bpm	O
)	O
.	O

The	O
median	O
time	O
from	O
symptom	O
onset	O
to	O
random	O
assignment	O
was	O
217	O
(	O
139	O
,	O
335	O
)	O
minutes	O
in	O
the	O
PCI	O
group	O
and	O
210	O
(	O
145	O
,	O
334	O
)	O
minutes	O
in	O
the	O
SK	O
group	O
.	O

Median	O
random	O
assignment	O
to	O
balloon	O
time	O
was	O
82	O
(	O
55	O
,	O
100	O
)	O
minutes	O
,	O
and	O
median	O
random	O
assignment	O
to	O
needle	O
time	O
was	O
15	O
(	O
10	O
,	O
26	O
)	O
minutes	O
(	O
P	O
<	O
.0001	O
)	O
.	O

TIMI	O
grade	O
3	O
flow	O
after	O
primary	O
PCI	O
was	O
obtained	O
in	O
85	O
%	O
of	O
patients	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
ST-segment	O
resolution	O
>	O
or	O
=50	O
%	O
at	O
120	O
minutes	O
was	O
80	O
%	O
in	O
the	O
PCI	O
group	O
and	O
50	O
%	O
in	O
the	O
SK	O
group	O
(	O
P	O
=.001	O
)	O
.	O

The	O
predischarge	O
angiogram	O
showed	O
the	O
presence	O
of	O
TIMI	O
3	O
flow	O
in	O
96	O
%	O
of	O
patients	O
who	O
received	O
PCI	O
and	O
65	O
%	O
of	O
patients	O
who	O
received	O
SK	O
(	O
P	O
<	O
.001	O
)	O
.	O

A	O
composite	O
of	O
in-hospital	O
death	O
,	O
reinfarction	O
,	O
severe	O
heart	O
failure	O
,	O
stroke	O
,	O
and	O
major	O
bleeding	O
occurred	O
in	O
15	O
%	O
of	O
patients	O
who	O
received	O
PCI	O
and	O
21	O
%	O
of	O
patients	O
who	O
received	O
SK	O
(	O
P	O
=.4	O
)	O
.	O

At	O
3	O
years	O
,	O
freedom	O
from	O
the	O
composite	O
end	O
point	O
of	O
AMI	O
,	O
postdischarge	O
revascularization	O
,	O
and	O
death	O
was	O
61	O
%	O
in	O
the	O
PCI	O
group	O
and	O
40	O
%	O
in	O
the	O
SK	O
group	O
(	O
P	O
=.025	O
)	O
.	O

CONCLUSIONS	O
Our	O
study	O
shows	O
that	O
primary	O
PCI	O
,	O
as	O
compared	O
with	O
SK	O
,	O
is	O
associated	O
with	O
more	O
effective	O
ST-segment	O
resolution	O
,	O
higher	O
patency	O
rates	O
in	O
the	O
infarct	O
vessel	O
at	O
7	O
days	O
,	O
and	O
more	O
favorable	O
clinical	O
outcomes	O
at	O
3	O
years	O
of	O
follow-up	O
.	O

Absolute	O
bioavailability	O
of	O
a	O
new	O
high	O
dose	O
methylprednisolone	O
tablet	O
formulation	O
.	O

This	O
was	O
a	O
single-blind	O
,	O
single-dose	O
,	O
randomized	O
crossover	O
study	O
to	O
determine	O
the	O
absolute	O
bioavailability	O
of	O
Medrol	O
,	O
a	O
new	O
high	O
dose	O
(	O
100	O
mg	O
)	O
methylprednisolone	O
tablet	O
product	O
,	O
by	O
comparing	O
it	O
with	O
100	O
mg	O
methylprednisolone	O
from	O
an	O
intravenous	O
formulation	O
,	O
Solu-Medrol	O
.	O

Fourteen	SampleSize
healthy	O
,	O
non-smoking	O
,	O
Caucasian	O
male	Sex
volunteers	O
took	O
part	O
.	O

On	O
treatment	O
days	O
volunteers	O
remained	O
recumbent	O
for	O
4	O
hours	O
after	O
drug	O
administration	O
,	O
with	O
food	O
and	O
fluid	O
intake	O
standardized	O
over	O
this	O
period	O
.	O

Serial	O
blood	O
samples	O
were	O
drawn	O
over	O
a	O
14-hour	O
period	O
after	O
drug	O
administration	O
.	O

Plasma	O
methylprednisolone	O
concentrations	O
were	O
determined	O
by	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
geometric	O
means	O
of	O
AUCi.v	O
.	O

and	O
AUCtablet	O
were	O
4,049	O
and	O
3,334	O
ng.h/ml	O
,	O
respectively	O
.	O

The	O
absolute	O
bioavailability	O
of	O
the	O
tablet	O
product	O
was	O
82	O
%	O
,	O
which	O
is	O
in	O
agreement	O
with	O
published	O
data	O
for	O
other	O
oral	O
dosage	O
forms	O
of	O
methylprednisolone	O
.	O

Volunteers	O
displayed	O
the	O
expected	O
rise	O
in	O
peripheral	O
blood	O
neutrophil	O
count	O
,	O
but	O
no	O
other	O
clinically	O
relevant	O
changes	O
in	O
hematology	O
or	O
clinical	O
chemistry	O
were	O
observed	O
.	O

No	O
adverse	O
drug	O
reactions	O
were	O
recorded	O
.	O

It	O
is	O
concluded	O
that	O
the	O
tablet	O
product	O
can	O
be	O
used	O
as	O
a	O
substitute	O
for	O
parenteral	O
methylprednisolone	O
in	O
situations	O
requiring	O
high-dose	O
therapy	O
.	O

Maintenance	O
of	O
response	O
following	O
stabilization	O
of	O
mixed	O
index	O
episodes	O
with	O
olanzapine	O
monotherapy	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
bipolar	Condition
1	Condition
disorder	Condition
.	O

BACKGROUND	O
In	O
a	O
population	O
of	O
patients	O
with	O
manic	O
and	O
mixed	O
mood	Condition
episodes	Condition
,	O
olanzapine	O
has	O
proven	O
effective	O
in	O
maintaining	O
response	O
,	O
as	O
compared	O
to	O
placebo	O
.	O

Whether	O
this	O
is	O
true	O
for	O
the	O
subpopulation	O
of	O
patients	O
with	O
a	O
mixed	O
index	O
episode	O
is	O
not	O
known	O
.	O

METHODS	O
Post-hoc	O
analyses	O
were	O
conducted	O
on	O
data	O
from	O
patients	O
presenting	O
with	O
a	O
mixed	O
index	O
episode	O
who	O
were	O
enrolled	O
in	O
a	O
larger	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

Patients	O
who	O
met	O
remission	O
criteria	O
at	O
2	O
consecutive	O
weekly	O
visits	O
during	O
6	O
to	O
12	O
weeks	O
of	O
open-label	O
olanzapine	O
treatment	O
were	O
randomly	O
assigned	O
to	O
olanzapine	O
or	O
placebo	O
treatment	O
for	O
48	O
weeks	O
.	O

The	O
incidence	O
of	O
and	O
time	O
to	O
symptomatic	O
relapse	O
were	O
calculated	O
for	O
any	O
mood	O
episode	O
,	O
and	O
for	O
depressive	O
,	O
manic	O
,	O
hypo-manic	O
,	O
and	O
mixed	O
mood	O
episodes	O
.	O

RESULTS	O
A	O
total	O
of	O
121	SampleSize
of	O
304	SampleSize
patients	O
(	O
39.8	O
%	O
)	O
met	O
criteria	O
for	O
symptomatic	O
remission	O
in	O
the	O
open-label	O
treatment	O
phase	O
and	O
were	O
randomly	O
assigned	O
to	O
olanzapine	O
(	O
n=76	O
)	O
or	O
placebo	O
(	O
n=45	O
)	O
.	O

Compared	O
to	O
the	O
placebo	O
group	O
,	O
the	O
olanzapine	O
group	O
had	O
a	O
lower	O
incidence	O
of	O
(	O
59.2	O
%	O
versus	O
91.1	O
%	O
,	O
p	O
<	O
0.001	O
)	O
and	O
a	O
longer	O
time	O
to	O
(	O
46	O
versus	O
15	O
days	O
,	O
p	O
<	O
0.001	O
)	O
symptomatic	O
relapse	O
of	O
any	O
kind	O
.	O

Olanzapine-treated	O
patients	O
also	O
experienced	O
longer	O
time	O
to	O
depressive	O
symptomatic	O
relapse	O
(	O
85	O
versus	O
22	O
days	O
,	O
p=0.001	O
)	O
and	O
manic	O
symptomatic	O
relapse	O
(	O
too	O
few	O
relapses	O
to	O
calculate	O
versus	O
42	O
days	O
,	O
p	O
<	O
0.001	O
)	O
than	O
did	O
placebo-treated	O
patients	O
.	O

CONCLUSIONS	O
Compared	O
with	O
placebo	O
,	O
olanzapine	O
treatment	O
was	O
associated	O
with	O
longer	O
maintenance	O
of	O
response	O
in	O
patients	O
presenting	O
with	O
a	O
mixed	Condition
index	Condition
episode	Condition
of	O
bipolar	Condition
I	Condition
disorder	Condition
.	O

Rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
:	O
prevention	O
of	O
fasciculations	O
with	O
pancuronium	O
versus	O
minidose	O
succinylcholine	O
.	O

INTRODUCTION	O
Fasciculations	O
during	O
rapid-sequence	O
intubation	O
may	O
lead	O
to	O
increased	O
intracranial	O
pressure	O
and	O
emesis	O
with	O
aspiration	O
.	O

Standard	O
rapid-sequence	O
intubation	O
requires	O
a	O
nondepolarizing	O
blocking	O
agent	O
before	O
succinylcholine	O
administration	O
.	O

HYPOTHESIS	O
Prevention	O
of	O
fasciculations	O
during	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
can	O
be	O
accomplished	O
as	O
safely	O
and	O
effectively	O
with	O
minidose	O
succinylcholine	O
as	O
with	O
a	O
defasciculating	O
dose	O
of	O
pancuronium	O
.	O

DESIGN	O
A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

SETTING	O
An	O
inner-city	O
county	O
trauma	O
center	O
with	O
70,000	O
patient	O
visits	O
per	O
year	O
.	O

PARTICIPANTS	O
Sequential	O
adult	Age
head	O
trauma	O
patients	O
requiring	O
rapid-sequence	O
intubation	O
who	O
had	O
no	O
contraindications	O
to	O
succinylcholine	O
or	O
pancuronium	O
.	O

INTERVENTIONS	O
Each	O
head	O
trauma	O
patient	O
requiring	O
rapid-sequence	O
intubation	O
who	O
met	O
the	O
inclusion	O
criteria	O
received	O
standard	O
rapid-sequence	O
intubation	O
maneuvers	O
and	O
lidocaine	O
(	O
1	O
mg/kg	O
)	O
IV	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
minidose	O
succinylcholine	O
(	O
0.1	O
mg/kg	O
)	O
or	O
pancuronium	O
(	O
0.03	O
mg/kg	O
)	O
IV	O
one	O
minute	O
prior	O
to	O
the	O
full	O
paralytic	O
dose	O
of	O
succinylcholine	O
(	O
1.5	O
mg/kg	O
)	O
IV	O
.	O

Fasciculations	O
were	O
recorded	O
using	O
a	O
graded	O
visual	O
scale	O
.	O

RESULTS	O
Of	O
46	SampleSize
patients	O
,	O
eight	O
of	O
19	O
(	O
42	O
%	O
)	O
in	O
the	O
pancuronium	O
group	O
and	O
six	O
of	O
27	O
(	O
22	O
%	O
)	O
in	O
the	O
succinylcholine	O
group	O
experienced	O
fasciculations	O
.	O

No	O
statistically	O
significant	O
difference	O
in	O
fasciculations	O
was	O
detected	O
between	O
the	O
two	O
groups	O
using	O
chi	O
2	O
analysis	O
.	O

Complete	O
relaxation	O
of	O
the	O
cords	O
was	O
present	O
in	O
all	O
but	O
two	O
patients	O
,	O
one	O
in	O
each	O
group	O
.	O

No	O
patient	O
in	O
either	O
group	O
experienced	O
emesis	O
or	O
significant	O
dysrhythmias	O
.	O

CONCLUSION	O
Pretreatment	O
with	O
minidose	O
succinylcholine	O
causes	O
no	O
greater	O
incidence	O
of	O
fasciculations	O
than	O
pancuronium	O
in	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
in	O
an	O
ED	O
setting	O
.	O

Thus	O
succinylcholine	O
may	O
be	O
used	O
as	O
the	O
sole	O
paralytic	O
agent	O
in	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
.	O

Atrophy	O
and	O
intestinal	Condition
metaplasia	Condition
one	O
year	O
after	O
cure	O
of	O
H.	O
pylori	O
infection	O
:	O
a	O
prospective	O
,	O
randomized	O
study	O
.	O

BACKGROUND	O
&	O
AIMS	O
Helicobacter	O
pylori-infected	O
gastric	O
mucosa	O
evolves	O
through	O
stages	O
of	O
chronic	O
gastritis	O
,	O
intestinal	O
metaplasia	O
(	O
IM	O
)	O
,	O
glandular	O
atrophy	O
(	O
GA	O
)	O
,	O
and	O
dysplasia	O
before	O
carcinoma	O
develops	O
.	O

We	O
studied	O
if	O
H.	O
pylori	O
eradication	O
would	O
alter	O
the	O
course	O
of	O
premalignant	O
histologic	O
changes	O
in	O
the	O
stomach	O
.	O

METHODS	O
Volunteers	O
from	O
the	O
Yantai	O
County	O
in	O
China	O
underwent	O
upper	O
endoscopy	O
with	O
biopsy	O
specimens	O
obtained	O
from	O
the	O
antrum	O
and	O
corpus	O
.	O

H.	O
pylori-infected	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
1-week	O
course	O
of	O
omeprazole	O
,	O
amoxicillin	O
,	O
and	O
clarithromycin	O
(	O
OAC	O
)	O
or	O
placebo	O
.	O

At	O
1	O
year	O
,	O
endoscopies	O
with	O
biopsies	O
were	O
repeated	O
.	O

RESULTS	O
A	O
total	O
of	O
587	SampleSize
H.	O
pylori-infected	O
subjects	O
were	O
randomized	O
to	O
OAC	O
(	O
n	O
=	O
295	O
)	O
and	O
placebo	O
(	O
n	O
=	O
292	O
)	O
.	O

At	O
1	O
year	O
,	O
H.	O
pylori	O
was	O
eradicated	O
in	O
226	O
subjects	O
assigned	O
to	O
OAC	O
.	O

In	O
the	O
placebo	O
group	O
,	O
245	SampleSize
patients	O
remained	O
H.	O
pylori	O
infected	O
.	O

Analysis	O
of	O
paired	O
samples	O
obtained	O
from	O
the	O
same	O
patients	O
showed	O
that	O
acute	O
and	O
chronic	O
gastritis	O
decreased	O
in	O
both	O
the	O
antrum	O
and	O
corpus	O
after	O
H.	O
pylori	O
eradication	O
(	O
P	O
<	O
0.001	O
)	O
and	O
activity	O
of	O
IM	O
decreased	O
in	O
antrum	O
(	O
P	O
=	O
0.014	O
)	O
.	O

In	O
the	O
H.	O
pylori-infected	O
group	O
,	O
antral	O
biopsy	O
specimens	O
had	O
more	O
pronounced	O
acute	O
gastritis	O
(	O
P	O
=	O
0.01	O
)	O
,	O
whereas	O
corpus	O
specimens	O
showed	O
increased	O
acute	O
and	O
chronic	O
gastritis	O
(	O
P	O
<	O
0.001	O
)	O
and	O
a	O
marginal	O
increase	O
in	O
GA	O
(	O
P	O
=	O
0.052	O
)	O
.	O

When	O
histologic	O
changes	O
were	O
compared	O
between	O
the	O
2	O
groups	O
,	O
decrease	O
in	O
acute	O
and	O
chronic	O
gastritis	O
was	O
more	O
frequent	O
after	O
H.	O
pylori	O
eradication	O
(	O
P	O
<	O
0.001	O
)	O
but	O
changes	O
in	O
IM	O
were	O
similar	O
.	O

In	O
the	O
H.	O
pylori-infected	O
group	O
,	O
increase	O
in	O
GA	O
was	O
seen	O
in	O
the	O
corpus	O
(	O
P	O
=	O
0.01	O
)	O
.	O

CONCLUSIONS	O
At	O
1	O
year	O
,	O
H.	O
pylori	O
eradication	O
is	O
beneficial	O
in	O
preventing	O
progression	O
of	O
pathologic	O
changes	O
of	O
the	O
gastric	O
mucosa	O
.	O

[	O
Treating	O
rheumatoid	O
arthritis	O
patients	O
of	O
Shen	O
deficiency	O
and	O
cold	O
invading	O
syndrome	O
by	O
bushen	O
quhan	O
zhiwang	O
decoction	O
combined	O
methotrexate	O
:	O
an	O
evaluation	O
of	O
clinical	O
efficacy	O
and	O
safety	O
]	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
bushen	O
quhan	O
zhiwang	O
decoction	O
(	O
BQZD	O
)	O
combined	O
methotrexate	O
(	O
MTX	O
)	O
in	O
treating	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
A	O
prospective	O
,	O
randomized	O
controlled	O
study	O
was	O
carried	O
out	O
.	O

RA	O
patients	O
of	O
Shen	O
deficiency	O
and	O
cold	O
invading	O
syndrome	O
in	O
the	O
treatment	O
group	O
(	O
120	O
cases	O
)	O
were	O
treated	O
with	O
BQZD	O
and	O
MTX	O
(	O
10	O
mg/week	O
)	O
,	O
while	O
those	O
in	O
the	O
control	O
group	O
(	O
120	O
cases	O
)	O
were	O
treated	O
with	O
MTX	O
(	O
10	O
mg/week	O
)	O
alone	O
.	O

The	O
therapeutic	O
course	O
for	O
all	O
was	O
24	O
weeks	O
.	O

The	O
efficacy	O
and	O
safety	O
indices	O
were	O
evaluated	O
at	O
the	O
baseline	O
and	O
24	O
weeks	O
after	O
treatment	O
,	O
including	O
clinical	O
signs	O
and	O
symptoms	O
,	O
condition	O
assessment	O
,	O
Health	O
Assessment	O
Questionnaire	O
(	O
HAQ	O
)	O
,	O
disease	O
activity	O
index	O
28	O
(	O
DAS28	O
)	O
,	O
laboratory	O
parameters	O
of	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
and	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
safety	O
indicators	O
,	O
and	O
Chinese	O
medical	O
syndrome	O
integrals	O
.	O

RESULTS	O
The	O
total	O
effective	O
rate	O
was	O
80	O
.	O

0	O
%	O
in	O
the	O
treatment	O
group	O
,	O
better	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
66.7	O
%	O
)	O
,	O
showing	O
statistical	O
difference	O
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
the	O
two	O
groups	O
significant	O
improvement	O
of	O
clinical	O
signs	O
and	O
symptoms	O
,	O
ESR	O
,	O
CRP	O
,	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
by	O
both	O
physicians	O
and	O
patients	O
,	O
HAQ	O
,	O
DAS28	O
,	O
and	O
Chinese	O
medical	O
syndrome	O
integrals	O
after	O
treatment	O
were	O
shown	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Better	O
effects	O
were	O
obtained	O
in	O
the	O
treatment	O
group	O
in	O
lessening	O
tender	O
joint	O
numbers	O
and	O
swollen	O
joint	O
numbers	O
,	O
VAS	O
by	O
both	O
physicians	O
and	O
patients	O
,	O
DAS28	O
,	O
and	O
Chinese	O
medical	O
syndrome	O
integrals	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Besides	O
,	O
adverse	O
reactions	O
occurred	O
less	O
in	O
the	O
treatment	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
BQZD	O
had	O
roles	O
in	O
relieving	O
symptoms	O
,	O
improving	O
joint	O
functions	O
,	O
signs	O
,	O
ESR	O
,	O
and	O
CRP	O
.	O

It	O
was	O
an	O
effective	O
herb	O
for	O
RA	O
patients	O
of	O
Shen	O
deficiency	O
and	O
cold	O
invading	O
syndrome	O
.	O

It	O
could	O
enhance	O
the	O
efficacy	O
and	O
reduce	O
adverse	O
reactions	O
of	O
MTX	O
through	O
synergistic	O
effects	O
with	O
MTX	O
.	O

Differential	O
effects	O
of	O
vitamin	O
K1	O
on	O
AFP	O
and	O
DCP	O
levels	O
in	O
patients	O
with	O
unresectable	Condition
HCC	Condition
and	O
in	O
HCC	Condition
cell	O
lines	O
.	O

PURPOSE	O
DCP	O
is	O
a	O
useful	O
HCC	O
tumor	O
marker	O
,	O
which	O
reflects	O
a	O
defect	O
in	O
vitamin	O
K	O
metabolism	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
vitamin	O
K	O
treatment	O
of	O
HCC	Condition
patients	O
might	O
suppress	O
this	O
marker	O
and	O
possibly	O
AFP	O
also	O
.	O

EXPERIMENTAL	O
DESIGN	O
HCC	Condition
patients	O
who	O
had	O
both	O
elevated	O
AFP	O
and	O
DCP	O
were	O
included	O
.	O

A	O
phase	O
I	O
cohort	O
was	O
treated	O
with	O
escalating	O
vitamin	O
K1	O
intravenous	O
weekly	O
doses	O
and	O
a	O
27-patient	SampleSize
phase	O
II	O
cohort	O
was	O
then	O
treated	O
with	O
a	O
fixed	O
oral	O
daily	O
dose	O
.	O

RESULTS	O
A	O
maximum	O
tolerated	O
dose	O
was	O
not	O
reached	O
up	O
to	O
100-fold	O
the	O
normal	O
vitamin	O
K1	O
dose	O
.	O

No	O
toxicities	O
were	O
found	O
up	O
to	O
1,000	O
mg/infusion	O
.	O

In	O
the	O
phase	O
II	O
cohort	O
,	O
93	O
%	O
of	O
patients	O
had	O
tumor	O
marker	O
responses	O
by	O
decreased	O
DCP	O
levels	O
,	O
but	O
only	O
22	O
%	O
had	O
responses	O
by	O
decreased	O
AFP	O
levels	O
.	O

CT	O
scans	O
showed	O
11	O
%	O
of	O
patients	O
had	O
PRs	O
,	O
59	O
%	O
had	O
stable	O
tumors	O
and	O
29.6	O
%	O
had	O
tumor	O
progression	O
.	O

Mechanism	O
studies	O
showed	O
that	O
vitamin	O
K1	O
induced	O
phosphorylation	O
of	O
JNK	O
and	O
c-Jun	O
and	O
caspase-mediated	O
apoptosis	O
.	O

CONCLUSIONS	O
Vitamin	O
K1	O
was	O
non-toxic	O
at	O
high	O
doses	O
,	O
strongly	O
inhibited	O
plasma	O
DCP	O
levels	O
,	O
but	O
weakly	O
suppressed	O
AFP	O
levels	O
.	O

The	O
results	O
provide	O
evidence	O
that	O
the	O
two	O
tumor	O
markers	O
are	O
not	O
directly	O
linked	O
and	O
that	O
DCP	O
levels	O
may	O
not	O
reflect	O
HCC	O
cell	O
growth	O
,	O
as	O
DCP	O
levels	O
were	O
decreased	O
in	O
patients	O
without	O
AFP	O
change	O
,	O
and	O
were	O
suppressed	O
in	O
vitro	O
at	O
1	O
%	O
of	O
the	O
vitamin	O
K1	O
concentration	O
needed	O
to	O
inhibit	O
AFP	O
.	O

Epileptogenic	O
activity	O
of	O
folic	O
acid	O
after	O
drug	O
induces	O
SLE	O
(	O
folic	O
acid	O
and	O
epilepsy	O
)	O
OBJECTIVE	O
To	O
study	O
the	O
effect	O
of	O
folic	O
acid-containing	O
multivitamin	O
supplementation	O
in	O
epileptic	O
women	O
before	O
and	O
during	O
pregnancy	O
in	O
order	O
to	O
determine	O
the	O
rate	O
of	O
structural	O
birth	O
defects	O
and	O
epilepsy-related	O
side	O
effects	O
.	O

STUDY	O
DESIGN	O
First	O
a	O
randomised	O
trial	O
,	O
later	O
periconception	O
care	O
including	O
in	O
total	O
12225	O
females	O
.	O

RESULTS	O
Of	O
60	O
epileptic	O
women	O
with	O
periconceptional	O
folic	O
acid	O
(	O
0.8	O
mg	O
)	O
-containing	O
multivitamin	O
supplementation	O
,	O
no	O
one	O
developed	O
epilepsy-related	O
side	O
effects	O
during	O
the	O
periconception	O
period	O
.	O

One	O
epileptic	O
woman	O
delivered	O
a	O
newborn	O
with	O
cleft	O
lip	O
and	O
palate	O
.	O

Another	O
patient	O
exhibited	O
with	O
a	O
cluster	O
of	O
seizures	O
after	O
the	O
periconception	O
period	O
using	O
another	O
multivitamin	O
.	O

This	O
22-year-old	O
epileptic	O
woman	O
was	O
treated	O
continuously	O
by	O
carbamazepine	O
and	O
a	O
folic	O
acid	O
(	O
1	O
mg	O
)	O
-containing	O
multivitamin	O
from	O
the	O
20th	O
week	O
of	O
gestation	O
.	O

She	O
developed	O
status	O
epilepticus	O
and	O
later	O
symptoms	O
of	O
systemic	O
lupus	O
erythematodes	O
.	O

Her	O
pregnancy	O
ended	O
with	O
stillbirth	O
.	O

CONCLUSIONS	O
The	O
epileptic	O
pregnant	O
patient	O
's	O
autoimmune	O
disease	O
(	O
probably	O
drug-induced	O
lupus	O
)	O
could	O
damage	O
the	O
blood-brain	O
barrier	O
,	O
therefore	O
the	O
therapeutic	O
dose	O
(	O
>	O
or	O
=1	O
mg	O
)	O
of	O
folic	O
acid	O
triggered	O
a	O
cluster	O
of	O
seizures	O
.	O

Physiological	O
dose	O
(	O
<	O
1	O
mg	O
)	O
of	O
folic	O
acid	O
both	O
in	O
healthy	O
and	O
60	O
epileptic	O
women	O
,	O
all	O
without	O
any	O
autoimmune	O
disease	O
,	O
did	O
not	O
increase	O
the	O
risk	O
for	O
epileptic	O
seizures	O
.	O

The	O
prognostic	O
value	O
of	O
testicular	O
biopsy	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
:	O
a	O
report	O
from	O
the	O
Childrens	O
Cancer	O
Study	O
Group	O
.	O

One	O
of	O
the	O
objectives	O
of	O
Childrens	O
Cancer	O
Study	O
Group	O
(	O
CCSG	O
)	O
study	O
141	O
(	O
CCG-141	O
)	O
was	O
to	O
determine	O
the	O
frequency	O
of	O
occult	O
testicular	O
leukemia	O
(	O
TL	O
)	O
after	O
3	O
years	O
of	O
disease-free	O
survival	O
(	O
DFS	O
)	O
and	O
to	O
retreat	O
boys	O
with	O
occult	O
TL	O
to	O
prolong	O
their	O
subsequent	O
DFS	O
.	O

Of	O
the	O
494	O
boys	O
entered	O
on	O
study	O
,	O
255	O
(	O
51.6	O
%	O
)	O
were	O
in	O
complete	O
continuous	O
remission	O
(	O
CCR	O
)	O
3	O
years	O
after	O
entering	O
remission	O
and	O
an	O
additional	O
eight	O
were	O
in	O
CCR	O
3	O
years	O
after	O
localized	O
extramedullary	O
relapse	O
and	O
retreatment	O
;	O
263	O
boys	O
were	O
eligible	O
for	O
testicular	O
biopsy	O
.	O

Elective	O
testicular	O
biopsy	O
was	O
performed	O
on	O
235	O
(	O
89.4	O
%	O
)	O
boys	O
.	O

Of	O
the	O
204	O
(	O
86.8	O
%	O
)	O
boys	O
with	O
negative	O
biopsies	O
,	O
175	O
(	O
85.8	O
%	O
)	O
remained	O
in	O
CCR	O
10	O
to	O
12	O
years	O
after	O
diagnosis	O
and	O
25	O
(	O
12.3	O
%	O
)	O
relapsed	O
,	O
11	O
(	O
44	O
%	O
)	O
of	O
whom	O
died	O
.	O

Isolated	O
overt	O
TL	O
occurred	O
in	O
four	O
(	O
2.0	O
%	O
)	O
and	O
all	O
remained	O
in	O
CCR	O
22+	O
to	O
60+	O
months	O
after	O
re-treatment	O
.	O

Of	O
the	O
26	O
boys	O
with	O
occult	O
TL	O
,	O
16	O
(	O
62	O
%	O
)	O
remained	O
in	O
CCR	O
.	O

Ten	O
(	O
38	O
%	O
)	O
relapsed	O
despite	O
local	O
testicular	O
irradiation	O
and	O
systemic	O
re-treatment	O
;	O
six	O
of	O
the	O
10	O
died	O
.	O

Of	O
the	O
26	O
boys	O
who	O
did	O
not	O
undergo	O
biopsy	O
,	O
21	O
(	O
80.8	O
%	O
)	O
remained	O
in	O
CCR	O
;	O
two	O
(	O
7.7	O
%	O
)	O
developed	O
isolated	O
overt	O
TL	O
.	O

DFS	O
after	O
testicular	O
biopsy	O
was	O
significantly	O
better	O
in	O
boys	O
without	O
occult	O
TL	O
(	O
P	O
=	O
.001	O
)	O
.	O

Occult	O
TL	O
after	O
3	O
years	O
of	O
CCR	O
represents	O
aggressive	O
minimal-residual	O
disease	O
and	O
carries	O
a	O
worse	O
prognosis	O
than	O
absence	O
of	O
TL	O
.	O

Initial	O
treatment	O
should	O
be	O
directed	O
at	O
obviating	O
occult	O
and	O
overt	O
testicular	O
relapse	O
.	O

Conventional	O
therapy	O
as	O
used	O
in	O
this	O
study	O
was	O
suboptimal	O
in	O
preventing	O
subsequent	O
bone	O
marrow	O
(	O
BM	O
)	O
relapse	O
and	O
death	O
.	O

If	O
occult	O
TR	O
is	O
identified	O
during	O
or	O
at	O
the	O
end	O
of	O
planned	O
therapy	O
,	O
a	O
higher	O
salvage	O
rate	O
may	O
require	O
intensified	O
alternate	O
therapy	O
.	O

As	O
such	O
,	O
testicular	O
biopsies	O
may	O
be	O
clinically	O
useful	O
.	O

Further	O
investigation	O
is	O
limited	O
by	O
the	O
relative	O
rarity	O
of	O
,	O
and	O
the	O
lack	O
of	O
identifying	O
features	O
in	O
boys	O
with	O
occult	O
TL	O
.	O

Antihistamines	O
do	O
not	O
inhibit	O
the	O
wheal	O
induced	O
by	O
the	O
intradermal	O
injection	O
of	O
autologous	O
serum	O
in	O
resistant	O
chronic	O
idiopathic	O
urticaria	O
.	O

Some	O
patients	O
with	O
chronic	O
idiopathic	O
urticaria	O
(	O
CIU	O
)	O
are	O
resistant	O
to	O
conventional	O
doses	O
of	O
antihistamines	O
(	O
AHs	O
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
check	O
whether	O
the	O
skin	O
wheal	O
and	O
flare	O
reaction	O
produced	O
by	O
the	O
intradermal	O
injection	O
of	O
autologous	O
serum	O
(	O
AS	O
)	O
and	O
by	O
histamine	O
differs	O
in	O
AH-resistant	O
and	O
AH	O
responder	O
CIU	O
patients	O
.	O

CIU	O
patients	O
with	O
treatment	O
failure	O
under	O
fexofenadine	O
at	O
180	O
mg	O
q.d	O
.	O

increased	O
their	O
daily	O
dose	O
of	O
AH	O
to	O
4	O
tablets	O
daily	O
.	O

Those	O
with	O
significant	O
improvement	O
of	O
urticaria	O
activity	O
score	O
under	O
fexofenadine	O
at	O
180	O
mg	O
were	O
included	O
in	O
the	O
CIU	O
group	O
.	O

Subjects	O
with	O
treatment	O
failure	O
despite	O
a	O
full	O
8-week	O
fourfold	O
fexofenadine	O
treatment	O
were	O
included	O
in	O
the	O
resistant	O
CIU	O
(	O
R-CIU	O
group	O
)	O
.	O

The	O
control	O
group	O
consisted	O
of	O
sex-	O
and	O
age-matched	O
patents	O
with	O
allergic	O
rhinitis	O
.	O

The	O
AS	O
skin	O
test	O
and	O
intradermal	O
histamine-induced	O
wheal	O
and	O
flare	O
reaction	O
were	O
performed	O
at	O
baseline	O
(	O
without	O
AH	O
)	O
,	O
after	O
8	O
and	O
16	O
weeks	O
(	O
under	O
AH	O
treatment	O
)	O
.	O

Forty-six	O
subjects	O
were	O
included	O
in	O
the	O
CIU	O
group	O
,	O
21	O
were	O
in	O
the	O
R-CIU	O
group	O
,	O
and	O
44	O
were	O
in	O
the	O
control	O
group	O
.	O

Under	O
AH	O
therapy	O
,	O
the	O
skin	O
reaction	O
to	O
intradermal	O
histamine	O
injection	O
was	O
significantly	O
diminished	O
in	O
all	O
study	O
groups	O
.	O

In	O
the	O
R-CIU	O
group	O
,	O
fexofenadine	O
at	O
180	O
mg	O
did	O
not	O
suppress	O
AS-induced	O
wheal	O
reaction	O
(	O
5.96	O
?	O
2.25	O
mm	O
;	O
p	O
=	O
0.85	O
)	O
,	O
and	O
with	O
a	O
fourfold	O
AH	O
dose	O
some	O
reduction	O
of	O
AS-induced	O
wheal	O
(	O
3.79	O
?	O
1.74	O
mm	O
;	O
p	O
=	O
0.008	O
)	O
was	O
observed	O
but	O
remained	O
larger	O
than	O
in	O
the	O
CIU	O
(	O
2.31	O
?	O
1.12	O
;	O
p	O
=	O
0.006	O
)	O
and	O
control	O
groups	O
(	O
2.52	O
?	O
1.36	O
;	O
p	O
=	O
0.037	O
)	O
.	O

AHs	O
do	O
not	O
inhibit	O
the	O
wheal	O
induced	O
by	O
the	O
intradermal	O
injection	O
of	O
AS	O
in	O
R-CIU	O
.	O

A	O
comparative	O
trial	O
of	O
liver	O
biopsy	O
needles	O
.	O

A	O
sheathed	O
needle	O
(	O
Tru-Cut	O
)	O
was	O
compared	O
with	O
a	O
suction	O
biopsy	O
needle	O
(	O
Menghini	O
)	O
in	O
a	O
randomised	O
prospective	O
trial	O
over	O
18	O
months	O
to	O
determine	O
whether	O
the	O
former	O
offered	O
any	O
special	O
advantages	O
in	O
routine	O
percutaneous	O
liver	O
biopsy	O
.	O

Seventy-seven	O
consecutive	O
biopsies	O
were	O
performed	O
by	O
a	O
single	O
operator	O
.	O

Although	O
biopsy	O
fragmentation	O
was	O
commoner	O
with	O
the	O
suction	O
needle	O
,	O
the	O
length	O
and	O
volume	O
of	O
the	O
largest	O
core	O
obtained	O
was	O
similar	O
to	O
results	O
with	O
the	O
sheathed	O
needle	O
.	O

Cytology	O
provided	O
useful	O
additional	O
information	O
with	O
the	O
Menghini	O
technique	O
.	O

The	O
suction	O
needle	O
was	O
repeatedly	O
reusable	O
and	O
considerably	O
cheaper	O
than	O
the	O
sheathed	O
needle	O
,	O
which	O
may	O
be	O
used	O
once	O
only	O
.	O

Combined	O
descriptive	O
and	O
explanatory	O
information	O
improves	O
peers	O
'	O
perceptions	O
of	O
autism	Condition
.	O

Authors	O
examined	O
the	O
combined	O
effects	O
of	O
descriptive	O
and	O
explanatory	O
information	O
on	O
peers	O
'	O
perceptions	O
and	O
behavioral	O
intentions	O
toward	O
an	O
unfamiliar	O
child	O
with	O
autism	Condition
.	O

Children	Age
(	O
N	O
=	O
576	O
;	O
M	O
age	O
=	O
10.06	O
)	O
were	O
randomly	O
assigned	O
to	O
view	O
two	O
videotapes	O
of	O
a	O
boy	O
engaging	O
in	O
typical	O
and	O
autistic	O
behaviors	O
receiving	O
either	O
descriptive	O
(	O
AUT-D	O
)	O
or	O
descriptive	O
and	O
explanatory	O
information	O
(	O
AUT-D	O
+	O
E	O
)	O
.	O

Children	Age
responded	O
to	O
measures	O
of	O
attitudes	O
(	O
Adjective	O
Checklist	O
)	O
and	O
behavioral	O
intentions	O
(	O
Shared	O
Activities	O
Questionnaire	O
)	O
.	O

Children	O
rated	O
the	O
typical	O
boy	O
more	O
favorably	O
than	O
the	O
boy	O
showing	O
autistic	O
symptoms	O
.	O

When	O
compared	O
to	O
descriptive	O
information	O
alone	O
,	O
the	O
combination	O
of	O
descriptive	O
and	O
explanatory	O
information	O
resulted	O
in	O
improved	O
third-	O
and	O
fourth-graders	O
'	O
but	O
not	O
fifth-graders	O
'	O
attitudes	O
toward	O
the	O
child	O
with	O
autism	O
.	O

Combined	O
information	O
improved	O
behavioral	O
intentions	O
across	O
grades	O
;	O
however	O
,	O
girls	O
(	O
vs.	O
boys	O
)	O
were	O
more	O
responsive	O
to	O
information	O
as	O
evidenced	O
by	O
differences	O
in	O
academic	O
intentions	O
.	O

The	O
combination	O
of	O
descriptive	O
and	O
explanatory	O
information	O
about	O
autism	O
appears	O
to	O
have	O
a	O
positive	O
effect	O
on	O
children	O
's	O
attitudes	O
and	O
behavioral	O
intentions	O
.	O

Implications	O
of	O
the	O
findings	O
are	O
briefly	O
discussed	O
as	O
well	O
as	O
study	O
limitations	O
and	O
recommendations	O
for	O
future	O
research	O
.	O

[	O
Supplementary	O
treatment	O
with	O
Esberitox	O
of	O
female	Condition
patients	Condition
undergoing	Condition
curative	Condition
adjuvant	Condition
irradiation	Condition
following	Condition
breast	Condition
cancer	Condition
]	Condition
.	O

1	O
.	O

The	O
study	O
was	O
supposed	O
to	O
investigate	O
a	O
possible	O
prevention	O
or	O
reduction	O
of	O
the	O
toxicity	O
of	O
radiotherapy	O
by	O
an	O
additional	O
treatment	O
with	O
Esberitox	O
.	O

This	O
question	O
arose	O
when	O
performing	O
an	O
investigation	O
about	O
the	O
effect	O
of	O
Esberitox	O
in	O
a	O
combined	O
chemo-radiotherapy	O
.	O

Whereas	O
the	O
latter	O
induces	O
above	O
all	O
a	O
systemic	O
damage	O
to	O
the	O
hemopoietic	O
system	O
,	O
radiotherapy	O
is	O
a	O
regional	O
noxa	O
.	O

2	O
.	O

The	O
present	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
with	O
50	O
patients	O
submitted	O
to	O
curative	O
adjuvant	O
irradiation	O
following	O
surgery	O
for	O
mammary	O
carcinoma	O
.	O

The	O
radiotherapy	O
was	O
performed	O
in	O
the	O
same	O
way	O
in	O
all	O
patients	O
with	O
irradiations	O
of	O
the	O
thoracic	O
wall	O
and	O
the	O
regional	O
lymph	O
nodes	O
.	O

Two	O
groups	O
were	O
built	O
by	O
randomization	O
.	O

The	O
study	O
group	O
received	O
an	O
additional	O
treatment	O
with	O
Esberitox	O
,	O
the	O
control	O
group	O
did	O
not	O
receive	O
an	O
additional	O
treatment	O
.	O

3	O
.	O

As	O
a	O
result	O
,	O
no	O
protective	O
influence	O
of	O
Esberitox	O
could	O
be	O
demonstrated	O
.	O

The	O
parameters	O
investigated	O
were	O
the	O
peripheral	O
blood	O
count	O
(	O
leucocytes	O
,	O
granulocytes	O
,	O
lymphocytes	O
,	O
monocytes	O
,	O
thrombocytes	O
,	O
hemoglobin	O
,	O
hematocrit	O
)	O
and	O
the	O
incidence	O
of	O
infections	O
.	O

4	O
.	O

This	O
result	O
diverging	O
from	O
literature	O
is	O
discussed	O
.	O

It	O
is	O
probably	O
affected	O
by	O
volume	O
and	O
extension	O
of	O
the	O
injury	O
induced	O
by	O
a	O
hematotoxic	O
noxa	O
and	O
furthermore	O
by	O
the	O
ability	O
of	O
regeneration	O
.	O

If	O
this	O
ability	O
is	O
exhausted	O
,	O
the	O
protective	O
effect	O
of	O
Esberitox	O
can	O
act	O
no	O
longer	O
.	O

Therefore	O
the	O
essential	O
factor	O
seems	O
to	O
be	O
the	O
duration	O
of	O
exposure	O
to	O
the	O
noxa	O
.	O

Esberitox	O
was	O
effective	O
in	O
case	O
of	O
a	O
short	O
toxicity	O
,	O
it	O
was	O
ineffective	O
in	O
case	O
of	O
prolonged	O
toxicity	O
,	O
if	O
the	O
treatment	O
continuity	O
(	O
noxa	O
)	O
was	O
not	O
broken	O
up	O
by	O
some	O
regeneration	O
intervals	O
.	O

The	O
radiotherapy	O
studied	O
in	O
this	O
trial	O
had	O
a	O
duration	O
of	O
50	O
days	O
,	O
and	O
its	O
effect	O
was	O
that	O
of	O
a	O
longterm	O
injury	O
.	O

Concomitant	O
radiochemotherapy	O
vs	O
radiotherapy	O
alone	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer	O
:	O
a	O
Hellenic	O
Cooperative	O
Oncology	O
Group	O
Phase	O
III	O
Study	O
.	O

The	O
primary	O
objective	O
of	O
the	O
present	O
randomized	O
phase	O
III	O
trial	O
was	O
to	O
compare	O
the	O
3-yr	O
survival	O
rate	O
of	O
patients	O
treated	O
with	O
standard	O
fractionated	O
radiotherapy	O
(	O
RT	O
)	O
alone	O
or	O
with	O
the	O
same	O
RT	O
concomitantly	O
with	O
cisplatin	O
(	O
DDP	O
)	O
or	O
carboplatin	O
(	O
Cb	O
)	O
.	O

From	O
January	O
1995	O
until	O
July	O
1999	O
,	O
124	O
patients	O
with	O
histologically	O
proven	O
locally	O
advanced	O
non-nasopharyngeal	O
head	O
and	O
neck	O
cancer	O
(	O
HNC	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
RT	O
monotherapy	O
(	O
70	O
Gy	O
,	O
Group	O
A	O
)	O
or	O
the	O
same	O
RT	O
concomitantly	O
with	O
DDP	O
(	O
100	O
mg/m2	O
on	O
d	O
2	O
,	O
22	O
,	O
42	O
,	O
Group	O
B	O
)	O
or	O
Cb	O
(	O
7	O
AUC	O
on	O
d	O
2	O
,	O
22	O
,	O
42	O
,	O
Group	O
C	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
complete	O
response	O
rates	O
between	O
patients	O
treated	O
with	O
RT	O
alone	O
or	O
combined	O
chemoradiotherapy	O
.	O

However	O
,	O
median	O
time	O
to	O
progression	O
(	O
TTP	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
significantly	O
longer	O
in	O
patients	O
treated	O
with	O
concomitant	O
chemoradiotherapy	O
.	O

Thus	O
,	O
median	O
TTP	O
was	O
6.3	O
,	O
45.2	O
,	O
and	O
17.7	O
mo	O
in	O
groups	O
A	O
,	O
B	O
,	O
and	O
C	O
respectively	O
(	O
p	O
=	O
0.0002	O
)	O
.	O

Similarly	O
,	O
median	O
OS	O
was	O
12.2	O
,	O
48.6	O
,	O
and	O
24.5	O
mo	O
,	O
respectively	O
(	O
p	O
=	O
0.0003	O
)	O
.	O

At	O
3	O
yr	O
follow-up	O
,	O
17.5	O
%	O
of	O
patients	O
in	O
group	O
A	O
were	O
alive	O
compared	O
to	O
52	O
%	O
in	O
group	O
B	O
and	O
42	O
%	O
in	O
group	O
C	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Patients	O
treated	O
with	O
concomitant	O
chemoradiotherapy	O
experienced	O
more	O
frequently	O
severe	O
hematological	O
toxicity	O
.	O

Also	O
,	O
severe	O
nausea/vomiting	O
was	O
more	O
pronounced	O
in	O
group	O
B	O
,	O
as	O
expected	O
.	O

The	O
present	O
study	O
clearly	O
demonstrated	O
that	O
concomitant	O
chemoradiotherapy	O
with	O
platinum	O
analogs	O
significantly	O
prolongs	O
3-yr	O
survival	O
and	O
median	O
OS	O
in	O
patients	O
with	O
locally	O
advanced	O
HNC	O
compared	O
to	O
conventional	O
RT	O
alone	O
.	O

Double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
risperidone	O
plus	O
topiramate	O
in	O
children	Age
with	O
autistic	Condition
disorder	Condition
.	O

BACKGROUND	O
Autism	O
is	O
a	O
complex	O
neurodevelopmental	O
disorder	O
that	O
forms	O
part	O
of	O
a	O
spectrum	O
of	O
related	O
disorders	O
referred	O
to	O
as	O
Autism	O
Spectrum	O
Disorders	O
.	O

The	O
present	O
study	O
assessed	O
the	O
effects	O
of	O
topiramate	O
plus	O
risperidone	O
in	O
the	O
treatment	O
of	O
autistic	Condition
disorder	Condition
.	O

METHOD	O
Forty	SampleSize
children	O
between	O
the	O
ages	Age
of	Age
4	Age
and	Age
12	Age
years	Age
with	O
a	O
DSM	Condition
IV	Condition
clinical	Condition
diagnosis	Condition
of	Condition
autism	Condition
who	O
were	O
outpatients	O
from	O
a	O
specialty	O
clinic	O
for	O
children	O
were	O
recruited	O
.	O

The	O
children	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
severely	Condition
disruptive	Condition
symptoms	Condition
related	O
to	O
autistic	Condition
disorder	Condition
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
topiramate+risperidone	O
(	O
Group	O
A	O
)	O
or	O
placebo+risperidone	O
(	O
Group	O
B	O
)	O
for	O
an	O
8-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

The	O
dose	O
of	O
risperidone	O
was	O
titrated	O
up	O
to	O
2	O
mg/day	O
for	O
children	O
between	O
10	O
and	O
40	O
kg	O
and	O
3	O
mg/day	O
for	O
children	O
weighting	O
above	O
40	O
kg	O
.	O

The	O
dose	O
of	O
topiramate	O
was	O
titrated	O
up	O
to	O
200	O
mg/day	O
depending	O
on	O
weight	O
(	O
100	O
mg/day	O
for	O
<	O
30	O
kg	O
and	O
200	O
mg/day	O
for	O
>	O
30	O
kg	O
)	O
.	O

Patients	O
were	O
assessed	O
at	O
baseline	O
and	O
after	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
weeks	O
after	O
starting	O
medication	O
.	O

Measure	O
of	O
outcome	O
was	O
the	O
Aberrant	O
Behavior	O
Checklist-Community	O
(	O
ABC-C	O
)	O
Rating	O
Scale	O
.	O

RESULTS	O
Difference	O
between	O
the	O
two	O
protocols	O
was	O
significant	O
as	O
the	O
group	O
that	O
received	O
topiramate	O
had	O
a	O
greater	O
reduction	O
in	O
ABC-C	O
subscale	O
scores	O
for	O
irritability	O
,	O
stereotypic	O
behavior	O
and	O
hyperactivity/noncompliance	O
.	O

CONCLUSION	O
The	O
results	O
suggest	O
that	O
the	O
combination	O
of	O
topiramate	O
with	O
risperidone	O
may	O
be	O
superior	O
to	O
risperidone	O
monotherapy	O
for	O
children	Age
with	O
autistic	Condition
disorder	Condition
.	O

However	O
the	O
results	O
need	O
to	O
be	O
further	O
confirmed	O
by	O
a	O
larger	O
randomized	O
controlled	O
trial	O
.	O

Comparative	O
evaluation	O
of	O
calcium	O
hydroxide	O
and	O
zinc	O
oxide	O
eugenol	O
as	O
root	Condition
canal	Condition
filling	Condition
materials	O
for	O
primary	Condition
molars	Condition
:	O
a	O
clinical	O
and	O
radiographic	O
study	O
.	O

Calcium	O
hydroxide	O
,	O
a	O
material	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
permanent	O
teeth	O
has	O
not	O
been	O
used	O
frequently	O
for	O
pulpectomy	O
in	O
primary	O
teeth	O
.	O

A	O
comparative	O
evaluation	O
of	O
calcium	O
hydroxide	O
and	O
zinc	O
oxide	O
eugenol	O
used	O
as	O
root	O
canal	O
filling	O
materials	O
in	O
primary	Condition
molars	Condition
is	O
presented	O
.	O

Influence	O
of	O
diets	O
rich	O
in	O
Maillard	O
reaction	O
products	O
on	O
calcium	O
bioavailability	O
.	O

Assays	O
in	O
male	Sex
adolescents	Age
and	O
in	O
Caco-2	O
cells	O
.	O

The	O
effects	O
of	O
the	O
high	O
intake	O
of	O
Maillard	O
reaction	O
products	O
(	O
MRP	O
)	O
on	O
calcium	O
availability	O
in	O
adolescents	O
and	O
across	O
Caco-2	O
cell	O
monolayers	O
were	O
examined	O
.	O

In	O
a	O
2	O
week	O
randomized	O
two-period	O
crossover	O
trial	O
,	O
18	SampleSize
male	Sex
adolescents	Age
consumed	O
two	O
diets	O
,	O
named	O
white	O
diet	O
(	O
WD	O
)	O
and	O
brown	O
diet	O
(	O
BD	O
)	O
,	O
which	O
were	O
poor	O
and	O
rich	O
in	O
MRP	O
,	O
respectively	O
.	O

A	O
3	O
day	O
balance	O
was	O
performed	O
at	O
the	O
end	O
of	O
each	O
period	O
,	O
and	O
fasting	O
blood	O
samples	O
were	O
collected	O
.	O

Calcium	O
solubility	O
and	O
absorption	O
across	O
Caco-2	O
cells	O
were	O
studied	O
after	O
the	O
in	O
vitro	O
digestion	O
of	O
the	O
diets	O
.	O

The	O
in	O
vitro	O
assay	O
showed	O
similar	O
solubility	O
after	O
the	O
in	O
vitro	O
digestion	O
and	O
similar	O
transport	O
across	O
Caco-2	O
cells	O
.	O

In	O
accordance	O
,	O
calcium	O
bioavailability	O
in	O
adolescents	O
did	O
not	O
vary	O
between	O
the	O
diets	O
(	O
%	O
WD	O
=	O
40.4	O
+/-	O
5.1	O
,	O
%	O
BD	O
=	O
38.2	O
+/-	O
3.6	O
)	O
.	O

Serum	O
and	O
urine	O
biochemical	O
parameters	O
related	O
to	O
calcium	O
status	O
and	O
bone	O
metabolism	O
remained	O
unaltered	O
.	O

Only	O
deoxypyridinoline	O
values	O
were	O
significantly	O
lower	O
after	O
consumption	O
of	O
the	O
BD	O
(	O
13.0	O
+/-	O
1.1	O
compared	O
to	O
18.3	O
+/-	O
2.1	O
nM/Mm	O
Cr	O
in	O
the	O
WD	O
)	O
,	O
possibly	O
indicative	O
of	O
less	O
efficient	O
bone	O
turnover	O
during	O
this	O
period	O
.	O

As	O
calcium	O
acquired	O
during	O
adolescence	O
is	O
essential	O
to	O
maximize	O
peak	O
bone	O
mass	O
and	O
to	O
prevent	O
osteoporosis	O
,	O
possible	O
long-term	O
effects	O
of	O
excessive	O
MRP	O
intake	O
during	O
this	O
period	O
warrant	O
attention	O
.	O

The	O
treatment	O
of	O
localized	O
non-Hodgkin	O
's	O
lymphoma	O
in	O
children	O
:	O
a	O
report	O
from	O
the	O
Children	O
's	O
Cancer	O
Study	O
Group	O
.	O

Investigators	O
of	O
the	O
Children	O
's	O
Cancer	O
Study	O
Group	O
entered	O
73	O
children	O
with	O
previously	O
untreated	O
localized	O
non-Hodgkin	O
's	O
lymphoma	O
on	O
a	O
prospective	O
randomized	O
trial	O
of	O
systemic	O
treatment	O
with	O
either	O
a	O
four-drug	O
program	O
(	O
cyclophosphamide	O
,	O
vincristine	O
,	O
methotrexate	O
,	O
prednisone	O
[	O
COMP	O
]	O
)	O
or	O
a	O
10-drug	O
(	O
LSA2-L2	O
modified	O
)	O
program	O
of	O
18	O
months	O
duration	O
.	O

All	O
patients	O
received	O
central	O
nervous	O
system	O
prophylaxis	O
with	O
intrathecal	O
methotrexate	O
and	O
most	O
received	O
local	O
or	O
regional	O
radiation	O
treatment	O
.	O

The	O
three-year	O
relapse-free	O
survival	O
rate	O
for	O
all	O
patients	O
(	O
N	O
=	O
73	O
)	O
was	O
84	O
%	O
;	O
for	O
COMP	O
(	O
N	O
=	O
42	O
)	O
was	O
85	O
%	O
,	O
and	O
for	O
LSA2-L2	O
(	O
N	O
=	O
31	O
)	O
was	O
84	O
%	O
.	O

Of	O
the	O
12	O
patients	O
who	O
suffered	O
adverse	O
events	O
eight	O
relapsed	O
and	O
four	O
died	O
of	O
toxicity	O
.	O

Histopathology	O
was	O
reviewed	O
centrally	O
.	O

Of	O
32	O
patients	O
with	O
nonlymphoblastic	O
disease	O
treated	O
with	O
COMP	O
only	O
one	O
relapsed	O
.	O

Of	O
26	O
patients	O
treated	O
with	O
LSA2-L2	O
,	O
four	O
relapsed	O
.	O

Patients	O
with	O
localized	O
lymphoblastic	O
disease	O
were	O
uncommon	O
.	O

None	O
of	O
three	O
patients	O
treated	O
with	O
LSA2-L2	O
relapsed	O
compared	O
with	O
three	O
of	O
nine	O
treated	O
with	O
COMP	O
.	O

COMP	O
is	O
an	O
excellent	O
treatment	O
for	O
patients	O
with	O
localized	O
disease	O
of	O
nonlymphoblastic	O
type	O
,	O
but	O
the	O
relative	O
value	O
of	O
the	O
two	O
regimens	O
for	O
patients	O
with	O
localized	O
lymphoblastic	O
disease	O
is	O
uncertain	O
.	O

Intra-operative	O
antibiotic	O
prophylaxis	O
in	O
neurosurgery	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
on	O
cefotiam	O
.	O

In	O
this	O
prospective	O
,	O
randomized	O
and	O
controlled	O
study	O
the	O
effect	O
of	O
cefotiam	O
for	O
the	O
prevention	O
of	O
wound	O
infections	O
following	O
trepanations	O
was	O
investigated	O
.	O

The	O
main	O
interest	O
was	O
centered	O
on	O
the	O
rate	O
of	O
post-operative	O
bone	O
flap	O
infections	O
requiring	O
operative	O
revision	O
.	O

Administration	O
of	O
cefotiam	O
was	O
randomized	O
for	O
patients	O
undergoing	O
major	O
craniotomies	O
.	O

The	O
antibiotic	O
was	O
administered	O
intravenously	O
in	O
a	O
single	O
dose	O
of	O
2	O
g	O
with	O
induction	O
of	O
anaesthesia	O
.	O

Only	O
clean	O
or	O
clean	O
contaminated	O
cases	O
were	O
included	O
.	O

Excluded	O
were	O
contaminated	O
cases	O
,	O
operations	O
with	O
a	O
transnasal-transsphenoidal	O
approach	O
,	O
shunt-operations	O
and	O
patients	O
with	O
any	O
other	O
preoperative	O
infection	O
or	O
antibiotic	O
therapy	O
.	O

Outpatients	O
were	O
excluded	O
due	O
to	O
difficulties	O
in	O
obtaining	O
sufficient	O
clinical	O
information	O
.	O

From	O
originally	O
918	SampleSize
consecutive	O
patients	O
operated	O
on	O
711	SampleSize
fulfilled	O
the	O
entry	O
criteria	O
.	O

With	O
regard	O
to	O
age	O
,	O
sex	O
,	O
diagnosis	O
and	O
the	O
site	O
of	O
te	O
trepanation	O
,	O
control	O
patients	O
(	O
n	O
=	O
355	SampleSize
)	O
and	O
cefotiam	O
treated	O
patients	O
(	O
n	O
=	O
356	SampleSize
)	O
were	O
shown	O
to	O
be	O
comparable	O
.	O

In	O
the	O
various	O
subgroups	O
formed	O
for	O
different	O
primary	O
diagnoses	O
,	O
concomitant	O
steroidal	O
therapy	O
and	O
concomitant	O
severe	O
internal	O
medical	O
diseases	O
cefotiam	O
treated	O
patients	O
and	O
controls	O
were	O
comparable	O
as	O
well	O
.	O

A	O
highly	O
significant	O
difference	O
for	O
bone	O
flap	O
infection	O
could	O
be	O
shown	O
with	O
0.3	O
%	O
in	O
the	O
cefotiam	O
group	O
versus	O
5.1	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

The	O
overall	O
rate	O
of	O
post-operative	O
deep	O
wound	O
infections	O
including	O
meningitis	O
and	O
abscesses	O
was	O
also	O
significantly	O
(	O
p	O
less	O
than	O
0.005	O
)	O
different	O
with	O
3.1	O
%	O
in	O
the	O
cefotiam	O
versus	O
9.0	O
%	O
in	O
the	O
control	O
group	O
.	O

Thus	O
it	O
was	O
concluded	O
that	O
a	O
single	O
dose	O
of	O
cefotiam	O
significantly	O
reduces	O
post-operative	O
deep	O
wound	O
infection	O
.	O

Evaluating	O
online	O
continuing	O
medical	O
education	O
seminars	O
:	O
evidence	O
for	O
improving	O
clinical	O
practices	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
for	O
online	O
continuing	O
medical	O
education	O
(	O
CME	O
)	O
seminars	O
to	O
improve	O
quality	O
of	O
care	O
.	O

Primary	O
care	O
physicians	O
(	O
113	O
)	O
participated	O
in	O
a	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
an	O
online	O
CME	O
series	O
.	O

Physicians	O
were	O
randomized	O
to	O
view	O
either	O
a	O
seminar	O
about	O
type	O
2	O
diabetes	O
or	O
a	O
seminar	O
about	O
systolic	O
heart	O
failure	O
.	O

Following	O
the	O
seminar	O
,	O
physicians	O
were	O
presented	O
with	O
4	O
clinical	O
vignettes	O
and	O
asked	O
to	O
describe	O
what	O
tests	O
,	O
treatments	O
,	O
counseling	O
,	O
or	O
referrals	O
they	O
would	O
recommend	O
.	O

Physicians	O
who	O
viewed	O
the	O
seminars	O
were	O
significantly	O
more	O
likely	O
to	O
recommend	O
guideline-consistent	O
care	O
to	O
patients	O
in	O
the	O
vignettes	O
.	O

For	O
example	O
,	O
physicians	O
who	O
viewed	O
the	O
diabetes	O
seminar	O
were	O
significantly	O
more	O
likely	O
to	O
order	O
an	O
eye	O
exam	O
for	O
diabetes	O
patients	O
(	O
63	O
%	O
)	O
compared	O
with	O
physicians	O
in	O
the	O
control	O
group	O
(	O
27	O
%	O
)	O
.	O

For	O
some	O
guidelines	O
there	O
were	O
no	O
group	O
differences	O
.	O

These	O
results	O
provide	O
early	O
evidence	O
of	O
the	O
effectiveness	O
of	O
online	O
CME	O
programs	O
to	O
improve	O
physician	O
clinical	O
practice	O
.	O

Randomized	O
Phase	O
II	O
trial	O
assessing	O
estramustine	O
and	O
vinblastine	O
combination	O
chemotherapy	O
vs	O
estramustine	O
alone	O
in	O
patients	O
with	O
progressive	Condition
hormone-escaped	Condition
metastatic	Condition
prostate	Condition
cancer	Condition
.	O

Based	O
on	O
the	O
results	O
of	O
combined	O
data	O
from	O
three	O
North	O
American	O
Phase	O
II	O
studies	O
,	O
a	O
randomised	O
Phase	O
II	O
study	O
in	O
the	O
same	O
patient	O
population	O
was	O
performed	O
,	O
using	O
combination	O
chemotherapy	O
with	O
estramustine	O
phosphate	O
(	O
EMP	O
)	O
and	O
vinblastine	O
(	O
VBL	O
)	O
in	O
hormone	O
refractory	O
prostate	O
cancer	O
patients	O
.	O

In	O
all	O
,	O
92	SampleSize
patients	O
were	O
randomised	O
into	O
a	O
Phase	O
II	O
study	O
of	O
oral	O
EMP	O
(	O
10	O
mg	O
kg	O
day	O
continuously	O
)	O
or	O
oral	O
EMP	O
in	O
combination	O
with	O
intravenous	O
VBL	O
(	O
4	O
mg	O
m	O
(	O
2	O
)	O
week	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
2	O
weeks	O
rest	O
)	O
.	O

The	O
end	O
points	O
were	O
toxicity	O
and	O
PSA	O
response	O
in	O
both	O
groups	O
,	O
with	O
the	O
option	O
to	O
continue	O
the	O
trial	O
as	O
a	O
Phase	O
III	O
study	O
with	O
time	O
to	O
progression	O
and	O
survival	O
as	O
end	O
points	O
,	O
if	O
sufficient	O
responses	O
were	O
observed	O
.	O

Toxicity	O
was	O
unexpectedly	O
high	O
in	O
both	O
treatment	O
arms	O
and	O
led	O
to	O
treatment	O
withdrawal	O
or	O
refusal	O
in	O
49	O
%	O
of	O
all	O
patients	O
,	O
predominantly	O
already	O
during	O
the	O
first	O
treatment	O
cycle	O
.	O

The	O
mean	O
treatment	O
duration	O
was	O
10	O
and	O
14	O
weeks	O
,	O
median	O
time	O
to	O
PSA	O
progression	O
was	O
27.2	O
and	O
30.8	O
weeks	O
,	O
median	O
survival	O
time	O
was	O
44	O
and	O
50.9	O
weeks	O
,	O
and	O
PSA	O
response	O
rate	O
was	O
only	O
24.6	O
and	O
28.9	O
%	O
in	O
the	O
EMP/VBL	O
and	O
EMP	O
arms	O
,	O
respectively	O
.	O

There	O
was	O
no	O
correlation	O
between	O
PSA	O
response	O
and	O
survival	O
.	O

While	O
the	O
PSA	O
response	O
in	O
the	O
patients	O
tested	O
was	O
less	O
than	O
half	O
that	O
recorded	O
in	O
the	O
North	O
American	O
studies	O
,	O
the	O
toxicity	O
of	O
EMP	O
monotherapy	O
or	O
in	O
combination	O
with	O
VBL	O
was	O
much	O
higher	O
than	O
expected	O
.	O

Further	O
research	O
on	O
more	O
effective	O
and	O
less	O
toxic	O
treatment	O
strategies	O
for	O
hormone	O
refractory	O
prostate	O
cancer	O
is	O
mandatory	O
.	O

Pre-vaccination	O
immunity	O
and	O
immune	O
responses	O
to	O
a	O
cell	O
culture-derived	O
whole-virus	O
H1N1	O
vaccine	O
are	O
similar	O
to	O
a	O
seasonal	O
influenza	O
vaccine	O
.	O

BACKGROUND	O
Immune	O
responses	O
to	O
novel	O
pandemic	O
influenza	O
vaccines	O
may	O
be	O
influenced	O
by	O
previous	O
exposure	O
to	O
antigenically	O
similar	O
seasonal	O
strains	O
.	O

METHODS	O
An	O
open-label	O
,	O
randomized	O
,	O
phase	O
I/II	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
immunogenicity	O
and	O
safety	O
of	O
a	O
non-adjuvanted	O
,	O
inactivated	O
whole-virus	O
H1N1	O
A/California/07/2009	O
vaccine	O
.	O

408	O
subjects	O
were	O
stratified	O
by	O
age	O
(	O
18-59	O
and	O
>	O
60	O
years	O
)	O
and	O
randomized	O
1:1	O
to	O
receive	O
two	O
vaccinations	O
with	O
either	O
3.75	O
or	O
7.5	O
?g	O
hemagglutinin	O
antigen	O
21	O
days	O
apart	O
.	O

Safety	O
,	O
immunogenicity	O
and	O
the	O
influence	O
of	O
seasonal	O
influenza	O
vaccination	O
and	O
antibody	O
cross-reactivity	O
with	O
a	O
seasonal	O
H1N1	O
strain	O
was	O
assessed	O
.	O

RESULTS	O
A	O
single	O
vaccination	O
with	O
either	O
dose	O
induced	O
substantial	O
increases	O
in	O
H1N1	O
A/California/07/2009	O
hemagglutination	O
inhibition	O
(	O
HI	O
)	O
and	O
neutralizing	O
(	O
MN	O
)	O
antibody	O
titers	O
in	O
both	O
adult	O
and	O
elderly	O
subjects	O
.	O

A	O
single	O
7.5	O
?g	O
dose	O
induced	O
seroprotection	O
rates	O
of	O
86.9	O
%	O
in	O
adults	O
and	O
75.2	O
%	O
in	O
elderly	O
subjects	O
.	O

Two	O
7.5	O
?g	O
vaccinations	O
induced	O
seroprotection	O
rates	O
in	O
adult	O
and	O
elderly	O
subjects	O
of	O
90.9	O
%	O
and	O
89.1	O
%	O
,	O
respectively	O
.	O

The	O
robust	O
immune	O
response	O
to	O
vaccination	O
was	O
confirmed	O
by	O
analyses	O
of	O
neutralizing	O
antibody	O
titers	O
.	O

Both	O
HI	O
and	O
MN	O
antibodies	O
persisted	O
for	O
?	O
6	O
months	O
post-vaccination	O
.	O

Between	O
34	O
%	O
and	O
49	O
%	O
of	O
subjects	O
had	O
seroprotective	O
levels	O
of	O
H1N1	O
A/California/07/2009	O
antibodies	O
at	O
baseline	O
.	O

Higher	O
baseline	O
HI	O
titers	O
were	O
associated	O
with	O
receipt	O
of	O
the	O
2008-09	O
or	O
2009-10	O
seasonal	O
influenza	O
vaccine	O
.	O

High	O
baseline	O
A/California/07/2009	O
neutralizing	O
antibody	O
titers	O
were	O
also	O
associated	O
with	O
high	O
baseline	O
titers	O
against	O
A/New	O
Caledonia/20/99	O
,	O
a	O
seasonal	O
H1N1	O
strain	O
which	O
circulated	O
and	O
was	O
included	O
in	O
the	O
seasonal	O
vaccine	O
from	O
2000-01	O
to	O
2006-07	O
.	O

Pre-adsorption	O
with	O
A/H1N1/New	O
Caledonia/20/99	O
antigen	O
reduced	O
A/H1N1/California/07/2009	O
baseline	O
titers	O
in	O
55	O
%	O
of	O
tested	O
sera	O
.	O

The	O
vaccine	O
was	O
well	O
tolerated	O
with	O
low	O
rates	O
of	O
fever	O
.	O

CONCLUSIONS	O
A	O
whole-virus	O
H1N1	O
A/California/07/2009	O
vaccine	O
was	O
safe	O
and	O
well	O
tolerated	O
and	O
a	O
single	O
dose	O
induced	O
substantial	O
immune	O
responses	O
similar	O
to	O
seasonal	O
influenza	O
vaccines	O
,	O
probably	O
due	O
to	O
immunological	O
priming	O
by	O
previous	O
seasonal	O
influenza	O
vaccines	O
or	O
infections	O
.	O

Trial	O
of	O
prophylactic	O
administration	O
of	O
TXA2	O
synthetase	O
inhibitor	O
,	O
ozagrel	O
hydrochloride	O
,	O
for	O
preeclampsia	Condition
.	O

OBJECTIVE	O
In	O
an	O
attempt	O
to	O
investigate	O
the	O
prophylactic	O
effect	O
of	O
a	O
thromboxane	O
A2	O
(	O
TXA2	O
)	O
synthetase	O
inhibitor	O
on	O
pregnant	O
women	Sex
with	O
a	O
high	O
risk	O
of	O
preeclampsia	Condition
,	O
the	O
following	O
clinical	O
study	O
was	O
undertaken	O
.	O

METHODS	O
Forty	SampleSize
pregnant	O
women	Sex
were	O
randomly	O
allocated	O
to	O
control	O
or	O
treatment	O
groups	O
.	O

Ozagrel	O
Hydrochloride	O
(	O
400	O
mg/day	O
,	O
orally	O
)	O
and	O
placebo	O
were	O
started	O
at	O
20	O
weeks	O
of	O
gestation	O
and	O
continued	O
until	O
delivery	O
.	O

RESULTS	O
Seventeen	O
of	O
20	O
(	O
85	O
%	O
)	O
women	O
in	O
the	O
control	O
group	O
developed	O
preeclampsia	O
,	O
whereas	O
9	O
of	O
20	O
(	O
45	O
%	O
)	O
in	O
the	O
treatment	O
group	O
developed	O
preeclampsia	O
.	O

Ozagrel	O
Hydrochloride	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
reduced	O
the	O
occurrence	O
of	O
preeclampsia	O
,	O
and	O
the	O
incidence	O
of	O
both	O
hypertension	O
(	O
p	O
<	O
0.05	O
)	O
and	O
proteinuria	O
(	O
p	O
<	O
0.01	O
)	O
was	O
significantly	O
less	O
in	O
the	O
treatment	O
group	O
compared	O
with	O
the	O
control	O
group	O
.	O

One	O
month	O
after	O
administration	O
,	O
the	O
mean	O
plasma	O
concentration	O
of	O
TXB2	O
,	O
a	O
metabolite	O
of	O
TXA2	O
,	O
was	O
significantly	O
decreased	O
(	O
p	O
<	O
0.01	O
)	O
to	O
62.4	O
+/-	O
13.6	O
%	O
,	O
whereas	O
that	O
of	O
6-keto	O
prostaglandin	O
F1	O
alpha	O
,	O
a	O
metabolite	O
of	O
PGI2	O
,	O
was	O
significantly	O
increased	O
(	O
p	O
<	O
0.01	O
)	O
to	O
206.7	O
+/-	O
52.8	O
%	O
.	O

There	O
were	O
no	O
maternal	O
or	O
fetal	O
side	O
effects	O
observed	O
.	O

CONCLUSIONS	O
It	O
seems	O
likely	O
that	O
Ozagrel	O
Hydrochloride	O
could	O
be	O
used	O
for	O
the	O
prevention	O
of	O
preeclampsia	Condition
in	O
high-risk	O
pregnant	O
women	O
.	O

The	O
influence	O
of	O
beta-adrenoceptor	O
blockade	O
on	O
left	O
ventricular	O
function	O
.	O

1	O
This	O
study	O
was	O
designed	O
to	O
compare	O
in	O
a	O
randomized	O
cross-over	O
trial	O
pindolol	O
,	O
a	O
beta-adrenoceptor	O
blocking	O
agent	O
with	O
intrinsic	O
sympathomimetic	O
activity	O
and	O
metoprolol	O
,	O
a	O
cardioselective	O
beta-adrenoceptor	O
blocker	O
lacking	O
sympathomimetic	O
activity	O
in	O
hypertensives	O
with	O
incipient	Condition
heart	Condition
failure	Condition
.	O

Cardiac	O
function	O
was	O
investigated	O
by	O
M-Mode	O
and	O
2D-echo-cardiography	O
.	O

2	O
Both	O
pindolol	O
and	O
metoprolol	O
in	O
equipotent	O
doses	O
lowered	O
blood	O
pressure	O
to	O
the	O
same	O
extent	O
.	O

3	O
There	O
was	O
no	O
difference	O
in	O
overall	O
left	O
ventricular	O
function	O
in	O
ventricular	O
geometry	O
or	O
in	O
wall	O
dynamics	O
after	O
either	O
drug	O
.	O

4	O
In	O
comparison	O
to	O
metoprolol	O
,	O
pindolol	O
produced	O
less	O
reduction	O
in	O
resting	O
heart	O
rate	O
,	O
cardiac	O
index	O
and	O
ejection	O
velocity	O
reflecting	O
the	O
intrinsic	O
sympathomimetic	O
activity	O
of	O
the	O
drug	O
.	O

The	O
relationship	O
of	O
alexithymia	O
to	O
emotional	O
dysregulation	O
within	O
an	O
alcohol	O
dependent	O
treatment	O
sample	O
.	O

Difficulties	O
regulating	O
emotions	O
have	O
implications	O
for	O
the	O
development	O
,	O
maintenance	O
,	O
and	O
recovery	O
from	O
alcohol	O
problems	O
.	O

One	O
construct	O
thought	O
to	O
impede	O
the	O
regulation	O
of	O
emotion	O
is	O
alexithymia	O
.	O

Alexithymia	O
is	O
characterized	O
by	O
difficulties	O
identifying	O
,	O
differentiating	O
and	O
expressing	O
feelings	O
,	O
a	O
limited	O
imagination	O
and	O
fantasy	O
life	O
,	O
and	O
an	O
externally-oriented	O
thinking	O
style	O
(	O
e.g.	O
,	O
prefer	O
talking	O
about	O
daily	O
activities	O
rather	O
than	O
feelings	O
)	O
.	O

Given	O
that	O
poor	O
emotion	O
regulation	O
skills	O
have	O
been	O
found	O
to	O
predict	O
posttreatment	O
levels	O
of	O
alcohol	O
use	O
,	O
and	O
that	O
several	O
defining	O
characteristics	O
of	O
alexithymia	O
bear	O
similarity	O
to	O
deficits	O
in	O
emotion	O
regulation	O
skills	O
,	O
it	O
is	O
possible	O
that	O
alexithymia	O
may	O
predict	O
poorer	O
alcohol	O
treatment	O
outcomes	O
.	O

Thus	O
,	O
the	O
present	O
study	O
first	O
examined	O
the	O
relationship	O
of	O
alexithymia	O
to	O
several	O
other	O
emotion	O
regulation	O
measures	O
and	O
then	O
investigated	O
the	O
impact	O
of	O
alexithymia	O
on	O
attrition	O
and	O
alcohol	O
treatment	O
outcomes	O
in	O
men	O
and	O
women	O
(	O
N=77	O
)	O
enrolled	O
in	O
a	O
12-week	O
cognitive-behavioral	O
intervention	O
for	O
alcohol	O
dependence	O
.	O

At	O
baseline	O
,	O
higher	O
scores	O
on	O
alexithymia	O
were	O
associated	O
poorer	O
emotion	O
regulation	O
skills	O
,	O
fewer	O
percent	O
days	O
abstinent	O
,	O
greater	O
alcohol	O
dependence	O
severity	O
,	O
and	O
several	O
high-risk	O
drinking	O
situations	O
.	O

Alexithymia	O
was	O
unrelated	O
to	O
attrition	O
and	O
to	O
level	O
of	O
alcohol	O
consumption	O
at	O
posttreatment	O
.	O

Overall	O
,	O
the	O
construct	O
of	O
alexithymia	O
is	O
shown	O
to	O
be	O
related	O
to	O
several	O
theoretically-related	O
constructs	O
(	O
e.g.	O
,	O
emotion	O
regulation	O
,	O
mindfulness	O
)	O
but	O
demonstrated	O
a	O
limited	O
relationship	O
to	O
drinking	O
outcomes	O
in	O
those	O
seeking	O
treatment	O
for	O
alcohol	O
dependence	O
.	O

Mindfulness-based	O
therapy	O
in	O
adults	Age
with	O
an	O
autism	Condition
spectrum	Condition
disorder	Condition
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

Research	O
shows	O
that	O
depression	O
and	O
anxiety	O
disorders	O
are	O
the	O
most	O
common	O
psychiatric	O
concern	O
in	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
.	O

Mindfulness-based	O
therapy	O
(	O
MBT	O
)	O
has	O
been	O
found	O
effective	O
in	O
reducing	O
anxiety	O
and	O
depression	O
symptoms	O
,	O
however	O
research	O
in	O
autism	O
is	O
limited	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
a	O
modified	O
MBT	O
protocol	O
(	O
MBT-AS	O
)	O
in	O
high-functioning	Condition
adults	Age
with	O
ASD	Condition
.	O

42	SampleSize
participants	O
were	O
randomized	O
into	O
a	O
9-week	O
MBT-AS	O
training	O
or	O
a	O
wait-list	O
control	O
group	O
.	O

Results	O
showed	O
a	O
significant	O
reduction	O
in	O
depression	O
,	O
anxiety	O
and	O
rumination	O
in	O
the	O
intervention	O
group	O
,	O
as	O
opposed	O
to	O
the	O
control	O
group	O
.	O

Furthermore	O
,	O
positive	O
affect	O
increased	O
in	O
the	O
intervention	O
group	O
,	O
but	O
not	O
in	O
the	O
control	O
group	O
.	O

Concluding	O
,	O
the	O
present	O
study	O
is	O
the	O
first	O
controlled	O
trial	O
to	O
demonstrate	O
that	O
adults	Age
with	O
ASD	Condition
can	O
benefit	O
from	O
MBT-AS	O
.	O

Effects	O
of	O
enalapril	O
and	O
eprosartan	O
on	O
the	O
renal	O
vascular	O
nitric	O
oxide	O
system	O
in	O
human	Condition
essential	Condition
hypertension	Condition
.	Condition

BACKGROUND	O
Experimental	O
data	O
in	O
humans	O
on	O
the	O
contribution	O
of	O
angiotensin-converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	O
II	O
type	O
1	O
receptor	O
blockers	O
to	O
the	O
nitric	O
oxide	O
system	O
of	O
the	O
renal	O
vasculature	O
are	O
inconsistent	O
.	O

Enalapril	O
and	O
eprosartan	O
,	O
alone	O
and	O
in	O
combination	O
,	O
were	O
used	O
to	O
determine	O
their	O
short-term	O
effects	O
on	O
the	O
renal	O
nitric	O
oxide	O
system	O
and	O
renal	O
hemodynamics	O
of	O
human	Condition
subjects	Condition
with	Condition
essential	Condition
hypertension	Condition
.	Condition

METHODS	O
Twenty	Condition
male	Condition
,	Condition
white	Condition
patients	Condition
(	Condition
27	Condition
+/-	Condition
1	Condition
years	Condition
)	Condition
with	Condition
mild	Condition
essential	Condition
hypertension	Condition
(	Condition
143	Condition
+/-	Condition
11/95	Condition
+/-	Condition
6	Condition
mm	Condition
Hg	Condition
)	Condition
were	O
included	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
fourfold	O
cross-over	O
study	O
with	O
placebo	O
,	O
enalapril	O
(	O
20	O
mg/day	O
)	O
,	O
eprosartan	O
(	O
600	O
mg/day	O
)	O
,	O
or	O
combination	O
of	O
both	O
drugs	O
(	O
10	O
and	O
300	O
mg/day	O
,	O
respectively	O
)	O
each	O
over	O
a	O
one	O
week	O
period	O
followed	O
by	O
a	O
two-week	O
washout	O
phase	O
.	O

After	O
each	O
study	O
phase	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
renal	O
plasma	O
flow	O
(	O
RPF	O
)	O
were	O
determined	O
.	O

Basal	O
nitric	O
oxide	O
synthesis	O
of	O
the	O
renal	O
vasculature	O
was	O
assessed	O
by	O
the	O
decrease	O
in	O
RPF	O
after	O
inhibition	O
of	O
nitric	O
oxide	O
synthase	O
with	O
NG-monomethyl-L-arginine	O
(	O
L-NMMA	O
;	O
4.25	O
mg/kg	O
)	O
.	O

RESULTS	O
After	O
one	O
week	O
of	O
therapy	O
,	O
the	O
combination	O
therapy	O
decreased	O
casual	O
blood	O
pressure	O
by	O
5	O
+/-	O
2/3	O
+/-	O
1	O
mm	O
Hg	O
versus	O
placebo	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Neither	O
enalapril	O
alone	O
(	O
-2	O
+/-	O
2/1	O
+/-	O
2	O
mm	O
Hg	O
,	O
NS	O
vs.	O
placebo	O
)	O
nor	O
eprosartan	O
alone	O
(	O
-1	O
+/-	O
1/0	O
+/-	O
2	O
mm	O
Hg	O
,	O
NS	O
vs.	O
placebo	O
)	O
had	O
a	O
clear-cut	O
significant	O
effect	O
on	O
casual	O
blood	O
pressure	O
.	O

In	O
the	O
combination	O
phase	O
,	O
RPF	O
increased	O
by	O
123	O
+/-	O
36	O
mL/min	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Neither	O
enalapril	O
alone	O
(	O
+59	O
+/-	O
46	O
mL/min	O
,	O
P	O
=	O
0.21	O
)	O
nor	O
eprosartan	O
alone	O
(	O
+113	O
+/-	O
51	O
mL/min	O
,	O
P	O
=	O
0.06	O
)	O
had	O
a	O
clear-cut	O
significant	O
effect	O
on	O
RPF	O
.	O

Changes	O
of	O
RPF	O
induced	O
by	O
treatment	O
correlated	O
with	O
the	O
L-NMMA	O
induced	O
decrease	O
in	O
RPF	O
in	O
the	O
combination	O
(	O
r	O
=	O
0.70	O
,	O
P	O
<	O
0.01	O
)	O
and	O
eprosartan	O
phase	O
(	O
r	O
=	O
0.86	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
in	O
the	O
enalapril	O
phase	O
(	O
r	O
=	O
-0.44	O
,	O
P	O
=	O
0.10	O
)	O
.	O

Renal	O
vascular	O
resistance	O
was	O
reduced	O
by	O
each	O
active	O
treatment	O
with	O
the	O
most	O
prominent	O
reduction	O
in	O
the	O
combination	O
phase	O
.	O

GFR	O
was	O
unaffected	O
by	O
any	O
treatment	O
.	O

CONCLUSIONS	O
In	O
contrast	O
to	O
the	O
effects	O
of	O
either	O
substance	O
alone	O
,	O
a	O
combination	O
of	O
half	O
the	O
dose	O
of	O
eprosartan	O
with	O
half	O
the	O
dose	O
of	O
enalapril	O
had	O
a	O
prominent	O
effect	O
on	O
renal	O
perfusion	O
.	O

The	O
effects	O
of	O
eprosartan	O
on	O
RPF	O
are	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
an	O
increased	O
bioavailability	O
of	O
nitric	O
oxide	O
in	O
the	O
renal	O
vasculature	O
.	O

Predictors	O
of	O
blood	O
pressure	O
change	O
in	O
a	O
series	O
of	O
controlled	O
dietary	O
intervention	O
studies	O
.	O

Three	O
controlled	O
dietary	O
intervention	O
studies	O
were	O
carried	O
out	O
in	O
1981-1983	O
in	O
North	O
Karelia	O
,	O
Finland	O
,	O
to	O
asses	O
the	O
impact	O
of	O
dietary	O
fat	O
intake	O
modification	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
.	O

All	O
these	O
studies	O
involved	O
middle-aged	O
men	O
and	O
women	O
in	O
rural	O
or	O
semirural	O
areas	O
and	O
comprised	O
a	O
baseline	O
period	O
,	O
a	O
six	O
week	O
(	O
or	O
12	O
weeks	O
in	O
the	O
third	O
study	O
)	O
intervention	O
period	O
and	O
a	O
four	O
to	O
six	O
week	O
return	O
to	O
baseline	O
.	O

During	O
the	O
intervention	O
period	O
the	O
total	O
fat	O
intake	O
was	O
reduced	O
from	O
39	O
%	O
to	O
24	O
%	O
of	O
energy	O
and	O
the	O
polyunsaturated/saturated	O
(	O
P/S	O
)	O
ratio	O
increased	O
from	O
0.2	O
to	O
0.4-1.2	O
.	O

In	O
all	O
groups	O
energy	O
intake	O
was	O
kept	O
constant	O
.	O

For	O
the	O
present	O
report	O
data	O
from	O
the	O
three	O
studies	O
were	O
pooled	O
for	O
a	O
series	O
of	O
stepwise	O
regression	O
analyses	O
to	O
predict	O
changes	O
in	O
BP	O
with	O
different	O
dietary	O
changes	O
.	O

For	O
both	O
systolic	O
(	O
SBP	O
)	O
and	O
diastolic	O
(	O
DBP	O
)	O
blood	O
pressure	O
,	O
change	O
in	O
polyunsaturated	O
fatty	O
acid	O
intake	O
was	O
the	O
strongest	O
dietary	O
predictor	O
of	O
BP	O
change	O
.	O

Changes	O
in	O
body	O
weight	O
,	O
total	O
fat	O
intake	O
,	O
urinary	O
sodium	O
and	O
potassium	O
did	O
not	O
have	O
significant	O
predictive	O
power	O
in	O
any	O
of	O
the	O
analyses	O
.	O

The	O
findings	O
support	O
the	O
hypothesis	O
that	O
modification	O
of	O
dietary	O
fat	O
intake	O
is	O
a	O
significant	O
predictor	O
of	O
change	O
in	O
BP	O
.	O

Increase	O
in	O
2-long	O
terminal	O
repeat	O
circles	O
and	O
decrease	O
in	O
D-dimer	O
after	O
raltegravir	O
intensification	O
in	O
patients	O
with	O
treated	O
HIV	Condition
infection	Condition
:	O
a	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O

BACKGROUND	O
The	O
degree	O
to	O
which	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
continues	O
to	O
replicate	O
during	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
is	O
controversial	O
.	O

We	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
to	O
assess	O
whether	O
raltegravir	O
intensification	O
reduces	O
low-level	O
viral	O
replication	O
,	O
as	O
defined	O
by	O
an	O
increase	O
in	O
the	O
level	O
of	O
2-long	O
terminal	O
repeat	O
(	O
2-LTR	O
)	O
circles	O
.	O

METHODS	O
Thirty-one	O
subjects	O
with	O
an	O
ART-suppressed	O
plasma	O
HIV	O
RNA	O
level	O
of	O
<	O
40	O
copies/mL	O
and	O
a	O
CD4	O
(	O
+	O
)	O
T-cell	O
count	O
of	O
?350	O
cells/mm	O
(	O
3	O
)	O
for	O
?1	O
year	O
were	O
randomly	O
assigned	O
to	O
receive	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
or	O
placebo	O
for	O
24	O
weeks	O
.	O

2-LTR	O
circles	O
were	O
analyzed	O
by	O
droplet	O
digital	O
polymerase	O
chain	O
reaction	O
at	O
weeks	O
0	O
,	O
1	O
,	O
2	O
,	O
and	O
8	O
.	O

RESULTS	O
The	O
median	O
duration	O
of	O
ART	O
suppression	O
was	O
3.8	O
years	O
.	O

The	O
raltegravir	O
group	O
had	O
a	O
significant	O
increase	O
in	O
the	O
level	O
of	O
2-LTR	O
circles	O
,	O
compared	O
to	O
the	O
placebo	O
group	O
.	O

The	O
week	O
1	O
to	O
0	O
ratio	O
was	O
8.8-fold	O
higher	O
(	O
P	O
=	O
.0025	O
)	O
and	O
the	O
week	O
2	O
to	O
0	O
ratio	O
was	O
5.7-fold	O
higher	O
(	O
P	O
=	O
.023	O
)	O
in	O
the	O
raltegravir	O
vs.	O
placebo	O
group	O
.	O

Intensification	O
also	O
led	O
to	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
D-dimer	O
level	O
,	O
compared	O
to	O
placebo	O
(	O
P	O
=	O
.045	O
)	O
.	O

CONCLUSIONS	O
Raltegravir	O
intensification	O
resulted	O
in	O
a	O
rapid	O
increase	O
in	O
the	O
level	O
of	O
2-LTR	O
circles	O
in	O
a	O
proportion	O
of	O
subjects	O
,	O
indicating	O
that	O
low-level	O
viral	O
replication	O
persists	O
in	O
some	O
individuals	O
even	O
after	O
long-term	O
ART	O
.	O

Intensification	O
also	O
reduced	O
the	O
D-dimer	O
level	O
,	O
a	O
coagulation	O
biomarker	O
that	O
is	O
predictive	O
of	O
morbidity	O
and	O
mortality	O
among	O
patients	O
receiving	O
treatment	O
for	O
HIV	O
infection	O
.	O

Changes	O
in	O
the	O
fatty	O
acid	O
composition	O
of	O
the	O
plasma	O
lipid	O
esters	O
during	O
lipid-lowering	O
treatment	O
with	O
diet	O
,	O
clofibrate	O
and	O
niceritrol	O
.	O

Reduction	O
of	O
the	O
proportion	O
of	O
linoleate	O
by	O
clofibrate	O
but	O
not	O
by	O
niceritrol	O
.	O

The	O
fatty	O
acid	O
composition	O
of	O
the	O
plasma	O
lipid	O
esters	O
has	O
been	O
studied	O
during	O
lipid-lowering	O
treatment	O
of	O
95	SampleSize
patients	O
with	O
atherosclerotic	Condition
disease	O
.	O

During	O
the	O
first	O
two	O
months	O
of	O
the	O
trial	O
only	O
a	O
diet	O
was	O
prescribed	O
.	O

During	O
the	O
ensuing	O
two	O
months	O
either	O
clofibrate	O
or	O
niceritrol	O
,	O
a	O
nicotinic	O
acid	O
ester	O
,	O
was	O
added	O
in	O
a	O
randomized	O
order	O
.	O

During	O
the	O
last	O
two	O
months	O
the	O
second	O
drug	O
was	O
added	O
.	O

The	O
combined	O
treatment	O
with	O
diet	O
,	O
clofibrate	O
and	O
niceritrol	O
caused	O
highly	O
significant	O
serum	O
lipid	O
reductions	O
.	O

The	O
fatty	O
acid	O
composition	O
in	O
the	O
plasma	O
lipid	O
esters	O
was	O
determined	O
in	O
samples	O
from	O
each	O
trial	O
period	O
to	O
measure	O
the	O
degree	O
of	O
dietary	O
adherence	O
.	O

During	O
dietary	O
treatment	O
the	O
relative	O
content	O
of	O
saturated	O
and	O
monounsaturated	O
fatty	O
acids	O
secreased	O
and	O
the	O
polyunsaturated	O
fatty	O
acids	O
increased	O
with	O
an	O
increasing	O
ratio	O
between	O
pulyunsaturated	O
and	O
saturated	O
fatty	O
acids	O
(	O
P/S	O
ratio	O
)	O
in	O
the	O
cholesterol	O
esters	O
and	O
triglycerides	O
.	O

Only	O
minor	O
changes	O
were	O
seen	O
in	O
the	O
phospholipids	O
.	O

The	O
changes	O
caused	O
by	O
the	O
diet	O
were	O
partly	O
reversed	O
by	O
clofibrate	O
while	O
niceritrol	O
did	O
not	O
cause	O
any	O
major	O
changes	O
of	O
the	O
fatty	O
acid	O
composition	O
.	O

Clofibrate	O
treatment	O
coincided	O
with	O
increasing	O
amounts	O
of	O
monounsaturated	O
fatty	O
acids	O
,	O
especially	O
oleate	O
(	O
18	O
:	O
1	O
)	O
,	O
in	O
the	O
cholesterol	O
esters	O
,	O
triglycerides	O
and	O
phospholipids	O
while	O
there	O
were	O
significant	O
reductions	O
of	O
the	O
content	O
of	O
linoleic	O
(	O
18	O
:	O
2	O
)	O
acid	O
in	O
both	O
the	O
cholesterol	O
esters	O
and	O
triglycerides	O
.	O

The	O
18	O
:	O
2/18	O
:	O
1	O
ratio	O
decreased	O
significantly	O
in	O
all	O
the	O
lipid	O
esters	O
analyzed	O
.	O

However	O
,	O
the	O
P/S	O
ratio	O
was	O
not	O
significantly	O
affected	O
,	O
partly	O
because	O
the	O
relative	O
content	O
of	O
saturated	O
fatty	O
acids	O
also	O
tended	O
to	O
decrease	O
during	O
clofibrate	O
treatment	O
.	O

It	O
is	O
concluded	O
that	O
addition	O
of	O
clofibrate	O
treatment	O
to	O
patients	O
who	O
are	O
on	O
a	O
diet	O
enriched	O
with	O
polyunsaturated	O
fats	O
is	O
associated	O
with	O
a	O
change	O
from	O
polyunsaturated	O
to	O
monounsaturated	O
fatty	O
acids	O
in	O
the	O
plasma	O
lipid	O
esters	O
but	O
does	O
not	O
significantly	O
effect	O
the	O
ratio	O
between	O
polyunsaturated	O
and	O
saturated	O
fatty	O
acids	O
.	O

The	O
fatty	O
acid	O
changes	O
caused	O
by	O
clofibrate	O
treatment	O
and	O
counteracted	O
by	O
an	O
increased	O
amount	O
of	O
polyunsaturated	O
fat	O
in	O
the	O
diet	O
.	O

[	O
Comparison	O
of	O
the	O
efficacy/tolerability	O
ratio	O
of	O
cibenzoline	O
and	O
propafenone	O
in	O
the	O
treatment	O
of	O
ventricular	Condition
arrhythmia	Condition
]	Condition
.	O

Cibenzoline	O
(	O
C	O
)	O
was	O
compared	O
with	O
propafenone	O
(	O
P	O
)	O
in	O
18	O
adult	O
patients	O
(	O
7	O
women	O
and	O
11	O
men	O
)	O
aged	O
50	O
+/-	O
7	O
in	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
trial	O
.	O

After	O
a	O
therapeutic	O
wash-out	O
period	O
corresponding	O
to	O
5	O
times	O
the	O
half-life	O
of	O
previous	O
anti-arrhythmic	O
drugs	O
,	O
patients	O
with	O
more	O
than	O
100	O
premature	O
ventricular	O
contractions	O
(	O
PVC	O
)	O
per	O
hour	O
in	O
two	O
24	O
hour	O
Holter	O
records	O
obtained	O
at	O
an	O
interval	O
of	O
7	O
days	O
were	O
treated	O
in	O
succession	O
and	O
after	O
randomised	O
by	O
C	O
(	O
390	O
mg/day	O
in	O
3	O
divided	O
doses	O
)	O
and	O
P	O
(	O
900	O
mg/day	O
in	O
3	O
divided	O
doses	O
)	O
for	O
a	O
period	O
of	O
two	O
weeks	O
,	O
each	O
active	O
sequence	O
being	O
followed	O
by	O
a	O
two	O
week	O
wash-out	O
period	O
.	O

Efficacy	O
(	O
based	O
upon	O
the	O
decrease	O
in	O
PVC/hour	O
in	O
a	O
24	O
hour	O
Holter	O
)	O
and	O
tolerability	O
were	O
evaluated	O
at	O
the	O
end	O
of	O
each	O
sequence	O
,	O
with	O
samples	O
drawn	O
at	O
the	O
same	O
times	O
for	O
assay	O
of	O
the	O
study	O
drugs	O
.	O

Three	O
patients	O
dropped	O
out	O
of	O
the	O
trial	O
,	O
1	O
with	O
each	O
active	O
drug	O
(	O
for	O
epigastric	O
pain	O
)	O
and	O
1	O
with	O
dummy	O
.	O

No	O
significant	O
difference	O
was	O
seen	O
between	O
the	O
two	O
drugs	O
regarding	O
the	O
decrease	O
in	O
the	O
total	O
number	O
of	O
PVC/hour	O
in	O
the	O
15	O
patients	O
completing	O
the	O
cross-over	O
protocol	O
.	O

A	O
reduction	O
in	O
PVC/hour	O
of	O
more	O
than	O
70	O
per	O
cent	O
was	O
seen	O
in	O
7	O
patients	O
with	O
C	O
and	O
in	O
9	O
patients	O
with	O
P.	O
C	O
was	O
better	O
tolerated	O
than	O
P	O
on	O
the	O
basis	O
of	O
both	O
clinical	O
and	O
electrocardiographic	O
parameters	O
.	O

One	O
patient	O
developed	O
troublesome	O
adverse	O
reactions	O
with	O
C	O
as	O
compared	O
with	O
4	O
patients	O
in	O
the	O
case	O
of	O
P.	O
A	O
more	O
than	O
20	O
per	O
cent	O
increase	O
in	O
QRS	O
was	O
seen	O
in	O
7	O
patients	O
with	O
C	O
and	O
in	O
10	O
patients	O
with	O
P	O
,	O
the	O
figures	O
for	O
PR	O
being	O
2	O
and	O
6	O
patients	O
respectively	O
.	O

One	O
patient	O
showed	O
a	O
proarrhythmic	O
effect	O
with	O
P.	O
Plasma	O
levels	O
of	O
C	O
were	O
significantly	O
higher	O
in	O
responders	O
(	O
328	O
+/-	O
149	O
ng/ml	O
)	O
than	O
in	O
non-responders	O
(	O
137	O
+/-	O
41	O
ng/ml	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
concerning	O
plasma	O
levels	O
of	O
P	O
(	O
578	O
+/-	O
477	O
ng/ml	O
compared	O
with	O
646	O
+/-	O
457	O
ng/ml	O
,	O
p	O
greater	O
than	O
0.05	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
efficacy/tolerability	O
ratio	O
in	O
this	O
population	O
with	O
a	O
low	O
risk	O
of	O
serious	O
rhythm	O
events	O
appeared	O
to	O
be	O
better	O
with	O
C	O
than	O
with	O
P	O
.	O

Sinemet	O
CR	O
in	O
Parkinson	O
's	O
disease	O
.	O

Sinemet	O
CR	O
,	O
a	O
controlled	O
release	O
carbidopa/levodopa	O
preparation	O
,	O
was	O
compared	O
to	O
conventional	O
carbidopa/levodopa	O
in	O
a	O
double	O
blind	O
,	O
placebo-controlled	O
trial	O
.	O

Comparable	O
clinical	O
benefits	O
and	O
adverse	O
effects	O
were	O
noted	O
with	O
the	O
two	O
medications	O
.	O

However	O
significantly	O
less	O
frequent	O
dosing	O
was	O
necessary	O
with	O
Sinemet	O
CR	O
.	O

Efficacy	O
of	O
different	O
gonadotropin	O
combinations	O
to	O
support	O
ovulation	O
induction	O
in	O
WHO	Condition
type	Condition
I	Condition
anovulation	Condition
infertility	Condition
:	O
clinical	O
evidences	O
of	O
human	O
recombinant	O
FSH/human	O
recombinant	O
LH	O
in	O
a	O
2:1	O
ratio	O
and	O
highly	O
purified	O
human	O
menopausal	O
gonadotropin	O
stimulation	O
protocols	O
.	O

BACKGROUND	O
The	O
World	O
Helath	O
Organization	O
(	O
WHO	O
)	O
Group	O
I	O
anovulation	O
,	O
or	O
hypogonadotropic	O
hypogonadism	O
(	O
HH	O
)	O
,	O
is	O
characterized	O
by	O
reduced	O
hypothalamic/pituitary	O
activity	O
which	O
results	O
in	O
abnormally	O
low	O
serum	O
FSH	O
and	O
LH	O
levels	O
and	O
negligible	O
estrogen	O
activity	O
.	O

AIM	O
To	O
compare	O
the	O
efficacy	O
of	O
human	O
recombinant	O
FSH	O
(	O
r-hFSH	O
)	O
plus	O
human	O
recombinant	O
LH	O
(	O
r-hLH	O
)	O
in	O
a	O
2:1	O
ratio	O
with	O
highly	O
purified	O
human	O
menopausal	O
gonadotropin	O
(	O
hMG-HP	O
)	O
urinary	O
extract	O
,	O
containing	O
LH-like	O
activity	O
,	O
in	O
women	Sex
with	O
HH	Condition
.	Condition

SUBJECTS	O
AND	O
METHODS	O
This	O
two-arm	O
randomized	O
open-label	O
study	O
included	O
35	SampleSize
HH	Condition
women	Sex
(	O
aged	O
25-36	O
yr	O
)	O
attending	O
our	O
Center	O
.	O

Eighteen	SampleSize
patients	O
received	O
150	O
IU	O
hMG-HP	O
(	O
150	O
IU	O
FSH	O
+	O
150	O
IU	O
LH-like	O
activity	O
)	O
and	O
seventeen	SampleSize
received	O
150IU	O
r-hFSH/75IU	O
rhLH	O
daily	O
for	O
a	O
maximum	O
of	O
16	O
days	O
.	O

Ovulation	O
was	O
induced	O
by	O
a	O
single	O
administration	O
of	O
hCG	O
on	O
the	O
day	O
after	O
the	O
last	O
hMG-HP	O
or	O
r-hFSH/r-hLH	O
.	O

RESULTS	O
The	O
primary	O
efficacy	O
endpoint	O
was	O
ovulation	O
induction	O
as	O
measured	O
by	O
follicle	O
?17	O
mm	O
,	O
pre-ovulatory	O
estradiol	O
(	O
E	O
2	O
)	O
?400	O
pmol/l	O
and	O
mid-luteal	O
phase	O
progesterone	O
(	O
P	O
4	O
)	O
?25	O
nmol/l	O
.	O

Secondary	O
efficacy	O
endpoints	O
included	O
E	O
2	O
levels/follicle	O
at	O
mid-cycle	O
,	O
number	O
of	O
follicles	O
at	O
mid-cycle	O
and	O
pregnancy	O
rate	O
(	O
PR	O
)	O
.	O

Following	O
a	O
total	O
of	O
70	O
cycles	O
,	O
70	O
%	O
of	O
r-hFSH/r-hLH	O
treated	O
patients	O
met	O
the	O
primary	O
endpoint	O
vs	O
88	O
%	O
in	O
hMG-HP	O
group	O
(	O
p=0.11	O
)	O
.	O

However	O
,	O
PR	O
in	O
r-hFSH/r-hLH	O
group	O
was	O
55.6	O
%	O
compared	O
to	O
23.3	O
%	O
in	O
hMG-HP	O
group	O
(	O
p=0.01	O
)	O
.	O

CONCLUSIONS	O
The	O
primary	O
endpoint	O
achievement	O
did	O
not	O
correlate	O
with	O
PR	O
.	O

This	O
study	O
has	O
shown	O
the	O
superiority	O
of	O
LH	O
compared	O
to	O
hCG	O
in	O
supporting	O
FSH-induced	O
follicular	O
development	O
in	O
HH	O
women	O
.	O

Speech	O
following	O
sign	O
language	O
training	O
in	O
autistic	Condition
children	Age
with	O
minimal	O
verbal	O
language	O
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
main	O
and	O
interaction	O
effects	O
of	O
training	O
condition	O
and	O
pretreatment-elicited	O
verbal	O
imitation	O
ability	O
when	O
predicting	O
spoken	O
language	O
use	O
during	O
language	O
training	O
of	O
60	SampleSize
minimally	Condition
verbal	Condition
autistic	Condition
children	Condition
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
Speech	O
Alone	O
,	O
Sign	O
Alone	O
,	O
Simultaneous	O
Presentation	O
of	O
Sign	O
and	O
Speech	O
,	O
and	O
Alternating	O
Presentation	O
of	O
Sign	O
and	O
Speech	O
training	O
conditions	O
.	O

Speech	O
Alone	O
,	O
Simultaneous	O
Presentation	O
,	O
and	O
Alternating	O
Presentation	O
condition	O
facilitated	O
more	O
child-initiated	O
speech	O
during	O
treatment	O
than	O
did	O
the	O
Sign	O
Alone	O
condition	O
.	O

Regardless	O
of	O
training	O
condition	O
,	O
pretreatment	O
verbal	O
imitation	O
ability	O
positively	O
predicted	O
the	O
size	O
of	O
child-initiated	O
spoken	O
vocabulary	O
observed	O
during	O
training	O
.	O

Exploratory	O
analyses	O
indicated	O
that	O
,	O
in	O
addition	O
to	O
verbal	O
imitation	O
,	O
pretreatment	O
age	O
and	O
IQ	O
may	O
also	O
predict	O
spoken	O
language	O
developed	O
during	O
training	O
.	O

Impact	O
of	O
a	O
16-community	O
trial	O
to	O
promote	O
judicious	O
antibiotic	O
use	O
in	O
Massachusetts	O
.	O

OBJECTIVES	O
Reducing	O
unnecessary	O
antibiotic	O
use	O
,	O
particularly	O
among	O
children	O
,	O
continues	O
to	O
be	O
a	O
public	O
health	O
priority	O
.	O

Previous	O
intervention	O
studies	O
have	O
been	O
limited	O
by	O
size	O
or	O
design	O
and	O
have	O
shown	O
mixed	O
results	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
impact	O
of	O
a	O
multifaceted	O
,	O
community-wide	O
intervention	O
on	O
overall	O
antibiotic	O
use	O
for	O
young	O
children	O
and	O
on	O
use	O
of	O
broad-spectrum	O
agents	O
.	O

In	O
addition	O
,	O
we	O
sought	O
to	O
compare	O
the	O
intervention	O
's	O
impact	O
on	O
commercially	O
and	O
Medicaid-insured	O
children	O
.	O

METHODS	O
We	O
conducted	O
a	O
controlled	O
,	O
community-level	O
,	O
cluster-randomized	O
trial	O
in	O
16	SampleSize
nonoverlapping	O
Massachusetts	O
communities	O
,	O
studied	O
from	O
1998	O
to	O
2003	O
.	O

During	O
3	O
years	O
,	O
we	O
implemented	O
a	O
physician	O
behavior-change	O
strategy	O
that	O
included	O
guideline	O
dissemination	O
,	O
small-group	O
education	O
,	O
frequent	O
updates	O
and	O
educational	O
materials	O
,	O
and	O
prescribing	O
feedback	O
.	O

Parents	O
received	O
educational	O
materials	O
by	O
mail	O
and	O
in	O
primary	O
care	O
practices	O
,	O
pharmacies	O
,	O
and	O
child	O
care	O
settings	O
.	O

Using	O
health-plan	O
data	O
,	O
we	O
measured	O
changes	O
in	O
antibiotics	O
dispensed	O
per	O
person-year	O
of	O
observation	O
among	O
children	Age
who	O
were	O
aged	Age
3	Age
to	Age
<	Age
72	Age
months	Age
,	O
resided	O
in	O
study	O
communities	O
,	O
and	O
were	O
insured	O
by	O
a	O
participating	O
commercial	O
health	O
plan	O
or	O
Medicaid	O
.	O

RESULTS	O
The	O
data	O
include	O
223,135	SampleSize
person-years	O
of	O
observation	O
.	O

Antibiotic-use	O
rates	O
at	O
baseline	O
were	O
2.8	O
,	O
1.7	O
,	O
and	O
1.4	O
antibiotics	O
per	O
person-year	O
among	O
those	O
aged	O
3	O
to	O
<	O
24	O
,	O
24	O
to	O
<	O
48	O
,	O
and	O
48	O
to	O
<	O
72	O
months	O
,	O
respectively	O
.	O

We	O
observed	O
a	O
substantial	O
downward	O
trend	O
in	O
antibiotic	O
prescribing	O
,	O
even	O
in	O
the	O
absence	O
of	O
intervention	O
.	O

The	O
intervention	O
had	O
no	O
additional	O
effect	O
among	O
children	O
aged	O
3	O
to	O
<	O
24	O
months	O
but	O
was	O
responsible	O
for	O
a	O
4.2	O
%	O
decrease	O
among	O
those	O
aged	O
24	O
to	O
<	O
48	O
months	O
and	O
a	O
6.7	O
%	O
decrease	O
among	O
those	O
aged	O
48	O
to	O
<	O
72	O
months	O
.	O

The	O
intervention	O
effect	O
was	O
greater	O
among	O
Medicaid-insured	O
children	O
and	O
for	O
broad-spectrum	O
agents	O
.	O

CONCLUSIONS	O
A	O
sustained	O
,	O
multifaceted	O
,	O
community-level	O
intervention	O
was	O
only	O
modestly	O
successful	O
at	O
decreasing	O
overall	O
antibiotic	O
use	O
beyond	O
substantial	O
secular	O
trends	O
.	O

The	O
more	O
robust	O
impact	O
among	O
Medicaid-insured	O
children	O
and	O
for	O
specific	O
medication	O
classes	O
provides	O
an	O
argument	O
for	O
specific	O
targeting	O
of	O
resources	O
for	O
patient	O
and	O
physician	O
behavior	O
change	O
.	O

Lack	O
of	O
effect	O
of	O
a	O
low-fat	O
,	O
high-fiber	O
diet	O
on	O
the	O
recurrence	O
of	O
colorectal	O
adenomas	O
.	O

Polyp	O
Prevention	O
Trial	O
Study	O
Group	O
.	O

BACKGROUND	O
We	O
tested	O
the	O
hypothesis	O
that	O
dietary	O
intervention	O
can	O
inhibit	O
the	O
development	O
of	O
recurrent	O
colorectal	O
adenomas	O
,	O
which	O
are	O
precursors	O
of	O
most	O
large-bowel	O
cancers	O
.	O

METHODS	O
We	O
randomly	O
assigned	O
2079	SampleSize
men	Sex
and	O
women	Sex
who	O
were	O
35	Age
years	O
of	O
age	O
or	O
older	O
and	O
who	O
had	O
had	O
one	O
or	O
more	O
histologically	O
confirmed	O
colorectal	Condition
adenomas	Condition
removed	O
within	O
six	O
months	O
before	O
randomization	O
to	O
one	O
of	O
two	O
groups	O
:	O
an	O
intervention	O
group	O
given	O
intensive	O
counseling	O
and	O
assigned	O
to	O
follow	O
a	O
diet	O
that	O
was	O
low	O
in	O
fat	O
(	O
20	O
percent	O
of	O
total	O
calories	O
)	O
and	O
high	O
in	O
fiber	O
(	O
18	O
g	O
of	O
dietary	O
fiber	O
per	O
1000	O
kcal	O
)	O
and	O
fruits	O
and	O
vegetables	O
(	O
3.5	O
servings	O
per	O
1000	O
kcal	O
)	O
,	O
and	O
a	O
control	O
group	O
given	O
a	O
standard	O
brochure	O
on	O
healthy	O
eating	O
and	O
assigned	O
to	O
follow	O
their	O
usual	O
diet	O
.	O

Subjects	O
entered	O
the	O
study	O
after	O
undergoing	O
complete	O
colonoscopy	O
and	O
removal	O
of	O
adenomatous	O
polyps	O
;	O
they	O
remained	O
in	O
the	O
study	O
for	O
approximately	O
four	O
years	O
,	O
undergoing	O
colonoscopy	O
one	O
and	O
four	O
years	O
after	O
randomization	O
.	O

RESULTS	O
A	O
total	O
of	O
1905	SampleSize
of	O
the	O
randomized	O
subjects	O
(	O
91.6	O
percent	O
)	O
completed	O
the	O
study	O
.	O

Of	O
the	O
958	O
subjects	O
in	O
the	O
intervention	O
group	O
and	O
the	O
947	O
in	O
the	O
control	O
group	O
who	O
completed	O
the	O
study	O
,	O
39.7	O
percent	O
and	O
39.5	O
percent	O
,	O
respectively	O
,	O
had	O
at	O
least	O
one	O
recurrent	O
adenoma	O
;	O
the	O
unadjusted	O
risk	O
ratio	O
was	O
1.00	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.90	O
to	O
1.12	O
)	O
.	O

Among	O
subjects	O
with	O
recurrent	O
adenomas	O
,	O
the	O
mean	O
(	O
+/-SE	O
)	O
number	O
of	O
such	O
lesions	O
was	O
1.85+/-0.08	O
in	O
the	O
intervention	O
group	O
and	O
1.84+/-0.07	O
in	O
the	O
control	O
group	O
.	O

The	O
rate	O
of	O
recurrence	O
of	O
large	O
adenomas	O
(	O
with	O
a	O
maximal	O
diameter	O
of	O
at	O
least	O
1	O
cm	O
)	O
and	O
advanced	O
adenomas	O
(	O
defined	O
as	O
lesions	O
that	O
had	O
a	O
maximal	O
diameter	O
of	O
at	O
least	O
1	O
cm	O
or	O
at	O
least	O
25	O
percent	O
villous	O
elements	O
or	O
evidence	O
of	O
high-grade	O
dysplasia	O
,	O
including	O
carcinoma	O
)	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
Adopting	O
a	O
diet	O
that	O
is	O
low	O
in	O
fat	O
and	O
high	O
in	O
fiber	O
,	O
fruits	O
,	O
and	O
vegetables	O
does	O
not	O
influence	O
the	O
risk	O
of	O
recurrence	O
of	O
colorectal	O
adenomas	O
.	O

The	O
tension-free	O
hernioplasty	O
in	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
The	O
tension-free	O
hernioplasty	O
as	O
introduced	O
by	O
Lichtenstein	O
has	O
gained	O
increasing	O
acceptance	O
during	O
the	O
last	O
decade	O
although	O
the	O
technique	O
has	O
not	O
been	O
evaluated	O
in	O
a	O
randomized	O
trial	O
.	O

METHODS	O
This	O
randomized	O
study	O
compares	O
the	O
2-year	O
follow-up	O
results	O
after	O
102	SampleSize
tension-free	O
hernioplasties	Condition
with	O
implantation	O
of	O
a	O
prolene	O
mesh	O
in	O
all	O
groin	Condition
hernias	Condition
to	O
53	SampleSize
Cooper	O
ligament	O
repairs	O
in	O
direct	Condition
hernias	Condition
and	O
53	SampleSize
abdominal	O
ring	O
repairs	O
in	O
indirect	Condition
hernias	Condition
.	O

RESULTS	O
After	O
tension-free	O
repairs	O
five	O
hernias	O
recurred	O
(	O
5	O
%	O
)	O
,	O
and	O
after	O
either	O
Cooper	O
ligament	O
or	O
abdominal	O
ring	O
repair	O
,	O
16	O
recurrences	O
were	O
found	O
(	O
15	O
%	O
)	O
(	O
P	O
=	O
0.025	O
)	O
.	O

No	O
indirect	O
hernias	O
recurred	O
after	O
a	O
tension-free	O
repair	O
;	O
2	O
recurred	O
after	O
abdominal	O
ring	O
repair	O
(	O
4	O
%	O
;	O
NS	O
)	O
.	O

The	O
recurrence	O
rate	O
after	O
tension-free	O
repairs	O
for	O
primary	O
direct	O
inguinal	O
hernias	O
was	O
7	O
%	O
as	O
compared	O
with	O
30	O
%	O
after	O
Cooper	O
ligament	O
repair	O
(	O
P	O
=	O
0.0081	O
)	O
.	O

No	O
difference	O
in	O
complication	O
rate	O
between	O
the	O
tested	O
methods	O
was	O
found	O
.	O

CONCLUSION	O
Recurrence	O
rate	O
is	O
reduced	O
to	O
one-third	O
after	O
tension-free	Condition
herniotomies	Condition
as	O
compared	O
with	O
the	O
conventionel	O
herniotomies	O
without	O
increase	O
in	O
complication	O
rate	O
.	O

Videotaped	O
training	O
in	O
alcohol	O
counseling	O
for	O
obstetric	O
care	O
practitioners	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
feasibility	O
of	O
videotaped	O
training	O
for	O
obstetric	O
care	O
practitioners	O
in	O
motivational	O
interviewing	O
skills	O
that	O
could	O
be	O
used	O
in	O
brief	O
patient	O
consultations	O
on	O
problem	O
drinking	O
.	O

METHODS	O
Thirty	O
health	O
care	O
practitioners	O
participated	O
in	O
a	O
clinical	O
trial	O
using	O
a	O
20-minute	O
videotape	O
to	O
instruct	O
them	O
in	O
motivational	O
interviewing	O
.	O

Participants	O
engaged	O
in	O
a	O
pretest	O
roleplay	O
with	O
an	O
actress	O
playing	O
a	O
drinking	O
pregnant	O
woman	O
.	O

Those	O
randomly	O
assigned	O
to	O
the	O
experimental	O
condition	O
watched	O
the	O
motivational	O
interviewing	O
videotape	O
.	O

Control	O
condition	O
participants	O
watched	O
a	O
20-minute	O
docudrama	O
of	O
a	O
pregnant	O
problem	O
drinker	O
.	O

Both	O
groups	O
then	O
engaged	O
in	O
a	O
post-test	O
roleplay	O
similar	O
to	O
the	O
pretest	O
.	O

Behavioral	O
ratings	O
of	O
the	O
roleplays	O
and	O
participant	O
evaluations	O
of	O
the	O
motivational	O
interviewing	O
video	O
constituted	O
the	O
outcome	O
measures	O
.	O

RESULTS	O
Participant	O
evaluations	O
indicated	O
that	O
the	O
training	O
video	O
was	O
clear	O
in	O
explaining	O
and	O
demonstrating	O
the	O
principles	O
and	O
skills	O
of	O
motivational	O
interviewing	O
.	O

Change	O
in	O
behavioral	O
ratings	O
from	O
pretest	O
to	O
post-test	O
showed	O
significant	O
differences	O
in	O
motivational	O
interviewing	O
skills	O
between	O
the	O
experimental	O
and	O
control	O
groups	O
.	O

Obstetric	O
care	O
practitioners	O
who	O
viewed	O
the	O
training	O
video	O
were	O
rated	O
as	O
showing	O
greater	O
empathy	O
,	O
minimizing	O
patient	O
defensiveness	O
,	O
and	O
supporting	O
women	O
's	O
beliefs	O
in	O
their	O
ability	O
to	O
change	O
.	O

CONCLUSION	O
Obstetric	O
care	O
practitioners	O
can	O
improve	O
their	O
alcohol	O
intervention	O
skills	O
through	O
the	O
use	O
of	O
a	O
20-minute	O
videotaped	O
instruction	O
in	O
motivational	O
interviewing	O
.	O

Clinicians	O
who	O
improve	O
their	O
skills	O
in	O
motivational	O
interviewing	O
can	O
intervene	O
more	O
effectively	O
with	O
their	O
drinking	O
pregnant	O
patients	O
.	O

Using	O
motivational	O
interviewing	O
with	O
this	O
population	O
holds	O
promise	O
for	O
helping	O
prevent	O
alcohol-related	O
health	O
problems	O
.	O

Randomized	O
controlled	O
trial	O
to	O
compare	O
the	O
dose	O
of	O
adjuvant	O
chemotherapy	O
after	O
curative	O
resection	O
of	O
hepatocellular	Condition
carcinoma	Condition
.	O

BACKGROUND	O
AND	O
AIM	O
Adjuvant	O
locoregional	O
chemotherapy	O
has	O
been	O
shown	O
to	O
be	O
useful	O
to	O
prevent	O
recurrence	O
after	O
curative	O
resection	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
in	O
some	O
retrospective	O
studies	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
dose	O
effect	O
in	O
the	O
prevention	O
of	O
tumor	O
recurrence	O
.	O

METHODS	O
A	O
prospective	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
patients	O
with	O
curative	O
resection	O
of	O
HCC	Condition
;	O
they	O
were	O
given	O
either	O
one	O
intra-arterial	O
dose	O
of	O
cisplatin/lipiodol	O
,	O
or	O
received	O
four	O
doses	O
,	O
once	O
every	O
3	O
months	O
.	O

The	O
rates	O
of	O
recurrence	O
,	O
disease-free	O
and	O
overall	O
survival	O
were	O
compared	O
.	O

RESULTS	O
During	O
a	O
median	O
follow	O
up	O
of	O
818	O
days	O
,	O
21	SampleSize
patients	O
received	O
one	O
dose	O
and	O
19	SampleSize
received	O
four	O
doses	O
,	O
with	O
10	O
(	O
47.6	O
%	O
)	O
and	O
eight	O
(	O
42.1	O
%	O
)	O
recurrences	O
,	O
respectively	O
.	O

The	O
1-year	O
,	O
2-year	O
and	O
3-year	O
disease-free	O
survival	O
rates	O
were	O
71	O
%	O
,	O
54	O
%	O
and	O
44	O
%	O
for	O
the	O
one-dose	O
group	O
and	O
74	O
%	O
,	O
60	O
%	O
and	O
40	O
%	O
for	O
the	O
four-dose	O
group	O
(	O
P	O
=	O
0.78	O
)	O
.	O

The	O
respective	O
overall	O
survival	O
rates	O
were	O
85	O
%	O
,	O
74	O
%	O
,	O
55	O
%	O
and	O
84	O
%	O
,	O
71	O
%	O
,	O
40	O
%	O
(	O
P	O
=	O
0.64	O
)	O
.	O

The	O
only	O
prognostic	O
factor	O
was	O
presence	O
of	O
vascular	O
permeation	O
.	O

The	O
side-effects	O
were	O
mild	O
and	O
tolerable	O
.	O

CONCLUSIONS	O
There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
survival	O
rates	O
between	O
the	O
two	O
groups	O
.	O

Adjuvant	O
chemotherapy	O
may	O
not	O
be	O
useful	O
.	O

Effect	O
of	O
antipyretic	O
drugs	O
in	O
children	Age
with	O
malaria	Condition
.	O

A	O
comparison	O
of	O
different	O
antipyretics	O
in	O
children	O
with	O
malaria	O
showed	O
a	O
small	O
effect	O
of	O
naproxen	O
,	O
but	O
not	O
of	O
metamizol	O
,	O
on	O
the	O
reduction	O
of	O
fever	O
peaks	O
.	O

Antipyretic	O
treatment	O
had	O
no	O
effect	O
on	O
fever	O
clearance	O
and	O
therefore	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
malaria	O
.	O

Comparison	O
of	O
quality	O
of	O
life	O
,	O
work	O
productivity	O
and	O
medical	O
resource	O
utilization	O
of	O
peginterferon	O
alpha	O
2a	O
vs	O
the	O
combination	O
of	O
interferon	O
alpha	O
2b	O
plus	O
ribavirin	O
as	O
initial	O
treatment	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C.	O
The	O
on-treatment	O
impact	O
of	O
interferon-based	O
therapies	O
on	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
,	O
work	O
productivity	O
,	O
and	O
medical	O
resource	O
utilization	O
has	O
not	O
been	O
systematically	O
studied	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
treatment	O
with	O
peginterferon	O
alpha	O
(	O
pegIFNalpha	O
)	O
2a	O
monotherapy	O
and	O
the	O
combination	O
of	O
interferon	O
alpha	O
(	O
IFNalpha	O
)	O
2b	O
plus	O
ribavirin	O
(	O
RBV	O
)	O
on	O
health-related	O
QOL	O
,	O
work	O
productivity	O
and	O
resource	O
utilization	O
.	O

A	O
total	O
of	O
412	SampleSize
patients	O
with	O
hepatitis	Condition
C	Condition
infection	Condition
were	O
randomized	O
to	O
open-label	O
treatment	O
with	O
either	O
pegIFNalpha	O
2a	O
(	O
n	O
=	O
206	O
)	O
or	O
IFNalpha	O
2b/RBV	O
(	O
n	O
=	O
206	O
)	O
.	O

PegIFNalpha	O
2a	O
was	O
administered	O
subcutaneously	O
at	O
a	O
dose	O
of	O
180	O
microg	O
once	O
weekly	O
for	O
48	O
weeks	O
;	O
and	O
IFNalpha	O
2b/RBV	O
at	O
doses	O
of	O
3	O
MU	O
thrice	O
weekly	O
subcutaneously	O
and	O
1000-1200	O
mg/day	O
orally	O
.	O

Outcome	O
measures	O
included	O
the	O
SF-36	O
Health	O
Survey	O
Questionnaire	O
and	O
additional	O
generic	O
and	O
specific	O
scales	O
.	O

During	O
treatment	O
,	O
for	O
all	O
SF-36	O
summary	O
and	O
Hepatitis	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
HQLQ	O
)	O
-specific	O
scales	O
,	O
the	O
pegIFNalpha	O
2a	O
group	O
experienced	O
less	O
impairment	O
than	O
did	O
the	O
IFNalpha	O
2b/RBV	O
patients	O
.	O

The	O
between-treatment	O
differences	O
were	O
significant	O
for	O
many	O
of	O
the	O
scores	O
particularly	O
in	O
the	O
first	O
24	O
weeks	O
of	O
treatment	O
.	O

Across	O
all	O
measures	O
of	O
work	O
functioning	O
and	O
productivity	O
at	O
each	O
visit	O
,	O
patients	O
randomized	O
to	O
pegIFNalpha	O
2a	O
treatment	O
showed	O
less	O
impairment	O
relative	O
to	O
the	O
group	O
treated	O
with	O
IFNalpha	O
2b/RBV	O
.	O

Hence	O
treatment	O
with	O
pegIFNalpha	O
2a	O
relative	O
to	O
IFNalpha	O
2b/RBV	O
minimizes	O
the	O
adverse	O
impact	O
of	O
therapy	O
on	O
health-related	O
QOL	O
.	O

Patients	O
randomized	O
to	O
pegIFNalpha	O
2a	O
had	O
improved	O
work	O
productivity	O
,	O
less	O
activity	O
impairment	O
,	O
decreased	O
need	O
for	O
prescription	O
drugs	O
to	O
treat	O
adverse	O
effects	O
,	O
and	O
better	O
adherence	O
to	O
therapy	O
.	O

Phenobarbital	O
compared	O
with	O
phenytoin	O
for	O
the	O
treatment	O
of	O
neonatal	O
seizures	O
.	O

BACKGROUND	O
Seizures	O
occur	O
in	O
1	O
to	O
2	O
percent	O
of	O
neonates	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

The	O
treatment	O
is	O
usually	O
with	O
either	O
phenobarbital	O
or	O
phenytoin	O
,	O
but	O
the	O
efficacy	O
of	O
the	O
two	O
drugs	O
has	O
not	O
been	O
compared	O
directly	O
.	O

METHODS	O
From	O
1990	O
to	O
1995	O
,	O
we	O
studied	O
59	O
neonates	O
with	O
seizures	O
that	O
were	O
confirmed	O
by	O
electroencephalography	O
.	O

The	O
neonates	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
phenobarbital	O
or	O
phenytoin	O
intravenously	O
,	O
at	O
doses	O
sufficient	O
to	O
achieve	O
free	O
plasma	O
concentrations	O
of	O
25	O
microg	O
per	O
milliliter	O
for	O
phenobarbital	O
and	O
3	O
microg	O
per	O
milliliter	O
for	O
phenytoin	O
.	O

Neonates	O
whose	O
seizures	O
were	O
not	O
controlled	O
by	O
the	O
assigned	O
drug	O
were	O
then	O
treated	O
with	O
both	O
drugs	O
.	O

Seizure	O
control	O
was	O
assessed	O
by	O
electroencephalographic	O
criteria	O
.	O

RESULTS	O
Seizures	O
were	O
controlled	O
in	O
13	O
of	O
the	O
30	O
neonates	O
assigned	O
to	O
receive	O
phenobarbital	O
(	O
43	O
percent	O
)	O
and	O
13	O
of	O
the	O
29	O
neonates	O
assigned	O
to	O
receive	O
phenytoin	O
(	O
45	O
percent	O
;	O
P=1.00	O
)	O
.	O

When	O
combined	O
treatment	O
is	O
considered	O
,	O
seizure	O
control	O
was	O
achieved	O
in	O
17	O
(	O
57	O
percent	O
)	O
of	O
the	O
neonates	O
assigned	O
to	O
receive	O
phenobarbital	O
first	O
and	O
18	O
(	O
62	O
percent	O
)	O
of	O
those	O
assigned	O
to	O
receive	O
phenytoin	O
first	O
(	O
P=0.67	O
)	O
.	O

The	O
severity	O
of	O
the	O
seizures	O
was	O
a	O
stronger	O
predictor	O
of	O
the	O
success	O
of	O
treatment	O
than	O
was	O
the	O
assigned	O
agent	O
.	O

Neonates	O
with	O
mild	O
seizures	O
or	O
with	O
seizures	O
that	O
were	O
decreasing	O
in	O
severity	O
before	O
treatment	O
were	O
more	O
likely	O
to	O
have	O
their	O
seizures	O
end	O
,	O
regardless	O
of	O
the	O
treatment	O
assignment	O
.	O

CONCLUSIONS	O
Phenobarbital	O
and	O
phenytoin	O
are	O
equally	O
but	O
incompletely	O
effective	O
as	O
anticonvulsants	O
in	O
neonates	O
.	O

With	O
either	O
drug	O
given	O
alone	O
,	O
the	O
seizures	O
were	O
controlled	O
in	O
fewer	O
than	O
half	O
of	O
the	O
neonates	O
.	O

Randomised	O
trial	O
of	O
efficacy	O
and	O
safety	O
of	O
oral	O
ganciclovir	O
in	O
the	O
prevention	O
of	O
cytomegalovirus	O
disease	O
in	O
liver-transplant	Condition
recipients	O
.	O

The	O
Oral	O
Ganciclovir	O
International	O
Transplantation	O
Study	O
Group	O
[	O
corrected	O
]	O
.	O

BACKGROUND	O
Cytomegalovirus	O
(	O
CMV	O
)	O
disease	O
is	O
a	O
frequent	O
cause	O
of	O
serious	O
morbidity	O
after	O
solid-organ	O
transplantation	O
.	O

The	O
prophylactic	O
regimens	O
used	O
to	O
prevent	O
CMV	O
infection	O
and	O
disease	O
have	O
shown	O
limited	O
benefit	O
in	O
seronegative	O
recipients	O
.	O

We	O
studied	O
the	O
safety	O
and	O
efficacy	O
of	O
oral	O
ganciclovir	O
in	O
the	O
prevention	O
of	O
CMV	O
disease	O
following	O
orthotopic	O
liver	O
transplantation	O
.	O

METHODS	O
Between	O
December	O
,	O
1993	O
,	O
and	O
April	O
,	O
1995	O
,	O
304	SampleSize
liver-transplant	O
recipients	O
were	O
randomised	O
to	O
receive	O
oral	O
ganciclovir	O
1000	O
mg	O
or	O
matching	O
placebo	O
three	O
times	O
a	O
day	O
.	O

Seronegative	O
recipients	O
of	O
seronegative	Condition
livers	Condition
were	O
excluded	O
.	O

Study	O
drug	O
was	O
administered	O
as	O
soon	O
as	O
the	O
patient	O
was	O
able	O
to	O
take	O
medication	O
by	O
mouth	O
(	O
no	O
later	O
than	O
day	O
10	O
)	O
until	O
the	O
98th	O
day	O
after	O
transplantation	O
.	O

Patients	O
were	O
assessed	O
at	O
specified	O
times	O
throughout	O
the	O
first	O
6	O
months	O
after	O
surgery	O
for	O
evidence	O
of	O
CMV	O
infection	O
,	O
CMV	O
disease	O
,	O
rejection	O
,	O
opportunistic	O
infections	O
,	O
and	O
possible	O
drug	O
toxicity	O
.	O

FINDINGS	O
The	O
Kaplan-Meier	O
estimate	O
of	O
the	O
6-month	O
incidence	O
of	O
CMV	O
disease	O
was	O
29	O
(	O
18.9	O
%	O
)	O
of	O
154	O
in	O
the	O
placebo	O
group	O
,	O
compared	O
with	O
seven	O
(	O
4.8	O
%	O
)	O
of	O
150	O
in	O
the	O
ganciclovir	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

In	O
the	O
high-risk	O
group	O
of	O
seronegative	O
recipients	O
(	O
R-	O
)	O
of	O
seropositive	O
livers	O
(	O
D+	O
)	O
,	O
incidence	O
of	O
CMV	O
disease	O
was	O
11	O
(	O
44.0	O
%	O
)	O
of	O
25	O
in	O
the	O
placebo	O
group	O
,	O
three	O
(	O
14.8	O
%	O
)	O
of	O
21	O
in	O
the	O
ganciclovir	O
group	O
(	O
p	O
=	O
0.02	O
)	O
.	O

Significant	O
benefit	O
was	O
also	O
observed	O
in	O
those	O
receiving	O
antibodies	O
to	O
lymphocytes	O
,	O
where	O
the	O
incidence	O
of	O
CMV	O
disease	O
was	O
12	O
(	O
32.9	O
%	O
)	O
of	O
37	O
in	O
the	O
placebo	O
group	O
and	O
two	O
(	O
4.6	O
%	O
)	O
of	O
44	O
in	O
the	O
ganciclovir	O
group	O
(	O
p	O
=	O
0.002	O
)	O
.	O

Oral	O
ganciclovir	O
reduced	O
the	O
incidence	O
of	O
CMV	O
infection	O
(	O
placebo	O
79	O
[	O
51.5	O
%	O
]	O
of	O
154	O
;	O
ganciclovir	O
37	O
[	O
24.5	O
%	O
]	O
of	O
150	O
;	O
p	O
<	O
0.001	O
)	O
and	O
also	O
reduced	O
symptomatic	O
herpes-simplex	O
infections	O
(	O
Kaplan-Meier	O
estimates	O
:	O
placebo	O
36	O
[	O
23.5	O
%	O
]	O
of	O
154	O
;	O
ganciclovir	O
five	O
[	O
3.5	O
%	O
]	O
of	O
150	O
;	O
p	O
<	O
0.001	O
)	O
.	O

INTERPRETATION	O
Oral	O
ganciclovir	O
is	O
a	O
safe	O
and	O
effective	O
method	O
for	O
the	O
prevention	O
of	O
CMV	O
disease	O
after	O
orthotopic	O
liver	Condition
transplantation	Condition
.	O

Dose	O
dependent	O
pharmacokinetics	O
of	O
theophylline	O
:	O
Michaelis-Menten	O
parameters	O
for	O
its	O
major	O
metabolic	O
pathways	O
.	O

Dose	O
Dependency	O
for	O
pharmacokinetics	O
of	O
theophylline	O
and	O
the	O
formation	O
of	O
its	O
major	O
metabolites	O
,	O
3-methylxanthine	O
(	O
3-MX	O
)	O
;	O
1-methyluric	O
acid	O
(	O
1-MU	O
)	O
;	O
1,3-dimethyluric	O
acid	O
(	O
DMU	O
)	O
,	O
were	O
examined	O
by	O
administering	O
three	O
single	O
oral	O
doses	O
(	O
250	O
,	O
375	O
,	O
500	O
mg	O
)	O
of	O
theophylline	O
to	O
six	SampleSize
healthy	O
adult	Age
volunteers	O
.	O

The	O
serum	O
and	O
urine	O
concentrations	O
of	O
theophylline	O
and	O
the	O
metabolites	O
in	O
serum	O
and	O
urine	O
were	O
determined	O
by	O
high-performance	O
liquid	O
chromatography	O
.	O

Total	O
clearance	O
of	O
theophylline	O
decreased	O
and	O
its	O
half	O
life	O
increased	O
over	O
the	O
range	O
of	O
doses	O
administered	O
(	O
p	O
<	O
0.01	O
)	O
.	O

There	O
was	O
a	O
significant	O
dose	O
related	O
decrease	O
in	O
the	O
fractional	O
recovery	O
of	O
3-MX	O
and	O
1-MU	O
(	O
p	O
<	O
0.001	O
)	O
and	O
a	O
dose	O
related	O
increase	O
in	O
fractional	O
excretion	O
of	O
DMU	O
and	O
unchanged	O
theophylline	O
(	O
p	O
<	O
0.01	O
and	O
p	O
<	O
0.001	O
respectively	O
)	O
.	O

No	O
significant	O
dose	O
related	O
changes	O
were	O
observed	O
in	O
the	O
renal	O
clearance	O
of	O
3-MX	O
,	O
1-MU	O
and	O
DMU	O
,	O
indicating	O
linear	O
urinary	O
excretion	O
kinetics	O
of	O
the	O
metabolites	O
.	O

Theophylline	O
metabolic	O
clearance	O
to	O
3-MX	O
as	O
well	O
as	O
to	O
1-MU	O
decreased	O
with	O
increasing	O
dose	O
but	O
clearance	O
to	O
DMU	O
remained	O
unnaffected	O
by	O
the	O
size	O
of	O
dose	O
.	O

The	O
individual	O
Michaelis-Menten	O
parameters	O
Km	O
and	O
Vmax	O
were	O
estimated	O
for	O
six	O
subjects	O
receiving	O
three	O
different	O
single	O
doses	O
.	O

The	O
Km	O
values	O
for	O
theophylline	O
metabolism	O
to	O
3-MX	O
,	O
1-MU	O
and	O
DMU	O
were	O
2.4+/-0.6	O
,	O
5.1+/-1.8+/-	O
and	O
112.3+/-36.8	O
mg/L	O
respectively	O
and	O
the	O
Vmax	O
values	O
were	O
3.5+/-0.7	O
,	O
7.5+/-2.6	O
and	O
112.3+/-36.8	O
mg/hr	O
respectively	O
.	O

The	O
Km	O
values	O
for	O
the	O
N-demethylation	O
pathways	O
(	O
3MX	O
and	O
1-MU	O
)	O
were	O
lower	O
corresponding	O
to	O
therapeutic	O
serum	O
concentrations	O
of	O
drug	O
.	O

These	O
results	O
suggest	O
that	O
the	O
elimination	O
kinetics	O
of	O
theophylline	O
is	O
nonlinear	O
in	O
the	O
human	O
in	O
the	O
therapeutic	O
range	O
of	O
serum	O
concenntrations	O
and	O
can	O
be	O
explained	O
by	O
saturable	O
formation	O
kinetics	O
of	O
3-MX	O
and	O
1-MU	O
.	O

In	O
contrast	O
to	O
previous	O
studies	O
we	O
did	O
n't	O
find	O
obvious	O
indication	O
for	O
nonlinear	O
formation	O
of	O
DMU	O
at	O
therapeutic	O
concentration	O
range	O
.	O

The	O
efficacy	O
of	O
early	O
continuous	O
positive	O
airway	O
pressure	O
therapy	O
in	O
patients	O
with	O
acute	Condition
cardiogenic	Condition
pulmonary	Condition
edema	Condition
.	Condition

Although	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
therapy	O
using	O
a	O
face	O
mask	O
is	O
known	O
to	O
improve	O
oxygenation	O
,	O
the	O
intrapulmonary	O
shunt	O
reduction	O
remains	O
unsettled	O
.	O

Our	O
study	O
was	O
designed	O
to	O
explore	O
this	O
issue	O
.	O

From	O
1985	O
to	O
1987	O
80	SampleSize
patients	O
with	O
acute	Condition
cardiogenic	Condition
pulmonary	Condition
edema	Condition
were	O
randomly	O
chosen	O
to	O
receive	O
either	O
serial	O
CPAP	O
therapy	O
or	O
high-flow	O
face	O
mask	O
oxygen	O
therapy	O
without	O
CPAP	O
(	O
control	O
)	O
for	O
the	O
purpose	O
of	O
evaluating	O
the	O
efficacy	O
of	O
CPAP	O
therapy	O
.	O

After	O
screening	O
for	O
exclusion	O
,	O
only	O
55	SampleSize
patients	O
were	O
included	O
in	O
the	O
first	O
3-hour	O
investigation	O
period	O
.	O

PaO2	O
in	O
the	O
CPAP	O
group	O
showed	O
a	O
significant	O
increase	O
by	O
the	O
end	O
of	O
the	O
initial	O
study	O
;	O
whereas	O
intrapulmonary	O
shunt	O
and	O
alveolar-arterial	O
oxygen	O
tension	O
gradient	O
AaDO2	O
revealed	O
simultaneously	O
a	O
significant	O
reduction	O
.	O

Conversely	O
,	O
neither	O
PaO2	O
nor	O
intrapulmonary	O
shunt	O
(	O
or	O
AaDO2	O
)	O
in	O
the	O
control	O
group	O
demonstrated	O
any	O
significant	O
beneficial	O
changes	O
.	O

As	O
for	O
cardiovascular	O
function	O
,	O
only	O
the	O
CPAP	O
therapy	O
achieved	O
a	O
significant	O
reduction	O
in	O
rate	O
pressure	O
product	O
in	O
contrast	O
to	O
the	O
control	O
(	O
face	O
mask	O
)	O
therapy	O
alone	O
.	O

In	O
terms	O
of	O
therapeutic	O
failure	O
,	O
10	O
patients	O
in	O
the	O
control	O
group	O
failed	O
.	O

However	O
,	O
in	O
the	O
CPAP	O
group	O
only	O
5	O
patients	O
had	O
failed	O
at	O
the	O
end	O
of	O
the	O
first	O
3-hour	O
study	O
period	O
.	O

Overall	O
,	O
the	O
cumulative	O
therapeutic	O
failure	O
rate	O
was	O
28	O
%	O
in	O
the	O
CPAP	O
group	O
and	O
60	O
%	O
in	O
the	O
control	O
group	O
during	O
a	O
6-hour	O
observation	O
study	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
in	O
24-hour	O
hospital	O
mortality	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Comparison	O
of	O
the	O
antiemetic	O
effect	O
of	O
ramosetron	O
and	O
combined	O
ramosetron	O
and	O
midazolam	O
in	O
children	O
:	O
a	O
double-blind	O
,	O
randomised	O
clinical	O
trial	O
.	O

CONTEXT	O
Postoperative	O
nausea	O
and	O
vomiting	O
remains	O
a	O
clinically	O
important	O
problem	O
after	O
strabismus	O
surgery	O
in	O
children	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
benefit	O
of	O
adding	O
midazolam	O
to	O
ramosetron	O
on	O
the	O
incidence	O
of	O
postoperative	O
nausea	O
,	O
retching	O
or	O
vomiting	O
and	O
on	O
the	O
incidence	O
of	O
postoperative	O
agitation	O
.	O

DESIGN	O
A	O
randomised	O
,	O
double-blind	O
comparison	O
.	O

SETTING	O
The	O
operating	O
theatre	O
suite	O
and	O
day	O
care	O
unit	O
of	O
Seoul	O
National	O
University	O
Hospital	O
.	O

The	O
study	O
period	O
was	O
January	O
to	O
December	O
2010	O
.	O

PATIENTS	O
In	O
total	O
,	O
405	O
paediatric	O
patients	O
(	O
aged	O
4-12	O
years	O
)	O
undergoing	O
strabismus	O
surgery	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
,	O
ramosetron	O
or	O
ramosetron	O
with	O
midazolam	O
.	O

INTERVENTION	O
Patients	O
received	O
either	O
ramosetron	O
6	O
?g	O
kg	O
or	O
ramosetron	O
6	O
?g	O
kg	O
and	O
midazolam	O
0.1	O
mg	O
kg	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
incidences	O
of	O
nausea	O
,	O
retching	O
or	O
vomiting	O
in	O
the	O
first	O
48	O
h	O
after	O
surgery	O
,	O
and	O
the	O
incidence	O
of	O
emergence	O
agitation	O
in	O
the	O
post-anaesthetic	O
care	O
unit	O
.	O

RESULT	O
The	O
incidences	O
of	O
nausea	O
,	O
retching	O
or	O
vomiting	O
during	O
the	O
first	O
and	O
second	O
24-h	O
periods	O
after	O
surgery	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

There	O
was	O
a	O
small	O
,	O
clinically	O
insignificant	O
reduction	O
in	O
delirium	O
scores	O
in	O
the	O
ramosetron	O
with	O
midazolam	O
group	O
.	O

CONCLUSION	O
Adding	O
midazolam	O
to	O
ramosetron	O
had	O
no	O
advantages	O
over	O
ramosetron	O
alone	O
in	O
reducing	O
the	O
incidence	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
in	O
children	O
undergoing	O
strabismus	O
surgery	O
.	O

Types	O
of	O
parent	Condition
verbal	O
responsiveness	O
that	O
predict	O
language	O
in	O
young	Condition
children	Condition
with	Condition
autism	Condition
spectrum	Condition
disorder	Condition
.	Condition

PURPOSE	O
This	O
study	O
examined	O
short-term	O
predictive	O
associations	O
between	O
5	O
different	O
types	O
of	O
parent	O
verbal	O
responsiveness	O
and	O
later	O
spoken	O
vocabulary	O
for	O
32	O
young	O
children	O
with	O
a	O
confirmed	O
diagnosis	O
of	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O

METHOD	O
Parent	O
verbal	O
utterances	O
were	O
coded	O
from	O
videotapes	O
of	O
naturalistic	O
parent-child	O
play	O
sessions	O
using	O
interval	O
and	O
event-based	O
coding	O
.	O

A	O
vocabulary	O
difference	O
score	O
,	O
calculated	O
using	O
the	O
MacArthur	O
Communicative	O
Development	O
Inventories	O
(	O
L.	O
Fenson	O
et	O
al.	O
,	O
1993	O
)	O
,	O
was	O
used	O
as	O
the	O
outcome	O
measure	O
of	O
spoken	O
vocabulary	O
6	O
months	O
later	O
.	O

RESULTS	O
Parent	O
follow-in	O
comments	O
and	O
follow-in	O
directives	O
predicted	O
spoken	O
vocabulary	O
after	O
controlling	O
for	O
child	O
engagement	O
.	O

Parent	O
expansions	O
of	O
child	O
verbal	O
utterances	O
predicted	O
spoken	O
vocabulary	O
after	O
controlling	O
for	O
child	O
talkativeness	O
.	O

When	O
entered	O
together	O
into	O
a	O
regression	O
analysis	O
,	O
metrics	O
that	O
represented	O
(	O
a	O
)	O
the	O
number	O
of	O
parent	O
utterances	O
following	O
into	O
the	O
child	O
's	O
focus	O
of	O
attention	O
and	O
(	O
b	O
)	O
the	O
number	O
of	O
parent	O
utterances	O
responding	O
to	O
child	O
verbal	O
communication	O
acts	O
both	O
accounted	O
for	O
unique	O
variance	O
in	O
predicting	O
change	O
in	O
spoken	O
vocabulary	O
from	O
Time	O
1	O
to	O
Time	O
2	O
.	O

CONCLUSION	O
Parent	O
verbal	O
utterances	O
that	O
follow	O
into	O
the	O
child	O
's	O
current	O
focus	O
of	O
attention	O
or	O
respond	O
to	O
child	O
verbal	O
communication	O
acts	O
may	O
facilitate	O
the	O
process	O
of	O
early	O
vocabulary	O
acquisition	O
by	O
mitigating	O
the	O
need	O
for	O
children	O
with	O
ASD	O
to	O
use	O
attention-following	O
as	O
a	O
word-learning	O
strategy	O
.	O

Effects	O
of	O
static	O
stretching	O
on	O
repeated	O
sprint	O
and	O
change	O
of	O
direction	O
performance	O
.	O

PURPOSE	O
To	O
examine	O
the	O
effects	O
of	O
static	O
stretching	O
during	O
the	O
recovery	O
periods	O
of	O
field-based	O
team	O
sports	O
on	O
subsequent	O
repeated	O
sprint	O
ability	O
(	O
RSA	O
)	O
and	O
change	O
of	O
direction	O
speed	O
(	O
CODS	O
)	O
performance	O
.	O

METHODS	O
On	O
four	O
separate	O
occasions	O
,	O
12	SampleSize
male	Sex
team-sport	O
players	O
performed	O
a	O
standardized	O
warm-up	O
,	O
followed	O
by	O
a	O
test	O
of	O
either	O
RSA	O
or	O
CODS	O
(	O
on	O
two	O
occasions	O
each	O
)	O
in	O
a	O
counterbalanced	O
design	O
.	O

Both	O
tests	O
involved	O
three	O
sets	O
of	O
six	O
maximal	O
sprint	O
repetitions	O
,	O
with	O
a	O
4-min	O
recovery	O
between	O
sets	O
.	O

During	O
the	O
break	O
between	O
sets	O
,	O
the	O
participants	O
either	O
rested	O
(	O
control	O
[	O
CON	O
]	O
)	O
or	O
completed	O
a	O
static	O
stretching	O
protocol	O
(	O
static	O
stretch	O
[	O
SS	O
]	O
)	O
.	O

The	O
RSA	O
test	O
involved	O
straight-line	O
sprints	O
,	O
whereas	O
the	O
CODS	O
test	O
required	O
a	O
change	O
of	O
direction	O
(	O
100	O
degrees	O
)	O
every	O
4	O
m	O
(	O
total	O
of	O
four	O
)	O
.	O

Mean	O
,	O
total	O
(	O
sum	O
of	O
six	O
sprints	O
)	O
,	O
first	O
,	O
and	O
best	O
sprint	O
times	O
(	O
MST	O
,	O
TST	O
,	O
FST	O
,	O
and	O
BST	O
,	O
respectively	O
)	O
were	O
recorded	O
for	O
each	O
set	O
.	O

RESULTS	O
There	O
was	O
a	O
consistent	O
tendency	O
for	O
RSA	O
times	O
to	O
be	O
slower	O
after	O
the	O
static	O
stretching	O
intervention	O
,	O
which	O
was	O
supported	O
by	O
statistical	O
significance	O
for	O
three	O
performance	O
variables	O
(	O
MST	O
0-5	O
m	O
set	O
2	O
,	O
MST	O
0-20	O
m	O
set	O
2	O
,	O
and	O
TST	O
set	O
2	O
;	O
P	O
<	O
0.05	O
)	O
.	O

This	O
tendency	O
was	O
also	O
supported	O
by	O
moderate	O
effect	O
sizes	O
and	O
qualitative	O
indications	O
of	O
likely	O
harmful	O
or	O
detrimental	O
effects	O
associated	O
with	O
RSA-SS	O
.	O

Further	O
,	O
sprint	O
times	O
again	O
tended	O
to	O
be	O
slower	O
in	O
the	O
CODS-SS	O
trial	O
compared	O
with	O
the	O
CODS-CON	O
across	O
all	O
sprint	O
variables	O
,	O
with	O
a	O
significantly	O
slower	O
(	O
P	O
<	O
0.05	O
)	O
BST	O
recorded	O
for	O
set	O
3	O
after	O
static	O
stretching	O
.	O

CONCLUSION	O
These	O
results	O
suggest	O
that	O
an	O
acute	O
bout	O
(	O
4	O
min	O
)	O
of	O
static	O
stretching	O
of	O
the	O
lower	O
limbs	O
during	O
recovery	O
periods	O
between	O
efforts	O
may	O
compromise	O
RSA	O
performance	O
but	O
has	O
less	O
effect	O
on	O
CODS	O
performance	O
.	O

Randomized	O
,	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
artesunate	O
plus	O
amodiaquine	O
,	O
administered	O
as	O
a	O
single	O
daily	O
intake	O
versus	O
two	O
daily	O
intakes	O
in	O
the	O
treatment	O
of	O
uncomplicated	Condition
falciparum	Condition
malaria	Condition
.	Condition

BACKGROUND	O
Artesunate	O
plus	O
amodiaquine	O
is	O
a	O
coblistered	O
ACT	O
,	O
given	O
as	O
a	O
single	O
daily	O
intake	O
.	O

It	O
has	O
been	O
suggested	O
that	O
,	O
in	O
view	O
of	O
the	O
number	O
of	O
tablets	O
to	O
be	O
taken	O
(	O
particularly	O
in	O
adults	O
)	O
,	O
it	O
may	O
be	O
possible	O
to	O
improve	O
compliance	O
by	O
allowing	O
patients	O
to	O
divide	O
the	O
daily	O
dose	O
.	O

The	O
objectives	O
of	O
this	O
randomized	O
,	O
comparative	O
,	O
open-label	O
,	O
multicentre	O
study	O
,	O
conducted	O
in	O
Senegal	O
and	O
in	O
Cameroon	O
in	O
2005	O
,	O
was	O
to	O
demonstrate	O
the	O
non-inferiority	O
and	O
to	O
compare	O
the	O
safety	O
of	O
artesunate	O
plus	O
amodiaquine	O
,	O
as	O
a	O
single	O
daily	O
intake	O
versus	O
two	O
daily	O
intakes	O
.	O

METHODS	O
A	O
three-day	O
treatment	O
period	O
and	O
14-day	O
follow-up	O
period	O
was	O
performed	O
in	O
any	O
subject	O
weighting	O
more	O
than	O
10	O
kg	O
,	O
presenting	O
with	O
a	O
malaria	O
paroxysm	O
confirmed	O
by	O
parasitaemia	O
>	O
or	O
=	O
1,000/microl	O
,	O
after	O
informed	O
consent	O
.	O

Patients	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
the	O
two	O
regimens	O
,	O
with	O
dosage	O
according	O
to	O
bodyweight	O
range	O
.	O

All	O
products	O
were	O
administered	O
by	O
an	O
authorized	O
person	O
,	O
blinded	O
to	O
both	O
the	O
investigating	O
physician	O
and	O
the	O
biologist	O
.	O

The	O
primary	O
endpoint	O
was	O
an	O
adequate	O
response	O
to	O
treatment	O
on	O
D14	O
(	O
WHO	O
definition	O
)	O
.	O

The	O
two-sided	O
90	O
%	O
confidence	O
interval	O
of	O
the	O
difference	O
was	O
calculated	O
on	O
intent	O
to	O
treat	O
(	O
ITT	O
)	O
population	O
;	O
the	O
acceptance	O
limit	O
for	O
non-inferiority	O
was	O
3	O
%	O
.	O

The	O
safety	O
was	O
evaluated	O
by	O
incidence	O
of	O
adverse	O
events	O
.	O

RESULTS	O
Three-hundred	SampleSize
and	SampleSize
sixteen	SampleSize
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
two	O
patient	O
groups	O
were	O
strictly	O
comparable	O
on	O
D0	O
.	O

The	O
adequate	O
responses	O
to	O
treatment	O
were	O
similar	O
for	O
the	O
two	O
treatment	O
regimens	O
on	O
D14	O
,	O
PCR-corrected	O
(	O
99,4	O
%	O
in	O
the	O
one-daily	O
intake	O
group	O
versus	O
99,3	O
%	O
in	O
the	O
comparative	O
group	O
)	O
.	O

The	O
statistical	O
analyses	O
demonstrated	O
the	O
non-inferiority	O
of	O
administering	O
artesunate/amodiaquine	O
as	O
two	O
intakes	O
.	O

The	O
drug	O
was	O
well	O
tolerated	O
.	O

The	O
main	O
adverse	O
events	O
were	O
gastrointestinal	O
disorders	O
(	O
2.5	O
%	O
)	O
and	O
pruritus	O
(	O
2.5	O
%	O
)	O
;	O
safety	O
profiles	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
This	O
pilot	O
study	O
confirms	O
the	O
efficacy	O
and	O
good	O
tolerability	O
of	O
artesunate	O
plus	O
amodiaquine	O
,	O
administrated	O
either	O
in	O
one	O
or	O
in	O
two	O
daily	O
intakes	O
.	O

An	O
evaluation	O
of	O
sealing	O
ability	O
of	O
calcium	O
hydroxide	O
sealers	O
.	O

Solid	O
core	O
filling	O
material	O
such	O
as	O
gutta-percha	O
has	O
been	O
used	O
to	O
fill	O
the	O
root	O
canal	O
in	O
conjunction	O
with	O
a	O
sealer	O
to	O
prevent	O
apical	O
leakage	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
apical	O
seal	O
of	O
five	O
different	O
root	O
canal	O
sealers	O
.	O

Sixty	O
roots	O
of	O
maxillary	O
central	O
incisors	O
were	O
cleansed	O
and	O
shaped	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
six	O
groups	O
of	O
ten	O
roots	O
each	O
.	O

The	O
root	O
canals	O
were	O
obturated	O
with	O
gutta-percha	O
and	O
one	O
of	O
the	O
sealers	O
by	O
the	O
lateral-vertical	O
condensation	O
technique	O
.	O

Groups	O
I	O
,	O
II	O
,	O
III	O
,	O
IV	O
,	O
and	O
V	O
consisted	O
of	O
roots	O
in	O
which	O
the	O
canal	O
was	O
filled	O
with	O
gutta-percha	O
along	O
with	O
either	O
Roth	O
's	O
sealer	O
,	O
AH26	O
,	O
Sealapex	O
,	O
CRCS	O
,	O
or	O
Nogenol	O
sealer	O
,	O
respectively	O
.	O

Group	O
VI	O
was	O
filled	O
with	O
gutta-percha	O
and	O
without	O
sealer	O
to	O
serve	O
as	O
a	O
control	O
.	O

The	O
access	O
opening	O
was	O
filled	O
with	O
amalgam	O
.	O

Each	O
tooth	O
was	O
then	O
placed	O
in	O
a	O
capped	O
vial	O
containing	O
2	O
X	O
2	O
inch	O
gauze	O
pads	O
saturated	O
with	O
distilled	O
water	O
,	O
and	O
the	O
sealer	O
was	O
allowed	O
to	O
set	O
at	O
37	O
degrees	O
C	O
in	O
the	O
humidor	O
for	O
48	O
hours	O
.	O

The	O
roots	O
,	O
except	O
for	O
the	O
apical	O
2	O
mm	O
,	O
were	O
coated	O
with	O
two	O
layers	O
of	O
nail	O
polish	O
.	O

The	O
roots	O
were	O
stained	O
with	O
india	O
ink	O
,	O
decalcified	O
,	O
dehydrated	O
,	O
and	O
then	O
placed	O
in	O
methylsalicylate	O
to	O
make	O
them	O
transparent	O
.	O

The	O
leakage	O
was	O
measured	O
with	O
a	O
filar	O
micrometer	O
eyepiece	O
under	O
a	O
dissecting	O
microscope	O
.	O

The	O
mean	O
apical	O
leakage	O
of	O
six	O
groups	O
was	O
as	O
follows	O
:	O
I	O
=	O
0.45	O
mm	O
,	O
II	O
=	O
0.277	O
mm	O
,	O
III	O
=	O
0.343	O
mm	O
,	O
IV	O
=	O
0.263	O
mm	O
,	O
V	O
=	O
0.336	O
mm	O
,	O
and	O
VI	O
=	O
2.310	O
mm	O
.	O

Results	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
apical	O
seal	O
produced	O
by	O
gutta-percha	O
and	O
the	O
tested	O
root	O
canal	O
sealers	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Fasting	O
and	O
meal-stimulated	O
plasma	O
levels	O
of	O
neurotensin	O
in	O
obese	Condition
patients	Condition
after	Condition
jejunoileal	Condition
bypass	Condition
with	Condition
3:1	Condition
or	Condition
1:3	Condition
jejunoileal	Condition
ratio	Condition
.	O

The	O
functional	O
role	O
of	O
the	O
jejunum	O
and	O
ileum	O
with	O
regard	O
to	O
peripheral	O
plasma	O
levels	O
of	O
intact	O
neurotensin	O
and	O
NH2-terminal	O
immunoreactivity	O
of	O
neurotensin	O
was	O
studied	O
by	O
using	O
jejunoileal	O
bypass	O
as	O
a	O
model	O
.	O

Plasma	O
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
before	O
and	O
after	O
jejunoileal	O
bypass	O
randomized	O
to	O
different	O
jejunoileal	O
ratios	O
.	O

Seven	SampleSize
patients	SampleSize
were	O
studied	O
before	O
bypass	Condition
surgery	Condition
and	O
28	SampleSize
were	O
examined	O
after	O
end-to-side	Condition
jejunoileal	Condition
bypass	Condition
with	Condition
50	Condition
cm	Condition
intestine	Condition
in	Condition
continuity	Condition
and	Condition
a	Condition
3:1	Condition
or	Condition
1:3	Condition
ratio	Condition
between	Condition
the	Condition
length	Condition
of	Condition
the	Condition
jejunal	Condition
and	Condition
ileal	Condition
segments	Condition
.	O

Fasting	O
levels	O
of	O
intact	O
neurotensin	O
were	O
unchanged	O
by	O
surgery	O
,	O
whereas	O
levels	O
of	O
NH2-terminal	O
immunoreactivity	O
were	O
higher	O
in	O
bypass	O
patients	O
with	O
a	O
long	O
ileal	O
segment	O
(	O
37.5	O
cm	O
)	O
than	O
in	O
unoperated	O
patients	O
and	O
in	O
those	O
with	O
a	O
short	O
ileal	O
segment	O
(	O
12.5	O
cm	O
)	O
.	O

Meal-stimulated	O
levels	O
of	O
intact	O
neurotensin	O
were	O
higher	O
after	O
1:3	O
than	O
3:1	O
jejunoileal	O
bypass	O
.	O

The	O
levels	O
of	O
NH2-terminal	O
immunoreactivity	O
in	O
patients	O
with	O
a	O
short	O
ileal	O
segment	O
and	O
in	O
controls	O
were	O
lower	O
than	O
in	O
patients	O
with	O
a	O
long	O
ileal	O
segment	O
.	O

The	O
results	O
show	O
that	O
postprandial	O
levels	O
of	O
both	O
intact	O
neurotensin	O
and	O
NH2-terminal	O
immunoreactivity	O
are	O
related	O
to	O
the	O
length	O
of	O
the	O
functioning	O
ileum	O
and	O
that	O
even	O
a	O
difference	O
in	O
length	O
of	O
25	O
cm	O
is	O
reflected	O
in	O
the	O
circulating	O
levels	O
of	O
neurotensin	O
.	O

The	O
therapeutic	O
efficacy	O
and	O
cost-effectiveness	O
of	O
aggressive	O
tocolysis	O
for	O
premature	Condition
labor	Condition
associated	Condition
with	Condition
premature	Condition
rupture	Condition
of	Condition
the	Condition
membranes	Condition
.	O

We	O
conducted	O
a	O
randomized	O
trial	O
comparing	O
bed	O
rest	O
with	O
tocolysis	O
to	O
determine	O
the	O
therapeutic	O
efficacy	O
,	O
safety	O
,	O
and	O
cost-effectiveness	O
of	O
tocolysis	O
for	O
the	O
treatment	O
of	O
preterm	Condition
labor	Condition
after	Condition
membrane	Condition
rupture	Condition
.	O

One	SampleSize
hundred	SampleSize
nine	SampleSize
women	SampleSize
participated	O
over	O
a	O
26-month	O
interval	O
.	O

Treatment	O
groups	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
gestational	O
age	O
at	O
membrane	O
rupture	O
,	O
gestational	O
age	O
at	O
delivery	O
,	O
birth	O
weight	O
,	O
maternal	O
or	O
fetal	O
infectious	O
morbidity	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
necrotizing	O
enterocolitis	O
,	O
or	O
perinatal	O
mortality	O
.	O

Prolongation	O
of	O
intrauterine	O
time	O
after	O
the	O
onset	O
of	O
uterine	O
contractions	O
was	O
seen	O
in	O
women	O
receiving	O
tocolysis	O
(	O
105.2	O
+/-	O
157	O
hours	O
versus	O
62.1	O
+/-	O
77	O
hours	O
,	O
p	O
=	O
0.06	O
)	O
.	O

This	O
prolongation	O
was	O
not	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
the	O
total	O
cost	O
per	O
surviving	O
infant	O
(	O
tocolysis	O
,	O
$	O
38,593	O
+/-	O
$	O
40,887	O
versus	O
bed	O
rest	O
,	O
$	O
43,158	O
+/-	O
$	O
37,116	O
;	O
p	O
=	O
0.445	O
)	O
.	O

The	O
cost	O
difference	O
was	O
artifactual	O
.	O

The	O
number	O
of	O
very	O
premature	O
infants	O
born	O
(	O
less	O
than	O
28	O
weeks	O
'	O
gestation	O
)	O
was	O
unequal	O
in	O
the	O
two	O
groups	O
(	O
12	O
in	O
the	O
bed	O
rest	O
group	O
and	O
5	O
in	O
the	O
tocolysis	O
group	O
)	O
and	O
skewed	O
the	O
results	O
.	O

Before	O
28	O
weeks	O
'	O
gestation	O
tocolysis	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
intrauterine	O
time	O
after	O
the	O
onset	O
of	O
regular	O
contractions	O
(	O
p	O
=	O
0.05	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
identifiable	O
perinatal	O
benefit	O
garnered	O
from	O
the	O
additional	O
5	O
days	O
.	O

After	O
28	O
weeks	O
there	O
were	O
no	O
significant	O
differences	O
between	O
treatment	O
groups	O
in	O
terms	O
of	O
intrauterine	O
time	O
after	O
the	O
onset	O
of	O
regular	O
contractions	O
and	O
total	O
cost	O
per	O
surviving	O
infant	O
.	O

Because	O
tocolysis	O
does	O
not	O
improve	O
perinatal	O
outcome	O
and	O
can	O
itself	O
be	O
associated	O
with	O
major	O
maternal	O
morbidity	O
,	O
it	O
should	O
be	O
avoided	O
after	O
28	O
weeks	O
'	O
gestation	O
.	O

Before	O
28	O
weeks	O
'	O
gestation	O
tocolysis	O
may	O
greatly	O
increase	O
intrauterine	O
time	O
,	O
but	O
the	O
benefit	O
of	O
this	O
prolongation	O
is	O
not	O
clear	O
.	O

Focal	O
therapeutic	O
efficacy	O
of	O
transcatheter	O
arterial	O
infusion	O
of	O
styrene	O
maleic	O
acid	O
neocarzinostatin	O
for	O
hepatocellular	O
carcinoma	O
.	O

We	O
evaluated	O
the	O
focal	O
therapeutic	O
effect	O
of	O
oily	O
carcinostatic	O
agents	O
administered	O
by	O
transcatheter	O
arterial	O
infusion	O
(	O
TAI	O
)	O
as	O
the	O
initial	O
therapy	O
in	O
patients	O
with	O
hepatocellular	O
carcinoma	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

Group	O
A	O
(	O
19	O
patients	O
)	O
received	O
4	O
mg	O
of	O
styrene	O
maleic	O
acid	O
neocarzinostatin	O
in	O
4	O
ml	O
of	O
Lipiodol	O
,	O
and	O
group	O
B	O
(	O
18	O
patients	O
)	O
received	O
100	O
mg	O
of	O
epirubicin	O
in	O
4	O
ml	O
of	O
Lipiodol	O
via	O
the	O
tumor	O
feeding	O
arteries	O
as	O
peripherally	O
as	O
possible	O
.	O

The	O
grade	O
of	O
Lipiodol	O
accumulation	O
and	O
the	O
tumor	O
regression	O
rate	O
were	O
determined	O
2	O
weeks	O
after	O
TAI	O
by	O
computerized	O
tomography	O
.	O

Adverse	O
effects	O
within	O
2	O
weeks	O
after	O
TAI	O
were	O
evaluated	O
by	O
subjective	O
signs	O
and	O
symptoms	O
such	O
as	O
fever	O
(	O
maximum	O
body	O
temperature	O
)	O
and	O
the	O
frequency	O
of	O
shaking	O
chills	O
and	O
abdominal	O
pain	O
,	O
and	O
by	O
biochemical	O
parameters	O
such	O
as	O
albumin	O
,	O
prothrombin	O
time	O
,	O
and	O
aspartate	O
and	O
alanine	O
aminotransferases	O
.	O

Lipiodol	O
accumulation	O
in	O
the	O
tumor	O
was	O
significantly	O
greater	O
in	O
group	O
A	O
(	O
12/19	O
;	O
63.2	O
%	O
showing	O
grade	O
IV	O
Lipiodol	O
accumulation	O
)	O
than	O
in	O
group	O
B	O
(	O
3/18	O
;	O
16.7	O
%	O
showing	O
grade	O
IV	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
tumor	O
regression	O
rate	O
was	O
also	O
significantly	O
greater	O
in	O
group	O
A	O
(	O
8/17	O
;	O
47.1	O
%	O
showing	O
more	O
than	O
25	O
%	O
tumor	O
regression	O
)	O
than	O
in	O
group	O
B	O
(	O
1/13	O
;	O
7.7	O
%	O
showing	O
more	O
than	O
25	O
%	O
tumor	O
regression	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Although	O
clinically	O
significant	O
elevations	O
of	O
aminotransferases	O
and	O
reductions	O
of	O
cholinesterase	O
,	O
and	O
shaking	O
chills	O
were	O
observed	O
more	O
often	O
in	O
group	O
A	O
than	O
in	O
group	O
B	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
these	O
factors	O
had	O
little	O
influence	O
on	O
the	O
clinical	O
outcome	O
.	O

Our	O
results	O
suggest	O
that	O
styrene	O
maleic	O
acid	O
neocarzinostatin	O
in	O
Lipiodol	O
exerts	O
a	O
more	O
favorable	O
focal	O
therapeutic	O
effect	O
than	O
does	O
epirubicin	O
in	O
Lipiodol	O
in	O
the	O
initial	O
treatment	O
of	O
hepatocellular	O
carcinoma	O
.	O

[	O
Efficacy	O
of	O
paliperidone	O
extended-release	O
tablets	O
in	O
the	O
improvement	O
of	O
social	O
functions	O
in	O
schizophrenics	Condition
:	O
a	O
randomized	O
and	O
controlled	O
study	O
]	O
.	O

OBJECTIVE	O
To	O
explore	O
the	O
efficacy	O
of	O
paliperidone	O
extended-release	O
tablets	O
in	O
the	O
improvement	O
of	O
social	O
functions	O
in	O
schizophrenics	Condition
.	O

METHODS	O
A	O
total	O
of	O
81	Condition
schizophrenics	Condition
were	O
randomly	O
divided	O
into	O
study	O
group	O
with	O
paliperidone	O
extended-release	O
tablets	O
and	O
control	O
group	O
with	O
risperidone	O
for	O
a	O
12-week	O
treatment	O
.	O

They	O
were	O
assessed	O
and	O
analyzed	O
by	O
positive	O
and	O
negative	O
symptoms	O
scales	O
(	O
PANSS	O
)	O
,	O
social	O
disability	O
screening	O
schedule	O
(	O
SDSS	O
)	O
and	O
treatment	O
emergent	O
symptom	O
scale	O
(	O
TESS	O
)	O
at	O
baseline	O
,	O
6	O
(	O
th	O
)	O
weekend	O
and	O
12	O
(	O
th	O
)	O
weekend	O
.	O

RESULTS	O
In	O
study	O
group	O
,	O
the	O
factors	O
and	O
total	O
scores	O
of	O
PANSS	O
in	O
the	O
12	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
[	O
(	O
12.0	O
?	O
2.8	O
)	O
,	O
(	O
12.1	O
?	O
3.6	O
)	O
,	O
(	O
26.2	O
?	O
5.0	O
)	O
,	O
(	O
50.2	O
?	O
8.7	O
)	O
]	O
were	O
all	O
significantly	O
lower	O
than	O
those	O
at	O
baseline	O
[	O
(	O
24.7	O
?	O
5.3	O
)	O
,	O
(	O
23.8	O
?	O
3.6	O
)	O
,	O
(	O
45.0	O
?	O
2.9	O
)	O
,	O
(	O
93.5	O
?	O
6.8	O
)	O
]	O
(	O
t	O
=	O
9.60-16.78	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
study	O
group	O
,	O
the	O
positive	O
factor	O
,	O
negative	O
factor	O
and	O
total	O
scores	O
of	O
PANSS	O
in	O
the	O
12	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
[	O
(	O
12.0	O
?	O
2.8	O
)	O
,	O
(	O
12.1	O
?	O
3.6	O
)	O
,	O
(	O
50.2	O
?	O
8.7	O
)	O
]	O
were	O
all	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
6	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
[	O
(	O
14.2	O
?	O
1.8	O
)	O
,	O
(	O
14.6	O
?	O
2.4	O
)	O
,	O
(	O
56.5	O
?	O
6.4	O
)	O
]	O
(	O
t	O
=	O
2.58-4.26	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
the	O
12	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
,	O
the	O
factors	O
and	O
total	O
scores	O
of	O
PANSS	O
in	O
study	O
group	O
[	O
(	O
12.0	O
?	O
2.8	O
)	O
,	O
(	O
12.1	O
?	O
3.6	O
)	O
,	O
(	O
26.2	O
?	O
5.0	O
)	O
,	O
(	O
50.2	O
?	O
8.7	O
)	O
]	O
were	O
all	O
significantly	O
lower	O
than	O
those	O
in	O
control	O
group	O
[	O
(	O
16.9	O
?	O
4.9	O
)	O
,	O
(	O
18.7	O
?	O
5.3	O
)	O
,	O
(	O
32.5	O
?	O
5.1	O
)	O
,	O
(	O
68.1	O
?	O
13.0	O
)	O
]	O
(	O
t	O
=	O
-4.28	O
--	O
5.67	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
study	O
group	O
,	O
the	O
total	O
scores	O
of	O
SDSS	O
in	O
the	O
12	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
(	O
5.93	O
?	O
2.78	O
)	O
were	O
significantly	O
lower	O
than	O
those	O
at	O
baseline	O
(	O
13.9	O
?	O
3.4	O
)	O
(	O
t	O
=	O
10.83	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
study	O
group	O
,	O
the	O
total	O
scores	O
of	O
SDSS	O
in	O
the	O
12	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
(	O
5.9	O
?	O
2.8	O
)	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
6	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
(	O
7.6	O
?	O
2.9	O
)	O
(	O
t	O
=	O
5.21	O
,	O
P	O
<	O
0.05	O
)	O
.	O

But	O
there	O
was	O
no	O
significant	O
improvement	O
in	O
control	O
group	O
(	O
t	O
=	O
1.88	O
,	O
P	O
>	O
0.05	O
)	O
.	O

In	O
the	O
12	O
(	O
th	O
)	O
weekend	O
of	O
treatment	O
,	O
the	O
total	O
scores	O
of	O
SDSS	O
in	O
study	O
group	O
(	O
5.9	O
?	O
2.8	O
)	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
control	O
group	O
(	O
8.8	O
?	O
2.9	O
)	O
(	O
t	O
=	O
-4.49	O
,	O
P	O
<	O
0.05	O
)	O
.	O

No	O
severe	O
adverse	O
effect	O
was	O
reported	O
in	O
either	O
group	O
.	O

CONCLUSION	O
Paliperidone	O
extended-release	O
tablets	O
are	O
effective	O
to	O
improve	O
social	O
functions	O
and	O
psychiatric	O
symptoms	O
of	O
schizophrenics	O
.	O

Effectiveness	O
of	O
N	O
,	O
N-dimethylglycine	O
in	O
autism	O
and	O
pervasive	O
developmental	O
disorder	O
.	O

N	O
,	O
N-dimethylglycine	O
,	O
a	O
dietary	O
supplement	O
,	O
has	O
been	O
reported	O
to	O
be	O
beneficial	O
in	O
children	O
with	O
autism	O
and	O
pervasive	O
developmental	O
disorder	O
.	O

We	O
examined	O
the	O
effectiveness	O
of	O
dimethylglycine	O
in	O
children	O
with	O
autism	O
and	O
pervasive	O
developmental	O
disorder	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

Thirty-seven	Age
children	Age
between	Age
3	Age
and	Age
11	Age
years	Age
of	Age
age	Age
with	Age
a	Age
diagnosis	Age
of	Age
autism	Age
and/or	Age
pervasive	Age
developmental	Age
disorder	Age
were	O
gender	O
and	O
age	O
matched	O
and	O
randomly	O
assigned	O
to	O
receive	O
either	O
placebo	O
or	O
dimethylglycine	O
for	O
4	O
weeks	O
.	O

All	O
children	O
were	O
assessed	O
before	O
and	O
after	O
treatment	O
on	O
two	O
behavioral	O
measures	O
,	O
the	O
Vineland	O
Maladaptive	O
Behavior	O
Domain	O
and	O
the	O
Aberrant	O
Behavior	O
Checklist	O
.	O

Standardized	O
neurologic	O
examinations	O
before	O
and	O
after	O
treatment	O
on	O
33	O
children	O
showed	O
no	O
change	O
.	O

An	O
overall	O
improvement	O
on	O
all	O
behavioral	O
measures	O
was	O
observed	O
for	O
both	O
the	O
placebo	O
and	O
the	O
dimethylglycine	O
groups	O
.	O

However	O
,	O
the	O
improvement	O
among	O
the	O
children	O
who	O
received	O
dimethylglycine	O
was	O
not	O
statistically	O
different	O
from	O
the	O
improvement	O
observed	O
among	O
the	O
children	O
who	O
received	O
the	O
placebo	O
.	O

The	O
children	O
who	O
participated	O
in	O
this	O
study	O
were	O
a	O
heterogeneous	O
group	O
,	O
and	O
their	O
apparent	O
responses	O
to	O
the	O
dimethylglycine	O
varied	O
.	O

Some	O
children	O
appeared	O
to	O
respond	O
positively	O
to	O
the	O
dimethylglycine	O
,	O
and	O
there	O
was	O
a	O
smaller	O
proportion	O
of	O
negative	O
changes	O
in	O
the	O
dimethylglycine	O
group	O
,	O
but	O
the	O
quantitative	O
changes	O
in	O
the	O
dimethylglycine	O
behavioral	O
assessments	O
were	O
not	O
significantly	O
different	O
from	O
what	O
was	O
observed	O
among	O
children	O
who	O
received	O
placebo	O
.	O

Effect	O
of	O
antioxidant	O
supplementation	O
on	O
ozone-induced	Condition
lung	Condition
injury	Condition
in	O
human	O
subjects	O
.	O

To	O
determine	O
whether	O
antioxidants	O
can	O
influence	O
human	O
susceptibility	O
to	O
ozone	O
(	O
O	O
(	O
3	O
)	O
)	O
-induced	O
changes	O
in	O
lung	O
function	O
and	O
airway	O
inflammation	O
,	O
we	O
placed	O
31	SampleSize
healthy	O
nonsmoking	O
adults	O
(	O
18	O
to	O
35	O
yr	O
old	O
)	O
on	O
a	O
diet	O
low	O
in	O
ascorbate	O
for	O
3	O
wk	O
.	O

At	O
1	O
wk	O
,	O
subjects	O
were	O
exposed	O
to	O
filtered	O
air	O
for	O
2	O
h	O
while	O
exercising	O
(	O
20	O
L/min/m	O
(	O
2	O
)	O
)	O
,	O
and	O
then	O
underwent	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
a	O
placebo	O
or	O
250	O
mg	O
of	O
vitamin	O
C	O
,	O
50	O
IU	O
of	O
alpha-tocopherol	O
,	O
and	O
12	O
oz	O
of	O
vegetable	O
cocktail	O
daily	O
for	O
2	O
wk	O
.	O

Subjects	O
were	O
then	O
exposed	O
to	O
0.4	O
ppm	O
O	O
(	O
3	O
)	O
for	O
2	O
h	O
and	O
underwent	O
a	O
second	O
BAL	O
.	O

On	O
the	O
day	O
of	O
the	O
O	O
(	O
3	O
)	O
exposure	O
,	O
supplemented	O
subjects	O
were	O
found	O
to	O
have	O
significantly	O
increased	O
levels	O
of	O
plasma	O
ascorbate	O
,	O
tocopherols	O
,	O
and	O
carotenoids	O
as	O
compared	O
with	O
those	O
of	O
the	O
placebo	O
group	O
.	O

Pulmonary	O
function	O
testing	O
showed	O
that	O
O	O
(	O
3	O
)	O
-induced	O
reductions	O
in	O
FEV	O
(	O
1	O
)	O
and	O
FVC	O
were	O
30	O
%	O
and	O
24	O
%	O
smaller	O
,	O
respectively	O
,	O
in	O
the	O
supplemented	O
cohort	O
.	O

In	O
contrast	O
,	O
the	O
inflammatory	O
response	O
to	O
O	O
(	O
3	O
)	O
inhalation	O
,	O
as	O
represented	O
by	O
the	O
percent	O
neutrophils	O
and	O
the	O
concentration	O
of	O
interleukin-6	O
recovered	O
in	O
the	O
BAL	O
fluid	O
at	O
1	O
h	O
after	O
O	O
(	O
3	O
)	O
exposure	O
was	O
not	O
different	O
for	O
the	O
two	O
groups	O
.	O

These	O
data	O
suggest	O
that	O
dietary	O
antioxidants	O
protect	O
against	O
O	O
(	O
3	O
)	O
-induced	O
pulmonary	O
function	O
decrements	O
in	O
humans	O
.	O

Randomised	O
trial	O
of	O
effect	O
of	O
amiodarone	O
on	O
mortality	O
in	O
patients	Condition
with	Condition
left-ventricular	Condition
dysfunction	Condition
after	Condition
recent	Condition
myocardial	Condition
infarction	Condition
:	Condition
EMIAT	Condition
.	Condition

European	O
Myocardial	O
Infarct	O
Amiodarone	O
Trial	O
Investigators	O
.	O

BACKGROUND	O
Ventricular	O
arrhythmias	O
are	O
a	O
major	O
cause	O
of	O
death	O
after	O
myocardial	O
infarction	O
,	O
especially	O
in	O
patients	O
with	O
poor	O
left-ventricular	O
function	O
.	O

Previous	O
attempts	O
to	O
identify	O
and	O
suppress	O
arrhythmias	O
with	O
various	O
antiarrhythmic	O
drugs	O
failed	O
to	O
reduce	O
or	O
actually	O
increase	O
mortality	O
.	O

Amiodarone	O
is	O
a	O
powerful	O
antiarrhythmic	O
drug	O
with	O
several	O
potentially	O
beneficial	O
actions	O
,	O
and	O
has	O
shown	O
benefit	O
in	O
several	O
small-scale	O
studies	O
.	O

We	O
postulated	O
that	O
this	O
drug	O
might	O
reduce	O
mortality	O
in	O
patients	O
at	O
high	O
risk	O
of	O
death	O
after	O
myocardial	O
infarction	O
because	O
of	O
impaired	O
ventricular	O
function	O
,	O
irrespective	O
of	O
whether	O
they	O
had	O
ventricular	O
arrhythmias	O
.	O

METHODS	O
The	O
European	O
Myocardial	O
Infarct	O
Amiodarone	O
Trial	O
(	O
EMIAT	O
)	O
was	O
a	O
randomised	O
double-blind	O
placebo-controlled	O
trial	O
to	O
assess	O
whether	O
amiodarone	O
reduced	O
all-cause	O
mortality	O
(	O
primary	O
endpoint	O
)	O
and	O
cardiac	O
mortality	O
and	O
arrhythmic	O
death	O
(	O
secondary	O
endpoints	O
)	O
in	O
survivors	O
of	O
myocardial	O
infarction	O
with	O
a	O
left-ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
of	O
40	O
%	O
or	O
less	O
.	O

Intention-to-treat	O
and	O
on-treatment	O
analyses	O
were	O
done	O
.	O

FINDINGS	O
EMIAT	O
enrolled	O
1486	O
patients	O
(	O
743	O
in	O
the	O
amiodarone	O
group	O
,	O
743	O
in	O
the	O
placebo	O
group	O
)	O
.	O

Median	O
follow-up	O
was	O
21	O
months	O
.	O

All-cause	O
mortality	O
(	O
103	O
deaths	O
in	O
the	O
amiodarone	O
group	O
,	O
102	O
in	O
the	O
placebo	O
group	O
)	O
and	O
cardiac	O
mortality	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

However	O
,	O
in	O
the	O
amiodarone	O
group	O
,	O
there	O
was	O
a	O
35	O
%	O
risk	O
reduction	O
(	O
95	O
%	O
CI	O
0-58	O
,	O
p	O
=	O
0.05	O
)	O
in	O
arrhythmic	O
deaths	O
.	O

INTERPRETATION	O
Our	O
findings	O
do	O
not	O
support	O
the	O
systematic	O
prophylactic	O
use	O
of	O
amiodarone	O
in	O
all	O
patients	O
with	O
depressed	O
left-ventricular	O
function	O
after	O
myocardial	O
infarction	O
.	O

However	O
,	O
the	O
lack	O
of	O
proarrhythmia	O
and	O
the	O
reduction	O
in	O
arrhythmic	O
death	O
support	O
the	O
use	O
of	O
amiodarone	O
in	O
patients	O
for	O
whom	O
antiarrhythmic	O
therapy	O
is	O
indicated	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
pentoxifylline	O
for	O
the	O
treatment	O
of	O
recurrent	O
aphthous	Condition
stomatitis	Condition
.	O

OBJECTIVE	O
To	O
evaluate	O
pentoxifylline	O
for	O
the	O
treatment	O
of	O
recurrent	O
aphthous	O
stomatitis	O
.	O

DESIGN	O
A	O
60-day	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
with	O
a	O
60-day	O
no	O
treatment	O
follow-up	O
.	O

SETTING	O
An	O
oral	O
medicine	O
specialist	O
referral	O
center	O
in	O
Manchester	O
.	O

PARTICIPANTS	O
Forty-nine	SampleSize
volunteers	O
who	O
passed	O
the	O
initial	O
assessment	O
for	O
recurrent	O
aphthous	Condition
stomatitis	Condition
entered	O
a	O
pretrial	O
phase	O
in	O
which	O
their	O
eligibility	O
for	O
the	O
trial	O
phase	O
of	O
the	O
study	O
was	O
assessed	O
.	O

Sixteen	SampleSize
subjects	O
were	O
deemed	O
ineligible	O
,	O
and	O
7	O
failed	O
to	O
attend	O
or	O
withdrew	O
.	O

The	O
remaining	O
26	SampleSize
subjects	O
were	O
randomized	O
to	O
placebo	O
or	O
treatment	O
.	O

Six	O
subjects	O
withdrew	O
because	O
of	O
adverse	O
effects	O
,	O
and	O
1	O
was	O
unavailable	O
for	O
follow-up	O
.	O

INTERVENTION	O
Pentoxifylline	O
(	O
also	O
called	O
oxpentifylline	O
)	O
,	O
400	O
mg	O
3	O
times	O
daily	O
,	O
or	O
matching	O
placebo	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
A	O
reduction	O
in	O
the	O
median	O
pain	O
score	O
,	O
ulcer	O
size	O
,	O
number	O
of	O
ulcers	O
,	O
or	O
total	O
number	O
of	O
ulcer	O
episodes	O
.	O

RESULTS	O
Patients	O
taking	O
pentoxifylline	O
had	O
less	O
pain	O
and	O
reported	O
smaller	O
and	O
fewer	O
ulcers	O
compared	O
with	O
baseline	O
.	O

Patients	O
taking	O
placebo	O
reported	O
no	O
improvement	O
in	O
these	O
variables	O
.	O

Patients	O
taking	O
pentoxifylline	O
also	O
reported	O
more	O
ulcer-free	O
days	O
than	O
those	O
taking	O
placebo	O
.	O

However	O
,	O
the	O
differences	O
were	O
small	O
and	O
,	O
with	O
the	O
exception	O
of	O
median	O
ulcer	O
size	O
(	O
P	O
=	O
.05	O
)	O
,	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Adverse	O
effects	O
were	O
common	O
with	O
pentoxifylline	O
,	O
but	O
not	O
significantly	O
different	O
from	O
those	O
experienced	O
by	O
patients	O
taking	O
placebo	O
.	O

CONCLUSIONS	O
Although	O
pentoxifylline	O
may	O
have	O
some	O
benefit	O
in	O
the	O
treatment	O
of	O
recurrent	O
aphthous	O
stomatitis	O
,	O
the	O
benefit	O
is	O
limited	O
.	O

It	O
may	O
have	O
a	O
role	O
in	O
the	O
treatment	O
of	O
patients	O
unresponsive	O
to	O
other	O
treatments	O
,	O
but	O
can	O
not	O
yet	O
be	O
recommended	O
as	O
a	O
first-line	O
treatment	O
.	O

Breathlessness	O
and	O
psychiatric	O
morbidity	O
in	O
chronic	O
bronchitis	O
and	O
emphysema	O
:	O
a	O
study	O
of	O
psychotherapeutic	O
management	O
.	O

This	O
paper	O
describes	O
a	O
study	O
of	O
the	O
outcome	O
of	O
psychotherapy	O
with	O
patients	O
disabled	O
by	O
chronic	O
obstructive	O
airways	O
disease	O
giving	O
rise	O
to	O
dyspnoea	O
.	O

Forty-three	SampleSize
men	O
and	SampleSize
22	SampleSize
women	O
with	O
severe	Condition
COAD	Condition
were	O
randomly	O
allocated	O
for	O
8	O
weeks	O
to	O
one	O
of	O
three	O
types	O
of	O
psychotherapy	O
or	O
to	O
an	O
untreated	O
control	O
group	O
,	O
and	O
were	O
followed	O
up	O
six	O
months	O
later	O
.	O

The	O
group	O
treated	O
by	O
a	O
medical	O
nurse	O
without	O
training	O
in	O
psychotherapy	O
experienced	O
sustained	O
relief	O
of	O
dyspnoea	O
but	O
tended	O
to	O
undergo	O
less	O
psychodynamic	O
change	O
;	O
psychiatric	O
symptoms	O
were	O
reduced	O
in	O
those	O
receiving	O
supportive	O
,	O
but	O
not	O
analytical	O
,	O
psychotherapy	O
.	O

The	O
psychosomatic	O
mechanisms	O
involved	O
and	O
the	O
implications	O
for	O
medical	O
and	O
nursing	O
practice	O
and	O
for	O
liaison	O
psychotherapy	O
are	O
discussed	O
.	O

Effect	O
of	O
pravastatin	O
on	O
cardiovascular	O
events	O
in	O
women	Condition
after	Condition
myocardial	Condition
infarction	Condition
:	Condition
the	O
cholesterol	O
and	O
recurrent	O
events	O
(	O
CARE	O
)	O
trial	O
.	O

OBJECTIVES	O
We	O
sought	O
to	O
determine	O
the	O
effect	O
of	O
pravastatin	O
on	O
recurrent	O
cardiovascular	O
events	O
in	O
women	O
with	O
average	O
cholesterol	O
levels	O
after	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

BACKGROUND	O
Little	O
information	O
is	O
available	O
on	O
the	O
effectiveness	O
of	O
lipid	O
lowering	O
in	O
secondary	O
prevention	O
of	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
in	O
women	O
;	O
in	O
particular	O
,	O
those	O
with	O
CHD	O
and	O
average	O
cholesterol	O
levels	O
.	O

METHODS	O
In	O
the	O
Cholesterol	O
and	O
Recurrent	O
Events	O
(	O
CARE	O
)	O
trial	O
,	O
576	O
postmenopausal	O
women	O
,	O
between	O
3	O
and	O
20	O
months	O
after	O
MI	O
,	O
with	O
a	O
total	O
cholesterol	O
level	O
<	O
240	O
mg/dl	O
and	O
a	O
low	O
density	O
lipoprotein	O
cholesterol	O
level	O
115	O
to	O
174	O
mg/dl	O
,	O
were	O
randomized	O
to	O
receive	O
pravastatin	O
40	O
mg/day	O
or	O
matching	O
placebo	O
for	O
a	O
median	O
follow-up	O
period	O
of	O
5	O
years	O
.	O

The	O
main	O
outcome	O
measures	O
were	O
combined	O
coronary	O
events	O
(	O
coronary	O
death	O
,	O
nonfatal	O
MI	O
,	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
[	O
PTCA	O
]	O
or	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
[	O
CABG	O
]	O
)	O
,	O
the	O
primary	O
trial	O
end	O
point	O
(	O
coronary	O
death	O
or	O
nonfatal	O
MI	O
)	O
and	O
stroke	O
.	O

RESULTS	O
Women	O
treated	O
with	O
pravastatin	O
had	O
a	O
risk	O
reduction	O
of	O
43	O
%	O
for	O
the	O
primary	O
end	O
point	O
(	O
p	O
=	O
0.035	O
)	O
,	O
46	O
%	O
for	O
combined	O
coronary	O
events	O
(	O
p	O
=	O
0.001	O
)	O
,	O
48	O
%	O
for	O
PTCA	O
(	O
p	O
=	O
0.025	O
)	O
,	O
40	O
%	O
for	O
CABG	O
(	O
p	O
=	O
0.14	O
)	O
and	O
56	O
%	O
for	O
stroke	O
(	O
p	O
=	O
0.07	O
)	O
.	O

The	O
3,583	O
men	O
in	O
the	O
CARE	O
trial	O
also	O
showed	O
a	O
reduction	O
in	O
risk	O
,	O
but	O
the	O
magnitude	O
tended	O
to	O
be	O
less	O
.	O

Pravastatin	O
improved	O
plasma	O
lipids	O
similarly	O
in	O
men	O
and	O
women	O
.	O

There	O
were	O
no	O
differences	O
in	O
risk	O
of	O
coronary	O
events	O
in	O
the	O
placebo	O
group	O
between	O
men	O
and	O
women	O
.	O

Minor	O
differences	O
between	O
men	O
and	O
women	O
were	O
present	O
in	O
baseline	O
characteristics	O
and	O
treatment	O
for	O
MI	O
,	O
in	O
general	O
,	O
conferring	O
a	O
higher	O
risk	O
status	O
and	O
a	O
lower	O
incidence	O
of	O
CABG	O
in	O
the	O
women	O
.	O

CONCLUSIONS	O
Pravastatin	O
led	O
to	O
significant	O
early	O
reduction	O
of	O
a	O
wide	O
range	O
of	O
cardiovascular	O
events	O
in	O
post-MI	O
women	O
with	O
average	O
cholesterol	O
levels	O
.	O

A	O
pilot	O
study	O
on	O
the	O
efficacy	O
of	O
melodic	O
based	O
communication	O
therapy	O
for	O
eliciting	O
speech	O
in	O
nonverbal	Condition
children	Age
with	O
autism	Condition
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
melodic	O
based	O
communication	O
therapy	O
(	O
MBCT	O
)	O
to	O
traditional	O
speech	O
and	O
language	O
therapy	O
for	O
eliciting	O
speech	O
in	O
nonverbal	Condition
children	O
with	O
autism	Condition
.	O

Participants	O
were	O
12	SampleSize
nonverbal	Condition
children	Condition
with	O
autism	Condition
ages	Age
5	Age
through	Age
7	Age
randomly	O
assigned	O
to	O
either	O
treatment	O
group	O
.	O

Both	O
groups	O
made	O
significant	O
progress	O
after	O
treatment	O
.	O

The	O
MBCT	O
group	O
progressed	O
significantly	O
in	O
number	O
of	O
verbal	O
attempts	O
after	O
weeks	O
1	O
through	O
4	O
and	O
number	O
of	O
correct	O
words	O
after	O
weeks	O
1	O
and	O
3	O
,	O
while	O
the	O
traditional	O
group	O
progressed	O
significantly	O
after	O
weeks	O
4	O
and	O
5	O
.	O

No	O
significant	O
differences	O
in	O
number	O
of	O
verbal	O
attempts	O
or	O
number	O
of	O
correct	O
words	O
were	O
noted	O
between	O
groups	O
following	O
treatment	O
.	O

A	O
significant	O
number	O
of	O
new	O
words	O
were	O
heard	O
in	O
the	O
home	O
environment	O
for	O
the	O
MBCT	O
group	O
(	O
p	O
=	O
.04	O
)	O
.	O

Participants	O
in	O
the	O
MBCT	O
group	O
had	O
more	O
imitative	O
attempts	O
(	O
p	O
=	O
.03	O
)	O
.	O

MBCT	O
appears	O
to	O
be	O
a	O
valid	O
form	O
of	O
intervention	O
for	O
children	Age
with	O
autism	Condition
.	O

Self-management	O
improvement	O
program	O
combined	O
with	O
community	O
involvement	O
in	O
Thai	Condition
hypertensive	Condition
population	O
:	O
an	O
action	O
research	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effectiveness	O
of	O
a	O
program	O
that	O
utilizes	O
community	O
involvement	O
to	O
improve	O
the	O
self-management	O
strategies	O
among	O
people	O
living	O
with	O
hypertension	Condition
.	O

MATERIAL	O
AND	O
METHOD	O
Forty-four	SampleSize
subjects	O
,	O
aged	O
35	Age
to	Age
59-year-old	Age
,	O
with	O
hypertension	Condition
in	O
Nakhon	O
Pathom	O
Province	O
,	O
Thailand	Condition
,	O
were	O
randomly	O
allocated	O
to	O
either	O
an	O
experimental	O
group	O
(	O
n	O
=	O
22	O
)	O
or	O
a	O
control	O
group	O
(	O
n	O
=	O
20	O
)	O
.	O

The	O
experimental	O
group	O
attended	O
a	O
program	O
to	O
improve	O
self-management	O
methods	O
based	O
on	O
social	O
cognitive	O
theory	O
(	O
SCT	O
)	O
.	O

The	O
program	O
lasted	O
12	O
weeks	O
,	O
consisted	O
of	O
1	O
1/2	O
hours	O
meeting	O
once	O
a	O
week	O
,	O
including	O
group	O
meetings	O
and	O
home	O
visit	O
monitoring	O
.	O

Mann-Whitney	O
U	O
test	O
and	O
Friedman	O
test	O
were	O
employed	O
to	O
analyze	O
the	O
program	O
's	O
effectiveness	O
.	O

RESULTS	O
After	O
the	O
program	O
,	O
the	O
mean	O
rank	O
of	O
the	O
perceived	O
self-efficacy	O
for	O
the	O
self-management	O
strategies	O
was	O
statistically	O
different	O
between	O
the	O
two	O
groups	O
(	O
p	O
=	O
0.023	O
)	O
.	O

In	O
the	O
experimental	O
group	O
,	O
after	O
the	O
twelve	O
week	O
,	O
the	O
mean	O
rank	O
of	O
perceived	O
self-efficacy	O
and	O
outcome	O
expectancy	O
increased	O
and	O
diastolic	O
blood	O
pressure	O
decreased	O
after	O
the	O
eight	O
week	O
.	O

CONCLUSION	O
The	O
program	O
applied	O
social	O
cognitive	O
theory	O
(	O
SCT	O
)	O
to	O
promote	O
self-management	O
techniques	O
,	O
increased	O
the	O
health	O
promoting	O
behavior	O
among	O
hypertensive	O
people	O
.	O

The	O
impact	O
of	O
different	O
doses	O
of	O
medroxyprogesterone	O
acetate	O
on	O
mood	O
symptoms	O
in	O
sequential	O
hormonal	O
therapy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
adverse	O
mood	O
effects	O
of	O
two	O
different	O
doses	O
of	O
medroxyprogesterone	O
acetate	O
(	O
MPA	O
)	O
during	O
postmenopausal	Condition
hormone	O
replacement	O
therapy	O
(	O
HRT	O
)	O
in	O
women	Sex
with	O
and	O
without	O
a	O
history	O
of	O
premenstrual	Condition
syndrome	Condition
(	Condition
PMS	Condition
)	Condition
.	Condition

The	O
study	O
was	O
designed	O
as	O
a	O
randomized	O
double-blind	O
cross-over	O
study	O
and	O
included	O
36	SampleSize
postmenopausal	Condition
women	Sex
at	O
three	O
health	O
care	O
areas	O
in	O
northern	O
Sweden	O
.	O

The	O
women	O
received	O
2	O
mg	O
estradiol	O
continuously	O
during	O
five	O
28-day	O
cycles	O
and	O
10	O
mg	O
or	O
20	O
mg	O
MPA	O
sequentially	O
for	O
12	O
days	O
during	O
each	O
cycle	O
.	O

The	O
main	O
outcome	O
measures	O
were	O
mood	O
and	O
physical	O
symptoms	O
noted	O
on	O
a	O
daily	O
rating	O
scale	O
.	O

We	O
found	O
that	O
physical	O
symptoms	O
did	O
not	O
differ	O
between	O
10	O
and	O
20	O
mg	O
MPA	O
.	O

Both	O
women	O
with	O
a	O
history	O
of	O
PMS	O
and	O
women	O
without	O
responded	O
with	O
more	O
negative	O
mood	O
symptoms	O
with	O
the	O
lower	O
dose	O
of	O
MPA	O
.	O

In	O
women	O
with	O
previous	O
PMS	O
the	O
higher	O
dose	O
of	O
MPA	O
enhanced	O
positive	O
mood	O
symptoms	O
.	O

With	O
respect	O
to	O
mood	O
and	O
physical	O
symptoms	O
,	O
the	O
aim	O
to	O
lower	O
MPA	O
doses	O
in	O
HRT	O
is	O
unwarranted	O
.	O

Randomized	O
controlled	O
study	O
of	O
customized	O
preventive	O
medicine	O
reminder	O
letters	O
in	O
a	O
community	O
practice	O
.	O

OBJECTIVE	O
To	O
test	O
the	O
effectiveness	O
of	O
customized	O
,	O
family-oriented	O
reminder	O
letters	O
in	O
activating	O
patients	O
to	O
seek	O
appropriate	O
preventive	O
services	O
.	O

DESIGN	O
Randomized	O
clinical	O
trial	O
.	O

One	O
group	O
received	O
computer-generated	O
,	O
customized	O
letters	O
explaining	O
recommended	O
preventive	O
procedures	O
for	O
each	O
family	O
member	O
.	O

A	O
second	O
group	O
received	O
a	O
form	O
letter	O
listing	O
recommendations	O
for	O
all	O
preventive	O
procedures	O
for	O
all	O
age	O
and	O
sex	O
groups	O
.	O

A	O
third	O
group	O
(	O
control	O
group	O
)	O
received	O
no	O
letters	O
.	O

SETTING	O
A	O
private	O
medical	O
centre	O
,	O
without	O
university	O
affiliation	O
,	O
in	O
rural	O
Quebec	O
.	O

PARTICIPANTS	O
From	O
8770	SampleSize
patients	O
who	O
met	O
study	O
criteria	O
,	O
719	SampleSize
families	O
were	O
randomly	O
selected	O
.	O

Data	O
were	O
available	O
for	O
1971	O
of	O
1998	O
patients	O
in	O
these	O
families	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
Family	O
Received	O
Index	O
is	O
the	O
proportion	O
of	O
all	O
procedures	O
for	O
which	O
a	O
family	O
was	O
overdue	O
that	O
they	O
received	O
.	O

The	O
Family	O
End-of-study	O
Up-to-date	O
Index	O
is	O
the	O
proportion	O
of	O
procedures	O
for	O
which	O
the	O
family	O
was	O
eligible	O
and	O
for	O
which	O
they	O
were	O
up-to-date	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

RESULTS	O
The	O
Family	O
Received	O
Index	O
for	O
families	O
mailed	O
customized	O
letters	O
was	O
more	O
than	O
double	O
the	O
index	O
for	O
patients	O
not	O
mailed	O
letters	O
(	O
Kruskal-Wallis	O
P	O
=	O
.0139	O
)	O
.	O

Comparison	O
of	O
the	O
Family	O
End-of-study	O
Up-to-date	O
indices	O
also	O
demonstrated	O
that	O
families	O
of	O
patients	O
sent	O
customized	O
letters	O
were	O
more	O
likely	O
to	O
be	O
up-to-date	O
than	O
families	O
not	O
sent	O
letters	O
(	O
Kruskal-Wallis	O
P	O
=	O
.0054	O
)	O
.	O

No	O
statistically	O
significant	O
difference	O
appeared	O
between	O
the	O
number	O
of	O
preventive	O
measures	O
received	O
by	O
the	O
control	O
group	O
and	O
the	O
form-letter	O
group	O
.	O

CONCLUSIONS	O
This	O
study	O
demonstrates	O
a	O
clinically	O
small	O
but	O
statistically	O
significant	O
value	O
to	O
customizing	O
reminder	O
letters	O
.	O

Adjuvant	O
therapy	O
with	O
pegylated	O
interferon	O
alfa-2b	O
versus	O
observation	O
in	O
resected	O
stage	O
III	O
melanoma	O
:	O
a	O
phase	O
III	O
randomized	O
controlled	O
trial	O
of	O
health-related	O
quality	O
of	O
life	O
and	O
symptoms	O
by	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Melanoma	O
Group	O
.	O

PURPOSE	O
Interferon	O
(	O
IFN	O
)	O
-based	O
adjuvant	O
therapy	O
in	O
melanoma	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
,	O
which	O
necessitates	O
evaluation	O
of	O
health-related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
.	O

Our	O
trial	O
examined	O
the	O
HRQOL	O
effects	O
of	O
adjuvant	O
pegylated	O
IFN-alpha-2b	O
(	O
PEG-IFN-alpha-2b	O
)	O
versus	O
observation	O
in	O
patients	O
with	O
stage	Condition
III	Condition
melanoma	Condition
.	O

METHODS	O
A	O
total	O
of	O
1,256	SampleSize
patients	O
with	O
stage	Condition
III	Condition
melanoma	Condition
were	O
randomly	O
assigned	O
after	O
full	O
lymphadenectomy	O
to	O
receive	O
either	O
observation	O
(	O
n	O
=	O
629	O
)	O
or	O
PEG-IFN-alpha-2b	O
(	O
n	O
=	O
627	O
)	O
:	O
induction	O
6	O
micrograms/kg/wk	O
[	O
DOSAGE	O
ERROR	O
CORRECTED	O
]	O
for	O
8	O
weeks	O
then	O
maintenance	O
3	O
micrograms/kg/wk	O
[	O
DOSAGE	O
ERROR	O
CORRECTED	O
]	O
for	O
an	O
intended	O
total	O
duration	O
of	O
5	O
years	O
.	O

The	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
was	O
used	O
to	O
assess	O
HRQOL	O
.	O

RESULTS	O
At	O
3.8	O
years	O
of	O
median	O
follow-up	O
,	O
for	O
the	O
primary	O
end	O
point	O
,	O
recurrence-free	O
survival	O
(	O
RFS	O
)	O
,	O
risk	O
was	O
reduced	O
by	O
18	O
%	O
(	O
hazard	O
rate	O
=	O
0.82	O
;	O
P	O
=	O
.01	O
)	O
in	O
the	O
PEG-IFN-alpha-2b	O
arm	O
compared	O
with	O
observation	O
.	O

Significant	O
and	O
clinically	O
meaningful	O
differences	O
occurred	O
with	O
the	O
PEG-IFN-alpha-2b	O
treatment	O
arm	O
compared	O
with	O
the	O
observation	O
group	O
,	O
showing	O
decreased	O
global	O
HRQOL	O
at	O
month	O
3	O
(	O
-11.6	O
points	O
;	O
99	O
%	O
CI	O
,	O
-8.2	O
to	O
-15.0	O
)	O
and	O
year	O
2	O
(	O
-10.5	O
points	O
;	O
99	O
%	O
CI	O
,	O
-6.6	O
to	O
-14.4	O
)	O
.	O

Many	O
of	O
the	O
other	O
scales	O
showed	O
statistically	O
significant	O
differences	O
between	O
scores	O
when	O
comparing	O
the	O
two	O
arms	O
.	O

From	O
a	O
clinical	O
point	O
of	O
view	O
,	O
important	O
differences	O
were	O
found	O
for	O
five	O
scales	O
:	O
two	O
functioning	O
scales	O
(	O
social	O
and	O
role	O
functioning	O
)	O
and	O
three	O
symptom	O
scales	O
(	O
appetite	O
loss	O
,	O
fatigue	O
,	O
and	O
dyspnea	O
)	O
,	O
with	O
the	O
PEG-IFN-alpha-2b	O
arm	O
being	O
most	O
impaired	O
.	O

CONCLUSION	O
PEG-IFN-alpha-2b	O
leads	O
to	O
a	O
significant	O
and	O
sustained	O
improvement	O
in	O
RFS	O
.	O

There	O
is	O
an	O
expected	O
negative	O
effect	O
on	O
global	O
HRQOL	O
and	O
selected	O
symptoms	O
when	O
patients	O
undergo	O
PEG-IFN-alpha-2b	O
treatment	O
.	O

The	O
effect	O
of	O
vitamin	O
A-fortified	O
coconut	O
cooking	O
oil	O
on	O
the	O
serum	Condition
retinol	Condition
concentration	Condition
of	O
Filipino	O
children	O
4-7	Age
years	O
old	O
.	O

A	O
6-month	O
intervention	O
trial	O
was	O
conducted	O
among	O
542	SampleSize
Filipino	O
children	O
aged	O
4	Age
to	Age
7	Age
years	O
to	O
determine	O
the	O
effect	O
of	O
vitamin	O
A-fortified	O
coconut	O
cooking	O
oil	O
intake	O
on	O
their	O
vitamin	O
A	O
status	O
and	O
to	O
identify	O
factors	O
that	O
influence	O
this	O
.	O

Children	O
were	O
randomly	O
assigned	O
to	O
the	O
Experimental	O
group	O
,	O
with	O
vitamin	O
A-fortified	O
cooking	O
oil	O
ration	O
;	O
to	O
Control-1	O
group	O
with	O
unfortified	O
cooking	O
oil	O
ration	O
;	O
and	O
to	O
Control-2	O
group	O
without	O
cooking	O
oil	O
ration	O
.	O

In	O
all	O
groups	O
,	O
children	O
's	O
serum	O
retinol	O
concentration	O
improved	O
.	O

Relative	O
change	O
in	O
serum	O
retinol	O
concentration	O
was	O
significantly	O
higher	O
among	O
the	O
Experimental	O
group	O
,	O
with	O
one-third	O
of	O
total	O
vitamin	O
A	O
intake	O
coming	O
from	O
vitamin	O
A-fortified	O
cooking	O
oil	O
intake	O
,	O
than	O
in	O
the	O
Control	O
groups	O
,	O
with	O
more	O
than	O
half	O
of	O
intake	O
from	O
other	O
vitamin	O
A-rich	O
foods	O
.	O

Determinants	O
of	O
post-intervention	O
serum	O
retinol	O
concentration	O
included	O
baseline	O
serum	O
retinol	O
concentration	O
,	O
caregiver	O
's	O
education	O
,	O
receipt	O
of	O
high-dose	O
vitamin	O
A	O
capsule	O
,	O
interaction	O
between	O
consumption	O
of	O
vitamin	O
A-fortified	O
cooking	O
oil	O
and	O
of	O
other	O
vitamin	O
A-rich	O
foods	O
,	O
and	O
between	O
households	O
purchasing	O
cooking	O
oil	O
and	O
food	O
expenditure	O
.	O

Intake	O
of	O
vitamin	O
A-fortified	O
cooking	O
oil	O
combined	O
with	O
vitamin	O
A-rich	O
foods	O
was	O
necessary	O
to	O
increase	O
serum	O
retinol	O
concentration	O
.	O

It	O
is	O
recommended	O
to	O
vigorously	O
promote	O
the	O
consumption	O
of	O
vitamin	O
A-fortified	O
cooking	O
oil	O
together	O
with	O
other	O
vitamin	O
A-rich	O
sources	O
to	O
sustain	O
the	O
prevention	O
and	O
control	O
of	O
vitamin	O
A	O
deficiency	O
.	O

A	O
placebo-controlled	O
trial	O
of	O
maintenance	O
therapy	O
with	O
fluconazole	O
after	O
treatment	O
of	O
cryptococcal	Condition
meningitis	Condition
in	O
the	O
acquired	Condition
immunodeficiency	Condition
syndrome	Condition
.	Condition

California	O
Collaborative	O
Treatment	O
Group	O
.	O

BACKGROUND	O
AND	O
METHODS	O
In	O
patients	O
with	O
the	O
acquired	Condition
immunodeficiency	Condition
syndrome	Condition
(	Condition
AIDS	Condition
)	Condition
,	O
the	O
rate	O
of	O
relapse	O
after	O
primary	O
treatment	O
for	O
cryptococcal	O
meningitis	O
remains	O
high	O
.	O

We	O
conducted	O
a	O
controlled	O
,	O
double-blind	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
maintenance	O
therapy	O
with	O
fluconazole	O
.	O

At	O
entry	O
into	O
the	O
study	O
,	O
all	O
participants	O
had	O
sterile	O
cultures	O
of	O
cerebrospinal	O
fluid	O
,	O
blood	O
,	O
and	O
urine	O
after	O
following	O
a	O
standardized	O
course	O
of	O
therapy	O
for	O
culture-proved	O
cryptococcal	Condition
meningitis	Condition
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
take	O
either	O
fluconazole	O
or	O
placebo	O
as	O
maintenance	O
therapy	O
.	O

The	O
dose	O
of	O
fluconazole	O
was	O
100	O
mg	O
daily	O
in	O
the	O
first	O
phase	O
of	O
study	O
and	O
200	O
mg	O
daily	O
in	O
the	O
second	O
phase	O
.	O

RESULTS	O
Of	O
84	SampleSize
patients	O
initially	O
enrolled	O
,	O
16	SampleSize
(	O
19	O
percent	O
)	O
were	O
found	O
to	O
have	O
silent	O
,	O
persistent	O
infection	Condition
on	O
the	O
basis	O
of	O
cultures	O
that	O
became	O
positive	O
after	O
entry	O
into	O
the	O
study	O
;	O
7	SampleSize
other	O
patients	O
were	O
lost	O
to	O
follow-up	O
shortly	O
after	O
entry	O
.	O

Of	O
the	O
remaining	O
61	SampleSize
patients	O
,	O
10	O
of	O
27	O
assigned	O
to	O
placebo	O
(	O
37	O
percent	O
)	O
and	O
1	O
of	O
34	O
assigned	O
to	O
fluconazole	O
(	O
3	O
percent	O
)	O
had	O
a	O
recurrence	O
of	O
cryptococcal	O
infection	O
at	O
any	O
site	O
(	O
difference	O
in	O
risk	O
,	O
34	O
percent	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
15	O
to	O
53	O
)	O
.	O

Of	O
the	O
11	O
recurrent	O
infections	O
,	O
7	O
were	O
detected	O
in	O
urine	O
obtained	O
after	O
prostatic	O
massage	O
.	O

There	O
were	O
four	O
recurrent	O
meningeal	O
infections	O
in	O
the	O
patients	O
taking	O
placebo	O
,	O
but	O
none	O
in	O
those	O
taking	O
fluconazole	O
(	O
mean	O
duration	O
of	O
follow-up	O
,	O
164	O
days	O
)	O
(	O
P	O
=	O
0.03	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
the	O
best	O
predictors	O
of	O
recurrence-free	O
survival	O
were	O
fluconazole	O
treatment	O
(	O
P	O
=	O
0.02	O
;	O
relative	O
hazard	O
,	O
13.2	O
)	O
,	O
a	O
lower	O
serum	O
cryptococcal-antigen	O
titer	O
(	O
P	O
=	O
0.05	O
;	O
relative	O
hazard	O
,	O
1.2	O
)	O
,	O
and	O
more	O
prolonged	O
primary	O
therapy	O
with	O
flucytosine	O
(	O
P	O
=	O
0.09	O
;	O
relative	O
hazard	O
,	O
1.1	O
)	O
.	O

Survival	O
and	O
toxicity	O
were	O
similar	O
in	O
the	O
two	O
maintenance-treatment	O
groups	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
AIDS	Condition
,	O
silent	O
persistent	O
infection	O
is	O
common	O
after	O
clinically	O
successful	O
treatment	O
for	O
cryptococcal	O
meningitis	O
.	O

Maintenance	O
therapy	O
with	O
fluconazole	O
is	O
highly	O
effective	O
in	O
preventing	O
recurrent	O
cryptococcal	O
infection	O
.	O

[	O
Acute	O
cardiovascular	O
and	O
metabolic	O
changes	O
in	O
interval	O
and	O
endurance	O
training	O
in	O
selected	Condition
patients	Condition
following	Condition
aortocoronary	Condition
bypass	Condition
operation	Condition
]	O
.	O

UNLABELLED	O
This	O
study	O
compared	O
the	O
acute	O
changes	O
of	O
cardiovascular	O
and	O
metabolic	O
reactions	O
during	O
interval	O
and	O
continuous	O
training	O
after	O
coronary	O
bypass	O
surgery	O
.	O

Two	O
groups	O
of	O
9	SampleSize
male	Sex
patients	O
(	O
age	Age
:	Age
59	Age
+/-	Age
4	Age
and	Age
56	Age
+/-	Age
6	Age
years	Age
,	Age
resp	Age
.	O

)	O
each	O
trained	O
on	O
bicycle	O
ergometer	O
start	O
on	O
post-operative	O
days	O
24	O
and	O
26	O
,	O
resp	O
.	O

In	O
both	O
training	O
groups	O
training	O
heart	O
rate	O
was	O
set	O
at	O
86	O
%	O
of	O
individual	O
maximum	O
heart	O
rate	O
.	O

In	O
the	O
last	O
week	O
of	O
training	O
the	O
exercise	O
intensity	O
in	O
the	O
group	O
of	O
patients	O
who	O
were	O
trained	O
by	O
the	O
continuous	O
method	O
was	O
at	O
83	O
watts	O
,	O
and	O
at	O
20:121	O
watts	O
in	O
the	O
group	O
of	O
patients	O
who	O
were	O
trained	O
by	O
interval	O
method	O
(	O
rest	O
:	O
work	O
each	O
1:1	O
min	O
)	O
.	O

At	O
this	O
exercise	O
training	O
that	O
lasted	O
for	O
20	O
min	O
the	O
acute	O
response	O
of	O
heart	O
rate	O
,	O
blood	O
pressure	O
,	O
rate-pressure	O
product	O
,	O
glucose	O
,	O
lactate	O
and	O
catecholamines	O
was	O
measured	O
.	O

RESULTS	O
In	O
both	O
methods	O
there	O
were	O
no	O
significant	O
differences	O
in	O
systolic	O
and	O
diastolic	O
pressure	O
,	O
rate-pressure	O
product	O
,	O
in	O
glucose	O
or	O
catecholamine	O
levels	O
.	O

However	O
,	O
there	O
was	O
a	O
significantly	O
higher	O
rate	O
of	O
lactate	O
in	O
the	O
second	O
10	O
min	O
of	O
the	O
interval	O
training	O
.	O

And	O
,	O
in	O
spite	O
of	O
higher	O
peripheral	O
exercise	O
intensity	O
by	O
interval	O
training	O
,	O
there	O
was	O
no	O
higher	O
cardiac	O
work	O
than	O
by	O
the	O
continuous	O
training	O
.	O

These	O
findings	O
suggest	O
that	O
interval	O
training	O
strains	O
the	O
oxidative	O
capacity	O
of	O
the	O
trained	O
muscles	O
in	O
a	O
more	O
intensive	O
and	O
direct	O
way	O
than	O
does	O
continuous	O
training	O
.	O

Comparative	O
study	O
of	O
actinic	Condition
keratosis	Condition
treatment	O
with	O
3	O
%	O
diclofenac	O
sodium	O
and	O
5	O
%	O
5-fluorouracil	O
.	O

BACKGROUND	O
Actinic	Condition
keratosis	Condition
is	O
a	O
frequent	O
lesion	O
which	O
occurs	O
in	O
sunlight	O
exposed	O
areas	O
.	O

Diclofenac	O
sodium	O
and	O
5-Fluorouracil	O
are	O
effective	O
,	O
non-invasive	O
and	O
easy-to-apply	O
topical	O
treatment	O
options	O
.	O

OBJECTIVES	O
To	O
assess	O
and	O
compare	O
the	O
effectiveness	O
of	O
3	O
%	O
diclofenac	O
sodium	O
associated	O
with	O
2.5	O
%	O
hyaluronic	O
acid	O
and	O
of	O
5	O
%	O
5-Fluorouracil	O
for	O
the	O
treatment	O
of	O
actinic	O
keratosis	O
,	O
as	O
well	O
as	O
the	O
patient	O
's	O
degree	O
of	O
satisfaction	O
and	O
tolerability	O
.	O

METHODS	O
28	SampleSize
patients	SampleSize
with	O
a	O
clinical	Condition
diagnosis	Condition
of	Condition
actinic	Condition
keratosis	Condition
were	O
randomized	O
to	O
receive	O
diclofenac	O
sodium	O
or	O
5-Fluorouracil	O
and	O
were	O
clinically	O
assessed	O
before	O
and	O
after	O
treatment	O
as	O
well	O
as	O
8	O
weeks	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Modified	O
versions	O
of	O
the	O
Investigator	O
and	O
Patient	O
Global	O
Improvement	O
Scores	O
were	O
used	O
.	O

RESULTS	O
The	O
average	O
number	O
of	O
lesions	O
in	O
the	O
diclofenac	O
sodium	O
group	O
before	O
and	O
after	O
treatment	O
was	O
13.6	O
and	O
6.6	O
(	O
p	O
<	O
0,001	O
)	O
,	O
respectively	O
,	O
while	O
it	O
was	O
17.4	O
and	O
3.15	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
5-Fluorouracil	O
group	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
lesions	O
in	O
the	O
5-Fluorouracil	O
group	O
in	O
relation	O
to	O
the	O
diclofenac	O
sodium	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

To	O
the	O
non-blinded	O
physician	O
,	O
there	O
was	O
a	O
higher	O
satisfactory	O
therapeutic	O
response	O
in	O
the	O
5-Fluorouracil	O
group	O
(	O
p	O
<	O
0.001	O
)	O
;	O
to	O
the	O
blinded	O
physician	O
,	O
there	O
was	O
a	O
higher	O
satisfactory	O
response	O
in	O
this	O
same	O
group	O
,	O
although	O
not	O
statistically	O
significant	O
(	O
p=0.09	O
)	O
.	O

There	O
was	O
a	O
high	O
degree	O
of	O
satisfaction	O
in	O
both	O
groups	O
(	O
73	O
%	O
in	O
the	O
diclofenac	O
sodium	O
group	O
and	O
77	O
%	O
in	O
the	O
5-Fluorouracil	O
group	O
;	O
p=0.827	O
)	O
.	O

Regarding	O
adverse	O
effects	O
,	O
the	O
diclofenac	O
sodium	O
group	O
presented	O
a	O
higher	O
degree	O
of	O
satisfaction	O
(	O
93.3	O
%	O
vs	O
38.4	O
%	O
;	O
p=0.008	O
)	O
.	O

Erythema	O
,	O
edema	O
,	O
crusts	O
and	O
itching	O
were	O
significantly	O
higher	O
in	O
the	O
5-Fluorouracil	O
group	O
.	O

CONCLUSION	O
We	O
concluded	O
that	O
5-Fluorouracil	O
was	O
more	O
effective	O
;	O
however	O
,	O
it	O
showed	O
lower	O
tolerability	O
than	O
diclofenac	O
sodium	O
.	O

[	O
Encephalopathy	O
therapeutic	O
tongue	O
acupoint	O
apparatus	O
(	O
ETTAA	O
)	O
for	O
42	O
cases	O
of	O
autism	Condition
]	O
.	O

OBJECTIVE	O
To	O
observe	O
the	O
efficacy	O
of	O
encephalopathy	O
therapeutic	O
tongue	O
acupoint	O
apparatus	O
(	O
ETTAA	O
)	O
in	O
the	O
treatment	O
of	O
autism	Condition
.	O

METHODS	O
Eighty-four	SampleSize
children	Age
of	O
autism	Condition
were	O
randomly	O
divided	O
into	O
a	O
tongue	O
acupuncture	O
group	O
(	O
group	O
A	O
)	O
and	O
a	O
conventional	O
training	O
group	O
(	O
group	O
B	O
)	O
,	O
42	O
cases	O
in	O
each	O
group	O
.	O

The	O
behavior	O
training	O
and	O
sensory	O
integration	O
training	O
were	O
carried	O
out	O
in	O
group	O
B	O
and	O
the	O
ETTAA	O
was	O
added	O
in	O
group	O
A	O
.	O

The	O
apparatus	O
was	O
switched	O
on	O
for	O
20	O
min	O
every	O
time	O
and	O
3	O
times	O
a	O
day	O
.	O

Treatment	O
of	O
two	O
months	O
were	O
carried	O
out	O
in	O
both	O
groups	O
.	O

The	O
score	O
of	O
childhood	O
autism	O
rating	O
scale	O
(	O
CARS	O
)	O
and	O
clinical	O
efficacy	O
in	O
both	O
groups	O
were	O
observed	O
before	O
and	O
after	O
treatment	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
CARS	O
in	O
both	O
groups	O
were	O
significantly	O
reduced	O
(	O
42.39	O
+/-	O
6.86	O
vs	O
32.15	O
+/-	O
5.12	O
,	O
P	O
<	O
0.001	O
;	O
44.58	O
+/-	O
6.76	O
vs	O
39.72	O
+/-	O
7.11	O
,	O
P	O
<	O
0.05	O
)	O
,	O
which	O
was	O
more	O
significant	O
in	O
group	O
A	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
totally	O
effective	O
rate	O
in	O
group	O
A	O
[	O
90.5	O
%	O
(	O
38/42	O
)	O
]	O
was	O
superior	O
to	O
that	O
in	O
group	O
B	O
[	O
66.7	O
%	O
(	O
28/42	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O

CONCLUSION	O
The	O
clinical	O
efficacy	O
in	O
tongue	O
acupuncture	O
group	O
is	O
apparently	O
superior	O
to	O
that	O
in	O
conventional	O
training	O
group	O
,	O
ETTAA	O
combined	O
with	O
conventional	O
training	O
have	O
a	O
better	O
curative	O
effect	O
in	O
the	O
treatment	O
of	O
autism	Condition
.	O

Comparative	O
effects	O
of	O
valsartan	O
versus	O
amlodipine	O
on	O
left	O
ventricular	O
mass	O
and	O
reactive	O
oxygen	O
species	O
formation	O
by	O
monocytes	O
in	O
hypertensive	O
patients	O
with	O
left	O
ventricular	O
hypertrophy	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
effects	O
of	O
the	O
angiotensin	O
receptor	O
blocker	O
(	O
ARB	O
)	O
valsartan	O
versus	O
the	O
calcium	O
channel	O
blocker	O
amlodipine	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
formation	O
by	O
monocytes	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
and	O
left	O
ventricular	O
(	O
LV	O
)	O
mass	O
were	O
studied	O
in	O
104	O
hypertensive	O
patients	O
with	O
left	O
ventricular	O
hypertrophy	O
(	O
LVH	O
)	O
.	O

BACKGROUND	O
There	O
is	O
evidence	O
that	O
ARBs	O
have	O
blood	O
pressure	O
(	O
BP	O
)	O
-independent	O
effects	O
on	O
LV	O
mass	O
.	O

Whether	O
regression	O
of	O
LV	O
mass	O
by	O
ARBs	O
is	O
correlated	O
to	O
ROS	O
formation	O
by	O
monocytes	O
and	O
CRP	O
is	O
not	O
fully	O
understood	O
yet	O
.	O

METHODS	O
A	O
cross-sectional	O
and	O
prospective	O
study	O
was	O
performed	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
either	O
the	O
80-mg	O
valsartan	O
(	O
n	O
=	O
52	O
)	O
or	O
5-mg	O
amlodipine	O
(	O
n	O
=	O
52	O
)	O
group	O
and	O
were	O
treated	O
for	O
eight	O
months	O
.	O

The	O
left	O
ventricular	O
mass	O
index	O
(	O
LVMI	O
)	O
was	O
calculated	O
from	O
two-dimensional	O
M-mode	O
echocardiography	O
.	O

Formation	O
of	O
ROS	O
by	O
monocytes	O
was	O
measured	O
by	O
gated	O
flow	O
cytometry	O
.	O

In	O
addition	O
,	O
CRP	O
,	O
plasma	O
renin	O
activity	O
,	O
plasma	O
aldosterone	O
,	O
and	O
traditional	O
risk	O
factors	O
were	O
assessed	O
.	O

RESULTS	O
Multiple	O
regression	O
analysis	O
showed	O
a	O
significant	O
correlation	O
between	O
LVMI	O
and	O
ROS	O
formation	O
by	O
monocytes	O
and	O
between	O
LVMI	O
and	O
CRP	O
.	O

Treatment	O
reduced	O
BP	O
to	O
a	O
similar	O
extent	O
in	O
both	O
groups	O
.	O

Valsartan	O
significantly	O
reduced	O
LVMI	O
after	O
eight	O
months	O
,	O
but	O
amlodipine	O
had	O
less	O
effect	O
(	O
16	O
%	O
vs.	O
1.2	O
%	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Formation	O
of	O
ROS	O
by	O
monocytes	O
was	O
reduced	O
to	O
a	O
greater	O
extent	O
with	O
valsartan	O
than	O
with	O
amlodipine	O
(	O
28	O
%	O
vs.	O
2	O
%	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Valsartan	O
but	O
not	O
amlodipine	O
reduced	O
CRP	O
levels	O
.	O

A	O
significant	O
correlation	O
between	O
changes	O
in	O
ROS	O
formation	O
by	O
monocytes	O
and	O
LVMI	O
or	O
between	O
CRP	O
and	O
LVMI	O
was	O
observed	O
.	O

CONCLUSIONS	O
The	O
ARB	O
valsartan	O
has	O
BP-independent	O
effects	O
on	O
LVH	O
,	O
ROS	O
formation	O
by	O
monocytes	O
,	O
and	O
CRP	O
in	O
hypertensive	O
patients	O
with	O
LVH	O
.	O

Randomised	O
Phase	O
I/II	O
trial	O
assessing	O
the	O
safety	O
and	O
efficacy	O
of	O
radiolabelled	O
anti-carcinoembryonic	O
antigen	O
I	O
(	O
131	O
)	O
KAb201	O
antibodies	O
given	O
intra-arterially	O
or	O
intravenously	O
in	O
patients	O
with	O
unresectable	O
pancreatic	O
adenocarcinoma	O
.	O

BACKGROUND	O
Advanced	O
pancreatic	O
cancer	O
has	O
a	O
poor	O
prognosis	O
,	O
and	O
the	O
current	O
standard	O
of	O
care	O
(	O
gemcitabine	O
based	O
chemotherapy	O
)	O
provides	O
a	O
small	O
survival	O
advantage	O
.	O

However	O
the	O
drawback	O
is	O
the	O
accompanying	O
systemic	O
toxicity	O
,	O
which	O
targeted	O
treatments	O
may	O
overcome	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
KAb201	O
,	O
an	O
anti-carcinoembryonic	O
antigen	O
monoclonal	O
antibody	O
,	O
labelled	O
with	O
I	O
(	O
131	O
)	O
in	O
pancreatic	O
cancer	O
(	O
ISRCTN	O
16857581	O
)	O
.	O

METHODS	O
Patients	O
with	O
histological/cytological	O
proven	O
inoperable	O
adenocarcinoma	O
of	O
the	O
head	O
of	O
pancreas	O
were	O
randomised	O
to	O
receive	O
KAb	O
201	O
via	O
either	O
the	O
intra-arterial	O
or	O
intravenous	O
delivery	O
route	O
.	O

The	O
dose	O
limiting	O
toxicities	O
within	O
each	O
group	O
were	O
determined	O
.	O

Patients	O
were	O
assessed	O
for	O
safety	O
and	O
efficacy	O
and	O
followed	O
up	O
until	O
death	O
.	O

RESULTS	O
Between	O
February	O
2003	O
and	O
July	O
2005	O
,	O
25	O
patients	O
were	O
enrolled	O
.	O

Nineteen	O
patients	O
were	O
randomised	O
,	O
9	O
to	O
the	O
intravenous	O
and	O
10	O
to	O
the	O
intra-arterial	O
arms	O
.	O

In	O
the	O
intra-arterial	O
arm	O
,	O
dose	O
limiting	O
toxicity	O
was	O
seen	O
in	O
2/6	O
(	O
33	O
%	O
)	O
patients	O
at	O
50	O
mCi	O
whereas	O
in	O
the	O
intravenous	O
arm	O
,	O
dose	O
limiting	O
toxicity	O
was	O
noted	O
in	O
1/6	O
patients	O
at	O
50	O
mCi	O
,	O
but	O
did	O
not	O
occur	O
at	O
75	O
mCi	O
(	O
0/3	O
)	O
.The	O
overall	O
response	O
rate	O
was	O
6	O
%	O
(	O
1/18	O
)	O
.	O

Median	O
overall	O
survival	O
was	O
5.2	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
=	O
3.3	O
to	O
9	O
months	O
)	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
intravenous	O
and	O
intra-arterial	O
arms	O
(	O
log	O
rank	O
test	O
p	O
=	O
0.79	O
)	O
.	O

One	O
patient	O
was	O
still	O
alive	O
at	O
the	O
time	O
of	O
this	O
analysis	O
.	O

CONCLUSION	O
Dose	O
limiting	O
toxicity	O
for	O
KAb201	O
with	O
I	O
(	O
131	O
)	O
by	O
the	O
intra-arterial	O
route	O
was	O
50	O
mCi	O
,	O
while	O
dose	O
limiting	O
toxicity	O
was	O
not	O
reached	O
in	O
the	O
intravenous	O
arm	O
.	O

Laparoscopic	Condition
hysterectomy	Condition
:	O
is	O
dissecting	O
the	O
ureter	O
necessary	O
?	O
Laparoscopic	O
hysterectomy	O
has	O
been	O
first	O
reported	O
by	O
Reich	O
et	O
al	O
.	O

in	O
1989	O
,	O
which	O
confirmed	O
the	O
possibility	O
of	O
laparoscopic	O
hysterectomy	O
being	O
employed	O
as	O
a	O
replacement	O
of	O
the	O
vast	O
majority	O
of	O
traditional	O
abdominal	O
hysterectomies	O
.	O

There	O
are	O
three	O
critical	O
points	O
in	O
laparoscopic	O
hysterectomy	O
.	O

The	O
most	O
important	O
critical	O
point	O
is	O
to	O
identify	O
uterine	O
arteries	O
from	O
the	O
ureter	O
in	O
the	O
paracervical	O
area	O
.	O

Several	O
ureteral	O
injuries	O
at	O
operative	O
laparoscopy	O
have	O
been	O
reported	O
.	O

We	O
performed	O
two	O
hundred	O
and	O
thirty	O
laparoscopic	Condition
hysterectomies	Condition
during	O
the	O
period	O
from	O
March	O
1991	O
to	O
October	O
1993	O
.	O

Sixty	SampleSize
patients	O
were	O
later	O
included	O
in	O
this	O
study	O
.	O

Thirty	O
of	O
these	O
applied	O
the	O
technique	O
of	O
dissecting	O
the	O
ureter	O
at	O
the	O
initiation	O
of	O
laparoscopic	O
hysterectomy	O
.	O

Most	O
of	O
the	O
patients	O
were	O
discharged	O
on	O
the	O
second	O
postoperative	O
day	O
.	O

Although	O
dissecting	O
the	O
ureter	O
at	O
the	O
beginning	O
of	O
the	O
operation	O
did	O
not	O
produce	O
a	O
significant	O
discrepancy	O
in	O
operation	O
time	O
,	O
blood	O
loss	O
,	O
hospitalization	O
day	O
and	O
ureter	O
injury	O
when	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
uterine	O
arteries	O
,	O
however	O
,	O
may	O
be	O
confidently	O
desiccated	O
once	O
the	O
path	O
of	O
the	O
ureter	O
near	O
the	O
uterosacral	O
ligament	O
is	O
identified	O
.	O

Anticholinergic	O
drugs	O
:	O
effects	O
on	O
oxygen	O
consumption	O
and	O
energy	O
expenditure	O
.	O

Premedication	O
has	O
been	O
shown	O
to	O
affect	O
both	O
oxygen	O
consumption	O
(	O
VO2	O
)	O
and	O
energy	O
expenditure	O
(	O
EE	O
)	O
.	O

The	O
metabolic	O
responses	O
to	O
anticholinergic	O
drugs	O
have	O
not	O
been	O
studied	O
.	O

In	O
this	O
study	O
the	O
effects	O
of	O
anticholinergic	O
drugs	O
on	O
VO2	O
and	O
EE	O
(	O
calculated	O
from	O
the	O
measured	O
rates	O
of	O
VO2	O
and	O
carbon	O
dioxide	O
production	O
[	O
VCO2	O
]	O
:	O
EE	O
[	O
kcal/d	O
]	O
=	O
3.581	O
x	O
VO2	O
[	O
L/d	O
]	O
+	O
1.448	O
x	O
VCO2	O
[	O
L/d	O
]	O
-	O
32.4	O
)	O
were	O
measured	O
in	O
six	SampleSize
healthy	O
female	Sex
volunteers	O
.	O

They	O
were	O
given	O
intramuscular	O
atropine	O
(	O
15	O
micrograms/kg	O
)	O
,	O
glycopyrrolate	O
(	O
8	O
micrograms/kg	O
)	O
,	O
scopolamine	O
(	O
8	O
micrograms/kg	O
)	O
,	O
and	O
placebo	O
in	O
a	O
random	O
double-blind	O
cross-over	O
design	O
.	O

The	O
consecutive	O
sessions	O
were	O
at	O
least	O
1	O
wk	O
apart	O
for	O
each	O
subject	O
.	O

VO2	O
and	O
EE	O
were	O
measured	O
using	O
an	O
indirect	O
calorimetry	O
(	O
Deltatrac	O
)	O
.	O

Cardiovascular	O
responses	O
were	O
assessed	O
using	O
standard	O
noninvasive	O
monitoring	O
.	O

Plasma	O
drug	O
concentrations	O
were	O
analyzed	O
using	O
a	O
sensitive	O
modification	O
of	O
radioreceptor	O
assay	O
.	O

Subjective	O
responses	O
were	O
measured	O
with	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
.	O

Atropine	O
and	O
glycopyrrolate	O
induced	O
a	O
significant	O
increase	O
in	O
heart	O
rate	O
with	O
a	O
simultaneous	O
decrease	O
in	O
pressure	O
rate	O
quotient	O
(	O
PRQ	O
)	O
,	O
while	O
scopolamine	O
caused	O
a	O
significant	O
decrease	O
in	O
heart	O
rate	O
with	O
a	O
simultaneous	O
increase	O
in	O
PRQ	O
.	O

Scopolamine	O
significantly	O
decreased	O
both	O
VO2	O
and	O
EE	O
,	O
whereas	O
glycopyrrolate	O
increased	O
VO2	O
.	O

Atropine	O
had	O
no	O
significant	O
effect	O
on	O
metabolic	O
variables	O
.	O

Only	O
scopolamine	O
induced	O
sedation	O
in	O
this	O
study	O
.	O

In	O
conclusion	O
,	O
atropine	O
,	O
glycopyrrolate	O
,	O
and	O
scopolamine	O
differ	O
not	O
only	O
in	O
their	O
cardiovascular	O
and	O
central	O
nervous	O
system	O
effects	O
,	O
but	O
also	O
in	O
their	O
effects	O
on	O
metabolism	O
.	O

Granulocyte-colony	O
stimulating	O
factor	O
for	O
mobilizing	O
bone	O
marrow	O
stem	O
cells	O
in	O
subacute	O
stroke	O
:	O
the	O
stem	O
cell	O
trial	O
of	O
recovery	O
enhancement	O
after	O
stroke	Condition
2	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Granulocyte-colony	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
is	O
neuroprotective	O
in	O
experimental	O
stroke	O
and	O
mobilizes	O
CD34	O
(	O
+	O
)	O
peripheral	O
blood	O
stem	O
cells	O
into	O
the	O
circulation	O
.	O

We	O
assessed	O
the	O
safety	O
of	O
G-CSF	O
in	O
recent	O
stroke	O
in	O
a	O
phase	O
IIb	O
single-center	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
G-CSF	O
(	O
10	O
?g/kg	O
)	O
or	O
placebo	O
(	O
ratio	O
2:1	O
)	O
was	O
given	O
SC	O
for	O
5	O
days	O
to	O
60	O
patients	O
3	O
to	O
30	O
days	O
after	O
ischemic	O
or	O
hemorrhagic	O
stroke	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
frequency	O
of	O
serious	O
adverse	O
events	O
.	O

Peripheral	O
blood	O
counts	O
,	O
CD34	O
(	O
+	O
)	O
count	O
,	O
and	O
functional	O
outcome	O
were	O
measured	O
.	O

MRI	O
assessed	O
lesion	O
volume	O
,	O
atrophy	O
,	O
and	O
the	O
presence	O
of	O
iron-labeled	O
CD34	O
(	O
+	O
)	O
cells	O
reinjected	O
on	O
day	O
6	O
.	O

RESULTS	O
Sixty	O
patients	O
were	O
recruited	O
at	O
mean	O
of	O
8	O
days	O
(	O
SD	O
?	O
5	O
)	O
post	O
ictus	O
,	O
with	O
mean	O
age	O
71	O
years	O
(	O
?	O
12	O
years	O
)	O
and	O
53	O
%	O
men	O
.	O

The	O
groups	O
were	O
well	O
matched	O
for	O
baseline	O
minimization/prognostic	O
factors	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
the	O
number	O
of	O
participants	O
with	O
serious	O
adverse	O
events	O
:	O
G-CSF	O
15	O
(	O
37.5	O
%	O
)	O
of	O
40	O
versus	O
placebo	O
7	O
(	O
35	O
%	O
)	O
of	O
20	O
,	O
death	O
or	O
dependency	O
(	O
modified	O
Rankin	O
Score	O
:	O
G-CSF	O
3.3	O
?	O
1.3	O
,	O
placebo	O
3.0	O
?	O
1.3	O
)	O
at	O
90	O
days	O
,	O
or	O
the	O
number	O
of	O
injections	O
received	O
.	O

G-CSF	O
increased	O
CD34	O
(	O
+	O
)	O
and	O
total	O
white	O
cell	O
counts	O
of	O
9.5-	O
and	O
4.2-fold	O
,	O
respectively	O
.	O

There	O
was	O
a	O
trend	O
toward	O
reduction	O
in	O
MRI	O
ischemic	O
lesion	O
volume	O
with	O
respect	O
to	O
change	O
from	O
baseline	O
in	O
G-CSF-treated	O
patients	O
(	O
P=0.06	O
)	O
.	O

In	O
1	O
participant	O
,	O
there	O
was	O
suggestion	O
that	O
labeled	O
CD34	O
(	O
+	O
)	O
cells	O
had	O
migrated	O
to	O
the	O
ischemic	O
lesion	O
.	O

CONCLUSIONS	O
This	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
suggests	O
that	O
G-CSF	O
is	O
safe	O
when	O
administered	O
subacutely	O
.	O

It	O
is	O
feasible	O
to	O
label	O
and	O
readminister	O
iron-labeled	O
CD34	O
(	O
+	O
)	O
cells	O
in	O
patients	O
with	O
ischemic	O
stroke	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
URL	O
:	O
www.controlled-trials.com	O
.	O

Unique	O
identifier	O
:	O
ISRCTN63336619	O
.	O

Oral	O
contraceptive	O
use	O
is	O
associated	O
with	O
increased	O
cardiovascular	O
reactivity	O
in	O
nonsmokers	O
.	O

Women	O
who	O
smoke	O
and	O
take	O
oral	O
contraceptives	O
(	O
OCs	O
)	O
have	O
significantly	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
,	O
but	O
the	O
exact	O
mechanismsfor	O
the	O
increased	O
risk	O
are	O
not	O
known	O
.	O

Cardiovascular	O
reactivity	O
to	O
psychological	O
stress	O
may	O
be	O
one	O
mechanism	O
for	O
the	O
enhanced	O
risk	O
,	O
but	O
the	O
small	O
number	O
of	O
studies	O
examining	O
whether	O
OC	O
users	O
who	O
smoke	O
have	O
greater	O
reactivity	O
have	O
produced	O
mixed	O
results	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
chronic	O
cigarette	O
smoking	O
,	O
acute	O
nicotine	O
administration	O
,	O
and	O
OC	O
use	O
on	O
cardiovascular	O
and	O
lipid	O
reactivity	O
.	O

Sixty	O
healthy	O
women	O
,	O
half	O
of	O
whom	O
had	O
been	O
using	O
OCs	O
for	O
at	O
least	O
the	O
previous	O
6	O
months	O
,	O
participated	O
in	O
the	O
study	O
.	O

Approximately	O
two	O
thirds	O
were	O
smokers	O
and	O
were	O
randomized	O
to	O
be	O
tested	O
after	O
either	O
a	O
12-hr	O
nicotine	O
deprivation	O
or	O
administration	O
of	O
nicotine	O
gum	O
.	O

One	O
third	O
were	O
nonsmokers	O
.	O

Heart	O
rate	O
,	O
blood	O
pressure	O
,	O
and	O
lipid	O
measures	O
were	O
taken	O
at	O
rest	O
,	O
during	O
a	O
videotaped	O
speech	O
task	O
,	O
and	O
during	O
recovery	O
from	O
the	O
task	O
.	O

Results	O
indicated	O
that	O
,	O
among	O
OC	O
nonusers	O
,	O
there	O
was	O
no	O
effect	O
of	O
smoking	O
status	O
or	O
nicotine	O
administration	O
on	O
cardiovascular	O
reactivity	O
.	O

However	O
,	O
among	O
OC	O
users	O
,	O
nonsmokers	O
had	O
significantly	O
greater	O
heart	O
rate	O
and	O
diastolic	O
blood	O
pressure	O
reactivity	O
to	O
stress	O
.	O

These	O
data	O
show	O
that	O
acute	O
nicotine	O
administration	O
,	O
in	O
the	O
form	O
of	O
nicotine	O
gum	O
,	O
has	O
no	O
effect	O
on	O
cardiovascular	O
or	O
lipid	O
stress	O
reactivity	O
in	O
women	O
.	O

However	O
OC	O
use	O
among	O
nonsmoking	O
women	O
is	O
associated	O
with	O
greater	O
cardiovascular	O
reactivity	O
to	O
stress	O
.	O

Reduction	O
of	O
oral	O
mucositis	O
by	O
filgrastim	O
(	O
r-metHuG-CSF	O
)	O
in	O
patients	Condition
receiving	Condition
chemotherapy	Condition
.	O

Mucositis	O
,	O
the	O
inflammation	O
and	O
necrosis	O
of	O
mucosal	O
membranes	O
,	O
is	O
a	O
serious	O
and	O
debilitating	O
consequence	O
of	O
many	O
cancer	O
therapies	O
.	O

We	O
were	O
interested	O
in	O
the	O
potential	O
role	O
of	O
filgrastim	O
(	O
recombinant	O
methionyl	O
human	O
granulocyte	O
colony-stimulating	O
factor	O
,	O
r-metHuG-CSF	O
)	O
in	O
the	O
reduction	O
of	O
mucositis	O
.	O

Patients	O
with	O
newly	Condition
diagnosed	Condition
small-cell	Condition
lung	Condition
cancer	Condition
(	Condition
SCLC	Condition
)	Condition
were	O
treated	O
with	O
CAE	O
chemotherapy	O
(	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
etoposide	O
)	O
and	O
placebo	O
or	O
filgrastim	O
.	O

If	O
patients	O
had	O
an	O
episode	O
of	O
febrile	O
neutropenia	O
,	O
they	O
received	O
unblinded	O
filgrastim	O
in	O
subsequent	O
CAE	O
cycles	O
.	O

Oral	O
mucositis	O
was	O
considered	O
to	O
have	O
occurred	O
if	O
a	O
patient	O
reported	O
any	O
clinical	O
sign	O
or	O
symptom	O
of	O
oral	O
mucositis	O
with	O
or	O
without	O
oral	O
candidiasis	O
.	O

Oral	O
mucositis	O
was	O
analyzed	O
using	O
the	O
unadjusted	O
chi-square	O
test	O
,	O
and	O
time	O
to	O
first	O
episode	O
of	O
mucositis	O
was	O
analyzed	O
using	O
the	O
stratified	O
log-rank	O
test	O
as	O
well	O
as	O
the	O
Cox	O
proportional	O
hazards	O
regression	O
model	O
.	O

During	O
cycle	O
1	O
,	O
placebo-treated	O
patients	O
had	O
more	O
episodes	O
of	O
mucositis	O
(	O
47	O
%	O
)	O
compared	O
with	O
those	O
patients	O
randomized	O
to	O
filgrastim	O
(	O
28	O
%	O
)	O
.	O

Across	O
all	O
cycles	O
of	O
treatment	O
,	O
70	O
%	O
of	O
placebo-treated	O
patients	O
experienced	O
mucositis	O
,	O
compared	O
with	O
53	O
%	O
of	O
patients	O
randomized	O
to	O
filgrastim	O
.	O

A	O
significant	O
reduction	O
in	O
the	O
incidence	O
of	O
chemotherapy-related	O
oral	O
mucositis	O
occurred	O
across	O
multiple	O
cycles	O
of	O
treatment	O
in	O
patients	O
treated	O
with	O
filgrastim	O
.	O

The	O
interaction	O
between	O
propofol	O
and	O
clonidine	O
for	O
loss	O
of	O
consciousness	O
.	O

UNLABELLED	O
Clonidine	O
premedication	O
reduces	O
the	O
intraoperative	O
requirement	O
for	O
opioids	O
and	O
volatile	O
anesthetics	O
.	O

Clonidine	O
also	O
reduces	O
the	O
induction	O
dose	O
of	O
IV	O
anesthetics	O
.	O

There	O
is	O
no	O
information	O
,	O
however	O
,	O
regarding	O
the	O
effect	O
of	O
oral	O
clonidine	O
premedication	O
on	O
the	O
propofol	O
blood	O
concentrations	O
required	O
for	O
loss	O
of	O
consciousness	O
,	O
and	O
the	O
interaction	O
between	O
propofol	O
and	O
clonidine	O
.	O

We	O
randomly	O
administered	O
target	O
effect-site	O
concentrations	O
of	O
propofol	O
ranging	O
from	O
0.5	O
to	O
5	O
.	O

0	O
microg/mL	O
by	O
using	O
computer-assisted	O
target-controlled	O
infusion	O
to	O
3	O
groups	O
of	O
healthy	Condition
male	Sex
patients	O
:	O
Control	O
(	O
n	O
=	O
35	SampleSize
)	O
,	O
2.5	O
microg/kg	O
Clonidine	O
(	O
n	O
=	O
36	SampleSize
)	O
,	O
and	O
5.0	O
microg/kg	O
Clonidine	O
(	O
n	O
=	O
36	SampleSize
)	O
groups	O
.	O

Nothing	O
was	O
administered	O
to	O
the	O
Control	O
group	O
.	O

Clonidine	O
(	O
2.5	O
or	O
5.0	O
microg/kg	O
)	O
was	O
administered	O
orally	O
90	O
min	O
before	O
the	O
induction	O
of	O
anesthesia	O
in	O
the	O
Clonidine	O
groups	O
.	O

After	O
equilibration	O
between	O
the	O
blood	O
and	O
effect-site	O
for	O
15	O
min	O
,	O
a	O
verbal	O
command	O
to	O
open	O
their	O
eyes	O
was	O
given	O
two	O
times	O
to	O
the	O
patients	O
.	O

Arterial	O
blood	O
samples	O
for	O
analysis	O
of	O
the	O
serum	O
propofol	O
and	O
clonidine	O
concentrations	O
were	O
taken	O
immediately	O
before	O
verbal	O
commands	O
were	O
given	O
.	O

Measured	O
serum	O
propofol	O
concentrations	O
in	O
equilibrium	O
with	O
the	O
effect-site	O
at	O
which	O
50	O
%	O
of	O
the	O
patients	O
did	O
not	O
respond	O
to	O
verbal	O
commands	O
(	O
EC50	O
for	O
loss	O
of	O
consciousness	O
)	O
were	O
determined	O
by	O
logistic	O
regression	O
.	O

The	O
EC50	O
+/-	O
SE	O
values	O
in	O
the	O
Control	O
,	O
2.5	O
microg/kg	O
Clonidine	O
,	O
and	O
5.0	O
microg/kg	O
Clonidine	O
groups	O
were	O
2.67	O
+/-	O
0.18	O
,	O
1.31	O
+/-	O
0.12	O
,	O
and	O
0.91	O
+/-	O
0.13	O
microg/mL	O
,	O
respectively	O
.	O

The	O
EC50	O
in	O
the	O
2.5	O
and	O
5.0	O
microg/kg	O
clonidine	O
groups	O
was	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
Control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
use	O
of	O
a	O
response	O
surface	O
modeling	O
analysis	O
indicated	O
that	O
there	O
was	O
an	O
additive	O
interaction	O
between	O
measured	O
arterial	O
propofol	O
and	O
clonidine	O
concentrations	O
in	O
relation	O
to	O
loss	O
of	O
consciousness	O
.	O

These	O
results	O
indicate	O
that	O
propofol	O
and	O
clonidine	O
act	O
additively	O
for	O
loss	O
of	O
consciousness	O
.	O

IMPLICATIONS	O
Oral	O
clonidine	O
2.5	O
and	O
5.0	O
microg/kg	O
premedication	O
decreases	O
the	O
propofol	O
concentration	O
required	O
for	O
loss	O
of	O
consciousness	O
.	O

Immune	O
reconstitution	O
after	O
allogeneic	O
marrow	O
transplantation	O
compared	O
with	O
blood	O
stem	O
cell	O
transplantation	O
.	O

Allogeneic	O
peripheral	O
blood	O
stem	O
cell	O
grafts	O
contain	O
about	O
10	O
times	O
more	O
T	O
and	O
B	O
cells	O
than	O
marrow	O
grafts	O
.	O

Because	O
these	O
cells	O
may	O
survive	O
in	O
transplant	O
recipients	O
for	O
a	O
long	O
time	O
,	O
recipients	O
of	O
blood	O
stem	O
cells	O
may	O
be	O
less	O
immunocompromised	O
than	O
recipients	O
of	O
marrow	O
.	O

Immune	O
reconstitution	O
was	O
studied	O
in	O
115	O
patients	O
randomly	O
assigned	O
to	O
receive	O
either	O
allogeneic	O
marrow	O
or	O
filgrastim-mobilized	O
blood	O
stem	O
cell	O
transplantation	O
.	O

Between	O
day	O
30	O
and	O
365	O
after	O
transplantation	O
,	O
counts	O
of	O
most	O
lymphocyte	O
subsets	O
were	O
higher	O
in	O
the	O
blood	O
stem	O
cell	O
recipients	O
.	O

The	O
difference	O
was	O
most	O
striking	O
for	O
CD4	O
T	O
cells	O
(	O
about	O
4-fold	O
higher	O
counts	O
for	O
CD45RA	O
(	O
high	O
)	O
CD4	O
T	O
cells	O
and	O
about	O
2-fold	O
higher	O
counts	O
for	O
CD45RA	O
(	O
low/-	O
)	O
CD4	O
T	O
cells	O
;	O
P	O
<	O
.05	O
)	O
.	O

On	O
assessment	O
using	O
phytohemagglutinin	O
and	O
herpesvirus	O
antigen-stimulated	O
proliferation	O
,	O
T	O
cells	O
in	O
the	O
2	O
groups	O
of	O
patients	O
appeared	O
equally	O
functional	O
.	O

Median	O
serum	O
IgG	O
levels	O
were	O
similar	O
in	O
the	O
2	O
groups	O
.	O

The	O
rate	O
of	O
definite	O
infections	O
after	O
engraftment	O
was	O
1.7-fold	O
higher	O
in	O
marrow	O
recipients	O
(	O
P	O
=.001	O
)	O
.	O

The	O
rate	O
of	O
severe	O
(	O
inpatient	O
treatment	O
required	O
)	O
definite	O
infections	O
after	O
engraftment	O
was	O
2.4-fold	O
higher	O
in	O
marrow	O
recipients	O
(	O
P	O
=.002	O
)	O
.	O

The	O
difference	O
in	O
the	O
rates	O
of	O
definite	O
infections	O
was	O
greatest	O
for	O
fungal	O
infections	O
,	O
intermediate	O
for	O
bacterial	O
infections	O
,	O
and	O
lowest	O
for	O
viral	O
infections	O
.	O

Death	O
associated	O
with	O
a	O
fungal	O
or	O
bacterial	O
infection	O
occurred	O
between	O
day	O
30	O
and	O
day	O
365	O
after	O
transplantation	O
in	O
9	O
marrow	O
recipients	O
and	O
no	O
blood	O
stem	O
cell	O
recipients	O
(	O
P	O
=.008	O
)	O
.	O

In	O
conclusion	O
,	O
blood	O
stem	O
cell	O
recipients	O
have	O
higher	O
lymphocyte-subset	O
counts	O
and	O
this	O
appears	O
to	O
result	O
in	O
fewer	O
infections	O
.	O

(	O
Blood	O
.	O

2001	O
;	O
97:3380-3389	O
)	O
